{
  "directed": true,
  "multigraph": true,
  "graph": {
    "pybel_version": "0.13.2-dev",
    "document_metadata": {
      "name": "Tau Modifications",
      "version": "1.9.5",
      "description": "Tau Modifications Sections of NESTOR",
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved",
      "authors": "Kristian Kolpeja",
      "licenses": "Private Ownership to Fraunhofer Institute SCAI",
      "contact": "charles.hoyt@scai.fraunhofer.de"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/90e1cb9e5e882703380c9db8d4915ac6f3cba137/export/hbp-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
      "MIRBASE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
      "CTO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns",
      "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns",
      "SCOMP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns",
      "SFAM": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns",
      "BRCO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/brain-region-ontology/brain-region-ontology-1.0.0.belns"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "TAXONOMY": "^\\d+$",
      "UNIPROT": "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\.\\d+)?$",
      "PUBCHEM": "^\\d+$",
      "CL": "^\\d{7}$"
    },
    "namespaces_uncached": [],
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_list": {
      "Tau_Structure": [
        "microtubule-binding region",
        "projection domain"
      ],
      "Tau_Domain": [
        "proline-rich domain"
      ],
      "Tau_Motif": [
        "KXGS",
        "PHF6"
      ],
      "Tau_State": [
        "Paired Helical Filament"
      ],
      "Tau_Antibody": [
        "9G3",
        "Anti-pS422",
        "TN1",
        "TOC1",
        "Tau-12",
        "Tau-13",
        "Tau-5",
        "TauC3",
        "pY18"
      ],
      "Method": [
        "Atomic Force Microscopy",
        "Bradford Assay",
        "CD Spectroscopy",
        "Cell Viability Assay, MTT",
        "Chromatin Immunoprecipitation",
        "Chromatography",
        "Chromatography, Affinity",
        "Chromatography, FPLC",
        "Chromatography, Gel filtration",
        "Chromatography, Immunoaffinity",
        "Chromatography, Ni-NTA-Sepharose",
        "Chymotrypsin Assay",
        "Co-Immunoprecipitation",
        "Comet Assay",
        "Confocal Laser Microscopy",
        "Confocal Microscopy",
        "Confocal Microscopy, Laser Scanning",
        "Deglycosylation Assay",
        "Degradation Assay, 20S Proteasomal",
        "Dephosphorylation Assay",
        "Dephosphorylation Assay, Colorimetric",
        "Dot Blot",
        "ELISA",
        "Electron Microscopy",
        "Electron Microscopy, Immunological",
        "Electron Microscopy, Transmission",
        "Electrophoretic Mobility Shift Assay",
        "Enhanced Chemioluminescence visualization (ECL)",
        "F-actin depolymerization assay",
        "Flow Cytometry",
        "Fluorescence Microscopy",
        "Fluorescence Microscopy, Confocal",
        "Fluorescence Resonance Energy Transfer",
        "Fluorescence Spectrophotometry",
        "Immunoaffinity Chromatography",
        "Immunoaffinity purification",
        "Immunoblotting",
        "Immunocytochemistry",
        "Immunofluorescence",
        "Immunofluorescence Imaging",
        "Immunohistochemistry",
        "Immunoprecipitation",
        "In vitro actin-bundling assay",
        "In-vivo two photon calcium imaging",
        "LDH Assay",
        "Laser Capture Microdissection",
        "Liquid Chromatography",
        "Mass Spectrometry",
        "Microarray",
        "Microtubule Co-Sedimentation Assay",
        "Microtubule Sedimentation Assay",
        "Microtubule polymerization Assay",
        "Microtubule-binding Assay",
        "NBT colorimetric fructosamine assay",
        "NMR Spectroscopy",
        "Non-denaturing Fast Halo Assay",
        "Phosphorylation Assay",
        "Protease-coupled Assay",
        "Pull-down Assay",
        "Pull-down Assay, GFP",
        "Pull-down Assay, GST",
        "Pull-down assay, GST",
        "Pull-down assay, His-tagged",
        "RNA Interference, shRNA",
        "RNA Interference, siRNA",
        "RP HPLC",
        "RT-PCR",
        "SDS-PAGE",
        "Scanning electron microscopy (SEM)",
        "Surface Plasmon Resonance",
        "Tandem Affinity Purification, TAP",
        "Tau aggregation assay",
        "Terminal Continuation RNA Amplification",
        "Thioflavin T Assay",
        "Thioflavin T Fluorescence Assay",
        "Transglutaminase Assay",
        "Transmission electron microscopy (TEM)",
        "Tubulin polymerization assay, light scattering method",
        "Turbidometric Analysis",
        "Ubiquitination Assay",
        "Western Blot",
        "Yeast Two-Hybrid Assay"
      ],
      "ExpMethod": [
        "in vitro",
        "in vivo"
      ],
      "ExpGroup": [
        "healthy controls"
      ],
      "Braak_Stage": [
        "Stage I",
        "Stage II",
        "Stage III",
        "Stage IV",
        "Stage V",
        "Stage VI"
      ],
      "Enzyme_Acitvity": [
        "1 U/ml"
      ],
      "Vmax": [
        "0.8-4 μM/min/mg",
        "106 nM/min/mg",
        "140 nM/min/mg",
        "2400 nM/min/mg",
        "59 μM",
        "650 nM/min/mg",
        "656 nM/min/mg",
        "80 nM/min/mg"
      ],
      "Km": [
        "114 μM",
        "16 μM",
        "2.7 µM",
        "200 μM",
        "5 μM",
        "59 μM",
        "8-15 μM"
      ],
      "Km_ATP": [
        "10 μM",
        "2 μM"
      ],
      "IC50": [
        "0.2 mM",
        "0.4 mM",
        "0.4 mg/ml",
        "0.6 mM",
        "160 mM",
        "19 nM",
        "2 mM",
        "30 nM",
        "35 mM",
        "38 nM",
        "4.5 mM",
        "45 nM",
        "450 nM",
        "5-50 nM",
        "50 mM",
        "54 nM",
        "62 nM",
        "65 nM",
        "78 nM",
        "90 nM"
      ],
      "Study_Group": [
        "Han chinese",
        "Korean population",
        "Spanish cohort",
        "Tet-mev-1 mice"
      ],
      "Research_Model": [
        "5xFAD mice",
        "APP/PS1 x rTg4510 mice",
        "APPPS1 mice",
        "APPswe x P301L transgenic mice",
        "E4FAD mice",
        "HD murine model",
        "K3 model with hyperphoshorylated tau resembling FTD",
        "LRRK2 transgenic mice",
        "P301S mice",
        "PS19 mice",
        "SAMP8 mice",
        "TPR50 mice",
        "Ts65Dn mice",
        "hTau E391 transgenic mice",
        "p25 transgenic mice",
        "pR5 mice",
        "rTg4510 mice",
        "streptozotocin (STZ)-induced DB murine model"
      ],
      "Ki": [
        "110 nM",
        "210 nM",
        "38 μM",
        "39 nM",
        "4-80 nM",
        "40 nM",
        "5 nM",
        "8 μM"
      ],
      "Substrate_Concentration": [
        "0.5 M"
      ],
      "Duration": [
        "2 hours"
      ],
      "Cell_Line": [
        "BV2",
        "CG-4",
        "CHO",
        "COS7",
        "Chicken embryo fibroblasts",
        "HCN2A",
        "HEK293",
        "HEK293T",
        "HNPC",
        "HeLa",
        "Human fibroblasts",
        "N2a",
        "NIH/3T3",
        "NT2",
        "PC12",
        "SH-SY5Y",
        "SK-N-SH",
        "neural stem cell"
      ],
      "HBP_Disease": [
        "Autism Spectrum Disorder (ASD)",
        "Corticobasal Degeneration",
        "Frontotemporal Lobar Degeneration",
        "Lewy Body Disease, Diffuse"
      ],
      "Disease_Progression": [
        "Early Stage",
        "Late Stage"
      ],
      "Half_life": [
        "29 min",
        "30 min",
        "70 min"
      ]
    },
    "path": "nestor/tau_modifications.bel"
  },
  "nodes": [
    {
      "function": "Abundance",
      "namespace": "BRCO",
      "name": "Astrocyte",
      "id": "2fec279f2e12d4bfb586fd5d872a6ead4cd7637e5b2897e657949084e1f467b1a41353b471782ac3c8767897d279fa56f7bb4fb3e37af488a9f056172a742cf0"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "(-)-epicatechin",
      "id": "d84a61f3321754ed2192bfcedff07bbeb8f616861367d084d76e9f7ecaf4150a1fb5b9776efe01b54568433e129dffe8797961905dd92dffdb0a9c4a531c9b7a"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "(-)-epigallocatechin 3-gallate",
      "id": "6ab1c80d3de724e6d924795da884f193d598624c7407acbe86dd59da673081130206c19bcf6637d2372ba76d86fdbe737a1dff9f7a9b685fb82284147388c222"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate",
      "id": "c09c66dff50d5f25db18c8aacaba73ed1331a189c8f9befc0ece147a92cc12ee9df000c48063fe83f6b7bbf4f9bba310b947f31639ab9d40e64e3098126fc5bc"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "D-glyceraldehyde 3-phosphate",
      "id": "e6622cdbeb459d4543f81a75975e918be4c38fcf918e1f26675304ed5b08fdf2b8aa6d4a83bb0994bf3d86a59909f8b477cc2ebc6f0c1e9f3c6d9de73c33d858"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "D-ribose",
      "id": "4e55f2d0bd4599b2ded20771d4e4ba963f59fbf352143a04034667125b357beb094f6481bb81cbb5276330fe1f5ef61d8aa4d1a39a3aa446497d6aa98d2bb656"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "L-ascorbic acid",
      "id": "057ef21ebfcc98e027461b955a40961d4baf6b79bed3a6d86500918dc83deaf34d851edaa9df6a0d9b809b957d2aef5154be8230798352ac3fc93b80ac153f5b"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "L-dopa",
      "id": "f0e9325f85058d56ea037d3a92f02e7bc7a10b2fe7d99fff892f6c584b0cc14a956bd34668a19b1687ef5ec25e043dc8affd9a04d1f56b4547e44bbcaa7a7ccb"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "acetyl-CoA",
      "id": "a5fa305d2e2001d715f893ae6c2d622f7e9190eff20a4c42d6ac7af0177896d9464cdd5304827d22ac2fce8b653837ad54d0a95422b99f8fbf8e348571b0e739"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "advanced glycation end-product",
      "id": "2f857e8764edb78fd3e91a0abd86df1cf1f943bf98ce167f9a565f27728ade7bd90dd4b46b6bb24babab810ddd8f82ea72daea90fb536895e1c16f2b9b3ca3e3"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "all-trans-retinoic acid",
      "id": "df1be1712b53ebbc3b8db7a99db20febb6ac30c8b6a3e24bb07b9b6e2f24bd7076b55afab356b4900766c8828c79a533b2abb4f9be2f6e4b2d809eabdc5f2807"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "amyloid-beta",
      "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "calcium dichloride",
      "id": "c8141819863dbeab71bd9ed76db92882a3a0022a129b05b6dae8307ce6450febfc50586fe83aa55fbc12c54347076a21d375058df2fbb10752934109cf65289e"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "calcium(2+)",
      "id": "4fb8648e4c5fea95cea6a46291d28175bba677d8b6fa8d607b1febef51c8370cbc1ff98d09312dc418ff31d04177d26f231d4f0a1a963f43fbc29cfb3269d3c9"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "diethyl pyrocarbonate",
      "id": "55ca698b9e959c549871f90d21125e31e349c108f9d75a623b409a6792b6b990e86e9ace3e0d3b5d0a12258f4177d448bc7411d2f4f18db1f0a5502f5107a376"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "dihydroxyacetone phosphate",
      "id": "47985c181d8fc4b492095ea546f7cdf67979b860336ae6a624d20d6568e7f4427bc56d494c0870c49d26c4bf4fae54e9faced2f44e6ed8292555e007115cb8ea"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "dimethyl fumarate",
      "id": "7d04ed27f9e6af6d1386bffd879cea36cd42822fef1e520dcfd3d7d4443e87689087df9fe0e7feff2c19ef8795ba47b9da2dd0a50d0f64384c4a72ecff01889b"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "folate(2-)",
      "id": "9aec6d047b8226fc629be25461498fadf3709b99f223a6b8f53004b1f579180f2f9245467e1ee5814a44a1d5505cb96c09a86e10c989709a4eb54a08b8b50406"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "folic acid",
      "id": "0067b63b17fb418f62f6e4c6b7f89668fcab7dcfd51227d8ba969f205f188f274c24057cc76d07ee1bd6f599a5c2d5c6eae57a57b3354f97e1ec5b36fff591f8"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "glutamate(1-)",
      "id": "fc1b84427efecfb8e3a837d65b6e115ffa8c7fc53ebacb54b967fd3aaafd25a6f47c147e986961e53c4ef1d5c36420fd9194019b5f81eeb5d33310f314818875"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "glycerol 2-phosphate",
      "id": "b0e23d155e5f0a47b951a7d8089ecab91c990f478d142df24956a1d54d78be943533d42bec6cc0cb0fabb42271c2fa9082b66c5044e7ee23d217f004d14dac2d"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "hydrogen peroxide",
      "id": "4d65b5d180890b98afe0bc10614fde44ee750b2d1af6fdd925fc31ead7ee9a7248bda3d67c52aebf220b8c048d999f2d878a97a70b0e027a7294cbd3c7bf61bf"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "lead diacetate",
      "id": "1c6b7d8e73d1c71b4d544171dd7149a815b94e16a39a2fcb4941d8e2e4515b651b85a077eb896b09cb7cbf54f4edaeefdbeebb1cd356446eb5b110437c6b2e7f"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "manganese(II) chloride",
      "id": "fa494f82d42a0b88cc58d9405b23c9745ecede1b86958dae273842a8c8ae084fa90d33518af02f8c18d797b865848d515e149ea9ba7313617ac02b04f0315e7a"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "methylene blue",
      "id": "bc17e9a0bb9e81081bd8fd81201449228e606bb9013e59ebf8a144c733531a8fbfe4e53776b79be7832ae7ea593e80a36ccc93367f04919f6241c7f32ab8e9f7"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "microcystin-LR",
      "id": "5139386b7d4ac0d89781c39abca16fac517b8ef54d67894ff5e4b91504c4a2c890c2471c3be91a91206226403a49c31695a2daf437d5f2c8c261c50b14cdf582"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "nitric oxide",
      "id": "fd0dcffbd4e00c161d74c931890123439e35f86a92cbcf20c1efaed0bb8b8469434bbafd8364de8822b9af6368de418ed1728b1534bb8eeb47320d5a9c895548"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "okadaic acid",
      "id": "676b3ff5997541b41ef095d98283a202a12cc877b431c8467f956ef1acf990f281c503ef40951a8135be2af35c9c46ccdfc87e4af3ac93d9f086dd911f85683c"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "phosphatidylinositol bisphosphate",
      "id": "d5400e29322881f575d13276331d398ade30955cda6d9a86b4b2a4b57f6032acc3ba2ffa71e1d55ba0ad553cb0acab7ad39698652a13e553794e2de00d5b2ab4"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "poly(lysine) polymer",
      "id": "348ab6ba06221a32e3c2bac3c6ba7ecfd27920c0eaa8561a38a40bfd5f4a4467cc40e022aa10e3e8d23df7f18483a4deeca781cfdb22a0523eb7144ebdf76b5d"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "pyridoxal 5'-phosphate",
      "id": "1fe110c94d31c4483b265dd3169391db42cc1e343d23ed07ddbc293a1eafeadbcb42b39f61cf725d3737db0fe9c67a7be6996be321745d439440fa1d031979a7"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "quinolinic acid",
      "id": "6b535dde05326764e0275b3ecf8f3a9a3b7f5050b149b27cea5732f0d390c669043b62bbdcf8ebf474a9cf6049e6b9062ad401a67c44cd12dd4c589365a3a846"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "sodium azide",
      "id": "07cf3d3c9ebb85dc2cece29a80fc3b6311b76ddd2fd77d957ba1a681e84d28dbf32a765c00d0fe00a3aa49209b291aecd868522afd1a24b503e4ef275cc54161"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "sodium chloride",
      "id": "17103388a013293b11abf66cd78ca9bee43ddeef211125f62e6ec3d3f0d6eea9ccbe01ff2a717a179c5ec0575f9c7f31e53c3b19c8dad8ebf62ffcb99c86acdc"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "sodium fluoride",
      "id": "6beaefc5d2480fb9dae3697d3abb52f0bd8a57af68c87d94f70f4db03f215880eb0382f2dc9320df562ac98335a68e51a46b2231b8259f64d743d0bf5318ae60"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "trans-5-O-caffeoyl-D-quinic acid",
      "id": "568939acd9986319ba3871a2c946739371ec258d660e4763ac34ea534eb03d274784aa85d3c4f6aba89065ba31dc984650779dc6058bed8c72e00e994e7e9a75"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "trichostatin A",
      "id": "8c8269fc63126d8bacd63c3b16d5a192e864dcb954f7c1ba24df2c409bb1e0c622f0e213d1c88064ff72a4e30c866f5e7716318547299bc0588a4c568c6058dd"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "Iproniazid",
      "id": "3fd77d84bf68eea6c65ba82bd82808f776779eb09a888691de6175aac3f47dc3c13df504f153047ef506ac216a664bf2387d32f5e0c3754324610aba7d1cddb0"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "Nilvadipine",
      "id": "8947c1d5cc222b9ddab1d201b50db6d7b63709282cfa1bd37e44f59d1346952d2271c98963eb6950447f8b5a928b418e15fb56adca21b476a8e64fa6267306d3"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "Phenylglyoxal",
      "id": "00b22d4e134c6fc0bba55a1b23ba4c80a28442bcc01e53157444eed3bb9d748296b691b90b79e9076e3d9aab313b805e6eaaa3cb1c8f41dca4bc7f23ecb068bd"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "Trolox",
      "id": "6d52e2aabbd1866ec8f3c99223dc0b27a112218407456b32d19f58ed39b1630ec3550888c5696b919a27a8046985e89f18c2655b81e100f83e870cc1b69e2b22"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "acrolein",
      "id": "98b0b858026915ca49dfe1a8f6f15eab84a462a46c99dd0a4b2a250c597080fef1cea20a51a1322fc49c82ddecdc3818b710ceb86ff64895cd97595038ce98d0"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "adrenaline",
      "id": "bcab81cfe7bd509bdde904d67700eb80bb81fdf2e41bc0ba71061d5ee5f1cf657b917d0e8ec104f9e788feaefe992904a4b7002fc52ca7c52840bfeb6858ca6a"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "alsterpaullone",
      "id": "705482bdfcfe21dad824136f3454a9dabc7e0609f463062e3701efa3fd9a6438a714c395d84a4094636f375a95e6b8e3c28c725bc8dbdf2423b9d1a3f775a94e"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "cinnamaldehyde",
      "id": "849588a349f9c8b549d94900c2d451370c0bd6170d3daa9bd9d877b83c347e4088ac221ce3e572205c4699dde1528325c3efd65cf256423a1ff148126d9b79fe"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "colchicine",
      "id": "163e44dea110e538be40965635ddb8c88448cb360eaf67456221344e3dbe1635dd37f84108a8541eb8ca0e16e0858d5f3d0bec2362065ae9423688efb3d0e7ed"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "daunorubicin",
      "id": "c8f7750cc3e70c4d6a0a4d895c9344a02d6e3fbea8c87906218f4a04b46e0f1378094f4a5d31773641c8d97cb4a5d7242e4c8b75dce5bf22b206bb922cc57608"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "dopamine",
      "id": "70f7314679db5bae3c2260b6feff9a6ef3407fb6a585f92a58c59fd066a2ec279c0091a72edba3465c4f2aa033afff7fded0b16c4a84f4bbcecd092a934ea66e"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "doxorubicin",
      "id": "9cc469dc0558ad5b1b342f8b0ae928f8ab1108da1d461376ef348e656969424e37665add936dc97e7056567659bc64b3a4232800424341c021db65415fae1e90"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "emodin",
      "id": "ef6a1145e4469eabd2ff780f5d341115c6cc84b06208af19d103f4ed533cf808700813a3ce5970a3baffc946d2e61eed2478d9627ba3416bbef8eea03558f404"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "glucose",
      "id": "ad228f723834a0438254651fae75410bfa5cb8ee6d9baa98af0240115b1e5ec55edb5d001429c764d8785ec034b6b90edc76a4b83d14572cae3624feacf85491"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "glutathione",
      "id": "a75431c9ce7065ec867a86011c2371dd04187869fb2f21220cb8b8686a5a63863e8f98d2e96f23b6133fe39f75169f6798972c8cae9fa7bcb3af79562e948af1"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "glyceraldehyde",
      "id": "2fe0ade741c61088d74dbdad3d1419f6d84f90566fc41b50fc216894b7f680fa37a69c304076bfffdf00c36ebc9e71dc27ddbdc230c2c5bdb0dff10a92e880bf"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "harmine",
      "id": "88eb8890bb924034af9c7b43b3a093fad2ec7cb49b84422b53a6fc172dba64001805d2a74a882a668c2c39d0d9fcc5141b28b5b50423c3a9d37a71253b0b401b"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "heparin",
      "id": "4374b8548ac69557a1b3cea92dd62e05515db3c3e3d7fd5ccab0175e73fe27191d80062cb46672a453ad02f3598f015b641d367cbb9e3e042312dbcab159a33d"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "homocysteine",
      "id": "7a15d69a1f5e63ea5883fdd1570ec1c58c8f891e16cc845d39de3cac7cea8f12c8d936c03cebb64958c2adc3df7c2e36ead35db704f152e5abc1825a20872da3"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "hypothemycin",
      "id": "440722a51b95eb45f386d3a2839484f5fa252e6a9fc426af07885b408f53756c7dce213f88f56a282fd6f61dacfc37697eaa71fa2de49c7d111046f5dc95b3de"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "iproclozide",
      "id": "6356b07e4936f2bb1b1f6b96628e2df795ee5d536b4a3f293d3807c789cf6993803f482d2cfade44a28efd1f0218c2560fc315eb304c1dcd5176b802d2e75413"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "isoniazide",
      "id": "6a76b0fed2b8a70b5d38a184101e486f6a8acf4a7eefe69774a5502d4c71589e4d24e2b30357c95afbac79b15b3074f9bd79e8699d742f5ea829053c5f04746a"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "linsidomine",
      "id": "701916cf955d571bbc4626c3643a177f7114e1a73a6a7ce2d24f98a11c76edce725247f2959b8b7d55211a81023a38b9cb2e82f5b4bd454e24a8b3e772d5f079"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "memantine",
      "id": "a6417701f850dae3b77bc52ab06561523bf34757aa461d008c48b9b489cf2293a3fb2bd592ae99ac7d23dd6143614f12df64ef718109abeaf9651954c612bfe7"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "methylglyoxal",
      "id": "54c816a0ea12a650e1d1b7da0774be93e85e2138371f1922cde158ea9aa45be1d3d48a142c4e5e3503c29fb65247006dec5cd6998278e726953eca1466348aee"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "myricetin",
      "id": "f0379aa465e94d18826e7d35b8f84a97b2e0281a59e71c8f2898fd6f0e20985a2f034f250e8f7f8ae060e6aca4707ac02fa8610931855136e370cab79bb37f93"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "noradrenaline",
      "id": "4553f1e4c5c615e68013cac87f15df1fff14c0afbce0727cddfcb8329488f1dbcb9f1fd9b88f78d222bb7b5cc67d2c05a5e1fad860c45047b0fac2778cb1ffac"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "paclitaxel",
      "id": "a74b9c461b771479e411ffae5b88f3a0863ad0d470c0e4d15c86a6a25308ca080e6a086d6e7acaf0a69ba2847910a3b782cf5c8b22efc9e3a7705b70235901b0"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "peroxynitrite",
      "id": "fe63a43025ec98b86b63f7a0ff59747da6d8d6bdb82dd95d68e59448e6125933848846d8ba1dcb68dbe9928a6c904be0be53c06869cbc1844a302a0d9650304d"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "phosphatidylinositol",
      "id": "37ffb4eeab6a8cf2a8277428473def12f02b3de90c0071536e31d35a6e875191b5943b4d220c3537386c70031cd06ac2a65d1e0ac60bc89eac00bd615e330646"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "quinalizarin",
      "id": "7ac384797eac60fb62593ee04f3e24963dea79a5d82d9fea63e4a1fd9b79030b7c836c73bf2fa4743615f7296e3b8d5b72a239da560aa4e89c9c103851f5c495"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "resveratrol",
      "id": "545daa8c15363de2760fcbff1fa1c472c83bfc4fa06d5cfaaaf1259fab8d6ac783ae0bdf7ae00fd6f6e0c5c7541242453b6423c657fbd723321fbcfb5bf953f7"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "rhodanine",
      "id": "fd4b23aaf35999289341c8dd0b34554cd9e86209692a9cd3327687e49fbe4e69be821e0daefd4b08512f45ad133206b8671f51459b01678f4073c2782c5a472c"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "rolipram",
      "id": "1c06ec9da456e4f4b407b64925ab7bff8a0a14cd1d6fc4f3a491b50d193e8641ad315d22846527831d701eca604acc61fdca31cab516ef08a8cbab4d53ec78a6"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "salsalate",
      "id": "6b61e1b1e803aa49edfb3a1a6755b0947054505736a27db51cc6d6507acce3b4ec6fabd0d074e6d502657a0f3d0cf56b1c0cded454a8b36485d7601288c3d743"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "serotonin",
      "id": "8d7ceea95cec905de8941facf48d632e3c509b6ce451f835af1fab5789daacc5bbf8d1bdb7cfd90863a70871a9a9a07b093896248712aa6567895ae8cf3b3502"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "sirolimus",
      "id": "102b031a00eed78fd9e5c4236defb90a8995463980f9060493bb5fd3159a3eb666cbb2b6a33a213c749a2b279ef6d149796b4f0b568e03b82eb5c89b0da77426"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "staurosporine",
      "id": "464d650f48027f6208c3bdf2689f01f41f8c4ceb454982e034ae863bd23e0deb8aac1be1b8ceea61fd5fcddbe1c837a1eb816b3193df4b76f754b0b7959c7c07"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "thiostrepton",
      "id": "df8ed0c59b300ac3e896047384eda80a5143a5ebb9625a60d2bdffc20d0c1d3a2ba269bbe878935c11cce604d2b574c410b9780c02441bd7ae97caa1255c2043"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "vorinostat",
      "id": "82ccdbc25f13c4670b6e495c550f1851ac164c1c40ac430c58704e70806ad970973e429c1de9a57b146424cade364ecc3beeb739af263e2b23f21875478fb0ab"
    },
    {
      "function": "Abundance",
      "namespace": "CL",
      "name": "0000127",
      "id": "e0e869618672ee859ce3428fd4ee767073424ef86e33d78abaa2fb49c1e94686395d1a1a79d55b33286bf9a5f17fe458f05fb66dd94b035f9310544ba2c87d39"
    },
    {
      "function": "Abundance",
      "namespace": "CL",
      "name": "0000128",
      "id": "1abf305df774bd0514608141880e4ab728e3809e6203f1c97db883b0c361194dc1464c40febb5e81bb79a29d1e0c2b84a087b55368f3dc7b80364451b84af92a"
    },
    {
      "function": "Abundance",
      "namespace": "CL",
      "name": "0000129",
      "id": "d4ab3b81fe959e03ec3b0777f910aeecbd00ccf49d06cf4fcbed1a75f982af319fd0ee307adbb0a8352188c3c24bc8c9050d475d5ebf1f9e062e3ab3d655b703"
    },
    {
      "function": "Abundance",
      "namespace": "GO",
      "name": "dendritic spine",
      "id": "50b68b3067609df23d68ed8be7713e3e896c5d94c5c9422cbfdb7c7a5856c1c67afb00619691ad2f190eda88738c1b51bccc9e52a506f6209908caddf176342b"
    },
    {
      "function": "Abundance",
      "namespace": "GO",
      "name": "neurofibrillary tangle",
      "id": "3b50c674ff9633f408e5173562a06cf3a856abc95a8b034db8e940b464f1cea72df6f9fa9b7b02b5daf4eb86a37a155f203289451f7203a7b9c9e6c65313eadf"
    },
    {
      "function": "Abundance",
      "namespace": "GO",
      "name": "neuron spine",
      "id": "59ba33462397a55d8f452acd92282a5bf13031dd400a0c2e05a0465079491446c0b88927317c908f94605928c8a86925caf51c1d0e737492906a2c1170548d12"
    },
    {
      "function": "Abundance",
      "namespace": "GO",
      "name": "neuron to neuron synapse",
      "id": "bec0f76a3d8df706d52b5fea2d7e18845ba61e6d9b092b2072dfdbffd4478c76ee173ff323a0d8dd5bcb2b39391258417c8a97ed4b52cd32a7d99678094818ab"
    },
    {
      "function": "Abundance",
      "namespace": "GO",
      "name": "synaptic vesicle",
      "id": "d145f42b1cf3732a644e504e8c09e68f21a2a7456136505a45e9eb8938e9f8279c86b95caa6feb96f8aa2d4771f263ca1f9820bd13f66df04f9ea377f1581406"
    },
    {
      "function": "Abundance",
      "namespace": "GO",
      "name": "axon",
      "id": "6bf6ad5b1ca0f98a8d7f7cc604dac0b2ee4a99fdc32f39c8cb4502aeab4f0f643c04de5bdd4c586bdbbd5ed7e732f1af293aa80e2bd7352332c37b8161d6276f"
    },
    {
      "function": "Abundance",
      "namespace": "GO",
      "name": "lysosome",
      "id": "61127e1e0a936d98ae38713263a7c5700a82083baeb5fb6c51025ddad10d280fd86e7d30ebfbabc384f77b08ddda66aae47116fd775ab82c25480f68fb78b46f"
    },
    {
      "function": "Abundance",
      "namespace": "GO",
      "name": "microtubule",
      "id": "0c753f37efe0eb149a47a1dd700eda093a03b462374275c68480b6aed3be0f81aa9793a179dfd97f8e0834f1fb9be4b4a6cff2165b176d9e8a8744f5e0d5bc2c"
    },
    {
      "function": "Abundance",
      "namespace": "GO",
      "name": "mitochondrion",
      "id": "674f8b6798b9e5c6e70640f0fdae9461fbd9279f9a4aa794f23fb4eda4c3f8fee87c44f82f9050526bf51e9009baf9864c3ac70d4c5941ee3656f48c684420a4"
    },
    {
      "function": "Abundance",
      "namespace": "GO",
      "name": "synapse",
      "id": "cc12602eef45267795bef1781b57fdcfc0800fd22ea1a8c57746d2be9789ec52c582f9244ba1318f068bf1cfa150d96ad79553596c1e96633df8fa625ad1af74"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "8-nitro-cGMP",
      "id": "ac338737f9f81197ff6f9fe356098bc21ed52af7088dc1d89321f526eb1345256064b9ac5feeab04b1a37cb5db7804c1a4a16be999f35854fb2b37a8696f72ca"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "ACY-1215",
      "id": "814981465d066613e710f54c561570ec98bcabfdfd0d9cbc1d25fa32c4568d1d855cbe5a8ffae27e1b6add2fbfc629afe196c41202bfc93af10b4c8abc1a5cff"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "APP processing",
      "id": "618e2b77c0381f30990a9efd718b9486d8714967d58d1b4cdf496d085b74e85bb4692cd7332f7e73af7d56d1bd2c1b9442e3975968605646051e4840f5a37034"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "BAY61-3606",
      "id": "6192a982f1f295dbc29e02e93c096027f9fcc5b2ddc5ba1018026e9689c8b141d45c946851634945888722e6a2c1ac2dfe908f3f9662f1bf1bb1549c26e341f1"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Biphenyl-4-yl-acrylohydroxamoc acids",
      "id": "15d6f3f705e0ce0de94c56ca1a69184ccacde61260090d22b1c3b10ec291f86105257513dfe7a776ad7a20da70a2935ee5dbb9cffa25c074751bfc6a516cab55"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Braak_Stage I",
      "id": "bd754427655a5931e043e75f64c1230804ba573faf95232fc414a15d13f3b5c04a8934837d6fabc9c1215da2496009e6395ab2f34b655ea3174de68f0919619d"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Braak_Stage II",
      "id": "77253fde89c536e092d50982db09abe19d9a52c0fc8160972b77d0beff557e7db2d222f96ea6c72ff29b4a6f591ae886eaf1f7f7514a3f9bceed4ea863e6cbf7"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Braak_Stage V",
      "id": "3a02187665ca5e161a6dd0808511da17028a568d3b66096d2bcfec9031d0e220ef61a7b6e98413f6fd682ea044dab47df36bf91d30219d4a15c458ab5f4b6b1b"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "C-30-27",
      "id": "50e357f9aeee8740ac45e189ddbbac934df6556ea60dae319b3b14dd40c2afa75e2cb22eb065dbc31a0046ebfcd5e9f258741c3ae4a5935a77e2263042f4f415"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "CM-414",
      "id": "cb2daa66f71b2a2396dd9339d1dc8401b1054e9607c42631949ee929f5d3f4dd821a69424e142d07653a794fbd523e7cb4c5c60a6a95ad30fc9594fcf573c9b3"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Chronic cerebral hypoperfusion",
      "id": "ee655f2b9d1cfedf05a384f6df468e1ad49cf468dc46a70a7153357d7ded4dbe683457b3237a3adcb2802e69d3650d3a5b9aefa06548958ce45ff9a7a7d318c6"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "GA-AGE",
      "id": "d55f6cf0bde3bc4286b8f2fff9ac8b8910b968506dcb2fe001534c0842fa2216a6c19e200302d595306adaf8ed501d94e8dcb2a453fde7222db49143f472d52f"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "GVD bodies",
      "id": "b0b8496f45b58de3d47bcef4e36f70280216c72f319d70ddd6ca5d2b86e871ca9a91cbd119092766d62c7c6ee9df3eb34fa118682f4270fc35b828913ef00cb0"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "ID-8",
      "id": "d7d9e9a472be76622e9fe4050161cce5af7bd7e82f3e57cf27c6b65339dec4e38357ea044ba01d9da36bbc7b012119f8d3dedf29588c54ed7e191487ae2e31a6"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "LDN-193594",
      "id": "b1a6132b65312900bd089c0ef62499f12ad790b39b2e0e9a31a061415099703d17dcd05e0f64a1fae5ea610b68df3b25ca0557a62d7f814bd4fdb6dc69e2f592"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "LDN-193665",
      "id": "02d49266080abb3095d2e7e7ca9436325a9093a965e5bd0a4f20b36be059cd7302ae6afb8195b58085f3a7c3562c48c3219efc02f6390c94ad9bd4834769740b"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "LDN-213843",
      "id": "328e0978f7cea1db31c9e0fb8efe88b26008d23639b893c675889475a40103d2f88f4f9d52b5ed69b0ba772878492c66f2a308ba17606224903aa28807186478"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "O-GlcNAcylation",
      "id": "259eed3210338b4a65e77722930b276c00317c9e6a9775f218cc4eca3be39f4bb9066fc917c48e987a8d2f22605a492cbdcd683fb708ca6bc189ff8b33e810db"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Pathological Tau Spreading",
      "id": "0a7d36c6924fa5dff54bd509cc96d2407f060d70f052204a340d4ecd728dd4643265aa3cccb31439ee2bb8d0656ebd0699117b65fdbe820493f221963a03dc17"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Purkinje cell layer of cerebellar cortex",
      "id": "91e4444d1df41034d993fd07ed9881e83d00d5b66ca7e54c4bbe769ad7069d5ffb58480c6d66a1521231f7d26454d9eab1316b4e38a790b420816632ac1a03d9"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "SL-327",
      "id": "03f36edda63dd7cc9822fd17fb54cf54e1c1dd27c01ee98b14e7b1d1c0b5293bf666ea4ca9594b85696a2d5d00bb908931fe91a84992ba6876471b493de12027"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tau Protein Secondary Structure, Turn",
      "id": "7d89c1e535e9fa2cde5b013604ec41c497023cf2a3ecc20026f668df5d02dc041836007094b47a40c4e5b6c85c548bce14241f16d8832e8df19cdeb8ad16835f"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tau aggregates",
      "id": "2f93b798e33773ea9681389870bbee41f6fa7ee04c087bda4bd1492520385f58d089a7261b1353e15c31d3e29a96ff31884886e6ab9fa477ef8f63f19cf154f7"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tau epitope, 12E8",
      "id": "c34be6135c1bcd4e691269a37f289417ef6eedb6703788075919639ed0c6acb23ba43df0be54976b5421f588702fdbbf831494230c26c570783d44d889d4a1aa"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tau epitope, AT100",
      "id": "29f2657150f230902d81e137b4206783c60d5e671218dbf4a5720234551eca983539a9a71a08b5af48d26493d0db101dbccf850ff2db0016f9266d69a00911ea"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tau epitope, AT180",
      "id": "b0b8cf64217d1ea9b2008e088c9190a538f9500a5238b79b7b7cd9c21003676daf0558c7665e06bd43d8390679ea61b08cafe4c0b6c9f997603dd3e5ee84fda7"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tau epitope, CP13",
      "id": "b265db51adfba5abdc9e0d401f21f82fa16dac7ae7b814311cfeb6e07bc5a9b5a348ba99b8eec10d87c3e3edf1dad111f32026d30dd93ea36983c6c22653836a"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tau epitope, PHF1",
      "id": "c133b6c209011d4109489ea5c061c0e42f0d3de18c0fed8add35868a1e7b4e855ef0807c5408696433a43e16957e93313e67d611f53a51cb81089f561d7069a7"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tau oligomers",
      "id": "d4ceff8aa5a5d05770aaa29b828d003b85d64e7e5337c6624b7c5a84111845897462b589e7b259b0eed6bcfc63f34cdaf1f9b988c788804799aea026d8731d98"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Thiamet G",
      "id": "9c87bcd9a5b64973866cab9379e486e08a063e7672ad3600431330dccaa9f168c0cad2dc07255ce823f6abcff145d2ac8ac9b18f6340c9b876b99d8adee54106"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Thioflavin S",
      "id": "d318d56679b51903566a06b7241f1663b9122a694795d9cdb2e0a31215a24b2c4856584ce2ad7f8b8f83bd1ea3f44cdecab722f6da291ee4c2bc79d02fe4460b"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tubastatin A",
      "id": "543d83ed00654be5a30b1189970df285c3a3dbbc5e4a9b7f8ed08986e84aa64aa6dca0804cad71b9bfef8f9ce23e468fd9b2f3e8dc8f2d61fce603243c374e11"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "USP14 Aptamer",
      "id": "2e26db861e30249f39f0b2cbd862a6738a2f246625f73d25175025a98371d29e485bd180aec356281bb3b577c7885c4bf361ccb7f4ef5adf5707ae06b4d8029d"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "advanced glycation end product",
      "id": "b606da9926a6aedd95a3e3bc39323e5326a30baae889e95c54f504370752dfb683372116ca5fa32d4145709a3ee24347cacc159cb1f2d3462a7e3a1b0fe18ed3"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "amyloid-beta oligomers",
      "id": "a0fc661406161db12bdd89333a13d0ee89b3aa089d5eb16676962cae3efd25d4d3dd6e593dbcaebf5fc0c26f9c8c070a98f2ff0fb94a0d52412c0fa0bf6c5b3b"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "cholinergic neuron",
      "id": "222e8baa384f196d88fa9367bc972387df34f9cadf56c3733d8ac55d2d2ba31f9fca6bd4517d95045cac9f2c5a9f2d92879d1df7ababae05f708fe9bccd541f8"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "cystein-dependent auto-acetylation",
      "id": "00ed3d399dca2a1ae08fcc6a0b03496fd11344857eaf3d952bfb5ae75c2ea4210d908ef34c7983754458bff3601c89ebe74de40b76f1c165fa627038f67051aa"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "dystrophic neurite",
      "id": "fefc1fd142102e9ec451f3defbfa09282680ba961ca9d6eda0211708b220ab75feecdeacefdd380dabe553134605ff79003d247ebd3c4420bc0a98959cfe38e7"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "granular layer of cerebellar cortex",
      "id": "394cae54c24c281590878facbf46895d1fbdbe53e1915f522fbc9e33a18d78d817c651e01395a86d677f5426ca4a77208252ec52523d57e17b4c7eb692309231"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "granulovacuolar degeneration",
      "id": "54b3df161c7ebc26f946c45b1ae5ca5b615f2be1fa76d947ef8072095dc05e7bf8be6f8b752b892d7440ec2fc1dde20db7c94c0717767859053d266cdd2616d8"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "microtubule-binding region",
      "id": "284e708151d3cdbad19b4883cd8b646d2cc4aca4e6b25b4267105e4c9dfe435cae86b0db038162e48956fb2de06ded489d92170df9e0c06d0d16a3b3376903c6"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "molecular layer of cerebellar cortex",
      "id": "f809e7785f6b94b3b5815a9a92df5e592c84af5e9f1cdd700a85b4fe8cec7a57d326ab70b814fdf25d76fc9e1a814993bf6a95732ffd526f7bb67f456bb3025a"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "paired helical filaments",
      "id": "8d87710f8ebf7593b6b0020396d36a868362a39b367908774a967b0efb7397212d51216da225ac3218af26e6abb0338cdd1d676c9db11cf8e6c16c127fd2305b"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "peripheral nervous system injury",
      "id": "32fb786aa36a893e7971c7db42a4450fd90b4fa0c1e53bd8e926e096cade4b4acd69512177b252c2d5ae8698a9bc958c6fbc77f272b76ed722da95e380e2baec"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "projection domain",
      "id": "31a22a4945740607c37eaffffee69204a782bb99d194666c1e1dfcedddecd16ea5e29806adcd3582432a92c7ff14f16209c61e6625d79a128be75e3e83339e7d"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "proline-rich domain",
      "id": "fa9f3c0d9b8afb90cac43e07d09daa57c9dc083ca98d8e49a6453f44d2d59c447910942a96e06d6cff58a40082f7e1cdcd33b3538954bf3553e15f7aca51f15e"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Astrogliosis",
      "id": "47c0ace975f6894865a2ab85c0ef2adf6663bac2f00f2d2316ec1da1886f9c507393915fc150cc7ea060f4f8eb559a8409eef92d8b5728e0984f4c0acad995f8"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "C646",
      "id": "07dc705c39483d5077f038aeb34262e11d5c7e30166f8c555aff7e3af00f9c06f4b9fec85b554e2b5bc0607eee111da80db060006b0af350fe8d21755cc0a672"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "CGP3466B",
      "id": "6356c831ff870fc99b3358f85910da4f563f5ab179690f7e6d43759118d012455af0466459db07cd5c9bec95d4077db79c015db6f7635c5876c63b3251366071"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Excitotoxicity",
      "id": "80f0fe9786f726038f985feb4dc24c6add06927628a431fd67220bcc4eee6f64d44b062beb6925b2e5d96998987c03cbc272ea5e23197ce62e58cf17fa7517b7"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "MPT0G211",
      "id": "6d3500e4fd41afa1436b3dcbc82c09c9c9db4d376179493bf80bfb418709f0b69cacef45c1481ef683b3c9b3ebb2f05dea9370c2845f5fdd81ab02bd0cbbd000"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Microgliosis",
      "id": "8cbd75925314cb55243c71a01132bde1090f5f7a882d6cd6e54c45af4a0fb659aefde98beada6563ae3ddc9bf7073903b6c3de8e582f694a4a09b3f4069f1a95"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Neurites",
      "id": "68b723241b535d7972a22324c1d495bb82c2b929985fcbcbfaea1900586235a7f52c144dc99813fa3b3a6c63c02f3041cbdd1fc9debfb066c6413440770a7487"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Neurodegeneration",
      "id": "52fac4ee7f9b3b0fbfcb98add48ce6b5926d97ec8d5b2d7be5e26abd9856e9a5fb4751523d7874eb2444348b726fedf3c0e18a99cf5383b69f3380c3be2f91ff"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "RGFP966",
      "id": "e110edb078b3235c8bfaf5a614c90638cf1e05d9b46190161f605b19b9a4487c4fef1ba04c9f40447fc33bf705ca9f8148df0760f6581d1b1767f923651ec334"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "ST7612AA1",
      "id": "715f9ec0057b157aa19f4f21ff660a05bbd4055d38f08e297876a9e8d040cf46f5f27c09659a244684f502530a29224e978baf580d179b020c5d413917a2ef9d"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Trithiocarbonates",
      "id": "cab44d265718d28b0fb47a5ca7c982a1fa950268c33eec66b82edb8d1a5bc66dcd04b816000b3c482edddf34aac8c955d2fafdd36edc261addadb80bd4948f95"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tubacin",
      "id": "dedc7e2e81e2f3f52ebb15e15196a8293a376a1c28fd1a6a3d5c3d427e91d4a14decf57c27d714a83e286a5f815cc1da700bc8c735b50305fc0b103248938299"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "crebinostat",
      "id": "a094b41982d856e0db569ae9306394b542dc773d18e9b7e152c79af639d3727865041e2545a39c01e2f79cea3ba7a6afb921154d1f9def86e3b63a4b87f569f0"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "diaminothiazole",
      "id": "3b45c2ad4c730232f0ee79d0ff4ed3609beb28cf4ba03d64787dff0cde3d80786c77c16669cbda18b4cef0a5f1546f8d6548faca525a9653dd9f3d3eea65868d"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "indirubin",
      "id": "77c7ac5623558d6d1a602cae10a16a4eb2336fa72124d14f385573417d61984d477aa6d40d1a139c85805bdb9077fa51b08f98edd5d83dd8c41b4f2d569ad1bc"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "isocarboxazide",
      "id": "4cf3738d716a02eb6457ef8eb745a237bb61dab570d9ed3b18eb408f3ff67a3ace9af1bdace1d0c895c634af8cc21a24d783492bb55acec6567f4d1a57ab48bf"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "isopentanyladenine",
      "id": "7e3918b986d810d57b4804ad84fd43c870fa496f2c0c0fee7e6bf4986c10038dad5f1fe5605210bbed43f38596a24cf2fb769af77158a8484206705f51cca7fa"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "maitotoxin",
      "id": "c2fdd780b5c9b3051d6a7f8845c1a12c6ccb63363f4e1e01e102d3eb54b9d7e518a5e5e05cf4b68e08986a915be8d17e79387c5ce320db55b96a012debc2e617"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "neuroinflammation",
      "id": "81fb27d30ab96c3501b38fdf7671e85423e8e196d875c6c367e2f54a3c95df7bf044cdbcb87a67091de83cbb4dc42e68cc385bd5e955f18d77c4082b02409b26"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "neurotoxicity",
      "id": "6b7106f4208714e93b995a2819bc36b00466f0ca04b7037093197acad869ef56ae1f9e6b2ceb0b83e8a93a28decaf6a762f8bf2b782d9c7afc649a3317516d37"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "olomoucine",
      "id": "a0c5e5b382cab52f62a657e9fa1f3283a502442f1c415ce1d5f491d25cc6d712a4e76e5e45647ddd3e0d7bcc87011a2282a0c586ede62abac80e24c876f9f159"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "oxazolidinedione",
      "id": "8094c43f34e1e5553625c8e50233053920acded7cefe617f5ea15a85ebaedbce9749ac1907d5590d4dfde2b0aa00236e4bdae4fa45b1646538b4b8ffb4f275a5"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "pretangles",
      "id": "82ed31423f81cad1748e2f7a16b9461807d9401881de4ddec0756f537a6ce0f7fe9877f6f38c94ed3dc43ae275d5943b7aa413e13689f0b98be0f1239ed0edfb"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "sudoxicam",
      "id": "dcf26437423cbcd0fe7354fc4c7b128e2ca84fdfd577cb7d9ad31112fc42890fefd40bc974f5c3cdf4291fa155f9184a9905acc27d818b16d3e3a2839ccaf76d"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "thiohydantoin",
      "id": "f535947e9cc27fd4ae63b9623f773a97dddc9396d3b802b996226bdb85157e3d47dcb97b41be16bc82ff3565e4637d6efa459f8c4f4123ef6829407f598e879a"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "thioxooxazolidine",
      "id": "72c6ecfe87525eed5c6b7e73478b37d037c727c7f8d1e10047b703f6e9f76b6608ed13bc973e715de0ca400f7cfb83839984b142dd97c189a33546b11b0806d8"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "tideglusib",
      "id": "3e24eb503be31c0d6d8a078ee54c8b93f5712c356bf969db9e5ce4ce93340808f274b0d24820aae72158473c180bec2512af04b61f86cdd27759e3cb936da634"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Dendritic Spines",
      "id": "9f5512cad4083a1d70bd15dfad45bd5889a3d7cc7d4a7b20effbf451a5db30df56867272bc3f9925642c92b2142969d33d0ea0f1e90dc59c2281e2178154651a"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Neuropil Threads",
      "id": "2674bac52da2313938bd01c8084dfe37febb56df5167432b356a373831e12c13e7969e7778ff158687e9280ce94b2c53fe1403bcc9d38c2cadb42f0f65f18e79"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Receptors, N-Methyl-D-Aspartate",
      "id": "bc0c849274509856f0839b39c84ee4c4d06be886e9c4a160c019e566da4f7b7da0f773b5326d9d72ab53f350fa5ff3371b3cf66ae89e844579e4eb6102565963"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Brain",
      "id": "9175288a6c7b6ef9b1d5b27898a9df1220476f7b15df878df555ca1003f86131d9293d04e396275cf70eb020d39ca118c7325524f243d1b6cdd28f86130be6f8"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Hippocampus",
      "id": "caff813aaa3f73ff030fa368884d30438c42f1f22aa2b372a08646bda846d5a6ee94d85bb4de2153aaa55ba41bd82a361353793ade6e39bccfe43c75f5a95750"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Neurons",
      "id": "130131072f276d163b9e361a4ca4814f1d254907d297db502ccb4f6e75dff10db1f2b384bb435c9b46e91310d585aea1db3108e00905a31bb1388ccda1f0c643"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Neuropil",
      "id": "186bc996a6a13f0bd5e8d61d989d4079eb2419c4b94a149532586d89d72001d642ebbe54b051ea1da13df175eab4f7ee96d4413e1d903e14a92baf9fef2e68a9"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "Wnt signaling pathway",
      "id": "bb7db3c69b4ba4b1b094d58c8bc59fac8c0b58b50dafdb59d4a6ed1e5b8cd8689f56bcfb6c0d6c9c12035693d75345e4fb5c95ab311a8673bd4fed15585c67c8"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "actin filament polymerization",
      "id": "0504af10703db0820e218db3c64b2815cc2bdff1e2adf121b143d4020ea5ebb1311bbd6f5e75fcb1f4e44b5cb7803bbe57e7c2c683a769577623120eda102f5f"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "amyloid fibril formation",
      "id": "2ab79747852690e9d610f625febe3335f8c5c48e496658b8ffe64499154b71c1e9026753ad4fa3c4c18997f0d75e69ec1333b17a7c70fa05441a5e789360b0cb"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "anterograde axonal transport",
      "id": "3e2a461cd655539ec9974778be985c658ff333fb9fa15a9f30d1c37ab22b3e9026879c53df6ea417eeb9f5e4378442b8d4a592cd24b9f15164cbf979e7988fcd"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "apoptotic process",
      "id": "1c5172472cbecf29eeb8e86a4cac2d13123fe572356f00e2f98302422560bbda2854e3b1f8fdf85396655393cf5ddb42e0db210c3d3fc146fa358cc8d0ed0254"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "axonal transport",
      "id": "05b46e2a47c4835f765deb7eb33b970b7abbb53b690b7881e2beda6bc739337253a12aaafa51ebf63ed9f7ad7f09bcd7f5ce4fda7373ed3f4f0eadedaf2c14d0"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "canonical glycolysis",
      "id": "eb1a70fecc7fafcd1bfcea306ab1405b356c8bcfce4130acb5e813b479b4329fa1c1c35487e0efc24f0d0f2ce1bd83e44ca34376f66ae4c876ae0b50d557aa24"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "cell-cell signaling via exosome",
      "id": "2e5b65d487c87133cf0698fb05bb2be68ff730599364f9b42166dc21d8c9224cbe00b630b63a61114fba05a676b3cf9780009f2de2dfe9f67be19c0a2248876b"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "cellular metabolic process",
      "id": "b385c80318acaa7d2bbbe11d5a18dcc1d4ade6a036d36f4fad9e9b0fbacc5a575b91a245bd4f35d7c73a2573d688a0c77b7eb25c46ddda938ffb52cddb75bc96"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "cellular senescence",
      "id": "773026c747082fe2bb1dd4d7fe68db9d7321caede3d47c421791f48b892d9732d752357d28d757e63303a0eb31bf5abcba3069bf4de640a872cf7c89c7b425bd"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "clathrin-dependent endocytosis",
      "id": "7639b43ef23b19d79d11020dab549264613ef3e5db7a2daf76d40b01e5234260732f8668affc59b84fc039419743e8e7ae81d1d7b66f55b4c1f43c261aae425e"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "dendrite arborization",
      "id": "77116d97f4285846de0f8975d608babcaa9a2913938e291e97c3342960fb0a46e8331e9d634b8ed71664c575c981582dca23a0ca08e54ca0aef61a7e612ba5ca"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "dendritic spine development",
      "id": "029b138afe9ee5eb8c4d1d98c10cde4b034ab06ae2de4d7d0dc194f0d892b910b1c7b9811560539f323c4bbb52253a9eb2d95951a727c0bff88662bbabd9cef6"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "glucose transmembrane transport",
      "id": "ae5d94e8371b331b049e64553165ff725737390f49ffc8cb3d749e5db23a5b61b7e4740a37760f05b877bd4e7055e34ee28114faf40f17a3d2caa9288e0c42ee"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "inflammatory response",
      "id": "422dfc2db00b1d942862470cbabe1e8312bf97b25050190db5ae19636adae95f4fa18c512574526825bd377b16c2278899435eb759e951ba850ad476e14f9900"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "microtubule depolymerization",
      "id": "cbc62aa7f87ffe4350701ec23c8ddf1148abf26bacc57be664ea8437f6626d6e51e860b0f28c5ae7aadf04cd58501bdc8cc60156643ce38b9fbc927d1522a6d5"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "microtubule polymerization",
      "id": "96a7816f8b02933054d24cccfe2f73fb8beb845049ee361c408761f17dbfda8aa44e9e83f8ee54cf90d9984d0676e2208acff137deee1e66e4c3c9bac2f35dcd"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "necrotic cell death",
      "id": "4ff5c7923d8501e9cbcc673b2444b19f08371237b043b38515376047e546f7e755374a2c7de8957f06343b202a9fce9ff281405069b2420ee0ea257b75926920"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "neurofibrillary tangle assembly",
      "id": "ddb806442eeaf16c4573d02545b21939cd739066593dc5fde6d82f5d5b7bad5b274420d38fb8d36b39d6ab68d6de55b663d56fca339fd516217d141e702e5815"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "neuron apoptotic process",
      "id": "b9dabb1ef70e6265bcd2b24c2109961235bb35268bf9525a7ce468bd3244274273d156fc8c743c001d71896f7e3fc4dd9cf8a2e06ecf33e2f55fba778d2fa6d7"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "neuron death",
      "id": "ad7c90f2bc746a5118759fd1c8857478c02207d574a26faaac9d6e4d6fa4661d8d87446139db0024a4011aae26027d3cabdfba663aec0ac0a8242868efb81dcd"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "neuron development",
      "id": "27cf3562f5b40a2912e2eda4e059696dea353a1f473f4a65628b30fe6b5413984892973166789895ac85f1db5ce5be08dfe0abd7884b7b75c1d5f2049b95cec8"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "neuron differentiation",
      "id": "364018ff10b13aaa6d5c043c9ec30cf4471bd288a36a9e4ffb40bdd49e025a79c4190f7bd128cdd9bc24c4cf452053b8c675f3a5d8794baafde8fdfba90e129f"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "neuron-neuron synaptic transmission",
      "id": "924f2cd36f31b5a64a5ae17ac693b7f97cc486552d7aca6cb0034fa45ce51a6f8188d4baa69a15905b072f5bff825ada6572a23c21013c92fbc1919da5ecfab2"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "tubulin complex assembly",
      "id": "6f0669952c4b7e7a0970c1be7ba291acf5805a584a0359cb504bfc666ecee115a2c5f765102936f026e36c56c575414e8ec75ce2f8408e5e672ff413af584415"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "aging",
      "id": "e656a7a9b8877eca28efc8bcece0149b9f17b643e48c2ae605fb3977fb925968220ed9a29a1649919bd2bdbfd43e6cd082182ead002a6eb840cd3f1e4f57d213"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "autophagy",
      "id": "f1a3202be460e565f65c1445ee061e99f63cc05f9ab70c5d4d8d93ba180d6a94f65cb8d1ac6c5ba53c0a4d2e153db32135e6a0bffcfdfd4d84e6727594a70b0a"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "learning",
      "id": "24fec79fe31de63921d3028dd6ce5e335372d8d221877724830f05136d6c879daa7585768231b87272f0ebb8a7f6038f1aabb8785a626cca0c95b33018cc1633"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "macroautophagy",
      "id": "568e5f70e05a1543c9a1d54019c461ab0802ff3556801ad06f2231e0687a80f2cbd21d12f808f5d72752f7cc8c484e0b32d830256321af323cfd08b1b63cc765"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "macropinocytosis",
      "id": "330dd34dae8d3c8832449c4d8b2519f2616096444061fc6d817cf07335c17f0de0c90747636816c810cbed08e2173d202e7b1c511832695ed5589181c0e9fd68"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "memory",
      "id": "87795d00588bdf77d28229ad379d58f00922f6339902a803d0672cc15e669269f8fe50785b2851e1e82046f4e1e49920534ec68c0b6911bea5a1b838dbc999cd"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "HBP",
      "name": "Tau aggregates",
      "id": "f2329dcf44005ddb4d8bd0cc60d3ba077a39d8b35211d3bd147fc5b1f82b4034ccc7a5606c8a7063f78b73e1b948ce8adadf08847080fd9370a63d72c2da2fcd"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "Body Mass Index",
      "id": "1770031420554e910229eb1471c9ed2502d6cb3c3d95fe78b33ee3492716d7cd369dd5069d95533c815dc1e2f12014a6394e4efccf108145892ed8ae34e3ff9a"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "Hot Temperature",
      "id": "e2fdd0bcaae16da3a0744518cfdb3cdfe63c64465dbbb8fc6a28da0848b132099b6951f0b0745f864bef44ef0e19d0975a512ea5fab410826271489dc20df5b5"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "Long-Term Potentiation",
      "id": "8fd3ed77e808eb724f4d4d35df48944d4a4adb70edfcf0f359766ac280c4a7fc9b47dd99814024ad92c576dd92f48e8bf052f04b303ba1c95ed51052e4a5ada9"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "Oxidative Stress",
      "id": "32bd3ab5e8a3a26be3209856c88741f0f0e2dff98d2587599a6a21b0f4793c5d8feb1194ea2166cf3cece076e7095530b116270e6655bc8feb35a437fda42cf6"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "Protein Conformation, alpha-Helical",
      "id": "9198cb2264005aa6de3a7334d81176b5b584f9dfc61a65afb796e91126011b8013af0e8fa39af233b0b95630ed202f3232dc7fd7cc969ad5c38cf730e8c8e614"
    },
    {
      "function": "Complex",
      "namespace": "GO",
      "name": "AMPA glutamate receptor complex",
      "id": "77687682f76339eb92f842bfa0781603ec4729e19f1b62ccefdaa6ff565ce7ae2a51575eed4b9d04b3aa75a7d25e350bc5c451d697406fb8a12dddf6f85e791f"
    },
    {
      "function": "Complex",
      "namespace": "GO",
      "name": "L-type voltage-gated calcium channel complex",
      "id": "71e300d8546bfb2c7252b935a6ff49a174a3a9b7aa02ddfe56c19826a43df275238e995fe96feb8fe544c1c26644614c42ec42b8ceecce3d2ae6207cbca9a943"
    },
    {
      "function": "Complex",
      "namespace": "GO",
      "name": "NMDA selective glutamate receptor complex",
      "id": "ff601ce817441d6f73341860ac4591acd9e7e635f5a1f73b2fd67f9b1457531324d68b76030e4b8ee15f12278e4b397e768aceafbf797bf7f58c91e07d045207"
    },
    {
      "function": "Complex",
      "namespace": "GO",
      "name": "Pick body",
      "id": "9c5d3ca57357e60048354eaffd134a2872126b0004b4d1a78b1f7ab20d3d2b1d73445c6a3d4cdc9c6f0dcb0925e7cf91abddff7902c498b7b5bd450f089c78be"
    },
    {
      "function": "Complex",
      "namespace": "GO",
      "name": "endoplasmic reticulum",
      "id": "ea1f557f82d2ca41bcd0c4fbf6823a9f2e0da47807dd7773cdb8448ea3fe6171f3dcd4752e0044517b369f30d2b04044b091d88d0e656d4943ab49af915b872d"
    },
    {
      "function": "Complex",
      "namespace": "GO",
      "name": "neurofibrillary tangle",
      "id": "83563b0bf7b4e8223bab3bc7bfc5d3f34eef173b06c17dc9313fe7f786eebd3eda569f012c7293bdcece2a95a9c825fee6f7643ff2c31525f6806be2449fbdcb"
    },
    {
      "function": "Complex",
      "namespace": "GO",
      "name": "proteasome complex",
      "id": "5deb6bcfdcfa66f95c4979205b8144cf23a26c8da492c2d4b71750a7f8e440a3d40a37452d67ccbdccfba2bd5cea7bf1bbba3d66e18875bae3fd8abd8d3d68f4"
    },
    {
      "function": "Complex",
      "namespace": "GO",
      "name": "protein phosphatase type 2A complex",
      "id": "052c9f5cf99d0c5c2e8b92b4b64bc3bd8f6ef3ea6ee659342b48b1d99644fa41f03b2c5c8519e63b12f671cbd835982cd3887c7e54fdfe3ef915a1477a60a50b"
    },
    {
      "function": "Complex",
      "namespace": "GO",
      "name": "respiratory chain complex I",
      "id": "e9472ae2cab1efe98e798c350785a71a5def60f4b5286f065d4775e017cfe95073ebf67eab42960b24991d6717178d6b0c1f9c6edb1e873f8f01cbeb042b2515"
    },
    {
      "function": "Complex",
      "namespace": "GO",
      "name": "tubulin complex",
      "id": "f618178fd46029e57d801459ce09e17907a2d566094b7f8dd4ff98faaf3de150c4118b96f7b36e71f49cf77e1bf6425f775ca94adb9697c0e208ccf633110294"
    },
    {
      "function": "Complex",
      "namespace": "GO",
      "name": "ubiquitin ligase complex",
      "id": "56b7e3898b32348f69aa8c9da7c26f2bef9d7835c4204624bfe206eb090ffbd777c2d1324fa8a8285b1c86927afcb39bcc70440caee849d093bb70cabe0ccdd2"
    },
    {
      "function": "Complex",
      "namespace": "GO",
      "name": "axon",
      "id": "7308516a8780d50c14c3e1022732825363d997dbf3d2f9c30bf1976f3b1cd2f2953381b216c757ce80ae33f5fc295dde5d40e9e28e178a0105df0b72734c1feb"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "(-)-epicatechin",
          "id": "d84a61f3321754ed2192bfcedff07bbeb8f616861367d084d76e9f7ecaf4150a1fb5b9776efe01b54568433e129dffe8797961905dd92dffdb0a9c4a531c9b7a"
        },
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "acrolein",
          "id": "98b0b858026915ca49dfe1a8f6f15eab84a462a46c99dd0a4b2a250c597080fef1cea20a51a1322fc49c82ddecdc3818b710ceb86ff64895cd97595038ce98d0"
        }
      ],
      "id": "e93094bcee28fad24c03fc4376edaec9e45480c8bbdb2463c8fad02ff32f5a825b96ce997ab703124e034923de6659fc15238dc20ee65680ac9ed9e43bb38ee6"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "harmine",
          "id": "88eb8890bb924034af9c7b43b3a093fad2ec7cb49b84422b53a6fc172dba64001805d2a74a882a668c2c39d0d9fcc5141b28b5b50423c3a9d37a71253b0b401b"
        },
        {
          "function": "Gene",
          "namespace": "HGNC",
          "name": "DYRK1A",
          "id": "9a6e290d12be2d0d5e399f4748070833eab7da81e5600eeab10f3ba569185ea682fcb90d4fdd48a8b122663f2c31061d65ec455adb72867fb447a12385d1dd73"
        }
      ],
      "id": "f0ec424a6bcbe9910ff6154983b8a7473d0a8e7750e1b0b97a169cdf2ee532ce186f572e0659b9f8e324f0ef34c867f5fe1637bb6214308891b77b61e9fbfecf"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "heparin",
          "id": "4374b8548ac69557a1b3cea92dd62e05515db3c3e3d7fd5ccab0175e73fe27191d80062cb46672a453ad02f3598f015b641d367cbb9e3e042312dbcab159a33d"
        },
        {
          "function": "Protein",
          "namespace": "HBP",
          "name": "Tau aggregates",
          "id": "1c9d48fe854c1832b8539731374dc5bf3dc2079c9e5fb4e074524c6557c9d37042d9cd5ea71ca88458e22e15fd3f713284ef876909910dc47484812b0a150983"
        }
      ],
      "id": "bcc057cd95fd2d73728653050655a8f7ffddffe23edd39441f4a6e392227e138f36981edce4ad502211bbc570091953ad0a2d7c260971511909f2781019ee3d1"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Gene",
          "namespace": "MIRBASE",
          "name": "rno-mir-195",
          "id": "3abe1afd5d284bd87679683bd9e8b80120eb734db591380ee21cc804345aef64498a8854b6b714b92cb071bbcd6634ac71784e0c9cadcb5844c2960bdda8e923"
        },
        {
          "function": "Protein",
          "namespace": "FPLX",
          "name": "NFkappaB",
          "id": "a76f3010d13c4b506ba95e6e6bef897dc400ea1bad5f8288ce4b084f2b57f9e7aa59f5146eff656ed56a6d2077d5907c41cbd4539f26d63411b79ffe7179e54a"
        }
      ],
      "id": "9bf38fb40c723d2cd7e1bf814d5ff752d0eb3eafa06392ae7ff47063d7dd5d6219a0b79c6731d0d9934eb19363689e4434476a9ee7c4522d618dcf33330c32b7"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Gene",
          "namespace": "RGD",
          "name": "Cdk5r1",
          "id": "e43c56f1fa095c561b322a6978f02b958fe9681d09771aa5f0a7c5daf1096c911067c432886741cfbe5559d4b349c931824af7e7a0e08cf86b10dad35c124e6f"
        },
        {
          "function": "miRNA",
          "namespace": "MIRBASE",
          "name": "rno-mir-195",
          "id": "f236af56a802ae2461edc4a961b4b625735112a7fa5e73f81044e31aa15f17d0aaa08634e6896d48935b242b560f0874e1d4817e322b0dc1089ed7445ad121b8"
        }
      ],
      "id": "2a61a570525691dd363ea8bf91a6400bb6d81d00b7fc4eeddd9e202d0b86c974ee4b9dcb6c802f42d0aea29db536d80b8470e92d13ae9e90d51963badeac1dea"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "FPLX",
          "name": "CEBP",
          "id": "bfea12e0f7e707c218765210859997c93d47f8bf54529c928786707b981e45932796250ec66a2de836353af17462d9a812c4710231935c217a6d640d7b6ea1c1"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "SUMO1",
          "id": "1e1844dc2cd090887d357b2e8c7ba537a86b2e799968b043145ec3044cd4d5d78eb341878421b15fa34602b1ca0c7d9b08a12806e3fd114cd82806ec54cea6b3"
        }
      ],
      "id": "1f59c057110c15c544bda012948210b85787b2cd319849c3c37b7648bf9605404febf4b7a557dc038a8178bee629ae2047d70a93263a3f2b84779579821b34c6"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "FPLX",
          "name": "PPP2",
          "id": "a9377307576389f08c186ac62c6f48293be2fe1495d38cb53c33f9185f3625cb580b310ee4f6d15c636acf1f460f4b54f0dc8c94808295084b9484f709c91fdd"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "MAPT",
          "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1"
        }
      ],
      "id": "79aa983460cb57b7dda5f4a3e58eb0734dae8f8fad4ca7576262fe7518213f9eca6b82af2b1389e5f7e8e97e4006d4a524e094b4bee1b6bf1ecfd6e48ff42808"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "ARHGEF2",
          "id": "aae94ad4efcd06f711726936ef51281e86831fdf9454973ba33e3a9c97d5819f285585dcb6e97d5e5dd767196e1bb102a653aecfdae5b2d483fd671f61d039a5"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "RHOA",
          "id": "29c25652678fc59b247c44fbb9f46b7b3854f81f5e6693c4a27f6dd2333d57474cd0a7e8d4e35d9b3361b99884cf7e4555764bed72320d0c5fe9ac8880a443d7"
        }
      ],
      "id": "39d1e6c1b3fa11eba45c96975a413898df567bf1d9fc3693801cfcdd6c609f25d5382c9cc91985d1e4cb324e2e7bce5e90b8a68bc7ef97645d8149666b229eae"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "BTRC",
          "id": "88f8adb07e4a8a5e450d264f17f555bd6bf90dfa583a4645139408b6ecd2f277e790f07a934265e04bb7be15b5fafac952e2dc8c31705264c3124b5909698f4b"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CUL1",
          "id": "b8998472147cc12d4718c12b635b8bb419df17e80b30d3e6ffdafb179ad4d834483fbdbbb779c6a81f1024d1ab6e00d28b2da76141a6e35d29d5d3e614ea2579"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "NFE2L2",
          "variants": [
            {
              "kind": "pmod",
              "identifier": {
                "namespace": "bel",
                "name": "Ph"
              }
            }
          ],
          "id": "4aa3820836653756d322f394a9033f1b7d649c765972e4653e7c51ecd6ef8e03c6ddc54224fd917491bfd34f251746916480f76c1aeb5d3d7ea7bca3b19b9668"
        }
      ],
      "id": "23d8fa006b59995d8a50b2e7f811bb2bdb3429c7f9673de7dbf2100ff16c8a71860a536725d2f478c73a5f14bda258ae7d19b5ad08390bc0f85f8a88db060738"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CDK5",
          "id": "a85beb5b2b9417fabbbcc2135b9533cb0766b38688caf02242632843ae455bad332fb625d6e8296ff77b40e841485a56854fc14e300552425d596e8a8e70fd3f"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CDK5R1",
          "id": "0207787ec1a245b4edc4d61e093cfdf729180ecde8b3c7ae6644ca38fc0a28cb03b727dba6caaf192b4a98594148ceee9ff9e34195a7f8915ee6f683b8a08526"
        }
      ],
      "id": "f4c257e967616f0f74693d60486361c7668ea8db16385c3e7dd5002889a12e3cdeaf9ebf5d1117a23aecf4b6e93d1817024b36ec26478a5d4212822cef5e88b3"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CDK5",
          "id": "a85beb5b2b9417fabbbcc2135b9533cb0766b38688caf02242632843ae455bad332fb625d6e8296ff77b40e841485a56854fc14e300552425d596e8a8e70fd3f"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "MAPT",
          "variants": [
            {
              "kind": "pmod",
              "identifier": {
                "namespace": "bel",
                "name": "Ph"
              },
              "code": "Ser",
              "pos": 202
            }
          ],
          "id": "49b56446b699c749fbb01c4560254bbf621f44bd52a02cb74e212fb0ef1b9b1616a31cfe6ca06023fee3689ef552a3e8fe71211987ebad4180c2d78535f4ad7a"
        }
      ],
      "id": "2c557434654268472f2d0a780e143ac8719313a6beccd0e2806f7641a44be71b36a6e20984c2f3ab6d04801ff5b25d7330da5f0f086accd439fca4166c915d5f"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CDK5",
          "id": "a85beb5b2b9417fabbbcc2135b9533cb0766b38688caf02242632843ae455bad332fb625d6e8296ff77b40e841485a56854fc14e300552425d596e8a8e70fd3f"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "MAPT",
          "variants": [
            {
              "kind": "pmod",
              "identifier": {
                "namespace": "bel",
                "name": "Ph"
              },
              "code": "Ser",
              "pos": 396
            }
          ],
          "id": "233ebce30d7505cee42acc956f9d268e5b725e14853bd56fab3b87a93a4e0c8141a6fdec062d10e9c4924f6e13a61184600872c2f5080656e3ca27227eb4cb93"
        }
      ],
      "id": "91afd2772ad68decda74c18795c8335d7fcb26c86899d2e78752a212b90fa64ddf07d03131e31a47d44cf4c91e1a19bfc82eb6263baf3623174dff1dba85b114"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CDK5",
          "id": "a85beb5b2b9417fabbbcc2135b9533cb0766b38688caf02242632843ae455bad332fb625d6e8296ff77b40e841485a56854fc14e300552425d596e8a8e70fd3f"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "MAPT",
          "variants": [
            {
              "kind": "pmod",
              "identifier": {
                "namespace": "bel",
                "name": "Ph"
              },
              "code": "Ser",
              "pos": 404
            }
          ],
          "id": "a448f901ddc919f32d50fa5284355b4eb4ed52e9ebf8705052086706d728d8ebef0cc66616b7fbfda3aeffd49db6e41134fb39996aa9b996a73bce331de95767"
        }
      ],
      "id": "f9ccbb4594b3be2ee1fc804701c59b97dba109cc2c9e5c059625cb2f4b0ec64d92212b8bd24411be2715e3eaf16b6f4a55535077930176d1881767ef9a925388"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CDK5",
          "id": "a85beb5b2b9417fabbbcc2135b9533cb0766b38688caf02242632843ae455bad332fb625d6e8296ff77b40e841485a56854fc14e300552425d596e8a8e70fd3f"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "MAPT",
          "variants": [
            {
              "kind": "pmod",
              "identifier": {
                "namespace": "bel",
                "name": "Ph"
              },
              "code": "Thr",
              "pos": 212
            }
          ],
          "id": "d10f7602e71867be5adc0f8e0dc989e83163432837ca2c5869ab7d763dad95b87dc4ebcacb9c440ac7c30a31e1b7f42adbacd9bac529384743ab44360f7dc34e"
        }
      ],
      "id": "acf5d610041ea8286504c48dc7c7a05852c2c895bfe05679d1935030f84ed500267993e61e728df917eb51a94da3ab1da54e4149ac20c2d211cdc0b3d0d8248c"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CDK5",
          "id": "a85beb5b2b9417fabbbcc2135b9533cb0766b38688caf02242632843ae455bad332fb625d6e8296ff77b40e841485a56854fc14e300552425d596e8a8e70fd3f"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "MAPT",
          "variants": [
            {
              "kind": "pmod",
              "identifier": {
                "namespace": "bel",
                "name": "Ph"
              },
              "code": "Thr",
              "pos": 217
            }
          ],
          "id": "b4d5af93a5669d322815fe554157d6084d3e61d0d7575b2364599e24718be87f316e289a0c882f7c5316ffdbc939554716d4349e10d245154edcc6ff90e53b13"
        }
      ],
      "id": "d68db9b01b417c2184955c62832ecd3e97e03d0e0546cda3a4feb19856f5e3bc3519bad74e567c5367efb093ea02b9bfb91d0f48268f00192e5dd1198e48c9a0"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CEP164",
          "id": "08e76f094fdee2c02ab1e880d939dbba1736144b79a6d81699f1a49fce5f84f6005243c07b8395b0d655af3ff6b6a4c97a67b4f54524a0e222dec5de56ce967d"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "DVL3",
          "id": "1abbfa8fc8bf58a12adb0ea6bf7dc1d3ad4e303448696355bbfde2891c69fd769bfea1923a29b440f5b88a41f321f328af3df0718e2994ec5574a83aba36bbb2"
        }
      ],
      "id": "eea89439dc043c7309f13678b4a51848fd5c8d860c650f193a2c1254e37ccc8d72f253207923e59db0e3e690846547fd03001448215e216b7ebd1c769e101c28"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CRBN",
          "id": "2df0227940d72ce89db99b182e910bdc3356e79f6cfc0eeddb750c7cbe961600065365d7c375be5985a10859898d21708df485200e427103c8c6e6c6b2ff39f4"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CUL4A",
          "id": "cd2337f4ff7d39dca70363a2d6b62fd1d1920e2b201af27416503a8388da5a10f2cda976a5f66f603818c5a1d961ce2ff7b4c34f1d9a36e96d4162e64de350b4"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CUL4B",
          "id": "e3e857fd5c5ba254530870be70727cb3f3c028a4c889ed39e10048dc17eae355ca7f02fd9bd5f9d5ca2a35fc8226c94a8fffb1e82bedc7e8e2a8601847a9a0f9"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "DDB1",
          "id": "b755eecfaa18cb1aec8341ad003eafe0adcbdfc9d6c453ca7da453b3ddb965aa2a575f7af1ddf94e7ba89fa967a413d1699c99f40e8c5305c34acee4657a3817"
        }
      ],
      "id": "4682c2b7792ea9794ed7c1f11eb511d1a91a898c6c0809e04a9b8dad219723adf05921b8a16c0fdb3a6652d32b0226a0e9d3f1efa6aaf65b452425c67ffb210f"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CUL3",
          "id": "e3c87e99847e4fbcfcf4437274ab159f5ff2cc75c4cc22b660f5cbee86b20c08cee308b6fe8590788acf25c50a7dc0bd82927798d06746fa2f6fac8ba63bd9b8"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "KEAP1",
          "id": "ac5b90f683c70d7c98852200b82d97e1b9c6dadc08a979341fb205cb99aa201796fb24c5c1c2e69b24015d83c9aa6da9f6e2f257aadde2ba87accdb9f5366e7b"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "NFE2L2",
          "id": "f707e81d79f55da8c33a4f0fad8eda52a2960c3256f2cd831a5d51542d824e4ed26a18f97cebba93ca1b75239d492efaa0acefa07f5cb15dd98f75c9078ac249"
        }
      ],
      "id": "03d19f6488df91cf4dabce821dbdb91f38bf3f871268b5803430547d7b2e4bb57159e5658d5259f973111f277c752a42af846595e537f67f93d3f29c09e895dc"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "FYN",
          "id": "ecffd0427f2e321c9ed5143ca2510464c2fef5432457c332ee991bda79dbdd12ace6375208ee66760cc5b9b7990248651b41a370f16eb9459d2b8682cb0da86b"
        },
        {
          "function": "Protein",
          "namespace": "MGI",
          "name": "Mapt",
          "id": "7d94454106658b1e4190b417a419f7ccbab4b525157cd679cbb4da8a006b08c3819b0a360b692358b3f80ea2648890248be2aa7c97e1d59962dc6aa097560f2d"
        }
      ],
      "id": "cacae42bfccf6660720843f0734ae3891ee8ebe856ae166892c3d712cf854ee968dd105316b11b47589df20e2bb23ef2fa1c3212be7db781e65863fb60569860"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "MAPT",
          "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "TGM2",
          "id": "954461bfca0f13db007c13a48240c616213276a3e047bbdb8830adef53040c76c0b0d21fcfab6420d59481c73e2b1766cb737abf75aa921354d5d7a8830d17d8"
        }
      ],
      "id": "f597b3fc1120f5aaa9233b42cec3e17ed1bd3027785249c65c954d9d9435e4e687965bb0d3faaf9bb9a270aeb8837e12169df586e446c49369028dafe7cdf93a"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "MAPT",
          "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1"
        },
        {
          "function": "Protein",
          "namespace": "INTERPRO",
          "name": "Triosephosphate isomerase",
          "variants": [
            {
              "kind": "pmod",
              "identifier": {
                "namespace": "bel",
                "name": "NO"
              }
            }
          ],
          "id": "9084a52d47969f6c4df607304cf072f93519825b10368eb8bfe860aafa8043a2e485e74549fb86f806ca96d24cf7e7069e1037de2990dcc7fe9663c5b47b9f88"
        }
      ],
      "id": "1a822cb1a15d34c2a22914b6bdf4f99702e91e314a140ea3fee9372ed245c7e7d6ec7f7aa21fd90a31462277b615f265fe6592e6f6a14c1f735618f55119130d"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "MAPT",
          "variants": [
            {
              "kind": "pmod",
              "identifier": {
                "namespace": "bel",
                "name": "Ph"
              }
            }
          ],
          "id": "526bae251987f8c4f55f6e2451662fa55e087c57585beae7c389b020d73487c739834e9b8ec841783de6a5b5fb9df8b138e9eff4406a9ec5e606766575dcac0e"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "SMAD2",
          "id": "ac9eb6340da114bccc3be554fb1b60e05ad8a2d5ea0ed8e6071fca40d08c35057421eb77165117ab24cd8b2d03f168ccd7ab57f9c60e050758f697c37fea433e"
        }
      ],
      "id": "9f8cced36ab45dc2bfa8ecaa02959b96f098e7aeb605feddb69ef831880304adef3daa41fcabca971b3915c51e7835e727b34caf97f04a2e7dab3d0e181210d6"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "MGI",
          "name": "Dapk1",
          "id": "9f6471994bf7d5037d53141c3bf0bd5c257b0a513a0a5f0431d5db8ddcb6320c8f4638359a1a00b58f9ffaafcd1b17649a8e454a1c4c9f4d079dd31478f55e3f"
        },
        {
          "function": "Protein",
          "namespace": "MGI",
          "name": "Mapt",
          "id": "7d94454106658b1e4190b417a419f7ccbab4b525157cd679cbb4da8a006b08c3819b0a360b692358b3f80ea2648890248be2aa7c97e1d59962dc6aa097560f2d"
        }
      ],
      "id": "b3cd9fc59b35a3421d647b4b85265a5600c65dbc17d18a921f6ce6e62ead416a3991b0418128d72fe41682fbae14d96ad503bff5425babbc08ab320f91a84b1a"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "MGI",
          "name": "Dcaf1",
          "id": "59b84bc42074f8bb1e399325b748b4615f4b4fdf12e2dfbfcdf217f1076a9eb3ad8d06c4a0538ce828bf96fb6282c3776eb9411f88ed77f1028b0727a9e4a775"
        },
        {
          "function": "Protein",
          "namespace": "MGI",
          "name": "Dyrk1a",
          "id": "2e7b2037076194038fbe01ac55b538f712182e5d06da9877c6d3f8e6d1e8db2e03bc2bb55d1bc1fc6c5431ad46716ad6fd44e090c9d09ae0552da0297a4447b0"
        }
      ],
      "id": "0e4e393c6c2d1da9d0d848402b26c663bd5ae2d9cfed46500ea80a59b85742ab1c3c6f050edca1a1af60c829c8425c1bacbd1773811f9616765cb4c853accbfe"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "MGI",
          "name": "Dpysl2",
          "variants": [
            {
              "kind": "pmod",
              "identifier": {
                "namespace": "bel",
                "name": "Ph"
              }
            }
          ],
          "id": "6a0c7b3a61d4846bbeae7c93eafeac42a6e3138c2966c8f4b236efecf20f4732c927ee70b5a543480f5fb91c18faf1fa177544066647e711a47ee42b3f63d45a"
        },
        {
          "function": "Protein",
          "namespace": "MGI",
          "name": "Mapt",
          "id": "7d94454106658b1e4190b417a419f7ccbab4b525157cd679cbb4da8a006b08c3819b0a360b692358b3f80ea2648890248be2aa7c97e1d59962dc6aa097560f2d"
        },
        {
          "function": "Protein",
          "namespace": "MGI",
          "name": "Wasf1",
          "variants": [
            {
              "kind": "pmod",
              "identifier": {
                "namespace": "bel",
                "name": "Ph"
              }
            }
          ],
          "id": "bd366fffd010b0efe59dc9f90a4a38b9448441d17a0dd08c4b9ea8f1be66445e387eec5817adf9947dba1111d2e16868c118f4f2e47879b7b1c52f6ebbe86bcf"
        }
      ],
      "id": "ad38a9d554620597a95a7a7d19846fa12598d2df694695258c690d2ce947fbe384791927468541b9de9cb96f3f0ec8c38929513d37143873d729275b6a9bc6db"
    },
    {
      "function": "Composite",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "L-ascorbic acid",
          "id": "057ef21ebfcc98e027461b955a40961d4baf6b79bed3a6d86500918dc83deaf34d851edaa9df6a0d9b809b957d2aef5154be8230798352ac3fc93b80ac153f5b"
        },
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "Trolox",
          "id": "6d52e2aabbd1866ec8f3c99223dc0b27a112218407456b32d19f58ed39b1630ec3550888c5696b919a27a8046985e89f18c2655b81e100f83e870cc1b69e2b22"
        },
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "glutathione",
          "id": "a75431c9ce7065ec867a86011c2371dd04187869fb2f21220cb8b8686a5a63863e8f98d2e96f23b6133fe39f75169f6798972c8cae9fa7bcb3af79562e948af1"
        }
      ],
      "id": "0762ee4db65d53d0faa7a4eee72c59b6500bfd22bfaa585117e3709fba50ec3276580a41678f6480fdda494ad884d16f1c001cd33f2860b19151a528dbfd3573"
    },
    {
      "function": "Composite",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "hydrogen peroxide",
          "id": "4d65b5d180890b98afe0bc10614fde44ee750b2d1af6fdd925fc31ead7ee9a7248bda3d67c52aebf220b8c048d999f2d878a97a70b0e027a7294cbd3c7bf61bf"
        },
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "sodium azide",
          "id": "07cf3d3c9ebb85dc2cece29a80fc3b6311b76ddd2fd77d957ba1a681e84d28dbf32a765c00d0fe00a3aa49209b291aecd868522afd1a24b503e4ef275cc54161"
        }
      ],
      "id": "4f7b1d1f3a3fb6d583e6376e662d2fb6ad6dcd5ed041d27ac7d4ebba5931c7e98fe69748db014ef91d1e620442adc0fe85c488cc24394246a949514d03556e6d"
    },
    {
      "function": "Composite",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "homocysteine",
          "id": "7a15d69a1f5e63ea5883fdd1570ec1c58c8f891e16cc845d39de3cac7cea8f12c8d936c03cebb64958c2adc3df7c2e36ead35db704f152e5abc1825a20872da3"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "BDNF",
          "id": "5bbeeb6a1045d125bd5495fbff1f4831c8697d0b4f9b77ff9f1127fd8bcf4d96eda74adab4e84332c6c9ba5bb97e102771278841e902a126ddbb438fddf7b8be"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "DYRK1A",
          "id": "8b164807125f35b205166f36de5783322fc6853c6256711e55eaeb05fd14ffd86288750b3063d01d8bd55376a17dd78d0a7b01fc8b840cb34edbff1b329d72d3"
        }
      ],
      "id": "6863832e4eaef9911b6a1e62e4ae917c2e8bbd2e5158b56b90f98487323bba4d8255e484e33ae5a211526948e291db1ceec0e1a2bb2d784f0bd3c2f6f85742ee"
    },
    {
      "function": "Composite",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "MAPT",
          "variants": [
            {
              "kind": "pmod",
              "identifier": {
                "namespace": "bel",
                "name": "Ac"
              },
              "code": "Lys",
              "pos": 163
            }
          ],
          "id": "924504e9d7736e6c101c69e8a2261f17d7d97c71b3d4da275e041d73e8ad108278c367e68b262b052e0d0d094b60db33c42030774355866c0c7cf719093d0eeb"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "MAPT",
          "variants": [
            {
              "kind": "pmod",
              "identifier": {
                "namespace": "bel",
                "name": "Ac"
              },
              "code": "Lys",
              "pos": 280
            }
          ],
          "id": "b3327a6bc072250a5fef544daab0adc8ed547e58a4c383a553009a015e532a34fda6016098f9ee83a94b315f11839b828a120df0ed08f97a336886c88160ae67"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "MAPT",
          "variants": [
            {
              "kind": "pmod",
              "identifier": {
                "namespace": "bel",
                "name": "Ac"
              },
              "code": "Lys",
              "pos": 281
            }
          ],
          "id": "16f5587b2883e91281ed04533207788ad03b349f3eea2ce26d77e44869e98e8531b4dc0551c6dc5a052867fa18f996e8d1c01ac2170f3c7da637cf12963f8bee"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "MAPT",
          "variants": [
            {
              "kind": "pmod",
              "identifier": {
                "namespace": "bel",
                "name": "Ac"
              },
              "code": "Lys",
              "pos": 369
            }
          ],
          "id": "adcb21423be952f37e9362c05da0bb337a9f42816c78be70c10ba771e4e82debfae8c2a9797454d4cd3f306c6912d5b13154d84a9164e8e9b5c4cff86a55ea9f"
        }
      ],
      "id": "14a3aa5ebd9a80abbd60d2a854b814b2e50962b1d3dd79c6abf09f228202b77ba5d3d3f25f59d8345a2f1c95e111d9a72124e52284f5f381bec8576dee2532b5"
    },
    {
      "function": "Gene",
      "namespace": "DBSNP",
      "name": "rs10807287",
      "id": "59de829904958d60f0be80a7fffc3be2ad8805ca49abf93596599111015e54c1f08d5be13d18c3fb0555b8110058368f8e8668113c91c6a2d385af1bc3450dac"
    },
    {
      "function": "Gene",
      "namespace": "DBSNP",
      "name": "rs242557",
      "id": "955bf122a8496d813d5024d8714356b1ffeba74d753a332f0dc9a5498c7559b4c02f71d4370c68c837d38de0ff42a8194f3eb693188ce2455cf9fe2c6fc77f9f"
    },
    {
      "function": "Gene",
      "namespace": "DBSNP",
      "name": "rs2471738",
      "id": "815c406b9ec0a5defb0eedfa3a73b449a40bd714b4be0497fc08d844d4894d187a7828ec7f6341369c5e067fc0fd336695041e9f5040a86d6f10b60e35fa155b"
    },
    {
      "function": "Gene",
      "namespace": "DBSNP",
      "name": "rs2651206",
      "id": "e0b854199da0b1edcf965403e98263357ae4d3cb2608579744a03df7d34d51fad7f7f2d793728a96b9a21d0578165436439dece96312457d9e3593523952cc77"
    },
    {
      "function": "Gene",
      "namespace": "DBSNP",
      "name": "rs63750688",
      "id": "005df9e4bd0398c3b0b6e8daac4a905c4bd578b0dd4457e17de7c7bd49be3695e5669e7f0da07344f38ff7832c814c67bd4fbd667968e4108e808b9bdb0094da"
    },
    {
      "function": "Gene",
      "namespace": "DBSNP",
      "name": "rs63751438",
      "id": "24079d044b85d98052f149078dbee22fb85ead338a3c82b169d8e5bef6be2b699362bc4dd0655486c23fc1f2cea29013f32db325a0ad6d7369d9fcef67cad247"
    },
    {
      "function": "Gene",
      "namespace": "DBSNP",
      "name": "rs761059",
      "id": "feb70180dda5b870c1609be91374ba4498a3a6184fc4e57fe55e30d556ac1c8a41a0fea61a2f4b36f6537f4bb294dd3a6f72bee7118de36ff0a67e88ab9efe07"
    },
    {
      "function": "Gene",
      "namespace": "DBSNP",
      "name": "rs7764257",
      "id": "3c7065f1ac75fc673b39e187effa7e2f19a7ac489dfa11fd7c081bc5a667873f82a7abe77eb3cf5b8f9cb84418c82abdf8756db1625208b6149f133bf9e33b28"
    },
    {
      "function": "Gene",
      "namespace": "DBSNP",
      "name": "rs8052688",
      "id": "82ee295bfe37c3b91748675ddda51d9627d1874f330bb041d6ebb50ce440d2b64faa77f70443a9f45195aaf28f7deed9fa19f2499e67237b06182021922da8a3"
    },
    {
      "function": "Gene",
      "namespace": "DBSNP",
      "name": "rs8063",
      "id": "0d6808fbfefde20566f7a2dc3e8ab58c5d64e00140e50e91b150858fd27c58d55d2472f12faeebf0e8b7de949034ce43a4e641475087970e52de3313ee1f405e"
    },
    {
      "function": "Gene",
      "namespace": "HGNC",
      "name": "DYRK1A",
      "id": "9a6e290d12be2d0d5e399f4748070833eab7da81e5600eeab10f3ba569185ea682fcb90d4fdd48a8b122663f2c31061d65ec455adb72867fb447a12385d1dd73"
    },
    {
      "function": "Gene",
      "namespace": "HGNC",
      "name": "OGT",
      "id": "0c459c82d4d92f1a7a19163cac8968e491e6ab32a0401441dfa38b45854d71603e7fb2e9fb98c0648076a78daae9a2a7a97f6e23f71150e687970b8fbd44ab5f"
    },
    {
      "function": "Gene",
      "namespace": "HGNC",
      "name": "TTBK1",
      "id": "d3088ed8372a0d8f52bb7599eceb25c3b1b4303d815a9eb6daa4e3ef7a9a917eeaf42a1c98247426336c19eca626fcb64a09bec1a433910de4049580d09efb89"
    },
    {
      "function": "Gene",
      "namespace": "MIRBASE",
      "name": "rno-mir-195",
      "id": "3abe1afd5d284bd87679683bd9e8b80120eb734db591380ee21cc804345aef64498a8854b6b714b92cb071bbcd6634ac71784e0c9cadcb5844c2960bdda8e923"
    },
    {
      "function": "Gene",
      "namespace": "RGD",
      "name": "Cdk5r1",
      "id": "e43c56f1fa095c561b322a6978f02b958fe9681d09771aa5f0a7c5daf1096c911067c432886741cfbe5559d4b349c931824af7e7a0e08cf86b10dad35c124e6f"
    },
    {
      "function": "miRNA",
      "namespace": "MIRBASE",
      "name": "hsa-mir-125b-1",
      "id": "4f114b0287df8afe002e7e5b59eecf33db0f67946659d0867736528ca23b86eb465b90d3e084a979b803ce727a61b0bdae356e594a327d3dab10f45c5f112fb6"
    },
    {
      "function": "miRNA",
      "namespace": "MIRBASE",
      "name": "rno-mir-195",
      "id": "f236af56a802ae2461edc4a961b4b625735112a7fa5e73f81044e31aa15f17d0aaa08634e6896d48935b242b560f0874e1d4817e322b0dc1089ed7445ad121b8"
    },
    {
      "function": "Protein",
      "namespace": "ECCODE",
      "name": "1.14.13.39",
      "id": "a3b5ac90813c3b128d295f19c43c9e19ee8cc488a5c68d6acf984fd9dd819eeb60a7e027b85e663cf8b2068bdf61b7e02533042a2e1069eb0af7b58f9e7254b9"
    },
    {
      "function": "Protein",
      "namespace": "ECCODE",
      "name": "1.6.3.1",
      "id": "170eb1220bbd23d374396060c383108f1614bb3c27e5c955cc03c8f346de32dc8e7ef21b009ec324b530d3db13f889300879f6306f2bc914e5c3b2410b3a61c5"
    },
    {
      "function": "Protein",
      "namespace": "ECCODE",
      "name": "2.3.2.13",
      "id": "ea7cabf9ef664ebf3125c44cb2fecd93b2d350aa5662c84b143235d96ee52cc218ab9f5b3e58e14f67b097b00cead0576bdb41fdc88182cc141f13d5da83c8f9"
    },
    {
      "function": "Protein",
      "namespace": "ECCODE",
      "name": "2.3.2.27",
      "id": "e0acd400dd5cd493f989b9ab376b522488afce5c37eac529c728c94e06e69754a9b93cdd5ea6ce809d69e80b1bfcefcd3ae41b26a317d98ad7489683d79e9387"
    },
    {
      "function": "Protein",
      "namespace": "ECCODE",
      "name": "2.5.1.18",
      "id": "88451e2de62b539b89ad5b3edffa69d73d33aaf01dfddcb00fe3ba11d8b4da480595b4ca24d9b8b77710416d9c0f1d8467b1a2e90140549464817068c26588a4"
    },
    {
      "function": "Protein",
      "namespace": "ECCODE",
      "name": "2.7.11.26",
      "id": "b3cf0de758d97974ae90f20e43beb0813e96824f7f988cd995af33c566d8c78b2033a8ec6e98d2578a9ca56e88da49255373e09ddd0b5b17def47185170d2a07"
    },
    {
      "function": "Protein",
      "namespace": "ECCODE",
      "name": "3.1.1.89",
      "id": "6ff1992a7139e55636eec801763d708b119fa7a2585084457cac01e1d70def68eb9e70b5b3564df43176b4bc5e95885d92269aea67bd7a74784cce614a2aecbe"
    },
    {
      "function": "Protein",
      "namespace": "ECCODE",
      "name": "3.2.1.169",
      "id": "0373ffc60f7c4b06c6a3815d090b4fceae641d2b98d1b557689efa93dbf55f8d9f3e83e352f9a69f88b021da21ebe83bdc5998376d00ac3125ead5dd61d0c4dc"
    },
    {
      "function": "Protein",
      "namespace": "ECCODE",
      "name": "3.4.22.52",
      "id": "88c9cac9e09a72617edb9ba7754450f3a47f36451a5f52cbc02843fe71623abb72444ded8b13efeb38c18ce1d32342e4ee219e536a7c60b9da9cd53ef03980b9"
    },
    {
      "function": "Protein",
      "namespace": "ECCODE",
      "name": "3.5.1.98",
      "id": "a1d6bf6362aa5a68fb0ba838680ea1b0a63195c18b7eb2f8dc41ee51838bd4144141c3cb2bcf5dfa770ec9f41e63d312f7f41821f99fd4829ea9f3b4a464ca43"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "CAMK2_complex",
      "id": "2c6d989e05bba1439ed18819e9d74c2d3a247c0c70287041ff8f1085c44c631acbd1c98b8726b0dc365e3ac3089319e14d3837f2225ff67307609b1bd1e4d8d3"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "Histone_H4",
      "id": "ce7009e1632b7215367f7f46732a7bca1005b33ac3b4a2d8b863f343ee1c72af886eab6364bd2fbf46a2a8de56eab751093bee1f74b7248cb123c6a70d2f14d3"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "Histone_H4",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          }
        }
      ],
      "id": "dad79d22fbc3528c6c1d08fc80b96f09a552109dd09806ee19943e2211c834635360c4f5fee0c2da9faa9463f748782c7c676759ca5a32289e25922522300db3"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "AKT",
      "id": "3263678a1e320013081e7134e7e64e91b2c66e6fbd10dd7fe4fd282cf0cc3ba29b5cacb5e8eb0a8ac0a194f73b80dabcea5465b0fec5b044290b259ba889cef1"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "AKT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 473
        }
      ],
      "id": "a03427be792e54c499404cee2333f1af5ce254ac1009d1697dc3dff377487eaa81466198765c389ba5c3d317a2b2520654ead9baae6194a980d783e1df597c5b"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "AP1",
      "id": "152c3282bd696d1586c26b1a87b87d48f40d29146128e5191f57f6ae7b5a362a722fa56a55307ec781f470fc45e5afa7846b32df5fc67d613d7fc8a8014f1504"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "Actin",
      "id": "57be0b6b7401099817c1860652cc169ac7862887c6a0457ffdf332de6f902939dcf65a93980fa9ef23187a476b3f87dd815b35d6149488db50800f1ed5fc6685"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "CALM",
      "id": "0ec9c189d22b2217d25b75629353f6f5d5b5e486d3b82cabea08668b2b248dc760ea36e76bb0e8b98c980e00a33d7f59c47bb98d6d602291bca5c9b70ee7a5fa"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "CEBP",
      "id": "bfea12e0f7e707c218765210859997c93d47f8bf54529c928786707b981e45932796250ec66a2de836353af17462d9a812c4710231935c217a6d640d7b6ea1c1"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "CREB",
      "id": "fe50c33cb42b7035c8602bc3ced677d7630fd479190cda030432dd4078ebe47da59de11b7b78ab3f4d0888b5839187872b3ad589a9109572fa628b6eac901edc"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "CREB",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "6cb2e6419fce9c178271bd052116cb33c4617910bf506c96132849b1850ecd6068fa569106a4d8cdbb101825d7929abbe3e136f3e85e72b8d5dc477d9bb80c71"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "CSNK1",
      "id": "a2dd0b6a7ea9eb45902dfde6051ab7e4d1de56bc2440fb441b5de5fb1c70513d3c927dc7bb1eefdd069b533fe297145d520f4e942891160073490a7c3a7413b1"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "CSNK2",
      "id": "2971711756e0fe62a5e4fcb77589eabb9c1ea4589e07d45c45275e210b7622e476620b3bd7ed346c26c6cdef032ffadd1b2f7b7ad7a790edacd5a444d2f9771d"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "ERK",
      "id": "d47253e059ce1284f4d182a53246f4d993b24c69ceb8bee74fb2a12d7d07c4a0ea65603dbb5d741283f27159ddf01ff72e2c045c05128734b83ba3ef067837b4"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "ERK",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "c5ed40d03c26ff2cead63f468094e0539b55b94d81228e1edbc704f621326ed2b3e8b68eb8b1764548f737183a2d4f8d75120062abf7908e6a7d2dbe0ce2ce6c"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "HDAC",
      "id": "d2e8833ff804c3b8c5a045ac8a4096c1c66c61101c9ed5ce1f0c355bf74149b9cec6584bc3e5186e942bbd700bdafa9ccf9bab0127fad62731702159604e5ab5"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "JNK",
      "id": "a9ed6db257ad5286099b1c787f20b6023ae9588e34100f98373865a084224f3815988fd9eafd8a85f974c668ef8c48bad8bee8de58c6e414fc8b084d8d066d6d"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "JNK",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "3b137982ae4b3040d5c26783fa43b51ac6b5dbb59c8146b59170d1026a40748e274e2fe0a7af9d2057cab5a0af0886623c51764d4ac5f3b12ca78f778ce1c929"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "MAPK",
      "id": "d5a4fba57d4e7f692f376029d628a2e921f430f50117c1db1ebae2bf2d76991ee3be15c962abcc1c8c20ebd8317b3afcbfa298bb3d83c9a46e53d44643a99339"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "NFkappaB",
      "id": "a76f3010d13c4b506ba95e6e6bef897dc400ea1bad5f8288ce4b084f2b57f9e7aa59f5146eff656ed56a6d2077d5907c41cbd4539f26d63411b79ffe7179e54a"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "NFkappaB",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 122
        }
      ],
      "id": "b462d0460e34605e24ebb15b4aa025f9fc0ac90db5fb75e13f7e854fafe77368ac3023b6d628203087db51b40525fb5d7064732632547cd40cb4566cf39773a3"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "PDE4",
      "id": "99df8652c2f781cbc4df1aba4c5fd31b8dea28723a256d86d85de47d183a5ee3a9573d296f67a81b056333518e7a0e63b3f515b77c4f59b5a460a34a60b60eed"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "PDH",
      "id": "17ccdfc42a2f1b27bacd23b8563bb3b991c167af677913a779834c0e23fbcb42f9097114dd49e7828f7928697f2a1517560caa2cc3dc7ad18dd95010aade5289"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "PDH",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "31e8754217678393e24913de11e25250aeca01b31409ca2580d070eef66f4f3fa7109564169db55491ce9d77ab82a61a3844840cfde2084754cfc90739caaabf"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "PKA",
      "id": "a312e28f30d661eb58c0cc3c07cda6812a6290acaa1b8c513be7a895fe1b15f1feb278ee6095359cd3e44eb43cf1864de0fd70d89d3cbcc5b18361fd31276f17"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "PLC",
      "id": "a954cf31d48b6ddffaacdf9ac551464d6edda5fead07120c8d6453a89aab5a325ac1795b97e6993441005e73dd31fed063aa1c7c5b0b2ac77d1783fc8006e68c"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "PPP2",
      "id": "a9377307576389f08c186ac62c6f48293be2fe1495d38cb53c33f9185f3625cb580b310ee4f6d15c636acf1f460f4b54f0dc8c94808295084b9484f709c91fdd"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "Tubulin",
      "id": "fda6d67b6c519070ba4a88c808f20602888c61eed2f10c48fcfc758a5a9e998e67454f28a16ba3aecd90edc4d31eddf94264a2a1e71d5e485e9800d9c0e079c6"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "Tubulin",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          }
        }
      ],
      "id": "bce59a74309d2d2ae4c323d3ab1f0e62df3dc9a06bf7c79a08ffaf9606c325518e9b3960f8f62944f29e6e5ff5ec28f8ebcf9f04cc4b210caf06b378a64c3a6e"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "p38",
      "id": "0973dca5b8a1f771d17ddce83d29c60554c01b82e4ae223ff069968db172de3f99c07021ca3bf7f3ce5d9a81584d2d5529d47a3732f780d19ed2fdd8d208fbd1"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "20 S Proteasome",
      "id": "8a56c0f6f2b52d0a7a53a70d49721d5c779a7997adc4becb3efaf48fe80367a66813d387789e058855832cdd189dc6f70f0977f4d03a07bd84eff74d279f3e39"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "3R tau",
      "id": "69e10fce57b3686846f5b3dfc26c631268b84a8a38eb814c13670588e4a660bca26f90187cc38c09c2891f39b1e5b3658911e774ced090fb08173eb8866545dd"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "4R tau",
      "id": "fed662167fa10f270ea26bf05155229f1c1fa7c54b4a2c13d46424e97c1c0be3dd98a23ccf6ebd1605ef472e4f2a923463d37869dcbc28a4bc3c3bf2bf19e239"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "APOE e3",
      "id": "bd29e2f2b9549d7957c20a8b0512e802b1dea89fca770d8861b46b8f6b4010603b52c8d92bac289df54d44cd60bd6cea17fecf8b4896587fa6fac997d1c6809d"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "APOE e4",
      "id": "a519d6630bc8e246f2e2604c283b9bad94ea08e43b589ba0c7b579cd4dd7776fd102b8bb0f102104720c312573c9bbadcf691c420a26bcaf53f05359810784c3"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "APP, ACR",
      "id": "989a7e7b0aedce985a8cce172a5083bb9272a1e5bb6c8eda163ecb75e971041cbf5d3097c1605cde7f2a61a8f8e251feb9430aebdcbfc1bdcfcb137dd27d0950"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "CDK5R1 p25",
      "id": "b9acb485fabc1c7883aa9ac67f71d55dff4e5c27418b7943228400bb500f3375ac4f4a4b270f27b62607362f97486edd6684f70ae85d0ca803fae12c9b21d2c9"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "CK1 superfamily",
      "id": "d33fc73ddb0aed0e39b4894afa1feea47a42c72e7fb2b199cd8edd0ef8e721eb72f44b19aa84893668be6c37f900d8b8c39b3a08eafdca78c5831905ee91356d"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "CRL4 complex",
      "id": "30b20d0595126c1de10d2907de4efe29dbd08d4773d359345450d8c8e87812d1b790c015a0c356556b33123d735ca2d00028b7b6c5339ec6471c82bacd304087"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "CagA peptide",
      "id": "401efa3c05178f3654ba14cb0cde70dbc83bbc2e99bde97b848bee383ac99d3ee84fc543d2d53b74f5dd3d65edb538c3d78b15d8dfc7232e2034914505ad78b8"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "DAPK, basic loop (BL) motif",
      "id": "748082f8a5192cd5339c22cd7be0b9cfd6ba67570291a8c2a5fd7c39a4bfc6734f53bec0a4ddd9881f0a9f0204d3c104c6c0ef49314f6b2d2c077eda014fd9fd"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Histone H3",
      "id": "1277da1180bdcfe996a8c87e1238c77ddc3e852c737c588d04d2c0776e6294839a5c4f087b4891d6682dc99c0a8232f7bb5f238802fc5e542e38713f96a0e5fe"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Histone H3",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 9
        }
      ],
      "id": "4fdf4228839ca4c25904450e2275cf7a9f77131e29ec673efda726c42fc29c9795f37b620f261222a0afab0347dafa951546d6438bcafce99ddc0e55798ae695"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "KXGS motif",
      "id": "179326042466720dcd1ccb921dc91bddf9b5d25bb7cae7b114853e8fa7cf4f3bc24eb1e583602e37d387461f0323881732d1d2e8f14304c5109c37dccfd265f5"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Kalirin 7",
      "id": "3cb3f78f1e4a930ad43d542a8bde9c3d1fddc5dfc57f796d6df8dee24788178d85ef0101d500ae5201bd2a4a1d01315d2b420a304fd1190f7fe27a84e30f94f6"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Kalirin 7",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 95
        }
      ],
      "id": "4b2860ec7dc41dcfc2d8e9b32624b8b03e42a553a35bb73a6583876ad9dda69699643835966373bad430baed4c95bd5c78baa1fa5cb902ca2c17a7461b92d0b0"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "MARK4 isoform 2 (688 aa)",
      "id": "17848b6dcd99dc292be367fe060647c935cca6b1c98168fb414eb23e3f2cc76c6cb4dc2e3284bdbcfa74f0991044cc2fa4d26afec0a2acbe41818b6c895ec7f5"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "NP_001387.2:p.Arg205del",
      "id": "af7b5a49201f6bd4f568445754a8f42be099b1569b66dd48f30ad2a1eda7c92e1941c15fdada36dc64167123d9f61a6d8fee9fbeb994ef6996110b98f40486c9"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "NP_001387.2:p.Glu239del",
      "id": "d04cb74265d5ca80f24da47f43be5f29b4ea6b215d6b929cbf85b5d8848e2027b01bcec47aad269ffa8d34a6b2ea1f329f27f3746aa29fab29a42d658c70d134"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "PrP106-126",
      "id": "19168ec84399fd45c2295c1dfc1f714156122dac79e7e28b26c462df1ba3f560712458ab698c89ca76620b1331df09cbe60e592e4f19ebcb57d626c47cbe7a0f"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau aggregates",
      "id": "1c9d48fe854c1832b8539731374dc5bf3dc2079c9e5fb4e074524c6557c9d37042d9cd5ea71ca88458e22e15fd3f713284ef876909910dc47484812b0a150983"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau antibody, AGG5759",
      "id": "6a7561f031e207c353920647220e9b54e60b810c09de314af6a47119c0154f84a64b399bd7d67eb46a795f10cefa707ec5dbdbbe1a40e7111dd609324ebebe92"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau antibody, RG7345",
      "id": "7dc822dfb4d3e3d8eac9d658cf5c76ff9408fdf426c71326429ed2bd183212f0b504ec71f5d687c5891276c988d983bc1fe69de64b0b6a541aac80e151598916"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau antibody, TNT1",
      "id": "2992f73814470957a2ae5ba68c96f88061379f4fa560c971404b5f4de915aa1fb96107e6346c3afb0d24f72136f02d8566abaca93c34cfd1860b408d95b025ec"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau antibody, TNT2",
      "id": "9e2f9e3a1e5c6f945854bec6f635f2db379999520e7d2f8533b6058b00d45dc66a6e7a2b669d89bc4bd4a32037ee068eedeb242d2f01d7b3040e52c50dbe5032"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau antibody, Tau-13",
      "id": "5b14c438a84a0d672fdd91149ba13d708be8538552d0fada0d49f1842c8a017ea2526fccc5a766e58aa55cfa0316b618bd20fc4eeb3bb494e40667b4177cc718"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau dimers",
      "id": "03fe8e048185733d4e2d42f460b76ca0accb4c08988b62a3516b6c64dca4a948fb711ffdaae1b2acc75c06a693d0395b500a336175efac78fd6a5cdf9f5bb94a"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau epitope, AD2",
      "id": "9287eff0cc9374b6798f4c4cb9ef16bb5c98af5e353d69de29fa8b0334906ebce982277c73306766299349a0ab30426cf4a87dbc999636458e5043ee17d04bfb"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau epitope, AP422",
      "id": "18c511f6925dbfb3ad1cf262963acec87901b9fb43fa4bc34824ad3d61cbab3775e4751b7988a600a604f72ba9d3f9ee0f7944f8dcb0ffc873c589cad2273612"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau epitope, AT180",
      "id": "5a98bb14668e1fa319d2fbbde552597c4742e9b49a3eafb28a2c34bf6e0e50700e25f2ab9c060cf6e86910012ccbbd0d3461dbf5ae01d577a59534c1ecee89e5"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau epitope, AT270",
      "id": "912fb22fb015a2b76d8a41a210c66064e32218c9a35889fe569d8b5c822df1207f9dfc4c2d1f1ef17624ce075d0a732c572a44e4afe4e8eafea900b6a03889fa"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau epitope, AT8",
      "id": "41962f318cfbbdc940cf240c51ccc8748ed33b59785b3f776e1cc1907c3e0b69b3340d9fa53ac1108ad1894a38c564cf329d40fbfe4a60ba76cdbd228bebf859"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau epitope, CP13",
      "id": "bbb9ee4e3f9ca7818c9cf1402c4ee5ff38de6800052d3f233d920b5a450a0a6309792905db6290265d662b0b14b268fdfdd2b934f873e08983b5452e8bcd832e"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau epitope, PHF1",
      "id": "45baeb1244c65b2af82497f35aa8f92c774e87753203dfbf22ef0c62fac4ae7b24297f4c08f05c2bc5a870bc9c85e1821dd4c734dd01c4b7f3506c8a164b45a0"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform B (381 aa)",
      "id": "7a1392dc957a5ef0724b75f6c268592fbf3c1d9072e58e0e2950411958100bf88575d173fca8618253b8af6548a9d0e4fe74934f70b9f583c6549dddcac2d818"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform B (381 aa)",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "glycation"
          }
        }
      ],
      "id": "db7e021d8b14d80b573627a28309361571990e5166068f2046337a7dfea4f6626079fcbff46817b7c30f0f44bcdf942db1aef1fe3a717db7796f82931eef7fb3"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform B (381 aa)",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "a3c5293ceb94330424bfd0dcf6c445aad6f6b3ae6bca874f065374d9fe6548b1d8a673f7f68bd56bf0902a57d737514ffd7760585d58240620a27b7429d2c011"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform C (410 aa)",
      "id": "90c0b29e2bc1a6ac4a39734ba64f73a12ef82c738fb9b7ea023b54c9e7f77bf494107c7c0c617adf6de46a6935b6ffe77a42ec0f154f3aa1d517e22a219c5f50"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform C (410 aa)",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "glycation"
          }
        }
      ],
      "id": "771e42b28c4b604d3560e5dcdce999437a71bf7e3d023748678a9a84b01db011f1aeec6745bcef3312c315e9ef0f0fde5afeb0ae4c760444b5df122d3380b634"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform D (383 aa)",
      "id": "a885b09efbbb1b5a4fd8c70427bd70ae64c59f603b45be3e6a0dc2fe01af0db09c357967c5b82a267f8d05dbd2ce073ede42d7b2f9780e48d796d145c2e745e3"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform D (383 aa)",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "glycation"
          }
        }
      ],
      "id": "578d53309277efd99665a0b0eb91c20d7db562cfeb953e2fca022aa576219b6a955cb3650c80f41670b0218351fef7582344768138dc0507f880bd11bf952e90"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform D (383 aa)",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "6d84c77dba81f69f300d48e0a82f568ea8837adc45faaff52267d64dc26c8d095108d62fde7362c017cdb92b45583c9356f11cbb13423e298a5a431dda16cbcc"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform E (412 aa)",
      "id": "428154eded959050664a0ee9bb617262e506c867fe2b8059cfedd3e192df9140c83569a63dd1f1bfb98b780a11887bfc19696f28bb2a64c4d6a4007214160211"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform E (412 aa)",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "glycation"
          }
        }
      ],
      "id": "ab38c2103eb27e772512ec1f42448a6417b4f4de9eed26f97624dc5a5183501abaeef1baca6b750235d926972d70ae79e70fc0db4b9001d7676f3ca121cb7ae6"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform E (412 aa)",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "c2544dbb4aedd7d0afb8ce63e931ca06ed2684380a94ada1bc0b9c862bdc7e3e14d55387d07606e5d82a7aeac65c429ebbf1c6619a61ba566b97bb80ebcd0d3b"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform F (441 aa)",
      "id": "6f77e66c8e6368b067f47a9e99af43c53de45b1decba4c781f56e3d00bc2250510977965c81031b9b64a3e71da16a521a52f27bb16fd9846d5816bd36abd9ee7"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform F (441 aa)",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "glycation"
          }
        }
      ],
      "id": "45dab0c4e8ede0d310611732b90a1b01282122d67b0285c1a1e45d3c1c432ff0892609911b4d0d74390eb338970a4b2ad056b9d466f62b448d02004fc36a5206"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform F (441 aa)",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "0776e4f9b462d785e10dc61cd1a3fa226acf33b9fbdb9f53abfb02fa89b331944bf6b07cbd940a4134319cb2d4bef9a104dcf3a731de7dfec3a068d9241f4ec5"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform Fetal-tau (352 aa)",
      "id": "34a61591a27bd14ba018bae24717ce7a3da5e791ace8bb1b3524b04e8300872f2fc834ccb43fbf8a4f8cc1293bced6f707cd0b6de7e3cf14b54a6415c642629d"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform Fetal-tau (352 aa)",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "glycation"
          }
        }
      ],
      "id": "75608ded0ed93e9382e1bfd6ab1bfa7f31b865716fd3c1cbbdea82e5d0b2d38b909632f41d7e91c369fbb9043cb2209c131c9b8823c1e09c3c55067117da3440"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "VQIINK motif",
      "id": "be3ed4113769fe92465e29467200db59861dbf232ebbe7fde78112fcfcda51d1905ed9f6701fa5bf19dfff7c09af4d350e3d43ae4c3fc27b9b650315ac67bd69"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "VQIVYK motif",
      "id": "d24410c0e1f7134ec904e57582699c3206010f0f52b68cbe7c0703edf4c6ef1628720acd2447aa7e65fa67801ba3140fdaea3a4b1e60d7e5ada7a737c830869e"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "cis p-tau",
      "id": "e7e8bd7b59a8f2394244f144152ec7fbeab3930f613281c43c0fe1534de82d85e1b6aa4f651e4782ac65953cbd71be6a273b84033bb5951ce56ecdf12e4aac2b"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "paired helical filaments",
      "id": "50de5721e1b866223703ef49fcf748522e974031731e9b7d792667545b73367e544d983be25c15c16bae0e0560e70f9b7a1bad23eb47f7e208234909137c95ba"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "phosphatase-activating domain",
      "id": "13b79ee497a2b5239e3ade45a0755015d95761404ee260005b56b78d57a40582afa3f4758ec8271987e918bdbc8ac86349e5ce62a2de5005a88a948eecbeec43"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "proline-rich region 2",
      "id": "3064d5d95ccdff0ea7592f34de8aa07f9c0652ce9f339b85475effd071567da7872ca97d2cb79419f94f384605a91559844fef4382e576f97e49ecd057aa3c2d"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "proline-rich region 2",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "a8ed9f065b836022521f4a9884a9bc4cc130dc84f0a39054907ecd5417b8ff1d1334a2488cf5b162fef9072f47d7440f2c89d1f311b85234777fa9f32e489edb"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "tubulin-binding repeat 1",
      "id": "f845a2b9ab9383332280869589a5d60e34c53afb41fce96f31da209e73e76633686741f634c3e8c4c6cdb6bd18224da44a7c116862764e777a42e2abe84019a9"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "tubulin-binding repeat 2",
      "id": "03ab3f7416f5c92ed862db8ac2122c116ec3f1e1c6b2dffb2fcc1c3ea7ed3ae4479e1d37350995c75c001558f62453782d6f60e3776ea8769debb8a601aa7059"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "tubulin-binding repeat 3",
      "id": "5aa28093ea3fef93baf2663bbf46aa247e003e90a4266213ee0ab34c6e0e30e6aa237ff9ba0e5b2431b549689faa0c4427e31879b1c83f67cde526af0ea6067b"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "tubulin-binding repeat 4",
      "id": "1498e07780888f3c7b76873f3ebfad3a0371e52a239450c0a4255feaec6cd69c1635b7f65869fc1e0b78723e1a39f6ebd77437e17588aeeb222536a85681ef03"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "PrPSc",
      "id": "99146caeba9a6a839ec76b0cca859fe6bd73ac8f3716cf73379cc5a5ee137abca072354923cf572c0d7cd428e6558e6a72eb291a63ac48cc76d212e9cf6b3bd7"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "RAC1b",
      "id": "e608d215212cbd287fa60e50f335765e0821aad1c73f8bf3db0d6e4e3e26cf350fa38576892d08625dc5bca0af8d35253cbdca23491d4169c2b75eaffc76a02f"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "neurotoxicity",
      "id": "f2d9b66956de8515be99744da047f00b49b5e488a151577ddb497a96a7cb374e2739e49cee7c66d00ef9b907f4a795fe0c2da90658e6021b637dfc878a529cc8"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "pretangles",
      "id": "50984dc5930c47498d2dad119831a7b54a55a99d3896337f6c83e66d61d12613e7be31e9fa0a19d6c5701270555b91ba964e25fa891314f5299b49d0af7b6d6e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "ABL1",
      "id": "d2c9c266b57718f71c9b5ea0da0e48ba77dbe172cbc7dc550631f8c9a9540767992c47b332bd0760ed1959c3b0e4a073a3f52d2cdc4985f132d91eb43e6ca027"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "AGER",
      "id": "7e397a005d17551ff46539ab6c2a5709d61f6e6a34c53dd914d2390a36fe3641cb438c1f1e5a08095695db19ea9e931449ec027bd08e3cdfafaf5acad2a74f4d"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "APOE",
      "id": "b17ad2f45c20f323d56bf6d806eceebc45de815de6578a61f820329d5bba1059af52aa63bfcba2bea3b71985bc404e5fc1bce130012d3c58f3a39023923ffb43"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "APOE",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ub"
          }
        }
      ],
      "id": "3826040f522ecd2b17d58fb123291428a618a967634d0ba25ebb461fbd1e467968aab7fea778a6f42a750e68ae7ff0da0d39ab00f8f5966d906232a5e5204005"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "APP",
      "id": "ed1d45f3255226e4210017e6c179950e0e04a300727326d7fea6a9659868e8818ff64fd5e8a2a92a703fb1566b3f48323750ac6c28e7adb40843053d276710bc"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "APP",
      "variants": [
        {
          "kind": "frag",
          "start": 672,
          "stop": 711
        }
      ],
      "id": "7cd67a8af4a0e8ec5892776b4d9ac8146e0569074c0ca2d3d844365df47b15173aeead47cc30a92a1f32cd22264f9bdeb311711bdffed82ff32b41d6224a0a27"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "APP",
      "variants": [
        {
          "kind": "frag",
          "start": 672,
          "stop": 713
        }
      ],
      "id": "3e5de8e845a1a7b00bc3bcb2e2ce192ad8c91a9c1beb7f894571f750d8d4cbcfb96c2dcabb2c5f461e38a63cd31bbb7233e393cfba29dea19455033cd38fbe28"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "APP",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "polysumoylation"
          }
        }
      ],
      "id": "ef45e04ea7f6836fa52e37bf638f6d1fd3c952768a6782551b3adde9c292d02ced7901aa01782e15ccbc2cc6cb617da93c90d2b0f7078c0aefef2d30a4aeda60"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "APP",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 668
        }
      ],
      "id": "4bac4a4edf8eaf3a4122c0d2d116d6232c3384ce93f10a31ea5401e604fb55ca2e6689b5ab23a9c1b333532273b712a01975fbbcd04059aeaceaf77cc38b82f7"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "APP",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Sumo"
          }
        }
      ],
      "id": "6956bf43429995ece5c447825b31ca3480de007d728f053edae483ca44d2f91e4009b2ecbd5cdf5f94e818d6659e4fe07eb75c3f80eeb53d6ea11add7395e2a7"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "APP",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Sumo"
          },
          "code": "Lys",
          "pos": 587
        }
      ],
      "id": "18a6e9f470baad47096030f09de4427171d57f17700bb150ee07c12baebcb80ca166689a8c8e260826cc47b979374acadb208db4076613eecb4b6ea625ec14f2"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "APP",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Sumo"
          },
          "code": "Lys",
          "pos": 595
        }
      ],
      "id": "baa05df1e45b18c9b7b73214c1add22f5ee950e4702cb5f3f39ddcdf04bc1b2a2ea6b87ce9f04e162e973195f1976d5c0522dbdf4800b99e1de3e4ac0c5cb194"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "ARHGEF2",
      "id": "aae94ad4efcd06f711726936ef51281e86831fdf9454973ba33e3a9c97d5819f285585dcb6e97d5e5dd767196e1bb102a653aecfdae5b2d483fd671f61d039a5"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "ARHGEF7",
      "id": "428d687533aecb96a7f3f1dc0fbc9e7288d1700e45aaef7705a445aec06fc59b9005d75b13bfdc7ce1e2848ebbdccda097643260f3cbef54b5634906de78d37e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "ARHGEF7",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 516
        }
      ],
      "id": "cee46500abbde83e7cb81fb49408fc35d4be146d69709a03c7c5af2ef5529188c02a7003cbe7d8a85ec3885b2682d2816e9af341ecd93f497977cc566ea6cf2a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "ATP6V0A1",
      "id": "b66f7d51577f1c9e59cca5007fb3da11417d7266b4b193ad82883f0dacc61aca42ab80f990003d5831e5cc1d9dc4715c83f888034bf04cbefc2e7a8efc7b8d31"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "ATP6V0A1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ub"
          }
        }
      ],
      "id": "96cb719424645b5a00ed9292bc2fb3ad13ddefd1c00a60c3b9a6a08937bac61b3e6e8c7758a7622345fb82bd39027d55b6a0cc1c262ba2ec119bf3294e4722c5"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "BACE1",
      "id": "88f17e7dffb6947c01414f79e5a3bb9cdd3e932c355af7f0c8907d2b5d07742883eaf63866fe7fc938401ce0c366856fd5e306f324e6c1f474c1a984c8e46a51"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "BCL2L2",
      "id": "cf0c3735f6ac0494632756c6a6902a0b5f827ac360e97fc878c5ca6722bde3b28fa5d9c21f8eadea8a4de81a91be7ac9fbf2c4e5048c8d976a7e41f88cb914c7"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "BDNF",
      "id": "5bbeeb6a1045d125bd5495fbff1f4831c8697d0b4f9b77ff9f1127fd8bcf4d96eda74adab4e84332c6c9ba5bb97e102771278841e902a126ddbb438fddf7b8be"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "BTRC",
      "id": "88f8adb07e4a8a5e450d264f17f555bd6bf90dfa583a4645139408b6ecd2f277e790f07a934265e04bb7be15b5fafac952e2dc8c31705264c3124b5909698f4b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CALML5",
      "id": "7520fa67646be9d2d64f6560af764e6b4fb05e3227876296c18a063fe9fa96ce9c30ca22ea52ffd6aaaff0014b19c6a69daafc1e91b95dd01e7c01de57e1beb4"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CAMK1",
      "id": "39ff2ca6b5327f83b4e7e4612530e0d1e50395892e0253721f85918b337e3083a4a9b17b8cb667abf28cc960f11743f13c24af2937f54a88ff9276f9258fd265"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CAMK2B",
      "id": "4c3bf6950e5c123022de139f876b9150f77558600158782b6145a33be7fa7b77527a16ae56ad97f780dc778afad4ef3f1f14005d283fa9aa29434790d6a95dc5"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CAMKV",
      "id": "01cb0a2447f180e00136dfd891df374bea41456c2208c0feda26373c58edc8ff5f4257b9e010dc52f2bf99dcfe3d03b62a7175a99382c9d4a493dc5fbf103111"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CAMKV",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 345
        }
      ],
      "id": "da67393cd93a28132dffa85f6a434d7e1aefac52d14cfbc4363d88d13d4d3bc84b9bb60cf851441a83afd45c0d03917f398fd68b5ee3b6e64019583f0deb14cc"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CASP1",
      "id": "573c1f59f79260b0e8231f27d98abeece26f3766396d321ebfa7b7b383c97b58b352e2a1d09292a03153a23832e0349cde21b58fd43b5609c74bbfdabf271d9c"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CASP3",
      "id": "3fc355e7c574083fad31aa9edc5d5685615c49fd58885c2fbd439371619da84fbe274bd3325695ab21c912b5ea592d8031ffa114a9147908170dc187400ba74c"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CCP110",
      "id": "ee0afa3c8e825f4b2f749fd4e0a8f779c4af45e30a5fcd2b85dc51e9d80d28f1e706e6a33d738e093fdca5ea81ccc9130de7970e387e4a7fbebfd86b98c5ad7b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CDK2",
      "id": "ad499bcb9c7ca2de8e3d699b60d3c3c75a3bfe51df16325064b57ad8de3442312f8213f77477e093234bd399a0c81575fdc0d2f9878d8cc7eedb3cca921efe2e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CDK5",
      "id": "a85beb5b2b9417fabbbcc2135b9533cb0766b38688caf02242632843ae455bad332fb625d6e8296ff77b40e841485a56854fc14e300552425d596e8a8e70fd3f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CDK5R1",
      "id": "0207787ec1a245b4edc4d61e093cfdf729180ecde8b3c7ae6644ca38fc0a28cb03b727dba6caaf192b4a98594148ceee9ff9e34195a7f8915ee6f683b8a08526"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CDK5R1",
      "variants": [
        {
          "kind": "frag",
          "start": 99,
          "stop": 307
        }
      ],
      "id": "a234b7a408b913207367f03b3eb2f3f0fea0c1c23092ed741a8fca4dd7f42df8ccafde54447a1efb079182a1961095bdffa56d3483cbb9abab57ebaf7b306080"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CEP164",
      "id": "08e76f094fdee2c02ab1e880d939dbba1736144b79a6d81699f1a49fce5f84f6005243c07b8395b0d655af3ff6b6a4c97a67b4f54524a0e222dec5de56ce967d"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CEP164",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "4a5a4876ae63ce3b660b12f1d9bf5685193b320a79eb6927cb53d554d72645b5bfcac1b599a7be96375fcf480a50d6cf97da129017d9ec471c84c95e87afd818"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CEP97",
      "id": "f9761167fa3d8f59b3f6f9892e637ce720fc53bf9c7ee12054c170401eb5e381ffc3738097297e6bba537b7dc9e1f8ee777ea8309d71e3b7b93771d0e8198b3b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CEP97",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "9aadae4c9eb51af93ddf1077a7f7f2df0b0895e332aa3e5ed2b6e103a88b75722b0c3b5efe3591005a01540879770b715a7bea123128dfc67811c83484b418de"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHEK2",
      "id": "680b7e8328ec903e05170b906ab13ba420c55ac9aee8d1baea919a5da64ecefe792eebc8fab97261557b7f79f5492774217c14ee13d08d7b278f67d621347f63"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CRBN",
      "id": "2df0227940d72ce89db99b182e910bdc3356e79f6cfc0eeddb750c7cbe961600065365d7c375be5985a10859898d21708df485200e427103c8c6e6c6b2ff39f4"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CSN3",
      "id": "e9584fd782731144d0e584591dedccbebba3baceffbafb0944099f1835360d8fd075a164b561b8e286dc4ede62a9c4401778b984f8a3801fb6605ed2315b71ad"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CSN3",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "ae2c7e7a2ee1304a044dd654b4e60820c7c1d78c359f154ffdd090ae06e5005c0b00259d0fde4643efe0ade44b3c913a24245ee36d04b775619edc3675d0ca9d"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CSNK1A1",
      "id": "55e8f15d97f4d338e9d7ef1da2fb6908c6c79766e9d827523457d8db998308a5049b5f2a3a1c28f5538e21379e0a889b1bc17fe925572e3604cb230b3c9f59aa"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CSNK1A1L",
      "id": "1531ce4a5b03df9b5d7fde48e0a92bac03afa2e31baade0e71c4d012ddf1b48ea3ca16be13e8c5a27a8677a09a872d803ded22cc4f00d7b755d7ebbb7d73862f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CSNK1D",
      "id": "48ce823b8e5bbf8fcb37b2d68d1a9cdecff0e7946eab8ef0acc72913ba9bd9d0a4a0d396674340b7ea4ca5215c31452b08c11c5a2c48dcfa5e3b5c15ed535f92"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CSNK1E",
      "id": "90949dda45d62fc842d810c9b3f9e0da206f18ffc1e2b8a7352bbca858acb234c0ee93d10fffac63e8aac2596b1959b9d2a9a6ef0dc698d55756debc8a0ffe5b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CSNK1G1",
      "id": "ab35088d9f510bd8f9f82b37a8bdfdbe112096548247c88f8cc070e17aae4ff2a529aaa4ad7e141606c7c7f5800c0913062eb51b9d68e32df499146678eddb24"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CSNK1G2",
      "id": "fb4c06a33a6cf699ed0bdd801d182ad4517f83a200eb86f9fd3d5d3ffcd4a8aaa827bf04466a9fc3e795c58db386b8a45e2ebab1ace94287de4fe015de3735a3"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CSNK1G3",
      "id": "d86283dca5f61f956d807c43a93e830668b497179368268c1b3ac0e7cf53714411def14eb3d41e279d5b852c913b5ddfa231c1e5fe47a1590bab2bb107979abb"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CSNK2B",
      "id": "bb1158ed4508942c7d0f3d6d601db430e795744fb6b99a1ca08b744d2b1cab30170f8f8bd83eb8b9433f64e25ca5e50b633adab3947b5361d09d8b683904c29d"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CSNK2B",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "29d08e8e2874c2b4c90b2dcce66b28a608ce15576982b41cfc0c91bf966e419cd607a159b7080a68fff3a33a1b77a4010a7145acb59640efa66babe96ab0a22c"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CTNNB1",
      "id": "a2bc0511621c6128941ce4889e2169d5ea15cda57b26de72e4a6212856db0cf989f1fba19328a884092694e5a710c81b67198481f8060b50a2a1c0580c4fa6d3"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CTNNB1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 49
        }
      ],
      "id": "b844092a6ebb620be54ff88be26e3b1c59002b23da1e3434068ecd2ad467559d78c89d2d42a0d54509501508c982fbe974e02733b2fa97b4be404ca7dfe9633f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CTNNB1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 33
        }
      ],
      "id": "3056d9629d9a84c5b747ae8ff7de0623cbee4426b8b051810a6d583607391993f23afac22da39650e0a47ea2bdb8456bcdf2d3a2818b08203473dc74532899f6"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CTNNB1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 35
        }
      ],
      "id": "72212638f1c403d2421411850e87bb1ee608222da4f9d3f1f931b1a0505a7c8af25f20ba5760cf8665b3beba0c6f23c50c4eab906e024fe29268d4a8bbea66d7"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CTNNB1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 37
        }
      ],
      "id": "f0137fa33e2af27d7578b5b6eb18c49b10ee69295e1f98f0e1746a006128f9084530530d07a59414591c15c346c1e684a02dc065423672f83f960a342209c3d8"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CTNNB1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 41
        }
      ],
      "id": "2716807ab02496eae7517f5ff15425b7af9269216cdcb0fbb66da795329b534d8990994cfb2ec817b50f19fff9994b0051b65f39db704a6dde0c99353aef9e25"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CTNNB1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ub"
          }
        }
      ],
      "id": "8b35a3621fc2b326829d315461adf5d9dbf6817b0097dade40bd7255369cd535194fe51ed762aa0eeeb98f3d660edee32bbfadb4022f5145f6678b1aa9f13e96"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CUL1",
      "id": "b8998472147cc12d4718c12b635b8bb419df17e80b30d3e6ffdafb179ad4d834483fbdbbb779c6a81f1024d1ab6e00d28b2da76141a6e35d29d5d3e614ea2579"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CUL3",
      "id": "e3c87e99847e4fbcfcf4437274ab159f5ff2cc75c4cc22b660f5cbee86b20c08cee308b6fe8590788acf25c50a7dc0bd82927798d06746fa2f6fac8ba63bd9b8"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CUL4A",
      "id": "cd2337f4ff7d39dca70363a2d6b62fd1d1920e2b201af27416503a8388da5a10f2cda976a5f66f603818c5a1d961ce2ff7b4c34f1d9a36e96d4162e64de350b4"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CUL4B",
      "id": "e3e857fd5c5ba254530870be70727cb3f3c028a4c889ed39e10048dc17eae355ca7f02fd9bd5f9d5ca2a35fc8226c94a8fffb1e82bedc7e8e2a8601847a9a0f9"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "DAPK1",
      "id": "849a420ea46c0dde5208e06636bcd077b083cd4f4358d77c67d6d2ba5ad664f0b96dc38c7c42d4db3c274966501f854dffdfc3e6ba7b389bccbea4d9f3a382ca"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "DAPK1",
      "variants": [
        {
          "kind": "frag",
          "start": 1271,
          "stop": 1423
        }
      ],
      "id": "52acd3b6e5ea6c16f29d384777bd08eb970d64f1ea085588f72b332f7cc625aa817f733bbfcf27faa5380bf7799eb6b8ca475c2f34715e206009605e6e787d0d"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "DAPK1",
      "variants": [
        {
          "kind": "frag",
          "start": 637,
          "stop": 1423
        }
      ],
      "id": "c85fed20efef171fdc572ddffdabb94f598be994d675cee6e18af18fc8819523da5056c9888def1cbb4b0378439f7e0a4da49209242076dbc2c8c745c92b152b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "DAPK1",
      "variants": [
        {
          "kind": "frag",
          "start": 848,
          "stop": 1423
        }
      ],
      "id": "65dd3a03cbef51f89d2ba34b231516a6d90d5c92cc8658ca9a77dd1ee5b953efabe3b906043a667527684b144d97664e43e4ed491eb19e0e21975fa8d95adbca"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "DAPK2",
      "id": "0ffb06dd35291f3fd4d1c957c43507afbd2b9bf8289026ad87ded4d103374f67f7464e808114201054c07fe7fd44c1948853de6142ba7365678d3d774b4285c9"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "DDB1",
      "id": "b755eecfaa18cb1aec8341ad003eafe0adcbdfc9d6c453ca7da453b3ddb965aa2a575f7af1ddf94e7ba89fa967a413d1699c99f40e8c5305c34acee4657a3817"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "DKK1",
      "id": "43353c695c37d05100ccc4d88cfc994417614c34fe111df6314c9f4143abc3ea6c90a9bf584c4c8e811efaaa5fc268e61dbdc6ca23c67cba998a28632f6400b7"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "DLG4",
      "id": "10e57c70ebcfa151dd8a44247ad31919f3578576f99380aa5e432d32d62e5473023f4cf88095ab72f3b5a4542b0cdd9fc471bf965bb6ded586746a4952e65b78"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "DPYSL2",
      "id": "f9d6de9d3af67f9e9378efaee963b6652f2603f0efda63e78455ab4ed0595c13f9ae30ed7cb747083e17dc5c890a345c1f387bec3be06d7f4b80c064fc9d3502"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "DPYSL2",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "c0b4a5e92a2fc66c0fd003bb1110e1e7e8c19b61cf5d1d71e8eab1c685bdc4522b32cd3ee712872dd0946444bd23542949042de6e510aeca67b13d39fdc860aa"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "DUSP6",
      "id": "ef836df72ae97c63b43e26788352defd6a562d659956d6d389beb85e2f0c79e200557dd50b875ed1baf3eb1c17f22f4ebcf7ae69eb84d92e7f28f50ebfaeab86"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "DVL3",
      "id": "1abbfa8fc8bf58a12adb0ea6bf7dc1d3ad4e303448696355bbfde2891c69fd769bfea1923a29b440f5b88a41f321f328af3df0718e2994ec5574a83aba36bbb2"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "DYRK1A",
      "id": "8b164807125f35b205166f36de5783322fc6853c6256711e55eaeb05fd14ffd86288750b3063d01d8bd55376a17dd78d0a7b01fc8b840cb34edbff1b329d72d3"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "DYRK1B",
      "id": "c11ac163d2ef70c208fbeb16414cff7b4eed6a71c306f817044fa8fca1a9e589f41f0c3a876948479ecc737dc5f8663df2d0be0b0336c16777365f9183399f91"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "EIF2S1",
      "id": "f9f140f1e21ce20744dd2f47644091ad5633013e7317059002f401ef9513a8cfed5a639c3a0691e4f1526d1c3c13134a521220f101ca7dfb1c34ea87c7e7f5f5"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "EIF2S1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "dd2b7c0fde0e07632f2d51f640cc4853b0f0ab2570ecde21bbc5804e7772ff30315d2906e1633e1d6ecef7ca291d854b58846ed5c671e9f4854db9601c69e5dc"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "EP300",
      "id": "3c067f7e78bc8b1d856b67e88bc2eba70461f2c31209460d6bb795a17f8564bc8546f83889f29e4a5bca1729e4100d6ab3822a313657b955e88db9ac12c972b1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "FGR",
      "id": "71775e56dd5189dbfd26dcb11f92c57db62ae99d934c890bfa9526f979706d77775a0bc297205fbef478b7824f3b5b27bf4974390f099ef52fd0a48949cb06fd"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "FKBP4",
      "id": "4b4d04660cce588fae0beec1c7476117f842e4de7495fb38ca6e84a1c0e432492353d48a26d4db9d75072c260d5bbc589bc6dd97ae31fc7b65151d4655878cb1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "FYN",
      "id": "ecffd0427f2e321c9ed5143ca2510464c2fef5432457c332ee991bda79dbdd12ace6375208ee66760cc5b9b7990248651b41a370f16eb9459d2b8682cb0da86b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "GLP1R",
      "id": "6235a250c9960ceacdbdc7c06eb8802bbf94c1e0d1e0cc7d60930984bfffcb4caddcdd080bfeaffa8e5cf6e6f4b61f81779b17d0141e9b3f4138bea13c549691"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "GRB2",
      "id": "f94af8faaaccda960957759a32709642d7b4d818e8c8ba3ed97d7ba05833b4af9c016e3eb270995a8fbcd1fa75f839418fc6a71673178efd3786e4f881a3df32"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "GRIK2",
      "id": "9f3b300d37cda7c7574591c39f40cd2398ac7d27376c005a8f9fa3db59218f29c581a128eae4ab354d8905cf9df3a8abd1afbfc62cb676bc6c447e93397096bb"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "GRIN2B",
      "id": "dd9815c83f93be031a07df6d80146f91f55b3ad8850ccdd967007048fd2354c2bc2fec0dd0a8f428c9c411568fced227500db81dfea20193b9138af7008527a0"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "GRIN2D",
      "id": "bab96f9039cecdea17efc38fd53b0cc231e88d46dc6d97369a326f7e508748b6426eb664e1aff81cf5c0b2de0631f26c1c846e40e594e875403a272362c435a0"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "GSK3B",
      "id": "ac819ecac7786e3ea9b6906b318167c6a94fbbf428aff46f85083b83c50b9604342d39c1c36ff49c2cb3a04e491913164c3e4e7889dedd513b6196d9b0560c7c"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "GSK3B",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 9
        }
      ],
      "id": "8d7ebbd9db06bfd2384321706d086542b1139faa7e1e65bfa46266a43582c9b2d1475fad41e42b54b51c5c64fe134658d3b53c01964ce52c62163f2077b4e180"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "HDAC3",
      "id": "9378a13aecaaef25a186c551ad4aed40a80541936c0688c1526e41e8d457d9e545b08435a44058b7bed2eb5753775a5cca704ffd7a7fd998ce2c5f8b21914668"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "HDAC6",
      "id": "c6e2cb3c91ba614ec9e19574656eba9d234344b755f57479d99a4d4ff77acc4917594446b9b19f9823e8a8a0d2d457d74b6f6a582d9f360f13df4136d902c7c3"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "ITPKB",
      "id": "747ba8ac0d739ede72875b4c07f9aa20f1327bb0c403cfadafa005a4144a4664c047f82bd504955429427a8c2236fee16e949ba2b5d4bb371bb2fefc6de5178d"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "JUN",
      "id": "54cf70b0e3223232ffad00658dfdeacf4c42283c91f943562a4debab6c786a69bb8021b49d44ab47268272c5c0c28f47a456172e7a4ce508bb34c8b6bcb23358"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "JUND",
      "id": "eeba45930fa6171b8db969858eff57de395dfc06a86bf0cd5f0331bb658add958ae73b67a1b6473474ba5408087a03fcc203035088bbe92c247ce83846c7553f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "KAT2B",
      "id": "bf0144846c071d9f33bb0bf7357860a1a583c7bdd69b00e6b1786af6de9472f13b8db7dff17416fa5455164e07d46436fdcf785424363b782d2a03500317cd98"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "KEAP1",
      "id": "ac5b90f683c70d7c98852200b82d97e1b9c6dadc08a979341fb205cb99aa201796fb24c5c1c2e69b24015d83c9aa6da9f6e2f257aadde2ba87accdb9f5366e7b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "KIF2A",
      "id": "8c67c27b0246961d7bdeb2287604c010d4204c7a7856804e77953780b97f2826835839bd34be8285d9ad2658eb6226e9d4c762073bca20113d56ae1bf2650474"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "KIF2A",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "def90e476505a855fb49dff85f836668c030e96d68198a6e87ad479b3c2bd3c941c7368fa9c312583aaad9ab6c2c07e54f86493e3df3d677c211c4afd4fc9dff"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "LCK",
      "id": "e01a7494db504930dec972b29f8a1db10e5b225cb2e9bdefb8a546f8604798b462417e23959e15a82df474279bb080449967ba87d4fa84bac141b8446b229ccf"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "LCMT1",
      "id": "e2a68198cf828292440cb930eb7764963660f8d24550bff835310d08f4bdebb8f5d54aad6c629264d0e95065ea865366ab23fd17420a0aec0b57c6a75e6919f2"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "LRRK2",
      "id": "f96ead302c9d5f0deee787cbc3ab3b9a683a4c41955ca6520d12263f2bfbc9810e87220fbe1c64675505d5e699f6e802c656ce2a11fb5936f0670423987e141e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAP2",
      "id": "33d1e22146b363031a90585aa4e0283a6fe98216b3b1134d987d21168d4e90f40dfbe31f1c7c7f258ba29a57691123bb7faf1b37ac31119688c5865f6731427a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAP2",
      "variants": [
        {
          "kind": "frag",
          "start": 332,
          "stop": 339
        }
      ],
      "id": "50ac9049f1f2e53dd20217e83a8c3cd8db00e7cdad802c7d0a30a3d78f9470cc2408c1abab00e1f62d70397cffa7a71feac929e002c351144540df001ae7dca4"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAP2",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          }
        }
      ],
      "id": "fc77c6080f531ef88091517a3de2309833231fcd983f0d501dcba1d3656ae8a220bd40c6be0a78921094f3ea811a9874ca7cffc9ddf31e534b5cd095697b31df"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAP3K5",
      "id": "adda7e3a61c84b23dfd402fb749d964765dfeb06753d35c0389dd05ca2b4d2591125addca06c4882b61d141b9423138e7e0a69fbf1e402ed63187327315f7169"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAP4",
      "id": "4f14c33e72a4859f9f60cae1bdb7414c4d9f055548f7ebb8391bc3f3f6d69c37689f5c3816758259d921733f12f95e78072ebb4dcfcbf9c96d8dd60079231ce9"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAP4",
      "variants": [
        {
          "kind": "frag",
          "start": 1023,
          "stop": 1030
        }
      ],
      "id": "c598265ab34224f0c352066586748e2f75e7ab48da6cadba495a41e855d0700933f96971266ed2e30af0f47cd4dfd9da2573ee77e9fb6cea071c26fd5fb2546e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAP4",
      "variants": [
        {
          "kind": "frag",
          "start": 992,
          "stop": 999
        }
      ],
      "id": "7b75b4b52c604a406b7c0a05cb411717cfc84877df3b22678cd0d0afcdef0265283f0a8a6030d2554c933b5a1d925889fa034bbe3c88ebd43c62eb659edd22b8"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPK1",
      "id": "1f8d432cf371d5eab6afc6946ffa43477e7ed01706159de18b753e9b1c0c993d6369c6f3bb636353986cf45a6554a4cc62c298e4a08211447fe23ff71bc8d48a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPK11",
      "id": "b100880ce561dcbd36d8c0fd3e8ab3631cc6235f042a3e1d8c874be78a6d35b5419bebec3406b40f6c089e27ae766b46508a39b5d4ec571b761750a6a7a76fd1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPK12",
      "id": "856006549b2e8e13c544e6c67bd58167ce9969f449667148e1eb2a3338488beae129eaf10d26a494ef6e279956d106718c002c45c5532e868160aaafffa03d3a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPK13",
      "id": "09a8c9fcd8ff34d51d5dbacf813c1c2b7416798b5aedcbbf8e7b2a783a24ebe74a03e37c192a512bf7e4194e4fe2260780d2525d89dc43786ddf3e2a6da378ac"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPK14",
      "id": "7c10ba4aa52bc8cb24fca9be53229a6eafa3cf7979169443f5748eac1db12270556317043e9ffdd7e8ad9225bf8825aa187b298f8566ac3c3e8ae485a0ce8656"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPK3",
      "id": "101b7522e38118afc87bed602cf6a518da21892838d8018ab78b2df63b8205feb7cf5c87023e79110c935f390b2bf0e70a18185846a9d007d749b5d91813a33d"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPK8",
      "id": "e370f32babf1d093baa470210581c5aaf7fe894eb3f730dea55f7b963c45470e6ef9fdb12686d208f0f4b4fdeaf6de23c15f4d077cf1cfaafaf2243ead13f2bb"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPK8",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "3849bd36f846d2af74d548d1bf778631ca8e438313e8f5e66ab87f8dea83ed7423fe02708dc0d7de4a32420270f10e281186c69502ae776afc8185c4ca64f431"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPRE1",
      "id": "2d05594824e950328408ebab5d39e3345f113d8561d0f3cd02a8d93b408a6e3158db6513d56c1fe553fec665c7b13720643719c788d315e608d8107a05c26a31"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "frag",
          "start": 1,
          "stop": 151
        }
      ],
      "id": "860a16fdbb3f05127020770dec43578bf30abef211907ecbce2be6e20cd39562564a2baa20b13344faa0ce7b4c2884492e1299c19c1cde6e6ad23457b79a1852"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "frag",
          "start": 235,
          "stop": 324
        }
      ],
      "id": "08b6f019184527fd17ddc4e887b3783c5ce51839a0964892283d310d23245e7f66e39e9f1d07c760aaab38d3af60a5bd4014cc4af33e742d93d052abca6c4389"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "frag",
          "start": 2,
          "stop": 18
        }
      ],
      "id": "4af52e09b5ab14838f6f77e19ed312f8884b60828a8d90cc29396d339d1fb4767da76ae3b0959e3b39110ff5ef5f4c4f4c5f320db40d9899c6ecd57ece04e9f6"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          }
        }
      ],
      "id": "477da027f4cc816801b48eb703818f9a718f49f94e52957b0352739cd31a2594baf534492a15c31da423a86a25f83960130c3a1b0228ada82473e50759feb1b1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 163
        }
      ],
      "id": "924504e9d7736e6c101c69e8a2261f17d7d97c71b3d4da275e041d73e8ad108278c367e68b262b052e0d0d094b60db33c42030774355866c0c7cf719093d0eeb"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 174
        }
      ],
      "id": "181ec0591a619b610662aea42b8b23044cbb323a81060cee49804d5a20a434973dff706a7b3a9e7f079305c63f5b638e5bcf8c96e023f87a30d63349f845ebf1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 180
        }
      ],
      "id": "3dcb14470d57805f1fe6270e17c328d4c77b14427fff062a5852e8cc7dc8a5904d4c644c367704f085730aba3e0b788cf336cf91061fbd34ae48c0be38a99787"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 225
        }
      ],
      "id": "c66dd132a2ebf4f796e49dfb02bc4f760896404ff87ea200d084adfee1d9b2ac3376cdfe61dcac1fd83dff94c5696acacbcba3a8cdd23f66648dd2281b205b85"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 254
        }
      ],
      "id": "b0dbc6d451db7bb92390f60660f8fb5dc03379e5585b7a2fad1f5d529a08992bc31976e0de6b459fc47174a1c301b6c750828f268589d91ffc71cf15fba1588c"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 259
        }
      ],
      "id": "a3365c9fb68c735385f4bd234fb3ea8ab0c89f1928b115a06fa428af68ac5edef093f9cb54a2686d5f7fd09700d62ce9a6a4042f866a53f2af69fc2aee2160f7"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 274
        }
      ],
      "id": "dd0a384100817ccce038c3f0cdfd6bee24a44f94b8aeed981415420aa3e3f5146bc84c6f4c98a2aac50be1fe68787ef056d2ad5727b5bfdc8b4dffbee6ceaba1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 280
        }
      ],
      "id": "b3327a6bc072250a5fef544daab0adc8ed547e58a4c383a553009a015e532a34fda6016098f9ee83a94b315f11839b828a120df0ed08f97a336886c88160ae67"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 281
        }
      ],
      "id": "16f5587b2883e91281ed04533207788ad03b349f3eea2ce26d77e44869e98e8531b4dc0551c6dc5a052867fa18f996e8d1c01ac2170f3c7da637cf12963f8bee"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 290
        }
      ],
      "id": "3bcbd0a59d82651a4fc9797d9353d357450dc5a8c060dfd7e8feca3f60726740ec7d0b8f8aefaec1bea50bf8c78d4b53dbd1a1ba0896af55bdf5d0f1120dd366"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 298
        }
      ],
      "id": "bdba7d01ed0809d206acabb7b85a21666fe37982a6a0493cc4baa514343014e0e20e372c191ffc76be47c15a7e612f017960fe5d8249589562ddd938eae4844f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 317
        }
      ],
      "id": "6e406a220875c668eb2c7329483ee726590f7b5f5bfa6285396cc1b99754bf55414da16f191e947f9b56c95ab7caa9fa6510cea74bec17b34368acb483b54fd4"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 321
        }
      ],
      "id": "06a4a4ca7e89ca74888b5f35cc84018d0861803576fb895985597ed59684d12f06586e4a56df22637d66e888fd72ddbe87a9f7b3e052833bbfe0e0b6a7b5d865"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 331
        }
      ],
      "id": "9af7938bd48bc70323c457e4a7efc9c559b52a5e6c9e5722073eb42b30919a2a2ad2f56666d1549e21697370f4b98497b4580381fca4caf37382e09cf60442dc"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 343
        }
      ],
      "id": "fb344526ada91518e52ca56b5b023a39803f8c0bd3b1aec52c99c396a8f6ff97afaeb6632c81c5529ba368ddd123004ebffbfac94f9ea7b0cf542806db33bd41"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 347
        }
      ],
      "id": "fc86e060f02d267b739ca33d4379cb905cbef2a0c5eed20de663d828a3324796bbee6c2ec802cb1060e13f3643f123b4385167f861aa643f4439a6d24807d256"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 352
        }
      ],
      "id": "76cb40b3f6655af1e440f76545dbecae1f8b73ca9ba0314a9ca69b947bdc4ef059c964193810b98c1fb3ae091a16da1daf8cf804b1e5014b63eee192eb86f2c4"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 369
        }
      ],
      "id": "adcb21423be952f37e9362c05da0bb337a9f42816c78be70c10ba771e4e82debfae8c2a9797454d4cd3f306c6912d5b13154d84a9164e8e9b5c4cff86a55ea9f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 370
        }
      ],
      "id": "e2c51c039f3393f6bce745a836e0e9e9052f32932054c81013f2ba6f03e364e1332f5262c8604f8a872365711128f7226c8e402f027b07b7d88f90e93ba91192"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 383
        }
      ],
      "id": "2483745d6c2db640c57bab1e548a659c7b72c5ba20ba0e4eb03bce2c372a173174a458c4d5e3ec4b268cf9c78df2e1fc1355a569c09d24b8a57e0327954dee9a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 385
        }
      ],
      "id": "6df22278fe4515239dd20ff4b510833040783d26506beb16865c48cc2319717e1d0d2aa72a2f62a28ed89f4474c451098d4800f481e60cf8a49a469273f0a9c6"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 395
        }
      ],
      "id": "b4ccb04c19341f9e37c4b033f2ed124a60c23c1a1df25de8599f32158e18761c2860c19758a1d05686e5a809cf46a01e418f48012e0f46d6ff7dd8da0d9ca2e6"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "O-GlcNAcylation"
          }
        }
      ],
      "id": "540b2c8483c571637a5144c6e10212577f9e9a2bb06cc332c8559c23992505bc78e695980e3b3a95bd29245afbe8cfac4a5b6c101b3d4c83c66123e6e424728a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "formylation"
          },
          "code": "Lys"
        }
      ],
      "id": "6f6f5cfc6a0ca9714f6e80aba61381d77eb91c24bfb8270e47c8d84e4e8ecd34b357a3fe65f37426267df899084ac7cf09ce47834adf736ea26d7fb102493643"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "glycation"
          }
        }
      ],
      "id": "0e5c75416e02ced058a7282374ee9bb59703a39c9981a529a1ad30073c362a484515135bd7d9554f750953b48c57b8f8827d5fc085c6a77b463df23d19736a24"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "hyperphosphorylation"
          }
        }
      ],
      "id": "ede67fb639f29861d91976fefa16d8279b53ae13a659f35d70ed12e01bf3f339ffcf701fc54c7c4e908fee9902c02aac3e0022dcae5a7afa217ed2d4dba133b0"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "nitration"
          }
        }
      ],
      "id": "859c1404d850e52a0b82b2fc010c579c498b5e752a798a9f7eb13b9054c1d9159e57b02d56cd977ffdb37162a2d64696b07768605cd8e0416ceadd25b1ff7929"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "nitration"
          },
          "code": "Tyr",
          "pos": 18
        }
      ],
      "id": "957e932e40081e4da9f8566065091c3828585e20973add76c66dedf5d4e16a9d5123d962985512496689be0ac93b4c89c801b5daa38f1371a49f7b1fc3a6cb50"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "nitration"
          },
          "code": "Tyr",
          "pos": 197
        }
      ],
      "id": "d37938274c43ebf71a6d34f66bc57b698311692a89aec8c372fd75c6f78362b8b5db58f24e27b43c129be09d5432b0a38c014d7aa38a3769ebdead3ba688c39d"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "nitration"
          },
          "code": "Tyr",
          "pos": 29
        }
      ],
      "id": "627c3951c630c254ce3bf9bac6333246569c85c31c965d2aa806f59f19f017a043b332a1c9734d87f59bc5acab4d7458a7fb2461df3e7b4b2b43dc3b79669fa7"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "nitration"
          },
          "code": "Tyr",
          "pos": 394
        }
      ],
      "id": "9bba9457b3ef962a7009a498b857f099da582fa60ff0507ed477367840000389c6f348fa65f40f8714942798c46c48aa0cb9f60ee48c6850b569f65736a9235c"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "polyamination"
          },
          "code": "Gln",
          "pos": 6
        }
      ],
      "id": "bd492aab477cc68c1863f8f31fad3bd7d7c22a4fc3ed6d3ce02130bec98eb5e827e562a14e38374953aba0f221c28eff6e9e3075ddcc3a515ad3bd191d38f5a0"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Me"
          },
          "code": "Lys"
        }
      ],
      "id": "c1a0b1028f8a7f858da6aa5081f652acc405267f3ca0b3070cca1a4eb51ac5492dd285f4a455d52a3b3cf9926084c2531bb5067e53b4af362a30db5a84b989df"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Me"
          },
          "code": "Lys",
          "pos": 163
        }
      ],
      "id": "a67f673689923811702272970ddf1bf670e2e888c180f6e5c014351b6105ca45950091ef7c74021334d40aaeef753700466bf27f758bf1cd3a0946b68ac170e3"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Me"
          },
          "code": "Lys",
          "pos": 174
        }
      ],
      "id": "59ae5959d9550bdc6e5248d0681bd2a94add5061f0999376683ce74a62b4928e06cb7714a4b06b8d8fe79899e4034e6981834dde48f37e85cc80a0bf8fcd2062"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Me"
          },
          "code": "Lys",
          "pos": 180
        }
      ],
      "id": "ef0388347d53fadf66b84cc28e845f6374c24bdd1bc7a57fc86e61f186f7e06661ff40fae0bc6c14b31e5e3e44938ed61a53663ad0f825be9de769ff571b6a7f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Me"
          },
          "code": "Lys",
          "pos": 190
        }
      ],
      "id": "b4db8aedee5ac2e6d8b986f8d21ee80d93f5b15491a389c838f10488c7e8ddb8d9e84a4408136177375fe393c2a2601247dbc95700366774ab434c6cb0695a58"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Me"
          },
          "code": "Lys",
          "pos": 24
        }
      ],
      "id": "5a06b49ad275126eadd4a57607f7d492ec1f75e9655a952190773d7acdc269347732ae35c26f9feed73917c2f0bd3ae5ceef0265e9d8f0e8d8816b1d472107f8"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Me"
          },
          "code": "Lys",
          "pos": 254
        }
      ],
      "id": "d533d6de40bd94a7ab17655338688d1fcd2ab0164653457266e11c6596d93059e0399751ba92e9b239aa7c182516272568ae0ea65824140e98fb044bfe1b463c"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Me"
          },
          "code": "Lys",
          "pos": 259
        }
      ],
      "id": "1524ad0ba3e77655cd317edbdfd9a08d2e2b8ba29f64c96b177a5c249567c66f7b31d725be69109132db14e406e7a64e6d6b63466dfe1b4199602f05d076bcaa"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Me"
          },
          "code": "Lys",
          "pos": 267
        }
      ],
      "id": "47d160c4febf4f6e2f30e83fde17d875c73b756510eec1d13b34122a10793bbb719dbf8b0cf9de2a07f29f2b738e05afec5f52f53bcfc50647070b6bc54f7e98"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Me"
          },
          "code": "Lys",
          "pos": 290
        }
      ],
      "id": "92446c4d03777b76ff78c0b24a78e97302ad7aa8eaf07ee5a4ead7083d4182dae970becb156d14557bb624b3e384cc52fe48ec90f2167084db42086b79d0a909"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Me"
          },
          "code": "Lys",
          "pos": 353
        }
      ],
      "id": "582b76e84d0c2b5cffd2a6e4e5cc5948f4809a3260775da4927f94939b7046578c435f14e8ab852b285c6b9770fdd2cba34a18ce5247c5061b3317dd88aa6308"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Me"
          },
          "code": "Lys",
          "pos": 44
        }
      ],
      "id": "5895e3e228f0c9083ea7e3336955e7f5139c3e032f48720a4cfab17cc9065bf005ff9078511b800f3de6dbcdc188c31527a9e5b89d9228bf409d16bd2aa2fddc"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Me"
          },
          "code": "Lys",
          "pos": 67
        }
      ],
      "id": "0c388c958cf017384386bcd493d76cd92215ef06a042c6af0474ae469114afd9f86218300b5936ca88fed3b62ca2515fc781961b2ada907a0c4844c62a1652e4"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Me2"
          },
          "code": "Lys",
          "pos": 311
        }
      ],
      "id": "42d96f245721dad3e244a0f1e9049ba2be04f05e387021dc8a010675e2cbd5c95f3f9f1dac42f0b4b9f39a238efad2032d11084fcf85c5b9f8e773f92b5dde35"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "NO"
          },
          "code": "Tyr",
          "pos": 29
        }
      ],
      "id": "456d8268959d53521ff07d6f1ef87cf2ef2fc46855fe23a1636c06050a08d32c1fdf6eeb562152d8109c7d798376303457cff482cb2897535ead6d9d3df968ea"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "526bae251987f8c4f55f6e2451662fa55e087c57585beae7c389b020d73487c739834e9b8ec841783de6a5b5fb9df8b138e9eff4406a9ec5e606766575dcac0e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 113
        }
      ],
      "id": "2d45567b15e65630ed1b93e762bc448d9a12567416bcdf836d5398ad517bbf1c094d567f995a02e816233dd20220bafd7e38f7cd7dd41c89a166ccc6743d537b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 185
        }
      ],
      "id": "75b42fa1c0aa953df52cb08d23e7dc966df5307e29a3ae1d0f7818df66e0101f640f6c7c22f0c634966b3f9c474d2f7ba524999afa0d4727ecc25339309e6fcc"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 191
        }
      ],
      "id": "91567106b0cc6e1d58876b25321df3319882fa1999664f9826f66c0cbb59c735fd536b429fd9e6aea9f27f2f5a326fb2bd79877052dc613fae468bec7003901c"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 198
        }
      ],
      "id": "23229e7f6dc2bf173403d9bc808422a5b6a100f2370367781711b66a26a18811ac115f209983947877e33dbeb33d95db28e3cd0e6f0aaf4fc6421272d3bc9bd3"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 199
        }
      ],
      "id": "a145df05055e4436ddc08a7d9e576954162015f2fd2fa4cdbb4e673261fe4932313e7e8984a94c3d8624252ea9edb21bb2b1a15071d766a2ce5e919d17a2735c"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 202
        }
      ],
      "id": "49b56446b699c749fbb01c4560254bbf621f44bd52a02cb74e212fb0ef1b9b1616a31cfe6ca06023fee3689ef552a3e8fe71211987ebad4180c2d78535f4ad7a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 202
        },
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 205
        }
      ],
      "id": "4fcea2746dc6350657bcde533c76e30c8b9f5df2483dc0af72514a8ce8cb0df294c86eec202ea5542d89528b21c678ed7636e10891996d79b04ab8bbf03000e5"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 202
        },
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 205
        },
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 208
        }
      ],
      "id": "2b548e317876d3db5d886d05db39556e7a9accfe388e06ca0595630ad2a6647b28d4f72f9d222b0b91737d55b83c7444d86385ea8e2b9ce9fd7578ecc468edd2"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 205
        }
      ],
      "id": "66b67f6eb9ade14075ce40f4c43a2e83ba332e2daaedccb416095a9abe9fd249cb23d95d9478191e54de776e55608add51910b340f1698012595b523aaaf1ce4"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 208
        }
      ],
      "id": "6d66f6a10862943ed63cfc384e3757160679622da832f5cbd75f0a1b1187e97c3acb12e5afc064f1b83b7b83aab93b9b3e93b507797f2b575759ba7c8ae185d5"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 210
        }
      ],
      "id": "fe30f3537e882c5dd3f43b2870048ef2032951e2c9f102125143f32514cf5dee3c2e2c3d8ea179a6263de877dded5c9ba6a0a9e5dff515310fd98650b4eca96a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 212
        }
      ],
      "id": "cef38fa2af273ce517efe12bef540f968517ee3c12bd664129c1c74237e06cc3d2b818698bdce0a324e8a672449bb2984524609f2cfe5bd1d4154c9ea5e1e280"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 214
        }
      ],
      "id": "46b14deb2ecfa74d6446d3e6b46a5346cb195bfb1f14bf84cda1781071705183d0e3122edc843b7716047c6050b9fa1b4c05319f6cdd0e15964d1e33098ed086"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 235
        }
      ],
      "id": "56b559ea103ba90d8fd62e908303bb518afc413fa2e659f3043602e7e227a4f345231987467945e1a02d74aeb5a1840ec6759bdae3109cd4836894ddd9936f95"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 237
        }
      ],
      "id": "1253693d98b286775fbc4f4d2da854a7387d16ee36b86e5148450178dbd67e1b83bce11e5d0332259b18df0d5f95261fb8da5b78c69e1c3566ffdbda36949f06"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 238
        }
      ],
      "id": "3f98afe734b0571a74435d1eb675eb8f6bcd8f59201d3b4f94f0cf76ff1b512db61971832fc2a235d150fd7d904248b5a344841e460ce0c3cd941f12c20ab7dc"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 258
        }
      ],
      "id": "813b2c9e98c372302231ab0cee4d998447b97427cc013bb818555b065f5942ee22e7986edadaea26a29637d0901e8ef0711cbc88c9138ea269e82576f0ebbd1a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 261
        }
      ],
      "id": "986ebffe4c75f05ff6d7e2ccd9d97a2807520848f6dcb45ec30b9077c36285264d7437d8eb13a43ddb37eb28f577e0541364cdc221c45b4237a5077657ed056e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 262
        }
      ],
      "id": "c20d653a77090fa48337a73d9915475bcb411eb52f7e239d287da66a8d92ac32ac84146976f90af86f112ccd6fb631b1dea88f465bf333cf545de4f9a44d07ef"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 289
        }
      ],
      "id": "f8a8662750833c70fb5890a753ed342acd2a7565ac70de5bdce6bfea5e2cb6d7822207e4db6435b434325ff01c298b7de12a7374dde2d2dbc0bc0daef4d60fdd"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 293
        }
      ],
      "id": "1b5143cde2b7897fa7a020b145e0a9fce4f2df640ac4ba9366d12105516cb8ead50636fce3f63a0c44b71f830b7a031eed8b5609566e66097b303ad88e7f528f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 305
        }
      ],
      "id": "7376a60ac62d5bc5c5b65540f315e9b119d47ee3e50e7be5c6539daa52ad13c455e024af511dc8c60fd243796104c6faae38902601f23d415c9a2610cd43c636"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 324
        }
      ],
      "id": "4805a0edf03796a5683c509e11a5b33bdc67387a40e06b23089c93257a13c3bc4533e83c5c74391ed15159cd6b8fa3deded29418730b0eaaca178c5870b9e44d"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 352
        }
      ],
      "id": "84ba1ed58bc4846e085bc47d9f8830633591c4796085ef2eaa9a94f63322b056b9ba57c398ddd966e53242f762569138173a8dec13591437bef6df1367be4ee7"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 356
        }
      ],
      "id": "48317023adebba2bdbc3547d0f7ee43578ecb436211b91ef867ec4d820c385520ab83ed151305262f74205eb47f03ee242509a03e3210e94a0ea5a87589d4241"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 396
        }
      ],
      "id": "233ebce30d7505cee42acc956f9d268e5b725e14853bd56fab3b87a93a4e0c8141a6fdec062d10e9c4924f6e13a61184600872c2f5080656e3ca27227eb4cb93"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 404
        }
      ],
      "id": "a448f901ddc919f32d50fa5284355b4eb4ed52e9ebf8705052086706d728d8ebef0cc66616b7fbfda3aeffd49db6e41134fb39996aa9b996a73bce331de95767"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 409
        }
      ],
      "id": "539ee3c1726a2627e811c0752ecca01c4b4e6805a0d33e648ea000a6c5e846850ac3bce1d7826ac13cf8f9b5a18fc2f59536e12cb0caa084c249ca493ca6f504"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 413
        }
      ],
      "id": "36a258cb3297b4d1f2d977824fb5deef793f37f08d05d612b3a9f803bc6d1a7121faf74e7967da2fc34609a4a67f7e73ff68bf48cdf8d3be9fae68f99306e484"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 416
        }
      ],
      "id": "95f21ca589c0cad8a7000b25e760154c63deef80068a34af7811664eb432812193036f90c3c493d415f3f4db9b41e43c8de288d03648905543503520c62df9ae"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 422
        }
      ],
      "id": "8e1f07e8873c9ebee75ec9b0a1a7ffb03dab9ea5b9c9044f19ab09dbbe2146bc4635b3ab6376ff363fa6042212c12f578c8377abfcf27f1505f826dc990acbaf"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 433
        }
      ],
      "id": "169d89993be9696690861c61b095f83b93ca65b5257571545a91c141bf1898e7b442f6a70abe85cd912c2bf663c304ba26bbb5ac17f840034b7e730f1aa5a3ce"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 435
        }
      ],
      "id": "9e30c0b2a4cf908b2be54d9b2a31288e2dbb5fcd3041c7e4c4f6a2ae5fd2339d1d97d969179be59aedb2e6871d860631699db76cbdbd6edbfd7ddbb43e9c88c7"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 68
        }
      ],
      "id": "fd1a762ed713b561a5aa9a6e1c75209ca25c87df139632fa91095d155d133427de2ef812a6ec21262925d291415b67511edcba3a99b4facfd6ec098bda50e97a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 123
        }
      ],
      "id": "6aa23f25cd1a330a5a42bceeae02cc5d855176226764066df5234e3d40f52fcb4dcc7daad9b6081578e43e955aeb7cab665ce4a9f688b3e82fb7947d71e42384"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 153
        }
      ],
      "id": "0b51808a15a059752bf6bbcf73ebe2cf1676847795a5970219cb4f39e01e68ec49c291a3702ad661475394e336df429656a4dfeb384076e337993ec86a5f390f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 17
        }
      ],
      "id": "7213323bda2e267bff101987d39a3cf3714667748cbeee0ae3758842c5b46ef622f95aa7b7b608364d4b6db4bb58a2bcbb21bff0f0ef18a0ea795f3f54e3f953"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 175
        }
      ],
      "id": "26f7fd6bd59cbf0fa5bc4f3d25bdf460fcd70316cba794b78ab64db9d3d1c7722f124f119503125597b407b479475892579bbb6e4cf37b39c97b19ab3f1eaca2"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 181
        }
      ],
      "id": "820b780f4d0abcec3e7acc5219d0bf0d994ff6274f5579982e73ee0337a49544a879a9cfee0a37d3bd9d93b5e34382eb0c319ef7f7c31ff6f74841594b6fb17a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 184
        }
      ],
      "id": "5e6936ede9465c5be198ae25c524751d6fe35c809b8412e2c1799577fa25a5d52080dc5663bd2b69e3ee02436d04a507f344c23ef5c3e4602593727c37e98667"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 205
        }
      ],
      "id": "24f81ecd30f95a3f531b41b720220bf9d7658f3707c73433cb4f0aa57bc57aafa73ff95df5991871c0528b3a9de6d2ff36d46cd5b85e906f33d54e6b47bce815"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 212
        }
      ],
      "id": "d10f7602e71867be5adc0f8e0dc989e83163432837ca2c5869ab7d763dad95b87dc4ebcacb9c440ac7c30a31e1b7f42adbacd9bac529384743ab44360f7dc34e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 214
        }
      ],
      "id": "f3d80f625ea3a70232c10f04642e56463dad5be961dfb2f627b976c84a9bd65d95a28476611f070f4bf8a3d951b449e0617c3fdbd719608500893e635082fb54"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 217
        }
      ],
      "id": "b4d5af93a5669d322815fe554157d6084d3e61d0d7575b2364599e24718be87f316e289a0c882f7c5316ffdbc939554716d4349e10d245154edcc6ff90e53b13"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 231
        }
      ],
      "id": "fd67fbe5c0c0911e8bffaf415eb40748a781d8776f2e2cdf8a3f4f97f0f2f312aaa680c7b670dc27b11d220f0079b4d5e41cbcf095a568bc644b6e9eaefc50b3"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 396
        }
      ],
      "id": "1762476d34099811da2cb4b7d10cb08b78d1a4ea24ce4abc52a18a5464f33664bd06c155188e940668d74791a76ecdc4aea55c5552f3b968d5e2f3864f570376"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 403
        }
      ],
      "id": "eb95f91ea089241e02cdd2480ae0a84ed872279e3b9ad05d68fc99be26393ad2e54856ce8c59dc98160f11516a0716f7db3560b368fcba813004e1d281cc817f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 427
        }
      ],
      "id": "84a094ed7326471c09539780f71bbebd4af0c38bcb28e4821dde2b6612d2fac6b05bbaf8d849837dd0a613907bc74494ab63e0ee823fa962449190f5a33cd161"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 69
        }
      ],
      "id": "1c3fef289df791ea6eb56503aea0d44632c075f1dc363dd2856b709d7ec9260da9c22df05fbf2c4079a5a446ea6a06994a043102528af9922d18eee2c1f6cd48"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 71
        }
      ],
      "id": "a4623e86c79fcc618b0182637ffaecf134b5e3b9488a3ddea4f1e7ab994969cf699b78bd03a5cd52aba84ce4b6550046c79b1216a5a011c5e011b95e88cc7f76"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Tyr",
          "pos": 18
        }
      ],
      "id": "5b045c071b780caaf6d0a4441b95389b9857364de91d6676af9d7497e2f4fd2ceda3e2ac4bb7f5e526690284a133fa5fce968527f72d8e1582029f1551a0c7bc"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Tyr",
          "pos": 197
        }
      ],
      "id": "9acb9ed919ba416b38c26f509c6c8861c1bb5c31a1521af3f3219653f2371049ce79f04f51f312bd747ad81ce355ddd88be74d446a2f31110d614e319ce5709b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Tyr",
          "pos": 363
        }
      ],
      "id": "e0d16a106ec96be2cd9c9d4132b4c5c80dcfab67461838cc261997ce80268df25897f50b37d80e6d41070677d36fe86beca7bbe6414ae10e6337d53e249ef6cf"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Tyr",
          "pos": 394
        }
      ],
      "id": "a6049a3fe7e4c819ff2c683d6a0b4603e380eb1a924cba6add2bf64e44f0d3bdc913d0ba77528062ad380e45e0f41a83069b70e52b528e119678559c79c89b4d"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Sumo"
          },
          "code": "Lys",
          "pos": 340
        }
      ],
      "id": "ec59d4c884da4185a8d0a14dbefb7d176ef3eae2d0c25f4226c8d2ba4d7c78ee48f2a3aca88997edb32239d5dc1c5e353391a54903f00dfcc90b3d4c21f81592"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ub"
          }
        }
      ],
      "id": "b82dd479625165a1698c7d2d4c226eda11a649423410a6c490322188f1626aa059f6c0ab1052a838dd260fb3b0cde95fa88b8b559dbf59e85e7ad83f6a623350"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ub"
          },
          "code": "Lys",
          "pos": 254
        }
      ],
      "id": "b001b02ccf84a76ed8f4e4fddc96fb8b9dd4524efc208761195655a5b2175f748e454ddcfb3549aebf51b3d5701899f2a9d50232ceec1785617a62430be9d090"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ub"
          },
          "code": "Lys",
          "pos": 257
        }
      ],
      "id": "ffcb9e20ecd4cddb46ce39d52055b2d85d2e3c75731f977b6722b5d856b3a65bb0d69cc33077e2d1465e6468aab5254fff06ede09790949b1bc34a8b528a7c51"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ub"
          },
          "code": "Lys",
          "pos": 311
        }
      ],
      "id": "5dbd7582d8949161c83812c8fabc8b2854c94bfc27874258c913167d937d082b49afd2d6978e2a16aa347ad7b196a455e7e6ae2507bdee6ba177d52d65c8f7d0"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Ala103*"
        }
      ],
      "id": "166f9ab6403a239e53340bbdf4d1b42979f1c57f0dbe50be263cf93e18d94a249d28b65c39b5da7bf8e81cc63fab069421f2299b7ffdff87a8dc95bdad3c1f8b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Ala2*"
        }
      ],
      "id": "0a77d771529d70f5a77d8a97ec1cc451616072256d2e2f3119059e5e576e04134c5decee4ed640350e035a82249e3251c7ac4f70f4726e415225840cd51e3964"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Arg406Trp"
        }
      ],
      "id": "e2c6b44ac23c144aae60bb608102b6b740cfc30e692b52b90aae62eaaf005d3daf38c0847fa5fa3eac5e41cf9ec4172e27a580dadb4f143af0bd607dbfaa1dcc"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Asp13*"
        }
      ],
      "id": "a045a745463abf75da4b62b66ac5d6bf45ef4a4db092c571e5d22fbf078b7701c7e959a5a1215748536215047a1f619f3f1bc8d5fc34b5d01fb8a7ae31f95970"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Asp25*"
        }
      ],
      "id": "fe658fa643e6cf28549ea355b9fc70eb755ef590abb611978bc51e7317d10b3ccfc87420473f01fed0a876c3ecf259acfc5ee65cc1b9d3f159cb82a2df0f1143"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Asp368*"
        }
      ],
      "id": "80d89a143fca0489ceb86f5d10019f4b6ca8e0382e30e3b56b64243ebb8ca768ac895093d453914877b4b7cd72e2eb7a1196327469675dcfd19ec1ee08eb0e3d"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Asp421*"
        }
      ],
      "id": "92d73f3c9b7556e37294688918f5267c5965a8c98864cd49667adafd050cc97a029cbbbf5743781743810dbb9ccf3b83319626a886dcf2e0db80e7aa302c3bf8"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Cys291Ala"
        }
      ],
      "id": "ac7681fe79a01fed6dd7da91a0aea7cbc64b8f0fa724019fcab78b6a86579091f8fff03f6c06ea8b445807c47afe1a8aeed95aebed5116871ad9b2a7ff597104"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Gln124*"
        }
      ],
      "id": "9c43d4a046336cfd07a6a8fe5eb0862fbbabe186451ccc7bba5a5837dcc4a30c6d0fd375c8dbacb87ef71b14a4ca0539be66155abb24cb0a0c7614ea770a13d5"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Glu12*"
        }
      ],
      "id": "434bf0f4bb91f11a9df4c6ff0e5a3923f11a8d3c5f616191f324aeaf2a569509419662c1959f817839732c9f90c6e7606b8f11f6a8abf1436d76dc9669161bda"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Glu391*"
        }
      ],
      "id": "80fa0884c528947e40dfa85db933a0b76e64f1e95f3d91e4f733ad5a8461c5d675446b7cb718a1b2ca55c88e0e9d4727cfc86b136efe7b2b83e1d0347dcca6a5"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Gly207Val"
        }
      ],
      "id": "8ec1c99579e6a8f5f190112097e0293035537f79b2ab43193ae958cc4310f1636805580580bc4a17fc62a8e541d4e63b73305576f0e8fa2be8e715fff53cffd4"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Gly261*"
        }
      ],
      "id": "2aada9911bcc38fa659a7dd9f59d6e5500b7e64af9d2d430b9d42090d0dcf584e65ef1025f187acd7536b0f7c690986cc363b7d3eb92246d8df070e0b586a557"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Gly272Val"
        }
      ],
      "id": "02d14869b6daba5cb929814210feeb293db957b1d4509edab9acbb35cacb9d98f8ee4b909d6ea377e35d17b4d69ac60003bc8de4f85b3760be5290b79b34d420"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Ile308*"
        }
      ],
      "id": "7be95f8ddafdbd2b87dc50192b753b9b79f6eed1e7aa0c1fdab659e474ec416984706b247964e17333e0b527d2c19a8b220621d50d8e8a2ea32a484ae80c28ef"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Lys174*"
        }
      ],
      "id": "74c1be70fbd8fd9e8050bdd2b79afda0e469d21921bc7e7b4658f86f2288dafc2d477645ca3302d21eca8c2a8c548805ad10be089834098f6d34fb7d83c010d7"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Lys224*"
        }
      ],
      "id": "68898a86c093e7fa64b1a499bf276a7bfd76b13ce743738852810375065386a10f87af564074a17f86b0a14ec0114070003f27853837ffee401b03c52a970b41"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Lys240*"
        }
      ],
      "id": "c2f581aba697ce93641d127701d08bef2d4adf3f529d6299eed539f6fdb75161dac5f696828d305311a9d421b58759c8a860bdb75821617d92c3ab5718e25df4"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Lys259*"
        }
      ],
      "id": "e621c14dae1bbfa7ad382c11b78b5a059b64dead39467ef7e1ee0effd9195860672ef5246caff84d95f1ee7b529e368ebd6cba829071dd9d2dbc79336f395751"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Lys280Gln"
        }
      ],
      "id": "7851cbc832eb1c1efa17d060a73d2163f52407b87479c3d403323a43b0a6ad4dd9ab801c3de50f1089a20ea581342a3091632c457a79b820b61f62433605b882"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Lys280del"
        }
      ],
      "id": "318218ac836a14f9a05a4b072076a1e4f76349b2ebf2f26a0f5313e2951f1e2ddc7db1bbbaf3e53c834901fd047efc6424dd216cc348563ec4ed04e4b04edcc9"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Lys311*"
        }
      ],
      "id": "ba386ef86089f4ca4c8b385c815eda3498f7502765d55a2aee86d3784534779124875ebfb55f97a7422dabd5b6f4c1c67363cb9ee3c7f5fad851f6e6a9d04fe1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Lys331*"
        }
      ],
      "id": "69da559177060c4a262c6caaa36cb3313368725cd9086804aa2b5836e5c08315458c07b77752928131b13f39aa5506f0c8d33b3bdb86366b6621e388d77cf237"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Lys395*"
        }
      ],
      "id": "2052fa117f9d9ab01d189e6e5089c681510bed8d0275cc6526b1afc2d0a993c616aaa993015c1f08c6666b778ad7349d5c80fafc257078cc548e4d5ef04dae6d"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Met11*"
        }
      ],
      "id": "adec66d11456a899f57c7ae52a1c4b266f2a607775939a55f92a970a74aacfd3625afcf0c7c11466f8f56b9b9c4a81c16ab9a817d27a312034a37f4532d0c467"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Met127*"
        }
      ],
      "id": "1f6e1bfa025bba40920585240c9fa990895c1d687238053df400550bbafa671a67863a089ec3f94d98dfe0c64f599dabad971b2e7b807d830d360831da294637"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Pro172*"
        }
      ],
      "id": "da6fb53aca9ab17004176d5ec0d266f4e378dd24b6fd78976a480a3ed36a43f2728e43a476d7b8ea2b79d1c80fdbc24716fa5ce8eb5d6ece44b2a5e63622460f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Pro301Leu"
        }
      ],
      "id": "69abd82dda56f5ab5ce8a6536350e0d44945d6d00ecff099a36fa97c05ac6435b6ddbac8400692d7b1b5c86850a820df0f7558d8fc0ec4d17ac23eae8501f650"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Pro301Ser"
        }
      ],
      "id": "fdefb9fccd419a680b6a483b61369698122adfd362204e80da9f615bcec85a7344a6eaa9a4227f5a4d1a549615ca53db17a685ade8e5c00bce64a93850284361"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Ser238*"
        }
      ],
      "id": "1d5636aa2e73312f142377b37491640f6b0d0f6ba9f1347fdb6ecaf3172a8db8fdbeeed814cb893334fd7d652da4e9a0ec07b8dddb348d601d1ff687bbc71953"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Val306*"
        }
      ],
      "id": "c55f06f34f56c1e5c7e0372bd0a85e99865f5aa780b3866924bee956d2bb1d7832e684f2df407ca708ee5c5378e7e4aa27cb0881ad28ddce14321e6d7ce307f9"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Val309*"
        }
      ],
      "id": "35ba2e7b78cbdb3e35e214a424ee58f337e835675b20701fb234f035daf5102f07a9e0ba5d8956969eebbfcbe06d4b636823ab5b8ecb9b8d40933a0f3c41c29d"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Val337Met"
        }
      ],
      "id": "76963e4bfedc72a5446a25ada3286d4d4b98f67b49cfdae9dad5a1056c7ad560536fb2c094c264540de944e0a8d5ec972cba7a1de6da23e77f511f669b7304e4"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "pGly207Val"
        }
      ],
      "id": "8ba439755cb052f867b6bf59fe34fb0451816505b10c612084e39ba1bc98b17547fe392fe1e16546a3c62ee63753fff68ea65f3ffac9b3de13f5587cb48a7454"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MARCH7",
      "id": "3fa519216f7b9b580fc4f5c64f7b0095805ccccbbc581e951ecee6c808f09923fce4dfe09d9e853cf5e43cf1fdfbbfed3b229d60cbed6a432faf0651fb7537ee"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MARK1",
      "id": "3b923d6973c25cbdfee62919800a0d68a70b6bc3f9665505c92f2e7c97df7d1db6363714dd203f8704bf8d1ed22d79db964d4cdcf19f7c7184fd20a7122d66bb"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MARK2",
      "id": "32e9705a2cfe2236e89f96b1de2674ed6b928f961ba06a2ee26a04d2758841c562de68ad629751e3068693935cde11d4c376ccf85a83ede814fd5b8c2721eeca"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MARK4",
      "id": "0eb599977421d74c59f891b0aff058c7ec15122510af384c9656142725a4594c439c39272421c252bf9977bc313414906559e5c89ec907f05c9a78d1e2d24290"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MARK4",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "3cd3bf071f4eb0920c756e2a89e45f0e6a1ebd784e7fd47c2eec9d3f60271d0d29f61d8e2bc4d60571b9d5fff725de0c728680c0972292375c16e0d5327cbb13"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MBP",
      "id": "0789ff9b645936d6355e834c17273561973b1747c999861abc6bf6182b031dec990ee08bc308f3c90c6e5ca68dfabe64fa6a8638e250f9f475f5095795c00aea"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MBP",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "072d9a8d1218be51608b7d75a8f1781472e2d474e082d80424c17f1e39da864bbca1a8843e7c168bf606838b3bcd246e8dbb2f2dbbdedfdfa59962c16facdec3"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MID1",
      "id": "782ec808a800122269ed7a89410e82b0c3b746250def02b9968ccee2fb354a1b8c82577b29bd7663de4f6bf91f42e70ae761b031f6078a50e963844f46036612"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MME",
      "id": "8495cf2e994033c3769854828c023757130813a9381008860adb2cc801bf37359fe1a6b0b00d3b9ef95d354e2e2dd1383299cd272d751421c61fc1eaa151af30"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "NFE2L2",
      "id": "f707e81d79f55da8c33a4f0fad8eda52a2960c3256f2cd831a5d51542d824e4ed26a18f97cebba93ca1b75239d492efaa0acefa07f5cb15dd98f75c9078ac249"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "NFE2L2",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "4aa3820836653756d322f394a9033f1b7d649c765972e4653e7c51ecd6ef8e03c6ddc54224fd917491bfd34f251746916480f76c1aeb5d3d7ea7bca3b19b9668"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "NFE2L2",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "UbPoly"
          }
        }
      ],
      "id": "a57f172cde497b89a2937d56501afd2cddf3c0c4a457b1b6be90ffe7e7b57f55f2e7dc249d8036d369518a8cc41d131e3755e378574405e0464ba5bb14f42e59"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "NGF",
      "id": "6280e1263996aa31e327521e5975bd06ec1fcc254924ed2e22ada8044eaafa6aeb9242e083f65427b4461e8f6a7d39b80be9b9a35d3509d266e3ced9c2b7afe4"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "NTN1",
      "id": "916a22478244efefd2278ec6cd5491b7b7afd930c757f2124e96096acf8c25f50b2ed4eaa618b308a20304a561d733e412aad74267b3eb0fcb7763fa7e442a3a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PDE5A",
      "id": "883c770a838b01c8e2e2aaecbf6e1c89ac935ce399f3d626d7deedfe803c3b668af790623b4a66b9769cd2cf694c5250906d48d8a986458ce0a56206a9f38bbf"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PIN1",
      "id": "a4b6cab238e3cf3e494c884c3b540f12c39b1604b07e59f53693996e4bc2658cc64c2c01ccfa634d6236037a0b85aec593bdb9b7667a3f19d8d33e93614f39c8"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PIN1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 46
        }
      ],
      "id": "aba337be4b0943f95a970431bc4ea73d75bd0515459057eef5689d60b10ee109740018268bd7640c7646847b5776f1c4d1af38bf3f1d4f95b4fcf59f62bbacad"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PIN1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 16
        }
      ],
      "id": "45a9218154f6f57968bbe193aff13d326ad67c90d428639546b73ff532c869d5dcebdc37bff7b64d2ae6adcc00764fa22bb7e3df27184e37761286dee1437eb1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PIN1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 65
        }
      ],
      "id": "a472300f82a51c46e2bd62114f1fcc1976c7cd8403b1bd7efe0b3c7b4a90dd024e0c863245c39d83b98102cf44655625b3fc6498a3de11d3de0b12157c3aced5"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PIN1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 71
        }
      ],
      "id": "21de7e66e7b03df8d297a44ad5a890e23f6af25ef163b5696a6c058d2a4cb4df778bb7747f94f453b6a42afe5d53b8c448f578e86a18ebf017cf22d39d07a398"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PPP1CA",
      "id": "19124953c156e3054e3f63443a0bfb399d6ddd2c4880303a9cd48094f841ee03d20cc9e2e684b7a031efed73344d0867ca2e933a249c417b75546dbb681bd266"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PPP1CC",
      "id": "e93ca2409cf1f7cec1f6c3fd68ba9772856d325bc4919b423dbec27b5242644b97b65d4dbe22d9c46b5cef234d7ad756e9695bc612cbc5ea94acbb31e846fc01"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PPP1R15A",
      "id": "079f6d9dfad3031b623d0d37c4145b5dfef92ec569f6cfadb9bb223935fd62a9b0529c5551e59bc931bd76fc1f445427b7a0dbd2c87c023032218225bda2da0c"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PPP1R2",
      "id": "838178b4cf6bb4321ab67c79abf10352015f11c7c5607ab40425f7f4ac6ab444be0506ba1808a8787e782edc6376b115b43f154fdf6664b1b6b1a1e9588926b3"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PPP1R2",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "e13b3605961c80172a5e7b896d0e3d43d755547ed8fa1f2c178b4b5478865e41d2913041827a5992c76471b2704c188efced1170cd87d66b298f6d7387f540c2"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PPP2CA",
      "id": "6baa9d09125d1244431e7a8a8d8788f573889554982a8abcbd5c5d85b5f5c28771ff34971f8ab09e92bd0d7517b229ff34958f0f1278cc23410b7141982490a1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PPP2CA",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Me"
          }
        }
      ],
      "id": "17c90267832eef6ddfa94d7ca01d8ee51e1bcca7e8efed68135eb6ca997542b7812ad6acb6209ecb1e074a9bad46bc1adaec1c6ee287957e93eaee62a2a01422"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PPP2CA",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Me"
          },
          "code": "Leu",
          "pos": 309
        }
      ],
      "id": "06573cfebf86de2b8622286919ccb36598415bd5c9b385fce726b146d85516b4113a049b1c921cf7e7b2e06c2685a22686af283210b6b5837e0817bb770986ff"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PPP2R5E",
      "id": "8ecab3f25b5b7665e70670a755cb36f72df322db8726eed95c91426312b41594b99f2862f4c8dc7f61c369d2b104b819aaf4f7d22ad2a7a1f5b8619f69340803"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PRKCB",
      "id": "89d6ea031c95a3b01154ff315aba7b882e1d4efa61e5266147bc1c1f31078561d7f4e634cc354c761725beb40395363aae82a1238ef07a12ee21c9155bf4c152"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PRKD1",
      "id": "65e6505e723c998e058d0283bf83a88458eac2bc0d3a1a359138d645754eb34be6cf37bc9d98e215a61647a59b33896339ca89e8b59d9fd6d3760826315777ed"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PSEN1",
      "id": "1bd45a944b5c10f3c058ae82889876ff98fedf45e982a4db6a034e656845574daa76c407b40b21386a2b59045178e42fa90d4c5b8226477d9f5c86c4b4aa727f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PSEN1",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Gly183Val"
        }
      ],
      "id": "ce136c370dd28346d02dbce65147fa5df1f1351938cf0583fafd8ed7d03db33b47dd7f35220be796f0994f1fff5854af67458ddd79fe18176a0c9e69d6f55945"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "RAB14",
      "id": "637ca48112880c43a7c7d20c095b983df54fbbd7ddd93b53469974d9c40d4339126af9935dd30f18e677b6a84a769c300264d8587a144b2c7b56436b47c2c645"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "RAB14",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ub"
          }
        }
      ],
      "id": "c0d9d01d0bd41da372ecddd52aeda5c86f98629a2dac23b84ef26bd71e285436ca3a3a687ef362ae4e333e59728a207c740c2ca939a89ed3a9ab0525147afe74"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "RAB3A",
      "id": "f0892e84616679057189d66cbb54099c6b1ff41598e6e29f533dc6e9506f225160c23c310257636329cb17e97f8eb07726caa386e09364dde95ef74e0cfeb4a6"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "RAB3A",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ub"
          }
        }
      ],
      "id": "41c82d26663159e00bfe32c56bd649fa3940643bd9feac4b8d4f171e40e623939f5d56c1936d0f8974a48453cddfc9c9dc18af26a32ed962e696feebbcec2f8a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "RAB5A",
      "id": "9ed8ca3851da7f03fc1479c502d152b264193c44ab5647c073985b3fe814db730dcb15e208232900e0d007c139d4c153488fb8cf0b3e5e90389e2a1512f2c225"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "RAC1",
      "id": "1fb022c2de2f8912cb3e05798b6e9f44f07e6bb387d9a93fd99151de2bb49ca2494576b2ce2935975991c9bb4d53372c2fad23454a01e170f139bbc85eb7aecc"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "RHOA",
      "id": "29c25652678fc59b247c44fbb9f46b7b3854f81f5e6693c4a27f6dd2333d57474cd0a7e8d4e35d9b3361b99884cf7e4555764bed72320d0c5fe9ac8880a443d7"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "RHOT1",
      "id": "1e80553c912815d51ee6947bc4301107007a2b8f23a8bbab692379227f6fe5f6ce19f3e052789a0c3b0e8b940e52a4f2e5a004e9d423f08eaed1b2eae306f240"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "S100B",
      "id": "f7c74d78e50e9084bbd32771955eff3c412004927980d769d1edc2fba3b569af908e85437a88a7eed468bdc0b56c2c60a4bc2559ff565f010a15f1040abfc855"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SCAMP1",
      "id": "4cc08e463d02e593c704c2247a62ff59aff1c5855d720bc9621a90077456464b9f330579c06d5f8bd4e3ec1371d2874b4592b9f8e43ac38ec83a67d7eee4fa08"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SCAMP1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ub"
          }
        }
      ],
      "id": "72f70449492f73b0fb4c0d65cd430e73323eb7f04c64e96ad3015f1bc5a7b9b1aacd57150f4f1750f7d54dfd8c066e44da77436fe277470d6d191e31991273ec"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SENP1",
      "id": "f5e1a5df2ff057f50593d6195792a684d7b83981686e91ff279463b9ddf523adaf1e504c5c8df717aeea7ece5f1f6cd67d0e5bb3a988189e109c29c4d3f212c4"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SIRT1",
      "id": "f8ae229ccf59eb0423431200e2fa1cf7719362512511880bbaa90df7dcf8590b8bd54bdd49b275529304bb7a982202caedda5bb0c8fcad07f6890aec3fb8f7f1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SLC17A7",
      "id": "d889b5ebf8dd0780ed1f2b05e9e4a6aaa16d4a321f5ccf024c018b23927dde16dd95e8cdc66d25bbc14c7796921c84c7ff2cb4674da8da2a92d41d5237d6f16e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SLC17A7",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ub"
          }
        }
      ],
      "id": "5b7e2b7d1706cb73140c9ed8d398db80ffb6b21c90b425edfbea4f4e22ac863c7740e5ec221b3e6b482823e58644e3655dd05694c8a801fb82750cc2395e5f20"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SLC5A1",
      "id": "5d82caad676897f5bafcdd466df1f475ff9afbc9c71cc8cb9f39b4e9ad591b95ebba0f410f771ac70e62f29a8d3baf10e7741009488d0d12eebb2ac7e4832ec1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SLC6A12",
      "id": "a6511f0f36d91af08d1c7eb9db4f582095b042e4ab9977e41f38083f17c3ef9bde1f7c74c1a7e02c1f463a532566331d58f4758b5fd00aeb26afcbb29da2950f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SMAD2",
      "id": "ac9eb6340da114bccc3be554fb1b60e05ad8a2d5ea0ed8e6071fca40d08c35057421eb77165117ab24cd8b2d03f168ccd7ab57f9c60e050758f697c37fea433e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SMAD3",
      "id": "f1df97604661ba3fb80211b8bce03e38d1a54a645379df8d662a585129a7fde66297e9f4fe99c9d3af6b799df93ac7898204b802ca5aa736ca1f6bb3484cc66a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SNAP25",
      "id": "8354ef5b34ee16cc14e04cab05bf959da036513b1631eb7e2f5fe73aa670ef1f79a5d0eda4064f912ccad361e3b719cde2b37eebec1f91048159ecd91ebc81bb"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SNAP25",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ub"
          }
        }
      ],
      "id": "83df778369a513a77862f89e9395fc55ef0e88ef40d61c61c12ed5800e0dd760e296b791046686cf6b3e7ac0f0827b812a3f971bbd6daa591a2cd7977e2d3f1b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SNCA",
      "id": "4345441d1f420dc0d830377737dba9467f21b1637ed3472a697534ce698f2566b780dd52cda47c96b782242b1bcfa70e9a6147fb3bb251d1f3e1e2a0bb7038f3"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SNCA",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Sumo"
          }
        }
      ],
      "id": "4a891893628516c7679d9e561fa8bf17959c1c849f8512fb7d393496107c09647ac4396f15ed7ffa7c9ec92a0db15023950d1f4e244395a354f728ee55abd51e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SRC",
      "id": "89cf6fe86000d59fa342b801d809a06408db3c65a224250ba500634f4976a061da0e71d6f72c101186d9032a0624af6fc3b50e209815858d6bdb51831883be6a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SRSF2",
      "id": "bca6d35e8fba56e113bdab5abe2a9f32e73d3bdb5bce41a17d7f737fb93da503d02200a2594df6110f7b25bf285dc005e3508bcf8789d29e5c4715bd19e1309b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SRSF2",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 52
        }
      ],
      "id": "760706185d66d710c6de5f5074939ff004148cb85156b92798079be9a1da8a3b1987f203519c46b77b0e2e1d9aba6bd74ce7ffd8e49c040f949af25e608b68e9"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "STUB1",
      "id": "7edf63ec4c2eaacc63944e79144be59c6ded86334f97e772d1e6ccbca7065106451bd7861e8acfbda8051ed22ecf6451dd68a33a35fc2d3b91083a48b53e1c68"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SUMO1",
      "id": "1e1844dc2cd090887d357b2e8c7ba537a86b2e799968b043145ec3044cd4d5d78eb341878421b15fa34602b1ca0c7d9b08a12806e3fd114cd82806ec54cea6b3"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SUMO2",
      "id": "c59f750e64aa2391aed2d82657e26d9874040282c6983fe94626a9f3c140147876e79e4aa13cba1fecd3454a51e67c5357e780550f1430551c04191c9683a18a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SUMO3",
      "id": "dd749a9402b088979d3e813c3fae9217e34c9c9f2df171c31a9c51544426a8f936c9bb3a747082f8a22bc92badfd655981611ec9a041fe2f341e66b20d374103"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SV2A",
      "id": "5e365e2af11cf5457b19a378393a9709a08ed8ded54bc5f1abbfd3af850f3f8b2ebad61645bd80fe755b146c1c3449df6b2f35cc4c4bb9d4d76abc67852ad632"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SV2A",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 42
        }
      ],
      "id": "60058bfaf363aeb998c7347125df10a88b4ddb83f729f737ae0ab8d9f77f826102d508ac742ff7cb42d935965cf422e74dd7d3b7337f7f954f72f1f49a23384d"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SV2A",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 45
        }
      ],
      "id": "d82553c41851e4fdaaee0ec6b15db6f304b7df920e3b399fc20effc6a9702fbf5a5b11c4f6ab87162d7ead67cfc53db110c94902fdadcfb5144855ed28e8ec34"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SV2A",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 47
        }
      ],
      "id": "51ef5ed8007d216a1268a344784c00b0c29370074592f3c371d342735889ab65a90489c27c89719bf77514f1da02d897d8faa8ac553335b192a980dc3ad8747a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SV2A",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 80
        }
      ],
      "id": "452e1b9e72b04000bf731e7d8047b8496fcb7523686d210ed0198fc2dacd04d1fde748284e1179fa3cbf52d89c45e8cbefe0c43dbae9692ccbc1c5accdf8c02a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SV2A",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 81
        }
      ],
      "id": "9d20d948cd90fbdcdaa54f90dad48c39a95c58a511808a648fa7823342c3cf35eacf83bc35092ebfea5e42745733a9f6b80444eca2240668ddaaf78d7ba7425e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SV2A",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 84
        }
      ],
      "id": "f21c8e9471e1d5b667b1112ee663308cdd92efe74c53be14951e6870f7773352970f472af90b14280a4809ba6e851517868b3cff2adda857d3fb369a44ce8c6d"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SV2A",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ub"
          }
        }
      ],
      "id": "2e94e905ae71929b4eecafe9a30325dc709cb69bf8666a88505a9a6bf5cbd6f9dfb5f6ba100ed363b1129af62077d465e4e34402655bb413ef443e74b1c8acab"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SV2B",
      "id": "4adab261c81a5295965a6f43737d27502f8ebcbb9d8e66fb4e66c565e358124d6ac7b1b7d445c8b3507effda973f80c67f9b42390dc7ea44a2724395351b3b74"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SV2B",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ub"
          }
        }
      ],
      "id": "1faa4a2b47135eecf36e6112c053d817588fea9ed524b04c67f16d20e2c4756f5a2c04973012d0a468c6081f8dbdf2b5b3c355fe87a0292b20d8d8fb2df73e63"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SYK",
      "id": "b0e9f727ba248d29d2019ec99a224ad35dd135d47bfa484f337a0769a1128f55c07c65e3af1d5377432da22220aae827b56233bafd024a629300d6aafcbf0996"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SYK",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "1b5a31fffa7b55b4a61e5b5f615f4646cd2dc618533401e83fd8253f8691a84e923d2d45aded1db9fc7e77b3b13cda697798d72271a30a47281e5bac5e8a060b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SYN1",
      "id": "a17913dd75a81e9bef38a6bf247480f64e8c54704bfde00a5119cc4282ab07929c47aae4270daba60bff6f3859e07f52ce1bb9d5ae24752e04911cc3a857c600"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SYN1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 551
        }
      ],
      "id": "0aee6be62864c4414424781c976406e0c31490e826fa64925330f1c3b238e5f6239c843080ed8f0f8575dd6d8fdbfc96ed7258f54be0aa8b37e453f01ab29286"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SYN1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 553
        }
      ],
      "id": "b925bdfd4291995d103931d6af5b40d502414a7ed9355a7114458d3ad3722880d3669ee4bd87ac35d6ea129dd6ce76215f05dae2887c79c4f6fc80709b471763"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SYN1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 62
        }
      ],
      "id": "bfd04910ddf00fcc74bbe0e139622f6af24bb30660d458c9218254e0a022c19a099e70ee7768efdc936a7991816ea95c258691d6d1e082a1ff4f0eab6ce17146"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SYN1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 67
        }
      ],
      "id": "1354985dba1deeb863aead956a534ab88a2ec68c589598aba8df02b58c1c899fd346dd7a2f863df3e1d8978bcaa7276168efddf2ff80d334ccb4045334abf38d"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SYN1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ub"
          }
        }
      ],
      "id": "370b9986c06164e3b46b08821adc91c21c39232f2ad4adcb45a26f1674b9065e1c76b4be1b47581d2e48ac13e78efb034f938d9328a9de1ea2a54b53b12e1daf"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SYN2",
      "id": "c5a2bdda5914723c21843fdcbeec3bda28f7605dd90001a41e0a64db08ac948db58c9b729c07d5957ed9d6353290d1a941adcaed7ed48fb6e91432be9f50da10"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SYN2",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ub"
          }
        }
      ],
      "id": "be12094d8d06e1c1a8823a54bd7ffcfde8f99591cf9be901927f838510d6b731d86c367b1d23e8386ad0461994b278681ffc5090e1a90cbe45ea786dc606edd9"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SYT1",
      "id": "b7a278b3abaab03d628ac2d176cf130b82a94485774ec548d33cdf51aa40065b2d08e06bc61c76aa9766c8ffa3ae713882da16f875fcee6ce2e24ce3b8df647b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SYT1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ub"
          }
        }
      ],
      "id": "0cafd4e8f9e2a773c0482bd4a0eb3f615da39762ae866376d9c152ba0963cd353cb6eb6cc77e48639c4c728fc7413c1914d89bb0c3449953529432245c888fb4"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SYT2",
      "id": "4b251cc5687f8d921388c20128b7f52a1b63098779b30274b81caee135c6dfcc0aa62142a4badc590903da483187026997b59784162bb16fe935f5abc65acfe7"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SYT2",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ub"
          }
        }
      ],
      "id": "06e3a814b8b350a2a9f26f943fe0be01a2ab488be0077af6f7fb0b1fcc66aa9da1d96c221ad5d7c68637b367249fcb8cb5807d41294bdc3e315bea3b539070e9"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TAOK1",
      "id": "d265dce5dbba6c39ad96b40e91db6af98ac9946dd473d2fd28f12bedcda60f430e5c03ce0fac826e2e7f966cdce019e96eb0a87481303b5da8157637906ef482"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TAOK2",
      "id": "c5b05bf7c2cb1a2cbc23888a098ed4b862ddcee8cb83333b71905f064d7c6b7a13ab9f4de3286f44360f051f4aa63ee031d042122c372503b4037ce9a5313a03"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TARDBP",
      "id": "96048ed5d196081ca480607e30326cb8bb474db3177bfdeea242002c3c7a4681b51247acdfdd0a3ae600face27455ed0e62e9c750e79b240b8e7418150b92963"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TARDBP",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "a245bcb4648885eef6ed6ba999e1cf95f842101325e0e95ba3f3b6ea37d03ece82cb1710fc854abf0a9cd67937f6ca977ee71c613de61eaac29c13c921ce66e5"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TARDBP",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 397
        }
      ],
      "id": "2aa67734e6a8d649e65aa59327e38d1313e930b99ae375039b6e45711d413919d6c352fe2761021dc1c0db236266b8ba5aa59010d12c4da3e93d6db432d94a19"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TARDBP",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 403
        }
      ],
      "id": "59416678d6351247c405b5cb5e66e44c0ec1e53b0c9d3174d6008619bbecb55b6e5b061f35d15ba2c9f7f03dc8215650bc01bf1ba46a9b50948e4d4f481d45c7"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TARDBP",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 404
        }
      ],
      "id": "25474111bc57b1c46fe4e0e5320438b1277db36f747e54088908fa5e4c5df14d661616c0624f4145b57c70e90f0c75d4a2c55660e485338b3752dc5469eb1a03"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TARDBP",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 409
        }
      ],
      "id": "450b935d09308719cf148bad48b216a44cde482c04459c10800fbcbec6c20e67140b3155b3bec43d7c1415b6360257ff595cb13aecba34c1d9a49b6de01679d2"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TARDBP",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 410
        }
      ],
      "id": "d4657961ad60751e0cb29fb70cb4c476c6724e2f0d8e56d0e4beceabca4f76736233c58345b6d708c026ba63ed326bc19debc659dd4787591e58008d1d03d6c9"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TGFB1",
      "id": "f313d14f17c9ec6c1fe807d5c8f5fbfee1ab713b6ff4f81c643f627f61b9dafb695bfd2b15fac60fa9237ed016912fd6606268686281fe0b14e2a1577374ce5d"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TGM1",
      "id": "c246bb3ea681ddb29d5c1dc007fe625338c669ee3ec5219df86f87a61d520dea805dba40891c6bf0b5b19d3524c4ef2cc71feacc14f7442953264ef82c9823a5"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TGM2",
      "id": "954461bfca0f13db007c13a48240c616213276a3e047bbdb8830adef53040c76c0b0d21fcfab6420d59481c73e2b1766cb737abf75aa921354d5d7a8830d17d8"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TIAM1",
      "id": "8fae68d4db79c3c2833f365d771160b3486ab6297790fcc46dd23d85746cec66cf4c300f63ef9b633354b4b469e6f01611a11c68e49f838198506e77f3f06875"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TIAM1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "4e81f741fc78d107c7a2459fb43f3e08c1abb2b85d6684bece98b9237df11ba01cd8c67a89935571c4149dcb305b76e3041f98982d6395102f2731a2fb323186"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TRAK1",
      "id": "65a470c40b91920a09857ebca7d42343e39017bf8f9fec1b5a0e9ae320bbab38273de5eb09637d61f79c7ee68b900ed248d2c642f726ebc3faa729ded7006266"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TTBK1",
      "id": "953b9e5f220bdc1890f924a08949fcef2a6ac710145c9005884fe9080cb2e1a6200ab01e05a8fd99c199dfc362414c6ba87a03b769a7927cfe59ae6dc79ea057"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TTBK2",
      "id": "06ce70fb709c20205eba0720857635bdae1ea741abe91af6e69a52042edbafb3b494de0399af5549f0ab45518d459cb8f5b38c35efa2b39611397110b0d48f38"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TTBK2",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Asp449*"
        }
      ],
      "id": "cd0f80d9d843dddbd95b8877b87a8265343bc7672cdefaeb7e7a4e1a16f981042c938ec662a7e7177eaa2fc823e5e29e9fd041c3575b3120ec194c58f9ea1ad6"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TTBK2",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Glu450*"
        }
      ],
      "id": "0fbde83fda1e9f743d9b1d0a62080e6005b6220f297a4760a3968854b510a3685ef9576fd11b852b3365daf79dba26c2d12d5f7f94631c65a116b536d1a6e6c9"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TTBK2",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Tyr448*"
        }
      ],
      "id": "f18164cbb96069e5e33368e0ae2a3e695c0007afcbd2d648999a3bb6d4647947a59171a700e80ff711af07737c2938c68f71ef41d0355e523b0eddc179d03084"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "UBE2I",
      "id": "58e219ea5b79e990d4f42dc4860759f0d5829ea10b069acef537280ade38f6094ef65ae617403c0dd2f5f3d6a45a2bd522dc482cc77f7de9eeb80d71750141e5"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "UNC5B",
      "id": "fd03f8660c0ae32628f61f5d448d1f404e95f4ae1276eb30b5e476c995f5d888466f8529d2c949d9111f55e7e02e66a2edad9c820b7e8502d5c7c655c408e4a1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "UNC5C",
      "id": "25485aa315bb8631ccabb17072804ba768b7dfbc0295ff313463f6755f89dd8250234fcaa3e857677b8e7475541822a9a284f3d3ca2dda2a1e30a6ebcb441bdb"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "UNC5C",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Thr835Met"
        }
      ],
      "id": "a260f6f318940500e7a744f82451f09254bf603de5d3447c224c27346a51835277246320e1b00b2ba15dc6dd1767b87251d82956248192641c781f5a1d0a9792"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "USP14",
      "id": "1470a3d143a2fd5929b833f4f8c5e0881731040826296bfe6062bd3ff1474e282150885ab09707960d7a54489ed5c13cf8251602f437c10c26dc5b0ca583a960"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "VAMP2",
      "id": "6c818f2d1362dbe865916238b9aea3c674022e87405ca8d0885ca53bbed181fa985f4210f8e45ae315b34295961a08e888279c8dfcf1ec556278c702fbc342cf"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "VAMP2",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ub"
          }
        }
      ],
      "id": "e39004df863e733cc5c130d053fc63d05e9925ad22818e635e53819d82ff2aa870f29670193c5e98ed7613b50f96d7278fdd76ea683e1b84b9b2de2a3a3864ac"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "VASH1",
      "id": "f8c241ee2a69c9e38663944ad902d21b36509a84fe5bf23a2448faa80355e49ca7b5e0e9fc010193462411120c4b19c44261cece75791fb3262541c659b3ab32"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "VASH2",
      "id": "965e2c8d2054ea6500e2fa82a5bd56b4efefede043978010701092736e69ea74c9b9df9917ddb3a35d51170d18b7013938ac2c2eab7a10359ecf1fd8f8e7b23f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "VEGFA",
      "id": "dc40b78f71c3fe81a63ca23d161cfe42c63f15c492d835f948a94a1969fa0d1a31ba93d61e4cfca819152138f259031e8b965bf29f29fb38a3f1d9cb98b597cd"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "VRK1",
      "id": "cc8208ec751e968579ca8e0a9d7d5f96d9cf55a3285b9afbdc07eb8ea10fd6953b09c4f461b81040d2b86dde2883b8315642d28dd2ecbd4cfa93573cedb5becf"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "VRK2",
      "id": "ad77f519ef4ac30297a972e6bba25409af1f3aa4ec51836b034a5c82e54a5aec800c698644b6bb27353306186c800e9e07782eedcaaa220f79962e60141a912c"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "VRK3",
      "id": "b756d934ba86170a63f67a50b5723cd7cae486344bb31618221fe84e2baf461c520bf79a081bc6db2cdb2593a3ad0cfad4d87e33ffeb1e4717df1db711550597"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "WWC1",
      "id": "503d747dcffa4d69957ef056fa02802b5108db038fdfa5fcf787f7aff1cc148efefd570c5e5e1eb9c60fd6c6be07ffa63474970c42d7e65eae6518c899f248dd"
    },
    {
      "function": "Protein",
      "namespace": "INTERPRO",
      "name": "14-3-3 domain",
      "id": "d0a251fc97189b6b4d9b4c6bd813845f13f5ba9188437860beb6c0cf651bf9404a1fbb658a8ba34896becba9c97f86aecc87333c1c9c7c57391fd420341eba65"
    },
    {
      "function": "Protein",
      "namespace": "INTERPRO",
      "name": "Alpha tubulin",
      "id": "aa266735094328399fecdc26bbd03b86015364bac25b0c1e41e924b4ea53edef3e03dbe38a9e0a694526a338d869893920bd67a38502b5496e91673f4c12b473"
    },
    {
      "function": "Protein",
      "namespace": "INTERPRO",
      "name": "Alpha tubulin",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "detyrosination"
          }
        }
      ],
      "id": "63178169a547ba876d0f352f3c0a2658dd82a36cd26c0a2ceac9a5fb0249225155a52e8b34bb515244fcc686a41f3657255a32d9e494cc2bc36812650eff201b"
    },
    {
      "function": "Protein",
      "namespace": "INTERPRO",
      "name": "Death domain",
      "id": "124fddc2787977a14bc75dfec94c01932a883605008e8f16e6f7d1b670a9b69da903140f4e810a5dc2c88e0568de040a91995acffed0a9ad04f88d9f2ccdcd7f"
    },
    {
      "function": "Protein",
      "namespace": "INTERPRO",
      "name": "FKBP-type peptidyl-prolyl cis-trans isomerase domain",
      "id": "6630b88e950c2725f22cf2ba8e0b2e1afc884c1b5d9b403e6db6ba769906c57b7ab776f23982a1d2e0aaddc6497e95e8275c504202efe3fa13d8793e88bfe6b3"
    },
    {
      "function": "Protein",
      "namespace": "INTERPRO",
      "name": "Heat shock protein Hsp90 family",
      "id": "2988f2a3c29b9ea53ca0dbbbe269b88585850e69e2c356cf8809a96231297fce42a977dbdb23678f7a3f8be0be9b59b9a38d7f416a831b8298b10fd5444ddea8"
    },
    {
      "function": "Protein",
      "namespace": "INTERPRO",
      "name": "Kinase associated domain 1 (KA1)",
      "id": "f985a7a001f12251daca2e3a0010feedd29fb50a2233a1e2bd87e7a5d563f67a5fa0e89df6fd6c167661c2f634029ac3dde0e148c413fdae15f6799dd95f887b"
    },
    {
      "function": "Protein",
      "namespace": "INTERPRO",
      "name": "Peptidase C2, calpain, catalytic domain",
      "id": "8a8d228e8be4ea2d2ddeae2f0d4818c02a6bcc74833d78a9fbe652882e7442070050d99ae48493d71df331f31a5cd0c1808041d1bf23ab54c54ab9caf688a83f"
    },
    {
      "function": "Protein",
      "namespace": "INTERPRO",
      "name": "SH3 domain",
      "id": "90b857227034f64ce1066fc20cf2bb0a5620046faab1c67a6fe2c03b8c711f7e3f209d248befe00fd1b0596ac9ecc2b2dd4b7f2925ac219ac8aef8f6c3172b5a"
    },
    {
      "function": "Protein",
      "namespace": "INTERPRO",
      "name": "Syntaxin, N-terminal domain",
      "id": "c81259cd874c7737dad48a307a0ef5f72160d691a0813868a486d3d4d475c6bed5a72967b1d6981d0c1d0a6d5a56a723fef01d854a09577959b5f4678b697710"
    },
    {
      "function": "Protein",
      "namespace": "INTERPRO",
      "name": "Triosephosphate isomerase",
      "id": "cdd7a5a73f10efa79a8817a487c502948843ac8ec80b0d84cbe0d91523cd1eff3b5d4a538101ceb190c290459183abce535a8f362b516eed4834226539dd808a"
    },
    {
      "function": "Protein",
      "namespace": "INTERPRO",
      "name": "Triosephosphate isomerase",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "NO"
          }
        }
      ],
      "id": "9084a52d47969f6c4df607304cf072f93519825b10368eb8bfe860aafa8043a2e485e74549fb86f806ca96d24cf7e7069e1037de2990dcc7fe9663c5b47b9f88"
    },
    {
      "function": "Protein",
      "namespace": "INTERPRO",
      "name": "Triosephosphate isomerase",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "NO"
          },
          "code": "Tyr",
          "pos": 164
        }
      ],
      "id": "dbc2bb686c3ebfe9545c7dfd57e878c6f99af8525f363abe52ebfbdc0fca74da4b8f6271c6521c9ed2ce0c239ce36104cfcdc03857749842b6e90abc09c11d6e"
    },
    {
      "function": "Protein",
      "namespace": "INTERPRO",
      "name": "Triosephosphate isomerase",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "NO"
          },
          "code": "Tyr",
          "pos": 208
        }
      ],
      "id": "2d316b24f197c869110ad06b0594b90ebb21c818449940509a721fc634e8d208df07655a1459983c9d666cf73de8905855a8f7833336ca5beef84aca4d8cad23"
    },
    {
      "function": "Protein",
      "namespace": "INTERPRO",
      "name": "Tubulin/FtsZ, GTPase domain",
      "id": "b52f674125417153c9471426864622a5f7505626edf3bc9a0a5fc7228ebb3ead701e49cb80b4e6bb4c86386fd0e812bb3ef690ed9955c0b322c828550543507d"
    },
    {
      "function": "Protein",
      "namespace": "INTERPRO",
      "name": "Tubulin/FtsZ, GTPase domain",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          }
        }
      ],
      "id": "28f7da3cf4bfd332ccb8d92d39cef783caa0f7fac86341057f925a91e885beca762e6d20d16e7e14a07f107ce7a155d61d384ef590025f651031b941e657b41d"
    },
    {
      "function": "Protein",
      "namespace": "MESH",
      "name": "Receptors, N-Methyl-D-Aspartate",
      "id": "ab91a476fe132c4c83d7b29153f974577ea615b5e5d8b9bf9e0fa9837b4c78ab8faeb90157fee0678d87fae0d5d4a5ceed372d81c6cf0b12f81ea0faf35d858d"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "App",
      "id": "78d5e866274e31ff2b09ef6663cb084c62dad139135478daf1645a32988a8214b14330f44be626991077159244c9e35920dcc0025af376746275c215fceafca6"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Bace1",
      "id": "0ed08903c69f611a662ac9b5d440fe052d2fa731e4ca12d3b56f81efcf760a1333e4ad10a5c3ede57dedebb2462cdb32f458ea86d531a9a2113aa8b026505c94"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Camk2b",
      "id": "d32f3d983cb93a7fcfcfbede26d3a3935c746126bf72f3f902c6ae4e42afa09938e3069b9743cc354e8f34192aa3ee0633612b77140e0cce188fccd71545cbb9"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Camk2b",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 287
        }
      ],
      "id": "41ae26d28d58e04017a2c0e88f77da91328aabe4e8893c5566cbc0fe7d5ccdd3020662a7942587f84e5fa5ebf067e6e645a707857c96ba869f414d2b09c28141"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Camk2b",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 306
        }
      ],
      "id": "85ae42060e46dbf4da7c668112cd52e6a171a7b79b135d362a6d8f3d62216af2ede07225da448936522aa30cb93a3f27df6aa08b3efbc4a675737fc3efa580a8"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Capn1",
      "id": "36fc602224eddf2edd678a0a0698dd9a052368df9dd171aa11f7bf555001aabfde238875b8f656d0e5d73c44b8b0fdf6766ea7369837d693478e830a187c6a66"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Capn2",
      "id": "8ec64e19c8f2af57c5123c75c0e05f891eab7e7b9d265540589318b468fb8592c7dd3aca18e6e82ca6883e2dee84e2ea2b70cdfaa32a78ae1881e9cf71618ca5"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Cdk5",
      "id": "2242415e42a04751fb07681acad9f9769f79233a0a87835fe653ed5eee7c77c637074541986216571a96f3ce1b3c69824b051ac84147deb6ef24b12f4bda30f6"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Cdk5r1",
      "id": "3d50e67a9f3663145ba6a1f0e6d443bba4283d6d0095a685abe8f8e624799511b4f796da0fac59b04f20c1a9af9f65ba68a216dc4abc5f91c4fa44b00229ed39"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Crh",
      "id": "296d5df4386b36079c00f57f90a87484cc714181f51e7e7a6bbe9cfdaa6a623931e5cb22ff8f471d2923e0d61de1dd75b5bf546390456d41fd018375d5bb5e33"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Crhr1",
      "id": "7c572ed2b3f5325df2083d26dcbf2f697ed311544b299d1b3ea3dd77de10f3c3fd9a554877ad7aec6231da0514b4ac26c06cf979b460f8af5ade5f9f54a304fb"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Dapk1",
      "id": "9f6471994bf7d5037d53141c3bf0bd5c257b0a513a0a5f0431d5db8ddcb6320c8f4638359a1a00b58f9ffaafcd1b17649a8e454a1c4c9f4d079dd31478f55e3f"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Dcaf1",
      "id": "59b84bc42074f8bb1e399325b748b4615f4b4fdf12e2dfbfcdf217f1076a9eb3ad8d06c4a0538ce828bf96fb6282c3776eb9411f88ed77f1028b0727a9e4a775"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Dnmt1",
      "id": "0d96591f5ea61a07ee213d18cd4112e046de567a32f541cec48f7bb6727aa00b3b6f5dc4e1e241efc8ef9914578772eed1875250ee8ef3c5fb880d3a01337b38"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Dpysl2",
      "id": "2873eaf227baf135ecf73bc7fe9ae397045ff0a766c2d4dc7126acd2b954c0c88aa985314df05f6f93d889648f5be32ee2bf917fe0f930fcb303a0bcf5c928d0"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Dpysl2",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "6a0c7b3a61d4846bbeae7c93eafeac42a6e3138c2966c8f4b236efecf20f4732c927ee70b5a543480f5fb91c18faf1fa177544066647e711a47ee42b3f63d45a"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Dyrk1a",
      "id": "2e7b2037076194038fbe01ac55b538f712182e5d06da9877c6d3f8e6d1e8db2e03bc2bb55d1bc1fc6c5431ad46716ad6fd44e090c9d09ae0552da0297a4447b0"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Ep300",
      "id": "c8b83a7b9a7e21c46f7aa370abdfa16213f962f4f2c6785e124c8a7aa80f91582fee9a362ff79855802e1210a1d15d315283789d36d1d7f060abbdf0548e855f"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Fyn",
      "id": "aee9e0d0ed2a634d63bf65e63187c6ecc9a3cd6d4baafa17be87b87d465e0077de34c9b969fbe2b92a789df5fce999229369754ed1bda1b65308c1b8aee8119c"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Gapdh",
      "id": "8163b753318965ae25ccae85e4c37f98dc6ecca94ed989786cc7d33e0f79c9b7a8e84731830721d62d8e1a18802274e884482d20e93acd8a1b83e81e0281f6f8"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Gapdh",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "NO"
          }
        }
      ],
      "id": "c723b0d41177775a582d9d8c07fd5eadf5085174373b536fb29836f696443d59115410868438f226543e90afa6886f47899545918c0aae3e47cffa7ebcf23251"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Glp1r",
      "id": "2fceef2fae04bc3c7086c26a5b847e962f71771956772def19dcb6ff15be7c1ff156bd8fc83e91fe7de7faf18eee7187133cf72f2bd5ed8683e987a67a90b4a2"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Grin2b",
      "id": "3723c33ec45447ea55ff3ce548756d5c6bc43bcf6f17536e3ba7511cec0771534d3959703ac639889d0252b61bd664a18b0db232fab4fa57013011d032658b70"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Grin2b",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Tyr",
          "pos": 1472
        }
      ],
      "id": "74acb36a0e2b29ec4cd8d936421e45bda3a712473a6830bfb1bba82fd66edb7cd8c68666a1ec7c7a83041a6502db63568c8b217271980a74105cda7f4cc32381"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Gsk3b",
      "id": "b736f9678213df5d00e417b39eb991aea58a169a9b2d00bc986629a81d8bc014dac30bb5e246f35a286104e3959c859ab388a6b724bbb1e7c8e6a98ca23de14f"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Gsk3b",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Tyr",
          "pos": 216
        }
      ],
      "id": "74f5aecf5e8b6e27caea18012a5b55d0accfa3d81cb317062b190393d6b7fe4c133d363324e4bc851caf130115b7a0230dc8d1832ecdebb5a438b047a1a738e9"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Gsk3b",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Tyr",
          "pos": 279
        }
      ],
      "id": "4d48ecebba2cf9cde2165a67e93b15e4d26efe920c8c363a0ef54692927fcc46e9ce99628b2e3caed6c8c748e7d56a125e99bd75bb1406da54eed99221c6b83f"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Hap1",
      "id": "2592d6d2ede217cc99a12da2a742eb2f5a4b5688876c4c1896e59d793c0472806326271ff34fd324fc6e7fd71f4639156e855503743815297b63343ec25f89ac"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Itpkb",
      "id": "787f3a90a7a0ed1df7f045e263e5e306566446cdd8301487415f96f65c75c8f62416dda391b87d73ffef3ebc2fa2c1ca4096cd4c07ebaea59f30d4f86c892258"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Map2k1",
      "id": "3f9f2a06413e908d4f58ebd547dee83ab0baedfea4ad5d91f22f605bbc241b90c9c371507243231e2cf9379436db1861f91736a1c1b87b61ba0abbfff5928361"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Map2k2",
      "id": "a5aea0f1d1ad8abe839ebd50d31bb928731ad001fcc0fc189384f44ea06338282af4458387e2e7ae76723e26ab23042b83651be8eda7ae35e2c0f559749d779f"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapk14",
      "id": "7b5bbe9333a98a327450f63551d28d2127108ea5652f06df7551f4f8ecbaadd305324a7b55f6e2c1f40ef6354773ef9a85f3d9ddceac7a2eec47fa3f19e5e664"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapk8",
      "id": "180370fe7647f0ed8873ea850caa7ecf749570fd473d7cc3323b70c27da7f06294077ae0914137ef66e09793571ce1a24d88d5e9aa35d98dc52998ce14d2b81a"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "id": "7d94454106658b1e4190b417a419f7ccbab4b525157cd679cbb4da8a006b08c3819b0a360b692358b3f80ea2648890248be2aa7c97e1d59962dc6aa097560f2d"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          }
        }
      ],
      "id": "f7f88373eefe8e35dbdd45235c15a3f973cc5b4ae594df8bbdb74b855432a11c17268b97df9fc604af82e9c11ae131a497e279734efa1f8f8458ad4cd3e747a4"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 174
        }
      ],
      "id": "f342d33f0bcbb4f3e2dba58e6532d4d105668417a6d00b309d7ccfccc75688a1d6b5fa9be196035da5bc54ff5d5019f948a727deb23e919e6e2023a240b4ff23"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ac"
          },
          "code": "Lys",
          "pos": 280
        }
      ],
      "id": "8d5a8636ffae554ea01cde0b13668a727ac628177bb955af39dc3e1d497c413e0b19e853b4190ea535ca1d89de9d6d22737bd090748912351cea722c2c6b5c4a"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "O-GlcNAcylation"
          }
        }
      ],
      "id": "bbcb2df365693602eaf0dc8146b0e49b0c110fa73bbb3aec3b0e60e613d232072ee14723f18b985e7a5c44a10c0cec38d179fd55bd32eb13050c72c6e1fe3c01"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "hyperphosphorylation"
          }
        }
      ],
      "id": "288a16bac682506988ebfa8afae90f04174b60844d23b90b45b4b0c9707eec496ff8c6b60c60d12b5b6519bfd5c1ea73cc7cf89166b95b0e1cb01b21e3d3ed0c"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "nitration"
          },
          "code": "Tyr",
          "pos": 488
        }
      ],
      "id": "760d36cb789a5c3bc36780eb17dc8db8899681d770b38a895ebc15282c278b8a48806639de0e12f5d0ed2d8541cfef2eec4ccb640e1e3fb8b6d9c5290104a555"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "nitration"
          },
          "code": "Tyr",
          "pos": 507
        }
      ],
      "id": "97bc64754cc13c14fc88fc57bc7d8f51cc9a3c529b7473d7676ef2e6912497448b1640f34c2cee4d90c62799d8f37612508a14afcb9ce3ea3f2669948065c435"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "866eb2548d3ebb8c575db22b2dbbed794da750619a04d31b30c8ffbd59b1562d89d2191f4ea30cc09874d9d44f251a203918593f4cc4e29a12eb1d52d0f58bd4"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 178
        }
      ],
      "id": "1020920779898ebfbd9b19dc36230a3b329f72f283dc74ccbb4fa04e8e281dbe4c3d225b6566f99ec768f29b6b8080cf0e128fed3e69f726a87a14ad9157ae7b"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 195
        }
      ],
      "id": "0fd3d9131996b8c4d2139061dea9486d97d62e8dd37ea32005ae570f410a3f564b37b504812272a1703882c09b681fa19eb81527cdfb42ff3594bd333455028f"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 198
        }
      ],
      "id": "6478b49c13bdb713c3fb67165e61be1b82b03dc3813633577818b6ab6b677a653b159d511a44447969cca934e8bd2dc6ce719d7303f1314dcdef589f7a16ba2f"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 199
        }
      ],
      "id": "9cc6386fa317245c3b93323545afa288d3bba82d474e5df97d2cc7abba8b2e73fd2ac192e8f9fae571b4b3905acf77e21d1b6055f11e3c8da8c361d172eebbd1"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 202
        }
      ],
      "id": "adeb05a2545ed7e47feacb95c1c9c3d4153b6290afd7a4d785a7d4d0c5012f970b0d922f6c7c784bf1eecf40d4db81b2ce754f523a92e217a81d7ca1fac5c970"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 214
        }
      ],
      "id": "2682a49657b632d8c1a55baa852ffd168b5105b756edd7070b3c811023decc0611fbae84878f7d60cf6fa8ee24a99b5ab5aad8f2cc83edc40afbf1a8af926820"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 214
        },
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 396
        }
      ],
      "id": "d965eb6a352b7be64c532663cc1ab21c95c01897413f283d137d4c3c16eb27e0e5194163c32a3fcdd654842b969725cbb978b1ffc22d153be9835674bf732674"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 235
        }
      ],
      "id": "24113381e0d97183a224639e03f1e2e5dd3732f0c59b9eb748a595d7b45c51a1242ee27f9e1a527d1f49369e295b6269ea9fe39a4db1157ae108fdb92816b122"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 239
        }
      ],
      "id": "32ef4ab005ba35ff8956f9883ad562da9c8636946b85c85e873c9dfe176e318b09b4eab137383abf5179222f33b784450a55055852fc7bfbc21068533751485e"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 262
        }
      ],
      "id": "774dc9ce9aa23d42a68d439c3ac0c14f505492f33ee4f53ae8f5d346e47ef0ee5e16cc78e93c0627f3418a7ad9bdb5daedcda352a48a8aa138b17104fc7e68ef"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 301
        }
      ],
      "id": "f54a2e2adf5b91142b482d19eba652e35566cacca79f1539f513eaf95f1a66a332b4ad63148ca6666c4df2858fbb8afc9184aa1474803ade16c41e3024bdd76d"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 396
        }
      ],
      "id": "69b41bb93945901dccbb1dcfd9330ab59edc188609471d780f4b5edf6ef9d2256e20f679d1dd3266da2c2fa35e123f4c6c797463f998a780c57daba53fc4fea1"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 400
        }
      ],
      "id": "a06fd6358cf1d994fe598c9d6eee64d552d1c744f65f91283f0175ef145154046d8636ec13630c2bebd8a29897bddf707c13d7111d65417a77e57d4e396d3298"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 404
        }
      ],
      "id": "442fce8f577e193abf091e9602d2d4f76a03a8c4049345c06f1affe7099e4b1a5b6a22208070d9ffa3e2ae06f1c17e281a86be1f56b04778b1e2232b4f2b6b34"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 422
        }
      ],
      "id": "e4489827a92cfa4fc7f643563742591b23e5802d8925b6419e7decebe404dbdf398e2e513b7af9b2366bcc205c6f751458aabb20a3c33a7251c6448594547e55"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 149
        }
      ],
      "id": "bc82151d7df4282c23faa4faf7be547c5f88d9928b2ee28b04fc0eeb79a5a9cce0aeaf64594feb64ead415ab78b5d7d84c62f569579669731d79635d12cea21d"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 153
        }
      ],
      "id": "7b7b9a027ae06334be3405f730b77a05cadd772ad81586c98efffaa01d1eee72fbe979329368e5fe5927ce3e2bf62757aa16c72804af0a0aa696865b243abf76"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 175
        }
      ],
      "id": "452b1b9549ebd413d8258af79fba71c2588ad26d04bf57ac3e93b3bdd66ea7b2c8385890849487f863aba7be0e08167a2d42622fb2fe6b65617e7befeb98b7a6"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 176
        }
      ],
      "id": "ad9e5e27a772b5f2b0a85b1e4eb053cf5a13d5f16dfea2defea1425e314451ec9482bac079a862fb368dadae7dae6378c21d570b52654c8cbc6ef44c06c9b543"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 205
        }
      ],
      "id": "1900d07fc7b40312b7bd5d0aa27de973c354be2820d28d8b146d63d9a5398584866618260085a240236627041c2bf98b06cead2fc4fde0e9b9cd5711635c2614"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 217
        }
      ],
      "id": "7bdf4890d4ca5177d3281282715779b43cf27d5259ab86c064d5521708498988d59fed7d79995bcdb4b85ed65a8d5ee7f25ab3bd7cc9baa36dde922621a07614"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 220
        }
      ],
      "id": "0317b1ad9030e7c6dd5ddcf4232875a092daf517b37807d16ac3a4b0e4cab1fd628161242c4a1fcaf64f410b88f97c46a69e3a393fd1622e4d6a6e7a7b278b73"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 231
        }
      ],
      "id": "06e5ed954c3bdc74a056a4bea35f334232e39354d3aa2eb01b340e1ae729752a85c6e01e7e666e178fa22ead5ec9c4dc9b99daed50c79b8eaa1bb6214bccc881"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 403
        }
      ],
      "id": "6516ffe17cd5ad75518c1e6f8c52c2067613b05584cb3e8a3f903076b9c53d0e76a919cd6b571f93b8491ba131fdfb08d56f20e4482f6d79c30ce16f1ed9dec1"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Tyr",
          "pos": 18
        }
      ],
      "id": "bd5ea39a5fa2ba78e8a1a907154cecabe700185666b8094188907ed8802603c46256ae94f545a2cf3b8d29bf715d6f9e3e41ab720f3f4d1f0cfd429121701384"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mef2d",
      "id": "094c77a51ab0c2fe95796cbab9510fc3e9a5dfeebf2ea90935e9bd712a39fc3f45df2bd753e27875e419a54c40f0949d31d2edcaba5db2fd9c2623d5bac66aaa"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Pde5a",
      "id": "0575d5a30b33fc268bda09006f94adc5d266322ca1f7e8802fc122353060ab03015787355d67a0c1cece7ff61828cec2bc3a1f275c1a43feb246b5a91e33338c"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Ppargc1a",
      "id": "789fea0eaba9cb060fdad67b6abff48e7a8fd3f92214b7aff10e4e8435d17e1c54c62e30ea9734bfbabe0739ec1e513be5acf1ceb1823a841614a31cdba9a445"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Ppp1ca",
      "id": "520b7128584cc13b73e3910e62a0418bf6f3d1fdef954ebbeed4864f7cf300525d8852c9bab5a06edb358165a6266f346be227392d8602d4b8096293e79a915a"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Ppp1cb",
      "id": "4d1852b47420f7b9f262838279d00b398e79d21e47cc4495309d39d4b28184af5e1854f285e464b9d0ea42adcb8ff20bf80ad1e30f9526f3712aad7ec5edd855"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Ppp1r1b",
      "id": "978f080da8d556dd3980714693815d79298a7d94347f1e18c387cfcc214f0c04f9a3ff5def0c7113391933161dd5c7babee4990916cfa86a1535f12e87e934ca"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Ppp1r1b",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "2018246e297521f150ba53db130014ed2e6d58e32de9275ce137486495edbd35c747b0aff7c07ee52e0760e0b557994b1b0092eb2f8782b9d059322ecb785d3b"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Ppp2ca",
      "id": "39d0ec1aa2afae2f5ae9fbaf3ca784a96935267b83e36efc04bd6d1ba639ec1fe8fd795771b1bbdd34d7496fe08dcf91b11cc8a9f5b372b7804dc6553edee0c2"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Ppp2ca",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Me"
          }
        }
      ],
      "id": "60c8486884335a995d3d2aa3f4ced01ccca72ce7bbec866d0fe13f39d0c4e82061638abd9311902fc4037e73c8de6ca47ac94dd7d67d09e0777b314f203cfe2a"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Ppp2ca",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Me"
          },
          "code": "Leu",
          "pos": 309
        }
      ],
      "id": "388ea51fa6444a3500bf41c7f9671fa03bb3f27fb36364fe7f33448d02de364e5541cb5120226e6baf1ffa9e531693a331099c05d81505f1d4187b5b8e048f0d"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Sirt1",
      "id": "cb7dadd2b2312d27fa3f7d0fbec0a22fc2158acbce77108909b5de892476ce2c7ddebcb2cf5ec22dd33f41d10e71fe9c4b046042c3478c64cc305463eea0bdf1"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Sirt1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "NO"
          }
        }
      ],
      "id": "3a792ae8861167cd8305686a3b8a9fd8fcd4bf242826c39d39191707b3d57f99a7536ab2981ba29614b0f6c0cc09d0407892ec92f2f4e6851f55fd4665983734"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Sirt3",
      "id": "6d5d0b48d18aa0ca1467c99fc69c3fcb88b65f887878fc05974b1cd0b87155fa47392df610f7ca0756f62d84cd4315a308b77d75d70c6ef5dcf651a3b76a7684"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Sumo3",
      "id": "c513cecdf0f0de06d7dce94a75815c4c46f8ae3d4319991995926c4f3ead22f5b3fcda5865f2e634cc97b183a3af8aaaab5b22eaed77bcc3ea07f38257f039a7"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Syk",
      "id": "bd11ebc1899f947ee537c7e9479799678cf93c6a28389f65a0e380baa84a0e3a8891d8189c60971f436ddc998000edcfea30556bec8b12eb0e9ed062518dc7aa"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Syk",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "8b80046791f916c59dc52f5965dd41e265211dc1289b118e44e95c73ba43a7a7798a443b11bae6fc92662657d5b4972e4d6a3ce0cb18b720636969da31157016"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Ttbk1",
      "id": "fbf35bc5b97940d11375c060ca0256de61e50678f944b5e8c037f313484086176539725fb60484b1ecf2789dbaeafbde583fdb3693d82c1fab6148333da3d8e9"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Wasf1",
      "id": "4bd04779fdfbf47c2e74550fcfb31de1d4168210b99844c3d60ddb94be5bc814d54ac2e96ecdff91ea11f000a688f31c3f9ef4ab2f86587a5a4edaeb1dde7fab"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Wasf1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "bd366fffd010b0efe59dc9f90a4a38b9448441d17a0dd08c4b9ea8f1be66445e387eec5817adf9947dba1111d2e16868c118f4f2e47879b7b1c52f6ebbe86bcf"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Akt1",
      "id": "fa95a2fae39432c06cda75cd618a17d4050da02eac8deb833c2dfda2bff3c90a41ee3e9ea54a4d8d1b1823e1bf5352b28c6611a5a1f1717fd972e7649991c0bf"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Akt1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "77f0258b256b436b5a5067ff783167e5cd989dcd2f91327d8c51a95f1843e409fb40a159689020536a95936154ecf739192fa9cb0ab103ccb745c3076c4056aa"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "App",
      "id": "5dad0776e6effcc7e9f851e2e9ad347571fa169bfaa3b15d4c17343cecd9b2fe9589a20e46697850223a5803903cf5b5b8a491c2235026a6058806538512a23b"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Bace1",
      "id": "a44fa59b5ff0113b24d5cb06f6eb8905411729543339114e82cf0f3547f1a3b9cabf8ee3bf53a4eb4bd2b559f30a4f431355d4f5d9b409a0c4ff83409339d34c"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Cdk5",
      "id": "fc81bffdcca54d97c9b18d9c3019e0e75caea943062ebf95e1918655318cfcc3b41b83c3549661d79cf2e83cb74f45315d0450244445d313476c190de5966edb"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Cdk5r1",
      "id": "0a31d9ef412caa7b86375c05ed1eaf67708897d7a340009d33e494764f0c5b38f11ec671ea93937b3100ebab3a111a671e5a8c62b040515c11b1eab56a50c380"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Cdk5r2",
      "id": "ff9fcfa6f7cebae4ca29e48b51d1b8e370988ef3a6be1f7589e1d7bb812d1518f32e0862ebce1369ca187c16008dc793ccad49e41c84160825c2e6b37e6b9674"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Dlg4",
      "id": "0738e7592f6a944a063575870c162bcf10d96a887a4fa772d7412248780aa48d858c8fbac036e9f431c16d76639221882222e5b46ae1ea7cb6c149c28e166909"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Egr1",
      "id": "0ede27155b623a03b8f910c87ef6f375bb31d757e9144b6fb0b495b51f3e60f7bab5233df878728046490586fefc7ffcdbb51093e3af576bc9bb3b81b1c6d4f4"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Gria1",
      "id": "afe07c7b65a6a221a601d678d2fa7036d83d05cb363a23f0b8e6785060baef77c81ed9e7c5ae0b0a2983a883db3c643e29fde598d96f09a4c42538a1de8f9904"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Gsk3b",
      "id": "137f1f82763ee1cc81cc9cf818fe0e88feeaf3b017e968939560e9f9e15ea0b3f3c1ea05938f4ebcbbfc7e4d8ff70ce216934a8afb7e72d1af253c39219d4d52"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Gsk3b",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "17cb6655c81bae53cb1fd8d0d71dee2c4d52b1c671bef207bbc79eacd6014584701b0c402460f727775379c06ab790b06351d781bea9766eefaaff99333b0377"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Hdac4",
      "id": "66222eb5a3d4303e7ac5f25c6296c68385271561aa2dcbfa0ff38cd49e5bfff8234baeb9f4a5a61d5a3d8e31ddac95f9702776281160ddf2e1d48c0647e320e8"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Irs1",
      "id": "04bbfb965e707114bbb8705f87445221f6b0f2b4f3fe94864c9c74f17cffbf0533e90e2d73d782db14e14f86f24ea79629eb274c83a591ee285fb7d510dfad74"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Irs1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "2638456521c0207caf2a0f539ddedd335573ec62386e014f24afc981fad982c1f1e720dd07a17d9788955afabf11927eacdb922ffd96c6aca684ac8992feb989"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Mapk11",
      "id": "0c3862554460ada66a2f2263299c0f89673a853250d50b5c427751537dfef4bc2e1efce2b4cd6e3e2108cbcfb9786b09c17a9363b0e166d916ed6f970aa9d494"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Mapk12",
      "id": "7bb4f5f9714c5f2968db167b59a974f18b9e16b018a4b4f12dc963ef04746f8a7deea4565d8055ac7edfe55a9d1d502b48e73f865cd14fc0b09b6a7f5e659346"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Mapk13",
      "id": "565773ab405e940c14b38272264e9595e8e293b8f5a1bbf3161269782b8d8bca66ad41a827abdde6b224ff05cd9795b4d7d580ad660ad4cc8a6b22f01d882074"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Mapk14",
      "id": "764ad0650c95fe1d3e93975bbe5c8019caed00ab79da402be63e705bfa6ef3180655ba8139adeb5507dc81ad64dd8304ef206c70aad0481c35b02890226d874a"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Mapt",
      "id": "d7ee72cc866dbe8148a83717b5c56b67f46b715c1c11fac47257b38efabf4f3947f73dc4a227db3e8e7a2039b162b0b1b1bbb0d7605e6e651f1dba7fedfc3bd4"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "nitration"
          }
        }
      ],
      "id": "9a8e7a927d8ccf91543e8ab73bbc9e28da8023ca976dcc7deb26ad7e5b408b64cfc190e52ad59f2075bbe7e4858976892d5207b323e2064b27d532fc50339d50"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "3b0967909beeb3e40181b42fd6d8b686507dc30354899f69d27bf9a7ea2017d23c8c8eacece7f76cec5a6edf1718c6a64dcbe256459eaf7543b8049d477f0c96"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 202
        }
      ],
      "id": "9fc4acd80445a710f7b7350176f8a9f5414a28c2091668b338cd04d369b40290aa1316eb936735a5981fbe122cde80814c97654c267789d69700b13f019755ab"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 262
        }
      ],
      "id": "2a9befcb1fefd888ff6a094bafc265bc3eed45799b070d8a4ae740e070b9b954ae1143fab8a534fde672bda4da6468e132a369462e29b7d7e3bc3a231f3bf78f"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 396
        }
      ],
      "id": "744bfea9f94f4f19a58d6c25effeb7f01a939815eda28815374fdcdabe7e3401a49ebcf69a608f91ea328bcd2356ea45069e6c42e9fd28cf5979bcdc268e34e7"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 404
        }
      ],
      "id": "44d1180733148bbe2d944cd81719fa844131fba59debcddf592466518cf8ed1d65465963da6bbaa6aa0bd83361a2e94fd2bd779d6fb55072612202c5c925662e"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Ser",
          "pos": 422
        }
      ],
      "id": "9435b4f65f5873ee53933f91c6fa871db34598e90e1bec2c1bbc74662633dd589627d3599480d67f40036bb7f99130b73c73cb0e6df19195eaa3162ba65d21ba"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 205
        }
      ],
      "id": "5d4514d8235372e88ab6b4c50a49cb7153fde54c3092153c9e62a89c76624123774c6d87ba8828e8c36db5c6a69475cf53972002661f550b2f2c8d2ca6630c44"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Thr",
          "pos": 231
        }
      ],
      "id": "3fb25b1a41e40568bdc8b0d5f7eaca362986d336d37d480f31bf2ec2b93316307929f2bf2ce8046613acbfce0f0171d2bf62c710bb6571edd28a2f9cda3ad4ae"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          },
          "code": "Tyr",
          "pos": 18
        }
      ],
      "id": "d0acc01d81ea164f55f6c0411270daf247531a1edcbfa2d5541d9d0f9a352e4ee428e453b0256bba6b4ac802bbff1b8010b5f5dd0884aad23a6a95e0816f581f"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Mapt",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Sumo"
          }
        }
      ],
      "id": "de7a2aea1a431a0260c33894ac73a51a1244c87a3b17193950b40c5ba290a3928dd95bb700d398afeb1a30e43051c014639439b1f231b3c8d58743402e105637"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Mtor",
      "id": "cf7ddbc758dede3857f35968cc76d112a04b66a60de26213b7a5f6e3f06e7cb624255f3fc25cb86011950a809a105f8dad0f86ef141f7be89ff2ef5e318199a0"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Mtor",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "2980a94594a75caa77217865583944b9ca611f619de27cd5eb7eb67591c0bfab3332606866b70cd590421f982c2a3c74cf4149dd820abfa52bfa12ef02b67b49"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Nr1h2",
      "id": "de5761ae9f1142f5efde9eb091376274ea721c39602ae9f7e018cd28576d7ec7ebab67426a9cb7cae284a346b627973d074e3b0a25af6b26e903148c8bf45ab1"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Nr1h2",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Sumo"
          }
        }
      ],
      "id": "f0d636ea69c589f0cc2c10eaff7184abf40bd50211687ed555946f1c12f6603b08d8fc737ec5409eeb2251a7bf6cd93b2c982c8ebb6b7c6520e103213c05e9d3"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Nr1h3",
      "id": "39177fb2df29eb03ef6ab639cb22bbe3fa40c78a8f4b261ecf300de4d2caa505edda81acbfdb084a6ebc7cbe5ddff8555a67faf6805919a023e1b7c1bbf8a3a3"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Nr1h3",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Sumo"
          }
        }
      ],
      "id": "996615f27d6093f261613ea278fcc3cdb1c4c60d3d3190d3ede73fd5a7047ce1bffdbfe5257efff7daec4f3c714c1b4a40306a231c737ec51f26a08b19a0963a"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Ntrk2",
      "id": "e45658b7fb74e2876600c6566314c067e15fdcd34b610b1e1a86dd0f4126e7afbbad95665a7c9949e35b3b6c156f6405afdc566f7e8c1f7d7fcea49954d629c5"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Ntrk2",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "4c6a95f76c561e3709accabe61b91a7223a88fcc782ecdcff4521d8f1ebed135ff6e9681b4e8ba5adef3f1cbc70987c8509fc087b4af665dc59014591a03e29e"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Pias1",
      "id": "4f454438de4b4eee5328db37d8ae5f12cd582d1d532d033341ac0f1b4733a9a1c8f0b2a4daf55e28fe97472ddd6e8c3e65125b177b3d3b67580684002a001365"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Ppp1ca",
      "id": "9535534b5d21c66a2e54722ea5585d1a01d32045ce17c4b693800e3b272824de6bd7df8b624b5f7493b07f0f90b06da2db216da5bcdc57e8aef703c9d07f1f56"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Ppp2ca",
      "id": "9c9f130febc7b564225e639af5b52a33bf1969e7df8bdc2a4fa054a3e4f6a519d4501b24153652518a7b9719486e7c5844a5c8adaf066ef4c22f5919343f3e16"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Ppp5c",
      "id": "1418f18465a281cffa1de4802a1b00fcf027b5af919e3840b4beb480f04f7197b2ca491e73b8ca74231664b5d8fb468f904a92274b67137e2782bc4188747e2b"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Ptpn1",
      "id": "3b9d3ef42ad6c171bdaa3c1b4dae8579f7b958c1d3a29047dd7152f3d50666a0461937a3d8014185435a197d9b0eb36da8fdd9eaed3cee0d48d38e5e28a0d091"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Stat1",
      "id": "786ae1fa414e172f40ce2d9279709b77ba431a321a119aa4723be179ee1dcf0986a9707fb934b4cd70911c44348a675dea636864282d65640ce0eb9dafe108a3"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Syk",
      "id": "1f78ad6f1008b69900d61f1e785312b02006370fedaf78608b7f58a69849da0390f85c1bcaa0022b4abb1ceb211ee892c63a6200fded58d91649e74f118ec874"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Syp",
      "id": "323feba9f6774bfef802e2a1aacf5b095de2bf77dc0a96ca88ac28eedbed61327520112d786c135f2ae0faaf8212b5d7a0f55bf363fc620da3ac61db62394781"
    },
    {
      "function": "Pathology",
      "namespace": "HBP",
      "name": "4R tauopathy",
      "id": "40f8e5f69fc907f874ac64725ddab5a455909b177a15a56fdbc6c9c77280782f5a005d66a5c0ee29068efadf2ac504db25791b62393228e3b9475ec51fd028ee"
    },
    {
      "function": "Pathology",
      "namespace": "HBP",
      "name": "Argyrophilic Grain Disease",
      "id": "1872c530b2447addf019451510495a69b509757cb3571a6ba9ed745e17fb224f50e5e621592da80ba1650c955a6dbcc1afc771511f316abf9d853f0c9400efcf"
    },
    {
      "function": "Pathology",
      "namespace": "HBP",
      "name": "Corticobasal Degeneration",
      "id": "7656fef05b91a845d805d93948be43a3bc4a961fd572e8ab84ede9dbbc830a8c04ca3da2e7b4e84b25207c032b4b2e5d4e1a6185bc2d5298c222ce9fb8c7d2d8"
    },
    {
      "function": "Pathology",
      "namespace": "HBP",
      "name": "Spinocerebellar Ataxia 11",
      "id": "576dbea995b9a5a2f7104a34ff37269b07b05717aa86f8cc515341aff54a4bc150b713bd60e8920b954e55888e364339e265583bb1f86c8f19646e50a3a28134"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Acidosis, Lactic",
      "id": "5aa6e2ab57eb0650dce39720e1eef8fb11ad2484380897676aeb9213d7a864f304324814ee171ce0825b47c8061ae8c0c4b38d41af70ea89c5cdb540685800af"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Alzheimer Disease",
      "id": "00f72839b5d655cb4cb088b0eb8874bd406284d98a2afd0bdd73de0a34adb78af374b0eb26990387f41d3b41cda0e32c1b5ff5f86ed63d0fdc841bac17865541"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Autism Spectrum Disorder",
      "id": "eab0bca058fefb09abf999426de449dbe235835fe60dcffc6a4e257471c42379a43eb7ca411959680409c348a44cd52d0530c2dc16e6e3781f64a446ba59627a"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Chronic Traumatic Encephalopathy",
      "id": "722029bc4287b44ae98bf376f9f8e4541b041f74195b8b8b43947dab3fa001577811cd0ac61270601c5c6b58478f925752c786f1c5d81659c45799b9435cb2eb"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Cognitive Dysfunction",
      "id": "bd78fa3131dd9ef6067a5fe3ee8689c946c79d0da1bedb054d1f4400b9ad0d3ae041837faa0fbacee0af5a57a4cd343d11e73fd53fd05269e3558803a56df69c"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Diabetes Mellitus, Type 2",
      "id": "383bfd5b931799ebef046b50fdc20130944af1dace438e725d86a0db3cc14c56fbd58f8301b26fede4d6a1af52a074e01a20f8b530928c417d7cda8130e8202b"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Frontotemporal Dementia",
      "id": "65b349369f9bedd1a6220b3923747475397a886cb45f96f65e9aad66d695cfd560911459bd006d087e0ee4cbf06d8829549b3e32854fe68093e2b5834049d726"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Niemann-Pick Diseases",
      "id": "53660bdd3acc18b687e8dfc5c8a0b98d10e8146fab1cdac433e2ac3b3871af2fb192d5a54d29ae5dc2a6711c54655b5d3d33c00be0c4b11a714a63a1eba4e015"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Parkinson Disease",
      "id": "d7f039170f83b3fcc27595412f3b0352cd1fe95f8481a2b1144ce311ac81bb5f0087a0a7e682f498d193e00b8e8fb29908a6e0b8e23da5ef349aeeb4723b9be0"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Pick Disease of the Brain",
      "id": "7917fa738d79ac0c2819622046fe373e477ef318b8693a75fd3871cd7df292afac3f425f2393f72cbb2813ca81347b925f64a4b874ca7d64c778c9d6e189eead"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Plaque, Amyloid",
      "id": "888c33ecabc995942e605aace0106831b95c6e6d4eb99ee4ac4c1de25ff7c58c0cb67b5e941c2d3f3a399aada51a34de03850a43011389d2ab7dae07536cea30"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Supranuclear Palsy, Progressive",
      "id": "06432576e845db5beb8ae7a4c0ae23454b691ca1773f3467bbd58f6ce3d484e768e57b6abbc21258bd43941d8ed10874fa0d45b24d91638ed7e42dcb0e5c7dd1"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Anxiety",
      "id": "28f6f3390e4ae722f1c1298abe2059a3e03a8a2de93e506a747733d9e980ed28bb2feb1074ec430fda167d3f38e3c1d930e10c16e5e04f371938ce866caba0dc"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Cognition",
      "id": "d8ff6334a72a605de87a6f1c577433b40d5732bc0387acd31217452afe3e60a4d5928028b8b819ce892d4784459379ebea852781c6e1c96bc81d3270f4a06b5a"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Fasting",
      "id": "f8e9e2b3e09b7441cc55e06ddacb68a155859df5d7c20c6801697cbe8a944deb111a102c744477861c19362a7b92dc72e566d98c4661b48c01cef1eb05377c14"
    },
    {
      "function": "RNA",
      "namespace": "HBP",
      "name": "TGM2 Isoform 3 (349 aa)",
      "id": "25a0cd7b3e5a85c298708851f06eb60b4df698f1fc55688ea5ba24ea965704f105ab877fe3f2dcef142ca7e9434e5d0ea8ff64871250522d9482ea150d6914fa"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "BDNF",
      "id": "0716d15a357b13aac3835d0a2ebf6523d6c878a1bc6f29defea119a74c9b1ee017c1a7d31b31dcfed4b4329c85f46fdf746dfdf6ad2234ec6be6ae17d0454a67"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "BRCA1",
      "id": "7174833f8cfcafb551b7dab8799d73dd743f78e688c69b6bd4c9009a444b2d5e0d4ada2bba1d31e724d2bc3c242a51d49d4ea139ea8bcc02d7a575504a65c39e"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "CDK5",
      "id": "ca8d059a3d0c3d5a5ee3df2fdadf0a052cddc171b5dcbabca4f923d0c2a62d03b219826115f9424038ba8c459a91fb5da2095403c12571cb9bf0df2e84c0bcd4"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "CEBPB",
      "id": "bc544bd86a178ed75ef781acfa4410a0a702a105eb6f36bd0dc5d962262ddcc5ff508b8b4aedd5177179a6ed236c00d0a64ebc2384cc0b97b1f351f437136a9e"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "CSF2",
      "id": "dba6422e7ca6bc275bf5d80a9fbb956451db347ac8bdee01cb0b22e6118afe8a4dfdb2c078f08d1cbb74b6cd10c1edf35329f9da7f7769dfbb4a5ced6168c93d"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "GAL",
      "id": "faeb530e3ec8332e527c5d052de6826102774a7111de4a95b88ad53de3cd1f02843627c916c4fee4bae37384c88dd25558b7bd9411c3d04bf545562d13353284"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "GAP43",
      "id": "700b280791036d5863d44b1a281557d2195f4e4b7853bb6e3fe84e7a57405785d1c098dbe755ecde338966c3472e4e65d49a201bab44c6a01c083cfae9824414"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "GAPDH",
      "id": "642cebc93aa006da87d20648125f6f7d655e7068b121ccd788938f3c8ef965ff562602c8af20e049d6278380b13143361143a80c1e6de6dfc44720a575c45dc8"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "IL1A",
      "id": "66ca175eac4164dffb5792d4e4bc4b0d6c90bf7773a21c86abfce933277cfe3b4b7fb502f941ba8f3ebf05ba69190018591a9ac34c63f4c450455de472d22890"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "LEP",
      "id": "f417cc4b058c4be23eb9681d8c8672a11cad3415bdbf1a38038241d36ef4c8974e2747ed5ff67528aee33890ec48c53461ce790a8ef0973aa41af59fa140ad78"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "MYC",
      "id": "3ea0c2327544c9904e1fee2974c300d16785d15b1c881cee114283d18a8d2947cd08a4629b2482fb03e1e46a2ac893ba37f9b66a80212832ff3904aad7b08523"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "NOS2",
      "id": "7c222d0f52c095955fc94c99a5af35d2a66c44534ef1674028745751155eccff567b75acf75e0d26b54c30cf2da5a07d8949f65e2ce54cde139969a5e120a761"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "SYP",
      "id": "5564a6ac0af9c7166799d349d201de4bfb9946af2894d60d7ef36ff7bf028fd33182e3be40b0e03456efa1a4975d9682fcc3ff48c3b4da79e2107da3ecc73e43"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "TGM1",
      "id": "a28937ac3cdafdb492d6f39952ea3c5e6cd09e8757a14cf1e7474f9b3fd8d5215525b4500a042053395dbbf7b156fb16b56186161f5092b5d5dbb7182b14fc18"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "TGM2",
      "id": "0e1d132a89e6bba6fbdcd561fafe4d774eeb3ede2bde6c02f87a699520dbaa8f0e8abf3bb93924a5269df24430916dfd4c2a6c3219502a86be23ec636a8b841e"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "WISP1",
      "id": "aee7314cfb17be9a310f95caaa7f33c530d1b9a66fc35443ceace5f0e2fca0bb4016b2926b95a1b310b61a57607d0a753a3619425ea7550ce7d626ce3dca8ca6"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "WNT1",
      "id": "5cfe403d2ef9aefae2e1123377e58901c25377094d5547401ddd529906d1b0b5187772ca9582cccb2d95583756237f6758291adf240a562f3c89704ed907debb"
    },
    {
      "function": "RNA",
      "namespace": "MGI",
      "name": "Dyrk1a",
      "id": "015c0f5633e162645c6ae819a015f2f60c846e60d993e75c054fc43c303c24a25af58cba6de647659ee023f27d21e54cc48ed86a2a6910600db0d18f1bb4b2d5"
    },
    {
      "function": "RNA",
      "namespace": "MGI",
      "name": "Il1b",
      "id": "33f63b3e4e2044589531432d2aa552bf4488e7e4fd06fb8a535eea402b1f0ddd74f248cfacff90b16638e89c86a6e3d06ef017606b8398ea936836911ccdc08d"
    },
    {
      "function": "RNA",
      "namespace": "MGI",
      "name": "Mapt",
      "id": "2b9c14bc5f6a1fc7a618e3033d279c071ef9eb5ee7989e50254f39b8c490642d54b712450230e4f2d6ce7e8e896a75877137a4d4a009b068650366ca083aa81d"
    },
    {
      "function": "RNA",
      "namespace": "MGI",
      "name": "Nos2",
      "id": "d32ef39516cdbc35b8f515a51acd1893aa36a1a2aa33cabdfbaa03e3754d8138fd2097738fb00fd80a0549f2b8716e98ba3bda130f3db112c58a930cea2aa394"
    },
    {
      "function": "RNA",
      "namespace": "RGD",
      "name": "Cdk5r1",
      "id": "9e5a89d59b4d4b9346eab4c9aa7be2546b0acebbdd2c29c8369c5355b27ae3f54392e9971b873dfbcf20896d2ba64878570e001f3d14c9729d2ad9a95ca7d1d6"
    },
    {
      "function": "RNA",
      "namespace": "RGD",
      "name": "Il6",
      "id": "f1e030c1371f029cef2edcd5bdec064bcb54c69c57dd639b3d469a63e0819bd03aea68b3d8fee9d0ad87cbb2515dd2890f90720f4241484bffa114ae9ecf1511"
    },
    {
      "function": "RNA",
      "namespace": "RGD",
      "name": "Irf1",
      "id": "422fdb8c8e572a636b8d5d629d72d575935cd5246a20e005d5a925522c3f411e16fe5551efd086c2feb184d246099e432ca630987690ed6820199b161813b218"
    },
    {
      "function": "RNA",
      "namespace": "RGD",
      "name": "Tnf",
      "id": "78a4961c010dea52c9b954b6fab23416910d7a57412e8b50fcb23025b82d5c661ba2c7c4149550a6df9d3732c9f49c3e86c8cbcc71f8fe67fcacfb77cf1cd17e"
    },
    {
      "function": "Reaction",
      "reactants": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "dihydroxyacetone phosphate",
          "id": "47985c181d8fc4b492095ea546f7cdf67979b860336ae6a624d20d6568e7f4427bc56d494c0870c49d26c4bf4fae54e9faced2f44e6ed8292555e007115cb8ea"
        }
      ],
      "products": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "D-glyceraldehyde 3-phosphate",
          "id": "e6622cdbeb459d4543f81a75975e918be4c38fcf918e1f26675304ed5b08fdf2b8aa6d4a83bb0994bf3d86a59909f8b477cc2ebc6f0c1e9f3c6d9de73c33d858"
        }
      ],
      "id": "74ca98a81a66f88b64d8feb86c47d418e2c3ed0441796244644c1aa6539b47497696f7712815a7e96e8241859814de8097649bbf6619f8e24fce8449fab4f158"
    }
  ],
  "links": [
    {
      "line": 116,
      "relation": "partOf",
      "evidence": "While several N and C-terminally truncated Tau species are observed in AD brains, only a limited number of specific Tau cleavage sites, after residues Asp13, Asp25, Asn368, Glu391 and Asp421, have been identified so far in situ. The species generated by these cleavages are found in neurofibrillary tangles, and their occurrence is correlated with the severity of the disease.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 601,
      "target": 81,
      "key": "4f9875a04ffbd508f492efe7fe9c532c863899681a848f8e376a4ff75546946ef37cb629a493ca24cae43e2ff33f2cd075b587ea2569941a1dd305e7c858915c"
    },
    {
      "line": 122,
      "relation": "positiveCorrelation",
      "evidence": "While several N and C-terminally truncated Tau species are observed in AD brains, only a limited number of specific Tau cleavage sites, after residues Asp13, Asp25, Asn368, Glu391 and Asp421, have been identified so far in situ. The species generated by these cleavages are found in neurofibrillary tangles, and their occurrence is correlated with the severity of the disease.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 601,
      "target": 908,
      "key": "73f3ef83b7d3720eb1220b7be9c6b943903d76a3ebed5b20c6b0db67579265df84786a6cdef931811c29d3ef808663d65c5a293f6508914f03893d1e8fd52a08"
    },
    {
      "line": 166,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Antibody": {
          "Tau-12": true,
          "Tau-13": true
        }
      },
      "source": 601,
      "target": 486,
      "key": "9c217f38e43d79f0ea24ee9c15484feb580ad29cf8c69e3901ef1312cd2ca24cb5ed387e54e12f3b640e7b8d3174b46fda809ebeed7cdbdc6efdd8effe758dbb"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 601,
      "key": "5196e97ddf617abc527ad009f422b7ede875114462c1435f064d4a8d62c392c23ca4260d4849b52bb9462b601c07138e0c173012d90d44eb4e38cc3198c6a277"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 602,
      "key": "6c77226d8391cec44c3b81408c43fcd256c45c00fd3c3ce7add42aaf94ad335e37d22e0892ecfb8201a214c527b1608b6186b8d11b95a0d08daf801b01620b96"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 603,
      "key": "cf2305b39ed0aef7311ad351a20d55330dd11485302ce1ddd4c9385050bf98077de7b8ff1d2bbf50034fc9b8225f342c8224dc72f43bccc86cdafe92d766f3ee"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 608,
      "key": "325654f53207600694e1af67b57104ea5f0fbd54b1533d1283d04052ec4dccbee920bdf7b851e3adfe341008e072feda17fa783ddd19844a0bb4f1924a24431e"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 604,
      "key": "a878b1574d5069d04b03219d1ceb128468d63caf1e248bc49cee5597013b28e5c8abe9a15bb47e2113e09342835faa220ac62abca28b2c6b0fb5d7d09abf7ed0"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 599,
      "key": "f78b5e80b4ce8a32b3cb1415f4d7a09076ea126559ce8c59ec5cce583448c7cad2bf330808dff623c2cfeab02f7a7a966eb5dc031eb5d07ce6ad4cef2ba718a5"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 522,
      "key": "75aa7c8a43ac855e87d287a30e20ea995cb7b50109570f40311c34fa9ace33c088cd709fbc36873669ddc9a8ecb698f325c9532fafcad78aeb4c46a1fe6dc78c"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 598,
      "key": "e8232eca8986cdad7b32ffa207745ea3b79e0b7904fc685a9e9605f35b2156e9d8dc223c81a67e738841667a9f07c1022db1cb02c8c78ccd8f51a3b5655ee289"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 606,
      "key": "d75583ba085a42acf5e4eca4b137a25263e7d6149f63b73391a1193bc17d274623dd1947f429978ae0fd4c1a707a718092df87b434048db3e7d007a0572a6401"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 623,
      "key": "f4a5eca5cc0846162c0bb0fe42c2feb0e4db53196c68576f0aee5f5a3ddb07f4bc51f992efa7268242b3214f9ec3d8340e8f2cb44b2be4f05e69bfea8353553c"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 624,
      "key": "3b12b91a7303ed0b7759fef901ab1b4fda54121d90d0fb185a199c601be7b5f90f73db20f86f0b1eb57c5c8757785f981f021ad4bf99fbf6adb6ebfb91419ee6"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 613,
      "key": "6fdb774b06188ce3fd1c103e92082683b296206ffe2ffad48867c5bc0e2daccd038df3232f7d24218e965c58744937c523a9891933b4c43e10770eb371b9e94a"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 614,
      "key": "7412689ee0c3085b8ef968955cec1d57012ef2fe51829a70220b19330c43b5602a54d881b9a7e79f8c9eaf72aa2f967cab6b5385daba0e7e3c05c9b02f4e4453"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 627,
      "key": "0f8f1d3362f87adf2dd1fc10cd85c2651f5e73a62adb84565286e8bfef856ea7e80ad7263475ffa8aacbc135f2370ea3f8f79179cfcaecafeea06d935a5fed25"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 615,
      "key": "a72ef5033bcaf9e87c7bda81958743f3c4a02ffd5c9dc78eece4b8c039a4b9032bfbfdb1b3e00e6c2437f9efeb6a836d12459994d3be859bacc9249f0b4ae586"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 616,
      "key": "184981ae878faad4ee05494a924e577d4fb54087d32379d7c3c842357bb63ed0272fd659ea0cf6c007fad65fd9c0da9de8e0486b196702066cdc6a07e003b555"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 610,
      "key": "4b7723e0c82c43c3c45646c93ddbd2cb6c518c9d64ed6b341f0684a1af63e9478c9512566d2d958a24d4fbe65516754bb9dfd1189ee87a5f31a4ac88bf54b056"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 628,
      "key": "b91395badb113e9939226a6fb33dc6eafabb3ead0323644b514587b22cccc5fd39e40550162e92f1a6a1a8a62acf1fd1e1bb2ffeefd7d5944082f7884ad9e46f"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 612,
      "key": "1ae1a573ffbfb0debe76ae28a44a8539bda387dcbfd8eafde3c4a3bfc746e90506065ea82c54cfedfb5c92522a49f4718cb4e99c92e9e76c06f2021115b43758"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 629,
      "key": "ea4d4bb8501adc0cabcc3693f56847891b26b65a51286dee878eeb27412604222fc793325526ab32f59da193906b1ee248dc0c2d727c9d0535f721d284a0f7be"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 619,
      "key": "7f3f9e88a2e0fcba28e30f535ac2b276e04e22a168cb8664dd105a212af93abb5eed21f4cb9eec978cd1ec5304fec88822d38858cc4a75e1754490186e8ab3b2"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 620,
      "key": "5459f21d3f14a0f5538c646a10bb17a018076163b442d11f45fd740ec777ad4597aa2138376baeb27cf8e3e88cf6e4a3f5f2d32c27785458b557d3c227286590"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 621,
      "key": "0cb97d5054d3e3e5d43a00ef4496659a4496d56828b02e806ad5413d5cc87a96e3681b14d6414d3eba3f7be43dfa83bc252fc316821e909d88df9f5771faa3bb"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 622,
      "key": "1070b210d3302010b5ee52f50ca74e4bdbddd3068b857ad5ed6ac3e8f07997307b1e092371d9dd555e2d34b335a47b517722171be1032c867885dcd7c792478a"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 607,
      "key": "292a29e110e991fb2585519af5e8a9d65ce18c0aa7f2cdfa070351b7d2112951cad14f562ecf9443f82667b25e2156c53269e06bebc183ca8e2408fbe08a4f7e"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 575,
      "key": "2d72e87620f44a4a0b86095d660d2dc96fe74ddf3f16ed9ece6050eae626ca3156e0b47c861f5cf2bf272e6f4cc907f63116197b4ef6efa6de0fe018fec3a37d"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 517,
      "key": "c755a243c8801219c163d4e46710afa8d12ffbc4d708fbac3f37c56598da5fa5f16337fac610ba5c73e1d883e815e367b64e8ce3f072c827d2ff5282e9634520"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 518,
      "key": "4ad669bbcd5d29a1650f1634886e69b8c1fa857c0a72d465bc712942048467be30356193c3ec80f5f5448507c2fad01b5d17af2bdde88f7e6fb97023911e029d"
    },
    {
      "line": 924,
      "relation": "negativeCorrelation",
      "evidence": "Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 486,
      "target": 518,
      "key": "a81d36c47da39a19a02e1af8462b1417a98d31d992fd908d625f9e5db7f5f7060580994cdc55e36349bcfcb9ea1d62d0096738fd025f69769c4476a1013a0851"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 520,
      "key": "750543557afa0a8d9a8c5ef96edc68b2be7a6ae2f8844ceaabe008f8cca224278a1ed18999a6e5f2a25e9f7abbbf08aeab8de80d2988dd6c8b424ff23221051a"
    },
    {
      "line": 925,
      "relation": "negativeCorrelation",
      "evidence": "Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 486,
      "target": 520,
      "key": "c53edab48408b91c7c36f9272963fdd74c860172867907a70da0545dd110aa358400a17652dd6d6bd2ed615131592a6d205fefdb713e8e448cd14d63ded81edd"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 519,
      "key": "3ac854b76cef562012fc8b8acf211e20a7996539c45ae26ba2f1a8adcba17ef368f29c86e0ece2ec0d3fc5fff87223d3465d2117bc63b39f22fcdf77926fac20"
    },
    {
      "line": 926,
      "relation": "negativeCorrelation",
      "evidence": "Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 486,
      "target": 519,
      "key": "c066880dac41f2a7934e6ba02312e1c8d2ad7fc58f34012076a094e8ca0c343e2296d81f70a294ab2d9870de42f40209127299ec13fba63e4320e8847662b136"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 521,
      "key": "5d37469120db288dcc4f6126359bfa083679b28c187bb80e803a55fc8fab6b2a5fd1c457e79f42cd634befc78bac7f83195c78c06b90120921bc86ac4863eadf"
    },
    {
      "line": 927,
      "relation": "negativeCorrelation",
      "evidence": "Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 486,
      "target": 521,
      "key": "0bf6e5036e34ee161a440af5b6504e8ce8c3202ea9499db09f08d05043c018e55b7f6206e21ca44597c5993c059ad666f1eb94e0f06c0ae4e54951ef9919718b"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 489,
      "key": "0662c40215b1b1b256cb68d414af558e136f9bd41bb7a3047a88052d207a8fbeb9eb9f48d5f5f02fae4b85f9d18abf74bca2a6e43f576dd12139dd5793af937d"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 487,
      "key": "20ed4f6da453c94c7d03810968d1fce7f215790e389e4539d75f1a971f355922cd2b7342679e7523a33f67ba791daa51e5e4f25fff5286382a03b422da43642e"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 569,
      "key": "758dd3f9f47d2ab5dd8538f81b0176cdeebcd1457b9595df319a2eae964617033716ca7e93bd32bda8d8f5ede1e80bd525915e1fff2980ba8d6b0a7ab6e7dfb4"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 536,
      "key": "f0f8c43f9ac74ab0e5ebbbe90c3ea6824354ceba0e95b4908b64af3aea2f319eaea65e1cae7153e20ce2c70f8f8f2c6b90a021eee6c34d28c93bd999978e5fdc"
    },
    {
      "line": 256,
      "relation": "association",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        },
        "Tau_Motif": {
          "PHF6": true
        }
      },
      "source": 486,
      "target": 536,
      "key": "97ba4dca9e3cc763c6ff32f2fbaac9bd99f39863665c70868d4eccea146cf1be0dbc560a8481ae89c4dac97bd0c682c5f9d4d8195f75b6c34b99eb60bee43741"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 530,
      "key": "d4725e3c767274ecce295d54d7250bc129dc6d3579e28692da2b4f73c4905b6ffeec98f051f30d4a84b2937da830ea17716decda1e8c11a0106c818cbd09661d"
    },
    {
      "line": 259,
      "relation": "association",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        },
        "Tau_Motif": {
          "KXGS": true
        }
      },
      "source": 486,
      "target": 530,
      "key": "a7d47d08f39333845c8295ec4c07b18a3cd69f480e460a1aebf75b2dd69adabb659096ce23aed175e0d5d5281c06f5473029d01e7ea27e6ac8f671a2a6c63861"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 532,
      "key": "d2dd0c77bcc1acb905d63ded30010c6844743a5c99e804ef38e9f7909eeb5434b8fef3077fbfb29098ef57e8949fa703f3e2f1d0392c31e46e7ea7a86c4739ce"
    },
    {
      "line": 260,
      "relation": "association",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        },
        "Tau_Motif": {
          "KXGS": true
        }
      },
      "source": 486,
      "target": 532,
      "key": "2ff0194d900a4df29be2c271dc339729b5659fe169069c87e36c9527b5ba0eda3a15a0412c181078feb226e853f7767c6198638ea9ace4497d3f427f6b64bad1"
    },
    {
      "line": 307,
      "relation": "association",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        }
      },
      "source": 486,
      "target": 532,
      "key": "ee9972f8c731d421be9d79f7c4145837e2f00ea441adc89522f16eb683afa2aa51a392aac9ef2add345ccd73d027c375a2d3b75434b8b09f1956ec9380e23b7a"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 533,
      "key": "e2cfe928963339a26e45ec80c274f2816b341e599bf9b363253a116b5fbfef1f19239be91eb73a9838737a056d86d4d03d57353ee07f0ffcffd31a412afa761e"
    },
    {
      "line": 261,
      "relation": "association",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        },
        "Tau_Motif": {
          "KXGS": true
        }
      },
      "source": 486,
      "target": 533,
      "key": "e93dee3625f60ea088ce5526f6683c35bd15575bf963fef51181b924aee3a0fa01e5e9cfbef14793268e7117d9a855eb7ed610220665ece35feb1d4399894188"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 528,
      "key": "0689bba350c57223d71a5332cc60744c6331a79cb4e87ee3a77836a7fc2161b680e348f90cce566be24517f3125346273cdf8333da5a796eb0362ff3f2ed12ce"
    },
    {
      "line": 264,
      "relation": "association",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 486,
      "target": 528,
      "key": "397af178d10818bb4b0f197de46f331e27fb7b3e6fe4145b9fd72a6a057bbbf0b9dc7ee0ff8e13770a5c1985697ecc7aa75c910f8d363337ddf83bc672ea1248"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 534,
      "key": "316bb86f2135f1ccf3312f475ec24ac5f236a47b95c184ee000b05f441f76a5597120c2636572a3ff7069b126ef6bb06a140e005b5496e0286d75c3317223a18"
    },
    {
      "line": 265,
      "relation": "association",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 486,
      "target": 534,
      "key": "bab3f6e3c0b88a1d589000fc9cb68363b06193746a5f7a916a5d067e8e5e67f447dc58163c815263f7b4275989d406261b4b27001c84f36cb5585043e7992fc3"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 535,
      "key": "957036579143afda83e87aa596a67a904d9223a69890c6dde29c03ba8e4372638d5318d706b9ff6c7bf6c670970968b61cfaf070afa0a51cb7eea53fc0934e64"
    },
    {
      "line": 266,
      "relation": "association",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 486,
      "target": 535,
      "key": "d5396fc109b9155c09c49eaded12ee282635fd27f4bd89b9c0294c5add25acde54601ae36e3dcc6c96b5bbe1e8ca8379f1ee000daec8341d4dbfacc43aa77d81"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 527,
      "key": "f36f840a1bc4e7be798c6cf61efbfdcefab37eb20cc1b9fc4e02d38c7673505abce1372f3e2f7ac8b2f0e5114ed43e9d7b927e139cb61ba0eb37604f76488a36"
    },
    {
      "line": 267,
      "relation": "association",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 486,
      "target": 527,
      "key": "b70b89f5b86e6e4ac30282358821bb0bc6389efcd6d02c494b8130d12e1b58aaa8a36a1b4dd333017dc4e9a4d26be7fb272ce389237c850b31c218b6e382b34a"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 523,
      "key": "54e740e3b4a1cce4c24c7da9e477f968f4de3f30a1f4fd10840ec05e7b10b9b71fc37a474f3eaa03be858ddf24848668cd8e31eab58129176d206622df2de5ec"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 524,
      "key": "f56b719991f51fea922fb5d3ee2bc77e72759bf27b7e7631c9a7c5b151e0b797980f905d93ff8854781a9d3642515899c66d287ed20f9a3aed7e040d39a8b164"
    },
    {
      "line": 295,
      "relation": "association",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 486,
      "target": 524,
      "key": "98ca9a6cc7bc293309fccc1fdb48a22f926b06a9d048a252c39f50306e5c643b87a737a8bdec36bada47021879589c966110bb9d5d556231ccb33940cf209d55"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 525,
      "key": "1d5e88a92d88d9dec592626c996ab5504af006b8169712a7c0ddcaca83f8fb3ed7a98b4fd0f7ee52954aaff837dc824ee17b16e9a90001df62946bf44c2e7ffb"
    },
    {
      "line": 297,
      "relation": "association",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 486,
      "target": 525,
      "key": "40bc135f0b517be1bac17c8245f2820af7240e68ad86b4ea89f7340391f09e0497d814e2c90467256f44ff02b75d262bbb77c367ce83da4179db6e7b096e780a"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 526,
      "key": "f959877b24d577c463f50c62c57a77dd0179f671cf4a34b68a3f8fea64e3620c447c7c58bca374326dac9e4a452370609d8a82ad3b36205b152a5c0e78f414d2"
    },
    {
      "line": 299,
      "relation": "association",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 486,
      "target": 526,
      "key": "c117b43752d9c69fc6e5cc52da97c340b9526290ba0325db2e248f2420e0b569152dad93c6e8d64f5582b358aac1e910303f942d04a5ae72c8945753759e906f"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 529,
      "key": "22b0385e111c88ba128776d4cf1e0c3682f25cbd9737e8250201e3441c55c00f9198c3e58ca7f3d7115c3accedb58b3ca17b8d2bced88dfe7ea219332bbb879a"
    },
    {
      "line": 304,
      "relation": "association",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        }
      },
      "source": 486,
      "target": 529,
      "key": "200146072e11eb18919116adb5db872dd3ce009e36b11c18bf9e50289276bbfff28e4b58622b20ce27ccdf70b0810624ec2750f568e70cd3fad22d93bb8cc521"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 595,
      "key": "fe79ee5dd30c19de3baab8a9f2f451230dc268d864af328971bd22abe107d9eea5e5245efbbe1d576097d5e157e4e94db6a671d6562f958173b95244e2c6c9c7"
    },
    {
      "line": 305,
      "relation": "association",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        }
      },
      "source": 486,
      "target": 595,
      "key": "cb399956c0d759e8f40d700e17fd554325534d619605546d4408484a789fe02014c1857b97c87910e0ef8674c69e95e9aa8175aaf71334975c962337e9dfe820"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 531,
      "key": "84af31ada5d98bc63c9f22af137cbc5d693bde97f7ce4254f9fd1a37310a19634e081061ed0dc8d47ab61c750902e77623742934e7bde453da9c4e7a5423a517"
    },
    {
      "line": 306,
      "relation": "association",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        }
      },
      "source": 486,
      "target": 531,
      "key": "2f4ffbf921558d6fe4153a16d31211d735d72733e7496506a284a1c0cf679a0ee1ce7141ab917f40ff08bd440d30a7c56568c5df76810581b5ca23280172aa00"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 538,
      "key": "c4e71f1866eab20795e7e1d4b54fe09effb8b376e41712f8a130fe5192e07d83b0749cc2e2297b62cbea4bb7b1033909ea6d6423fa06166cb07543cee4249d48"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 579,
      "key": "1db8f17343211693622cb88d2cde2cdb16e928f591973bfefdad7cd961f5833254d55f34dfca66cd04cf34c2ac98ccc894b662b9d10420aa749361cc7d7f8677"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 577,
      "key": "213a46846a62680cc05d2ed2719a937dff6a8fabf62eab17e78a50282285efef229adb3605d9160e01e020062742249185e5f3756340776a7a7cac3951c27468"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 551,
      "key": "7e2720882d6fa374e003f55619af6acd72fd0b6b0e056fde3d6279807f12e1a267d65521562730f5dba91f947c117b5e137ea104b51b15316054d30a3af35372"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 564,
      "key": "09505215df0db1264915198df6f54ea647eb376b6ede05f22846b2d289a2907fa049769b8eb45a919e706a2eb7c7a96704537753eeb5e7c30a012888cd5296de"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 515,
      "key": "12f00e027663d2c3c27b9031ece1b5e2672eea22a2771fe6f90d024f0b58e8431e6a321a3cca2cee2ca3374e7b17a78cac015d0e6952c61f420e98a854681a38"
    },
    {
      "line": 643,
      "relation": "association",
      "evidence": "Taupositive material was present in the immunoprecipitates indicating that tau becomes associated to nitroTPI in an Ab dose-dependent pattern (Fig. 5A).TPI and nitro-TPI were incubated with tau protein and samples were analysed by Atomic Force Microscopy (Fig. 7A–D) and TEM (Fig. 7F and G). Abundant paired helical filament-like structures were found in samples containing nitro-TPI plus tau",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        }
      },
      "source": 486,
      "target": 764,
      "key": "3ceda801789d7694a3be6364a1e6511b24c66aaf0732862b66dea5a1802126039962da18e7946a830c068a8be8a17c1a21ee4282c450e9132170ca57f129051a"
    },
    {
      "line": 644,
      "relation": "partOf",
      "evidence": "Taupositive material was present in the immunoprecipitates indicating that tau becomes associated to nitroTPI in an Ab dose-dependent pattern (Fig. 5A).TPI and nitro-TPI were incubated with tau protein and samples were analysed by Atomic Force Microscopy (Fig. 7A–D) and TEM (Fig. 7F and G). Abundant paired helical filament-like structures were found in samples containing nitro-TPI plus tau",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        }
      },
      "source": 486,
      "target": 239,
      "key": "6f29cd1d58ca740f2300b1f827869333cc2fe694124bad4705ae13826ff0b3da0fe3968e6794c12d165ea8ed5663509c8f1fa78ab320c96fe9c242302ccec217"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 513,
      "key": "7a5416e59612c374a3a5c6700211dc1b53ebdcab558fbbf695ee4c468852d9e896b3460f9b5fd9218e13e47c11b609233c4bd1f15244ef740563a3a2768efe25"
    },
    {
      "line": 801,
      "relation": "positiveCorrelation",
      "evidence": "For these studies, SH-SY5Y cells stably overexpressing tTG were used. tTG coimmunoprecipitated with tau, and elevating intracellular calcium levels with maitotoxin resulted in a 52 +/- 4% increase in the amount of tTG that coimmunoprecipitated with tau. The increase in association of tTG with tau after treatment with maitotoxin corresponded to a coimmunolocalization of tTG, tTG activity, and tau in the cells. Further, tau was modified by tTG in situ in response to maitotoxin treatment. In vitro polyaminated tau was significantly less susceptible to micro-calpain proteolysis; however, tTG-mediated polyamination of tau did not significantly alter the microtubule-binding capacity of tau.",
      "citation": {
        "type": "PubMed",
        "reference": "10537045",
        "name": "Journal of neurochemistry",
        "title": "Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination.",
        "volume": "73",
        "pages": "1871-80",
        "date": "1999-11-01",
        "first": "Tucholski J",
        "last": "Johnson GV",
        "authors": [
          "Johnson GV",
          "Kuret J",
          "Tucholski J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 486,
      "target": 730,
      "key": "0db02277aaa5846c0b12fcd015b1a1ac281e6fc579eb87550c216e675144b697b594ddc33d924a494ae8fa2ac3bc458dc41117f8813368f42687f5a07ce508a0"
    },
    {
      "line": 803,
      "relation": "partOf",
      "evidence": "For these studies, SH-SY5Y cells stably overexpressing tTG were used. tTG coimmunoprecipitated with tau, and elevating intracellular calcium levels with maitotoxin resulted in a 52 +/- 4% increase in the amount of tTG that coimmunoprecipitated with tau. The increase in association of tTG with tau after treatment with maitotoxin corresponded to a coimmunolocalization of tTG, tTG activity, and tau in the cells. Further, tau was modified by tTG in situ in response to maitotoxin treatment. In vitro polyaminated tau was significantly less susceptible to micro-calpain proteolysis; however, tTG-mediated polyamination of tau did not significantly alter the microtubule-binding capacity of tau.",
      "citation": {
        "type": "PubMed",
        "reference": "10537045",
        "name": "Journal of neurochemistry",
        "title": "Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination.",
        "volume": "73",
        "pages": "1871-80",
        "date": "1999-11-01",
        "first": "Tucholski J",
        "last": "Johnson GV",
        "authors": [
          "Johnson GV",
          "Kuret J",
          "Tucholski J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 486,
      "target": 238,
      "key": "88e0cd6bb0b8b64b98bf1720a5e2d6efe42965f83d80fad75e71d8e3771e7072644d4a8a7290277a09ae7fd9a270b3bdf3e58442da832da27759160dbe93b8df"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 537,
      "key": "3ad083744538b3f7519be5b164991b2be27a6d67fcc17e9cadf31a004b03a4a873157d230cac2292c4eaf0d6eb183f4aaa99ac17cc19b8772f4acadbd7763c31"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 514,
      "key": "b73b43ed20dd33c2dd82cb5765b88c8350e2a19afc2a5e15dbebf79372f29ddcdb78185e07e9938834f7a2c0fa71e838dd80671eedab018fdfe9a26de8b39cd1"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 625,
      "key": "22a66102eb7ed43a8161d57177ac2432b8efbfabab3d503feffcd533074b10723c8f4779d1742d699a20b9f2075e0382190e440d27216df7140376a51c33ac0c"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 543,
      "key": "3dd217dbf24e05387967c81e77bc580eae4bb79dbbaa0ec812338e6abafcc6f5c8365a7efe2732b7e571e9e3cec08e53f75be35fb922dff737ec143c8103218b"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 544,
      "key": "57f6dfc4cb18d002fb185a5f8ddb26897f5c0e93f59d9f1ee55374a026a04da6c975e40dd70e3f890ef9f9793c8b77bf916ea47533ecfee045a95797915ad8ba"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 582,
      "key": "0d694edef5a43e0242a38b64a47d77c72e2440986dadfa23882fab98821d3dcde3cf57689f20f472342626a733d0e8fb9ed38aa20ae300bed5e01cf6dd3bbd23"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 583,
      "key": "43f3a05a562aea7d640aaac845125159fcfbdd06303b001b5cf1eec04af58dabda000353c3cf4551bae1aea91c8b1be6e3f2669e44287e4a25d0655b1d33aab4"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 565,
      "key": "50403cc7ef5ce4172930d644a5740cda8918061439e7d529c0f888ba1b049a77a5339ec7d3482657b832429d9e62714c7fafa0d13366824ad8debfc61eaefc20"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 580,
      "key": "5dfb58d8aaec19dca766f910c5daa3183e4e9eada1060622d91815a34356c7e7c82c726922e016bfea5b95401a58e39fdb92eeec41d0717970c206adc5276ab5"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 542,
      "key": "8d6bf5089dd5843561afd9eb68f1d01f3e6bffe12e4edcfc4c3991b9a862612ca3ce419a5d8074a59bfa9a5e495eb82808b10154cae9a3ef1de7ae4404e96e6a"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 548,
      "key": "3b6ffebeddbebde6c3905b01aaa4be230b94b17322cab62b5d8c64683772441e4eab8a1a3bdc3096a7cace38d5c493f74403405c847500990d0def53c38a78bc"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 549,
      "key": "7391a54abfd55423811d434067fd745d72a2f722a56868eb1338cef88c90901f5a8111168581998fd4707fbea406351a9877b6c8483e9ddd61218759c52b2080"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 584,
      "key": "6837e9f753c8a9a6822155b2aab76c6bfa02af33060602567cf2aa84fb01af8eac3205af72c3931778468d5cdbda3073392fef579d33fb0c67e535fd6a025faf"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 631,
      "key": "9390623ad9aff33234038e9710d59807723d1d736dbe2117cc800c94e5fdc5779600e3c4bbe018e8993399913eac1e341809b58f798b33a4d39c436271cc41a4"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 545,
      "key": "4bd03865d374824d2c1f09c2c012d0221b222d9c1898e93390a95ce833f14388df6827ccfd76f42001eaa49ca0a99d5fb0399f6dda67d786dfe4b54064a144c0"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 609,
      "key": "a44b2a0acc217cefa2b912ebe8137a3d15ae0c631964aa4fca85278289a9463bd87f503c71a2e847a3be846881a3b1a2b15ccdeab1c3a435672508e7814f7d32"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 546,
      "key": "371e8cc9f0485dfcbef36e8aba2c14e12d1f158f75e0d6276d32381b73291dd9b4d96eb0b6b9599602a26c2c728ad8bac1a5f1d825498a797cca83eb9504a59a"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 589,
      "key": "9cfb692e3b39903e05776d10e5ec184405b65b7ee2afbee7a958ac60be2e0a8de0d684efe5a7fcc4198d4d76591b906798952e7cda8584eb982d9758803184ed"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 572,
      "key": "58986c791f2e9f99e5f781c0d69ab10d244a9a868bf00afa6fa0816f18a13812a6dccae802411e9fef1b837d251d13ea81f00cc45f6a72a58a7493509453241b"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 587,
      "key": "5397fd32265c905a6792f7c5cb5381db4b46c62fef27f2a5b997d8ba981ca2c9d3b338f432309425570a0ac71b345251b6534744793ee1a57fbc1bb33a734428"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 588,
      "key": "9946aa2b95523f16edeb9d91887cc43c97409fb07f17a38fb069a0ecc2b60eea026aef342cf08dc43f39c16b3ee15063941a692f0b1c061d2232bd01d523679f"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 539,
      "key": "26e2c1f0f2cf7cadbd4e42d4b3b4bd79417c1af3abb72efdc6389347f1c4e78f3817ec8f10203266fa8f1459650cfe3419fb3b6e7a04d170a08162f0b5be6a40"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 573,
      "key": "6af95cd3daa66f301c13a26a4b037321a9fb66a678d9f64f2d19d2bfdbe9ee159c6fd0655a2fff897c669331bfafaee10bd3c7b7f32325d97a1340077935e971"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 574,
      "key": "84e8acc0aa10f59a01f26ce977684a46fa9010b398561e2594a469634430a7cb85e3a15e33ddf4c30372aad96e9eb97b3883943ba6cc0be87b35b5970d1c52b0"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 576,
      "key": "853118bca69b576a2a4a46704657df9405d5104fd01a8f488081a80842b011145bbd3f09d71ccc746bebf4ab5b819a0baa3f0c184568769348885ef61f50904c"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 578,
      "key": "f7392e0b951faef5a91ea100fc0ece624cab52e7e1bbb3146b24727b5b5e8fd242900dd5067925624b40086aa6d29a08e64eb70b9b6ed8482b4eddbcc997dafb"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 540,
      "key": "8d763fb8cc515a10da84e1e985c0044693b017851461c4ce766f78246936a8ed37510f0baa19cecbd401b10898b937c5a1acf0fd9c09f4b1499ad86dba28fa15"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 541,
      "key": "307167a600941985823e285304ad324877a8eafe275c0102fe64aea696a1384d2561f18fabac841712c952a6375ab0fa8fc814c0538d76bbb9f6dcf06c9ccce9"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 590,
      "key": "b5a7580436fab73483c3bf632d8d96c31184a0db526b830295612a8803372d4a10f1dcb86deb274827053122aeb2c70c8301b931ee0b11eabe854e38f9a29917"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 553,
      "key": "8f1ab924405f8e4b64387d57b9e93aaf0f64285cc474dca7562ff63298b2c3c37ef2736dd341c057f4fdddc7f47801603db36c08750ce2e1d7455affb1e8affc"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 554,
      "key": "a76c10c9bcf6ebecd615cd5e760cd39399f3b556aebeb8fc76b2405796231be03deeabcce99d551d194342a20e46898528c6f4af2f0c7acfd6a62eebf1f21c5a"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 555,
      "key": "080e052d346c7207b5e8d99ee6253330bf52cebda6a7c9f26bfc6d05416823d810affa9cf5c7e991ed9f64d7d76eaa4f3e71bb9d233f158a8e5dd972ee06f7f8"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 557,
      "key": "7c4dab41f0b789fe1a52f61758835723c3b320276f1f4dd19c15f5910c60497a112c4ec2b291ad3da3ffec9bbc530290dd67b167ac4d3ad55e2338982297e705"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 558,
      "key": "1b09944e54c63ceda69aff0e55d2784333b55f9cc3686da1e19f5c35f602f7e628a32e898ace34bfac83eab37e5796ebc6eb6ab862f754bf46307ce4b9edc150"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 563,
      "key": "1ea70b1fdc71c02106277625f2caa4a966e913c03fe8ad751981023e6b74cc994370be7baa25ecf05138e10d08c4f2af7320c3a733cae82b6b055734105d1821"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 592,
      "key": "f331474061d8420a9d0b22a9a209adeca0b96c80867792cb1c63830cc912c379a03f93fa521f0b83be162a4d1dd520b68c8d8819746325caef389ec2dccb2f34"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 585,
      "key": "70bb42654369e9156dad866efda47054af4e2d3a10f1bfc9827c6dfe9f03d13855f63d5260f9ff8d90c3bfba7f38342019a74f0bd32758288754a0cb20a5ce15"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 566,
      "key": "9bae280a28a0f7af1bddc5b7e14dfa5ea0abd59fc8a942651e577f658624e9ffffd8003d3eef27f5898ca65e3a0e76b6bd0a6c97aa75f3f8761023e6ea27020b"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 571,
      "key": "ea9c4ec49db06f14df2fa2c8ea89f71ed0de857005fc7644e5b763133bdbd5ba7d77397fb959c529b4ab78a5dba94abe1acdc7b06c3c7957767e7a938c293ebc"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 586,
      "key": "b6d004a88e78d2a2755017f41e258be1af3b715fca02d7e5135708759f2bc1d2d854175cf09021c4d9e4c0c2339207d2cad881d8e1da04a31b1e6f5970a2b0b1"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 570,
      "key": "668ccdb77eecd40539c9e953f53c103cc890ea75980fea28d46ce7e3b401c3a815c17f2391ce50f9736112b8ae0c8794537904be0d2270a702ffaac245bec798"
    },
    {
      "line": 1643,
      "relation": "decreases",
      "evidence": "An additional “knot” of tau being entangled in epigenetic landscape of neurodegeneration comes from the finding that by acting as a HDAC6 inhibitor, tau is being indirectly involved in both (dys)regulation of transcriptional activity and impairment of autophagic clearance by the ubiquitin proteasome system [81,82].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 486,
      "target": 459,
      "key": "f4fbd21c80321656d876bbc30fe9945997c452a41335e60f08dd30c4837247ae0773920bb80405cb1162ccc434d71e8502135109b4fae3dafc67f5ab8dd9aa06"
    },
    {
      "line": 3365,
      "relation": "positiveCorrelation",
      "evidence": "HDAC6 inhibition leads to a significant reduction in tau levels as detected by the human tau-specific antibody E1 (Fig. 6 (a and c) and supplemental Fig. S6). We also observed a striking decrease in phosphorylation at Ser-324, which was statistically significant even when normalizing to E1 to control for the reduction in tau levels (Fig. 6 (a and b) and supplemental Fig. S6).",
      "citation": {
        "type": "PubMed",
        "reference": "28760828",
        "name": "The Journal of biological chemistry",
        "title": "An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.",
        "volume": "292",
        "pages": "15277-15286",
        "date": "2017-09-15",
        "first": "Carlomagno Y",
        "last": "Cook C",
        "authors": [
          "Carlomagno Y",
          "Castanedes-Casey M",
          "Chung DC",
          "Cook C",
          "DeTure M",
          "Dickson DW",
          "Dunmore J",
          "Madden BJ",
          "Petrucelli L",
          "Tong J",
          "Yue M"
        ]
      },
      "source": 486,
      "target": 459,
      "key": "86f5d2d3c278e5b0c24aab2b62b7071e12ebed9c33dd357c469f96c69a50f3e6c57df738b1a3aa6d8c36255089a44ea6393af06831a85b472da8c38d0925fcba"
    },
    {
      "line": 1644,
      "relation": "decreases",
      "evidence": "An additional “knot” of tau being entangled in epigenetic landscape of neurodegeneration comes from the finding that by acting as a HDAC6 inhibitor, tau is being indirectly involved in both (dys)regulation of transcriptional activity and impairment of autophagic clearance by the ubiquitin proteasome system [81,82].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 486,
      "target": 196,
      "key": "490f65ba4949ac43669ba9763e4bf075187907c4db08e7aafd0de11661de8d96e854cba00ecb50b7b2d826c336f65c34ded616554c234d56e9a72d530fa7de5d"
    },
    {
      "line": 1645,
      "relation": "negativeCorrelation",
      "evidence": "An additional “knot” of tau being entangled in epigenetic landscape of neurodegeneration comes from the finding that by acting as a HDAC6 inhibitor, tau is being indirectly involved in both (dys)regulation of transcriptional activity and impairment of autophagic clearance by the ubiquitin proteasome system [81,82].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 486,
      "target": 213,
      "key": "faacbdd86a5739c56797bac42d4605f100b74d7f4fc48487f067bd10665f53c8788139df455c38c20620c2b2721ae582837e05643d734616dd76d007f5b6fd8e"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 630,
      "key": "80f6dbd9d5f4cd94a43ed5e9fa36c0d95ff399a19f3590e5214f0a39fc4b6694b922fd86728f068084f4cf3f66026c36c236e69ea343f97b99cc7ebe9454d7d3"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 611,
      "key": "62a45f17b83cfb6b20d936779cf9f0724799d42a7844ea847ef7324bfac1f6cf0fb496948b3340de9aabecc2753ce39e56abe9a1af41d9e125d9e184cfca3bf2"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 600,
      "key": "e2e938bb0b35b668961b012e725e5e18c71d04f56eba0c156c98b789b5069843a1fe599925caf5303c5e6cce444e0f7a91d6e50f01d331f35fa1a403f784f313"
    },
    {
      "line": 1707,
      "relation": "positiveCorrelation",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 486,
      "target": 180,
      "key": "27e0a436c6bb56bf628e030e45ad825d06601cfe2fa2b044bbe7b2aaa99a7cbdc9ddf9844138e6cb6834d8cc37cf45e9066632782b1694709004ece076421478"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 497,
      "key": "69c01b0d6c247180799c5c9e06f248562b622a3bfef9d7718216b5084448efcdd928b55e823d5a1d86350962633367c3818de3ca83844d5a405a6e9e9c165590"
    },
    {
      "line": 1990,
      "relation": "positiveCorrelation",
      "evidence": "DAPK1-mediated increase in tau protein expression and stability were accompanied by increased Pin1 Ser71 phosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24853415",
        "name": "Cell death &amp; disease",
        "title": "Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function.",
        "volume": "5",
        "pages": "e1237",
        "date": "2014-05-22",
        "first": "Kim BM",
        "last": "Lee TH",
        "authors": [
          "Chen CH",
          "Hong Y",
          "Kim BM",
          "Kimchi A",
          "Lee S",
          "Lee TH",
          "You MH",
          "Zhou XZ"
        ]
      },
      "source": 486,
      "target": 431,
      "key": "008200052abd39ef4b4f7f9521c528b8b2d98aa69c35fdfc6b02d2816ba85d826ef37168ef7ba2c538d7ed89712f10b39f6adbce11bc6e1c792a20fe52dbe508"
    },
    {
      "line": 1991,
      "relation": "positiveCorrelation",
      "evidence": "DAPK1-mediated increase in tau protein expression and stability were accompanied by increased Pin1 Ser71 phosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24853415",
        "name": "Cell death &amp; disease",
        "title": "Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function.",
        "volume": "5",
        "pages": "e1237",
        "date": "2014-05-22",
        "first": "Kim BM",
        "last": "Lee TH",
        "authors": [
          "Chen CH",
          "Hong Y",
          "Kim BM",
          "Kimchi A",
          "Lee S",
          "Lee TH",
          "You MH",
          "Zhou XZ"
        ]
      },
      "source": 486,
      "target": 651,
      "key": "a45cccac0f3a1271cf1d1ad8177b0e99e89ee0b45ecb6b66f1c8bd5ad89f5c56645e501a82638d598a3b75bd37ff247fa7cbc7c9faab944b73062a8fa95d3209"
    },
    {
      "line": 3987,
      "relation": "negativeCorrelation",
      "evidence": "Because Pin1 has at least 4 major isovariants in addition to the native polypeptide, this means that Pin1 has 4 (possibly more) posttranslational modifications including phosphorylation at 3 sites (Ser16 and Ser65/Ser71), N-acetylation (amino-terminus and Lys46) and oxidation (Met130 and 146). In all experimental conditions, including tau-overexpressing cells, tau transgenic mice and AD brains, global levels of Pin1 posttranslational modifications were decreased compared with control conditions.",
      "citation": {
        "type": "PubMed",
        "reference": "22926167",
        "name": "Neurobiology of aging",
        "title": "Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker.",
        "volume": "34",
        "pages": "757-69",
        "date": "2013-03-01",
        "first": "Ando K",
        "last": "Buée L",
        "authors": [
          "Ando K",
          "Blum D",
          "Bretteville A",
          "Buée L",
          "Bégard S",
          "Bélarbi K",
          "Caillet-Boudin ML",
          "Demey-Thomas E",
          "Dourlen P",
          "Drobecq H",
          "Eddarkaoui S",
          "Galas MC",
          "Ghestem A",
          "Hamdane M",
          "Landrieu I",
          "Lippens G",
          "Maurage CA",
          "Melnyk P",
          "Sambo AV",
          "Sergeant N",
          "Smet C",
          "Verdier Y",
          "Vingtdeux V",
          "Vinh J"
        ]
      },
      "source": 486,
      "target": 651,
      "key": "882481b116cf767dc62eecb3bcac8fd687aa7b81638091bba06bdeb12bc78c38785889c002e2ad07caa648657a2e4a8b56bc05284438a41845012cb29ca0e537"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 516,
      "key": "9fbd9218812f1cd82827e2d73f3b6af04acbe1f408aaedcdc53c6fc17a36272c67cdcc254874f5473ba4443fa19971fe4877420e735c04f4f7353480d8e1f8b2"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 591,
      "key": "95c5dd8b94bb7d99770ceb32f637aa8bb1a23274675e1d4bfb7c8312569c0669e5978b90e21ec5ff71ac056579588f2a0f26135e2660a9e1e8a4f0b032a309c6"
    },
    {
      "line": 2466,
      "relation": "negativeCorrelation",
      "evidence": "Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift in mobility as a result of phosphorylation-like changes, we conclude that they have the characteristics of hyperphosphorylated tau. These mutants will therefore be referred to as pseudo-hyperphosphorylated tau throughout the manuscript. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.",
      "citation": {
        "type": "PubMed",
        "reference": "19459590",
        "name": "Biochemistry",
        "title": "Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.",
        "volume": "48",
        "pages": "6002-11",
        "date": "2009-06-30",
        "first": "Sun Q",
        "last": "Gamblin TC",
        "authors": [
          "Gamblin TC",
          "Sun Q"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 486,
      "target": 336,
      "key": "e1c57aa849846f87931fbc7cec29aa103d304303d074ac244e43a7bc8f1ba96f14dea8bcaf8ebf7bc2762c8ee96ba040cb7d2a903e8f6d79c3cbc338df687ffc"
    },
    {
      "line": 2472,
      "relation": "positiveCorrelation",
      "evidence": "Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift in mobility as a result of phosphorylation-like changes, we conclude that they have the characteristics of hyperphosphorylated tau. These mutants will therefore be referred to as pseudo-hyperphosphorylated tau throughout the manuscript. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.",
      "citation": {
        "type": "PubMed",
        "reference": "19459590",
        "name": "Biochemistry",
        "title": "Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.",
        "volume": "48",
        "pages": "6002-11",
        "date": "2009-06-30",
        "first": "Sun Q",
        "last": "Gamblin TC",
        "authors": [
          "Gamblin TC",
          "Sun Q"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 486,
      "target": 186,
      "key": "c58fd41d8b0c8d780a4eca1c2b759ab32c2498517c466468f690fc4e0999fab346864d3397d7c3baa0b16c14485c64f882a6431c4ff8e33732ad76007cf4c5ab"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 581,
      "key": "8a75480ff70fd9adcc89e12a581be5859a807e9d87fae8969e9836fb234054de96e6731cace1e5d05476fb935981f3330e3af5096a5274f7f49d95e41ae762f8"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 550,
      "key": "4c46fb70a1f5956c4c897e7f61782fcb9f00a9be8f18d3238edc94df33820ae62e15953cb8f120e2ba5ba56deb1039e7ad93e42c5f4d2c8a6a17e5271cb131b0"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 626,
      "key": "427a39437aea06845d630b8661247d2d66da94393818d49f37598de82807414c0b4813eaae08492083dbc80d0e50cf49b60d5cdc7dc68673446f1e391b2342fa"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 547,
      "key": "1ee32df2ae849bd7650d1e3213e49e1e9b95c7021ca9f399cb48eb8373782b304a8360a069373af387b20f38d6ca9f8d2c18a5b0cdc62ba0f7d0a7433b918810"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 561,
      "key": "c28131e97f8ddda4cb5d66338c512fa72d213478d3fb903b8c56be8fa837ddff3d924706e0f313af666e52f58ab0a35cc9e27bbc842535cf78fc089b80c6649f"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 559,
      "key": "a589c91b7da07245f713a8f9a53701e0008f348024f3b4d7269a3669aa6d8aed7ae4b796af132d744cc9019d6ca8a5fbbe1efad97628a39edf287178d99d12f6"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 560,
      "key": "20e1ea78e96cb36f525e0e45cc7f5332dd2df238c65814ebddbe5d5cf482816b61a22c5dbadc5bbff243ff55622579401238c919a9fd8686159c4ff68f8f04e4"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 562,
      "key": "e9376004be7b84bf56f47e4828a8c984e20f8eddac066713a1529dfe57e77179abf2c734918af3b3cdbd08f58710111c218212eca535f3091dba78a4bda76cc7"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 567,
      "key": "b30e07545cadedd019962e98505f37579c951a63724c05c1355db47823fa8f034428326271a189d53d8cef0537bd22bd9c41fafddded82ec8e9c7c308b728b29"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 568,
      "key": "6f4878c34a13760637b7aecdee2a92b15391a9e5a5973a01ec0e5343ffadeff0507e745fff54c9faa3b156353be93b3ea35d188b12c321e4413d1b29a237c51d"
    },
    {
      "line": 2672,
      "relation": "positiveCorrelation",
      "evidence": "In particular, previous studies have demonstrated that the tau ubiquitin ligase, CHIP, is unable to bind and ubiquitinate tau species phosphorylated by Par-1/MARK2 on the 12E8 epitope (S262/356) [33], a p-tau species that is also resistant to degradation upon treatment with Hsp90 inhibitors [32,33]. Tau phosphorylated at the PHF1 epitope (S396/404) is still susceptible to degradation following Hsp90 inhibition and actually exhibits an enhanced interaction with Hsp90",
      "citation": {
        "type": "PubMed",
        "reference": "25031639",
        "name": "Alzheimer's research &amp; therapy",
        "title": "Acetylation: a new key to unlock tau's role in neurodegeneration.",
        "volume": "6",
        "pages": "29",
        "date": "2014-01-01",
        "first": "Cook C",
        "last": "Petrucelli L",
        "authors": [
          "Carlomagno Y",
          "Cook C",
          "Petrucelli L",
          "Stankowski JN",
          "Stetler C"
        ]
      },
      "subject": {
        "modifier": "Degradation"
      },
      "source": 486,
      "target": 117,
      "key": "1383dcc38330e46382c38852b20898c7644abcfa398437074b25357a783c2112132329a86143c3a9dd43dc5f44deadf2999e90a3816096f0335d3a76063ae97d"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 552,
      "key": "3a92d83cf4f01b5d9f4ae62a3edc3e4a042a47a573fa4b50cb6d784ff585d49dd9aeaba4095ff2e3f02430ffaf3ac3aa1ed0dfe5af3a57a673725f8886e4a800"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 488,
      "key": "8428f58f7ba296d28f281b1dc20a09bf9dfe5d48ed78ebdf4a1537c175799f3ffa1186317341f22c4680be482ac57273d49ef5d62c115ff4681171740ee07f29"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 556,
      "key": "6cdd26f576b0484323bdae54ed2e1d49f46bd14052b96ec4422a8f7d45215dd0c13bc7b8eba82d668789b5bdda7c22074493e508e75b0f7e54cf67947ce4ae70"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 605,
      "key": "a84abc378cbbb33b139780577a88855eea495e2439921be736c40dbf3b60edfda70e8a214374b765c07dd5fb1282faa81411f40b92e9b91e794a3337ecedf06d"
    },
    {
      "line": 3054,
      "relation": "negativeCorrelation",
      "evidence": "After pretreating hTau neurons with oligo Aβ-42 (1000 ng/ml), Sirt3 levels were reduced (Fig. 6b and e). This reduction in Sirt3 was translated into an increase in total tau and Ac-tau.",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 486,
      "target": 849,
      "key": "befc906bd13d79f09a1dff73797d840552934e079b8adc502e76f2b86c432d2dba7b0f1da935b5f3d3c7c7a2aa5983ca84a09fbe0c546a435cb3e808ce6f668f"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 490,
      "key": "1631b68679802335af5ff80fe434043dfaf84a54c8fd6d5f4e8025cff98c232f694b486c452a1c033e6638fc5cbc258e8b76477f903d862587dfe4da3cf06896"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 498,
      "key": "3102342f91f0888797568c603e6b58356f87b8b2977787095327eeedc4f9f1ec8b15f59b277a90bc2929127856303b9189985c88371094fc75ededb943df392f"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 491,
      "key": "90f955cdf4e52ade389e8e80c810d7959b0792ad78f8a86eaa0083bda9938d1d2db7bd4c0dbcf878a564b623a955468f922ba3315a7cf693d58a9889670c6686"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 499,
      "key": "79cc3a5bf744bfb5eed35e094825c131342fe825bec9ce844c021b95a862cb9ac19f33787997f01a3caeeeb5ec72a2a3b8c0b6a98517c59ed43010d75b49b670"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 508,
      "key": "2714f25fd551cc93a6168f53f7fcf9c2596f16b86ba72d1f433f89c41071dbde24149a95f0bbae9412f913ef2cebc7ae8c3db37e22ff9d9b9e208f1ff4ffa468"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 617,
      "key": "e499926b8b3d7f1926116fe07c8b5aa1437d887bb4a334136e7a3b37d3f547dd1195817013840402b54f104b3dca488d287826d6391c02c82a473c52b1389ad0"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 492,
      "key": "8fa4b56112f5e7dda49e8717fd7d14532c9d727b48e3e38b961d647d0b12c64a107f38d078c6d16acdc829d6394ad597d560257a8d9d5031e8a611f61be8ce10"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 494,
      "key": "99299e9b17b27d90106adee13c13e47ea34bafd04ad3745eb130339e40c428d49e1bdd3c74af11d93ee8a22240b1c336af3c0a758b0e708713bb83734f9d5976"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 496,
      "key": "e1055b2103f62666e9b9901d8de09cd00e41082aa4331fa9691c178b132fd642566afd9cd6f698ea101b53fd24f588969e613aa3baf2c6cf52dead3fbdda1d2d"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 502,
      "key": "46943c887dd9e811ba4a4c9852441f23a0122626a7519ad57c4a9d1d86cbabdd28a41ba3af57bc4bbb0b49320173ede3d68f56edc739e7d10aec21ceb16bfbc9"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 503,
      "key": "078c742698d53179d7016109c55d53d4e7dd9a366bcc900f91a381ed967651bbd76a8e08adb07a81f4252889b5b440ab9f2ccfecc0a7d93a218c4e2d6cc38077"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 504,
      "key": "f277e5a8684b70395a690e1e32db41f7b2e60e13cb883fa133b68e7055583c1016f7e7b4895b59d57c1c02775719968036427a8593f25a41e831de8f928df09c"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 505,
      "key": "9025f60b66ec3f549ae4a1a0ee9d77fa428e56b88d92de6c274f1e912784f4dc4ab0f908e5a06de45c693d614a2ccbc3f65f48bd50f6bb1ac14f0d4bd5e538bb"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 506,
      "key": "41e7e318787e4a92134f1ce929eea6494c6c4df83fd1f324f608032bacf1dbbc55c0fb1ba8c3bef3e2cc414b6524f1c90059a5837bd6a6e3703117926e908028"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 511,
      "key": "90a6c378f94c9844416d6ad3e3627b3b08caf39e72519388ff95370e106cb9cde183b066c4e1d208031608c195fa64b4f09eceab6692f45950cbc0a3d5615e30"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 493,
      "key": "2036677a22f0540542c4293a42a992b1e06ca924d454dd87915e5d8e632c722212a41aa40426c7ca2da41be9bb17b8bf97befdf3470d177bef3e5e559ad08eea"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 495,
      "key": "48434f1a0950c1e259ca1d0ee4ba246e9b3b6dc5c83a3b4962e01e09b9ff1e6c32370ffdf1cfa0e0bf13b74ab856463c1753770d6b239fdf8a8457b21ca5e1c3"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 500,
      "key": "f807efa795193e2277fd27d6898fdd78cf1f8f4bf17beb00dd53697b6493f47fbbf864410c18e80a6c51351f44199fc0b1158773ab29ebc889da9b6ad7d37db9"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 501,
      "key": "4737e895104c68da1ac7227e4da9508ccdf1da28dc5cdde6abc32fa233eec1913b232c6f55aa102cba382f6048b0649ff9b8440bcebf87574e5453fba5b17af8"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 507,
      "key": "2e9afa0e3f757ad3ec552d58b35161aa2aad8333c51f883b7fd085fe870898715e075b936ff8e3e2a2ecda3313386ea8f6113a424e64061fa6a19fd80f130eee"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 509,
      "key": "6e80cb7af05a0aeb0fd1a5a6a379c00886c30a49efc737f0bf6b55b65fb80aafe668021c816e60c0df56d3e756d7c04d84e2548a8924b84ab267bda69c09d245"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 510,
      "key": "d8f5dbe27e2f901b00245591d8c644f36471e040fe61f154b667ec94a3b2a34a2eaeae82e26aa5c4d8486adc484bf9af398389a6762c8bb8b2787f1417f6366f"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 512,
      "key": "1fa9714bfe01a17bd6ebb45683cb13f63610cbf173da4e9f09f28f4a4726128b3c709fcbf20996f2fceb16912480f6ae969dd45c8cb3b1cff2b468fc0381284d"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 594,
      "key": "233175822018f00d5bba682b71d9619e69b1ffcbc798ef965753963c52979fe53377c90e3fec2a692a31e92e3e0183cf12a6286f7e77474e51b0e10554f3d71b"
    },
    {
      "line": 3487,
      "relation": "positiveCorrelation",
      "evidence": "Furthermore, the enhanced SUMO-immunoreactivity, costained with the hyperphosphorylated tau, is detected in cerebral cortex of the AD brains, and β-amyloid exposure of rat primary hippocampal neurons induces a dose-dependent SUMOylation of the hyperphosphorylated tau. Our findings suggest that tau SUMOylation reciprocally stimulates its phosphorylation and inhibits the ubiquitination-mediated tau degradation, which provides a new insight into the AD-like tau accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "25378699",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination.",
        "volume": "111",
        "pages": "16586-91",
        "date": "2014-11-18",
        "first": "Luo HB",
        "last": "Wang JZ",
        "authors": [
          "Feng Y",
          "Jiang J",
          "Liu XH",
          "Liu ZC",
          "Luo HB",
          "Shu XJ",
          "Wang JZ",
          "Wang XC",
          "Xia YY",
          "Xiong YS",
          "Ye K",
          "Yin G",
          "Yu G",
          "Zeng K"
        ]
      },
      "subject": {
        "modifier": "Degradation"
      },
      "source": 486,
      "target": 594,
      "key": "bf785e3f7946efe72898b8897c4aac73bddf83f152ae446ae015717ea07c3352a43772c0834f7bbd4fa88104b0af3378a9f67f5292ebbf185a7311fa452320d2"
    },
    {
      "line": 3513,
      "relation": "negativeCorrelation",
      "evidence": "We show that axotrophin/MARCH7, a RING-variant domain containing protein with similarity to E3 ubiquitin ligases interacts with tau. We find here that tau becomes mono-ubiquitinated by recombinant tau-interacting RING-variant domain, which diminishes its microtubule-binding. Tau becomes mono-ubiquitinated by recombinant tau-interacting RING-variant domain reducing microtubule-binding.",
      "citation": {
        "type": "PubMed",
        "reference": "24905733",
        "name": "Biochimica et biophysica acta",
        "title": "Axotrophin/MARCH7 acts as an E3 ubiquitin ligase and ubiquitinates tau protein in vitro impairing microtubule binding.",
        "volume": "1842",
        "pages": "1527-38",
        "date": "2014-09-01",
        "first": "Flach K",
        "last": "Holzer M",
        "authors": [
          "Albrecht F",
          "Arendt T",
          "Arsalan-Werner A",
          "Flach K",
          "Goedert M",
          "Herrmann L",
          "Hilbrich I",
          "Holzer M",
          "Ramminger E"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 486,
      "target": 594,
      "key": "35f6f2fed1297d47f7da5ba8dcf671ed44a3b02cf657de5432b1f5e66df845dfffc0a768b7cd9ecb6c7389c5a03419fb232e2ec9ee03af7d060ba6c17e9f258e"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 593,
      "key": "481cd63ca4930ecfe5c4e431566dc145030aa1941e132a2ad2fd08f815e25fbb138e10c64f6ecaa549df0147f863989105960777e3de08c419f54e26e5864b95"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 596,
      "key": "73a53de2c4e7b28700ca3d6df7535c422dfc602e288bb10f70bbf3a9c7f8900e5788e81ca413de0df847a70d089bd9e85ffd6e1e895fea1816877443bd565186"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 597,
      "key": "758dbf2f96744f2ed36fa0683491d58ec9e2af98512023191f10fb0b013f31d68aec6b065498cbdf5408faf20e20379de4fcdc861f456f5f3c04c231f99d769b"
    },
    {
      "relation": "hasVariant",
      "source": 486,
      "target": 618,
      "key": "48d009066693f0c5cf1d09a48e396a171f7616a3073a7681f306857eb792aef0af1ec0f0ae3f5cce7d27d47836b23bdecd8678ba6f18c411fc7af7b5f8e7c594"
    },
    {
      "line": 3985,
      "relation": "negativeCorrelation",
      "evidence": "Because Pin1 has at least 4 major isovariants in addition to the native polypeptide, this means that Pin1 has 4 (possibly more) posttranslational modifications including phosphorylation at 3 sites (Ser16 and Ser65/Ser71), N-acetylation (amino-terminus and Lys46) and oxidation (Met130 and 146). In all experimental conditions, including tau-overexpressing cells, tau transgenic mice and AD brains, global levels of Pin1 posttranslational modifications were decreased compared with control conditions.",
      "citation": {
        "type": "PubMed",
        "reference": "22926167",
        "name": "Neurobiology of aging",
        "title": "Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker.",
        "volume": "34",
        "pages": "757-69",
        "date": "2013-03-01",
        "first": "Ando K",
        "last": "Buée L",
        "authors": [
          "Ando K",
          "Blum D",
          "Bretteville A",
          "Buée L",
          "Bégard S",
          "Bélarbi K",
          "Caillet-Boudin ML",
          "Demey-Thomas E",
          "Dourlen P",
          "Drobecq H",
          "Eddarkaoui S",
          "Galas MC",
          "Ghestem A",
          "Hamdane M",
          "Landrieu I",
          "Lippens G",
          "Maurage CA",
          "Melnyk P",
          "Sambo AV",
          "Sergeant N",
          "Smet C",
          "Verdier Y",
          "Vingtdeux V",
          "Vinh J"
        ]
      },
      "source": 486,
      "target": 649,
      "key": "105c0efb8a24fe685b7cb1758376a90916c0ce3c71330c1b0132b0e3eba5146796a1286276e083db208185d30ce7911319c7c3bd978535a21621dcce5ba562f0"
    },
    {
      "line": 3986,
      "relation": "negativeCorrelation",
      "evidence": "Because Pin1 has at least 4 major isovariants in addition to the native polypeptide, this means that Pin1 has 4 (possibly more) posttranslational modifications including phosphorylation at 3 sites (Ser16 and Ser65/Ser71), N-acetylation (amino-terminus and Lys46) and oxidation (Met130 and 146). In all experimental conditions, including tau-overexpressing cells, tau transgenic mice and AD brains, global levels of Pin1 posttranslational modifications were decreased compared with control conditions.",
      "citation": {
        "type": "PubMed",
        "reference": "22926167",
        "name": "Neurobiology of aging",
        "title": "Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker.",
        "volume": "34",
        "pages": "757-69",
        "date": "2013-03-01",
        "first": "Ando K",
        "last": "Buée L",
        "authors": [
          "Ando K",
          "Blum D",
          "Bretteville A",
          "Buée L",
          "Bégard S",
          "Bélarbi K",
          "Caillet-Boudin ML",
          "Demey-Thomas E",
          "Dourlen P",
          "Drobecq H",
          "Eddarkaoui S",
          "Galas MC",
          "Ghestem A",
          "Hamdane M",
          "Landrieu I",
          "Lippens G",
          "Maurage CA",
          "Melnyk P",
          "Sambo AV",
          "Sergeant N",
          "Smet C",
          "Verdier Y",
          "Vingtdeux V",
          "Vinh J"
        ]
      },
      "source": 486,
      "target": 650,
      "key": "67f16cc08ce4823fc7e6e99a676be4864d0db004d29bed879377e0c6d78271b5a4bc4b6fada078267c1514ff2da3ce51d52261d031ac4b247d35737ef7f119ef"
    },
    {
      "line": 3988,
      "relation": "negativeCorrelation",
      "evidence": "Because Pin1 has at least 4 major isovariants in addition to the native polypeptide, this means that Pin1 has 4 (possibly more) posttranslational modifications including phosphorylation at 3 sites (Ser16 and Ser65/Ser71), N-acetylation (amino-terminus and Lys46) and oxidation (Met130 and 146). In all experimental conditions, including tau-overexpressing cells, tau transgenic mice and AD brains, global levels of Pin1 posttranslational modifications were decreased compared with control conditions.",
      "citation": {
        "type": "PubMed",
        "reference": "22926167",
        "name": "Neurobiology of aging",
        "title": "Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker.",
        "volume": "34",
        "pages": "757-69",
        "date": "2013-03-01",
        "first": "Ando K",
        "last": "Buée L",
        "authors": [
          "Ando K",
          "Blum D",
          "Bretteville A",
          "Buée L",
          "Bégard S",
          "Bélarbi K",
          "Caillet-Boudin ML",
          "Demey-Thomas E",
          "Dourlen P",
          "Drobecq H",
          "Eddarkaoui S",
          "Galas MC",
          "Ghestem A",
          "Hamdane M",
          "Landrieu I",
          "Lippens G",
          "Maurage CA",
          "Melnyk P",
          "Sambo AV",
          "Sergeant N",
          "Smet C",
          "Verdier Y",
          "Vingtdeux V",
          "Vinh J"
        ]
      },
      "source": 486,
      "target": 648,
      "key": "cb126746dd9ca1eb10ae95a8370765c85e9177cb7c0dab9405e00f1ccb718a93f97bfc283f39db8580fcea01418ffafdab45f6c4f25aadd701a46aecc595feed"
    },
    {
      "line": 444,
      "relation": "positiveCorrelation",
      "evidence": "We were prompted to carry out this study because Acr is mainly localized in the neurons [54], is found in association with NFTs and dystrophic neurites surrounding senile plaques [55], is highly toxic to neurons, is found elevated 2–5 fold in affected regions of AD brain. EC can sequester highly reactive and toxic byproducts of oxidation such as acrolein.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 81,
      "target": 41,
      "key": "e457c6f8f2b075ad8deec9b2d780da3df00ffa5b53b70fec614188c6cead2ea506c0a5e39152582adc7388ce847f5abc8e186ac087c0f92655ef785bc4f62d7b"
    },
    {
      "line": 724,
      "relation": "positiveCorrelation",
      "evidence": "Protein and mRNA levels of transglutaminase 1 were increased in globus pallidus of PSP as compared to controls. There were also significantly higher mRNA levels of the short form of transglutaminase 2 in globus pallidus of PSP (974% of control). Transglutaminase 1 mRNA and the long isoform of transglutaminase 2 mRNA (2212% of control) were significantly higher in PSP in the dentate of cerebellum. Together, these findings suggest that transglutaminase 1 and 2 enzymes may be involved in the formation and/or stabilization of neurofibrillary tangles in selectively vulnerable brain regions in PSP. These transglutaminases may be potential targets for therapeutic intervention.",
      "citation": {
        "type": "PubMed",
        "reference": "12578227",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy.",
        "volume": "62",
        "pages": "173-84",
        "date": "2003-02-01",
        "first": "Zemaitaitis MO",
        "last": "Muma NA",
        "authors": [
          "Halverson RA",
          "Kim SY",
          "Lee JM",
          "Muma NA",
          "Troncoso JC",
          "Zemaitaitis MO"
        ]
      },
      "source": 81,
      "target": 729,
      "key": "cc18e6bd74307b83e1ba331809409ad1d4fd13b74b3aed4e5ca1bdca1b24f999c392c035b322044eb0bba0472674d767013c96bb6a275252ab70d39333aedc58"
    },
    {
      "line": 725,
      "relation": "positiveCorrelation",
      "evidence": "Protein and mRNA levels of transglutaminase 1 were increased in globus pallidus of PSP as compared to controls. There were also significantly higher mRNA levels of the short form of transglutaminase 2 in globus pallidus of PSP (974% of control). Transglutaminase 1 mRNA and the long isoform of transglutaminase 2 mRNA (2212% of control) were significantly higher in PSP in the dentate of cerebellum. Together, these findings suggest that transglutaminase 1 and 2 enzymes may be involved in the formation and/or stabilization of neurofibrillary tangles in selectively vulnerable brain regions in PSP. These transglutaminases may be potential targets for therapeutic intervention.",
      "citation": {
        "type": "PubMed",
        "reference": "12578227",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy.",
        "volume": "62",
        "pages": "173-84",
        "date": "2003-02-01",
        "first": "Zemaitaitis MO",
        "last": "Muma NA",
        "authors": [
          "Halverson RA",
          "Kim SY",
          "Lee JM",
          "Muma NA",
          "Troncoso JC",
          "Zemaitaitis MO"
        ]
      },
      "source": 81,
      "target": 730,
      "key": "8485350c0c03924e8171f9865e2bbd2e1424ef256239512a858b037671a5bf9a05929a1c6289fdd77425c52e9ebb2bf27dea7b5eb7846d5e6dfd3ee354d71c98"
    },
    {
      "line": 777,
      "relation": "positiveCorrelation",
      "evidence": "Total transglutaminase activity was significantly higher in the Alzheimer's disease prefrontal cortex compared to control. In addition the levels of tissue transglutaminase, as determined by quantitative immunoblotting, were elevated approximately 3-fold in Alzheimer's disease prefrontal cortex compared to control. To our knowledge, this is the first demonstration that transglutaminase is increased in Alzheimer's disease brain. There were no significant differences in transglutaminase activity or levels in the cerebellum between control and Alzheimer's disease cases. Because the elevation of transglutaminase in the Alzheimer's disease samples occurred in the prefrontal cortex, where neurofibrillary pathology is usually abundant, and not in the cerebellum, which is usually spared in Alzheimer's disease, it can be suggested that transglutaminase could be a contributing factor in neurofibrillary tangle formation.",
      "citation": {
        "type": "PubMed",
        "reference": "9099822",
        "name": "Brain research",
        "title": "Transglutaminase activity is increased in Alzheimer's disease brain.",
        "volume": "751",
        "pages": "323-9",
        "date": "1997-03-21",
        "first": "Johnson GV",
        "last": "Powers RE",
        "authors": [
          "Cox TM",
          "Johnson GV",
          "Lockhart JP",
          "Miller ML",
          "Powers RE",
          "Zinnerman MD"
        ]
      },
      "annotations": {
        "Method": {
          "Transglutaminase Assay": true,
          "Immunoblotting": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "prefrontal cortex": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 81,
      "target": 730,
      "key": "ec4faa0db172566c4614e4f4886f67601ee6070039df4ed58ec492f4723948bf111a17e60277416b14d4ac65ddb396084c1d6c7fcbfe147f18ffc03710c9339f"
    },
    {
      "line": 738,
      "relation": "positiveCorrelation",
      "evidence": "There were significantly higher levels of epsilon-(gamma-glutamyl) lysine cross-linking of PHF-tau in globus pallidus and pons regions of PSP cases compared to barely detectable cross-links in controls. The occipital cortex, an area spared from neurofibrillary pathology in PSP, showed no detectable cross-linking of PHF-tau protein in either PSP cases or control cases. Double-label immunofluorescence demonstrated the colocalization of the cross-link and PHF-tau in NFT in pons of PSP Previous studies and present data are consistent with the hypothesis that transglutaminase-induced cross-linking may be a factor contributing to the abnormal polymerization and stabilization of tau in straight and PHFs leading to neurofibrillary tangle formation in neurodegenerative diseases, including PSP and AD.",
      "citation": {
        "type": "PubMed",
        "reference": "11089576",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Transglutaminase-induced cross-linking of tau proteins in progressive supranuclear palsy.",
        "volume": "59",
        "pages": "983-9",
        "date": "2000-11-01",
        "first": "Zemaitaitis MO",
        "last": "Muma NA",
        "authors": [
          "Lee JM",
          "Muma NA",
          "Troncoso JC",
          "Zemaitaitis MO"
        ]
      },
      "annotations": {
        "Anatomy": {
          "pons": true,
          "globus pallidus": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 81,
      "target": 267,
      "key": "90c407ab9db386668a11537f7dee78d0e2b498806c8bc03eef2ab3b2114402b10137a84870d31cc80465f307d27b041f5be8ac92280c31e3d1a3e63e84215531"
    },
    {
      "line": 754,
      "relation": "positiveCorrelation",
      "evidence": "The number of neurons that are immunoreactive with an antibody directed at the epsilon-(gamma-glutamyl)lysine bond was significantly higher in AD cortex compared with age-matched controls and schizophrenics. PHF tau-directed antibodies AT8, MC-1 and PHF-1 co-localized with epsilon(gamma-glutamyl)lysine immunolabeling in AD NFT. Immunoaffinity purification and immunoblotting experiments demonstrated that PHF tau contains epsilon(gamma-glutamyl)lysine bonds in parietal and frontal cortex in AD. In control cases with NFT present in the entorhinal cortex and hippocampus, indicative of Braak and Braak stage II, epsilon(gamma-glutamyl)lysine bonds were present in PHF tau in parietal and frontal cortex, despite the lack of microscopically detectable NFT or senile plaques in these cortical regions. The presence of PHF tau with epsilon(gamma-glutamyl)lysine bonds in brain regions devoid of NFT in stage II (but regions, which would be expected to contain NFT in stage III) suggests that these bonds occur early in the formation of NFT.",
      "citation": {
        "type": "PubMed",
        "reference": "11738469",
        "name": "Neurochemistry international",
        "title": "Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer's disease.",
        "volume": "40",
        "pages": "17-30",
        "date": "2002-01-01",
        "first": "Singer SM",
        "last": "Muma NA",
        "authors": [
          "Lee JM",
          "Muma NA",
          "Norlund MA",
          "Singer SM",
          "Zainelli GM"
        ]
      },
      "annotations": {
        "Method": {
          "Immunoaffinity purification": true,
          "Immunoblotting": true,
          "Confocal Microscopy": true,
          "Fluorescence Microscopy": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "parietal cortex": true,
          "frontal cortex": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 81,
      "target": 267,
      "key": "671e03ac9b088093aa346f6c5334086601fed058e12c09ebbd02012fdb791638290954a4ba208db5e85643388770d0eee6dd4d6ddacdb1d8cf9a8834f4eaf7bf"
    },
    {
      "line": 790,
      "relation": "positiveCorrelation",
      "evidence": "Degenerating neurons from the AD hippocampus, compared to neurons from the normal aged hippocampus, exhibited increased immunoreactivity for TGase and demonstrated co-labeling for PHF1 and anti-TGase. Our results suggest that TGase may be associated with the neurofibrillary degeneration observed in AD, thereby implicating TGase as a potential factor in the pathogenesis of Alzheimer's disease.",
      "citation": {
        "type": "PubMed",
        "reference": "8985134",
        "name": "The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society",
        "title": "Localization of transglutaminase in hippocampal neurons: implications for Alzheimer's disease.",
        "volume": "44",
        "pages": "1421-7",
        "date": "1996-12-01",
        "first": "Appelt DM",
        "last": "Balin BJ",
        "authors": [
          "Appelt DM",
          "Balin BJ",
          "Boyne LJ",
          "Kopen GC"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 81,
      "target": 267,
      "key": "95bda13980a5fff6c945babdb5d2053ebc0aa977bb2e2a40da5bfc3ec851aeddff373042a4268ab85ea0b03e5e867c6c778eeccc2e47f0e9be92a937751a8cc6"
    },
    {
      "line": 1298,
      "relation": "association",
      "evidence": "The pSer422 antibody displayed an almost identical pattern to that of AT8, in that it stained NFTs (Figure 5A–D), neuropil threads and neuritic plaques (Figure 5E–H)",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "source": 81,
      "target": 336,
      "key": "6c94c15cdabcbfb71d277e9a7cca4bb919dc5a4d32d4b9b0669ebe89ac38d6d3e1e99f5bb4b54e609b75bcbf9a59457fce2704aca65f392daa6b3e8c721fd876"
    },
    {
      "line": 1691,
      "relation": "negativeCorrelation",
      "evidence": "In a prospective study three different synaptic protein (synaptophysin, SNAP-25 and syntaxin) were found to be progressively decreased in neocortex at Braak stages III-VI [158], NFT-bearing neurons demonstrating, for example, a 35%–57% reduction in synaptophysin mRNA in AD brain [159].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "Braak_Stage": {
          "Stage III": true,
          "Stage VI": true
        }
      },
      "source": 81,
      "target": 935,
      "key": "ac2f8c88e709f87dd4fb3b02d36346212a88e7df9968af1b83805ccde3e9f25426ab4175ad7eb0bd1d4c2ca16db70e03d558213242c79ec5caff26a855bebad7"
    },
    {
      "line": 1692,
      "relation": "negativeCorrelation",
      "evidence": "In a prospective study three different synaptic protein (synaptophysin, SNAP-25 and syntaxin) were found to be progressively decreased in neocortex at Braak stages III-VI [158], NFT-bearing neurons demonstrating, for example, a 35%–57% reduction in synaptophysin mRNA in AD brain [159].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "Braak_Stage": {
          "Stage III": true,
          "Stage VI": true
        }
      },
      "source": 81,
      "target": 684,
      "key": "4cd60e41461bc88cd184d6d00cb126d7dfcc66823bd046399c600d1c5923fdf1ccdeb7d31eb637424150eebdc6dcd76a32128af910fc282298c8864b9ed21f1f"
    },
    {
      "line": 1693,
      "relation": "negativeCorrelation",
      "evidence": "In a prospective study three different synaptic protein (synaptophysin, SNAP-25 and syntaxin) were found to be progressively decreased in neocortex at Braak stages III-VI [158], NFT-bearing neurons demonstrating, for example, a 35%–57% reduction in synaptophysin mRNA in AD brain [159].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "Braak_Stage": {
          "Stage III": true,
          "Stage VI": true
        }
      },
      "source": 81,
      "target": 762,
      "key": "a23466e9a65d030c5443aeadac05ecfd0137d241cad0374baa77a36ff0090153818c9a7d2dc1bd08617469b007929cc87fa5349c6917fc94bdcdfdd976c21678"
    },
    {
      "line": 2314,
      "relation": "positiveCorrelation",
      "evidence": "The accumulation of p25 involves neurofibrillary tangle (NFT) formation via regulation of tau phosphorylation (Wen et al. 2007; Su and Tsai 2011)",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "source": 81,
      "target": 311,
      "key": "fea943038b13c8418f56411b7779694e815927397f71cf7be66bb412ad0f48b0f968522ff7e8f7d53f43f20eb0789e42c0a4d6488ccb39e2c57f8ae79b2c9eca"
    },
    {
      "line": 2580,
      "relation": "positiveCorrelation",
      "evidence": "E391-3610 mice (higher expressers) exhibit robust somatodendritic distribution of phospho- Ser 202/Thr 205 tau throughout the cortex, in hippocampal CA3 pyramidal neurons, CA1 apical dendrites and cell bodies and dentate granule cells.",
      "citation": {
        "type": "PubMed",
        "reference": "22002427",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Truncation of tau at E391 promotes early pathologic changes in transgenic mice.",
        "volume": "70",
        "pages": "1006-19",
        "date": "2011-11-01",
        "first": "McMillan PJ",
        "last": "Schellenberg G",
        "authors": [
          "Kraemer BC",
          "Leverenz JB",
          "McMillan PJ",
          "Raskind M",
          "Robinson L",
          "Schellenberg G"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "hTau E391 transgenic mice": true
        },
        "Anatomy": {
          "cerebral cortex": true,
          "CA1 field of hippocampus": true,
          "CA3 field of hippocampus": true,
          "dentate gyrus granule cell layer": true
        }
      },
      "source": 81,
      "target": 544,
      "key": "b95d2718e3f9c217747ce3bfa45ce1378fc8db43e671e2c59b1ecd53ac3f9c4a95850b0718dcaa70a7ca506e2f17caa5f00a06dd523cdab74185e0f79d696ca5"
    },
    {
      "line": 2581,
      "relation": "positiveCorrelation",
      "evidence": "E391-3610 mice (higher expressers) exhibit robust somatodendritic distribution of phospho- Ser 202/Thr 205 tau throughout the cortex, in hippocampal CA3 pyramidal neurons, CA1 apical dendrites and cell bodies and dentate granule cells.",
      "citation": {
        "type": "PubMed",
        "reference": "22002427",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Truncation of tau at E391 promotes early pathologic changes in transgenic mice.",
        "volume": "70",
        "pages": "1006-19",
        "date": "2011-11-01",
        "first": "McMillan PJ",
        "last": "Schellenberg G",
        "authors": [
          "Kraemer BC",
          "Leverenz JB",
          "McMillan PJ",
          "Raskind M",
          "Robinson L",
          "Schellenberg G"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "hTau E391 transgenic mice": true
        },
        "Anatomy": {
          "cerebral cortex": true,
          "CA1 field of hippocampus": true,
          "CA3 field of hippocampus": true,
          "dentate gyrus granule cell layer": true
        }
      },
      "source": 81,
      "target": 547,
      "key": "a54cbad09089f23529895507e360e17778f6cad0d5ac4b094e58c96226a9429384f3ff408e59856f53b58befab7e112ebad8208330fe708dceb7881a1ad9d625"
    },
    {
      "line": 117,
      "relation": "partOf",
      "evidence": "While several N and C-terminally truncated Tau species are observed in AD brains, only a limited number of specific Tau cleavage sites, after residues Asp13, Asp25, Asn368, Glu391 and Asp421, have been identified so far in situ. The species generated by these cleavages are found in neurofibrillary tangles, and their occurrence is correlated with the severity of the disease.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 602,
      "target": 81,
      "key": "ad3dcfc05f5602eca8a9c3a78fd0dac590d11bbfe56e8328a4f63df3dafca72350a8b5135383f43055949a2619e882eabc61621a8adb439cf6962cf2cd959b66"
    },
    {
      "line": 123,
      "relation": "positiveCorrelation",
      "evidence": "While several N and C-terminally truncated Tau species are observed in AD brains, only a limited number of specific Tau cleavage sites, after residues Asp13, Asp25, Asn368, Glu391 and Asp421, have been identified so far in situ. The species generated by these cleavages are found in neurofibrillary tangles, and their occurrence is correlated with the severity of the disease.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 602,
      "target": 908,
      "key": "d63890ce542d2ffefb76605a5b5dc2d6294ccf64c9f348a0012408845225bea59445f1297984d23cb88fd187427f6f325bb20b8909428c2385321f59e26e4366"
    },
    {
      "line": 118,
      "relation": "partOf",
      "evidence": "While several N and C-terminally truncated Tau species are observed in AD brains, only a limited number of specific Tau cleavage sites, after residues Asp13, Asp25, Asn368, Glu391 and Asp421, have been identified so far in situ. The species generated by these cleavages are found in neurofibrillary tangles, and their occurrence is correlated with the severity of the disease.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 603,
      "target": 81,
      "key": "ce08d9d1f9fa77d57b647b46d52a13e53f3efcb5597d7379229f6223121d717c5baeada982d369d2bf1732cfa1ced5d805bdea26ed500ac2b2f6db9ae36b95fc"
    },
    {
      "line": 124,
      "relation": "positiveCorrelation",
      "evidence": "While several N and C-terminally truncated Tau species are observed in AD brains, only a limited number of specific Tau cleavage sites, after residues Asp13, Asp25, Asn368, Glu391 and Asp421, have been identified so far in situ. The species generated by these cleavages are found in neurofibrillary tangles, and their occurrence is correlated with the severity of the disease.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 603,
      "target": 908,
      "key": "3a319ce8af83552ec0634eaaf77f081a486492d30dc2756e1c3aafa51f83677e290cf3aa7d9c98bff164178a63076e90f198b54c197a737f790a58ea636ee244"
    },
    {
      "line": 119,
      "relation": "partOf",
      "evidence": "While several N and C-terminally truncated Tau species are observed in AD brains, only a limited number of specific Tau cleavage sites, after residues Asp13, Asp25, Asn368, Glu391 and Asp421, have been identified so far in situ. The species generated by these cleavages are found in neurofibrillary tangles, and their occurrence is correlated with the severity of the disease.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 608,
      "target": 81,
      "key": "ee8e957a2e5d15c1c28eb6ae85a58f29df11b6154249050a41e48d75d0d7d9c5ccbcbff9be900c777db726f14a8d6baa2a8bb852792ab9f2afd7b3db55fd95e3"
    },
    {
      "line": 2582,
      "relation": "partOf",
      "evidence": "E391-3610 mice (higher expressers) exhibit robust somatodendritic distribution of phospho- Ser 202/Thr 205 tau throughout the cortex, in hippocampal CA3 pyramidal neurons, CA1 apical dendrites and cell bodies and dentate granule cells.",
      "citation": {
        "type": "PubMed",
        "reference": "22002427",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Truncation of tau at E391 promotes early pathologic changes in transgenic mice.",
        "volume": "70",
        "pages": "1006-19",
        "date": "2011-11-01",
        "first": "McMillan PJ",
        "last": "Schellenberg G",
        "authors": [
          "Kraemer BC",
          "Leverenz JB",
          "McMillan PJ",
          "Raskind M",
          "Robinson L",
          "Schellenberg G"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "hTau E391 transgenic mice": true
        },
        "Anatomy": {
          "cerebral cortex": true,
          "CA1 field of hippocampus": true,
          "CA3 field of hippocampus": true,
          "dentate gyrus granule cell layer": true
        }
      },
      "source": 608,
      "target": 81,
      "key": "2cfdd6aea28bbb3b4ac2d6271e038e63ad34220dbb22c9ba08666d017925e292573beae0171d97584f3a73e6a2ba06c4734b08528fb978804d27e26ac962396f"
    },
    {
      "line": 125,
      "relation": "positiveCorrelation",
      "evidence": "While several N and C-terminally truncated Tau species are observed in AD brains, only a limited number of specific Tau cleavage sites, after residues Asp13, Asp25, Asn368, Glu391 and Asp421, have been identified so far in situ. The species generated by these cleavages are found in neurofibrillary tangles, and their occurrence is correlated with the severity of the disease.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 608,
      "target": 908,
      "key": "76560eadf5f0bd560ea8fcd6d15b3ed4fcf1803fecf93c0fd485206d9642346c5f3cd642d2df925653e9f7851740e06a191b6cf35b8c34e2c2c0fd2e1fccf1af"
    },
    {
      "line": 160,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        }
      },
      "source": 608,
      "target": 486,
      "key": "efea7439d516ab5c59cdc43bf8ad31759115c8ba9c98e815fec257cb51c0d8948e88be3c945a89dc2aa41a37ebe70924fbfabe19068410a5d649a436d5140fa7"
    },
    {
      "line": 1685,
      "relation": "association",
      "evidence": "The tau fragment first isolated from the PHF core is approximately 100 amino acids in length. Its N-terminus was defined by sequence analysis [30,56], and its C-terminus was defined by epitope mapping of MN423. Immunoreactivity was shown to depend on a specific C-terminal trunctation at Glu391 [33,150].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 608,
      "target": 358,
      "key": "9a0f7707051f0c221b8e44c17712a7832a0cb109a5e3b44894bd39ece8609907922b3826e4aa0fe8e5428d2687973b0c8f7d9d825073755c1a9ec3cbe9c146c7"
    },
    {
      "line": 2578,
      "relation": "positiveCorrelation",
      "evidence": "E391-3610 mice (higher expressers) exhibit robust somatodendritic distribution of phospho- Ser 202/Thr 205 tau throughout the cortex, in hippocampal CA3 pyramidal neurons, CA1 apical dendrites and cell bodies and dentate granule cells.",
      "citation": {
        "type": "PubMed",
        "reference": "22002427",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Truncation of tau at E391 promotes early pathologic changes in transgenic mice.",
        "volume": "70",
        "pages": "1006-19",
        "date": "2011-11-01",
        "first": "McMillan PJ",
        "last": "Schellenberg G",
        "authors": [
          "Kraemer BC",
          "Leverenz JB",
          "McMillan PJ",
          "Raskind M",
          "Robinson L",
          "Schellenberg G"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "hTau E391 transgenic mice": true
        },
        "Anatomy": {
          "cerebral cortex": true,
          "CA1 field of hippocampus": true,
          "CA3 field of hippocampus": true,
          "dentate gyrus granule cell layer": true
        }
      },
      "source": 608,
      "target": 544,
      "key": "f4f54bdd83c2bf669bab3c5bcb40562447da359a76f0b3e11a3fed00cbd97b0348f43aae3c205632817470aad9c9471416cece5bc8a8d854bb22d862d44368d3"
    },
    {
      "line": 2579,
      "relation": "positiveCorrelation",
      "evidence": "E391-3610 mice (higher expressers) exhibit robust somatodendritic distribution of phospho- Ser 202/Thr 205 tau throughout the cortex, in hippocampal CA3 pyramidal neurons, CA1 apical dendrites and cell bodies and dentate granule cells.",
      "citation": {
        "type": "PubMed",
        "reference": "22002427",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Truncation of tau at E391 promotes early pathologic changes in transgenic mice.",
        "volume": "70",
        "pages": "1006-19",
        "date": "2011-11-01",
        "first": "McMillan PJ",
        "last": "Schellenberg G",
        "authors": [
          "Kraemer BC",
          "Leverenz JB",
          "McMillan PJ",
          "Raskind M",
          "Robinson L",
          "Schellenberg G"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "hTau E391 transgenic mice": true
        },
        "Anatomy": {
          "cerebral cortex": true,
          "CA1 field of hippocampus": true,
          "CA3 field of hippocampus": true,
          "dentate gyrus granule cell layer": true
        }
      },
      "source": 608,
      "target": 547,
      "key": "758e12101438d25474f92da5fbe96bc00076c4ee6f5e4491546bd4299a36c5273cc6df59b032068bf2f7fc48d31626882725717c4a2ca14969ac39822749cc7d"
    },
    {
      "line": 120,
      "relation": "partOf",
      "evidence": "While several N and C-terminally truncated Tau species are observed in AD brains, only a limited number of specific Tau cleavage sites, after residues Asp13, Asp25, Asn368, Glu391 and Asp421, have been identified so far in situ. The species generated by these cleavages are found in neurofibrillary tangles, and their occurrence is correlated with the severity of the disease.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 604,
      "target": 81,
      "key": "eac9ddd86d0cab51c024641dd2af71e6445973eb207e81888bec65b174a524291c661f98135c3c56f9706f6589f4aaa59c6c71774262d7bfa1b470121a91992c"
    },
    {
      "line": 126,
      "relation": "positiveCorrelation",
      "evidence": "While several N and C-terminally truncated Tau species are observed in AD brains, only a limited number of specific Tau cleavage sites, after residues Asp13, Asp25, Asn368, Glu391 and Asp421, have been identified so far in situ. The species generated by these cleavages are found in neurofibrillary tangles, and their occurrence is correlated with the severity of the disease.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 604,
      "target": 908,
      "key": "6dae651b7565e6eee5c2d42d6feb78b05865f9b02daa2a4565b508468a1cfa5f3acceeaea2f918c6778a81a26d1b60645ffa3442c17328eb2e6aa0c98aef71d2"
    },
    {
      "line": 238,
      "relation": "biomarkerFor",
      "evidence": "We performed immunohistochemistry and immunofluorescence on fixed brain sections and biochemical analysis of fresh brain extracts to characterize the presence of PAD-exposed tau (TNT1 antibody), tau oligomers (TOC1 antibody), tau phosphorylated at S422 (pS422 antibody), and tau truncated at D421 (TauC3 antibody) in the brains of 9-11 cases with CTE and cases of nondemented aged controls and AD (Braak VI) (n = 6, each). These 4 markers are particularly useful in understanding potential posttraumatic events in CTE because PAD exposure impairs axonal transport (24), oligomers confer toxicity (28, 38–40), pS422 correlates with cognitive decline (15), and D421 truncated tau may be related to cell toxicity (41, 42). All 3 early tau markers (ie, TNT1, TOC1, and pS422) were present in CTE and displayed extensive colocalization in perivascular tau lesions that are considered diagnostic for CTE.",
      "citation": {
        "type": "PubMed",
        "reference": "26671985",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.",
        "volume": "75",
        "pages": "19-34",
        "date": "2016-01-01",
        "first": "Kanaan NM",
        "last": "McKee AC",
        "authors": [
          "Alvarez VE",
          "Cox K",
          "Kanaan NM",
          "McKee AC",
          "Poncil S",
          "Stein TD"
        ]
      },
      "annotations": {
        "Method": {
          "Immunofluorescence": true,
          "ELISA": true,
          "Immunohistochemistry": true
        },
        "Tau_Antibody": {
          "TN1": true,
          "Anti-pS422": true,
          "TauC3": true,
          "TOC1": true
        },
        "MeSHDisease": {
          "Chronic Traumatic Encephalopathy": true
        }
      },
      "source": 604,
      "target": 910,
      "key": "c95470205ba510a37b07761ac7893acbdf795d61b3c2b37726454799db992b5acb7650be99f5e6c9a14afb07dbbcffd39fcfd3ca9400b18e090010c723a2b661"
    },
    {
      "line": 241,
      "relation": "positiveCorrelation",
      "evidence": "We performed immunohistochemistry and immunofluorescence on fixed brain sections and biochemical analysis of fresh brain extracts to characterize the presence of PAD-exposed tau (TNT1 antibody), tau oligomers (TOC1 antibody), tau phosphorylated at S422 (pS422 antibody), and tau truncated at D421 (TauC3 antibody) in the brains of 9-11 cases with CTE and cases of nondemented aged controls and AD (Braak VI) (n = 6, each). These 4 markers are particularly useful in understanding potential posttraumatic events in CTE because PAD exposure impairs axonal transport (24), oligomers confer toxicity (28, 38–40), pS422 correlates with cognitive decline (15), and D421 truncated tau may be related to cell toxicity (41, 42). All 3 early tau markers (ie, TNT1, TOC1, and pS422) were present in CTE and displayed extensive colocalization in perivascular tau lesions that are considered diagnostic for CTE.",
      "citation": {
        "type": "PubMed",
        "reference": "26671985",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.",
        "volume": "75",
        "pages": "19-34",
        "date": "2016-01-01",
        "first": "Kanaan NM",
        "last": "McKee AC",
        "authors": [
          "Alvarez VE",
          "Cox K",
          "Kanaan NM",
          "McKee AC",
          "Poncil S",
          "Stein TD"
        ]
      },
      "annotations": {
        "Method": {
          "Immunofluorescence": true,
          "ELISA": true,
          "Immunohistochemistry": true
        },
        "Tau_Antibody": {
          "TN1": true,
          "Anti-pS422": true,
          "TauC3": true,
          "TOC1": true
        },
        "MeSHDisease": {
          "Chronic Traumatic Encephalopathy": true
        }
      },
      "source": 604,
      "target": 368,
      "key": "b21fe7fa6f6be8ed9376f1ab862833dd7d6e3dae2d782a18c230401ef2c0ed75c6cb22049a497beaa601b3208c4b919268f3431028cc7c5e2d8ccd9eea768954"
    },
    {
      "line": 122,
      "relation": "positiveCorrelation",
      "evidence": "While several N and C-terminally truncated Tau species are observed in AD brains, only a limited number of specific Tau cleavage sites, after residues Asp13, Asp25, Asn368, Glu391 and Asp421, have been identified so far in situ. The species generated by these cleavages are found in neurofibrillary tangles, and their occurrence is correlated with the severity of the disease.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 908,
      "target": 601,
      "key": "2c9d372a6fa17347d826895992c322f7a6f1084209a3791dce11df46fef4b65b6c2d0b1d2eacad5fa2144605369de16cad1edf3483fb3e4c9271d853e89ae2ca"
    },
    {
      "line": 123,
      "relation": "positiveCorrelation",
      "evidence": "While several N and C-terminally truncated Tau species are observed in AD brains, only a limited number of specific Tau cleavage sites, after residues Asp13, Asp25, Asn368, Glu391 and Asp421, have been identified so far in situ. The species generated by these cleavages are found in neurofibrillary tangles, and their occurrence is correlated with the severity of the disease.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 908,
      "target": 602,
      "key": "16a2cc5583be6798308c7745bffac7500963bca8fd323bad1b2e7d13baf0b3166a1526c5891dd0b339f9c0a498fdc7f618aea1a72aaca322d21e4646a445d97f"
    },
    {
      "line": 124,
      "relation": "positiveCorrelation",
      "evidence": "While several N and C-terminally truncated Tau species are observed in AD brains, only a limited number of specific Tau cleavage sites, after residues Asp13, Asp25, Asn368, Glu391 and Asp421, have been identified so far in situ. The species generated by these cleavages are found in neurofibrillary tangles, and their occurrence is correlated with the severity of the disease.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 908,
      "target": 603,
      "key": "370a8242545921b8416d35aa35c2541e6d5763598cfcb1e8c3a963d75eaa0a150ca96b307be932d12a0356deec618fb548a1fd13b2656306a4e8b14b74b11885"
    },
    {
      "line": 125,
      "relation": "positiveCorrelation",
      "evidence": "While several N and C-terminally truncated Tau species are observed in AD brains, only a limited number of specific Tau cleavage sites, after residues Asp13, Asp25, Asn368, Glu391 and Asp421, have been identified so far in situ. The species generated by these cleavages are found in neurofibrillary tangles, and their occurrence is correlated with the severity of the disease.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 908,
      "target": 608,
      "key": "5b95292768d50a6abc98f1e6226be49d22b904065e6032d43bc77a2ea8c8d35fd45cda59fe31341aada363d9740da522522541e5d32f61fb1ccafd7faecfef80"
    },
    {
      "line": 126,
      "relation": "positiveCorrelation",
      "evidence": "While several N and C-terminally truncated Tau species are observed in AD brains, only a limited number of specific Tau cleavage sites, after residues Asp13, Asp25, Asn368, Glu391 and Asp421, have been identified so far in situ. The species generated by these cleavages are found in neurofibrillary tangles, and their occurrence is correlated with the severity of the disease.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 908,
      "target": 604,
      "key": "c477f96c01470d97bc91ade47293358a99cabdadfc79a954657a44fda2766acdb603b7f8fc7893dd827c008c3a18faec288db9960a93ada6569141258224538d"
    },
    {
      "line": 447,
      "relation": "positiveCorrelation",
      "evidence": "We were prompted to carry out this study because Acr is mainly localized in the neurons [54], is found in association with NFTs and dystrophic neurites surrounding senile plaques [55], is highly toxic to neurons, is found elevated 2–5 fold in affected regions of AD brain. EC can sequester highly reactive and toxic byproducts of oxidation such as acrolein.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 908,
      "target": 41,
      "key": "0df4bdc2426bda0b3746d0a9150880a2fb9fb7d75ed7e2cfe7898bc6924df4246a4c913ed9a75450190f24dd8e71f84a65e668f52cf6ca1895c7eebfff02de88"
    },
    {
      "line": 611,
      "relation": "negativeCorrelation",
      "evidence": "Triosephosphate isomerase (TPI) is a key enzyme in cell metabolism that controls the glycolytic flow and energy production through the interconversion of dihydroxyacetone phosphate (DHAP) and D-glyceraldehyde 3-phosphate (G3P) (Richard, 1993). Notably, TPI is the only glycolytic enzyme whose functional deficiency is associated to neurodegeneration (Eber et al., 1991; Ovadi et al., 2004). In particular, inefficient glycolysis (Hoyer et al., 1988) and ATP depletion (Keil et al., 2004) are characteristic in Alzheimer’s disease brains.",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        }
      },
      "source": 908,
      "target": 176,
      "key": "0512276a11d765d3c7dc5b7ced43c79746b54af59f8a6be8ad26ca74c05bb5a4f2f1384c9ed37cd350c7a2bdeac12650422e860b9e4a20c821af81c65310b951"
    },
    {
      "line": 622,
      "relation": "positiveCorrelation",
      "evidence": "Ab induced nitro-oxidative stress on human neuroblastoma cells, resulting in nitrotyrosination of TPI. Moreover, higher levels of nitro-TPI were also detected in extracts from hippocampus (Fig. 1F) and frontal cortex (Fig. 1G) obtained from Alzheimer’s disease brains, compared with healthy subjects.",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "frontal cortex": true,
          "hippocampal formation": true
        }
      },
      "source": 908,
      "target": 765,
      "key": "b47b24d4ff2a7574be58e0815dc924e71655e4bbc53d6ef1686cdf8077f63274ecfe48d143ab62a28d0452eb9cf740120c84ebe62dd312bf68356d548d8ae453"
    },
    {
      "line": 623,
      "relation": "positiveCorrelation",
      "evidence": "Ab induced nitro-oxidative stress on human neuroblastoma cells, resulting in nitrotyrosination of TPI. Moreover, higher levels of nitro-TPI were also detected in extracts from hippocampus (Fig. 1F) and frontal cortex (Fig. 1G) obtained from Alzheimer’s disease brains, compared with healthy subjects.",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "frontal cortex": true,
          "hippocampal formation": true
        }
      },
      "source": 908,
      "target": 766,
      "key": "e795c5984f47e771893dd779b32269f4bf056603208ae9616573c87c648e2d7d1a27ca0df97a4018006ce1847b2d9d40bd44aa9aedef20fd691705b7bf3d58e6"
    },
    {
      "line": 753,
      "relation": "positiveCorrelation",
      "evidence": "The number of neurons that are immunoreactive with an antibody directed at the epsilon-(gamma-glutamyl)lysine bond was significantly higher in AD cortex compared with age-matched controls and schizophrenics. PHF tau-directed antibodies AT8, MC-1 and PHF-1 co-localized with epsilon(gamma-glutamyl)lysine immunolabeling in AD NFT. Immunoaffinity purification and immunoblotting experiments demonstrated that PHF tau contains epsilon(gamma-glutamyl)lysine bonds in parietal and frontal cortex in AD. In control cases with NFT present in the entorhinal cortex and hippocampus, indicative of Braak and Braak stage II, epsilon(gamma-glutamyl)lysine bonds were present in PHF tau in parietal and frontal cortex, despite the lack of microscopically detectable NFT or senile plaques in these cortical regions. The presence of PHF tau with epsilon(gamma-glutamyl)lysine bonds in brain regions devoid of NFT in stage II (but regions, which would be expected to contain NFT in stage III) suggests that these bonds occur early in the formation of NFT.",
      "citation": {
        "type": "PubMed",
        "reference": "11738469",
        "name": "Neurochemistry international",
        "title": "Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer's disease.",
        "volume": "40",
        "pages": "17-30",
        "date": "2002-01-01",
        "first": "Singer SM",
        "last": "Muma NA",
        "authors": [
          "Lee JM",
          "Muma NA",
          "Norlund MA",
          "Singer SM",
          "Zainelli GM"
        ]
      },
      "annotations": {
        "Method": {
          "Immunoaffinity purification": true,
          "Immunoblotting": true,
          "Confocal Microscopy": true,
          "Fluorescence Microscopy": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "parietal cortex": true,
          "frontal cortex": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 908,
      "target": 267,
      "key": "873d1526b3e7d90425f9d4e163514a5d3a1c589ac5780e1b48ce19bb80417a80bb52e8ced6a68cb8ed2ad5572592886c3a0c38d40f42215b64a6ec69655cf71c"
    },
    {
      "line": 789,
      "relation": "positiveCorrelation",
      "evidence": "Degenerating neurons from the AD hippocampus, compared to neurons from the normal aged hippocampus, exhibited increased immunoreactivity for TGase and demonstrated co-labeling for PHF1 and anti-TGase. Our results suggest that TGase may be associated with the neurofibrillary degeneration observed in AD, thereby implicating TGase as a potential factor in the pathogenesis of Alzheimer's disease.",
      "citation": {
        "type": "PubMed",
        "reference": "8985134",
        "name": "The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society",
        "title": "Localization of transglutaminase in hippocampal neurons: implications for Alzheimer's disease.",
        "volume": "44",
        "pages": "1421-7",
        "date": "1996-12-01",
        "first": "Appelt DM",
        "last": "Balin BJ",
        "authors": [
          "Appelt DM",
          "Balin BJ",
          "Boyne LJ",
          "Kopen GC"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 908,
      "target": 267,
      "key": "a36efe122629a7f359f605842525d7ab37aebff6f298dad19acfb2eb8950f25baab06f721db72e3af6a159c27ff5442a0d739e4ad14617ac95cf14f5863510cf"
    },
    {
      "line": 776,
      "relation": "increases",
      "evidence": "Total transglutaminase activity was significantly higher in the Alzheimer's disease prefrontal cortex compared to control. In addition the levels of tissue transglutaminase, as determined by quantitative immunoblotting, were elevated approximately 3-fold in Alzheimer's disease prefrontal cortex compared to control. To our knowledge, this is the first demonstration that transglutaminase is increased in Alzheimer's disease brain. There were no significant differences in transglutaminase activity or levels in the cerebellum between control and Alzheimer's disease cases. Because the elevation of transglutaminase in the Alzheimer's disease samples occurred in the prefrontal cortex, where neurofibrillary pathology is usually abundant, and not in the cerebellum, which is usually spared in Alzheimer's disease, it can be suggested that transglutaminase could be a contributing factor in neurofibrillary tangle formation.",
      "citation": {
        "type": "PubMed",
        "reference": "9099822",
        "name": "Brain research",
        "title": "Transglutaminase activity is increased in Alzheimer's disease brain.",
        "volume": "751",
        "pages": "323-9",
        "date": "1997-03-21",
        "first": "Johnson GV",
        "last": "Powers RE",
        "authors": [
          "Cox TM",
          "Johnson GV",
          "Lockhart JP",
          "Miller ML",
          "Powers RE",
          "Zinnerman MD"
        ]
      },
      "annotations": {
        "Method": {
          "Transglutaminase Assay": true,
          "Immunoblotting": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "prefrontal cortex": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 908,
      "target": 730,
      "key": "0fb51b84d3ee8ff6d86af78c948270cf8e721a2de4c296b3c13067de900ec65ca337dc2be887cd38830933f4cb47a2ce914e66b8ac7b6a49fad524c074a655c7"
    },
    {
      "line": 844,
      "relation": "positiveCorrelation",
      "evidence": "Tau-nY29 detects soluble tau and paired helical filament tau from severely affected Alzheimer's brain but fails to recognize tau from normal aged brain. This observation suggests that nitration at Tyr29 is a disease-related event that may alter the intrinsic ability of tau to self-polymerize. In Alzheimer's brain, Tau-nY29 labels the fibrillar triad of tau lesions, including neurofibrillary tangles, neuritic plaques, and, to a lesser extent, neuropil threads. Intriguingly, although Tau-nY29 stains both the neuronal and glial tau pathology of Pick disease, it detects only the neuronal pathology in corticobasal degeneration and progressive supranuclear palsy without labeling the predominant glial pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "17050703",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.",
        "volume": "26",
        "pages": "10636-45",
        "date": "2006-10-18",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Bigio EH",
          "Binder LI",
          "Fu Y",
          "Guillozet-Bongaarts AL",
          "Reyes JF",
          "Reynolds MR"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 908,
      "target": 520,
      "key": "632d9df28c77300b2ed8d438bc53463b63b7ca46f0ed66ea0870a42a6a7824c742dc186fc289dcdeccaa2fde1b7981d6270a9710c93952371ab45a6232e5515f"
    },
    {
      "line": 1324,
      "relation": "association",
      "evidence": "Haplotype analysis of the block formed by rs2651206, rs10807287, and rs7764257 showed that the combination of the three frequent alleles (CTA) was significantly (p = 0.02) overrepresented in the AD group (67%) compared to the control group (63%), and this result was still significant after multiple testing corrections with 10,000 permutations (p = 0.05).",
      "citation": {
        "type": "PubMed",
        "reference": "20096481",
        "name": "Neurobiology of aging",
        "title": "Genetic variations in tau-tubulin kinase-1 are linked to Alzheimer's disease in a Spanish case-control cohort.",
        "volume": "32",
        "pages": "550.e5-9",
        "date": "2011-03-01",
        "first": "Vázquez-Higuera JL",
        "last": "Combarros O",
        "authors": [
          "Berciano J",
          "Bullido MJ",
          "Combarros O",
          "Frank A",
          "Martínez-García A",
          "Mateo I",
          "Pozueta A",
          "Rodríguez-Rodríguez E",
          "Sánchez-Juan P",
          "Valdivieso F",
          "Vázquez-Higuera JL"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Spanish cohort": true
        }
      },
      "source": 908,
      "target": 251,
      "key": "493232eec94fde5a8ec9122c4f533f4a731232d58e6d86269d0d3d664c52108a2b4d8f1ce9e3be16c587aa68456b18eb5fe3cbb4bd7015757d666c6f33a9cdcb"
    },
    {
      "line": 1384,
      "relation": "positiveCorrelation",
      "evidence": "Significant association with a reduced risk of LOAD (odds ratio/OR=0.69). rs2651206 polymorphism was strongly associated with LOAD (OR=0.72) (age, gender, and APOE adjusted). The TG haplotype, deriving from the two minor alleles, decreases risk of LOAD (OR=0.78, P=0.037).",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Han chinese": true
        }
      },
      "source": 908,
      "target": 251,
      "key": "d6af7222d93ce93a9ddc3eda7916c0716d7331731e3c490f4a630fca0dfd93911e9cfed17b2d2f97bf72ec953e04d59983238aac845a94b4a643548bd650ec65"
    },
    {
      "line": 1325,
      "relation": "association",
      "evidence": "Haplotype analysis of the block formed by rs2651206, rs10807287, and rs7764257 showed that the combination of the three frequent alleles (CTA) was significantly (p = 0.02) overrepresented in the AD group (67%) compared to the control group (63%), and this result was still significant after multiple testing corrections with 10,000 permutations (p = 0.05).",
      "citation": {
        "type": "PubMed",
        "reference": "20096481",
        "name": "Neurobiology of aging",
        "title": "Genetic variations in tau-tubulin kinase-1 are linked to Alzheimer's disease in a Spanish case-control cohort.",
        "volume": "32",
        "pages": "550.e5-9",
        "date": "2011-03-01",
        "first": "Vázquez-Higuera JL",
        "last": "Combarros O",
        "authors": [
          "Berciano J",
          "Bullido MJ",
          "Combarros O",
          "Frank A",
          "Martínez-García A",
          "Mateo I",
          "Pozueta A",
          "Rodríguez-Rodríguez E",
          "Sánchez-Juan P",
          "Valdivieso F",
          "Vázquez-Higuera JL"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Spanish cohort": true
        }
      },
      "source": 908,
      "target": 248,
      "key": "ed58ab932f940a8aeced458f7f971f595c825732fd7d1b9ce993eb058eea240b15148de279435a45928aa5ca91add856e71885c83081f4fa6b5307bf7bfe2b27"
    },
    {
      "line": 1326,
      "relation": "association",
      "evidence": "Haplotype analysis of the block formed by rs2651206, rs10807287, and rs7764257 showed that the combination of the three frequent alleles (CTA) was significantly (p = 0.02) overrepresented in the AD group (67%) compared to the control group (63%), and this result was still significant after multiple testing corrections with 10,000 permutations (p = 0.05).",
      "citation": {
        "type": "PubMed",
        "reference": "20096481",
        "name": "Neurobiology of aging",
        "title": "Genetic variations in tau-tubulin kinase-1 are linked to Alzheimer's disease in a Spanish case-control cohort.",
        "volume": "32",
        "pages": "550.e5-9",
        "date": "2011-03-01",
        "first": "Vázquez-Higuera JL",
        "last": "Combarros O",
        "authors": [
          "Berciano J",
          "Bullido MJ",
          "Combarros O",
          "Frank A",
          "Martínez-García A",
          "Mateo I",
          "Pozueta A",
          "Rodríguez-Rodríguez E",
          "Sánchez-Juan P",
          "Valdivieso F",
          "Vázquez-Higuera JL"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Spanish cohort": true
        }
      },
      "source": 908,
      "target": 255,
      "key": "9704b2f2f0a8b5bbc24dc586eea7d199847a307b8a7cab0277dd62c02d5f11b4c1e612dec59c8d6dfffe886d2574160f1d6c081e63ae25fc702ee82f85ea0af0"
    },
    {
      "line": 1579,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 589,
      "key": "a50404f6c10945c684ad89246bbd23f7c908d89a8dacfdbcd9d39e92c2454d3aef457e47a7b242d805b08773d6c3245f1e1925f7a04fd01b3094372409d927cd"
    },
    {
      "line": 1580,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 572,
      "key": "25f03ad4df3d5df40140d373364e7628e1deebbfefce587cccae93135c7cd958349db00434cf27d4a3963c182eaade504873eec8264f3d4efe4f9927f363ae76"
    },
    {
      "line": 1581,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 587,
      "key": "d2ef1876b8ec60271d50d4095e96518746e1773b151d73d48d327fec3821068d951336afb57dcae79b3c9b60ffce58525ffef8cbb0169733da9d5f4c97381bb6"
    },
    {
      "line": 1582,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 588,
      "key": "12e852e38c75c088ce764c8d0c1dd0f50f93cb749b474c3387856e0c47e03fa8c161c0532d9a148987874e6647e7cf660ab49e8e3b862e295b8ea344122f2127"
    },
    {
      "line": 1583,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 539,
      "key": "8ac17b52da876c8a273b50f5c0e15223e8de450d5578ca94440ca3b1dec7b31bb33c339c14035054750e436c90ba5902e48292936fd11f242df3fb8aa4faed63"
    },
    {
      "line": 1584,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 573,
      "key": "323b7e517af09eaaf419c917d0708cf7d02dabb09b5727c435fa0eef385d0c11ba27b9f55f1cf43e5b2e36356903236eafe5a9152195ca035d0418fa521c71a7"
    },
    {
      "line": 1585,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 574,
      "key": "aeb13f61f30f2dc6ef8a7f2a282cf99eb1d08d8674ac9536d00f3576ebd3641fbae7e2d2c65a7d8460f8acf19fe2cd875142be49b6f0fb5f92a2c4a2a6185865"
    },
    {
      "line": 1586,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 576,
      "key": "53c424e67630e0dd1b9139ccf2cff5e88f914bb399337e27da51e1c7d69b6a6aae38558f4a6d1df1fe77a84be9e0b701089e721d5db74c8434a643da912c7d3b"
    },
    {
      "line": 1587,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 578,
      "key": "561eda4a4094398d7c3660f8babad743ffafbfe96bde6befa38455a9d7220cbbcdd55b371490af1da247dbfa5d2bd6be685b3432b995b107ff3736332f4c3c3a"
    },
    {
      "line": 1588,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 540,
      "key": "552a8d18dce3b24a0c8d51db2b6e355947bd79ae42ecd12c063a7c47d84b567dda868332358c58a97232be2e22a3081eefd30c98daca221c33a17391b4acf5d7"
    },
    {
      "line": 1589,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 541,
      "key": "f2686388401733ab4b1692d0cd50ffe90c9181290c264c1d815c6d4e11d8b865c89b46332e18d3d39213b674074c8eac6d5334a33a7e47cb8428e7f204526a80"
    },
    {
      "line": 1590,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 590,
      "key": "cf935a2126a717946e7a17c598c6fc5ec776dd25ff8f672c6efb29cc046ddcfb1f7022b9c7e44459ff149b3d28d60e071926c2c26277267edb3be1d0753083ee"
    },
    {
      "line": 1591,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 548,
      "key": "40592d0a51c7bf1474f56d1a95f6bb976320ae1c76b05f6e6323245e05fc9bf6345911661a3f245cad67dba80513060b600b08f515a3d6e88dba77c80ad1bf34"
    },
    {
      "line": 1592,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 549,
      "key": "31acfc29a0216786eba05b308489cb34627fb4645c7f0d3df4fec9483791f759eb0ffb6cdcceff69012b069038e9bb46209347bb770f4116b1a75c773c178d92"
    },
    {
      "line": 1593,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 551,
      "key": "bdd528b74a6ebb74956992611bff5fe2adc9370ac8f14724b28a3b9e0e1420eb40b5a573bf17521e6dce8c0c3c8b6e3c129c7f4ed7d6c1d0b30678b3e378139d"
    },
    {
      "line": 1594,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 553,
      "key": "261645c461f55f282ef2300b8ceae1c8b2e5e5e55bf9dfe82404e550dfe51d7e93d66129dfdb3476a823dcec8c74f94eea66ab0438815f516d6b7235f45f808b"
    },
    {
      "line": 1595,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 554,
      "key": "05ff4805647cfa70702de12d0273231fbcf71d2a9af9fae60e37d526d113f63c2d7f5b9b176228539868e9cbff708dc963d1fb63d722dd5a7bc8fcb13f777c48"
    },
    {
      "line": 1596,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 555,
      "key": "a2359b2c2a37d75d734be1cc29222e9c5bfd9bcedc9014397c495d1bff428c6d8d292899b1802a770be823e32d34f885cea3c0e46be82ee60dbe78d7b4324cd6"
    },
    {
      "line": 1597,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 557,
      "key": "2bc025cd611293f61150b94fbf714e4dad4775f1e79ce20dcf6e207dea1d58c38ffd771a817669f8b8d9caea9bb8b7b0ea359edaa86c0ef622921c18e060fb34"
    },
    {
      "line": 1598,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 558,
      "key": "5f00d985c797a3793f168d7883ece7fe8e63a5c90666dfa76eae401bca37f81bfdb5bd4b66196d71eab7cbe5241a98f07bccc1a0731737e649326730ee4a598f"
    },
    {
      "line": 1599,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 563,
      "key": "4dd385942760f56086711686a72562a264f427bb36201dc8961a5af008a6f2ca371f6f29a8aa5a4c07298c22ef9623beb2b305bd44db5f2d378c57f0140fdb4c"
    },
    {
      "line": 1600,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 592,
      "key": "f6ab58c20358f8f61a306f217b95394d9910ab052e676fc36731e20ed1a8d1f05fcfc2f577614f920a3dc8136af1d559ff1161b4c779bf86adbfe94e90a04da8"
    },
    {
      "line": 1601,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 585,
      "key": "203b267b5220475eb68fb2d9c20b7537e07dc7e051ec69d4d2bb2d87846fc0e178102f1e66d53dda1f69f142dad6a37958f3e406e78d0f16ca61e0f5c8d009ee"
    },
    {
      "line": 1602,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 566,
      "key": "1600b564192ad8dc18b9208ece455f36bab552f80d95617ae6da6a991f47a8fde7e7ed118df1a8e081a181aea7fbeabfe8f76fd2a7d2278c2ad9e348fedea4c6"
    },
    {
      "line": 1603,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 571,
      "key": "0c2ea3824d5f175deacc97652d5be58cd323d6327d15a4bf61c7a12a5c4126cc2ff9279110053a93d23e8904af2b1cf6186c5b7a2a85d29e53f9fd88c7683e61"
    },
    {
      "line": 1604,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 586,
      "key": "2f628ea2e48754cd7734ea930d66d98c71909d00adc0f2c433ab7d3402ec483dbee4b263f59ecc38386ce8a049c63ed1f4d9826571a805b871435e580a1336cb"
    },
    {
      "line": 1605,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 570,
      "key": "66e8b21d031a65dd9472856a06be818451454502815bb2cedde0d7f32d2af3ab55c00ee3aae33eb001795bc80505331d9ed7414a2ee2a8c8dc8d20d2dc566421"
    },
    {
      "line": 1606,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 569,
      "key": "9925ef0a7b74f27240339dc89a30fcb37dc698a2a5fdc40b840184e6a77f8c7fe362683ce33cfeb89901ea83a6f5ef0f1d2f91b238a1009eb438e6c117bd5824"
    },
    {
      "line": 1854,
      "relation": "positiveCorrelation",
      "evidence": "In cells, a CagA peptide inhibited tau phosphorylation at Ser²6² mediated by MARK4 but not other MARK isoforms. A strong and significant elevation of MARK4 expression and MARK4-tau interactions in AD brains correlated with the Braak stages of the disease.",
      "citation": {
        "type": "PubMed",
        "reference": "23666762",
        "name": "Neuromolecular medicine",
        "title": "Role of individual MARK isoforms in phosphorylation of tau at Ser²⁶² in Alzheimer's disease.",
        "volume": "15",
        "pages": "458-69",
        "date": "2013-09-01",
        "first": "Gu GJ",
        "last": "Kamali-Moghaddam M",
        "authors": [
          "Blokzijl A",
          "Classon C",
          "Gu GJ",
          "Kamali-Moghaddam M",
          "Landegren U",
          "Lund H",
          "Sunnemark D",
          "Wu D",
          "von Euler G"
        ]
      },
      "source": 908,
      "target": 635,
      "key": "ea625f646f4e3ac3d84037067bab260ccda4063920340e3e5777cd75d67c6ce965e5a8db4c113d456eb7504ee3b4477e3dc346cf3ac76a51cdd56e7e1bcbe796"
    },
    {
      "line": 2311,
      "relation": "positiveCorrelation",
      "evidence": "To perform its function, Cdk5 must bind to the neuron-specific regulatory subunit protein p35, which is beneficial for neuronal development (Tsai et al. 1994; Chae et al. 1997). However, truncation of p35 and conversion to p25 (Patrick et al. 1999) is found in the forebrain of rats after focal cerebral ischemia and in AD patients, and these alterations are deleterious to the brain",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "source": 908,
      "target": 311,
      "key": "64bc2e6cab2cf48144b64e0a2e05228a4bb3a502b897d167a8f4e71a50fdadf622a4b414744f56349cd22fe510f433a6f62bbadd4d392c4d81e2710bccf3de5d"
    },
    {
      "line": 2615,
      "relation": "positiveCorrelation",
      "evidence": "This sequence (Fig. 3G–N) is supported by Western blot analysis, phosphorylated Thr231 in three AD cases and their age-matched controls, suggesting that tau phosphorylation at Thr231 occurs before the formation of oligomers (Fig. 3O).",
      "citation": {
        "type": "PubMed",
        "reference": "22253473",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.",
        "volume": "26",
        "pages": "1946-59",
        "date": "2012-05-01",
        "first": "Lasagna-Reeves CA",
        "last": "Kayed R",
        "authors": [
          "Castillo-Carranza DL",
          "Jackson GR",
          "Kayed R",
          "Lasagna-Reeves CA",
          "Sarmiento J",
          "Sengupta U",
          "Troncoso J"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Disease_Progression": {
          "Early Stage": true
        }
      },
      "source": 908,
      "target": 583,
      "key": "2647cdb4a17ca840e3cb385ae9d6e7d29da3f3027833221ad43a3536f60fb907b3373478a812f48375785d6e2d2b9ef5e4d71ea7beb8c3a88f95a07725b1cf34"
    },
    {
      "line": 2832,
      "relation": "increases",
      "evidence": "The highly vulnerable CA1 pyramidal neurons were characterized by age- and disease-unrelated increases in PRCKB levels and by age- and disease-related increases in MAPK1 levels. In contrast, low PRKCB levels were found in CA2 pyramidal neurons, and MAPK1 levels were elevated in controls and intermediate AD stages. Both PRKCB and MAPK1 were increased in the late AD stages. MAPK1 and PRKCB levels were low in the brainstem and cerebellum.",
      "citation": {
        "type": "PubMed",
        "reference": "21910444",
        "name": "Journal of the American Chemical Society",
        "title": "Structural impact of proline-directed pseudophosphorylation at AT8, AT100, and PHF1 epitopes on 441-residue tau.",
        "volume": "133",
        "pages": "15842-5",
        "date": "2011-10-12",
        "first": "Bibow S",
        "last": "Zweckstetter M",
        "authors": [
          "Bibow S",
          "Biernat J",
          "Blackledge M",
          "Mandelkow E",
          "Ozenne V",
          "Zweckstetter M"
        ]
      },
      "annotations": {
        "Anatomy": {
          "pyramidal layer of CA1": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Braak_Stage": {
          "Stage I": true,
          "Stage II": true
        }
      },
      "source": 908,
      "target": 477,
      "key": "9a8c7d1eb6f920f98e6b5ac4fe6f2bd00ae2155473ab83514cc3de2a86e3f5ba3914b32db23a5d7fa354cdcaa7fbcead89588ad0894b6b467bd65d5c2c7878e2"
    },
    {
      "line": 2834,
      "relation": "increases",
      "evidence": "The highly vulnerable CA1 pyramidal neurons were characterized by age- and disease-unrelated increases in PRCKB levels and by age- and disease-related increases in MAPK1 levels. In contrast, low PRKCB levels were found in CA2 pyramidal neurons, and MAPK1 levels were elevated in controls and intermediate AD stages. Both PRKCB and MAPK1 were increased in the late AD stages. MAPK1 and PRKCB levels were low in the brainstem and cerebellum.",
      "citation": {
        "type": "PubMed",
        "reference": "21910444",
        "name": "Journal of the American Chemical Society",
        "title": "Structural impact of proline-directed pseudophosphorylation at AT8, AT100, and PHF1 epitopes on 441-residue tau.",
        "volume": "133",
        "pages": "15842-5",
        "date": "2011-10-12",
        "first": "Bibow S",
        "last": "Zweckstetter M",
        "authors": [
          "Bibow S",
          "Biernat J",
          "Blackledge M",
          "Mandelkow E",
          "Ozenne V",
          "Zweckstetter M"
        ]
      },
      "annotations": {
        "Anatomy": {
          "pyramidal layer of CA1": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 908,
      "target": 661,
      "key": "161a6332dde3705cbdf7934bd1f37c8993aafe3c47e5d7fde3843cb966154863fc819b294df84e42f0aae0274fad6bd89e81859c157ea912a54b9f18fa184f9e"
    },
    {
      "line": 2856,
      "relation": "increases",
      "evidence": "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24401760",
        "name": "Brain : a journal of neurology",
        "title": "Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.",
        "volume": "137",
        "pages": "537-52",
        "date": "2014-02-01",
        "first": "Stygelbout V",
        "last": "Brion JP",
        "authors": [
          "Ando K",
          "Brion JP",
          "D'Amico E",
          "Duyckaerts C",
          "Erneux C",
          "Jia Y",
          "Leroy K",
          "Luo HR",
          "Pouillon V",
          "Schurmans S",
          "Stygelbout V"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 908,
      "target": 460,
      "key": "4f2e94cd2d11f59e73924ed05f76619302e3c021d9eda9264c964af7757d61cfcf6680a7612f25095661c333cc403fede248a7f2cca0c659bc47380666c1ce58"
    },
    {
      "line": 3044,
      "relation": "negativeCorrelation",
      "evidence": "Here we show that the protein deacetylase SIRT1 reduces tau acetylation in a mouse model of neurodegeneration. SIRT1 deficiency in the brain aggravates synapse loss and behavioral disinhibition, and SIRT1 overexpression ameliorates propagation of tau pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "P301S mice": true
        }
      },
      "source": 908,
      "target": 847,
      "key": "d901aca3ddfbabeec2989593dff3ec51f2b47394a214f3d5ed70150b87b5f8915679079a02967131cd55f1470b13b9a66965c7028f5270451d31b548d5348bb3"
    },
    {
      "line": 3061,
      "relation": "negativeCorrelation",
      "evidence": "Sirt3 levels were reduced in the entorhinal cortex, the middle temporal gyrus, and the superior frontal gyrus of AD subjects compared to those of CN and was associated with poorer test scores of neuropsychological evaluation and the severity of tau pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "annotations": {
        "Anatomy": {
          "entorhinal cortex": true,
          "middle temporal gyrus": true,
          "superior frontal gyrus": true
        }
      },
      "source": 908,
      "target": 849,
      "key": "caf018b5c469092327716d6f0707d4407eb8704ee7bff695d93959dd3c24d5cde3b20d70527924bd8ec1a7c33091f860643ffb2abd90f311cc3ca05bafa12cad"
    },
    {
      "line": 3072,
      "relation": "positiveCorrelation",
      "evidence": "We also tested for ac-tau 280 in early stage Alzheimer's disease (Braak stage 1). Histopathological examination using the ac tau 280 antibody was performed in three Alzheimer's cases and three CTE patients. Presence of ac-tau 280 was confirmed in all cases at early sites of disease manifestation. These findings suggest that tau acetylation may precede tau phosphorylation and could be the first ",
      "citation": {
        "type": "PubMed",
        "reference": "29276758",
        "name": "Journal of neurology and neurosurgery",
        "title": "Role of Tau Acetylation in Alzheimer's Disease and Chronic Traumatic Encephalopathy: The Way Forward for Successful Treatment.",
        "volume": "4",
        "date": "2017-01-01",
        "first": "Lucke-Wold B",
        "last": "Ross J",
        "authors": [
          "Lucke-Wold B",
          "Nolan R",
          "Omalu B",
          "Ornstein M",
          "Rosen C",
          "Ross J",
          "Seidel K",
          "Udo R"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Braak_Stage": {
          "Stage I": true
        }
      },
      "source": 908,
      "target": 498,
      "key": "12d449a1ffb7620845498c1e6b5928cdb054e54ae295d1af953188e446d25866245726f01ddddc26436a82f8314ecd3d0de76d85b173a4861e69ecb9d8961440"
    },
    {
      "line": 3278,
      "relation": "positiveCorrelation",
      "evidence": "Thus, K280 acetylation is a feature found in a variety of human 4R or 3R/4R tauopathies including AD, but not 3R-tauopathies such as PiD.",
      "citation": {
        "type": "PubMed",
        "reference": "21427723",
        "name": "Nature communications",
        "title": "The acetylation of tau inhibits its function and promotes pathological tau aggregation.",
        "volume": "2",
        "pages": "252",
        "date": "2011-01-01",
        "first": "Cohen TJ",
        "last": "Lee VM",
        "authors": [
          "Cohen TJ",
          "Guo JL",
          "Hurtado DE",
          "Kwong LK",
          "Lee VM",
          "Mills IP",
          "Trojanowski JQ"
        ]
      },
      "source": 908,
      "target": 498,
      "key": "d729fc3abb3248782db8e0317e68b7000f12fd392804226daaf9eab49128aba2364d4b15275c8cae2222a71512e601fa768365a5192f96ee5fdf0a966c06cbc8"
    },
    {
      "line": 3280,
      "relation": "isA",
      "evidence": "Thus, K280 acetylation is a feature found in a variety of human 4R or 3R/4R tauopathies including AD, but not 3R-tauopathies such as PiD.",
      "citation": {
        "type": "PubMed",
        "reference": "21427723",
        "name": "Nature communications",
        "title": "The acetylation of tau inhibits its function and promotes pathological tau aggregation.",
        "volume": "2",
        "pages": "252",
        "date": "2011-01-01",
        "first": "Cohen TJ",
        "last": "Lee VM",
        "authors": [
          "Cohen TJ",
          "Guo JL",
          "Hurtado DE",
          "Kwong LK",
          "Lee VM",
          "Mills IP",
          "Trojanowski JQ"
        ]
      },
      "source": 908,
      "target": 903,
      "key": "1ab3acad4fca5f9112dcf459ec9e907049bae23c55e971a49735aee4ff40cf96440f1b724c5570c27c8f7be868ac5042ccac724494fd3a9bd423f0944131c296"
    },
    {
      "line": 3340,
      "relation": "negativeCorrelation",
      "evidence": "SIRT1 activation or elevation ameliorates pathology and neurodegeneration in AD (Qin et al., 2006; Kim et al., 2007). Loss of SIRT1 induces impairment of learning and memory (Gao et al., 2010; Michán et al., 2010).",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 908,
      "target": 677,
      "key": "b1ac9987550af5d8d78ddf464f0fb292a353f4258f216cb7d9759765b0ded233e4a42f80afd529df32d37af743b138620d597a0740e941120dcfaf7561f7e6f7"
    },
    {
      "line": 3416,
      "relation": "negativeCorrelation",
      "evidence": " This post-translational modification is likely an indicator of good health since its intracellular level correlates with the availability of extracellular glucose. From a more practical point of view, it has been shown that O-GlcNAcylation impairments contribute to the etiology of cardiovascular diseases, type-2 diabetes and Alzheimer's disease (AD), three illnesses common in occidental societies.",
      "citation": {
        "type": "PubMed",
        "reference": "19732809",
        "name": "Biochimica et biophysica acta",
        "title": "Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease.",
        "volume": "1800",
        "pages": "67-79",
        "date": "2010-02-01",
        "first": "Lefebvre T",
        "last": "Michalski JC",
        "authors": [
          "Dehennaut V",
          "Drougat L",
          "Guinez C",
          "Lefebvre T",
          "Michalski JC",
          "Mir AM",
          "Mortuaire M",
          "Olivier S",
          "Vercoutter-Edouart AS"
        ]
      },
      "source": 908,
      "target": 107,
      "key": "a508a0d7adeb8a26496d805bd2337b7a76ad727883fe26ba2a9c8e3ce65798848526d9d17244a0acf74a33ddda7ba58aea0e88c764574a2ffc67f041e81e2493"
    },
    {
      "line": 3621,
      "relation": "positiveCorrelation",
      "evidence": "The plasma level of SUMO1 was significantly increased in dementia patients, as compared to control groups. The levels of SUMO1 correlated to decreased Mini-Mental State Examination (r =-0.123, p = 0.029). These results suggest that elevated plasma SUMO1 levels may be associated with AD.",
      "citation": {
        "type": "PubMed",
        "reference": "27716675",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases.",
        "volume": "55",
        "pages": "1083-1099",
        "date": "2017-01-01",
        "first": "Nilson AN",
        "last": "Kayed R",
        "authors": [
          "Barton Whittle T",
          "Castillo-Carranza DL",
          "English KC",
          "Gerson JE",
          "Gupta P",
          "Kayed R",
          "Nicolas Crain C",
          "Nilson AN",
          "Sengupta U",
          "Xue J",
          "Zhang W"
        ]
      },
      "source": 908,
      "target": 692,
      "key": "8a1a5012496e665b797068000473d86cae81076dbc739569702446e210dfb79d4b24522d83735a10bc7eba6082eb44eaff440545fd2b86be70a108984aa8e8d0"
    },
    {
      "line": 3630,
      "relation": "positiveCorrelation",
      "evidence": "The genotype distribution of a polymorphism in intron 7 (rs761059) differed between AD cases and controls, with an adjusted odds ratio (OR) of 1.45 (p=0.046, 95% CI: 1.01-2.08). One haplotype (ht2 CAGAG) was found in 14.0% of the AD patients and in 11.1% of the controls (p=0.04, OR=1.43. 95% CI; 1.01-2.01). Stratification by the ApoE gave no significant difference between the groups but when stratified by gender, two SNPs (rs8052688, rs8063) were significantly associated with the risk of MCI among women.",
      "citation": {
        "type": "PubMed",
        "reference": "19765634",
        "name": "Neuroscience letters",
        "title": "Ubc9 gene polymorphisms and late-onset Alzheimer's disease in the Korean population: a genetic association study.",
        "volume": "465",
        "pages": "272-5",
        "date": "2009-11-20",
        "first": "Ahn K",
        "last": "Koh YH",
        "authors": [
          "Ahn K",
          "Jo SA",
          "Kim DK",
          "Koh YH",
          "Park MH",
          "Song JH"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Korean population": true
        }
      },
      "source": 908,
      "target": 254,
      "key": "884afa56903cdb4e820da5190583b398db2309ab76ef7195fcdde9da4a43ef755c351b19624e96e9fd9a6e13f4dcfae2f158875f376831239e7840be4b079ff8"
    },
    {
      "line": 3921,
      "relation": "decreases",
      "evidence": "Western blot analyses showed a decrease of methyl-PP2A and an increase of demethyl-PP2A with a concomitant reduction in the methyl/demethyl PP2A ratio in both PSP (74%) and AD (76%) brains, associated with an LCMT-1 decrease and a demethylating enzyme increase, protein phosphatase methylesterase (PME-1), in both diseases.",
      "citation": {
        "type": "PubMed",
        "reference": "29281045",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.",
        "volume": "77",
        "pages": "139-148",
        "date": "2018-02-01",
        "first": "Park HJ",
        "last": "Mouradian MM",
        "authors": [
          "Adler CH",
          "Beach TG",
          "Braithwaite SP",
          "Lee KW",
          "Mouradian MM",
          "Oh S",
          "Park HJ",
          "Stock JB",
          "Voronkov M",
          "Yan R",
          "Zhang J"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true
        }
      },
      "source": 908,
      "target": 468,
      "key": "8b9f5668aedda52da704420f97221f8d32b6bdb709a76d1dc145f4b6adc1d18cbffd7740a15320bbe72f74498dd934eb64e25e8c26d7739740fc75960eca5a93"
    },
    {
      "line": 3923,
      "relation": "increases",
      "evidence": "Western blot analyses showed a decrease of methyl-PP2A and an increase of demethyl-PP2A with a concomitant reduction in the methyl/demethyl PP2A ratio in both PSP (74%) and AD (76%) brains, associated with an LCMT-1 decrease and a demethylating enzyme increase, protein phosphatase methylesterase (PME-1), in both diseases.",
      "citation": {
        "type": "PubMed",
        "reference": "29281045",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.",
        "volume": "77",
        "pages": "139-148",
        "date": "2018-02-01",
        "first": "Park HJ",
        "last": "Mouradian MM",
        "authors": [
          "Adler CH",
          "Beach TG",
          "Braithwaite SP",
          "Lee KW",
          "Mouradian MM",
          "Oh S",
          "Park HJ",
          "Stock JB",
          "Voronkov M",
          "Yan R",
          "Zhang J"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true
        }
      },
      "source": 908,
      "target": 271,
      "key": "e503af7c9ebf12dad3a20f9cc05592fe20a5c11b499eccf4b17859da5f50b579a6df11b11778bb35e062f2dae9dcff867b178ac28228c219ae45debe7b55db7a"
    },
    {
      "line": 3955,
      "relation": "negativeCorrelation",
      "evidence": "Pin1 accelerates cis to trans conversion to prevent accumulation of pathogenic cis p-tau conformation in AD, providing the first structural evidence for how Pin1 protects against AD.",
      "citation": {
        "type": "PubMed",
        "reference": "23157676",
        "name": "Current molecular medicine",
        "title": "Distinct functions of cis and trans phosphorylated tau in Alzheimer's disease and their therapeutic implications.",
        "volume": "13",
        "pages": "1098-109",
        "date": "2013-08-01",
        "first": "Nakamura K",
        "last": "Lu KP",
        "authors": [
          "Lu KP",
          "Nakamura K",
          "Zhou XZ"
        ]
      },
      "source": 908,
      "target": 357,
      "key": "812156d21b2a82fbabc4f5eaa5cd6ddf9a2c0e67bc7b144e0aa185d6e3d3efdadb4f8f64743991992919c29156c9c0f691137c6794d1e8de0a960c76eb8cf44d"
    },
    {
      "line": 137,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Antibody": {
          "Tau-5": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 599,
      "target": 486,
      "key": "4a91f32aa27ee4af64592295a810fe9cc4f251907f61e35c7d93f77b6f4de76e0421cdce245759f4522a46ce669fe860225dc9f2fd2c86a2d7b00190e6bc1d60"
    },
    {
      "line": 139,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 522,
      "target": 486,
      "key": "3ffdecd6651f4fac6030349e98edfdda8c974fdc330dfc1c91ff3bb17578f02e11e643ff989c4674fdadb96845b67cc779f8931fe19bbed94c19dc9d20d20bf1"
    },
    {
      "line": 141,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 598,
      "target": 486,
      "key": "8a6854456e479d825fb8f4fc90dde8fb92b4b1fe4a40318b38c4911a6250d1d6747f446c787fd33a63e7ff3ff6f05d095d08f900d2609f1085cd3cac054f46d6"
    },
    {
      "line": 142,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 606,
      "target": 486,
      "key": "0c7dc27a6bb57018cfa4f7eba47ade1c4c107c382df2b2ab59bdbef9915c1763a3fe34ff17d58fc16250f2afbd511154e600efa6997def72a62f71936c01b675"
    },
    {
      "line": 171,
      "relation": "increases",
      "evidence": "Regarding the effect of N-terminally truncated Tau, the Met11-Tau fragment showed the same properties as FL-Tau while Gln124-Tau was associated with a markedly increased level of acetylated tubulin compared to FL-Tau.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 606,
      "target": 303,
      "key": "7d4cfbe2b86f6450c52e023d14e723ffaf1d4d25edb9dd64ce3202a262e4a063c3f1f4e7440603ae95b1bc070779203a11c647aca7d6ee8c5601857f036694b5"
    },
    {
      "line": 176,
      "relation": "increases",
      "evidence": "In agreement with this possibility, the investigation of another posttranslational modification of tubulin, detyrosination, which is also representative of a stable population of microtubules, revealed that it was significantly increased with Gln124-Tau when compared to FL-Tau",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 606,
      "target": 755,
      "key": "daa6521c5a3cc8ac4323b7f81dd07bea08b1d1420a151c318e74b92ed087840f81f393b8ab95421e2854d871c4cd89aaf935f989700575cc4903ae3296a5768a"
    },
    {
      "line": 178,
      "relation": "positiveCorrelation",
      "evidence": "In agreement with this possibility, the investigation of another posttranslational modification of tubulin, detyrosination, which is also representative of a stable population of microtubules, revealed that it was significantly increased with Gln124-Tau when compared to FL-Tau",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 606,
      "target": 746,
      "key": "c044debc16aa34bbac03e967ef9780d84c447bed292f1fa66216f1b40c81d8361d4131219c66f68f4d0bf176b131584b5708a33362869277e2266cb6ff41c489"
    },
    {
      "line": 179,
      "relation": "positiveCorrelation",
      "evidence": "In agreement with this possibility, the investigation of another posttranslational modification of tubulin, detyrosination, which is also representative of a stable population of microtubules, revealed that it was significantly increased with Gln124-Tau when compared to FL-Tau",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 606,
      "target": 747,
      "key": "560505d5f54ced0da36ab01e89d13807120fa454b8071353dd33b49f46e70ca7e23ada30d6acbba5c7aa36cfbf166938af7a5d4c7b241f64ded14152bf0e03ef"
    },
    {
      "line": 143,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 623,
      "target": 486,
      "key": "fb1b3d36043d273e5dcbf1d1dee0bd3de6ab3c305b636156154472d7f75af66b451d5afdde1d83b26fa0bef08fb92aa63ed329715ef27ffee5f95bb2fb6decd7"
    },
    {
      "line": 144,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 624,
      "target": 486,
      "key": "d8515584019d943649808fd5a83813dd2f5d0b313f31501e117a9069311c5e01794dde63a5674f58f5901976fde0b069fc771882ebf04cadca93976c7b80f464"
    },
    {
      "line": 145,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 613,
      "target": 486,
      "key": "92aa9c7c7a2b9bc3b1e68e2b22cc296239efb70c96318361bee2ef91d804e8d97b232d6b4b6ea5692f33b48605549453852e418e7e5b9560fc88fdf21363577f"
    },
    {
      "line": 148,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Domain": {
          "proline-rich domain": true
        }
      },
      "source": 614,
      "target": 486,
      "key": "d3d8bdb4c51872bb0bd7d28b698e33718b01b580637c4868e880dd7a3bbf0e4e9dd8cd36c43300192c58f359f2b6acdde6ca21e05b114b8d692f0077ebd7cd4b"
    },
    {
      "line": 149,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Domain": {
          "proline-rich domain": true
        }
      },
      "source": 627,
      "target": 486,
      "key": "bdc07001813e44fac808603eea8cd27154501d68d2c77781014fd41ed5431eb30bd546d1395837931a98028ca942c9b72b633a66863123c36caf5e0e4cccd4cd"
    },
    {
      "line": 152,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        }
      },
      "source": 615,
      "target": 486,
      "key": "87216750ef0653eaca371a956cc8efef9d5ea5fddf0cd9c170d1c7545206461d8202d0f673166705107738b19e8e38b6dd9b991a29fd6a9f78e6216ca0abd9ce"
    },
    {
      "line": 153,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        }
      },
      "source": 616,
      "target": 486,
      "key": "50ca55f34b3da9a0c6f8fd694cf3a5d35fbf96dfc5d18074d1e076cf1b5a43a0427ffac332b482b9ab6620c4f6f592cc653558c5dfc1c6b82b5faf5a4c231fee"
    },
    {
      "line": 154,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        }
      },
      "source": 610,
      "target": 486,
      "key": "2aa4fb09d36aaac4e3e04aeabbe1b99f4c9202fc4c5dc09bdf37fc5f0815ed60f8aa6fe513d17556b84b2991f9e3225885557e63d06db9b26dec5d8386006f96"
    },
    {
      "line": 155,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        }
      },
      "source": 628,
      "target": 486,
      "key": "ed13ab091fcaf0ec97247c6d74e83dea2a81958ece3b8b4a4e6fcb968079fe1a8eb5b9770e3f060fd3c3563c5c0a408e161ee17774c3cf9aefd182d840888562"
    },
    {
      "line": 156,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        }
      },
      "source": 612,
      "target": 486,
      "key": "8bed7abda4807cae10098403bd7d2ea00cad65688406aaa5c24bbf73fb1eb05e1ba6ecc55b050f9107d804ad19196ab4288d8f85eaf66b60a07f7ef38077f706"
    },
    {
      "line": 157,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        }
      },
      "source": 629,
      "target": 486,
      "key": "e73d4a5929d9131ec80182b31c04cc728b781d38567dc62baf67203f28e467e2cc6bb025d0709b8b10f86b1829b11ce3acaee6d3b217ffb7c690e9def201c31f"
    },
    {
      "line": 158,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        }
      },
      "source": 619,
      "target": 486,
      "key": "473314eafbfaf45368f1236fea068f281aeb1933f23603be014c80fd9f0d874c9b21e0e09c4a70a45e502b92b513c6f8eb4e59dfa2efbe169009fe6a57fd157e"
    },
    {
      "line": 159,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        }
      },
      "source": 620,
      "target": 486,
      "key": "7a600dd4ba99a0842e134fb90fa82b42e402b7e5f4b08b146fc011fbcdc50c7cf7a361a878db34239b193aaf3479d1457b376e05f3db050c4c510e835f4bf74b"
    },
    {
      "line": 161,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        }
      },
      "source": 621,
      "target": 486,
      "key": "cad14f741b7ffdaccba27648e5f2586e3b2f006a007529d2f0fdd94b73e844f5390c02940270debb04f9a41ae333c5b4dd24002585727cfaecf96d8df46aaa3e"
    },
    {
      "line": 164,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Antibody": {
          "Tau-12": true,
          "Tau-13": true
        }
      },
      "source": 622,
      "target": 486,
      "key": "665eaa4bc2537fd58931d2878d6ef5e4fc5646f031e1dbb66b87fc94edcdbd137045074d21d6d2aa3c18e195a095251c1fb16339fd253a35713cda3b3285e272"
    },
    {
      "line": 165,
      "relation": "isA",
      "evidence": "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1), Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Tau_Antibody": {
          "Tau-12": true,
          "Tau-13": true
        }
      },
      "source": 607,
      "target": 486,
      "key": "d7a1ebf7e872bb22464f37177ca91abd1d82e15444f9d8ee79ee133e6854a900c2fc4f0b0b931d3adb0f667e8285c7edded8918150af121307cc832caf56f14f"
    },
    {
      "line": 2979,
      "relation": "negativeCorrelation",
      "evidence": "In the present study, we tested the potential of two selective HDAC6 inhibitors, tubastatin A and ACY-1215, to rescue cognitive deficits in a mouse model of AD. We found that both tubastatin A and ACY-1215 alleviated behavioral deficits, altered amyloid-β (Aβ) load, and reduced tau hyperphosphorylation in AD mice without obvious adverse effects. Our data suggested that tubastatin A and ACY-1215 not only promoted tubulin acetylation, but also reduced production and facilitated autophagic clearance of Aβ and hyperphosphorylated tau.",
      "citation": {
        "type": "PubMed",
        "reference": "24844691",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice.",
        "volume": "41",
        "pages": "1193-205",
        "date": "2014-01-01",
        "first": "Zhang L",
        "last": "Qin C",
        "authors": [
          "Huang L",
          "Liu C",
          "Qin C",
          "Sheng SL",
          "Sui XL",
          "Tao JJ",
          "Wu J",
          "Xu YF",
          "Yao ZG",
          "Zhang L",
          "Zhu H"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 303,
      "target": 459,
      "key": "296a0ec9ff636b321449ae03feba9dc14a2024c5d9a1c8b6231011e7976c8ec3024c0e4d518d908e783ab905e2a0a9552d51db9bb464c29a00d36607cea724d2"
    },
    {
      "relation": "hasVariant",
      "source": 302,
      "target": 303,
      "key": "f7587bd6ec9fab4771e0f1f4f430135744afa45b49e56dd5befeb316e047f889341b9fed54ce459e7770e7a72d49a3e07e36b8b113696c750a086e1cdc9b4bca"
    },
    {
      "relation": "hasVariant",
      "source": 754,
      "target": 755,
      "key": "ee8036efe3ae7a38372d57e42547820df8f758d68df110b28c0eadc0ad7c4098fe9bf4c7ae4f33d895665e0a4eb00a9b62e94507933a3d8a8b437290960692bc"
    },
    {
      "line": 178,
      "relation": "positiveCorrelation",
      "evidence": "In agreement with this possibility, the investigation of another posttranslational modification of tubulin, detyrosination, which is also representative of a stable population of microtubules, revealed that it was significantly increased with Gln124-Tau when compared to FL-Tau",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 746,
      "target": 606,
      "key": "091a398bb396e9315e9dc1b1845a1f56f39ec51d1a8d9aa2f4fceaf71325598baec16650b35863fcf6663ce46da13779891fb19471ec044f9555e20ebd6355e9"
    },
    {
      "line": 180,
      "relation": "increases",
      "evidence": "In agreement with this possibility, the investigation of another posttranslational modification of tubulin, detyrosination, which is also representative of a stable population of microtubules, revealed that it was significantly increased with Gln124-Tau when compared to FL-Tau",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 746,
      "target": 755,
      "key": "2d4c8927b70479f202df58292190e800d374265c7dbd74e88ce85f5f6ac2d38a1faee9bf5f6d81c5af258e373f6574ee9e67d0558be16fae702e1171fc61dbd7"
    },
    {
      "line": 179,
      "relation": "positiveCorrelation",
      "evidence": "In agreement with this possibility, the investigation of another posttranslational modification of tubulin, detyrosination, which is also representative of a stable population of microtubules, revealed that it was significantly increased with Gln124-Tau when compared to FL-Tau",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 747,
      "target": 606,
      "key": "2254e10c503ddc8900b54c8b438de65a57f085f27f7d20ec9666b8b5b326ca2889e3167c8e024b2c35cd1f0af22339beb7366b04739a168feee96d8e6b7ed046"
    },
    {
      "line": 181,
      "relation": "increases",
      "evidence": "In agreement with this possibility, the investigation of another posttranslational modification of tubulin, detyrosination, which is also representative of a stable population of microtubules, revealed that it was significantly increased with Gln124-Tau when compared to FL-Tau",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Method": {
          "Liquid Chromatography": true,
          "Mass Spectrometry": true,
          "Western Blot": true,
          "Immunoprecipitation": true
        },
        "Anatomy": {
          "cerebral cortex": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 747,
      "target": 755,
      "key": "b8b8fb447289178d72f4999ec8f9c64280bfe71720ef51732c55cf531af81c988fd56a7dc54936b99ce7d0a47c6acd8672887230fc7371565094cbed609200fe"
    },
    {
      "line": 188,
      "relation": "directlyIncreases",
      "evidence": "Hyperphosphorylation with Prostate-derived sterile 20-like kinase 1 alpha/beta (PSK1/TAOK2), Prostate-derived sterile 20-like kinase 2 (PSK2/TAOK1), CK1.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Tau_Antibody": {
          "Tau-12": true,
          "Tau-13": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 719,
      "target": 575,
      "key": "9d7443d5fa99fdf28a4943fd160be3f8d9b1860ec3613e18af0d8c8e131e45ef367bba542c8e6c8597c8595124abc63fc82a8b71c099aaa5212337d881ebd5c7"
    },
    {
      "line": 191,
      "relation": "isA",
      "evidence": "Hyperphosphorylation with Prostate-derived sterile 20-like kinase 1 alpha/beta (PSK1/TAOK2), Prostate-derived sterile 20-like kinase 2 (PSK2/TAOK1), CK1.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Tau_Antibody": {
          "Tau-12": true,
          "Tau-13": true
        }
      },
      "source": 575,
      "target": 486,
      "key": "7fffd8e3c05d1021c0c6c5cf2e79aafa89a8b4efa419faed36a2c46ac76d6c980ccc5487af1bbab3fc610a694db2a69649d148ba2269e7fc07b259d92d5038b4"
    },
    {
      "line": 189,
      "relation": "directlyIncreases",
      "evidence": "Hyperphosphorylation with Prostate-derived sterile 20-like kinase 1 alpha/beta (PSK1/TAOK2), Prostate-derived sterile 20-like kinase 2 (PSK2/TAOK1), CK1.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Tau_Antibody": {
          "Tau-12": true,
          "Tau-13": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 720,
      "target": 575,
      "key": "b1ea162f0b6267f62cfa008a44dc4cb9b8535b605c8970b65ef7a72fc8328655e8d0741da04ef76298f6af4dadd685c4b183e25f6e4199e307df210fcb798e39"
    },
    {
      "line": 190,
      "relation": "directlyIncreases",
      "evidence": "Hyperphosphorylation with Prostate-derived sterile 20-like kinase 1 alpha/beta (PSK1/TAOK2), Prostate-derived sterile 20-like kinase 2 (PSK2/TAOK1), CK1.",
      "citation": {
        "type": "PubMed",
        "reference": "25974414",
        "name": "Scientific reports",
        "title": "Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms.",
        "volume": "5",
        "pages": "9659",
        "date": "2015-05-14",
        "first": "Derisbourg M",
        "last": "Hamdane M",
        "authors": [
          "Blum D",
          "Buée L",
          "Buée-Scherrer V",
          "Carrier S",
          "Chiappetta G",
          "Demeyer D",
          "Derisbourg M",
          "Fernandez-Gomez FJ",
          "Hamdane M",
          "Laurent C",
          "Leghay C",
          "Sergeant N",
          "Verdier Y",
          "Vinh J"
        ]
      },
      "annotations": {
        "Tau_Antibody": {
          "Tau-12": true,
          "Tau-13": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 411,
      "target": 575,
      "key": "382c4691e87773235c74ced0a6600a42fa5d90c522e8ab70fc5294c71bc48cc6e6776acbde20d0d163020ca629b79f2731fb90916d31c1f7a4abb145573998a9"
    },
    {
      "line": 1399,
      "relation": "isA",
      "evidence": "The CK1 group of eukaryotic protein kinases are composed of seven CK1 isoforms (CK1α, CK1α2, CK1δ, CK1ε, CK1γ1, CK1γ2, and CK1γ3), two Tau–tubulin kinase isoforms (TTBK1 and TTBK2), and three VRK isoforms (VRK1, VRK2, and VRK3)",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 411,
      "target": 286,
      "key": "697a7eb082f2a9c8e7da5b4635900c38ce01802f7dca7e3ca9663d97cdd582fe1426e8ad51f871f1590d32f04eac4d7eec337d68151bda596f4d9abea7d4da37"
    },
    {
      "line": 3003,
      "relation": "increases",
      "evidence": "The N-terminus of β-catenin has phosphorylation, ubiquitination, and acetylation sites that regulate its stability and signaling. In the absence of a Wnt signal, Ser33, Ser37, and Thr41 are constitutively phosphorylated by glycogen synthase kinase 3β (GSK3β). β-Catenin phosphorylated at these sites is recognized by β-transducin repeat-containing protein (βTrCP), which results in ubiquitination and degradation by the ubiquitin-proteasome pathway. The N-terminal regulatory domain of β-catenin also includes Ser45, a phosphorylation site for Casein Kinase 1α (CK1α) and Lys49, which is acetylated by the acetyltransferase p300/CBP-associated factor (PCAF). The relevance of Lys49 acetylation and Ser45 phosphorylation to the function of β-catenin is an active area of investigation. We find that HDAC6 inhibitors increase Lys49 acetylation and Ser45 phosphorylation but do not affect Ser33, Ser37, and Thr41 phosphorylation. Lys49 acetylation results in decreased ubiquitination of β-catenin in the presence of proteasome inhibition. While increased Lys49 acetylation does not affect total levels of β-catenin, it results in increased membrane localization of β-catenin.",
      "citation": {
        "type": "PubMed",
        "reference": "25546293",
        "name": "ACS chemical biology",
        "title": "HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of β-catenin in human iPSC-derived neuronal cells.",
        "volume": "10",
        "pages": "883-90",
        "date": "2015-03-20",
        "first": "Iaconelli J",
        "last": "Karmacharya R",
        "authors": [
          "Berkovitch SS",
          "Chattopadhyay S",
          "Haggarty SJ",
          "Huang JH",
          "Iaconelli J",
          "Karmacharya R",
          "Mazitschek R",
          "Schreiber SL"
        ]
      },
      "source": 411,
      "target": 423,
      "key": "4f99102af0b3763d567c5a700e4cebbd6b25c0d4d193fe52fb869a821210617ee45c06f8f0ffaa51360141b83688a642ff63b12eab2e5f89c582b3fb3b920fa8"
    },
    {
      "line": 200,
      "relation": "increases",
      "evidence": "Previously, we showed that peroxynitrite (ONOO-) induces the oxidative 3,3¢- dityrosine (3,3¢-DT) cross-linking and site-selective nitration of tau monomers [Reynolds et al. (2005)",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "source": 65,
      "target": 517,
      "key": "fbce9f7a8556b360405b1a6d06a0f4b35480951ded0b641d8ddfc0d862c9bee9a03f65528c841bb585ba09d9019b55bb53cfa0301f8e2b755be56b5bddb61cd3"
    },
    {
      "line": 859,
      "relation": "increases",
      "evidence": "PN-treated wild-type tau and 5XY→F tau consistently displayed lysine formylation throughout tau in a non-sequence specific distribution. Lysine formylation likely results from reactive free radical exposure caused by PN treatment.",
      "citation": {
        "type": "PubMed",
        "reference": "21210655",
        "name": "Biochemistry",
        "title": "Peroxynitrite-induced nitrative and oxidative modifications alter tau filament formation.",
        "volume": "50",
        "pages": "1203-12",
        "date": "2011-02-22",
        "first": "Vana L",
        "last": "Binder LI",
        "authors": [
          "Binder LI",
          "Hakala K",
          "Kanaan NM",
          "Vana L",
          "Weintraub ST"
        ]
      },
      "source": 65,
      "target": 514,
      "key": "c4fc6ac0631313a4424478885c9279ff670b45ad6b4d3c353732c0644f3658f782fb7da25aaffda52ddf65a2316d5b989f229e05ddc74f68668b70e676229005"
    },
    {
      "line": 889,
      "relation": "increases",
      "evidence": "In the present study we injected bilaterally 3-morpholino-sydnonimine (SIN-1), a recognized and widely used peroxynitrite donor (25–30), into rat hippocampus, and investigated whether or not peroxynitrite could induce simultaneously nitration and hyperphosphorylation of tau and the underlying mechanisms in vivo. The level of nitrated and hyperphosphorylated tau was markedly increased in rat hippocampus 24 h, and prevented by preinjection of uric acid, a natural scavenger of peroxynitrite. GSK-3beta and p38 MAPKs, including p38alpha, p38beta, and p38delta activity was increased, but no change in the activity of p38gamma, ERK, and c-Jun amino-terminal kinase (JNK). Both nitrated tau and hyperphosphorylated tau were aggregated in the hippocampus, with activity of 20S proteasome significantly arrested in SIN-1-injected rats. Hyperphosphorylated tau was degraded as efficiently as normal tau by 20S proteasome, but the nitrated tau with an unorderly secondary structure became more resistant to the proteolysis, providing evidence that peroxynitrite simultaneously induces tau hyperphosphorylation, nitration, and accumulation, and that activation of GSK-3beta, p38alpha, p38beta, p38delta isoforms and the inhibition of proteasome activity are respectively responsible for the peroxynitrite-induced tau hyperphosphorylation and accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "16816118",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms.",
        "volume": "20",
        "pages": "1431-42",
        "date": "2006-07-01",
        "first": "Zhang YJ",
        "last": "Wang JZ",
        "authors": [
          "Li HL",
          "Liu YH",
          "Wang JZ",
          "Wang Q",
          "Xu YF",
          "Yin J",
          "Zhang YJ"
        ]
      },
      "annotations": {
        "ExpMethod": {
          "in vivo": true
        },
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 65,
      "target": 877,
      "key": "b5aa3e6883cd3e13a2fa368e5031d1c41dbc068b97419a44b396b29277d858b8d37ec7c5a8171fbf6d174fbc78ff4da4aaa1e79dd8aafc4a6dceee04a56e5e36"
    },
    {
      "line": 890,
      "relation": "increases",
      "evidence": "In the present study we injected bilaterally 3-morpholino-sydnonimine (SIN-1), a recognized and widely used peroxynitrite donor (25–30), into rat hippocampus, and investigated whether or not peroxynitrite could induce simultaneously nitration and hyperphosphorylation of tau and the underlying mechanisms in vivo. The level of nitrated and hyperphosphorylated tau was markedly increased in rat hippocampus 24 h, and prevented by preinjection of uric acid, a natural scavenger of peroxynitrite. GSK-3beta and p38 MAPKs, including p38alpha, p38beta, and p38delta activity was increased, but no change in the activity of p38gamma, ERK, and c-Jun amino-terminal kinase (JNK). Both nitrated tau and hyperphosphorylated tau were aggregated in the hippocampus, with activity of 20S proteasome significantly arrested in SIN-1-injected rats. Hyperphosphorylated tau was degraded as efficiently as normal tau by 20S proteasome, but the nitrated tau with an unorderly secondary structure became more resistant to the proteolysis, providing evidence that peroxynitrite simultaneously induces tau hyperphosphorylation, nitration, and accumulation, and that activation of GSK-3beta, p38alpha, p38beta, p38delta isoforms and the inhibition of proteasome activity are respectively responsible for the peroxynitrite-induced tau hyperphosphorylation and accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "16816118",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms.",
        "volume": "20",
        "pages": "1431-42",
        "date": "2006-07-01",
        "first": "Zhang YJ",
        "last": "Wang JZ",
        "authors": [
          "Li HL",
          "Liu YH",
          "Wang JZ",
          "Wang Q",
          "Xu YF",
          "Yin J",
          "Zhang YJ"
        ]
      },
      "annotations": {
        "ExpMethod": {
          "in vivo": true
        },
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 65,
      "target": 876,
      "key": "69db52113ef15ec8647b622ea327782a97bef7efa52020ffc8ebb1bd622660a92c642386d65ff3faa9ebb718324e5975a41375d6a3d034f6783e3c414e4bacbe"
    },
    {
      "line": 891,
      "relation": "increases",
      "evidence": "In the present study we injected bilaterally 3-morpholino-sydnonimine (SIN-1), a recognized and widely used peroxynitrite donor (25–30), into rat hippocampus, and investigated whether or not peroxynitrite could induce simultaneously nitration and hyperphosphorylation of tau and the underlying mechanisms in vivo. The level of nitrated and hyperphosphorylated tau was markedly increased in rat hippocampus 24 h, and prevented by preinjection of uric acid, a natural scavenger of peroxynitrite. GSK-3beta and p38 MAPKs, including p38alpha, p38beta, and p38delta activity was increased, but no change in the activity of p38gamma, ERK, and c-Jun amino-terminal kinase (JNK). Both nitrated tau and hyperphosphorylated tau were aggregated in the hippocampus, with activity of 20S proteasome significantly arrested in SIN-1-injected rats. Hyperphosphorylated tau was degraded as efficiently as normal tau by 20S proteasome, but the nitrated tau with an unorderly secondary structure became more resistant to the proteolysis, providing evidence that peroxynitrite simultaneously induces tau hyperphosphorylation, nitration, and accumulation, and that activation of GSK-3beta, p38alpha, p38beta, p38delta isoforms and the inhibition of proteasome activity are respectively responsible for the peroxynitrite-induced tau hyperphosphorylation and accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "16816118",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms.",
        "volume": "20",
        "pages": "1431-42",
        "date": "2006-07-01",
        "first": "Zhang YJ",
        "last": "Wang JZ",
        "authors": [
          "Li HL",
          "Liu YH",
          "Wang JZ",
          "Wang Q",
          "Xu YF",
          "Yin J",
          "Zhang YJ"
        ]
      },
      "annotations": {
        "ExpMethod": {
          "in vivo": true
        },
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 65,
      "target": 866,
      "key": "903bf887211f6a97d8ce23ecd1deb6de8b6aae421d8c7b0b9e951f1a9ad53c4f5db5ed636153cfc4ffd0b110666f40eea8fbe45a68441f0167c04bdc7d5124e1"
    },
    {
      "line": 892,
      "relation": "increases",
      "evidence": "In the present study we injected bilaterally 3-morpholino-sydnonimine (SIN-1), a recognized and widely used peroxynitrite donor (25–30), into rat hippocampus, and investigated whether or not peroxynitrite could induce simultaneously nitration and hyperphosphorylation of tau and the underlying mechanisms in vivo. The level of nitrated and hyperphosphorylated tau was markedly increased in rat hippocampus 24 h, and prevented by preinjection of uric acid, a natural scavenger of peroxynitrite. GSK-3beta and p38 MAPKs, including p38alpha, p38beta, and p38delta activity was increased, but no change in the activity of p38gamma, ERK, and c-Jun amino-terminal kinase (JNK). Both nitrated tau and hyperphosphorylated tau were aggregated in the hippocampus, with activity of 20S proteasome significantly arrested in SIN-1-injected rats. Hyperphosphorylated tau was degraded as efficiently as normal tau by 20S proteasome, but the nitrated tau with an unorderly secondary structure became more resistant to the proteolysis, providing evidence that peroxynitrite simultaneously induces tau hyperphosphorylation, nitration, and accumulation, and that activation of GSK-3beta, p38alpha, p38beta, p38delta isoforms and the inhibition of proteasome activity are respectively responsible for the peroxynitrite-induced tau hyperphosphorylation and accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "16816118",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms.",
        "volume": "20",
        "pages": "1431-42",
        "date": "2006-07-01",
        "first": "Zhang YJ",
        "last": "Wang JZ",
        "authors": [
          "Li HL",
          "Liu YH",
          "Wang JZ",
          "Wang Q",
          "Xu YF",
          "Yin J",
          "Zhang YJ"
        ]
      },
      "annotations": {
        "ExpMethod": {
          "in vivo": true
        },
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 65,
      "target": 874,
      "key": "a9d31a28af2305b10496a769525ce8d77420dcefca75d4501542c3b4947af83c9e1db4cbb44cf1e06cdfb192adbf3e84445b61d59b5f0af4ec6e9d57c65ecc68"
    },
    {
      "line": 893,
      "relation": "increases",
      "evidence": "In the present study we injected bilaterally 3-morpholino-sydnonimine (SIN-1), a recognized and widely used peroxynitrite donor (25–30), into rat hippocampus, and investigated whether or not peroxynitrite could induce simultaneously nitration and hyperphosphorylation of tau and the underlying mechanisms in vivo. The level of nitrated and hyperphosphorylated tau was markedly increased in rat hippocampus 24 h, and prevented by preinjection of uric acid, a natural scavenger of peroxynitrite. GSK-3beta and p38 MAPKs, including p38alpha, p38beta, and p38delta activity was increased, but no change in the activity of p38gamma, ERK, and c-Jun amino-terminal kinase (JNK). Both nitrated tau and hyperphosphorylated tau were aggregated in the hippocampus, with activity of 20S proteasome significantly arrested in SIN-1-injected rats. Hyperphosphorylated tau was degraded as efficiently as normal tau by 20S proteasome, but the nitrated tau with an unorderly secondary structure became more resistant to the proteolysis, providing evidence that peroxynitrite simultaneously induces tau hyperphosphorylation, nitration, and accumulation, and that activation of GSK-3beta, p38alpha, p38beta, p38delta isoforms and the inhibition of proteasome activity are respectively responsible for the peroxynitrite-induced tau hyperphosphorylation and accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "16816118",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms.",
        "volume": "20",
        "pages": "1431-42",
        "date": "2006-07-01",
        "first": "Zhang YJ",
        "last": "Wang JZ",
        "authors": [
          "Li HL",
          "Liu YH",
          "Wang JZ",
          "Wang Q",
          "Xu YF",
          "Yin J",
          "Zhang YJ"
        ]
      },
      "annotations": {
        "ExpMethod": {
          "in vivo": true
        },
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 65,
      "target": 871,
      "key": "2db7bfcd182a849da5a6425dbd84176a2ddf689eb711382216f9dfc6f26bcfe5170b03a61bee092d87930a3ea3426df7284ed330859f5b52ed1ef0d3620d9e7b"
    },
    {
      "line": 894,
      "relation": "increases",
      "evidence": "In the present study we injected bilaterally 3-morpholino-sydnonimine (SIN-1), a recognized and widely used peroxynitrite donor (25–30), into rat hippocampus, and investigated whether or not peroxynitrite could induce simultaneously nitration and hyperphosphorylation of tau and the underlying mechanisms in vivo. The level of nitrated and hyperphosphorylated tau was markedly increased in rat hippocampus 24 h, and prevented by preinjection of uric acid, a natural scavenger of peroxynitrite. GSK-3beta and p38 MAPKs, including p38alpha, p38beta, and p38delta activity was increased, but no change in the activity of p38gamma, ERK, and c-Jun amino-terminal kinase (JNK). Both nitrated tau and hyperphosphorylated tau were aggregated in the hippocampus, with activity of 20S proteasome significantly arrested in SIN-1-injected rats. Hyperphosphorylated tau was degraded as efficiently as normal tau by 20S proteasome, but the nitrated tau with an unorderly secondary structure became more resistant to the proteolysis, providing evidence that peroxynitrite simultaneously induces tau hyperphosphorylation, nitration, and accumulation, and that activation of GSK-3beta, p38alpha, p38beta, p38delta isoforms and the inhibition of proteasome activity are respectively responsible for the peroxynitrite-induced tau hyperphosphorylation and accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "16816118",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms.",
        "volume": "20",
        "pages": "1431-42",
        "date": "2006-07-01",
        "first": "Zhang YJ",
        "last": "Wang JZ",
        "authors": [
          "Li HL",
          "Liu YH",
          "Wang JZ",
          "Wang Q",
          "Xu YF",
          "Yin J",
          "Zhang YJ"
        ]
      },
      "annotations": {
        "ExpMethod": {
          "in vivo": true
        },
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 65,
      "target": 873,
      "key": "7e8b14c243b392f2ec3765990ea058094f5ba49a4cc2f3820c0956c847d30803fd91bba31ce82c5cc2c577077cf0f79014df0ea0b7128702bc5440a0dea0a5f5"
    },
    {
      "line": 895,
      "relation": "causesNoChange",
      "evidence": "In the present study we injected bilaterally 3-morpholino-sydnonimine (SIN-1), a recognized and widely used peroxynitrite donor (25–30), into rat hippocampus, and investigated whether or not peroxynitrite could induce simultaneously nitration and hyperphosphorylation of tau and the underlying mechanisms in vivo. The level of nitrated and hyperphosphorylated tau was markedly increased in rat hippocampus 24 h, and prevented by preinjection of uric acid, a natural scavenger of peroxynitrite. GSK-3beta and p38 MAPKs, including p38alpha, p38beta, and p38delta activity was increased, but no change in the activity of p38gamma, ERK, and c-Jun amino-terminal kinase (JNK). Both nitrated tau and hyperphosphorylated tau were aggregated in the hippocampus, with activity of 20S proteasome significantly arrested in SIN-1-injected rats. Hyperphosphorylated tau was degraded as efficiently as normal tau by 20S proteasome, but the nitrated tau with an unorderly secondary structure became more resistant to the proteolysis, providing evidence that peroxynitrite simultaneously induces tau hyperphosphorylation, nitration, and accumulation, and that activation of GSK-3beta, p38alpha, p38beta, p38delta isoforms and the inhibition of proteasome activity are respectively responsible for the peroxynitrite-induced tau hyperphosphorylation and accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "16816118",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms.",
        "volume": "20",
        "pages": "1431-42",
        "date": "2006-07-01",
        "first": "Zhang YJ",
        "last": "Wang JZ",
        "authors": [
          "Li HL",
          "Liu YH",
          "Wang JZ",
          "Wang Q",
          "Xu YF",
          "Yin J",
          "Zhang YJ"
        ]
      },
      "annotations": {
        "ExpMethod": {
          "in vivo": true
        },
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 65,
      "target": 872,
      "key": "c2559a173fa0ba6f76b7c51a834dcc57fc65f772ab62440c933181ec3fd7abe025ee5726a328b8adbb374049499a27400e62e8b3edf343ec52e6b5ec30765d5f"
    },
    {
      "line": 896,
      "relation": "causesNoChange",
      "evidence": "In the present study we injected bilaterally 3-morpholino-sydnonimine (SIN-1), a recognized and widely used peroxynitrite donor (25–30), into rat hippocampus, and investigated whether or not peroxynitrite could induce simultaneously nitration and hyperphosphorylation of tau and the underlying mechanisms in vivo. The level of nitrated and hyperphosphorylated tau was markedly increased in rat hippocampus 24 h, and prevented by preinjection of uric acid, a natural scavenger of peroxynitrite. GSK-3beta and p38 MAPKs, including p38alpha, p38beta, and p38delta activity was increased, but no change in the activity of p38gamma, ERK, and c-Jun amino-terminal kinase (JNK). Both nitrated tau and hyperphosphorylated tau were aggregated in the hippocampus, with activity of 20S proteasome significantly arrested in SIN-1-injected rats. Hyperphosphorylated tau was degraded as efficiently as normal tau by 20S proteasome, but the nitrated tau with an unorderly secondary structure became more resistant to the proteolysis, providing evidence that peroxynitrite simultaneously induces tau hyperphosphorylation, nitration, and accumulation, and that activation of GSK-3beta, p38alpha, p38beta, p38delta isoforms and the inhibition of proteasome activity are respectively responsible for the peroxynitrite-induced tau hyperphosphorylation and accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "16816118",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms.",
        "volume": "20",
        "pages": "1431-42",
        "date": "2006-07-01",
        "first": "Zhang YJ",
        "last": "Wang JZ",
        "authors": [
          "Li HL",
          "Liu YH",
          "Wang JZ",
          "Wang Q",
          "Xu YF",
          "Yin J",
          "Zhang YJ"
        ]
      },
      "annotations": {
        "ExpMethod": {
          "in vivo": true
        },
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 65,
      "target": 288,
      "key": "bc00669ba209641da110285cc8034cd4b9b7e62757d169eaeb32e2607379bc6a93fab8b18d11d2a3df8eaeac4fa8c102be3234629f44b441f62a102bec38d9d5"
    },
    {
      "line": 897,
      "relation": "causesNoChange",
      "evidence": "In the present study we injected bilaterally 3-morpholino-sydnonimine (SIN-1), a recognized and widely used peroxynitrite donor (25–30), into rat hippocampus, and investigated whether or not peroxynitrite could induce simultaneously nitration and hyperphosphorylation of tau and the underlying mechanisms in vivo. The level of nitrated and hyperphosphorylated tau was markedly increased in rat hippocampus 24 h, and prevented by preinjection of uric acid, a natural scavenger of peroxynitrite. GSK-3beta and p38 MAPKs, including p38alpha, p38beta, and p38delta activity was increased, but no change in the activity of p38gamma, ERK, and c-Jun amino-terminal kinase (JNK). Both nitrated tau and hyperphosphorylated tau were aggregated in the hippocampus, with activity of 20S proteasome significantly arrested in SIN-1-injected rats. Hyperphosphorylated tau was degraded as efficiently as normal tau by 20S proteasome, but the nitrated tau with an unorderly secondary structure became more resistant to the proteolysis, providing evidence that peroxynitrite simultaneously induces tau hyperphosphorylation, nitration, and accumulation, and that activation of GSK-3beta, p38alpha, p38beta, p38delta isoforms and the inhibition of proteasome activity are respectively responsible for the peroxynitrite-induced tau hyperphosphorylation and accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "16816118",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms.",
        "volume": "20",
        "pages": "1431-42",
        "date": "2006-07-01",
        "first": "Zhang YJ",
        "last": "Wang JZ",
        "authors": [
          "Li HL",
          "Liu YH",
          "Wang JZ",
          "Wang Q",
          "Xu YF",
          "Yin J",
          "Zhang YJ"
        ]
      },
      "annotations": {
        "ExpMethod": {
          "in vivo": true
        },
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 65,
      "target": 291,
      "key": "c422c5f825ab1d8f4efb012a85d31f1c1d8509f73a1976c72f376c83e1e54a91381fff77d05ef2dd08a8c9aba212370376ed833a8c196d6849c29612b83928b0"
    },
    {
      "line": 900,
      "relation": "increases",
      "evidence": "In the present study we injected bilaterally 3-morpholino-sydnonimine (SIN-1), a recognized and widely used peroxynitrite donor (25–30), into rat hippocampus, and investigated whether or not peroxynitrite could induce simultaneously nitration and hyperphosphorylation of tau and the underlying mechanisms in vivo. The level of nitrated and hyperphosphorylated tau was markedly increased in rat hippocampus 24 h, and prevented by preinjection of uric acid, a natural scavenger of peroxynitrite. GSK-3beta and p38 MAPKs, including p38alpha, p38beta, and p38delta activity was increased, but no change in the activity of p38gamma, ERK, and c-Jun amino-terminal kinase (JNK). Both nitrated tau and hyperphosphorylated tau were aggregated in the hippocampus, with activity of 20S proteasome significantly arrested in SIN-1-injected rats. Hyperphosphorylated tau was degraded as efficiently as normal tau by 20S proteasome, but the nitrated tau with an unorderly secondary structure became more resistant to the proteolysis, providing evidence that peroxynitrite simultaneously induces tau hyperphosphorylation, nitration, and accumulation, and that activation of GSK-3beta, p38alpha, p38beta, p38delta isoforms and the inhibition of proteasome activity are respectively responsible for the peroxynitrite-induced tau hyperphosphorylation and accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "16816118",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms.",
        "volume": "20",
        "pages": "1431-42",
        "date": "2006-07-01",
        "first": "Zhang YJ",
        "last": "Wang JZ",
        "authors": [
          "Li HL",
          "Liu YH",
          "Wang JZ",
          "Wang Q",
          "Xu YF",
          "Yin J",
          "Zhang YJ"
        ]
      },
      "annotations": {
        "ExpMethod": {
          "in vivo": true
        },
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 65,
      "target": 188,
      "key": "43d465cfe4f14a78fd40fae908b414e9f4ee5ca181f91fbf8d9027ece5a68001b564259f70289b16fef6795299f586c44e8aa5cf3ead7321fc1c901d520bd3b8"
    },
    {
      "line": 916,
      "relation": "increases",
      "evidence": "Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "source": 65,
      "target": 518,
      "key": "8cad963e9628d76d481251e15129c3a31ef3bf1f71bd4530f08c92d5059898bd88a07f5eb0fd7bed3ed39473d9b3a7b483c2befa76e2dc8c0f5eaf8a1c40296e"
    },
    {
      "line": 917,
      "relation": "increases",
      "evidence": "Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "source": 65,
      "target": 520,
      "key": "f555c3e1d6d7df9eb409d1413f38d4c8357ad709e76359f79f5edb79f275b874d4b64099291ffa7f3924806bb2cccc4880057815df7a75f8fde0065b045eaa32"
    },
    {
      "line": 918,
      "relation": "increases",
      "evidence": "Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "source": 65,
      "target": 519,
      "key": "77b650d4399cecb6a899730ac18178fbeaf891cf0dbe65dd4be6ba3ccd4d67e533fbebc290fedbdecc7cd9b8ea0f46ced8c1694e1d02eb039ec7f6546b878e22"
    },
    {
      "line": 919,
      "relation": "increases",
      "evidence": "Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "source": 65,
      "target": 521,
      "key": "4063eed223b51628a0048a7b8615b114f3f55154d5f1456feab40ae55a0aa49eb191c19b373f2ddfd299caf3465a7d505774404fd5563480fb1248262b2fd915"
    },
    {
      "line": 205,
      "relation": "decreases",
      "evidence": "Further, select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation [Reynolds et al. (2005) Biochemistry 44, 13997-14009], inhibits the ability of monomeric tau to promote tubulin assembly.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "annotations": {
        "Tau_Antibody": {
          "Tau-12": true,
          "9G3": true,
          "Tau-13": true,
          "pY18": true
        }
      },
      "source": 518,
      "target": 194,
      "key": "a0b8d65a4979863448591ce784d3774a93f5d10fa5b04b8372b78eef1ee5f830485c16609b85e992878452ad56ef2e273a017ff061d12094ea84cb0ad4abf1e7"
    },
    {
      "line": 818,
      "relation": "positiveCorrelation",
      "evidence": "Tau-nY18 did not label the classical pathological lesions of CBD or PSP but did label the neuronal lesions associated with PiD. Tau-nY29 revealed some, but not all classes of tau inclusions associated with both CBD and PSP but did label numerous Pick body inclusions in PiD. Tau-nY197 was restricted to the neuropil threads in both CBD and PSP; however, similar to Tau-nY29, extensive Pick body pathology was clearly labeled. Tau-nY394 did not detect any of the lesions associated with these disorders.",
      "citation": {
        "type": "PubMed",
        "reference": "22057784",
        "name": "Acta neuropathologica",
        "title": "Selective tau tyrosine nitration in non-AD tauopathies.",
        "volume": "123",
        "pages": "119-32",
        "date": "2012-01-01",
        "first": "Reyes JF",
        "last": "Binder LI",
        "authors": [
          "Binder LI",
          "Geula C",
          "Reyes JF",
          "Vana L"
        ]
      },
      "source": 518,
      "target": 916,
      "key": "5a67f61f7d0b7fbc233c4d1bd094ae0e3ddc5ab7f2987c3f7d2853aa0c81f43d0fd5e57877df93dbb68f50198903c0a3f8c2c0d855fa9e6d39b5ea9d0014ccb7"
    },
    {
      "line": 835,
      "relation": "association",
      "evidence": "This antibody detects nitrated tau in soluble preparations from both severe AD brains (Braak stage V, VI) and age-matched controls, suggesting that nitration at Tyr 18 may be linked to astrocyte activation, an early event associated with amyloid plaque formation",
      "citation": {
        "type": "PubMed",
        "reference": "18562203",
        "name": "Neurobiology of disease",
        "title": "A possible link between astrocyte activation and tau nitration in Alzheimer's disease.",
        "volume": "31",
        "pages": "198-208",
        "date": "2008-08-01",
        "first": "Reyes JF",
        "last": "Binder LI",
        "authors": [
          "Berry R",
          "Binder LI",
          "Fu Y",
          "Guillozet-Bongaarts AL",
          "Horowitz PM",
          "Reyes JF",
          "Reynolds MR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 518,
      "target": 0,
      "key": "987d76f3c622459496b175366ca225f5a5ec40589ab50ea5cfc781568240a7cbe12ee3503b626ce0d384474d74447fe1faab24de1c33293eee847541b7e421e7"
    },
    {
      "line": 836,
      "relation": "positiveCorrelation",
      "evidence": "This antibody detects nitrated tau in soluble preparations from both severe AD brains (Braak stage V, VI) and age-matched controls, suggesting that nitration at Tyr 18 may be linked to astrocyte activation, an early event associated with amyloid plaque formation",
      "citation": {
        "type": "PubMed",
        "reference": "18562203",
        "name": "Neurobiology of disease",
        "title": "A possible link between astrocyte activation and tau nitration in Alzheimer's disease.",
        "volume": "31",
        "pages": "198-208",
        "date": "2008-08-01",
        "first": "Reyes JF",
        "last": "Binder LI",
        "authors": [
          "Berry R",
          "Binder LI",
          "Fu Y",
          "Guillozet-Bongaarts AL",
          "Horowitz PM",
          "Reyes JF",
          "Reynolds MR"
        ]
      },
      "source": 518,
      "target": 917,
      "key": "1c5397f4d0b05de5b196547cd2389d4cba8c7873bfd238e127c0676d864c31cbb973c99c00accfe93c079c9806050283590794945c7e6556e9930252c1479186"
    },
    {
      "line": 852,
      "relation": "isA",
      "evidence": "Tau-nY29 detects soluble tau and paired helical filament tau from severely affected Alzheimer's brain but fails to recognize tau from normal aged brain. This observation suggests that nitration at Tyr29 is a disease-related event that may alter the intrinsic ability of tau to self-polymerize. In Alzheimer's brain, Tau-nY29 labels the fibrillar triad of tau lesions, including neurofibrillary tangles, neuritic plaques, and, to a lesser extent, neuropil threads. Intriguingly, although Tau-nY29 stains both the neuronal and glial tau pathology of Pick disease, it detects only the neuronal pathology in corticobasal degeneration and progressive supranuclear palsy without labeling the predominant glial pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "17050703",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.",
        "volume": "26",
        "pages": "10636-45",
        "date": "2006-10-18",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Bigio EH",
          "Binder LI",
          "Fu Y",
          "Guillozet-Bongaarts AL",
          "Reyes JF",
          "Reynolds MR"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 518,
      "target": 517,
      "key": "82c99dd51869786c5c411b621cff843b74ed417a5c9eaf62baab88228ff6be79e8f38b30adaa0b590520a0d818b5cc7691c0bf71d8176028ea14f980a9a57caa"
    },
    {
      "line": 920,
      "relation": "positiveCorrelation",
      "evidence": "Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "source": 518,
      "target": 132,
      "key": "d34ac7d64f772364679c712fd70b35903a5c5132c248e01d9bc5f91e50dc59afd02200f02bee02eb86b5c9bc369d1a9f0feab5cf6cf43e0b3b97632a65189037"
    },
    {
      "line": 924,
      "relation": "negativeCorrelation",
      "evidence": "Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 518,
      "target": 486,
      "key": "6b4d4bdba26ede32390656af16ca6d2e7b1fbd836c420201b6e3eefc1776798190517f08b98b4f03662ddb4bfddbcd7570b53fd5e4131a8c29ae6fd9b60f3128"
    },
    {
      "line": 206,
      "relation": "decreases",
      "evidence": "Further, select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation [Reynolds et al. (2005) Biochemistry 44, 13997-14009], inhibits the ability of monomeric tau to promote tubulin assembly.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "annotations": {
        "Tau_Antibody": {
          "Tau-12": true,
          "9G3": true,
          "Tau-13": true,
          "pY18": true
        }
      },
      "source": 520,
      "target": 194,
      "key": "a7e51f902aeb9135948916005b96a054364fde51423401da5a8a4beb9b4294f1590d31b02f55c60a31d98bc3780a7bae8f298e11e9fdcec0c9522f2c2bd6c81e"
    },
    {
      "line": 819,
      "relation": "positiveCorrelation",
      "evidence": "Tau-nY18 did not label the classical pathological lesions of CBD or PSP but did label the neuronal lesions associated with PiD. Tau-nY29 revealed some, but not all classes of tau inclusions associated with both CBD and PSP but did label numerous Pick body inclusions in PiD. Tau-nY197 was restricted to the neuropil threads in both CBD and PSP; however, similar to Tau-nY29, extensive Pick body pathology was clearly labeled. Tau-nY394 did not detect any of the lesions associated with these disorders.",
      "citation": {
        "type": "PubMed",
        "reference": "22057784",
        "name": "Acta neuropathologica",
        "title": "Selective tau tyrosine nitration in non-AD tauopathies.",
        "volume": "123",
        "pages": "119-32",
        "date": "2012-01-01",
        "first": "Reyes JF",
        "last": "Binder LI",
        "authors": [
          "Binder LI",
          "Geula C",
          "Reyes JF",
          "Vana L"
        ]
      },
      "source": 520,
      "target": 916,
      "key": "f49018f08e7c00f78502cb745c9c53305c45a19ee1530ac10a03c2956804273c52a451f05ae99a56cf6196e3736d8b8d929504b716e39b12ec69f56f6d179c65"
    },
    {
      "line": 844,
      "relation": "positiveCorrelation",
      "evidence": "Tau-nY29 detects soluble tau and paired helical filament tau from severely affected Alzheimer's brain but fails to recognize tau from normal aged brain. This observation suggests that nitration at Tyr29 is a disease-related event that may alter the intrinsic ability of tau to self-polymerize. In Alzheimer's brain, Tau-nY29 labels the fibrillar triad of tau lesions, including neurofibrillary tangles, neuritic plaques, and, to a lesser extent, neuropil threads. Intriguingly, although Tau-nY29 stains both the neuronal and glial tau pathology of Pick disease, it detects only the neuronal pathology in corticobasal degeneration and progressive supranuclear palsy without labeling the predominant glial pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "17050703",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.",
        "volume": "26",
        "pages": "10636-45",
        "date": "2006-10-18",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Bigio EH",
          "Binder LI",
          "Fu Y",
          "Guillozet-Bongaarts AL",
          "Reyes JF",
          "Reynolds MR"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 520,
      "target": 908,
      "key": "67002e4f7e384f46f4a289246006ecd600eb11d14de4a5d97c5e0ec171ee6f3a96220f2e64352f2cdb81aaf15d0bbed93ffa3bb1546f42ff2fc31abc8ac71f7c"
    },
    {
      "line": 845,
      "relation": "positiveCorrelation",
      "evidence": "Tau-nY29 detects soluble tau and paired helical filament tau from severely affected Alzheimer's brain but fails to recognize tau from normal aged brain. This observation suggests that nitration at Tyr29 is a disease-related event that may alter the intrinsic ability of tau to self-polymerize. In Alzheimer's brain, Tau-nY29 labels the fibrillar triad of tau lesions, including neurofibrillary tangles, neuritic plaques, and, to a lesser extent, neuropil threads. Intriguingly, although Tau-nY29 stains both the neuronal and glial tau pathology of Pick disease, it detects only the neuronal pathology in corticobasal degeneration and progressive supranuclear palsy without labeling the predominant glial pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "17050703",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.",
        "volume": "26",
        "pages": "10636-45",
        "date": "2006-10-18",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Bigio EH",
          "Binder LI",
          "Fu Y",
          "Guillozet-Bongaarts AL",
          "Reyes JF",
          "Reynolds MR"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 520,
      "target": 188,
      "key": "89272b582582372b5ac7ff3bdcb4d4bae5f6da3bc6daf156b03f3fba4aee043e07fae281969d7a458d6684f54d6408e6af00513c91d578380ff828a459c5d4c5"
    },
    {
      "line": 846,
      "relation": "partOf",
      "evidence": "Tau-nY29 detects soluble tau and paired helical filament tau from severely affected Alzheimer's brain but fails to recognize tau from normal aged brain. This observation suggests that nitration at Tyr29 is a disease-related event that may alter the intrinsic ability of tau to self-polymerize. In Alzheimer's brain, Tau-nY29 labels the fibrillar triad of tau lesions, including neurofibrillary tangles, neuritic plaques, and, to a lesser extent, neuropil threads. Intriguingly, although Tau-nY29 stains both the neuronal and glial tau pathology of Pick disease, it detects only the neuronal pathology in corticobasal degeneration and progressive supranuclear palsy without labeling the predominant glial pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "17050703",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.",
        "volume": "26",
        "pages": "10636-45",
        "date": "2006-10-18",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Bigio EH",
          "Binder LI",
          "Fu Y",
          "Guillozet-Bongaarts AL",
          "Reyes JF",
          "Reynolds MR"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 520,
      "target": 81,
      "key": "a6245dde0df148aa5a37e9ba37dc38d1c0e17cd5d3d1dc82bf8ab609a5f1ff4bb259a257ec3a897a12afe3051c838514439943cc2f8d6d478bdb9c833e020118"
    },
    {
      "line": 847,
      "relation": "partOf",
      "evidence": "Tau-nY29 detects soluble tau and paired helical filament tau from severely affected Alzheimer's brain but fails to recognize tau from normal aged brain. This observation suggests that nitration at Tyr29 is a disease-related event that may alter the intrinsic ability of tau to self-polymerize. In Alzheimer's brain, Tau-nY29 labels the fibrillar triad of tau lesions, including neurofibrillary tangles, neuritic plaques, and, to a lesser extent, neuropil threads. Intriguingly, although Tau-nY29 stains both the neuronal and glial tau pathology of Pick disease, it detects only the neuronal pathology in corticobasal degeneration and progressive supranuclear palsy without labeling the predominant glial pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "17050703",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.",
        "volume": "26",
        "pages": "10636-45",
        "date": "2006-10-18",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Bigio EH",
          "Binder LI",
          "Fu Y",
          "Guillozet-Bongaarts AL",
          "Reyes JF",
          "Reynolds MR"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 520,
      "target": 917,
      "key": "ea816aede1942c1a7a06fab199541c5e9b8330ab1f10477c2698f720c05156f4d71e56f690c204887f4e0ff22a5209433fe21467f810c5432a3eef6458d53c5b"
    },
    {
      "line": 848,
      "relation": "association",
      "evidence": "Tau-nY29 detects soluble tau and paired helical filament tau from severely affected Alzheimer's brain but fails to recognize tau from normal aged brain. This observation suggests that nitration at Tyr29 is a disease-related event that may alter the intrinsic ability of tau to self-polymerize. In Alzheimer's brain, Tau-nY29 labels the fibrillar triad of tau lesions, including neurofibrillary tangles, neuritic plaques, and, to a lesser extent, neuropil threads. Intriguingly, although Tau-nY29 stains both the neuronal and glial tau pathology of Pick disease, it detects only the neuronal pathology in corticobasal degeneration and progressive supranuclear palsy without labeling the predominant glial pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "17050703",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.",
        "volume": "26",
        "pages": "10636-45",
        "date": "2006-10-18",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Bigio EH",
          "Binder LI",
          "Fu Y",
          "Guillozet-Bongaarts AL",
          "Reyes JF",
          "Reynolds MR"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 520,
      "target": 905,
      "key": "06ee90425f993849ff59ab92ddeba8ca086725303002e420fac0b19b0694b96c71f9b42aecd661e75ceb9165b9ee2f70a0871c6e4bd1244481572bce5f249beb"
    },
    {
      "line": 849,
      "relation": "association",
      "evidence": "Tau-nY29 detects soluble tau and paired helical filament tau from severely affected Alzheimer's brain but fails to recognize tau from normal aged brain. This observation suggests that nitration at Tyr29 is a disease-related event that may alter the intrinsic ability of tau to self-polymerize. In Alzheimer's brain, Tau-nY29 labels the fibrillar triad of tau lesions, including neurofibrillary tangles, neuritic plaques, and, to a lesser extent, neuropil threads. Intriguingly, although Tau-nY29 stains both the neuronal and glial tau pathology of Pick disease, it detects only the neuronal pathology in corticobasal degeneration and progressive supranuclear palsy without labeling the predominant glial pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "17050703",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.",
        "volume": "26",
        "pages": "10636-45",
        "date": "2006-10-18",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Bigio EH",
          "Binder LI",
          "Fu Y",
          "Guillozet-Bongaarts AL",
          "Reyes JF",
          "Reynolds MR"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 520,
      "target": 918,
      "key": "6ae40dd364aa75c98e35f077c7fe1b9278d4894db4677bb1e7c3fa3021f2d234ff8b2629793433f473487bba1470a66ec09a708a00b1450737d61acb2a940b8f"
    },
    {
      "line": 851,
      "relation": "isA",
      "evidence": "Tau-nY29 detects soluble tau and paired helical filament tau from severely affected Alzheimer's brain but fails to recognize tau from normal aged brain. This observation suggests that nitration at Tyr29 is a disease-related event that may alter the intrinsic ability of tau to self-polymerize. In Alzheimer's brain, Tau-nY29 labels the fibrillar triad of tau lesions, including neurofibrillary tangles, neuritic plaques, and, to a lesser extent, neuropil threads. Intriguingly, although Tau-nY29 stains both the neuronal and glial tau pathology of Pick disease, it detects only the neuronal pathology in corticobasal degeneration and progressive supranuclear palsy without labeling the predominant glial pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "17050703",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.",
        "volume": "26",
        "pages": "10636-45",
        "date": "2006-10-18",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Bigio EH",
          "Binder LI",
          "Fu Y",
          "Guillozet-Bongaarts AL",
          "Reyes JF",
          "Reynolds MR"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 520,
      "target": 517,
      "key": "e765a2458b366a23eb60865ca8a04414489b79ac5c037505930e135ddf5d38b2b29c8c0b344eb06b63243e5703e6106c16cea63529190dd41ff2e43594d6abda"
    },
    {
      "line": 921,
      "relation": "positiveCorrelation",
      "evidence": "Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "source": 520,
      "target": 132,
      "key": "7041afeea5424eee7a83db182fc1e9c83cc5b804739bab32407c0883a6381766915ae3c7131905ce2ef6802acb7bd759e377504818e8b2827632512f47224795"
    },
    {
      "line": 925,
      "relation": "negativeCorrelation",
      "evidence": "Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 520,
      "target": 486,
      "key": "f768fdf8a3364181747379f852016dd8135101122255dea43112f223b86830fc228af76f4a378264c4c1e540b24425e171aaf9d98d296b6c9214e19f17fab5fb"
    },
    {
      "line": 207,
      "relation": "decreases",
      "evidence": "Further, select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation [Reynolds et al. (2005) Biochemistry 44, 13997-14009], inhibits the ability of monomeric tau to promote tubulin assembly.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "annotations": {
        "Tau_Antibody": {
          "Tau-12": true,
          "9G3": true,
          "Tau-13": true,
          "pY18": true
        }
      },
      "source": 519,
      "target": 194,
      "key": "e5816fb96c70ea0d6e9dfa48d7d80651adc36e44d5acd3dd813c2cea775180501b7efa0689764d9240f1cb7d0aeda4b41a4de81a776c0ebbb8f11880c3eaeeaf"
    },
    {
      "line": 823,
      "relation": "positiveCorrelation",
      "evidence": "Tau-nY18 did not label the classical pathological lesions of CBD or PSP but did label the neuronal lesions associated with PiD. Tau-nY29 revealed some, but not all classes of tau inclusions associated with both CBD and PSP but did label numerous Pick body inclusions in PiD. Tau-nY197 was restricted to the neuropil threads in both CBD and PSP; however, similar to Tau-nY29, extensive Pick body pathology was clearly labeled. Tau-nY394 did not detect any of the lesions associated with these disorders.",
      "citation": {
        "type": "PubMed",
        "reference": "22057784",
        "name": "Acta neuropathologica",
        "title": "Selective tau tyrosine nitration in non-AD tauopathies.",
        "volume": "123",
        "pages": "119-32",
        "date": "2012-01-01",
        "first": "Reyes JF",
        "last": "Binder LI",
        "authors": [
          "Binder LI",
          "Geula C",
          "Reyes JF",
          "Vana L"
        ]
      },
      "annotations": {
        "Disease": {
          "progressive supranuclear palsy": true
        },
        "HBP_Disease": {
          "Corticobasal Degeneration": true
        },
        "Anatomy": {
          "neuropil": true
        }
      },
      "source": 519,
      "target": 918,
      "key": "476789433e85040560f1480300a50cda2b87f3db2c9cbe97b59ab81c2dcc9a7947092870fb65b707409b8c1f5e4bdae362e16e36ca561f70304498976b717a1b"
    },
    {
      "line": 824,
      "relation": "positiveCorrelation",
      "evidence": "Tau-nY18 did not label the classical pathological lesions of CBD or PSP but did label the neuronal lesions associated with PiD. Tau-nY29 revealed some, but not all classes of tau inclusions associated with both CBD and PSP but did label numerous Pick body inclusions in PiD. Tau-nY197 was restricted to the neuropil threads in both CBD and PSP; however, similar to Tau-nY29, extensive Pick body pathology was clearly labeled. Tau-nY394 did not detect any of the lesions associated with these disorders.",
      "citation": {
        "type": "PubMed",
        "reference": "22057784",
        "name": "Acta neuropathologica",
        "title": "Selective tau tyrosine nitration in non-AD tauopathies.",
        "volume": "123",
        "pages": "119-32",
        "date": "2012-01-01",
        "first": "Reyes JF",
        "last": "Binder LI",
        "authors": [
          "Binder LI",
          "Geula C",
          "Reyes JF",
          "Vana L"
        ]
      },
      "annotations": {
        "Disease": {
          "progressive supranuclear palsy": true
        },
        "HBP_Disease": {
          "Corticobasal Degeneration": true
        },
        "Anatomy": {
          "neuropil": true
        }
      },
      "source": 519,
      "target": 905,
      "key": "7af199b9e5267d443b0daf77eaebc0be0feae5bd2f97fbadf6b280d69948b35d9e20901ce76dcbe04abeb58b4bb440580aa2cb4f601365b28181e997fe60ea67"
    },
    {
      "line": 825,
      "relation": "partOf",
      "evidence": "Tau-nY18 did not label the classical pathological lesions of CBD or PSP but did label the neuronal lesions associated with PiD. Tau-nY29 revealed some, but not all classes of tau inclusions associated with both CBD and PSP but did label numerous Pick body inclusions in PiD. Tau-nY197 was restricted to the neuropil threads in both CBD and PSP; however, similar to Tau-nY29, extensive Pick body pathology was clearly labeled. Tau-nY394 did not detect any of the lesions associated with these disorders.",
      "citation": {
        "type": "PubMed",
        "reference": "22057784",
        "name": "Acta neuropathologica",
        "title": "Selective tau tyrosine nitration in non-AD tauopathies.",
        "volume": "123",
        "pages": "119-32",
        "date": "2012-01-01",
        "first": "Reyes JF",
        "last": "Binder LI",
        "authors": [
          "Binder LI",
          "Geula C",
          "Reyes JF",
          "Vana L"
        ]
      },
      "annotations": {
        "Disease": {
          "progressive supranuclear palsy": true
        },
        "HBP_Disease": {
          "Corticobasal Degeneration": true
        },
        "Anatomy": {
          "neuropil": true
        }
      },
      "source": 519,
      "target": 164,
      "key": "6640ce46438bf2c93d1a32c4e01a85d861d0074c730ece2bfdcf4b3ce4cc037132d867e4bd0f67e47294d38e877a13c252a65ba9f7acaf89f27b5374c40c8ea6"
    },
    {
      "line": 853,
      "relation": "isA",
      "evidence": "Tau-nY29 detects soluble tau and paired helical filament tau from severely affected Alzheimer's brain but fails to recognize tau from normal aged brain. This observation suggests that nitration at Tyr29 is a disease-related event that may alter the intrinsic ability of tau to self-polymerize. In Alzheimer's brain, Tau-nY29 labels the fibrillar triad of tau lesions, including neurofibrillary tangles, neuritic plaques, and, to a lesser extent, neuropil threads. Intriguingly, although Tau-nY29 stains both the neuronal and glial tau pathology of Pick disease, it detects only the neuronal pathology in corticobasal degeneration and progressive supranuclear palsy without labeling the predominant glial pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "17050703",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.",
        "volume": "26",
        "pages": "10636-45",
        "date": "2006-10-18",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Bigio EH",
          "Binder LI",
          "Fu Y",
          "Guillozet-Bongaarts AL",
          "Reyes JF",
          "Reynolds MR"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 519,
      "target": 517,
      "key": "a99455abd4a1597ed5537d1143fc823baad89c8269ab921090641fce8d5d2539a49abe8783644c59cd2c13136c8f8555f8e11dffd5482d7837fa18f39397b398"
    },
    {
      "line": 922,
      "relation": "positiveCorrelation",
      "evidence": "Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "source": 519,
      "target": 132,
      "key": "b58b9e4b904db062d88720ca57e7cfc3e953ce103dd2cafebe7818e0f2a2d33b79fbb42dde4acfa5b746be544c40f99f3df84911288c9793f74e8d852f71759f"
    },
    {
      "line": 926,
      "relation": "negativeCorrelation",
      "evidence": "Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 519,
      "target": 486,
      "key": "4e16f293f3b06f43e51885c62e26c438e34c06b95b3394bf8f821a18cf3361d97a906c8cfe05cf277be7f715474c29db1cf03a489fc8b2f50d0806c4a1452340"
    },
    {
      "line": 208,
      "relation": "decreases",
      "evidence": "Further, select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation [Reynolds et al. (2005) Biochemistry 44, 13997-14009], inhibits the ability of monomeric tau to promote tubulin assembly.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "annotations": {
        "Tau_Antibody": {
          "Tau-12": true,
          "9G3": true,
          "Tau-13": true,
          "pY18": true
        }
      },
      "source": 521,
      "target": 194,
      "key": "b1db221de8f98f39c5201bd24b7adbf394534546fad60553adbfbe426ca292a3718801b3c645515ce6cb4d6dba209f218bbfbefc653f2066ce2d6034c0274f4a"
    },
    {
      "line": 923,
      "relation": "positiveCorrelation",
      "evidence": "Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "source": 521,
      "target": 132,
      "key": "f625dbbd91dd27ecce84c743830bbb84f9a5b4096257f02b248d67c47b72ec1d163bbfc9b881e72944b5803c7a0af667f17b74e657c137d08baa0882dc167eaa"
    },
    {
      "line": 927,
      "relation": "negativeCorrelation",
      "evidence": "Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 521,
      "target": 486,
      "key": "b04e0bd96f54d673523593a02b39183c1abaac54fbe89808579eae71f36bb14a7ae71d354d45f4022b83e4ffd0ea38d7e8827c9c2681d5cafb24041637df7aed"
    },
    {
      "line": 218,
      "relation": "increases",
      "evidence": "Several lines of evidence in other tauopathies suggest that tau oligomer formation induces neurotoxicity and that tau oligomer-mediated neurotoxicity involves induction of axonal dysfunction through exposure of an N-terminal motif in tau, the phosphatase-activating domain (PAD).",
      "citation": {
        "type": "PubMed",
        "reference": "26671985",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.",
        "volume": "75",
        "pages": "19-34",
        "date": "2016-01-01",
        "first": "Kanaan NM",
        "last": "McKee AC",
        "authors": [
          "Alvarez VE",
          "Cox K",
          "Kanaan NM",
          "McKee AC",
          "Poncil S",
          "Stein TD"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 118,
      "target": 155,
      "key": "c5f69c7dda4dfd3d6b08c9b84c407fc7ba66da2ebd0c7e5babe63845f96244d818e080d7bb5fe80738e623da58e6f6841ed898ed26c6f429d4131bf518cccf6f"
    },
    {
      "line": 219,
      "relation": "decreases",
      "evidence": "Several lines of evidence in other tauopathies suggest that tau oligomer formation induces neurotoxicity and that tau oligomer-mediated neurotoxicity involves induction of axonal dysfunction through exposure of an N-terminal motif in tau, the phosphatase-activating domain (PAD).",
      "citation": {
        "type": "PubMed",
        "reference": "26671985",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.",
        "volume": "75",
        "pages": "19-34",
        "date": "2016-01-01",
        "first": "Kanaan NM",
        "last": "McKee AC",
        "authors": [
          "Alvarez VE",
          "Cox K",
          "Kanaan NM",
          "McKee AC",
          "Poncil S",
          "Stein TD"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 118,
      "target": 218,
      "key": "e03677b9c9340d7dff7fe99eeb8e5c35500b4f0a756a52246940aefcb597d9d5f4197851b05578ce424077c3d539b7be7004c24bee2f624e27f1b8c699b61651"
    },
    {
      "line": 220,
      "relation": "positiveCorrelation",
      "evidence": "Several lines of evidence in other tauopathies suggest that tau oligomer formation induces neurotoxicity and that tau oligomer-mediated neurotoxicity involves induction of axonal dysfunction through exposure of an N-terminal motif in tau, the phosphatase-activating domain (PAD).",
      "citation": {
        "type": "PubMed",
        "reference": "26671985",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.",
        "volume": "75",
        "pages": "19-34",
        "date": "2016-01-01",
        "first": "Kanaan NM",
        "last": "McKee AC",
        "authors": [
          "Alvarez VE",
          "Cox K",
          "Kanaan NM",
          "McKee AC",
          "Poncil S",
          "Stein TD"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 118,
      "target": 359,
      "key": "91c11c019dfa3635ec9ce3386e7fcfb654f1964f86e5f4307d00fe57fc07e4e1379dbb29135e842132d84f7877c3ca11af6900a6a4c7f78c6ff74470548dd2fb"
    },
    {
      "line": 2632,
      "relation": "partOf",
      "evidence": "Oligomers positive for pS202/pT205 accumulate at synapses in AD",
      "citation": {
        "type": "PubMed",
        "reference": "22486774",
        "name": "Brain pathology (Zurich, Switzerland)",
        "title": "Extensive p-tau pathology and SDS-stable p-tau oligomers in Alzheimer's cortical synapses.",
        "volume": "22",
        "pages": "826-33",
        "date": "2012-11-01",
        "first": "Henkins KM",
        "last": "Gylys KH",
        "authors": [
          "Cornwell LB",
          "Gylys KH",
          "Henkins KM",
          "Miller CA",
          "Poon WW",
          "Saing T",
          "Sokolow S",
          "Vinters HV"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 118,
      "target": 89,
      "key": "baf17cc6c8f0c7cf01d896e42055d6c1526d50127e0335725f81b249382b47a88262f4b1089cec62c3f38f8422946b50d37571bb0152ac13c77b001ad148e597"
    },
    {
      "line": 3604,
      "relation": "positiveCorrelation",
      "evidence": "Tau Oligomers co-localize with astrocytes, microglia, and HMGB1, a pro-inflammatory cytokine, are present in the retina and are associated with inflammatory cells.",
      "citation": {
        "type": "PubMed",
        "reference": "27716675",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases.",
        "volume": "55",
        "pages": "1083-1099",
        "date": "2017-01-01",
        "first": "Nilson AN",
        "last": "Kayed R",
        "authors": [
          "Barton Whittle T",
          "Castillo-Carranza DL",
          "English KC",
          "Gerson JE",
          "Gupta P",
          "Kayed R",
          "Nicolas Crain C",
          "Nilson AN",
          "Sengupta U",
          "Xue J",
          "Zhang W"
        ]
      },
      "source": 118,
      "target": 154,
      "key": "6190cb777f06bc5a483bbd12d8eafb055908213f260d72b1926fe4d3d77613bf964517aa5eac9ed60d9482ce7189db4c77399de683e9622d86dbe4841d227a42"
    },
    {
      "line": 3609,
      "relation": "increases",
      "evidence": "This work supports the hypothesis that tau oligomers are toxic species that can drive the spread of tau pathology and neurodegeneration.",
      "citation": {
        "type": "PubMed",
        "reference": "27716675",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases.",
        "volume": "55",
        "pages": "1083-1099",
        "date": "2017-01-01",
        "first": "Nilson AN",
        "last": "Kayed R",
        "authors": [
          "Barton Whittle T",
          "Castillo-Carranza DL",
          "English KC",
          "Gerson JE",
          "Gupta P",
          "Kayed R",
          "Nicolas Crain C",
          "Nilson AN",
          "Sengupta U",
          "Xue J",
          "Zhang W"
        ]
      },
      "source": 118,
      "target": 108,
      "key": "971887ea3428c9a54e3e6c30dcf297ab9df61048b420a704d4630fa2785b296a9fca1eb067543e238b918efcb4c9edf809f5caf198556c5f556842f1cb8dce2a"
    },
    {
      "line": 225,
      "relation": "negativeCorrelation",
      "evidence": "Several lines of evidence in other tauopathies suggest that tau oligomer formation induces neurotoxicity and that tau oligomer-mediated neurotoxicity involves induction of axonal dysfunction through exposure of an N-terminal motif in tau, the phosphatase-activating domain (PAD).",
      "citation": {
        "type": "PubMed",
        "reference": "26671985",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.",
        "volume": "75",
        "pages": "19-34",
        "date": "2016-01-01",
        "first": "Kanaan NM",
        "last": "McKee AC",
        "authors": [
          "Alvarez VE",
          "Cox K",
          "Kanaan NM",
          "McKee AC",
          "Poncil S",
          "Stein TD"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 155,
      "target": 218,
      "key": "cec10b5670a2053d08d59c2181b29964875659e621955034c84a38d4d5181010c1b7d27860a06fd862621c4f87e807d72c492850ceeaa54e0569a99dcca5be58"
    },
    {
      "line": 225,
      "relation": "negativeCorrelation",
      "evidence": "Several lines of evidence in other tauopathies suggest that tau oligomer formation induces neurotoxicity and that tau oligomer-mediated neurotoxicity involves induction of axonal dysfunction through exposure of an N-terminal motif in tau, the phosphatase-activating domain (PAD).",
      "citation": {
        "type": "PubMed",
        "reference": "26671985",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.",
        "volume": "75",
        "pages": "19-34",
        "date": "2016-01-01",
        "first": "Kanaan NM",
        "last": "McKee AC",
        "authors": [
          "Alvarez VE",
          "Cox K",
          "Kanaan NM",
          "McKee AC",
          "Poncil S",
          "Stein TD"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 218,
      "target": 155,
      "key": "29e9f5bbd601c6fd46d510845409daba376d5602bac5c2bf61d8f63bec0bd438acb0b0b67a727d61d7522112bd2b4009109f8d3a5f46d83c72951bcdc95f9b1a"
    },
    {
      "line": 220,
      "relation": "positiveCorrelation",
      "evidence": "Several lines of evidence in other tauopathies suggest that tau oligomer formation induces neurotoxicity and that tau oligomer-mediated neurotoxicity involves induction of axonal dysfunction through exposure of an N-terminal motif in tau, the phosphatase-activating domain (PAD).",
      "citation": {
        "type": "PubMed",
        "reference": "26671985",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.",
        "volume": "75",
        "pages": "19-34",
        "date": "2016-01-01",
        "first": "Kanaan NM",
        "last": "McKee AC",
        "authors": [
          "Alvarez VE",
          "Cox K",
          "Kanaan NM",
          "McKee AC",
          "Poncil S",
          "Stein TD"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 359,
      "target": 118,
      "key": "2d48c326e9ad2fb68b2e1bd35a6508ac1451a01da65060acb1d75437ba03cb888db04ce4d3c0e52d4ec7bced02fb1ef185e035e82e25c14c1b7966ff188c55a4"
    },
    {
      "line": 221,
      "relation": "equivalentTo",
      "evidence": "Several lines of evidence in other tauopathies suggest that tau oligomer formation induces neurotoxicity and that tau oligomer-mediated neurotoxicity involves induction of axonal dysfunction through exposure of an N-terminal motif in tau, the phosphatase-activating domain (PAD).",
      "citation": {
        "type": "PubMed",
        "reference": "26671985",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.",
        "volume": "75",
        "pages": "19-34",
        "date": "2016-01-01",
        "first": "Kanaan NM",
        "last": "McKee AC",
        "authors": [
          "Alvarez VE",
          "Cox K",
          "Kanaan NM",
          "McKee AC",
          "Poncil S",
          "Stein TD"
        ]
      },
      "source": 359,
      "target": 489,
      "key": "2e809c559c62bfa06ffb36af4f00d68356f8515a58e9c0d6d29f5495b120433c48e4b837cbd074d65b38c93626080a380f2ed9ca1230998357c91627814e6aa3"
    },
    {
      "line": 224,
      "relation": "decreases",
      "evidence": "Several lines of evidence in other tauopathies suggest that tau oligomer formation induces neurotoxicity and that tau oligomer-mediated neurotoxicity involves induction of axonal dysfunction through exposure of an N-terminal motif in tau, the phosphatase-activating domain (PAD).",
      "citation": {
        "type": "PubMed",
        "reference": "26671985",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.",
        "volume": "75",
        "pages": "19-34",
        "date": "2016-01-01",
        "first": "Kanaan NM",
        "last": "McKee AC",
        "authors": [
          "Alvarez VE",
          "Cox K",
          "Kanaan NM",
          "McKee AC",
          "Poncil S",
          "Stein TD"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 359,
      "target": 218,
      "key": "591d64163c0a5961e7a372fcdd8580ac4456ca88e5ea2789ca32a935272e7f0de013a7655aa5bea2e28423b9a42af3b3bdc1944d26fb9795ca8e119a12f91802"
    },
    {
      "line": 237,
      "relation": "biomarkerFor",
      "evidence": "We performed immunohistochemistry and immunofluorescence on fixed brain sections and biochemical analysis of fresh brain extracts to characterize the presence of PAD-exposed tau (TNT1 antibody), tau oligomers (TOC1 antibody), tau phosphorylated at S422 (pS422 antibody), and tau truncated at D421 (TauC3 antibody) in the brains of 9-11 cases with CTE and cases of nondemented aged controls and AD (Braak VI) (n = 6, each). These 4 markers are particularly useful in understanding potential posttraumatic events in CTE because PAD exposure impairs axonal transport (24), oligomers confer toxicity (28, 38–40), pS422 correlates with cognitive decline (15), and D421 truncated tau may be related to cell toxicity (41, 42). All 3 early tau markers (ie, TNT1, TOC1, and pS422) were present in CTE and displayed extensive colocalization in perivascular tau lesions that are considered diagnostic for CTE.",
      "citation": {
        "type": "PubMed",
        "reference": "26671985",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.",
        "volume": "75",
        "pages": "19-34",
        "date": "2016-01-01",
        "first": "Kanaan NM",
        "last": "McKee AC",
        "authors": [
          "Alvarez VE",
          "Cox K",
          "Kanaan NM",
          "McKee AC",
          "Poncil S",
          "Stein TD"
        ]
      },
      "annotations": {
        "Method": {
          "Immunofluorescence": true,
          "ELISA": true,
          "Immunohistochemistry": true
        },
        "Tau_Antibody": {
          "TN1": true,
          "Anti-pS422": true,
          "TauC3": true,
          "TOC1": true
        },
        "MeSHDisease": {
          "Chronic Traumatic Encephalopathy": true
        }
      },
      "source": 359,
      "target": 910,
      "key": "0c0ed84d85bec8c3111bc9ce613eb4f69316e1509c847e5d8cf77d6f13e0351c29f761168181a3e8da41cd61ef3c7b62eb483a8b2835d2241021428489391d85"
    },
    {
      "line": 240,
      "relation": "decreases",
      "evidence": "We performed immunohistochemistry and immunofluorescence on fixed brain sections and biochemical analysis of fresh brain extracts to characterize the presence of PAD-exposed tau (TNT1 antibody), tau oligomers (TOC1 antibody), tau phosphorylated at S422 (pS422 antibody), and tau truncated at D421 (TauC3 antibody) in the brains of 9-11 cases with CTE and cases of nondemented aged controls and AD (Braak VI) (n = 6, each). These 4 markers are particularly useful in understanding potential posttraumatic events in CTE because PAD exposure impairs axonal transport (24), oligomers confer toxicity (28, 38–40), pS422 correlates with cognitive decline (15), and D421 truncated tau may be related to cell toxicity (41, 42). All 3 early tau markers (ie, TNT1, TOC1, and pS422) were present in CTE and displayed extensive colocalization in perivascular tau lesions that are considered diagnostic for CTE.",
      "citation": {
        "type": "PubMed",
        "reference": "26671985",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.",
        "volume": "75",
        "pages": "19-34",
        "date": "2016-01-01",
        "first": "Kanaan NM",
        "last": "McKee AC",
        "authors": [
          "Alvarez VE",
          "Cox K",
          "Kanaan NM",
          "McKee AC",
          "Poncil S",
          "Stein TD"
        ]
      },
      "annotations": {
        "Method": {
          "Immunofluorescence": true,
          "ELISA": true,
          "Immunohistochemistry": true
        },
        "Tau_Antibody": {
          "TN1": true,
          "Anti-pS422": true,
          "TauC3": true,
          "TOC1": true
        },
        "MeSHDisease": {
          "Chronic Traumatic Encephalopathy": true
        }
      },
      "source": 359,
      "target": 175,
      "key": "8ef167c9dd506ac601d2a373fd568142bbea30bcf62ce18eb19117c329b9228f1b248a5bf0bc6d7d4efdc847f2ccf3b855b5e961cf418d2cef7f82969c78e9b6"
    },
    {
      "line": 3534,
      "relation": "association",
      "evidence": "Previously, we have shown that TNT1 is a marker of PAD exposure and that this event occurs early in the progression of Alzheimer’s disease. Establishing whether this was true for all N-terminal antibodies was important for understanding more about PAD exposure in Alzheimer’s disease. We significantly extend these findings with TNT1 and show that TNT2 behaves similarly as a marker of PAD exposure. In contrast, other N-terminal antibodies, with slightly different epitopes, do not function as pathological, PAD exposure-specific markers and recognize all forms of tau similarly. Here, we found that TNT1 and TNT2 appear in Braak I–II stages and do not colocalize with ThR in the diffuse, granular pre-tangle pathology conclusively demonstrating that PAD exposure is an early event.",
      "citation": {
        "type": "PubMed",
        "reference": "27260838",
        "name": "Neurobiology of disease",
        "title": "Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodies.",
        "volume": "94",
        "pages": "18-31",
        "date": "2016-10-01",
        "first": "Combs B",
        "last": "Kanaan NM",
        "authors": [
          "Combs B",
          "Hamel C",
          "Kanaan NM"
        ]
      },
      "annotations": {
        "Braak_Stage": {
          "Stage I": true,
          "Stage II": true
        }
      },
      "source": 359,
      "target": 328,
      "key": "fa8e385996bba28925d97b60ea456a530dbe9c7180ea6818163aca0ecbfef9b6bfc6c1ca702df41d9be755367a37cbc33ae08e42347b8ef5aa333c42090b735f"
    },
    {
      "line": 3535,
      "relation": "association",
      "evidence": "Previously, we have shown that TNT1 is a marker of PAD exposure and that this event occurs early in the progression of Alzheimer’s disease. Establishing whether this was true for all N-terminal antibodies was important for understanding more about PAD exposure in Alzheimer’s disease. We significantly extend these findings with TNT1 and show that TNT2 behaves similarly as a marker of PAD exposure. In contrast, other N-terminal antibodies, with slightly different epitopes, do not function as pathological, PAD exposure-specific markers and recognize all forms of tau similarly. Here, we found that TNT1 and TNT2 appear in Braak I–II stages and do not colocalize with ThR in the diffuse, granular pre-tangle pathology conclusively demonstrating that PAD exposure is an early event.",
      "citation": {
        "type": "PubMed",
        "reference": "27260838",
        "name": "Neurobiology of disease",
        "title": "Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodies.",
        "volume": "94",
        "pages": "18-31",
        "date": "2016-10-01",
        "first": "Combs B",
        "last": "Kanaan NM",
        "authors": [
          "Combs B",
          "Hamel C",
          "Kanaan NM"
        ]
      },
      "annotations": {
        "Braak_Stage": {
          "Stage I": true,
          "Stage II": true
        }
      },
      "source": 359,
      "target": 329,
      "key": "bbe5955b93ae893783eb6d3f5de8aeb531d35a20f377c991051c4513f18c8be7c7af84494094f006bb1a7c6da79e54d46444f0d1c28328abac1be6dd601d8367"
    },
    {
      "line": 3539,
      "relation": "positiveCorrelation",
      "evidence": "Apparent ThR-positive ghost tangles (i.e., without nuclei (Braak et al., 1994)) are no longer labeled by TNT1 or TNT2, which confirms that PAD exposure is lost in the latest stages of NFT evolution.",
      "citation": {
        "type": "PubMed",
        "reference": "27260838",
        "name": "Neurobiology of disease",
        "title": "Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodies.",
        "volume": "94",
        "pages": "18-31",
        "date": "2016-10-01",
        "first": "Combs B",
        "last": "Kanaan NM",
        "authors": [
          "Combs B",
          "Hamel C",
          "Kanaan NM"
        ]
      },
      "source": 359,
      "target": 369,
      "key": "136a819feb6e554df0f6bd5544fc81873c1f137c7f9e9be2f6992dc0854550641e13f69442906b4a3a5c9b1d272e8b82c47170de88c6114650e02601ed7c38de"
    },
    {
      "line": 3546,
      "relation": "positiveCorrelation",
      "evidence": "Aggregation-induced increases in PAD exposure and oligomerization are common features among all tau isoforms. The extent of PAD exposure and oligomerization was larger for tau aggregates composed of 4-repeat isoforms compared with those made of 3-repeat isoforms.",
      "citation": {
        "type": "PubMed",
        "reference": "27574109",
        "name": "Neurobiology of aging",
        "title": "Analysis of isoform-specific tau aggregates suggests a common toxic mechanism involving similar pathological conformations and axonal transport inhibition.",
        "volume": "47",
        "pages": "113-126",
        "date": "2016-11-01",
        "first": "Cox K",
        "last": "Kanaan NM",
        "authors": [
          "Abdelmesih B",
          "Brady ST",
          "Combs B",
          "Cox K",
          "Kanaan NM",
          "Morfini G"
        ]
      },
      "source": 359,
      "target": 307,
      "key": "03e7e9fe945fde72dc17d78a31d662a0d1a81b35b75a9e24d256ea59945d75d20e7095a9b0d10cacaa2d31e812f6680e42ac6f066d79175309abd8e6a00d58a5"
    },
    {
      "line": 3567,
      "relation": "positiveCorrelation",
      "evidence": "Highlighting the relevance of these findings to human disease, pS422 tau was found to colocalize with tau oligomers and with a fraction of tau showing increased PAD exposure in the human AD brain. This study identifies novel effects of pS422 on tau biochemical properties, including prolonged nucleation and enhanced dimer formation, which correlate with a distinct inhibitory effect on FAT.",
      "citation": {
        "type": "PubMed",
        "reference": "27373205",
        "name": "Experimental neurology",
        "title": "Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport.",
        "volume": "283",
        "pages": "318-29",
        "date": "2016-09-01",
        "first": "Tiernan CT",
        "last": "Kanaan NM",
        "authors": [
          "Brady ST",
          "Combs B",
          "Counts SE",
          "Cox K",
          "Kanaan NM",
          "Morfini G",
          "Tiernan CT"
        ]
      },
      "source": 359,
      "target": 569,
      "key": "0365bac2d8b1bacec58891ffa7d1a4ce15f96b9b9d324fb4a8569b9472452737a693b9b233c0a7a62780f3d4271d072b43170f8cf83a2da89cf3281927da2cea"
    },
    {
      "line": 3845,
      "relation": "directlyIncreases",
      "evidence": "Filamentous, but not soluble, forms of wild-type tau inhibit anterograde, kinesin-based fast axonal transport (FAT) by activating axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK3), independent of microtubule binding. Amino acids 2-18 of tau, comprising a phosphatase-activating domain (PAD), are necessary and sufficient for activation of this pathway. Various pathogenic forms of tau displaying increased exposure of PAD inhibited anterograde FAT in squid axoplasm. Immunohistochemical studies using a novel PAD-specific monoclonal antibody in human postmortem tissue indicated that increased PAD exposure represents an early pathogenic event in AD that closely associates in time with AT8 immunoreactivity. We propose a model of pathogenesis in which disease-associated changes in tau conformation lead to increased exposure of PAD, activation of PP1-GSK3, and inhibition of FAT",
      "citation": {
        "type": "PubMed",
        "reference": "21734277",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "volume": "31",
        "pages": "9858-68",
        "date": "2011-07-06",
        "first": "Kanaan NM",
        "last": "Binder LI",
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 359,
      "target": 652,
      "key": "d7010e998d00ae5562894157af60c496c975427260dd9b74d78ee408cf54c538180d78f0f5d0498e93cfb07b1442e513fa777ce44cf98dff18177066d2ad9ed1"
    },
    {
      "line": 221,
      "relation": "equivalentTo",
      "evidence": "Several lines of evidence in other tauopathies suggest that tau oligomer formation induces neurotoxicity and that tau oligomer-mediated neurotoxicity involves induction of axonal dysfunction through exposure of an N-terminal motif in tau, the phosphatase-activating domain (PAD).",
      "citation": {
        "type": "PubMed",
        "reference": "26671985",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.",
        "volume": "75",
        "pages": "19-34",
        "date": "2016-01-01",
        "first": "Kanaan NM",
        "last": "McKee AC",
        "authors": [
          "Alvarez VE",
          "Cox K",
          "Kanaan NM",
          "McKee AC",
          "Poncil S",
          "Stein TD"
        ]
      },
      "source": 489,
      "target": 359,
      "key": "81679d02f5de1cedc784788579b5e8e662384e62aa6355bea6cf8304b26bb99c6d16959a1a367b7b5c12a949817cce55a02f8d04b6983ee330140f4376e4013d"
    },
    {
      "line": 222,
      "relation": "partOf",
      "evidence": "Several lines of evidence in other tauopathies suggest that tau oligomer formation induces neurotoxicity and that tau oligomer-mediated neurotoxicity involves induction of axonal dysfunction through exposure of an N-terminal motif in tau, the phosphatase-activating domain (PAD).",
      "citation": {
        "type": "PubMed",
        "reference": "26671985",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.",
        "volume": "75",
        "pages": "19-34",
        "date": "2016-01-01",
        "first": "Kanaan NM",
        "last": "McKee AC",
        "authors": [
          "Alvarez VE",
          "Cox K",
          "Kanaan NM",
          "McKee AC",
          "Poncil S",
          "Stein TD"
        ]
      },
      "source": 489,
      "target": 487,
      "key": "8bf7c0fcba0bf0d875c5cd22982ebb5c6bed7c3fef60757a06265a2a24d31b119d4737f63633fc1de4536adad427250f42609a84eaa937b909690867883825b7"
    },
    {
      "line": 3077,
      "relation": "positiveCorrelation",
      "evidence": "We also tested for ac-tau 280 in early stage Alzheimer's disease (Braak stage 1). Histopathological examination using the ac tau 280 antibody was performed in three Alzheimer's cases and three CTE patients. Presence of ac-tau 280 was confirmed in all cases at early sites of disease manifestation. These findings suggest that tau acetylation may precede tau phosphorylation and could be the first ",
      "citation": {
        "type": "PubMed",
        "reference": "29276758",
        "name": "Journal of neurology and neurosurgery",
        "title": "Role of Tau Acetylation in Alzheimer's Disease and Chronic Traumatic Encephalopathy: The Way Forward for Successful Treatment.",
        "volume": "4",
        "date": "2017-01-01",
        "first": "Lucke-Wold B",
        "last": "Ross J",
        "authors": [
          "Lucke-Wold B",
          "Nolan R",
          "Omalu B",
          "Ornstein M",
          "Rosen C",
          "Ross J",
          "Seidel K",
          "Udo R"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Chronic Traumatic Encephalopathy": true
        }
      },
      "source": 910,
      "target": 498,
      "key": "417305002abf02f3c879b95f8713f39a10cdbfacdeb114f3b43cc79152b6f6ebda000fb4ab190eefb88b74224d08d87114d6bc978b0cb4f1ec667a928865dc8d"
    },
    {
      "line": 239,
      "relation": "biomarkerFor",
      "evidence": "We performed immunohistochemistry and immunofluorescence on fixed brain sections and biochemical analysis of fresh brain extracts to characterize the presence of PAD-exposed tau (TNT1 antibody), tau oligomers (TOC1 antibody), tau phosphorylated at S422 (pS422 antibody), and tau truncated at D421 (TauC3 antibody) in the brains of 9-11 cases with CTE and cases of nondemented aged controls and AD (Braak VI) (n = 6, each). These 4 markers are particularly useful in understanding potential posttraumatic events in CTE because PAD exposure impairs axonal transport (24), oligomers confer toxicity (28, 38–40), pS422 correlates with cognitive decline (15), and D421 truncated tau may be related to cell toxicity (41, 42). All 3 early tau markers (ie, TNT1, TOC1, and pS422) were present in CTE and displayed extensive colocalization in perivascular tau lesions that are considered diagnostic for CTE.",
      "citation": {
        "type": "PubMed",
        "reference": "26671985",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.",
        "volume": "75",
        "pages": "19-34",
        "date": "2016-01-01",
        "first": "Kanaan NM",
        "last": "McKee AC",
        "authors": [
          "Alvarez VE",
          "Cox K",
          "Kanaan NM",
          "McKee AC",
          "Poncil S",
          "Stein TD"
        ]
      },
      "annotations": {
        "Method": {
          "Immunofluorescence": true,
          "ELISA": true,
          "Immunohistochemistry": true
        },
        "Tau_Antibody": {
          "TN1": true,
          "Anti-pS422": true,
          "TauC3": true,
          "TOC1": true
        },
        "MeSHDisease": {
          "Chronic Traumatic Encephalopathy": true
        }
      },
      "source": 569,
      "target": 910,
      "key": "fd415d691e6b00151cdda7d2c3b8d006ddcdd2469c1a335de0dfa7c946d6d783cbbfc59b15ad03572caf361bcc81ceb578a16bf1d3b7b0d654bd04271ba79e18"
    },
    {
      "line": 242,
      "relation": "increases",
      "evidence": "We performed immunohistochemistry and immunofluorescence on fixed brain sections and biochemical analysis of fresh brain extracts to characterize the presence of PAD-exposed tau (TNT1 antibody), tau oligomers (TOC1 antibody), tau phosphorylated at S422 (pS422 antibody), and tau truncated at D421 (TauC3 antibody) in the brains of 9-11 cases with CTE and cases of nondemented aged controls and AD (Braak VI) (n = 6, each). These 4 markers are particularly useful in understanding potential posttraumatic events in CTE because PAD exposure impairs axonal transport (24), oligomers confer toxicity (28, 38–40), pS422 correlates with cognitive decline (15), and D421 truncated tau may be related to cell toxicity (41, 42). All 3 early tau markers (ie, TNT1, TOC1, and pS422) were present in CTE and displayed extensive colocalization in perivascular tau lesions that are considered diagnostic for CTE.",
      "citation": {
        "type": "PubMed",
        "reference": "26671985",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.",
        "volume": "75",
        "pages": "19-34",
        "date": "2016-01-01",
        "first": "Kanaan NM",
        "last": "McKee AC",
        "authors": [
          "Alvarez VE",
          "Cox K",
          "Kanaan NM",
          "McKee AC",
          "Poncil S",
          "Stein TD"
        ]
      },
      "annotations": {
        "Method": {
          "Immunofluorescence": true,
          "ELISA": true,
          "Immunohistochemistry": true
        },
        "Tau_Antibody": {
          "TN1": true,
          "Anti-pS422": true,
          "TauC3": true,
          "TOC1": true
        },
        "MeSHDisease": {
          "Chronic Traumatic Encephalopathy": true
        }
      },
      "source": 569,
      "target": 911,
      "key": "a5f271ae33ec1b913b5c391e632963d829b45ce5bb5624952dceb4d236699efce1abf0b44de658a95db19aae6b26c2f4d72a867eb905ceae3d22866c01dbcc7b"
    },
    {
      "line": 1128,
      "relation": "positiveCorrelation",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 569,
      "target": 299,
      "key": "44cf457f153eae95954d19878dbe72dd693db6d8c23ce76b1ab8157ad05970d9281d04ca47fce63d8b97708210ccac3710687d192ea0055395cc0f6d576e46a9"
    },
    {
      "line": 1302,
      "relation": "partOf",
      "evidence": "The pSer422 antibody displayed an almost identical pattern to that of AT8, in that it stained NFTs (Figure 5A–D), neuropil threads and neuritic plaques (Figure 5E–H)",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "source": 569,
      "target": 81,
      "key": "07f95dfb27e1a3bbb590863f851d532bc565da71862e0ca64365a19edb0902b4948be5739b6ca88acf7e5b3021130eeb070f984bb819270f8d50c8dc00187b5a"
    },
    {
      "line": 1303,
      "relation": "partOf",
      "evidence": "The pSer422 antibody displayed an almost identical pattern to that of AT8, in that it stained NFTs (Figure 5A–D), neuropil threads and neuritic plaques (Figure 5E–H)",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "source": 569,
      "target": 164,
      "key": "a2b8deda46608ce11055808b455c1be7c5f5d75c2e1dfd052ea209395381eae0ae982afa1e8dc3311b9a716fe92930ec399b2c2b8737aa39e7db2799b57526ae"
    },
    {
      "line": 1304,
      "relation": "partOf",
      "evidence": "The pSer422 antibody displayed an almost identical pattern to that of AT8, in that it stained NFTs (Figure 5A–D), neuropil threads and neuritic plaques (Figure 5E–H)",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "source": 569,
      "target": 917,
      "key": "22cfd39b7b0b94849a0606abec71101905b2757e81568950857198bc3bc0c2687ad4b2c7b8c49ac0f9e1b1286c1267335be0f25c895d164fae8391fef2c3bd4e"
    },
    {
      "line": 1310,
      "relation": "association",
      "evidence": "These data suggest a role for TTBK1 in pre-tangle formation prior to the formation of fibrillar tau and strengthen the idea that tau is phosphorylated at Ser422 at an early intermediate stage in NFT formation.",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "source": 569,
      "target": 158,
      "key": "6c1d77628f70c7e470ba8482f2fbf005528e92e05272b3da401e034a2108486264b573bdbc7b907853e3b0a89c0ed5d36fdb53a29013f39add7cf7b966ae638a"
    },
    {
      "line": 1529,
      "relation": "partOf",
      "evidence": "Finally, phosphorylation of S422 in tau, as recognisedby antibody AP422, was generated most e¤ciently by SAPK3/p38gamma, SAPK4/p38delta and SAPK2b/p38beta",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Enzyme_Acitvity": {
          "1 U/ml": true
        }
      },
      "source": 569,
      "target": 333,
      "key": "dd494c25575b9771b75a1f81990f411a5313410632f67b5db4738a1925ba9de701eafc737bdad7e14133229d4e2f1b8d2e9c3c17cdbd4636f43006553c2f1282"
    },
    {
      "line": 1606,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 569,
      "target": 908,
      "key": "9e038f859f08b66e225fc8f67f3f20182519d38ba090cabad0fd87c5902996aad8e21ad8c176ca448633ff6a46f6d51efe9a8689bc37b4c2d48f72a06a47757e"
    },
    {
      "line": 1728,
      "relation": "partOf",
      "evidence": "A quite different strategy is to target tau clearance—e.g., by rapamycin that induces macroautophagy [175], inhibitors of Hsp90 chaperone protein that binds to misfolded proteins or by immunotherapeutic approaches [176].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 569,
      "target": 325,
      "key": "13a4ee00013a50b8ec6c291ef3fb12911cd74881e19359c16342c18bc9f831ffd5706571cfab135256baffa9729f4f6d69acc3e2ededf06369d45b604f95c99d"
    },
    {
      "line": 2335,
      "relation": "negativeCorrelation",
      "evidence": "Endogenous miR-195 was knocked down using over-expression of its antisense molecule (pre-AMO-miR-195) via a lentivirus (lenti-pre-AMO-miR-195); this knockdown increased the tau phosphorylation at Ser202/Thr205, Ser262, Thr231, Ser422, and the Cdk5/p25 activation, but over-expression of miR-195 using lenti-pre-miR-195 decreased the tau phosphorylation and Cdk5/p25 activation.",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 569,
      "target": 264,
      "key": "56c571bbfb9fb0366ac6435e74450fa9d07e07de3087c68a44b0367fde318a380a9c08096e0720885ad964b5d8e192b4fdd09d949241384cf246a71a294ae835"
    },
    {
      "line": 2545,
      "relation": "positiveCorrelation",
      "evidence": "We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia. In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes. Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3α/β at tyrosine 279/216 also showed an intense rather than moderate AT8 (phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with fibrillar tau pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "23294633",
        "name": "Neurobiology of aging",
        "title": "Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.",
        "volume": "34",
        "pages": "1369-79",
        "date": "2013-05-01",
        "first": "Köhler C",
        "last": "Götz J",
        "authors": [
          "Dinekov M",
          "Götz J",
          "Köhler C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "pR5 mice": true
        }
      },
      "source": 569,
      "target": 625,
      "key": "bfef79ea31f1dd48fa4674691fca6b9bed57032242d344960cf93a45ebcee3af1bcba0ec962c90e5f1105e1b40d57baf6c64338338e9848504c34a175f312940"
    },
    {
      "line": 3567,
      "relation": "positiveCorrelation",
      "evidence": "Highlighting the relevance of these findings to human disease, pS422 tau was found to colocalize with tau oligomers and with a fraction of tau showing increased PAD exposure in the human AD brain. This study identifies novel effects of pS422 on tau biochemical properties, including prolonged nucleation and enhanced dimer formation, which correlate with a distinct inhibitory effect on FAT.",
      "citation": {
        "type": "PubMed",
        "reference": "27373205",
        "name": "Experimental neurology",
        "title": "Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport.",
        "volume": "283",
        "pages": "318-29",
        "date": "2016-09-01",
        "first": "Tiernan CT",
        "last": "Kanaan NM",
        "authors": [
          "Brady ST",
          "Combs B",
          "Counts SE",
          "Cox K",
          "Kanaan NM",
          "Morfini G",
          "Tiernan CT"
        ]
      },
      "source": 569,
      "target": 359,
      "key": "4b955247f0af27016a5951a47f30424c4f403f539b12e12ca73d4e5134da12c8515b3aa8c7d87f62979aeb7fa513a0a2dd5a538fdb0d197efeace023ceffe3cd"
    },
    {
      "line": 3568,
      "relation": "positiveCorrelation",
      "evidence": "Highlighting the relevance of these findings to human disease, pS422 tau was found to colocalize with tau oligomers and with a fraction of tau showing increased PAD exposure in the human AD brain. This study identifies novel effects of pS422 on tau biochemical properties, including prolonged nucleation and enhanced dimer formation, which correlate with a distinct inhibitory effect on FAT.",
      "citation": {
        "type": "PubMed",
        "reference": "27373205",
        "name": "Experimental neurology",
        "title": "Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport.",
        "volume": "283",
        "pages": "318-29",
        "date": "2016-09-01",
        "first": "Tiernan CT",
        "last": "Kanaan NM",
        "authors": [
          "Brady ST",
          "Combs B",
          "Counts SE",
          "Cox K",
          "Kanaan NM",
          "Morfini G",
          "Tiernan CT"
        ]
      },
      "source": 569,
      "target": 331,
      "key": "8276b038ad71accc311e20d2c183a54192f264ef09f80a1ec0e26b8cd55bb328b467090b94b73d64082bac51fe8174c203633c3d960624596c017b677495de4a"
    },
    {
      "line": 3569,
      "relation": "decreases",
      "evidence": "Highlighting the relevance of these findings to human disease, pS422 tau was found to colocalize with tau oligomers and with a fraction of tau showing increased PAD exposure in the human AD brain. This study identifies novel effects of pS422 on tau biochemical properties, including prolonged nucleation and enhanced dimer formation, which correlate with a distinct inhibitory effect on FAT.",
      "citation": {
        "type": "PubMed",
        "reference": "27373205",
        "name": "Experimental neurology",
        "title": "Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport.",
        "volume": "283",
        "pages": "318-29",
        "date": "2016-09-01",
        "first": "Tiernan CT",
        "last": "Kanaan NM",
        "authors": [
          "Brady ST",
          "Combs B",
          "Counts SE",
          "Cox K",
          "Kanaan NM",
          "Morfini G",
          "Tiernan CT"
        ]
      },
      "source": 569,
      "target": 173,
      "key": "5ba5f4ef4fc652d96acf484323444dadb4e11de1cca01d34543bdfa01c5337090f0536cf275abf6f09f5f2301f5181576923d0302fce9017e9964aed3baf7b93"
    },
    {
      "line": 3852,
      "relation": "negativeCorrelation",
      "evidence": "Filamentous, but not soluble, forms of wild-type tau inhibit anterograde, kinesin-based fast axonal transport (FAT) by activating axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK3), independent of microtubule binding. Amino acids 2-18 of tau, comprising a phosphatase-activating domain (PAD), are necessary and sufficient for activation of this pathway. Various pathogenic forms of tau displaying increased exposure of PAD inhibited anterograde FAT in squid axoplasm. Immunohistochemical studies using a novel PAD-specific monoclonal antibody in human postmortem tissue indicated that increased PAD exposure represents an early pathogenic event in AD that closely associates in time with AT8 immunoreactivity. We propose a model of pathogenesis in which disease-associated changes in tau conformation lead to increased exposure of PAD, activation of PP1-GSK3, and inhibition of FAT",
      "citation": {
        "type": "PubMed",
        "reference": "21734277",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "volume": "31",
        "pages": "9858-68",
        "date": "2011-07-06",
        "first": "Kanaan NM",
        "last": "Binder LI",
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 175,
      "target": 652,
      "key": "01c8d2e0bf23b3155145823ee21661efea3324d834093d9daad351be278ad78208ff148121a51d487b91de1caec76620a4d6beecf4246650f08e12de8159a51c"
    },
    {
      "line": 241,
      "relation": "positiveCorrelation",
      "evidence": "We performed immunohistochemistry and immunofluorescence on fixed brain sections and biochemical analysis of fresh brain extracts to characterize the presence of PAD-exposed tau (TNT1 antibody), tau oligomers (TOC1 antibody), tau phosphorylated at S422 (pS422 antibody), and tau truncated at D421 (TauC3 antibody) in the brains of 9-11 cases with CTE and cases of nondemented aged controls and AD (Braak VI) (n = 6, each). These 4 markers are particularly useful in understanding potential posttraumatic events in CTE because PAD exposure impairs axonal transport (24), oligomers confer toxicity (28, 38–40), pS422 correlates with cognitive decline (15), and D421 truncated tau may be related to cell toxicity (41, 42). All 3 early tau markers (ie, TNT1, TOC1, and pS422) were present in CTE and displayed extensive colocalization in perivascular tau lesions that are considered diagnostic for CTE.",
      "citation": {
        "type": "PubMed",
        "reference": "26671985",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.",
        "volume": "75",
        "pages": "19-34",
        "date": "2016-01-01",
        "first": "Kanaan NM",
        "last": "McKee AC",
        "authors": [
          "Alvarez VE",
          "Cox K",
          "Kanaan NM",
          "McKee AC",
          "Poncil S",
          "Stein TD"
        ]
      },
      "annotations": {
        "Method": {
          "Immunofluorescence": true,
          "ELISA": true,
          "Immunohistochemistry": true
        },
        "Tau_Antibody": {
          "TN1": true,
          "Anti-pS422": true,
          "TauC3": true,
          "TOC1": true
        },
        "MeSHDisease": {
          "Chronic Traumatic Encephalopathy": true
        }
      },
      "source": 368,
      "target": 604,
      "key": "e940f0e08506ca75eddfc00fb5854f57dbeec24c986438f7cdad8a75d966793fb4ae9d6ee99c3af527274d69aeab195c438194db9af98e528259e97b3bda93a0"
    },
    {
      "line": 3632,
      "relation": "positiveCorrelation",
      "evidence": "The genotype distribution of a polymorphism in intron 7 (rs761059) differed between AD cases and controls, with an adjusted odds ratio (OR) of 1.45 (p=0.046, 95% CI: 1.01-2.08). One haplotype (ht2 CAGAG) was found in 14.0% of the AD patients and in 11.1% of the controls (p=0.04, OR=1.43. 95% CI; 1.01-2.01). Stratification by the ApoE gave no significant difference between the groups but when stratified by gender, two SNPs (rs8052688, rs8063) were significantly associated with the risk of MCI among women.",
      "citation": {
        "type": "PubMed",
        "reference": "19765634",
        "name": "Neuroscience letters",
        "title": "Ubc9 gene polymorphisms and late-onset Alzheimer's disease in the Korean population: a genetic association study.",
        "volume": "465",
        "pages": "272-5",
        "date": "2009-11-20",
        "first": "Ahn K",
        "last": "Koh YH",
        "authors": [
          "Ahn K",
          "Jo SA",
          "Kim DK",
          "Koh YH",
          "Park MH",
          "Song JH"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Korean population": true
        },
        "Gender": {
          "Female": true
        }
      },
      "source": 911,
      "target": 256,
      "key": "a4f2a337655cc08daee0f8042c2ad3345fd082cb247819decd44de53d654e9562675451da9f46e8ff150eb74be75d81a9fdcb9b8ed6cc57583ac4f771722a5c5"
    },
    {
      "line": 3633,
      "relation": "positiveCorrelation",
      "evidence": "The genotype distribution of a polymorphism in intron 7 (rs761059) differed between AD cases and controls, with an adjusted odds ratio (OR) of 1.45 (p=0.046, 95% CI: 1.01-2.08). One haplotype (ht2 CAGAG) was found in 14.0% of the AD patients and in 11.1% of the controls (p=0.04, OR=1.43. 95% CI; 1.01-2.01). Stratification by the ApoE gave no significant difference between the groups but when stratified by gender, two SNPs (rs8052688, rs8063) were significantly associated with the risk of MCI among women.",
      "citation": {
        "type": "PubMed",
        "reference": "19765634",
        "name": "Neuroscience letters",
        "title": "Ubc9 gene polymorphisms and late-onset Alzheimer's disease in the Korean population: a genetic association study.",
        "volume": "465",
        "pages": "272-5",
        "date": "2009-11-20",
        "first": "Ahn K",
        "last": "Koh YH",
        "authors": [
          "Ahn K",
          "Jo SA",
          "Kim DK",
          "Koh YH",
          "Park MH",
          "Song JH"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Korean population": true
        },
        "Gender": {
          "Female": true
        }
      },
      "source": 911,
      "target": 257,
      "key": "ab179eb095a2038a190f79e029ede6d4537a1bef2898fdbf457a89ee388f0e2e8b4b0a3afc5f32e31f8a4a0ead96b7f8db7d807be63648747384e3d535f2b938"
    },
    {
      "line": 256,
      "relation": "association",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        },
        "Tau_Motif": {
          "PHF6": true
        }
      },
      "source": 536,
      "target": 486,
      "key": "0744be66d29fb2dea1851ea249b05b8bbb0d7437c947b4dd9898e83b1df49ae9ed5481587cb02005f1d535c9b857c3e31ce4ee60f97eac5146381cf8ce15e52c"
    },
    {
      "line": 259,
      "relation": "association",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        },
        "Tau_Motif": {
          "KXGS": true
        }
      },
      "source": 530,
      "target": 486,
      "key": "9f6ca7cc2e5fee6f92477341bd432e4ad7f1b976fc9473cf6122bda9255a6901bb449d59ff54e02cb39ed21e21b52252ed06b47b84e0193f77651f644fb47c14"
    },
    {
      "line": 274,
      "relation": "isA",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        }
      },
      "source": 530,
      "target": 523,
      "key": "bbb5afac27d421c43d1ce5a5b8bbff13907aed2c7dc3fddfa87c5514d052742f5d564d74342dd313b9d8d311820987fbb1361b237db0a2bb7059a6c5dc1a5e14"
    },
    {
      "line": 260,
      "relation": "association",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        },
        "Tau_Motif": {
          "KXGS": true
        }
      },
      "source": 532,
      "target": 486,
      "key": "f8b8bf408536a8f817d42137a9f06aaa23c87965b3d8337f4e7ef6b47e459454e9c658f08634fd0fb1ee9aa1350b1b12a629b0c1af3eef02728275c1d2bc76d8"
    },
    {
      "line": 307,
      "relation": "association",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        }
      },
      "source": 532,
      "target": 486,
      "key": "c679d9a2643eeb2dfbce6f7c2b617b5a3bbd4eff8dfa0b27526546b0150bec938056bf13f5e0b75039a34a5315bbb01d74d50f8a1aa8ac7d3f891036712d142b"
    },
    {
      "line": 275,
      "relation": "isA",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        }
      },
      "source": 532,
      "target": 523,
      "key": "a82397f973a6dc3cc57e37c68a25184d22185cfd2b51dfcbe93af56006b01843bfaccb5eaa2d98d811bee539ed9ba0f86a2404775079edf4b640256f2e9f9746"
    },
    {
      "line": 310,
      "relation": "partOf",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        }
      },
      "source": 532,
      "target": 363,
      "key": "9c7fb6cd8d3f52ae2e34eb7e1d868fd269dfb5a33130f7353433639c22b44a6374a8664201aa8de7769d0325a83f1716214a1fedf573805f519c76368bbf0262"
    },
    {
      "line": 261,
      "relation": "association",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        },
        "Tau_Motif": {
          "KXGS": true
        }
      },
      "source": 533,
      "target": 486,
      "key": "d57be1f74b4154622f028c793eac8729cc60a1a3ae023756c27a0b5e8ace4da86f805a67b9ce9ac7f371a6c0b0997efe57815c02134ebcf8379c309117337831"
    },
    {
      "line": 276,
      "relation": "isA",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        }
      },
      "source": 533,
      "target": 523,
      "key": "4af6618c38d6a3b6ff7d4455f7c40a1d8350d8a0ebe88d6698d03296676054f8045611453511589ac855beca76cd77cd3d031e3874b91746dd44411b25778253"
    },
    {
      "line": 264,
      "relation": "association",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 528,
      "target": 486,
      "key": "d151d1ccaaedbdc0734943986d40425c2e1f791063f8d70a461d345b2c9106523906e83f90def8c30e6dc93015e319ddb4cdf9c08e23875cbe6e80b59d846397"
    },
    {
      "line": 270,
      "relation": "isA",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        }
      },
      "source": 528,
      "target": 523,
      "key": "17d86157feb54fab6cd71a52513a2379da65c8598f22f1743d0e0a6585c048e1a852b463c2b422120a1682f621731eb383e203f87edf090a733e9cb442967813"
    },
    {
      "line": 265,
      "relation": "association",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 534,
      "target": 486,
      "key": "8f2c63ace914a50400bfb1da4b3d5061fa9b5960d7cd63b9b1ed396ea3e251fb6ea5bc1e292fb07aa2c83d8931ead0d2cf0032179c1d1f502cae57224a4c8987"
    },
    {
      "line": 271,
      "relation": "isA",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        }
      },
      "source": 534,
      "target": 523,
      "key": "b954d82f14b78370a53f760407d1d03c0218c4d04fc3bd62eedc9e4575b8c3ddae77b1f267a63999b8834dff4d8e8326823145689badb9f61bc9458e25c4c102"
    },
    {
      "line": 266,
      "relation": "association",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 535,
      "target": 486,
      "key": "ca7c25e8c1a383f568171bc7ec0dec76c50bfa279453799b4655675adc867e0fa5e4aa9153f3c42c7c07d374c209f83ba882a9c415fe3c9f8b55f62f6db1bde4"
    },
    {
      "line": 272,
      "relation": "isA",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        }
      },
      "source": 535,
      "target": 523,
      "key": "35a15072fb5e33a8b638c2f68ecdc54cdab625462929b2d8a79ff62eb392ce71dc4a3e13c22aa59dde42edab690fadff0aacc24fabdc35fbeb3a9723fc7446a2"
    },
    {
      "line": 267,
      "relation": "association",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 527,
      "target": 486,
      "key": "7fc5a68d77f559abf4e68694b32c2851edf91f6ed55dc4836503937cd755334d7240cbf1a2fdfdbe05026b5e29100422bbb28f6d4c32e49215713b313fca091a"
    },
    {
      "line": 273,
      "relation": "isA",
      "evidence": "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        }
      },
      "source": 527,
      "target": 523,
      "key": "a291ad25821fb33ee4582d36da76b6d7830b4c822023f41495b43157820c6d1299e771dabb0e718248e916cd7355d9e0ce41bcbdf36326e87a38ee9502a157e8"
    },
    {
      "line": 280,
      "relation": "decreases",
      "evidence": "These data indicate that Lys methylation depressed the intrinsic aggregation propensity of tau, and did so in part by increasing the concentration of tau needed to support fibril formation.",
      "citation": {
        "type": "PubMed",
        "reference": "24869773",
        "name": "The Biochemical journal",
        "title": "Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.",
        "volume": "462",
        "pages": "77-88",
        "date": "2014-08-15",
        "first": "Funk KE",
        "last": "Kuret J",
        "authors": [
          "Clark DJ",
          "Cooper GL",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Schafer KN",
          "Thomas SN",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Tubulin polymerization assay, light scattering method": true,
          "Liquid Chromatography": true,
          "CD Spectroscopy": true,
          "Tau aggregation assay": true,
          "Mass Spectrometry": true
        }
      },
      "source": 523,
      "target": 112,
      "key": "ce8a3576703cde27f777fd57c4a3f13fe9202fab0be6e801bfc8aca41fab869bd23c1f3d75a417b0552740a29569e713a2d2a6ef56612c751a56a68f34422f88"
    },
    {
      "line": 1698,
      "relation": "positiveCorrelation",
      "evidence": "The most recent data obtained indicate that tau pathology indeed may be induced and propagated after the injection of tau oligomers or aggregates in either wild-type or mutated MAPT transgenic mice [164], and that tau aggregates can be transferred from cell to cell in vitro [164,165] and in vivo [166,167].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          }
        }
      },
      "source": 112,
      "target": 112,
      "key": "7bf73cfa375cdaae4779c9a7cddf579df588fe8a40788c7833fda2543e708ca209b48a20b819ad597a2cd423d20dbe4fd1cc164a49a507b152602901200e0fed"
    },
    {
      "line": 1698,
      "relation": "positiveCorrelation",
      "evidence": "The most recent data obtained indicate that tau pathology indeed may be induced and propagated after the injection of tau oligomers or aggregates in either wild-type or mutated MAPT transgenic mice [164], and that tau aggregates can be transferred from cell to cell in vitro [164,165] and in vivo [166,167].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "subject": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          }
        }
      },
      "source": 112,
      "target": 112,
      "key": "ac3cd0fc8ff4b1bfab6b7dff54908d1c9506b0ffbeebec17b5fe7595498f6bbb514147a6ed1cb0df737b0d41d7500818e375cd39fb7c651adc4d233f614218c8"
    },
    {
      "line": 2429,
      "relation": "positiveCorrelation",
      "evidence": "CRF-OE mice had significantly elevated tau-P compared to wild type (WT) mice at the AT8 (S202/T204), PHF-1 (S396/404), S262, and S422 sites. Treating CRF-OE mice with R121919 blocked phosphorylation at the AT8 (S202/T204) and PHF-1 (S396/404) sites, but not at the S262 and S422 sites and reduced phosphorylation of c-Jun N Terminal Kinase (JNK).",
      "citation": {
        "type": "PubMed",
        "reference": "25125464",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.",
        "volume": "43",
        "pages": "967-76",
        "date": "2015-01-01",
        "first": "Campbell SN",
        "last": "Rissman RA",
        "authors": [
          "Campbell SN",
          "Masliah E",
          "Monte L",
          "Rice KC",
          "Rissman RA",
          "Roe AD",
          "Taché Y",
          "Zhang C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 112,
      "target": 780,
      "key": "77e8c412c8dc917a63e5dcfc1f1a15993e53d3baa11ca7e9cd64d66dcaf0c3c412b7fd07d451eef22248b78057eebea8457298efe84860c1c08391ee52423ff7"
    },
    {
      "line": 295,
      "relation": "association",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 524,
      "target": 486,
      "key": "942a9f7a4547509f2326c136471a1c80d7c9ccb4e63f8c2364d46e8f366aabe5a4a19a5a1838b9a82ea33649830c3de1ab62261e62bbfd866fa232c0ab593e35"
    },
    {
      "line": 296,
      "relation": "partOf",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 524,
      "target": 135,
      "key": "5885c8d081084473862543e953820bd191f1a2b9865423db5c26b4a64f2e9bd3631349364f14ac8824fd2abfc0a73a536c622a5dae27d0de8f4c16c14f9e3c81"
    },
    {
      "line": 301,
      "relation": "association",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 135,
      "target": 281,
      "key": "ce579c6aa5d14358c37a492cd9c43bc855aff93906d8f86b119536f7877c1ee1f091b0c6ea9c8c8204a4d848aecb9ec9825831afe4c385164f74dbd1049883e1"
    },
    {
      "line": 302,
      "relation": "association",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 135,
      "target": 761,
      "key": "931479c6c6a184d7653e95df22aabdb8961adcbb3116631444fcbec704ebb0adbd95ea34fcf5482eed716f669673dce65c409f41e44f193183abf60f67a7ae13"
    },
    {
      "line": 297,
      "relation": "association",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 525,
      "target": 486,
      "key": "46273b2b8148a154cd221a6fa22f35642b828d9ee75d63756c6c21099577ef67a87b6342d65686d179266b1537f9e041e308ff14e0a44df51d0e6894ff6fc115"
    },
    {
      "line": 298,
      "relation": "partOf",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 525,
      "target": 135,
      "key": "be6aa95e14d10df8252e54dba1fc95955c26663b32b6373c58814a1f3a144fadd1f47030156881f6f3e39ac7c2651f6f1345af9040087cecf2d308ea57fbfe3d"
    },
    {
      "line": 299,
      "relation": "association",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 526,
      "target": 486,
      "key": "cc84bfb9200f012fde8f30fe62587958d55cca1ff8179e30eb5da1df9076b9dfbf1e37d6aac3fc795b98c853dd17137ad891909d66aef7b690488fd8c6477603"
    },
    {
      "line": 300,
      "relation": "partOf",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 526,
      "target": 135,
      "key": "2a0f83151aa5d98dc0a58f17544398ca0392de626f4568a00e8bb49a59c798ec3e8559c32910505d1c26760bfd699124f19cd70ac02ef6737cabe9bde81c64a6"
    },
    {
      "line": 301,
      "relation": "association",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 281,
      "target": 135,
      "key": "8e324d49de64b9b324af95d3ef8207db453ebc7d87697647380e59d4738f15c108c9e5fcf28d89cf15ca0b0a8c959098374c6479ccf1549062d278a86a7ef416"
    },
    {
      "line": 302,
      "relation": "association",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "projection domain": true
        }
      },
      "source": 761,
      "target": 135,
      "key": "dd96938df0a6ca11d5e24e2ab0f1456e6d7a657264c5e2fbc903ce87cc829733afec6f3504b79d88f8466665d23dbf36d73b4c6896dfc8ed42473f9e3262dbe8"
    },
    {
      "line": 304,
      "relation": "association",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        }
      },
      "source": 529,
      "target": 486,
      "key": "eb6c7147a4002286070a88b86a3eab4b94b750a6f78e36505dfa762326df601d1c19e7a32f5420a34b842d60774cfc1a7b06a7af91c3c5bcbcaef16bfd195f5a"
    },
    {
      "line": 308,
      "relation": "partOf",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        }
      },
      "source": 529,
      "target": 362,
      "key": "04acfc6051fade2f9b7cd7d43e227e20d6ee07353b3dab224c7d04552bb495bfbfddd618a5408e1f71a6a8221dc16fbd9c2b4bb9aef01c86b31ff691a31e7595"
    },
    {
      "line": 305,
      "relation": "association",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        }
      },
      "source": 595,
      "target": 486,
      "key": "3c41fd74b4946e0ab4966bda16dd18c96a92d338e9ed3d59f696a62e1ad9badb195ede0521c7cb07c52109175b28deb0897e7d10514a95c6e608a89975e96212"
    },
    {
      "line": 3518,
      "relation": "positiveCorrelation",
      "evidence": "Ubiquitination occurs at lysines (K254, K257 K311) in repeat domain; participates in triage process",
      "citation": {
        "type": "PubMed",
        "reference": "8391280",
        "name": "Neuron",
        "title": "Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments.",
        "volume": "10",
        "pages": "1151-60",
        "date": "1993-06-01",
        "first": "Morishima-Kawashima M",
        "last": "Ihara Y",
        "authors": [
          "Hasegawa M",
          "Ihara Y",
          "Morishima-Kawashima M",
          "Suzuki M",
          "Takio K",
          "Titani K"
        ]
      },
      "source": 595,
      "target": 132,
      "key": "74a87d18c96d8b7ab3f02521fe3a50206f7b0d790c32f67d18e99e1d11a6bd4176b2e69d1d5f3b9475946ff2d6524bcdc0e42ca961799bc7869679a623ef31f2"
    },
    {
      "line": 306,
      "relation": "association",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        }
      },
      "source": 531,
      "target": 486,
      "key": "8ed0324ddb30f81a9c50b925fd2cea28124468ada4dd027518316b682ead5a24f5192dc5cc8e4d6049eb28e4a019ddf21772ba8cccb93d0b201fb0948eaa1286"
    },
    {
      "line": 309,
      "relation": "partOf",
      "evidence": "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180) reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and phospholipase Cc [54]. In contrast, K254, K267, and K290 are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative methylation and ubiquitylation of K254.",
      "citation": {
        "type": "PubMed",
        "reference": "22033876",
        "name": "Acta neuropathologica",
        "title": "Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.",
        "volume": "123",
        "pages": "105-17",
        "date": "2012-01-01",
        "first": "Thomas SN",
        "last": "Yang AJ",
        "authors": [
          "Davies P",
          "Funk KE",
          "Kuret J",
          "Liao Z",
          "Thomas SN",
          "Wan Y",
          "Yang AJ"
        ]
      },
      "annotations": {
        "Method": {
          "Immunohistochemistry": true,
          "Liquid Chromatography": true,
          "Chromatography, Immunoaffinity": true,
          "Fluorescence Microscopy, Confocal": true,
          "Mass Spectrometry": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Tau_State": {
          "Paired Helical Filament": true
        },
        "Tau_Structure": {
          "microtubule-binding region": true
        }
      },
      "source": 531,
      "target": 362,
      "key": "e7dcef521e89e648bb83995bfeb5b696108cf1f4520e2eefb872204b197607eba3126715ac9e4b9eb6c0ac0307ea7dc93f71c5f52c2b3d25a578b5f77b61cd44"
    },
    {
      "line": 1613,
      "relation": "association",
      "evidence": "Apart from binding to MT, the repeat domains of tau also bind to tubulin deacetylase, histone deacetylase 6 (HDAC6) [68] and apolipoprotein E (apoE) more with the ",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 362,
      "target": 308,
      "key": "219d04819d2ec6052dada3c91c240d0974420853cda501f89d4ec0d99dc4655f01f57cf9812360f83d0d0949435bbb6c61a046d4d5ecea94ae8468d56bb6e5ba"
    },
    {
      "line": 1615,
      "relation": "partOf",
      "evidence": "Apart from binding to MT, the repeat domains of tau also bind to tubulin deacetylase, histone deacetylase 6 (HDAC6) [68] and apolipoprotein E (apoE) more with the ",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 362,
      "target": 130,
      "key": "75c339d62550ff477341f0f2b40a694c9eac2d3c05cc4bdda40abf8fc333da26a9b759c90519880f60306b676c2df16bf3098ea7f4452b5bda2062f35642a693"
    },
    {
      "line": 325,
      "relation": "increases",
      "evidence": "Notably, methylation of PP2A catalytic C subunit on the Leu- 309 residue by leucine carboxyl methyltransferase 1 (LCMT1) promotes the biogenesis and stabilization of PP2A/B\u0001 enzymes (20). We have shown that decreased LCMT1 activity and/or expression levels correlate with down-regulation of PP2A methylation and PP2A/B\u0001 expression levels and with concomitant accumulation of phospho-Tau in AD-affected brain regions (21), in cultured N2a neuroblastoma cells and in vivo",
      "citation": {
        "type": "PubMed",
        "reference": "23943618",
        "name": "The Journal of biological chemistry",
        "title": "Leucine carboxyl methyltransferase 1 (LCMT1)-dependent methylation regulates the association of protein phosphatase 2A and Tau protein with plasma membrane microdomains in neuroblastoma cells.",
        "volume": "288",
        "pages": "27396-405",
        "date": "2013-09-20",
        "first": "Sontag JM",
        "last": "Sontag E",
        "authors": [
          "Nunbhakdi-Craig V",
          "Sontag E",
          "Sontag JM"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        },
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "Western Blot": true
        }
      },
      "source": 468,
      "target": 659,
      "key": "a03e93bdb39bc5102396929b3d71ff639643d58bd79a873922fe558acb5b4165cee764bcdb233eb6721d153de85587b4038e8af2e5e7e99e3e9787ee51a2eeba"
    },
    {
      "line": 3926,
      "relation": "increases",
      "evidence": "Western blot analyses showed a decrease of methyl-PP2A and an increase of demethyl-PP2A with a concomitant reduction in the methyl/demethyl PP2A ratio in both PSP (74%) and AD (76%) brains, associated with an LCMT-1 decrease and a demethylating enzyme increase, protein phosphatase methylesterase (PME-1), in both diseases.",
      "citation": {
        "type": "PubMed",
        "reference": "29281045",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.",
        "volume": "77",
        "pages": "139-148",
        "date": "2018-02-01",
        "first": "Park HJ",
        "last": "Mouradian MM",
        "authors": [
          "Adler CH",
          "Beach TG",
          "Braithwaite SP",
          "Lee KW",
          "Mouradian MM",
          "Oh S",
          "Park HJ",
          "Stock JB",
          "Voronkov M",
          "Yan R",
          "Zhang J"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true
        }
      },
      "source": 468,
      "target": 659,
      "key": "6674fe008cb39a9e157abfb636f63590fc2d454a437a1cf40fbf1ed2152657818a33da51c9b5414187a7ec0e6d31923cccb0cbfe79174861ed91052ae86106f1"
    },
    {
      "line": 326,
      "relation": "increases",
      "evidence": "Notably, methylation of PP2A catalytic C subunit on the Leu- 309 residue by leucine carboxyl methyltransferase 1 (LCMT1) promotes the biogenesis and stabilization of PP2A/B\u0001 enzymes (20). We have shown that decreased LCMT1 activity and/or expression levels correlate with down-regulation of PP2A methylation and PP2A/B\u0001 expression levels and with concomitant accumulation of phospho-Tau in AD-affected brain regions (21), in cultured N2a neuroblastoma cells and in vivo",
      "citation": {
        "type": "PubMed",
        "reference": "23943618",
        "name": "The Journal of biological chemistry",
        "title": "Leucine carboxyl methyltransferase 1 (LCMT1)-dependent methylation regulates the association of protein phosphatase 2A and Tau protein with plasma membrane microdomains in neuroblastoma cells.",
        "volume": "288",
        "pages": "27396-405",
        "date": "2013-09-20",
        "first": "Sontag JM",
        "last": "Sontag E",
        "authors": [
          "Nunbhakdi-Craig V",
          "Sontag E",
          "Sontag JM"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        },
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "Western Blot": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 659,
      "target": 301,
      "key": "5b153b2a365016f5de4498a7def59bf36f4663ee5441dd776c2beb24011b39bff9eb448a2a754a5c010d077827c1d071860eb69a2dc933ffc357273c1738a8df"
    },
    {
      "relation": "hasVariant",
      "source": 657,
      "target": 659,
      "key": "bcf159e64307b2f317201cd5f7934830bd52fe140ca32ff54d8e4666665ea36c75635eeff3f2283b6a7afc4b0ae25f3bf51efdc7af2b554cf83df11abaf8df9f"
    },
    {
      "relation": "hasVariant",
      "source": 657,
      "target": 658,
      "key": "55029c8f32b0d23172b9e645fcd77c21b255fe931bc23d16279ad9cf9b280d07211274b30dcd8b57da1f8d911497bd2e056a38c979f842c91dc1ed374a7e89e7"
    },
    {
      "line": 3766,
      "relation": "directlyDecreases",
      "evidence": "These findings suggest a scenario in which MC-LR-mediated demethylation of PP2Ac is associated with GSK-3β phosphorylation at Ser9 and contributes to dissociation of Bα from PP2Ac, which would result in Bα degradation and disruption of PP2A/Bα-tau interactions, thus promoting tau hyperphosphorylation and paired helical filaments-tau accumulation and, consequently, axonal degeneration and cell death.",
      "citation": {
        "type": "PubMed",
        "reference": "29228318",
        "name": "Toxicological sciences : an official journal of the Society of Toxicology",
        "title": "Microcystin-Leucine-Arginine Induces Tau Pathology Through Bα Degradation via Protein Phosphatase 2A Demethylation and Associated Glycogen Synthase Kinase-3β Phosphorylation.",
        "volume": "162",
        "pages": "475-487",
        "date": "2018-04-01",
        "first": "Zhang Y",
        "last": "Yuan T",
        "authors": [
          "Fan Y",
          "Feng Y",
          "Li Y",
          "Qian W",
          "Wang E",
          "Wang Y",
          "Yin H",
          "Yuan T",
          "Zhang J",
          "Zhang Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 657,
      "target": 457,
      "key": "7dac460f73e543928dda7be6d6a6c851ff3094b62490ee0fd9fdf34feb397180bcc4b0fdee7c5367266faa554fcbb4889970a76f38cb7d836a0a419754dc8807"
    },
    {
      "line": 3792,
      "relation": "negativeCorrelation",
      "evidence": "Here we show that resveratrol treatment directly interferes with the MID1-α4-PP2A degradation complex by reducing MID1 protein expression in vitro and in vivo. This leads to an increase of microtubule-associated PP2A activity and a time- and dose-dependent dephosphorylation of Tau. Interestingly, we further show that MID1 expression is elevated in AD tissue.",
      "citation": {
        "type": "PubMed",
        "reference": "29062069",
        "name": "Scientific reports",
        "title": "Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex.",
        "volume": "7",
        "pages": "13753",
        "date": "2017-10-23",
        "first": "Schweiger S",
        "last": "Krauß S",
        "authors": [
          "Ehninger D",
          "Hettich MM",
          "Kickstein E",
          "Krauß S",
          "Matthes F",
          "Pfurtscheller S",
          "Posey K",
          "Schneider R",
          "Schweiger S",
          "Weber S"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 657,
      "target": 538,
      "key": "ed17c97f2de5a6de0b20ba50235aeec8b9f0e691997c2bfc56f2c43273381d9af3d51a75e182f81f53c3eb61be9d45c57d761af34b46ba14a9167ae261137f6c"
    },
    {
      "line": 4008,
      "relation": "positiveCorrelation",
      "evidence": "Pin1 is indicated to facilitate Tau dephosphorylation via PP2A by binding to the phospho-Thr-231-Pro or phospho-Thr-212-Pro site",
      "citation": {
        "type": "PubMed",
        "reference": "19401603",
        "name": "The Journal of biological chemistry",
        "title": "Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau.",
        "volume": "284",
        "pages": "16840-7",
        "date": "2009-06-19",
        "first": "Yotsumoto K",
        "last": "Hisanaga S",
        "authors": [
          "Asada A",
          "Hasegawa M",
          "Hisanaga S",
          "Ishiguro K",
          "Kimura T",
          "Oikawa T",
          "Saito T",
          "Uchida C",
          "Uchida T",
          "Yotsumoto K"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 657,
      "target": 647,
      "key": "aeb53642a6e224afc2ed5426dcc60b324ff475012f9e3c65c5f833a4040a2b87b3d6ab7bdace551ac72e56d85e6734ffe50eed9a196680069d74afaccac7b366"
    },
    {
      "line": 4009,
      "relation": "directlyDecreases",
      "evidence": "Pin1 is indicated to facilitate Tau dephosphorylation via PP2A by binding to the phospho-Thr-231-Pro or phospho-Thr-212-Pro site",
      "citation": {
        "type": "PubMed",
        "reference": "19401603",
        "name": "The Journal of biological chemistry",
        "title": "Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau.",
        "volume": "284",
        "pages": "16840-7",
        "date": "2009-06-19",
        "first": "Yotsumoto K",
        "last": "Hisanaga S",
        "authors": [
          "Asada A",
          "Hasegawa M",
          "Hisanaga S",
          "Ishiguro K",
          "Kimura T",
          "Oikawa T",
          "Saito T",
          "Uchida C",
          "Uchida T",
          "Yotsumoto K"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 657,
      "target": 583,
      "key": "e89e56af73894bcc51cae512775388697aa640ee7d1342856cb3e68aa7a58aed4070f2dcf45174bababd6f2b4b8a32095d9aa9f3dfcf2c405b694528ab80708f"
    },
    {
      "line": 4010,
      "relation": "directlyDecreases",
      "evidence": "Pin1 is indicated to facilitate Tau dephosphorylation via PP2A by binding to the phospho-Thr-231-Pro or phospho-Thr-212-Pro site",
      "citation": {
        "type": "PubMed",
        "reference": "19401603",
        "name": "The Journal of biological chemistry",
        "title": "Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau.",
        "volume": "284",
        "pages": "16840-7",
        "date": "2009-06-19",
        "first": "Yotsumoto K",
        "last": "Hisanaga S",
        "authors": [
          "Asada A",
          "Hasegawa M",
          "Hisanaga S",
          "Ishiguro K",
          "Kimura T",
          "Oikawa T",
          "Saito T",
          "Uchida C",
          "Uchida T",
          "Yotsumoto K"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 657,
      "target": 580,
      "key": "2db9a78ebdad1f9d809fd1333e798274d6431e57d0e7e94d2628f3dcf08d3261f87a69086933d86d7e44938983d76a3123f7d13c95e7bc28118c1654a5cef549"
    },
    {
      "line": 327,
      "relation": "positiveCorrelation",
      "evidence": "Notably, methylation of PP2A catalytic C subunit on the Leu- 309 residue by leucine carboxyl methyltransferase 1 (LCMT1) promotes the biogenesis and stabilization of PP2A/B\u0001 enzymes (20). We have shown that decreased LCMT1 activity and/or expression levels correlate with down-regulation of PP2A methylation and PP2A/B\u0001 expression levels and with concomitant accumulation of phospho-Tau in AD-affected brain regions (21), in cultured N2a neuroblastoma cells and in vivo",
      "citation": {
        "type": "PubMed",
        "reference": "23943618",
        "name": "The Journal of biological chemistry",
        "title": "Leucine carboxyl methyltransferase 1 (LCMT1)-dependent methylation regulates the association of protein phosphatase 2A and Tau protein with plasma membrane microdomains in neuroblastoma cells.",
        "volume": "288",
        "pages": "27396-405",
        "date": "2013-09-20",
        "first": "Sontag JM",
        "last": "Sontag E",
        "authors": [
          "Nunbhakdi-Craig V",
          "Sontag E",
          "Sontag JM"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        },
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "Western Blot": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 301,
      "target": 225,
      "key": "a29da3b086852b9643721eb8bc55b0d4f7c1bfe6c88fae8d210ac64822089d6f54c7d8c74e5dad66a4a92edd29bde80e6a8afc6173784a9036292a582415a9bd"
    },
    {
      "line": 1904,
      "relation": "positiveCorrelation",
      "evidence": "Overexpression of UNC5B induces neuronal death by activating death-associated protein kinase (DAPK1) (19) via protein phosphatase 2A-mediated dephosphorylation of DAPK1 (20).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 301,
      "target": 740,
      "key": "e2859f988f3c53324603f80892891118e2b3068d989421dadc350d5ce04d127797bb8a2674faa9dfc729f87a4c461cd4357f4c34bfc6e4fd8670b3914065f81a"
    },
    {
      "line": 1905,
      "relation": "increases",
      "evidence": "Overexpression of UNC5B induces neuronal death by activating death-associated protein kinase (DAPK1) (19) via protein phosphatase 2A-mediated dephosphorylation of DAPK1 (20).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 301,
      "target": 431,
      "key": "dd6612a630b4a839e18acea8449202a5e9014b2e66d1a216f2e176fa30f22519ce5a711c3109be39eb7b7283f48feae8506b9ba2c03e9f06deb134eeaaf387e5"
    },
    {
      "relation": "hasComponent",
      "source": 225,
      "target": 301,
      "key": "e29a0849a9f0649598caa05941374e0f92af27b5027795392cb2532dcc769c5bba1536c68632107ff589e10a0355464b742c6481e0d66f4c82de7dd806cf54ee"
    },
    {
      "line": 327,
      "relation": "positiveCorrelation",
      "evidence": "Notably, methylation of PP2A catalytic C subunit on the Leu- 309 residue by leucine carboxyl methyltransferase 1 (LCMT1) promotes the biogenesis and stabilization of PP2A/B\u0001 enzymes (20). We have shown that decreased LCMT1 activity and/or expression levels correlate with down-regulation of PP2A methylation and PP2A/B\u0001 expression levels and with concomitant accumulation of phospho-Tau in AD-affected brain regions (21), in cultured N2a neuroblastoma cells and in vivo",
      "citation": {
        "type": "PubMed",
        "reference": "23943618",
        "name": "The Journal of biological chemistry",
        "title": "Leucine carboxyl methyltransferase 1 (LCMT1)-dependent methylation regulates the association of protein phosphatase 2A and Tau protein with plasma membrane microdomains in neuroblastoma cells.",
        "volume": "288",
        "pages": "27396-405",
        "date": "2013-09-20",
        "first": "Sontag JM",
        "last": "Sontag E",
        "authors": [
          "Nunbhakdi-Craig V",
          "Sontag E",
          "Sontag JM"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        },
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "Western Blot": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 225,
      "target": 301,
      "key": "b684b7f80799b464a274b70040e4abe2ea3685c40c9e79c46bb94f2201d39277907feab923b24381e22119958023adbaade0d824b538ae319aab24036f713e11"
    },
    {
      "relation": "hasComponent",
      "source": 225,
      "target": 486,
      "key": "6bb1b259233959cc610bbc1fe71dc66c93df89ff357203529ff5e102e81b73ce91a46d6ae77f6f99c273c9a713abf84b30255108dba497b7250710991cf8ffc9"
    },
    {
      "line": 328,
      "relation": "negativeCorrelation",
      "evidence": "Notably, methylation of PP2A catalytic C subunit on the Leu- 309 residue by leucine carboxyl methyltransferase 1 (LCMT1) promotes the biogenesis and stabilization of PP2A/B\u0001 enzymes (20). We have shown that decreased LCMT1 activity and/or expression levels correlate with down-regulation of PP2A methylation and PP2A/B\u0001 expression levels and with concomitant accumulation of phospho-Tau in AD-affected brain regions (21), in cultured N2a neuroblastoma cells and in vivo",
      "citation": {
        "type": "PubMed",
        "reference": "23943618",
        "name": "The Journal of biological chemistry",
        "title": "Leucine carboxyl methyltransferase 1 (LCMT1)-dependent methylation regulates the association of protein phosphatase 2A and Tau protein with plasma membrane microdomains in neuroblastoma cells.",
        "volume": "288",
        "pages": "27396-405",
        "date": "2013-09-20",
        "first": "Sontag JM",
        "last": "Sontag E",
        "authors": [
          "Nunbhakdi-Craig V",
          "Sontag E",
          "Sontag JM"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        },
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "Western Blot": true
        }
      },
      "source": 225,
      "target": 538,
      "key": "86d398a589a6ae48dc8f7982e97f954723191a2e31bd45e3caa3ab61b322d699c84a17a7e8bdc758393c273ee51a4c71809ae528223d6521ff9512b563b3a9da"
    },
    {
      "line": 328,
      "relation": "negativeCorrelation",
      "evidence": "Notably, methylation of PP2A catalytic C subunit on the Leu- 309 residue by leucine carboxyl methyltransferase 1 (LCMT1) promotes the biogenesis and stabilization of PP2A/B\u0001 enzymes (20). We have shown that decreased LCMT1 activity and/or expression levels correlate with down-regulation of PP2A methylation and PP2A/B\u0001 expression levels and with concomitant accumulation of phospho-Tau in AD-affected brain regions (21), in cultured N2a neuroblastoma cells and in vivo",
      "citation": {
        "type": "PubMed",
        "reference": "23943618",
        "name": "The Journal of biological chemistry",
        "title": "Leucine carboxyl methyltransferase 1 (LCMT1)-dependent methylation regulates the association of protein phosphatase 2A and Tau protein with plasma membrane microdomains in neuroblastoma cells.",
        "volume": "288",
        "pages": "27396-405",
        "date": "2013-09-20",
        "first": "Sontag JM",
        "last": "Sontag E",
        "authors": [
          "Nunbhakdi-Craig V",
          "Sontag E",
          "Sontag JM"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        },
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "Western Blot": true
        }
      },
      "source": 538,
      "target": 225,
      "key": "ab35d46ca4e5b9f5e42dac8b6791477bfb683da215b3560f0b9a20e23d45a368ec78494131ad0ff3afd3dbb087402817d5d59efcd71acbe299d09fb5c11846ff"
    },
    {
      "line": 690,
      "relation": "negativeCorrelation",
      "evidence": "We recently discovered that the human brain tau is also modified by O-GlcNAcylation in addition to phosphorylation and that O-GlcNAcylation modulates phosphorylation of tau inversely (Liu et al.,2004a). We found that fasting induced a time-dependent decrease in tau O-GlcNAcylation and concurrent hyperphosphorylation of tau at most of the phosphorylation sites studied.",
      "citation": {
        "type": "PubMed",
        "reference": "16630055",
        "name": "The European journal of neuroscience",
        "title": "Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting.",
        "volume": "23",
        "pages": "2078-86",
        "date": "2006-04-01",
        "first": "Li X",
        "last": "Gong CX",
        "authors": [
          "Gong CX",
          "Li X",
          "Lu F",
          "Wang JZ"
        ]
      },
      "source": 538,
      "target": 513,
      "key": "5dc2dd20fc77f1f77246619f0e1d4d62c1e1c2a5100ac84a2a2b01b091758dfe3fa0b6d68bb3e4e08deacaf685f8c217b8fea9a653ff4bd663c96c4294f8cb50"
    },
    {
      "line": 3485,
      "relation": "positiveCorrelation",
      "evidence": "Furthermore, the enhanced SUMO-immunoreactivity, costained with the hyperphosphorylated tau, is detected in cerebral cortex of the AD brains, and β-amyloid exposure of rat primary hippocampal neurons induces a dose-dependent SUMOylation of the hyperphosphorylated tau. Our findings suggest that tau SUMOylation reciprocally stimulates its phosphorylation and inhibits the ubiquitination-mediated tau degradation, which provides a new insight into the AD-like tau accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "25378699",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination.",
        "volume": "111",
        "pages": "16586-91",
        "date": "2014-11-18",
        "first": "Luo HB",
        "last": "Wang JZ",
        "authors": [
          "Feng Y",
          "Jiang J",
          "Liu XH",
          "Liu ZC",
          "Luo HB",
          "Shu XJ",
          "Wang JZ",
          "Wang XC",
          "Xia YY",
          "Xiong YS",
          "Ye K",
          "Yin G",
          "Yu G",
          "Zeng K"
        ]
      },
      "source": 538,
      "target": 593,
      "key": "dc49d915c8f6dfe77ae5770897d21fea066dba25cb7c249ea842c0c2f62cc63c2f1e9c7ce5c80d1f3e234ae7ba7f980b66fc7acd9d5c4fbf655af622dbef522e"
    },
    {
      "line": 3792,
      "relation": "negativeCorrelation",
      "evidence": "Here we show that resveratrol treatment directly interferes with the MID1-α4-PP2A degradation complex by reducing MID1 protein expression in vitro and in vivo. This leads to an increase of microtubule-associated PP2A activity and a time- and dose-dependent dephosphorylation of Tau. Interestingly, we further show that MID1 expression is elevated in AD tissue.",
      "citation": {
        "type": "PubMed",
        "reference": "29062069",
        "name": "Scientific reports",
        "title": "Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex.",
        "volume": "7",
        "pages": "13753",
        "date": "2017-10-23",
        "first": "Schweiger S",
        "last": "Krauß S",
        "authors": [
          "Ehninger D",
          "Hettich MM",
          "Kickstein E",
          "Krauß S",
          "Matthes F",
          "Pfurtscheller S",
          "Posey K",
          "Schneider R",
          "Schweiger S",
          "Weber S"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 538,
      "target": 657,
      "key": "2277cd03464270ef55b3d8cfac97e44880056fdfebabe9e97dd261d82085c5b8b975c19d1d78149544aba6f2207506f7ca0fab16712219269dc30d5148c8e712"
    },
    {
      "line": 4015,
      "relation": "positiveCorrelation",
      "evidence": "Taken together, these results indicate that the binding of P-Tau to microtubules suppresses its dephosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "19401603",
        "name": "The Journal of biological chemistry",
        "title": "Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau.",
        "volume": "284",
        "pages": "16840-7",
        "date": "2009-06-19",
        "first": "Yotsumoto K",
        "last": "Hisanaga S",
        "authors": [
          "Asada A",
          "Hasegawa M",
          "Hisanaga S",
          "Ishiguro K",
          "Kimura T",
          "Oikawa T",
          "Saito T",
          "Uchida C",
          "Uchida T",
          "Yotsumoto K"
        ]
      },
      "source": 538,
      "target": 216,
      "key": "0c378ec5dd8a4e8a7d55ea01b08fb50a80f87f80647a032816d6a42dabc78559d732e21ef027fe24d23f3da215d340496450b580e402074a6fe79ad705923ae9"
    },
    {
      "line": 339,
      "relation": "decreases",
      "evidence": "Incubation of human SH-SY5Y neuroblastoma cells for 2 h with L-dopa induced a dose-dependent decrease in both soluble and insoluble methylated PP2A C subunit levels, and concomitant accumulation of demethylated PP2A enzymes",
      "citation": {
        "type": "PubMed",
        "reference": "22764226",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain.",
        "volume": "32",
        "pages": "9173-81",
        "date": "2012-07-04",
        "first": "Bottiglieri T",
        "last": "Sontag E",
        "authors": [
          "Arning E",
          "Bottiglieri T",
          "Nunbhakdi-Craig V",
          "Sontag E",
          "Sontag JM",
          "Wasek B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Confocal Microscopy": true
        },
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 7,
      "target": 658,
      "key": "6b1ccb2a1aaafdfdf48689d1b7b05850e113d3d5906885e8b689c19302af010af7dd52babd6ec046ad9565704d8cf5a8c48fce0d173f9d96838bbf4a46803a2b"
    },
    {
      "line": 346,
      "relation": "decreases",
      "evidence": "Significantly, we found similar effects in human dopaminergic neurons (Fig. 2F). Treatment of neurons with L-Dopa induced a 40–49% decrease in methylated PP2A and concomitant 168–179% increase in endogenous p-Tau (PHF-1) levels (Fig. 2G).",
      "citation": {
        "type": "PubMed",
        "reference": "22764226",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain.",
        "volume": "32",
        "pages": "9173-81",
        "date": "2012-07-04",
        "first": "Bottiglieri T",
        "last": "Sontag E",
        "authors": [
          "Arning E",
          "Bottiglieri T",
          "Nunbhakdi-Craig V",
          "Sontag E",
          "Sontag JM",
          "Wasek B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Confocal Microscopy": true
        },
        "Anatomy": {
          "dopaminergic cell groups": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 7,
      "target": 658,
      "key": "cec517eef367a925ffe0c7607d992884523f70627c226e7f786ed8bbf910c13512a3361d3809f9357ddae0dd8f458d91a5586167ae4d059a8c8909bc35fe483b"
    },
    {
      "line": 347,
      "relation": "increases",
      "evidence": "Significantly, we found similar effects in human dopaminergic neurons (Fig. 2F). Treatment of neurons with L-Dopa induced a 40–49% decrease in methylated PP2A and concomitant 168–179% increase in endogenous p-Tau (PHF-1) levels (Fig. 2G).",
      "citation": {
        "type": "PubMed",
        "reference": "22764226",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain.",
        "volume": "32",
        "pages": "9173-81",
        "date": "2012-07-04",
        "first": "Bottiglieri T",
        "last": "Sontag E",
        "authors": [
          "Arning E",
          "Bottiglieri T",
          "Nunbhakdi-Craig V",
          "Sontag E",
          "Sontag JM",
          "Wasek B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Confocal Microscopy": true
        },
        "Anatomy": {
          "dopaminergic cell groups": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 7,
      "target": 117,
      "key": "fd93608bdfdee4f556158360abc8edf1d7b367246ac40dd4724a463151f1d74d111e6419837ba35fd9deffd2c5b9dc40d43de19f38f43c4f8bc57bc40100d4e7"
    },
    {
      "line": 351,
      "relation": "negativeCorrelation",
      "evidence": "Folate starvation in the presence of L-dopa resulted in a 200–210% increase in demethylated PP2A levels, and 235–250% increase in p-Tau levels in the dopaminergic neurons, relative to untreated controls maintained in NF medium.",
      "citation": {
        "type": "PubMed",
        "reference": "22764226",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain.",
        "volume": "32",
        "pages": "9173-81",
        "date": "2012-07-04",
        "first": "Bottiglieri T",
        "last": "Sontag E",
        "authors": [
          "Arning E",
          "Bottiglieri T",
          "Nunbhakdi-Craig V",
          "Sontag E",
          "Sontag JM",
          "Wasek B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Confocal Microscopy": true
        },
        "Anatomy": {
          "dopaminergic cell groups": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 7,
      "target": 17,
      "key": "a8b0e043c7bb57595aabfc1b590d19f24bfe640089bf29ee0f050edf3bb9de69c6f5c9f3f1de86a8688af5222a6e155dcc961e30ed549c920dea01969651ed4c"
    },
    {
      "line": 359,
      "relation": "negativeCorrelation",
      "evidence": "Here, we found that administration of L-dopa led to a significant 5-fold increase in plasma tHcy concentrations, when compared to saline treated mice (Table 1). This L-dopa induced increase in plasma tHcy was significantly greater in mice that had been reared on either low folate (LF) or FD diets (Table 1).",
      "citation": {
        "type": "PubMed",
        "reference": "22764226",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain.",
        "volume": "32",
        "pages": "9173-81",
        "date": "2012-07-04",
        "first": "Bottiglieri T",
        "last": "Sontag E",
        "authors": [
          "Arning E",
          "Bottiglieri T",
          "Nunbhakdi-Craig V",
          "Sontag E",
          "Sontag JM",
          "Wasek B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Confocal Microscopy": true
        },
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "blood plasma": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 7,
      "target": 17,
      "key": "a5c232c20d76afc71b1a28b498a8c8b2219c0f1e82b68b15db3bb870658f4d1525e8d08ddd45e47d7731ce27061af2f20fe05b2863bbab2c768157e3676b705c"
    },
    {
      "line": 358,
      "relation": "increases",
      "evidence": "Here, we found that administration of L-dopa led to a significant 5-fold increase in plasma tHcy concentrations, when compared to saline treated mice (Table 1). This L-dopa induced increase in plasma tHcy was significantly greater in mice that had been reared on either low folate (LF) or FD diets (Table 1).",
      "citation": {
        "type": "PubMed",
        "reference": "22764226",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain.",
        "volume": "32",
        "pages": "9173-81",
        "date": "2012-07-04",
        "first": "Bottiglieri T",
        "last": "Sontag E",
        "authors": [
          "Arning E",
          "Bottiglieri T",
          "Nunbhakdi-Craig V",
          "Sontag E",
          "Sontag JM",
          "Wasek B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Confocal Microscopy": true
        },
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "blood plasma": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 7,
      "target": 55,
      "key": "d849d1878d1809dd5d43389c0365e262fd7706e7cce026fab53c4f37d32c7719a2dce821abb51884ebdf4d162703960ec41bd664485ed9b41212959fbf14e0d0"
    },
    {
      "line": 362,
      "relation": "decreases",
      "evidence": "Reductions in PP2A methylation were associated with a concomitant increase in each brain region of p-Tau at the PHF-1 epitope (Fig. 6A,B).",
      "citation": {
        "type": "PubMed",
        "reference": "22764226",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain.",
        "volume": "32",
        "pages": "9173-81",
        "date": "2012-07-04",
        "first": "Bottiglieri T",
        "last": "Sontag E",
        "authors": [
          "Arning E",
          "Bottiglieri T",
          "Nunbhakdi-Craig V",
          "Sontag E",
          "Sontag JM",
          "Wasek B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Confocal Microscopy": true
        },
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "blood plasma": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 7,
      "target": 845,
      "key": "5af799e2c9e0985b9bb296ad49bd1c07459a6736e051126c9e7dfe156a57f237a23c0e78265f1f89406a6d11f02d9eab35b55d29d5a04c36148ebea9fd001466"
    },
    {
      "line": 3765,
      "relation": "increases",
      "evidence": "These findings suggest a scenario in which MC-LR-mediated demethylation of PP2Ac is associated with GSK-3β phosphorylation at Ser9 and contributes to dissociation of Bα from PP2Ac, which would result in Bα degradation and disruption of PP2A/Bα-tau interactions, thus promoting tau hyperphosphorylation and paired helical filaments-tau accumulation and, consequently, axonal degeneration and cell death.",
      "citation": {
        "type": "PubMed",
        "reference": "29228318",
        "name": "Toxicological sciences : an official journal of the Society of Toxicology",
        "title": "Microcystin-Leucine-Arginine Induces Tau Pathology Through Bα Degradation via Protein Phosphatase 2A Demethylation and Associated Glycogen Synthase Kinase-3β Phosphorylation.",
        "volume": "162",
        "pages": "475-487",
        "date": "2018-04-01",
        "first": "Zhang Y",
        "last": "Yuan T",
        "authors": [
          "Fan Y",
          "Feng Y",
          "Li Y",
          "Qian W",
          "Wang E",
          "Wang Y",
          "Yin H",
          "Yuan T",
          "Zhang J",
          "Zhang Y"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 658,
      "target": 657,
      "key": "99c4ef09ef569bbe5f82daaf6cd6f2522de82e4fb148a5d69750eecac3d8ea0e6d8cdbb1ce3a49bb29addd6912886705ea1883c47408e119ff4a7a4fe7ad12b0"
    },
    {
      "line": 363,
      "relation": "negativeCorrelation",
      "evidence": "Reductions in PP2A methylation were associated with a concomitant increase in each brain region of p-Tau at the PHF-1 epitope (Fig. 6A,B).",
      "citation": {
        "type": "PubMed",
        "reference": "22764226",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain.",
        "volume": "32",
        "pages": "9173-81",
        "date": "2012-07-04",
        "first": "Bottiglieri T",
        "last": "Sontag E",
        "authors": [
          "Arning E",
          "Bottiglieri T",
          "Nunbhakdi-Craig V",
          "Sontag E",
          "Sontag JM",
          "Wasek B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Confocal Microscopy": true
        },
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "blood plasma": true
        }
      },
      "source": 117,
      "target": 845,
      "key": "05b536f02ecd71a957b5d1e9e5cf8ba32fc0107eea721c9cfd59d7a179ef72ad958bbf06c2702cbdfd881c0376dc132064131ed4955212a013feba8cdaa3b6d7"
    },
    {
      "line": 1805,
      "relation": "positiveCorrelation",
      "evidence": "We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "source": 117,
      "target": 113,
      "key": "430dcade83b291ddd71b46fc7316407e4f7bc6ee35416d75974754e690c392821f26c263f2bb743c44384451b5a5e137c4937805d7cec9212f31365537fd54c9"
    },
    {
      "line": 1806,
      "relation": "positiveCorrelation",
      "evidence": "We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "source": 117,
      "target": 564,
      "key": "ff548ca67b04fb5573817eaa257c76a78d88de8c2cfc947c65d8b7cc52b7af85e54f16abfdec9fa75f770bfaadcd7e4dc3aff65e1a23bd38a186f5b97dde3e9e"
    },
    {
      "line": 1807,
      "relation": "positiveCorrelation",
      "evidence": "We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "source": 117,
      "target": 565,
      "key": "d621af086784aeac0a05ee47c16e4b242ded3f8e68326bd6b0eb4fff01f4262a414718ea84df97f3f1fa13cbf430195d32db5c04bb29cc26c8cca58bec49152c"
    },
    {
      "line": 2425,
      "relation": "positiveCorrelation",
      "evidence": "CRF-OE mice had significantly elevated tau-P compared to wild type (WT) mice at the AT8 (S202/T204), PHF-1 (S396/404), S262, and S422 sites. Treating CRF-OE mice with R121919 blocked phosphorylation at the AT8 (S202/T204) and PHF-1 (S396/404) sites, but not at the S262 and S422 sites and reduced phosphorylation of c-Jun N Terminal Kinase (JNK).",
      "citation": {
        "type": "PubMed",
        "reference": "25125464",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.",
        "volume": "43",
        "pages": "967-76",
        "date": "2015-01-01",
        "first": "Campbell SN",
        "last": "Rissman RA",
        "authors": [
          "Campbell SN",
          "Masliah E",
          "Monte L",
          "Rice KC",
          "Rissman RA",
          "Roe AD",
          "Taché Y",
          "Zhang C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 117,
      "target": 780,
      "key": "5cc1b45614633d4a0283231ba87aec7b5ac7bb023fa38003dbe00eb15f8bb3b749ca99639ae89ced245c322ecdf629ac420a7dee4b898eb8e382663f839ef718"
    },
    {
      "line": 2470,
      "relation": "decreases",
      "evidence": "Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift in mobility as a result of phosphorylation-like changes, we conclude that they have the characteristics of hyperphosphorylated tau. These mutants will therefore be referred to as pseudo-hyperphosphorylated tau throughout the manuscript. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.",
      "citation": {
        "type": "PubMed",
        "reference": "19459590",
        "name": "Biochemistry",
        "title": "Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.",
        "volume": "48",
        "pages": "6002-11",
        "date": "2009-06-30",
        "first": "Sun Q",
        "last": "Gamblin TC",
        "authors": [
          "Gamblin TC",
          "Sun Q"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 117,
      "target": 486,
      "key": "24723f23c26eb78d3e0a2bbd05f100756dc467839ecb9364cb7b6ca5c63f8f0240556322c1fee4eaa4758083daaa4b8fdabbde259de9f576f74002b6ccff38a8"
    },
    {
      "line": 2672,
      "relation": "positiveCorrelation",
      "evidence": "In particular, previous studies have demonstrated that the tau ubiquitin ligase, CHIP, is unable to bind and ubiquitinate tau species phosphorylated by Par-1/MARK2 on the 12E8 epitope (S262/356) [33], a p-tau species that is also resistant to degradation upon treatment with Hsp90 inhibitors [32,33]. Tau phosphorylated at the PHF1 epitope (S396/404) is still susceptible to degradation following Hsp90 inhibition and actually exhibits an enhanced interaction with Hsp90",
      "citation": {
        "type": "PubMed",
        "reference": "25031639",
        "name": "Alzheimer's research &amp; therapy",
        "title": "Acetylation: a new key to unlock tau's role in neurodegeneration.",
        "volume": "6",
        "pages": "29",
        "date": "2014-01-01",
        "first": "Cook C",
        "last": "Petrucelli L",
        "authors": [
          "Carlomagno Y",
          "Cook C",
          "Petrucelli L",
          "Stankowski JN",
          "Stetler C"
        ]
      },
      "object": {
        "modifier": "Degradation"
      },
      "source": 117,
      "target": 486,
      "key": "69e3ef62b7b9b61483e859880139c460a06d29b3a39175d2d7bc37de3c794fe6834e291116bdc3b4b03a934130fb356c43280fbb29c454e0cb3a6171c0552de9"
    },
    {
      "line": 2693,
      "relation": "positiveCorrelation",
      "evidence": "Consistent with previous reports (11,34), treatment of rat hippocampal neurons with synthetic Aβ, prepared using a well-characterized procedure that enriches for Aβ oligomers (37), resulted in increased tau phosphorylation at the 12E8 sites (Fig. 2A), suggesting that Aβ treatment had activated MARK kinases. Increased phosphorylation of tau at a site recognized by the PHF-1 phospho-tau antibody was also observed (data not shown).",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 117,
      "target": 11,
      "key": "58b9de2c75fd0366294320c73734d6e4577a0de90808c585ac6001214460fc83416b0237b32c7a85a2fb154647d381e41e657bcb17521d42f5f3a77c4006f09e"
    },
    {
      "line": 351,
      "relation": "negativeCorrelation",
      "evidence": "Folate starvation in the presence of L-dopa resulted in a 200–210% increase in demethylated PP2A levels, and 235–250% increase in p-Tau levels in the dopaminergic neurons, relative to untreated controls maintained in NF medium.",
      "citation": {
        "type": "PubMed",
        "reference": "22764226",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain.",
        "volume": "32",
        "pages": "9173-81",
        "date": "2012-07-04",
        "first": "Bottiglieri T",
        "last": "Sontag E",
        "authors": [
          "Arning E",
          "Bottiglieri T",
          "Nunbhakdi-Craig V",
          "Sontag E",
          "Sontag JM",
          "Wasek B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Confocal Microscopy": true
        },
        "Anatomy": {
          "dopaminergic cell groups": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 17,
      "target": 7,
      "key": "632a252ae98ed5b1c60e364971765383355e2cbf5b014a8d6fcce38cc873a362d9147e66225185d13942cb242c825d316092abb29da549439588ffe4a7b8e53c"
    },
    {
      "line": 359,
      "relation": "negativeCorrelation",
      "evidence": "Here, we found that administration of L-dopa led to a significant 5-fold increase in plasma tHcy concentrations, when compared to saline treated mice (Table 1). This L-dopa induced increase in plasma tHcy was significantly greater in mice that had been reared on either low folate (LF) or FD diets (Table 1).",
      "citation": {
        "type": "PubMed",
        "reference": "22764226",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain.",
        "volume": "32",
        "pages": "9173-81",
        "date": "2012-07-04",
        "first": "Bottiglieri T",
        "last": "Sontag E",
        "authors": [
          "Arning E",
          "Bottiglieri T",
          "Nunbhakdi-Craig V",
          "Sontag E",
          "Sontag JM",
          "Wasek B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Confocal Microscopy": true
        },
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "blood plasma": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 17,
      "target": 7,
      "key": "d42208f5668ff03eb225bab48666575daddd846846edec1a0d4984fe9e2771ef60695ce0f38d25d4f120791e74c03798a71cbc781b6f19b33f1e5154f40ced1e"
    },
    {
      "line": 2152,
      "relation": "biomarkerFor",
      "evidence": "Receiver-operating characteristic curves and logistic regression analyses showed that combined assessment of DYRK1A, BDNF and homocysteine has a sensitivity of 0.952, a specificity of 0.889 and an accuracy of 0.933 in testing for AD. The blood levels of these markers provide a diagnosis assessment profile. Combined assessment of these three markers outperforms most of the previous markers and could become a useful substitute to the current panel of AD biomarkers.",
      "citation": {
        "type": "PubMed",
        "reference": "28632203",
        "name": "Translational psychiatry",
        "title": "Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer's disease.",
        "volume": "7",
        "pages": "e1154",
        "date": "2017-06-20",
        "first": "Janel N",
        "last": "Delabar JM",
        "authors": [
          "Alexopoulos P",
          "Arbones M",
          "Badel A",
          "Camproux AC",
          "Delabar JM",
          "Dubois B",
          "Feraudet-Tarisse C",
          "Janel N",
          "Lagarde J",
          "Lamari F",
          "Lamourette P",
          "Paul JL",
          "Potier MC",
          "Sarazin M",
          "Simon S"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Anatomy": {
          "blood plasma": true
        }
      },
      "source": 55,
      "target": 908,
      "key": "75a37907739ff948e7e0b40878cc1901c4bd97a15ea0aa1c728651c4fc1801d762538c7783f2289c1cb19b35afe013784364d3727494efcf8a26d98a0f05aaea"
    },
    {
      "line": 363,
      "relation": "negativeCorrelation",
      "evidence": "Reductions in PP2A methylation were associated with a concomitant increase in each brain region of p-Tau at the PHF-1 epitope (Fig. 6A,B).",
      "citation": {
        "type": "PubMed",
        "reference": "22764226",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain.",
        "volume": "32",
        "pages": "9173-81",
        "date": "2012-07-04",
        "first": "Bottiglieri T",
        "last": "Sontag E",
        "authors": [
          "Arning E",
          "Bottiglieri T",
          "Nunbhakdi-Craig V",
          "Sontag E",
          "Sontag JM",
          "Wasek B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Confocal Microscopy": true
        },
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "blood plasma": true
        }
      },
      "source": 845,
      "target": 117,
      "key": "b2d5f68c6b15ea2d8da487735bbbd34d4e72267be1dc30b77633c31a1569837387ff99b5be3e96c46dcc4b6401e9c97ac1d83af7abe95bd1e667fbb4288f2f60"
    },
    {
      "relation": "hasVariant",
      "source": 844,
      "target": 845,
      "key": "c8f27f71c0f4d69c2e0e917aa8ebfb9f20e426993b88bc764b0295b621b5b7979bce874576b81af475472c6d8c938e9e661af951c4fac374ae74f5b1a0fb9a45"
    },
    {
      "relation": "hasVariant",
      "source": 844,
      "target": 846,
      "key": "ab9cf11e7afadc1e347774eca7e859ba5da5f3f38e8fbdf47e3dab0b0bb25fd16b719ab74d37ce2f14ac0bb7f7d7ad424adcacc31e0c8d52a6a820c6ab0a4326"
    },
    {
      "line": 3822,
      "relation": "negativeCorrelation",
      "evidence": "We found strong Tau hyperphosphorylation in brain samples from R6/2 and 140CAG Tg knock-in, associated with a significant reduction in the levels of Tau phosphatases (PP1, PP2A and PP2B), with no apparent involvement of major Tau kinases.",
      "citation": {
        "type": "PubMed",
        "reference": "25143394",
        "name": "Human molecular genetics",
        "title": "Mutant huntingtin alters Tau phosphorylation and subcellular distribution.",
        "volume": "24",
        "pages": "76-85",
        "date": "2015-01-01",
        "first": "Blum D",
        "last": "Outeiro TF",
        "authors": [
          "Basquin M",
          "Blum D",
          "Brouillet E",
          "Buée L",
          "Demeyer D",
          "Francelle L",
          "Gerhardt E",
          "Herrera F",
          "Mendes T",
          "Obriot H",
          "Outeiro TF",
          "Sergeant N"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "HD murine model": true
        }
      },
      "source": 844,
      "target": 808,
      "key": "a396d237c6b3060ce1137fe737ba025bc28b259f996297a697ffa692c824ebf09549b981281ece4abcfb829b0439598595c85efc26d5199dfc6716172282a73f"
    },
    {
      "line": 375,
      "relation": "negativeCorrelation",
      "evidence": "The levels of sRAGE consistently decreased with age (R = −0.264, p = <0.001) and with the indices of obesity, such as BMI. However, of special interest was the highly significant and previ-ously not reported independent correlation with fat free mass (p < 0.001).",
      "citation": {
        "type": "PubMed",
        "reference": "25681682",
        "name": "Mechanisms of ageing and development",
        "title": "Age and genetic determinants of variation of circulating levels of the receptor for advanced glycation end products (RAGE) in the general human population.",
        "volume": "145",
        "pages": "18-25",
        "date": "2015-01-01",
        "first": "Prakash J",
        "last": "Livshits G",
        "authors": [
          "Livshits G",
          "Pichchadze G",
          "Prakash J",
          "Trofimov S"
        ]
      },
      "annotations": {
        "Anatomy": {
          "blood plasma": true
        }
      },
      "source": 371,
      "target": 195,
      "key": "62b398fbb1f4b74be6bb06b1812aca08599e0487f30982af311bc8fcc6ffba0d78d9d8bfb26d96ed8e3cacd3da3b5a1ac13a92710aa5e5afcaed3358df4807d6"
    },
    {
      "line": 376,
      "relation": "negativeCorrelation",
      "evidence": "The levels of sRAGE consistently decreased with age (R = −0.264, p = <0.001) and with the indices of obesity, such as BMI. However, of special interest was the highly significant and previ-ously not reported independent correlation with fat free mass (p < 0.001).",
      "citation": {
        "type": "PubMed",
        "reference": "25681682",
        "name": "Mechanisms of ageing and development",
        "title": "Age and genetic determinants of variation of circulating levels of the receptor for advanced glycation end products (RAGE) in the general human population.",
        "volume": "145",
        "pages": "18-25",
        "date": "2015-01-01",
        "first": "Prakash J",
        "last": "Livshits G",
        "authors": [
          "Livshits G",
          "Pichchadze G",
          "Prakash J",
          "Trofimov S"
        ]
      },
      "annotations": {
        "Anatomy": {
          "blood plasma": true
        }
      },
      "source": 371,
      "target": 202,
      "key": "387535749bf22e5c493238c1f7ece0fc1ce19c44114a99e661d9ffaae90f98d0c1285a34d9957edd9f69399f71742100c0e9473173faa00862c6163d618d1a6f"
    },
    {
      "line": 386,
      "relation": "increases",
      "evidence": "Recently, Li et al. (2012b) have demonstrated in their study that AGEs can induce tau hyperphosphorylation through receptor for advanced glycation end product (RAGE)-mediated glycogen synthase kinase 3 (GSK-3) activation and targeting RAGE/GSK-3 pathway can improve AD-like changes.",
      "citation": {
        "type": "PubMed",
        "reference": "24183963",
        "name": "Neuroscience",
        "title": "Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation.",
        "volume": "256",
        "pages": "137-46",
        "date": "2014-01-03",
        "first": "Chen S",
        "last": "Gao XD",
        "authors": [
          "An FM",
          "Chen S",
          "Gao XD",
          "Liu AR",
          "Yao WB",
          "Yin DK",
          "Yin L"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 371,
      "target": 456,
      "key": "49a9cfba1700ed13151e9f2cd68f1ece8591f3a783eceb79c16e46f83692f7403bae7681a361b48d978900f377b206de95fc0682d30b8310a7e40398fa0fdef1"
    },
    {
      "line": 659,
      "relation": "increases",
      "evidence": "Collectively, these studies demonstrate that the soluble, astroglial-derived S100B protein interacts with RAGE leading to the JNK phosphorylation and the pJNK-dependent up-regulation of c-Jun, a component of the AP-1 complex.",
      "citation": {
        "type": "PubMed",
        "reference": "18494933",
        "name": "Journal of cellular and molecular medicine",
        "title": "S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells.",
        "volume": "12",
        "pages": "914-27",
        "date": "2008-06-01",
        "first": "Esposito G",
        "last": "Steardo L",
        "authors": [
          "De Filippis D",
          "Esposito G",
          "Iuvone T",
          "Lu J",
          "Savani C",
          "Scuderi C",
          "Sheen V",
          "Steardo L",
          "Steardo L Jr"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "neural stem cell": true
        },
        "Method": {
          "Electrophoretic Mobility Shift Assay": true,
          "Western Blot": true,
          "RT-PCR": true,
          "Immunofluorescence": true,
          "RNA Interference, siRNA": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 371,
      "target": 484,
      "key": "92d1a08c63c1ed22a69820637a85e183aeecc3700f7110cb7f3011d87ef093d7a301175ebcf2f42ba4225a7e1f449841c886d90d63b71b3e74ada72cdd3e8c1e"
    },
    {
      "line": 375,
      "relation": "negativeCorrelation",
      "evidence": "The levels of sRAGE consistently decreased with age (R = −0.264, p = <0.001) and with the indices of obesity, such as BMI. However, of special interest was the highly significant and previ-ously not reported independent correlation with fat free mass (p < 0.001).",
      "citation": {
        "type": "PubMed",
        "reference": "25681682",
        "name": "Mechanisms of ageing and development",
        "title": "Age and genetic determinants of variation of circulating levels of the receptor for advanced glycation end products (RAGE) in the general human population.",
        "volume": "145",
        "pages": "18-25",
        "date": "2015-01-01",
        "first": "Prakash J",
        "last": "Livshits G",
        "authors": [
          "Livshits G",
          "Pichchadze G",
          "Prakash J",
          "Trofimov S"
        ]
      },
      "annotations": {
        "Anatomy": {
          "blood plasma": true
        }
      },
      "source": 195,
      "target": 371,
      "key": "b658744a0af17a9c6e86624e8a1dd0dca79c1c1d4a46291ab8b1764488114f3133ecebdfa911f5c7b3146a584cf74cbc4c33afcd2c9d5adbd87f264f49fc376c"
    },
    {
      "line": 3776,
      "relation": "increases",
      "evidence": "Interestingly, the middle-aged rats have higher levels of PTP-1B, lower phosphorylation of IRS-1, Akt, GSK3β, mTOR, and TrkB. Also, the aging process increased Tau phosphorylation and β-amyloid content in the hippocampus region. In summary, this study provides new evidence that aging-related PTP1B increasing, contributing to insulin resistance and the onset of the AD.",
      "citation": {
        "type": "PubMed",
        "reference": "29421605",
        "name": "Experimental gerontology",
        "title": "Impaired insulin signaling and spatial learning in middle-aged rats: The role of PTP1B.",
        "volume": "104",
        "pages": "66-71",
        "date": "2018-04-01",
        "first": "Kuga GK",
        "last": "Pauli JR",
        "authors": [
          "Botezelli JD",
          "Cintra DE",
          "Gaspar RC",
          "Gomes RJ",
          "Kuga GK",
          "Leme JACA",
          "Muñoz VR",
          "Nakandakari SCBR",
          "Pauli JR",
          "Ropelle ER",
          "da Silva ASR",
          "de Moura LP"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 195,
      "target": 899,
      "key": "a65bd3d7638c01359143c795b74fcb81eb26cdd666ad79130f04fbb5c9c270a83b031ead573b30a9fd308fd2b4ecd0cd9bdb60a5565542cdad0d339fe369bdb0"
    },
    {
      "line": 376,
      "relation": "negativeCorrelation",
      "evidence": "The levels of sRAGE consistently decreased with age (R = −0.264, p = <0.001) and with the indices of obesity, such as BMI. However, of special interest was the highly significant and previ-ously not reported independent correlation with fat free mass (p < 0.001).",
      "citation": {
        "type": "PubMed",
        "reference": "25681682",
        "name": "Mechanisms of ageing and development",
        "title": "Age and genetic determinants of variation of circulating levels of the receptor for advanced glycation end products (RAGE) in the general human population.",
        "volume": "145",
        "pages": "18-25",
        "date": "2015-01-01",
        "first": "Prakash J",
        "last": "Livshits G",
        "authors": [
          "Livshits G",
          "Pichchadze G",
          "Prakash J",
          "Trofimov S"
        ]
      },
      "annotations": {
        "Anatomy": {
          "blood plasma": true
        }
      },
      "source": 202,
      "target": 371,
      "key": "3be95ffdfff6dd784c5ac5e64835179a3a02d93aa68715fc50201063845d2de60b08dcf07f416ac01c6c636d2d4afffcf9f922a6c851cb419cf5b4e730456697"
    },
    {
      "line": 378,
      "relation": "directlyIncreases",
      "evidence": "The levels of sRAGE consistently decreased with age (R = −0.264, p = <0.001) and with the indices of obesity, such as BMI. However, of special interest was the highly significant and previ-ously not reported independent correlation with fat free mass (p < 0.001).",
      "citation": {
        "type": "PubMed",
        "reference": "25681682",
        "name": "Mechanisms of ageing and development",
        "title": "Age and genetic determinants of variation of circulating levels of the receptor for advanced glycation end products (RAGE) in the general human population.",
        "volume": "145",
        "pages": "18-25",
        "date": "2015-01-01",
        "first": "Prakash J",
        "last": "Livshits G",
        "authors": [
          "Livshits G",
          "Pichchadze G",
          "Prakash J",
          "Trofimov S"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 9,
      "target": 371,
      "key": "da885511c60e3cbd50fec3af72ecd22db444a7713100a534de1e67c6da6a4a301d7c6be084012356e5f518695fe2c664c3c813adcee868a21cdc604d16c37974"
    },
    {
      "line": 385,
      "relation": "directlyIncreases",
      "evidence": "Recently, Li et al. (2012b) have demonstrated in their study that AGEs can induce tau hyperphosphorylation through receptor for advanced glycation end product (RAGE)-mediated glycogen synthase kinase 3 (GSK-3) activation and targeting RAGE/GSK-3 pathway can improve AD-like changes.",
      "citation": {
        "type": "PubMed",
        "reference": "24183963",
        "name": "Neuroscience",
        "title": "Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation.",
        "volume": "256",
        "pages": "137-46",
        "date": "2014-01-03",
        "first": "Chen S",
        "last": "Gao XD",
        "authors": [
          "An FM",
          "Chen S",
          "Gao XD",
          "Liu AR",
          "Yao WB",
          "Yin DK",
          "Yin L"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 9,
      "target": 371,
      "key": "bc2c461be40f83fe86e46f09e1454c6db3066c68db8dcad1cce5e7d23f346dec58b6ecbdd65fe98f8b44834c3a15561a7915acd4dccd6dd01f8c1c0e471df3b8"
    },
    {
      "line": 388,
      "relation": "increases",
      "evidence": "Recently, Li et al. (2012b) have demonstrated in their study that AGEs can induce tau hyperphosphorylation through receptor for advanced glycation end product (RAGE)-mediated glycogen synthase kinase 3 (GSK-3) activation and targeting RAGE/GSK-3 pathway can improve AD-like changes.",
      "citation": {
        "type": "PubMed",
        "reference": "24183963",
        "name": "Neuroscience",
        "title": "Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation.",
        "volume": "256",
        "pages": "137-46",
        "date": "2014-01-03",
        "first": "Chen S",
        "last": "Gao XD",
        "authors": [
          "An FM",
          "Chen S",
          "Gao XD",
          "Liu AR",
          "Yao WB",
          "Yin DK",
          "Yin L"
        ]
      },
      "source": 9,
      "target": 538,
      "key": "14ea1b527b8f304f9f72aae40e14ac6b558c4db3612983616bb353a0c98090a1719f6abf6caf177b0864637de671ca5ddc3e1beda9ba5c16dd3791893189445a"
    },
    {
      "line": 539,
      "relation": "increases",
      "evidence": "Thus, our results suggest that Tau hyperphosphorylation was a result of ribosylated AGEs, rather than due to a direct reaction involving D-ribose.",
      "citation": {
        "type": "PubMed",
        "reference": "26095350",
        "name": "Aging cell",
        "title": "Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII.",
        "volume": "14",
        "pages": "754-63",
        "date": "2015-10-01",
        "first": "Wei Y",
        "last": "He R",
        "authors": [
          "Han C",
          "He R",
          "Liu Y",
          "Su T",
          "Wang Y",
          "Wei Y",
          "Wu B"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Method": {
          "Immunofluorescence": true,
          "Western Blot": true,
          "Immunohistochemistry": true
        },
        "Cell_Line": {
          "N2a": true
        }
      },
      "source": 9,
      "target": 817,
      "key": "28219bfedf19a5fecd5208c063e458f06f3e958838ef03bb91e4680db39c0e484058491709d4d93c3ed5157252c79e3f3079e1875ddd0a355f048a47ac26f284"
    },
    {
      "line": 540,
      "relation": "increases",
      "evidence": "Thus, our results suggest that Tau hyperphosphorylation was a result of ribosylated AGEs, rather than due to a direct reaction involving D-ribose.",
      "citation": {
        "type": "PubMed",
        "reference": "26095350",
        "name": "Aging cell",
        "title": "Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII.",
        "volume": "14",
        "pages": "754-63",
        "date": "2015-10-01",
        "first": "Wei Y",
        "last": "He R",
        "authors": [
          "Han C",
          "He R",
          "Liu Y",
          "Su T",
          "Wang Y",
          "Wei Y",
          "Wu B"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Method": {
          "Immunofluorescence": true,
          "Western Blot": true,
          "Immunohistochemistry": true
        },
        "Cell_Line": {
          "N2a": true
        }
      },
      "source": 9,
      "target": 823,
      "key": "9a96ae26342e3db880ea2352a499100efb806273e6012560cecef7c8963992e1a9b392b56252a91d979aacbaf7e468afb562b3ab8a0ceb4fb5fb33e4e54167ed"
    },
    {
      "line": 562,
      "relation": "increases",
      "evidence": "Taken all together, we think that activation of GSK-3b and p38 should be responsible for MG-induced tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 9,
      "target": 794,
      "key": "d3f15ec17371c4648adb0064d80b8fe9aea07084d1f33b6a60d51c92a2237d20a83492a36a6815a495dea93d9561dace9a1412bd63e5060123074827f9e22f4c"
    },
    {
      "line": 563,
      "relation": "increases",
      "evidence": "Taken all together, we think that activation of GSK-3b and p38 should be responsible for MG-induced tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 9,
      "target": 801,
      "key": "bba30de32933415a2ae1d376622249fa5fe80b87c059a1e74e4a3d95293ebfaf3099fc1f202db68bc56c76278d0a125af60e3ad2af4bf829a7d3e3cc16bc57ad"
    },
    {
      "line": 702,
      "relation": "decreases",
      "evidence": "Glycation by AGE (Advanced Glycation End products) decreases MT binding, promotes aggregation, activates RAGE",
      "citation": {
        "type": "PubMed",
        "reference": "8063802",
        "name": "The Journal of biological chemistry",
        "title": "Analysis of microtubule-associated protein tau glycation in paired helical filaments.",
        "volume": "269",
        "pages": "21614-9",
        "date": "1994-08-26",
        "first": "Ledesma MD",
        "last": "Avila J",
        "authors": [
          "Avila J",
          "Bonay P",
          "Colaço C",
          "Ledesma MD"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 9,
      "target": 486,
      "key": "c5b8a7dfb8b44932dcb96fb80e6dd5e7b86a88c2d22bd042afbc227f4d9bf8bf5a1dd3558e5ca4a4fbe72e7818d7c1daf1a493fd42de3eb4a6f9d89ec825df47"
    },
    {
      "line": 703,
      "relation": "increases",
      "evidence": "Glycation by AGE (Advanced Glycation End products) decreases MT binding, promotes aggregation, activates RAGE",
      "citation": {
        "type": "PubMed",
        "reference": "8063802",
        "name": "The Journal of biological chemistry",
        "title": "Analysis of microtubule-associated protein tau glycation in paired helical filaments.",
        "volume": "269",
        "pages": "21614-9",
        "date": "1994-08-26",
        "first": "Ledesma MD",
        "last": "Avila J",
        "authors": [
          "Avila J",
          "Bonay P",
          "Colaço C",
          "Ledesma MD"
        ]
      },
      "source": 9,
      "target": 188,
      "key": "92cb1ca7a89d4b32a83c044aac086d5ee7210b079fadae660f008f67780f0b4c2efc35bb3c43546a2a3904182016d5ced18de564a091e77e3833fb521fe775d0"
    },
    {
      "line": 387,
      "relation": "increases",
      "evidence": "Recently, Li et al. (2012b) have demonstrated in their study that AGEs can induce tau hyperphosphorylation through receptor for advanced glycation end product (RAGE)-mediated glycogen synthase kinase 3 (GSK-3) activation and targeting RAGE/GSK-3 pathway can improve AD-like changes.",
      "citation": {
        "type": "PubMed",
        "reference": "24183963",
        "name": "Neuroscience",
        "title": "Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation.",
        "volume": "256",
        "pages": "137-46",
        "date": "2014-01-03",
        "first": "Chen S",
        "last": "Gao XD",
        "authors": [
          "An FM",
          "Chen S",
          "Gao XD",
          "Liu AR",
          "Yao WB",
          "Yin DK",
          "Yin L"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 538,
      "key": "db8195289edda596f9c0dc3922b24abc127916fa894846d149ca9edb33e914de853eefc4eaa8525f3824487eb68b663b683f6582268de07561ee44a79296be8b"
    },
    {
      "line": 671,
      "relation": "increases",
      "evidence": "In addition, as revealed by Western blot, small interfering RNA and immunofluorescence analysis, S100B-induced JNK activation increased expression of Dickopff-1 that, in turn, promoted glycogen synthase kinase 3-beta phosphorylation and beta-catenin degradation, causing canonical Wnt pathway disruption and tau protein hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "18494933",
        "name": "Journal of cellular and molecular medicine",
        "title": "S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells.",
        "volume": "12",
        "pages": "914-27",
        "date": "2008-06-01",
        "first": "Esposito G",
        "last": "Steardo L",
        "authors": [
          "De Filippis D",
          "Esposito G",
          "Iuvone T",
          "Lu J",
          "Savani C",
          "Scuderi C",
          "Sheen V",
          "Steardo L",
          "Steardo L Jr"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "neural stem cell": true
        },
        "Method": {
          "Electrophoretic Mobility Shift Assay": true,
          "Western Blot": true,
          "RT-PCR": true,
          "Immunofluorescence": true,
          "RNA Interference, siRNA": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 538,
      "key": "dab57261d50295b097d318dd78d3ba46af075ff7f7f538bbb3bb1bcde1ca2cbb61f61517df1be0c8050928343fbf315e20761f7e7314c386bf604dcd4b961ff6"
    },
    {
      "line": 1030,
      "relation": "directlyIncreases",
      "evidence": "Taken together, our results show that DMF reduces GSK-3 activity in vivo as determined by a significant and subtle reduction in the phosphorylation levels of its two substrates TAU and CRMP2 respectively.",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 538,
      "key": "ce3d06b9b738203ac15c76b00537be666031019ba5b1ed016775f19844cf930d67cf3ab64840d0edc6b8baceabfb5a14f72c5ae56569cda59b5a805aea6beb81"
    },
    {
      "line": 1202,
      "relation": "increases",
      "evidence": "Alsterpaullone, the most active paullone, was demonstrated to act by competing with ATP for binding to GSK-3beta. Alsterpaullone inhibits the phosphorylation of tau in vivo at sites which are typically phosphorylated by GSK-3beta in Alzheimer's disease. Alsterpaullone also inhibits the CDK5/p25-dependent phosphorylation of DARPP-32 in mouse striatum slices in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "10998059",
        "name": "European journal of biochemistry",
        "title": "Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.",
        "volume": "267",
        "pages": "5983-94",
        "date": "2000-10-01",
        "first": "Leost M",
        "last": "Meijer L",
        "authors": [
          "Bibb JA",
          "Biernat J",
          "Greengard P",
          "Gussio R",
          "Kunick C",
          "Leost M",
          "Link A",
          "Mandelkow EM",
          "Meijer L",
          "Sausville EA",
          "Schultz C",
          "Senderowicz AM",
          "Snyder GL",
          "Wu YZ",
          "Zaharevitz DW"
        ]
      },
      "annotations": {
        "Ki": {
          "4-80 nM": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 538,
      "key": "7e8cd51a1f72b05594bdc95c42e311bbda6be3d2dc628de4c1183a6568c6d4f1273f0ff0c7a3336c5ffabac9fcc12ff891091b9c69012eeb0cce98b3c797b0e9"
    },
    {
      "relation": "hasVariant",
      "source": 456,
      "target": 457,
      "key": "c32cc4766e32f47c9607f6acfe2046eef85dae6a416e8f80bdf283a7b82d64714996d02bc368875e92e9cabfbc0ea8d565da15b5b80cee241c4e9d55b8920cea"
    },
    {
      "line": 1000,
      "relation": "increases",
      "evidence": "The second mechanism is related to GSK-3, which phosphorylates NRF2 creating a recognition site for β-Transducin Repeat Containing E3 Ubiquitin Protein Ligase (β-TrCP). β-TrCP leads to Cullin-1/Rbx1-mediated NRF2 ubiquitination and its subsequent degradation [8]. Since GSK-3β is inhibited by phosphorylation at Ser9 by Ser/Thr protein kinases such as AKT, it has been suggested that NRF2 might be up-regulated through activation of AKT and permanent inactivation of GSK-3 [9], [10].",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "source": 456,
      "target": 642,
      "key": "e2564c6da24953477a9e142f0300400dd82d3b52839f2def59624d8a0ec80f2ff2aa5862ead4f4c8904bd0f0b6616962d8467e6a83ad0e14238bdf444d5502c9"
    },
    {
      "line": 1008,
      "relation": "decreases",
      "evidence": "The second mechanism is related to GSK-3, which phosphorylates NRF2 creating a recognition site for β-Transducin Repeat Containing E3 Ubiquitin Protein Ligase (β-TrCP). β-TrCP leads to Cullin-1/Rbx1-mediated NRF2 ubiquitination and its subsequent degradation [8]. Since GSK-3β is inhibited by phosphorylation at Ser9 by Ser/Thr protein kinases such as AKT, it has been suggested that NRF2 might be up-regulated through activation of AKT and permanent inactivation of GSK-3 [9], [10].",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "source": 456,
      "target": 641,
      "key": "1a183b613b5f0bb8fdefa1106040e01d02be2e22c097140085dd0aeaa6351a7008d2551ad55e9f9ea616b7758e6cf196e37f583324f2387d783d10c127067277"
    },
    {
      "line": 2804,
      "relation": "decreases",
      "evidence": "Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor known to increase the level of many antioxidants, including glutathione-S transferase (GST), and is negatively regulated by the activity of GSK-3β. Our results indicated the increased nuclear localization of Nrf2 and level of GST, suggesting the increased activity of the transcription factor as a result of GSK-3β suppression, consistent with the decreased oxidative stress observed. Consistent with the improved learning and memory, and consistent with GSK-3b being a tau kinase, we observed decreased tau phosphorylation in brain of GAO-treated SAMP8 mice compared to that of RAO-treated SAMP8 mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24355211",
        "name": "Free radical biology &amp; medicine",
        "title": "Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease.",
        "volume": "67",
        "pages": "387-95",
        "date": "2014-02-01",
        "first": "Farr SA",
        "last": "Butterfield DA",
        "authors": [
          "Butterfield DA",
          "Farr SA",
          "Kumar V",
          "Morley JE",
          "Murphy MP",
          "Niehoff ML",
          "Platt TL",
          "Ripley JL",
          "Sultana R",
          "Zhang Z"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "SAMP8 mice": true
        }
      },
      "source": 456,
      "target": 641,
      "key": "91246fb3660e2dbf2ae195883db117401ad89976f68e859655a63f1a16a884be9ddf29f860fbc19e6616dcff221fdeda678e94ffc48ce9f48490e837dfa77d53"
    },
    {
      "line": 1029,
      "relation": "directlyIncreases",
      "evidence": "Taken together, our results show that DMF reduces GSK-3 activity in vivo as determined by a significant and subtle reduction in the phosphorylation levels of its two substrates TAU and CRMP2 respectively.",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 440,
      "key": "f2ec1e8fb8f3896bd10a95b5bc86343b351b13d205d91e658b7b1f09a030fad28c9b1b8cf25c4a472cf9b3e60a9bb21caf4e7af8b9fde4c2def543862144796b"
    },
    {
      "line": 1068,
      "relation": "increases",
      "evidence": "Vm (nM/min/mg) is 2400, 80, 106, 650, and 140; Km is 200, 59, 114, 16 (all uM) and 5mg/ml for phospho-CREB peptide, myelin basic protein, k-casein, phosphatase Inhibitor-2 and phosvitin",
      "citation": {
        "type": "PubMed",
        "reference": "7514173",
        "name": "The Journal of biological chemistry",
        "title": "Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation.",
        "volume": "269",
        "pages": "14566-74",
        "date": "1994-05-20",
        "first": "Wang QM",
        "last": "Roach PJ",
        "authors": [
          "DePaoli-Roach AA",
          "Fiol CJ",
          "Roach PJ",
          "Wang QM"
        ]
      },
      "annotations": {
        "Vmax": {
          "2400 nM/min/mg": true
        },
        "Km": {
          "200 μM": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 285,
      "key": "7b2ea866e78d31e8994db907a1574c39897f4df7b73475df9b326fa56bb7ef9f18c19e932ffc6a8822dda5a9ecacb6059b4fe2e19a944361c25c1fe04b85640c"
    },
    {
      "line": 1071,
      "relation": "increases",
      "evidence": "Vm (nM/min/mg) is 2400, 80, 106, 650, and 140; Km is 200, 59, 114, 16 (all uM) and 5mg/ml for phospho-CREB peptide, myelin basic protein, k-casein, phosphatase Inhibitor-2 and phosvitin",
      "citation": {
        "type": "PubMed",
        "reference": "7514173",
        "name": "The Journal of biological chemistry",
        "title": "Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation.",
        "volume": "269",
        "pages": "14566-74",
        "date": "1994-05-20",
        "first": "Wang QM",
        "last": "Roach PJ",
        "authors": [
          "DePaoli-Roach AA",
          "Fiol CJ",
          "Roach PJ",
          "Wang QM"
        ]
      },
      "annotations": {
        "Vmax": {
          "80 nM/min/mg": true
        },
        "Km": {
          "59 μM": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 638,
      "key": "81f10dbc5891845e23df89f7cc6fac3ceef8ecf92e9ce1e545182b1e92d62858eca15fddcfc627fbd6bdd4859d2f4064d119033a13e79abee2090c294263ba1d"
    },
    {
      "line": 1074,
      "relation": "increases",
      "evidence": "Vm (nM/min/mg) is 2400, 80, 106, 650, and 140; Km is 200, 59, 114, 16 (all uM) and 5mg/ml for phospho-CREB peptide, myelin basic protein, k-casein, phosphatase Inhibitor-2 and phosvitin",
      "citation": {
        "type": "PubMed",
        "reference": "7514173",
        "name": "The Journal of biological chemistry",
        "title": "Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation.",
        "volume": "269",
        "pages": "14566-74",
        "date": "1994-05-20",
        "first": "Wang QM",
        "last": "Roach PJ",
        "authors": [
          "DePaoli-Roach AA",
          "Fiol CJ",
          "Roach PJ",
          "Wang QM"
        ]
      },
      "annotations": {
        "Vmax": {
          "106 nM/min/mg": true
        },
        "Km": {
          "114 μM": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 410,
      "key": "df5a36ceaaa6f1667b1ebe242fe066d89b854bd83ff7f90b500cf67b531d53a08b77547768ee11ad9f48c832001ae34354eb843963125bebd49c6624e9166d22"
    },
    {
      "line": 1077,
      "relation": "increases",
      "evidence": "Vm (nM/min/mg) is 2400, 80, 106, 650, and 140; Km is 200, 59, 114, 16 (all uM) and 5mg/ml for phospho-CREB peptide, myelin basic protein, k-casein, phosphatase Inhibitor-2 and phosvitin",
      "citation": {
        "type": "PubMed",
        "reference": "7514173",
        "name": "The Journal of biological chemistry",
        "title": "Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation.",
        "volume": "269",
        "pages": "14566-74",
        "date": "1994-05-20",
        "first": "Wang QM",
        "last": "Roach PJ",
        "authors": [
          "DePaoli-Roach AA",
          "Fiol CJ",
          "Roach PJ",
          "Wang QM"
        ]
      },
      "annotations": {
        "Vmax": {
          "140 nM/min/mg": true
        },
        "Km": {
          "5 μM": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 656,
      "key": "54f81b096580b8c6ac8087a2e89ddda998a0afdee87f86f7319b128521eec1c3b145eac10042f1b565eefc5b511a6d578c86462ca07df1d7e788017478e21513"
    },
    {
      "line": 1080,
      "relation": "increases",
      "evidence": "Vm (nM/min/mg) is 2400, 80, 106, 650, and 140; Km is 200, 59, 114, 16 (all uM) and 5mg/ml for phospho-CREB peptide, myelin basic protein, k-casein, phosphatase Inhibitor-2 and phosvitin",
      "citation": {
        "type": "PubMed",
        "reference": "7514173",
        "name": "The Journal of biological chemistry",
        "title": "Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation.",
        "volume": "269",
        "pages": "14566-74",
        "date": "1994-05-20",
        "first": "Wang QM",
        "last": "Roach PJ",
        "authors": [
          "DePaoli-Roach AA",
          "Fiol CJ",
          "Roach PJ",
          "Wang QM"
        ]
      },
      "annotations": {
        "Vmax": {
          "650 nM/min/mg": true
        },
        "Km": {
          "16 μM": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 419,
      "key": "f45ca93162de7b3eddef3da324e646d001e877d2e9ce8505a37aeed33c831ebc2da1e2b2f9b3c93d06ea5626bc9f22208dc0822120ef8381e3810c6eed6d9dad"
    },
    {
      "line": 1110,
      "relation": "increases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 577,
      "key": "20287a7bcbb66d2ed3aaa705b7ccda5046846dba63a03ddc65afa5a158c5778372b7fa4c7945b32f11fd8daf97182260bc3758d37bc9b2b419d2949699cadfac"
    },
    {
      "line": 1111,
      "relation": "increases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 543,
      "key": "b05ae3d9e1ef5e8adfd4719a1a1f3d284d2b08df8dce0f8dbc74f4fd71b8702ed0156c7da5a1c1d8b2ad9fc31fdfe41b8830d74b456e7c697f421e1cba6cd61e"
    },
    {
      "line": 2462,
      "relation": "increases",
      "evidence": "Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift in mobility as a result of phosphorylation-like changes, we conclude that they have the characteristics of hyperphosphorylated tau. These mutants will therefore be referred to as pseudo-hyperphosphorylated tau throughout the manuscript. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.",
      "citation": {
        "type": "PubMed",
        "reference": "19459590",
        "name": "Biochemistry",
        "title": "Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.",
        "volume": "48",
        "pages": "6002-11",
        "date": "2009-06-30",
        "first": "Sun Q",
        "last": "Gamblin TC",
        "authors": [
          "Gamblin TC",
          "Sun Q"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 543,
      "key": "f62a3c8de8be418c9f721a94d3da88ee74b6e7f4d48d86baa8750bd6459bedc81b74164b380da69cb8d62928528adb83c1b5264b1868dac4b2165503125599c2"
    },
    {
      "line": 3849,
      "relation": "directlyIncreases",
      "evidence": "Filamentous, but not soluble, forms of wild-type tau inhibit anterograde, kinesin-based fast axonal transport (FAT) by activating axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK3), independent of microtubule binding. Amino acids 2-18 of tau, comprising a phosphatase-activating domain (PAD), are necessary and sufficient for activation of this pathway. Various pathogenic forms of tau displaying increased exposure of PAD inhibited anterograde FAT in squid axoplasm. Immunohistochemical studies using a novel PAD-specific monoclonal antibody in human postmortem tissue indicated that increased PAD exposure represents an early pathogenic event in AD that closely associates in time with AT8 immunoreactivity. We propose a model of pathogenesis in which disease-associated changes in tau conformation lead to increased exposure of PAD, activation of PP1-GSK3, and inhibition of FAT",
      "citation": {
        "type": "PubMed",
        "reference": "21734277",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "volume": "31",
        "pages": "9858-68",
        "date": "2011-07-06",
        "first": "Kanaan NM",
        "last": "Binder LI",
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 456,
      "target": 543,
      "key": "e455cf5a72dc5328f3d4fa9fc6f1cbed7fb0f54da8d0adc7d7a638d83edba85cdc69de8bd2a98476135eeddd861a2c32e7e9f1d3a68ac0dd994c8e9c7945eed4"
    },
    {
      "line": 1112,
      "relation": "increases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 544,
      "key": "daf33a5d3a06f049dd07c557955d67758ad93c59150fc7e209b92e202cf2b993cc11ff191cd0407b68fd47816ac7b7672ed5f42e26c4e11cfadd0dabe524eef9"
    },
    {
      "line": 3850,
      "relation": "directlyIncreases",
      "evidence": "Filamentous, but not soluble, forms of wild-type tau inhibit anterograde, kinesin-based fast axonal transport (FAT) by activating axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK3), independent of microtubule binding. Amino acids 2-18 of tau, comprising a phosphatase-activating domain (PAD), are necessary and sufficient for activation of this pathway. Various pathogenic forms of tau displaying increased exposure of PAD inhibited anterograde FAT in squid axoplasm. Immunohistochemical studies using a novel PAD-specific monoclonal antibody in human postmortem tissue indicated that increased PAD exposure represents an early pathogenic event in AD that closely associates in time with AT8 immunoreactivity. We propose a model of pathogenesis in which disease-associated changes in tau conformation lead to increased exposure of PAD, activation of PP1-GSK3, and inhibition of FAT",
      "citation": {
        "type": "PubMed",
        "reference": "21734277",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "volume": "31",
        "pages": "9858-68",
        "date": "2011-07-06",
        "first": "Kanaan NM",
        "last": "Binder LI",
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 456,
      "target": 544,
      "key": "7dcf9eb2816016636cc77287dcdea842b169e28c98d24d61f8f8470b310b24701b660720dce8d478eb30b80481f28e2a32c5990f676cfd809355083259974cf0"
    },
    {
      "line": 1113,
      "relation": "increases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 579,
      "key": "15d89e9d216b2c064343fe7416b9e5722b38aec3fdb1628ce3f7e49f71e497075a6e82a437336f4a22cdaf324d10bc568a3e18b82e3c3de2f352fd0472b060ed"
    },
    {
      "line": 3851,
      "relation": "directlyIncreases",
      "evidence": "Filamentous, but not soluble, forms of wild-type tau inhibit anterograde, kinesin-based fast axonal transport (FAT) by activating axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK3), independent of microtubule binding. Amino acids 2-18 of tau, comprising a phosphatase-activating domain (PAD), are necessary and sufficient for activation of this pathway. Various pathogenic forms of tau displaying increased exposure of PAD inhibited anterograde FAT in squid axoplasm. Immunohistochemical studies using a novel PAD-specific monoclonal antibody in human postmortem tissue indicated that increased PAD exposure represents an early pathogenic event in AD that closely associates in time with AT8 immunoreactivity. We propose a model of pathogenesis in which disease-associated changes in tau conformation lead to increased exposure of PAD, activation of PP1-GSK3, and inhibition of FAT",
      "citation": {
        "type": "PubMed",
        "reference": "21734277",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "volume": "31",
        "pages": "9858-68",
        "date": "2011-07-06",
        "first": "Kanaan NM",
        "last": "Binder LI",
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 456,
      "target": 579,
      "key": "964f4bc0a5d9b8237c50b221bdc0fce870d0cd90f44f2ecad0bb6cdfd5bc145983e742e95e253696bc4eab6d5f96c26d54f4737a8bc341956a09b217a868bc1e"
    },
    {
      "line": 1114,
      "relation": "increases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 582,
      "key": "be21fff161dc246831b972c48b24298350595cbc76f78641f157d926b74b23fc260b63fc554cb6452694afa84fefa63b094664c0133cd3892410130b2985bfa2"
    },
    {
      "line": 1115,
      "relation": "increases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 583,
      "key": "02bcb3da558fe2c42e7d7ec6c3d0941ad68d76bbfea5d4ee4efd299d97777228c03a9bc94265d5ee64ba9ba8d2ba83fc63a94c973dd286e6feef6764e9e94521"
    },
    {
      "line": 1116,
      "relation": "increases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 564,
      "key": "f078e4939b4bcb1e7f51c80ea951b942f71e44c6eb4a5ac6ec4a5aa05d9e13f25cc443f2d5633379c1715985cce8dd84f0686a6d31ca897299e6f0a27b7057a4"
    },
    {
      "line": 2464,
      "relation": "increases",
      "evidence": "Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift in mobility as a result of phosphorylation-like changes, we conclude that they have the characteristics of hyperphosphorylated tau. These mutants will therefore be referred to as pseudo-hyperphosphorylated tau throughout the manuscript. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.",
      "citation": {
        "type": "PubMed",
        "reference": "19459590",
        "name": "Biochemistry",
        "title": "Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.",
        "volume": "48",
        "pages": "6002-11",
        "date": "2009-06-30",
        "first": "Sun Q",
        "last": "Gamblin TC",
        "authors": [
          "Gamblin TC",
          "Sun Q"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 564,
      "key": "e3691709488e492d76563df6e4cf63d6b294d745ac0102574a5c9553f2e90ebcf04b695bb5dcc6f52cd0659db64da4e168e87d5de277b3a3db274840aa5e8b82"
    },
    {
      "line": 3395,
      "relation": "positiveCorrelation",
      "evidence": "This study aimed to investigate the protective effects and mechanism of the novel HDAC6 inhibitor, MPT0G211, using an AD model. Our results indicated that MPT0G211 significantly reduced tau phosphorylation and aggregation, the processes highly correlated with the formation of NFTs. This HDAC6 inhibitory activity resulted in an increase in acetylated Hsp90, which decreased Hsp90 and HDAC6 binding, causing ubiquitination of phosphorylated tau proteins. In addition, a significant increase of phospho-glycogen synthase kinase-3β (phospho-GSK3β) on Ser9 (the inactive form) through Akt phosphorylation was associated with the inhibition of phospho-tau Ser396 in response to MPT0G211 treatment.",
      "citation": {
        "type": "PubMed",
        "reference": "29844403",
        "name": "Cell death &amp; disease",
        "title": "The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.",
        "volume": "9",
        "pages": "655",
        "date": "2018-05-29",
        "first": "Fan SJ",
        "last": "Yang CR",
        "authors": [
          "Fan SJ",
          "Huang FI",
          "Liou JP",
          "Yang CR"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true,
          "SH-SY5Y": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 456,
      "target": 564,
      "key": "a16c8438b51435b58c848ea16883464c6675d4fd2781deaae0aa755bdb253e34753280c6b72758c0ff80c96cc40ce855ae410f182bb2aca91e12fc2a5ff39e80"
    },
    {
      "line": 1117,
      "relation": "increases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 569,
      "key": "888d0aebffa9b7dc4149a76244af3256c845c20e9aa363a1f82568f987118edf58c79b141dc674f7b36f4f1f7eeff14adefcb084b0654df9357014ce7667027e"
    },
    {
      "line": 1118,
      "relation": "increases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 565,
      "key": "2f465eb423870aba37881de25c775d2dba1c77837652d7d174e142af1060ea328724d95b0ac2453ebc7fa45b5b54bed857dc35d2ac12d5c2733d3997e5e6ef90"
    },
    {
      "line": 2465,
      "relation": "increases",
      "evidence": "Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift in mobility as a result of phosphorylation-like changes, we conclude that they have the characteristics of hyperphosphorylated tau. These mutants will therefore be referred to as pseudo-hyperphosphorylated tau throughout the manuscript. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.",
      "citation": {
        "type": "PubMed",
        "reference": "19459590",
        "name": "Biochemistry",
        "title": "Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.",
        "volume": "48",
        "pages": "6002-11",
        "date": "2009-06-30",
        "first": "Sun Q",
        "last": "Gamblin TC",
        "authors": [
          "Gamblin TC",
          "Sun Q"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 565,
      "key": "98bb32e796e7a576216063e6b35ba9f51257239b186c33960c7c5de9b64627a7447fb14e207660ee75fe2dc9702e04dd61a0cb3ed2d4d4bdc901fe7e2d82d2f4"
    },
    {
      "line": 1119,
      "relation": "increases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 580,
      "key": "c30aefaf492a5cb2db875628e15abc1b98ee4fa6bf9605b9db6a92ec31af4cb0258df2740fd6183fd330c5d6af63aad856ddd0221f730808d9dc76fd3311a3f9"
    },
    {
      "line": 1164,
      "relation": "increases",
      "evidence": "By using a yeast two hybrid system, TPKI was found to interact with pyruvate dehydrogenase (PDH), which is a key enzyme in the glycolytic pathway. PDH was phosphorylated in vitro by TPKI to reduce the activity converting pyruvate into acetyl-CoA, which is required for acetylcholine synthesis.",
      "citation": {
        "type": "PubMed",
        "reference": "9089387",
        "name": "Journal of biochemistry",
        "title": "Physiology and pathology of tau protein kinases in relation to Alzheimer's disease.",
        "volume": "121",
        "pages": "179-88",
        "date": "1997-02-01",
        "first": "Imahori K",
        "last": "Uchida T",
        "authors": [
          "Imahori K",
          "Uchida T"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 298,
      "key": "77f6654764a811f58407bb54c7193a86be1b27023d9829b1e09c4ae7ba70261c3395f7f9062b6acc2c2fd581ca3f9cde4dd0ffa63b70c97b997a45981c1772fb"
    },
    {
      "line": 1167,
      "relation": "isA",
      "evidence": "By using a yeast two hybrid system, TPKI was found to interact with pyruvate dehydrogenase (PDH), which is a key enzyme in the glycolytic pathway. PDH was phosphorylated in vitro by TPKI to reduce the activity converting pyruvate into acetyl-CoA, which is required for acetylcholine synthesis.",
      "citation": {
        "type": "PubMed",
        "reference": "9089387",
        "name": "Journal of biochemistry",
        "title": "Physiology and pathology of tau protein kinases in relation to Alzheimer's disease.",
        "volume": "121",
        "pages": "179-88",
        "date": "1997-02-01",
        "first": "Imahori K",
        "last": "Uchida T",
        "authors": [
          "Imahori K",
          "Uchida T"
        ]
      },
      "source": 456,
      "target": 270,
      "key": "8e2bd56d369e595d349444e447e0528aa29e3b79064ebc7d24280910856552a36aaef2593e3b4323048db4b0351d1c038fc9211b6529b02711e27f0560e52d5e"
    },
    {
      "line": 2232,
      "relation": "partOf",
      "evidence": "Pretangles contained either paired helical filaments (PHFs) or PtdIns(4,5)P2-immunopositive small vesicles (approximately 1 µm in diameter) with nearly identical topology to granulovacuolar degeneration (GVD) bodies. Various combinations of these vesicles and GVD bodies, the latter of which are pathological hallmarks observed within the neurons of AD patients, were found concurrently in neurons.These vesicles and GVD bodies were both immunopositive not only for PtdIns(4,5)P2, but also for several tau kinases such as glycogen synthase kinase-3ß and spleen tyrosine kinase.",
      "citation": {
        "type": "PubMed",
        "reference": "26501932",
        "name": "Neuropathology and applied neurobiology",
        "title": "The identification of raft-derived tau-associated vesicles that are incorporated into immature tangles and paired helical filaments.",
        "volume": "42",
        "pages": "639-653",
        "date": "2016-12-01",
        "first": "Nishikawa T",
        "last": "Matsumoto M",
        "authors": [
          "Hosomi N",
          "Izumi Y",
          "Maruyama H",
          "Matsumoto M",
          "Miyazaki Y",
          "Nakamori M",
          "Nishikawa T",
          "Takahashi T"
        ]
      },
      "source": 456,
      "target": 102,
      "key": "7b99cd63e3a2cb1ac681484bf2b32a5d275f4d80e0598573fd94b921afb918a97996bfb167d949c2444765d08aab3047f47db8e1cd199d774becd754f584e007"
    },
    {
      "line": 2262,
      "relation": "increases",
      "evidence": "We further validated Syk as a target-regulating Aβ by showing that pharmacological inhibition of Syk or down-regulation of Syk expression reduces Aβ production and increases the clearance of Aβ across the BBB mimicking (-)-nilvadipine effects. Moreover, treatment of transgenic mice overexpressing Aβ and transgenic Tau P301S mice with a selective Syk inhibitor respectively decreased brain Aβ accumulation and Tau hyperphosphorylation at multiple AD relevant epitopes.",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 117,
      "key": "63c4803e671fb5000574af188e2dab04411434eb52fcd283bf5d88ffbe71fb834f7f86e5ec168ea3fcae11a8502cb5fbaef2bcbe9d89bd4b7ada3a4da0a2085f"
    },
    {
      "line": 2272,
      "relation": "positiveCorrelation",
      "evidence": "We observed that pharmacological inhibition of Syk with BAY61-3606 stimulates Ser-9 phosphorylation of GSK3β in SH-SY5Y cells (Fig. 9, A and B) suggesting that blocking Syk activity results in GSK3β inhibition.",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 456,
      "target": 705,
      "key": "0606e3e25741081b101e1fc280248a186aefe07ddf5713aa4c911b512b1b235c0a385576d84fd87460171e9b0450a4ec3d8a4a748c598007505d386403c06ac3"
    },
    {
      "line": 2279,
      "relation": "positiveCorrelation",
      "evidence": "We found that GSK3β mRNA was overexpressed only in patients with initial AD, with no effect on the levels of the protein. On the other hand, we unexpectedly observed the decrease of the inactive GSK3β in cortex from AD patients at Braak stages I-II, whereas considerable increase was observed in AD patients at stages V-VI compared to the control subjects.",
      "citation": {
        "type": "PubMed",
        "reference": "28176663",
        "name": "Current Alzheimer research",
        "title": "GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.",
        "volume": "14",
        "pages": "753-759",
        "date": "2017-01-01",
        "first": "Nicolia V",
        "last": "Fuso A",
        "authors": [
          "Cavallaro RA",
          "Ciraci V",
          "Ferrer I",
          "Fuso A",
          "Nicolia V",
          "Scarpa S"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 95,
      "key": "cf442862d8518e96f21c3fc84a7b857526082a87f61f16dba92730eb8e48ced0f0bd9d935d07c42bd106198477b709e1f31be67cf12428d1ce4f1a50498d7d25"
    },
    {
      "line": 2280,
      "relation": "positiveCorrelation",
      "evidence": "We found that GSK3β mRNA was overexpressed only in patients with initial AD, with no effect on the levels of the protein. On the other hand, we unexpectedly observed the decrease of the inactive GSK3β in cortex from AD patients at Braak stages I-II, whereas considerable increase was observed in AD patients at stages V-VI compared to the control subjects.",
      "citation": {
        "type": "PubMed",
        "reference": "28176663",
        "name": "Current Alzheimer research",
        "title": "GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.",
        "volume": "14",
        "pages": "753-759",
        "date": "2017-01-01",
        "first": "Nicolia V",
        "last": "Fuso A",
        "authors": [
          "Cavallaro RA",
          "Ciraci V",
          "Ferrer I",
          "Fuso A",
          "Nicolia V",
          "Scarpa S"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 96,
      "key": "2933fb9eb116d81726d4d67a6adb252297654e417ccaca73ed9d00e05ef7aa88d7722f668a9b661df8dcddb62c029db94ebd82ad068eaf7f06a1fc39f9b74dd6"
    },
    {
      "line": 2282,
      "relation": "negativeCorrelation",
      "evidence": "We found that GSK3β mRNA was overexpressed only in patients with initial AD, with no effect on the levels of the protein. On the other hand, we unexpectedly observed the decrease of the inactive GSK3β in cortex from AD patients at Braak stages I-II, whereas considerable increase was observed in AD patients at stages V-VI compared to the control subjects.",
      "citation": {
        "type": "PubMed",
        "reference": "28176663",
        "name": "Current Alzheimer research",
        "title": "GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.",
        "volume": "14",
        "pages": "753-759",
        "date": "2017-01-01",
        "first": "Nicolia V",
        "last": "Fuso A",
        "authors": [
          "Cavallaro RA",
          "Ciraci V",
          "Ferrer I",
          "Fuso A",
          "Nicolia V",
          "Scarpa S"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 97,
      "key": "a12c34fb18f1bf92b9877fc94fd6d1d12479a1897602a0af5eb862f985cfcd6cbde65e87d8f156e16cbb76e416af175cf69558301167e4e6eee84f2256a63070"
    },
    {
      "line": 2463,
      "relation": "increases",
      "evidence": "Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift in mobility as a result of phosphorylation-like changes, we conclude that they have the characteristics of hyperphosphorylated tau. These mutants will therefore be referred to as pseudo-hyperphosphorylated tau throughout the manuscript. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.",
      "citation": {
        "type": "PubMed",
        "reference": "19459590",
        "name": "Biochemistry",
        "title": "Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.",
        "volume": "48",
        "pages": "6002-11",
        "date": "2009-06-30",
        "first": "Sun Q",
        "last": "Gamblin TC",
        "authors": [
          "Gamblin TC",
          "Sun Q"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 336,
      "key": "b5453fb8ab91baffdf91a753158d49279efbf7682d71cf52ed2b601af77a84c9fc11273fc4afa69ecc21e8df2d0079ff8bf100a08046724c0544337c30de1e30"
    },
    {
      "line": 2805,
      "relation": "positiveCorrelation",
      "evidence": "Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor known to increase the level of many antioxidants, including glutathione-S transferase (GST), and is negatively regulated by the activity of GSK-3β. Our results indicated the increased nuclear localization of Nrf2 and level of GST, suggesting the increased activity of the transcription factor as a result of GSK-3β suppression, consistent with the decreased oxidative stress observed. Consistent with the improved learning and memory, and consistent with GSK-3b being a tau kinase, we observed decreased tau phosphorylation in brain of GAO-treated SAMP8 mice compared to that of RAO-treated SAMP8 mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24355211",
        "name": "Free radical biology &amp; medicine",
        "title": "Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease.",
        "volume": "67",
        "pages": "387-95",
        "date": "2014-02-01",
        "first": "Farr SA",
        "last": "Butterfield DA",
        "authors": [
          "Butterfield DA",
          "Farr SA",
          "Kumar V",
          "Morley JE",
          "Murphy MP",
          "Niehoff ML",
          "Platt TL",
          "Ripley JL",
          "Sultana R",
          "Zhang Z"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "SAMP8 mice": true
        }
      },
      "source": 456,
      "target": 205,
      "key": "31a4f1ca81aa0ee846d5e86e04b14799245e10cb650cae9a1fe18bbe8ec2bd1328b18dbecf8e737b9e21d7f7d35019c21bc151aa05e819dc7f0a19c5e2466bf8"
    },
    {
      "line": 2806,
      "relation": "negativeCorrelation",
      "evidence": "Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor known to increase the level of many antioxidants, including glutathione-S transferase (GST), and is negatively regulated by the activity of GSK-3β. Our results indicated the increased nuclear localization of Nrf2 and level of GST, suggesting the increased activity of the transcription factor as a result of GSK-3β suppression, consistent with the decreased oxidative stress observed. Consistent with the improved learning and memory, and consistent with GSK-3b being a tau kinase, we observed decreased tau phosphorylation in brain of GAO-treated SAMP8 mice compared to that of RAO-treated SAMP8 mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24355211",
        "name": "Free radical biology &amp; medicine",
        "title": "Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease.",
        "volume": "67",
        "pages": "387-95",
        "date": "2014-02-01",
        "first": "Farr SA",
        "last": "Butterfield DA",
        "authors": [
          "Butterfield DA",
          "Farr SA",
          "Kumar V",
          "Morley JE",
          "Murphy MP",
          "Niehoff ML",
          "Platt TL",
          "Ripley JL",
          "Sultana R",
          "Zhang Z"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "SAMP8 mice": true
        }
      },
      "source": 456,
      "target": 197,
      "key": "e511cbaa1a92fd510784b4fb1fd05a7305c89595abd3d2aef432e8fefd386d90ae5487ab9a5e458de70b59b070669c34d0b5caf245423a7b766b83735353a010"
    },
    {
      "line": 2807,
      "relation": "negativeCorrelation",
      "evidence": "Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor known to increase the level of many antioxidants, including glutathione-S transferase (GST), and is negatively regulated by the activity of GSK-3β. Our results indicated the increased nuclear localization of Nrf2 and level of GST, suggesting the increased activity of the transcription factor as a result of GSK-3β suppression, consistent with the decreased oxidative stress observed. Consistent with the improved learning and memory, and consistent with GSK-3b being a tau kinase, we observed decreased tau phosphorylation in brain of GAO-treated SAMP8 mice compared to that of RAO-treated SAMP8 mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24355211",
        "name": "Free radical biology &amp; medicine",
        "title": "Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease.",
        "volume": "67",
        "pages": "387-95",
        "date": "2014-02-01",
        "first": "Farr SA",
        "last": "Butterfield DA",
        "authors": [
          "Butterfield DA",
          "Farr SA",
          "Kumar V",
          "Morley JE",
          "Murphy MP",
          "Niehoff ML",
          "Platt TL",
          "Ripley JL",
          "Sultana R",
          "Zhang Z"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "SAMP8 mice": true
        }
      },
      "source": 456,
      "target": 200,
      "key": "5933ba81101d746373291c3cfc310809a849fd85aba792ec78084c6314ad975c00805d2908d8751cb844cf42731b03fa1d541e9f8e6ef101ecbb7f0da58a4c8f"
    },
    {
      "line": 2808,
      "relation": "directlyIncreases",
      "evidence": "Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor known to increase the level of many antioxidants, including glutathione-S transferase (GST), and is negatively regulated by the activity of GSK-3β. Our results indicated the increased nuclear localization of Nrf2 and level of GST, suggesting the increased activity of the transcription factor as a result of GSK-3β suppression, consistent with the decreased oxidative stress observed. Consistent with the improved learning and memory, and consistent with GSK-3b being a tau kinase, we observed decreased tau phosphorylation in brain of GAO-treated SAMP8 mice compared to that of RAO-treated SAMP8 mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24355211",
        "name": "Free radical biology &amp; medicine",
        "title": "Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease.",
        "volume": "67",
        "pages": "387-95",
        "date": "2014-02-01",
        "first": "Farr SA",
        "last": "Butterfield DA",
        "authors": [
          "Butterfield DA",
          "Farr SA",
          "Kumar V",
          "Morley JE",
          "Murphy MP",
          "Niehoff ML",
          "Platt TL",
          "Ripley JL",
          "Sultana R",
          "Zhang Z"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "SAMP8 mice": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 834,
      "key": "b7439c5e720206c9646a0a5b1e7697f0cfa8dc556f7edf9ae90d26e2aa050d95182c029aafa113c903eea44af3f7384f41f12a33753f3a640d96891dbbd0faaf"
    },
    {
      "line": 2809,
      "relation": "directlyIncreases",
      "evidence": "Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor known to increase the level of many antioxidants, including glutathione-S transferase (GST), and is negatively regulated by the activity of GSK-3β. Our results indicated the increased nuclear localization of Nrf2 and level of GST, suggesting the increased activity of the transcription factor as a result of GSK-3β suppression, consistent with the decreased oxidative stress observed. Consistent with the improved learning and memory, and consistent with GSK-3b being a tau kinase, we observed decreased tau phosphorylation in brain of GAO-treated SAMP8 mice compared to that of RAO-treated SAMP8 mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24355211",
        "name": "Free radical biology &amp; medicine",
        "title": "Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease.",
        "volume": "67",
        "pages": "387-95",
        "date": "2014-02-01",
        "first": "Farr SA",
        "last": "Butterfield DA",
        "authors": [
          "Butterfield DA",
          "Farr SA",
          "Kumar V",
          "Morley JE",
          "Murphy MP",
          "Niehoff ML",
          "Platt TL",
          "Ripley JL",
          "Sultana R",
          "Zhang Z"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "SAMP8 mice": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 819,
      "key": "aab40d2adc72e76ced69a631b6997076d55313e63e12db5556e7e9b633c46af9f6040ddca219c33c1b3d878d6e29b6ebbb0cb7a7dc225976c002ff351006b4e5"
    },
    {
      "line": 2997,
      "relation": "directlyIncreases",
      "evidence": "The N-terminus of β-catenin has phosphorylation, ubiquitination, and acetylation sites that regulate its stability and signaling. In the absence of a Wnt signal, Ser33, Ser37, and Thr41 are constitutively phosphorylated by glycogen synthase kinase 3β (GSK3β). β-Catenin phosphorylated at these sites is recognized by β-transducin repeat-containing protein (βTrCP), which results in ubiquitination and degradation by the ubiquitin-proteasome pathway. The N-terminal regulatory domain of β-catenin also includes Ser45, a phosphorylation site for Casein Kinase 1α (CK1α) and Lys49, which is acetylated by the acetyltransferase p300/CBP-associated factor (PCAF). The relevance of Lys49 acetylation and Ser45 phosphorylation to the function of β-catenin is an active area of investigation. We find that HDAC6 inhibitors increase Lys49 acetylation and Ser45 phosphorylation but do not affect Ser33, Ser37, and Thr41 phosphorylation. Lys49 acetylation results in decreased ubiquitination of β-catenin in the presence of proteasome inhibition. While increased Lys49 acetylation does not affect total levels of β-catenin, it results in increased membrane localization of β-catenin.",
      "citation": {
        "type": "PubMed",
        "reference": "25546293",
        "name": "ACS chemical biology",
        "title": "HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of β-catenin in human iPSC-derived neuronal cells.",
        "volume": "10",
        "pages": "883-90",
        "date": "2015-03-20",
        "first": "Iaconelli J",
        "last": "Karmacharya R",
        "authors": [
          "Berkovitch SS",
          "Chattopadhyay S",
          "Haggarty SJ",
          "Huang JH",
          "Iaconelli J",
          "Karmacharya R",
          "Mazitschek R",
          "Schreiber SL"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 422,
      "key": "6afabcfed57d75f038e357697b060314e72e53d8a29d2f3c827ae1cc11d6f8437f94eb2fb8f063af148017bf4ffcf27b171548dfafee4e53e66b486e90a78a77"
    },
    {
      "line": 2998,
      "relation": "directlyIncreases",
      "evidence": "The N-terminus of β-catenin has phosphorylation, ubiquitination, and acetylation sites that regulate its stability and signaling. In the absence of a Wnt signal, Ser33, Ser37, and Thr41 are constitutively phosphorylated by glycogen synthase kinase 3β (GSK3β). β-Catenin phosphorylated at these sites is recognized by β-transducin repeat-containing protein (βTrCP), which results in ubiquitination and degradation by the ubiquitin-proteasome pathway. The N-terminal regulatory domain of β-catenin also includes Ser45, a phosphorylation site for Casein Kinase 1α (CK1α) and Lys49, which is acetylated by the acetyltransferase p300/CBP-associated factor (PCAF). The relevance of Lys49 acetylation and Ser45 phosphorylation to the function of β-catenin is an active area of investigation. We find that HDAC6 inhibitors increase Lys49 acetylation and Ser45 phosphorylation but do not affect Ser33, Ser37, and Thr41 phosphorylation. Lys49 acetylation results in decreased ubiquitination of β-catenin in the presence of proteasome inhibition. While increased Lys49 acetylation does not affect total levels of β-catenin, it results in increased membrane localization of β-catenin.",
      "citation": {
        "type": "PubMed",
        "reference": "25546293",
        "name": "ACS chemical biology",
        "title": "HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of β-catenin in human iPSC-derived neuronal cells.",
        "volume": "10",
        "pages": "883-90",
        "date": "2015-03-20",
        "first": "Iaconelli J",
        "last": "Karmacharya R",
        "authors": [
          "Berkovitch SS",
          "Chattopadhyay S",
          "Haggarty SJ",
          "Huang JH",
          "Iaconelli J",
          "Karmacharya R",
          "Mazitschek R",
          "Schreiber SL"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 424,
      "key": "459392357c6333f63402315327bb081e5b4b5bb62236224ee1e19b696624d8bd5fe51e8877edb39a19a2832de5ac36fa3ee002560e4890efbca9e3b68b4dfe41"
    },
    {
      "line": 2999,
      "relation": "directlyIncreases",
      "evidence": "The N-terminus of β-catenin has phosphorylation, ubiquitination, and acetylation sites that regulate its stability and signaling. In the absence of a Wnt signal, Ser33, Ser37, and Thr41 are constitutively phosphorylated by glycogen synthase kinase 3β (GSK3β). β-Catenin phosphorylated at these sites is recognized by β-transducin repeat-containing protein (βTrCP), which results in ubiquitination and degradation by the ubiquitin-proteasome pathway. The N-terminal regulatory domain of β-catenin also includes Ser45, a phosphorylation site for Casein Kinase 1α (CK1α) and Lys49, which is acetylated by the acetyltransferase p300/CBP-associated factor (PCAF). The relevance of Lys49 acetylation and Ser45 phosphorylation to the function of β-catenin is an active area of investigation. We find that HDAC6 inhibitors increase Lys49 acetylation and Ser45 phosphorylation but do not affect Ser33, Ser37, and Thr41 phosphorylation. Lys49 acetylation results in decreased ubiquitination of β-catenin in the presence of proteasome inhibition. While increased Lys49 acetylation does not affect total levels of β-catenin, it results in increased membrane localization of β-catenin.",
      "citation": {
        "type": "PubMed",
        "reference": "25546293",
        "name": "ACS chemical biology",
        "title": "HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of β-catenin in human iPSC-derived neuronal cells.",
        "volume": "10",
        "pages": "883-90",
        "date": "2015-03-20",
        "first": "Iaconelli J",
        "last": "Karmacharya R",
        "authors": [
          "Berkovitch SS",
          "Chattopadhyay S",
          "Haggarty SJ",
          "Huang JH",
          "Iaconelli J",
          "Karmacharya R",
          "Mazitschek R",
          "Schreiber SL"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 456,
      "target": 425,
      "key": "5628a1d52e4e83894e1afc7b4887da9884f9e29c4b918e86c395f8a9f808c81bfe40b2911c323e598b4a4c787c64d594e8e3fc3992ae00bfec8183e878c7aacd"
    },
    {
      "line": 397,
      "relation": "increases",
      "evidence": "Primary hippocampal neuron cells at different concentrations (0, 50, 100, 200 lg/ml) of glucose–BSA were incubated together for 24 h, and then thr205- phosphorylated tau was estimated by the western immunoblotting method. Western blot analysis of each experimental group showed that glucose–BSA promoted tau thr205-phosphorylation in a concentration-dependent manner (Fig. 3(a)). In the present study, it was also shown that 100 nM GLP-1 or Ex-4 treatment reduced tau hyperphosphorylation induced by glucose–BSA (Fig. 3(b, c)).",
      "citation": {
        "type": "PubMed",
        "reference": "24183963",
        "name": "Neuroscience",
        "title": "Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation.",
        "volume": "256",
        "pages": "137-46",
        "date": "2014-01-03",
        "first": "Chen S",
        "last": "Gao XD",
        "authors": [
          "An FM",
          "Chen S",
          "Gao XD",
          "Liu AR",
          "Yao WB",
          "Yin DK",
          "Yin L"
        ]
      },
      "annotations": {
        "Anatomy": {
          "hippocampal formation": true
        },
        "Method": {
          "Cell Viability Assay, MTT": true,
          "Western Blot": true,
          "Confocal Laser Microscopy": true
        }
      },
      "source": 50,
      "target": 579,
      "key": "87da64a6b0bf13bce5b61644707574bb114224a0354b84e9f56a7a5a65ba4363190a8be5f61ee2e571e96b6415dbb94df2b85471d1f8edf077609f8f6ec975c2"
    },
    {
      "line": 405,
      "relation": "decreases",
      "evidence": "Western blot analysis of different experimental groups, primary hippocampal neuron cells concurrent treatment with different concentrations (0, 50, 100, 200 lg/ml) of glucose–BSA for 24 h, also showed that glucose–BSA inhibited the phosphorylation of GSK-3b in a concentration-dependent manner (Fig. 4(a)). And 100 nM GLP-1 or Ex-4 can up-regulate phosphorylation of GSK-3b at Ser9, which was decreased by treatment with glucose–BSA (Fig. 4(b, c)).",
      "citation": {
        "type": "PubMed",
        "reference": "24183963",
        "name": "Neuroscience",
        "title": "Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation.",
        "volume": "256",
        "pages": "137-46",
        "date": "2014-01-03",
        "first": "Chen S",
        "last": "Gao XD",
        "authors": [
          "An FM",
          "Chen S",
          "Gao XD",
          "Liu AR",
          "Yao WB",
          "Yin DK",
          "Yin L"
        ]
      },
      "annotations": {
        "Anatomy": {
          "hippocampal formation": true
        },
        "Method": {
          "Cell Viability Assay, MTT": true,
          "Western Blot": true,
          "Confocal Laser Microscopy": true
        }
      },
      "source": 50,
      "target": 457,
      "key": "853813a5a8a9aa53fb53e72ab4a3225a0083c810c121eeb5a382aa22b846bc9c250c4bcb25ed9b0a155217874e3a0864dcf1fc387c031a8d2d7f1319ec0010e5"
    },
    {
      "line": 695,
      "relation": "negativeCorrelation",
      "evidence": "We recently discovered that the human brain tau is also modified by O-GlcNAcylation in addition to phosphorylation and that O-GlcNAcylation modulates phosphorylation of tau inversely (Liu et al.,2004a). We found that fasting induced a time-dependent decrease in tau O-GlcNAcylation and concurrent hyperphosphorylation of tau at most of the phosphorylation sites studied.",
      "citation": {
        "type": "PubMed",
        "reference": "16630055",
        "name": "The European journal of neuroscience",
        "title": "Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting.",
        "volume": "23",
        "pages": "2078-86",
        "date": "2006-04-01",
        "first": "Li X",
        "last": "Gong CX",
        "authors": [
          "Gong CX",
          "Li X",
          "Lu F",
          "Wang JZ"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true
        }
      },
      "source": 50,
      "target": 921,
      "key": "2fef4c78d9e04bd58a2fd425f90ffbbb52e1e1d855c4b0c8b32ec65ccd0a407b763c19ecade8185374c8591e385744ef810120823cdd2a8e7005004efe617946"
    },
    {
      "line": 1124,
      "relation": "positiveCorrelation",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 579,
      "target": 299,
      "key": "e0743fe9706d8f6353d08e0e5712599e5626d402f85b9f41cd4f167b9a4b69fb3a048c0fe2055ec5c1a9a43a3306f9a901a7b261c084faf8edaaf364242e533f"
    },
    {
      "line": 1295,
      "relation": "partOf",
      "evidence": "Epitopes S198, S199, S202, T205, S422 (Lund 2013)",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "source": 579,
      "target": 336,
      "key": "da9ede1f3f483b4c032f1f194cbaaa93e4445a44aaf84bed6b503af83b3285e85d397851f726b5a75c2b6c41e11600bc16551f5a7ed947645ce25f49f712a3ef"
    },
    {
      "line": 1544,
      "relation": "partOf",
      "evidence": "When combined with ERK2 catalyzed phosphorylation, the turn-like disrupting G207V mutation in TauF8 hence leads to fast aggregation that already occurs during the phosphorylation reaction.",
      "citation": {
        "type": "PubMed",
        "reference": "28784767",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Identification of the Tau phosphorylation pattern that drives its aggregation.",
        "volume": "114",
        "pages": "9080-9085",
        "date": "2017-08-22",
        "first": "Despres C",
        "last": "Smet-Nocca C",
        "authors": [
          "Baulieu EE",
          "Byrne C",
          "Cantrelle FX",
          "Chambraud B",
          "Despres C",
          "Huvent I",
          "Jacquot Y",
          "Landrieu I",
          "Lippens G",
          "Qi H",
          "Smet-Nocca C"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "NMR Spectroscopy": true,
          "Thioflavin T Assay": true
        }
      },
      "source": 579,
      "target": 336,
      "key": "0c83d70bf47e9e3595fead70044117c5e45686cee8a349e68fd457be9cadb043d207eece9c0ec187643959a2c1bce6b065dbbf5fc8efd3977e83a51b200f2657"
    },
    {
      "line": 2332,
      "relation": "negativeCorrelation",
      "evidence": "Endogenous miR-195 was knocked down using over-expression of its antisense molecule (pre-AMO-miR-195) via a lentivirus (lenti-pre-AMO-miR-195); this knockdown increased the tau phosphorylation at Ser202/Thr205, Ser262, Thr231, Ser422, and the Cdk5/p25 activation, but over-expression of miR-195 using lenti-pre-miR-195 decreased the tau phosphorylation and Cdk5/p25 activation.",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 579,
      "target": 264,
      "key": "28ed2f012fd38c4d64f9e1b5a58444f4b769c1abc99c5a1eb8ba70a708a5332f56ccd55d21d71da20681792b9e9cffdec7a0daff48c48fefb8dea5151c346b56"
    },
    {
      "line": 2507,
      "relation": "positiveCorrelation",
      "evidence": "Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Research_Model": {
          "rTg4510 mice": true
        }
      },
      "source": 579,
      "target": 513,
      "key": "72ccf29ee9c3cc799684ea8327d4a6bd0eb8fc2cefc231da60372fb4a396602b8edd56ab5cfb239df577d2b3508a4fabfb4dde3e8562581a8386c5499518374d"
    },
    {
      "line": 2524,
      "relation": "positiveCorrelation",
      "evidence": "We developed a transgenic mouse, named TPR50, harboring human P301S tau. Tau phosphorylation in the hippocampus of TPR50 mice increased with age, particularly at S202/T205. Therefore, cognitive dysfunction in TPR50 mice may result from early MT dysfunction and impaired axonal transport rather than accumulation of insoluble tau and neurodegeneration.",
      "citation": {
        "type": "PubMed",
        "reference": "24406748",
        "name": "Neuroscience research",
        "title": "Early-onset cognitive deficits and axonal transport dysfunction in P301S mutant tau transgenic mice.",
        "volume": "80",
        "pages": "76-85",
        "date": "2014-03-01",
        "first": "Onishi T",
        "last": "Iwashita H",
        "authors": [
          "Hattori M",
          "Horiguchi T",
          "Iwashita H",
          "Matsumoto Y",
          "Nakamura K",
          "Obayashi Y",
          "Onishi T",
          "Yano T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "TPR50 mice": true
        }
      },
      "source": 579,
      "target": 626,
      "key": "8c2c2cd46b7a9db97539888ede19e19bfc6902e15a00ca8c825320dab915b9e5a361cbb959b99808ebe3829eb0db5791cbd1fb65e7b3fa5e29688a4016a93e26"
    },
    {
      "line": 2543,
      "relation": "positiveCorrelation",
      "evidence": "We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia. In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes. Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3α/β at tyrosine 279/216 also showed an intense rather than moderate AT8 (phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with fibrillar tau pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "23294633",
        "name": "Neurobiology of aging",
        "title": "Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.",
        "volume": "34",
        "pages": "1369-79",
        "date": "2013-05-01",
        "first": "Köhler C",
        "last": "Götz J",
        "authors": [
          "Dinekov M",
          "Götz J",
          "Köhler C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "pR5 mice": true
        }
      },
      "source": 579,
      "target": 625,
      "key": "70b72ae48c0bebbe333f00dbc56158176696f6f3be8d9719b3d99d8098ae68dba4424ac101eb98ed85b7b3c7e94891da2b031b8ef2bbb3446136446b6628ad9d"
    },
    {
      "line": 2621,
      "relation": "partOf",
      "evidence": "Phosphorylation at the epitope Ser202/Thr205 is regarded as a good marker for late-stage NFTs (5, 72). Hyman and colleagues (5) demonstrated that AT8 immunoreactivity is present primarily in eNFTs and in certain cases in iNFTs. These investigators also found that AT8 revealed dense neuropil thread staining.",
      "citation": {
        "type": "PubMed",
        "reference": "22253473",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.",
        "volume": "26",
        "pages": "1946-59",
        "date": "2012-05-01",
        "first": "Lasagna-Reeves CA",
        "last": "Kayed R",
        "authors": [
          "Castillo-Carranza DL",
          "Jackson GR",
          "Kayed R",
          "Lasagna-Reeves CA",
          "Sarmiento J",
          "Sengupta U",
          "Troncoso J"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Disease_Progression": {
          "Late Stage": true
        }
      },
      "source": 579,
      "target": 81,
      "key": "bceba1f946ae45359442accdc9326e92a831ddf1c228fea3605d1ba39320032d707c0cb869f996ad4fc5cb53327d68d7db8c8df595b4f3b2a12a3e5c7b1ff51d"
    },
    {
      "line": 2631,
      "relation": "partOf",
      "evidence": "Oligomers positive for pS202/pT205 accumulate at synapses in AD",
      "citation": {
        "type": "PubMed",
        "reference": "22486774",
        "name": "Brain pathology (Zurich, Switzerland)",
        "title": "Extensive p-tau pathology and SDS-stable p-tau oligomers in Alzheimer's cortical synapses.",
        "volume": "22",
        "pages": "826-33",
        "date": "2012-11-01",
        "first": "Henkins KM",
        "last": "Gylys KH",
        "authors": [
          "Cornwell LB",
          "Gylys KH",
          "Henkins KM",
          "Miller CA",
          "Poon WW",
          "Saing T",
          "Sokolow S",
          "Vinters HV"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 579,
      "target": 118,
      "key": "8b221d2ec935d3e90753d4c572a368642d568f80d7fcb3bac2a79a37eb69094e252532d4848de377a42898561a9f4d5a60cb68828c99ea94e02e2a9e670d27c7"
    },
    {
      "line": 398,
      "relation": "decreases",
      "evidence": "Primary hippocampal neuron cells at different concentrations (0, 50, 100, 200 lg/ml) of glucose–BSA were incubated together for 24 h, and then thr205- phosphorylated tau was estimated by the western immunoblotting method. Western blot analysis of each experimental group showed that glucose–BSA promoted tau thr205-phosphorylation in a concentration-dependent manner (Fig. 3(a)). In the present study, it was also shown that 100 nM GLP-1 or Ex-4 treatment reduced tau hyperphosphorylation induced by glucose–BSA (Fig. 3(b, c)).",
      "citation": {
        "type": "PubMed",
        "reference": "24183963",
        "name": "Neuroscience",
        "title": "Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation.",
        "volume": "256",
        "pages": "137-46",
        "date": "2014-01-03",
        "first": "Chen S",
        "last": "Gao XD",
        "authors": [
          "An FM",
          "Chen S",
          "Gao XD",
          "Liu AR",
          "Yao WB",
          "Yin DK",
          "Yin L"
        ]
      },
      "annotations": {
        "Anatomy": {
          "hippocampal formation": true
        },
        "Method": {
          "Cell Viability Assay, MTT": true,
          "Western Blot": true,
          "Confocal Laser Microscopy": true
        }
      },
      "source": 451,
      "target": 579,
      "key": "1a583d10191f79b3519cc88092362d5d8f68a0b1f874d0b1de045930432bf39f42affa19c21ab132c0937ca19cd955af0270cdf7043bf881141785a3c15fee5e"
    },
    {
      "line": 406,
      "relation": "increases",
      "evidence": "Western blot analysis of different experimental groups, primary hippocampal neuron cells concurrent treatment with different concentrations (0, 50, 100, 200 lg/ml) of glucose–BSA for 24 h, also showed that glucose–BSA inhibited the phosphorylation of GSK-3b in a concentration-dependent manner (Fig. 4(a)). And 100 nM GLP-1 or Ex-4 can up-regulate phosphorylation of GSK-3b at Ser9, which was decreased by treatment with glucose–BSA (Fig. 4(b, c)).",
      "citation": {
        "type": "PubMed",
        "reference": "24183963",
        "name": "Neuroscience",
        "title": "Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation.",
        "volume": "256",
        "pages": "137-46",
        "date": "2014-01-03",
        "first": "Chen S",
        "last": "Gao XD",
        "authors": [
          "An FM",
          "Chen S",
          "Gao XD",
          "Liu AR",
          "Yao WB",
          "Yin DK",
          "Yin L"
        ]
      },
      "annotations": {
        "Anatomy": {
          "hippocampal formation": true
        },
        "Method": {
          "Cell Viability Assay, MTT": true,
          "Western Blot": true,
          "Confocal Laser Microscopy": true
        }
      },
      "source": 451,
      "target": 457,
      "key": "915cbec30bd07892299da2cbe43bc459680b54d95c8adf68499a04ec6dc0f98affd57c94e80a9f65005eb858b298478ae2c549e76cc7b3380026412b0fa7e424"
    },
    {
      "line": 2403,
      "relation": "decreases",
      "evidence": "In this study, we demonstrated that GLP-1RA could inhibit oxidative stress and repair mitochondrial damage in addition to decreasing tau hyperphosphorylation in PC12 cells treated with AGEs. Importantly, we first observed AGEs in the circulatory system could induce tau hyperphosphorylation after we injected AGEs (1μg/kg bodyweight) into the mice tail vein. We found GLP-1RA could promote mitochondrial biogenesis and antioxidant system via regulating peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) signaling pathway in vivo besides down-regulating the activity of glycogen synthase kinase 3β (GSK-3β) to reverse tau hyperphosphorylation directly.",
      "citation": {
        "type": "PubMed",
        "reference": "25987199",
        "name": "Neuroscience",
        "title": "Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: Studies in vivo and in vitro.",
        "volume": "300",
        "pages": "75-84",
        "date": "2015-08-06",
        "first": "An FM",
        "last": "Gao XD",
        "authors": [
          "An FM",
          "Chen S",
          "Gao XD",
          "Liu AR",
          "Wang Y",
          "Xu Z",
          "Yao WB",
          "Yin L"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "PC12": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 451,
      "target": 205,
      "key": "c736de607136e69e9c87b8a83d4b329c51fd9ec48b97239af6e00185790f89ce8511a4fbc58eb49dd3719192d1f4b56158cea4edcf4b9cfede218b290f4cd497"
    },
    {
      "line": 2404,
      "relation": "increases",
      "evidence": "In this study, we demonstrated that GLP-1RA could inhibit oxidative stress and repair mitochondrial damage in addition to decreasing tau hyperphosphorylation in PC12 cells treated with AGEs. Importantly, we first observed AGEs in the circulatory system could induce tau hyperphosphorylation after we injected AGEs (1μg/kg bodyweight) into the mice tail vein. We found GLP-1RA could promote mitochondrial biogenesis and antioxidant system via regulating peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) signaling pathway in vivo besides down-regulating the activity of glycogen synthase kinase 3β (GSK-3β) to reverse tau hyperphosphorylation directly.",
      "citation": {
        "type": "PubMed",
        "reference": "25987199",
        "name": "Neuroscience",
        "title": "Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: Studies in vivo and in vitro.",
        "volume": "300",
        "pages": "75-84",
        "date": "2015-08-06",
        "first": "An FM",
        "last": "Gao XD",
        "authors": [
          "An FM",
          "Chen S",
          "Gao XD",
          "Liu AR",
          "Wang Y",
          "Xu Z",
          "Yao WB",
          "Yin L"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "PC12": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 451,
      "target": 88,
      "key": "cff2bfc4c323dda7592d0cef7718470c6839f6a2a8568329be50d2ec5341c22a22e5dff17051da5a4056a188678f05444e7ec1a4da33169fbd9caf85d69c1cd5"
    },
    {
      "line": 407,
      "relation": "decreases",
      "evidence": "Western blot analysis of different experimental groups, primary hippocampal neuron cells concurrent treatment with different concentrations (0, 50, 100, 200 lg/ml) of glucose–BSA for 24 h, also showed that glucose–BSA inhibited the phosphorylation of GSK-3b in a concentration-dependent manner (Fig. 4(a)). And 100 nM GLP-1 or Ex-4 can up-regulate phosphorylation of GSK-3b at Ser9, which was decreased by treatment with glucose–BSA (Fig. 4(b, c)).",
      "citation": {
        "type": "PubMed",
        "reference": "24183963",
        "name": "Neuroscience",
        "title": "Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation.",
        "volume": "256",
        "pages": "137-46",
        "date": "2014-01-03",
        "first": "Chen S",
        "last": "Gao XD",
        "authors": [
          "An FM",
          "Chen S",
          "Gao XD",
          "Liu AR",
          "Yao WB",
          "Yin DK",
          "Yin L"
        ]
      },
      "annotations": {
        "Anatomy": {
          "hippocampal formation": true
        },
        "Method": {
          "Cell Viability Assay, MTT": true,
          "Western Blot": true,
          "Confocal Laser Microscopy": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 457,
      "target": 456,
      "key": "59dd0f2faf01a371fa14f7a23f3944182e7d97a162e4ab2bb90645a45653d3ee151e82b94ebbf60990f1efb7089599fe3ad24df3146ea435baf514fbed66e8e9"
    },
    {
      "line": 1006,
      "relation": "decreases",
      "evidence": "The second mechanism is related to GSK-3, which phosphorylates NRF2 creating a recognition site for β-Transducin Repeat Containing E3 Ubiquitin Protein Ligase (β-TrCP). β-TrCP leads to Cullin-1/Rbx1-mediated NRF2 ubiquitination and its subsequent degradation [8]. Since GSK-3β is inhibited by phosphorylation at Ser9 by Ser/Thr protein kinases such as AKT, it has been suggested that NRF2 might be up-regulated through activation of AKT and permanent inactivation of GSK-3 [9], [10].",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 457,
      "target": 456,
      "key": "ccde2f7a500d887662ac55d1792dc28c41eb3a08b4b4f56061f169e6bfe8e8b8cb7da504859dd954b5389167a0af7b6e30ad06838abc477f9c45f633565ba4ee"
    },
    {
      "line": 3394,
      "relation": "directlyDecreases",
      "evidence": "This study aimed to investigate the protective effects and mechanism of the novel HDAC6 inhibitor, MPT0G211, using an AD model. Our results indicated that MPT0G211 significantly reduced tau phosphorylation and aggregation, the processes highly correlated with the formation of NFTs. This HDAC6 inhibitory activity resulted in an increase in acetylated Hsp90, which decreased Hsp90 and HDAC6 binding, causing ubiquitination of phosphorylated tau proteins. In addition, a significant increase of phospho-glycogen synthase kinase-3β (phospho-GSK3β) on Ser9 (the inactive form) through Akt phosphorylation was associated with the inhibition of phospho-tau Ser396 in response to MPT0G211 treatment.",
      "citation": {
        "type": "PubMed",
        "reference": "29844403",
        "name": "Cell death &amp; disease",
        "title": "The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.",
        "volume": "9",
        "pages": "655",
        "date": "2018-05-29",
        "first": "Fan SJ",
        "last": "Yang CR",
        "authors": [
          "Fan SJ",
          "Huang FI",
          "Liou JP",
          "Yang CR"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true,
          "SH-SY5Y": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 457,
      "target": 456,
      "key": "5652f5cfca61dde3aa1b6ffb3a65e5bd4e450501f8a6360842d9240a84f2f4da014adae22895399e6e9290caef6a302afdac08f47a6bcae2c5b9cfbc9fc50c5b"
    },
    {
      "line": 3847,
      "relation": "directlyDecreases",
      "evidence": "Filamentous, but not soluble, forms of wild-type tau inhibit anterograde, kinesin-based fast axonal transport (FAT) by activating axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK3), independent of microtubule binding. Amino acids 2-18 of tau, comprising a phosphatase-activating domain (PAD), are necessary and sufficient for activation of this pathway. Various pathogenic forms of tau displaying increased exposure of PAD inhibited anterograde FAT in squid axoplasm. Immunohistochemical studies using a novel PAD-specific monoclonal antibody in human postmortem tissue indicated that increased PAD exposure represents an early pathogenic event in AD that closely associates in time with AT8 immunoreactivity. We propose a model of pathogenesis in which disease-associated changes in tau conformation lead to increased exposure of PAD, activation of PP1-GSK3, and inhibition of FAT",
      "citation": {
        "type": "PubMed",
        "reference": "21734277",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "volume": "31",
        "pages": "9858-68",
        "date": "2011-07-06",
        "first": "Kanaan NM",
        "last": "Binder LI",
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 457,
      "target": 456,
      "key": "aab37cc757ded01575a7b82611f77862a2c7628c99f2dd8225a27c684db8c1a48ad14fd1735ef3ec327aa9350e0c373618561e678022fb18df52e892f7be2c48"
    },
    {
      "line": 2271,
      "relation": "negativeCorrelation",
      "evidence": "We observed that pharmacological inhibition of Syk with BAY61-3606 stimulates Ser-9 phosphorylation of GSK3β in SH-SY5Y cells (Fig. 9, A and B) suggesting that blocking Syk activity results in GSK3β inhibition.",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 457,
      "target": 705,
      "key": "8c1881b9d522328799beb979c5334b3fbd4a49f0291451f840919874013a0aca07df91f937d5d62b86dd9966eeca6643369d85b35bca6d84141ea268a0561ac5"
    },
    {
      "line": 417,
      "relation": "decreases",
      "evidence": "CA and the oxidized form of EC (ECox) inhibited tau aggregation in vitro due to their interaction with the two cysteine residues in tau. A synthetic peptide, SKCGS, representing the actual tau sequence, identified the thiol as reacting with CA and ECox which necessitates of cysteine for aggregation inhibition by CA.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "source": 44,
      "target": 318,
      "key": "67bc2f02f0731305b4c8c39041e06230486d60cc219496a418c5455e0525415c16844c6910876a3dbf9798386569c8dc1fa355cc2d69824767a7251540cd96ec"
    },
    {
      "line": 424,
      "relation": "decreases",
      "evidence": "CA and the oxidized form of EC (ECox) inhibited tau aggregation in vitro due to their interaction with the two cysteine residues in tau. A synthetic peptide, SKCGS, representing the actual tau sequence, identified the thiol as reacting with CA and ECox which necessitates of cysteine for aggregation inhibition by CA.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "source": 44,
      "target": 188,
      "key": "26ef701d26a7d35a5bccbd760d7ebbb68c5b6460f0da282d031b4355f26ee39a0c2f355594b151d327ab424aa9bf7d97d359e04ffcda824dcff4ac1242b129a7"
    },
    {
      "line": 431,
      "relation": "causesNoChange",
      "evidence": "The data (Fig. 8B) shows that no significant difference in the extent of tubulin assembly could be observed with normal tau or tau incubated with CA. These results also indicate that once assembled, the microtubules remained stable to the same extent in the presence or in the absence of CA.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "source": 44,
      "target": 186,
      "key": "8467c8342961d639210ea352f2329c743bce6b72223028e052f52297b3c6429b8866a99a51ffd2d68152a619a6b08ce783716667bbf9b0ddd09ca21439a5f5fc"
    },
    {
      "line": 435,
      "relation": "decreases",
      "evidence": "We found that CA (lane 4) and EC (lane 6) substantially prevented the H2O2 induced formation of the high molecular weight species.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 44,
      "target": 21,
      "key": "91bc4d60d8aa7e014af75255ea65efba7676d23d8a000045c80117e035fd7d7cea8183987056ae7097f668b12e50a97d1c74dc8e2c6538d6138183e4f80f1c5d"
    },
    {
      "line": 418,
      "relation": "positiveCorrelation",
      "evidence": "CA and the oxidized form of EC (ECox) inhibited tau aggregation in vitro due to their interaction with the two cysteine residues in tau. A synthetic peptide, SKCGS, representing the actual tau sequence, identified the thiol as reacting with CA and ECox which necessitates of cysteine for aggregation inhibition by CA.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "source": 318,
      "target": 356,
      "key": "59c2ddd0c659ea58613302f84dc3801236468a0013f46337eccaffee2ffee5ebac20c00bcfa98bf19ffb8924f3678975647bdcaa78b716c36d1e94bc71563e13"
    },
    {
      "line": 2663,
      "relation": "increases",
      "evidence": "We demonstrate that elevated HDAC6 activity increases phosphorylation of tau at the 12E8 epitope (pS262/356), a phospho-epitope present within the KXGS motifs of tau’s microtubule-binding domain. The phosphorylation of KXGS motifs within tau by the kinase Par-1/MARK2 is required for tau proteotoxicity in Drosophila [29], observed at very early stages of NFT formation in AD brain [30], and appears to prime tau for subsequent phosphorylation events",
      "citation": {
        "type": "PubMed",
        "reference": "25031639",
        "name": "Alzheimer's research &amp; therapy",
        "title": "Acetylation: a new key to unlock tau's role in neurodegeneration.",
        "volume": "6",
        "pages": "29",
        "date": "2014-01-01",
        "first": "Cook C",
        "last": "Petrucelli L",
        "authors": [
          "Carlomagno Y",
          "Cook C",
          "Petrucelli L",
          "Stankowski JN",
          "Stetler C"
        ]
      },
      "source": 318,
      "target": 81,
      "key": "752fe590c90012e313152ab6792055ff0379496237bf608b9f4c929acf4ae7ac31afa77ec13acb996902619cfbcc94840bc1e417373afb54b07bd0e2b87f6449"
    },
    {
      "line": 418,
      "relation": "positiveCorrelation",
      "evidence": "CA and the oxidized form of EC (ECox) inhibited tau aggregation in vitro due to their interaction with the two cysteine residues in tau. A synthetic peptide, SKCGS, representing the actual tau sequence, identified the thiol as reacting with CA and ECox which necessitates of cysteine for aggregation inhibition by CA.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "source": 356,
      "target": 318,
      "key": "712f2031f0066c668914306e3971623a4f5cd53974802dd2b955bf7ff5a9fad83912090e5215b9476e485898dfcd674cbeb0afa81210ddd4adcbba788cf9a992"
    },
    {
      "line": 420,
      "relation": "partOf",
      "evidence": "CA and the oxidized form of EC (ECox) inhibited tau aggregation in vitro due to their interaction with the two cysteine residues in tau. A synthetic peptide, SKCGS, representing the actual tau sequence, identified the thiol as reacting with CA and ECox which necessitates of cysteine for aggregation inhibition by CA.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "source": 356,
      "target": 364,
      "key": "39794e0159c7a1f868c5f8d087b8edfb0401cb7be645684bc2b73263a06ee3a3814d5fd02277d0165bcb275b87c607b992e1df19b4f4e12c450ab6b072f97a48"
    },
    {
      "line": 423,
      "relation": "increases",
      "evidence": "CA and the oxidized form of EC (ECox) inhibited tau aggregation in vitro due to their interaction with the two cysteine residues in tau. A synthetic peptide, SKCGS, representing the actual tau sequence, identified the thiol as reacting with CA and ECox which necessitates of cysteine for aggregation inhibition by CA.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "source": 356,
      "target": 188,
      "key": "b1c805e8b548286c8c6d0ec285854533e281e4794cbd37f4875d217e055d8a6691963e0d47321b787443804321d4bb759807b5fb9f56ebcd207d2a65031bc20e"
    },
    {
      "line": 3154,
      "relation": "equivalentTo",
      "evidence": "All three MAPs possess highly lysine-rich MTBRs that mediate MAP-MT electrostatic interactions, indicating the potential for conserved acetylation within their repeats. Notably, tau/MAP4 alignments showed conservation of critical tau residues K280/K281 within the 2nd repeat motif 275VQIINK/K281, and the combined tau/MAP2c/MAP4 alignment showed conservation of the 3rd repeat motif harboring tau lysine K311, 306VQIVYK311",
      "citation": {
        "type": "PubMed",
        "reference": "28002468",
        "name": "PloS one",
        "title": "Conserved Lysine Acetylation within the Microtubule-Binding Domain Regulates MAP2/Tau Family Members.",
        "volume": "11",
        "pages": "e0168913",
        "date": "2016-01-01",
        "first": "Hwang AW",
        "last": "Cohen TJ",
        "authors": [
          "Cohen TJ",
          "Friedmann D",
          "Hwang AW",
          "Lee VM",
          "Marmorstein R",
          "Trzeciakiewicz H",
          "Yuan CX"
        ]
      },
      "source": 356,
      "target": 471,
      "key": "0df19464e19b39185e483ffb52cbf59a98e5b609a6b4bbd84205aa6788b9383a0361d740c9997bd518788e9c2775b8a40c18471554678bb58e43bd74ad48dc0b"
    },
    {
      "line": 3578,
      "relation": "positiveCorrelation",
      "evidence": "We also show that two of the tau mutations found in hereditary frontotemporal dementias, DeltaK280 and P301L, have a much stronger tendency for PHF aggregation which correlates with their high propensity for beta-structure around the hexapeptide motifs.",
      "citation": {
        "type": "PubMed",
        "reference": "11606569",
        "name": "The Journal of biological chemistry",
        "title": "Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure.",
        "volume": "276",
        "pages": "48165-74",
        "date": "2001-12-21",
        "first": "von Bergen M",
        "last": "Mandelkow E",
        "authors": [
          "Barghorn S",
          "Biernat J",
          "Li L",
          "Mandelkow E",
          "Mandelkow EM",
          "Marx A",
          "von Bergen M"
        ]
      },
      "source": 356,
      "target": 618,
      "key": "d9393f7b64205051cb1eed2da3a93ebe2aa9f79344673c5b0522babdfcceda358c4b98f7cc9546c3bacf80e89d26fb9475a72ba5c6f1cc75cc3371c7033df9ac"
    },
    {
      "line": 3580,
      "relation": "positiveCorrelation",
      "evidence": "We also show that two of the tau mutations found in hereditary frontotemporal dementias, DeltaK280 and P301L, have a much stronger tendency for PHF aggregation which correlates with their high propensity for beta-structure around the hexapeptide motifs.",
      "citation": {
        "type": "PubMed",
        "reference": "11606569",
        "name": "The Journal of biological chemistry",
        "title": "Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure.",
        "volume": "276",
        "pages": "48165-74",
        "date": "2001-12-21",
        "first": "von Bergen M",
        "last": "Mandelkow E",
        "authors": [
          "Barghorn S",
          "Biernat J",
          "Li L",
          "Mandelkow E",
          "Mandelkow EM",
          "Marx A",
          "von Bergen M"
        ]
      },
      "source": 356,
      "target": 625,
      "key": "223d570e24234983a8c9299891b44ed762cc5fc526c3714c2cdf7c132b67d7f53afdb46187d33e264291c144e7c124b11d1744f4ad4d47b7209bbea4de5fb6b2"
    },
    {
      "line": 3583,
      "relation": "increases",
      "evidence": "We also show that two of the tau mutations found in hereditary frontotemporal dementias, DeltaK280 and P301L, have a much stronger tendency for PHF aggregation which correlates with their high propensity for beta-structure around the hexapeptide motifs.",
      "citation": {
        "type": "PubMed",
        "reference": "11606569",
        "name": "The Journal of biological chemistry",
        "title": "Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure.",
        "volume": "276",
        "pages": "48165-74",
        "date": "2001-12-21",
        "first": "von Bergen M",
        "last": "Mandelkow E",
        "authors": [
          "Barghorn S",
          "Biernat J",
          "Li L",
          "Mandelkow E",
          "Mandelkow EM",
          "Marx A",
          "von Bergen M"
        ]
      },
      "source": 356,
      "target": 325,
      "key": "1ac5534917999ba456c8e366ea020e2465e323328fe02d39a376792d0c99ec23bf930100ef643a9f4cd17a67609aab88c3d664818f921f00d4e60648aea960d2"
    },
    {
      "line": 3962,
      "relation": "association",
      "evidence": "We identified a novel molecular interaction implying the PHF6 peptide of Tau and the FK1/FK2 domains of FKBP52 independent of FK506 binding; suggesting a non-catalytic molecular interaction that might govern the effect of FKBP52 on Tau.",
      "citation": {
        "type": "PubMed",
        "reference": "26903089",
        "name": "Journal of molecular biology",
        "title": "Isomerization and Oligomerization of Truncated and Mutated Tau Forms by FKBP52 are Independent Processes.",
        "volume": "428",
        "pages": "1080-1090",
        "date": "2016-03-27",
        "first": "Kamah A",
        "last": "Lippens G",
        "authors": [
          "Baulieu EE",
          "Byrne C",
          "Cantrelle FX",
          "Chambraud B",
          "Giustiniani J",
          "Guillemeau K",
          "Huvent I",
          "Jacquot Y",
          "Kamah A",
          "Landrieu I",
          "Lippens G",
          "Smet C"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 356,
      "target": 449,
      "key": "7814c42be6752b664a9cfcc2597ab07563626d8b3d0e99d184ba708316f16e8d54185ef67118eb81b55a14f61c928a1ecb28b5a6ca0e202ea47004c4455e1fb3"
    },
    {
      "line": 419,
      "relation": "decreases",
      "evidence": "CA and the oxidized form of EC (ECox) inhibited tau aggregation in vitro due to their interaction with the two cysteine residues in tau. A synthetic peptide, SKCGS, representing the actual tau sequence, identified the thiol as reacting with CA and ECox which necessitates of cysteine for aggregation inhibition by CA.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "source": 1,
      "target": 318,
      "key": "30f1b98abdd7fb6ed1827f666bccd82827d1ada2d3f864eabab341bd7c7f21ae70212d1ddba0705bfcd5e2184704def62f4e4499c32c9cb1e0f06d57aaa83fc6"
    },
    {
      "line": 425,
      "relation": "decreases",
      "evidence": "CA and the oxidized form of EC (ECox) inhibited tau aggregation in vitro due to their interaction with the two cysteine residues in tau. A synthetic peptide, SKCGS, representing the actual tau sequence, identified the thiol as reacting with CA and ECox which necessitates of cysteine for aggregation inhibition by CA.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "source": 1,
      "target": 188,
      "key": "7786fb3b846367c487faa23ca356a20ba09e2655d44b13c045870c851c29c240964970865ee9389e9014de0189cd3718aaabff9bc5a6814b32b0f8f5d4921338"
    },
    {
      "line": 436,
      "relation": "decreases",
      "evidence": "We found that CA (lane 4) and EC (lane 6) substantially prevented the H2O2 induced formation of the high molecular weight species.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 1,
      "target": 21,
      "key": "7ae3b8b39104a616ce2d75bae2f1d85641fd078a717d1f32cee8a5c71191d2118572d4c09e40c3af42caadf158f905f19449be08f82200ab488f773742feda68"
    },
    {
      "line": 442,
      "relation": "increases",
      "evidence": "We were prompted to carry out this study because Acr is mainly localized in the neurons [54], is found in association with NFTs and dystrophic neurites surrounding senile plaques [55], is highly toxic to neurons, is found elevated 2–5 fold in affected regions of AD brain. EC can sequester highly reactive and toxic byproducts of oxidation such as acrolein.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "source": 1,
      "target": 219,
      "key": "5063c031d96b9b9533e9b35ddb9ca9c3a45f7b493409ebf827379798ca8e2e5316f5b9901b18161ba66529d9b8bf325f5db3b64ce6531d63fb9087c9bd697cdc"
    },
    {
      "line": 421,
      "relation": "partOf",
      "evidence": "CA and the oxidized form of EC (ECox) inhibited tau aggregation in vitro due to their interaction with the two cysteine residues in tau. A synthetic peptide, SKCGS, representing the actual tau sequence, identified the thiol as reacting with CA and ECox which necessitates of cysteine for aggregation inhibition by CA.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "source": 364,
      "target": 130,
      "key": "bb615908cb09d73083df82622d078539a7ec8dd1b44ad475c279c85903fc0d100f2bdcd3bc52899013fb871609ac9c2042832c90e1b24495d6bdb5db329c91a1"
    },
    {
      "line": 3976,
      "relation": "increases",
      "evidence": "We then investigated the function of FK506-binding protein (FKBP) 12, which is known to accumulate in neurofibrillary tangles in vivo, on aggregation of the R3 peptide and found that FKBP12 completely prevented the peptide from aggregating at a concentration ratio of 1 : 4 (peptide:FKBP12). FKBP12 also restored the oligomer of the peptide to its monomeric status. Mutational studies on the catalytic center of FKBP12 indicated that peptidyl-prolyl isomerase activity of FKBP12 was essential for prevention of aggregation. Assuming that the propensity of aggregation of the peptide is different in each cis-/trans-isomer, we propose that the aggregation behavior of the R3 peptide can be theoretically described with a simple kinetic scheme, in which only the cis-isomer can aggregate and FKBP12 catalyzes isomerization of the peptide in both the monomeric and aggregative states.",
      "citation": {
        "type": "PubMed",
        "reference": "23832849",
        "name": "Protein engineering, design &amp; selection : PEDS",
        "title": "Peptidyl-prolyl isomerase activity of FK506 binding protein 12 prevents tau peptide from aggregating.",
        "volume": "26",
        "pages": "539-46",
        "date": "2013-09-01",
        "first": "Ikura T",
        "last": "Ito N",
        "authors": [
          "Ikura T",
          "Ito N"
        ]
      },
      "source": 364,
      "target": 112,
      "key": "76137dfc38374fbb35cb5d0b4e6b585f8de63869abd9895d8f6f8f5c2606a3bfa35af764d7a63ea525fbbcda6ed68381fbdbb305d48b0e75297ffea42c182010"
    },
    {
      "line": 422,
      "relation": "partOf",
      "evidence": "CA and the oxidized form of EC (ECox) inhibited tau aggregation in vitro due to their interaction with the two cysteine residues in tau. A synthetic peptide, SKCGS, representing the actual tau sequence, identified the thiol as reacting with CA and ECox which necessitates of cysteine for aggregation inhibition by CA.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "source": 130,
      "target": 486,
      "key": "f028d41761a8001cfc5bfb4dd9d86a47618d79b766aa48162b586afb905e7c3f70630fd0b6cc65c68bce0301152ac84eddd91a010de40daa9ab048bf790ae52f"
    },
    {
      "line": 808,
      "relation": "partOf",
      "evidence": "For these studies, SH-SY5Y cells stably overexpressing tTG were used. tTG coimmunoprecipitated with tau, and elevating intracellular calcium levels with maitotoxin resulted in a 52 +/- 4% increase in the amount of tTG that coimmunoprecipitated with tau. The increase in association of tTG with tau after treatment with maitotoxin corresponded to a coimmunolocalization of tTG, tTG activity, and tau in the cells. Further, tau was modified by tTG in situ in response to maitotoxin treatment. In vitro polyaminated tau was significantly less susceptible to micro-calpain proteolysis; however, tTG-mediated polyamination of tau did not significantly alter the microtubule-binding capacity of tau.",
      "citation": {
        "type": "PubMed",
        "reference": "10537045",
        "name": "Journal of neurochemistry",
        "title": "Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination.",
        "volume": "73",
        "pages": "1871-80",
        "date": "1999-11-01",
        "first": "Tucholski J",
        "last": "Johnson GV",
        "authors": [
          "Johnson GV",
          "Kuret J",
          "Tucholski J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 130,
      "target": 486,
      "key": "465a2024a9f4c3299a91778e6a6741b9a6011573376e4f76035cdd20357703b5b0d3c67a9609d797c1d35a79219513dd220cea8cdf32ac8c84918ba445064483"
    },
    {
      "line": 1616,
      "relation": "partOf",
      "evidence": "Apart from binding to MT, the repeat domains of tau also bind to tubulin deacetylase, histone deacetylase 6 (HDAC6) [68] and apolipoprotein E (apoE) more with the ",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 130,
      "target": 486,
      "key": "6a6d3487eacefb04ccf4b671d4f0e1b389971ef0f4acb0b54147abc7ea8ec4483cf619bb16f85455c7e976e1ec9fb9fc6f9e8b7d88cff071354c6fcde8377aad"
    },
    {
      "line": 807,
      "relation": "association",
      "evidence": "For these studies, SH-SY5Y cells stably overexpressing tTG were used. tTG coimmunoprecipitated with tau, and elevating intracellular calcium levels with maitotoxin resulted in a 52 +/- 4% increase in the amount of tTG that coimmunoprecipitated with tau. The increase in association of tTG with tau after treatment with maitotoxin corresponded to a coimmunolocalization of tTG, tTG activity, and tau in the cells. Further, tau was modified by tTG in situ in response to maitotoxin treatment. In vitro polyaminated tau was significantly less susceptible to micro-calpain proteolysis; however, tTG-mediated polyamination of tau did not significantly alter the microtubule-binding capacity of tau.",
      "citation": {
        "type": "PubMed",
        "reference": "10537045",
        "name": "Journal of neurochemistry",
        "title": "Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination.",
        "volume": "73",
        "pages": "1871-80",
        "date": "1999-11-01",
        "first": "Tucholski J",
        "last": "Johnson GV",
        "authors": [
          "Johnson GV",
          "Kuret J",
          "Tucholski J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 130,
      "target": 730,
      "key": "50e9ddc78b7c2e558e2d52b8a7f2521d3cc26cafe5d01464166f0ec4ae6a60d1a4e931fcd6a6ab5a8dca477ddc7dbc3cf1db0fd0c6bc949b66f12968c6d1af85"
    },
    {
      "line": 1612,
      "relation": "association",
      "evidence": "Apart from binding to MT, the repeat domains of tau also bind to tubulin deacetylase, histone deacetylase 6 (HDAC6) [68] and apolipoprotein E (apoE) more with the ",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 130,
      "target": 459,
      "key": "3c6dcbcb4a7e1ad40a19b29a91ad2d97cc8752ec9110a309d7648d4646cc6374e0868bb97fac76621bf04e94007b7297e8df7b761c7c41a8e15884a158b34d15"
    },
    {
      "line": 437,
      "relation": "positiveCorrelation",
      "evidence": "We found that CA (lane 4) and EC (lane 6) substantially prevented the H2O2 induced formation of the high molecular weight species.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 188,
      "target": 21,
      "key": "5ddab93460bdf8a14c8d2a99f5c96051ec30abb2b4a8fd55df60a0f8441db89e40d334bdcdaa1a20af9cc5c42f6c5b3de0a8aad5dafececa87e9e096e226d925"
    },
    {
      "line": 457,
      "relation": "negativeCorrelation",
      "evidence": "However, granule cells of the dentate gyrus mainly express 3R isoforms, which resist Tau aggregation in AD, but accumulate 3R aggregates in Pick's disease [14]. 3R Tau is a major Tau isoform in laser microdissected Pick bodies [15].",
      "citation": {
        "type": "PubMed",
        "reference": "26655600",
        "name": "Biochimica et biophysica acta",
        "title": "Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property.",
        "volume": "1862",
        "pages": "192-201",
        "date": "2016-02-01",
        "first": "Liu K",
        "last": "Qing H",
        "authors": [
          "Deng Y",
          "Iqbal J",
          "Li L",
          "Liu K",
          "Liu Y",
          "Qin P",
          "Qing H"
        ]
      },
      "annotations": {
        "Anatomy": {
          "dentate gyrus granule cell layer": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 188,
      "target": 306,
      "key": "2c7cb0923ba7b5bdf6ba4fc12037aa257f424778178462ce9575664c4fcc6e1cf725930920c3017adb2416ec124ae6f45f7573765920c228c625a8360abe0303"
    },
    {
      "line": 845,
      "relation": "positiveCorrelation",
      "evidence": "Tau-nY29 detects soluble tau and paired helical filament tau from severely affected Alzheimer's brain but fails to recognize tau from normal aged brain. This observation suggests that nitration at Tyr29 is a disease-related event that may alter the intrinsic ability of tau to self-polymerize. In Alzheimer's brain, Tau-nY29 labels the fibrillar triad of tau lesions, including neurofibrillary tangles, neuritic plaques, and, to a lesser extent, neuropil threads. Intriguingly, although Tau-nY29 stains both the neuronal and glial tau pathology of Pick disease, it detects only the neuronal pathology in corticobasal degeneration and progressive supranuclear palsy without labeling the predominant glial pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "17050703",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.",
        "volume": "26",
        "pages": "10636-45",
        "date": "2006-10-18",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Bigio EH",
          "Binder LI",
          "Fu Y",
          "Guillozet-Bongaarts AL",
          "Reyes JF",
          "Reynolds MR"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 188,
      "target": 520,
      "key": "6662a14847e1a6845486d06219e752c863de6316cf6342acaba5b624523ef12cfbbbb3cacda92f138a3d2a59483ae83eb9945599020503166fb6d36534ab6dde"
    },
    {
      "line": 901,
      "relation": "negativeCorrelation",
      "evidence": "In the present study we injected bilaterally 3-morpholino-sydnonimine (SIN-1), a recognized and widely used peroxynitrite donor (25–30), into rat hippocampus, and investigated whether or not peroxynitrite could induce simultaneously nitration and hyperphosphorylation of tau and the underlying mechanisms in vivo. The level of nitrated and hyperphosphorylated tau was markedly increased in rat hippocampus 24 h, and prevented by preinjection of uric acid, a natural scavenger of peroxynitrite. GSK-3beta and p38 MAPKs, including p38alpha, p38beta, and p38delta activity was increased, but no change in the activity of p38gamma, ERK, and c-Jun amino-terminal kinase (JNK). Both nitrated tau and hyperphosphorylated tau were aggregated in the hippocampus, with activity of 20S proteasome significantly arrested in SIN-1-injected rats. Hyperphosphorylated tau was degraded as efficiently as normal tau by 20S proteasome, but the nitrated tau with an unorderly secondary structure became more resistant to the proteolysis, providing evidence that peroxynitrite simultaneously induces tau hyperphosphorylation, nitration, and accumulation, and that activation of GSK-3beta, p38alpha, p38beta, p38delta isoforms and the inhibition of proteasome activity are respectively responsible for the peroxynitrite-induced tau hyperphosphorylation and accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "16816118",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms.",
        "volume": "20",
        "pages": "1431-42",
        "date": "2006-07-01",
        "first": "Zhang YJ",
        "last": "Wang JZ",
        "authors": [
          "Li HL",
          "Liu YH",
          "Wang JZ",
          "Wang Q",
          "Xu YF",
          "Yin J",
          "Zhang YJ"
        ]
      },
      "annotations": {
        "ExpMethod": {
          "in vivo": true
        },
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 188,
      "target": 305,
      "key": "c990b9b5ad263eb58a892ebbb174a57129032f3df8425d9ee3c26561aea4668befe50d40049dfd6a3eaa16bb45c1930a8510bbe519dbfceef4afead866766540"
    },
    {
      "line": 2472,
      "relation": "positiveCorrelation",
      "evidence": "Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift in mobility as a result of phosphorylation-like changes, we conclude that they have the characteristics of hyperphosphorylated tau. These mutants will therefore be referred to as pseudo-hyperphosphorylated tau throughout the manuscript. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.",
      "citation": {
        "type": "PubMed",
        "reference": "19459590",
        "name": "Biochemistry",
        "title": "Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.",
        "volume": "48",
        "pages": "6002-11",
        "date": "2009-06-30",
        "first": "Sun Q",
        "last": "Gamblin TC",
        "authors": [
          "Gamblin TC",
          "Sun Q"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 186,
      "target": 486,
      "key": "85ae91dceef546c45a74cb0814ed271f8d0f223ec8a26bb44d3c51a4be9a8272989000ddf8ed002048281b81f01f1946c1500179e277ccd271ab3e36f2c7d3a7"
    },
    {
      "line": 437,
      "relation": "positiveCorrelation",
      "evidence": "We found that CA (lane 4) and EC (lane 6) substantially prevented the H2O2 induced formation of the high molecular weight species.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 21,
      "target": 188,
      "key": "e3de30b83ee6ff30a391fd42de8e4a2695c487ab9af2c81c383968c267d18f7fc4b928e8c099389536e06e55640f2209c9cbbb773763c33a69af9a77c6f5cee8"
    },
    {
      "line": 2724,
      "relation": "increases",
      "evidence": "Primary cortical neurons exposed to the mitochondrial toxin NaN3 (0.1-3 mM) were submitted to oxidative stress with H2O2 (30-150 μM), to mimic conditions observed in neurodegenerative disorders. The effects of such treatment on a series of parameters useful in characterizing neuronal damage were investigated: (i) the basal release of glutamate, evaluated as (3)H-d-Aspartate efflux, was sharply, concentration-dependently, increased; (ii) the phosphorylation status of intracellular markers known to be involved in the neurodegenerative processes, in particular in Alzheimer disease: tau and GSK3β were increased, as well as the protein level of β-secretase (BACE1) and p35/25 evaluated by Western blotting, while (iii) the cell metabolic activity, measured with the MTT method, was reduced, in a concentration- and time-dependent manner. The latter effect, as well as tau hyperphosphorylation, was prevented both by a mixture of antioxidant drugs (100 μM ascorbic acid, 10 μM trolox, 100 μM glutathione) and by the anti-Alzheimer drug, memantine, 20 μM.",
      "citation": {
        "type": "PubMed",
        "reference": "23722080",
        "name": "Neurochemistry international",
        "title": "In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease.",
        "volume": "63",
        "pages": "112-20",
        "date": "2013-08-01",
        "first": "Selvatici R",
        "last": "Siniscalchi A",
        "authors": [
          "Marani L",
          "Marino S",
          "Selvatici R",
          "Siniscalchi A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 21,
      "target": 205,
      "key": "5327cc7e33ed056e50a0e6ebc8a69682caa12ac75414b1c8b2b06652f011d34ec0e47536bde76cba5277532491bbb19fb2d532cec92ac20264c645377cae17ff"
    },
    {
      "line": 2727,
      "relation": "positiveCorrelation",
      "evidence": "Primary cortical neurons exposed to the mitochondrial toxin NaN3 (0.1-3 mM) were submitted to oxidative stress with H2O2 (30-150 μM), to mimic conditions observed in neurodegenerative disorders. The effects of such treatment on a series of parameters useful in characterizing neuronal damage were investigated: (i) the basal release of glutamate, evaluated as (3)H-d-Aspartate efflux, was sharply, concentration-dependently, increased; (ii) the phosphorylation status of intracellular markers known to be involved in the neurodegenerative processes, in particular in Alzheimer disease: tau and GSK3β were increased, as well as the protein level of β-secretase (BACE1) and p35/25 evaluated by Western blotting, while (iii) the cell metabolic activity, measured with the MTT method, was reduced, in a concentration- and time-dependent manner. The latter effect, as well as tau hyperphosphorylation, was prevented both by a mixture of antioxidant drugs (100 μM ascorbic acid, 10 μM trolox, 100 μM glutathione) and by the anti-Alzheimer drug, memantine, 20 μM.",
      "citation": {
        "type": "PubMed",
        "reference": "23722080",
        "name": "Neurochemistry international",
        "title": "In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease.",
        "volume": "63",
        "pages": "112-20",
        "date": "2013-08-01",
        "first": "Selvatici R",
        "last": "Siniscalchi A",
        "authors": [
          "Marani L",
          "Marino S",
          "Selvatici R",
          "Siniscalchi A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 21,
      "target": 245,
      "key": "fcc150ffedd509db3db98cd6cc7fa30528249dbc5ef2ef2ce134c1ae31168d539e8d5b253e798d96f6ca2b9c8b1a0e1b72ffbff4f3535f25f000b69bdb8d0390"
    },
    {
      "relation": "hasComponent",
      "source": 219,
      "target": 1,
      "key": "a40c9dddfec0dc19315eba0414ce91800564934f1cd83502c6700d3e20de1fb9d4caa549307191881be67ef9e0764cb29d6508285fcc55eb54c5a9eb9b2f68d3"
    },
    {
      "relation": "hasComponent",
      "source": 219,
      "target": 41,
      "key": "cebe2c96b49368e72b92cf7cd5e26f776eebc4b6de20ebb3495824f9a47909b96ae3ed4515a71138439f0d9db848717e90ada679d5570b1cd088e43019149d46"
    },
    {
      "line": 443,
      "relation": "decreases",
      "evidence": "We were prompted to carry out this study because Acr is mainly localized in the neurons [54], is found in association with NFTs and dystrophic neurites surrounding senile plaques [55], is highly toxic to neurons, is found elevated 2–5 fold in affected regions of AD brain. EC can sequester highly reactive and toxic byproducts of oxidation such as acrolein.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 219,
      "target": 41,
      "key": "3218a4dd8468609bac695b1122b4e8c67b7abde35e09fce7d7d8f9fd09c9a7a91613108a8340f8fe28556929cebc8fd8c6d0f77dd6e419056bb34ac2955e485a"
    },
    {
      "line": 444,
      "relation": "positiveCorrelation",
      "evidence": "We were prompted to carry out this study because Acr is mainly localized in the neurons [54], is found in association with NFTs and dystrophic neurites surrounding senile plaques [55], is highly toxic to neurons, is found elevated 2–5 fold in affected regions of AD brain. EC can sequester highly reactive and toxic byproducts of oxidation such as acrolein.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 41,
      "target": 81,
      "key": "f2a55a5d3a8c9eb6c65e1413566d5ebdbce3ff2e22869df6b83ae04ad652c0f2be1d34682ef3900a0f95edc4818f8115194544b5473f383e4b83d5fa93e828ef"
    },
    {
      "line": 681,
      "relation": "increases",
      "evidence": "Acrolein and methylglyoxal were the most reactive compounds followed by glyoxal and malondialdehyde in terms of formation of Tau dimers and higher molecular weight oligomers. Analysis of the Tau aggregates by electron microscopy study showed that formation of fibrils using wild-type Tau and several Tau mutants could be observed with acrolein and methylglyoxal but not with glyoxal and malondialdehyde.",
      "citation": {
        "type": "PubMed",
        "reference": "17082178",
        "name": "The Journal of biological chemistry",
        "title": "Effect of pseudophosphorylation and cross-linking by lipid peroxidation and advanced glycation end product precursors on tau aggregation and filament formation.",
        "volume": "282",
        "pages": "6984-91",
        "date": "2007-03-09",
        "first": "Kuhla B",
        "last": "Münch G",
        "authors": [
          "Arendt T",
          "Flach K",
          "Haase C",
          "Kuhla B",
          "Lüth HJ",
          "Münch G"
        ]
      },
      "annotations": {
        "Method": {
          "SDS-PAGE": true,
          "Western Blot": true,
          "Electron Microscopy": true,
          "Thioflavin T Assay": true
        }
      },
      "source": 41,
      "target": 81,
      "key": "e9fc5da3b4219efa766faf67d044e448c0db389aec73709a9c53a2d56c0239f125be0a5542490786de4f74b159339f57ee15106ca8939e39b60417a6b6e02178"
    },
    {
      "line": 445,
      "relation": "positiveCorrelation",
      "evidence": "We were prompted to carry out this study because Acr is mainly localized in the neurons [54], is found in association with NFTs and dystrophic neurites surrounding senile plaques [55], is highly toxic to neurons, is found elevated 2–5 fold in affected regions of AD brain. EC can sequester highly reactive and toxic byproducts of oxidation such as acrolein.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 41,
      "target": 917,
      "key": "e2079d67b1f7c9d37ef3ee57c6185d83a785554da7b3a7b64ab99770d72e921674622cfa886c45c65ac47e666be386554558b8cf270d436d0bb8adc865271266"
    },
    {
      "line": 446,
      "relation": "decreases",
      "evidence": "We were prompted to carry out this study because Acr is mainly localized in the neurons [54], is found in association with NFTs and dystrophic neurites surrounding senile plaques [55], is highly toxic to neurons, is found elevated 2–5 fold in affected regions of AD brain. EC can sequester highly reactive and toxic byproducts of oxidation such as acrolein.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 41,
      "target": 168,
      "key": "25cabe33426325fa499cde2f08d8bbacae33c4f491f596fbb3776378e9072cc8b9682b7dac2c74fc699166b6ab07e40b5e372934082aec17bd5de3b6be91d7b1"
    },
    {
      "line": 447,
      "relation": "positiveCorrelation",
      "evidence": "We were prompted to carry out this study because Acr is mainly localized in the neurons [54], is found in association with NFTs and dystrophic neurites surrounding senile plaques [55], is highly toxic to neurons, is found elevated 2–5 fold in affected regions of AD brain. EC can sequester highly reactive and toxic byproducts of oxidation such as acrolein.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 41,
      "target": 908,
      "key": "139525d549ea72380aaca55918a9aadcae98a9c682103d576f9bbd69c64038c4b2310f2b6a1413d70a195ea4274d2b10b332e77165007ceb9586af820497c0fe"
    },
    {
      "line": 445,
      "relation": "positiveCorrelation",
      "evidence": "We were prompted to carry out this study because Acr is mainly localized in the neurons [54], is found in association with NFTs and dystrophic neurites surrounding senile plaques [55], is highly toxic to neurons, is found elevated 2–5 fold in affected regions of AD brain. EC can sequester highly reactive and toxic byproducts of oxidation such as acrolein.",
      "citation": {
        "type": "PubMed",
        "reference": "23531502",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.",
        "volume": "36",
        "pages": "21-40",
        "date": "2013-01-01",
        "first": "George RC",
        "last": "Graves DJ",
        "authors": [
          "George RC",
          "Graves DJ",
          "Lew J"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "Mass Spectrometry": true
        },
        "ExpMethod": {
          "in vitro": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 917,
      "target": 41,
      "key": "8bddd65802bed2cf5bb6d3c17148143280bc6ed00dfc7df85c326a58e05cb394e8d9c1556cbbc2c6c6b47f52dcb8bd4c574077c5e3eb08ded566e752029f8ff7"
    },
    {
      "line": 836,
      "relation": "positiveCorrelation",
      "evidence": "This antibody detects nitrated tau in soluble preparations from both severe AD brains (Braak stage V, VI) and age-matched controls, suggesting that nitration at Tyr 18 may be linked to astrocyte activation, an early event associated with amyloid plaque formation",
      "citation": {
        "type": "PubMed",
        "reference": "18562203",
        "name": "Neurobiology of disease",
        "title": "A possible link between astrocyte activation and tau nitration in Alzheimer's disease.",
        "volume": "31",
        "pages": "198-208",
        "date": "2008-08-01",
        "first": "Reyes JF",
        "last": "Binder LI",
        "authors": [
          "Berry R",
          "Binder LI",
          "Fu Y",
          "Guillozet-Bongaarts AL",
          "Horowitz PM",
          "Reyes JF",
          "Reynolds MR"
        ]
      },
      "source": 917,
      "target": 518,
      "key": "60d9315da4ba4efd9a73ab45ed32085913745f7e8022d1fbd1c4654509e4baa45fafb5c17ac50a151926e419a15e2d6c4e09b443c48981e175519840c29e7aba"
    },
    {
      "line": 1249,
      "relation": "association",
      "evidence": "We found that the immunoreactivities of p-WAVE1 and pCRMP2 colocalized with p-tau and were located near peripheral amyloid plaques in the cerebral cortices of 23- month-old 33Tg (Fig. 3A) and 17-month-old APPswe/ PS1DE9 (Fig. 3B) mice.",
      "citation": {
        "type": "PubMed",
        "reference": "26400044",
        "name": "Journal of neuroscience research",
        "title": "Colocalization of phosphorylated forms of WAVE1, CRMP2, and tau in Alzheimer's disease model mice: Involvement of Cdk5 phosphorylation and the effect of ATRA treatment.",
        "volume": "94",
        "pages": "15-26",
        "date": "2016-01-01",
        "first": "Watamura N",
        "last": "Ohshima T",
        "authors": [
          "Nikkuni M",
          "Ohshima T",
          "Toba J",
          "Watamura N",
          "Yoshii A"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 917,
      "target": 243,
      "key": "be2185117cb42ff40acadf6261f078a7e3347a3e571c23c3af0d0d51915928ef7d067e91399379bb88e29227dce7b3d4251407131c6a10821c292d949b1d3459"
    },
    {
      "line": 1300,
      "relation": "association",
      "evidence": "The pSer422 antibody displayed an almost identical pattern to that of AT8, in that it stained NFTs (Figure 5A–D), neuropil threads and neuritic plaques (Figure 5E–H)",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "source": 917,
      "target": 336,
      "key": "1c687dc8404a296435df59b0fdfb8ba4c3d6fc43ea9ff3e45d29a38b808921551a4f6844d4ccbb3bac69cca8daf2486a83428e9b01386c966ad79386cdb28313"
    },
    {
      "line": 2191,
      "relation": "positiveCorrelation",
      "evidence": "The upregulation of Syk activation observed in the brains of Tg APPsw and Tg PS1/APPsw is mainly attributable to pSyk accumulations in dystrophic neurites that are associated with Aβ plaques and increase with age and Aβ burden.",
      "citation": {
        "type": "PubMed",
        "reference": "28877763",
        "name": "Acta neuropathologica communications",
        "title": "Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.",
        "volume": "5",
        "pages": "69",
        "date": "2017-09-06",
        "first": "Schweig JE",
        "last": "Paris D",
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Mouzon B",
          "Mullan M",
          "Paris D",
          "Schweig JE",
          "Yao H"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "APPPS1 mice": true
        }
      },
      "source": 917,
      "target": 852,
      "key": "82df66d1fb9d71e7841671407565ff69ef970093fe3616bca2f8a33e5c6c86e444cda16bdbe3e57f992defa095e2fb0ba9a9fccd8bd7bd186691559f3cbe5dd2"
    },
    {
      "line": 2207,
      "relation": "positiveCorrelation",
      "evidence": "We found an increase in Syk activation in DNs surrounding Aβ deposits as well as in neurons displaying an accumulation of phosphorylated Tau at Y18 and elevated levels of MC1 pathogenic tau conformers in AD brain sections whereas only weak immunoreactivity for pSyk was observed in brain sections from a non-demented control",
      "citation": {
        "type": "PubMed",
        "reference": "28877763",
        "name": "Acta neuropathologica communications",
        "title": "Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.",
        "volume": "5",
        "pages": "69",
        "date": "2017-09-06",
        "first": "Schweig JE",
        "last": "Paris D",
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Mouzon B",
          "Mullan M",
          "Paris D",
          "Schweig JE",
          "Yao H"
        ]
      },
      "source": 917,
      "target": 706,
      "key": "d2ce9604a10d52f1d6d697ad785f2ac6f48932429ef36c524b8a1a4e41ce5f75349ff4a606a889e3a32f74c058681d00fa77bc2dbc5222833382d9d356df468c"
    },
    {
      "line": 2857,
      "relation": "positiveCorrelation",
      "evidence": "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24401760",
        "name": "Brain : a journal of neurology",
        "title": "Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.",
        "volume": "137",
        "pages": "537-52",
        "date": "2014-02-01",
        "first": "Stygelbout V",
        "last": "Brion JP",
        "authors": [
          "Ando K",
          "Brion JP",
          "D'Amico E",
          "Duyckaerts C",
          "Erneux C",
          "Jia Y",
          "Leroy K",
          "Luo HR",
          "Pouillon V",
          "Schurmans S",
          "Stygelbout V"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 917,
      "target": 460,
      "key": "fabb551c58ebbd7c3faa175b5ac36aaf7d963abd81104baf8bab41571e35672a1ddea911f4b42bff8deeb38f11d8c6f2dbbf1b55e7b60acfdf20900f5d76e722"
    },
    {
      "line": 2858,
      "relation": "partOf",
      "evidence": "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24401760",
        "name": "Brain : a journal of neurology",
        "title": "Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.",
        "volume": "137",
        "pages": "537-52",
        "date": "2014-02-01",
        "first": "Stygelbout V",
        "last": "Brion JP",
        "authors": [
          "Ando K",
          "Brion JP",
          "D'Amico E",
          "Duyckaerts C",
          "Erneux C",
          "Jia Y",
          "Leroy K",
          "Luo HR",
          "Pouillon V",
          "Schurmans S",
          "Stygelbout V"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 917,
      "target": 127,
      "key": "98c8271fb3ace5e65a88b336a7200fe1ae9503da41112c31173cb701dbe6678dc97f3586ba60d2d14750573487a8ec4f63fde228d2185fa309e9000e3b4a63d6"
    },
    {
      "line": 971,
      "relation": "increases",
      "evidence": "These observations suggest that CaMKv blocks RhoA activity by preventing its interaction with Lfc. These results demonstrate that CaMKv regulates spine maintenance through RhoA inhibition. The suppression of the Lfc/RhoA pathway by AMPA receptors is implicated in dendritic spine maintenance10. Given that CaMKv expression is upregulated by synaptic activity, CaMKv may be a key signalling protein that transduces the signals from AMPA receptors to suppress RhoA during activity-dependent spine maintenance. Corroborating this, the AMPA receptor blocker NBQX attenuated CaMKv expression in neurons (Fig. 3i,j). Importantly, CaMKv overexpression completely rescued NBQX-induced spine loss (Fig. 3k,l). These findings collectively reveal that activity-dependent CaMKv expression and the subsequent inhibition of Lfc/RhoA are required to mediate AMPA receptor function in spine maintenance.",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 168,
      "target": 394,
      "key": "58e6b96cdb0cd802c77ccfab2f6c543959c0bacbbc4357f40185d6d2ced91eae302f8bca1a46123c2f5938ebe8469ec0113afeaed1fecc5c23762d7ae020396d"
    },
    {
      "line": 2380,
      "relation": "positiveCorrelation",
      "evidence": "Our data showed that CDK5 knock down induced an increase in p35 protein levels and Rac activity in triple transgenic Alzheimer's mice, which correlated with the recovery of cognitive function; these findings confirm that increased p35 and active Rac are involved in neuroprotection. In summary, our data suggest that p35 acts as a mediator of Rho GTPase activity and contributes to the neuroprotection induced by CDK5 RNAi.",
      "citation": {
        "type": "PubMed",
        "reference": "27087442",
        "name": "Current Alzheimer research",
        "title": "APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.",
        "volume": "13",
        "pages": "1048-55",
        "date": "2016-01-01",
        "first": "Zhou M",
        "last": "Chen X",
        "authors": [
          "Chen X",
          "Collins N",
          "Dai X",
          "Huang T",
          "LaDu MJ",
          "Lin L",
          "Shen H",
          "Wei Z",
          "Wu X",
          "Xiao N",
          "York J",
          "Zhang J",
          "Zhou M",
          "Zhu Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 168,
      "target": 778,
      "key": "188a930fdd6228ea0a3428463d5e6736751f1d027a4f7f4039089d4fcf055fcd9b0ff51901d6339af78ef8429cfe1d909a6aa17994e3c6362e0bfb8b94239c8a"
    },
    {
      "line": 2381,
      "relation": "positiveCorrelation",
      "evidence": "Our data showed that CDK5 knock down induced an increase in p35 protein levels and Rac activity in triple transgenic Alzheimer's mice, which correlated with the recovery of cognitive function; these findings confirm that increased p35 and active Rac are involved in neuroprotection. In summary, our data suggest that p35 acts as a mediator of Rho GTPase activity and contributes to the neuroprotection induced by CDK5 RNAi.",
      "citation": {
        "type": "PubMed",
        "reference": "27087442",
        "name": "Current Alzheimer research",
        "title": "APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.",
        "volume": "13",
        "pages": "1048-55",
        "date": "2016-01-01",
        "first": "Zhou M",
        "last": "Chen X",
        "authors": [
          "Chen X",
          "Collins N",
          "Dai X",
          "Huang T",
          "LaDu MJ",
          "Lin L",
          "Shen H",
          "Wei Z",
          "Wu X",
          "Xiao N",
          "York J",
          "Zhang J",
          "Zhou M",
          "Zhu Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 168,
      "target": 367,
      "key": "1d27df6c7eea1c1be043f6ba7e69631045dc6f49e009d04d86faa5bca8be0dccf4bb561e8de8da6f0d6143a4ff4bcf425ab51083c4b2b90d28a193679abb9bdf"
    },
    {
      "line": 2382,
      "relation": "negativeCorrelation",
      "evidence": "Our data showed that CDK5 knock down induced an increase in p35 protein levels and Rac activity in triple transgenic Alzheimer's mice, which correlated with the recovery of cognitive function; these findings confirm that increased p35 and active Rac are involved in neuroprotection. In summary, our data suggest that p35 acts as a mediator of Rho GTPase activity and contributes to the neuroprotection induced by CDK5 RNAi.",
      "citation": {
        "type": "PubMed",
        "reference": "27087442",
        "name": "Current Alzheimer research",
        "title": "APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.",
        "volume": "13",
        "pages": "1048-55",
        "date": "2016-01-01",
        "first": "Zhou M",
        "last": "Chen X",
        "authors": [
          "Chen X",
          "Collins N",
          "Dai X",
          "Huang T",
          "LaDu MJ",
          "Lin L",
          "Shen H",
          "Wei Z",
          "Wu X",
          "Xiao N",
          "York J",
          "Zhang J",
          "Zhou M",
          "Zhu Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 168,
      "target": 777,
      "key": "1169d20e7cd1dfb27ff3921a0b8aab3012edc74192c9e1d3156ab9d92def818ced95c81d3269a4512cde95d364f7f3c8ac7850ffc57c517bad383f3649ff173b"
    },
    {
      "line": 457,
      "relation": "negativeCorrelation",
      "evidence": "However, granule cells of the dentate gyrus mainly express 3R isoforms, which resist Tau aggregation in AD, but accumulate 3R aggregates in Pick's disease [14]. 3R Tau is a major Tau isoform in laser microdissected Pick bodies [15].",
      "citation": {
        "type": "PubMed",
        "reference": "26655600",
        "name": "Biochimica et biophysica acta",
        "title": "Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property.",
        "volume": "1862",
        "pages": "192-201",
        "date": "2016-02-01",
        "first": "Liu K",
        "last": "Qing H",
        "authors": [
          "Deng Y",
          "Iqbal J",
          "Li L",
          "Liu K",
          "Liu Y",
          "Qin P",
          "Qing H"
        ]
      },
      "annotations": {
        "Anatomy": {
          "dentate gyrus granule cell layer": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 306,
      "target": 188,
      "key": "b60b561606e811c8091bfc4329215d3ab70beeed3203dccb324ea0dc93dd1c339bcc6aedff3e9fc503cbc7209370190cca554d0114acd3a684b581d2f102af0b"
    },
    {
      "line": 460,
      "relation": "positiveCorrelation",
      "evidence": "However, granule cells of the dentate gyrus mainly express 3R isoforms, which resist Tau aggregation in AD, but accumulate 3R aggregates in Pick's disease [14]. 3R Tau is a major Tau isoform in laser microdissected Pick bodies [15].",
      "citation": {
        "type": "PubMed",
        "reference": "26655600",
        "name": "Biochimica et biophysica acta",
        "title": "Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property.",
        "volume": "1862",
        "pages": "192-201",
        "date": "2016-02-01",
        "first": "Liu K",
        "last": "Qing H",
        "authors": [
          "Deng Y",
          "Iqbal J",
          "Li L",
          "Liu K",
          "Liu Y",
          "Qin P",
          "Qing H"
        ]
      },
      "annotations": {
        "Anatomy": {
          "dentate gyrus granule cell layer": true
        },
        "Disease": {
          "Pick's disease": true
        }
      },
      "source": 306,
      "target": 210,
      "key": "4b42ea450ccaef848081b6a8ce04d8de2ae37293df900a83580c06c5deba8d74036bcb419253c639d0bd859ff535b3910e4cb68c5e92892e395e304ac34f2760"
    },
    {
      "line": 1658,
      "relation": "positiveCorrelation",
      "evidence": "On the other side, sarkosyl extracts from the filaments of PSP [129], corticobasal degeneration (CBD; [130]), argyrophilic grain disease (AgD; [131]), and some cases of FTDP-17, contain tau protein that separates as doublets of 64 and 69 kDa and are predominantly composed of tau isoforms with 4R (class II tauopathies), whereas sarkosyl extracts from filaments of Pick’s disease are characterized by the presence of pathological tau doublets of 60 and 64 kDa and contain mainly 3R tau isoforms (class III tauopathy).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 306,
      "target": 914,
      "key": "dc82aeff0e55cb5decc00940ee1e365597299c81e50c86e567b140b0b8284ffd09b7b0b13d047be24011cf387b964d276d0c0eb674801e3000ae88fcd06540b5"
    },
    {
      "line": 2131,
      "relation": "positiveCorrelation",
      "evidence": "Inhibition of Dyrk1A enhanced tau exon 10 inclusion, leading to an increase in 4R-tau/3R-tau ratio in differentiated-human neuronal progenitors and in the neonatal rat brains. Accompanied with overexpression of Dyrk1A, 3R-tau was increased and 4R-tau was decreased in the neonatal brains of Ts65Dn mice, a model of Down syndrome.",
      "citation": {
        "type": "PubMed",
        "reference": "28775333",
        "name": "Scientific reports",
        "title": "Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D.",
        "volume": "7",
        "pages": "7240",
        "date": "2017-08-03",
        "first": "Wang P",
        "last": "Sun X",
        "authors": [
          "Chen L",
          "Sun X",
          "Wang L",
          "Wang P"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 306,
      "target": 786,
      "key": "f08c0bfd58e8bb6911a69e162196aa95d19111381c3daa7e58d984b9f00e780f46c239e45650ac6e59bbde66b900bda98a11214dda4c0f336739ef542f998515"
    },
    {
      "line": 2137,
      "relation": "negativeCorrelation",
      "evidence": "Treatment with Dyrk1A inhibitor, green tea flavonol epigallocatechin-gallate (EGCG), from gestation to adulthood suppressed 3R-tau expression and rescued anxiety and memory deficits in Ts65Dn mouse brains.",
      "citation": {
        "type": "PubMed",
        "reference": "28775333",
        "name": "Scientific reports",
        "title": "Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D.",
        "volume": "7",
        "pages": "7240",
        "date": "2017-08-03",
        "first": "Wang P",
        "last": "Sun X",
        "authors": [
          "Chen L",
          "Sun X",
          "Wang L",
          "Wang P"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 306,
      "target": 2,
      "key": "1037e007cc6d1d553a870e67076a861257f85b77ff988b60fefb9ef0cb46b464e21378a5577f800e1ff93e8cd4e6f46d26b25f3fac65828d07a02ef22969573a"
    },
    {
      "line": 460,
      "relation": "positiveCorrelation",
      "evidence": "However, granule cells of the dentate gyrus mainly express 3R isoforms, which resist Tau aggregation in AD, but accumulate 3R aggregates in Pick's disease [14]. 3R Tau is a major Tau isoform in laser microdissected Pick bodies [15].",
      "citation": {
        "type": "PubMed",
        "reference": "26655600",
        "name": "Biochimica et biophysica acta",
        "title": "Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property.",
        "volume": "1862",
        "pages": "192-201",
        "date": "2016-02-01",
        "first": "Liu K",
        "last": "Qing H",
        "authors": [
          "Deng Y",
          "Iqbal J",
          "Li L",
          "Liu K",
          "Liu Y",
          "Qin P",
          "Qing H"
        ]
      },
      "annotations": {
        "Anatomy": {
          "dentate gyrus granule cell layer": true
        },
        "Disease": {
          "Pick's disease": true
        }
      },
      "source": 210,
      "target": 306,
      "key": "51ed8c191a0e2a62ed5fcbc36499793ff7664c725305a7ff2f3cb72ff1f27d396313555694d4af42560ae61d25f06fd3c62bbb4307577c099c873eb6ea86c7b2"
    },
    {
      "line": 467,
      "relation": "increases",
      "evidence": "The results show that 4R2N and 3R2N Tau increase their aggregation extent with glycation while 3R1N decreases aggregation properties with glycation",
      "citation": {
        "type": "PubMed",
        "reference": "26655600",
        "name": "Biochimica et biophysica acta",
        "title": "Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property.",
        "volume": "1862",
        "pages": "192-201",
        "date": "2016-02-01",
        "first": "Liu K",
        "last": "Qing H",
        "authors": [
          "Deng Y",
          "Iqbal J",
          "Li L",
          "Liu K",
          "Liu Y",
          "Qin P",
          "Qing H"
        ]
      },
      "annotations": {
        "Method": {
          "Mass Spectrometry": true,
          "Thioflavin T Fluorescence Assay": true,
          "Liquid Chromatography": true
        }
      },
      "source": 351,
      "target": 188,
      "key": "f184ec07992c96bcf464a00bfa1666d02cb2cbc88ddf87dcfea077e7b2028575c7fd74a3baff697226c9b76628e1fcf52256ccee9f7b8d3efa3ac3596adda8f3"
    },
    {
      "line": 472,
      "relation": "negativeCorrelation",
      "evidence": "On the other hand, the MS analysis shows that in the combined reaction of 4R2N Tau the level of phosphorylation is increased and the level of glycation is decreased.",
      "citation": {
        "type": "PubMed",
        "reference": "26655600",
        "name": "Biochimica et biophysica acta",
        "title": "Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property.",
        "volume": "1862",
        "pages": "192-201",
        "date": "2016-02-01",
        "first": "Liu K",
        "last": "Qing H",
        "authors": [
          "Deng Y",
          "Iqbal J",
          "Li L",
          "Liu K",
          "Liu Y",
          "Qin P",
          "Qing H"
        ]
      },
      "annotations": {
        "Method": {
          "Mass Spectrometry": true,
          "Thioflavin T Fluorescence Assay": true,
          "Liquid Chromatography": true
        }
      },
      "source": 351,
      "target": 352,
      "key": "798b1f74c697940cfa47f7b404f7e63a5d7bce222ed3df25bc7e977e037ee5291abe87fe52dd3cf9c1fb3e256a0bf45e9343d00a8918dd5164d5fb6406c1eced"
    },
    {
      "relation": "hasVariant",
      "source": 350,
      "target": 351,
      "key": "f769a827fb29a54bccb3cde5eb81bccb35a60b512fb8835de66cddb9ce78b0dada7627fc516a74fac5106070773585af675dde9728d651f950ea6a321dd1b78d"
    },
    {
      "relation": "hasVariant",
      "source": 350,
      "target": 352,
      "key": "ebb7b09e0fcb52031f40add32d5bb02e8649790bb80d913ef1780d8c4113e19d72fc873474ee35bfa6ab34b815da283894da2a987b309bc71047dc71cd55ace2"
    },
    {
      "line": 468,
      "relation": "increases",
      "evidence": "The results show that 4R2N and 3R2N Tau increase their aggregation extent with glycation while 3R1N decreases aggregation properties with glycation",
      "citation": {
        "type": "PubMed",
        "reference": "26655600",
        "name": "Biochimica et biophysica acta",
        "title": "Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property.",
        "volume": "1862",
        "pages": "192-201",
        "date": "2016-02-01",
        "first": "Liu K",
        "last": "Qing H",
        "authors": [
          "Deng Y",
          "Iqbal J",
          "Li L",
          "Liu K",
          "Liu Y",
          "Qin P",
          "Qing H"
        ]
      },
      "annotations": {
        "Method": {
          "Mass Spectrometry": true,
          "Thioflavin T Fluorescence Assay": true,
          "Liquid Chromatography": true
        }
      },
      "source": 343,
      "target": 188,
      "key": "44e16990d815a3b5c91fb5b0a6e43e6702be45eff6cb40c2958f7cf836862e4f116f249d613e4872aea3568419bc02f6cd9f3aa723a0fa3de7adfe0d97ef7a97"
    },
    {
      "relation": "hasVariant",
      "source": 342,
      "target": 343,
      "key": "cf83cc140357c05768b5cc792b68f3fa9b632f50b9bf6066f4511e66315c9a2ca94f479711617a690ac9d508fd17394e8424c7f42fca146130828a21b4878ac7"
    },
    {
      "line": 469,
      "relation": "decreases",
      "evidence": "The results show that 4R2N and 3R2N Tau increase their aggregation extent with glycation while 3R1N decreases aggregation properties with glycation",
      "citation": {
        "type": "PubMed",
        "reference": "26655600",
        "name": "Biochimica et biophysica acta",
        "title": "Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property.",
        "volume": "1862",
        "pages": "192-201",
        "date": "2016-02-01",
        "first": "Liu K",
        "last": "Qing H",
        "authors": [
          "Deng Y",
          "Iqbal J",
          "Li L",
          "Liu K",
          "Liu Y",
          "Qin P",
          "Qing H"
        ]
      },
      "annotations": {
        "Method": {
          "Mass Spectrometry": true,
          "Thioflavin T Fluorescence Assay": true,
          "Liquid Chromatography": true
        }
      },
      "source": 340,
      "target": 188,
      "key": "5e67b782f1e4fe82707bea6f73c15ba1686c18e71af32a724f3c91d302c849fefd86a47d392714c36e83a9dd25689b09dada1dbae42808a091bd05718b33e82e"
    },
    {
      "relation": "hasVariant",
      "source": 339,
      "target": 340,
      "key": "8c6dd90409f5181d54ec4db09f8e46c61d429448cfa37ea78e86f06259b9f07959a61406d4306128b99720257c2f10f3ee8410755a918f86ae2a8a5bbc4578fd"
    },
    {
      "relation": "hasVariant",
      "source": 339,
      "target": 341,
      "key": "84540086a91c510a75157689db09c5012f12dd2b3609b439ed99973afdf7f1b0b957ffab4c65f9947dbf2c1e3ea5f1f21d69b5f24557cc1c65ee857a30b01052"
    },
    {
      "line": 472,
      "relation": "negativeCorrelation",
      "evidence": "On the other hand, the MS analysis shows that in the combined reaction of 4R2N Tau the level of phosphorylation is increased and the level of glycation is decreased.",
      "citation": {
        "type": "PubMed",
        "reference": "26655600",
        "name": "Biochimica et biophysica acta",
        "title": "Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property.",
        "volume": "1862",
        "pages": "192-201",
        "date": "2016-02-01",
        "first": "Liu K",
        "last": "Qing H",
        "authors": [
          "Deng Y",
          "Iqbal J",
          "Li L",
          "Liu K",
          "Liu Y",
          "Qin P",
          "Qing H"
        ]
      },
      "annotations": {
        "Method": {
          "Mass Spectrometry": true,
          "Thioflavin T Fluorescence Assay": true,
          "Liquid Chromatography": true
        }
      },
      "source": 352,
      "target": 351,
      "key": "dd3637b39797c4cf83e82d93b01f75072862a64787aff1c52e8e59d20f9d68159078a684a32352cee773f6f3ebe2f8468c2e5787e0503fe088b5363ccfdb23bc"
    },
    {
      "line": 475,
      "relation": "decreases",
      "evidence": "Glycation and phosphorylation of both 4R1Nand 4R0NTau reduce its aggregation.",
      "citation": {
        "type": "PubMed",
        "reference": "26655600",
        "name": "Biochimica et biophysica acta",
        "title": "Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property.",
        "volume": "1862",
        "pages": "192-201",
        "date": "2016-02-01",
        "first": "Liu K",
        "last": "Qing H",
        "authors": [
          "Deng Y",
          "Iqbal J",
          "Li L",
          "Liu K",
          "Liu Y",
          "Qin P",
          "Qing H"
        ]
      },
      "annotations": {
        "Method": {
          "Mass Spectrometry": true,
          "Thioflavin T Fluorescence Assay": true,
          "Liquid Chromatography": true
        }
      },
      "source": 345,
      "target": 188,
      "key": "f8d6c8f3442670b679a66bba9f956ce5e6f6dad2ff8b0c66e37e0963362cf3d8dbdb6249adcbd9246b157979932c3024271a3a8f4bf3f085d25371d9318467da"
    },
    {
      "relation": "hasVariant",
      "source": 344,
      "target": 345,
      "key": "77da6acfa22ea03dc9e07e30349041b2fc2bfa3ba8e1258b53fa309ca61ccbc613fb221937cf5018bb14fac87fd4c305b1fc36b1ba3868b034ca8e92c2559913"
    },
    {
      "relation": "hasVariant",
      "source": 344,
      "target": 346,
      "key": "c9d0e5ffd615e9f8a09a8f605c10ae6c82739d35e61ec5e7a4e2024e9687063b6362dc03342f6223ed5291937950962a8c230b92de64c5130f74db860f25c14a"
    },
    {
      "line": 476,
      "relation": "decreases",
      "evidence": "Glycation and phosphorylation of both 4R1Nand 4R0NTau reduce its aggregation.",
      "citation": {
        "type": "PubMed",
        "reference": "26655600",
        "name": "Biochimica et biophysica acta",
        "title": "Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property.",
        "volume": "1862",
        "pages": "192-201",
        "date": "2016-02-01",
        "first": "Liu K",
        "last": "Qing H",
        "authors": [
          "Deng Y",
          "Iqbal J",
          "Li L",
          "Liu K",
          "Liu Y",
          "Qin P",
          "Qing H"
        ]
      },
      "annotations": {
        "Method": {
          "Mass Spectrometry": true,
          "Thioflavin T Fluorescence Assay": true,
          "Liquid Chromatography": true
        }
      },
      "source": 348,
      "target": 188,
      "key": "dd11586944e5c023bcb4b892db35cc6961a28cafd4ca8e5a42977424d680579ff56e86cfb54150140765c2fb1c92addbff98b4ab03df10478302a40d30de63ba"
    },
    {
      "relation": "hasVariant",
      "source": 347,
      "target": 348,
      "key": "c876acb4b7e57fd83efcb8bed700e854b4628a0fee7727f18c1f8f9455c77531840c86db8bb756d97dd96ae5f921e6e8b06ce1d8420f4fb14a4f2c6b2246009a"
    },
    {
      "relation": "hasVariant",
      "source": 347,
      "target": 349,
      "key": "83f732b8c2a309d9e6ebcc5e7e3d19807239b3165433aa711ff39984e1b086872f2fad046f1f8b4aeb085d3c691c68d422cf21e2c397ddf5237644a59626e31e"
    },
    {
      "line": 477,
      "relation": "decreases",
      "evidence": "Glycation and phosphorylation of both 4R1Nand 4R0NTau reduce its aggregation.",
      "citation": {
        "type": "PubMed",
        "reference": "26655600",
        "name": "Biochimica et biophysica acta",
        "title": "Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property.",
        "volume": "1862",
        "pages": "192-201",
        "date": "2016-02-01",
        "first": "Liu K",
        "last": "Qing H",
        "authors": [
          "Deng Y",
          "Iqbal J",
          "Li L",
          "Liu K",
          "Liu Y",
          "Qin P",
          "Qing H"
        ]
      },
      "annotations": {
        "Method": {
          "Mass Spectrometry": true,
          "Thioflavin T Fluorescence Assay": true,
          "Liquid Chromatography": true
        }
      },
      "source": 346,
      "target": 188,
      "key": "6f0e9109a9352e6095725802043b0cd449bfae591fa96892d06bed42e1ff28aebb00b44b1ffea436fac3bc8fa7158e1310071f62da5b9d806e6026454a0c7249"
    },
    {
      "line": 478,
      "relation": "decreases",
      "evidence": "Glycation and phosphorylation of both 4R1Nand 4R0NTau reduce its aggregation.",
      "citation": {
        "type": "PubMed",
        "reference": "26655600",
        "name": "Biochimica et biophysica acta",
        "title": "Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property.",
        "volume": "1862",
        "pages": "192-201",
        "date": "2016-02-01",
        "first": "Liu K",
        "last": "Qing H",
        "authors": [
          "Deng Y",
          "Iqbal J",
          "Li L",
          "Liu K",
          "Liu Y",
          "Qin P",
          "Qing H"
        ]
      },
      "annotations": {
        "Method": {
          "Mass Spectrometry": true,
          "Thioflavin T Fluorescence Assay": true,
          "Liquid Chromatography": true
        }
      },
      "source": 349,
      "target": 188,
      "key": "cf31baf5018d4a03bd0085cdb3b7e68ff415d34bbc49aae067e13ddaa69794f2b3fc915b967a2f8989222f89f0327bb22e7764eb69600f7ca560eb949ceaf79e"
    },
    {
      "line": 481,
      "relation": "increases",
      "evidence": "Despite 4R1N having no significant change, the same modified 4R2N Tau promotes its aggregation significantly (Fig. 6A, C, E).",
      "citation": {
        "type": "PubMed",
        "reference": "26655600",
        "name": "Biochimica et biophysica acta",
        "title": "Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property.",
        "volume": "1862",
        "pages": "192-201",
        "date": "2016-02-01",
        "first": "Liu K",
        "last": "Qing H",
        "authors": [
          "Deng Y",
          "Iqbal J",
          "Li L",
          "Liu K",
          "Liu Y",
          "Qin P",
          "Qing H"
        ]
      },
      "annotations": {
        "Method": {
          "Mass Spectrometry": true,
          "Thioflavin T Fluorescence Assay": true,
          "Liquid Chromatography": true
        }
      },
      "source": 341,
      "target": 188,
      "key": "2f7ac0f6e3b9005dc57a38f6c605ae508a561bdbd6222b5cd8d503986259a67246398fb20a1d13c5165bab11ad182331978350a18df51aff32b60dd6eaa5fae0"
    },
    {
      "line": 482,
      "relation": "increases",
      "evidence": "Despite 4R1N having no significant change, the same modified 4R2N Tau promotes its aggregation significantly (Fig. 6A, C, E).",
      "citation": {
        "type": "PubMed",
        "reference": "26655600",
        "name": "Biochimica et biophysica acta",
        "title": "Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property.",
        "volume": "1862",
        "pages": "192-201",
        "date": "2016-02-01",
        "first": "Liu K",
        "last": "Qing H",
        "authors": [
          "Deng Y",
          "Iqbal J",
          "Li L",
          "Liu K",
          "Liu Y",
          "Qin P",
          "Qing H"
        ]
      },
      "annotations": {
        "Method": {
          "Mass Spectrometry": true,
          "Thioflavin T Fluorescence Assay": true,
          "Liquid Chromatography": true
        }
      },
      "source": 354,
      "target": 188,
      "key": "f11658ba0aacaae3834533c487a229d959a5b9adedd8e55c5605695d1903134d8c34786c2afbbb86199afce72c93f13eaa0d55664da499037626fcf1420e26db"
    },
    {
      "relation": "hasVariant",
      "source": 353,
      "target": 354,
      "key": "63240f8fa1a540739adcdd6bc4d03eedd25a55e451c2a752f78923ba3cb813636a381a2c7f62e8ebe2950da31140abd534a7f2f082d27c68ec1aba313bb12215"
    },
    {
      "line": 493,
      "relation": "decreases",
      "evidence": "A relationship has recently been reported between the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and apoptotic events14. Real-time RT-PCR experiments showed that the expression of GAPDH was significantly increased by the addition of GA (Fig. 2a). These results suggested that GA caused cell toxicity concomitant with increases in the gene expression of GAPDH in SH-SY5Y cells.",
      "citation": {
        "type": "PubMed",
        "reference": "26304819",
        "name": "Scientific reports",
        "title": "Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells.",
        "volume": "5",
        "pages": "13313",
        "date": "2015-08-25",
        "first": "Koriyama Y",
        "last": "Takeuchi M",
        "authors": [
          "Furukawa A",
          "Koriyama Y",
          "Muramatsu M",
          "Takeuchi M",
          "Takino J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        },
        "Method": {
          "Immunoblotting": true,
          "Bradford Assay": true,
          "RT-PCR": true,
          "Fluorescence Microscopy": true
        }
      },
      "source": 52,
      "target": 176,
      "key": "39ea99392a43946eb23ae5ddc936ac0368f49b7af23f12c920ac1d0eaeafaa2e979b7df405858b0be501ba130fa7d377aa448abbd3e6283fc83e91a07250e00e"
    },
    {
      "line": 494,
      "relation": "increases",
      "evidence": "A relationship has recently been reported between the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and apoptotic events14. Real-time RT-PCR experiments showed that the expression of GAPDH was significantly increased by the addition of GA (Fig. 2a). These results suggested that GA caused cell toxicity concomitant with increases in the gene expression of GAPDH in SH-SY5Y cells.",
      "citation": {
        "type": "PubMed",
        "reference": "26304819",
        "name": "Scientific reports",
        "title": "Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells.",
        "volume": "5",
        "pages": "13313",
        "date": "2015-08-25",
        "first": "Koriyama Y",
        "last": "Takeuchi M",
        "authors": [
          "Furukawa A",
          "Koriyama Y",
          "Muramatsu M",
          "Takeuchi M",
          "Takino J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        },
        "Method": {
          "Immunoblotting": true,
          "Bradford Assay": true,
          "RT-PCR": true,
          "Fluorescence Microscopy": true
        }
      },
      "source": 52,
      "target": 930,
      "key": "1d4af5f30f04cc59fecdea98ce6525c0a40fac03426a37e019fc84eee1760f5960fe01289a544f721cf243a981442b12057482f30d70cf2b5099bb1b29cf4c5d"
    },
    {
      "line": 495,
      "relation": "increases",
      "evidence": "A relationship has recently been reported between the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and apoptotic events14. Real-time RT-PCR experiments showed that the expression of GAPDH was significantly increased by the addition of GA (Fig. 2a). These results suggested that GA caused cell toxicity concomitant with increases in the gene expression of GAPDH in SH-SY5Y cells.",
      "citation": {
        "type": "PubMed",
        "reference": "26304819",
        "name": "Scientific reports",
        "title": "Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells.",
        "volume": "5",
        "pages": "13313",
        "date": "2015-08-25",
        "first": "Koriyama Y",
        "last": "Takeuchi M",
        "authors": [
          "Furukawa A",
          "Koriyama Y",
          "Muramatsu M",
          "Takeuchi M",
          "Takino J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        },
        "Method": {
          "Immunoblotting": true,
          "Bradford Assay": true,
          "RT-PCR": true,
          "Fluorescence Microscopy": true
        }
      },
      "source": 52,
      "target": 174,
      "key": "01b4da08983e77e59c50d6d824b7248c79b5eab418954b498e27e202216d69cd09b7e16fb3e684533ff8333bcb706146ed29aed68332430f5075f89bb1c19040"
    },
    {
      "line": 499,
      "relation": "increases",
      "evidence": "GA dose-dependently increased the production of GA-AGEs in SH-SY5Y cells.",
      "citation": {
        "type": "PubMed",
        "reference": "26304819",
        "name": "Scientific reports",
        "title": "Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells.",
        "volume": "5",
        "pages": "13313",
        "date": "2015-08-25",
        "first": "Koriyama Y",
        "last": "Takeuchi M",
        "authors": [
          "Furukawa A",
          "Koriyama Y",
          "Muramatsu M",
          "Takeuchi M",
          "Takino J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        },
        "Method": {
          "Immunoblotting": true,
          "Bradford Assay": true,
          "RT-PCR": true,
          "Fluorescence Microscopy": true
        }
      },
      "source": 52,
      "target": 101,
      "key": "56fa2a35cbfe55ae023342f423e6df9c40dd5d9acc388162eefb1e69ac00f7ef250d78e327f0acb934bdc302fee4f9dbb93c483e6eb2c4a668a44a3a8ebdbc4a"
    },
    {
      "line": 504,
      "relation": "decreases",
      "evidence": "Aβ 42 in the medium decreased in a GA dose-dependent manner (Fig. 3a). In contrast, GA significantly increased tau and its phosphorylated form, p-tauT181 (Fig. 3b,c) in the medium. In addition, VEGF (Fig. 3e) and TGF-β (Fig. 3f), which are also AD biomarkers,  were increased when the concentration of GA added was greater than 0.7 mM.",
      "citation": {
        "type": "PubMed",
        "reference": "26304819",
        "name": "Scientific reports",
        "title": "Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells.",
        "volume": "5",
        "pages": "13313",
        "date": "2015-08-25",
        "first": "Koriyama Y",
        "last": "Takeuchi M",
        "authors": [
          "Furukawa A",
          "Koriyama Y",
          "Muramatsu M",
          "Takeuchi M",
          "Takino J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        },
        "Method": {
          "Immunoblotting": true,
          "Bradford Assay": true,
          "RT-PCR": true,
          "Fluorescence Microscopy": true
        }
      },
      "source": 52,
      "target": 376,
      "key": "c4453313cbf7105bb873b64a0cf4a63f3a8283d309a49a1fdeae36a4c90dec4b1a404a266a9cc1257af97117829f0bbd9da1940d19c7f2ce43404ad88311207a"
    },
    {
      "line": 505,
      "relation": "increases",
      "evidence": "Aβ 42 in the medium decreased in a GA dose-dependent manner (Fig. 3a). In contrast, GA significantly increased tau and its phosphorylated form, p-tauT181 (Fig. 3b,c) in the medium. In addition, VEGF (Fig. 3e) and TGF-β (Fig. 3f), which are also AD biomarkers,  were increased when the concentration of GA added was greater than 0.7 mM.",
      "citation": {
        "type": "PubMed",
        "reference": "26304819",
        "name": "Scientific reports",
        "title": "Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells.",
        "volume": "5",
        "pages": "13313",
        "date": "2015-08-25",
        "first": "Koriyama Y",
        "last": "Takeuchi M",
        "authors": [
          "Furukawa A",
          "Koriyama Y",
          "Muramatsu M",
          "Takeuchi M",
          "Takino J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        },
        "Method": {
          "Immunoblotting": true,
          "Bradford Assay": true,
          "RT-PCR": true,
          "Fluorescence Microscopy": true
        }
      },
      "source": 52,
      "target": 486,
      "key": "8ae4a7c1240f935184e5183b151592c303c238684fbe3274b4d84354a73245f7c016c375472da6fc6973f2ea3cdf235c01e6eec4bb039931589ef20fd718ccad"
    },
    {
      "line": 506,
      "relation": "increases",
      "evidence": "Aβ 42 in the medium decreased in a GA dose-dependent manner (Fig. 3a). In contrast, GA significantly increased tau and its phosphorylated form, p-tauT181 (Fig. 3b,c) in the medium. In addition, VEGF (Fig. 3e) and TGF-β (Fig. 3f), which are also AD biomarkers,  were increased when the concentration of GA added was greater than 0.7 mM.",
      "citation": {
        "type": "PubMed",
        "reference": "26304819",
        "name": "Scientific reports",
        "title": "Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells.",
        "volume": "5",
        "pages": "13313",
        "date": "2015-08-25",
        "first": "Koriyama Y",
        "last": "Takeuchi M",
        "authors": [
          "Furukawa A",
          "Koriyama Y",
          "Muramatsu M",
          "Takeuchi M",
          "Takino J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        },
        "Method": {
          "Immunoblotting": true,
          "Bradford Assay": true,
          "RT-PCR": true,
          "Fluorescence Microscopy": true
        }
      },
      "source": 52,
      "target": 577,
      "key": "a65a1d1ecc997eff875bfda6f92d795ecbe647e70517d5eb4809489e20b296014224c4001f87ba3f4da9f56060ad7e0b5df6f71d4736d4516ba1a9a23d83e289"
    },
    {
      "line": 507,
      "relation": "increases",
      "evidence": "Aβ 42 in the medium decreased in a GA dose-dependent manner (Fig. 3a). In contrast, GA significantly increased tau and its phosphorylated form, p-tauT181 (Fig. 3b,c) in the medium. In addition, VEGF (Fig. 3e) and TGF-β (Fig. 3f), which are also AD biomarkers,  were increased when the concentration of GA added was greater than 0.7 mM.",
      "citation": {
        "type": "PubMed",
        "reference": "26304819",
        "name": "Scientific reports",
        "title": "Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells.",
        "volume": "5",
        "pages": "13313",
        "date": "2015-08-25",
        "first": "Koriyama Y",
        "last": "Takeuchi M",
        "authors": [
          "Furukawa A",
          "Koriyama Y",
          "Muramatsu M",
          "Takeuchi M",
          "Takino J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        },
        "Method": {
          "Immunoblotting": true,
          "Bradford Assay": true,
          "RT-PCR": true,
          "Fluorescence Microscopy": true
        }
      },
      "source": 52,
      "target": 748,
      "key": "49af670ba07880c2ea79b82bb628214ee56f61659625774d209c2d9a2b2b7073017453b0032e69b85784d7d8ab55dfd9dd98e5c7c2d84d3d3c02a82c134fd2dd"
    },
    {
      "line": 508,
      "relation": "increases",
      "evidence": "Aβ 42 in the medium decreased in a GA dose-dependent manner (Fig. 3a). In contrast, GA significantly increased tau and its phosphorylated form, p-tauT181 (Fig. 3b,c) in the medium. In addition, VEGF (Fig. 3e) and TGF-β (Fig. 3f), which are also AD biomarkers,  were increased when the concentration of GA added was greater than 0.7 mM.",
      "citation": {
        "type": "PubMed",
        "reference": "26304819",
        "name": "Scientific reports",
        "title": "Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells.",
        "volume": "5",
        "pages": "13313",
        "date": "2015-08-25",
        "first": "Koriyama Y",
        "last": "Takeuchi M",
        "authors": [
          "Furukawa A",
          "Koriyama Y",
          "Muramatsu M",
          "Takeuchi M",
          "Takino J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        },
        "Method": {
          "Immunoblotting": true,
          "Bradford Assay": true,
          "RT-PCR": true,
          "Fluorescence Microscopy": true
        }
      },
      "source": 52,
      "target": 728,
      "key": "dcb39057166964b858fb269fc20c69415f251c79b766c2947b160b8bc7cdda713b425392802821a9743f0cbe852390cc88544514ffd32732203cef7c7b83a1fb"
    },
    {
      "line": 611,
      "relation": "negativeCorrelation",
      "evidence": "Triosephosphate isomerase (TPI) is a key enzyme in cell metabolism that controls the glycolytic flow and energy production through the interconversion of dihydroxyacetone phosphate (DHAP) and D-glyceraldehyde 3-phosphate (G3P) (Richard, 1993). Notably, TPI is the only glycolytic enzyme whose functional deficiency is associated to neurodegeneration (Eber et al., 1991; Ovadi et al., 2004). In particular, inefficient glycolysis (Hoyer et al., 1988) and ATP depletion (Keil et al., 2004) are characteristic in Alzheimer’s disease brains.",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        }
      },
      "source": 176,
      "target": 908,
      "key": "ade1df11d8749c08155cda9b5b941fc30a9fdbbef9c763f4ff3be795668fe55f9ec0eef63dbe3cd0c13d7e23c33ea6692d5cdeadb5b42ed003ef531bb8e0de82"
    },
    {
      "line": 496,
      "relation": "association",
      "evidence": "A relationship has recently been reported between the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and apoptotic events14. Real-time RT-PCR experiments showed that the expression of GAPDH was significantly increased by the addition of GA (Fig. 2a). These results suggested that GA caused cell toxicity concomitant with increases in the gene expression of GAPDH in SH-SY5Y cells.",
      "citation": {
        "type": "PubMed",
        "reference": "26304819",
        "name": "Scientific reports",
        "title": "Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells.",
        "volume": "5",
        "pages": "13313",
        "date": "2015-08-25",
        "first": "Koriyama Y",
        "last": "Takeuchi M",
        "authors": [
          "Furukawa A",
          "Koriyama Y",
          "Muramatsu M",
          "Takeuchi M",
          "Takino J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        },
        "Method": {
          "Immunoblotting": true,
          "Bradford Assay": true,
          "RT-PCR": true,
          "Fluorescence Microscopy": true
        }
      },
      "source": 930,
      "target": 174,
      "key": "57990e0bdcde4748aea2e5960ce5688e57ca701fbd80634a0419ab98c43b946006b2aa957acca08169fe537c90ac78cc4478ef89263185684d43899e2b7a0a14"
    },
    {
      "line": 496,
      "relation": "association",
      "evidence": "A relationship has recently been reported between the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and apoptotic events14. Real-time RT-PCR experiments showed that the expression of GAPDH was significantly increased by the addition of GA (Fig. 2a). These results suggested that GA caused cell toxicity concomitant with increases in the gene expression of GAPDH in SH-SY5Y cells.",
      "citation": {
        "type": "PubMed",
        "reference": "26304819",
        "name": "Scientific reports",
        "title": "Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells.",
        "volume": "5",
        "pages": "13313",
        "date": "2015-08-25",
        "first": "Koriyama Y",
        "last": "Takeuchi M",
        "authors": [
          "Furukawa A",
          "Koriyama Y",
          "Muramatsu M",
          "Takeuchi M",
          "Takino J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        },
        "Method": {
          "Immunoblotting": true,
          "Bradford Assay": true,
          "RT-PCR": true,
          "Fluorescence Microscopy": true
        }
      },
      "source": 174,
      "target": 930,
      "key": "5da143a507c86f0819a46dd4d97cbe99b212c6a7ffbfeeea96c6d2672b77177f1159c7079e177027f8fa8230a2195d24888a62182d037ac3f07270419b32fd26"
    },
    {
      "line": 2000,
      "relation": "negativeCorrelation",
      "evidence": "These data suggest that tau hyperphosphorylation at Thr231, Ser262, and Ser396 by DAPK1 renders the cells more resistant to the kinase-induced apoptotic cell death, providing new insights into the tau-involved apoptotic abortion in the course of chronic neurodegeneration.",
      "citation": {
        "type": "PubMed",
        "reference": "23948915",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Phosphorylation of tau by death-associated protein kinase 1 antagonizes the kinase-induced cell apoptosis.",
        "volume": "37",
        "pages": "795-808",
        "date": "2013-01-01",
        "first": "Duan DX",
        "last": "Liu GP",
        "authors": [
          "Chai GS",
          "Chen NN",
          "Cheng XS",
          "Duan DX",
          "Hu Y",
          "Liu GP",
          "Luo Y",
          "Ni ZF",
          "Wang JZ"
        ]
      },
      "source": 174,
      "target": 557,
      "key": "3f1104694d0497b00b8a253d39404c19a7c8fd780dde35ccde2c37b1ae266e1a04278440820c3eaf9fec85604df25db767ad115efdfe9f648f8bee1afc856c4d"
    },
    {
      "line": 2001,
      "relation": "negativeCorrelation",
      "evidence": "These data suggest that tau hyperphosphorylation at Thr231, Ser262, and Ser396 by DAPK1 renders the cells more resistant to the kinase-induced apoptotic cell death, providing new insights into the tau-involved apoptotic abortion in the course of chronic neurodegeneration.",
      "citation": {
        "type": "PubMed",
        "reference": "23948915",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Phosphorylation of tau by death-associated protein kinase 1 antagonizes the kinase-induced cell apoptosis.",
        "volume": "37",
        "pages": "795-808",
        "date": "2013-01-01",
        "first": "Duan DX",
        "last": "Liu GP",
        "authors": [
          "Chai GS",
          "Chen NN",
          "Cheng XS",
          "Duan DX",
          "Hu Y",
          "Liu GP",
          "Luo Y",
          "Ni ZF",
          "Wang JZ"
        ]
      },
      "source": 174,
      "target": 564,
      "key": "0e875531a526b51c13b1de4917a7684776ef214f46341a2e5be0431bbba302727a24d6e34ce610a8f7970b4b975f4451470b9adf0df3a581505c23887d82e4b1"
    },
    {
      "line": 2002,
      "relation": "negativeCorrelation",
      "evidence": "These data suggest that tau hyperphosphorylation at Thr231, Ser262, and Ser396 by DAPK1 renders the cells more resistant to the kinase-induced apoptotic cell death, providing new insights into the tau-involved apoptotic abortion in the course of chronic neurodegeneration.",
      "citation": {
        "type": "PubMed",
        "reference": "23948915",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Phosphorylation of tau by death-associated protein kinase 1 antagonizes the kinase-induced cell apoptosis.",
        "volume": "37",
        "pages": "795-808",
        "date": "2013-01-01",
        "first": "Duan DX",
        "last": "Liu GP",
        "authors": [
          "Chai GS",
          "Chen NN",
          "Cheng XS",
          "Duan DX",
          "Hu Y",
          "Liu GP",
          "Luo Y",
          "Ni ZF",
          "Wang JZ"
        ]
      },
      "source": 174,
      "target": 583,
      "key": "79dc7520fefbfe877149bea0ba8a606ffcb3796c1a7677e7f16a1ae05ebf4b754cb5724ed034f80d7611f86e24d5a3d0ab20412f4f32b1412bb2b665e7e2a1ac"
    },
    {
      "line": 500,
      "relation": "isA",
      "evidence": "GA dose-dependently increased the production of GA-AGEs in SH-SY5Y cells.",
      "citation": {
        "type": "PubMed",
        "reference": "26304819",
        "name": "Scientific reports",
        "title": "Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells.",
        "volume": "5",
        "pages": "13313",
        "date": "2015-08-25",
        "first": "Koriyama Y",
        "last": "Takeuchi M",
        "authors": [
          "Furukawa A",
          "Koriyama Y",
          "Muramatsu M",
          "Takeuchi M",
          "Takino J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        },
        "Method": {
          "Immunoblotting": true,
          "Bradford Assay": true,
          "RT-PCR": true,
          "Fluorescence Microscopy": true
        }
      },
      "source": 101,
      "target": 9,
      "key": "6f266caec52fc20c1960d60e732620002d153606f6ef1eca1a9854291e1cdbf3682e65bf86a8ffde1a7fc3b16098fa07fcbe3cf7c173b04f11384ba364d738ae"
    },
    {
      "line": 1881,
      "relation": "positiveCorrelation",
      "evidence": "DAPK1, but not its kinase deficient mutant (K42A), significantly increased human Aβ secretion in neuronal cell culture models. Moreover, knockdown of DAPK1 expression or inhibition of DAPK1 catalytic activity significantly decreased Aβ secretion. Furthermore, DAPK1, but not K42A, triggered Thr668 phosphorylation of APP, which may initiate and facilitate amyloidogenic APP processing leading to the generation of Aβ.",
      "citation": {
        "type": "PubMed",
        "reference": "27094130",
        "name": "Human molecular genetics",
        "title": "Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein.",
        "volume": "25",
        "pages": "2498-2513",
        "date": "2016-06-15",
        "first": "Kim BM",
        "last": "Ho Lee T",
        "authors": [
          "Chen CH",
          "Ho Lee T",
          "Kim BM",
          "Suh J",
          "Tanzi RE",
          "You MH"
        ]
      },
      "subject": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "bel",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "bel",
            "name": "extracellular space"
          }
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 376,
      "target": 431,
      "key": "a991a23de83cda40e775e255dbeb2060d51be218d0962dd4e0e936fe213266be20d9e3d4c82a61476da2c91d18a1bf9be5f17b3add57f229b5bc90cdb1a73741"
    },
    {
      "line": 3053,
      "relation": "negativeCorrelation",
      "evidence": "After pretreating hTau neurons with oligo Aβ-42 (1000 ng/ml), Sirt3 levels were reduced (Fig. 6b and e). This reduction in Sirt3 was translated into an increase in total tau and Ac-tau.",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 376,
      "target": 849,
      "key": "0f1d8fa886825cfafa468e7be2ba43144a29a13c9100b59c228d3002a183860b59d0c2a37e9933ab836e5a0b70112769f909aebebb01131a04b0f3a50f71b68e"
    },
    {
      "line": 3105,
      "relation": "increases",
      "evidence": "We found that NO production and tau acetylation at Lys280 occurred in the brain tissue in mice and in cultured mouse cortical neurons in response to exposure to amyloid-β1-42 (Aβ1-42), a peptide that is also implicated in AD. An increased abundance of NO facilitated the S-nitrosylation (SNO) of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). S-nitrosylated GAPDH (GAPDH-SNO) promoted the acetylation and activation of the acetyltransferase p300 and facilitated the nitrosylation and inactivation of the deacetylase sirtuin 1 (SIRT1). The abundance of GAPDH-SNO was increased in postmortem brain samples from AD patients. Preventing the increase in GAPDH-SNO abundance in both cultured neurons and mice, either by overexpression of the nitrosylation mutant of GAPDH (GAPDH C150S) or by treatment with the GAPDH nitrosylation inhibitor CGP3466B (also known as omigapil), abrogated Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice, suggesting that this drug might be repurposed to treat patients with AD.",
      "citation": {
        "type": "PubMed",
        "reference": "29559585",
        "name": "Science signaling",
        "title": "Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-β.",
        "volume": "11",
        "date": "2018-03-20",
        "first": "Sen T",
        "last": "Sen N",
        "authors": [
          "Saha P",
          "Sen N",
          "Sen T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 376,
      "target": 804,
      "key": "88dc964c4fbd23336c93f250b30f595fe7b06746253830285c5ab72b0bccc0b825659f623f4815534fd5c114352e4444af06137c0fac63b4daa782690e4da71d"
    },
    {
      "line": 3106,
      "relation": "increases",
      "evidence": "We found that NO production and tau acetylation at Lys280 occurred in the brain tissue in mice and in cultured mouse cortical neurons in response to exposure to amyloid-β1-42 (Aβ1-42), a peptide that is also implicated in AD. An increased abundance of NO facilitated the S-nitrosylation (SNO) of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). S-nitrosylated GAPDH (GAPDH-SNO) promoted the acetylation and activation of the acetyltransferase p300 and facilitated the nitrosylation and inactivation of the deacetylase sirtuin 1 (SIRT1). The abundance of GAPDH-SNO was increased in postmortem brain samples from AD patients. Preventing the increase in GAPDH-SNO abundance in both cultured neurons and mice, either by overexpression of the nitrosylation mutant of GAPDH (GAPDH C150S) or by treatment with the GAPDH nitrosylation inhibitor CGP3466B (also known as omigapil), abrogated Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice, suggesting that this drug might be repurposed to treat patients with AD.",
      "citation": {
        "type": "PubMed",
        "reference": "29559585",
        "name": "Science signaling",
        "title": "Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-β.",
        "volume": "11",
        "date": "2018-03-20",
        "first": "Sen T",
        "last": "Sen N",
        "authors": [
          "Saha P",
          "Sen N",
          "Sen T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 376,
      "target": 26,
      "key": "252a7cb9b52a1561c16e85a21306af7b50cfd058aca73ad2c6a5b63056ce51b3b851621e423f49f5962edb4aae8f08294dde30526b728b3fbee532780bed2c05"
    },
    {
      "relation": "hasVariant",
      "source": 374,
      "target": 376,
      "key": "9d44773427e1eed6ab28c10287c0853b0b8f96cb18e386c11adda985c497a37ab8f1a9885e7aa89ae401eb253a13b5d15c3869f64a0290b2f3cb6785c37d289e"
    },
    {
      "relation": "hasVariant",
      "source": 374,
      "target": 375,
      "key": "281b58c450e137e65feb6fb7075b0aa4a69373fa62487aa67346fc7d625a5fa7c596586234b370c0b9837a418315ab3165191673b9c726f29b976747a3859235"
    },
    {
      "line": 1887,
      "relation": "association",
      "evidence": "In contrast, the DAPK1 fragments from 1 to 1423, from 637 to 1423 and from 848 to 1423 efficiently bound to APP, suggesting that the death domain (1271–1423, DD) is likely bound to APP (Fig. 4F).",
      "citation": {
        "type": "PubMed",
        "reference": "27094130",
        "name": "Human molecular genetics",
        "title": "Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein.",
        "volume": "25",
        "pages": "2498-2513",
        "date": "2016-06-15",
        "first": "Kim BM",
        "last": "Ho Lee T",
        "authors": [
          "Chen CH",
          "Ho Lee T",
          "Kim BM",
          "Suh J",
          "Tanzi RE",
          "You MH"
        ]
      },
      "source": 374,
      "target": 433,
      "key": "687b7cd94e523b1fcee39434d24173f5a48664ba544e00365c47ed1170e4ea2ae1717eb3f2252a1f14cf84a36faa22e274abab7a917dbb4a3c45f3ab5969da72"
    },
    {
      "line": 1888,
      "relation": "association",
      "evidence": "In contrast, the DAPK1 fragments from 1 to 1423, from 637 to 1423 and from 848 to 1423 efficiently bound to APP, suggesting that the death domain (1271–1423, DD) is likely bound to APP (Fig. 4F).",
      "citation": {
        "type": "PubMed",
        "reference": "27094130",
        "name": "Human molecular genetics",
        "title": "Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein.",
        "volume": "25",
        "pages": "2498-2513",
        "date": "2016-06-15",
        "first": "Kim BM",
        "last": "Ho Lee T",
        "authors": [
          "Chen CH",
          "Ho Lee T",
          "Kim BM",
          "Suh J",
          "Tanzi RE",
          "You MH"
        ]
      },
      "source": 374,
      "target": 434,
      "key": "4df37d50b36089023e0253ce5d3a97c7ed930ee45330953388fc083a1bb495df2fdf5c32bef34b2b4f119d8e75f82bf95fc880ad3a4a6cdbd44ac8fd16f92263"
    },
    {
      "line": 1889,
      "relation": "association",
      "evidence": "In contrast, the DAPK1 fragments from 1 to 1423, from 637 to 1423 and from 848 to 1423 efficiently bound to APP, suggesting that the death domain (1271–1423, DD) is likely bound to APP (Fig. 4F).",
      "citation": {
        "type": "PubMed",
        "reference": "27094130",
        "name": "Human molecular genetics",
        "title": "Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein.",
        "volume": "25",
        "pages": "2498-2513",
        "date": "2016-06-15",
        "first": "Kim BM",
        "last": "Ho Lee T",
        "authors": [
          "Chen CH",
          "Ho Lee T",
          "Kim BM",
          "Suh J",
          "Tanzi RE",
          "You MH"
        ]
      },
      "source": 374,
      "target": 432,
      "key": "355e8efd10ba23b89d3454cadbf8bc0c55bf95e1054a36b363c06b912ed3edcafbf9828ff58ff6d4e9e5716d418e268c3460429204d79f319df90c59bec99461"
    },
    {
      "relation": "hasVariant",
      "source": 374,
      "target": 378,
      "key": "8b3d031d3b7716de8c3da89db7c9be033dc4101e1cb6b1c7c0fb0b66773dc064fa4a59436e2118a9f47b9eb3feae609933ceb45802225bc78c74d527e4f9acf1"
    },
    {
      "relation": "hasVariant",
      "source": 374,
      "target": 380,
      "key": "bbbff9dbe65b75d8443be62e10c3bad4ce51a65499ba3393f83ceda7523603db1b8a3264d3b69ce7be5486c134b89be437db086d69b6d166c6c2fa8264af4937"
    },
    {
      "relation": "hasVariant",
      "source": 374,
      "target": 381,
      "key": "1bcaf19ced854239b87b9f005ad2c04207307f96aed17ea968b90b2029d2cfc988c67b1fa3843270a177fff8ed73b68efef5023b95481921e5d2ab71a973e15f"
    },
    {
      "relation": "hasVariant",
      "source": 374,
      "target": 379,
      "key": "de5603129444d8712428ae30378ee3183ee894a500ce27935085ab0072bf8c9df1942f4363f6d369de0d3d351a74d2a93a7caf36908dd590fe756f1ded1abfea"
    },
    {
      "relation": "hasVariant",
      "source": 374,
      "target": 377,
      "key": "06e0848ce19638171862c22d14f0fc0cccc7afb3124282fe98b3f8bd97a37c33195e37f9d491635b2dad821f765032983d102c75e63918eed142623db0878a15"
    },
    {
      "line": 1121,
      "relation": "positiveCorrelation",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 577,
      "target": 299,
      "key": "ebb0e638d191a5340a58a02bed9f63b150f1dfbf88b3404bdc0fc881d34af4015041d6d698895efd2467859f4376e7727a4e92fa7f8940678a294637145c6fdd"
    },
    {
      "line": 1508,
      "relation": "partOf",
      "evidence": "All five SAP kinases generated the AT270 epitope, indicative of phosphorylation of T181 in tau.",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Enzyme_Acitvity": {
          "1 U/ml": true
        }
      },
      "source": 577,
      "target": 335,
      "key": "45cd108e2b8d6e8d3594de5c74b8dbdf274265f38696f522cccaa24d16f778962d3a383d09f23149e65c3963d7142850bddf1f903b74412cf5ddd0d6236d8119"
    },
    {
      "line": 2291,
      "relation": "positiveCorrelation",
      "evidence": "Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.",
      "citation": {
        "type": "PubMed",
        "reference": "28176663",
        "name": "Current Alzheimer research",
        "title": "GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.",
        "volume": "14",
        "pages": "753-759",
        "date": "2017-01-01",
        "first": "Nicolia V",
        "last": "Fuso A",
        "authors": [
          "Cavallaro RA",
          "Ciraci V",
          "Ferrer I",
          "Fuso A",
          "Nicolia V",
          "Scarpa S"
        ]
      },
      "source": 577,
      "target": 5,
      "key": "16da206b51775b8652fadd993d9dbaf952071c38ba9bfa01024155d0180133c5dbaa81cddaff3ee7a78ab754b6714c3abfc64f387ff749a2be0738d37e9e8b9e"
    },
    {
      "line": 509,
      "relation": "biomarkerFor",
      "evidence": "Aβ 42 in the medium decreased in a GA dose-dependent manner (Fig. 3a). In contrast, GA significantly increased tau and its phosphorylated form, p-tauT181 (Fig. 3b,c) in the medium. In addition, VEGF (Fig. 3e) and TGF-β (Fig. 3f), which are also AD biomarkers,  were increased when the concentration of GA added was greater than 0.7 mM.",
      "citation": {
        "type": "PubMed",
        "reference": "26304819",
        "name": "Scientific reports",
        "title": "Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells.",
        "volume": "5",
        "pages": "13313",
        "date": "2015-08-25",
        "first": "Koriyama Y",
        "last": "Takeuchi M",
        "authors": [
          "Furukawa A",
          "Koriyama Y",
          "Muramatsu M",
          "Takeuchi M",
          "Takino J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        },
        "Method": {
          "Immunoblotting": true,
          "Bradford Assay": true,
          "RT-PCR": true,
          "Fluorescence Microscopy": true
        }
      },
      "source": 748,
      "target": 908,
      "key": "15c3a3499ef813fff773beed2b056c03f22527147479a71187501fe4066ed44556bce556a40eebe37ed81ec94148b3d3476f39ca3473c8143dafcd99d1e1b997"
    },
    {
      "line": 510,
      "relation": "biomarkerFor",
      "evidence": "Aβ 42 in the medium decreased in a GA dose-dependent manner (Fig. 3a). In contrast, GA significantly increased tau and its phosphorylated form, p-tauT181 (Fig. 3b,c) in the medium. In addition, VEGF (Fig. 3e) and TGF-β (Fig. 3f), which are also AD biomarkers,  were increased when the concentration of GA added was greater than 0.7 mM.",
      "citation": {
        "type": "PubMed",
        "reference": "26304819",
        "name": "Scientific reports",
        "title": "Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells.",
        "volume": "5",
        "pages": "13313",
        "date": "2015-08-25",
        "first": "Koriyama Y",
        "last": "Takeuchi M",
        "authors": [
          "Furukawa A",
          "Koriyama Y",
          "Muramatsu M",
          "Takeuchi M",
          "Takino J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        },
        "Method": {
          "Immunoblotting": true,
          "Bradford Assay": true,
          "RT-PCR": true,
          "Fluorescence Microscopy": true
        }
      },
      "source": 728,
      "target": 908,
      "key": "5e46e1dd22266780291377dc0a0c4a9250d52cda962610d7216081eec26a14387185fb21993f561919576ad63e7e26e2f9b728eb92f980591668980e1545ccd0"
    },
    {
      "line": 521,
      "relation": "increases",
      "evidence": "Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.",
      "citation": {
        "type": "PubMed",
        "reference": "26095350",
        "name": "Aging cell",
        "title": "Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII.",
        "volume": "14",
        "pages": "754-63",
        "date": "2015-10-01",
        "first": "Wei Y",
        "last": "He R",
        "authors": [
          "Han C",
          "He R",
          "Liu Y",
          "Su T",
          "Wang Y",
          "Wei Y",
          "Wu B"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Method": {
          "Immunofluorescence": true,
          "Western Blot": true,
          "Immunohistochemistry": true
        },
        "Anatomy": {
          "brain": true
        }
      },
      "source": 5,
      "target": 9,
      "key": "b452de138472c5c24e7784b5a6599413b2c66556ede9a39a3191271b7a1248a649f5baafb6745ebbd1d6965eacc076f5724835d3b0783f0a79a0301ff39cd3de"
    },
    {
      "line": 522,
      "relation": "positiveCorrelation",
      "evidence": "Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.",
      "citation": {
        "type": "PubMed",
        "reference": "26095350",
        "name": "Aging cell",
        "title": "Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII.",
        "volume": "14",
        "pages": "754-63",
        "date": "2015-10-01",
        "first": "Wei Y",
        "last": "He R",
        "authors": [
          "Han C",
          "He R",
          "Liu Y",
          "Su T",
          "Wang Y",
          "Wei Y",
          "Wu B"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Method": {
          "Immunofluorescence": true,
          "Western Blot": true,
          "Immunohistochemistry": true
        },
        "Anatomy": {
          "brain": true
        }
      },
      "source": 5,
      "target": 817,
      "key": "41a21e0fb4f547209d2273b87d455290af3149451c32a5350c9b2259dcdba55affcd4e5b20b55f40385f2c9aa6a2e84efaca69b95a5c981cef975a42af81e55d"
    },
    {
      "line": 523,
      "relation": "positiveCorrelation",
      "evidence": "Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.",
      "citation": {
        "type": "PubMed",
        "reference": "26095350",
        "name": "Aging cell",
        "title": "Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII.",
        "volume": "14",
        "pages": "754-63",
        "date": "2015-10-01",
        "first": "Wei Y",
        "last": "He R",
        "authors": [
          "Han C",
          "He R",
          "Liu Y",
          "Su T",
          "Wang Y",
          "Wei Y",
          "Wu B"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Method": {
          "Immunofluorescence": true,
          "Western Blot": true,
          "Immunohistochemistry": true
        },
        "Anatomy": {
          "brain": true
        }
      },
      "source": 5,
      "target": 823,
      "key": "904f51297187a0a2c5475e851b06e3cfbac05d8297c630e0dfbd1495e25488be45b2f4561e90981b54738a5912b4fb0bb9acc8e8c9036924e04cdd952bafa9f6"
    },
    {
      "line": 524,
      "relation": "positiveCorrelation",
      "evidence": "Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.",
      "citation": {
        "type": "PubMed",
        "reference": "26095350",
        "name": "Aging cell",
        "title": "Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII.",
        "volume": "14",
        "pages": "754-63",
        "date": "2015-10-01",
        "first": "Wei Y",
        "last": "He R",
        "authors": [
          "Han C",
          "He R",
          "Liu Y",
          "Su T",
          "Wang Y",
          "Wei Y",
          "Wu B"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Method": {
          "Immunofluorescence": true,
          "Western Blot": true,
          "Immunohistochemistry": true
        },
        "Anatomy": {
          "brain": true
        }
      },
      "source": 5,
      "target": 818,
      "key": "fd9c6690c94eb31f2fb48b99318dd88368d9d5cb80eed6ee18f9597ef417acc437ec3b2bd1f7478a9fd323bf6d107cb47485dc5bff560c614e6384e14f7a3175"
    },
    {
      "line": 527,
      "relation": "increases",
      "evidence": "Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.",
      "citation": {
        "type": "PubMed",
        "reference": "26095350",
        "name": "Aging cell",
        "title": "Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII.",
        "volume": "14",
        "pages": "754-63",
        "date": "2015-10-01",
        "first": "Wei Y",
        "last": "He R",
        "authors": [
          "Han C",
          "He R",
          "Liu Y",
          "Su T",
          "Wang Y",
          "Wei Y",
          "Wu B"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Method": {
          "Immunofluorescence": true,
          "Western Blot": true,
          "Immunohistochemistry": true
        },
        "Cell_Line": {
          "N2a": true
        }
      },
      "source": 5,
      "target": 551,
      "key": "a205065644165fe29aca5162709653f635e355828f77b1b5f8fac37fffb0695f167bb1cba68b38930901c17698ec71b362cda98fb0d2fff35071a749bebeb1c3"
    },
    {
      "line": 2292,
      "relation": "positiveCorrelation",
      "evidence": "Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.",
      "citation": {
        "type": "PubMed",
        "reference": "28176663",
        "name": "Current Alzheimer research",
        "title": "GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.",
        "volume": "14",
        "pages": "753-759",
        "date": "2017-01-01",
        "first": "Nicolia V",
        "last": "Fuso A",
        "authors": [
          "Cavallaro RA",
          "Ciraci V",
          "Ferrer I",
          "Fuso A",
          "Nicolia V",
          "Scarpa S"
        ]
      },
      "source": 5,
      "target": 551,
      "key": "d51c5e9a78a6da4cfd873b9b2cd28bbb6e791278e8b59de1001b4931e6387c695e0c2d99321e064355b4496459be2bbca84e65d0a1ce4fd63849ded24bc45a94"
    },
    {
      "line": 528,
      "relation": "increases",
      "evidence": "Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.",
      "citation": {
        "type": "PubMed",
        "reference": "26095350",
        "name": "Aging cell",
        "title": "Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII.",
        "volume": "14",
        "pages": "754-63",
        "date": "2015-10-01",
        "first": "Wei Y",
        "last": "He R",
        "authors": [
          "Han C",
          "He R",
          "Liu Y",
          "Su T",
          "Wang Y",
          "Wei Y",
          "Wu B"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Method": {
          "Immunofluorescence": true,
          "Western Blot": true,
          "Immunohistochemistry": true
        },
        "Cell_Line": {
          "N2a": true
        }
      },
      "source": 5,
      "target": 564,
      "key": "f844fcbd9f93fc4da1463f8779c6f4a95c32519f9fabfa5fba74778b79b49845ad621b7cc8b1064ee394a94f242f2a5ac713e7098ec8da3851a74716d9729f5c"
    },
    {
      "line": 2293,
      "relation": "positiveCorrelation",
      "evidence": "Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.",
      "citation": {
        "type": "PubMed",
        "reference": "28176663",
        "name": "Current Alzheimer research",
        "title": "GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.",
        "volume": "14",
        "pages": "753-759",
        "date": "2017-01-01",
        "first": "Nicolia V",
        "last": "Fuso A",
        "authors": [
          "Cavallaro RA",
          "Ciraci V",
          "Ferrer I",
          "Fuso A",
          "Nicolia V",
          "Scarpa S"
        ]
      },
      "source": 5,
      "target": 564,
      "key": "7ed3682047cd0ed4f6fe864921ed782634b17f9624bd402151305878037696e912521ee76f03ad9e04d18d939c0895eb68e8969c92f2127620d7d0ca2a0a71a8"
    },
    {
      "line": 529,
      "relation": "increases",
      "evidence": "Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.",
      "citation": {
        "type": "PubMed",
        "reference": "26095350",
        "name": "Aging cell",
        "title": "Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII.",
        "volume": "14",
        "pages": "754-63",
        "date": "2015-10-01",
        "first": "Wei Y",
        "last": "He R",
        "authors": [
          "Han C",
          "He R",
          "Liu Y",
          "Su T",
          "Wang Y",
          "Wei Y",
          "Wu B"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Method": {
          "Immunofluorescence": true,
          "Western Blot": true,
          "Immunohistochemistry": true
        },
        "Cell_Line": {
          "N2a": true
        }
      },
      "source": 5,
      "target": 577,
      "key": "b2b60e1ab117a5a5f9a4a1b27f4917e69e00975bea30fdb721017b2e9fe59563462d4500676d1113545955370ece046d176e061a6165c96bc0c6419bd58e0d00"
    },
    {
      "line": 2291,
      "relation": "positiveCorrelation",
      "evidence": "Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.",
      "citation": {
        "type": "PubMed",
        "reference": "28176663",
        "name": "Current Alzheimer research",
        "title": "GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.",
        "volume": "14",
        "pages": "753-759",
        "date": "2017-01-01",
        "first": "Nicolia V",
        "last": "Fuso A",
        "authors": [
          "Cavallaro RA",
          "Ciraci V",
          "Ferrer I",
          "Fuso A",
          "Nicolia V",
          "Scarpa S"
        ]
      },
      "source": 5,
      "target": 577,
      "key": "feaafdb6592cbb31f99e3b3d886486d35ca88bf6b11cf760a98ea8bf75894a5080a8a0b031c5c80d41d921d84800f53069d133fff851d5fc4cfc1e6b3827afc5"
    },
    {
      "line": 533,
      "relation": "increases",
      "evidence": "The treatment of 10 mM D-ribose for 24 h resulted in a significant increase in active form of CaMKII (p-Thr286/287), yet simultaneously in a decrease in inactive form of CaMKII (p-Thr305/306) phosphorylation (Fig. 4e). The enzyme activity assay supported this result.",
      "citation": {
        "type": "PubMed",
        "reference": "26095350",
        "name": "Aging cell",
        "title": "Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII.",
        "volume": "14",
        "pages": "754-63",
        "date": "2015-10-01",
        "first": "Wei Y",
        "last": "He R",
        "authors": [
          "Han C",
          "He R",
          "Liu Y",
          "Su T",
          "Wang Y",
          "Wei Y",
          "Wu B"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Method": {
          "Immunofluorescence": true,
          "Western Blot": true,
          "Immunohistochemistry": true
        },
        "Cell_Line": {
          "N2a": true
        }
      },
      "source": 5,
      "target": 773,
      "key": "90a6e39ff3d52168a4c4611714fdb9f362216a41da308c2b4a7fc2394706620be56da5532c2d46e274b1421654c713f3b5d7c4a8885b5b64275015571d7c5dc6"
    },
    {
      "line": 535,
      "relation": "decreases",
      "evidence": "The treatment of 10 mM D-ribose for 24 h resulted in a significant increase in active form of CaMKII (p-Thr286/287), yet simultaneously in a decrease in inactive form of CaMKII (p-Thr305/306) phosphorylation (Fig. 4e). The enzyme activity assay supported this result.",
      "citation": {
        "type": "PubMed",
        "reference": "26095350",
        "name": "Aging cell",
        "title": "Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII.",
        "volume": "14",
        "pages": "754-63",
        "date": "2015-10-01",
        "first": "Wei Y",
        "last": "He R",
        "authors": [
          "Han C",
          "He R",
          "Liu Y",
          "Su T",
          "Wang Y",
          "Wei Y",
          "Wu B"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Method": {
          "Immunofluorescence": true,
          "Western Blot": true,
          "Immunohistochemistry": true
        },
        "Cell_Line": {
          "N2a": true
        }
      },
      "source": 5,
      "target": 774,
      "key": "ba716ab7a36dd26c9f75fc75b6f7edc726551d087dc813b4a06da2351acd9445e91560ed0b1004245f8e3d260fd418fb8e6fa65951854402bc3977a9b24c652a"
    },
    {
      "line": 589,
      "relation": "increases",
      "evidence": "Tau is rapidly glycated in the presence of D-ribose, resulting in oligomerization and polymerization with Glycated derivatives appearing after 24 h. Advanced glycation end-products (AGEs) were formed during initial stages of glycation. Thioflavin T-positive (ThT-positive) aggregations (day 4) indicated the globular-like features. Atomic force microscopy revealed that the surface morphology of ribosylated Tau40 was globular-like.",
      "citation": {
        "type": "PubMed",
        "reference": "19517062",
        "name": "Cellular and molecular life sciences : CMLS",
        "title": "D-Ribosylated Tau forms globular aggregates with high cytotoxicity.",
        "volume": "66",
        "pages": "2559-71",
        "date": "2009-08-01",
        "first": "Chen L",
        "last": "He R",
        "authors": [
          "Chen L",
          "He R",
          "Wang X",
          "Wei Y"
        ]
      },
      "annotations": {
        "Method": {
          "NBT colorimetric fructosamine assay": true,
          "Fluorescence Spectrophotometry": true,
          "Cell Viability Assay, MTT": true,
          "Atomic Force Microscopy": true,
          "Flow Cytometry": true
        },
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 5,
      "target": 325,
      "key": "cc6ef77d74d6e6077881503d22e2936b6d7f2998d869c9956d69c1fa387c30cd0165a6596b602cfbc8e53bbaf6a3b82bf5a34625671dcde404936ad19913b737"
    },
    {
      "line": 590,
      "relation": "increases",
      "evidence": "Tau is rapidly glycated in the presence of D-ribose, resulting in oligomerization and polymerization with Glycated derivatives appearing after 24 h. Advanced glycation end-products (AGEs) were formed during initial stages of glycation. Thioflavin T-positive (ThT-positive) aggregations (day 4) indicated the globular-like features. Atomic force microscopy revealed that the surface morphology of ribosylated Tau40 was globular-like.",
      "citation": {
        "type": "PubMed",
        "reference": "19517062",
        "name": "Cellular and molecular life sciences : CMLS",
        "title": "D-Ribosylated Tau forms globular aggregates with high cytotoxicity.",
        "volume": "66",
        "pages": "2559-71",
        "date": "2009-08-01",
        "first": "Chen L",
        "last": "He R",
        "authors": [
          "Chen L",
          "He R",
          "Wang X",
          "Wei Y"
        ]
      },
      "annotations": {
        "Method": {
          "NBT colorimetric fructosamine assay": true,
          "Fluorescence Spectrophotometry": true,
          "Cell Viability Assay, MTT": true,
          "Atomic Force Microscopy": true,
          "Flow Cytometry": true
        },
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 5,
      "target": 515,
      "key": "7d36188026e1f6be80bdd5ede417e74eba89083299ec9961aabf35643ca85bf6fbf408048f8fe50ba4a01d73730690cbe24e08cde92333852204de473606e6d6"
    },
    {
      "line": 2290,
      "relation": "increases",
      "evidence": "Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.",
      "citation": {
        "type": "PubMed",
        "reference": "28176663",
        "name": "Current Alzheimer research",
        "title": "GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.",
        "volume": "14",
        "pages": "753-759",
        "date": "2017-01-01",
        "first": "Nicolia V",
        "last": "Fuso A",
        "authors": [
          "Cavallaro RA",
          "Ciraci V",
          "Ferrer I",
          "Fuso A",
          "Nicolia V",
          "Scarpa S"
        ]
      },
      "source": 5,
      "target": 123,
      "key": "755cdd5c1d872dfad6d20389cdbc6251dc7e164c9bfbd057cc640e9a4ad4fe88b23102523aa687b06d3aaaa863a959d0a31e72cb3a359b456f05cbd3b9740078"
    },
    {
      "line": 522,
      "relation": "positiveCorrelation",
      "evidence": "Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.",
      "citation": {
        "type": "PubMed",
        "reference": "26095350",
        "name": "Aging cell",
        "title": "Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII.",
        "volume": "14",
        "pages": "754-63",
        "date": "2015-10-01",
        "first": "Wei Y",
        "last": "He R",
        "authors": [
          "Han C",
          "He R",
          "Liu Y",
          "Su T",
          "Wang Y",
          "Wei Y",
          "Wu B"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Method": {
          "Immunofluorescence": true,
          "Western Blot": true,
          "Immunohistochemistry": true
        },
        "Anatomy": {
          "brain": true
        }
      },
      "source": 817,
      "target": 5,
      "key": "cf411aec885dcc475e66a7f197bc177d5eaaeed357ef635c431d6dc086fa92e5f1dd888cca61e0df378112ff648f6c99364a50462ae733e64d9cc7920b5bc9eb"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 817,
      "key": "35f02882b25b90fa418faa6872fc9df452b478e0462b0484770f8e9e7e62ef4ab09d8f942c8bf326bc77d289d99ea491f2bb1e9dbd106df7dc6a32a6e32cfe13"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 823,
      "key": "236e073bbb571677b2ad9f7f80b447ada7dcb730abdc1d692dd2903d85d543a9acbc9dbec0da53221727d9a5f7df3e3aaeed7a4f34d272eb69c6e014dbf77618"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 818,
      "key": "0bd47d6cc0fbdfcaba8ba8f72155b5fb2b140b31ba7cba3c4d20ea8071ec549b33acc031bcdcc88e9c25a8af2c3b763d3037adf80b546ed215084980b8a62dfc"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 825,
      "key": "78acbec1b5efe954594351e762b63a7ad805141a73fad036556b1ea96136826e75e0f26f5f1a27b3a8dccf75468586348397610adba661a6741048f6a0a564ba"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 814,
      "key": "46dcd9f0776b6f87262c6ec86305ceefd7103ae714025b1dbaea66503b76520ef0d33c937778995ae0773df3a53272e1a20c03462e642e65b8af07eb0545394f"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 815,
      "key": "60745eefe428c409a6fba6fce7414c095644d917dc8772cd81315d3f3c57abcd2f563570a11ab1290f176fc587068bc46c246508994064c40050deb990206176"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 816,
      "key": "1706b00f5d063ca5b2926c3a8d0c054d2888343cd9432a91a19f20810c939bc2e48ff513189d7ff5298ca72d123f9779ee78e045f3cc68f1f1923af987437177"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 834,
      "key": "104f641ebd90878128afc3d34d7d41f392094db80666fee072e6e75c77a78bd8f9fc3ac13c66bb96578dbc2dabf5c589efefcc0617c3c13648bb73bbaf0ad15e"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 831,
      "key": "3884b883e766d84170da506a993768566db2b8c9389238565a06d229658af54a3ad45b9c36c1f4da963b33dbb9232db660d807847a8afb41f744471cc9716e21"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 807,
      "key": "c3228644706c7d7254e5f83e1919fbf17e062d33a306d2013da465a94dd255fad572ace2b3c8ef855fbd587a7fba82aa854d3404d0dc03805da1b69adf6c5d78"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 811,
      "key": "2c2ea9b1bf222f9bdc74a04eea4aea1ce45cab18586adb11e8c9889ab3c25edcd3db437e123224f5555bba399383b0c940ffbabee03881d8e5f45b8c2605a862"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 809,
      "key": "d9e8bac3518395140e2c19a3ce2fc83edda7006e4407ad02a2baa7c6a4927a81bf4673a383b6adad4b651fb1b74d7c0ba185f23cad7546bcd79ffefa7854c23f"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 810,
      "key": "f61404d750c5d5e66057aa5633cb9c373473ec8b7eea50f9a8464b0ea631a1a4fd7b59d1b1f3dafd9b3242fc2e25be5404a45ce688befcf2ee217a2166316aae"
    },
    {
      "line": 1241,
      "relation": "increases",
      "evidence": "First, we verified the colocalization of p-WAVE1 and pCRMP2 with aggregated hyperphosphorylated tau in the hippocampus at 23 months of age. Biochemical analysis revealed the inclusion of p-WAVE1, p-CRMP2, and tau in the sarkosyl-insoluble fractions of hippocampal homogenates",
      "citation": {
        "type": "PubMed",
        "reference": "26400044",
        "name": "Journal of neuroscience research",
        "title": "Colocalization of phosphorylated forms of WAVE1, CRMP2, and tau in Alzheimer's disease model mice: Involvement of Cdk5 phosphorylation and the effect of ATRA treatment.",
        "volume": "94",
        "pages": "15-26",
        "date": "2016-01-01",
        "first": "Watamura N",
        "last": "Ohshima T",
        "authors": [
          "Nikkuni M",
          "Ohshima T",
          "Toba J",
          "Watamura N",
          "Yoshii A"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 803,
      "target": 243,
      "key": "57270d750e2f3a4299134220e8bb16e009f0862ca5f622e734cef5498cd4a7f816a20e1c0a8df934ab2c441d6b77a5fa7e00df6b6c494f081d81a489e39f512c"
    },
    {
      "line": 1963,
      "relation": "association",
      "evidence": "Direct interaction of DAPK1 with Tau causes spine loss and subsequently neuronal death. DAPK1 phosphorylates Tau protein at Ser262 (pS(262)) in cortical neurons of stroke mice.",
      "citation": {
        "type": "PubMed",
        "reference": "25995053",
        "name": "Cerebral cortex (New York, N.Y. : 1991)",
        "title": "A Novel Mechanism of Spine Damages in Stroke via DAPK1 and Tau.",
        "volume": "25",
        "pages": "4559-71",
        "date": "2015-11-01",
        "first": "Pei L",
        "last": "Lu Y",
        "authors": [
          "Bi L",
          "Guo Y",
          "Jin H",
          "Li H",
          "Lu Y",
          "Pang P",
          "Pei L",
          "Shang Y",
          "Shu S",
          "Tian Q",
          "Tian T",
          "Wang S",
          "Wei N",
          "Wu J",
          "Xu M",
          "Yan H",
          "Yang X",
          "Yao C",
          "Zhu LQ"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Stroke": true
        }
      },
      "source": 803,
      "target": 781,
      "key": "4b130d5508b6f320141f0b9257388032859e562ee26f7b92dd9aa1018a8df260bf632680eed4aff42852a9fae71a085eaef3fd9d693117a462b5467ad91f523c"
    },
    {
      "line": 1965,
      "relation": "partOf",
      "evidence": "Direct interaction of DAPK1 with Tau causes spine loss and subsequently neuronal death. DAPK1 phosphorylates Tau protein at Ser262 (pS(262)) in cortical neurons of stroke mice.",
      "citation": {
        "type": "PubMed",
        "reference": "25995053",
        "name": "Cerebral cortex (New York, N.Y. : 1991)",
        "title": "A Novel Mechanism of Spine Damages in Stroke via DAPK1 and Tau.",
        "volume": "25",
        "pages": "4559-71",
        "date": "2015-11-01",
        "first": "Pei L",
        "last": "Lu Y",
        "authors": [
          "Bi L",
          "Guo Y",
          "Jin H",
          "Li H",
          "Lu Y",
          "Pang P",
          "Pei L",
          "Shang Y",
          "Shu S",
          "Tian Q",
          "Tian T",
          "Wang S",
          "Wei N",
          "Wu J",
          "Xu M",
          "Yan H",
          "Yang X",
          "Yao C",
          "Zhu LQ"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Stroke": true
        }
      },
      "source": 803,
      "target": 241,
      "key": "41974059adbd62836b14565c6a2ead7fd17063d4a983519ef127cbcae23c7fde44aa9f06b3138c2316ac86051f77a4cd4b58b71663387986fd3966c7c9743638"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 821,
      "key": "b37e63da59ca72497105c69e28d2832fe3a157e4c307256e1ee270b3a65512e533c6ed47cbe1494b8f706fd00eae03e8e95b09b6e67eabf1f6ec73b4d10d50a3"
    },
    {
      "line": 2062,
      "relation": "negativeCorrelation",
      "evidence": "Normalizing the gene dosage of Dyrk1A in the TS mouse rescued the density of senescent cells in the cingulate cortex, hippocampus and septum, prevented cholinergic neuron degeneration, and reduced App expression in the hippocampus, Aß load in the cortex and hippocampus, the expression of phosphorylated tau at the Ser202 residue in the hippocampus and cerebellum and the levels of total tau in the cortex, hippocampus and cerebellum.",
      "citation": {
        "type": "PubMed",
        "reference": "29221819",
        "name": "Neurobiology of disease",
        "title": "Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.",
        "volume": "110",
        "pages": "206-217",
        "date": "2018-02-01",
        "first": "García-Cerro S",
        "last": "Martínez-Cué C",
        "authors": [
          "Berciano MT",
          "García-Cerro S",
          "Lafarga M",
          "Lantigua S",
          "Martínez-Cué C",
          "Padro D",
          "Ramos-Cabrer P",
          "Rueda N",
          "Vidal V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        },
        "Anatomy": {
          "cerebellum": true,
          "hippocampal formation": true,
          "cerebral cortex": true
        }
      },
      "source": 803,
      "target": 786,
      "key": "c3e797a052e3cca78f8cf5688d37b82ddca5d336c1e4d1c20c0d77117a48182e9733a1f9352dfdb185899973b588a91e48bc928ea22bca305db26fae30866324"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 822,
      "key": "07bcca0cef84090616066e422eb841899f220272cf6dbf6bf524a258400c020b3817ae053c54cb330dd0d087d3f7a4284c42782ef5c42a3a9938f02f9e5492be"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 836,
      "key": "d5db8fc2859a81e5ceec5b883595af9f6e17ffecbe5b8710edda39597d442ad7927951a5c1d8f30d8dca49a7d803a1a1d4a8c1256cd33941d1701aeb218dbaf1"
    },
    {
      "line": 2200,
      "relation": "positiveCorrelation",
      "evidence": "Interestingly, Syk upregulation in SH-SY5Y cells leads to a significant increase (1.7-fold) in phosphorylated tau at Y18 (Fig. 14c, p < 0.01) and at S396/404 (Fig. 14d, 3-fold, p < 0.0001) compared to control cells. Total tau levels are also significantly increased following Syk overexpression (Fig. 14e, 4.2-fold, p < 0.0001).",
      "citation": {
        "type": "PubMed",
        "reference": "28877763",
        "name": "Acta neuropathologica communications",
        "title": "Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.",
        "volume": "5",
        "pages": "69",
        "date": "2017-09-06",
        "first": "Schweig JE",
        "last": "Paris D",
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Mouzon B",
          "Mullan M",
          "Paris D",
          "Schweig JE",
          "Yao H"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "APPPS1 mice": true
        },
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 803,
      "target": 851,
      "key": "0ceef3fb315495d415c47a21e4fca2da24c4b555c15ae1d4fc4ba1a5acb3eac5bd6e3c5226e5ec43e252b9e8f8390498449e91e29e28dcf9d48f5173259e58b8"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 808,
      "key": "f0be9855bf765f882e040f72ff4194fbe68fb934a20409df1f37665928cd5319c3b09c985e9843a2ecc6002610632713195f31b1e843ff4e1ed5611f95f539d2"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 826,
      "key": "8991973a19f9d405f8a4b1ac51582c7624f1c4d40bef22c1c815efbf0734f0b4dbd68b22c0a34a74c3fa132b15329d6b05f9267501e9ae9c004c52f39dfa6d6c"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 829,
      "key": "ac0c71d8fb60765bf6a95acad306ad8f86ac8120e28c4f6ca9f583a650c496dc5e91f0a5582e7a685d64c785b7fdbfaed75a07039a1e14820b19ae41d372538c"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 830,
      "key": "9593d66f98449976b2608575f7ff501337ebecbff32a841aec51d1e77f11d3d386261e1553c59ace9bb510a216877f696bb9e0df90cbf515382a3515e7f871d3"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 812,
      "key": "293d1a0b51be3119f2b441652625e32df03af67ffa70985611ea2b08539175ca6e8aab4c598d857c62314cb66430cae61f427a90b8561134484c1af64afa115e"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 813,
      "key": "9db3084f0afd4ddc3170efc52d297cda12ee4d98db0f46410b54990db28d3eb83715f3032cd498abd70f5130f7f4e0a9ba16bc95ca62092383edb7c38bc93231"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 832,
      "key": "eb78bb5daab696724f267cdab98674ec7582f7062a98d85bccbdea685c4be46878fe50e8a7717b9a8bc9b556db783c182a5b4014752955d584b34f284c48a1a4"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 833,
      "key": "efb6d3d1e3cdf855ad899ae9bc2a33b0af5ec9772714dee520799ff270def75f0249d0a26c4b72dbaa485252d03d24e947acc5a3afdffc2d48f05f5f9cd2b118"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 819,
      "key": "a610bd3cf0b557ae6e38082049e00ecab28bc04dd4d1c0a1c113bc578801a14941b8e69c129ac6d6dc4d28016b686318fd732f65e37bb3082d4b86ae24f596aa"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 820,
      "key": "610a246f19b0fbac4109c6124416d97a7318db07eede86588e7b9a80b73194208e0c49b7d94a6da10b82179ffc517a7d8640a5de67aff1560e6461d5a90ffcee"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 824,
      "key": "f177ac97183e576dbee606fc7e8d19c6784616bf4f9f0efea20728a9ca1cedd2b404dfbeaabda7b632679871275e7708a1cc0c2ec51c597e5fc128f5d6d0c9ab"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 835,
      "key": "9866269b0b5ab96af07db6e636ffb99c1846b5631c3594a68fd7fc8a0a0ef61c5e20372c3299f296833f4dd11b9ad96276af873892eda6fc29a129d66b89c176"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 827,
      "key": "4de56822f54b2247fb22af8b741617910c0fd936942000b9cabda766c4165fdca75891bbe54f8657d5ad6248befd67a7ac2632074bccde589aaf26ec9362d140"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 828,
      "key": "3d3d62ee000c4490072c32bcb00c7d91915a7a79c45fe45f65ad8429bbb88f57d5dd11412bd020594149d3ead9e87b0b91391b26a43b68351d7fa9c0b3f68795"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 805,
      "key": "2838f2b6aa488f1dab7d414bce2eb4a96af4e41d2e7307fed919fdb92598cc39c7523c164380f42fc8b2852dc9856377ea930345997c4e8e0b89e5a7fd82138f"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 804,
      "key": "3d28c618d3a4197e53eefe2dfebb82819f62ecdf34fa8bfa130f5a5b28ca99989068cff10a255238b33f3071560eefda5f13238e09b4d63c42a0c3cda493acf8"
    },
    {
      "relation": "hasVariant",
      "source": 803,
      "target": 806,
      "key": "ee7c372eee00a92f230676585ec3ee73da1353c3e73348d616c5b45991b260b289e62bff2538f655c9a235542491e0dd3273bda92b72e337c215e6159e2dfe20"
    },
    {
      "line": 523,
      "relation": "positiveCorrelation",
      "evidence": "Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.",
      "citation": {
        "type": "PubMed",
        "reference": "26095350",
        "name": "Aging cell",
        "title": "Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII.",
        "volume": "14",
        "pages": "754-63",
        "date": "2015-10-01",
        "first": "Wei Y",
        "last": "He R",
        "authors": [
          "Han C",
          "He R",
          "Liu Y",
          "Su T",
          "Wang Y",
          "Wei Y",
          "Wu B"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Method": {
          "Immunofluorescence": true,
          "Western Blot": true,
          "Immunohistochemistry": true
        },
        "Anatomy": {
          "brain": true
        }
      },
      "source": 823,
      "target": 5,
      "key": "aadc76079e19cb85859ded1fc8f609206dec716387a3effa40a9358941ebffa8d5cab9bf49a8f7ee8b1b9116589f1bd8ab677d09f8ff3a5825f36015878c81c8"
    },
    {
      "line": 2198,
      "relation": "positiveCorrelation",
      "evidence": "Interestingly, Syk upregulation in SH-SY5Y cells leads to a significant increase (1.7-fold) in phosphorylated tau at Y18 (Fig. 14c, p < 0.01) and at S396/404 (Fig. 14d, 3-fold, p < 0.0001) compared to control cells. Total tau levels are also significantly increased following Syk overexpression (Fig. 14e, 4.2-fold, p < 0.0001).",
      "citation": {
        "type": "PubMed",
        "reference": "28877763",
        "name": "Acta neuropathologica communications",
        "title": "Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.",
        "volume": "5",
        "pages": "69",
        "date": "2017-09-06",
        "first": "Schweig JE",
        "last": "Paris D",
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Mouzon B",
          "Mullan M",
          "Paris D",
          "Schweig JE",
          "Yao H"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "APPPS1 mice": true
        },
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 823,
      "target": 851,
      "key": "001aebff53790bc5dc15fa025614b84c545103b9911397d46883fb14977b03db2e072aaaaf0365a9dafc8c8d79a4ee3c841b55a4f24e7fb4ccd4592426bed668"
    },
    {
      "line": 2260,
      "relation": "positiveCorrelation",
      "evidence": "We further validated Syk as a target-regulating Aβ by showing that pharmacological inhibition of Syk or down-regulation of Syk expression reduces Aβ production and increases the clearance of Aβ across the BBB mimicking (-)-nilvadipine effects. Moreover, treatment of transgenic mice overexpressing Aβ and transgenic Tau P301S mice with a selective Syk inhibitor respectively decreased brain Aβ accumulation and Tau hyperphosphorylation at multiple AD relevant epitopes.",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 823,
      "target": 851,
      "key": "7ce5131ada17cf72ed5ae12b19fe95fec5d7e97740b8dc6a89f3a44c97d097cfc09ec1a98b77160fe2eda05db712b46d2791cc6c5822d2f57f3f3b0938d14085"
    },
    {
      "line": 524,
      "relation": "positiveCorrelation",
      "evidence": "Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.",
      "citation": {
        "type": "PubMed",
        "reference": "26095350",
        "name": "Aging cell",
        "title": "Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII.",
        "volume": "14",
        "pages": "754-63",
        "date": "2015-10-01",
        "first": "Wei Y",
        "last": "He R",
        "authors": [
          "Han C",
          "He R",
          "Liu Y",
          "Su T",
          "Wang Y",
          "Wei Y",
          "Wu B"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Method": {
          "Immunofluorescence": true,
          "Western Blot": true,
          "Immunohistochemistry": true
        },
        "Anatomy": {
          "brain": true
        }
      },
      "source": 818,
      "target": 5,
      "key": "fdc2ed5c22990d24be763bfb6fb95b1bcd03a631d74f9b4b74ad7dfda26c97235c87b1b91a84ceb955c501f9adc6c74091069efc7457ded6de5edba94fb5f990"
    },
    {
      "line": 1593,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 551,
      "target": 908,
      "key": "5d3d969990ea39442a29bf242cef5c1e59f44ab51a017312176368abe2123b88796e03a1b25ac89e224fee67c6f63a11d7864dcd06bbf1308e1192d1a6a89dfd"
    },
    {
      "line": 2292,
      "relation": "positiveCorrelation",
      "evidence": "Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.",
      "citation": {
        "type": "PubMed",
        "reference": "28176663",
        "name": "Current Alzheimer research",
        "title": "GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.",
        "volume": "14",
        "pages": "753-759",
        "date": "2017-01-01",
        "first": "Nicolia V",
        "last": "Fuso A",
        "authors": [
          "Cavallaro RA",
          "Ciraci V",
          "Ferrer I",
          "Fuso A",
          "Nicolia V",
          "Scarpa S"
        ]
      },
      "source": 551,
      "target": 5,
      "key": "62b463e645753461c61e68f52a4d12f1f658ce229dfb4636e843b73f22007947944815c6ec04b99dd0c54b19dca3ff4ac4c811577c8525fee4eeb034bd173140"
    },
    {
      "line": 2821,
      "relation": "decreases",
      "evidence": ">8 phosphates per tau molecules (vs 2 in adult healthy brain); can also be increased during development, hibernation and temperature, heat and oxydative stress These phosphorylated states are detected by specific antibodies and are targets of proline-directed kinases (SP motifs), non-proline kinases (KXGS motif) Weakens tau-MT interaction especially S261 in R1 and S214 in proline-rich domain",
      "citation": {
        "type": "PubMed",
        "reference": "8226987",
        "name": "The Journal of biological chemistry",
        "title": "Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease.",
        "volume": "268",
        "pages": "24374-84",
        "date": "1993-11-15",
        "first": "Köpke E",
        "last": "Grundke-Iqbal I",
        "authors": [
          "Alonso AC",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Köpke E",
          "Shaikh S",
          "Tung YC"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 551,
      "target": 486,
      "key": "d74becbda417c30061c58ee349991e9a230ba27ee2d352775590224c774ead5a93ca70328388d1cdfbe2f61deeadec495ebfff344b57cb69779cc13ebcae4430"
    },
    {
      "line": 1127,
      "relation": "positiveCorrelation",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 564,
      "target": 299,
      "key": "ec72dd4057b841bebbf154a0c23ad149a53c85e56ccbc22df8e4a62097adc7714175e59253868e69ebafcceae24fa047f7307e23c784ebbbe028c32dce190861"
    },
    {
      "line": 1156,
      "relation": "partOf",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 564,
      "target": 230,
      "key": "bcb537382746ba29bfd5a68f4fd1078d5b9bcec7d4f6b22b66646d424598ac5800b41fc03fcda60dfc02e5c2164a87480d064cdf15acbb811b29e193792538a3"
    },
    {
      "line": 1806,
      "relation": "positiveCorrelation",
      "evidence": "We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "source": 564,
      "target": 117,
      "key": "42ed9b4958f344cd28187ee13b5f59b7707cfc831da6651338b979896d3c0d991437feb12eaf4894fb440c3c1f98eb3b3ca645368a660265231308d12e85b8b2"
    },
    {
      "line": 2001,
      "relation": "negativeCorrelation",
      "evidence": "These data suggest that tau hyperphosphorylation at Thr231, Ser262, and Ser396 by DAPK1 renders the cells more resistant to the kinase-induced apoptotic cell death, providing new insights into the tau-involved apoptotic abortion in the course of chronic neurodegeneration.",
      "citation": {
        "type": "PubMed",
        "reference": "23948915",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Phosphorylation of tau by death-associated protein kinase 1 antagonizes the kinase-induced cell apoptosis.",
        "volume": "37",
        "pages": "795-808",
        "date": "2013-01-01",
        "first": "Duan DX",
        "last": "Liu GP",
        "authors": [
          "Chai GS",
          "Chen NN",
          "Cheng XS",
          "Duan DX",
          "Hu Y",
          "Liu GP",
          "Luo Y",
          "Ni ZF",
          "Wang JZ"
        ]
      },
      "source": 564,
      "target": 174,
      "key": "6ed14b0a081f69b5c9bb76ce77de1d1a16df74683e5717bda842e943b80a6a9b7bdc915ec346aa2c409bd68ab3bade8dcebb1bf97b45e634b455a498856c6cbd"
    },
    {
      "line": 2293,
      "relation": "positiveCorrelation",
      "evidence": "Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells.",
      "citation": {
        "type": "PubMed",
        "reference": "28176663",
        "name": "Current Alzheimer research",
        "title": "GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.",
        "volume": "14",
        "pages": "753-759",
        "date": "2017-01-01",
        "first": "Nicolia V",
        "last": "Fuso A",
        "authors": [
          "Cavallaro RA",
          "Ciraci V",
          "Ferrer I",
          "Fuso A",
          "Nicolia V",
          "Scarpa S"
        ]
      },
      "source": 564,
      "target": 5,
      "key": "8f170e83d0b2e206b16b6a9b90be553e3677dd5ded1919ae3d5a108b4588e8b85f4835cc9436959b24af590dd98d111f8e9b7f59de8e6f463a7019a5db7562fb"
    },
    {
      "line": 2510,
      "relation": "positiveCorrelation",
      "evidence": "Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Research_Model": {
          "rTg4510 mice": true
        }
      },
      "source": 564,
      "target": 513,
      "key": "93061d0c48394bdd5635c18c131dc69dec6ed2ff9e829ebca485d6ae64560bb60b7a4dc7e2d8b1f2f292c00952051ee4947bc79ab4553d543002f1f1db00953d"
    },
    {
      "line": 3395,
      "relation": "positiveCorrelation",
      "evidence": "This study aimed to investigate the protective effects and mechanism of the novel HDAC6 inhibitor, MPT0G211, using an AD model. Our results indicated that MPT0G211 significantly reduced tau phosphorylation and aggregation, the processes highly correlated with the formation of NFTs. This HDAC6 inhibitory activity resulted in an increase in acetylated Hsp90, which decreased Hsp90 and HDAC6 binding, causing ubiquitination of phosphorylated tau proteins. In addition, a significant increase of phospho-glycogen synthase kinase-3β (phospho-GSK3β) on Ser9 (the inactive form) through Akt phosphorylation was associated with the inhibition of phospho-tau Ser396 in response to MPT0G211 treatment.",
      "citation": {
        "type": "PubMed",
        "reference": "29844403",
        "name": "Cell death &amp; disease",
        "title": "The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.",
        "volume": "9",
        "pages": "655",
        "date": "2018-05-29",
        "first": "Fan SJ",
        "last": "Yang CR",
        "authors": [
          "Fan SJ",
          "Huang FI",
          "Liou JP",
          "Yang CR"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true,
          "SH-SY5Y": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 564,
      "target": 456,
      "key": "f13ed02ecfd16d298f503f40f452d143e2bde0c75526ddd3bd22ab908459e6667f80c28fe96bf8816714d109e9819d6e431a83b73a75f3d7c9cea199c0e10858"
    },
    {
      "line": 534,
      "relation": "increases",
      "evidence": "The treatment of 10 mM D-ribose for 24 h resulted in a significant increase in active form of CaMKII (p-Thr286/287), yet simultaneously in a decrease in inactive form of CaMKII (p-Thr305/306) phosphorylation (Fig. 4e). The enzyme activity assay supported this result.",
      "citation": {
        "type": "PubMed",
        "reference": "26095350",
        "name": "Aging cell",
        "title": "Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII.",
        "volume": "14",
        "pages": "754-63",
        "date": "2015-10-01",
        "first": "Wei Y",
        "last": "He R",
        "authors": [
          "Han C",
          "He R",
          "Liu Y",
          "Su T",
          "Wang Y",
          "Wei Y",
          "Wu B"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Method": {
          "Immunofluorescence": true,
          "Western Blot": true,
          "Immunohistochemistry": true
        },
        "Cell_Line": {
          "N2a": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 773,
      "target": 772,
      "key": "752da1abb9dd4d22d959e555a82fca429094a64ef9321463c0f3187ff7148e59847205c88bce0156b3ea5e88743f2a07b15953826082745b2982a7a24e1b6fcf"
    },
    {
      "relation": "hasVariant",
      "source": 772,
      "target": 773,
      "key": "1f9758e65f18d674ea0c7fbbe0340896c885bbb438ad4d9785fb7ace5be33ad9ab558ea6f16ff2147e729af10f9989e17b87d14c6b1997a42bb0932d34fd4bc5"
    },
    {
      "relation": "hasVariant",
      "source": 772,
      "target": 774,
      "key": "f9dfde94d27d74ee9a056017ece4abdd95352e2cf3f0078b91bcba80f63eca0ce6187a25f5a73ec186c65c3264c203ffb4a573ede815bad7b41c2729b1f6bf74"
    },
    {
      "line": 536,
      "relation": "decreases",
      "evidence": "The treatment of 10 mM D-ribose for 24 h resulted in a significant increase in active form of CaMKII (p-Thr286/287), yet simultaneously in a decrease in inactive form of CaMKII (p-Thr305/306) phosphorylation (Fig. 4e). The enzyme activity assay supported this result.",
      "citation": {
        "type": "PubMed",
        "reference": "26095350",
        "name": "Aging cell",
        "title": "Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII.",
        "volume": "14",
        "pages": "754-63",
        "date": "2015-10-01",
        "first": "Wei Y",
        "last": "He R",
        "authors": [
          "Han C",
          "He R",
          "Liu Y",
          "Su T",
          "Wang Y",
          "Wei Y",
          "Wu B"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Method": {
          "Immunofluorescence": true,
          "Western Blot": true,
          "Immunohistochemistry": true
        },
        "Cell_Line": {
          "N2a": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 774,
      "target": 772,
      "key": "c7f0b5eb33bb686198897993d6e08eeda867439660b461659fdc3d1525c22dfde9afbf1513fde70a97ce6dcae7d6e788f8846baa1a3bd0130807fa69f4168bf3"
    },
    {
      "line": 550,
      "relation": "increases",
      "evidence": "Here, we found that MG could induce tau hyperphosphorylation at multiple AD-related sites in neuroblastoma 2a cells under maintaining normal cell viability. MG treatment increased the level of advanced glycation end products (AGEs) and the receptor of AGEs (RAGE).",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "source": 61,
      "target": 825,
      "key": "58673a5d000fb2903cbe636eb0ee89d4d2113fa2c04a25967a065a298c530c422b5d6184dd241b6adda3942350cb2a8a8931540e0e24dd21e063b234f84a49d4"
    },
    {
      "line": 551,
      "relation": "increases",
      "evidence": "Here, we found that MG could induce tau hyperphosphorylation at multiple AD-related sites in neuroblastoma 2a cells under maintaining normal cell viability. MG treatment increased the level of advanced glycation end products (AGEs) and the receptor of AGEs (RAGE).",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "source": 61,
      "target": 814,
      "key": "6f86774f5d762b5ca06408ab18f4d050fa7474ed78188acb093b0e5ef5abb714192761638f0518f9d4d992f8f0d709fde54401eee65a47d2a5ef63f728abf340"
    },
    {
      "line": 552,
      "relation": "increases",
      "evidence": "Here, we found that MG could induce tau hyperphosphorylation at multiple AD-related sites in neuroblastoma 2a cells under maintaining normal cell viability. MG treatment increased the level of advanced glycation end products (AGEs) and the receptor of AGEs (RAGE).",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "source": 61,
      "target": 815,
      "key": "adc6f43222f951f3389bbbfd6a73f4947f40cf04cf2c510552371115f51929e8e245818493e4b9009ace7b7b22c1bd2be0d8ffcc8dab3da043111296ff339e9f"
    },
    {
      "line": 553,
      "relation": "increases",
      "evidence": "Here, we found that MG could induce tau hyperphosphorylation at multiple AD-related sites in neuroblastoma 2a cells under maintaining normal cell viability. MG treatment increased the level of advanced glycation end products (AGEs) and the receptor of AGEs (RAGE).",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "source": 61,
      "target": 816,
      "key": "6e2c01fbf8f52bf97d1847b2e2b8ff298bcafd9a1e74e97ec87c5b859a5ad739b6919d55119ea556681f446edae1dc6ba4a4be27eb47f12bb7103aa423f139ba"
    },
    {
      "line": 554,
      "relation": "increases",
      "evidence": "Here, we found that MG could induce tau hyperphosphorylation at multiple AD-related sites in neuroblastoma 2a cells under maintaining normal cell viability. MG treatment increased the level of advanced glycation end products (AGEs) and the receptor of AGEs (RAGE).",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "source": 61,
      "target": 834,
      "key": "8267b7e69d4a7cddeda6c47bee03856737f9811cac469e14350ce6ec86e222d0e19b7d84b4ede66510670f14df2e0619c583463d903b83d42626df0b17965dce"
    },
    {
      "line": 555,
      "relation": "increases",
      "evidence": "Here, we found that MG could induce tau hyperphosphorylation at multiple AD-related sites in neuroblastoma 2a cells under maintaining normal cell viability. MG treatment increased the level of advanced glycation end products (AGEs) and the receptor of AGEs (RAGE).",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "source": 61,
      "target": 823,
      "key": "edf17bd786fe15243a391b1294a2cb6a3a882084e7f7cc4d01020a23f3db04f470fdb6ca4d720f6c24b597341378c29930699d27883348bda835fc6c6b86f958"
    },
    {
      "line": 556,
      "relation": "increases",
      "evidence": "Here, we found that MG could induce tau hyperphosphorylation at multiple AD-related sites in neuroblastoma 2a cells under maintaining normal cell viability. MG treatment increased the level of advanced glycation end products (AGEs) and the receptor of AGEs (RAGE).",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "source": 61,
      "target": 831,
      "key": "75255cd476a4ce63f3c520c6090fe3348c2816d17103f1cfe1b35e5af666e686370dd71fbee3201a9ad1685508bbf7370657dc10762d890ac166fd13d996405c"
    },
    {
      "line": 558,
      "relation": "increases",
      "evidence": "Here, we found that MG could induce tau hyperphosphorylation at multiple AD-related sites in neuroblastoma 2a cells under maintaining normal cell viability. MG treatment increased the level of advanced glycation end products (AGEs) and the receptor of AGEs (RAGE).",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "source": 61,
      "target": 9,
      "key": "ec79bce1623a43c0894e288654609f453ad60de7e17bea386977c773b6605af9abfb26cfca27d43fb01474819617bdb95949b6dc8c0aa32936f5a9aa09c1e7db"
    },
    {
      "line": 559,
      "relation": "increases",
      "evidence": "Here, we found that MG could induce tau hyperphosphorylation at multiple AD-related sites in neuroblastoma 2a cells under maintaining normal cell viability. MG treatment increased the level of advanced glycation end products (AGEs) and the receptor of AGEs (RAGE).",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "source": 61,
      "target": 371,
      "key": "c9a9488bacb2823ed1ae121a779f3c0d58c447c86ec0dd4d14c30ce7df7946dfdb1cee81aa865a9b18d18708180ca70a433909c482370caafe6bd4cfbed42d41"
    },
    {
      "line": 638,
      "relation": "negativeCorrelation",
      "evidence": "In accordance with the decreased efficiency of nitro-TPI we found a significant increase in methylglyoxal production (P50.05), independent of whether DHAP or GAP was used as substrate (Fig. 2E). Thus, nitrotyrosination of TPI results in reduced catalytic activity and increased occupancy of the enzyme by the substrate, and consequently, a higher production of the toxic methylglyoxal.",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 61,
      "target": 763,
      "key": "77b4d78d7dfd3ed2101c3a3583b91de9fb815a6e10ac81741f311ebbfcfa6cd170e4b37abaef2ec30b5301717974813cdb5dad09a91a6ae772c36b17bbe3600c"
    },
    {
      "line": 682,
      "relation": "increases",
      "evidence": "Acrolein and methylglyoxal were the most reactive compounds followed by glyoxal and malondialdehyde in terms of formation of Tau dimers and higher molecular weight oligomers. Analysis of the Tau aggregates by electron microscopy study showed that formation of fibrils using wild-type Tau and several Tau mutants could be observed with acrolein and methylglyoxal but not with glyoxal and malondialdehyde.",
      "citation": {
        "type": "PubMed",
        "reference": "17082178",
        "name": "The Journal of biological chemistry",
        "title": "Effect of pseudophosphorylation and cross-linking by lipid peroxidation and advanced glycation end product precursors on tau aggregation and filament formation.",
        "volume": "282",
        "pages": "6984-91",
        "date": "2007-03-09",
        "first": "Kuhla B",
        "last": "Münch G",
        "authors": [
          "Arendt T",
          "Flach K",
          "Haase C",
          "Kuhla B",
          "Lüth HJ",
          "Münch G"
        ]
      },
      "annotations": {
        "Method": {
          "SDS-PAGE": true,
          "Western Blot": true,
          "Electron Microscopy": true,
          "Thioflavin T Assay": true
        }
      },
      "source": 61,
      "target": 81,
      "key": "f2ebf4ba6c1f11dbc4cb095f409945f1f3f9f1467d593d4344ce9bfb8bac41276eb10d9b50133716d262dce46361b15ccf8c642ca86ecf1e026003f6fabfb89d"
    },
    {
      "line": 2199,
      "relation": "positiveCorrelation",
      "evidence": "Interestingly, Syk upregulation in SH-SY5Y cells leads to a significant increase (1.7-fold) in phosphorylated tau at Y18 (Fig. 14c, p < 0.01) and at S396/404 (Fig. 14d, 3-fold, p < 0.0001) compared to control cells. Total tau levels are also significantly increased following Syk overexpression (Fig. 14e, 4.2-fold, p < 0.0001).",
      "citation": {
        "type": "PubMed",
        "reference": "28877763",
        "name": "Acta neuropathologica communications",
        "title": "Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.",
        "volume": "5",
        "pages": "69",
        "date": "2017-09-06",
        "first": "Schweig JE",
        "last": "Paris D",
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Mouzon B",
          "Mullan M",
          "Paris D",
          "Schweig JE",
          "Yao H"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "APPPS1 mice": true
        },
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 825,
      "target": 851,
      "key": "660cf310168c4483e78018482b56db60970f9a11db1fb5d6f8d02d0203910cf5a8cef9345726147be9da0cec7a687a35489de673bf272bff69e24c62b108fbcc"
    },
    {
      "line": 2261,
      "relation": "positiveCorrelation",
      "evidence": "We further validated Syk as a target-regulating Aβ by showing that pharmacological inhibition of Syk or down-regulation of Syk expression reduces Aβ production and increases the clearance of Aβ across the BBB mimicking (-)-nilvadipine effects. Moreover, treatment of transgenic mice overexpressing Aβ and transgenic Tau P301S mice with a selective Syk inhibitor respectively decreased brain Aβ accumulation and Tau hyperphosphorylation at multiple AD relevant epitopes.",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 825,
      "target": 851,
      "key": "6288a24710ce60cb60c133c2055a157f3628dbf5f4f77ee72c65d31f7360c106c31b12d30ecb080e323846ce444fe888365d9eba86a11dd09af4e4d922fb9120"
    },
    {
      "line": 2059,
      "relation": "negativeCorrelation",
      "evidence": "Normalizing the gene dosage of Dyrk1A in the TS mouse rescued the density of senescent cells in the cingulate cortex, hippocampus and septum, prevented cholinergic neuron degeneration, and reduced App expression in the hippocampus, Aß load in the cortex and hippocampus, the expression of phosphorylated tau at the Ser202 residue in the hippocampus and cerebellum and the levels of total tau in the cortex, hippocampus and cerebellum.",
      "citation": {
        "type": "PubMed",
        "reference": "29221819",
        "name": "Neurobiology of disease",
        "title": "Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.",
        "volume": "110",
        "pages": "206-217",
        "date": "2018-02-01",
        "first": "García-Cerro S",
        "last": "Martínez-Cué C",
        "authors": [
          "Berciano MT",
          "García-Cerro S",
          "Lafarga M",
          "Lantigua S",
          "Martínez-Cué C",
          "Padro D",
          "Ramos-Cabrer P",
          "Rueda N",
          "Vidal V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        },
        "Anatomy": {
          "cerebellum": true,
          "hippocampal formation": true
        }
      },
      "source": 816,
      "target": 786,
      "key": "9b3e1ee8569a3748d3e26064665d4ddf87b7acd68524e46d97b4b69a765e40e3b772f2be776e24719454af973bb50490b77b4bd2c7a1dc99e82ce00a507843cf"
    },
    {
      "line": 2263,
      "relation": "positiveCorrelation",
      "evidence": "We further validated Syk as a target-regulating Aβ by showing that pharmacological inhibition of Syk or down-regulation of Syk expression reduces Aβ production and increases the clearance of Aβ across the BBB mimicking (-)-nilvadipine effects. Moreover, treatment of transgenic mice overexpressing Aβ and transgenic Tau P301S mice with a selective Syk inhibitor respectively decreased brain Aβ accumulation and Tau hyperphosphorylation at multiple AD relevant epitopes.",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 816,
      "target": 851,
      "key": "e5424f4b03799b3d469d1af9a7da6fc2b422134d92ed4cbad903ae2c96a737775317e763f3cd7193d18e910ff17ec653cfba207af9e3ebadd91148a79b15fa30"
    },
    {
      "line": 564,
      "relation": "directlyIncreases",
      "evidence": "Taken all together, we think that activation of GSK-3b and p38 should be responsible for MG-induced tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 794,
      "target": 825,
      "key": "ca78e13b4d3ca754cdbadd8217e4bb913515e8b5b80f51ae0074f4d2fa8c0c2ed4e652399252bd500950f7ecbec1d458a6579f3c264d7873d9bbbcdd326f88f2"
    },
    {
      "line": 565,
      "relation": "directlyIncreases",
      "evidence": "Taken all together, we think that activation of GSK-3b and p38 should be responsible for MG-induced tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 794,
      "target": 814,
      "key": "c960fd328cc2dd434fbf2c4c8020a9a04e731de970d74024c295e3d5cea654c0d905516315647ba9f633423299c85d5135ff4e1166932426ee75c4bf28a6c1f5"
    },
    {
      "line": 566,
      "relation": "directlyIncreases",
      "evidence": "Taken all together, we think that activation of GSK-3b and p38 should be responsible for MG-induced tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 794,
      "target": 815,
      "key": "c5e60aec296e676590f8e103bc8fdce7775d5218d5437a847c92acc9b43e564b88ccc1e7354c0e9126eff15b18cfd4b35ea71e526e403e7245b718242c8c0edd"
    },
    {
      "line": 567,
      "relation": "directlyIncreases",
      "evidence": "Taken all together, we think that activation of GSK-3b and p38 should be responsible for MG-induced tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 794,
      "target": 816,
      "key": "5b8d007ec5bb1044018b270adf2acc4636546435d2d7f74e185bd62659846583db4a05fcab1a81d4830b6159afecf52f9482ee57281186970fb7bdc763af4329"
    },
    {
      "line": 568,
      "relation": "directlyIncreases",
      "evidence": "Taken all together, we think that activation of GSK-3b and p38 should be responsible for MG-induced tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 794,
      "target": 834,
      "key": "516062725fcf9487f6f37848f98fa1042748d401555c9afe326659823c8d9335846d1aa48638c681e818b2e4855c40f348df712b8b0ba27a5f74653d8975b9b1"
    },
    {
      "line": 569,
      "relation": "directlyIncreases",
      "evidence": "Taken all together, we think that activation of GSK-3b and p38 should be responsible for MG-induced tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 794,
      "target": 823,
      "key": "ce77fed8143f73ef01cff2ddcc125efc53df79c5d8efa39329828ac3cad1fd54a6c0fcdc9f3a2b37077762dddce92a243a196dda92485dcd0e913c56616247fe"
    },
    {
      "line": 570,
      "relation": "directlyIncreases",
      "evidence": "Taken all together, we think that activation of GSK-3b and p38 should be responsible for MG-induced tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 794,
      "target": 831,
      "key": "82b71902b350ba269fdbcbeecfb2ed048c4ab320af1d1993bc84c9da1e1c86998976a5a316ae72f574d3959a3fc33825eb098edcacb37eb16bb8995efb604197"
    },
    {
      "relation": "hasVariant",
      "source": 794,
      "target": 796,
      "key": "0ac2733708072f3f33af869d4a4b90bd0757ba7fc13a7284fc61c8e52fbe72e1e73bb98c62e537753c60c84d87b375c8c9d522a7bbdc1b95e82fc1cd9f8bf015"
    },
    {
      "relation": "hasVariant",
      "source": 794,
      "target": 795,
      "key": "bdae9cbbdc0cb40d6a55c7612e4870e37cf7c3e4de87614b313edb426f5fc4945941073c2148c8e6238ca7affb58e04ced494cd4e46cf578bd4e40a8f7495f37"
    },
    {
      "line": 571,
      "relation": "directlyIncreases",
      "evidence": "Taken all together, we think that activation of GSK-3b and p38 should be responsible for MG-induced tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 801,
      "target": 825,
      "key": "04bb0fe8acc0f3e384b707b9e124663d1e5b8720bf7833929b60782eaeb31a4b3b85c4607a105a2b96404e697d135ccce10c52b4d45378461d99224c8f46a412"
    },
    {
      "line": 572,
      "relation": "directlyIncreases",
      "evidence": "Taken all together, we think that activation of GSK-3b and p38 should be responsible for MG-induced tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 801,
      "target": 814,
      "key": "3c67c34bd97a2c90b043dccf4cfbeadce4a74e08c82dd6c32bf2f32160d242e5a8fd5ff64749405f4dacc0139acd49ffb7061c811588fbb29f3002728a362206"
    },
    {
      "line": 573,
      "relation": "directlyIncreases",
      "evidence": "Taken all together, we think that activation of GSK-3b and p38 should be responsible for MG-induced tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 801,
      "target": 815,
      "key": "5db8b274243bd5377775a1511d6e726808594ab8b580b1851e40bf6d397f6ff43a6f7c9a26d4392c7d119ce5a815e280d419cde600b2064f30bd8aa6b57f6beb"
    },
    {
      "line": 574,
      "relation": "directlyIncreases",
      "evidence": "Taken all together, we think that activation of GSK-3b and p38 should be responsible for MG-induced tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 801,
      "target": 816,
      "key": "0f4e0d13226d2ca8f6059895d2d9cb037e325cdf5eb066cceb91156ab869ae38f073d971782ff287a9932c421066fad5479716f8ae7accc9a78e5be67db40615"
    },
    {
      "line": 575,
      "relation": "directlyIncreases",
      "evidence": "Taken all together, we think that activation of GSK-3b and p38 should be responsible for MG-induced tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 801,
      "target": 834,
      "key": "0ffe3ff3d2b938fa36fb2989457cc50a1a96a188b0b2e263559b4d822d269b66af28657bd7dc07d96ee54b2e3864eb2a3060374280c4e13e900badc8b013eee8"
    },
    {
      "line": 576,
      "relation": "directlyIncreases",
      "evidence": "Taken all together, we think that activation of GSK-3b and p38 should be responsible for MG-induced tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 801,
      "target": 823,
      "key": "ac1afdb2dfa61f7c5d8c4f207cb5687d35179664b5c547570dd017c33be7f3e0632e60c6bcdbf878d1671f70de35a279f3abca7c2f1db9055a611f695f27e2a2"
    },
    {
      "line": 577,
      "relation": "directlyIncreases",
      "evidence": "Taken all together, we think that activation of GSK-3b and p38 should be responsible for MG-induced tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "22798221",
        "name": "Neuromolecular medicine",
        "title": "Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.",
        "volume": "14",
        "pages": "338-48",
        "date": "2012-12-01",
        "first": "Li XH",
        "last": "Zhou XW",
        "authors": [
          "Cheng XS",
          "Du LL",
          "Jiang X",
          "Li XH",
          "Lv BL",
          "Wang JZ",
          "Xie JZ",
          "Zhang JY",
          "Zhou XW"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true
        },
        "Method": {
          "ELISA": true,
          "Dot Blot": true,
          "Immunofluorescence": true,
          "Western Blot": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 801,
      "target": 831,
      "key": "8f60c582a3db09fe159b166a6ef4409735cdef303055eb6256dbdd53ef69a33e8ded4e90f8e08536755b263c97668d82758b840dce369f9c12af77b976ff6889"
    },
    {
      "line": 595,
      "relation": "increases",
      "evidence": "D-ribosylated Tau aggregates were highly toxic to SHSY5Y cells and resulted in both apoptosis and necrosis",
      "citation": {
        "type": "PubMed",
        "reference": "19517062",
        "name": "Cellular and molecular life sciences : CMLS",
        "title": "D-Ribosylated Tau forms globular aggregates with high cytotoxicity.",
        "volume": "66",
        "pages": "2559-71",
        "date": "2009-08-01",
        "first": "Chen L",
        "last": "He R",
        "authors": [
          "Chen L",
          "He R",
          "Wang X",
          "Wei Y"
        ]
      },
      "annotations": {
        "Method": {
          "NBT colorimetric fructosamine assay": true,
          "Fluorescence Spectrophotometry": true,
          "Cell Viability Assay, MTT": true,
          "Atomic Force Microscopy": true,
          "Flow Cytometry": true
        },
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 325,
      "target": 174,
      "key": "4c73aa81daff7e83152ce1328e8d06976c39067d288020979559b57de3311c847de8a3f4e503493c0b143d440df5a1997e83a16c63f0b4973df7481ad82d5faa"
    },
    {
      "line": 596,
      "relation": "increases",
      "evidence": "D-ribosylated Tau aggregates were highly toxic to SHSY5Y cells and resulted in both apoptosis and necrosis",
      "citation": {
        "type": "PubMed",
        "reference": "19517062",
        "name": "Cellular and molecular life sciences : CMLS",
        "title": "D-Ribosylated Tau forms globular aggregates with high cytotoxicity.",
        "volume": "66",
        "pages": "2559-71",
        "date": "2009-08-01",
        "first": "Chen L",
        "last": "He R",
        "authors": [
          "Chen L",
          "He R",
          "Wang X",
          "Wei Y"
        ]
      },
      "annotations": {
        "Method": {
          "NBT colorimetric fructosamine assay": true,
          "Fluorescence Spectrophotometry": true,
          "Cell Viability Assay, MTT": true,
          "Atomic Force Microscopy": true,
          "Flow Cytometry": true
        },
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 325,
      "target": 187,
      "key": "b2201b26505421a9ac547fe24501fe3a87f8427db2cc61031c71fc6d1d7045e254abe1b6b5e7ea364adbe64910416996f5eedb78407de23d6474f96ed4b9a156"
    },
    {
      "line": 1708,
      "relation": "partOf",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 325,
      "target": 221,
      "key": "433af810669ab4b16a16e866f7fe87d50d4a75c2aab63f333202cfb384600729dbc56861784b3c700999966da63880eeac783b916f3fbce30bef923eb8a81855"
    },
    {
      "line": 1738,
      "relation": "positiveCorrelation",
      "evidence": "Recently, it has been proposed that tau protein acetylation may be responsible for tau aggregation in AD. Grinberg and collaborators detected tau acetylation at Lys274 in all tauopathies (both primary and secondary), except in AgD",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 325,
      "target": 497,
      "key": "cbcd85a7f7322c600d736f64343f92b5c352ea380ac781aeba3fd25c981157d243acd5c28371488bba04e53782aa6bbc7e7a11f14edfbf697e700bba5333e6e3"
    },
    {
      "line": 3361,
      "relation": "positiveCorrelation",
      "evidence": "Our findings indicate that several acetylation sites in tau are responsive to HDAC6 and that acetylation on Lys-321 (within a KCGS motif) is both essential for acetylation-mediated inhibition of tau aggregation in vitro and a molecular tactic for preventing phosphorylation on the downstream Ser-324 residue. Tau phosphorylation of Ser-324 (pSer-324) has not previously been evaluated in the context of tauopathy, and here we observed increased deposition of pSer-324-positive tau both in mouse models of tauopathy and in patients with Alzheimer's disease. These findings uncover a novel acetylation-phosphorylation switch at Lys-321/Ser-324 that coordinately regulates tau polymerization and function.",
      "citation": {
        "type": "PubMed",
        "reference": "28760828",
        "name": "The Journal of biological chemistry",
        "title": "An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.",
        "volume": "292",
        "pages": "15277-15286",
        "date": "2017-09-15",
        "first": "Carlomagno Y",
        "last": "Cook C",
        "authors": [
          "Carlomagno Y",
          "Castanedes-Casey M",
          "Chung DC",
          "Cook C",
          "DeTure M",
          "Dickson DW",
          "Dunmore J",
          "Madden BJ",
          "Petrucelli L",
          "Tong J",
          "Yue M"
        ]
      },
      "source": 325,
      "target": 561,
      "key": "64dc368457911aa66449d9dc2b348d57d8602d88c1835c5b6117908e2eac0eb2c0631a041db1f670726bdd695225ef53a3f90b2fa8fc46deb511dca0c1c4eda7"
    },
    {
      "line": 3591,
      "relation": "positiveCorrelation",
      "evidence": "In the HEK cell biosensor assay, tau from AD cases with plaques enhanced tau aggregates compared to tau from cases without plaques. In APP/PS1 cross with rTg4510 mice (P301L mutant human tau), tau seeding activity was threefold increased over the rTg4510 strain, without change in tau production or extracellular release.",
      "citation": {
        "type": "PubMed",
        "reference": "28500862",
        "name": "The American journal of pathology",
        "title": "Enhanced Tau Aggregation in the Presence of Amyloid β.",
        "volume": "187",
        "pages": "1601-1612",
        "date": "2017-07-01",
        "first": "Bennett RE",
        "last": "Hyman BT",
        "authors": [
          "Bennett RE",
          "Carlson GA",
          "Corjuc B",
          "DeVos SL",
          "Dujardin S",
          "Frosch MP",
          "Gonzalez J",
          "Gor R",
          "Hyman BT",
          "Pitstick R",
          "Roe AD"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "APP/PS1 x rTg4510 mice": true
        }
      },
      "source": 325,
      "target": 11,
      "key": "c50de00beec1a93108eb986d04695138b52aeed4ef3fabbfd3dc73295a2e08497bc5201506a5d2fd05eeb80b68f50b427bcb8b69f4b1793d8bf5491c94cd53ec"
    },
    {
      "line": 591,
      "relation": "increases",
      "evidence": "Tau is rapidly glycated in the presence of D-ribose, resulting in oligomerization and polymerization with Glycated derivatives appearing after 24 h. Advanced glycation end-products (AGEs) were formed during initial stages of glycation. Thioflavin T-positive (ThT-positive) aggregations (day 4) indicated the globular-like features. Atomic force microscopy revealed that the surface morphology of ribosylated Tau40 was globular-like.",
      "citation": {
        "type": "PubMed",
        "reference": "19517062",
        "name": "Cellular and molecular life sciences : CMLS",
        "title": "D-Ribosylated Tau forms globular aggregates with high cytotoxicity.",
        "volume": "66",
        "pages": "2559-71",
        "date": "2009-08-01",
        "first": "Chen L",
        "last": "He R",
        "authors": [
          "Chen L",
          "He R",
          "Wang X",
          "Wei Y"
        ]
      },
      "annotations": {
        "Method": {
          "NBT colorimetric fructosamine assay": true,
          "Fluorescence Spectrophotometry": true,
          "Cell Viability Assay, MTT": true,
          "Atomic Force Microscopy": true,
          "Flow Cytometry": true
        },
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 515,
      "target": 9,
      "key": "abb42fe6d9759934007ab404e6a2b42f4fe14f8b742ac5f61174c1a3bdc97bd9d857c35463877c245908f950fadd0648c8305493a0e8283729f14344ac0d7fd3"
    },
    {
      "line": 592,
      "relation": "partOf",
      "evidence": "Tau is rapidly glycated in the presence of D-ribose, resulting in oligomerization and polymerization with Glycated derivatives appearing after 24 h. Advanced glycation end-products (AGEs) were formed during initial stages of glycation. Thioflavin T-positive (ThT-positive) aggregations (day 4) indicated the globular-like features. Atomic force microscopy revealed that the surface morphology of ribosylated Tau40 was globular-like.",
      "citation": {
        "type": "PubMed",
        "reference": "19517062",
        "name": "Cellular and molecular life sciences : CMLS",
        "title": "D-Ribosylated Tau forms globular aggregates with high cytotoxicity.",
        "volume": "66",
        "pages": "2559-71",
        "date": "2009-08-01",
        "first": "Chen L",
        "last": "He R",
        "authors": [
          "Chen L",
          "He R",
          "Wang X",
          "Wei Y"
        ]
      },
      "annotations": {
        "Method": {
          "NBT colorimetric fructosamine assay": true,
          "Fluorescence Spectrophotometry": true,
          "Cell Viability Assay, MTT": true,
          "Atomic Force Microscopy": true,
          "Flow Cytometry": true
        },
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 515,
      "target": 325,
      "key": "8e66c274a84dd773033a1eb19c798b7b31d46e38e2b8cefbde2a7ab2ebfe115a580675e2d0abbe02567ae14e5fcf10be052e0cb0c30ea2c114554d922f17c390"
    },
    {
      "line": 608,
      "relation": "increases",
      "evidence": "Triosephosphate isomerase (TPI) is a key enzyme in cell metabolism that controls the glycolytic flow and energy production through the interconversion of dihydroxyacetone phosphate (DHAP) and D-glyceraldehyde 3-phosphate (G3P) (Richard, 1993). Notably, TPI is the only glycolytic enzyme whose functional deficiency is associated to neurodegeneration (Eber et al., 1991; Ovadi et al., 2004). In particular, inefficient glycolysis (Hoyer et al., 1988) and ATP depletion (Keil et al., 2004) are characteristic in Alzheimer’s disease brains.",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 763,
      "target": 948,
      "key": "2fe4d3d723416c05dcc8fcc467505db12768032c5b9e2077cd3c24b4eacd00810b6ffa23176ea13ae26cb0faa18b9c6c12e651c6ebc92d38696c5bf86261b518"
    },
    {
      "line": 609,
      "relation": "partOf",
      "evidence": "Triosephosphate isomerase (TPI) is a key enzyme in cell metabolism that controls the glycolytic flow and energy production through the interconversion of dihydroxyacetone phosphate (DHAP) and D-glyceraldehyde 3-phosphate (G3P) (Richard, 1993). Notably, TPI is the only glycolytic enzyme whose functional deficiency is associated to neurodegeneration (Eber et al., 1991; Ovadi et al., 2004). In particular, inefficient glycolysis (Hoyer et al., 1988) and ATP depletion (Keil et al., 2004) are characteristic in Alzheimer’s disease brains.",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        }
      },
      "source": 763,
      "target": 176,
      "key": "672e9508f4bf205b270a761aa3de8c33024aa251ab03eea07798f1b68a4eadd7f3c8bd780753da0eb61ba942d907d0c32cc6f3ff044d6981e37cca24939e671e"
    },
    {
      "line": 610,
      "relation": "negativeCorrelation",
      "evidence": "Triosephosphate isomerase (TPI) is a key enzyme in cell metabolism that controls the glycolytic flow and energy production through the interconversion of dihydroxyacetone phosphate (DHAP) and D-glyceraldehyde 3-phosphate (G3P) (Richard, 1993). Notably, TPI is the only glycolytic enzyme whose functional deficiency is associated to neurodegeneration (Eber et al., 1991; Ovadi et al., 2004). In particular, inefficient glycolysis (Hoyer et al., 1988) and ATP depletion (Keil et al., 2004) are characteristic in Alzheimer’s disease brains.",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 763,
      "target": 143,
      "key": "c83fbcd7980fbe54a4c8369d100fb3770affdbc6677edf3d2110c6fb063798237bba4942ec65e55562840bfd477066f72f9ccd6c59cb0951049c31d5fbe4f8f4"
    },
    {
      "relation": "hasVariant",
      "source": 763,
      "target": 765,
      "key": "9d9a3bf410fae77fc535dc4bd80ff2bcbb6d80de119ba0036b9fbbe1865728c0c34933d62120f992f17d668c48ff16130649caecbc966c6bfb14097c6bcca8cd"
    },
    {
      "relation": "hasVariant",
      "source": 763,
      "target": 766,
      "key": "44b4d34c786b596e76f83d7ed96dfc80a743fe5b371195254abbac32b6a7ba69aed961e0b76c70c727c835925cca9b8c707550e4d3d863e0295490dfb0ba131a"
    },
    {
      "relation": "hasVariant",
      "source": 763,
      "target": 764,
      "key": "47c2282b6581d92b748737f34930d2945c4e2eeeb4b39ad777e3db449a90529b317728cacf3f76944f69fcb011ec60c07ce86a4bc6f1086eb261b98f459c24e7"
    },
    {
      "line": 638,
      "relation": "negativeCorrelation",
      "evidence": "In accordance with the decreased efficiency of nitro-TPI we found a significant increase in methylglyoxal production (P50.05), independent of whether DHAP or GAP was used as substrate (Fig. 2E). Thus, nitrotyrosination of TPI results in reduced catalytic activity and increased occupancy of the enzyme by the substrate, and consequently, a higher production of the toxic methylglyoxal.",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 763,
      "target": 61,
      "key": "3e221d14fbfd1ede9d8df6859999b536ab17a5962d5e5b83929ee2354c31307f069ad1ef9a2e2492110c91dc1fe2de3e71f212434945bfccbf0f79a175ca5975"
    },
    {
      "relation": "hasReactant",
      "source": 948,
      "target": 15,
      "key": "93a3872fa05d531c2ef522bfe8c01f4a591a728986c5f1bdc0f40250f5a99ed2102a7014aafc3cc5c5c98ead3149a31ca86bf281a40f25fdf907295f1355ae93"
    },
    {
      "relation": "hasProduct",
      "source": 948,
      "target": 4,
      "key": "2f4f9034f7a4b33fb66e5d4b563418a6645d8214f27d2127ab3a57cb1b29916d74b43bb8b0b639ac38ef5b9d96ce8e5d393082cfef3ad56d1a31b6dc18de61fd"
    },
    {
      "line": 610,
      "relation": "negativeCorrelation",
      "evidence": "Triosephosphate isomerase (TPI) is a key enzyme in cell metabolism that controls the glycolytic flow and energy production through the interconversion of dihydroxyacetone phosphate (DHAP) and D-glyceraldehyde 3-phosphate (G3P) (Richard, 1993). Notably, TPI is the only glycolytic enzyme whose functional deficiency is associated to neurodegeneration (Eber et al., 1991; Ovadi et al., 2004). In particular, inefficient glycolysis (Hoyer et al., 1988) and ATP depletion (Keil et al., 2004) are characteristic in Alzheimer’s disease brains.",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 143,
      "target": 763,
      "key": "2908000778cc99a7a52c088fb74109de77245252c593af692ddf30965c7aea561579f90a6629744e1677978165e8f4ef7c923d36243f2da7f39307acc093f429"
    },
    {
      "line": 2759,
      "relation": "positiveCorrelation",
      "evidence": "Using transgenic Drosophila expressing human tau, we found that RNAi-mediated knockdown of milton or Miro, an adaptor protein essential for axonal transport of mitochondria, enhanced human tau-induced neurodegeneration. Tau phosphorylation at an AD-related site Ser262 increased with knockdown of milton or Miro; and partitioning defective-1 (PAR-1), the Drosophila homolog of mammalian microtubule affinity-regulating kinase, mediated this increase of tau phosphorylation. Tau phosphorylation at Ser262 has been reported to promote tau detachment from microtubules, and we found that the levels of microtubule-unbound free tau increased by milton knockdown. Blocking tau phosphorylation at Ser262 site by PAR-1 knockdown or by mutating the Ser262 site to unphosphorylatable alanine suppressed the enhancement of tau-induced neurodegeneration caused by milton knockdown. Furthermore, knockdown of milton or Miro increased the levels of active PAR-1.",
      "citation": {
        "type": "PubMed",
        "reference": "22952452",
        "name": "PLoS genetics",
        "title": "Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1.",
        "volume": "8",
        "pages": "e1002918",
        "date": "2012-01-01",
        "first": "Iijima-Ando K",
        "last": "Iijima KM",
        "authors": [
          "Iijima KM",
          "Iijima-Ando K",
          "Lu B",
          "Maruko-Otake A",
          "Ohtake Y",
          "Sekiya M",
          "Suzuki E"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "source": 143,
      "target": 557,
      "key": "c525077e7344a009bc819a71316d1dbd018d7b1015b7c9604f85d9e39c7e48bd711df865a33ffc7a23c912a0269214f367e9fcf59981e2a9a6ec3711afa494ac"
    },
    {
      "line": 622,
      "relation": "positiveCorrelation",
      "evidence": "Ab induced nitro-oxidative stress on human neuroblastoma cells, resulting in nitrotyrosination of TPI. Moreover, higher levels of nitro-TPI were also detected in extracts from hippocampus (Fig. 1F) and frontal cortex (Fig. 1G) obtained from Alzheimer’s disease brains, compared with healthy subjects.",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "frontal cortex": true,
          "hippocampal formation": true
        }
      },
      "source": 765,
      "target": 908,
      "key": "1d63bdb205ab721d7e64f24f655916f3b3281d85cce50fd937819c3d85ffb0e8bf5706d4c484718426a0a6bf80a43d35927267a4ece7921f12423dbb41372cf0"
    },
    {
      "line": 630,
      "relation": "decreases",
      "evidence": "Nitration of Tyr164 and Tyr208 would destabilize the closed state of loop 6 because the interaction between Tyr208 and Ala176 through an H-bond would be compromised (Fig. 2A and B; Supplementary Fig. S2). Indeed, purified TPI after nitrotyrosination with a peroxynitrite donor (SIN-1) displayed a significant decrease in isomerase activity in both directions of the catalysis, i.e. using DHAP (Fig. 2C) or GAP (Fig. 2D) as substrate.",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 765,
      "target": 763,
      "key": "49c11cb3f5c3fde46530391c4ea1e8e8dd058a3a02eff2ea504298f6f2f6332fcb9dba11a051a12a415fa86b90c06a87f1a02f83f9d6f2a719f53fba0fdd187a"
    },
    {
      "line": 633,
      "relation": "isA",
      "evidence": "Nitration of Tyr164 and Tyr208 would destabilize the closed state of loop 6 because the interaction between Tyr208 and Ala176 through an H-bond would be compromised (Fig. 2A and B; Supplementary Fig. S2). Indeed, purified TPI after nitrotyrosination with a peroxynitrite donor (SIN-1) displayed a significant decrease in isomerase activity in both directions of the catalysis, i.e. using DHAP (Fig. 2C) or GAP (Fig. 2D) as substrate.",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        }
      },
      "source": 765,
      "target": 764,
      "key": "b7a7cac9a86d0d407c939a7b1331d112d8a4cbfa09283bda5d4f88d5b0c42045544c7c5eaea467f24d0e320163984b6586e6312e4e9060f6e52807c32b1a5771"
    },
    {
      "line": 623,
      "relation": "positiveCorrelation",
      "evidence": "Ab induced nitro-oxidative stress on human neuroblastoma cells, resulting in nitrotyrosination of TPI. Moreover, higher levels of nitro-TPI were also detected in extracts from hippocampus (Fig. 1F) and frontal cortex (Fig. 1G) obtained from Alzheimer’s disease brains, compared with healthy subjects.",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "frontal cortex": true,
          "hippocampal formation": true
        }
      },
      "source": 766,
      "target": 908,
      "key": "725c5e6d43edd1ff2a999c77cb239eadb631e7981e9db1155b05f0b3350ef6d413544c3bef703fa8f9f020816c29d393a851d6e3eddd16d8192a87ccc8fa4dd0"
    },
    {
      "line": 631,
      "relation": "decreases",
      "evidence": "Nitration of Tyr164 and Tyr208 would destabilize the closed state of loop 6 because the interaction between Tyr208 and Ala176 through an H-bond would be compromised (Fig. 2A and B; Supplementary Fig. S2). Indeed, purified TPI after nitrotyrosination with a peroxynitrite donor (SIN-1) displayed a significant decrease in isomerase activity in both directions of the catalysis, i.e. using DHAP (Fig. 2C) or GAP (Fig. 2D) as substrate.",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 766,
      "target": 763,
      "key": "4f80c05ab1447e4debde901250c2b9fdf1f9eba35a024fc1141da2a275dfc813008fa3c5b89e9a228ad7e3503f7e36c0c1c653b4c1b176554ff33cbeed22e674"
    },
    {
      "line": 632,
      "relation": "isA",
      "evidence": "Nitration of Tyr164 and Tyr208 would destabilize the closed state of loop 6 because the interaction between Tyr208 and Ala176 through an H-bond would be compromised (Fig. 2A and B; Supplementary Fig. S2). Indeed, purified TPI after nitrotyrosination with a peroxynitrite donor (SIN-1) displayed a significant decrease in isomerase activity in both directions of the catalysis, i.e. using DHAP (Fig. 2C) or GAP (Fig. 2D) as substrate.",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        }
      },
      "source": 766,
      "target": 764,
      "key": "66b7668d28610ddba0f5cd2dcfb2b8fd71f7d67dad3ca57c1cc5fb3edd011586851be443f304d660687560898646204ce2a3a33ee6f08c15def028101e00744e"
    },
    {
      "line": 643,
      "relation": "association",
      "evidence": "Taupositive material was present in the immunoprecipitates indicating that tau becomes associated to nitroTPI in an Ab dose-dependent pattern (Fig. 5A).TPI and nitro-TPI were incubated with tau protein and samples were analysed by Atomic Force Microscopy (Fig. 7A–D) and TEM (Fig. 7F and G). Abundant paired helical filament-like structures were found in samples containing nitro-TPI plus tau",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        }
      },
      "source": 764,
      "target": 486,
      "key": "118878467b960c28ffc618a094f55874bf19b60762ea467ebf638dfc22eedf22665b7a6a327b8d9985f9b88601541d4690951dacf0f14d0bbb66df5200810b7c"
    },
    {
      "line": 645,
      "relation": "partOf",
      "evidence": "Taupositive material was present in the immunoprecipitates indicating that tau becomes associated to nitroTPI in an Ab dose-dependent pattern (Fig. 5A).TPI and nitro-TPI were incubated with tau protein and samples were analysed by Atomic Force Microscopy (Fig. 7A–D) and TEM (Fig. 7F and G). Abundant paired helical filament-like structures were found in samples containing nitro-TPI plus tau",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        }
      },
      "source": 764,
      "target": 239,
      "key": "96f38020ec1318a970b9e6d51b0f199e4b83ae4836997cf715ab6fdb4f07a48c529123728705e83eccdbb27814f5c3edf19f6bc98be92f5ab4aa45ec9439f3da"
    },
    {
      "relation": "hasComponent",
      "source": 239,
      "target": 486,
      "key": "d219b880e82975a633f73c3039dcafe24a84fde30391e97ecca5b657ad1a05a6f38fe833b97b6bffbf3e31df33c59168ae7c94422b756989e3cc2ffa4c739f6f"
    },
    {
      "relation": "hasComponent",
      "source": 239,
      "target": 764,
      "key": "6f28c1eba78448ef4835cf29d30dff4df877579871530350e72845c5b93d9a3cee4f670a32828fe9c564a9e1842f436f698f69e3151e95d8a539221ae79383bf"
    },
    {
      "line": 646,
      "relation": "positiveCorrelation",
      "evidence": "Taupositive material was present in the immunoprecipitates indicating that tau becomes associated to nitroTPI in an Ab dose-dependent pattern (Fig. 5A).TPI and nitro-TPI were incubated with tau protein and samples were analysed by Atomic Force Microscopy (Fig. 7A–D) and TEM (Fig. 7F and G). Abundant paired helical filament-like structures were found in samples containing nitro-TPI plus tau",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        }
      },
      "source": 239,
      "target": 11,
      "key": "184a9148cba1d4e371b97e76aa4c674933f591b7ffb7b9350edff73d08810fff7d6b86ee7746a7ce02a675e977b6b06650a2d1bf9c24cd2481cb72319899c4e0"
    },
    {
      "line": 647,
      "relation": "partOf",
      "evidence": "Taupositive material was present in the immunoprecipitates indicating that tau becomes associated to nitroTPI in an Ab dose-dependent pattern (Fig. 5A).TPI and nitro-TPI were incubated with tau protein and samples were analysed by Atomic Force Microscopy (Fig. 7A–D) and TEM (Fig. 7F and G). Abundant paired helical filament-like structures were found in samples containing nitro-TPI plus tau",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        }
      },
      "source": 239,
      "target": 81,
      "key": "e1f36e17dcb9f4ede67576360431c06c17ccbfc2524a8f7681adf516ed490adfe0ae7a7b4d60ee752c6c43b2787c73bd5c6556263a6987b405f6f1ae891e9305"
    },
    {
      "line": 646,
      "relation": "positiveCorrelation",
      "evidence": "Taupositive material was present in the immunoprecipitates indicating that tau becomes associated to nitroTPI in an Ab dose-dependent pattern (Fig. 5A).TPI and nitro-TPI were incubated with tau protein and samples were analysed by Atomic Force Microscopy (Fig. 7A–D) and TEM (Fig. 7F and G). Abundant paired helical filament-like structures were found in samples containing nitro-TPI plus tau",
      "citation": {
        "type": "PubMed",
        "reference": "19251756",
        "name": "Brain : a journal of neurology",
        "title": "Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.",
        "volume": "132",
        "pages": "1335-45",
        "date": "2009-05-01",
        "first": "Guix FX",
        "last": "Muñoz FJ",
        "authors": [
          "Bravo R",
          "Coma M",
          "Fernàndez-Busquets X",
          "Guix FX",
          "Ill-Raga G",
          "Miscione GP",
          "Muñoz FJ",
          "Nakaya T",
          "Suzuki T",
          "Valverde MA",
          "Villà-Freixa J",
          "de Fabritiis G",
          "de Strooper B"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true,
          "Turbidometric Analysis": true,
          "Atomic Force Microscopy": true,
          "Immunofluorescence": true,
          "Confocal Microscopy": true,
          "Electron Microscopy, Transmission": true,
          "Immunoprecipitation": true
        }
      },
      "source": 11,
      "target": 239,
      "key": "ba45d8e28e570f7957d08d6d3612dec97b590fa4b05fc0e3d59f007965d60439628312bffd507f823d94c0d302b77a0da0ab82a900ad7c6b9d8965b7882c1679"
    },
    {
      "line": 910,
      "relation": "increases",
      "evidence": "During Abeta-associated inflammation, reactive nitrogen and oxygen species are generated that can cause neuronal dysfunction and death (34-37). Prevalent among these species is peroxynitrite (ONOO-)",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "source": 11,
      "target": 184,
      "key": "adc49964dd909bc8b69559fc46845f1182891383f92bc114d65651adabdaee96a7bd02fd8b29dd185b9a3950192fd72e9ab53d817ab728a7a7f4dc4538c960f3"
    },
    {
      "line": 2056,
      "relation": "negativeCorrelation",
      "evidence": "Normalizing the gene dosage of Dyrk1A in the TS mouse rescued the density of senescent cells in the cingulate cortex, hippocampus and septum, prevented cholinergic neuron degeneration, and reduced App expression in the hippocampus, Aß load in the cortex and hippocampus, the expression of phosphorylated tau at the Ser202 residue in the hippocampus and cerebellum and the levels of total tau in the cortex, hippocampus and cerebellum.",
      "citation": {
        "type": "PubMed",
        "reference": "29221819",
        "name": "Neurobiology of disease",
        "title": "Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.",
        "volume": "110",
        "pages": "206-217",
        "date": "2018-02-01",
        "first": "García-Cerro S",
        "last": "Martínez-Cué C",
        "authors": [
          "Berciano MT",
          "García-Cerro S",
          "Lafarga M",
          "Lantigua S",
          "Martínez-Cué C",
          "Padro D",
          "Ramos-Cabrer P",
          "Rueda N",
          "Vidal V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        },
        "Anatomy": {
          "hippocampal formation": true,
          "cerebral cortex": true
        }
      },
      "source": 11,
      "target": 786,
      "key": "36803efd04349623b63dccf386af4c9599e84216f8fd9d55f5486c897402a3ebe0018357ebaad3bba6ecad09a381a4963a322b0ed493d856b7d7a11cbd20d797"
    },
    {
      "line": 2258,
      "relation": "positiveCorrelation",
      "evidence": "We further validated Syk as a target-regulating Aβ by showing that pharmacological inhibition of Syk or down-regulation of Syk expression reduces Aβ production and increases the clearance of Aβ across the BBB mimicking (-)-nilvadipine effects. Moreover, treatment of transgenic mice overexpressing Aβ and transgenic Tau P301S mice with a selective Syk inhibitor respectively decreased brain Aβ accumulation and Tau hyperphosphorylation at multiple AD relevant epitopes.",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 11,
      "target": 851,
      "key": "49aed4a305db9f5fc55dab97a55066e61cf2986fb23a5e6bcab6497fa3a7ee6d6783fdcaa1a3839ac491b8f51874ebecb4367b6fa6f084f9373af4a366890689"
    },
    {
      "line": 2349,
      "relation": "negativeCorrelation",
      "evidence": "Chronic Brain hypoperfusion (CBH) elevates nuclear factor-kB (NF-kB), which binds with the promoter sequences of miR-195 and negatively regulates its expression. Down-regulated miR-195 up-regulates APP and BACE1 and increases Aß levels. Some Aß then enter the intracellular space and activate calpain, promoting the conversion of Cdk5/p35 to Cdk5/p25 and catalyzes the degradation of IkB (inhibitor of NF-?B)and directly phosphorylates Tau. Down-regulated miR-195 up-regulates p35, which provides the active substrates of p25",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 11,
      "target": 264,
      "key": "0568ac99981a7461a3db287558036d2278f87e3627ba03b4eae13539b92719a15bdd0ddf4c3f82eae3538fa4a081bd967bdc2a7ded6690af6acb456d253f735c"
    },
    {
      "line": 2350,
      "relation": "increases",
      "evidence": "Chronic Brain hypoperfusion (CBH) elevates nuclear factor-kB (NF-kB), which binds with the promoter sequences of miR-195 and negatively regulates its expression. Down-regulated miR-195 up-regulates APP and BACE1 and increases Aß levels. Some Aß then enter the intracellular space and activate calpain, promoting the conversion of Cdk5/p35 to Cdk5/p25 and catalyzes the degradation of IkB (inhibitor of NF-?B)and directly phosphorylates Tau. Down-regulated miR-195 up-regulates p35, which provides the active substrates of p25",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 11,
      "target": 760,
      "key": "760aefcb7e5137db1b343f93c950290451cb09efc05228127a1a6216fe6e05cb7639d348b1f93e6a4562340dc4bd7ed380bf4734092122ccc8479201b07c9e7c"
    },
    {
      "line": 2692,
      "relation": "increases",
      "evidence": "Consistent with previous reports (11,34), treatment of rat hippocampal neurons with synthetic Aβ, prepared using a well-characterized procedure that enriches for Aβ oligomers (37), resulted in increased tau phosphorylation at the 12E8 sites (Fig. 2A), suggesting that Aβ treatment had activated MARK kinases. Increased phosphorylation of tau at a site recognized by the PHF-1 phospho-tau antibody was also observed (data not shown).",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 11,
      "target": 635,
      "key": "3ffd286a41025ace84926a6619b17832faabe76a890dae838619f783511d9450b4617e2d05f362baf14680818dece58e8b70af361a34d5a42af87d099f183f75"
    },
    {
      "line": 2693,
      "relation": "positiveCorrelation",
      "evidence": "Consistent with previous reports (11,34), treatment of rat hippocampal neurons with synthetic Aβ, prepared using a well-characterized procedure that enriches for Aβ oligomers (37), resulted in increased tau phosphorylation at the 12E8 sites (Fig. 2A), suggesting that Aβ treatment had activated MARK kinases. Increased phosphorylation of tau at a site recognized by the PHF-1 phospho-tau antibody was also observed (data not shown).",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 11,
      "target": 117,
      "key": "05848719e271780a186556f64bb99893ac17a64b1f019938fa684e865b55047f3f5d343ca7384a359f58633d10849b1282d9626c91cfe8f74a0119876adda495"
    },
    {
      "line": 2866,
      "relation": "positiveCorrelation",
      "evidence": "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24401760",
        "name": "Brain : a journal of neurology",
        "title": "Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.",
        "volume": "137",
        "pages": "537-52",
        "date": "2014-02-01",
        "first": "Stygelbout V",
        "last": "Brion JP",
        "authors": [
          "Ando K",
          "Brion JP",
          "D'Amico E",
          "Duyckaerts C",
          "Erneux C",
          "Jia Y",
          "Leroy K",
          "Luo HR",
          "Pouillon V",
          "Schurmans S",
          "Stygelbout V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Cell_Line": {
          "N2a": true
        }
      },
      "source": 11,
      "target": 771,
      "key": "f0782595fd697586a41e84439ccaff8e214622b044cebc7eb59f3b826d2e5900ee3035f4f8213e525a9f2ac375cf4959bb1860de98db874ebee23bd35106c10c"
    },
    {
      "line": 3128,
      "relation": "negativeCorrelation",
      "evidence": "We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter, thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties. We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo. These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo.",
      "citation": {
        "type": "PubMed",
        "reference": "28855586",
        "name": "Scientific reports",
        "title": "Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity.",
        "volume": "7",
        "pages": "9984",
        "date": "2017-08-30",
        "first": "Gorsky MK",
        "last": "Partridge L",
        "authors": [
          "Augustin H",
          "Burnouf S",
          "Dols J",
          "Gorsky MK",
          "Grönke S",
          "Partridge L",
          "Sofola-Adesakin O",
          "Weigelt CM"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 11,
      "target": 247,
      "key": "f72b2ab9c112b42ce234e1928e99c67b32ddfe49865e7ee7c28d28dcc9e2d826ee69fcee5c52f92ba297f70abca3f873fc23b42899cbc8acbda791de90a79940"
    },
    {
      "line": 3490,
      "relation": "increases",
      "evidence": "Furthermore, the enhanced SUMO-immunoreactivity, costained with the hyperphosphorylated tau, is detected in cerebral cortex of the AD brains, and β-amyloid exposure of rat primary hippocampal neurons induces a dose-dependent SUMOylation of the hyperphosphorylated tau. Our findings suggest that tau SUMOylation reciprocally stimulates its phosphorylation and inhibits the ubiquitination-mediated tau degradation, which provides a new insight into the AD-like tau accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "25378699",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination.",
        "volume": "111",
        "pages": "16586-91",
        "date": "2014-11-18",
        "first": "Luo HB",
        "last": "Wang JZ",
        "authors": [
          "Feng Y",
          "Jiang J",
          "Liu XH",
          "Liu ZC",
          "Luo HB",
          "Shu XJ",
          "Wang JZ",
          "Wang XC",
          "Xia YY",
          "Xiong YS",
          "Ye K",
          "Yin G",
          "Yu G",
          "Zeng K"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 11,
      "target": 886,
      "key": "c263b6b02720dbca8c09968f3a267bf7678e093a06a33fa9cd187d90b5128d56e9fb584c133a6d0ca642a494020e104b2c489b935460da378ed78ac71f15885a"
    },
    {
      "line": 3591,
      "relation": "positiveCorrelation",
      "evidence": "In the HEK cell biosensor assay, tau from AD cases with plaques enhanced tau aggregates compared to tau from cases without plaques. In APP/PS1 cross with rTg4510 mice (P301L mutant human tau), tau seeding activity was threefold increased over the rTg4510 strain, without change in tau production or extracellular release.",
      "citation": {
        "type": "PubMed",
        "reference": "28500862",
        "name": "The American journal of pathology",
        "title": "Enhanced Tau Aggregation in the Presence of Amyloid β.",
        "volume": "187",
        "pages": "1601-1612",
        "date": "2017-07-01",
        "first": "Bennett RE",
        "last": "Hyman BT",
        "authors": [
          "Bennett RE",
          "Carlson GA",
          "Corjuc B",
          "DeVos SL",
          "Dujardin S",
          "Frosch MP",
          "Gonzalez J",
          "Gor R",
          "Hyman BT",
          "Pitstick R",
          "Roe AD"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "APP/PS1 x rTg4510 mice": true
        }
      },
      "source": 11,
      "target": 325,
      "key": "2a3b9a94af9db894289227ef4622cd38eda6d84468de47bc2e6265036bdb6b9f640928ed6502270dbc5d6d2c948e6f6c523a56641b39400758e305432277607d"
    },
    {
      "line": 656,
      "relation": "increases",
      "evidence": "Collectively, these studies demonstrate that the soluble, astroglial-derived S100B protein interacts with RAGE leading to the JNK phosphorylation and the pJNK-dependent up-regulation of c-Jun, a component of the AP-1 complex.",
      "citation": {
        "type": "PubMed",
        "reference": "18494933",
        "name": "Journal of cellular and molecular medicine",
        "title": "S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells.",
        "volume": "12",
        "pages": "914-27",
        "date": "2008-06-01",
        "first": "Esposito G",
        "last": "Steardo L",
        "authors": [
          "De Filippis D",
          "Esposito G",
          "Iuvone T",
          "Lu J",
          "Savani C",
          "Scuderi C",
          "Sheen V",
          "Steardo L",
          "Steardo L Jr"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "neural stem cell": true
        },
        "Method": {
          "Electrophoretic Mobility Shift Assay": true,
          "Western Blot": true,
          "RT-PCR": true,
          "Immunofluorescence": true,
          "RNA Interference, siRNA": true
        }
      },
      "source": 673,
      "target": 292,
      "key": "48b2dc57989214d0dc8c6f19f478fcfbaf8d8de54b98204e7f59af4ab1b8896bc4f4998b8cd9f92bd2eb7c3444f99171176829fcf0d9a81f079b0a23d374eb62"
    },
    {
      "line": 658,
      "relation": "directlyIncreases",
      "evidence": "Collectively, these studies demonstrate that the soluble, astroglial-derived S100B protein interacts with RAGE leading to the JNK phosphorylation and the pJNK-dependent up-regulation of c-Jun, a component of the AP-1 complex.",
      "citation": {
        "type": "PubMed",
        "reference": "18494933",
        "name": "Journal of cellular and molecular medicine",
        "title": "S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells.",
        "volume": "12",
        "pages": "914-27",
        "date": "2008-06-01",
        "first": "Esposito G",
        "last": "Steardo L",
        "authors": [
          "De Filippis D",
          "Esposito G",
          "Iuvone T",
          "Lu J",
          "Savani C",
          "Scuderi C",
          "Sheen V",
          "Steardo L",
          "Steardo L Jr"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "neural stem cell": true
        },
        "Method": {
          "Electrophoretic Mobility Shift Assay": true,
          "Western Blot": true,
          "RT-PCR": true,
          "Immunofluorescence": true,
          "RNA Interference, siRNA": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 673,
      "target": 371,
      "key": "475311e87477b9f975246ce80b035369befaaa12c7a67be86bc700b3e8e71102255676955c6c6aa6d03c77df5f3e577073341d7f68fbfb06becaf80c0fdab322"
    },
    {
      "line": 669,
      "relation": "decreases",
      "evidence": "In addition, as revealed by Western blot, small interfering RNA and immunofluorescence analysis, S100B-induced JNK activation increased expression of Dickopff-1 that, in turn, promoted glycogen synthase kinase 3-beta phosphorylation and beta-catenin degradation, causing canonical Wnt pathway disruption and tau protein hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "18494933",
        "name": "Journal of cellular and molecular medicine",
        "title": "S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells.",
        "volume": "12",
        "pages": "914-27",
        "date": "2008-06-01",
        "first": "Esposito G",
        "last": "Steardo L",
        "authors": [
          "De Filippis D",
          "Esposito G",
          "Iuvone T",
          "Lu J",
          "Savani C",
          "Scuderi C",
          "Sheen V",
          "Steardo L",
          "Steardo L Jr"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "neural stem cell": true
        },
        "Method": {
          "Electrophoretic Mobility Shift Assay": true,
          "Western Blot": true,
          "RT-PCR": true,
          "Immunofluorescence": true,
          "RNA Interference, siRNA": true
        }
      },
      "source": 673,
      "target": 170,
      "key": "60dc743c75eca2bee8c766f626e8bf14559d9d84d2d34b2162ed5e34b855bc468ca8be77d25d9d6ba1f9d991e0010599cc065ce3f78c55f1088c2a951c01b38e"
    },
    {
      "line": 670,
      "relation": "increases",
      "evidence": "In addition, as revealed by Western blot, small interfering RNA and immunofluorescence analysis, S100B-induced JNK activation increased expression of Dickopff-1 that, in turn, promoted glycogen synthase kinase 3-beta phosphorylation and beta-catenin degradation, causing canonical Wnt pathway disruption and tau protein hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "18494933",
        "name": "Journal of cellular and molecular medicine",
        "title": "S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells.",
        "volume": "12",
        "pages": "914-27",
        "date": "2008-06-01",
        "first": "Esposito G",
        "last": "Steardo L",
        "authors": [
          "De Filippis D",
          "Esposito G",
          "Iuvone T",
          "Lu J",
          "Savani C",
          "Scuderi C",
          "Sheen V",
          "Steardo L",
          "Steardo L Jr"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "neural stem cell": true
        },
        "Method": {
          "Electrophoretic Mobility Shift Assay": true,
          "Western Blot": true,
          "RT-PCR": true,
          "Immunofluorescence": true,
          "RNA Interference, siRNA": true
        }
      },
      "source": 673,
      "target": 538,
      "key": "076a7b245cb524a5362115a7cd09e9ab116d97020e145b2804f4148fbbd7e2fec6c64f1656bcbaba797cc0a4e76b6e40758c350804e8ac794d98c149e54c1070"
    },
    {
      "line": 657,
      "relation": "positiveCorrelation",
      "evidence": "Collectively, these studies demonstrate that the soluble, astroglial-derived S100B protein interacts with RAGE leading to the JNK phosphorylation and the pJNK-dependent up-regulation of c-Jun, a component of the AP-1 complex.",
      "citation": {
        "type": "PubMed",
        "reference": "18494933",
        "name": "Journal of cellular and molecular medicine",
        "title": "S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells.",
        "volume": "12",
        "pages": "914-27",
        "date": "2008-06-01",
        "first": "Esposito G",
        "last": "Steardo L",
        "authors": [
          "De Filippis D",
          "Esposito G",
          "Iuvone T",
          "Lu J",
          "Savani C",
          "Scuderi C",
          "Sheen V",
          "Steardo L",
          "Steardo L Jr"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "neural stem cell": true
        },
        "Method": {
          "Electrophoretic Mobility Shift Assay": true,
          "Western Blot": true,
          "RT-PCR": true,
          "Immunofluorescence": true,
          "RNA Interference, siRNA": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 292,
      "target": 291,
      "key": "57abe755b05e9392a2b05dd44b19c77f0d0164f6a0df19cbc5f3e2b2df7fb3d6c8ff8d706a9601e31979df7fa9197cb95c92bce33c6090b773c628bc669ec52f"
    },
    {
      "relation": "hasVariant",
      "source": 291,
      "target": 292,
      "key": "17933e508d51db48f42ef35a908a9586a2a37a9dcec7203d400738956906f68d76a83da041475ddc1afe0db6c1d3b7f5e8d8f63861c3be3c70576651faeb6d99"
    },
    {
      "line": 657,
      "relation": "positiveCorrelation",
      "evidence": "Collectively, these studies demonstrate that the soluble, astroglial-derived S100B protein interacts with RAGE leading to the JNK phosphorylation and the pJNK-dependent up-regulation of c-Jun, a component of the AP-1 complex.",
      "citation": {
        "type": "PubMed",
        "reference": "18494933",
        "name": "Journal of cellular and molecular medicine",
        "title": "S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells.",
        "volume": "12",
        "pages": "914-27",
        "date": "2008-06-01",
        "first": "Esposito G",
        "last": "Steardo L",
        "authors": [
          "De Filippis D",
          "Esposito G",
          "Iuvone T",
          "Lu J",
          "Savani C",
          "Scuderi C",
          "Sheen V",
          "Steardo L",
          "Steardo L Jr"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "neural stem cell": true
        },
        "Method": {
          "Electrophoretic Mobility Shift Assay": true,
          "Western Blot": true,
          "RT-PCR": true,
          "Immunofluorescence": true,
          "RNA Interference, siRNA": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 291,
      "target": 292,
      "key": "83a71c2b4b5ab2120d3b58ee77aff42e8cd20c10b2084d791b8e5f4783e658b82f106949928aaf1301bcaf4ff7e36aafd44271739c5de7316ee7bcd8786d75e9"
    },
    {
      "line": 666,
      "relation": "increases",
      "evidence": "In addition, as revealed by Western blot, small interfering RNA and immunofluorescence analysis, S100B-induced JNK activation increased expression of Dickopff-1 that, in turn, promoted glycogen synthase kinase 3-beta phosphorylation and beta-catenin degradation, causing canonical Wnt pathway disruption and tau protein hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "18494933",
        "name": "Journal of cellular and molecular medicine",
        "title": "S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells.",
        "volume": "12",
        "pages": "914-27",
        "date": "2008-06-01",
        "first": "Esposito G",
        "last": "Steardo L",
        "authors": [
          "De Filippis D",
          "Esposito G",
          "Iuvone T",
          "Lu J",
          "Savani C",
          "Scuderi C",
          "Sheen V",
          "Steardo L",
          "Steardo L Jr"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "neural stem cell": true
        },
        "Method": {
          "Electrophoretic Mobility Shift Assay": true,
          "Western Blot": true,
          "RT-PCR": true,
          "Immunofluorescence": true,
          "RNA Interference, siRNA": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 291,
      "target": 437,
      "key": "bcc2ed7cbede70bc76b340d42cdfbe856f33b952306f05e842351679c3b8c6625fb2358c8e70f412af110687ea4b4dcb5359926f88e7f79d87a64a7ce2de4951"
    },
    {
      "line": 1920,
      "relation": "positiveCorrelation",
      "evidence": "Overexpression of wild-type UNC5C causes low-grade death, intensified by an AD-linked mutation T835M inhibited by a AD-linked survival factor, calmodulin-like skin protein (CLSP), and a natural ligand of UNC5C, netrin1. T835M-UNC5C-induced neuronal cell death is mediated by an intracellular death-signaling cascade, consisting of DAPK1/protein kinase D/apoptosis signal-regulating kinase 1 (ASK1)/JNK/NADPH oxidase/caspases, which merges at ASK1 with a death-signaling cascade, mediated by amyloid ß precursor protein (APP).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 291,
      "target": 266,
      "key": "fb940f08c5271e64aabd23a2e4f9acb5b3728ed5bf4f712236cc88fe7e2c6a1d02c4705e21bc428a252d3e1a9d92daddbb4c83c5dffe69cacf090e64d787793c"
    },
    {
      "line": 1921,
      "relation": "association",
      "evidence": "Overexpression of wild-type UNC5C causes low-grade death, intensified by an AD-linked mutation T835M inhibited by a AD-linked survival factor, calmodulin-like skin protein (CLSP), and a natural ligand of UNC5C, netrin1. T835M-UNC5C-induced neuronal cell death is mediated by an intracellular death-signaling cascade, consisting of DAPK1/protein kinase D/apoptosis signal-regulating kinase 1 (ASK1)/JNK/NADPH oxidase/caspases, which merges at ASK1 with a death-signaling cascade, mediated by amyloid ß precursor protein (APP).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 291,
      "target": 397,
      "key": "f93854d12c927eb1b60611586cef21b38f60c878116b9305e578c1be5f54f2d21ccfc3b422a5176469257a63a4ee6fe9061e82f4ba36a33ad9df8ed8c2284a78"
    },
    {
      "line": 660,
      "relation": "increases",
      "evidence": "Collectively, these studies demonstrate that the soluble, astroglial-derived S100B protein interacts with RAGE leading to the JNK phosphorylation and the pJNK-dependent up-regulation of c-Jun, a component of the AP-1 complex.",
      "citation": {
        "type": "PubMed",
        "reference": "18494933",
        "name": "Journal of cellular and molecular medicine",
        "title": "S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells.",
        "volume": "12",
        "pages": "914-27",
        "date": "2008-06-01",
        "first": "Esposito G",
        "last": "Steardo L",
        "authors": [
          "De Filippis D",
          "Esposito G",
          "Iuvone T",
          "Lu J",
          "Savani C",
          "Scuderi C",
          "Sheen V",
          "Steardo L",
          "Steardo L Jr"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "neural stem cell": true
        },
        "Method": {
          "Electrophoretic Mobility Shift Assay": true,
          "Western Blot": true,
          "RT-PCR": true,
          "Immunofluorescence": true,
          "RNA Interference, siRNA": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 484,
      "target": 483,
      "key": "a5772165222239fdea3fef1dd6e7b78fd6dfd064a7322c7fb9063a459102bacfbabaff912fa55c2a9b71965cf096cd309cfccd68b19bfe1cc673c2c53c0d2403"
    },
    {
      "relation": "hasVariant",
      "source": 483,
      "target": 484,
      "key": "afd3e53bbee6da817643299a48701f08e0c43f5df7546657ff3bc186ea2a9e76dd3db29973de6515b70c24ba4aaaa88511cb574d07ae527b1ec19823f0bbcc42"
    },
    {
      "line": 661,
      "relation": "increases",
      "evidence": "Collectively, these studies demonstrate that the soluble, astroglial-derived S100B protein interacts with RAGE leading to the JNK phosphorylation and the pJNK-dependent up-regulation of c-Jun, a component of the AP-1 complex.",
      "citation": {
        "type": "PubMed",
        "reference": "18494933",
        "name": "Journal of cellular and molecular medicine",
        "title": "S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells.",
        "volume": "12",
        "pages": "914-27",
        "date": "2008-06-01",
        "first": "Esposito G",
        "last": "Steardo L",
        "authors": [
          "De Filippis D",
          "Esposito G",
          "Iuvone T",
          "Lu J",
          "Savani C",
          "Scuderi C",
          "Sheen V",
          "Steardo L",
          "Steardo L Jr"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "neural stem cell": true
        },
        "Method": {
          "Electrophoretic Mobility Shift Assay": true,
          "Western Blot": true,
          "RT-PCR": true,
          "Immunofluorescence": true,
          "RNA Interference, siRNA": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 483,
      "target": 461,
      "key": "e569f0c4d5d65429fba971a351afa1de50780410dfad97ffe1ca3d024b0002b453134fee7097bdee6f986bf536548cebb77449b6654fc80760b9a55af51b3281"
    },
    {
      "line": 1506,
      "relation": "increases",
      "evidence": "All five SAP kinases generated the AT270 epitope, indicative of phosphorylation of T181 in tau.",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Enzyme_Acitvity": {
          "1 U/ml": true
        }
      },
      "source": 483,
      "target": 577,
      "key": "c3a27a8a5dce4447b1fb34503f8b3072f70b2919af7dfc88a1c18d7b13c0ad9ff7f15131e27f3d81aea7ef2bcd8552189f739c41c1a387f2b73fc61058dc37f2"
    },
    {
      "line": 662,
      "relation": "partOf",
      "evidence": "Collectively, these studies demonstrate that the soluble, astroglial-derived S100B protein interacts with RAGE leading to the JNK phosphorylation and the pJNK-dependent up-regulation of c-Jun, a component of the AP-1 complex.",
      "citation": {
        "type": "PubMed",
        "reference": "18494933",
        "name": "Journal of cellular and molecular medicine",
        "title": "S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells.",
        "volume": "12",
        "pages": "914-27",
        "date": "2008-06-01",
        "first": "Esposito G",
        "last": "Steardo L",
        "authors": [
          "De Filippis D",
          "Esposito G",
          "Iuvone T",
          "Lu J",
          "Savani C",
          "Scuderi C",
          "Sheen V",
          "Steardo L",
          "Steardo L Jr"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "neural stem cell": true
        },
        "Method": {
          "Electrophoretic Mobility Shift Assay": true,
          "Western Blot": true,
          "RT-PCR": true,
          "Immunofluorescence": true,
          "RNA Interference, siRNA": true
        }
      },
      "source": 461,
      "target": 280,
      "key": "4512f4ee63b261ea0753d25c962e4c081d504fe3890867d3e28dd8198d84cada5275da994c47a7c4b63f97a632f3aafdf83c38617befced766e72657cd02731b"
    },
    {
      "line": 667,
      "relation": "increases",
      "evidence": "In addition, as revealed by Western blot, small interfering RNA and immunofluorescence analysis, S100B-induced JNK activation increased expression of Dickopff-1 that, in turn, promoted glycogen synthase kinase 3-beta phosphorylation and beta-catenin degradation, causing canonical Wnt pathway disruption and tau protein hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "18494933",
        "name": "Journal of cellular and molecular medicine",
        "title": "S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells.",
        "volume": "12",
        "pages": "914-27",
        "date": "2008-06-01",
        "first": "Esposito G",
        "last": "Steardo L",
        "authors": [
          "De Filippis D",
          "Esposito G",
          "Iuvone T",
          "Lu J",
          "Savani C",
          "Scuderi C",
          "Sheen V",
          "Steardo L",
          "Steardo L Jr"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "neural stem cell": true
        },
        "Method": {
          "Electrophoretic Mobility Shift Assay": true,
          "Western Blot": true,
          "RT-PCR": true,
          "Immunofluorescence": true,
          "RNA Interference, siRNA": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 437,
      "target": 456,
      "key": "c19142e5bc6938b9a7eed66e36740463606697abf2f10b29f2655e9e2e08d7b6945f552d1e22e6435adc82ffb081bec97df2303bb2fe39298d6c3d3146a34cc4"
    },
    {
      "line": 668,
      "relation": "positiveCorrelation",
      "evidence": "In addition, as revealed by Western blot, small interfering RNA and immunofluorescence analysis, S100B-induced JNK activation increased expression of Dickopff-1 that, in turn, promoted glycogen synthase kinase 3-beta phosphorylation and beta-catenin degradation, causing canonical Wnt pathway disruption and tau protein hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "18494933",
        "name": "Journal of cellular and molecular medicine",
        "title": "S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells.",
        "volume": "12",
        "pages": "914-27",
        "date": "2008-06-01",
        "first": "Esposito G",
        "last": "Steardo L",
        "authors": [
          "De Filippis D",
          "Esposito G",
          "Iuvone T",
          "Lu J",
          "Savani C",
          "Scuderi C",
          "Sheen V",
          "Steardo L",
          "Steardo L Jr"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "neural stem cell": true
        },
        "Method": {
          "Electrophoretic Mobility Shift Assay": true,
          "Western Blot": true,
          "RT-PCR": true,
          "Immunofluorescence": true,
          "RNA Interference, siRNA": true
        }
      },
      "object": {
        "modifier": "Degradation"
      },
      "source": 437,
      "target": 420,
      "key": "ccff27a8e72a12b482a21da6d88b1d5116c67fefce8d61797abb65711032995110c1015da976ac9d1364a0d7c3562a146273f6fdabc8904a3aebe357aa4de7e8"
    },
    {
      "line": 668,
      "relation": "positiveCorrelation",
      "evidence": "In addition, as revealed by Western blot, small interfering RNA and immunofluorescence analysis, S100B-induced JNK activation increased expression of Dickopff-1 that, in turn, promoted glycogen synthase kinase 3-beta phosphorylation and beta-catenin degradation, causing canonical Wnt pathway disruption and tau protein hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "18494933",
        "name": "Journal of cellular and molecular medicine",
        "title": "S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells.",
        "volume": "12",
        "pages": "914-27",
        "date": "2008-06-01",
        "first": "Esposito G",
        "last": "Steardo L",
        "authors": [
          "De Filippis D",
          "Esposito G",
          "Iuvone T",
          "Lu J",
          "Savani C",
          "Scuderi C",
          "Sheen V",
          "Steardo L",
          "Steardo L Jr"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "neural stem cell": true
        },
        "Method": {
          "Electrophoretic Mobility Shift Assay": true,
          "Western Blot": true,
          "RT-PCR": true,
          "Immunofluorescence": true,
          "RNA Interference, siRNA": true
        }
      },
      "subject": {
        "modifier": "Degradation"
      },
      "source": 420,
      "target": 437,
      "key": "0b6475e2e937bec9593e208c46623ce824090136f7ec14762513b33b5c686aefcf62d8a67fc2193fa2fe5ac851c9a3d0c0cdcd125bc0e4301a3b54e8afb9aaec"
    },
    {
      "relation": "hasVariant",
      "source": 420,
      "target": 422,
      "key": "44d72a748013265f718cbc0d95cc26297df2fb7eaf6a20102c9380032e65b859020340c5a574ad706ba5924fe68a99a654e47fafaf019393bd9264bf1a40906e"
    },
    {
      "relation": "hasVariant",
      "source": 420,
      "target": 424,
      "key": "d7289007b8872f5035386cea4cc4c7f256e0a36137bbc283f40207ce39298fe21719dcd364cdd953d0b22f520f70e5d387894b7e7c3eded36052a876fcbcce06"
    },
    {
      "relation": "hasVariant",
      "source": 420,
      "target": 425,
      "key": "5382c4fdbe5b81e3667c65905b800236c5e08f99bb697bf1f219fa45d2ef431bf50b639e9026ade606c187de92cc147b1224b6528fd94076d744b58308595710"
    },
    {
      "relation": "hasVariant",
      "source": 420,
      "target": 423,
      "key": "b9f1ab211269a647d9bc61ed9441a55a89d8af0df2ee0cef7c8b925ad76a3d2d9f9d58aa4af8e79f0363b66cec7d56c95a39e5377e5e4168a41eba53389f3720"
    },
    {
      "relation": "hasVariant",
      "source": 420,
      "target": 421,
      "key": "5040c74eb933ec19553319ed30d4788fb6bf5a9d746a8033cd9815a0390f06116302e0de80e961055521e2d427f5b9e8e26890946df53ea31e145bc6b54ca344"
    },
    {
      "relation": "hasVariant",
      "source": 420,
      "target": 426,
      "key": "c4918fc88b768eecf0c4bc8b7ff9eb60ea04fd3ff47eaced28d9a1cf79e5106c4fedfe3ded740b09f3ebf397e00cfc8ac9abfaba98f08db2405a7e48c7a26e13"
    },
    {
      "line": 690,
      "relation": "negativeCorrelation",
      "evidence": "We recently discovered that the human brain tau is also modified by O-GlcNAcylation in addition to phosphorylation and that O-GlcNAcylation modulates phosphorylation of tau inversely (Liu et al.,2004a). We found that fasting induced a time-dependent decrease in tau O-GlcNAcylation and concurrent hyperphosphorylation of tau at most of the phosphorylation sites studied.",
      "citation": {
        "type": "PubMed",
        "reference": "16630055",
        "name": "The European journal of neuroscience",
        "title": "Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting.",
        "volume": "23",
        "pages": "2078-86",
        "date": "2006-04-01",
        "first": "Li X",
        "last": "Gong CX",
        "authors": [
          "Gong CX",
          "Li X",
          "Lu F",
          "Wang JZ"
        ]
      },
      "source": 513,
      "target": 538,
      "key": "c8488d2e4dd67eb26437bae5a03166a4b1e100e6428055079278b8eba9bb64645c3fad0785460158f9719fde10dabaa142a485937692f90d647f12449723011a"
    },
    {
      "line": 2506,
      "relation": "positiveCorrelation",
      "evidence": "Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Research_Model": {
          "rTg4510 mice": true
        }
      },
      "source": 513,
      "target": 544,
      "key": "bb4409ddd643ba0bbacf5e96e9f564a7a37cbadeec45b750ad011a7670a26ce7a6a2e20a08cc5f498d44eaa5e0e864361cb7cd2b0687c2f91938dc2be629191a"
    },
    {
      "line": 2507,
      "relation": "positiveCorrelation",
      "evidence": "Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Research_Model": {
          "rTg4510 mice": true
        }
      },
      "source": 513,
      "target": 579,
      "key": "4dfe9dc57f3eadbe1818055e7960b961386b19aaa78939d94bd1114aaecc868c125f8d30fb9e80cde10ea7371880590e4bea4681cf91d0b9b058f91e02abfdc1"
    },
    {
      "line": 2508,
      "relation": "positiveCorrelation",
      "evidence": "Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Research_Model": {
          "rTg4510 mice": true
        }
      },
      "source": 513,
      "target": 557,
      "key": "2d4109e569f1110503d59f93389a4dbbf15da57c25cb375384ac98702f838edd0970f22d3be4f5a40121eb78af20ca8dcd2474c29effeeeae3300ae47ff947c4"
    },
    {
      "line": 2509,
      "relation": "positiveCorrelation",
      "evidence": "Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Research_Model": {
          "rTg4510 mice": true
        }
      },
      "source": 513,
      "target": 563,
      "key": "49c2c8b48b5b8466f9c0a985470406fa950332e2cd01f1503752560573e4cebd4d278de13573ca62136dc8912dfc1435c4a4682a31a8be13b091d9fbc0777f08"
    },
    {
      "line": 2510,
      "relation": "positiveCorrelation",
      "evidence": "Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Research_Model": {
          "rTg4510 mice": true
        }
      },
      "source": 513,
      "target": 564,
      "key": "229eea8a082e3274da64c3ca4991dcfe6cba99502604f9286b486d23869734d334bad6f5ab3d238b192b0147ebcd0f0f4a45c67e369b22bac076f28db377ce2d"
    },
    {
      "line": 2513,
      "relation": "decreases",
      "evidence": "This indicates that O-GlcNAcylation prevents the aggregation of tau in a manner that does not affect its normal phosphorylation state.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Research_Model": {
          "rTg4510 mice": true
        }
      },
      "source": 513,
      "target": 112,
      "key": "0a957ba6dedd7f28f206a5d73bbffe2186535e6905cbc00016caef9f1311388e15e807fb0e107e230e1fc1366ecdeffbfa6a569abcc6a763177e4a797757e0d3"
    },
    {
      "line": 3436,
      "relation": "negativeCorrelation",
      "evidence": "These results are in accord with our previous study showing that Tau hyperphosphorylation is associated with a decrease in its O-GlcNAcylation level. A recent observation argues for the hypothesis that O-GlcNAcylation occurs first and that its modification reflects on the phosphorylation status.",
      "citation": {
        "type": "PubMed",
        "reference": "19732809",
        "name": "Biochimica et biophysica acta",
        "title": "Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease.",
        "volume": "1800",
        "pages": "67-79",
        "date": "2010-02-01",
        "first": "Lefebvre T",
        "last": "Michalski JC",
        "authors": [
          "Dehennaut V",
          "Drougat L",
          "Guinez C",
          "Lefebvre T",
          "Michalski JC",
          "Mir AM",
          "Mortuaire M",
          "Olivier S",
          "Vercoutter-Edouart AS"
        ]
      },
      "source": 513,
      "target": 516,
      "key": "0c32ee0328f1023c42a5a861e2adaadfaa690a76c51bef8c14ea2d6b2e907a4295c02bfe6d53c69033db8e93f3400662bf714495f4d89b315ea493b7e9609630"
    },
    {
      "line": 693,
      "relation": "decreases",
      "evidence": "We recently discovered that the human brain tau is also modified by O-GlcNAcylation in addition to phosphorylation and that O-GlcNAcylation modulates phosphorylation of tau inversely (Liu et al.,2004a). We found that fasting induced a time-dependent decrease in tau O-GlcNAcylation and concurrent hyperphosphorylation of tau at most of the phosphorylation sites studied.",
      "citation": {
        "type": "PubMed",
        "reference": "16630055",
        "name": "The European journal of neuroscience",
        "title": "Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting.",
        "volume": "23",
        "pages": "2078-86",
        "date": "2006-04-01",
        "first": "Li X",
        "last": "Gong CX",
        "authors": [
          "Gong CX",
          "Li X",
          "Lu F",
          "Wang JZ"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true
        }
      },
      "source": 921,
      "target": 807,
      "key": "f51f4b37b05cef3b3c408dc4565b50406f5deeebac1423bf21b0640b87bc41e1682c8bfa8d1fa56e0ed9aa983a5b3b4fb0d3a75f9b5688bb74be7ce2b7213dd5"
    },
    {
      "line": 694,
      "relation": "increases",
      "evidence": "We recently discovered that the human brain tau is also modified by O-GlcNAcylation in addition to phosphorylation and that O-GlcNAcylation modulates phosphorylation of tau inversely (Liu et al.,2004a). We found that fasting induced a time-dependent decrease in tau O-GlcNAcylation and concurrent hyperphosphorylation of tau at most of the phosphorylation sites studied.",
      "citation": {
        "type": "PubMed",
        "reference": "16630055",
        "name": "The European journal of neuroscience",
        "title": "Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting.",
        "volume": "23",
        "pages": "2078-86",
        "date": "2006-04-01",
        "first": "Li X",
        "last": "Gong CX",
        "authors": [
          "Gong CX",
          "Li X",
          "Lu F",
          "Wang JZ"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true
        }
      },
      "source": 921,
      "target": 811,
      "key": "6d10d91826a230446fdece6ff6d7661f01cab7504efe0e28fa9638ea8c15c38ce84b8292f30d7743884d00e14821d796aaeac77b2a872712c7d177dcd2891973"
    },
    {
      "line": 695,
      "relation": "negativeCorrelation",
      "evidence": "We recently discovered that the human brain tau is also modified by O-GlcNAcylation in addition to phosphorylation and that O-GlcNAcylation modulates phosphorylation of tau inversely (Liu et al.,2004a). We found that fasting induced a time-dependent decrease in tau O-GlcNAcylation and concurrent hyperphosphorylation of tau at most of the phosphorylation sites studied.",
      "citation": {
        "type": "PubMed",
        "reference": "16630055",
        "name": "The European journal of neuroscience",
        "title": "Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting.",
        "volume": "23",
        "pages": "2078-86",
        "date": "2006-04-01",
        "first": "Li X",
        "last": "Gong CX",
        "authors": [
          "Gong CX",
          "Li X",
          "Lu F",
          "Wang JZ"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Method": {
          "Western Blot": true,
          "Immunohistochemistry": true
        }
      },
      "source": 921,
      "target": 50,
      "key": "49d708ca48f004f54256d1cba941b1eee3b591e2612b743dc319d01189d0fa9f40f59291c8cc14d339492d37ffdbb8b704e47d6b8c86ebe5542c5f86990e4b3a"
    },
    {
      "line": 716,
      "relation": "increases",
      "evidence": "Protein and mRNA levels of transglutaminase 1 were increased in globus pallidus of PSP as compared to controls. There were also significantly higher mRNA levels of the short form of transglutaminase 2 in globus pallidus of PSP (974% of control). Transglutaminase 1 mRNA and the long isoform of transglutaminase 2 mRNA (2212% of control) were significantly higher in PSP in the dentate of cerebellum. Together, these findings suggest that transglutaminase 1 and 2 enzymes may be involved in the formation and/or stabilization of neurofibrillary tangles in selectively vulnerable brain regions in PSP. These transglutaminases may be potential targets for therapeutic intervention.",
      "citation": {
        "type": "PubMed",
        "reference": "12578227",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy.",
        "volume": "62",
        "pages": "173-84",
        "date": "2003-02-01",
        "first": "Zemaitaitis MO",
        "last": "Muma NA",
        "authors": [
          "Halverson RA",
          "Kim SY",
          "Lee JM",
          "Muma NA",
          "Troncoso JC",
          "Zemaitaitis MO"
        ]
      },
      "annotations": {
        "Anatomy": {
          "globus pallidus": true
        }
      },
      "source": 918,
      "target": 729,
      "key": "f35a28a9682462277ae881fbcdc01f400615cac7aa005083d5429e5d544d3c7cd38dd28dffa4e2b867dc013cb606aea46f612598452bebd0d6e85e577cf94070"
    },
    {
      "line": 717,
      "relation": "increases",
      "evidence": "Protein and mRNA levels of transglutaminase 1 were increased in globus pallidus of PSP as compared to controls. There were also significantly higher mRNA levels of the short form of transglutaminase 2 in globus pallidus of PSP (974% of control). Transglutaminase 1 mRNA and the long isoform of transglutaminase 2 mRNA (2212% of control) were significantly higher in PSP in the dentate of cerebellum. Together, these findings suggest that transglutaminase 1 and 2 enzymes may be involved in the formation and/or stabilization of neurofibrillary tangles in selectively vulnerable brain regions in PSP. These transglutaminases may be potential targets for therapeutic intervention.",
      "citation": {
        "type": "PubMed",
        "reference": "12578227",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy.",
        "volume": "62",
        "pages": "173-84",
        "date": "2003-02-01",
        "first": "Zemaitaitis MO",
        "last": "Muma NA",
        "authors": [
          "Halverson RA",
          "Kim SY",
          "Lee JM",
          "Muma NA",
          "Troncoso JC",
          "Zemaitaitis MO"
        ]
      },
      "annotations": {
        "Anatomy": {
          "globus pallidus": true
        }
      },
      "source": 918,
      "target": 936,
      "key": "daf15222e41e93d0a3b473111a1310334a6980bab898dc385c160daa8131eb28446aaa2efde0ce95ca2cc1f0543c3fb2b0a7a3a6c1e4c7896b70b0764ff2ed7b"
    },
    {
      "line": 718,
      "relation": "increases",
      "evidence": "Protein and mRNA levels of transglutaminase 1 were increased in globus pallidus of PSP as compared to controls. There were also significantly higher mRNA levels of the short form of transglutaminase 2 in globus pallidus of PSP (974% of control). Transglutaminase 1 mRNA and the long isoform of transglutaminase 2 mRNA (2212% of control) were significantly higher in PSP in the dentate of cerebellum. Together, these findings suggest that transglutaminase 1 and 2 enzymes may be involved in the formation and/or stabilization of neurofibrillary tangles in selectively vulnerable brain regions in PSP. These transglutaminases may be potential targets for therapeutic intervention.",
      "citation": {
        "type": "PubMed",
        "reference": "12578227",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy.",
        "volume": "62",
        "pages": "173-84",
        "date": "2003-02-01",
        "first": "Zemaitaitis MO",
        "last": "Muma NA",
        "authors": [
          "Halverson RA",
          "Kim SY",
          "Lee JM",
          "Muma NA",
          "Troncoso JC",
          "Zemaitaitis MO"
        ]
      },
      "annotations": {
        "Anatomy": {
          "globus pallidus": true
        }
      },
      "source": 918,
      "target": 922,
      "key": "8e5e72671212c57b0a500a0ed368cf4da688431a512187ec037bcbef297eb8559c36c0036b8e90b1ec4166522949b566ddf94b58c890d5efe702e5cd4ad38116"
    },
    {
      "line": 722,
      "relation": "increases",
      "evidence": "Protein and mRNA levels of transglutaminase 1 were increased in globus pallidus of PSP as compared to controls. There were also significantly higher mRNA levels of the short form of transglutaminase 2 in globus pallidus of PSP (974% of control). Transglutaminase 1 mRNA and the long isoform of transglutaminase 2 mRNA (2212% of control) were significantly higher in PSP in the dentate of cerebellum. Together, these findings suggest that transglutaminase 1 and 2 enzymes may be involved in the formation and/or stabilization of neurofibrillary tangles in selectively vulnerable brain regions in PSP. These transglutaminases may be potential targets for therapeutic intervention.",
      "citation": {
        "type": "PubMed",
        "reference": "12578227",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy.",
        "volume": "62",
        "pages": "173-84",
        "date": "2003-02-01",
        "first": "Zemaitaitis MO",
        "last": "Muma NA",
        "authors": [
          "Halverson RA",
          "Kim SY",
          "Lee JM",
          "Muma NA",
          "Troncoso JC",
          "Zemaitaitis MO"
        ]
      },
      "annotations": {
        "Anatomy": {
          "dentate nucleus": true
        }
      },
      "source": 918,
      "target": 937,
      "key": "9697f8dc2d8e4b45f366e1ea11f651c66d14719c41cd70808c2507b3616d1be1b2d7af51894517d14e76b35d2d427d2c723e6f128d20f83b33af1687e3146910"
    },
    {
      "line": 737,
      "relation": "positiveCorrelation",
      "evidence": "There were significantly higher levels of epsilon-(gamma-glutamyl) lysine cross-linking of PHF-tau in globus pallidus and pons regions of PSP cases compared to barely detectable cross-links in controls. The occipital cortex, an area spared from neurofibrillary pathology in PSP, showed no detectable cross-linking of PHF-tau protein in either PSP cases or control cases. Double-label immunofluorescence demonstrated the colocalization of the cross-link and PHF-tau in NFT in pons of PSP Previous studies and present data are consistent with the hypothesis that transglutaminase-induced cross-linking may be a factor contributing to the abnormal polymerization and stabilization of tau in straight and PHFs leading to neurofibrillary tangle formation in neurodegenerative diseases, including PSP and AD.",
      "citation": {
        "type": "PubMed",
        "reference": "11089576",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Transglutaminase-induced cross-linking of tau proteins in progressive supranuclear palsy.",
        "volume": "59",
        "pages": "983-9",
        "date": "2000-11-01",
        "first": "Zemaitaitis MO",
        "last": "Muma NA",
        "authors": [
          "Lee JM",
          "Muma NA",
          "Troncoso JC",
          "Zemaitaitis MO"
        ]
      },
      "annotations": {
        "Anatomy": {
          "pons": true,
          "globus pallidus": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 918,
      "target": 267,
      "key": "c5698264f739eb67cb96963e5b47bd38b29c610253797c6ee904012e5cc1b76396dbbf443ea32dd6a44fc4a1b270aedd2701122339477f73ed30c54feec937c3"
    },
    {
      "line": 823,
      "relation": "positiveCorrelation",
      "evidence": "Tau-nY18 did not label the classical pathological lesions of CBD or PSP but did label the neuronal lesions associated with PiD. Tau-nY29 revealed some, but not all classes of tau inclusions associated with both CBD and PSP but did label numerous Pick body inclusions in PiD. Tau-nY197 was restricted to the neuropil threads in both CBD and PSP; however, similar to Tau-nY29, extensive Pick body pathology was clearly labeled. Tau-nY394 did not detect any of the lesions associated with these disorders.",
      "citation": {
        "type": "PubMed",
        "reference": "22057784",
        "name": "Acta neuropathologica",
        "title": "Selective tau tyrosine nitration in non-AD tauopathies.",
        "volume": "123",
        "pages": "119-32",
        "date": "2012-01-01",
        "first": "Reyes JF",
        "last": "Binder LI",
        "authors": [
          "Binder LI",
          "Geula C",
          "Reyes JF",
          "Vana L"
        ]
      },
      "annotations": {
        "Disease": {
          "progressive supranuclear palsy": true
        },
        "HBP_Disease": {
          "Corticobasal Degeneration": true
        },
        "Anatomy": {
          "neuropil": true
        }
      },
      "source": 918,
      "target": 519,
      "key": "2d5a49957a4ee27f4d85cbf75b3e79269be79a60f70fd8887942e7d81fbff2954dbbb821a6c91a41902d38b7be352531743704dec9e1ff5956ccf6669602c655"
    },
    {
      "line": 849,
      "relation": "association",
      "evidence": "Tau-nY29 detects soluble tau and paired helical filament tau from severely affected Alzheimer's brain but fails to recognize tau from normal aged brain. This observation suggests that nitration at Tyr29 is a disease-related event that may alter the intrinsic ability of tau to self-polymerize. In Alzheimer's brain, Tau-nY29 labels the fibrillar triad of tau lesions, including neurofibrillary tangles, neuritic plaques, and, to a lesser extent, neuropil threads. Intriguingly, although Tau-nY29 stains both the neuronal and glial tau pathology of Pick disease, it detects only the neuronal pathology in corticobasal degeneration and progressive supranuclear palsy without labeling the predominant glial pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "17050703",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.",
        "volume": "26",
        "pages": "10636-45",
        "date": "2006-10-18",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Bigio EH",
          "Binder LI",
          "Fu Y",
          "Guillozet-Bongaarts AL",
          "Reyes JF",
          "Reynolds MR"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 918,
      "target": 520,
      "key": "10aef8709680aedb3de539edb197a9dcd9bc5a170beac9ae93a38525ce87e5815055df4ace08c6ea5f6f01a6745567a9f0151b4881e111ad4ca0b800100f15b7"
    },
    {
      "line": 1656,
      "relation": "positiveCorrelation",
      "evidence": "On the other side, sarkosyl extracts from the filaments of PSP [129], corticobasal degeneration (CBD; [130]), argyrophilic grain disease (AgD; [131]), and some cases of FTDP-17, contain tau protein that separates as doublets of 64 and 69 kDa and are predominantly composed of tau isoforms with 4R (class II tauopathies), whereas sarkosyl extracts from filaments of Pick’s disease are characterized by the presence of pathological tau doublets of 60 and 64 kDa and contain mainly 3R tau isoforms (class III tauopathy).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 918,
      "target": 307,
      "key": "c50e994046aab899cabd6f57627394b555b822035bb523b627452c9cc3b116f517c0dbdfb8d1a6aaca739d67414c9bd9bdd4c337ea5f77d6ae5bc19bb95655be"
    },
    {
      "line": 3922,
      "relation": "decreases",
      "evidence": "Western blot analyses showed a decrease of methyl-PP2A and an increase of demethyl-PP2A with a concomitant reduction in the methyl/demethyl PP2A ratio in both PSP (74%) and AD (76%) brains, associated with an LCMT-1 decrease and a demethylating enzyme increase, protein phosphatase methylesterase (PME-1), in both diseases.",
      "citation": {
        "type": "PubMed",
        "reference": "29281045",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.",
        "volume": "77",
        "pages": "139-148",
        "date": "2018-02-01",
        "first": "Park HJ",
        "last": "Mouradian MM",
        "authors": [
          "Adler CH",
          "Beach TG",
          "Braithwaite SP",
          "Lee KW",
          "Mouradian MM",
          "Oh S",
          "Park HJ",
          "Stock JB",
          "Voronkov M",
          "Yan R",
          "Zhang J"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true
        }
      },
      "source": 918,
      "target": 468,
      "key": "0476bf4cad124e43c143045b06c721f1daf01eb4f9fe84921c80833f69c710300c9746515e5789c8e4b7429bcf32c3e1d1ea6c20ae9a3c9be61be03fbb01ccfd"
    },
    {
      "line": 3924,
      "relation": "increases",
      "evidence": "Western blot analyses showed a decrease of methyl-PP2A and an increase of demethyl-PP2A with a concomitant reduction in the methyl/demethyl PP2A ratio in both PSP (74%) and AD (76%) brains, associated with an LCMT-1 decrease and a demethylating enzyme increase, protein phosphatase methylesterase (PME-1), in both diseases.",
      "citation": {
        "type": "PubMed",
        "reference": "29281045",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.",
        "volume": "77",
        "pages": "139-148",
        "date": "2018-02-01",
        "first": "Park HJ",
        "last": "Mouradian MM",
        "authors": [
          "Adler CH",
          "Beach TG",
          "Braithwaite SP",
          "Lee KW",
          "Mouradian MM",
          "Oh S",
          "Park HJ",
          "Stock JB",
          "Voronkov M",
          "Yan R",
          "Zhang J"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true
        }
      },
      "source": 918,
      "target": 271,
      "key": "aaf968df529ec44b7fe26dc26e09b9c35728c0f9a282db4be9818c85f214dc96b56d2edb28ba75fcec532479702dbed834f5d937d0bdc4a83fa0e9f6bb299914"
    },
    {
      "line": 724,
      "relation": "positiveCorrelation",
      "evidence": "Protein and mRNA levels of transglutaminase 1 were increased in globus pallidus of PSP as compared to controls. There were also significantly higher mRNA levels of the short form of transglutaminase 2 in globus pallidus of PSP (974% of control). Transglutaminase 1 mRNA and the long isoform of transglutaminase 2 mRNA (2212% of control) were significantly higher in PSP in the dentate of cerebellum. Together, these findings suggest that transglutaminase 1 and 2 enzymes may be involved in the formation and/or stabilization of neurofibrillary tangles in selectively vulnerable brain regions in PSP. These transglutaminases may be potential targets for therapeutic intervention.",
      "citation": {
        "type": "PubMed",
        "reference": "12578227",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy.",
        "volume": "62",
        "pages": "173-84",
        "date": "2003-02-01",
        "first": "Zemaitaitis MO",
        "last": "Muma NA",
        "authors": [
          "Halverson RA",
          "Kim SY",
          "Lee JM",
          "Muma NA",
          "Troncoso JC",
          "Zemaitaitis MO"
        ]
      },
      "source": 729,
      "target": 81,
      "key": "473798baef2f9104c9121d55c872d80f8e42952b9d6d60cbfc2a888500e61a736330e2df72fc126174728201703c1b1c64ad1e8d9b5dafdcdbf1ac5ee7c1f04d"
    },
    {
      "line": 726,
      "relation": "isA",
      "evidence": "Protein and mRNA levels of transglutaminase 1 were increased in globus pallidus of PSP as compared to controls. There were also significantly higher mRNA levels of the short form of transglutaminase 2 in globus pallidus of PSP (974% of control). Transglutaminase 1 mRNA and the long isoform of transglutaminase 2 mRNA (2212% of control) were significantly higher in PSP in the dentate of cerebellum. Together, these findings suggest that transglutaminase 1 and 2 enzymes may be involved in the formation and/or stabilization of neurofibrillary tangles in selectively vulnerable brain regions in PSP. These transglutaminases may be potential targets for therapeutic intervention.",
      "citation": {
        "type": "PubMed",
        "reference": "12578227",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy.",
        "volume": "62",
        "pages": "173-84",
        "date": "2003-02-01",
        "first": "Zemaitaitis MO",
        "last": "Muma NA",
        "authors": [
          "Halverson RA",
          "Kim SY",
          "Lee JM",
          "Muma NA",
          "Troncoso JC",
          "Zemaitaitis MO"
        ]
      },
      "source": 729,
      "target": 267,
      "key": "d810e6045fb61c82e4f9390d6e604f5c5312ff8913859be258309f7deb756efbbdade13f01c488f8020b1fd4d41512f0adc89a7e095bbd6348db9a3a80e53204"
    },
    {
      "line": 719,
      "relation": "isA",
      "evidence": "Protein and mRNA levels of transglutaminase 1 were increased in globus pallidus of PSP as compared to controls. There were also significantly higher mRNA levels of the short form of transglutaminase 2 in globus pallidus of PSP (974% of control). Transglutaminase 1 mRNA and the long isoform of transglutaminase 2 mRNA (2212% of control) were significantly higher in PSP in the dentate of cerebellum. Together, these findings suggest that transglutaminase 1 and 2 enzymes may be involved in the formation and/or stabilization of neurofibrillary tangles in selectively vulnerable brain regions in PSP. These transglutaminases may be potential targets for therapeutic intervention.",
      "citation": {
        "type": "PubMed",
        "reference": "12578227",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy.",
        "volume": "62",
        "pages": "173-84",
        "date": "2003-02-01",
        "first": "Zemaitaitis MO",
        "last": "Muma NA",
        "authors": [
          "Halverson RA",
          "Kim SY",
          "Lee JM",
          "Muma NA",
          "Troncoso JC",
          "Zemaitaitis MO"
        ]
      },
      "annotations": {
        "Anatomy": {
          "globus pallidus": true
        }
      },
      "source": 922,
      "target": 937,
      "key": "50c266293603f51e4fab9671680f671f2ba372834744b1e5885823e2ea6ef3ba4f90b8e60af09d0142740e42c6bec216b9eaf4e3518f868219926a8710800fa8"
    },
    {
      "line": 725,
      "relation": "positiveCorrelation",
      "evidence": "Protein and mRNA levels of transglutaminase 1 were increased in globus pallidus of PSP as compared to controls. There were also significantly higher mRNA levels of the short form of transglutaminase 2 in globus pallidus of PSP (974% of control). Transglutaminase 1 mRNA and the long isoform of transglutaminase 2 mRNA (2212% of control) were significantly higher in PSP in the dentate of cerebellum. Together, these findings suggest that transglutaminase 1 and 2 enzymes may be involved in the formation and/or stabilization of neurofibrillary tangles in selectively vulnerable brain regions in PSP. These transglutaminases may be potential targets for therapeutic intervention.",
      "citation": {
        "type": "PubMed",
        "reference": "12578227",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy.",
        "volume": "62",
        "pages": "173-84",
        "date": "2003-02-01",
        "first": "Zemaitaitis MO",
        "last": "Muma NA",
        "authors": [
          "Halverson RA",
          "Kim SY",
          "Lee JM",
          "Muma NA",
          "Troncoso JC",
          "Zemaitaitis MO"
        ]
      },
      "source": 730,
      "target": 81,
      "key": "10cb66405d370844295872046890dfdd7e93c334314af94f6de9a1b9223fbc2143fecb32d407a45878c08a8c8ffe14131bf592ba4ee43edfb810b2a07ba0b841"
    },
    {
      "line": 777,
      "relation": "positiveCorrelation",
      "evidence": "Total transglutaminase activity was significantly higher in the Alzheimer's disease prefrontal cortex compared to control. In addition the levels of tissue transglutaminase, as determined by quantitative immunoblotting, were elevated approximately 3-fold in Alzheimer's disease prefrontal cortex compared to control. To our knowledge, this is the first demonstration that transglutaminase is increased in Alzheimer's disease brain. There were no significant differences in transglutaminase activity or levels in the cerebellum between control and Alzheimer's disease cases. Because the elevation of transglutaminase in the Alzheimer's disease samples occurred in the prefrontal cortex, where neurofibrillary pathology is usually abundant, and not in the cerebellum, which is usually spared in Alzheimer's disease, it can be suggested that transglutaminase could be a contributing factor in neurofibrillary tangle formation.",
      "citation": {
        "type": "PubMed",
        "reference": "9099822",
        "name": "Brain research",
        "title": "Transglutaminase activity is increased in Alzheimer's disease brain.",
        "volume": "751",
        "pages": "323-9",
        "date": "1997-03-21",
        "first": "Johnson GV",
        "last": "Powers RE",
        "authors": [
          "Cox TM",
          "Johnson GV",
          "Lockhart JP",
          "Miller ML",
          "Powers RE",
          "Zinnerman MD"
        ]
      },
      "annotations": {
        "Method": {
          "Transglutaminase Assay": true,
          "Immunoblotting": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "prefrontal cortex": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 730,
      "target": 81,
      "key": "8878ceeb0b57a46e6d53029757bbd0e7a608e9f9f81a0d0890a7359c84a7299809f4e63ea0bd5188a24f1fff557b99801ba230e05cbd3ce1478a6f9d825dae95"
    },
    {
      "line": 727,
      "relation": "isA",
      "evidence": "Protein and mRNA levels of transglutaminase 1 were increased in globus pallidus of PSP as compared to controls. There were also significantly higher mRNA levels of the short form of transglutaminase 2 in globus pallidus of PSP (974% of control). Transglutaminase 1 mRNA and the long isoform of transglutaminase 2 mRNA (2212% of control) were significantly higher in PSP in the dentate of cerebellum. Together, these findings suggest that transglutaminase 1 and 2 enzymes may be involved in the formation and/or stabilization of neurofibrillary tangles in selectively vulnerable brain regions in PSP. These transglutaminases may be potential targets for therapeutic intervention.",
      "citation": {
        "type": "PubMed",
        "reference": "12578227",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy.",
        "volume": "62",
        "pages": "173-84",
        "date": "2003-02-01",
        "first": "Zemaitaitis MO",
        "last": "Muma NA",
        "authors": [
          "Halverson RA",
          "Kim SY",
          "Lee JM",
          "Muma NA",
          "Troncoso JC",
          "Zemaitaitis MO"
        ]
      },
      "source": 730,
      "target": 267,
      "key": "4a9c146c1a27049ef765a3bf1a73c8dfe12e19813db8cf9a4624e99959c4f05230e96853bd9332b6df0e7b320535bbdbc451f409430241b7bef0c43ff1e9acfb"
    },
    {
      "line": 801,
      "relation": "positiveCorrelation",
      "evidence": "For these studies, SH-SY5Y cells stably overexpressing tTG were used. tTG coimmunoprecipitated with tau, and elevating intracellular calcium levels with maitotoxin resulted in a 52 +/- 4% increase in the amount of tTG that coimmunoprecipitated with tau. The increase in association of tTG with tau after treatment with maitotoxin corresponded to a coimmunolocalization of tTG, tTG activity, and tau in the cells. Further, tau was modified by tTG in situ in response to maitotoxin treatment. In vitro polyaminated tau was significantly less susceptible to micro-calpain proteolysis; however, tTG-mediated polyamination of tau did not significantly alter the microtubule-binding capacity of tau.",
      "citation": {
        "type": "PubMed",
        "reference": "10537045",
        "name": "Journal of neurochemistry",
        "title": "Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination.",
        "volume": "73",
        "pages": "1871-80",
        "date": "1999-11-01",
        "first": "Tucholski J",
        "last": "Johnson GV",
        "authors": [
          "Johnson GV",
          "Kuret J",
          "Tucholski J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 730,
      "target": 486,
      "key": "58bc2b78874c96563789e15c989a6fee251d44b2076664124c73b0515ff8174c19c7c9d0e7be9057c72462d3e0928810043819f1a232204cb2fb53d11b0a28de"
    },
    {
      "line": 802,
      "relation": "partOf",
      "evidence": "For these studies, SH-SY5Y cells stably overexpressing tTG were used. tTG coimmunoprecipitated with tau, and elevating intracellular calcium levels with maitotoxin resulted in a 52 +/- 4% increase in the amount of tTG that coimmunoprecipitated with tau. The increase in association of tTG with tau after treatment with maitotoxin corresponded to a coimmunolocalization of tTG, tTG activity, and tau in the cells. Further, tau was modified by tTG in situ in response to maitotoxin treatment. In vitro polyaminated tau was significantly less susceptible to micro-calpain proteolysis; however, tTG-mediated polyamination of tau did not significantly alter the microtubule-binding capacity of tau.",
      "citation": {
        "type": "PubMed",
        "reference": "10537045",
        "name": "Journal of neurochemistry",
        "title": "Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination.",
        "volume": "73",
        "pages": "1871-80",
        "date": "1999-11-01",
        "first": "Tucholski J",
        "last": "Johnson GV",
        "authors": [
          "Johnson GV",
          "Kuret J",
          "Tucholski J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 730,
      "target": 238,
      "key": "22cdd55e8bba7e40e98095e25358c20da2196b327e39fdfe3b9f209223d2677f6f82f15788d6814191cce055208fb2738e17afc0007a7f1ce4921f15cda1c2b7"
    },
    {
      "line": 807,
      "relation": "association",
      "evidence": "For these studies, SH-SY5Y cells stably overexpressing tTG were used. tTG coimmunoprecipitated with tau, and elevating intracellular calcium levels with maitotoxin resulted in a 52 +/- 4% increase in the amount of tTG that coimmunoprecipitated with tau. The increase in association of tTG with tau after treatment with maitotoxin corresponded to a coimmunolocalization of tTG, tTG activity, and tau in the cells. Further, tau was modified by tTG in situ in response to maitotoxin treatment. In vitro polyaminated tau was significantly less susceptible to micro-calpain proteolysis; however, tTG-mediated polyamination of tau did not significantly alter the microtubule-binding capacity of tau.",
      "citation": {
        "type": "PubMed",
        "reference": "10537045",
        "name": "Journal of neurochemistry",
        "title": "Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination.",
        "volume": "73",
        "pages": "1871-80",
        "date": "1999-11-01",
        "first": "Tucholski J",
        "last": "Johnson GV",
        "authors": [
          "Johnson GV",
          "Kuret J",
          "Tucholski J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 730,
      "target": 130,
      "key": "057b3d0aede30ff81edafa0c000d50281908cace68e41756cf4b67fe4595b08550c45aa677bc9df25d3e0694bf65981838301db27cc0c4827d78efc1bdd6a3dc"
    },
    {
      "line": 737,
      "relation": "positiveCorrelation",
      "evidence": "There were significantly higher levels of epsilon-(gamma-glutamyl) lysine cross-linking of PHF-tau in globus pallidus and pons regions of PSP cases compared to barely detectable cross-links in controls. The occipital cortex, an area spared from neurofibrillary pathology in PSP, showed no detectable cross-linking of PHF-tau protein in either PSP cases or control cases. Double-label immunofluorescence demonstrated the colocalization of the cross-link and PHF-tau in NFT in pons of PSP Previous studies and present data are consistent with the hypothesis that transglutaminase-induced cross-linking may be a factor contributing to the abnormal polymerization and stabilization of tau in straight and PHFs leading to neurofibrillary tangle formation in neurodegenerative diseases, including PSP and AD.",
      "citation": {
        "type": "PubMed",
        "reference": "11089576",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Transglutaminase-induced cross-linking of tau proteins in progressive supranuclear palsy.",
        "volume": "59",
        "pages": "983-9",
        "date": "2000-11-01",
        "first": "Zemaitaitis MO",
        "last": "Muma NA",
        "authors": [
          "Lee JM",
          "Muma NA",
          "Troncoso JC",
          "Zemaitaitis MO"
        ]
      },
      "annotations": {
        "Anatomy": {
          "pons": true,
          "globus pallidus": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 267,
      "target": 918,
      "key": "e1754edfdd530861f7188118b4506efa5243d4162a587490d77ccd5827af6b2381bac7914d1dfbf4453735ba398bd4bbd3af6d261f40ddb3f6e22aacaddd7733"
    },
    {
      "line": 738,
      "relation": "positiveCorrelation",
      "evidence": "There were significantly higher levels of epsilon-(gamma-glutamyl) lysine cross-linking of PHF-tau in globus pallidus and pons regions of PSP cases compared to barely detectable cross-links in controls. The occipital cortex, an area spared from neurofibrillary pathology in PSP, showed no detectable cross-linking of PHF-tau protein in either PSP cases or control cases. Double-label immunofluorescence demonstrated the colocalization of the cross-link and PHF-tau in NFT in pons of PSP Previous studies and present data are consistent with the hypothesis that transglutaminase-induced cross-linking may be a factor contributing to the abnormal polymerization and stabilization of tau in straight and PHFs leading to neurofibrillary tangle formation in neurodegenerative diseases, including PSP and AD.",
      "citation": {
        "type": "PubMed",
        "reference": "11089576",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Transglutaminase-induced cross-linking of tau proteins in progressive supranuclear palsy.",
        "volume": "59",
        "pages": "983-9",
        "date": "2000-11-01",
        "first": "Zemaitaitis MO",
        "last": "Muma NA",
        "authors": [
          "Lee JM",
          "Muma NA",
          "Troncoso JC",
          "Zemaitaitis MO"
        ]
      },
      "annotations": {
        "Anatomy": {
          "pons": true,
          "globus pallidus": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 267,
      "target": 81,
      "key": "9d5cbd9f6653c43868ff21c843d48b027373ed3a20c4b0a302f4df0220c692e2fdb36f0bb73cc1b2c02c4615c86165ebe291b34c941e6211bcb74aae960df2d1"
    },
    {
      "line": 754,
      "relation": "positiveCorrelation",
      "evidence": "The number of neurons that are immunoreactive with an antibody directed at the epsilon-(gamma-glutamyl)lysine bond was significantly higher in AD cortex compared with age-matched controls and schizophrenics. PHF tau-directed antibodies AT8, MC-1 and PHF-1 co-localized with epsilon(gamma-glutamyl)lysine immunolabeling in AD NFT. Immunoaffinity purification and immunoblotting experiments demonstrated that PHF tau contains epsilon(gamma-glutamyl)lysine bonds in parietal and frontal cortex in AD. In control cases with NFT present in the entorhinal cortex and hippocampus, indicative of Braak and Braak stage II, epsilon(gamma-glutamyl)lysine bonds were present in PHF tau in parietal and frontal cortex, despite the lack of microscopically detectable NFT or senile plaques in these cortical regions. The presence of PHF tau with epsilon(gamma-glutamyl)lysine bonds in brain regions devoid of NFT in stage II (but regions, which would be expected to contain NFT in stage III) suggests that these bonds occur early in the formation of NFT.",
      "citation": {
        "type": "PubMed",
        "reference": "11738469",
        "name": "Neurochemistry international",
        "title": "Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer's disease.",
        "volume": "40",
        "pages": "17-30",
        "date": "2002-01-01",
        "first": "Singer SM",
        "last": "Muma NA",
        "authors": [
          "Lee JM",
          "Muma NA",
          "Norlund MA",
          "Singer SM",
          "Zainelli GM"
        ]
      },
      "annotations": {
        "Method": {
          "Immunoaffinity purification": true,
          "Immunoblotting": true,
          "Confocal Microscopy": true,
          "Fluorescence Microscopy": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "parietal cortex": true,
          "frontal cortex": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 267,
      "target": 81,
      "key": "9ea19ea9c2a382dace6d43a435c3c13c48e60e7211a710a3a1fad5c492c9cca79c62f29bdfbbf622d14fc5b9a1a298598b5052941c6ed1e0c2f195eb4a151e8c"
    },
    {
      "line": 790,
      "relation": "positiveCorrelation",
      "evidence": "Degenerating neurons from the AD hippocampus, compared to neurons from the normal aged hippocampus, exhibited increased immunoreactivity for TGase and demonstrated co-labeling for PHF1 and anti-TGase. Our results suggest that TGase may be associated with the neurofibrillary degeneration observed in AD, thereby implicating TGase as a potential factor in the pathogenesis of Alzheimer's disease.",
      "citation": {
        "type": "PubMed",
        "reference": "8985134",
        "name": "The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society",
        "title": "Localization of transglutaminase in hippocampal neurons: implications for Alzheimer's disease.",
        "volume": "44",
        "pages": "1421-7",
        "date": "1996-12-01",
        "first": "Appelt DM",
        "last": "Balin BJ",
        "authors": [
          "Appelt DM",
          "Balin BJ",
          "Boyne LJ",
          "Kopen GC"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 267,
      "target": 81,
      "key": "ed6314fbb45218ae5c0d8cbaecce2a2ef569db327e1718fd6296b42111c9628c65b39fb64e18365d7889702eedb4813104d2a9ddf32fd8fe31b49b060444e674"
    },
    {
      "line": 753,
      "relation": "positiveCorrelation",
      "evidence": "The number of neurons that are immunoreactive with an antibody directed at the epsilon-(gamma-glutamyl)lysine bond was significantly higher in AD cortex compared with age-matched controls and schizophrenics. PHF tau-directed antibodies AT8, MC-1 and PHF-1 co-localized with epsilon(gamma-glutamyl)lysine immunolabeling in AD NFT. Immunoaffinity purification and immunoblotting experiments demonstrated that PHF tau contains epsilon(gamma-glutamyl)lysine bonds in parietal and frontal cortex in AD. In control cases with NFT present in the entorhinal cortex and hippocampus, indicative of Braak and Braak stage II, epsilon(gamma-glutamyl)lysine bonds were present in PHF tau in parietal and frontal cortex, despite the lack of microscopically detectable NFT or senile plaques in these cortical regions. The presence of PHF tau with epsilon(gamma-glutamyl)lysine bonds in brain regions devoid of NFT in stage II (but regions, which would be expected to contain NFT in stage III) suggests that these bonds occur early in the formation of NFT.",
      "citation": {
        "type": "PubMed",
        "reference": "11738469",
        "name": "Neurochemistry international",
        "title": "Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer's disease.",
        "volume": "40",
        "pages": "17-30",
        "date": "2002-01-01",
        "first": "Singer SM",
        "last": "Muma NA",
        "authors": [
          "Lee JM",
          "Muma NA",
          "Norlund MA",
          "Singer SM",
          "Zainelli GM"
        ]
      },
      "annotations": {
        "Method": {
          "Immunoaffinity purification": true,
          "Immunoblotting": true,
          "Confocal Microscopy": true,
          "Fluorescence Microscopy": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "parietal cortex": true,
          "frontal cortex": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 267,
      "target": 908,
      "key": "60504bcc88a7051c20e9be9b1ca1f06f0effe28795c278319d79918a1b283a52da2fef2d58c51e962ac8273f575e254c5464ed41e6d272196a53faea1d21c818"
    },
    {
      "line": 789,
      "relation": "positiveCorrelation",
      "evidence": "Degenerating neurons from the AD hippocampus, compared to neurons from the normal aged hippocampus, exhibited increased immunoreactivity for TGase and demonstrated co-labeling for PHF1 and anti-TGase. Our results suggest that TGase may be associated with the neurofibrillary degeneration observed in AD, thereby implicating TGase as a potential factor in the pathogenesis of Alzheimer's disease.",
      "citation": {
        "type": "PubMed",
        "reference": "8985134",
        "name": "The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society",
        "title": "Localization of transglutaminase in hippocampal neurons: implications for Alzheimer's disease.",
        "volume": "44",
        "pages": "1421-7",
        "date": "1996-12-01",
        "first": "Appelt DM",
        "last": "Balin BJ",
        "authors": [
          "Appelt DM",
          "Balin BJ",
          "Boyne LJ",
          "Kopen GC"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 267,
      "target": 908,
      "key": "86063dbf92f808c63794e328207c5d03c10493f8d29a19f45e4082584fe46653c7164f6461d22dca06f7ebf603ba5e0744ff543cbfdd384846008566d51900fa"
    },
    {
      "relation": "hasComponent",
      "source": 238,
      "target": 486,
      "key": "c0f8236462af68714242e099fe0cbb912799f18a41814be29cff657ec922e911b219eb1a8f6ce64cf106109279a3350ad4f5df47f779fa557e143f3cbd72377c"
    },
    {
      "relation": "hasComponent",
      "source": 238,
      "target": 730,
      "key": "c9edcc9ed955ce06f83ff5c7a8f060cd1e2d6ec561411d1c3e75dc19af6a60ccdc0280843c618a391d7f578ad7735017bb9d2d70485d3108f30d3e93ef2d5378"
    },
    {
      "line": 805,
      "relation": "positiveCorrelation",
      "evidence": "For these studies, SH-SY5Y cells stably overexpressing tTG were used. tTG coimmunoprecipitated with tau, and elevating intracellular calcium levels with maitotoxin resulted in a 52 +/- 4% increase in the amount of tTG that coimmunoprecipitated with tau. The increase in association of tTG with tau after treatment with maitotoxin corresponded to a coimmunolocalization of tTG, tTG activity, and tau in the cells. Further, tau was modified by tTG in situ in response to maitotoxin treatment. In vitro polyaminated tau was significantly less susceptible to micro-calpain proteolysis; however, tTG-mediated polyamination of tau did not significantly alter the microtubule-binding capacity of tau.",
      "citation": {
        "type": "PubMed",
        "reference": "10537045",
        "name": "Journal of neurochemistry",
        "title": "Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination.",
        "volume": "73",
        "pages": "1871-80",
        "date": "1999-11-01",
        "first": "Tucholski J",
        "last": "Johnson GV",
        "authors": [
          "Johnson GV",
          "Kuret J",
          "Tucholski J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 238,
      "target": 13,
      "key": "0926e193d3edefad2e6c1a376bac360ccee78ecc2e762020e066ec87850ff75f93c7f036ef9fad6818746b48cb6d26d7060f0bfce49c5fde7793650579c69b7f"
    },
    {
      "line": 804,
      "relation": "increases",
      "evidence": "For these studies, SH-SY5Y cells stably overexpressing tTG were used. tTG coimmunoprecipitated with tau, and elevating intracellular calcium levels with maitotoxin resulted in a 52 +/- 4% increase in the amount of tTG that coimmunoprecipitated with tau. The increase in association of tTG with tau after treatment with maitotoxin corresponded to a coimmunolocalization of tTG, tTG activity, and tau in the cells. Further, tau was modified by tTG in situ in response to maitotoxin treatment. In vitro polyaminated tau was significantly less susceptible to micro-calpain proteolysis; however, tTG-mediated polyamination of tau did not significantly alter the microtubule-binding capacity of tau.",
      "citation": {
        "type": "PubMed",
        "reference": "10537045",
        "name": "Journal of neurochemistry",
        "title": "Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination.",
        "volume": "73",
        "pages": "1871-80",
        "date": "1999-11-01",
        "first": "Tucholski J",
        "last": "Johnson GV",
        "authors": [
          "Johnson GV",
          "Kuret J",
          "Tucholski J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 153,
      "target": 13,
      "key": "eb3b9ddc999857b17a09bbbbea992d97104af974ebee0eed77d9ae9738be833d602fed1d492616e87648be52a9f37e8b9e32646dbf313652d3d09c31c8b1f9b0"
    },
    {
      "line": 806,
      "relation": "increases",
      "evidence": "For these studies, SH-SY5Y cells stably overexpressing tTG were used. tTG coimmunoprecipitated with tau, and elevating intracellular calcium levels with maitotoxin resulted in a 52 +/- 4% increase in the amount of tTG that coimmunoprecipitated with tau. The increase in association of tTG with tau after treatment with maitotoxin corresponded to a coimmunolocalization of tTG, tTG activity, and tau in the cells. Further, tau was modified by tTG in situ in response to maitotoxin treatment. In vitro polyaminated tau was significantly less susceptible to micro-calpain proteolysis; however, tTG-mediated polyamination of tau did not significantly alter the microtubule-binding capacity of tau.",
      "citation": {
        "type": "PubMed",
        "reference": "10537045",
        "name": "Journal of neurochemistry",
        "title": "Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination.",
        "volume": "73",
        "pages": "1871-80",
        "date": "1999-11-01",
        "first": "Tucholski J",
        "last": "Johnson GV",
        "authors": [
          "Johnson GV",
          "Kuret J",
          "Tucholski J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 153,
      "target": 730,
      "key": "f65255f19e4e1ada5be30ccb0dbf9b921d6456dfb1d96a826ded016b23011644f1c91a6bd61e84f450f28e75b798e86aa83d5a3ce1d2e8715ce97b2a550e2ffe"
    },
    {
      "line": 805,
      "relation": "positiveCorrelation",
      "evidence": "For these studies, SH-SY5Y cells stably overexpressing tTG were used. tTG coimmunoprecipitated with tau, and elevating intracellular calcium levels with maitotoxin resulted in a 52 +/- 4% increase in the amount of tTG that coimmunoprecipitated with tau. The increase in association of tTG with tau after treatment with maitotoxin corresponded to a coimmunolocalization of tTG, tTG activity, and tau in the cells. Further, tau was modified by tTG in situ in response to maitotoxin treatment. In vitro polyaminated tau was significantly less susceptible to micro-calpain proteolysis; however, tTG-mediated polyamination of tau did not significantly alter the microtubule-binding capacity of tau.",
      "citation": {
        "type": "PubMed",
        "reference": "10537045",
        "name": "Journal of neurochemistry",
        "title": "Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination.",
        "volume": "73",
        "pages": "1871-80",
        "date": "1999-11-01",
        "first": "Tucholski J",
        "last": "Johnson GV",
        "authors": [
          "Johnson GV",
          "Kuret J",
          "Tucholski J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 13,
      "target": 238,
      "key": "702e9e1fcced2c75780dbf2928c0a771a0d92b24839196d082fc77ad64933b41a0bae0deb807a6e0d7f6895151daa5582c05bca485b211c7b5b61699dad792db"
    },
    {
      "line": 818,
      "relation": "positiveCorrelation",
      "evidence": "Tau-nY18 did not label the classical pathological lesions of CBD or PSP but did label the neuronal lesions associated with PiD. Tau-nY29 revealed some, but not all classes of tau inclusions associated with both CBD and PSP but did label numerous Pick body inclusions in PiD. Tau-nY197 was restricted to the neuropil threads in both CBD and PSP; however, similar to Tau-nY29, extensive Pick body pathology was clearly labeled. Tau-nY394 did not detect any of the lesions associated with these disorders.",
      "citation": {
        "type": "PubMed",
        "reference": "22057784",
        "name": "Acta neuropathologica",
        "title": "Selective tau tyrosine nitration in non-AD tauopathies.",
        "volume": "123",
        "pages": "119-32",
        "date": "2012-01-01",
        "first": "Reyes JF",
        "last": "Binder LI",
        "authors": [
          "Binder LI",
          "Geula C",
          "Reyes JF",
          "Vana L"
        ]
      },
      "source": 916,
      "target": 518,
      "key": "fd60f05895ec494c03c69f821cdaaffa88aa20779b600c193c768b289a19674dbc6209fc0eb70d447a07142cd4ea403b88f96f8bc4e16df660287249a3012b23"
    },
    {
      "line": 819,
      "relation": "positiveCorrelation",
      "evidence": "Tau-nY18 did not label the classical pathological lesions of CBD or PSP but did label the neuronal lesions associated with PiD. Tau-nY29 revealed some, but not all classes of tau inclusions associated with both CBD and PSP but did label numerous Pick body inclusions in PiD. Tau-nY197 was restricted to the neuropil threads in both CBD and PSP; however, similar to Tau-nY29, extensive Pick body pathology was clearly labeled. Tau-nY394 did not detect any of the lesions associated with these disorders.",
      "citation": {
        "type": "PubMed",
        "reference": "22057784",
        "name": "Acta neuropathologica",
        "title": "Selective tau tyrosine nitration in non-AD tauopathies.",
        "volume": "123",
        "pages": "119-32",
        "date": "2012-01-01",
        "first": "Reyes JF",
        "last": "Binder LI",
        "authors": [
          "Binder LI",
          "Geula C",
          "Reyes JF",
          "Vana L"
        ]
      },
      "source": 916,
      "target": 520,
      "key": "fdb3f7093962ff5591221d5cab0be4b4cf46df1f95525b23c4a54437e47bdb8d9cc8427f7be0c5c54ab3dece93e1dc7ce121f0b800bf0a6fcd3345f567c92c4f"
    },
    {
      "line": 828,
      "relation": "positiveCorrelation",
      "evidence": "Tau-nY18 did not label the classical pathological lesions of CBD or PSP but did label the neuronal lesions associated with PiD. Tau-nY29 revealed some, but not all classes of tau inclusions associated with both CBD and PSP but did label numerous Pick body inclusions in PiD. Tau-nY197 was restricted to the neuropil threads in both CBD and PSP; however, similar to Tau-nY29, extensive Pick body pathology was clearly labeled. Tau-nY394 did not detect any of the lesions associated with these disorders.",
      "citation": {
        "type": "PubMed",
        "reference": "22057784",
        "name": "Acta neuropathologica",
        "title": "Selective tau tyrosine nitration in non-AD tauopathies.",
        "volume": "123",
        "pages": "119-32",
        "date": "2012-01-01",
        "first": "Reyes JF",
        "last": "Binder LI",
        "authors": [
          "Binder LI",
          "Geula C",
          "Reyes JF",
          "Vana L"
        ]
      },
      "annotations": {
        "Disease": {
          "progressive supranuclear palsy": true
        },
        "HBP_Disease": {
          "Corticobasal Degeneration": true
        },
        "MeSHDisease": {
          "Pick Disease of the Brain": true
        }
      },
      "source": 916,
      "target": 537,
      "key": "6296cb81e665eb3386788a3180bdcea7c7024129e55b794cb3c01d0555887e7cff8e9847dbfa6cdbb6dfc8493a8ca6057c9bd70925555ca3312041c6880e9269"
    },
    {
      "line": 824,
      "relation": "positiveCorrelation",
      "evidence": "Tau-nY18 did not label the classical pathological lesions of CBD or PSP but did label the neuronal lesions associated with PiD. Tau-nY29 revealed some, but not all classes of tau inclusions associated with both CBD and PSP but did label numerous Pick body inclusions in PiD. Tau-nY197 was restricted to the neuropil threads in both CBD and PSP; however, similar to Tau-nY29, extensive Pick body pathology was clearly labeled. Tau-nY394 did not detect any of the lesions associated with these disorders.",
      "citation": {
        "type": "PubMed",
        "reference": "22057784",
        "name": "Acta neuropathologica",
        "title": "Selective tau tyrosine nitration in non-AD tauopathies.",
        "volume": "123",
        "pages": "119-32",
        "date": "2012-01-01",
        "first": "Reyes JF",
        "last": "Binder LI",
        "authors": [
          "Binder LI",
          "Geula C",
          "Reyes JF",
          "Vana L"
        ]
      },
      "annotations": {
        "Disease": {
          "progressive supranuclear palsy": true
        },
        "HBP_Disease": {
          "Corticobasal Degeneration": true
        },
        "Anatomy": {
          "neuropil": true
        }
      },
      "source": 905,
      "target": 519,
      "key": "8c1964f6fbcc488a8267c3d8ab85fc23657b13626a4662a6542409040093f75ea1c7cfdcc05b3adc31057a5d1168697d201efe240191f013ba0e26da0f1a2690"
    },
    {
      "line": 848,
      "relation": "association",
      "evidence": "Tau-nY29 detects soluble tau and paired helical filament tau from severely affected Alzheimer's brain but fails to recognize tau from normal aged brain. This observation suggests that nitration at Tyr29 is a disease-related event that may alter the intrinsic ability of tau to self-polymerize. In Alzheimer's brain, Tau-nY29 labels the fibrillar triad of tau lesions, including neurofibrillary tangles, neuritic plaques, and, to a lesser extent, neuropil threads. Intriguingly, although Tau-nY29 stains both the neuronal and glial tau pathology of Pick disease, it detects only the neuronal pathology in corticobasal degeneration and progressive supranuclear palsy without labeling the predominant glial pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "17050703",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.",
        "volume": "26",
        "pages": "10636-45",
        "date": "2006-10-18",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Bigio EH",
          "Binder LI",
          "Fu Y",
          "Guillozet-Bongaarts AL",
          "Reyes JF",
          "Reynolds MR"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 905,
      "target": 520,
      "key": "387d5259518ef7e7f92820fb266c6fdf14d6698ac8d12f5c7021951f7a1b8c26893dffc21d1d3ab3edf61b2cf1fba68d9d92bd07fdf675559230be10840391c1"
    },
    {
      "line": 1654,
      "relation": "positiveCorrelation",
      "evidence": "On the other side, sarkosyl extracts from the filaments of PSP [129], corticobasal degeneration (CBD; [130]), argyrophilic grain disease (AgD; [131]), and some cases of FTDP-17, contain tau protein that separates as doublets of 64 and 69 kDa and are predominantly composed of tau isoforms with 4R (class II tauopathies), whereas sarkosyl extracts from filaments of Pick’s disease are characterized by the presence of pathological tau doublets of 60 and 64 kDa and contain mainly 3R tau isoforms (class III tauopathy).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 905,
      "target": 307,
      "key": "176b6dd210b6b40c32960551b396efe756d4556627c9de17b2ef1149e7d230db84cf5de4fde9dde79315a5d2c5b946381502c08a91423af9d1d190d7a66e0a65"
    },
    {
      "line": 3279,
      "relation": "positiveCorrelation",
      "evidence": "Thus, K280 acetylation is a feature found in a variety of human 4R or 3R/4R tauopathies including AD, but not 3R-tauopathies such as PiD.",
      "citation": {
        "type": "PubMed",
        "reference": "21427723",
        "name": "Nature communications",
        "title": "The acetylation of tau inhibits its function and promotes pathological tau aggregation.",
        "volume": "2",
        "pages": "252",
        "date": "2011-01-01",
        "first": "Cohen TJ",
        "last": "Lee VM",
        "authors": [
          "Cohen TJ",
          "Guo JL",
          "Hurtado DE",
          "Kwong LK",
          "Lee VM",
          "Mills IP",
          "Trojanowski JQ"
        ]
      },
      "source": 905,
      "target": 498,
      "key": "d1b4416c955ad7544b73188675400dce6f2ec41a406c7693b81a43644e5b574aead664a00fde0555274a194aacdd50d38d13561047756f8b167bc34dc9b8bcb7"
    },
    {
      "line": 3281,
      "relation": "isA",
      "evidence": "Thus, K280 acetylation is a feature found in a variety of human 4R or 3R/4R tauopathies including AD, but not 3R-tauopathies such as PiD.",
      "citation": {
        "type": "PubMed",
        "reference": "21427723",
        "name": "Nature communications",
        "title": "The acetylation of tau inhibits its function and promotes pathological tau aggregation.",
        "volume": "2",
        "pages": "252",
        "date": "2011-01-01",
        "first": "Cohen TJ",
        "last": "Lee VM",
        "authors": [
          "Cohen TJ",
          "Guo JL",
          "Hurtado DE",
          "Kwong LK",
          "Lee VM",
          "Mills IP",
          "Trojanowski JQ"
        ]
      },
      "source": 905,
      "target": 903,
      "key": "a432d29d204b43048c44f0f7480fa9ac2362b49a1cffcd0b7acf7e6a5d887a98f80f15f4dabd968380529a931f2e5dbdd3297c43195d9b44d9e1519abb7eb2d1"
    },
    {
      "line": 1299,
      "relation": "association",
      "evidence": "The pSer422 antibody displayed an almost identical pattern to that of AT8, in that it stained NFTs (Figure 5A–D), neuropil threads and neuritic plaques (Figure 5E–H)",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "source": 164,
      "target": 336,
      "key": "bbd209f4ecb0d3ea15143e395e3eadb1d26db68490db321bd684c7c2d80a8fd6dbee774e179b5a57d8bb83815f4a974ff1fd34832f1cd66d251ee5af15180ccb"
    },
    {
      "line": 828,
      "relation": "positiveCorrelation",
      "evidence": "Tau-nY18 did not label the classical pathological lesions of CBD or PSP but did label the neuronal lesions associated with PiD. Tau-nY29 revealed some, but not all classes of tau inclusions associated with both CBD and PSP but did label numerous Pick body inclusions in PiD. Tau-nY197 was restricted to the neuropil threads in both CBD and PSP; however, similar to Tau-nY29, extensive Pick body pathology was clearly labeled. Tau-nY394 did not detect any of the lesions associated with these disorders.",
      "citation": {
        "type": "PubMed",
        "reference": "22057784",
        "name": "Acta neuropathologica",
        "title": "Selective tau tyrosine nitration in non-AD tauopathies.",
        "volume": "123",
        "pages": "119-32",
        "date": "2012-01-01",
        "first": "Reyes JF",
        "last": "Binder LI",
        "authors": [
          "Binder LI",
          "Geula C",
          "Reyes JF",
          "Vana L"
        ]
      },
      "annotations": {
        "Disease": {
          "progressive supranuclear palsy": true
        },
        "HBP_Disease": {
          "Corticobasal Degeneration": true
        },
        "MeSHDisease": {
          "Pick Disease of the Brain": true
        }
      },
      "source": 537,
      "target": 916,
      "key": "98c5d21bc882e077cc411d0c0c422ff3e80ec7cc08fdf17bfa62bb2b4d8f650af5992f6ec1cadeef51caf0bbeed92df329e26577b10dc091e5be394661b4ac78"
    },
    {
      "line": 835,
      "relation": "association",
      "evidence": "This antibody detects nitrated tau in soluble preparations from both severe AD brains (Braak stage V, VI) and age-matched controls, suggesting that nitration at Tyr 18 may be linked to astrocyte activation, an early event associated with amyloid plaque formation",
      "citation": {
        "type": "PubMed",
        "reference": "18562203",
        "name": "Neurobiology of disease",
        "title": "A possible link between astrocyte activation and tau nitration in Alzheimer's disease.",
        "volume": "31",
        "pages": "198-208",
        "date": "2008-08-01",
        "first": "Reyes JF",
        "last": "Binder LI",
        "authors": [
          "Berry R",
          "Binder LI",
          "Fu Y",
          "Guillozet-Bongaarts AL",
          "Horowitz PM",
          "Reyes JF",
          "Reynolds MR"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 0,
      "target": 518,
      "key": "af4ea2c071b6fd1d4a14115aee590cf76efa8bf9e1480583412b66b6dfe6d3a3aee8072842f00f2d3c383eba8134bb105f0cbda915262e7ac2fc6725ee02cdb1"
    },
    {
      "line": 869,
      "relation": "causesNoChange",
      "evidence": "It was possible to find nitrated Tyr 488 (numbers refer to mouse tau P10637 in the Swiss-Prot/ThEMBL data bank) which corresponds to Tyr 507 in rat tau (Table 1) in accordance with the data reported above for tau in PC12 cells.",
      "citation": {
        "type": "PubMed",
        "reference": "17768677",
        "name": "Neurochemical research",
        "title": "Tau is endogenously nitrated in mouse brain: identification of a tyrosine residue modified in vivo by NO.",
        "volume": "33",
        "pages": "518-25",
        "date": "2008-03-01",
        "first": "Nonnis S",
        "last": "Tedeschi G",
        "authors": [
          "Cappelletti G",
          "Grassi E",
          "Negri A",
          "Nonnis S",
          "Ronchi C",
          "Ronchi S",
          "Taverna F",
          "Tedeschi G"
        ]
      },
      "annotations": {
        "ExpMethod": {
          "in vivo": true
        },
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 809,
      "target": 803,
      "key": "7fccaaec24e0d49e6659ef73f850fd0819f9f939759737e47883b4708816ac85b83d53b1acc0ad8163a7a68fed50cf4c3755a7b4a173917bb9a57a032b9e1eb6"
    },
    {
      "line": 871,
      "relation": "partOf",
      "evidence": "It was possible to find nitrated Tyr 488 (numbers refer to mouse tau P10637 in the Swiss-Prot/ThEMBL data bank) which corresponds to Tyr 507 in rat tau (Table 1) in accordance with the data reported above for tau in PC12 cells.",
      "citation": {
        "type": "PubMed",
        "reference": "17768677",
        "name": "Neurochemical research",
        "title": "Tau is endogenously nitrated in mouse brain: identification of a tyrosine residue modified in vivo by NO.",
        "volume": "33",
        "pages": "518-25",
        "date": "2008-03-01",
        "first": "Nonnis S",
        "last": "Tedeschi G",
        "authors": [
          "Cappelletti G",
          "Grassi E",
          "Negri A",
          "Nonnis S",
          "Ronchi C",
          "Ronchi S",
          "Taverna F",
          "Tedeschi G"
        ]
      },
      "annotations": {
        "ExpMethod": {
          "in vivo": true
        },
        "Species": {
          "10116": true
        }
      },
      "source": 810,
      "target": 166,
      "key": "d54d87a408d8c91c119e8469fea0b870964c07434ee054aa18ba7693490a6227dcc00c20839093247fdbd54c78edc2b1bb338f35e23a6b0ed7b792100b9d020c"
    },
    {
      "line": 888,
      "relation": "increases",
      "evidence": "In the present study we injected bilaterally 3-morpholino-sydnonimine (SIN-1), a recognized and widely used peroxynitrite donor (25–30), into rat hippocampus, and investigated whether or not peroxynitrite could induce simultaneously nitration and hyperphosphorylation of tau and the underlying mechanisms in vivo. The level of nitrated and hyperphosphorylated tau was markedly increased in rat hippocampus 24 h, and prevented by preinjection of uric acid, a natural scavenger of peroxynitrite. GSK-3beta and p38 MAPKs, including p38alpha, p38beta, and p38delta activity was increased, but no change in the activity of p38gamma, ERK, and c-Jun amino-terminal kinase (JNK). Both nitrated tau and hyperphosphorylated tau were aggregated in the hippocampus, with activity of 20S proteasome significantly arrested in SIN-1-injected rats. Hyperphosphorylated tau was degraded as efficiently as normal tau by 20S proteasome, but the nitrated tau with an unorderly secondary structure became more resistant to the proteolysis, providing evidence that peroxynitrite simultaneously induces tau hyperphosphorylation, nitration, and accumulation, and that activation of GSK-3beta, p38alpha, p38beta, p38delta isoforms and the inhibition of proteasome activity are respectively responsible for the peroxynitrite-induced tau hyperphosphorylation and accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "16816118",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms.",
        "volume": "20",
        "pages": "1431-42",
        "date": "2006-07-01",
        "first": "Zhang YJ",
        "last": "Wang JZ",
        "authors": [
          "Li HL",
          "Liu YH",
          "Wang JZ",
          "Wang Q",
          "Xu YF",
          "Yin J",
          "Zhang YJ"
        ]
      },
      "annotations": {
        "ExpMethod": {
          "in vivo": true
        },
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 59,
      "target": 65,
      "key": "cb4cc5f57452826ad6b45487ffaa9a45adce032ebd47906c61b4af48dc8446ffcb7b854fdd3e02639818eac0e09b7fc884b0d7d0b914a90304e016e7675938d6"
    },
    {
      "line": 898,
      "relation": "decreases",
      "evidence": "In the present study we injected bilaterally 3-morpholino-sydnonimine (SIN-1), a recognized and widely used peroxynitrite donor (25–30), into rat hippocampus, and investigated whether or not peroxynitrite could induce simultaneously nitration and hyperphosphorylation of tau and the underlying mechanisms in vivo. The level of nitrated and hyperphosphorylated tau was markedly increased in rat hippocampus 24 h, and prevented by preinjection of uric acid, a natural scavenger of peroxynitrite. GSK-3beta and p38 MAPKs, including p38alpha, p38beta, and p38delta activity was increased, but no change in the activity of p38gamma, ERK, and c-Jun amino-terminal kinase (JNK). Both nitrated tau and hyperphosphorylated tau were aggregated in the hippocampus, with activity of 20S proteasome significantly arrested in SIN-1-injected rats. Hyperphosphorylated tau was degraded as efficiently as normal tau by 20S proteasome, but the nitrated tau with an unorderly secondary structure became more resistant to the proteolysis, providing evidence that peroxynitrite simultaneously induces tau hyperphosphorylation, nitration, and accumulation, and that activation of GSK-3beta, p38alpha, p38beta, p38delta isoforms and the inhibition of proteasome activity are respectively responsible for the peroxynitrite-induced tau hyperphosphorylation and accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "16816118",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms.",
        "volume": "20",
        "pages": "1431-42",
        "date": "2006-07-01",
        "first": "Zhang YJ",
        "last": "Wang JZ",
        "authors": [
          "Li HL",
          "Liu YH",
          "Wang JZ",
          "Wang Q",
          "Xu YF",
          "Yin J",
          "Zhang YJ"
        ]
      },
      "annotations": {
        "ExpMethod": {
          "in vivo": true
        },
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 59,
      "target": 305,
      "key": "3bf2c348fcc105841d091a2001ff19ea3a8960cdc4cef5ce5cb3c6b8964b93d711d0105da33165153c776a4417e9382005bc82b7a7033b6bd66087c27fbb0020"
    },
    {
      "relation": "hasVariant",
      "source": 875,
      "target": 877,
      "key": "13dfd5e324e943b5b15969ee80cc94c2ee476ba98038149d2d3eea748cda06d59bc0296a07e95ac18a414ec8c83ff561354f04122550f1c3479a8907fea110a6"
    },
    {
      "relation": "hasVariant",
      "source": 875,
      "target": 876,
      "key": "471e2b161d929b5867ffc920766abf126e84ca92e71240cf19e08fa509d6a1d56bd9774f20ee54fd83521905a71e2d12bace41848a5ef5f817145138173db5e6"
    },
    {
      "relation": "hasVariant",
      "source": 875,
      "target": 885,
      "key": "d54b652ceaf9c230cd5130d362eabc90a3b90f64e1f3f5dc70df69c36f5f5a86732c9e09d1a4580550f67e1f8585a57529fc760cb82db154dadabf4320cb4d91"
    },
    {
      "relation": "hasVariant",
      "source": 875,
      "target": 878,
      "key": "78e51e2244dbace1759f98a72fd1345b0dfa85cf87941fc46615f7bfa376c3708e30fd7fbef604161557ec7bf65409a4232d0266ecab15c1177add4b254c4a75"
    },
    {
      "relation": "hasVariant",
      "source": 875,
      "target": 883,
      "key": "2813bd0fb6deee528cd267bd31a8ebcf77e8f75f347bbe6dbd09116f017bf5d7cda019feb693a0a247acff98ad5d3d3d67eadbedfbaa350159d7111261ca084e"
    },
    {
      "relation": "hasVariant",
      "source": 875,
      "target": 879,
      "key": "abd6f9e073b83889dfec5ff22f40ffdd7f159de6b132c5dd60a301d77d422a14cdff9995669093eca535037b022f90c7e7293053f49d2b4418cb6e9f9a6ffaca"
    },
    {
      "relation": "hasVariant",
      "source": 875,
      "target": 884,
      "key": "927676b9e87641b9e11f4087091b9253de770bc8336f4500eca8aacf50f248e1e8fe9ac7a4f09c0137d90614b8ae094b8be8fa626349ce8458e5d62ebcca62e0"
    },
    {
      "relation": "hasVariant",
      "source": 875,
      "target": 882,
      "key": "88905dcaf316fafd54d6ac556028beb366a95a673c3bc102ca49fe43b6db25df6bd5af4f3ad10dedf7eef7e8d91877a80c2dec0f7e6620f2ade983427d108850"
    },
    {
      "relation": "hasVariant",
      "source": 875,
      "target": 881,
      "key": "a0f3960d9a55cef14ed4971e55151b2d67acadc04f72ea11e8f648b3648074f65d4a0fd5056c156537c3d9a4264719ad1294eef02c3225d511115cedfb771630"
    },
    {
      "relation": "hasVariant",
      "source": 875,
      "target": 886,
      "key": "d0c4f659c055c4723a0a74d3d5517ea7094c57b70b476c41161ba18249b0bab947f63e8abf7a76822af4b004568edce1db46bf77083dc87d5843342e63aad245"
    },
    {
      "relation": "hasVariant",
      "source": 875,
      "target": 880,
      "key": "2bba626db0242764c369450eec2de6d4628da74a9860db79f00d246975cd3b6c1a46422f649c3cac311a820a5200a9f45503e3e4a9c9f06ecc39e94ac01b0c36"
    },
    {
      "line": 899,
      "relation": "negativeCorrelation",
      "evidence": "In the present study we injected bilaterally 3-morpholino-sydnonimine (SIN-1), a recognized and widely used peroxynitrite donor (25–30), into rat hippocampus, and investigated whether or not peroxynitrite could induce simultaneously nitration and hyperphosphorylation of tau and the underlying mechanisms in vivo. The level of nitrated and hyperphosphorylated tau was markedly increased in rat hippocampus 24 h, and prevented by preinjection of uric acid, a natural scavenger of peroxynitrite. GSK-3beta and p38 MAPKs, including p38alpha, p38beta, and p38delta activity was increased, but no change in the activity of p38gamma, ERK, and c-Jun amino-terminal kinase (JNK). Both nitrated tau and hyperphosphorylated tau were aggregated in the hippocampus, with activity of 20S proteasome significantly arrested in SIN-1-injected rats. Hyperphosphorylated tau was degraded as efficiently as normal tau by 20S proteasome, but the nitrated tau with an unorderly secondary structure became more resistant to the proteolysis, providing evidence that peroxynitrite simultaneously induces tau hyperphosphorylation, nitration, and accumulation, and that activation of GSK-3beta, p38alpha, p38beta, p38delta isoforms and the inhibition of proteasome activity are respectively responsible for the peroxynitrite-induced tau hyperphosphorylation and accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "16816118",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms.",
        "volume": "20",
        "pages": "1431-42",
        "date": "2006-07-01",
        "first": "Zhang YJ",
        "last": "Wang JZ",
        "authors": [
          "Li HL",
          "Liu YH",
          "Wang JZ",
          "Wang Q",
          "Xu YF",
          "Yin J",
          "Zhang YJ"
        ]
      },
      "annotations": {
        "ExpMethod": {
          "in vivo": true
        },
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 876,
      "target": 305,
      "key": "3825af4475b3ae5ae73d2a3dfd69a2fb9daaa7d2b08c57a68ada2e62fbdc94afda817efa5174fd97f7c7e5d7c6c4e63bcd857e9b22a38d4babb444d1a9d25d17"
    },
    {
      "relation": "hasVariant",
      "source": 866,
      "target": 867,
      "key": "e6db7439d7d14f834d3d243be8266283b0ee3abaa8427eefb460d9c0cb2f30a3536bad180d5ff481c4eab4d1e7f3cc5f443acef094bd8880861df58017d6d785"
    },
    {
      "relation": "hasVariant",
      "source": 288,
      "target": 289,
      "key": "bb0815ea687d7d2826ae28dc90dcc7e887f8b96a55fb690e506ecaf9a28aed1fda1e1b2e509336613c00249fbbc8b525939a8f8a053c9836e42b3009b7da31e5"
    },
    {
      "line": 3246,
      "relation": "positiveCorrelation",
      "evidence": "Here we show through systematic epigenetic studies that the histone acetyltransferase p300/CBP-associated factor (PCAF) promotes acetylation of histone 3 Lys 9 at the promoters of established key regeneration-associated genes following a peripheral but not a central axonal injury. Furthermore, we find that extracellular signal-regulated kinase (ERK)-mediated retrograde signalling is required for PCAF-dependent regenerative gene reprogramming. Finally, PCAF is necessary for conditioning-dependent axonal regeneration and also singularly promotes regeneration after spinal cord injury. ",
      "citation": {
        "type": "PubMed",
        "reference": "24686445",
        "name": "Nature communications",
        "title": "PCAF-dependent epigenetic changes promote axonal regeneration in the central nervous system.",
        "volume": "5",
        "pages": "3527",
        "date": "2014-04-01",
        "first": "Puttagunta R",
        "last": "Di Giovanni S",
        "authors": [
          "Boutillier AL",
          "Bradke F",
          "Di Giovanni S",
          "Gaub P",
          "Hervera A",
          "Joshi Y",
          "Laskowski CJ",
          "Lindner R",
          "Nguyen T",
          "Puttagunta R",
          "Rathore KI",
          "Schmandke A",
          "Sória MG",
          "Tedeschi A"
        ]
      },
      "annotations": {
        "Anatomy": {
          "dorsal root ganglion": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 288,
      "target": 463,
      "key": "19f346d893fc0109f2a74f8ebba8bb544a0c854faa09e1d401e96ad2a36819ee6d7f1eb3a3d3f06dc6302bf5130b44f3256a084fd762a74a8be4be416ea420b8"
    },
    {
      "line": 899,
      "relation": "negativeCorrelation",
      "evidence": "In the present study we injected bilaterally 3-morpholino-sydnonimine (SIN-1), a recognized and widely used peroxynitrite donor (25–30), into rat hippocampus, and investigated whether or not peroxynitrite could induce simultaneously nitration and hyperphosphorylation of tau and the underlying mechanisms in vivo. The level of nitrated and hyperphosphorylated tau was markedly increased in rat hippocampus 24 h, and prevented by preinjection of uric acid, a natural scavenger of peroxynitrite. GSK-3beta and p38 MAPKs, including p38alpha, p38beta, and p38delta activity was increased, but no change in the activity of p38gamma, ERK, and c-Jun amino-terminal kinase (JNK). Both nitrated tau and hyperphosphorylated tau were aggregated in the hippocampus, with activity of 20S proteasome significantly arrested in SIN-1-injected rats. Hyperphosphorylated tau was degraded as efficiently as normal tau by 20S proteasome, but the nitrated tau with an unorderly secondary structure became more resistant to the proteolysis, providing evidence that peroxynitrite simultaneously induces tau hyperphosphorylation, nitration, and accumulation, and that activation of GSK-3beta, p38alpha, p38beta, p38delta isoforms and the inhibition of proteasome activity are respectively responsible for the peroxynitrite-induced tau hyperphosphorylation and accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "16816118",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms.",
        "volume": "20",
        "pages": "1431-42",
        "date": "2006-07-01",
        "first": "Zhang YJ",
        "last": "Wang JZ",
        "authors": [
          "Li HL",
          "Liu YH",
          "Wang JZ",
          "Wang Q",
          "Xu YF",
          "Yin J",
          "Zhang YJ"
        ]
      },
      "annotations": {
        "ExpMethod": {
          "in vivo": true
        },
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 305,
      "target": 876,
      "key": "7ed7bfc8ed54a6bab1186d6da6bfee27e5916c856b12fd45293ce67d6bd5191a7e7fecd284f602e27305b2589e570f03d1832a8492739b78150b2018500dc753"
    },
    {
      "line": 901,
      "relation": "negativeCorrelation",
      "evidence": "In the present study we injected bilaterally 3-morpholino-sydnonimine (SIN-1), a recognized and widely used peroxynitrite donor (25–30), into rat hippocampus, and investigated whether or not peroxynitrite could induce simultaneously nitration and hyperphosphorylation of tau and the underlying mechanisms in vivo. The level of nitrated and hyperphosphorylated tau was markedly increased in rat hippocampus 24 h, and prevented by preinjection of uric acid, a natural scavenger of peroxynitrite. GSK-3beta and p38 MAPKs, including p38alpha, p38beta, and p38delta activity was increased, but no change in the activity of p38gamma, ERK, and c-Jun amino-terminal kinase (JNK). Both nitrated tau and hyperphosphorylated tau were aggregated in the hippocampus, with activity of 20S proteasome significantly arrested in SIN-1-injected rats. Hyperphosphorylated tau was degraded as efficiently as normal tau by 20S proteasome, but the nitrated tau with an unorderly secondary structure became more resistant to the proteolysis, providing evidence that peroxynitrite simultaneously induces tau hyperphosphorylation, nitration, and accumulation, and that activation of GSK-3beta, p38alpha, p38beta, p38delta isoforms and the inhibition of proteasome activity are respectively responsible for the peroxynitrite-induced tau hyperphosphorylation and accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "16816118",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms.",
        "volume": "20",
        "pages": "1431-42",
        "date": "2006-07-01",
        "first": "Zhang YJ",
        "last": "Wang JZ",
        "authors": [
          "Li HL",
          "Liu YH",
          "Wang JZ",
          "Wang Q",
          "Xu YF",
          "Yin J",
          "Zhang YJ"
        ]
      },
      "annotations": {
        "ExpMethod": {
          "in vivo": true
        },
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 305,
      "target": 188,
      "key": "df27eefbaae1cb7beead0f9cec1b297f320a93993cfb96366481c1761751b934bf2d37a9a927602986c9a57637325105558b47b8b3643271145440ce5c50e24d"
    },
    {
      "line": 911,
      "relation": "increases",
      "evidence": "During Abeta-associated inflammation, reactive nitrogen and oxygen species are generated that can cause neuronal dysfunction and death (34-37). Prevalent among these species is peroxynitrite (ONOO-)",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "source": 184,
      "target": 65,
      "key": "c0236a96f442302ed86b70e47463bcc5afe9012acc22675c3c38d3625ec362a4fcf8e985518e86468cdced12739fe3155882d511554e552aff0cdb98b2b0e0b1"
    },
    {
      "line": 920,
      "relation": "positiveCorrelation",
      "evidence": "Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "source": 132,
      "target": 518,
      "key": "6e2b5369717c8f28489cdf71fbe551d1b2f2778589820fc6e282577fb3c2f9230feea873ac0186cd4e3bf38fe2eadd4e40cd9046e2e2db723bc823dbbd801553"
    },
    {
      "line": 921,
      "relation": "positiveCorrelation",
      "evidence": "Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "source": 132,
      "target": 520,
      "key": "dd830ffeacbcfab4fd4973197bd3b71c5037f612306121e0fef890ab34b792bad06c33cac3572cef431dfc8c21e005d6a862f81ca5910dbf8c690f740d861705"
    },
    {
      "line": 922,
      "relation": "positiveCorrelation",
      "evidence": "Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "source": 132,
      "target": 519,
      "key": "399fe5e756e4d08847f337abb5ed4911291c4878f043ed8f1e130ef1bcc6882cde293beb9da73f9f0bbed7a27a0399f7535564a4e2d595454e605ca414b565a8"
    },
    {
      "line": 923,
      "relation": "positiveCorrelation",
      "evidence": "Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs, suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers.",
      "citation": {
        "type": "PubMed",
        "reference": "16566606",
        "name": "Biochemistry",
        "title": "Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms.",
        "volume": "45",
        "pages": "4314-26",
        "date": "2006-04-04",
        "first": "Reynolds MR",
        "last": "Binder LI",
        "authors": [
          "Berry RW",
          "Binder LI",
          "Lukas TJ",
          "Reynolds MR"
        ]
      },
      "source": 132,
      "target": 521,
      "key": "469248073c9e6dec273cf73c33da1eeaae50bc17b04b9309be2a135c8893355151011439077c53cc74c6f1e6433a13bba692f2937f295f84f0b4e217581dadde"
    },
    {
      "line": 2936,
      "relation": "positiveCorrelation",
      "evidence": "Though whole tau assembled poorly, constructs containing three internal repeats (corresponding to the fetal tau isoform) formed PHFs reproducibly. This ability depended on intermolecular disulfide bridges formed by the single Cys-322. Blocking the SH group, mutating Cys for Ala, or keeping T in a reducing environment all inhibited assembly. On the other hand, Cys-322 can be oxidized, and this leads to PHF assembly (ref. 11; this report). In vitro this is achieved most easily by using constructs of the 'fetal' isoform of T (htau23) that has only three repeats. Conversely, reducing agents or the second repeat or T can be viewed as 'antidotes' against PHF assembly.The synthetic PHFs bound the dye thioflavin S used in Alzheimer disease diagnostics.",
      "citation": {
        "type": "PubMed",
        "reference": "7667312",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments.",
        "volume": "92",
        "pages": "8463-7",
        "date": "1995-08-29",
        "first": "Schweers O",
        "last": "Mandelkow E",
        "authors": [
          "Biernat J",
          "Mandelkow E",
          "Mandelkow EM",
          "Schweers O"
        ]
      },
      "source": 132,
      "target": 120,
      "key": "8eee2de7a12070b042ba5329a560e1a560c78157b3741e4dd8133098fd75f6124c8f3d01cd0ea50dbe75d6334ce0556bf5ce3c6030d2887bf59c14e75fa2b711"
    },
    {
      "line": 2938,
      "relation": "partOf",
      "evidence": "Though whole tau assembled poorly, constructs containing three internal repeats (corresponding to the fetal tau isoform) formed PHFs reproducibly. This ability depended on intermolecular disulfide bridges formed by the single Cys-322. Blocking the SH group, mutating Cys for Ala, or keeping T in a reducing environment all inhibited assembly. On the other hand, Cys-322 can be oxidized, and this leads to PHF assembly (ref. 11; this report). In vitro this is achieved most easily by using constructs of the 'fetal' isoform of T (htau23) that has only three repeats. Conversely, reducing agents or the second repeat or T can be viewed as 'antidotes' against PHF assembly.The synthetic PHFs bound the dye thioflavin S used in Alzheimer disease diagnostics.",
      "citation": {
        "type": "PubMed",
        "reference": "7667312",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments.",
        "volume": "92",
        "pages": "8463-7",
        "date": "1995-08-29",
        "first": "Schweers O",
        "last": "Mandelkow E",
        "authors": [
          "Biernat J",
          "Mandelkow E",
          "Mandelkow EM",
          "Schweers O"
        ]
      },
      "source": 132,
      "target": 212,
      "key": "706997e5d1e308fd4e27e79e0055e4462c4b67d546d47868a23f44ecfba181eedb8268c4058d695b441ea07da6b3a20e523eea7d17984a07473415d6f3315d66"
    },
    {
      "line": 3518,
      "relation": "positiveCorrelation",
      "evidence": "Ubiquitination occurs at lysines (K254, K257 K311) in repeat domain; participates in triage process",
      "citation": {
        "type": "PubMed",
        "reference": "8391280",
        "name": "Neuron",
        "title": "Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments.",
        "volume": "10",
        "pages": "1151-60",
        "date": "1993-06-01",
        "first": "Morishima-Kawashima M",
        "last": "Ihara Y",
        "authors": [
          "Hasegawa M",
          "Ihara Y",
          "Morishima-Kawashima M",
          "Suzuki M",
          "Takio K",
          "Titani K"
        ]
      },
      "source": 132,
      "target": 595,
      "key": "8a895e681a23ef04b9b24390ddbbfe87df0e92d6e9d5950c97472db81829ff31af2639222d891fd8f8be502a964df35a4c443fd79fab13233589ada771643dc6"
    },
    {
      "line": 3519,
      "relation": "positiveCorrelation",
      "evidence": "Ubiquitination occurs at lysines (K254, K257 K311) in repeat domain; participates in triage process",
      "citation": {
        "type": "PubMed",
        "reference": "8391280",
        "name": "Neuron",
        "title": "Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments.",
        "volume": "10",
        "pages": "1151-60",
        "date": "1993-06-01",
        "first": "Morishima-Kawashima M",
        "last": "Ihara Y",
        "authors": [
          "Hasegawa M",
          "Ihara Y",
          "Morishima-Kawashima M",
          "Suzuki M",
          "Takio K",
          "Titani K"
        ]
      },
      "source": 132,
      "target": 596,
      "key": "637b2418ddf9e1b9c85e3d6ed32e0cdd3ae9403a8605321d7f0b542af5e02cd49b32a1de57450814554e17a2d1d7e8256253a72d0a172b19dce6b7ce52bb98a9"
    },
    {
      "line": 3520,
      "relation": "positiveCorrelation",
      "evidence": "Ubiquitination occurs at lysines (K254, K257 K311) in repeat domain; participates in triage process",
      "citation": {
        "type": "PubMed",
        "reference": "8391280",
        "name": "Neuron",
        "title": "Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments.",
        "volume": "10",
        "pages": "1151-60",
        "date": "1993-06-01",
        "first": "Morishima-Kawashima M",
        "last": "Ihara Y",
        "authors": [
          "Hasegawa M",
          "Ihara Y",
          "Morishima-Kawashima M",
          "Suzuki M",
          "Takio K",
          "Titani K"
        ]
      },
      "source": 132,
      "target": 597,
      "key": "fc4f7be0a0a56ae0edf48a77ebb70dead4d24cc37368b50a8f294c9effd271776723ea975227742950197de5e7e2fc1a2bc51ead95ced4e50a99a0827beecdd0"
    },
    {
      "line": 936,
      "relation": "decreases",
      "evidence": "Rac1 and RhoA are the best-studied members that regulate spine dynamics; their activation facilitates and prevents dendritic spine formation, respectively",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 671,
      "target": 182,
      "key": "73cd70e06b98246919c47078e80fe943bb131708227b2c840140e5a37fca1c7bd0beecc32588c82769236f9a098a58f9560db1cbfd94bef3bf9da872956d5566"
    },
    {
      "line": 959,
      "relation": "negativeCorrelation",
      "evidence": "In contrast, much less is known about how RhoA is regulated by excitatory glutamate receptors. The Rho-GEF Lfc (also known as GEF-H1) is one notable link between RhoA activity and glutamate receptors18. Lfc is inhibited by AMPA receptors; Lfc and RhoA inhibition is implicated in spine maintenance10. RhoA hyperactivity can lead to spine loss and impaired synaptic function.",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 671,
      "target": 163,
      "key": "4791795ebb921fb1a11ab3336b542adafd7a57988a3ad459149cb01933f4019fd356e98d5a4bb1f9e1a7f96623ed6468ec932df34671afe307bc355840c8ab63"
    },
    {
      "line": 969,
      "relation": "positiveCorrelation",
      "evidence": "These observations suggest that CaMKv blocks RhoA activity by preventing its interaction with Lfc. These results demonstrate that CaMKv regulates spine maintenance through RhoA inhibition. The suppression of the Lfc/RhoA pathway by AMPA receptors is implicated in dendritic spine maintenance10. Given that CaMKv expression is upregulated by synaptic activity, CaMKv may be a key signalling protein that transduces the signals from AMPA receptors to suppress RhoA during activity-dependent spine maintenance. Corroborating this, the AMPA receptor blocker NBQX attenuated CaMKv expression in neurons (Fig. 3i,j). Importantly, CaMKv overexpression completely rescued NBQX-induced spine loss (Fig. 3k,l). These findings collectively reveal that activity-dependent CaMKv expression and the subsequent inhibition of Lfc/RhoA are required to mediate AMPA receptor function in spine maintenance.",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 671,
      "target": 226,
      "key": "4fb2d797063b900040847c431b83535b39fc78e48d0b85606c7c38a106bb49c382ddae3752126480dd9754c47c21a5d4db64e9321208f1bb6aede4fad0113766"
    },
    {
      "line": 938,
      "relation": "positiveCorrelation",
      "evidence": "Rac1 and RhoA are the best-studied members that regulate spine dynamics; their activation facilitates and prevents dendritic spine formation, respectively",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "source": 182,
      "target": 163,
      "key": "adf1c55ecb59a95a68c5399d88dd422766c9a347d13d3da16db850a69658451ef986326dc1e0e35f39cb54c39de3f00d3ded92767fb2938f1976a9fa3050cc71"
    },
    {
      "line": 937,
      "relation": "increases",
      "evidence": "Rac1 and RhoA are the best-studied members that regulate spine dynamics; their activation facilitates and prevents dendritic spine formation, respectively",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 670,
      "target": 182,
      "key": "8390380455e0687741785026c0ec1963cad8346faf5dc52482f2b4d4583a9d7690c5ead9f0253693c57ca0c46576c6fef2ed1c8c8018b3320547906409ca7b14"
    },
    {
      "line": 938,
      "relation": "positiveCorrelation",
      "evidence": "Rac1 and RhoA are the best-studied members that regulate spine dynamics; their activation facilitates and prevents dendritic spine formation, respectively",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "source": 163,
      "target": 182,
      "key": "8779c65159e4cf8ab4fbe5a22d8e83d834c208fd700c3741748445fa1c1e0da08d77a4cdc95ad3f0348ebabb98d2f2d3dd369ee611fe6ce8669f5f001abbea75"
    },
    {
      "line": 959,
      "relation": "negativeCorrelation",
      "evidence": "In contrast, much less is known about how RhoA is regulated by excitatory glutamate receptors. The Rho-GEF Lfc (also known as GEF-H1) is one notable link between RhoA activity and glutamate receptors18. Lfc is inhibited by AMPA receptors; Lfc and RhoA inhibition is implicated in spine maintenance10. RhoA hyperactivity can lead to spine loss and impaired synaptic function.",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 163,
      "target": 671,
      "key": "fda6ce2395f3bc8afefbc6d66a6b3e6c10081e5e26ab4e8fbbf0c945d9efb335360b7c44952854aca651a8b85479947a599f27a10f9f99006b114a0d6f0fb8fe"
    },
    {
      "line": 943,
      "relation": "increases",
      "evidence": "CaMKs functionally link NMDA (N-methyl-d-aspartate) receptors to Rac1 activation via the phosphorylation of specific guanine nucleotide exchange factors (GEFs) such as Kalirin-7, TIAM1 and β-PIX",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 165,
      "target": 670,
      "key": "339cb2dde1095636703aa2619458ff2baff08fb857864e3ecd7be93c9df70f05ec80d19f2a7f919b0d3fe0aac767fecbc83103cfd479e8a0403168f263657a1f"
    },
    {
      "line": 944,
      "relation": "increases",
      "evidence": "CaMKs functionally link NMDA (N-methyl-d-aspartate) receptors to Rac1 activation via the phosphorylation of specific guanine nucleotide exchange factors (GEFs) such as Kalirin-7, TIAM1 and β-PIX",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "source": 165,
      "target": 732,
      "key": "9531d981a165d2af35c1b2ecec53259b75483b24ebd20a05a8ef762e304fad284f0f2b5001f090a4da4640228f275497eda7d821f572d2fd587e167320db73d1"
    },
    {
      "line": 2479,
      "relation": "increases",
      "evidence": "Hence, LTD-inducing NMDA receptor activation leads to an increase in tau phosphorylation at sites PHF-1, AT180, as well as AT8 and to a reduction at AT100.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 165,
      "target": 336,
      "key": "518551f9d2cd674a8ab7312afd9c49d507f9e2ba8241e52ee6a00f0c248611f228091b96b45554cda59b0c1b9e92d0562f21c75c8ade4466c3128221d42f1719"
    },
    {
      "line": 2480,
      "relation": "increases",
      "evidence": "Hence, LTD-inducing NMDA receptor activation leads to an increase in tau phosphorylation at sites PHF-1, AT180, as well as AT8 and to a reduction at AT100.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 165,
      "target": 117,
      "key": "8652052e6fcb670bd520944cfaa7e4d698b33f5e68c1bf9a0d860cf435e4bdf8e790d834ad25fcbd0bee6143d21a2bdec13ff7cdbdff3de9e7c8da580934a609"
    },
    {
      "line": 2481,
      "relation": "increases",
      "evidence": "Hence, LTD-inducing NMDA receptor activation leads to an increase in tau phosphorylation at sites PHF-1, AT180, as well as AT8 and to a reduction at AT100.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 165,
      "target": 115,
      "key": "e8278938abf2f4056f9ddba3a708863ad66c3d377ed5a3de6add27c5fa309d195f3e8e30cb528ee25d324640da1476b5a3841ce1b432b5bbe83ddf6b8a62853f"
    },
    {
      "line": 2483,
      "relation": "decreases",
      "evidence": "Hence, LTD-inducing NMDA receptor activation leads to an increase in tau phosphorylation at sites PHF-1, AT180, as well as AT8 and to a reduction at AT100.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 165,
      "target": 114,
      "key": "d5d7e4675b7b8ad49644137e1b9c5d62bf1e6ca51d269ba0a8231737d5eb04b728e531e54f7c4f05c0324335621dfae704fe21f10df61f2c12f26ea539cea90f"
    },
    {
      "line": 945,
      "relation": "increases",
      "evidence": "CaMKs functionally link NMDA (N-methyl-d-aspartate) receptors to Rac1 activation via the phosphorylation of specific guanine nucleotide exchange factors (GEFs) such as Kalirin-7, TIAM1 and β-PIX",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 732,
      "target": 670,
      "key": "535b50126f1372b6700b92e6693c56af2aa1eb37b554836c3eb2dd666c4d6827b560713eb12cc77f1cac8895e011da558e79e1261cc8bc4a186ec9dc2a9e209b"
    },
    {
      "relation": "hasVariant",
      "source": 731,
      "target": 732,
      "key": "5d9d060e7d27eb9f04a79cabd30b9fd9e946d883175acddf4236cbc55a02510a3119c793eb598c04903c1193f1e857ef1c8bc5b66210a960f9918fd122a5ee98"
    },
    {
      "line": 946,
      "relation": "increases",
      "evidence": "CaMKs functionally link NMDA (N-methyl-d-aspartate) receptors to Rac1 activation via the phosphorylation of specific guanine nucleotide exchange factors (GEFs) such as Kalirin-7, TIAM1 and β-PIX",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "source": 393,
      "target": 320,
      "key": "a1ec52fe25a1cc13c8ba312b9d15f21b90188f93c792eb2e38bdf4a37dc74ae0c23f526fbf55847012837d7287fd47a5e5c56be3735a35a8bd5a18e5ac9e160d"
    },
    {
      "line": 947,
      "relation": "increases",
      "evidence": "CaMKs functionally link NMDA (N-methyl-d-aspartate) receptors to Rac1 activation via the phosphorylation of specific guanine nucleotide exchange factors (GEFs) such as Kalirin-7, TIAM1 and β-PIX",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 320,
      "target": 319,
      "key": "1983b89e81faf80d7af42b414c844601621ab90d754dfe894849ef7f773469a64896f6ece43cebf6c14f4a9d67a8896e343ee7fe1630c86e96c8631e6c37916b"
    },
    {
      "relation": "hasVariant",
      "source": 319,
      "target": 320,
      "key": "228ae75307826bb13878304bdd9c2e74455450225a5b0f8130ff3c3c81bd8a6c23c179dd2f2d9cadb3bf11d78dc62d2bbffc6160521081ab335fcb84ce668f7a"
    },
    {
      "line": 948,
      "relation": "increases",
      "evidence": "CaMKs functionally link NMDA (N-methyl-d-aspartate) receptors to Rac1 activation via the phosphorylation of specific guanine nucleotide exchange factors (GEFs) such as Kalirin-7, TIAM1 and β-PIX",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 319,
      "target": 670,
      "key": "1e7f8d9411df2dd50dfdb0fc6fb3a841995013cadc7fb69cba444fdf7bd16740ce4c8b928218e8ee303c069207a314e4bd86e83403aec2f33f53278b7884cd63"
    },
    {
      "line": 949,
      "relation": "increases",
      "evidence": "CaMKs functionally link NMDA (N-methyl-d-aspartate) receptors to Rac1 activation via the phosphorylation of specific guanine nucleotide exchange factors (GEFs) such as Kalirin-7, TIAM1 and β-PIX",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "source": 392,
      "target": 384,
      "key": "058dd0d508c3fd76d89227e4502574a878d5892a2809e35df7dd0bc0ba2c76755247305d5906763ac96c698f2c19bb3d16de6535865fed13fb656c8612296164"
    },
    {
      "line": 950,
      "relation": "increases",
      "evidence": "CaMKs functionally link NMDA (N-methyl-d-aspartate) receptors to Rac1 activation via the phosphorylation of specific guanine nucleotide exchange factors (GEFs) such as Kalirin-7, TIAM1 and β-PIX",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 384,
      "target": 383,
      "key": "974832eef8db5690280409cc6b0cf1efd5782ac5856aebbaee470f8199b012911ee0d057ee02a4f12526641c29909cf251625b2bb63255c5672880a27bd7255d"
    },
    {
      "relation": "hasVariant",
      "source": 383,
      "target": 384,
      "key": "617b5ff3730d0729e73d6b7b12724f2ba7fbc1b1ce347e4bcd0fbf5ae4f85a85db8a5705f6a83393eac513055ee3d546b3eb376d4fbce7dadc8629b3b9b4605a"
    },
    {
      "line": 951,
      "relation": "increases",
      "evidence": "CaMKs functionally link NMDA (N-methyl-d-aspartate) receptors to Rac1 activation via the phosphorylation of specific guanine nucleotide exchange factors (GEFs) such as Kalirin-7, TIAM1 and β-PIX",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 383,
      "target": 670,
      "key": "0f5797e719fc742141954302f4ed4d74b8199c724403d415ec6a37c05d91a89a3b20699268262f5bfc18d92eba816821513c9aacc1d09b903a86d0250f0ac82d"
    },
    {
      "line": 957,
      "relation": "decreases",
      "evidence": "In contrast, much less is known about how RhoA is regulated by excitatory glutamate receptors. The Rho-GEF Lfc (also known as GEF-H1) is one notable link between RhoA activity and glutamate receptors18. Lfc is inhibited by AMPA receptors; Lfc and RhoA inhibition is implicated in spine maintenance10. RhoA hyperactivity can lead to spine loss and impaired synaptic function.",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 207,
      "target": 382,
      "key": "3f36e0b8ab8f851f16996912645c0ec7fa2c21ea52f0613a3cd4793f974156c7a38512484d4076bd10ace94f7e48a57223a90c7db43359b9e9a172bce5aec06a"
    },
    {
      "line": 958,
      "relation": "regulates",
      "evidence": "In contrast, much less is known about how RhoA is regulated by excitatory glutamate receptors. The Rho-GEF Lfc (also known as GEF-H1) is one notable link between RhoA activity and glutamate receptors18. Lfc is inhibited by AMPA receptors; Lfc and RhoA inhibition is implicated in spine maintenance10. RhoA hyperactivity can lead to spine loss and impaired synaptic function.",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 382,
      "target": 163,
      "key": "8dd5738a29534a1304859badcb714056c1c1fb6e47fca1c57d9710d41ca5038a292235668e65b94674d0eefa685aa96ec4034e6c464f0fbe04138dc7c822ae44"
    },
    {
      "line": 968,
      "relation": "decreases",
      "evidence": "These observations suggest that CaMKv blocks RhoA activity by preventing its interaction with Lfc. These results demonstrate that CaMKv regulates spine maintenance through RhoA inhibition. The suppression of the Lfc/RhoA pathway by AMPA receptors is implicated in dendritic spine maintenance10. Given that CaMKv expression is upregulated by synaptic activity, CaMKv may be a key signalling protein that transduces the signals from AMPA receptors to suppress RhoA during activity-dependent spine maintenance. Corroborating this, the AMPA receptor blocker NBQX attenuated CaMKv expression in neurons (Fig. 3i,j). Importantly, CaMKv overexpression completely rescued NBQX-induced spine loss (Fig. 3k,l). These findings collectively reveal that activity-dependent CaMKv expression and the subsequent inhibition of Lfc/RhoA are required to mediate AMPA receptor function in spine maintenance.",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 394,
      "target": 226,
      "key": "6ddf440a2afcb567341746891738714d10c47bdf451f00f681238f2f59095dc5a5aba8a78402a427546bc8200c6cf64b83645281493d3c1b29c3a5e160edba7a"
    },
    {
      "line": 970,
      "relation": "decreases",
      "evidence": "These observations suggest that CaMKv blocks RhoA activity by preventing its interaction with Lfc. These results demonstrate that CaMKv regulates spine maintenance through RhoA inhibition. The suppression of the Lfc/RhoA pathway by AMPA receptors is implicated in dendritic spine maintenance10. Given that CaMKv expression is upregulated by synaptic activity, CaMKv may be a key signalling protein that transduces the signals from AMPA receptors to suppress RhoA during activity-dependent spine maintenance. Corroborating this, the AMPA receptor blocker NBQX attenuated CaMKv expression in neurons (Fig. 3i,j). Importantly, CaMKv overexpression completely rescued NBQX-induced spine loss (Fig. 3k,l). These findings collectively reveal that activity-dependent CaMKv expression and the subsequent inhibition of Lfc/RhoA are required to mediate AMPA receptor function in spine maintenance.",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 394,
      "target": 671,
      "key": "5bf79f7e692f97650f9b7fe72d6f7cc06d24d001076a5d696f64d25dfe916d13233ec932c403dd100603a80e226ac22ce89970be5a970bfe4453748d23ed6e49"
    },
    {
      "relation": "hasVariant",
      "source": 394,
      "target": 395,
      "key": "bfc800a00b0e38e052902bd2675f9286e3198af865de1007729dc447f39d9c8047bc9878a7324c33c533cb95c414aaaa1b73308a0284fa2641203386a0896fad"
    },
    {
      "line": 980,
      "relation": "regulates",
      "evidence": "These findings suggest that CaMKv is required for both synaptic transmission and protein synthesis-dependent LTP in the hippocampus.",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "annotations": {
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 394,
      "target": 193,
      "key": "3285b8441038adbb23934f3f390d3dfddcc842a7f276f444b79873b4d032e12d3954cbec878cf052b1be709ce45c56930c806fdbf852a2547b43da20749cc3dc"
    },
    {
      "line": 981,
      "relation": "association",
      "evidence": "These findings suggest that CaMKv is required for both synaptic transmission and protein synthesis-dependent LTP in the hippocampus.",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "annotations": {
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 394,
      "target": 204,
      "key": "194bb80813bedfa9d43c744cbde8ff706e8422e1a9133c62c0869d70599a67c68879b011a49801d369b00f2b283b5c8a39bd8e1bd89f28eb2425d40c92d3e58d"
    },
    {
      "relation": "hasComponent",
      "source": 226,
      "target": 382,
      "key": "2e2deb2397ebc3925e9af0920ed1b4d034360b274c65edde78eda9d8a4e82179f0e946224c878fa8170e71e2a02da76f1289b49a16d753f1d46b33180dd3b2cd"
    },
    {
      "relation": "hasComponent",
      "source": 226,
      "target": 671,
      "key": "4b761f401dbd21c373efb7db1f1211ea426918a8bda2e1ab0f2a75973af4b8a3aede959d459610284bf7b7f91890c4eea99f1a4e94972477131ac45ba4788042"
    },
    {
      "line": 969,
      "relation": "positiveCorrelation",
      "evidence": "These observations suggest that CaMKv blocks RhoA activity by preventing its interaction with Lfc. These results demonstrate that CaMKv regulates spine maintenance through RhoA inhibition. The suppression of the Lfc/RhoA pathway by AMPA receptors is implicated in dendritic spine maintenance10. Given that CaMKv expression is upregulated by synaptic activity, CaMKv may be a key signalling protein that transduces the signals from AMPA receptors to suppress RhoA during activity-dependent spine maintenance. Corroborating this, the AMPA receptor blocker NBQX attenuated CaMKv expression in neurons (Fig. 3i,j). Importantly, CaMKv overexpression completely rescued NBQX-induced spine loss (Fig. 3k,l). These findings collectively reveal that activity-dependent CaMKv expression and the subsequent inhibition of Lfc/RhoA are required to mediate AMPA receptor function in spine maintenance.",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 226,
      "target": 671,
      "key": "acafa7048b64b83ec227d59cf6381bd66c7e742858e5b105a4958c617f95a12385cd90b47f9d12082a7f7760f0b989ab89056be31b349a8a5e92ff5f63d3c3e0"
    },
    {
      "line": 975,
      "relation": "increases",
      "evidence": "However, co-expression of the phospho-mimetic T345E failed to restore the defects in spine density after CaMKv depletion (Fig. 4l,m), suggesting that CaMKv phosphorylation by Cdk5 at Thr345 inhibits its function.",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "source": 400,
      "target": 395,
      "key": "778157e27fa730ddfdcdff3f054cdf3db6355e34abda6b74c845ad161060bf6325b3ce54065cabe4d527229efe8246d98be2b03ff4003d425abbdae99ef2967a"
    },
    {
      "line": 1134,
      "relation": "increases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 400,
      "target": 577,
      "key": "ca376640462675a0ea57e13cc25db31f2129b450eed10b1c37a478db331f878cfd6b97b772b6336993f180d5664fb335388120ad4651b74ef975fa409e802989"
    },
    {
      "line": 1135,
      "relation": "increases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 400,
      "target": 543,
      "key": "5e4cd0012ca70f924475a6a9e579debec51c3db840baa5a69b90eddb59462ee0b5e8886f532ace21f61d2283df3a3a2062f9953a2a36777b17d58c4ec5ac078b"
    },
    {
      "line": 1136,
      "relation": "increases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 400,
      "target": 579,
      "key": "e33f64f056647410f45f37a3af9e775196e0da616c3a2c580ab9779eacc93341ab73fd3e1e7b7e68323fc559135cf2b67049dfcc1b7e9d0e70e3d0505702e464"
    },
    {
      "line": 1137,
      "relation": "increases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 400,
      "target": 583,
      "key": "0e883ec62374a7a185679328dbe7616097813e6faba46b33c35b202d35cc67b7044116429b746620af05b614203d3cd1acdbecaacc048e6dcef08ddf1d77334d"
    },
    {
      "line": 1138,
      "relation": "increases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 400,
      "target": 569,
      "key": "57351fd3eb2f0c7fedd61b0207a0c059e21c2af864fc38968cf50f2fb0f4df2e17e9c927a006a509f444d1c6e12ea5234f2bcab7c6f2dea0b65d279a6e4d9706"
    },
    {
      "line": 1147,
      "relation": "increases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 400,
      "target": 229,
      "key": "237025c94834ecce4f2b26e397c2e038c7e0a91dd4d00433190f58007e39c4feffec937009bb0cdb3c374af8d9135cce74c08f1f3e7fc02bee611d648e1af74b"
    },
    {
      "line": 1149,
      "relation": "increases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 400,
      "target": 232,
      "key": "4e0c164126eb437ba616bffd1601cbd16061364fd9b5ca3156be23ae0b9e5bb436088d26a1f3776d7e113980cb821a9ea80fc2b0670c7034dca13e17f37010dd"
    },
    {
      "line": 1151,
      "relation": "increases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 400,
      "target": 233,
      "key": "1ada98521c095a61a9a74023dd9ee0c18bbc8a125ea00603ab8c727ef80910432be8e3fccbbe062e7c90d3f6b40860c18c69ab18526ffb4ad2fe9d39030468bb"
    },
    {
      "line": 1153,
      "relation": "increases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 400,
      "target": 231,
      "key": "fe4badff6fcb23f84c4f8ec776ffe172e234658619f96a004da6d39de48cba0bd4597c09ddd87e4f0244de63a897c5100a3a6a63d41875cd27c13b6922777a5d"
    },
    {
      "line": 1155,
      "relation": "increases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 400,
      "target": 230,
      "key": "2f8946f37adac25000a2d256b271588b1e3fc63025e92e7611dbc27149681c16472b9d9d2f5f66cd1ca4af7783b657c0cdf6f44dea6af68eccf6b1167d26654b"
    },
    {
      "line": 1219,
      "relation": "increases",
      "evidence": "The phosphorylation sites were determined to be Ser551 and Ser553 with Cdk5-p23, and Ser62, Ser67, and Ser551 with MAP kinase. Upon phosphorylation with MAP kinase, synapsin I showed reduced F-actin bundling activity, while no significant effect on the interaction was observed with the protein phosphorylated with Cdk5-p23.",
      "citation": {
        "type": "PubMed",
        "reference": "8702879",
        "name": "The Journal of biological chemistry",
        "title": "Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions.",
        "volume": "271",
        "pages": "21108-13",
        "date": "1996-08-30",
        "first": "Matsubara M",
        "last": "Taniguchi H",
        "authors": [
          "Ishiguro K",
          "Kusubata M",
          "Matsubara M",
          "Taniguchi H",
          "Titani K",
          "Uchida T"
        ]
      },
      "annotations": {
        "Duration": {
          "2 hours": true
        },
        "Substrate_Concentration": {
          "0.5 M": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 400,
      "target": 708,
      "key": "4bdd2cedfc76ae3612c6cee85dcc078fb6785c4417fdb658fde22bf40ee4e700e71840eb468451170fac078abdc62657b2e2a45cec271965156ce58ab8313d16"
    },
    {
      "line": 1220,
      "relation": "increases",
      "evidence": "The phosphorylation sites were determined to be Ser551 and Ser553 with Cdk5-p23, and Ser62, Ser67, and Ser551 with MAP kinase. Upon phosphorylation with MAP kinase, synapsin I showed reduced F-actin bundling activity, while no significant effect on the interaction was observed with the protein phosphorylated with Cdk5-p23.",
      "citation": {
        "type": "PubMed",
        "reference": "8702879",
        "name": "The Journal of biological chemistry",
        "title": "Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions.",
        "volume": "271",
        "pages": "21108-13",
        "date": "1996-08-30",
        "first": "Matsubara M",
        "last": "Taniguchi H",
        "authors": [
          "Ishiguro K",
          "Kusubata M",
          "Matsubara M",
          "Taniguchi H",
          "Titani K",
          "Uchida T"
        ]
      },
      "annotations": {
        "Duration": {
          "2 hours": true
        },
        "Substrate_Concentration": {
          "0.5 M": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 400,
      "target": 709,
      "key": "1b7a9f6c27967f4a70d4d5990ab8226b90f1e0c8632163c67d8b2a9fb07c7a92f0e233e8c81eb22cd7e7ebfebe634c6a969574b855ae980c88f14448aa41fc32"
    },
    {
      "line": 2306,
      "relation": "increases",
      "evidence": "To perform its function, Cdk5 must bind to the neuron-specific regulatory subunit protein p35, which is beneficial for neuronal development (Tsai et al. 1994; Chae et al. 1997). However, truncation of p35 and conversion to p25 (Patrick et al. 1999) is found in the forebrain of rats after focal cerebral ischemia and in AD patients, and these alterations are deleterious to the brain",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "source": 400,
      "target": 228,
      "key": "6313c481ac9459d16550f617ec63adc04e73b671cd77497d1c60700530ee6d6314fb2d09654eafe49dce1710f9b25919dd1be84bf12f0524ff4a03c460edc35c"
    },
    {
      "line": 3911,
      "relation": "directlyIncreases",
      "evidence": "In primary neurons, overexpression of miR-125b causes tau hyperphosphorylation and an upregulation of p35, cdk5, and p44/42-MAPK signaling. In parallel, the phosphatases DUSP6 and PPP1CA and the anti-apoptotic factor Bcl-W are downregulated as direct targets of miR-125b. Knockdown of these phosphatases induces tau hyperphosphorylation, and overexpression of PPP1CA and Bcl-W prevents miR-125b-induced tau phosphorylation, suggesting that they mediate the effects of miR-125b on tau. Conversely, suppression of miR-125b in neurons by tough decoys reduces tau phosphorylation and kinase expression/activity. Injecting miR-125b into the hippocampus of mice impairs associative learning and is accompanied by downregulation of Bcl-W, DUSP6, and PPP1CA, resulting in increased tau phosphorylation in vivo. Importantly, DUSP6 and PPP1CA are also reduced in AD brains.",
      "citation": {
        "type": "PubMed",
        "reference": "25001178",
        "name": "The EMBO journal",
        "title": "MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease.",
        "volume": "33",
        "pages": "1667-80",
        "date": "2014-08-01",
        "first": "Banzhaf-Strathmann J",
        "last": "Edbauer D",
        "authors": [
          "Arzberger T",
          "Banzhaf-Strathmann J",
          "Benito E",
          "Edbauer D",
          "Fischer A",
          "Kretzschmar H",
          "May S",
          "Tahirovic S"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 400,
      "target": 516,
      "key": "286f291644eefdc8928d4e4da33dd76f5eb2926b41da1720603200d69fca7f6ef5335dc8f6bac39fefa738799012a983bfaebdef7f35b83996be9d0a21bc298b"
    },
    {
      "line": 3915,
      "relation": "positiveCorrelation",
      "evidence": "Since Erk1/2 activity has been shown to induce cdk5 (Harada et al, 2001), miR-125b-induced Erk1/2 activation through DUSP6 downregulation might ultimately stimulate aberrant cdk5/p35 activation and, consequently, enhance pathological tau phosphorylation at multiple sites",
      "citation": {
        "type": "PubMed",
        "reference": "25001178",
        "name": "The EMBO journal",
        "title": "MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease.",
        "volume": "33",
        "pages": "1667-80",
        "date": "2014-08-01",
        "first": "Banzhaf-Strathmann J",
        "last": "Edbauer D",
        "authors": [
          "Arzberger T",
          "Banzhaf-Strathmann J",
          "Benito E",
          "Edbauer D",
          "Fischer A",
          "Kretzschmar H",
          "May S",
          "Tahirovic S"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 400,
      "target": 477,
      "key": "9fbe4326cab7d2b3098ec7c4f71c8d6ad0319b5875cb88bfacd179a2e0d60ba17aa16cf4f8634e413e32c1597d57467f27c88bac7e3bdf1353558b0fc89c2238"
    },
    {
      "line": 976,
      "relation": "decreases",
      "evidence": "However, co-expression of the phospho-mimetic T345E failed to restore the defects in spine density after CaMKv depletion (Fig. 4l,m), suggesting that CaMKv phosphorylation by Cdk5 at Thr345 inhibits its function.",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 395,
      "target": 394,
      "key": "e0ce5376d5527ae3497418bdddcd17bfb55508b550314aaf4a7cd95ed9135bc8bfb5be8f25c37475ef44f01b1d19f207d664cc647e604e6e118132809067a47c"
    },
    {
      "line": 981,
      "relation": "association",
      "evidence": "These findings suggest that CaMKv is required for both synaptic transmission and protein synthesis-dependent LTP in the hippocampus.",
      "citation": {
        "type": "PubMed",
        "reference": "27796283",
        "name": "Nature communications",
        "title": "The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines.",
        "volume": "7",
        "pages": "13282",
        "date": "2016-10-31",
        "first": "Liang Z",
        "last": "Ip NY",
        "authors": [
          "Ip NY",
          "Lai KO",
          "Liang Z",
          "Plattner F",
          "Shen Y",
          "Wong CC",
          "Yates JR 3rd",
          "Zhan Y"
        ]
      },
      "annotations": {
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 204,
      "target": 394,
      "key": "bba29018430c70c32ea8a9b136c202ecaa1b36ab354f6555ea1bf85f0acc18fa0f3db46540e9d255a6d64e3a3243278fa15af525fd15d24e6b32726e2a1ac3ea"
    },
    {
      "line": 3177,
      "relation": "negativeCorrelation",
      "evidence": "Here we report abnormal acetylation of K274 and K281 on tau, identified in AD brains, promotes memory loss and disrupts synaptic plasticity by reducing postsynaptic KIdney/BRAin (KIBRA) protein, a memory-associated protein.Transgenic mice expressing human tau with lysine-to-glutamine mutations to mimic K274 and K281 acetylation (tauKQ) exhibit AD-related memory deficits and impaired hippocampal long-term potentiation (LTP). TauKQ reduces synaptic KIBRA levels and disrupts activity-induced postsynaptic actin remodeling and AMPA receptor insertion. The LTP deficit was rescued by promoting actin polymerization or by KIBRA expression. In AD patients with dementia, we found enhanced tau acetylation is linked to loss of KIBRA.",
      "citation": {
        "type": "PubMed",
        "reference": "27041503",
        "name": "Neuron",
        "title": "Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss.",
        "volume": "90",
        "pages": "245-60",
        "date": "2016-04-20",
        "first": "Tracy TE",
        "last": "Gan L",
        "authors": [
          "Cong X",
          "Ellerby LM",
          "Gan L",
          "Huganir RL",
          "Le D",
          "Li Y",
          "Lo I",
          "Min SW",
          "Minami SS",
          "Ponnusamy R",
          "Schilling B",
          "Sohn PD",
          "Tracy TE",
          "Wang C",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 204,
      "target": 171,
      "key": "4076e7da94ff21edaff9e37f8533559bb29afc9b419bb9c8c26054afa313d7c08f6523622552869f83e14d0232115ef7c3b585f0e6d1bc1c544cae850183d8af"
    },
    {
      "line": 3178,
      "relation": "negativeCorrelation",
      "evidence": "Here we report abnormal acetylation of K274 and K281 on tau, identified in AD brains, promotes memory loss and disrupts synaptic plasticity by reducing postsynaptic KIdney/BRAin (KIBRA) protein, a memory-associated protein.Transgenic mice expressing human tau with lysine-to-glutamine mutations to mimic K274 and K281 acetylation (tauKQ) exhibit AD-related memory deficits and impaired hippocampal long-term potentiation (LTP). TauKQ reduces synaptic KIBRA levels and disrupts activity-induced postsynaptic actin remodeling and AMPA receptor insertion. The LTP deficit was rescued by promoting actin polymerization or by KIBRA expression. In AD patients with dementia, we found enhanced tau acetylation is linked to loss of KIBRA.",
      "citation": {
        "type": "PubMed",
        "reference": "27041503",
        "name": "Neuron",
        "title": "Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss.",
        "volume": "90",
        "pages": "245-60",
        "date": "2016-04-20",
        "first": "Tracy TE",
        "last": "Gan L",
        "authors": [
          "Cong X",
          "Ellerby LM",
          "Gan L",
          "Huganir RL",
          "Le D",
          "Li Y",
          "Lo I",
          "Min SW",
          "Minami SS",
          "Ponnusamy R",
          "Schilling B",
          "Sohn PD",
          "Tracy TE",
          "Wang C",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 204,
      "target": 752,
      "key": "6f85740ac6fdcd8e676176c73e297abb13bfd161550b03a581c758592f8606da02b882bdf38dd748f154a083af23294e01ba99bd116003230a8fe7e03d8834a9"
    },
    {
      "line": 3179,
      "relation": "positiveCorrelation",
      "evidence": "Here we report abnormal acetylation of K274 and K281 on tau, identified in AD brains, promotes memory loss and disrupts synaptic plasticity by reducing postsynaptic KIdney/BRAin (KIBRA) protein, a memory-associated protein.Transgenic mice expressing human tau with lysine-to-glutamine mutations to mimic K274 and K281 acetylation (tauKQ) exhibit AD-related memory deficits and impaired hippocampal long-term potentiation (LTP). TauKQ reduces synaptic KIBRA levels and disrupts activity-induced postsynaptic actin remodeling and AMPA receptor insertion. The LTP deficit was rescued by promoting actin polymerization or by KIBRA expression. In AD patients with dementia, we found enhanced tau acetylation is linked to loss of KIBRA.",
      "citation": {
        "type": "PubMed",
        "reference": "27041503",
        "name": "Neuron",
        "title": "Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss.",
        "volume": "90",
        "pages": "245-60",
        "date": "2016-04-20",
        "first": "Tracy TE",
        "last": "Gan L",
        "authors": [
          "Cong X",
          "Ellerby LM",
          "Gan L",
          "Huganir RL",
          "Le D",
          "Li Y",
          "Lo I",
          "Min SW",
          "Minami SS",
          "Ponnusamy R",
          "Schilling B",
          "Sohn PD",
          "Tracy TE",
          "Wang C",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 204,
      "target": 200,
      "key": "e334bbe241c697d7fdc3589fa26355c43d3f61ebecdc665e25fc8f4d472b8a19fa6ffe4161196f10ca631348f2c8eb7de2ebad62b174f3be55a1591b7da50fcf"
    },
    {
      "line": 990,
      "relation": "increases",
      "evidence": "NRF2 is regulated principally by two different mechanisms. The best established mechanism is the control of protein stability by Kelch-like ECH-associated protein 1 (KEAP1). KEAP1 is an ubiquitin E3 ligase substrate adapter for a Cullin3/Rbx1-dependent E3 ubiquitin ligase complex; henceforth binding of KEAP1 to NRF2 mediates ubiquitination and subsequent proteasomal degradation of NRF2 [7].",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "source": 464,
      "target": 236,
      "key": "4f64e08791ffc77df7b62d5aba648ba4fc2ab21f024795f57709230ffdf68061bd19a9273a061870ae4515fa7fafa5ba2ab75ea570fbc3180b162c5ec587bb71"
    },
    {
      "line": 1011,
      "relation": "isA",
      "evidence": "The second mechanism is related to GSK-3, which phosphorylates NRF2 creating a recognition site for β-Transducin Repeat Containing E3 Ubiquitin Protein Ligase (β-TrCP). β-TrCP leads to Cullin-1/Rbx1-mediated NRF2 ubiquitination and its subsequent degradation [8]. Since GSK-3β is inhibited by phosphorylation at Ser9 by Ser/Thr protein kinases such as AKT, it has been suggested that NRF2 might be up-regulated through activation of AKT and permanent inactivation of GSK-3 [9], [10].",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "source": 464,
      "target": 268,
      "key": "9ecca3270d69b94cb5455f6a624144af3c0b9d02f9652548b7df00047c3db58d2b692e5544c8ab8d12f086074e6faf6a1b3489fb4d873b84e846e905e7900611"
    },
    {
      "relation": "hasComponent",
      "source": 236,
      "target": 428,
      "key": "21bd397242aeeafa9f1eeae2bc8cec718ba5424a72291c737adf8e0fe23b857cf68fcb2a5f77e35fb841107b8bec486033ab388d0063839afc8a6d6d93753eaa"
    },
    {
      "relation": "hasComponent",
      "source": 236,
      "target": 464,
      "key": "cb94e7d2676b61e3a679f4061d57d9e65a8498c2fc4f8dec542720738ae3faad367dfb1debe2bb8d38b024e44ce74fec4dec58e366bde87a773737f5960dc38c"
    },
    {
      "relation": "hasComponent",
      "source": 236,
      "target": 641,
      "key": "184bc1c82558388d951aaf74d8939da11579e7fb864ff195881474db183c887131584629080c11f628a418ddfb7100cb1922d76edb7c0d945df19d5e78c7dafd"
    },
    {
      "line": 993,
      "relation": "increases",
      "evidence": "NRF2 is regulated principally by two different mechanisms. The best established mechanism is the control of protein stability by Kelch-like ECH-associated protein 1 (KEAP1). KEAP1 is an ubiquitin E3 ligase substrate adapter for a Cullin3/Rbx1-dependent E3 ubiquitin ligase complex; henceforth binding of KEAP1 to NRF2 mediates ubiquitination and subsequent proteasomal degradation of NRF2 [7].",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "source": 236,
      "target": 643,
      "key": "2761b746d4914a4cfe0f5f2a176681bbbdd0eaf555662acca87ad0944b213b90cdeba0d2659dfae015320d9c4e548e246d50fdc3abe865ed9dd0391203aef19e"
    },
    {
      "line": 992,
      "relation": "partOf",
      "evidence": "NRF2 is regulated principally by two different mechanisms. The best established mechanism is the control of protein stability by Kelch-like ECH-associated protein 1 (KEAP1). KEAP1 is an ubiquitin E3 ligase substrate adapter for a Cullin3/Rbx1-dependent E3 ubiquitin ligase complex; henceforth binding of KEAP1 to NRF2 mediates ubiquitination and subsequent proteasomal degradation of NRF2 [7].",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "source": 428,
      "target": 236,
      "key": "c06d1b2204bec25a2f2f4b9ee8f24504094cdf353303d543eaca067e9263603b8dc52ea2c5c105d1817d709aa77d53e5cc62967fe9a0ec1c0899ef5d8767606e"
    },
    {
      "line": 991,
      "relation": "partOf",
      "evidence": "NRF2 is regulated principally by two different mechanisms. The best established mechanism is the control of protein stability by Kelch-like ECH-associated protein 1 (KEAP1). KEAP1 is an ubiquitin E3 ligase substrate adapter for a Cullin3/Rbx1-dependent E3 ubiquitin ligase complex; henceforth binding of KEAP1 to NRF2 mediates ubiquitination and subsequent proteasomal degradation of NRF2 [7].",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "source": 641,
      "target": 236,
      "key": "7fa30f7360e50b789ae29f0d119577079902908f5a4bab567c762bf808558bd0dc5be6591120265fe7353925fc4c78f7093552c23d1c8acf491f02293bcdea0c"
    },
    {
      "relation": "hasVariant",
      "source": 641,
      "target": 643,
      "key": "aa2a90016467d51d5b9e8baa726fcf759e29ab18d945f5fec805637b4cd0ceeb85a9bfb940745ce8320eb6c5fc0ce18f62c1cb405218671d6a82d2f91e21b662"
    },
    {
      "relation": "hasVariant",
      "source": 641,
      "target": 642,
      "key": "3bc1f131c1bbf09e612df8271c472f6e973ca64e2f70a3d1c282a39c411a96c26794ced37f824b48742247999c3e4d7d69e46aa38f529555ab011d75dc94a995"
    },
    {
      "line": 1007,
      "relation": "positiveCorrelation",
      "evidence": "The second mechanism is related to GSK-3, which phosphorylates NRF2 creating a recognition site for β-Transducin Repeat Containing E3 Ubiquitin Protein Ligase (β-TrCP). β-TrCP leads to Cullin-1/Rbx1-mediated NRF2 ubiquitination and its subsequent degradation [8]. Since GSK-3β is inhibited by phosphorylation at Ser9 by Ser/Thr protein kinases such as AKT, it has been suggested that NRF2 might be up-regulated through activation of AKT and permanent inactivation of GSK-3 [9], [10].",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "source": 641,
      "target": 278,
      "key": "98dff585ce13bef294904629f32fa5c7ce48558a145362f8d7bd6687676c61669b53026b59c88a3381e813121b38ba350294235fac21b5c2d60255545702e799"
    },
    {
      "line": 2803,
      "relation": "increases",
      "evidence": "Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor known to increase the level of many antioxidants, including glutathione-S transferase (GST), and is negatively regulated by the activity of GSK-3β. Our results indicated the increased nuclear localization of Nrf2 and level of GST, suggesting the increased activity of the transcription factor as a result of GSK-3β suppression, consistent with the decreased oxidative stress observed. Consistent with the improved learning and memory, and consistent with GSK-3b being a tau kinase, we observed decreased tau phosphorylation in brain of GAO-treated SAMP8 mice compared to that of RAO-treated SAMP8 mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24355211",
        "name": "Free radical biology &amp; medicine",
        "title": "Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease.",
        "volume": "67",
        "pages": "387-95",
        "date": "2014-02-01",
        "first": "Farr SA",
        "last": "Butterfield DA",
        "authors": [
          "Butterfield DA",
          "Farr SA",
          "Kumar V",
          "Morley JE",
          "Murphy MP",
          "Niehoff ML",
          "Platt TL",
          "Ripley JL",
          "Sultana R",
          "Zhang Z"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "SAMP8 mice": true
        }
      },
      "source": 641,
      "target": 269,
      "key": "fd6fd33284af3cb4e8286f7de1a92802e173bf8266172465556d380a654d0146eaede050ae7d5b8ebc54a34fb4ad69426d20e55c059237e7d6eec6c98e0afdd2"
    },
    {
      "line": 994,
      "relation": "increases",
      "evidence": "NRF2 is regulated principally by two different mechanisms. The best established mechanism is the control of protein stability by Kelch-like ECH-associated protein 1 (KEAP1). KEAP1 is an ubiquitin E3 ligase substrate adapter for a Cullin3/Rbx1-dependent E3 ubiquitin ligase complex; henceforth binding of KEAP1 to NRF2 mediates ubiquitination and subsequent proteasomal degradation of NRF2 [7].",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "object": {
        "modifier": "Degradation"
      },
      "source": 643,
      "target": 641,
      "key": "8494cf9d50f9a64a05da8f17c638c63c94611f4d0710693037bdf2be8ea92fcf140256095ec0db7f85f6679c2f86fe0d9d1ba1ae85675a47516c526f12df66eb"
    },
    {
      "line": 1002,
      "relation": "partOf",
      "evidence": "The second mechanism is related to GSK-3, which phosphorylates NRF2 creating a recognition site for β-Transducin Repeat Containing E3 Ubiquitin Protein Ligase (β-TrCP). β-TrCP leads to Cullin-1/Rbx1-mediated NRF2 ubiquitination and its subsequent degradation [8]. Since GSK-3β is inhibited by phosphorylation at Ser9 by Ser/Thr protein kinases such as AKT, it has been suggested that NRF2 might be up-regulated through activation of AKT and permanent inactivation of GSK-3 [9], [10].",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "source": 642,
      "target": 227,
      "key": "8af4bea2cce83a7d3cc2d298a4bc7cf4dae709456e42ec820cc03cd8eeceaace82ed04c1aaadd3d14a0f652b746b4887bf16ba0909a5187af7962b2f44013aa2"
    },
    {
      "line": 1001,
      "relation": "increases",
      "evidence": "The second mechanism is related to GSK-3, which phosphorylates NRF2 creating a recognition site for β-Transducin Repeat Containing E3 Ubiquitin Protein Ligase (β-TrCP). β-TrCP leads to Cullin-1/Rbx1-mediated NRF2 ubiquitination and its subsequent degradation [8]. Since GSK-3β is inhibited by phosphorylation at Ser9 by Ser/Thr protein kinases such as AKT, it has been suggested that NRF2 might be up-regulated through activation of AKT and permanent inactivation of GSK-3 [9], [10].",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "source": 390,
      "target": 227,
      "key": "3bb19a6fdf57832b081e0e8d0dc6c6e075c47b741f42d9aae68129cdc37a1ff56e494b7a8e0730f0f4661e2f5f339f4ecbdc8c153dd247b2bfc6f59b6b4d7e08"
    },
    {
      "line": 1010,
      "relation": "isA",
      "evidence": "The second mechanism is related to GSK-3, which phosphorylates NRF2 creating a recognition site for β-Transducin Repeat Containing E3 Ubiquitin Protein Ligase (β-TrCP). β-TrCP leads to Cullin-1/Rbx1-mediated NRF2 ubiquitination and its subsequent degradation [8]. Since GSK-3β is inhibited by phosphorylation at Ser9 by Ser/Thr protein kinases such as AKT, it has been suggested that NRF2 might be up-regulated through activation of AKT and permanent inactivation of GSK-3 [9], [10].",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "source": 390,
      "target": 268,
      "key": "d06d1e924a2cef01730e947666b071b82c8ef49b33e0bd5d92b64500b861d6b42d942d03ed0312978f904c43756f21036d38d5a22833e35e67441b2496e43831"
    },
    {
      "relation": "hasComponent",
      "source": 227,
      "target": 390,
      "key": "b79e41da828dd6ff4d96beecb303eafc2172bc59669e118ebd912a9b080a0be3b06f27e5a1aecb3160995c61a34195e35d3a7f8f2edbf5ed9adf371ecd100a18"
    },
    {
      "relation": "hasComponent",
      "source": 227,
      "target": 427,
      "key": "3d0c6b8431ee5692a526fec23a08b640f1f91b4d986bcef49e771bfc3df659053633aee95e8eaec262fb345e2635c636aef56eb9c267ba027e1a5fdfb931bc0d"
    },
    {
      "relation": "hasComponent",
      "source": 227,
      "target": 642,
      "key": "f1b24cf272b767174a504099e447a61355b5baa3a7ab0e85d5352a685ec4d8790f0531abaa702c334f229de9af0ecc904ef8ab9f25c55e3f657cf78088b99528"
    },
    {
      "line": 1004,
      "relation": "increases",
      "evidence": "The second mechanism is related to GSK-3, which phosphorylates NRF2 creating a recognition site for β-Transducin Repeat Containing E3 Ubiquitin Protein Ligase (β-TrCP). β-TrCP leads to Cullin-1/Rbx1-mediated NRF2 ubiquitination and its subsequent degradation [8]. Since GSK-3β is inhibited by phosphorylation at Ser9 by Ser/Thr protein kinases such as AKT, it has been suggested that NRF2 might be up-regulated through activation of AKT and permanent inactivation of GSK-3 [9], [10].",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "source": 227,
      "target": 643,
      "key": "1d78f4a62627a20b7dd0ce52f20c57c432c00c59d66638cb5a8f68bbab43b8b0a1e437148ffdd073eabb7921446a8223c93f8edab55891018e59b74a2dc5e983"
    },
    {
      "line": 1003,
      "relation": "partOf",
      "evidence": "The second mechanism is related to GSK-3, which phosphorylates NRF2 creating a recognition site for β-Transducin Repeat Containing E3 Ubiquitin Protein Ligase (β-TrCP). β-TrCP leads to Cullin-1/Rbx1-mediated NRF2 ubiquitination and its subsequent degradation [8]. Since GSK-3β is inhibited by phosphorylation at Ser9 by Ser/Thr protein kinases such as AKT, it has been suggested that NRF2 might be up-regulated through activation of AKT and permanent inactivation of GSK-3 [9], [10].",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "source": 427,
      "target": 227,
      "key": "160644844908580572d88a4454d0b70ef4474837fe72203d23be23714c4a582550ab787d411f26f864687e2462bd4e7ed8f623434f73c7ac855d93972d614967"
    },
    {
      "line": 1005,
      "relation": "increases",
      "evidence": "The second mechanism is related to GSK-3, which phosphorylates NRF2 creating a recognition site for β-Transducin Repeat Containing E3 Ubiquitin Protein Ligase (β-TrCP). β-TrCP leads to Cullin-1/Rbx1-mediated NRF2 ubiquitination and its subsequent degradation [8]. Since GSK-3β is inhibited by phosphorylation at Ser9 by Ser/Thr protein kinases such as AKT, it has been suggested that NRF2 might be up-regulated through activation of AKT and permanent inactivation of GSK-3 [9], [10].",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "source": 278,
      "target": 457,
      "key": "e3db1b68cf7bf6e4501b7ef60b31ba81522703b1aad81c6dd7a86d3a4a03a9fc1a3d29159fe09301d7174b8a91cb8eb0b469f957b7424f1f99f5c4dc0cd868c0"
    },
    {
      "line": 1007,
      "relation": "positiveCorrelation",
      "evidence": "The second mechanism is related to GSK-3, which phosphorylates NRF2 creating a recognition site for β-Transducin Repeat Containing E3 Ubiquitin Protein Ligase (β-TrCP). β-TrCP leads to Cullin-1/Rbx1-mediated NRF2 ubiquitination and its subsequent degradation [8]. Since GSK-3β is inhibited by phosphorylation at Ser9 by Ser/Thr protein kinases such as AKT, it has been suggested that NRF2 might be up-regulated through activation of AKT and permanent inactivation of GSK-3 [9], [10].",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "source": 278,
      "target": 641,
      "key": "c9f355c665c49e67b13dbee557182d974fd56de8b7f2b693a1f08b3a4dba9c39220ce694bc5ee61bfa87862bffb8b2b94e1d688314859cc45eebfb24842fa4a8"
    },
    {
      "relation": "hasVariant",
      "source": 278,
      "target": 279,
      "key": "a1e9680e012ba6a69064a7671ba3c9b78ef9ba74a447bd4f3beaf3f83131af3f526c6797555e43aa1740e228e1c1db2421bc57f7b50721ff26325f84a235dc83"
    },
    {
      "line": 1016,
      "relation": "increases",
      "evidence": "Wild-type MEFs treated with DMF (20 μM) showed a time-dependent response effect activating phosphorylation of ERK (Fig. 2A, B) and p38 (Fig. 2A, C), that was maximal within 5 min. The Ser/Thr protein kinase AKT, an upstream regulator of GSK-3β, was also activated after 5 min as determined by increased phosphorylation of S473 (Fig. 2A, D)",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 16,
      "target": 288,
      "key": "08628b918f3294e19afbfd8c63c9d2d274b9af0fbc02fc26bd359d1ac4d146dff620980398ea54e3c10e0b65fd95f5c0ded73d12b63e14595321f93a728407ed"
    },
    {
      "line": 1017,
      "relation": "increases",
      "evidence": "Wild-type MEFs treated with DMF (20 μM) showed a time-dependent response effect activating phosphorylation of ERK (Fig. 2A, B) and p38 (Fig. 2A, C), that was maximal within 5 min. The Ser/Thr protein kinase AKT, an upstream regulator of GSK-3β, was also activated after 5 min as determined by increased phosphorylation of S473 (Fig. 2A, D)",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 16,
      "target": 304,
      "key": "24bf49e9564c24c8113f7cd683056367c682fff3998f2eca5257325e54f7ffe84471fe0960ada51c9fe833b0c3a1140b2765dcbb255a94508bd113ff38d97a9d"
    },
    {
      "line": 1018,
      "relation": "positiveCorrelation",
      "evidence": "Wild-type MEFs treated with DMF (20 μM) showed a time-dependent response effect activating phosphorylation of ERK (Fig. 2A, B) and p38 (Fig. 2A, C), that was maximal within 5 min. The Ser/Thr protein kinase AKT, an upstream regulator of GSK-3β, was also activated after 5 min as determined by increased phosphorylation of S473 (Fig. 2A, D)",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 16,
      "target": 279,
      "key": "d5205a55d26754cb6e0dbc4f0e8eb35090eb83fe304da9f93edd9ec1ac351b73af6f2dc67dbbd44e7ce7df3a8a857b45bf5139016b7e11e6a236629416eed657"
    },
    {
      "line": 1023,
      "relation": "increases",
      "evidence": "DMF increased the phosphorylation levels of GSK-3βSer9 in both genotypes, indicating that this effect is upstream of NRF2 as shown in Fig. 3A.",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 16,
      "target": 457,
      "key": "f31717e22405b4fff65bda8e2a513056d5d1cbf67191bb986d84d20511d264bb2927e5691cc5242944633931f63514b78529a1725db5bd3529a4baf43b2fa036"
    },
    {
      "line": 1027,
      "relation": "decreases",
      "evidence": "Taken together, our results show that DMF reduces GSK-3 activity in vivo as determined by a significant and subtle reduction in the phosphorylation levels of its two substrates TAU and CRMP2 respectively.",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 16,
      "target": 538,
      "key": "942f7f9f3110f39f35c883819fe8728eeb726ebc7bdb5fb071d41816d4f96868b564d1e3c1041f5a3fa1fdc007ab2d630839435a85310b99f76d0315797c49ae"
    },
    {
      "line": 1028,
      "relation": "negativeCorrelation",
      "evidence": "Taken together, our results show that DMF reduces GSK-3 activity in vivo as determined by a significant and subtle reduction in the phosphorylation levels of its two substrates TAU and CRMP2 respectively.",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 16,
      "target": 440,
      "key": "e2c00a1c0b96a64e11be056de6a07f628c7b47623f848a81d49184058bec8900bf18c6ec68a3dfdafd343fdb0c10f5ca360f30fef6792f2e73fa73baf12a86fb"
    },
    {
      "line": 1037,
      "relation": "decreases",
      "evidence": "Astrocytes displayed enlarged bodies and ramifications (Type B morphology), consistent with a reactive state after TAUP301L expression in Nrf2+/+ and Nrf2−/− mice (Fig. 6A left panels). However, only astrocytes from Nrf2+/+ mice treated with DMF were maintained in a resting morphology (Type A) (Fig. 6A right panels). Concerning microglia, TAUP301L expression induced a very significant increase in IBA1+ microglia at the ipsilateral hippocampal side of Nrf2+/+ and Nrf2−/− mice  (Fig. 7A), which was confirmed by stereological quantification (Fig. 7B). DMF treatment reduced significantly this microgliosis in Nrf2+/+ but not in Nrf2−/− mice, reinforcing the idea of NRF2-dependent anti-inflammatory effect",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 16,
      "target": 136,
      "key": "e817eae1656e6b9ee771073b162578e092395cf3a29630452683d069d8aefb24d02b8b46a1464dbf8252ced0eee1e3bbf75e1bab596bc96eb681ffda19d18858"
    },
    {
      "line": 1038,
      "relation": "decreases",
      "evidence": "Astrocytes displayed enlarged bodies and ramifications (Type B morphology), consistent with a reactive state after TAUP301L expression in Nrf2+/+ and Nrf2−/− mice (Fig. 6A left panels). However, only astrocytes from Nrf2+/+ mice treated with DMF were maintained in a resting morphology (Type A) (Fig. 6A right panels). Concerning microglia, TAUP301L expression induced a very significant increase in IBA1+ microglia at the ipsilateral hippocampal side of Nrf2+/+ and Nrf2−/− mice  (Fig. 7A), which was confirmed by stereological quantification (Fig. 7B). DMF treatment reduced significantly this microgliosis in Nrf2+/+ but not in Nrf2−/− mice, reinforcing the idea of NRF2-dependent anti-inflammatory effect",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 16,
      "target": 141,
      "key": "6dee8f1a17e9538b40741c7ddd4b0dc2740df1765e6c598629c86fe40f1ba8c86fa9c17815915a55e95eade346f43d90a41ae219d3dd7aee99746ca25c3457d0"
    },
    {
      "line": 1043,
      "relation": "decreases",
      "evidence": "Messenger RNA analysis of two pro-inflammatory markers such as IL-1β and inducible nitric oxide synthase (iNOS) indicate that TAUP301L expression induce Il-1β (Fig. 6D) and iNOS (Fig. 7D) mRNA expression in both genotypes and DMF treatment decreased this expression only in Nrf2+/+ mice.",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 16,
      "target": 941,
      "key": "2bdeb9f5c2903656b2cb878f04d29796a8d4b52baa5059dc52dabda219c20dc9e9c5d0d4214e863691a6b4e9063f65a78358ef6aa3ef4b1e793581e674406368"
    },
    {
      "line": 1044,
      "relation": "decreases",
      "evidence": "Messenger RNA analysis of two pro-inflammatory markers such as IL-1β and inducible nitric oxide synthase (iNOS) indicate that TAUP301L expression induce Il-1β (Fig. 6D) and iNOS (Fig. 7D) mRNA expression in both genotypes and DMF treatment decreased this expression only in Nrf2+/+ mice.",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 16,
      "target": 943,
      "key": "393ec0cbbec3a56ccff8e4c4bbfd948dc98a09effdd89ccc6a31de8c71eed059baf0969a9eb9683becd2f14ce2eadb285effaf613935874b02d20d44d9393feb"
    },
    {
      "line": 1049,
      "relation": "decreases",
      "evidence": "Messenger RNA analysis of two pro-inflammatory markers such as IL-1β and inducible nitric oxide synthase (iNOS) indicate that TAUP301L expression induce Il-1β (Fig. 6D) and iNOS (Fig. 7D) mRNA expression in both genotypes and DMF treatment decreased this expression only in Nrf2+/+ mice.",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 16,
      "target": 184,
      "key": "fa29714be53ac51c4352870b760e003b3a52bd3ddf7336ef754624714ccbffebb76b7f3826893bcc4ef1b731c352d59c11bb0b4ce1529de5b43815ba5947fd6a"
    },
    {
      "line": 1018,
      "relation": "positiveCorrelation",
      "evidence": "Wild-type MEFs treated with DMF (20 μM) showed a time-dependent response effect activating phosphorylation of ERK (Fig. 2A, B) and p38 (Fig. 2A, C), that was maximal within 5 min. The Ser/Thr protein kinase AKT, an upstream regulator of GSK-3β, was also activated after 5 min as determined by increased phosphorylation of S473 (Fig. 2A, D)",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 279,
      "target": 16,
      "key": "d2308e29411bae4355b8edefe2d9dc6c45e7b05a302018600100d7b162bbb235b83c60e9a67ed8389475f0d4b16a0d8128f9761d0748ef227bd7be877c66e297"
    },
    {
      "line": 1019,
      "relation": "increases",
      "evidence": "Wild-type MEFs treated with DMF (20 μM) showed a time-dependent response effect activating phosphorylation of ERK (Fig. 2A, B) and p38 (Fig. 2A, C), that was maximal within 5 min. The Ser/Thr protein kinase AKT, an upstream regulator of GSK-3β, was also activated after 5 min as determined by increased phosphorylation of S473 (Fig. 2A, D)",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 279,
      "target": 278,
      "key": "95ad00e0d2f8fe1e807ebf842a45cddce5a77713c1c6d4b0778ac7b39dc7096f8a06b8261b655360d1d545f25be2e55f0052e558f75360850a7cd1ed644cdf00"
    },
    {
      "line": 1028,
      "relation": "negativeCorrelation",
      "evidence": "Taken together, our results show that DMF reduces GSK-3 activity in vivo as determined by a significant and subtle reduction in the phosphorylation levels of its two substrates TAU and CRMP2 respectively.",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 440,
      "target": 16,
      "key": "497ab12b0b151813a65831712605ee7446df226eebc58c07c95adfef5de7a26931ade3afcd62b2ee87b24e9e2c2ac8342ad56d1d902e6d05b527a8cdb42f1ade"
    },
    {
      "relation": "hasVariant",
      "source": 439,
      "target": 440,
      "key": "412edd6a7a5f227dd42ca599c4a1217478881ba0644f7144a68047ca542d1f4dc97c0e81cf45c4704f534639c09b0cc745965bbe54792da27063cbfe957ebde3"
    },
    {
      "line": 1035,
      "relation": "increases",
      "evidence": "Astrocytes displayed enlarged bodies and ramifications (Type B morphology), consistent with a reactive state after TAUP301L expression in Nrf2+/+ and Nrf2−/− mice (Fig. 6A left panels). However, only astrocytes from Nrf2+/+ mice treated with DMF were maintained in a resting morphology (Type A) (Fig. 6A right panels). Concerning microglia, TAUP301L expression induced a very significant increase in IBA1+ microglia at the ipsilateral hippocampal side of Nrf2+/+ and Nrf2−/− mice  (Fig. 7A), which was confirmed by stereological quantification (Fig. 7B). DMF treatment reduced significantly this microgliosis in Nrf2+/+ but not in Nrf2−/− mice, reinforcing the idea of NRF2-dependent anti-inflammatory effect",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 625,
      "target": 136,
      "key": "e90c41c65c0c5fb65596f1cb222347f679d80518cc6276453348f79d343878201a9116d34184344cea75fe765ef0395de32080d4c5cdffebec6b80a763b9f5e4"
    },
    {
      "line": 1036,
      "relation": "increases",
      "evidence": "Astrocytes displayed enlarged bodies and ramifications (Type B morphology), consistent with a reactive state after TAUP301L expression in Nrf2+/+ and Nrf2−/− mice (Fig. 6A left panels). However, only astrocytes from Nrf2+/+ mice treated with DMF were maintained in a resting morphology (Type A) (Fig. 6A right panels). Concerning microglia, TAUP301L expression induced a very significant increase in IBA1+ microglia at the ipsilateral hippocampal side of Nrf2+/+ and Nrf2−/− mice  (Fig. 7A), which was confirmed by stereological quantification (Fig. 7B). DMF treatment reduced significantly this microgliosis in Nrf2+/+ but not in Nrf2−/− mice, reinforcing the idea of NRF2-dependent anti-inflammatory effect",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 625,
      "target": 141,
      "key": "a1d90e00dcbaeb90613e3fbe5da8653b57fa7db7c1efc31d91ec39352b950c9f51c3342c8d58659d4f219d2acd5aeb1fdba9f08af07020daeddba73db420d703"
    },
    {
      "line": 1045,
      "relation": "increases",
      "evidence": "Messenger RNA analysis of two pro-inflammatory markers such as IL-1β and inducible nitric oxide synthase (iNOS) indicate that TAUP301L expression induce Il-1β (Fig. 6D) and iNOS (Fig. 7D) mRNA expression in both genotypes and DMF treatment decreased this expression only in Nrf2+/+ mice.",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 625,
      "target": 941,
      "key": "25abc2bd8954fd0f27ceaca4487ca830b8dafb2f91228bd6528c3bb8337a253b8fd22d6c60c192591bab8a08bc930deceacc426604588318b6f1000c0fee6009"
    },
    {
      "line": 1046,
      "relation": "increases",
      "evidence": "Messenger RNA analysis of two pro-inflammatory markers such as IL-1β and inducible nitric oxide synthase (iNOS) indicate that TAUP301L expression induce Il-1β (Fig. 6D) and iNOS (Fig. 7D) mRNA expression in both genotypes and DMF treatment decreased this expression only in Nrf2+/+ mice.",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 625,
      "target": 943,
      "key": "817768f50e7d01eda1c91f18e4c7a7c1d9e7e29e49015ddd535a345513ab410fddfe2155f3784519590b7e66b3731481dc7ccdff90fba7b5cc7318a642adcca0"
    },
    {
      "line": 1665,
      "relation": "positiveCorrelation",
      "evidence": "Poorkaj et al. reported two exonic mutations (P301L and V337M) in two families with FTDP-17 [139], while Hutton et al. reported six different mutations in 10 families: three of these mutations (G272V, P301L and R406W) were missense mutations in exons, while the other three were in the 5' splice site of exon 10 [140].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 625,
      "target": 913,
      "key": "2d2ae540083dbb47c53da88e2c8941b02e595188faacd31ac87c7145a76f0eb0f6644aeafb7cbcae98d0607115cdc83c95880c8c87ff0b0c8956f3f69b4605b5"
    },
    {
      "line": 2538,
      "relation": "positiveCorrelation",
      "evidence": "We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia. In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes. Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3α/β at tyrosine 279/216 also showed an intense rather than moderate AT8 (phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with fibrillar tau pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "23294633",
        "name": "Neurobiology of aging",
        "title": "Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.",
        "volume": "34",
        "pages": "1369-79",
        "date": "2013-05-01",
        "first": "Köhler C",
        "last": "Götz J",
        "authors": [
          "Dinekov M",
          "Götz J",
          "Köhler C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "pR5 mice": true
        }
      },
      "source": 625,
      "target": 796,
      "key": "0732dc8673545bda283dad5b5e6769ee8e9d85a77b808a5c978faea5fe645107681800f7d8bfcbe4dad45222dc8df93913f8565fe8baa2c5374917ed11b3d68e"
    },
    {
      "line": 2539,
      "relation": "positiveCorrelation",
      "evidence": "We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia. In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes. Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3α/β at tyrosine 279/216 also showed an intense rather than moderate AT8 (phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with fibrillar tau pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "23294633",
        "name": "Neurobiology of aging",
        "title": "Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.",
        "volume": "34",
        "pages": "1369-79",
        "date": "2013-05-01",
        "first": "Köhler C",
        "last": "Götz J",
        "authors": [
          "Dinekov M",
          "Götz J",
          "Köhler C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "pR5 mice": true
        }
      },
      "source": 625,
      "target": 795,
      "key": "7377ff8796ebdf7d307770662b6705fbd49d4b44fbc8d0bc5e9c0978af91803cc5741488073d2652d74e01be936184bc1bde93dd9e5ea7c9922e7473735c050f"
    },
    {
      "line": 2542,
      "relation": "positiveCorrelation",
      "evidence": "We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia. In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes. Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3α/β at tyrosine 279/216 also showed an intense rather than moderate AT8 (phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with fibrillar tau pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "23294633",
        "name": "Neurobiology of aging",
        "title": "Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.",
        "volume": "34",
        "pages": "1369-79",
        "date": "2013-05-01",
        "first": "Köhler C",
        "last": "Götz J",
        "authors": [
          "Dinekov M",
          "Götz J",
          "Köhler C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "pR5 mice": true
        }
      },
      "source": 625,
      "target": 544,
      "key": "c4769a870fc1dea47e665b0513b4bd446df2f81b1912b7dcb313ac3bab83c0f051d57a88be71e9aa9d3ac6001313919f966ed435a6c9b94c2fef3bdf6f48adfe"
    },
    {
      "line": 2543,
      "relation": "positiveCorrelation",
      "evidence": "We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia. In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes. Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3α/β at tyrosine 279/216 also showed an intense rather than moderate AT8 (phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with fibrillar tau pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "23294633",
        "name": "Neurobiology of aging",
        "title": "Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.",
        "volume": "34",
        "pages": "1369-79",
        "date": "2013-05-01",
        "first": "Köhler C",
        "last": "Götz J",
        "authors": [
          "Dinekov M",
          "Götz J",
          "Köhler C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "pR5 mice": true
        }
      },
      "source": 625,
      "target": 579,
      "key": "ea89fe42e3e1276474e5013f44647efc80cdd8ca89fb0fe074afb8046c0c14d103da4a1a8333f6a2d95645ae83d2c45ad60539e8bcf1fbe59aefc8c31501df35"
    },
    {
      "line": 2544,
      "relation": "positiveCorrelation",
      "evidence": "We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia. In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes. Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3α/β at tyrosine 279/216 also showed an intense rather than moderate AT8 (phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with fibrillar tau pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "23294633",
        "name": "Neurobiology of aging",
        "title": "Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.",
        "volume": "34",
        "pages": "1369-79",
        "date": "2013-05-01",
        "first": "Köhler C",
        "last": "Götz J",
        "authors": [
          "Dinekov M",
          "Götz J",
          "Köhler C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "pR5 mice": true
        }
      },
      "source": 625,
      "target": 114,
      "key": "2352a7d2e28919363b784341320070b4dca56e8055a296e6ea1c4a2ab56f36fb01d27f57d23796e72b6af33b70ba0019d547099f1fa17551eadbac0ad3638c14"
    },
    {
      "line": 2545,
      "relation": "positiveCorrelation",
      "evidence": "We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia. In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes. Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3α/β at tyrosine 279/216 also showed an intense rather than moderate AT8 (phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with fibrillar tau pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "23294633",
        "name": "Neurobiology of aging",
        "title": "Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.",
        "volume": "34",
        "pages": "1369-79",
        "date": "2013-05-01",
        "first": "Köhler C",
        "last": "Götz J",
        "authors": [
          "Dinekov M",
          "Götz J",
          "Köhler C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "pR5 mice": true
        }
      },
      "source": 625,
      "target": 569,
      "key": "65326b5831e91a7cfca3baf17626bfa04452988a2645350f0ee7d716edd5b3e177ad9bba5c3594e8fcd0c88668172beba0c6a32b9800b9caeb67e05b68e4e508"
    },
    {
      "line": 3579,
      "relation": "positiveCorrelation",
      "evidence": "We also show that two of the tau mutations found in hereditary frontotemporal dementias, DeltaK280 and P301L, have a much stronger tendency for PHF aggregation which correlates with their high propensity for beta-structure around the hexapeptide motifs.",
      "citation": {
        "type": "PubMed",
        "reference": "11606569",
        "name": "The Journal of biological chemistry",
        "title": "Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure.",
        "volume": "276",
        "pages": "48165-74",
        "date": "2001-12-21",
        "first": "von Bergen M",
        "last": "Mandelkow E",
        "authors": [
          "Barghorn S",
          "Biernat J",
          "Li L",
          "Mandelkow E",
          "Mandelkow EM",
          "Marx A",
          "von Bergen M"
        ]
      },
      "source": 625,
      "target": 355,
      "key": "5133da520254e1b6aa6280ce95dd4d484ad6ef415ac2ddbee3d818a4656527dfe4709a7dad8f43f9e97968afd172c88ca02716ee9759b7f1b8678518eb91bac3"
    },
    {
      "line": 3580,
      "relation": "positiveCorrelation",
      "evidence": "We also show that two of the tau mutations found in hereditary frontotemporal dementias, DeltaK280 and P301L, have a much stronger tendency for PHF aggregation which correlates with their high propensity for beta-structure around the hexapeptide motifs.",
      "citation": {
        "type": "PubMed",
        "reference": "11606569",
        "name": "The Journal of biological chemistry",
        "title": "Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure.",
        "volume": "276",
        "pages": "48165-74",
        "date": "2001-12-21",
        "first": "von Bergen M",
        "last": "Mandelkow E",
        "authors": [
          "Barghorn S",
          "Biernat J",
          "Li L",
          "Mandelkow E",
          "Mandelkow EM",
          "Marx A",
          "von Bergen M"
        ]
      },
      "source": 625,
      "target": 356,
      "key": "43b533a9b3e7f6beddf31ff4f0817d9caedffb6ab617bdf33c5c8f1bb4a1bd5bee27e53fd0cd98df41bcec0490df53d0984951379604ac99d374a4c0239a608b"
    },
    {
      "line": 3600,
      "relation": "positiveCorrelation",
      "evidence": "The tauopathy mice that we used contained the P301L mutation, which is implicated in some genetic tauopathies. In addition, this mutation, along with the related P301S mutation, has been associated with increased inflammation in the brain as well as retinal deficits",
      "citation": {
        "type": "PubMed",
        "reference": "27716675",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases.",
        "volume": "55",
        "pages": "1083-1099",
        "date": "2017-01-01",
        "first": "Nilson AN",
        "last": "Kayed R",
        "authors": [
          "Barton Whittle T",
          "Castillo-Carranza DL",
          "English KC",
          "Gerson JE",
          "Gupta P",
          "Kayed R",
          "Nicolas Crain C",
          "Nilson AN",
          "Sengupta U",
          "Xue J",
          "Zhang W"
        ]
      },
      "source": 625,
      "target": 154,
      "key": "14bf6db9a518af74302ecdae2fbc3e0f2d293eba1712c0766d2c6df925c27a50bdd9a225293e7006753223804b957d450c50c824b82f135d4756e1cb86d16880"
    },
    {
      "line": 2878,
      "relation": "biomarkerFor",
      "evidence": "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24401760",
        "name": "Brain : a journal of neurology",
        "title": "Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.",
        "volume": "137",
        "pages": "537-52",
        "date": "2014-02-01",
        "first": "Stygelbout V",
        "last": "Brion JP",
        "authors": [
          "Ando K",
          "Brion JP",
          "D'Amico E",
          "Duyckaerts C",
          "Erneux C",
          "Jia Y",
          "Leroy K",
          "Luo HR",
          "Pouillon V",
          "Schurmans S",
          "Stygelbout V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "5xFAD mice": true
        }
      },
      "source": 136,
      "target": 908,
      "key": "783a0041aa206afa668f609664d3bbcd8b74b669926873319756b6adbd6a92087ad93bbea4f5cba98d865bd1be6b95efee8ec0b7b924e627bca9e0a7ea63910b"
    },
    {
      "line": 1047,
      "relation": "biomarkerFor",
      "evidence": "Messenger RNA analysis of two pro-inflammatory markers such as IL-1β and inducible nitric oxide synthase (iNOS) indicate that TAUP301L expression induce Il-1β (Fig. 6D) and iNOS (Fig. 7D) mRNA expression in both genotypes and DMF treatment decreased this expression only in Nrf2+/+ mice.",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 941,
      "target": 184,
      "key": "405d658d6a7ae50da0f3028c6b3ac5edb6c767e484e6d58476a156f7edde2ea4f796f846410234142839dd86a3f73520c92f37f40277ac6d0af1be11734adafa"
    },
    {
      "line": 1048,
      "relation": "biomarkerFor",
      "evidence": "Messenger RNA analysis of two pro-inflammatory markers such as IL-1β and inducible nitric oxide synthase (iNOS) indicate that TAUP301L expression induce Il-1β (Fig. 6D) and iNOS (Fig. 7D) mRNA expression in both genotypes and DMF treatment decreased this expression only in Nrf2+/+ mice.",
      "citation": {
        "type": "PubMed",
        "reference": "29121589",
        "name": "Redox biology",
        "title": "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.",
        "volume": "14",
        "pages": "522-534",
        "date": "2018-04-01",
        "first": "Cuadrado A",
        "last": "Lastres-Becker I",
        "authors": [
          "Cuadrado A",
          "Kügler S",
          "Lastres-Becker I"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 943,
      "target": 184,
      "key": "58203853bb0eb19171ac0c2e23b85c41f6d4be69ea5bee68efa2cd2ee1862d6371819011c55633c20341e292389e02168364a53593eb2f5b32658da436e2facd"
    },
    {
      "line": 1058,
      "relation": "directlyIncreases",
      "evidence": "p39, but not p35, is selectively upregulated by histone acetylation-mediated transcription, underlying the robust increase of Cdk5 activity during rat and mouse neuronal differentiation. Loss of p39 attenuates Cdk5 activity in neurons and preferentially affects phosphorylation of specific Cdk5 targets, leading to aberrant axonal growth and impaired dendritic spine and synapse formation.",
      "citation": {
        "type": "PubMed",
        "reference": "27807169",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "p39 Is Responsible for Increasing Cdk5 Activity during Postnatal Neuron Differentiation and Governs Neuronal Network Formation and Epileptic Responses.",
        "volume": "36",
        "pages": "11283-11294",
        "date": "2016-11-02",
        "first": "Li W",
        "last": "Feng Y",
        "authors": [
          "Allen ME",
          "Bankston AN",
          "Feng Y",
          "Ku L",
          "Li W",
          "Liu G",
          "Rui Y",
          "Zheng JQ"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 862,
      "target": 860,
      "key": "5b271b708d2735f9de1a8d4fe8292580ef3077d7ce5711c2db79a9d418c4c4a4098d367a71999e445c2f8043d876f60786c9e370f7f726f8e039e7b349c4d4b1"
    },
    {
      "line": 1059,
      "relation": "positiveCorrelation",
      "evidence": "p39, but not p35, is selectively upregulated by histone acetylation-mediated transcription, underlying the robust increase of Cdk5 activity during rat and mouse neuronal differentiation. Loss of p39 attenuates Cdk5 activity in neurons and preferentially affects phosphorylation of specific Cdk5 targets, leading to aberrant axonal growth and impaired dendritic spine and synapse formation.",
      "citation": {
        "type": "PubMed",
        "reference": "27807169",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "p39 Is Responsible for Increasing Cdk5 Activity during Postnatal Neuron Differentiation and Governs Neuronal Network Formation and Epileptic Responses.",
        "volume": "36",
        "pages": "11283-11294",
        "date": "2016-11-02",
        "first": "Li W",
        "last": "Feng Y",
        "authors": [
          "Allen ME",
          "Bankston AN",
          "Feng Y",
          "Ku L",
          "Li W",
          "Liu G",
          "Rui Y",
          "Zheng JQ"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 862,
      "target": 80,
      "key": "5caf5046fc039ca4ddfae36df91179032aec482bef10e58d1b3b0daaa7336e4ccda7dad1dc42ec53e20c67906b6e3da6b9158642a30b443fc078844195ba464f"
    },
    {
      "line": 1060,
      "relation": "positiveCorrelation",
      "evidence": "p39, but not p35, is selectively upregulated by histone acetylation-mediated transcription, underlying the robust increase of Cdk5 activity during rat and mouse neuronal differentiation. Loss of p39 attenuates Cdk5 activity in neurons and preferentially affects phosphorylation of specific Cdk5 targets, leading to aberrant axonal growth and impaired dendritic spine and synapse formation.",
      "citation": {
        "type": "PubMed",
        "reference": "27807169",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "p39 Is Responsible for Increasing Cdk5 Activity during Postnatal Neuron Differentiation and Governs Neuronal Network Formation and Epileptic Responses.",
        "volume": "36",
        "pages": "11283-11294",
        "date": "2016-11-02",
        "first": "Li W",
        "last": "Feng Y",
        "authors": [
          "Allen ME",
          "Bankston AN",
          "Feng Y",
          "Ku L",
          "Li W",
          "Liu G",
          "Rui Y",
          "Zheng JQ"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 862,
      "target": 89,
      "key": "c2780f9d2b027a2bc17ff925beb060f917278136fa742e7c3e9331e7f3f536c18d9c410c66b84cb58f89b9bd8e80721dc4bd27ad5a940a3c6697eb4b3dcfec7e"
    },
    {
      "line": 3861,
      "relation": "directlyIncreases",
      "evidence": "In NGF-exposed PC12 cells, Egr-1 activates Cdk5 to promote phosphorylation of tau and inactivates PP1 via phosphorylation. Cdk5 phosphorylates Ser(396/404) directly. By phosphorylating and inactivating PP1, Cdk5 promotes tau phosphorylation at Ser(262) indirectly.",
      "citation": {
        "type": "PubMed",
        "reference": "21489990",
        "name": "The Journal of biological chemistry",
        "title": "Early growth response 1 (Egr-1) regulates phosphorylation of microtubule-associated protein tau in mammalian brain.",
        "volume": "286",
        "pages": "20569-81",
        "date": "2011-06-10",
        "first": "Lu Y",
        "last": "Paudel HK",
        "authors": [
          "Han D",
          "Li T",
          "Lu Y",
          "Paudel HK",
          "Qureshi HY"
        ]
      },
      "annotations": {
        "CellLine": {
          "PC12": true
        },
        "Species": {
          "10116": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 860,
      "target": 880,
      "key": "a57d3f5ebc98391a21a419f675cd1d3871a722c14f6036471b39e0c3efdb2ba094ceff14acd039c1ae14e1f7f4aca6e09c5a69ad13f580aab77eded697c6d977"
    },
    {
      "line": 3862,
      "relation": "directlyIncreases",
      "evidence": "In NGF-exposed PC12 cells, Egr-1 activates Cdk5 to promote phosphorylation of tau and inactivates PP1 via phosphorylation. Cdk5 phosphorylates Ser(396/404) directly. By phosphorylating and inactivating PP1, Cdk5 promotes tau phosphorylation at Ser(262) indirectly.",
      "citation": {
        "type": "PubMed",
        "reference": "21489990",
        "name": "The Journal of biological chemistry",
        "title": "Early growth response 1 (Egr-1) regulates phosphorylation of microtubule-associated protein tau in mammalian brain.",
        "volume": "286",
        "pages": "20569-81",
        "date": "2011-06-10",
        "first": "Lu Y",
        "last": "Paudel HK",
        "authors": [
          "Han D",
          "Li T",
          "Lu Y",
          "Paudel HK",
          "Qureshi HY"
        ]
      },
      "annotations": {
        "CellLine": {
          "PC12": true
        },
        "Species": {
          "10116": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 860,
      "target": 881,
      "key": "7abfdaaa0e638e1c18caa2213116fae67eeb30ff12139d50a0f856e4ed65b6e12653b69df0ec0f22563a5d31d83a24c7d9e414e2d65d990c394f7a5eb324cca0"
    },
    {
      "line": 3863,
      "relation": "directlyDecreases",
      "evidence": "In NGF-exposed PC12 cells, Egr-1 activates Cdk5 to promote phosphorylation of tau and inactivates PP1 via phosphorylation. Cdk5 phosphorylates Ser(396/404) directly. By phosphorylating and inactivating PP1, Cdk5 promotes tau phosphorylation at Ser(262) indirectly.",
      "citation": {
        "type": "PubMed",
        "reference": "21489990",
        "name": "The Journal of biological chemistry",
        "title": "Early growth response 1 (Egr-1) regulates phosphorylation of microtubule-associated protein tau in mammalian brain.",
        "volume": "286",
        "pages": "20569-81",
        "date": "2011-06-10",
        "first": "Lu Y",
        "last": "Paudel HK",
        "authors": [
          "Han D",
          "Li T",
          "Lu Y",
          "Paudel HK",
          "Qureshi HY"
        ]
      },
      "annotations": {
        "CellLine": {
          "PC12": true
        },
        "Species": {
          "10116": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 860,
      "target": 896,
      "key": "4ef95eeba9703dc7fed908de65f558bd54be33323610e7027007a237abbed3eecec87b21d6080717ded935d6a35c1d702538cf866d137669e6080d816d701867"
    },
    {
      "line": 1059,
      "relation": "positiveCorrelation",
      "evidence": "p39, but not p35, is selectively upregulated by histone acetylation-mediated transcription, underlying the robust increase of Cdk5 activity during rat and mouse neuronal differentiation. Loss of p39 attenuates Cdk5 activity in neurons and preferentially affects phosphorylation of specific Cdk5 targets, leading to aberrant axonal growth and impaired dendritic spine and synapse formation.",
      "citation": {
        "type": "PubMed",
        "reference": "27807169",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "p39 Is Responsible for Increasing Cdk5 Activity during Postnatal Neuron Differentiation and Governs Neuronal Network Formation and Epileptic Responses.",
        "volume": "36",
        "pages": "11283-11294",
        "date": "2016-11-02",
        "first": "Li W",
        "last": "Feng Y",
        "authors": [
          "Allen ME",
          "Bankston AN",
          "Feng Y",
          "Ku L",
          "Li W",
          "Liu G",
          "Rui Y",
          "Zheng JQ"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 80,
      "target": 862,
      "key": "0a16d399160f54fa8a090b56a19a12bf0ed5a8d75b52c8ab02fca1f3b72b20a55d20f51891f14e4d48fc60c767f386053fbd162adc94df0c5b0f9cc31ce284bd"
    },
    {
      "line": 2685,
      "relation": "negativeCorrelation",
      "evidence": "Overexpression of MARK4 led to tau hyperphosphorylation, reduced expression of synaptic markers, and loss of dendritic spines and synapses, phenotypes also observed after Aβ treatment. Importantly, expression of a non-phosphorylatable form of tau with the PAR-1/MARK site mutated blocked the synaptic toxicity induced by MARK4 overexpression or Aβ treatment. To probe the involvement of endogenous MARK kinases in mediating the synaptic toxicity of Aβ, we employed a peptide inhibitor capable of effectively and specifically inhibiting the activities of all PAR-1/MARK family members. This inhibitor abrogated the toxic effects of Aβ oligomers on dendritic spines and synapses as assayed at the morphological and electrophysiological levels.",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 80,
      "target": 635,
      "key": "8b87309cb5f6860bcf48b3af41a342593b2a93f84f422ca953902bab83bc7023b3c90f529bab2bbefafd469f28c70051c5bdaa3d2956307f23ddd3eabfeec381"
    },
    {
      "line": 1060,
      "relation": "positiveCorrelation",
      "evidence": "p39, but not p35, is selectively upregulated by histone acetylation-mediated transcription, underlying the robust increase of Cdk5 activity during rat and mouse neuronal differentiation. Loss of p39 attenuates Cdk5 activity in neurons and preferentially affects phosphorylation of specific Cdk5 targets, leading to aberrant axonal growth and impaired dendritic spine and synapse formation.",
      "citation": {
        "type": "PubMed",
        "reference": "27807169",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "p39 Is Responsible for Increasing Cdk5 Activity during Postnatal Neuron Differentiation and Governs Neuronal Network Formation and Epileptic Responses.",
        "volume": "36",
        "pages": "11283-11294",
        "date": "2016-11-02",
        "first": "Li W",
        "last": "Feng Y",
        "authors": [
          "Allen ME",
          "Bankston AN",
          "Feng Y",
          "Ku L",
          "Li W",
          "Liu G",
          "Rui Y",
          "Zheng JQ"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 89,
      "target": 862,
      "key": "ed4f51b93dd192117eee4a82aa7847c7cab1e51235aef2a209c01aed98548321cf7c15a6c8d72ccc343b1ffba4a07a1e3fbfbe34108d67eadf728734b591be00"
    },
    {
      "line": 2686,
      "relation": "negativeCorrelation",
      "evidence": "Overexpression of MARK4 led to tau hyperphosphorylation, reduced expression of synaptic markers, and loss of dendritic spines and synapses, phenotypes also observed after Aβ treatment. Importantly, expression of a non-phosphorylatable form of tau with the PAR-1/MARK site mutated blocked the synaptic toxicity induced by MARK4 overexpression or Aβ treatment. To probe the involvement of endogenous MARK kinases in mediating the synaptic toxicity of Aβ, we employed a peptide inhibitor capable of effectively and specifically inhibiting the activities of all PAR-1/MARK family members. This inhibitor abrogated the toxic effects of Aβ oligomers on dendritic spines and synapses as assayed at the morphological and electrophysiological levels.",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 89,
      "target": 635,
      "key": "b582e314c955996ff50244b3edec8d149bc6dbd21e48a3180ae9f5de5e7735cf1d6240a0f5fcefabc627695a501a8fb8bea0590af9f3735fb5a3e1695618d42e"
    },
    {
      "relation": "hasVariant",
      "source": 284,
      "target": 285,
      "key": "a4440f8cc17b924e751fdc8e79da7008f147b2aaafc4376d9f523080e545ce1d607b11e244bda0420fda1df83a4094f3d8023ee07c7047e67164af8f1ae05ee9"
    },
    {
      "line": 3091,
      "relation": "negativeCorrelation",
      "evidence": "Here we report the discovery of a new first-in-class small-molecule (CM-414) that acts as a dual inhibitor of PDE5 and HDACs. We have used this compound as a chemical probe to validate this systems therapeutics strategy, where an increase in the activation of cAMP/cGMP-responsive element-binding protein (CREB) induced by PDE5 inhibition, combined with moderate HDAC class I inhibition, leads to efficient histone acetylation. This molecule rescued the impaired long-term potentiation evident in hippocampal slices from APP/PS1 mice. Chronic treatment of Tg2576 mice with CM-414 diminished brain Aβ and tau phosphorylation (pTau) levels, increased the inactive form of GSK3β, reverted the decrease in dendritic spine density on hippocampal neurons, and reversed their cognitive deficits, at least in part by inducing the expression of genes related to synaptic transmission.",
      "citation": {
        "type": "PubMed",
        "reference": "27550730",
        "name": "Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology",
        "title": "A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice.",
        "volume": "42",
        "pages": "524-539",
        "date": "2017-01-01",
        "first": "Cuadrado-Tejedor M",
        "last": "Garcia-Osta A",
        "authors": [
          "Cuadrado-Tejedor M",
          "Franco R",
          "Garcia-Barroso C",
          "Garcia-Osta A",
          "Mederos S",
          "Oyarzabal J",
          "Perea G",
          "Pérez-González M",
          "Rabal O",
          "Segura V",
          "Sánchez-Arias JA",
          "Ugarte A"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 284,
      "target": 646,
      "key": "17e70407c50df5d25a0aea62d57246e4ad80bf683b024a30466bfd82339fc449570503abff91f5744c7788ca2222be63ebd58e767707393d279ff6ed35c0de05"
    },
    {
      "relation": "hasVariant",
      "source": 637,
      "target": 638,
      "key": "ba4b2ca59ccd71e516ef2da55e1fa5ab193f31874635407b1005b39a920666ae21be0cad78199993cf892556a20e9f21b71e14a17dce89afe4ccfbc698ea51e9"
    },
    {
      "relation": "hasVariant",
      "source": 409,
      "target": 410,
      "key": "cf1c55abc958f28ae81a1520680d2ebf433b348ddbd810ca92e1653b43a9777f5ed6a2a254b291f2edae57790f2e8d81e50b061606751468e9fbe8b6eedf0db1"
    },
    {
      "relation": "hasVariant",
      "source": 655,
      "target": 656,
      "key": "f2b45a647932629d6a9cf1ffb94cc8a182d022f82b7890c6e955887ef9fed5b67bc84c2e55d62e9b12ca5ceb19b8afa22a35d7298a8a09f65de1c79d5ed3e01d"
    },
    {
      "relation": "hasVariant",
      "source": 418,
      "target": 419,
      "key": "8504e0015385bbfc31eefdbbdcbdc8be6a18de477c42fea5600647155470d7b5b633d8865c703b9fc50169457d7f493b4d8be8da0e81230ae43439f592216547"
    },
    {
      "line": 1085,
      "relation": "decreases",
      "evidence": "Vm (nM/min/mg) is 2400, 80, 106, 650, and 140; Km is 200, 59, 114, 16 (all uM) and 5mg/ml for phospho-CREB peptide, myelin basic protein, k-casein, phosphatase Inhibitor-2 and phosvitin",
      "citation": {
        "type": "PubMed",
        "reference": "7514173",
        "name": "The Journal of biological chemistry",
        "title": "Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation.",
        "volume": "269",
        "pages": "14566-74",
        "date": "1994-05-20",
        "first": "Wang QM",
        "last": "Roach PJ",
        "authors": [
          "DePaoli-Roach AA",
          "Fiol CJ",
          "Roach PJ",
          "Wang QM"
        ]
      },
      "annotations": {
        "IC50": {
          "50 mM": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 20,
      "target": 456,
      "key": "e65513c7c949635a470afe5a23811f7f82debe4694cfad7cf1d5dadceac2f53394e61b63869faaab3ccf6f6982c41c3840687930dc1ac1a36d2968db2b9b7c5b"
    },
    {
      "line": 1087,
      "relation": "decreases",
      "evidence": "Vm (nM/min/mg) is 2400, 80, 106, 650, and 140; Km is 200, 59, 114, 16 (all uM) and 5mg/ml for phospho-CREB peptide, myelin basic protein, k-casein, phosphatase Inhibitor-2 and phosvitin",
      "citation": {
        "type": "PubMed",
        "reference": "7514173",
        "name": "The Journal of biological chemistry",
        "title": "Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation.",
        "volume": "269",
        "pages": "14566-74",
        "date": "1994-05-20",
        "first": "Wang QM",
        "last": "Roach PJ",
        "authors": [
          "DePaoli-Roach AA",
          "Fiol CJ",
          "Roach PJ",
          "Wang QM"
        ]
      },
      "annotations": {
        "IC50": {
          "0.2 mM": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 14,
      "target": 456,
      "key": "e6c11985610113c9d0304394996d1ee9c2329af10d00653be219df2e8e8081c41611c880e3c305b715b8c0650d8c380779ede1feb4e1785ba4662034bf064899"
    },
    {
      "line": 1089,
      "relation": "decreases",
      "evidence": "Vm (nM/min/mg) is 2400, 80, 106, 650, and 140; Km is 200, 59, 114, 16 (all uM) and 5mg/ml for phospho-CREB peptide, myelin basic protein, k-casein, phosphatase Inhibitor-2 and phosvitin",
      "citation": {
        "type": "PubMed",
        "reference": "7514173",
        "name": "The Journal of biological chemistry",
        "title": "Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation.",
        "volume": "269",
        "pages": "14566-74",
        "date": "1994-05-20",
        "first": "Wang QM",
        "last": "Roach PJ",
        "authors": [
          "DePaoli-Roach AA",
          "Fiol CJ",
          "Roach PJ",
          "Wang QM"
        ]
      },
      "annotations": {
        "IC50": {
          "0.6 mM": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 30,
      "target": 456,
      "key": "13957d017ccce535f479fdcdd3ecabe13e47997c7cc65b76cf6523b746babab396ef0d96ba27d082ba50e900196e3630183a0f9eca0232d34022a751a6dadbe8"
    },
    {
      "line": 1091,
      "relation": "decreases",
      "evidence": "Vm (nM/min/mg) is 2400, 80, 106, 650, and 140; Km is 200, 59, 114, 16 (all uM) and 5mg/ml for phospho-CREB peptide, myelin basic protein, k-casein, phosphatase Inhibitor-2 and phosvitin",
      "citation": {
        "type": "PubMed",
        "reference": "7514173",
        "name": "The Journal of biological chemistry",
        "title": "Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation.",
        "volume": "269",
        "pages": "14566-74",
        "date": "1994-05-20",
        "first": "Wang QM",
        "last": "Roach PJ",
        "authors": [
          "DePaoli-Roach AA",
          "Fiol CJ",
          "Roach PJ",
          "Wang QM"
        ]
      },
      "annotations": {
        "IC50": {
          "2 mM": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 39,
      "target": 456,
      "key": "df8d6e6e3d42deec9efb4db71ee1df20e67c47fa215029ab1bf09c594ef936c23c978b0dd29a3b68ad59ab15dbbb8e591f656f86a50ae8beffecffe8cc5aefa5"
    },
    {
      "line": 1093,
      "relation": "decreases",
      "evidence": "Vm (nM/min/mg) is 2400, 80, 106, 650, and 140; Km is 200, 59, 114, 16 (all uM) and 5mg/ml for phospho-CREB peptide, myelin basic protein, k-casein, phosphatase Inhibitor-2 and phosvitin",
      "citation": {
        "type": "PubMed",
        "reference": "7514173",
        "name": "The Journal of biological chemistry",
        "title": "Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation.",
        "volume": "269",
        "pages": "14566-74",
        "date": "1994-05-20",
        "first": "Wang QM",
        "last": "Roach PJ",
        "authors": [
          "DePaoli-Roach AA",
          "Fiol CJ",
          "Roach PJ",
          "Wang QM"
        ]
      },
      "annotations": {
        "IC50": {
          "0.4 mg/ml": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 29,
      "target": 456,
      "key": "4cfd147d82628fd0bc847fb522172505abc3132a7ba2fd40e7907ca601dc10fa3f9c43f6a6b86acba675637a95a3e1b3edb7f1dbc81a4c8556a9f664cda54aad"
    },
    {
      "line": 1095,
      "relation": "decreases",
      "evidence": "Vm (nM/min/mg) is 2400, 80, 106, 650, and 140; Km is 200, 59, 114, 16 (all uM) and 5mg/ml for phospho-CREB peptide, myelin basic protein, k-casein, phosphatase Inhibitor-2 and phosvitin",
      "citation": {
        "type": "PubMed",
        "reference": "7514173",
        "name": "The Journal of biological chemistry",
        "title": "Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation.",
        "volume": "269",
        "pages": "14566-74",
        "date": "1994-05-20",
        "first": "Wang QM",
        "last": "Roach PJ",
        "authors": [
          "DePaoli-Roach AA",
          "Fiol CJ",
          "Roach PJ",
          "Wang QM"
        ]
      },
      "annotations": {
        "IC50": {
          "160 mM": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 33,
      "target": 456,
      "key": "598baab47ae3822d727962b61b7ef54c45474ef6dc1f2277379df6a0b3e7edbd8040e0ef55ddc8c4eedff817b34cd96fdf40580d1edd5e1613a787e898f00aec"
    },
    {
      "line": 1097,
      "relation": "decreases",
      "evidence": "Vm (nM/min/mg) is 2400, 80, 106, 650, and 140; Km is 200, 59, 114, 16 (all uM) and 5mg/ml for phospho-CREB peptide, myelin basic protein, k-casein, phosphatase Inhibitor-2 and phosvitin",
      "citation": {
        "type": "PubMed",
        "reference": "7514173",
        "name": "The Journal of biological chemistry",
        "title": "Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation.",
        "volume": "269",
        "pages": "14566-74",
        "date": "1994-05-20",
        "first": "Wang QM",
        "last": "Roach PJ",
        "authors": [
          "DePaoli-Roach AA",
          "Fiol CJ",
          "Roach PJ",
          "Wang QM"
        ]
      },
      "annotations": {
        "IC50": {
          "35 mM": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 34,
      "target": 456,
      "key": "f470b0154c12785114e7d90d1a6862e6bd493935e85e125a5466ed419c332ca040cfa3992987eee88ca05452baf4e5cfe52212cda4d30e8a10402f1445a1ff96"
    },
    {
      "line": 1099,
      "relation": "decreases",
      "evidence": "Vm (nM/min/mg) is 2400, 80, 106, 650, and 140; Km is 200, 59, 114, 16 (all uM) and 5mg/ml for phospho-CREB peptide, myelin basic protein, k-casein, phosphatase Inhibitor-2 and phosvitin",
      "citation": {
        "type": "PubMed",
        "reference": "7514173",
        "name": "The Journal of biological chemistry",
        "title": "Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation.",
        "volume": "269",
        "pages": "14566-74",
        "date": "1994-05-20",
        "first": "Wang QM",
        "last": "Roach PJ",
        "authors": [
          "DePaoli-Roach AA",
          "Fiol CJ",
          "Roach PJ",
          "Wang QM"
        ]
      },
      "annotations": {
        "IC50": {
          "0.4 mM": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 23,
      "target": 456,
      "key": "7def384c04c4a1e34fcc253cf2a353d8a841bd41cf8d71a9b70b4e36d927188bef8eb5ae283111f408d17f37b3746f2171d8fd0e1b78e8a6732b61bf5849cb27"
    },
    {
      "line": 1101,
      "relation": "decreases",
      "evidence": "Vm (nM/min/mg) is 2400, 80, 106, 650, and 140; Km is 200, 59, 114, 16 (all uM) and 5mg/ml for phospho-CREB peptide, myelin basic protein, k-casein, phosphatase Inhibitor-2 and phosvitin",
      "citation": {
        "type": "PubMed",
        "reference": "7514173",
        "name": "The Journal of biological chemistry",
        "title": "Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation.",
        "volume": "269",
        "pages": "14566-74",
        "date": "1994-05-20",
        "first": "Wang QM",
        "last": "Roach PJ",
        "authors": [
          "DePaoli-Roach AA",
          "Fiol CJ",
          "Roach PJ",
          "Wang QM"
        ]
      },
      "annotations": {
        "IC50": {
          "4.5 mM": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 12,
      "target": 456,
      "key": "9dfb07fc31563b15a62d63c697aa01497e6b37c54e36eaf3024d2dab5aaee183371e548719f35481d0acdab8078fe623d2c45881d3ae380110b5b41b3ff9e438"
    },
    {
      "line": 1122,
      "relation": "positiveCorrelation",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 543,
      "target": 299,
      "key": "a9b08c60d07f2a396b6141c803afcc9bb526653a4939060372e3a9a8503e19a41a652d2a5fb8a1cbca4d04b784ca4f3ee5d90af9dc68edcafcb70dded9eb0b38"
    },
    {
      "line": 2249,
      "relation": "partOf",
      "evidence": "Western blot analyses of brain homogenates show that (−)-nilvadipine significantly reduces Tau phosphorylation in AT8 (phosphorylated Ser-199/Ser-202/Thr-205) and PHF-1 (phosphorylated Ser-396/Ser-404) epitopes",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "source": 543,
      "target": 336,
      "key": "ed62f7f7f1c4759d7b30c9c414672d3708d58eaf66aa2b1c45579d2c42a2c4f5c87cd0d25b83b79f3237df0b57faf8b4858eec41594c47720d86261eaa1ac742"
    },
    {
      "line": 2467,
      "relation": "partOf",
      "evidence": "Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift in mobility as a result of phosphorylation-like changes, we conclude that they have the characteristics of hyperphosphorylated tau. These mutants will therefore be referred to as pseudo-hyperphosphorylated tau throughout the manuscript. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.",
      "citation": {
        "type": "PubMed",
        "reference": "19459590",
        "name": "Biochemistry",
        "title": "Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.",
        "volume": "48",
        "pages": "6002-11",
        "date": "2009-06-30",
        "first": "Sun Q",
        "last": "Gamblin TC",
        "authors": [
          "Gamblin TC",
          "Sun Q"
        ]
      },
      "source": 543,
      "target": 336,
      "key": "9e7ad898d3b9c3457252cc95e1e82616c6c4b932ff9cca5cb9ee7395128fea0a32af25d0f0b83e400e1eef54a5265ac013672d7c01dbe75afa2b1bb624f006d0"
    },
    {
      "line": 1123,
      "relation": "positiveCorrelation",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 544,
      "target": 299,
      "key": "ecbdeab17d837213ab6ea2ce3f49da93de740cfad726d4c1b25154abe37dcb9ded28c31e45bfa45066717ef68d7639b63588edd1081c5dd5269871ea491622d1"
    },
    {
      "line": 1148,
      "relation": "partOf",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 544,
      "target": 229,
      "key": "47725076bc805bea33fecc283d9507ebe8ac688565a8abdc03a08f909ac15055f7a86505d96027a4cc310313a3dba15738f42526fda7fcd39491641eebdfd250"
    },
    {
      "line": 1294,
      "relation": "partOf",
      "evidence": "Epitopes S198, S199, S202, T205, S422 (Lund 2013)",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "source": 544,
      "target": 336,
      "key": "fffada5e71eced6f441ca2f0137fb86b13b18eb41c035311e95eb0db97bd9dfd44b730245b09e8b1f1906601bae3c14e737b00eeccd14609de2fc864c0f1ef95"
    },
    {
      "line": 1543,
      "relation": "partOf",
      "evidence": "When combined with ERK2 catalyzed phosphorylation, the turn-like disrupting G207V mutation in TauF8 hence leads to fast aggregation that already occurs during the phosphorylation reaction.",
      "citation": {
        "type": "PubMed",
        "reference": "28784767",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Identification of the Tau phosphorylation pattern that drives its aggregation.",
        "volume": "114",
        "pages": "9080-9085",
        "date": "2017-08-22",
        "first": "Despres C",
        "last": "Smet-Nocca C",
        "authors": [
          "Baulieu EE",
          "Byrne C",
          "Cantrelle FX",
          "Chambraud B",
          "Despres C",
          "Huvent I",
          "Jacquot Y",
          "Landrieu I",
          "Lippens G",
          "Qi H",
          "Smet-Nocca C"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "NMR Spectroscopy": true,
          "Thioflavin T Assay": true
        }
      },
      "source": 544,
      "target": 336,
      "key": "0baf1d8af8fd3d3fe680e0233a872d3c72594ddd48e087a7357c22704da9c32fb8ec1a0a7dfb464d31357dedf5a4db834f443d523622a8d54633a638ae7f6811"
    },
    {
      "line": 2264,
      "relation": "equivalentTo",
      "evidence": "We further validated Syk as a target-regulating Aβ by showing that pharmacological inhibition of Syk or down-regulation of Syk expression reduces Aβ production and increases the clearance of Aβ across the BBB mimicking (-)-nilvadipine effects. Moreover, treatment of transgenic mice overexpressing Aβ and transgenic Tau P301S mice with a selective Syk inhibitor respectively decreased brain Aβ accumulation and Tau hyperphosphorylation at multiple AD relevant epitopes.",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 544,
      "target": 116,
      "key": "2710ccb8bf7e09fac02a578d26d2a292826064c69f3add3150a9a50b00f2c0ee405741d93015f78a7a1c5b0334e9985c5db1737265a15630e20dd7e122aba625"
    },
    {
      "line": 2331,
      "relation": "negativeCorrelation",
      "evidence": "Endogenous miR-195 was knocked down using over-expression of its antisense molecule (pre-AMO-miR-195) via a lentivirus (lenti-pre-AMO-miR-195); this knockdown increased the tau phosphorylation at Ser202/Thr205, Ser262, Thr231, Ser422, and the Cdk5/p25 activation, but over-expression of miR-195 using lenti-pre-miR-195 decreased the tau phosphorylation and Cdk5/p25 activation.",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 544,
      "target": 264,
      "key": "df20d0c28d944c873f143d0d0c4457c3fe4bbb2423c3f823a187d0ec78cc86a470a96ce08cb2306c8dc74e9fe23d8f59a60aa1bb684347e0a41752f542161d11"
    },
    {
      "line": 2468,
      "relation": "equivalentTo",
      "evidence": "Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift in mobility as a result of phosphorylation-like changes, we conclude that they have the characteristics of hyperphosphorylated tau. These mutants will therefore be referred to as pseudo-hyperphosphorylated tau throughout the manuscript. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.",
      "citation": {
        "type": "PubMed",
        "reference": "19459590",
        "name": "Biochemistry",
        "title": "Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.",
        "volume": "48",
        "pages": "6002-11",
        "date": "2009-06-30",
        "first": "Sun Q",
        "last": "Gamblin TC",
        "authors": [
          "Gamblin TC",
          "Sun Q"
        ]
      },
      "source": 544,
      "target": 337,
      "key": "8b307c65647a2c97be2adabbd4b107fcd63872382c3f863a39d1d8fe2697441d2f3a640600c4a7476cbd2cdb33088ae27ef30197dbb5ebc6af410ac15c3afd9e"
    },
    {
      "line": 2506,
      "relation": "positiveCorrelation",
      "evidence": "Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Research_Model": {
          "rTg4510 mice": true
        }
      },
      "source": 544,
      "target": 513,
      "key": "65f36ef4b0f02c75ade243d3c727b69fa57984ab7b2e698116766238e5d9f86c18ccb30e164a2b062fec2375677e1c537c6d5bee6a177473ed73761efb2a0818"
    },
    {
      "line": 2523,
      "relation": "positiveCorrelation",
      "evidence": "We developed a transgenic mouse, named TPR50, harboring human P301S tau. Tau phosphorylation in the hippocampus of TPR50 mice increased with age, particularly at S202/T205. Therefore, cognitive dysfunction in TPR50 mice may result from early MT dysfunction and impaired axonal transport rather than accumulation of insoluble tau and neurodegeneration.",
      "citation": {
        "type": "PubMed",
        "reference": "24406748",
        "name": "Neuroscience research",
        "title": "Early-onset cognitive deficits and axonal transport dysfunction in P301S mutant tau transgenic mice.",
        "volume": "80",
        "pages": "76-85",
        "date": "2014-03-01",
        "first": "Onishi T",
        "last": "Iwashita H",
        "authors": [
          "Hattori M",
          "Horiguchi T",
          "Iwashita H",
          "Matsumoto Y",
          "Nakamura K",
          "Obayashi Y",
          "Onishi T",
          "Yano T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "TPR50 mice": true
        }
      },
      "source": 544,
      "target": 626,
      "key": "3bd383265d263b43553760435fea9846a349c1cbae1c2c6fd7afb033032aac428ee67eb0ea6f625490bdb04080542352e6515350ef84bb7fad826301048a4af9"
    },
    {
      "line": 2542,
      "relation": "positiveCorrelation",
      "evidence": "We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia. In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes. Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3α/β at tyrosine 279/216 also showed an intense rather than moderate AT8 (phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with fibrillar tau pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "23294633",
        "name": "Neurobiology of aging",
        "title": "Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.",
        "volume": "34",
        "pages": "1369-79",
        "date": "2013-05-01",
        "first": "Köhler C",
        "last": "Götz J",
        "authors": [
          "Dinekov M",
          "Götz J",
          "Köhler C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "pR5 mice": true
        }
      },
      "source": 544,
      "target": 625,
      "key": "001783fcf0cf1de501ebabd8f76e747aca963d8e5c573a47c1cbdf844d44d7adad2a4979f9ad6a065d0cb6f4e30d9ba6a84e66e3bdddbbc7055480505980bcf0"
    },
    {
      "line": 2578,
      "relation": "positiveCorrelation",
      "evidence": "E391-3610 mice (higher expressers) exhibit robust somatodendritic distribution of phospho- Ser 202/Thr 205 tau throughout the cortex, in hippocampal CA3 pyramidal neurons, CA1 apical dendrites and cell bodies and dentate granule cells.",
      "citation": {
        "type": "PubMed",
        "reference": "22002427",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Truncation of tau at E391 promotes early pathologic changes in transgenic mice.",
        "volume": "70",
        "pages": "1006-19",
        "date": "2011-11-01",
        "first": "McMillan PJ",
        "last": "Schellenberg G",
        "authors": [
          "Kraemer BC",
          "Leverenz JB",
          "McMillan PJ",
          "Raskind M",
          "Robinson L",
          "Schellenberg G"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "hTau E391 transgenic mice": true
        },
        "Anatomy": {
          "cerebral cortex": true,
          "CA1 field of hippocampus": true,
          "CA3 field of hippocampus": true,
          "dentate gyrus granule cell layer": true
        }
      },
      "source": 544,
      "target": 608,
      "key": "996ba4db2b821403912f6920c967d1348b549dd0ec073e22458dd9266755a5a3f15c255f93d557806fd8ce9cac7f8bc2c63defe8e833537cb84fa0e8784acbb8"
    },
    {
      "line": 2580,
      "relation": "positiveCorrelation",
      "evidence": "E391-3610 mice (higher expressers) exhibit robust somatodendritic distribution of phospho- Ser 202/Thr 205 tau throughout the cortex, in hippocampal CA3 pyramidal neurons, CA1 apical dendrites and cell bodies and dentate granule cells.",
      "citation": {
        "type": "PubMed",
        "reference": "22002427",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Truncation of tau at E391 promotes early pathologic changes in transgenic mice.",
        "volume": "70",
        "pages": "1006-19",
        "date": "2011-11-01",
        "first": "McMillan PJ",
        "last": "Schellenberg G",
        "authors": [
          "Kraemer BC",
          "Leverenz JB",
          "McMillan PJ",
          "Raskind M",
          "Robinson L",
          "Schellenberg G"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "hTau E391 transgenic mice": true
        },
        "Anatomy": {
          "cerebral cortex": true,
          "CA1 field of hippocampus": true,
          "CA3 field of hippocampus": true,
          "dentate gyrus granule cell layer": true
        }
      },
      "source": 544,
      "target": 81,
      "key": "0fc30b501566033787c57d8072449624c9a17243dc8ada1d285d16b6e59196b1919b6a7d82af9d20a5dd5183808ada2545707b3ede8879949318a913f5ed74d8"
    },
    {
      "line": 2620,
      "relation": "partOf",
      "evidence": "Phosphorylation at the epitope Ser202/Thr205 is regarded as a good marker for late-stage NFTs (5, 72). Hyman and colleagues (5) demonstrated that AT8 immunoreactivity is present primarily in eNFTs and in certain cases in iNFTs. These investigators also found that AT8 revealed dense neuropil thread staining.",
      "citation": {
        "type": "PubMed",
        "reference": "22253473",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.",
        "volume": "26",
        "pages": "1946-59",
        "date": "2012-05-01",
        "first": "Lasagna-Reeves CA",
        "last": "Kayed R",
        "authors": [
          "Castillo-Carranza DL",
          "Jackson GR",
          "Kayed R",
          "Lasagna-Reeves CA",
          "Sarmiento J",
          "Sengupta U",
          "Troncoso J"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Disease_Progression": {
          "Late Stage": true
        }
      },
      "source": 544,
      "target": 81,
      "key": "2014d618334200e0f6130a080cc68987d583eb0766bad680ba1283f9651242cbd62bf6cb401864dd2b9ea7fbfeeead1d0473b149e3f0f7c44ad1f1d6fe61973f"
    },
    {
      "line": 2630,
      "relation": "partOf",
      "evidence": "Oligomers positive for pS202/pT205 accumulate at synapses in AD",
      "citation": {
        "type": "PubMed",
        "reference": "22486774",
        "name": "Brain pathology (Zurich, Switzerland)",
        "title": "Extensive p-tau pathology and SDS-stable p-tau oligomers in Alzheimer's cortical synapses.",
        "volume": "22",
        "pages": "826-33",
        "date": "2012-11-01",
        "first": "Henkins KM",
        "last": "Gylys KH",
        "authors": [
          "Cornwell LB",
          "Gylys KH",
          "Henkins KM",
          "Miller CA",
          "Poon WW",
          "Saing T",
          "Sokolow S",
          "Vinters HV"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 544,
      "target": 118,
      "key": "1e53f6ac5a07cb870842c51ad62bc21cd3d7e5a4dcbcd0521a648b8a2370247597e7f1718a9fa777f315162c92be4fd173a5af12a43e4067cf1586334a80c223"
    },
    {
      "line": 3717,
      "relation": "positiveCorrelation",
      "evidence": "Both brain proteins were preferentially modified by SUMO1, as compared with SUMO2 or SUMO3. Tau contains two SUMO consensus sequences with Lys(340) as the major sumoylation site. Although both tau and alpha-synuclein are targets for proteasomal degradation, only tau sumoylation was affected by inhibitors of the proteasome pathway. Treatment with the phosphatase inhibitor, okadaic acid, or the microtubule depolymerizing drug, colchicine, up-regulated tau sumoylation.",
      "citation": {
        "type": "PubMed",
        "reference": "16464864",
        "name": "The Journal of biological chemistry",
        "title": "Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein.",
        "volume": "281",
        "pages": "9919-24",
        "date": "2006-04-14",
        "first": "Dorval V",
        "last": "Fraser PE",
        "authors": [
          "Dorval V",
          "Fraser PE"
        ]
      },
      "source": 544,
      "target": 27,
      "key": "d78c76f6eb18ce13bd1359ff9bd1baac44049cf1f46cb6398613c95bcf8a54ddbd38182cac5fae1beb55254a68f697e3d3e85c38c3cf379c3db13cea2141b7f6"
    },
    {
      "line": 3718,
      "relation": "positiveCorrelation",
      "evidence": "Both brain proteins were preferentially modified by SUMO1, as compared with SUMO2 or SUMO3. Tau contains two SUMO consensus sequences with Lys(340) as the major sumoylation site. Although both tau and alpha-synuclein are targets for proteasomal degradation, only tau sumoylation was affected by inhibitors of the proteasome pathway. Treatment with the phosphatase inhibitor, okadaic acid, or the microtubule depolymerizing drug, colchicine, up-regulated tau sumoylation.",
      "citation": {
        "type": "PubMed",
        "reference": "16464864",
        "name": "The Journal of biological chemistry",
        "title": "Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein.",
        "volume": "281",
        "pages": "9919-24",
        "date": "2006-04-14",
        "first": "Dorval V",
        "last": "Fraser PE",
        "authors": [
          "Dorval V",
          "Fraser PE"
        ]
      },
      "source": 544,
      "target": 593,
      "key": "11bb0e7ff90066697583dac13041756c2036c5356a8af0445b30b90bfca0ae573a176d00b7be7bda450d18dd5a4dbea6b9f693940f234502a5a2a0747cdf6f42"
    },
    {
      "line": 1125,
      "relation": "positiveCorrelation",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 582,
      "target": 299,
      "key": "4980742f27b19a5a74470c115046235d667a83cc1713c00fc3c79c9f2d96356a77a57a9ebeb2eb65a8b40dd45782ad87825c5f541733260dcbef517349218480"
    },
    {
      "line": 1152,
      "relation": "partOf",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 582,
      "target": 233,
      "key": "ca37ddf9f3d90be500afb7e3b1267abe27dad11ed05d9831ffdf1c0c72fd6d544aacb415ebb96c0835d3787210846e14b336a74daa5701f3fe8af4ecbb94d517"
    },
    {
      "line": 2792,
      "relation": "partOf",
      "evidence": "In this study, we address the structural impact of phosphorylation of the Tau protein by Nuclear Magnetic Resonance (NMR) spectroscopy on a functional fragment of Tau (Tau[Ser208-Ser324] = TauF4). TauF4 was phosphorylated by the proline-directed CDK2/CycA3 kinase on Thr231 (generating the AT180 epitope), Ser235, and equally on Thr212 and Thr217 in the Proline-rich region (Tau[Ser208-Gln244] or PRR). These modifications strongly decrease the capacity of TauF4 to polymerize tubulin into microtubules. While all the NMR parameters are consistent with a globally disordered Tau protein fragment, local clusters of structuration can be defined. The most salient result of our NMR analysis is that phosphorylation in the PRR stabilizes a short α-helix that runs from pSer235 till the very beginning of the microtubule-binding region (Tau[Thr245-Ser324] or MTBR of TauF4).",
      "citation": {
        "type": "PubMed",
        "reference": "22072628",
        "name": "Proteins",
        "title": "Structural characterization by nuclear magnetic resonance of the impact of phosphorylation in the proline-rich region of the disordered Tau protein.",
        "volume": "80",
        "pages": "454-62",
        "date": "2012-02-01",
        "first": "Sibille N",
        "last": "Landrieu I",
        "authors": [
          "Amniai L",
          "Fauquant C",
          "Huvent I",
          "Landrieu I",
          "Leroy A",
          "Lippens G",
          "Sibille N",
          "Verdegem D",
          "Wieruszeski JM"
        ]
      },
      "source": 582,
      "target": 361,
      "key": "d4bc0f406d860c51e6eefad6453085d8e65f00672cdc1966e59b81537046721d823e6e399051b292626f6e57c622ff45ed94feba0151e7aa791ea6759ae6d8d3"
    },
    {
      "line": 1126,
      "relation": "positiveCorrelation",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 583,
      "target": 299,
      "key": "a22d71720bf042cae00452bfe6cda72faf20cd60de111ba94acb03adebd2244eec268a0e85039c5ff9aef8f8666f123331ca4e3578688e263aa5d4dc289271d0"
    },
    {
      "line": 2002,
      "relation": "negativeCorrelation",
      "evidence": "These data suggest that tau hyperphosphorylation at Thr231, Ser262, and Ser396 by DAPK1 renders the cells more resistant to the kinase-induced apoptotic cell death, providing new insights into the tau-involved apoptotic abortion in the course of chronic neurodegeneration.",
      "citation": {
        "type": "PubMed",
        "reference": "23948915",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Phosphorylation of tau by death-associated protein kinase 1 antagonizes the kinase-induced cell apoptosis.",
        "volume": "37",
        "pages": "795-808",
        "date": "2013-01-01",
        "first": "Duan DX",
        "last": "Liu GP",
        "authors": [
          "Chai GS",
          "Chen NN",
          "Cheng XS",
          "Duan DX",
          "Hu Y",
          "Liu GP",
          "Luo Y",
          "Ni ZF",
          "Wang JZ"
        ]
      },
      "source": 583,
      "target": 174,
      "key": "a1ba7daa2d6be9f3cd5701f7d2548779703809c942a91b0f343e54702c56a0d5b8d104ea6398248f118bf8c1e78add5198a923b0214960f8e45b4ab50ec8031c"
    },
    {
      "line": 2334,
      "relation": "negativeCorrelation",
      "evidence": "Endogenous miR-195 was knocked down using over-expression of its antisense molecule (pre-AMO-miR-195) via a lentivirus (lenti-pre-AMO-miR-195); this knockdown increased the tau phosphorylation at Ser202/Thr205, Ser262, Thr231, Ser422, and the Cdk5/p25 activation, but over-expression of miR-195 using lenti-pre-miR-195 decreased the tau phosphorylation and Cdk5/p25 activation.",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 583,
      "target": 264,
      "key": "cfdaf1f6fbb176df9c97070b4eca8fda6518cd785eeebb8139f2a4c29db478f03407e5505e8c704b7ee944781064bc91748a1165dd0332513b3f3942f943a0bd"
    },
    {
      "line": 2482,
      "relation": "equivalentTo",
      "evidence": "Hence, LTD-inducing NMDA receptor activation leads to an increase in tau phosphorylation at sites PHF-1, AT180, as well as AT8 and to a reduction at AT100.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 583,
      "target": 115,
      "key": "f1d1296823801a00921bcf85193e8f9c7f2c10d1a04b177a41fd269cf2bdf83e3d0f87bcbbc3e046386f337eb620dae20f5159f0a0ed89fd5221f3033a81a5e9"
    },
    {
      "line": 2615,
      "relation": "positiveCorrelation",
      "evidence": "This sequence (Fig. 3G–N) is supported by Western blot analysis, phosphorylated Thr231 in three AD cases and their age-matched controls, suggesting that tau phosphorylation at Thr231 occurs before the formation of oligomers (Fig. 3O).",
      "citation": {
        "type": "PubMed",
        "reference": "22253473",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.",
        "volume": "26",
        "pages": "1946-59",
        "date": "2012-05-01",
        "first": "Lasagna-Reeves CA",
        "last": "Kayed R",
        "authors": [
          "Castillo-Carranza DL",
          "Jackson GR",
          "Kayed R",
          "Lasagna-Reeves CA",
          "Sarmiento J",
          "Sengupta U",
          "Troncoso J"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Disease_Progression": {
          "Early Stage": true
        }
      },
      "source": 583,
      "target": 908,
      "key": "785d3d846aa7d3f302ec0c41e5a8c3f88ac74053fe2a194c6a7c9965a103e01d4c85bebb55fa72d0cbb16704221609ae926f8d39ee8807b0f9106240fb105896"
    },
    {
      "line": 3881,
      "relation": "equivalentTo",
      "evidence": "QA appears to act through NMDA receptor activation similar to other agonists, glutamate and NMDA and was abrogated by the NMDAR antagonist memantine. NMDA receptor agonists, glutamate and NMDA at equimolar concentrations (500 nM) increased tau phosphorylation at serine 199/202 (AT8) and threonine 231 (AT-180), similar to QA.",
      "citation": {
        "type": "PubMed",
        "reference": "19623258",
        "name": "PloS one",
        "title": "The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.",
        "volume": "4",
        "pages": "e6344",
        "date": "2009-07-22",
        "first": "Rahman A",
        "last": "Guillemin GJ",
        "authors": [
          "Braidy N",
          "Brew BJ",
          "Cullen KM",
          "Guillemin GJ",
          "Rahman A",
          "Ting K"
        ]
      },
      "source": 583,
      "target": 334,
      "key": "a659f67d51f3b5dd7d6d5b8759f3852ad3f7f4b7bd0e3612c4ec9815e9354c0c70181cced3ba836805fa38ac165bc6c44ef0c5ed388ec2762979f64bfc9c8332"
    },
    {
      "line": 3996,
      "relation": "increases",
      "evidence": "Pin1 binds to phosphorylated Thr231 of tau and facilitates the dephosphorylation of phosphoThr231 through isomerization (Galas et al., 2006; Hamdane et al., 2006; Lu et al., 1999a). Phosphorylation at Thr231 on tau is associated with the early events of tau aggregation and NFT (Augustinack et al., 2002). Pin1 binds and isomerizes the proline imidic peptide bond following the phosphothreonine 231",
      "citation": {
        "type": "PubMed",
        "reference": "22926167",
        "name": "Neurobiology of aging",
        "title": "Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker.",
        "volume": "34",
        "pages": "757-69",
        "date": "2013-03-01",
        "first": "Ando K",
        "last": "Buée L",
        "authors": [
          "Ando K",
          "Blum D",
          "Bretteville A",
          "Buée L",
          "Bégard S",
          "Bélarbi K",
          "Caillet-Boudin ML",
          "Demey-Thomas E",
          "Dourlen P",
          "Drobecq H",
          "Eddarkaoui S",
          "Galas MC",
          "Ghestem A",
          "Hamdane M",
          "Landrieu I",
          "Lippens G",
          "Maurage CA",
          "Melnyk P",
          "Sambo AV",
          "Sergeant N",
          "Smet C",
          "Verdier Y",
          "Vingtdeux V",
          "Vinh J"
        ]
      },
      "source": 583,
      "target": 112,
      "key": "3f1dd4af034d1901ae8a40914f2a717b0cc92aef4da51726ae16a21868362ec8779cc4529dca862ab9db7b38b160123db14735c5dd59df55b1ba09c4b2fe09a0"
    },
    {
      "line": 1130,
      "relation": "negativeCorrelation",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 565,
      "target": 299,
      "key": "d5aa4bb1b39d7e9e51802aad236230175d006b30ef397fed427e0d1bd59db325f0f099843999558a366f0a306490f5c6740d82bd9dacfa83ef9ce8e0a6aafc72"
    },
    {
      "line": 1154,
      "relation": "partOf",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 565,
      "target": 231,
      "key": "e5b3afafbcd41cc8afaa7bba2a5ef948da4ab2759f54fe92e1e8d10128b4d0bdd5521660ca5a612e004b2f855e6b8cf53704ff5006cbac6ca373ed058d5f0741"
    },
    {
      "line": 1522,
      "relation": "partOf",
      "evidence": "The AD2 epitope, which corresponds to phosphorylated S396 and S404 in tau, was generated most effectively by SAPK3/p38gamma and SAPK4/p38delta",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Enzyme_Acitvity": {
          "1 U/ml": true
        }
      },
      "source": 565,
      "target": 332,
      "key": "6c810eed44d51464e10be75ff7d1b28c137d3a13ef863d9957a22463f9f9307c046e418569f9dcb8578dbdeb1113ee69a04efab7e1e73f2ff771b2d19b74ac01"
    },
    {
      "line": 1807,
      "relation": "positiveCorrelation",
      "evidence": "We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "source": 565,
      "target": 117,
      "key": "1804f23f7941d5a8d885a25db7dcabe0ba00b433f13549a1c667538b01c6fb00bbaa8423cb18fd61da22fff86d88b3ffd77c8e7000c6c71b801a9bf599a00174"
    },
    {
      "line": 1131,
      "relation": "negativeCorrelation",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 580,
      "target": 299,
      "key": "c7e2d8a226012f214176cab21fe7ace67c63726033f393159552a6632373ab88975780fb571d1b053e3d6a6dda87a8d67cf8d8e217ce09e258a0cbdaa5e11b44"
    },
    {
      "line": 1150,
      "relation": "partOf",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 580,
      "target": 232,
      "key": "1cd23cb529681e1839241594913fbe2de79e55b503b1b07bfdc6e49a80d3ff860c6e32d6aff0f485b2f26be215ca9df3278da25104d91fab25c6efbca9de8f01"
    },
    {
      "line": 2791,
      "relation": "partOf",
      "evidence": "In this study, we address the structural impact of phosphorylation of the Tau protein by Nuclear Magnetic Resonance (NMR) spectroscopy on a functional fragment of Tau (Tau[Ser208-Ser324] = TauF4). TauF4 was phosphorylated by the proline-directed CDK2/CycA3 kinase on Thr231 (generating the AT180 epitope), Ser235, and equally on Thr212 and Thr217 in the Proline-rich region (Tau[Ser208-Gln244] or PRR). These modifications strongly decrease the capacity of TauF4 to polymerize tubulin into microtubules. While all the NMR parameters are consistent with a globally disordered Tau protein fragment, local clusters of structuration can be defined. The most salient result of our NMR analysis is that phosphorylation in the PRR stabilizes a short α-helix that runs from pSer235 till the very beginning of the microtubule-binding region (Tau[Thr245-Ser324] or MTBR of TauF4).",
      "citation": {
        "type": "PubMed",
        "reference": "22072628",
        "name": "Proteins",
        "title": "Structural characterization by nuclear magnetic resonance of the impact of phosphorylation in the proline-rich region of the disordered Tau protein.",
        "volume": "80",
        "pages": "454-62",
        "date": "2012-02-01",
        "first": "Sibille N",
        "last": "Landrieu I",
        "authors": [
          "Amniai L",
          "Fauquant C",
          "Huvent I",
          "Landrieu I",
          "Leroy A",
          "Lippens G",
          "Sibille N",
          "Verdegem D",
          "Wieruszeski JM"
        ]
      },
      "source": 580,
      "target": 361,
      "key": "0437791b0113d2a1ee8966c1d57cd65f0a7c30ab84c089895def24193da0c037f9d91fc71ad8b638170916cc5a34be45a70aa1d3714ba362446b45bc45a1f24a"
    },
    {
      "line": 1121,
      "relation": "positiveCorrelation",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 299,
      "target": 577,
      "key": "d153ea06f4c6df9733c87afdb60004ac3cadb0efd29f58105dece37838a4df2673cfb0bdf3466ceb14ecee4e89dee669a4fdc9d3cafe3d98215b161a04a11051"
    },
    {
      "line": 1122,
      "relation": "positiveCorrelation",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 299,
      "target": 543,
      "key": "395166322fbf93a54b115c73c336bddd97ec407abb202ca40c2ce45f8a910f59f998cbe0fa78e5df2005a1cf50df23ea8f4e724595de24b39a4c6e8f350b782d"
    },
    {
      "line": 1123,
      "relation": "positiveCorrelation",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 299,
      "target": 544,
      "key": "102bb970967ce9aa2b3b524963874120455a08919f4b62f44ad75ffbd8cd82fabf35ea828e42d637c25a390d21e442919f9ddbf3d47465f0ed5c4cc2001c371f"
    },
    {
      "line": 1124,
      "relation": "positiveCorrelation",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 299,
      "target": 579,
      "key": "a1c098b95e2f2eeee1ac1f9f55a158107278e288f6f8babdf409a18429a1bae6328cbcbd929cc69b8bc461c0a7cd882da2df143b7023f7c1f240bdddacd17f60"
    },
    {
      "line": 1125,
      "relation": "positiveCorrelation",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 299,
      "target": 582,
      "key": "c73a425975f01439588d929cff9609b9b9ef92f3b662678d8561557ebe47e6b6797dc6b12989e6387836fa1f0e8f80aa6b6c3f028691ff58dcd8207a2b4e4145"
    },
    {
      "line": 1126,
      "relation": "positiveCorrelation",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 299,
      "target": 583,
      "key": "425359abea24117743d444b9cd84363204db192ac95e7fa1c35b977e49b45d1fc04c9854d83cded8dd753e4c045d80357c64bd1f9842afe4ed241a38f82bdf75"
    },
    {
      "line": 1127,
      "relation": "positiveCorrelation",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 299,
      "target": 564,
      "key": "ccfc0863cec88d79860dada598685c155129e44d21d3c671a29e9cefe15647c262c8fb3b58f73de1e9ebcb4a0e3b999aa01c10c60ed8236e5e9d633aebd5daa9"
    },
    {
      "line": 1128,
      "relation": "positiveCorrelation",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 299,
      "target": 569,
      "key": "fc20f93223c632cdd85c258e064a212c5850e8f4e93950345172df87275472b0cddb20e5a06bf49b1b93be7d35ad78bbd8de37ddae0245e8442d2b9c24aa85c0"
    },
    {
      "line": 1130,
      "relation": "negativeCorrelation",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 299,
      "target": 565,
      "key": "b25b68c0ec646133490c99f0755805f18cff5eb0a5e6107949a9660f1c86dfe0b2081e6d2f17a16b76e172dff768dc100604c60a36058f65a24719c53fb026e9"
    },
    {
      "line": 1131,
      "relation": "negativeCorrelation",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 299,
      "target": 580,
      "key": "bd402e9ec39a225e573d4a3a54267a05a4f60f749b7157c4c2ffb37bed41fd8128c6edac0133eeb75a8283c34feac4afe59ad7b1b1a765866b402ee5f2f963d7"
    },
    {
      "line": 1140,
      "relation": "decreases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 299,
      "target": 229,
      "key": "5e8ceb2ccf4c5a86e7b148b8987c39832a8e05e1f661602155da928e4d0b9d6a66a9822eecc009756b3abca4b1237d57b9621aa9a895ffd2cdaf55d6d40a757e"
    },
    {
      "line": 1141,
      "relation": "decreases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 299,
      "target": 232,
      "key": "92077aa7cdaee22153ed244fe00504004d9800df7333967e832b4b2eb217eb0f63fec69cf542b30a88af32a024421257fac08ab05610cadace221dd0a6de0faa"
    },
    {
      "line": 1142,
      "relation": "decreases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 299,
      "target": 233,
      "key": "cb3e5a8480bb45ab8bf6d2dcb1b40dbd8d369761bc88656dca3ce268f7e33529bd1d741275722679b636b0d2b9c60682669eb4b63b3b9aea60c99a5317048a20"
    },
    {
      "line": 1143,
      "relation": "decreases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 299,
      "target": 231,
      "key": "0b727981d997bcdb5a3c3c12b561de93bfaa902db53c86ead2b3fd6acd10faddf689bfa147dff47bee17ea5508bf51bdf8c04368ab0898e2c16ee33dd9dfe768"
    },
    {
      "line": 1145,
      "relation": "increases",
      "evidence": "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422, but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396.",
      "citation": {
        "type": "PubMed",
        "reference": "17078951",
        "name": "FEBS letters",
        "title": "PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.",
        "volume": "580",
        "pages": "6269-74",
        "date": "2006-11-13",
        "first": "Liu F",
        "last": "Gong CX",
        "authors": [
          "El-Akkad E",
          "Gong CX",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Liang Z",
          "Liu F",
          "Shi J",
          "Yin D"
        ]
      },
      "source": 299,
      "target": 230,
      "key": "7b7082d8e63d3d1fe41672ed538ca068a7ef1d4eb3d8bdc0236baacba998d8383f7c694848f3369bd44a2c33c70d55ae923ad4d6b0c30f1762dc6f247045213f"
    },
    {
      "line": 2771,
      "relation": "directlyIncreases",
      "evidence": "Several kinases such as microtubule-affinity regulating kinase (MARK), protein kinase A, calcium calmodulin kinase II, and checkpoint kinase 2 are known to phosphorylate tau on Ser(262) in vitro. In this study, we took advantage of the in situ proximity ligation assay to investigate the role of MARK2, one of the four MARK isoforms, in AD. We demonstrate that MARK2 interacts with tau and phosphorylates tau at Ser(262) in stably transfected NIH/3T3 cells expressing human recombinant tau. Staurosporine, a protein kinase inhibitor, significantly reduced the interaction between MARK2 and tau, and also phosphorylation of tau at Ser(262).",
      "citation": {
        "type": "PubMed",
        "reference": "23001711",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Elevated MARK2-dependent phosphorylation of Tau in Alzheimer's disease.",
        "volume": "33",
        "pages": "699-713",
        "date": "2013-01-01",
        "first": "Gu GJ",
        "last": "Kamali-Moghaddam M",
        "authors": [
          "Agerman K",
          "Eckersley S",
          "Gu GJ",
          "Kamali-Moghaddam M",
          "Kvist AJ",
          "Landegren U",
          "Lund H",
          "Milner R",
          "Nilsson LN",
          "Sunnemark D",
          "Wu D"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 299,
      "target": 557,
      "key": "dfea10e94bade9f0886239fcb8f49e16b951cd1195212f2b86fe34cc5ea98ca9ad4b4496fa5a177874059771dccfb3e0a64b2579426c4b71afbd4ce075451bcf"
    },
    {
      "line": 3500,
      "relation": "positiveCorrelation",
      "evidence": "Rolipram is a specific phosphodiesterase type 4 (PDE4) inhibitor that increases cAMP levels in multiple tissues in vivo. The chymotrypsin-like activity of the 26S proteasomes in crude extracts was elevated after administration of db-cAMP or rolipram but was blocked by epoxomicin",
      "citation": {
        "type": "PubMed",
        "reference": "26692334",
        "name": "Nature medicine",
        "title": "Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.",
        "volume": "22",
        "pages": "46-53",
        "date": "2016-01-01",
        "first": "Myeku N",
        "last": "Duff KE",
        "authors": [
          "Clelland CL",
          "Duff KE",
          "Emrani S",
          "Goldberg AL",
          "Kukushkin NV",
          "Myeku N",
          "Yu WH"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 299,
      "target": 70,
      "key": "19ffd6ab96b2ab2c7436c02f58adf943971d19cb7c60d1c6b2baed2677dceea5e69547e56085dd4789b0ca87a7efce873f48f6f1eb3a0cab6ee2e870056e23cd"
    },
    {
      "line": 3505,
      "relation": "positiveCorrelation",
      "evidence": "PKA stimulation attenuated proteasome dysfunction, probably through proteasome subunit phosphorylation resulting in lower levels of aggregated tau and improvements in cognitive performance.",
      "citation": {
        "type": "PubMed",
        "reference": "26692334",
        "name": "Nature medicine",
        "title": "Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.",
        "volume": "22",
        "pages": "46-53",
        "date": "2016-01-01",
        "first": "Myeku N",
        "last": "Duff KE",
        "authors": [
          "Clelland CL",
          "Duff KE",
          "Emrani S",
          "Goldberg AL",
          "Kukushkin NV",
          "Myeku N",
          "Yu WH"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 299,
      "target": 213,
      "key": "020ab735b2f2d85f66059cf8dbbcc021da1cff3c957d6e11f1ade070a75be0817acf3a6699adc8917d882b927ec5d8c4aab996f7b5caf75f51cc2c636f4d9603"
    },
    {
      "relation": "hasComponent",
      "source": 229,
      "target": 400,
      "key": "73c8da6985571677c3019b9416d9677ad29285ec575ff1a4da08705757f55d07a50b2f868ef80b29694296be00d9cd88edeffe0ee78edc41bb251668ae4bdcc0"
    },
    {
      "relation": "hasComponent",
      "source": 229,
      "target": 544,
      "key": "09c016d301aee387b70cc05a8cdeecfd924cdf428c14695b747e55ece45ec37885bfc1e5295c44a7ddc272733b430802989eac8cd212cb8759ea54bcdb5464f7"
    },
    {
      "relation": "hasComponent",
      "source": 232,
      "target": 400,
      "key": "aae3ad26f6c4181b28b49d5347592f6d39c08b322adb08caca0d067428736e1cf447a405bc42cf1a7b991589d748191686e5a45ff0ed1133b0dbb6174b837395"
    },
    {
      "relation": "hasComponent",
      "source": 232,
      "target": 580,
      "key": "3067e4d861e43a3ba0acaa9becd2ea4d959d8a5bd1b6f4615412c53599d3546c19d3971f66441d237eb9b440fc7628a3d88447676d586f839a1beff26e4ae8b0"
    },
    {
      "relation": "hasComponent",
      "source": 233,
      "target": 400,
      "key": "92e469d5dcc2091cdff568d1acb16b5a977d34b9fa13c938271c4e5c456e964fbb94b973c6991b99daed0143b928641d2c2018f49869b6ca9dc5e53ed2f6eed6"
    },
    {
      "relation": "hasComponent",
      "source": 233,
      "target": 582,
      "key": "2000e3000581bfba648a2557212f95214a47c3ecbb3dcf7f8736d895cdd4f76b183de17c2eb230f9a4a60bc48ef4e5fe799886f241f99f482f3b9cfb136b4b83"
    },
    {
      "relation": "hasComponent",
      "source": 231,
      "target": 400,
      "key": "df3be2ca4be239159808f3fad8256e890df01417ccf98bf216444bbef4e24f613c86a605e1acd3453680232df85ccd511d39e76a8596edb7a4f7bbb89740f40f"
    },
    {
      "relation": "hasComponent",
      "source": 231,
      "target": 565,
      "key": "1ed4b76e7759bb7b306993dfde8a7a8dfe2858bfd32d4bab982eb8eb2702ae989a3a81600d34e82002a9f48560e2348f820a742255017a5f4e49b351d2c10ece"
    },
    {
      "relation": "hasComponent",
      "source": 230,
      "target": 400,
      "key": "935debee5a1dde4afb11f92f8e92d1e49729dd925315fc3554e46f965c483594dfac3608328c31e30580438a39fbcbb521dc8d4655833b8b7a2857cb340d28b5"
    },
    {
      "relation": "hasComponent",
      "source": 230,
      "target": 564,
      "key": "e697e93998c4f010e8119c813ee3817a7d9d666aee7b8c341410fea7a7f96c689412f0df412dad8ca37a0d878377f23cddde0d43a5a1ce69537c2f4e24350d3d"
    },
    {
      "line": 1165,
      "relation": "negativeCorrelation",
      "evidence": "By using a yeast two hybrid system, TPKI was found to interact with pyruvate dehydrogenase (PDH), which is a key enzyme in the glycolytic pathway. PDH was phosphorylated in vitro by TPKI to reduce the activity converting pyruvate into acetyl-CoA, which is required for acetylcholine synthesis.",
      "citation": {
        "type": "PubMed",
        "reference": "9089387",
        "name": "Journal of biochemistry",
        "title": "Physiology and pathology of tau protein kinases in relation to Alzheimer's disease.",
        "volume": "121",
        "pages": "179-88",
        "date": "1997-02-01",
        "first": "Imahori K",
        "last": "Uchida T",
        "authors": [
          "Imahori K",
          "Uchida T"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 298,
      "target": 298,
      "key": "627e5e0bc1e29fbb9898b211dbea531f8a6ec425cbd01ba1aedbdcc237eae7775e8835f4b2abadaf0b8f846a479899d854609987b33b73e10e09969a85b3c44d"
    },
    {
      "line": 1165,
      "relation": "negativeCorrelation",
      "evidence": "By using a yeast two hybrid system, TPKI was found to interact with pyruvate dehydrogenase (PDH), which is a key enzyme in the glycolytic pathway. PDH was phosphorylated in vitro by TPKI to reduce the activity converting pyruvate into acetyl-CoA, which is required for acetylcholine synthesis.",
      "citation": {
        "type": "PubMed",
        "reference": "9089387",
        "name": "Journal of biochemistry",
        "title": "Physiology and pathology of tau protein kinases in relation to Alzheimer's disease.",
        "volume": "121",
        "pages": "179-88",
        "date": "1997-02-01",
        "first": "Imahori K",
        "last": "Uchida T",
        "authors": [
          "Imahori K",
          "Uchida T"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 298,
      "target": 298,
      "key": "103e79ec7a24821bb2691020ed021bbf7314d2f5797042b557b66e218dd1feb98b04fb56d8f346951402641a0117b69472d47b725509550a28bf59b91dc0394c"
    },
    {
      "relation": "hasVariant",
      "source": 297,
      "target": 298,
      "key": "15d2dd3e4a6358ed66bc4fbbd1e86d33e11012648f3905eaec86043c78affb71642785cab0a34abfabca7183457e5c1f4ebb9b42224451a4d5f288e4ba5f4ddb"
    },
    {
      "line": 1174,
      "relation": "decreases",
      "evidence": "We report here that tideglusib inhibits GSK-3β irreversibly, as demonstrated by the lack of recovery in enzyme function after the unbound drug has been removed from the reaction medium and the fact that its dissociation rate constant is non-significantly different from zero.",
      "citation": {
        "type": "PubMed",
        "reference": "22102280",
        "name": "The Journal of biological chemistry",
        "title": "Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib.",
        "volume": "287",
        "pages": "893-904",
        "date": "2012-01-06",
        "first": "Domínguez JM",
        "last": "Medina M",
        "authors": [
          "Delgado E",
          "Domínguez JM",
          "Fuertes A",
          "Medina M",
          "Orozco L",
          "del Monte-Millán M"
        ]
      },
      "annotations": {
        "Ki": {
          "5 nM": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 162,
      "target": 456,
      "key": "069a66e7118aa2b913ac073c8c966b04f8e2640b6bd4659eea5d7409112431ebc94f5ba2de900e7586e04ca474e9e3e9cd8d7cec4f49435ba8a6d0aa23b1c4c0"
    },
    {
      "line": 1179,
      "relation": "decreases",
      "evidence": "Inhibition caused by hypothemycin and tideglusib on a panel of selected human recombinant kinases",
      "citation": {
        "type": "PubMed",
        "reference": "22102280",
        "name": "The Journal of biological chemistry",
        "title": "Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib.",
        "volume": "287",
        "pages": "893-904",
        "date": "2012-01-06",
        "first": "Domínguez JM",
        "last": "Medina M",
        "authors": [
          "Delgado E",
          "Domínguez JM",
          "Fuertes A",
          "Medina M",
          "Orozco L",
          "del Monte-Millán M"
        ]
      },
      "annotations": {
        "Ki": {
          "210 nM": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 56,
      "target": 456,
      "key": "dec5529e8a80aa25299ed2c28b1b1c2bf99e80e2bd3d254c6ff729ee0753197e2834dfdbaa8c3be2fad86edf0047efb5c0342a77acab025bf37cbe0064816276"
    },
    {
      "line": 1184,
      "relation": "decreases",
      "evidence": "Alsterpaullone showed identical results with the wild-type and the mutant enzymes, demonstrating that its mechanism of inhibition is independent of the presence of the Cys-199 residue.",
      "citation": {
        "type": "PubMed",
        "reference": "22102280",
        "name": "The Journal of biological chemistry",
        "title": "Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib.",
        "volume": "287",
        "pages": "893-904",
        "date": "2012-01-06",
        "first": "Domínguez JM",
        "last": "Medina M",
        "authors": [
          "Delgado E",
          "Domínguez JM",
          "Fuertes A",
          "Medina M",
          "Orozco L",
          "del Monte-Millán M"
        ]
      },
      "annotations": {
        "Ki": {
          "40 nM": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 43,
      "target": 456,
      "key": "d24b6bb46550d8ea1040e4cf87fd81dcee8fbe242527f247c9a6e3b9f272e426e67f830a3ee6860eff148a2861afdf644b538d21b01eb653c93a4676ad557f6c"
    },
    {
      "line": 1201,
      "relation": "decreases",
      "evidence": "Alsterpaullone, the most active paullone, was demonstrated to act by competing with ATP for binding to GSK-3beta. Alsterpaullone inhibits the phosphorylation of tau in vivo at sites which are typically phosphorylated by GSK-3beta in Alzheimer's disease. Alsterpaullone also inhibits the CDK5/p25-dependent phosphorylation of DARPP-32 in mouse striatum slices in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "10998059",
        "name": "European journal of biochemistry",
        "title": "Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.",
        "volume": "267",
        "pages": "5983-94",
        "date": "2000-10-01",
        "first": "Leost M",
        "last": "Meijer L",
        "authors": [
          "Bibb JA",
          "Biernat J",
          "Greengard P",
          "Gussio R",
          "Kunick C",
          "Leost M",
          "Link A",
          "Mandelkow EM",
          "Meijer L",
          "Sausville EA",
          "Schultz C",
          "Senderowicz AM",
          "Snyder GL",
          "Wu YZ",
          "Zaharevitz DW"
        ]
      },
      "annotations": {
        "Ki": {
          "4-80 nM": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 43,
      "target": 456,
      "key": "27059793a73eef8a45b3b42744f701ee09c714bc12ea422e19fa1b1671d2daf4f91e33284282a864bcc3a4128c67dac7ab111b5295897d48ed301a6c5d2440f2"
    },
    {
      "line": 1200,
      "relation": "decreases",
      "evidence": "Alsterpaullone, the most active paullone, was demonstrated to act by competing with ATP for binding to GSK-3beta. Alsterpaullone inhibits the phosphorylation of tau in vivo at sites which are typically phosphorylated by GSK-3beta in Alzheimer's disease. Alsterpaullone also inhibits the CDK5/p25-dependent phosphorylation of DARPP-32 in mouse striatum slices in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "10998059",
        "name": "European journal of biochemistry",
        "title": "Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.",
        "volume": "267",
        "pages": "5983-94",
        "date": "2000-10-01",
        "first": "Leost M",
        "last": "Meijer L",
        "authors": [
          "Bibb JA",
          "Biernat J",
          "Greengard P",
          "Gussio R",
          "Kunick C",
          "Leost M",
          "Link A",
          "Mandelkow EM",
          "Meijer L",
          "Sausville EA",
          "Schultz C",
          "Senderowicz AM",
          "Snyder GL",
          "Wu YZ",
          "Zaharevitz DW"
        ]
      },
      "annotations": {
        "Ki": {
          "4-80 nM": true
        }
      },
      "source": 43,
      "target": 538,
      "key": "13f5b385c8804d468560df0e05816e5e25f6a0e05948dfcd24a4ea4e0414c6f33067ad1599398ee1bb3c3fa6c37f7755a21c77477ed8e0fa553ce371f66df707"
    },
    {
      "line": 1205,
      "relation": "decreases",
      "evidence": "Alsterpaullone, the most active paullone, was demonstrated to act by competing with ATP for binding to GSK-3beta. Alsterpaullone inhibits the phosphorylation of tau in vivo at sites which are typically phosphorylated by GSK-3beta in Alzheimer's disease. Alsterpaullone also inhibits the CDK5/p25-dependent phosphorylation of DARPP-32 in mouse striatum slices in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "10998059",
        "name": "European journal of biochemistry",
        "title": "Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.",
        "volume": "267",
        "pages": "5983-94",
        "date": "2000-10-01",
        "first": "Leost M",
        "last": "Meijer L",
        "authors": [
          "Bibb JA",
          "Biernat J",
          "Greengard P",
          "Gussio R",
          "Kunick C",
          "Leost M",
          "Link A",
          "Mandelkow EM",
          "Meijer L",
          "Sausville EA",
          "Schultz C",
          "Senderowicz AM",
          "Snyder GL",
          "Wu YZ",
          "Zaharevitz DW"
        ]
      },
      "annotations": {
        "Ki": {
          "4-80 nM": true
        },
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "striatum": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 43,
      "target": 777,
      "key": "6b22043037ad640a71c87773b712ebeb3daac8bf99e030a91f9bd7f9d6c09192e7a3db7118893d59f808828bf41e3357cc4f05a038d3862de8ef982f09f85bbd"
    },
    {
      "line": 1207,
      "relation": "decreases",
      "evidence": "Alsterpaullone, the most active paullone, was demonstrated to act by competing with ATP for binding to GSK-3beta. Alsterpaullone inhibits the phosphorylation of tau in vivo at sites which are typically phosphorylated by GSK-3beta in Alzheimer's disease. Alsterpaullone also inhibits the CDK5/p25-dependent phosphorylation of DARPP-32 in mouse striatum slices in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "10998059",
        "name": "European journal of biochemistry",
        "title": "Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.",
        "volume": "267",
        "pages": "5983-94",
        "date": "2000-10-01",
        "first": "Leost M",
        "last": "Meijer L",
        "authors": [
          "Bibb JA",
          "Biernat J",
          "Greengard P",
          "Gussio R",
          "Kunick C",
          "Leost M",
          "Link A",
          "Mandelkow EM",
          "Meijer L",
          "Sausville EA",
          "Schultz C",
          "Senderowicz AM",
          "Snyder GL",
          "Wu YZ",
          "Zaharevitz DW"
        ]
      },
      "annotations": {
        "Ki": {
          "4-80 nM": true
        },
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "striatum": true
        }
      },
      "source": 43,
      "target": 843,
      "key": "6cfe0ea226cabbd2862d7ee30d7f1602bd882ff48aa892beeeaa323cf065d8953b490fdbb0f846b72d7762290f2866ac9e6270a06f5115d09d46ef0fa357bef6"
    },
    {
      "line": 1191,
      "relation": "decreases",
      "evidence": "We report here that indirubins are also powerful inhibitors (IC(50): 5-50 nm) of an evolutionarily related kinase, glycogen synthase kinase-3beta (GSK-3 beta).",
      "citation": {
        "type": "PubMed",
        "reference": "11013232",
        "name": "The Journal of biological chemistry",
        "title": "Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?",
        "volume": "276",
        "pages": "251-60",
        "date": "2001-01-05",
        "first": "Leclerc S",
        "last": "Meijer L",
        "authors": [
          "Bibb JA",
          "Biernat J",
          "Eisenbrand G",
          "Garnier M",
          "Greengard P",
          "Hoessel R",
          "Leclerc S",
          "Mandelkow EM",
          "Marko D",
          "Meijer L",
          "Snyder GL",
          "Wu YZ"
        ]
      },
      "annotations": {
        "IC50": {
          "5-50 nM": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 150,
      "target": 456,
      "key": "434a2fec3f6a7ad9fbf7f5409805fee57f69c2fb14c67dc5f6915384535dfe94b4beb49c9445960951b352541d2cc0d094252da2008ef7cef56cd8742d3fe87b"
    },
    {
      "line": 1206,
      "relation": "increases",
      "evidence": "Alsterpaullone, the most active paullone, was demonstrated to act by competing with ATP for binding to GSK-3beta. Alsterpaullone inhibits the phosphorylation of tau in vivo at sites which are typically phosphorylated by GSK-3beta in Alzheimer's disease. Alsterpaullone also inhibits the CDK5/p25-dependent phosphorylation of DARPP-32 in mouse striatum slices in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "10998059",
        "name": "European journal of biochemistry",
        "title": "Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.",
        "volume": "267",
        "pages": "5983-94",
        "date": "2000-10-01",
        "first": "Leost M",
        "last": "Meijer L",
        "authors": [
          "Bibb JA",
          "Biernat J",
          "Greengard P",
          "Gussio R",
          "Kunick C",
          "Leost M",
          "Link A",
          "Mandelkow EM",
          "Meijer L",
          "Sausville EA",
          "Schultz C",
          "Senderowicz AM",
          "Snyder GL",
          "Wu YZ",
          "Zaharevitz DW"
        ]
      },
      "annotations": {
        "Ki": {
          "4-80 nM": true
        },
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "striatum": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 777,
      "target": 843,
      "key": "7b8d4490381ba0adbf228b3e820d84d448f27b4dfffed1e53f8c75c205e0f6180ec4da631b89e73c478bb5a4fa4948b40510fe11f02f413b923d650cd2eafab8"
    },
    {
      "line": 1239,
      "relation": "increases",
      "evidence": "First, we verified the colocalization of p-WAVE1 and pCRMP2 with aggregated hyperphosphorylated tau in the hippocampus at 23 months of age. Biochemical analysis revealed the inclusion of p-WAVE1, p-CRMP2, and tau in the sarkosyl-insoluble fractions of hippocampal homogenates",
      "citation": {
        "type": "PubMed",
        "reference": "26400044",
        "name": "Journal of neuroscience research",
        "title": "Colocalization of phosphorylated forms of WAVE1, CRMP2, and tau in Alzheimer's disease model mice: Involvement of Cdk5 phosphorylation and the effect of ATRA treatment.",
        "volume": "94",
        "pages": "15-26",
        "date": "2016-01-01",
        "first": "Watamura N",
        "last": "Ohshima T",
        "authors": [
          "Nikkuni M",
          "Ohshima T",
          "Toba J",
          "Watamura N",
          "Yoshii A"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 777,
      "target": 855,
      "key": "06de890e5fd3f503bf46e8a19bef829903193c1b68a60fef57dacb487a3adc48e07e02f5b4453f20710c60ae8f166abdbb0f8a475e94b21ada7d246056bfc03b"
    },
    {
      "line": 1240,
      "relation": "increases",
      "evidence": "First, we verified the colocalization of p-WAVE1 and pCRMP2 with aggregated hyperphosphorylated tau in the hippocampus at 23 months of age. Biochemical analysis revealed the inclusion of p-WAVE1, p-CRMP2, and tau in the sarkosyl-insoluble fractions of hippocampal homogenates",
      "citation": {
        "type": "PubMed",
        "reference": "26400044",
        "name": "Journal of neuroscience research",
        "title": "Colocalization of phosphorylated forms of WAVE1, CRMP2, and tau in Alzheimer's disease model mice: Involvement of Cdk5 phosphorylation and the effect of ATRA treatment.",
        "volume": "94",
        "pages": "15-26",
        "date": "2016-01-01",
        "first": "Watamura N",
        "last": "Ohshima T",
        "authors": [
          "Nikkuni M",
          "Ohshima T",
          "Toba J",
          "Watamura N",
          "Yoshii A"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 777,
      "target": 785,
      "key": "d461f26b30f9d42c65cc9e362fad659e4ec25e606bfd75c47bdcfea387dc606ddb4f335b786aad31027bde06ca2f3725f73ada3480d75e8069f464e70b5f9f9a"
    },
    {
      "line": 1492,
      "relation": "negativeCorrelation",
      "evidence": "Overexpression of TTBK1 was sufficient in inducing spatial learning impairment in mice, which is associated with enhanced Cdk5 activity and reduction in cell surface level of NR2B. Over-expressionof TTBK1 transgene in JNPL3 mice resulted in accumulation of pre-tangle forms of tau. Inaddition, TTBK1 expression plays a unique role in accelerating motor neuron degeneration and neuroinflammation in JNPL3mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24808823",
        "name": "Frontiers in molecular neuroscience",
        "title": "Tau-tubulin kinase.",
        "volume": "7",
        "pages": "33",
        "date": "2014-01-01",
        "first": "Ikezu S",
        "last": "Ikezu T",
        "authors": [
          "Ikezu S",
          "Ikezu T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 777,
      "target": 197,
      "key": "e4f6e2d9a940f96f2a67b19a2e4f13af22238f5dea645b6855be0d092608b9c552ab5f6b70561cf8a1f4dcce34517ecac8711958257ed6a25c5cb9fc4de4bfdf"
    },
    {
      "line": 2377,
      "relation": "negativeCorrelation",
      "evidence": "Our data showed that CDK5 knock down induced an increase in p35 protein levels and Rac activity in triple transgenic Alzheimer's mice, which correlated with the recovery of cognitive function; these findings confirm that increased p35 and active Rac are involved in neuroprotection. In summary, our data suggest that p35 acts as a mediator of Rho GTPase activity and contributes to the neuroprotection induced by CDK5 RNAi.",
      "citation": {
        "type": "PubMed",
        "reference": "27087442",
        "name": "Current Alzheimer research",
        "title": "APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.",
        "volume": "13",
        "pages": "1048-55",
        "date": "2016-01-01",
        "first": "Zhou M",
        "last": "Chen X",
        "authors": [
          "Chen X",
          "Collins N",
          "Dai X",
          "Huang T",
          "LaDu MJ",
          "Lin L",
          "Shen H",
          "Wei Z",
          "Wu X",
          "Xiao N",
          "York J",
          "Zhang J",
          "Zhou M",
          "Zhu Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 777,
      "target": 778,
      "key": "770ddea40332c85cd6fc36786af10eed48aee097a9ff04595074e52da0677b3df97fbb7694acbe812e25f8f40368978711512b8253cbb8c377506229bf963596"
    },
    {
      "line": 2378,
      "relation": "negativeCorrelation",
      "evidence": "Our data showed that CDK5 knock down induced an increase in p35 protein levels and Rac activity in triple transgenic Alzheimer's mice, which correlated with the recovery of cognitive function; these findings confirm that increased p35 and active Rac are involved in neuroprotection. In summary, our data suggest that p35 acts as a mediator of Rho GTPase activity and contributes to the neuroprotection induced by CDK5 RNAi.",
      "citation": {
        "type": "PubMed",
        "reference": "27087442",
        "name": "Current Alzheimer research",
        "title": "APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.",
        "volume": "13",
        "pages": "1048-55",
        "date": "2016-01-01",
        "first": "Zhou M",
        "last": "Chen X",
        "authors": [
          "Chen X",
          "Collins N",
          "Dai X",
          "Huang T",
          "LaDu MJ",
          "Lin L",
          "Shen H",
          "Wei Z",
          "Wu X",
          "Xiao N",
          "York J",
          "Zhang J",
          "Zhou M",
          "Zhu Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 777,
      "target": 367,
      "key": "efcda014b9c95774ee2525659403c9afb49982ff977f789c74c3992e7ab3a74ddfb2dfd226122d27d780524f6733652a8690b95e0cbe206b8789fd96be4d76f1"
    },
    {
      "line": 2379,
      "relation": "negativeCorrelation",
      "evidence": "Our data showed that CDK5 knock down induced an increase in p35 protein levels and Rac activity in triple transgenic Alzheimer's mice, which correlated with the recovery of cognitive function; these findings confirm that increased p35 and active Rac are involved in neuroprotection. In summary, our data suggest that p35 acts as a mediator of Rho GTPase activity and contributes to the neuroprotection induced by CDK5 RNAi.",
      "citation": {
        "type": "PubMed",
        "reference": "27087442",
        "name": "Current Alzheimer research",
        "title": "APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.",
        "volume": "13",
        "pages": "1048-55",
        "date": "2016-01-01",
        "first": "Zhou M",
        "last": "Chen X",
        "authors": [
          "Chen X",
          "Collins N",
          "Dai X",
          "Huang T",
          "LaDu MJ",
          "Lin L",
          "Shen H",
          "Wei Z",
          "Wu X",
          "Xiao N",
          "York J",
          "Zhang J",
          "Zhou M",
          "Zhu Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 777,
      "target": 920,
      "key": "b1b927a29f3add89f9ba748677a5496951655b4b3050d88f9a90880e1d60e69713f60a5e747b936f5ff64ee56a61cbf0f56c7f7ffb4b94aa26a87ef81e002e8c"
    },
    {
      "line": 2382,
      "relation": "negativeCorrelation",
      "evidence": "Our data showed that CDK5 knock down induced an increase in p35 protein levels and Rac activity in triple transgenic Alzheimer's mice, which correlated with the recovery of cognitive function; these findings confirm that increased p35 and active Rac are involved in neuroprotection. In summary, our data suggest that p35 acts as a mediator of Rho GTPase activity and contributes to the neuroprotection induced by CDK5 RNAi.",
      "citation": {
        "type": "PubMed",
        "reference": "27087442",
        "name": "Current Alzheimer research",
        "title": "APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.",
        "volume": "13",
        "pages": "1048-55",
        "date": "2016-01-01",
        "first": "Zhou M",
        "last": "Chen X",
        "authors": [
          "Chen X",
          "Collins N",
          "Dai X",
          "Huang T",
          "LaDu MJ",
          "Lin L",
          "Shen H",
          "Wei Z",
          "Wu X",
          "Xiao N",
          "York J",
          "Zhang J",
          "Zhou M",
          "Zhu Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 777,
      "target": 168,
      "key": "3cec61ca0d620beb251b60af9f869cc9680f0c52d642b8d8dc7aaf467d2bb4116358c3532fe992447bdc7ea8a41198ef1384bfe3f02c57cee7eb29949b336947"
    },
    {
      "line": 2555,
      "relation": "directlyIncreases",
      "evidence": "Tau peptides containing phosphorylated S202, T205, and T396 were found only in Tg mice, supporting our results using AT8 and PHF1 antibodies",
      "citation": {
        "type": "PubMed",
        "reference": "14642273",
        "name": "Neuron",
        "title": "Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.",
        "volume": "40",
        "pages": "471-83",
        "date": "2003-10-30",
        "first": "Cruz JC",
        "last": "Tsai LH",
        "authors": [
          "Cruz JC",
          "Goldman JA",
          "Shih H",
          "Tsai LH",
          "Tseng HC"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "p25 transgenic mice": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 777,
      "target": 829,
      "key": "72f7f0609349582236792f28fd36a05836ddc490e699564da7529d42a620ba742eed2346bdfbd7ae19eaa1f54421415e24e9d97ed0225d3f84434e2fd767262b"
    },
    {
      "line": 2556,
      "relation": "directlyIncreases",
      "evidence": "Tau peptides containing phosphorylated S202, T205, and T396 were found only in Tg mice, supporting our results using AT8 and PHF1 antibodies",
      "citation": {
        "type": "PubMed",
        "reference": "14642273",
        "name": "Neuron",
        "title": "Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.",
        "volume": "40",
        "pages": "471-83",
        "date": "2003-10-30",
        "first": "Cruz JC",
        "last": "Tsai LH",
        "authors": [
          "Cruz JC",
          "Goldman JA",
          "Shih H",
          "Tsai LH",
          "Tseng HC"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "p25 transgenic mice": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 777,
      "target": 830,
      "key": "b22d3c67c59e78e123ea70f598e85c943b481858b60a76d32531e3609e134715b3efd899fc99ce7c75a04f56d7162383da75c90bde5fd1102246b4bc347738ca"
    },
    {
      "line": 2557,
      "relation": "directlyIncreases",
      "evidence": "Tau peptides containing phosphorylated S202, T205, and T396 were found only in Tg mice, supporting our results using AT8 and PHF1 antibodies",
      "citation": {
        "type": "PubMed",
        "reference": "14642273",
        "name": "Neuron",
        "title": "Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.",
        "volume": "40",
        "pages": "471-83",
        "date": "2003-10-30",
        "first": "Cruz JC",
        "last": "Tsai LH",
        "authors": [
          "Cruz JC",
          "Goldman JA",
          "Shih H",
          "Tsai LH",
          "Tseng HC"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "p25 transgenic mice": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 777,
      "target": 812,
      "key": "d0ef4c77871823bcbc1d50a6968aa0cf2381aa8ee0d7383a0cede7f44c0069aa75ab7187b81165556eb9fc97461f0dafe44caf9ee16b0aa07140cfdbbd5b7110"
    },
    {
      "line": 2558,
      "relation": "directlyIncreases",
      "evidence": "Tau peptides containing phosphorylated S202, T205, and T396 were found only in Tg mice, supporting our results using AT8 and PHF1 antibodies",
      "citation": {
        "type": "PubMed",
        "reference": "14642273",
        "name": "Neuron",
        "title": "Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.",
        "volume": "40",
        "pages": "471-83",
        "date": "2003-10-30",
        "first": "Cruz JC",
        "last": "Tsai LH",
        "authors": [
          "Cruz JC",
          "Goldman JA",
          "Shih H",
          "Tsai LH",
          "Tseng HC"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "p25 transgenic mice": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 777,
      "target": 813,
      "key": "51abaebefbffe4d966a71e652f3ec8529b95018941d0ee3c7ee892dda19b6815a99384ace95e6eb315d72dac858d8df5b2bb7e0293772e4955b434b424606396"
    },
    {
      "line": 2559,
      "relation": "directlyIncreases",
      "evidence": "Tau peptides containing phosphorylated S202, T205, and T396 were found only in Tg mice, supporting our results using AT8 and PHF1 antibodies",
      "citation": {
        "type": "PubMed",
        "reference": "14642273",
        "name": "Neuron",
        "title": "Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.",
        "volume": "40",
        "pages": "471-83",
        "date": "2003-10-30",
        "first": "Cruz JC",
        "last": "Tsai LH",
        "authors": [
          "Cruz JC",
          "Goldman JA",
          "Shih H",
          "Tsai LH",
          "Tseng HC"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "p25 transgenic mice": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 777,
      "target": 814,
      "key": "6cd7de978b6eaaaf4f5e0b0cb14df7bd631f6e1084a122756f745a1c8d87dc0c1b54a822ab1685defc88a13b0f9b172d59969ac8e7a74f4d481a0b152e94450b"
    },
    {
      "line": 2560,
      "relation": "directlyIncreases",
      "evidence": "Tau peptides containing phosphorylated S202, T205, and T396 were found only in Tg mice, supporting our results using AT8 and PHF1 antibodies",
      "citation": {
        "type": "PubMed",
        "reference": "14642273",
        "name": "Neuron",
        "title": "Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.",
        "volume": "40",
        "pages": "471-83",
        "date": "2003-10-30",
        "first": "Cruz JC",
        "last": "Tsai LH",
        "authors": [
          "Cruz JC",
          "Goldman JA",
          "Shih H",
          "Tsai LH",
          "Tseng HC"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "p25 transgenic mice": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 777,
      "target": 336,
      "key": "b698d67707a56d8dcfcbfc857bd51810ccb1ab80382428ac330ed90e34a1877343087b750ba9100c0d27f474fde4e518a0973e01c28154205de18dce7af7a0f6"
    },
    {
      "line": 2561,
      "relation": "directlyIncreases",
      "evidence": "Tau peptides containing phosphorylated S202, T205, and T396 were found only in Tg mice, supporting our results using AT8 and PHF1 antibodies",
      "citation": {
        "type": "PubMed",
        "reference": "14642273",
        "name": "Neuron",
        "title": "Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.",
        "volume": "40",
        "pages": "471-83",
        "date": "2003-10-30",
        "first": "Cruz JC",
        "last": "Tsai LH",
        "authors": [
          "Cruz JC",
          "Goldman JA",
          "Shih H",
          "Tsai LH",
          "Tseng HC"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "p25 transgenic mice": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 777,
      "target": 832,
      "key": "8d0242cae8f6004a0a93330c7ef6f635e3f71b31057b37634de58a721ce9e7bb2eb1a7fc257691be5bcc0857d43cb43d5533d57a0c918e6f477177d4dab19cc9"
    },
    {
      "line": 2562,
      "relation": "directlyIncreases",
      "evidence": "Tau peptides containing phosphorylated S202, T205, and T396 were found only in Tg mice, supporting our results using AT8 and PHF1 antibodies",
      "citation": {
        "type": "PubMed",
        "reference": "14642273",
        "name": "Neuron",
        "title": "Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.",
        "volume": "40",
        "pages": "471-83",
        "date": "2003-10-30",
        "first": "Cruz JC",
        "last": "Tsai LH",
        "authors": [
          "Cruz JC",
          "Goldman JA",
          "Shih H",
          "Tsai LH",
          "Tseng HC"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "p25 transgenic mice": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 777,
      "target": 833,
      "key": "81fe05686345074fafebe2cffaaa9ab76c1e1d09f864b3155b9abace43b702fde00d40f6b850b80df0811b7df514fbc60a8fd0599375a9a26a870cbe1993d444"
    },
    {
      "line": 2563,
      "relation": "directlyIncreases",
      "evidence": "Tau peptides containing phosphorylated S202, T205, and T396 were found only in Tg mice, supporting our results using AT8 and PHF1 antibodies",
      "citation": {
        "type": "PubMed",
        "reference": "14642273",
        "name": "Neuron",
        "title": "Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.",
        "volume": "40",
        "pages": "471-83",
        "date": "2003-10-30",
        "first": "Cruz JC",
        "last": "Tsai LH",
        "authors": [
          "Cruz JC",
          "Goldman JA",
          "Shih H",
          "Tsai LH",
          "Tseng HC"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "p25 transgenic mice": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 777,
      "target": 819,
      "key": "e23a215f8908b85a32de8f12e3df629a6a71e28ab5b947a6a120e5ca48250df70d3cfd43716ba36320073fb1333111e1d6ef411f416d66ee01693b13c16815cd"
    },
    {
      "line": 2564,
      "relation": "directlyIncreases",
      "evidence": "Tau peptides containing phosphorylated S202, T205, and T396 were found only in Tg mice, supporting our results using AT8 and PHF1 antibodies",
      "citation": {
        "type": "PubMed",
        "reference": "14642273",
        "name": "Neuron",
        "title": "Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.",
        "volume": "40",
        "pages": "471-83",
        "date": "2003-10-30",
        "first": "Cruz JC",
        "last": "Tsai LH",
        "authors": [
          "Cruz JC",
          "Goldman JA",
          "Shih H",
          "Tsai LH",
          "Tseng HC"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "p25 transgenic mice": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 777,
      "target": 820,
      "key": "2abdd24a3f54ea357b3d262227ddcdbf43a63a8c1fa1f7bfc42e07a38387ba37c99f407adf91f9749688306e04aff09333f4013ae349a2d2eb48f4b44b5acc0b"
    },
    {
      "line": 2565,
      "relation": "directlyIncreases",
      "evidence": "Tau peptides containing phosphorylated S202, T205, and T396 were found only in Tg mice, supporting our results using AT8 and PHF1 antibodies",
      "citation": {
        "type": "PubMed",
        "reference": "14642273",
        "name": "Neuron",
        "title": "Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.",
        "volume": "40",
        "pages": "471-83",
        "date": "2003-10-30",
        "first": "Cruz JC",
        "last": "Tsai LH",
        "authors": [
          "Cruz JC",
          "Goldman JA",
          "Shih H",
          "Tsai LH",
          "Tseng HC"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "p25 transgenic mice": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 777,
      "target": 823,
      "key": "8ca48c02831a9be9899a99f883c894531d1dd12e08da639fd11101466085c356211c5017cd9892a64736c995f9217767def95c75b502093dc98c37c0a5b2453e"
    },
    {
      "line": 2566,
      "relation": "directlyIncreases",
      "evidence": "Tau peptides containing phosphorylated S202, T205, and T396 were found only in Tg mice, supporting our results using AT8 and PHF1 antibodies",
      "citation": {
        "type": "PubMed",
        "reference": "14642273",
        "name": "Neuron",
        "title": "Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.",
        "volume": "40",
        "pages": "471-83",
        "date": "2003-10-30",
        "first": "Cruz JC",
        "last": "Tsai LH",
        "authors": [
          "Cruz JC",
          "Goldman JA",
          "Shih H",
          "Tsai LH",
          "Tseng HC"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "p25 transgenic mice": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 777,
      "target": 824,
      "key": "7a2b51d71d3820990b6a61e79538db7c83f529530bef6cb6c236c46b9aa60507be38c89c6a8301f1938b80b3313bc674f7b07e166370dd808f3592e55f73179e"
    },
    {
      "line": 2567,
      "relation": "directlyIncreases",
      "evidence": "Tau peptides containing phosphorylated S202, T205, and T396 were found only in Tg mice, supporting our results using AT8 and PHF1 antibodies",
      "citation": {
        "type": "PubMed",
        "reference": "14642273",
        "name": "Neuron",
        "title": "Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.",
        "volume": "40",
        "pages": "471-83",
        "date": "2003-10-30",
        "first": "Cruz JC",
        "last": "Tsai LH",
        "authors": [
          "Cruz JC",
          "Goldman JA",
          "Shih H",
          "Tsai LH",
          "Tseng HC"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "p25 transgenic mice": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 777,
      "target": 835,
      "key": "52a6f69623fd6741c136265c673c7ddc566618bea0c88636e298efdf0eefaa374badb6ba7c7da9fe8096f3913ccd934ab3143957c15b37bddcd6d327134419d5"
    },
    {
      "relation": "hasVariant",
      "source": 842,
      "target": 843,
      "key": "4ecdce77eb7836f4bcc32c4d3516ea032384fe1872dfbc3bf0f73b24b219516b30804968cb5b2443f17e2881fc06205f004da2544a463d113e0efad8cf56e9da"
    },
    {
      "line": 1231,
      "relation": "negativeCorrelation",
      "evidence": "The phosphorylation sites were determined to be Ser551 and Ser553 with Cdk5-p23, and Ser62, Ser67, and Ser551 with MAP kinase. Upon phosphorylation with MAP kinase, synapsin I showed reduced F-actin bundling activity, while no significant effect on the interaction was observed with the protein phosphorylated with Cdk5-p23.",
      "citation": {
        "type": "PubMed",
        "reference": "8702879",
        "name": "The Journal of biological chemistry",
        "title": "Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions.",
        "volume": "271",
        "pages": "21108-13",
        "date": "1996-08-30",
        "first": "Matsubara M",
        "last": "Taniguchi H",
        "authors": [
          "Ishiguro K",
          "Kusubata M",
          "Matsubara M",
          "Taniguchi H",
          "Titani K",
          "Uchida T"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 708,
      "target": 707,
      "key": "349f5d8fca0af9007b95043d7db020b12992867f4809f2d5f1c80491cafa68af611f38459bc7769d9afe03cb8c1b251c35a76e395311331eed39bd58e15dd4f1"
    },
    {
      "relation": "hasVariant",
      "source": 707,
      "target": 708,
      "key": "3b29443c021e0f206703d7c9cbcbd46512b4305cb5be1758787bd9b1492379489cd3eecc765c99d13a03f0b9719e6a5be98932779d60f2cf2bc7925822b4d1ed"
    },
    {
      "line": 1231,
      "relation": "negativeCorrelation",
      "evidence": "The phosphorylation sites were determined to be Ser551 and Ser553 with Cdk5-p23, and Ser62, Ser67, and Ser551 with MAP kinase. Upon phosphorylation with MAP kinase, synapsin I showed reduced F-actin bundling activity, while no significant effect on the interaction was observed with the protein phosphorylated with Cdk5-p23.",
      "citation": {
        "type": "PubMed",
        "reference": "8702879",
        "name": "The Journal of biological chemistry",
        "title": "Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions.",
        "volume": "271",
        "pages": "21108-13",
        "date": "1996-08-30",
        "first": "Matsubara M",
        "last": "Taniguchi H",
        "authors": [
          "Ishiguro K",
          "Kusubata M",
          "Matsubara M",
          "Taniguchi H",
          "Titani K",
          "Uchida T"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 707,
      "target": 708,
      "key": "5cae9595766a9d00af45116535a841ea69efe634b0bf2b42dfb17623b001b176afe48e03e9c9dbef02e31979ff323728eb1d6f663b06752174176d9f1ed4b7bf"
    },
    {
      "relation": "hasVariant",
      "source": 707,
      "target": 709,
      "key": "a7e68e05f88addda361a363a509ce9501631b1fdfed5ad4737e443f44cb6d63108afdbfdedf70cd0ee51ad3a7c88f84cee1827c903b41b360db7cea93e115abf"
    },
    {
      "relation": "hasVariant",
      "source": 707,
      "target": 710,
      "key": "5bc4a6fe511aa0dfd10ab6b4ad9cd4a25bef283340e57596c9b706e43bf4d378a33ca0ff69f707ace2b7b54d2fd59431829b14e8ff60e4c047f9cb34d2f43276"
    },
    {
      "line": 1229,
      "relation": "negativeCorrelation",
      "evidence": "The phosphorylation sites were determined to be Ser551 and Ser553 with Cdk5-p23, and Ser62, Ser67, and Ser551 with MAP kinase. Upon phosphorylation with MAP kinase, synapsin I showed reduced F-actin bundling activity, while no significant effect on the interaction was observed with the protein phosphorylated with Cdk5-p23.",
      "citation": {
        "type": "PubMed",
        "reference": "8702879",
        "name": "The Journal of biological chemistry",
        "title": "Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions.",
        "volume": "271",
        "pages": "21108-13",
        "date": "1996-08-30",
        "first": "Matsubara M",
        "last": "Taniguchi H",
        "authors": [
          "Ishiguro K",
          "Kusubata M",
          "Matsubara M",
          "Taniguchi H",
          "Titani K",
          "Uchida T"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 707,
      "target": 710,
      "key": "8d1550dbbb2272219b625aad9d9068e8ae21457833cbd6ad46cee1d9e157235d63dcf3e7704bc1355c07e3059d5bfbe4f7c69434e9689e98d982002bb9482fa9"
    },
    {
      "relation": "hasVariant",
      "source": 707,
      "target": 711,
      "key": "57cae75d6c0fdf0041d3ee1b9c0cb629187f1214690e27d1a57dbc85ee2250222ae1cc90bf352aece5b3a5b01dabc3003265fc9f9bffd655283257937084dfed"
    },
    {
      "line": 1230,
      "relation": "negativeCorrelation",
      "evidence": "The phosphorylation sites were determined to be Ser551 and Ser553 with Cdk5-p23, and Ser62, Ser67, and Ser551 with MAP kinase. Upon phosphorylation with MAP kinase, synapsin I showed reduced F-actin bundling activity, while no significant effect on the interaction was observed with the protein phosphorylated with Cdk5-p23.",
      "citation": {
        "type": "PubMed",
        "reference": "8702879",
        "name": "The Journal of biological chemistry",
        "title": "Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions.",
        "volume": "271",
        "pages": "21108-13",
        "date": "1996-08-30",
        "first": "Matsubara M",
        "last": "Taniguchi H",
        "authors": [
          "Ishiguro K",
          "Kusubata M",
          "Matsubara M",
          "Taniguchi H",
          "Titani K",
          "Uchida T"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 707,
      "target": 711,
      "key": "b84c7f94cd012daeddbbf04ed33afe7a3fdb9e1cb08f3116ea002f316783cc9ca9a4decfec2dc3915d20579976d58d6476d07efd969a499d6395d2efe31218f6"
    },
    {
      "relation": "hasVariant",
      "source": 707,
      "target": 712,
      "key": "e424f241b25481adb87435fedeb9d8b22e826e143143e9a0c50b71f7e333f40f7f4a8cd1970d783c4fe8e20cd687956f72fba840b4b88a8a7c8b3087b693a515"
    },
    {
      "line": 1225,
      "relation": "increases",
      "evidence": "The phosphorylation sites were determined to be Ser551 and Ser553 with Cdk5-p23, and Ser62, Ser67, and Ser551 with MAP kinase. Upon phosphorylation with MAP kinase, synapsin I showed reduced F-actin bundling activity, while no significant effect on the interaction was observed with the protein phosphorylated with Cdk5-p23.",
      "citation": {
        "type": "PubMed",
        "reference": "8702879",
        "name": "The Journal of biological chemistry",
        "title": "Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions.",
        "volume": "271",
        "pages": "21108-13",
        "date": "1996-08-30",
        "first": "Matsubara M",
        "last": "Taniguchi H",
        "authors": [
          "Ishiguro K",
          "Kusubata M",
          "Matsubara M",
          "Taniguchi H",
          "Titani K",
          "Uchida T"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 293,
      "target": 710,
      "key": "2c9c4c1df4ddca63d6282fecf4e7b7f19aa23ba9ef39fb20166d8aafb0511a1114c6253b10ca839bb01a9ae1d243f9a03ddcaabbdd036740148d6ebe4dd66cae"
    },
    {
      "line": 1226,
      "relation": "increases",
      "evidence": "The phosphorylation sites were determined to be Ser551 and Ser553 with Cdk5-p23, and Ser62, Ser67, and Ser551 with MAP kinase. Upon phosphorylation with MAP kinase, synapsin I showed reduced F-actin bundling activity, while no significant effect on the interaction was observed with the protein phosphorylated with Cdk5-p23.",
      "citation": {
        "type": "PubMed",
        "reference": "8702879",
        "name": "The Journal of biological chemistry",
        "title": "Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions.",
        "volume": "271",
        "pages": "21108-13",
        "date": "1996-08-30",
        "first": "Matsubara M",
        "last": "Taniguchi H",
        "authors": [
          "Ishiguro K",
          "Kusubata M",
          "Matsubara M",
          "Taniguchi H",
          "Titani K",
          "Uchida T"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 293,
      "target": 711,
      "key": "5bd41c125ea9f01fecee163009b066ebb0e707b469d2139902cdf51714e8ea1dae549c58ba7b66ed18b857759530cd2642f4476f7751af7071a26f17a081ec34"
    },
    {
      "line": 1227,
      "relation": "increases",
      "evidence": "The phosphorylation sites were determined to be Ser551 and Ser553 with Cdk5-p23, and Ser62, Ser67, and Ser551 with MAP kinase. Upon phosphorylation with MAP kinase, synapsin I showed reduced F-actin bundling activity, while no significant effect on the interaction was observed with the protein phosphorylated with Cdk5-p23.",
      "citation": {
        "type": "PubMed",
        "reference": "8702879",
        "name": "The Journal of biological chemistry",
        "title": "Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions.",
        "volume": "271",
        "pages": "21108-13",
        "date": "1996-08-30",
        "first": "Matsubara M",
        "last": "Taniguchi H",
        "authors": [
          "Ishiguro K",
          "Kusubata M",
          "Matsubara M",
          "Taniguchi H",
          "Titani K",
          "Uchida T"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 293,
      "target": 708,
      "key": "91c242e73631329776cfde9bcdc209dc6558559cb09527b6c10d2056b580fa64b25ebc78e04232f59021810d578674dfdbceeae0ef9d11ecde870143ae9a03c8"
    },
    {
      "line": 1229,
      "relation": "negativeCorrelation",
      "evidence": "The phosphorylation sites were determined to be Ser551 and Ser553 with Cdk5-p23, and Ser62, Ser67, and Ser551 with MAP kinase. Upon phosphorylation with MAP kinase, synapsin I showed reduced F-actin bundling activity, while no significant effect on the interaction was observed with the protein phosphorylated with Cdk5-p23.",
      "citation": {
        "type": "PubMed",
        "reference": "8702879",
        "name": "The Journal of biological chemistry",
        "title": "Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions.",
        "volume": "271",
        "pages": "21108-13",
        "date": "1996-08-30",
        "first": "Matsubara M",
        "last": "Taniguchi H",
        "authors": [
          "Ishiguro K",
          "Kusubata M",
          "Matsubara M",
          "Taniguchi H",
          "Titani K",
          "Uchida T"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 710,
      "target": 707,
      "key": "e58925ab9292012990b73371144103371cfc74c838397b57ae721287135cbb018d4962ca65de6c5199cd9c6c9d7e1781a4b52ea684895e516a1c577c82c85471"
    },
    {
      "line": 1230,
      "relation": "negativeCorrelation",
      "evidence": "The phosphorylation sites were determined to be Ser551 and Ser553 with Cdk5-p23, and Ser62, Ser67, and Ser551 with MAP kinase. Upon phosphorylation with MAP kinase, synapsin I showed reduced F-actin bundling activity, while no significant effect on the interaction was observed with the protein phosphorylated with Cdk5-p23.",
      "citation": {
        "type": "PubMed",
        "reference": "8702879",
        "name": "The Journal of biological chemistry",
        "title": "Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions.",
        "volume": "271",
        "pages": "21108-13",
        "date": "1996-08-30",
        "first": "Matsubara M",
        "last": "Taniguchi H",
        "authors": [
          "Ishiguro K",
          "Kusubata M",
          "Matsubara M",
          "Taniguchi H",
          "Titani K",
          "Uchida T"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 711,
      "target": 707,
      "key": "7635e4585b8e96b1cb90b1f76fbe1361ef1dc059550e9da0bf7dfb0946553626c76e85a80d5ad2610c87b64ee7cd5b364b84a92a11e6a08e280e88ea4b324f2c"
    },
    {
      "line": 1242,
      "relation": "partOf",
      "evidence": "First, we verified the colocalization of p-WAVE1 and pCRMP2 with aggregated hyperphosphorylated tau in the hippocampus at 23 months of age. Biochemical analysis revealed the inclusion of p-WAVE1, p-CRMP2, and tau in the sarkosyl-insoluble fractions of hippocampal homogenates",
      "citation": {
        "type": "PubMed",
        "reference": "26400044",
        "name": "Journal of neuroscience research",
        "title": "Colocalization of phosphorylated forms of WAVE1, CRMP2, and tau in Alzheimer's disease model mice: Involvement of Cdk5 phosphorylation and the effect of ATRA treatment.",
        "volume": "94",
        "pages": "15-26",
        "date": "2016-01-01",
        "first": "Watamura N",
        "last": "Ohshima T",
        "authors": [
          "Nikkuni M",
          "Ohshima T",
          "Toba J",
          "Watamura N",
          "Yoshii A"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 855,
      "target": 243,
      "key": "6e7339850a99f2b931275c6e6897414ce493b82a5c3d39dd464f7c290da3ee7fa46971f2ed574577ed9cea52e16ee92e7c1689ea66879c20a33fa633e7a61a74"
    },
    {
      "relation": "hasVariant",
      "source": 854,
      "target": 855,
      "key": "4789b8881f8740532658f991d483400ae208705ea224d62bcbab70010524def3ab3ba6f32757784fb342fa70b003912efaa12af308ae2278991d978269816555"
    },
    {
      "line": 1243,
      "relation": "partOf",
      "evidence": "First, we verified the colocalization of p-WAVE1 and pCRMP2 with aggregated hyperphosphorylated tau in the hippocampus at 23 months of age. Biochemical analysis revealed the inclusion of p-WAVE1, p-CRMP2, and tau in the sarkosyl-insoluble fractions of hippocampal homogenates",
      "citation": {
        "type": "PubMed",
        "reference": "26400044",
        "name": "Journal of neuroscience research",
        "title": "Colocalization of phosphorylated forms of WAVE1, CRMP2, and tau in Alzheimer's disease model mice: Involvement of Cdk5 phosphorylation and the effect of ATRA treatment.",
        "volume": "94",
        "pages": "15-26",
        "date": "2016-01-01",
        "first": "Watamura N",
        "last": "Ohshima T",
        "authors": [
          "Nikkuni M",
          "Ohshima T",
          "Toba J",
          "Watamura N",
          "Yoshii A"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 785,
      "target": 243,
      "key": "99164425b30d9eb358c25c0c37d1294356abed60519b45d5fd052465c31342b35dc90db560392d7f13a542cd20bd41bdb39487bd0901374ee2038901508b33de"
    },
    {
      "relation": "hasVariant",
      "source": 784,
      "target": 785,
      "key": "dd272d79ddd5b6c9ce59ad8ab12d2a46e563d902ee9bed37345e390050e4401affb637bc40cad91d9bb13c5614eb48a53d757e04f4ed75bf94895d70932e6411"
    },
    {
      "relation": "hasComponent",
      "source": 243,
      "target": 785,
      "key": "f718b0561f18eec465c862bad54d219ff0a3c249e0e8ce21da1c4c4e839ad2e9668ffba824aab8ae59431b9aa9cb224bdfe95fe4ad76f8be1b2931327c347eb0"
    },
    {
      "relation": "hasComponent",
      "source": 243,
      "target": 803,
      "key": "d5a385dc7c59ef3a2e8f234abbac135239c3acf9d6988d8e87fa0b4e4c2204d0e1586bf18a0946755d97bd1aa74c61ecf71fce02955ebcf26beabb15f034081c"
    },
    {
      "relation": "hasComponent",
      "source": 243,
      "target": 855,
      "key": "af730e90f83002a0ef0272dd84c76f63a69559ac413b2be3a40b22c22c2eb5b04fdcd2799f53b8c7f27f7b563991e3ebd4db9eda684371c8cda560282c16e5b1"
    },
    {
      "line": 1249,
      "relation": "association",
      "evidence": "We found that the immunoreactivities of p-WAVE1 and pCRMP2 colocalized with p-tau and were located near peripheral amyloid plaques in the cerebral cortices of 23- month-old 33Tg (Fig. 3A) and 17-month-old APPswe/ PS1DE9 (Fig. 3B) mice.",
      "citation": {
        "type": "PubMed",
        "reference": "26400044",
        "name": "Journal of neuroscience research",
        "title": "Colocalization of phosphorylated forms of WAVE1, CRMP2, and tau in Alzheimer's disease model mice: Involvement of Cdk5 phosphorylation and the effect of ATRA treatment.",
        "volume": "94",
        "pages": "15-26",
        "date": "2016-01-01",
        "first": "Watamura N",
        "last": "Ohshima T",
        "authors": [
          "Nikkuni M",
          "Ohshima T",
          "Toba J",
          "Watamura N",
          "Yoshii A"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 243,
      "target": 917,
      "key": "cd7433546d45f2939d3434943f5c164fea33363f96db0fc928697e6687e317f36fc7648676a011eb3611ffdb00d8b34e9bdf09a369e760fbff791d4ae23f2830"
    },
    {
      "line": 1255,
      "relation": "decreases",
      "evidence": "ATRA prevents the accumulation of amyloid plaques and APP processing into Ab through downregulation of Cdk5 in APP/PS1 mice. These results suggested that the administration of ATRA inhibited activity of Cdk5 and GSK3b and attenuated the formation of p-tau aggregation, including p-CRMP2 and p-WAVE1 in the 33Tg mouse brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26400044",
        "name": "Journal of neuroscience research",
        "title": "Colocalization of phosphorylated forms of WAVE1, CRMP2, and tau in Alzheimer's disease model mice: Involvement of Cdk5 phosphorylation and the effect of ATRA treatment.",
        "volume": "94",
        "pages": "15-26",
        "date": "2016-01-01",
        "first": "Watamura N",
        "last": "Ohshima T",
        "authors": [
          "Nikkuni M",
          "Ohshima T",
          "Toba J",
          "Watamura N",
          "Yoshii A"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 10,
      "target": 917,
      "key": "917f357e5b180ca4f87fcfb7723f688f891bfcce5d64c823c0dce2ef0ef37c83c4a473594a25c436180252ed6ca8d86e3fe7fc3b59c3a572b8b16a4e9ae57a8a"
    },
    {
      "line": 1256,
      "relation": "decreases",
      "evidence": "ATRA prevents the accumulation of amyloid plaques and APP processing into Ab through downregulation of Cdk5 in APP/PS1 mice. These results suggested that the administration of ATRA inhibited activity of Cdk5 and GSK3b and attenuated the formation of p-tau aggregation, including p-CRMP2 and p-WAVE1 in the 33Tg mouse brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26400044",
        "name": "Journal of neuroscience research",
        "title": "Colocalization of phosphorylated forms of WAVE1, CRMP2, and tau in Alzheimer's disease model mice: Involvement of Cdk5 phosphorylation and the effect of ATRA treatment.",
        "volume": "94",
        "pages": "15-26",
        "date": "2016-01-01",
        "first": "Watamura N",
        "last": "Ohshima T",
        "authors": [
          "Nikkuni M",
          "Ohshima T",
          "Toba J",
          "Watamura N",
          "Yoshii A"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 10,
      "target": 92,
      "key": "2ccae7b34edc8923aa7028506bfbcff7a489f8cc320c77bd4300de74e32fa812d1c8356b76d2f76182632886742f69f97c07e6ea7c2ea57713cf758d4f7d7583"
    },
    {
      "line": 1257,
      "relation": "decreases",
      "evidence": "ATRA prevents the accumulation of amyloid plaques and APP processing into Ab through downregulation of Cdk5 in APP/PS1 mice. These results suggested that the administration of ATRA inhibited activity of Cdk5 and GSK3b and attenuated the formation of p-tau aggregation, including p-CRMP2 and p-WAVE1 in the 33Tg mouse brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26400044",
        "name": "Journal of neuroscience research",
        "title": "Colocalization of phosphorylated forms of WAVE1, CRMP2, and tau in Alzheimer's disease model mice: Involvement of Cdk5 phosphorylation and the effect of ATRA treatment.",
        "volume": "94",
        "pages": "15-26",
        "date": "2016-01-01",
        "first": "Watamura N",
        "last": "Ohshima T",
        "authors": [
          "Nikkuni M",
          "Ohshima T",
          "Toba J",
          "Watamura N",
          "Yoshii A"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 10,
      "target": 777,
      "key": "91035934e0f2ddb27b1e3313a3f7dc5bcfda3ae6f73f10554ce39ed6769e4cc577b76420f61c4496c3bdff1732f90a1c24991a020ed3b49518d7034103b00e32"
    },
    {
      "line": 1258,
      "relation": "decreases",
      "evidence": "ATRA prevents the accumulation of amyloid plaques and APP processing into Ab through downregulation of Cdk5 in APP/PS1 mice. These results suggested that the administration of ATRA inhibited activity of Cdk5 and GSK3b and attenuated the formation of p-tau aggregation, including p-CRMP2 and p-WAVE1 in the 33Tg mouse brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26400044",
        "name": "Journal of neuroscience research",
        "title": "Colocalization of phosphorylated forms of WAVE1, CRMP2, and tau in Alzheimer's disease model mice: Involvement of Cdk5 phosphorylation and the effect of ATRA treatment.",
        "volume": "94",
        "pages": "15-26",
        "date": "2016-01-01",
        "first": "Watamura N",
        "last": "Ohshima T",
        "authors": [
          "Nikkuni M",
          "Ohshima T",
          "Toba J",
          "Watamura N",
          "Yoshii A"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 10,
      "target": 794,
      "key": "767b96280366bcb8a960419a03722b5dc98d7bfd262a4c5e2e9f6feea0f48cb9da9b1aff37025b15f992c817599b2f2ace5c85c1dff6f5411fdf577821e1320f"
    },
    {
      "line": 1259,
      "relation": "decreases",
      "evidence": "ATRA prevents the accumulation of amyloid plaques and APP processing into Ab through downregulation of Cdk5 in APP/PS1 mice. These results suggested that the administration of ATRA inhibited activity of Cdk5 and GSK3b and attenuated the formation of p-tau aggregation, including p-CRMP2 and p-WAVE1 in the 33Tg mouse brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26400044",
        "name": "Journal of neuroscience research",
        "title": "Colocalization of phosphorylated forms of WAVE1, CRMP2, and tau in Alzheimer's disease model mice: Involvement of Cdk5 phosphorylation and the effect of ATRA treatment.",
        "volume": "94",
        "pages": "15-26",
        "date": "2016-01-01",
        "first": "Watamura N",
        "last": "Ohshima T",
        "authors": [
          "Nikkuni M",
          "Ohshima T",
          "Toba J",
          "Watamura N",
          "Yoshii A"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 10,
      "target": 243,
      "key": "8eab18b70e05b67c12998c4ebfd21ad610f7bdd9de3e60a72615ae626f80c2367b88c3d3445af344aca3ea64a0f080f52009382b416fa86628b80cd36dfc296a"
    },
    {
      "line": 1266,
      "relation": "decreases",
      "evidence": "The kinase activity was inhibited by staurosporine, isopentanyladenine and olomoucine in a dose dependent manner. Kinetic studies indicated Ki values of 39 nM, 38 microM and 8 microM, respectively for staurosporine, isopentanyladenine and olomoucine.",
      "citation": {
        "type": "PubMed",
        "reference": "8726973",
        "name": "Neurochemical research",
        "title": "Inhibition of neuronal cyclin-dependent kinase-5 by staurosporine and purine analogs is independent of activation by Munc-18.",
        "volume": "21",
        "pages": "629-36",
        "date": "1996-05-01",
        "first": "Veeranna",
        "last": "Pant HC",
        "authors": [
          "Albers RW",
          "Amin N",
          "Grant P",
          "Pant HC",
          "Shetty KT",
          "Veeranna"
        ]
      },
      "annotations": {
        "Ki": {
          "39 nM": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 74,
      "target": 400,
      "key": "2b4a4dab6928ae1fd6c414c908bcd2fce7ba04692497052fbcc0b41baf5bc55bf0286e6a92c67d724bf58898fe566b62c6d2603dc60b7f2712d1c2369510980d"
    },
    {
      "line": 1850,
      "relation": "decreases",
      "evidence": "In parallel, phosphorylation of tau at Ser262 in MARK-transfected cells was investigated using a rabbit antibody recognizing phosphorylated Ser262 of tau (AGG5759) and a mouse anti-tau antibody (SC-21796) (Fig. S1a3). Tau was shown to interact with each of the transfected MARK isoforms (Fig. 1) and to be phosphorylated at Ser262 (Fig. 2). Staurosporine, a non-selective kinase inhibitor, significantly inhibited interactions between tau and each of the four MARK isoforms after treatment with 20 lM staurosporine for 1 h (Fig. 1; p = 0.02 for MARK1–, MARK2– and MARK3–tau interactions and p = 3 9 10-6 for MARK4–tau interaction). Treatment with staurosporine also significantly reduced PLA signals for tau phosphorylation at Ser262 (Fig. 2; p = 0.04 for MARK1- and p = 0.02 for MARK2- and MARK3- and p = 1 9 10-5 for MARK4-mediated tau phosphorylation)",
      "citation": {
        "type": "PubMed",
        "reference": "23666762",
        "name": "Neuromolecular medicine",
        "title": "Role of individual MARK isoforms in phosphorylation of tau at Ser²⁶² in Alzheimer's disease.",
        "volume": "15",
        "pages": "458-69",
        "date": "2013-09-01",
        "first": "Gu GJ",
        "last": "Kamali-Moghaddam M",
        "authors": [
          "Blokzijl A",
          "Classon C",
          "Gu GJ",
          "Kamali-Moghaddam M",
          "Landegren U",
          "Lund H",
          "Sunnemark D",
          "Wu D",
          "von Euler G"
        ]
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 74,
      "target": 759,
      "key": "7a61d0d0f17b6fa2a6dcc8101060b094a5a9379091ce55567e1fba6b01b2bdea38c1f798df1c8e71fce084726c22af91131bbc866e01954d32b9ad015a7fa055"
    },
    {
      "line": 2776,
      "relation": "decreases",
      "evidence": "Several kinases such as microtubule-affinity regulating kinase (MARK), protein kinase A, calcium calmodulin kinase II, and checkpoint kinase 2 are known to phosphorylate tau on Ser(262) in vitro. In this study, we took advantage of the in situ proximity ligation assay to investigate the role of MARK2, one of the four MARK isoforms, in AD. We demonstrate that MARK2 interacts with tau and phosphorylates tau at Ser(262) in stably transfected NIH/3T3 cells expressing human recombinant tau. Staurosporine, a protein kinase inhibitor, significantly reduced the interaction between MARK2 and tau, and also phosphorylation of tau at Ser(262).",
      "citation": {
        "type": "PubMed",
        "reference": "23001711",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Elevated MARK2-dependent phosphorylation of Tau in Alzheimer's disease.",
        "volume": "33",
        "pages": "699-713",
        "date": "2013-01-01",
        "first": "Gu GJ",
        "last": "Kamali-Moghaddam M",
        "authors": [
          "Agerman K",
          "Eckersley S",
          "Gu GJ",
          "Kamali-Moghaddam M",
          "Kvist AJ",
          "Landegren U",
          "Lund H",
          "Milner R",
          "Nilsson LN",
          "Sunnemark D",
          "Wu D"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "NIH/3T3": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 74,
      "target": 634,
      "key": "92df9e300db62d7c2a9c542993b86c4f991615edc2d53d1e345f60985f0c21ea9f874167feeb753763d3777c6372bb5944f81b4d68799d1fd00b658c3990f41b"
    },
    {
      "line": 2777,
      "relation": "decreases",
      "evidence": "Several kinases such as microtubule-affinity regulating kinase (MARK), protein kinase A, calcium calmodulin kinase II, and checkpoint kinase 2 are known to phosphorylate tau on Ser(262) in vitro. In this study, we took advantage of the in situ proximity ligation assay to investigate the role of MARK2, one of the four MARK isoforms, in AD. We demonstrate that MARK2 interacts with tau and phosphorylates tau at Ser(262) in stably transfected NIH/3T3 cells expressing human recombinant tau. Staurosporine, a protein kinase inhibitor, significantly reduced the interaction between MARK2 and tau, and also phosphorylation of tau at Ser(262).",
      "citation": {
        "type": "PubMed",
        "reference": "23001711",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Elevated MARK2-dependent phosphorylation of Tau in Alzheimer's disease.",
        "volume": "33",
        "pages": "699-713",
        "date": "2013-01-01",
        "first": "Gu GJ",
        "last": "Kamali-Moghaddam M",
        "authors": [
          "Agerman K",
          "Eckersley S",
          "Gu GJ",
          "Kamali-Moghaddam M",
          "Kvist AJ",
          "Landegren U",
          "Lund H",
          "Milner R",
          "Nilsson LN",
          "Sunnemark D",
          "Wu D"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "NIH/3T3": true
        }
      },
      "source": 74,
      "target": 557,
      "key": "f49227ef09e124976ddc76284a4c2d05c924e128b677207c7c15f71fa883200e631cdfd91d93f879f6958f424007a534a9254bdb3367bb83e4be99d8a512b2f1"
    },
    {
      "line": 1268,
      "relation": "decreases",
      "evidence": "The kinase activity was inhibited by staurosporine, isopentanyladenine and olomoucine in a dose dependent manner. Kinetic studies indicated Ki values of 39 nM, 38 microM and 8 microM, respectively for staurosporine, isopentanyladenine and olomoucine.",
      "citation": {
        "type": "PubMed",
        "reference": "8726973",
        "name": "Neurochemical research",
        "title": "Inhibition of neuronal cyclin-dependent kinase-5 by staurosporine and purine analogs is independent of activation by Munc-18.",
        "volume": "21",
        "pages": "629-36",
        "date": "1996-05-01",
        "first": "Veeranna",
        "last": "Pant HC",
        "authors": [
          "Albers RW",
          "Amin N",
          "Grant P",
          "Pant HC",
          "Shetty KT",
          "Veeranna"
        ]
      },
      "annotations": {
        "Ki": {
          "38 μM": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 152,
      "target": 400,
      "key": "d526db59274ac0a83727b4103ea44301d3bcda39bed7764aac3d8ca5f79898eb84ea0312b391cc91f915a8ffe658d34cbba5d423caf0c805c65c7d1a92587e50"
    },
    {
      "line": 1270,
      "relation": "decreases",
      "evidence": "The kinase activity was inhibited by staurosporine, isopentanyladenine and olomoucine in a dose dependent manner. Kinetic studies indicated Ki values of 39 nM, 38 microM and 8 microM, respectively for staurosporine, isopentanyladenine and olomoucine.",
      "citation": {
        "type": "PubMed",
        "reference": "8726973",
        "name": "Neurochemical research",
        "title": "Inhibition of neuronal cyclin-dependent kinase-5 by staurosporine and purine analogs is independent of activation by Munc-18.",
        "volume": "21",
        "pages": "629-36",
        "date": "1996-05-01",
        "first": "Veeranna",
        "last": "Pant HC",
        "authors": [
          "Albers RW",
          "Amin N",
          "Grant P",
          "Pant HC",
          "Shetty KT",
          "Veeranna"
        ]
      },
      "annotations": {
        "Ki": {
          "8 μM": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 156,
      "target": 400,
      "key": "a945316235161efc5922e19e32d2013f2f296516ba24d8b4269dbac43da6848caa14431f96ae53fa4d2565aa3bae3c7083d36d64adc41aa1434f183b8ab2cb44"
    },
    {
      "line": 1279,
      "relation": "increases",
      "evidence": "Tau-phosphorylation properties dependent on co-factors (Km 8 to 15 uM, Vmax 0.8 to 4 uM/min/mg protein) and Km for ATP is 2uM",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "annotations": {
        "Vmax": {
          "0.8-4 μM/min/mg": true
        },
        "Km": {
          "8-15 μM": true
        },
        "Km_ATP": {
          "2 μM": true
        }
      },
      "source": 413,
      "target": 538,
      "key": "6ad96a748c26f17f655c23eb65138c29eabad0ec3be35185b9cddc2d0564e3c153314a55fdc2758b39bcad64f4d935ced21f9b5d364a09c1daa41f76b0ed3129"
    },
    {
      "line": 1401,
      "relation": "isA",
      "evidence": "The CK1 group of eukaryotic protein kinases are composed of seven CK1 isoforms (CK1α, CK1α2, CK1δ, CK1ε, CK1γ1, CK1γ2, and CK1γ3), two Tau–tubulin kinase isoforms (TTBK1 and TTBK2), and three VRK isoforms (VRK1, VRK2, and VRK3)",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 413,
      "target": 286,
      "key": "548993e51c8577f30b1edb8fb592ff79b752a95edd1668fc0cd30b57277f5c753d714a662925a33b8cec1cbcd33cb146454a130977e563a1ff4eeb2eed289a46"
    },
    {
      "line": 1288,
      "relation": "increases",
      "evidence": "Epitopes S198, S199, S202, T205, S422 (Lund 2013)",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "source": 734,
      "target": 542,
      "key": "5508ba1bdd36522fe015cc7ca4b0d8dbb9119530065ee42cbb571c0dc7fd43e15b2df3dd04cd64fd9f2a0c0655381139de88bdaef484cadd52cc5a7679d49fc3"
    },
    {
      "line": 1289,
      "relation": "increases",
      "evidence": "Epitopes S198, S199, S202, T205, S422 (Lund 2013)",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "source": 734,
      "target": 543,
      "key": "b45370f48dc13b644f6914f349f84912b54b5a8f479c4c08f3d6de0558f82c32c34971f2b43788d0e607d96afa8f862b5d07cbc8da7a2747c988a57489ddded1"
    },
    {
      "line": 1290,
      "relation": "increases",
      "evidence": "Epitopes S198, S199, S202, T205, S422 (Lund 2013)",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "source": 734,
      "target": 544,
      "key": "e754a8e2fee6698aed215f3ace31d79aded0c6785be00b799bcc39241b7512a3ff6d50ecc1e03f13eba6caef26203bca40c5be8aaf4c43faafe2d0120b8db5d0"
    },
    {
      "line": 1291,
      "relation": "increases",
      "evidence": "Epitopes S198, S199, S202, T205, S422 (Lund 2013)",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "source": 734,
      "target": 579,
      "key": "cd9c7822ba93e017ca611cd105687ec3f441dc77d7d8d14ef7abe80e886dbf1e2a6a43b6ff0e9e0ab4d15bb284de4d27aa5391692cc6ffe50acf9850fb62a585"
    },
    {
      "line": 1292,
      "relation": "increases",
      "evidence": "Epitopes S198, S199, S202, T205, S422 (Lund 2013)",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "source": 734,
      "target": 569,
      "key": "1be45af82688542840eba27e735233ecf859ec94a843f06d82aabc8f8df9919a346044101ca2f78013066cfe484501c12d86a3a9529ec6e7bbad5702d85ca58a"
    },
    {
      "line": 1309,
      "relation": "association",
      "evidence": "These data suggest a role for TTBK1 in pre-tangle formation prior to the formation of fibrillar tau and strengthen the idea that tau is phosphorylated at Ser422 at an early intermediate stage in NFT formation.",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "source": 734,
      "target": 158,
      "key": "a0a08d61d50e0f85e92bd8bb6bee2c5a44c2f6b5918fccf674e05064498b259f1d6e327ac20a4f6c12dbb06105f15994a327928ea159cfc96fa8787da3a91759"
    },
    {
      "line": 1317,
      "relation": "increases",
      "evidence": "Activates cdk5 and GSK3; genetic variation protects against AD in Spanish cohort",
      "citation": {
        "type": "PubMed",
        "reference": "20096481",
        "name": "Neurobiology of aging",
        "title": "Genetic variations in tau-tubulin kinase-1 are linked to Alzheimer's disease in a Spanish case-control cohort.",
        "volume": "32",
        "pages": "550.e5-9",
        "date": "2011-03-01",
        "first": "Vázquez-Higuera JL",
        "last": "Combarros O",
        "authors": [
          "Berciano J",
          "Bullido MJ",
          "Combarros O",
          "Frank A",
          "Martínez-García A",
          "Mateo I",
          "Pozueta A",
          "Rodríguez-Rodríguez E",
          "Sánchez-Juan P",
          "Valdivieso F",
          "Vázquez-Higuera JL"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Spanish cohort": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 734,
      "target": 400,
      "key": "39599457057755dcb5c62b339a7ec5fde340796c88f9c033a68a108e60b0478b688b31522e61658df5643790c18751b34791feb2e469beeb7105cd39e8173066"
    },
    {
      "line": 1318,
      "relation": "increases",
      "evidence": "Activates cdk5 and GSK3; genetic variation protects against AD in Spanish cohort",
      "citation": {
        "type": "PubMed",
        "reference": "20096481",
        "name": "Neurobiology of aging",
        "title": "Genetic variations in tau-tubulin kinase-1 are linked to Alzheimer's disease in a Spanish case-control cohort.",
        "volume": "32",
        "pages": "550.e5-9",
        "date": "2011-03-01",
        "first": "Vázquez-Higuera JL",
        "last": "Combarros O",
        "authors": [
          "Berciano J",
          "Bullido MJ",
          "Combarros O",
          "Frank A",
          "Martínez-García A",
          "Mateo I",
          "Pozueta A",
          "Rodríguez-Rodríguez E",
          "Sánchez-Juan P",
          "Valdivieso F",
          "Vázquez-Higuera JL"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Spanish cohort": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 734,
      "target": 456,
      "key": "bac41cf0cb5e47fc6d10159a823ef90ef72791c518c6fcdbd08ad0616f73cc0828e752d7d0dd796eca58991ef898a1c3c2df87f4f451de8bd62a475b0f3f9f65"
    },
    {
      "line": 1372,
      "relation": "increases",
      "evidence": "TTBK1-Tg mice show significant age-dependent memory impairment as determined by radial arm water maze test, which is associated with enhancement of tau and neurofilament phosphorylation, increased levels of p25 and p35, both activators of cyclin-dependent protein kinase 5 (CDK5), enhanced calpain I activity, and reduced levels of hippocampal NMDA receptor types 2B (NR2B) and D. Enhanced CDK5/p35 complex formation is strongly correlated with dissociation of F-actin from p35, suggesting the inhibitory mechanism of CDK5/p35 complex formation by F-actin.",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "source": 734,
      "target": 401,
      "key": "9238e9cb2416aec5062fb9cf935f7c4b8b90fc803bc9869e1658fa9a849a07eb6899034b4b4d983098ef02f8702dfc73a61bc3b4574fc986539b763d9541adf5"
    },
    {
      "line": 1374,
      "relation": "positiveCorrelation",
      "evidence": "TTBK1-Tg mice show significant age-dependent memory impairment as determined by radial arm water maze test, which is associated with enhancement of tau and neurofilament phosphorylation, increased levels of p25 and p35, both activators of cyclin-dependent protein kinase 5 (CDK5), enhanced calpain I activity, and reduced levels of hippocampal NMDA receptor types 2B (NR2B) and D. Enhanced CDK5/p35 complex formation is strongly correlated with dissociation of F-actin from p35, suggesting the inhibitory mechanism of CDK5/p35 complex formation by F-actin.",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 734,
      "target": 273,
      "key": "89276444f51ac70af18901c8b4e97a94327862771d2aa85f2b20ec747d30399328f6aa3eaef3542243a6ac7ba6922d5c6396ca71a309f4b11eb67442badff7b7"
    },
    {
      "line": 1375,
      "relation": "negativeCorrelation",
      "evidence": "TTBK1-Tg mice show significant age-dependent memory impairment as determined by radial arm water maze test, which is associated with enhancement of tau and neurofilament phosphorylation, increased levels of p25 and p35, both activators of cyclin-dependent protein kinase 5 (CDK5), enhanced calpain I activity, and reduced levels of hippocampal NMDA receptor types 2B (NR2B) and D. Enhanced CDK5/p35 complex formation is strongly correlated with dissociation of F-actin from p35, suggesting the inhibitory mechanism of CDK5/p35 complex formation by F-actin.",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "source": 734,
      "target": 454,
      "key": "e905dd6d7d859ae9ec4e60a88eda56a4bdaf100645cff1017f69b680c2042dae13cbbabbc65aa479aa4f91b60e38e9e924ffe8934e21116b3f77f17e78dad26c"
    },
    {
      "line": 1376,
      "relation": "negativeCorrelation",
      "evidence": "TTBK1-Tg mice show significant age-dependent memory impairment as determined by radial arm water maze test, which is associated with enhancement of tau and neurofilament phosphorylation, increased levels of p25 and p35, both activators of cyclin-dependent protein kinase 5 (CDK5), enhanced calpain I activity, and reduced levels of hippocampal NMDA receptor types 2B (NR2B) and D. Enhanced CDK5/p35 complex formation is strongly correlated with dissociation of F-actin from p35, suggesting the inhibitory mechanism of CDK5/p35 complex formation by F-actin.",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "source": 734,
      "target": 455,
      "key": "d2ae1eed251fe01f251300a3910ee0fce466689b6b5cddc5fa78fce5f5b8d29a23d39178c5b5653c5252a8cc5da0167ce9b61f961d84bfce1eb6214b60fb56c1"
    },
    {
      "line": 1393,
      "relation": "isA",
      "evidence": "The CK1 group of eukaryotic protein kinases are composed of seven CK1 isoforms (CK1α, CK1α2, CK1δ, CK1ε, CK1γ1, CK1γ2, and CK1γ3), two Tau–tubulin kinase isoforms (TTBK1 and TTBK2), and three VRK isoforms (VRK1, VRK2, and VRK3)",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 734,
      "target": 312,
      "key": "4d3521c09a565ec94acbde7458983b2ca06f74b9680de48d1ffb6ec2e7fb0fa6a738a6e197c65ae8b309d9977fb6e222668068c8a35b1af8241825114d228bc5"
    },
    {
      "line": 1419,
      "relation": "increases",
      "evidence": "We demonstrate that Casein kinase 1 family members, including isoforms of Tau-tubulin protein kinases (TTBK1 and TTBK2), phosphorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84). These residues are also phosphorylated in vivo, and the phosphorylation of Thr84 within Cluster-2 is essential for triggering binding to the C2B domain of human synaptotagmin-1",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 734,
      "target": 696,
      "key": "2f6e6eb0c8216ebc53283066f766491f80eb40b1c69caeb427a548c451016e9e3423ce9ad62d4bebe351bcd5ed98530e3c7a861140bc9a97d1d8de467cbd28bd"
    },
    {
      "line": 1420,
      "relation": "increases",
      "evidence": "We demonstrate that Casein kinase 1 family members, including isoforms of Tau-tubulin protein kinases (TTBK1 and TTBK2), phosphorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84). These residues are also phosphorylated in vivo, and the phosphorylation of Thr84 within Cluster-2 is essential for triggering binding to the C2B domain of human synaptotagmin-1",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 734,
      "target": 697,
      "key": "ad839b4f34048e9f9683b6a2fb8480f54fd1ab6b939b54c890e9c8e36847535556ad23d59e7bc74f7b585c6f86b5116c43a626238d47e735ffdbc3d416705944"
    },
    {
      "line": 1421,
      "relation": "increases",
      "evidence": "We demonstrate that Casein kinase 1 family members, including isoforms of Tau-tubulin protein kinases (TTBK1 and TTBK2), phosphorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84). These residues are also phosphorylated in vivo, and the phosphorylation of Thr84 within Cluster-2 is essential for triggering binding to the C2B domain of human synaptotagmin-1",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 734,
      "target": 698,
      "key": "0cad67cc207e241f3c9ede02c16f2c9c9e6afb516ef4952616eb292badf8a2c41aa6584ea616308add19334b1a67ab26aece2466e269b5ec6da6b3653bae5253"
    },
    {
      "line": 1422,
      "relation": "increases",
      "evidence": "We demonstrate that Casein kinase 1 family members, including isoforms of Tau-tubulin protein kinases (TTBK1 and TTBK2), phosphorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84). These residues are also phosphorylated in vivo, and the phosphorylation of Thr84 within Cluster-2 is essential for triggering binding to the C2B domain of human synaptotagmin-1",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 734,
      "target": 699,
      "key": "02aabb4a78aaf14036c37822d1f33d8c025be3f990f2d858e46c8b73e210dfc9767dc9c81e188a50178e082924068bc07cb5b3c13d1605a5f653bc3f5e0827aa"
    },
    {
      "line": 1423,
      "relation": "increases",
      "evidence": "We demonstrate that Casein kinase 1 family members, including isoforms of Tau-tubulin protein kinases (TTBK1 and TTBK2), phosphorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84). These residues are also phosphorylated in vivo, and the phosphorylation of Thr84 within Cluster-2 is essential for triggering binding to the C2B domain of human synaptotagmin-1",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 734,
      "target": 700,
      "key": "8dbbdd27da843de74b3a08cb869cf7e5084d8954e22eab2c5e6e2ef484402f985317c61a06c1c7796275cc638f607b182df217e56e93b9c734ee9c936d97446c"
    },
    {
      "line": 1424,
      "relation": "increases",
      "evidence": "We demonstrate that Casein kinase 1 family members, including isoforms of Tau-tubulin protein kinases (TTBK1 and TTBK2), phosphorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84). These residues are also phosphorylated in vivo, and the phosphorylation of Thr84 within Cluster-2 is essential for triggering binding to the C2B domain of human synaptotagmin-1",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 734,
      "target": 701,
      "key": "20fbf9a28429c6ab366f598cf78e6193464061e2b1a3fb1b67fbe02c8052cc37e532368f67363301444289cf093e4855f86a82073bd1eb9c60f4143326ea081e"
    },
    {
      "line": 1439,
      "relation": "directlyIncreases",
      "evidence": "Using refined methodology, we demonstrate TTBK1 and TTBK2 directly phosphorylate TDP-43 in vitro and promote TDP-43 phosphorylation in mammalian cultured cells. TTBK1/2 overexpression drives phosphorylation and relocalization of TDP-43 from the nucleus to cytoplasmic inclusions reminiscent of neuropathologic changes in disease states.",
      "citation": {
        "type": "PubMed",
        "reference": "25473830",
        "name": "PLoS genetics",
        "title": "The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43.",
        "volume": "10",
        "pages": "e1004803",
        "date": "2014-12-01",
        "first": "Liachko NF",
        "last": "Kraemer BC",
        "authors": [
          "Bird TD",
          "Ghetti B",
          "Greenup L",
          "Kraemer BC",
          "Leverenz JB",
          "Liachko NF",
          "Loomis E",
          "McMillan PJ",
          "Montine TJ",
          "Murrell JR",
          "Raskind MA",
          "Strovas TJ"
        ]
      },
      "source": 734,
      "target": 722,
      "key": "c982cf26d9131b51a20c8036f0019f0b77d7f287ae3d10d34368a05f9a200211bf3e83a40e30beab6380e0898b60cf3fbc0ead10a8317d2d30f8ffbed6a117d5"
    },
    {
      "line": 1441,
      "relation": "increases",
      "evidence": "Using refined methodology, we demonstrate TTBK1 and TTBK2 directly phosphorylate TDP-43 in vitro and promote TDP-43 phosphorylation in mammalian cultured cells. TTBK1/2 overexpression drives phosphorylation and relocalization of TDP-43 from the nucleus to cytoplasmic inclusions reminiscent of neuropathologic changes in disease states.",
      "citation": {
        "type": "PubMed",
        "reference": "25473830",
        "name": "PLoS genetics",
        "title": "The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43.",
        "volume": "10",
        "pages": "e1004803",
        "date": "2014-12-01",
        "first": "Liachko NF",
        "last": "Kraemer BC",
        "authors": [
          "Bird TD",
          "Ghetti B",
          "Greenup L",
          "Kraemer BC",
          "Leverenz JB",
          "Liachko NF",
          "Loomis E",
          "McMillan PJ",
          "Montine TJ",
          "Murrell JR",
          "Raskind MA",
          "Strovas TJ"
        ]
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "nucleus"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "cytoplasm"
          }
        }
      },
      "source": 734,
      "target": 722,
      "key": "b760abb40027e4583b39579ae244f0809a8bcff69289e1086c5c865d95a4d7ab07b879b85938c46a1ca27cdfbfa3e70963d8fad9e9492a29599a3149045e45d2"
    },
    {
      "line": 2451,
      "relation": "directlyIncreases",
      "evidence": "The single kinase and sequential kinase-catalyzed Fc-phosphorylations points to dramatic changes around the Fc group in the Fc-phosphorylated tau films. Additional surface characterization of the Fc-tau films by time-of-flight secondary ion-mass spectrometry and X-ray photoelectron spectroscopy revealed that Fc-phosphorylations influence the tau orientation and conformation on surfaces.",
      "citation": {
        "type": "PubMed",
        "reference": "23687953",
        "name": "ACS chemical neuroscience",
        "title": "Electrochemical investigations into kinase-catalyzed transformations of tau protein.",
        "volume": "4",
        "pages": "1194-203",
        "date": "2013-08-21",
        "first": "Rains MK",
        "last": "Kraatz HB",
        "authors": [
          "Freeman D",
          "Kraatz HB",
          "Martić S",
          "Rains MK"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 734,
      "target": 590,
      "key": "6c3f40d1261b265a61909de689d156b1d5ba96845a17b33a6ce8673b5bf2c7596afb25ee637caa52196e8406b37f12f0d1033e70a1e757e0b6ae001f8e7213a4"
    },
    {
      "line": 1298,
      "relation": "association",
      "evidence": "The pSer422 antibody displayed an almost identical pattern to that of AT8, in that it stained NFTs (Figure 5A–D), neuropil threads and neuritic plaques (Figure 5E–H)",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "source": 336,
      "target": 81,
      "key": "b7312ee8b9f11b66eaa04d818148ec2cd94d8b3b5c0f3b14513d4f72b82ba7909652e4a3088df909e58aea020a421a44f29545c722d6bf297b6cf11556b45168"
    },
    {
      "line": 1299,
      "relation": "association",
      "evidence": "The pSer422 antibody displayed an almost identical pattern to that of AT8, in that it stained NFTs (Figure 5A–D), neuropil threads and neuritic plaques (Figure 5E–H)",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "source": 336,
      "target": 164,
      "key": "1602de95e319ee9a0e73b630ad0ce0d17e8c998ed171c6ad0d5e3a329c10d06daf931583f34f4d636a87634e303980def6ab20d96bbc02ac415791af4f61e13f"
    },
    {
      "line": 1300,
      "relation": "association",
      "evidence": "The pSer422 antibody displayed an almost identical pattern to that of AT8, in that it stained NFTs (Figure 5A–D), neuropil threads and neuritic plaques (Figure 5E–H)",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "source": 336,
      "target": 917,
      "key": "0b68df7f4b9fbcd88a92318bb313feedc09d07b398103cd6463039d0cddc175df6f36d80d0868740e09cd8919d49f6389d4a236dd37a998a9068699b4a6d184e"
    },
    {
      "line": 1560,
      "relation": "equivalentTo",
      "evidence": "Indeed, Tau phosphorylation at the three positions, Ser202/Thr205/Ser208, while not at Ser262, is sufficient to induce aggregation without the addition of any exogenous aggregation inducer.",
      "citation": {
        "type": "PubMed",
        "reference": "28784767",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Identification of the Tau phosphorylation pattern that drives its aggregation.",
        "volume": "114",
        "pages": "9080-9085",
        "date": "2017-08-22",
        "first": "Despres C",
        "last": "Smet-Nocca C",
        "authors": [
          "Baulieu EE",
          "Byrne C",
          "Cantrelle FX",
          "Chambraud B",
          "Despres C",
          "Huvent I",
          "Jacquot Y",
          "Landrieu I",
          "Lippens G",
          "Qi H",
          "Smet-Nocca C"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "NMR Spectroscopy": true,
          "Thioflavin T Assay": true
        }
      },
      "source": 336,
      "target": 546,
      "key": "afa9a3ab36243203697620b3135dab227b907ff01faf0a786cf7d82e6c746dda370beb8d5239a70eb998ad8f4c2878d40abc89595a6292641aed35c0e0c5234a"
    },
    {
      "line": 1561,
      "relation": "increases",
      "evidence": "Indeed, Tau phosphorylation at the three positions, Ser202/Thr205/Ser208, while not at Ser262, is sufficient to induce aggregation without the addition of any exogenous aggregation inducer.",
      "citation": {
        "type": "PubMed",
        "reference": "28784767",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Identification of the Tau phosphorylation pattern that drives its aggregation.",
        "volume": "114",
        "pages": "9080-9085",
        "date": "2017-08-22",
        "first": "Despres C",
        "last": "Smet-Nocca C",
        "authors": [
          "Baulieu EE",
          "Byrne C",
          "Cantrelle FX",
          "Chambraud B",
          "Despres C",
          "Huvent I",
          "Jacquot Y",
          "Landrieu I",
          "Lippens G",
          "Qi H",
          "Smet-Nocca C"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "NMR Spectroscopy": true,
          "Thioflavin T Assay": true
        }
      },
      "source": 336,
      "target": 201,
      "key": "2f3a1e847cd7c416fa64b868ed5054753b779a8a0adc8c17c932b352dcbebc1b7802ed98a071ff0ef3c890665643acfed1d0b8b3a243145ccffdb4c17be5f18a"
    },
    {
      "line": 2389,
      "relation": "positiveCorrelation",
      "evidence": "We demonstrated that the treatment of cultured hippocampal neurons with 125 µM glutamate for 20 min induced the cleavage of p35 to produce the p25 fragment 6 h after glutamate treatment, and the maximal levels of p25 were detected at 12 h (Fig. 1A), which is consistent with a peak in tau hyperphosphorylation (AT8).",
      "citation": {
        "type": "PubMed",
        "reference": "27087442",
        "name": "Current Alzheimer research",
        "title": "APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.",
        "volume": "13",
        "pages": "1048-55",
        "date": "2016-01-01",
        "first": "Zhou M",
        "last": "Chen X",
        "authors": [
          "Chen X",
          "Collins N",
          "Dai X",
          "Huang T",
          "LaDu MJ",
          "Lin L",
          "Shen H",
          "Wei Z",
          "Wu X",
          "Xiao N",
          "York J",
          "Zhang J",
          "Zhou M",
          "Zhu Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 336,
      "target": 311,
      "key": "eb865dc89efb459450c615749b5c61a47bd4cdbe7fdcdd305cb03874d1ad2c7a4f2129bf64668746c47f25ea63889a3f8ea40ce6339aa2558f57b5159da5e508"
    },
    {
      "line": 2424,
      "relation": "positiveCorrelation",
      "evidence": "CRF-OE mice had significantly elevated tau-P compared to wild type (WT) mice at the AT8 (S202/T204), PHF-1 (S396/404), S262, and S422 sites. Treating CRF-OE mice with R121919 blocked phosphorylation at the AT8 (S202/T204) and PHF-1 (S396/404) sites, but not at the S262 and S422 sites and reduced phosphorylation of c-Jun N Terminal Kinase (JNK).",
      "citation": {
        "type": "PubMed",
        "reference": "25125464",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.",
        "volume": "43",
        "pages": "967-76",
        "date": "2015-01-01",
        "first": "Campbell SN",
        "last": "Rissman RA",
        "authors": [
          "Campbell SN",
          "Masliah E",
          "Monte L",
          "Rice KC",
          "Rissman RA",
          "Roe AD",
          "Taché Y",
          "Zhang C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 336,
      "target": 780,
      "key": "709375605236079d47502905dab02e943efeea459aa65b8a9356eefb6287d3f6582c096087b2c17baa74cfeddb5d2cefca538a0a682b3b282f6ef99fc4f6f859"
    },
    {
      "line": 2466,
      "relation": "negativeCorrelation",
      "evidence": "Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift in mobility as a result of phosphorylation-like changes, we conclude that they have the characteristics of hyperphosphorylated tau. These mutants will therefore be referred to as pseudo-hyperphosphorylated tau throughout the manuscript. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.",
      "citation": {
        "type": "PubMed",
        "reference": "19459590",
        "name": "Biochemistry",
        "title": "Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.",
        "volume": "48",
        "pages": "6002-11",
        "date": "2009-06-30",
        "first": "Sun Q",
        "last": "Gamblin TC",
        "authors": [
          "Gamblin TC",
          "Sun Q"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 336,
      "target": 486,
      "key": "fa4402b6ffbd9aa56ead97c94816e6fae0304e7240e06cdf968b7793c5dc8bed916845cd1cb3941d3a6c7caf31dfba5a340d34842c608827878bf572e790d0d3"
    },
    {
      "line": 2469,
      "relation": "decreases",
      "evidence": "Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift in mobility as a result of phosphorylation-like changes, we conclude that they have the characteristics of hyperphosphorylated tau. These mutants will therefore be referred to as pseudo-hyperphosphorylated tau throughout the manuscript. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.",
      "citation": {
        "type": "PubMed",
        "reference": "19459590",
        "name": "Biochemistry",
        "title": "Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.",
        "volume": "48",
        "pages": "6002-11",
        "date": "2009-06-30",
        "first": "Sun Q",
        "last": "Gamblin TC",
        "authors": [
          "Gamblin TC",
          "Sun Q"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 336,
      "target": 486,
      "key": "777746edf61ce338343ccee16d099cc5ce3bbd29673fab840711634e2c077399ae9f9356d904c4e10edc38cc5c4d6d76f2011dd6c584141351e1ad720617b2cd"
    },
    {
      "line": 2493,
      "relation": "increases",
      "evidence": "This result is supported by recent studies showing that the interaction between Fyn and tau is regulated through tau phosphorylation at the AT8 site, increasing tau-Fyn interaction by 42-fold after tau is phosphorylated or bearing a phosphomimetic mutation at the AT8 site (63). In our experiments, tau phosphorylation at AT8 is strongly up-regulated through the activation of NMDA receptors (Fig. 3), suggesting that NMDA receptor activation could massively enhance the interaction between tau and Fyn.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 336,
      "target": 237,
      "key": "78e478f0a6b7a3005225f518a87fa202ea9ff13a36b015488678035d0424d04d7cf4c1e36198b474af806ebfef2e8f08cc6b2a2f45cdf46144ad457eb2e25a94"
    },
    {
      "line": 2622,
      "relation": "positiveCorrelation",
      "evidence": "Phosphorylation at the epitope Ser202/Thr205 is regarded as a good marker for late-stage NFTs (5, 72). Hyman and colleagues (5) demonstrated that AT8 immunoreactivity is present primarily in eNFTs and in certain cases in iNFTs. These investigators also found that AT8 revealed dense neuropil thread staining.",
      "citation": {
        "type": "PubMed",
        "reference": "22253473",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.",
        "volume": "26",
        "pages": "1946-59",
        "date": "2012-05-01",
        "first": "Lasagna-Reeves CA",
        "last": "Kayed R",
        "authors": [
          "Castillo-Carranza DL",
          "Jackson GR",
          "Kayed R",
          "Lasagna-Reeves CA",
          "Sarmiento J",
          "Sengupta U",
          "Troncoso J"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Disease_Progression": {
          "Late Stage": true
        }
      },
      "source": 336,
      "target": 169,
      "key": "7b6fb3cd18a605558c4a0ba6f81c5f1c61ac6afc1dcbf5f138253c60a8761cd8794ed3fc0587d5421d27535957e1b762ead069cb67ce0eb642fa9a9769da30ee"
    },
    {
      "line": 3321,
      "relation": "positiveCorrelation",
      "evidence": "Thus, the increase in ac-tau induced by SIRT1 deficiency is accompanied by accumulation of pathogenic p-tau in primary neurons. In mouse brains, deleting SIRT1, which elevated ac-tau, also increased AT8-positive p-tau.",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 336,
      "target": 490,
      "key": "123bacf913592cb00bc29d22a76cdaca3e1c2734654fa8002d49a5b2911ec85a11ef0bb6edbfa11ac19970f9c51bdd40e33cf90a9e6bcdca285fa22ff20b5927"
    },
    {
      "line": 3322,
      "relation": "negativeCorrelation",
      "evidence": "Thus, the increase in ac-tau induced by SIRT1 deficiency is accompanied by accumulation of pathogenic p-tau in primary neurons. In mouse brains, deleting SIRT1, which elevated ac-tau, also increased AT8-positive p-tau.",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 336,
      "target": 677,
      "key": "f0d323f5ab20dca0b4e6c8279bae79fbd2e5e55dcff786913e1c2a64878ee41fbb50e5abd99f6719c654d47932d0740996c08ca8ee5f5147846640f7ef84b9cd"
    },
    {
      "line": 3879,
      "relation": "positiveCorrelation",
      "evidence": "QA appears to act through NMDA receptor activation similar to other agonists, glutamate and NMDA and was abrogated by the NMDAR antagonist memantine. NMDA receptor agonists, glutamate and NMDA at equimolar concentrations (500 nM) increased tau phosphorylation at serine 199/202 (AT8) and threonine 231 (AT-180), similar to QA.",
      "citation": {
        "type": "PubMed",
        "reference": "19623258",
        "name": "PloS one",
        "title": "The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.",
        "volume": "4",
        "pages": "e6344",
        "date": "2009-07-22",
        "first": "Rahman A",
        "last": "Guillemin GJ",
        "authors": [
          "Braidy N",
          "Brew BJ",
          "Cullen KM",
          "Guillemin GJ",
          "Rahman A",
          "Ting K"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 336,
      "target": 209,
      "key": "36e37906425d87cc668fbc497e59b0656732013c100b1bb4bbced16daee47c1357f92421e458d7d59337b070d484364dcba96c7830123652867b6ba4f6f03601"
    },
    {
      "line": 1309,
      "relation": "association",
      "evidence": "These data suggest a role for TTBK1 in pre-tangle formation prior to the formation of fibrillar tau and strengthen the idea that tau is phosphorylated at Ser422 at an early intermediate stage in NFT formation.",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "source": 158,
      "target": 734,
      "key": "e1935a3800d76f6d018260507b9307e3b8a1b80be5107b30f1b5a0141d75f367b0c738db8807f10ed6e190f88b9495235e46d8abb7c2b4074b5be1f2af5ea9b1"
    },
    {
      "line": 1310,
      "relation": "association",
      "evidence": "These data suggest a role for TTBK1 in pre-tangle formation prior to the formation of fibrillar tau and strengthen the idea that tau is phosphorylated at Ser422 at an early intermediate stage in NFT formation.",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "source": 158,
      "target": 569,
      "key": "908dbaa5781441c65427b88cb9766c6b17a79259b0d4ac09bdcbb79f083fd6f1e0d2358fefb450a72e353d82510b6b0366e6e0aa2b90af2159625c456b4ceac5"
    },
    {
      "line": 1311,
      "relation": "isA",
      "evidence": "These data suggest a role for TTBK1 in pre-tangle formation prior to the formation of fibrillar tau and strengthen the idea that tau is phosphorylated at Ser422 at an early intermediate stage in NFT formation.",
      "citation": {
        "type": "PubMed",
        "reference": "18239272",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.",
        "volume": "31",
        "pages": "193-200",
        "date": "2008-02-01",
        "first": "Kawakami F",
        "last": "Ohtsuki K",
        "authors": [
          "Kawakami F",
          "Ohtsuki K",
          "Suzuki K"
        ]
      },
      "source": 158,
      "target": 81,
      "key": "3b7654e8088336cc4d2a69a3d7a9fd894ef8ddf9dfb3500f7b6a648e27f476c8fe2ae4b137a81a43e29f4c8dd57c4e35d20802b637c306ba4bb3bf1d2ecc6e44"
    },
    {
      "line": 1324,
      "relation": "association",
      "evidence": "Haplotype analysis of the block formed by rs2651206, rs10807287, and rs7764257 showed that the combination of the three frequent alleles (CTA) was significantly (p = 0.02) overrepresented in the AD group (67%) compared to the control group (63%), and this result was still significant after multiple testing corrections with 10,000 permutations (p = 0.05).",
      "citation": {
        "type": "PubMed",
        "reference": "20096481",
        "name": "Neurobiology of aging",
        "title": "Genetic variations in tau-tubulin kinase-1 are linked to Alzheimer's disease in a Spanish case-control cohort.",
        "volume": "32",
        "pages": "550.e5-9",
        "date": "2011-03-01",
        "first": "Vázquez-Higuera JL",
        "last": "Combarros O",
        "authors": [
          "Berciano J",
          "Bullido MJ",
          "Combarros O",
          "Frank A",
          "Martínez-García A",
          "Mateo I",
          "Pozueta A",
          "Rodríguez-Rodríguez E",
          "Sánchez-Juan P",
          "Valdivieso F",
          "Vázquez-Higuera JL"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Spanish cohort": true
        }
      },
      "source": 251,
      "target": 908,
      "key": "144a48213fbff9a002c195e64f9e64933b2df5f16d69a814dc4b13d9b7b10086f4c9188af4b6fe6b27e22399f30ed7d90d2f5fcf1a0602d0ac2b532480262419"
    },
    {
      "line": 1384,
      "relation": "positiveCorrelation",
      "evidence": "Significant association with a reduced risk of LOAD (odds ratio/OR=0.69). rs2651206 polymorphism was strongly associated with LOAD (OR=0.72) (age, gender, and APOE adjusted). The TG haplotype, deriving from the two minor alleles, decreases risk of LOAD (OR=0.78, P=0.037).",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Han chinese": true
        }
      },
      "source": 251,
      "target": 908,
      "key": "65d708775041a2e24c9d2e76e303d20fbbe03992b3fe558deaac7e199afa8d5e2962f8d1aeaa3bc573bbba3791a1a2e92df0c604a6724e73c609c63935e25f01"
    },
    {
      "line": 1328,
      "relation": "association",
      "evidence": "Haplotype analysis of the block formed by rs2651206, rs10807287, and rs7764257 showed that the combination of the three frequent alleles (CTA) was significantly (p = 0.02) overrepresented in the AD group (67%) compared to the control group (63%), and this result was still significant after multiple testing corrections with 10,000 permutations (p = 0.05).",
      "citation": {
        "type": "PubMed",
        "reference": "20096481",
        "name": "Neurobiology of aging",
        "title": "Genetic variations in tau-tubulin kinase-1 are linked to Alzheimer's disease in a Spanish case-control cohort.",
        "volume": "32",
        "pages": "550.e5-9",
        "date": "2011-03-01",
        "first": "Vázquez-Higuera JL",
        "last": "Combarros O",
        "authors": [
          "Berciano J",
          "Bullido MJ",
          "Combarros O",
          "Frank A",
          "Martínez-García A",
          "Mateo I",
          "Pozueta A",
          "Rodríguez-Rodríguez E",
          "Sánchez-Juan P",
          "Valdivieso F",
          "Vázquez-Higuera JL"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Spanish cohort": true
        }
      },
      "source": 251,
      "target": 260,
      "key": "bd9519d3bd6fe2c558251fa668d18a1f395b97190b406c2b3212760b742ddbdfd9711ea38dd6f23fdf22094c7003237c150de20dd57158eb9bc045af6bb5320e"
    },
    {
      "line": 1385,
      "relation": "isA",
      "evidence": "Significant association with a reduced risk of LOAD (odds ratio/OR=0.69). rs2651206 polymorphism was strongly associated with LOAD (OR=0.72) (age, gender, and APOE adjusted). The TG haplotype, deriving from the two minor alleles, decreases risk of LOAD (OR=0.78, P=0.037).",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Han chinese": true
        }
      },
      "source": 251,
      "target": 260,
      "key": "714b67371d4546d12cec107da0b29f01add209392da040aeb17142b65aa7ae3e4ab2bac692e03105946acb78fb7004aa604f9c3a24a8bca79787b53ac8f5b780"
    },
    {
      "line": 1325,
      "relation": "association",
      "evidence": "Haplotype analysis of the block formed by rs2651206, rs10807287, and rs7764257 showed that the combination of the three frequent alleles (CTA) was significantly (p = 0.02) overrepresented in the AD group (67%) compared to the control group (63%), and this result was still significant after multiple testing corrections with 10,000 permutations (p = 0.05).",
      "citation": {
        "type": "PubMed",
        "reference": "20096481",
        "name": "Neurobiology of aging",
        "title": "Genetic variations in tau-tubulin kinase-1 are linked to Alzheimer's disease in a Spanish case-control cohort.",
        "volume": "32",
        "pages": "550.e5-9",
        "date": "2011-03-01",
        "first": "Vázquez-Higuera JL",
        "last": "Combarros O",
        "authors": [
          "Berciano J",
          "Bullido MJ",
          "Combarros O",
          "Frank A",
          "Martínez-García A",
          "Mateo I",
          "Pozueta A",
          "Rodríguez-Rodríguez E",
          "Sánchez-Juan P",
          "Valdivieso F",
          "Vázquez-Higuera JL"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Spanish cohort": true
        }
      },
      "source": 248,
      "target": 908,
      "key": "84b8df6b0b1a4e44cb2a09768070148cedaab03df01831b685ee48e9371c6d08ccfa4ba0b73bb63429b636d968e31a566cec38388b15ad414f9b3c6b55d41120"
    },
    {
      "line": 1329,
      "relation": "association",
      "evidence": "Haplotype analysis of the block formed by rs2651206, rs10807287, and rs7764257 showed that the combination of the three frequent alleles (CTA) was significantly (p = 0.02) overrepresented in the AD group (67%) compared to the control group (63%), and this result was still significant after multiple testing corrections with 10,000 permutations (p = 0.05).",
      "citation": {
        "type": "PubMed",
        "reference": "20096481",
        "name": "Neurobiology of aging",
        "title": "Genetic variations in tau-tubulin kinase-1 are linked to Alzheimer's disease in a Spanish case-control cohort.",
        "volume": "32",
        "pages": "550.e5-9",
        "date": "2011-03-01",
        "first": "Vázquez-Higuera JL",
        "last": "Combarros O",
        "authors": [
          "Berciano J",
          "Bullido MJ",
          "Combarros O",
          "Frank A",
          "Martínez-García A",
          "Mateo I",
          "Pozueta A",
          "Rodríguez-Rodríguez E",
          "Sánchez-Juan P",
          "Valdivieso F",
          "Vázquez-Higuera JL"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Spanish cohort": true
        }
      },
      "source": 248,
      "target": 260,
      "key": "fbb518790cdad8d1a3cae609409f5f0fa235e8c48cf8ec6053bf52fcf40ce213f6ee73bf2d1d8c9ea0a498e62879be6a31ce58f49e0574054f6e348cc484dd31"
    },
    {
      "line": 1326,
      "relation": "association",
      "evidence": "Haplotype analysis of the block formed by rs2651206, rs10807287, and rs7764257 showed that the combination of the three frequent alleles (CTA) was significantly (p = 0.02) overrepresented in the AD group (67%) compared to the control group (63%), and this result was still significant after multiple testing corrections with 10,000 permutations (p = 0.05).",
      "citation": {
        "type": "PubMed",
        "reference": "20096481",
        "name": "Neurobiology of aging",
        "title": "Genetic variations in tau-tubulin kinase-1 are linked to Alzheimer's disease in a Spanish case-control cohort.",
        "volume": "32",
        "pages": "550.e5-9",
        "date": "2011-03-01",
        "first": "Vázquez-Higuera JL",
        "last": "Combarros O",
        "authors": [
          "Berciano J",
          "Bullido MJ",
          "Combarros O",
          "Frank A",
          "Martínez-García A",
          "Mateo I",
          "Pozueta A",
          "Rodríguez-Rodríguez E",
          "Sánchez-Juan P",
          "Valdivieso F",
          "Vázquez-Higuera JL"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Spanish cohort": true
        }
      },
      "source": 255,
      "target": 908,
      "key": "2fd8c0a6536e92819ce4814a4c909cc0b7236dc9b6a21bdf80ede7dce275052175fedd9e80b1cc193148c6839cd9bfbdb720560defff24c34e41e44d9232b619"
    },
    {
      "line": 1330,
      "relation": "association",
      "evidence": "Haplotype analysis of the block formed by rs2651206, rs10807287, and rs7764257 showed that the combination of the three frequent alleles (CTA) was significantly (p = 0.02) overrepresented in the AD group (67%) compared to the control group (63%), and this result was still significant after multiple testing corrections with 10,000 permutations (p = 0.05).",
      "citation": {
        "type": "PubMed",
        "reference": "20096481",
        "name": "Neurobiology of aging",
        "title": "Genetic variations in tau-tubulin kinase-1 are linked to Alzheimer's disease in a Spanish case-control cohort.",
        "volume": "32",
        "pages": "550.e5-9",
        "date": "2011-03-01",
        "first": "Vázquez-Higuera JL",
        "last": "Combarros O",
        "authors": [
          "Berciano J",
          "Bullido MJ",
          "Combarros O",
          "Frank A",
          "Martínez-García A",
          "Mateo I",
          "Pozueta A",
          "Rodríguez-Rodríguez E",
          "Sánchez-Juan P",
          "Valdivieso F",
          "Vázquez-Higuera JL"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Spanish cohort": true
        }
      },
      "source": 255,
      "target": 260,
      "key": "9e968a122c3d20f1be6e784b4b104e678b4b48d544f503becc2148ebc6a7c66e041165458a2d4f1031eabd133b95d7672fcac0592dfb23276b294d3675b12a78"
    },
    {
      "line": 1328,
      "relation": "association",
      "evidence": "Haplotype analysis of the block formed by rs2651206, rs10807287, and rs7764257 showed that the combination of the three frequent alleles (CTA) was significantly (p = 0.02) overrepresented in the AD group (67%) compared to the control group (63%), and this result was still significant after multiple testing corrections with 10,000 permutations (p = 0.05).",
      "citation": {
        "type": "PubMed",
        "reference": "20096481",
        "name": "Neurobiology of aging",
        "title": "Genetic variations in tau-tubulin kinase-1 are linked to Alzheimer's disease in a Spanish case-control cohort.",
        "volume": "32",
        "pages": "550.e5-9",
        "date": "2011-03-01",
        "first": "Vázquez-Higuera JL",
        "last": "Combarros O",
        "authors": [
          "Berciano J",
          "Bullido MJ",
          "Combarros O",
          "Frank A",
          "Martínez-García A",
          "Mateo I",
          "Pozueta A",
          "Rodríguez-Rodríguez E",
          "Sánchez-Juan P",
          "Valdivieso F",
          "Vázquez-Higuera JL"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Spanish cohort": true
        }
      },
      "source": 260,
      "target": 251,
      "key": "49ea06e4e428eea9e92f7c5878e7266e6d1f66de6cd2fbc1736e3db4b99b7220365398a1c394df3c41d997d9e96ba7727a927a8f07b66c3b4f11612d65fb6b0e"
    },
    {
      "line": 1329,
      "relation": "association",
      "evidence": "Haplotype analysis of the block formed by rs2651206, rs10807287, and rs7764257 showed that the combination of the three frequent alleles (CTA) was significantly (p = 0.02) overrepresented in the AD group (67%) compared to the control group (63%), and this result was still significant after multiple testing corrections with 10,000 permutations (p = 0.05).",
      "citation": {
        "type": "PubMed",
        "reference": "20096481",
        "name": "Neurobiology of aging",
        "title": "Genetic variations in tau-tubulin kinase-1 are linked to Alzheimer's disease in a Spanish case-control cohort.",
        "volume": "32",
        "pages": "550.e5-9",
        "date": "2011-03-01",
        "first": "Vázquez-Higuera JL",
        "last": "Combarros O",
        "authors": [
          "Berciano J",
          "Bullido MJ",
          "Combarros O",
          "Frank A",
          "Martínez-García A",
          "Mateo I",
          "Pozueta A",
          "Rodríguez-Rodríguez E",
          "Sánchez-Juan P",
          "Valdivieso F",
          "Vázquez-Higuera JL"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Spanish cohort": true
        }
      },
      "source": 260,
      "target": 248,
      "key": "7fa3f08fb3702e3a1ecf84a17dbcfcd4e0cb885e4c668b7172aa421ea9bd682c5a86fe1511ff59f18ade31a8e204d7cf4a5e5e933d711f5f5fe1184442acf612"
    },
    {
      "line": 1330,
      "relation": "association",
      "evidence": "Haplotype analysis of the block formed by rs2651206, rs10807287, and rs7764257 showed that the combination of the three frequent alleles (CTA) was significantly (p = 0.02) overrepresented in the AD group (67%) compared to the control group (63%), and this result was still significant after multiple testing corrections with 10,000 permutations (p = 0.05).",
      "citation": {
        "type": "PubMed",
        "reference": "20096481",
        "name": "Neurobiology of aging",
        "title": "Genetic variations in tau-tubulin kinase-1 are linked to Alzheimer's disease in a Spanish case-control cohort.",
        "volume": "32",
        "pages": "550.e5-9",
        "date": "2011-03-01",
        "first": "Vázquez-Higuera JL",
        "last": "Combarros O",
        "authors": [
          "Berciano J",
          "Bullido MJ",
          "Combarros O",
          "Frank A",
          "Martínez-García A",
          "Mateo I",
          "Pozueta A",
          "Rodríguez-Rodríguez E",
          "Sánchez-Juan P",
          "Valdivieso F",
          "Vázquez-Higuera JL"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Spanish cohort": true
        }
      },
      "source": 260,
      "target": 255,
      "key": "830bf5b65ffcf4c9be03a1929a059662386ac216ed54fe2954e0d821edd9cc4e4854e2c592c6ca386e92ab79f1a676167959b23d10efd0418f4e238abb202a9b"
    },
    {
      "line": 1338,
      "relation": "increases",
      "evidence": "Tau-tubulin kinase 2 (TTBK2) is a Ser/Thr kinase that putatively phosphorylates residues Ser208 and Ser210 (numbered according to a 441-residue human tau isoform) in tau protein.",
      "citation": {
        "type": "PubMed",
        "reference": "17620722",
        "name": "Acta crystallographica. Section F, Structural biology and crystallization communications",
        "title": "Expression, purification and crystallization of a human tau-tubulin kinase 2 that phosphorylates tau protein.",
        "volume": "63",
        "pages": "602-4",
        "date": "2007-07-01",
        "first": "Kitano-Takahashi M",
        "last": "Kohno T",
        "authors": [
          "Kato R",
          "Kitano-Takahashi M",
          "Kohno T",
          "Kondo S",
          "Morita H",
          "Shirota Y",
          "Sugio S",
          "Takahashi H",
          "Tanio M",
          "Tomizawa K"
        ]
      },
      "source": 735,
      "target": 548,
      "key": "cd1efb588035e6ca4af5a6954271ab102ffa2cee64763ef79353d49045d67eecf7be4239b87e04e269e280d4d0a5c615a0b70f37c61e069f2383e11eeb057393"
    },
    {
      "line": 1339,
      "relation": "increases",
      "evidence": "Tau-tubulin kinase 2 (TTBK2) is a Ser/Thr kinase that putatively phosphorylates residues Ser208 and Ser210 (numbered according to a 441-residue human tau isoform) in tau protein.",
      "citation": {
        "type": "PubMed",
        "reference": "17620722",
        "name": "Acta crystallographica. Section F, Structural biology and crystallization communications",
        "title": "Expression, purification and crystallization of a human tau-tubulin kinase 2 that phosphorylates tau protein.",
        "volume": "63",
        "pages": "602-4",
        "date": "2007-07-01",
        "first": "Kitano-Takahashi M",
        "last": "Kohno T",
        "authors": [
          "Kato R",
          "Kitano-Takahashi M",
          "Kohno T",
          "Kondo S",
          "Morita H",
          "Shirota Y",
          "Sugio S",
          "Takahashi H",
          "Tanio M",
          "Tomizawa K"
        ]
      },
      "source": 735,
      "target": 549,
      "key": "f71162a8faa774aa988b16326c376a7c914770919d060da2b8e9c1c7819fa0cf8629e1e2309fcf4d5b3f5a8e672b1fff34c092c4f0e68020253272e228d15ab6"
    },
    {
      "relation": "hasVariant",
      "source": 735,
      "target": 738,
      "key": "ddaead9f0de78bcdbc3a55125d2ecf39313a739e123d8d4ae911c8f98b1b7563f655290463d78ab86b0639b1dc617c8ad6916555002532af1d9d9a0808e1b0a6"
    },
    {
      "relation": "hasVariant",
      "source": 735,
      "target": 736,
      "key": "445fa4779bf2b63eb525178bbfdc22dabdebd11488a630e2e8c4725511d0746bf271b934f5eb3b084604a30cf187d9378f65e71bdb848cd5be8d1d8ef9781aca"
    },
    {
      "relation": "hasVariant",
      "source": 735,
      "target": 737,
      "key": "6daa108db0334d9db00957c18b7dd30edc8a97ec7c7cda9d83438db33a8e7bbc1ebac48f0ddce9673c4fd54507a285e4058ce9e76386209c56f0dac418425d07"
    },
    {
      "line": 1394,
      "relation": "isA",
      "evidence": "The CK1 group of eukaryotic protein kinases are composed of seven CK1 isoforms (CK1α, CK1α2, CK1δ, CK1ε, CK1γ1, CK1γ2, and CK1γ3), two Tau–tubulin kinase isoforms (TTBK1 and TTBK2), and three VRK isoforms (VRK1, VRK2, and VRK3)",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 735,
      "target": 312,
      "key": "dc3875d4bcb6691463642380b69568d65b468d0756c7409bd25a43043f59e9bc1612b8946219df91308c9ef0f64adf2bc6e2071701474994680dbffb19088e96"
    },
    {
      "line": 1426,
      "relation": "increases",
      "evidence": "We demonstrate that Casein kinase 1 family members, including isoforms of Tau-tubulin protein kinases (TTBK1 and TTBK2), phosphorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84). These residues are also phosphorylated in vivo, and the phosphorylation of Thr84 within Cluster-2 is essential for triggering binding to the C2B domain of human synaptotagmin-1",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 735,
      "target": 696,
      "key": "7214a19007f81cc1703455f573ff456fff89eab7a493cfdd4c1670e427d8dc0f8c2767d719b6b4fa5e77735bacf8c9a5fbd1e81385bede588afb46b79d1ba7e4"
    },
    {
      "line": 1427,
      "relation": "increases",
      "evidence": "We demonstrate that Casein kinase 1 family members, including isoforms of Tau-tubulin protein kinases (TTBK1 and TTBK2), phosphorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84). These residues are also phosphorylated in vivo, and the phosphorylation of Thr84 within Cluster-2 is essential for triggering binding to the C2B domain of human synaptotagmin-1",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 735,
      "target": 697,
      "key": "e9b851161ba519dcd2ce039c668bc8ab6272905391fcfd74ea09e3e652a0d67b2d4aadb4a5c6f884025f06181a511e96d917731d455ddf63b1d36d379cef75d0"
    },
    {
      "line": 1428,
      "relation": "increases",
      "evidence": "We demonstrate that Casein kinase 1 family members, including isoforms of Tau-tubulin protein kinases (TTBK1 and TTBK2), phosphorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84). These residues are also phosphorylated in vivo, and the phosphorylation of Thr84 within Cluster-2 is essential for triggering binding to the C2B domain of human synaptotagmin-1",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 735,
      "target": 698,
      "key": "57814b6a2427805ac1dec885a26a55b2728290b04d53cdb61a7f63125152287d364e9af355a2d88ad1ef04cc4692e85839c53978c35db4f620d6e9c6f727113c"
    },
    {
      "line": 1429,
      "relation": "increases",
      "evidence": "We demonstrate that Casein kinase 1 family members, including isoforms of Tau-tubulin protein kinases (TTBK1 and TTBK2), phosphorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84). These residues are also phosphorylated in vivo, and the phosphorylation of Thr84 within Cluster-2 is essential for triggering binding to the C2B domain of human synaptotagmin-1",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 735,
      "target": 699,
      "key": "313e70cf26f84c2908234a16a355fb5e323b59d28246e009b6b976ade44e1aab08e994962145f1c16ac1c2e7bbda4943f1408f96b496d1a9691651cb27848b93"
    },
    {
      "line": 1430,
      "relation": "increases",
      "evidence": "We demonstrate that Casein kinase 1 family members, including isoforms of Tau-tubulin protein kinases (TTBK1 and TTBK2), phosphorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84). These residues are also phosphorylated in vivo, and the phosphorylation of Thr84 within Cluster-2 is essential for triggering binding to the C2B domain of human synaptotagmin-1",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 735,
      "target": 700,
      "key": "b1a0e20ce89ceddce4d9422a700341b6889cd3b95d1b20f11656457d9e96ba504cc4c4bdf021f129a407f5c24137bac26ecf038f400188bbb6a6efe466b75607"
    },
    {
      "line": 1431,
      "relation": "increases",
      "evidence": "We demonstrate that Casein kinase 1 family members, including isoforms of Tau-tubulin protein kinases (TTBK1 and TTBK2), phosphorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84). These residues are also phosphorylated in vivo, and the phosphorylation of Thr84 within Cluster-2 is essential for triggering binding to the C2B domain of human synaptotagmin-1",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 735,
      "target": 701,
      "key": "dd3cbed08b89bb4af782e7af56520852321c71e65dfaeb45132f688bc5459c53dcbb639428a710f15766c737e572b2af1f01268990d45664925f4e1037471cbd"
    },
    {
      "line": 1440,
      "relation": "directlyIncreases",
      "evidence": "Using refined methodology, we demonstrate TTBK1 and TTBK2 directly phosphorylate TDP-43 in vitro and promote TDP-43 phosphorylation in mammalian cultured cells. TTBK1/2 overexpression drives phosphorylation and relocalization of TDP-43 from the nucleus to cytoplasmic inclusions reminiscent of neuropathologic changes in disease states.",
      "citation": {
        "type": "PubMed",
        "reference": "25473830",
        "name": "PLoS genetics",
        "title": "The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43.",
        "volume": "10",
        "pages": "e1004803",
        "date": "2014-12-01",
        "first": "Liachko NF",
        "last": "Kraemer BC",
        "authors": [
          "Bird TD",
          "Ghetti B",
          "Greenup L",
          "Kraemer BC",
          "Leverenz JB",
          "Liachko NF",
          "Loomis E",
          "McMillan PJ",
          "Montine TJ",
          "Murrell JR",
          "Raskind MA",
          "Strovas TJ"
        ]
      },
      "source": 735,
      "target": 722,
      "key": "f813dd5dc43a614fecae4b54bddd68d069a00a4ed44854d0c834da938523ec1e7ca83b71c68c1e6a9e95488a841142015642187a88c7c598b979257d9b5c300a"
    },
    {
      "line": 1442,
      "relation": "increases",
      "evidence": "Using refined methodology, we demonstrate TTBK1 and TTBK2 directly phosphorylate TDP-43 in vitro and promote TDP-43 phosphorylation in mammalian cultured cells. TTBK1/2 overexpression drives phosphorylation and relocalization of TDP-43 from the nucleus to cytoplasmic inclusions reminiscent of neuropathologic changes in disease states.",
      "citation": {
        "type": "PubMed",
        "reference": "25473830",
        "name": "PLoS genetics",
        "title": "The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43.",
        "volume": "10",
        "pages": "e1004803",
        "date": "2014-12-01",
        "first": "Liachko NF",
        "last": "Kraemer BC",
        "authors": [
          "Bird TD",
          "Ghetti B",
          "Greenup L",
          "Kraemer BC",
          "Leverenz JB",
          "Liachko NF",
          "Loomis E",
          "McMillan PJ",
          "Montine TJ",
          "Murrell JR",
          "Raskind MA",
          "Strovas TJ"
        ]
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "nucleus"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "cytoplasm"
          }
        }
      },
      "source": 735,
      "target": 722,
      "key": "7aaaf24239d2252d6e4f6ac39a1eba0a0041a8f5c453039549281d4845d61c424cd1ff09d0f05d239fc69320384acf6de84b50cbd0aeac134adee2cf33765126"
    },
    {
      "line": 1448,
      "relation": "decreases",
      "evidence": "TTBK2 down-regulates GluK2 activity by decreasing the receptor protein abundance in the cell membrane via RAB5-dependent endocytosis, an effect that may protect against neuroexcitotoxicity.",
      "citation": {
        "type": "PubMed",
        "reference": "27607061",
        "name": "Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology",
        "title": "Tau Tubulin Kinase TTBK2 Sensitivity of Glutamate Receptor GluK2.",
        "volume": "39",
        "pages": "1444-52",
        "date": "2016-01-01",
        "first": "Nieding K",
        "last": "Strutz-Seebohm N",
        "authors": [
          "Lang F",
          "Matschke V",
          "Meuth SG",
          "Nieding K",
          "Seebohm G",
          "Strutz-Seebohm N"
        ]
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "bel",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "bel",
            "name": "cell surface"
          }
        }
      },
      "source": 735,
      "target": 453,
      "key": "83fc97b2db530ac031f4c2cf4a8582b304956e9488a0ab7e7a6f97baf468d87344da4061131f5b73b48df2ced0560be4743eab6a2d50d9d1b877d7fb28904d10"
    },
    {
      "line": 1455,
      "relation": "increases",
      "evidence": "These findings indicate that TTBK2 with EB1/3 phosphorylates KIF2A and antagonizes KIF2A-induced depolymerization at MT plus ends for cell migration.",
      "citation": {
        "type": "PubMed",
        "reference": "26323690",
        "name": "The Journal of cell biology",
        "title": "TTBK2 with EB1/3 regulates microtubule dynamics in migrating cells through KIF2A phosphorylation.",
        "volume": "210",
        "pages": "737-51",
        "date": "2015-08-31",
        "first": "Watanabe T",
        "last": "Kaibuchi K",
        "authors": [
          "Arimura N",
          "Hoshino M",
          "Ishidate F",
          "Kaibuchi K",
          "Kakeno M",
          "Matsui T",
          "Matsuzawa K",
          "Nishioka T",
          "Shirahige A",
          "Sugiyama I",
          "Taya S",
          "Watanabe T"
        ]
      },
      "source": 735,
      "target": 466,
      "key": "72e056b713607bddc3bb03e440734f36c39ec0547b5d1ab75d9dff16818a2020f3a3f214c2880de0d839c3fb324abe62a71ef7faeee5e7648b93d1c4540961a5"
    },
    {
      "line": 1461,
      "relation": "increases",
      "evidence": "Upregulation of Na+Cl- coupled betaine/GABA transporter BGT1 for organic osmolytes",
      "citation": {
        "type": "PubMed",
        "reference": "26323690",
        "name": "The Journal of cell biology",
        "title": "TTBK2 with EB1/3 regulates microtubule dynamics in migrating cells through KIF2A phosphorylation.",
        "volume": "210",
        "pages": "737-51",
        "date": "2015-08-31",
        "first": "Watanabe T",
        "last": "Kaibuchi K",
        "authors": [
          "Arimura N",
          "Hoshino M",
          "Ishidate F",
          "Kaibuchi K",
          "Kakeno M",
          "Matsui T",
          "Matsuzawa K",
          "Nishioka T",
          "Shirahige A",
          "Sugiyama I",
          "Taya S",
          "Watanabe T"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 735,
      "target": 681,
      "key": "6b11498ab5b48088d6a7986195413c0c060917bd5722961992f8fd70bd2a323c5b312f43c4948935f89c7f7acce6b86a362bf6b2669dffd93c8458744921f2ab"
    },
    {
      "line": 1466,
      "relation": "increases",
      "evidence": "Upregulation of SLC5A1 Na-copled Glucose transport",
      "citation": {
        "type": "PubMed",
        "reference": "26323690",
        "name": "The Journal of cell biology",
        "title": "TTBK2 with EB1/3 regulates microtubule dynamics in migrating cells through KIF2A phosphorylation.",
        "volume": "210",
        "pages": "737-51",
        "date": "2015-08-31",
        "first": "Watanabe T",
        "last": "Kaibuchi K",
        "authors": [
          "Arimura N",
          "Hoshino M",
          "Ishidate F",
          "Kaibuchi K",
          "Kakeno M",
          "Matsui T",
          "Matsuzawa K",
          "Nishioka T",
          "Shirahige A",
          "Sugiyama I",
          "Taya S",
          "Watanabe T"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 735,
      "target": 680,
      "key": "e693daecb88fdf33e018434217ea5a5b094b48188a4b141e8a19e0928f7350b2e73d20efdec1673b01654ab8a970840c1f56f7849508a288375c7599d858fb1c"
    },
    {
      "line": 1475,
      "relation": "association",
      "evidence": "TTBK2 bound EB1 and Cep164 through its SxIP motifs and a proline-rich motif, respectively. Using TTBK2 variants that contained mutations in the SxIP or proline-rich motifs, we obtained evidence that Cep164, but not EB1, is essential for centriolar localization of TTBK2. Therefore, Cep164 binding is essential for the function of TTBK2 in promoting CP110 removal and ciliogenesis. We also provide evidence that TTBK2 has the potential to effectively phosphorylate Cep164 and Cep97 and inhibits the interaction between Cep164 and its binding partner Dishevelled-3 (an important regulator of ciliogenesis) in a kinase activity-dependent manner.",
      "citation": {
        "type": "PubMed",
        "reference": "26323690",
        "name": "The Journal of cell biology",
        "title": "TTBK2 with EB1/3 regulates microtubule dynamics in migrating cells through KIF2A phosphorylation.",
        "volume": "210",
        "pages": "737-51",
        "date": "2015-08-31",
        "first": "Watanabe T",
        "last": "Kaibuchi K",
        "authors": [
          "Arimura N",
          "Hoshino M",
          "Ishidate F",
          "Kaibuchi K",
          "Kakeno M",
          "Matsui T",
          "Matsuzawa K",
          "Nishioka T",
          "Shirahige A",
          "Sugiyama I",
          "Taya S",
          "Watanabe T"
        ]
      },
      "source": 735,
      "target": 403,
      "key": "1e284f8f1fc7976c2c4c601f73659f889b627a68be5958f9d8369896c5c93f43b8369f87751de028f3759fa7b4bf833e189f68c37ca5f9281c4bd7fd23a2868d"
    },
    {
      "line": 1477,
      "relation": "positiveCorrelation",
      "evidence": "TTBK2 bound EB1 and Cep164 through its SxIP motifs and a proline-rich motif, respectively. Using TTBK2 variants that contained mutations in the SxIP or proline-rich motifs, we obtained evidence that Cep164, but not EB1, is essential for centriolar localization of TTBK2. Therefore, Cep164 binding is essential for the function of TTBK2 in promoting CP110 removal and ciliogenesis. We also provide evidence that TTBK2 has the potential to effectively phosphorylate Cep164 and Cep97 and inhibits the interaction between Cep164 and its binding partner Dishevelled-3 (an important regulator of ciliogenesis) in a kinase activity-dependent manner.",
      "citation": {
        "type": "PubMed",
        "reference": "26323690",
        "name": "The Journal of cell biology",
        "title": "TTBK2 with EB1/3 regulates microtubule dynamics in migrating cells through KIF2A phosphorylation.",
        "volume": "210",
        "pages": "737-51",
        "date": "2015-08-31",
        "first": "Watanabe T",
        "last": "Kaibuchi K",
        "authors": [
          "Arimura N",
          "Hoshino M",
          "Ishidate F",
          "Kaibuchi K",
          "Kakeno M",
          "Matsui T",
          "Matsuzawa K",
          "Nishioka T",
          "Shirahige A",
          "Sugiyama I",
          "Taya S",
          "Watanabe T"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 735,
      "target": 403,
      "key": "7b345e9ea540d6a301d3ed292f106c846e799ea9ff23f5f42fe97bb6fcc83b7a2210537857f8c4cfd590eb784e4cf623a0fb9df61a21093e9dd45cc59ef6c444"
    },
    {
      "line": 1476,
      "relation": "association",
      "evidence": "TTBK2 bound EB1 and Cep164 through its SxIP motifs and a proline-rich motif, respectively. Using TTBK2 variants that contained mutations in the SxIP or proline-rich motifs, we obtained evidence that Cep164, but not EB1, is essential for centriolar localization of TTBK2. Therefore, Cep164 binding is essential for the function of TTBK2 in promoting CP110 removal and ciliogenesis. We also provide evidence that TTBK2 has the potential to effectively phosphorylate Cep164 and Cep97 and inhibits the interaction between Cep164 and its binding partner Dishevelled-3 (an important regulator of ciliogenesis) in a kinase activity-dependent manner.",
      "citation": {
        "type": "PubMed",
        "reference": "26323690",
        "name": "The Journal of cell biology",
        "title": "TTBK2 with EB1/3 regulates microtubule dynamics in migrating cells through KIF2A phosphorylation.",
        "volume": "210",
        "pages": "737-51",
        "date": "2015-08-31",
        "first": "Watanabe T",
        "last": "Kaibuchi K",
        "authors": [
          "Arimura N",
          "Hoshino M",
          "Ishidate F",
          "Kaibuchi K",
          "Kakeno M",
          "Matsui T",
          "Matsuzawa K",
          "Nishioka T",
          "Shirahige A",
          "Sugiyama I",
          "Taya S",
          "Watanabe T"
        ]
      },
      "source": 735,
      "target": 485,
      "key": "d751688995cb9f5df21c8a1eaa2c62a1076b4db8ba074823c1c3ea8b6d148051afa692be7ba4adc04f4b2933a89eead72ab3aec4218e083c387ba57caf887899"
    },
    {
      "line": 1478,
      "relation": "decreases",
      "evidence": "TTBK2 bound EB1 and Cep164 through its SxIP motifs and a proline-rich motif, respectively. Using TTBK2 variants that contained mutations in the SxIP or proline-rich motifs, we obtained evidence that Cep164, but not EB1, is essential for centriolar localization of TTBK2. Therefore, Cep164 binding is essential for the function of TTBK2 in promoting CP110 removal and ciliogenesis. We also provide evidence that TTBK2 has the potential to effectively phosphorylate Cep164 and Cep97 and inhibits the interaction between Cep164 and its binding partner Dishevelled-3 (an important regulator of ciliogenesis) in a kinase activity-dependent manner.",
      "citation": {
        "type": "PubMed",
        "reference": "26323690",
        "name": "The Journal of cell biology",
        "title": "TTBK2 with EB1/3 regulates microtubule dynamics in migrating cells through KIF2A phosphorylation.",
        "volume": "210",
        "pages": "737-51",
        "date": "2015-08-31",
        "first": "Watanabe T",
        "last": "Kaibuchi K",
        "authors": [
          "Arimura N",
          "Hoshino M",
          "Ishidate F",
          "Kaibuchi K",
          "Kakeno M",
          "Matsui T",
          "Matsuzawa K",
          "Nishioka T",
          "Shirahige A",
          "Sugiyama I",
          "Taya S",
          "Watanabe T"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 735,
      "target": 398,
      "key": "85be1f4b2b3842a1f15d746290351ee0bef14bcd83a360a2147e27c7eeab4f796a13ad7caec8d4808ecea3345d6857976fc0799de2eaeea9c6b9aeba463656f8"
    },
    {
      "line": 1479,
      "relation": "increases",
      "evidence": "TTBK2 bound EB1 and Cep164 through its SxIP motifs and a proline-rich motif, respectively. Using TTBK2 variants that contained mutations in the SxIP or proline-rich motifs, we obtained evidence that Cep164, but not EB1, is essential for centriolar localization of TTBK2. Therefore, Cep164 binding is essential for the function of TTBK2 in promoting CP110 removal and ciliogenesis. We also provide evidence that TTBK2 has the potential to effectively phosphorylate Cep164 and Cep97 and inhibits the interaction between Cep164 and its binding partner Dishevelled-3 (an important regulator of ciliogenesis) in a kinase activity-dependent manner.",
      "citation": {
        "type": "PubMed",
        "reference": "26323690",
        "name": "The Journal of cell biology",
        "title": "TTBK2 with EB1/3 regulates microtubule dynamics in migrating cells through KIF2A phosphorylation.",
        "volume": "210",
        "pages": "737-51",
        "date": "2015-08-31",
        "first": "Watanabe T",
        "last": "Kaibuchi K",
        "authors": [
          "Arimura N",
          "Hoshino M",
          "Ishidate F",
          "Kaibuchi K",
          "Kakeno M",
          "Matsui T",
          "Matsuzawa K",
          "Nishioka T",
          "Shirahige A",
          "Sugiyama I",
          "Taya S",
          "Watanabe T"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 735,
      "target": 404,
      "key": "cbfd78df9d0f537c1a6e0104c4ec5c2f181ab3e56ec51a9945c8f57d671d967ac236b34453defb8a1eac3be5975948477202842e9c8d0b87a3b837f71e565085"
    },
    {
      "line": 1480,
      "relation": "increases",
      "evidence": "TTBK2 bound EB1 and Cep164 through its SxIP motifs and a proline-rich motif, respectively. Using TTBK2 variants that contained mutations in the SxIP or proline-rich motifs, we obtained evidence that Cep164, but not EB1, is essential for centriolar localization of TTBK2. Therefore, Cep164 binding is essential for the function of TTBK2 in promoting CP110 removal and ciliogenesis. We also provide evidence that TTBK2 has the potential to effectively phosphorylate Cep164 and Cep97 and inhibits the interaction between Cep164 and its binding partner Dishevelled-3 (an important regulator of ciliogenesis) in a kinase activity-dependent manner.",
      "citation": {
        "type": "PubMed",
        "reference": "26323690",
        "name": "The Journal of cell biology",
        "title": "TTBK2 with EB1/3 regulates microtubule dynamics in migrating cells through KIF2A phosphorylation.",
        "volume": "210",
        "pages": "737-51",
        "date": "2015-08-31",
        "first": "Watanabe T",
        "last": "Kaibuchi K",
        "authors": [
          "Arimura N",
          "Hoshino M",
          "Ishidate F",
          "Kaibuchi K",
          "Kakeno M",
          "Matsui T",
          "Matsuzawa K",
          "Nishioka T",
          "Shirahige A",
          "Sugiyama I",
          "Taya S",
          "Watanabe T"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 735,
      "target": 406,
      "key": "b47d54df5279e99f9c00bfb6ba4108e57ae7f492f3051d9b869e173f72ac96ff85be9c4eaafe5e8ce81a9e2752ff9d192bdbe5b1c68806d20f7c0491a9dca01c"
    },
    {
      "line": 1537,
      "relation": "partOf",
      "evidence": "Only very recently has the crystal structure of its fragment antigen body (Fab) with different phosphorylated peptides suggested that a third phosphorylation event at position Ser208 might lead to an epitope with an even better affinity (15).",
      "citation": {
        "type": "PubMed",
        "reference": "28784767",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Identification of the Tau phosphorylation pattern that drives its aggregation.",
        "volume": "114",
        "pages": "9080-9085",
        "date": "2017-08-22",
        "first": "Despres C",
        "last": "Smet-Nocca C",
        "authors": [
          "Baulieu EE",
          "Byrne C",
          "Cantrelle FX",
          "Chambraud B",
          "Despres C",
          "Huvent I",
          "Jacquot Y",
          "Landrieu I",
          "Lippens G",
          "Qi H",
          "Smet-Nocca C"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "NMR Spectroscopy": true,
          "Thioflavin T Assay": true
        }
      },
      "source": 548,
      "target": 336,
      "key": "f5607d24357c6c3442aa230f6bb46f876aa2360bdf3bc69a37e2cd6751715496aeac93dcc269b6d6f4a3b13a8f7fee9a31b3e42a86c1b342e12b048188c29739"
    },
    {
      "line": 1562,
      "relation": "decreases",
      "evidence": "Indeed, Tau phosphorylation at the three positions, Ser202/Thr205/Ser208, while not at Ser262, is sufficient to induce aggregation without the addition of any exogenous aggregation inducer.",
      "citation": {
        "type": "PubMed",
        "reference": "28784767",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Identification of the Tau phosphorylation pattern that drives its aggregation.",
        "volume": "114",
        "pages": "9080-9085",
        "date": "2017-08-22",
        "first": "Despres C",
        "last": "Smet-Nocca C",
        "authors": [
          "Baulieu EE",
          "Byrne C",
          "Cantrelle FX",
          "Chambraud B",
          "Despres C",
          "Huvent I",
          "Jacquot Y",
          "Landrieu I",
          "Lippens G",
          "Qi H",
          "Smet-Nocca C"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "NMR Spectroscopy": true,
          "Thioflavin T Assay": true
        }
      },
      "source": 548,
      "target": 111,
      "key": "43b1df51eeaab6fe1a2e2e826450bb5c3b4ab1662fe851cac2e7117c508e91e70fbe6e0d077aee454b4a5bbdc66ea8913a604d963482235355dfe9d511c84a1d"
    },
    {
      "line": 1591,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 548,
      "target": 908,
      "key": "f3a350abdfcac8b88b0af1cb06e239c4650191071ec04cec484c6c4b6016e8d6b81a08348f5649d6fd2a39c0bb57e2469d9818265961630ca40625c924174ccb"
    },
    {
      "line": 1592,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 549,
      "target": 908,
      "key": "9b172c1240d48ccb72d1c18e945006682f1226d6a7541fb90fded5750ba2ac4c78bf84038b736af8e1d632cc39572b0faa61418d61e14c5475c4447e98950ab2"
    },
    {
      "line": 1344,
      "relation": "increases",
      "evidence": "The results provide a molecular basis to explain the synergistic action of casein kinase II and GSK-3 that is also observed with native glycogen synthase.",
      "citation": {
        "type": "PubMed",
        "reference": "2820993",
        "name": "The Journal of biological chemistry",
        "title": "Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3.",
        "volume": "262",
        "pages": "14042-8",
        "date": "1987-10-15",
        "first": "Fiol CJ",
        "last": "Roach PJ",
        "authors": [
          "Fiol CJ",
          "Mahrenholz AM",
          "Roach PJ",
          "Roeske RW",
          "Wang Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 287,
      "target": 456,
      "key": "8fbbb7823f67e0e4f5de19c3c4a2def519e5f9a9ced65ca081f45a85292a15e50f9899314907114b43252d7db751b08fed8ac64374a673a78790434a9913508c"
    },
    {
      "line": 1350,
      "relation": "positiveCorrelation",
      "evidence": "SCA11 truncating mutations promote TTBK2 protein expression, suppress kinase activity and lead to enhanced nuclear localization. Using a SCA11-mutation-carrying knockin mouse we show that this leads to inhibition of endogenous TTBK2 protein kinase activity.",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "source": 738,
      "target": 906,
      "key": "82796edfa1d8c82fb697a38316b48d80643ef26462c4100afb301e23d613ca170f8bcb199a9ac411ef0aa3bde9b06aeff33a0c25dc38455abd53a8d1ffdbfc47"
    },
    {
      "line": 1354,
      "relation": "increases",
      "evidence": "SCA11 truncating mutations promote TTBK2 protein expression, suppress kinase activity and lead to enhanced nuclear localization. Using a SCA11-mutation-carrying knockin mouse we show that this leads to inhibition of endogenous TTBK2 protein kinase activity.",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "source": 738,
      "target": 735,
      "key": "46d26b4cd74fda3ffd21018134bf7958f6bb4528ceb1b1d3cd423545276418e0cfb454da0dacfc020a073e1d84aeb12d3cdbca685ff0a6dbe0ef4105715cefed"
    },
    {
      "line": 1358,
      "relation": "decreases",
      "evidence": "SCA11 truncating mutations promote TTBK2 protein expression, suppress kinase activity and lead to enhanced nuclear localization. Using a SCA11-mutation-carrying knockin mouse we show that this leads to inhibition of endogenous TTBK2 protein kinase activity.",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 738,
      "target": 735,
      "key": "b6019eabf4e922626d6d608c835df02030142083de17cb809fc1445d7830e453a314ee6964161319eee2c2b6b93cb51d443fc0f5bb851fe8ff99eae335925920"
    },
    {
      "line": 1350,
      "relation": "positiveCorrelation",
      "evidence": "SCA11 truncating mutations promote TTBK2 protein expression, suppress kinase activity and lead to enhanced nuclear localization. Using a SCA11-mutation-carrying knockin mouse we show that this leads to inhibition of endogenous TTBK2 protein kinase activity.",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "source": 906,
      "target": 738,
      "key": "8bbf5edfb59b848e40762fb4a3b9f937e21ffdbaad2b2ec085193ef5652f825e709bde7ac699396546a9ff66bd45c080419ff41d6edf93bc97379d2502c6602c"
    },
    {
      "line": 1351,
      "relation": "positiveCorrelation",
      "evidence": "SCA11 truncating mutations promote TTBK2 protein expression, suppress kinase activity and lead to enhanced nuclear localization. Using a SCA11-mutation-carrying knockin mouse we show that this leads to inhibition of endogenous TTBK2 protein kinase activity.",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "source": 906,
      "target": 736,
      "key": "3bc96856f0d8885ae797158e257aa30c9a0669d5304daf90786410e652fd9fb0574937fcfcd00ca39bd64318fb2cff5292ed2cb9df40a9b89815cb09ee141878"
    },
    {
      "line": 1352,
      "relation": "positiveCorrelation",
      "evidence": "SCA11 truncating mutations promote TTBK2 protein expression, suppress kinase activity and lead to enhanced nuclear localization. Using a SCA11-mutation-carrying knockin mouse we show that this leads to inhibition of endogenous TTBK2 protein kinase activity.",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "source": 906,
      "target": 737,
      "key": "c5bebc44c1cef4ff83293fb1226e942c0102d8a657a9292a993d8e4ebc7c08ea1ee524b15638822ffda7ec158e5fee0041962110b1b12487f1cb33b225689d0e"
    },
    {
      "line": 1351,
      "relation": "positiveCorrelation",
      "evidence": "SCA11 truncating mutations promote TTBK2 protein expression, suppress kinase activity and lead to enhanced nuclear localization. Using a SCA11-mutation-carrying knockin mouse we show that this leads to inhibition of endogenous TTBK2 protein kinase activity.",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "source": 736,
      "target": 906,
      "key": "6ab0e95bba956fdb722056da06bcc139b1f0cfc64af3d80fa763eceee47e4394ef769f1918fda0ecbc568494ac4d3defa7cec4664d5843277946e76baeee7b31"
    },
    {
      "line": 1355,
      "relation": "increases",
      "evidence": "SCA11 truncating mutations promote TTBK2 protein expression, suppress kinase activity and lead to enhanced nuclear localization. Using a SCA11-mutation-carrying knockin mouse we show that this leads to inhibition of endogenous TTBK2 protein kinase activity.",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "source": 736,
      "target": 735,
      "key": "9bc5a7b7ee3e2d1565b655f5e2726671bc2de0afe6abce70286b35e11be3c6a44012f26e81f36a8d807156c581c88a2615b31297cedeb4058f4259f2238bd94b"
    },
    {
      "line": 1359,
      "relation": "decreases",
      "evidence": "SCA11 truncating mutations promote TTBK2 protein expression, suppress kinase activity and lead to enhanced nuclear localization. Using a SCA11-mutation-carrying knockin mouse we show that this leads to inhibition of endogenous TTBK2 protein kinase activity.",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 736,
      "target": 735,
      "key": "9c83cdf10c3310f6d2de9dcee033f4272ec4d685f277374e1a24db029cde95a2b9037bee52c0d49e047ffb9ad04e60fee686310e3a66f6cbad73ee7daf05bbcb"
    },
    {
      "line": 1352,
      "relation": "positiveCorrelation",
      "evidence": "SCA11 truncating mutations promote TTBK2 protein expression, suppress kinase activity and lead to enhanced nuclear localization. Using a SCA11-mutation-carrying knockin mouse we show that this leads to inhibition of endogenous TTBK2 protein kinase activity.",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "source": 737,
      "target": 906,
      "key": "3d0352d30a48a2eca348a0c9d8f7f87c99ac5b2b4b5d4a2b8ae817ec2f7530c02d7ab638bca8ffac953161fabf84d1e364ac0a5f2e8b010bf196e05e2fb83a35"
    },
    {
      "line": 1356,
      "relation": "increases",
      "evidence": "SCA11 truncating mutations promote TTBK2 protein expression, suppress kinase activity and lead to enhanced nuclear localization. Using a SCA11-mutation-carrying knockin mouse we show that this leads to inhibition of endogenous TTBK2 protein kinase activity.",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "source": 737,
      "target": 735,
      "key": "373437249398c6b0e4cacad36518c6ecd19e3423f4e7f1b94c84f3636eb1e7709262f2030da0dc928fe07d3bb9f3b8c651c26b3e7b79052403fa4e130a4a12f4"
    },
    {
      "line": 1360,
      "relation": "decreases",
      "evidence": "SCA11 truncating mutations promote TTBK2 protein expression, suppress kinase activity and lead to enhanced nuclear localization. Using a SCA11-mutation-carrying knockin mouse we show that this leads to inhibition of endogenous TTBK2 protein kinase activity.",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 737,
      "target": 735,
      "key": "ac11857cf97228d7dd54c5d3924e6f23cb3ea86c29f5a6d3431e9731270c5a60baecf6c54965aa13fc16ce5203a108ed52493450f0b14905dff53385a0fbffef"
    },
    {
      "line": 1373,
      "relation": "increases",
      "evidence": "TTBK1-Tg mice show significant age-dependent memory impairment as determined by radial arm water maze test, which is associated with enhancement of tau and neurofilament phosphorylation, increased levels of p25 and p35, both activators of cyclin-dependent protein kinase 5 (CDK5), enhanced calpain I activity, and reduced levels of hippocampal NMDA receptor types 2B (NR2B) and D. Enhanced CDK5/p35 complex formation is strongly correlated with dissociation of F-actin from p35, suggesting the inhibitory mechanism of CDK5/p35 complex formation by F-actin.",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 401,
      "target": 400,
      "key": "1dfef19beef4be18316aa0b51570c65fd7d965ae57c78f549dc7e309bca172743e49f1bfc7c55d1cd677d0e68e510d31856b3eee9659d91dc76c1523f8085f22"
    },
    {
      "line": 2307,
      "relation": "partOf",
      "evidence": "To perform its function, Cdk5 must bind to the neuron-specific regulatory subunit protein p35, which is beneficial for neuronal development (Tsai et al. 1994; Chae et al. 1997). However, truncation of p35 and conversion to p25 (Patrick et al. 1999) is found in the forebrain of rats after focal cerebral ischemia and in AD patients, and these alterations are deleterious to the brain",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "source": 401,
      "target": 228,
      "key": "c30715ad1e225bd3f5eff9a2351c52a1f86b0ceafc6b96fef73941ee5077dcc916f82fd138a94cf7ba4ecca1759abf787370589d7996bc6ac40acba7ee2c64d7"
    },
    {
      "line": 2309,
      "relation": "negativeCorrelation",
      "evidence": "To perform its function, Cdk5 must bind to the neuron-specific regulatory subunit protein p35, which is beneficial for neuronal development (Tsai et al. 1994; Chae et al. 1997). However, truncation of p35 and conversion to p25 (Patrick et al. 1999) is found in the forebrain of rats after focal cerebral ischemia and in AD patients, and these alterations are deleterious to the brain",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "source": 401,
      "target": 311,
      "key": "52c9f0c0c2901a13b288bc02d8f5e04f6348cd48b9cf24ead98421b019ce9ac98c051fa0da35f64a7986028aca3923640d715277de54d42bae4628126ac60fe9"
    },
    {
      "relation": "hasVariant",
      "source": 401,
      "target": 402,
      "key": "1cdd48fda869945529a8aaaa6d6b9375e991f4594450df5d699e16b2abfa5af9fc8fbc25c4b6dd1478361ca4fb7739a825b0cc381152a5347d81bd16974f1b2b"
    },
    {
      "line": 1374,
      "relation": "positiveCorrelation",
      "evidence": "TTBK1-Tg mice show significant age-dependent memory impairment as determined by radial arm water maze test, which is associated with enhancement of tau and neurofilament phosphorylation, increased levels of p25 and p35, both activators of cyclin-dependent protein kinase 5 (CDK5), enhanced calpain I activity, and reduced levels of hippocampal NMDA receptor types 2B (NR2B) and D. Enhanced CDK5/p35 complex formation is strongly correlated with dissociation of F-actin from p35, suggesting the inhibitory mechanism of CDK5/p35 complex formation by F-actin.",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 273,
      "target": 734,
      "key": "01f992c4d8b9f3911b7140069f69d39018de155bb4da6432f94c6d02305907d51d9c72e0ac00ae5d82371ceec41bcd293608ff993a7594e966e08c8a7401fd92"
    },
    {
      "line": 1375,
      "relation": "negativeCorrelation",
      "evidence": "TTBK1-Tg mice show significant age-dependent memory impairment as determined by radial arm water maze test, which is associated with enhancement of tau and neurofilament phosphorylation, increased levels of p25 and p35, both activators of cyclin-dependent protein kinase 5 (CDK5), enhanced calpain I activity, and reduced levels of hippocampal NMDA receptor types 2B (NR2B) and D. Enhanced CDK5/p35 complex formation is strongly correlated with dissociation of F-actin from p35, suggesting the inhibitory mechanism of CDK5/p35 complex formation by F-actin.",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "source": 454,
      "target": 734,
      "key": "3ab7b71522c53f5e0573c01975331ea06c9f09fab5d935b52e56086cf638419fd5738b7a6416eeabd7b85e8fb5c064ebfbf127480464fd59dad457d3a014f283"
    },
    {
      "line": 1376,
      "relation": "negativeCorrelation",
      "evidence": "TTBK1-Tg mice show significant age-dependent memory impairment as determined by radial arm water maze test, which is associated with enhancement of tau and neurofilament phosphorylation, increased levels of p25 and p35, both activators of cyclin-dependent protein kinase 5 (CDK5), enhanced calpain I activity, and reduced levels of hippocampal NMDA receptor types 2B (NR2B) and D. Enhanced CDK5/p35 complex formation is strongly correlated with dissociation of F-actin from p35, suggesting the inhibitory mechanism of CDK5/p35 complex formation by F-actin.",
      "citation": {
        "type": "PubMed",
        "reference": "21548880",
        "name": "The Biochemical journal",
        "title": "TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.",
        "volume": "437",
        "pages": "157-67",
        "date": "2011-07-01",
        "first": "Bouskila M",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Begley MJ",
          "Bouskila M",
          "Cantley LC",
          "Deak M",
          "Esoof N",
          "Fang EH",
          "Gay L",
          "Prescott A",
          "Storey KG"
        ]
      },
      "source": 455,
      "target": 734,
      "key": "0d84013a93308c5371674d116da9e4e9ea579ea80e9023e47b6b4b3ca72bc5ddd6bd5db2ad3d8d4b6c9324a194e776f67294e475bbc15d5f5a432d71d2efbb5b"
    },
    {
      "line": 1395,
      "relation": "isA",
      "evidence": "The CK1 group of eukaryotic protein kinases are composed of seven CK1 isoforms (CK1α, CK1α2, CK1δ, CK1ε, CK1γ1, CK1γ2, and CK1γ3), two Tau–tubulin kinase isoforms (TTBK1 and TTBK2), and three VRK isoforms (VRK1, VRK2, and VRK3)",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 749,
      "target": 312,
      "key": "3927d8e481d987ccd609a92b5051dedd2d317ebbc11abda5828156e251ce52abb12ae7f6e3580cba374b3601f7f6609e228ee7adad357a41d92ae6b9be04a981"
    },
    {
      "line": 1396,
      "relation": "isA",
      "evidence": "The CK1 group of eukaryotic protein kinases are composed of seven CK1 isoforms (CK1α, CK1α2, CK1δ, CK1ε, CK1γ1, CK1γ2, and CK1γ3), two Tau–tubulin kinase isoforms (TTBK1 and TTBK2), and three VRK isoforms (VRK1, VRK2, and VRK3)",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 750,
      "target": 312,
      "key": "ac23068662effb0c66f84c337ebd7f41a4e9f9fc14ab1428ac3e2ae5c26b5bd2c2054316bafd50ffbd5a4f912035c7ac5656a7625326fc0ff5c354659eebd07e"
    },
    {
      "line": 1397,
      "relation": "isA",
      "evidence": "The CK1 group of eukaryotic protein kinases are composed of seven CK1 isoforms (CK1α, CK1α2, CK1δ, CK1ε, CK1γ1, CK1γ2, and CK1γ3), two Tau–tubulin kinase isoforms (TTBK1 and TTBK2), and three VRK isoforms (VRK1, VRK2, and VRK3)",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 751,
      "target": 312,
      "key": "1a1fbca4d7566d267674156b71a5bc1bb926405c0254ef7157bdba02e4b086f80c75bc0847c3ea5078a23462030c8552621d53671added210887f25fb8c0a86c"
    },
    {
      "line": 1407,
      "relation": "isA",
      "evidence": "The CK1 group of eukaryotic protein kinases are composed of seven CK1 isoforms (CK1α, CK1α2, CK1δ, CK1ε, CK1γ1, CK1γ2, and CK1γ3), two Tau–tubulin kinase isoforms (TTBK1 and TTBK2), and three VRK isoforms (VRK1, VRK2, and VRK3)",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 286,
      "target": 312,
      "key": "3ae2b27ffb210da9754287f42c320882b751644f0fffd92f06dc437e7ab229a6f16e5d67e186bc8cdff362e5333015ebeba7c88b4f42183caea091d0968c0986"
    },
    {
      "line": 1412,
      "relation": "increases",
      "evidence": "We demonstrate that Casein kinase 1 family members, including isoforms of Tau-tubulin protein kinases (TTBK1 and TTBK2), phosphorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84). These residues are also phosphorylated in vivo, and the phosphorylation of Thr84 within Cluster-2 is essential for triggering binding to the C2B domain of human synaptotagmin-1",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 286,
      "target": 696,
      "key": "583b0b06bf1bb7b0db24857997abc9f736ebe2ae8f7cd7fa323095b0c7b1a5b98c4df7a4230d789dee4dbb9cbd059333609fc9ebedafde659c2a75cd8f97e8c1"
    },
    {
      "line": 1413,
      "relation": "increases",
      "evidence": "We demonstrate that Casein kinase 1 family members, including isoforms of Tau-tubulin protein kinases (TTBK1 and TTBK2), phosphorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84). These residues are also phosphorylated in vivo, and the phosphorylation of Thr84 within Cluster-2 is essential for triggering binding to the C2B domain of human synaptotagmin-1",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 286,
      "target": 697,
      "key": "c5290d5913377b790a5f7081099de891838f708ba996c177cd5941896463d2c71811b8555b66141c89c1ee768c7c78bea1a5a62da027cfcde9f2493dee18712b"
    },
    {
      "line": 1414,
      "relation": "increases",
      "evidence": "We demonstrate that Casein kinase 1 family members, including isoforms of Tau-tubulin protein kinases (TTBK1 and TTBK2), phosphorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84). These residues are also phosphorylated in vivo, and the phosphorylation of Thr84 within Cluster-2 is essential for triggering binding to the C2B domain of human synaptotagmin-1",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 286,
      "target": 698,
      "key": "b4da72af12658d5303b304811030fbdfe37cac04e8e003fc0ede815a216924198ae16fc818967f31f0c3cdf7f1f7d7a08546804d67e8092e616ed44cded4c032"
    },
    {
      "line": 1415,
      "relation": "increases",
      "evidence": "We demonstrate that Casein kinase 1 family members, including isoforms of Tau-tubulin protein kinases (TTBK1 and TTBK2), phosphorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84). These residues are also phosphorylated in vivo, and the phosphorylation of Thr84 within Cluster-2 is essential for triggering binding to the C2B domain of human synaptotagmin-1",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 286,
      "target": 699,
      "key": "794490e8b0920b2e7883e510d260ab76a21a1e63ade069545649a343972eee636bfc20fff79b4e76a11e71439a4994732f19b3d52cf404bc0097a9fbc0305474"
    },
    {
      "line": 1416,
      "relation": "increases",
      "evidence": "We demonstrate that Casein kinase 1 family members, including isoforms of Tau-tubulin protein kinases (TTBK1 and TTBK2), phosphorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84). These residues are also phosphorylated in vivo, and the phosphorylation of Thr84 within Cluster-2 is essential for triggering binding to the C2B domain of human synaptotagmin-1",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 286,
      "target": 700,
      "key": "2b2f6788d47a0ebe6006e71a6d44ee207f2e86f2fec301179348b04e207d2e483adee92b578c35e599bd4a1de7487c02899068ede388e277c1961307224ea007"
    },
    {
      "line": 1417,
      "relation": "increases",
      "evidence": "We demonstrate that Casein kinase 1 family members, including isoforms of Tau-tubulin protein kinases (TTBK1 and TTBK2), phosphorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84). These residues are also phosphorylated in vivo, and the phosphorylation of Thr84 within Cluster-2 is essential for triggering binding to the C2B domain of human synaptotagmin-1",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 286,
      "target": 701,
      "key": "c072c569532721442fd967151ba443062a573e2ca22c737822321b0a28346482ea665e24ab9ebdc286268daafea2e1b3e3b01b8fdd159979997946df64710eee"
    },
    {
      "line": 1556,
      "relation": "increases",
      "evidence": "Phosphorylation at Ser208 might be catalyzed by Casein kinase 1 (44), and its identification as a potential site for O-GlcNacylation (45) points to the important role of this residue.",
      "citation": {
        "type": "PubMed",
        "reference": "28784767",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Identification of the Tau phosphorylation pattern that drives its aggregation.",
        "volume": "114",
        "pages": "9080-9085",
        "date": "2017-08-22",
        "first": "Despres C",
        "last": "Smet-Nocca C",
        "authors": [
          "Baulieu EE",
          "Byrne C",
          "Cantrelle FX",
          "Chambraud B",
          "Despres C",
          "Huvent I",
          "Jacquot Y",
          "Landrieu I",
          "Lippens G",
          "Qi H",
          "Smet-Nocca C"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "NMR Spectroscopy": true,
          "Thioflavin T Assay": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 286,
      "target": 548,
      "key": "625f47fbcaf24ed885eac7cc97b9351735a9696d5c758c7214b3b7528db09f934cfb558b236c4db770150cbe7112e40323178c40edbcbfc49ab100dc7648ca7f"
    },
    {
      "line": 1400,
      "relation": "isA",
      "evidence": "The CK1 group of eukaryotic protein kinases are composed of seven CK1 isoforms (CK1α, CK1α2, CK1δ, CK1ε, CK1γ1, CK1γ2, and CK1γ3), two Tau–tubulin kinase isoforms (TTBK1 and TTBK2), and three VRK isoforms (VRK1, VRK2, and VRK3)",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 412,
      "target": 286,
      "key": "3ec837787d60f0f5bae258cb7dd3be73d01277fa068b1faffd11a02724f653484c13b6001788b54fe7796f348da4b85bde85068ee498d76ab5922f4e58ba159d"
    },
    {
      "line": 1402,
      "relation": "isA",
      "evidence": "The CK1 group of eukaryotic protein kinases are composed of seven CK1 isoforms (CK1α, CK1α2, CK1δ, CK1ε, CK1γ1, CK1γ2, and CK1γ3), two Tau–tubulin kinase isoforms (TTBK1 and TTBK2), and three VRK isoforms (VRK1, VRK2, and VRK3)",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 414,
      "target": 286,
      "key": "2fe32897b1c122884d6936f2eeae35cac6c5caefa91fdb095e0b67be7b3b5d72e3285e6fc69b70d9f4063dc36aef1bac1c9b0dacc0ab5c16a65b5a9aca80a1ad"
    },
    {
      "line": 1403,
      "relation": "isA",
      "evidence": "The CK1 group of eukaryotic protein kinases are composed of seven CK1 isoforms (CK1α, CK1α2, CK1δ, CK1ε, CK1γ1, CK1γ2, and CK1γ3), two Tau–tubulin kinase isoforms (TTBK1 and TTBK2), and three VRK isoforms (VRK1, VRK2, and VRK3)",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 415,
      "target": 286,
      "key": "3ec9909595e5e435843f5c9e070aea568affcb57d707ba8639d43c572645c298270c2bc2075cf18f06c7837c008fd86dbea055ea350ca0b67840027328f39de0"
    },
    {
      "line": 1404,
      "relation": "isA",
      "evidence": "The CK1 group of eukaryotic protein kinases are composed of seven CK1 isoforms (CK1α, CK1α2, CK1δ, CK1ε, CK1γ1, CK1γ2, and CK1γ3), two Tau–tubulin kinase isoforms (TTBK1 and TTBK2), and three VRK isoforms (VRK1, VRK2, and VRK3)",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 416,
      "target": 286,
      "key": "ec02cc518e13ce0275c9abed841674cc7d93d9ef895a9f4bd83756d56696558aea78553928888095e8f57618279e10fafb6a5357bacb96c4a643074cd4eb8e02"
    },
    {
      "line": 1405,
      "relation": "isA",
      "evidence": "The CK1 group of eukaryotic protein kinases are composed of seven CK1 isoforms (CK1α, CK1α2, CK1δ, CK1ε, CK1γ1, CK1γ2, and CK1γ3), two Tau–tubulin kinase isoforms (TTBK1 and TTBK2), and three VRK isoforms (VRK1, VRK2, and VRK3)",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 417,
      "target": 286,
      "key": "d3c6060886f2d37d1f4a82b53bec7d5cb0206342290c402a12cd62aec1bed1dc4681c0316177eb37a3618439df132c90b1c8ec98111a0d73b4265924eb0d919f"
    },
    {
      "relation": "hasVariant",
      "source": 695,
      "target": 696,
      "key": "c196617f18eb399efeeca90b6ffd1e069338d44e6b72fe4fbd36b4f5a1423c169d285c844f9c273cc8e4ab0f13959f324daafb9879b8997b83cead4fdf003c29"
    },
    {
      "relation": "hasVariant",
      "source": 695,
      "target": 697,
      "key": "4d39471a6198ef9ffff37bedcf32c3044674ef288f681ea9d23d16a8f71268727591b77d61aec2b6c3a6a04264911a8db63a418d13ae7e142eae9961203bbda1"
    },
    {
      "relation": "hasVariant",
      "source": 695,
      "target": 698,
      "key": "6b9336d94d8801ef65b4e467f05fad39b0806a124752e7d37e09afc01b90e5391c4e04c412851de9b07a2db2bbb5c5b2d4310bd00a65ce8649337f48efbc721a"
    },
    {
      "relation": "hasVariant",
      "source": 695,
      "target": 699,
      "key": "1a48876374a1d57cd208054a6599994a2a1bb116198212a4511c0ec49b8ea71b6adceb1044b7807f1845a85ee6889509cf9eca8e4974bb27691feeab87c88149"
    },
    {
      "relation": "hasVariant",
      "source": 695,
      "target": 700,
      "key": "b998343d6d1d27d25b16aaead1df03a7a5e10d28542f9531b4205e4f8de5ab22179669cccf8317a93a8c6d32865c16519d389b5a9aeab41993e49771ae65ddd3"
    },
    {
      "relation": "hasVariant",
      "source": 695,
      "target": 701,
      "key": "b3b60e681d7fd7f5446ec4d8bf0e5800950f02b0c7237d38fb053c58a26bd6f7c335bf98cf3866eef6b5ded3d091fea54db9252b7e6e8ffe3a6dd9c1bb0993e7"
    },
    {
      "relation": "hasVariant",
      "source": 695,
      "target": 702,
      "key": "bf86f5bfe178ed4abc8984660768a702ba4b648fdc46b355b90112fb10e606ce1e0ab026c7596f844a339f9f75dc1a879693c8e0f1052da2400c21a41d844924"
    },
    {
      "line": 1433,
      "relation": "association",
      "evidence": "We demonstrate that Casein kinase 1 family members, including isoforms of Tau-tubulin protein kinases (TTBK1 and TTBK2), phosphorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84). These residues are also phosphorylated in vivo, and the phosphorylation of Thr84 within Cluster-2 is essential for triggering binding to the C2B domain of human synaptotagmin-1",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 701,
      "target": 715,
      "key": "1e62bf4d591d9f51c2385c9b3885220e64356b9a1d11ab3a262913c3d27ef8b65d95551a27f34780072a3c6ab0216d6b6942aad3ec4ec98854d9c87f61439d39"
    },
    {
      "line": 1433,
      "relation": "association",
      "evidence": "We demonstrate that Casein kinase 1 family members, including isoforms of Tau-tubulin protein kinases (TTBK1 and TTBK2), phosphorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84). These residues are also phosphorylated in vivo, and the phosphorylation of Thr84 within Cluster-2 is essential for triggering binding to the C2B domain of human synaptotagmin-1",
      "citation": {
        "type": "PubMed",
        "reference": "25673844",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Phosphorylation of synaptic vesicle protein 2A at Thr84 by casein kinase 1 family kinases controls the specific retrieval of synaptotagmin-1.",
        "volume": "35",
        "pages": "2492-507",
        "date": "2015-02-11",
        "first": "Zhang N",
        "last": "Alessi DR",
        "authors": [
          "Alessi DR",
          "Campbell DG",
          "Cousin MA",
          "Esoof N",
          "Fritsch MJ",
          "Gordon SL",
          "Gourlay R",
          "Macartney T",
          "Peggie M",
          "Velupillai S",
          "Zhang N",
          "van Aalten DM"
        ]
      },
      "source": 715,
      "target": 701,
      "key": "a5e89122cc1449990c14f5483ddbe0c86d58281e683ffa659e792e0506a869568c4c00bdaea743237ae3331e64076ce555ee1cd916d0d3d30087afaac20cd8af"
    },
    {
      "relation": "hasVariant",
      "source": 715,
      "target": 716,
      "key": "4046add3c8aec95ef1316e46c0c13d3720cd2e7b3c3f0bc2abd73c32a21c4082cc91fda070cc407f79da529db63d85f58243d068d43750160b61105c712ef81a"
    },
    {
      "relation": "hasVariant",
      "source": 721,
      "target": 722,
      "key": "c0c10f012ba76f57711e26ecf8b7cb7013128c377221635e6811cfe4afd4099cf9a455bbba3c5f96cef299137f00040de87d6b83ecc2dc642c26d31626220ff5"
    },
    {
      "line": 3740,
      "relation": "increases",
      "evidence": "We recently found that overexpression of TDP-43 enhances tau exon 10 inclusion and tau mRNA instability. Overexpression of PP1α and PP1γ, but not PP1β, suppressed TDP-43 phosphorylation at Ser403/404 and Ser409/410 and TDP-43-induced tau exon 10 inclusion.",
      "citation": {
        "type": "PubMed",
        "reference": "29334120",
        "name": "FEBS letters",
        "title": "Protein Phosphatase 1 dephosphorylates TDP-43 and suppresses its function in tau exon 10 inclusion.",
        "volume": "592",
        "pages": "402-410",
        "date": "2018-02-01",
        "first": "Gu J",
        "last": "Liu F",
        "authors": [
          "Chen F",
          "Gong CX",
          "Gu J",
          "Hu W",
          "Iqbal K",
          "Liu F",
          "Miao S",
          "Wang W",
          "Wu F"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 721,
      "target": 307,
      "key": "de388447bbfcadcbcf2cec2831c91cdc526c99b5978c020c3186b0c1cf4cc90d73b6bcf43fb716c95789361a70283deafdecb94629f0e7282158502864ffd821"
    },
    {
      "relation": "hasVariant",
      "source": 721,
      "target": 724,
      "key": "8555793e8edbf6ac69b7c5d77ebec21e5f33a204e0fe959a1e21ae32e041b929a848f20e1ea0164a7c454cfb94a41ef59a2987abc3a0d7fc350fe12655c839d4"
    },
    {
      "relation": "hasVariant",
      "source": 721,
      "target": 725,
      "key": "c971d4b3b9831f4d15b24dd6bfe795e2f0b29710af398a787609d127e9cf0bbca75b53fd5947a3ac10b4bdd1297b79bf8ea9a4963996b771d6fcf6d7e5d68167"
    },
    {
      "relation": "hasVariant",
      "source": 721,
      "target": 726,
      "key": "999db192c43e555062683f6835be549255f4f5c688d27c48d5f87ab528784d97614380ed60d3bf9554fea10551195ef0985fb86002e1cd42d4ba92412558e201"
    },
    {
      "relation": "hasVariant",
      "source": 721,
      "target": 727,
      "key": "903a082307aff81dffc9fa4003fd2cd289dc0ea9cfc4b9650703adf9630abd119d3d9578f3dd39846868f57816edb76d488d3bf5d63cfc84b1be6e7fa0737f5b"
    },
    {
      "relation": "hasVariant",
      "source": 721,
      "target": 723,
      "key": "ab6e4939a7f077633fec91595bc01cafd1b8d0e48ebbac73236e760347c67d40c41ed98c4ee751cd9d02e85b0398773b7b1a7b64fd26de580a57364eb435ed58"
    },
    {
      "line": 1449,
      "relation": "negativeCorrelation",
      "evidence": "TTBK2 down-regulates GluK2 activity by decreasing the receptor protein abundance in the cell membrane via RAB5-dependent endocytosis, an effect that may protect against neuroexcitotoxicity.",
      "citation": {
        "type": "PubMed",
        "reference": "27607061",
        "name": "Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology",
        "title": "Tau Tubulin Kinase TTBK2 Sensitivity of Glutamate Receptor GluK2.",
        "volume": "39",
        "pages": "1444-52",
        "date": "2016-01-01",
        "first": "Nieding K",
        "last": "Strutz-Seebohm N",
        "authors": [
          "Lang F",
          "Matschke V",
          "Meuth SG",
          "Nieding K",
          "Seebohm G",
          "Strutz-Seebohm N"
        ]
      },
      "subject": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "bel",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "bel",
            "name": "cell surface"
          }
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 453,
      "target": 669,
      "key": "2eea1c2e6e78a809c4629bc76d0a15e0cb839bb3920ec71049af3fc7de7594a9cbc6ca3c38d6b6ea579c132f8fa666854ea0ed451dd23d4217eda22ef9c03b04"
    },
    {
      "line": 1449,
      "relation": "negativeCorrelation",
      "evidence": "TTBK2 down-regulates GluK2 activity by decreasing the receptor protein abundance in the cell membrane via RAB5-dependent endocytosis, an effect that may protect against neuroexcitotoxicity.",
      "citation": {
        "type": "PubMed",
        "reference": "27607061",
        "name": "Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology",
        "title": "Tau Tubulin Kinase TTBK2 Sensitivity of Glutamate Receptor GluK2.",
        "volume": "39",
        "pages": "1444-52",
        "date": "2016-01-01",
        "first": "Nieding K",
        "last": "Strutz-Seebohm N",
        "authors": [
          "Lang F",
          "Matschke V",
          "Meuth SG",
          "Nieding K",
          "Seebohm G",
          "Strutz-Seebohm N"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "bel",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "bel",
            "name": "cell surface"
          }
        }
      },
      "source": 669,
      "target": 453,
      "key": "ad57bbbe1eca80b2aa72e46fdcca0626cc23dafb656904a7ff346e8d20486de61c7987b7140c39d2d7d95e242f731ec50bbd0ca43f92157f4e0f6f4b14f0611f"
    },
    {
      "line": 1450,
      "relation": "partOf",
      "evidence": "TTBK2 down-regulates GluK2 activity by decreasing the receptor protein abundance in the cell membrane via RAB5-dependent endocytosis, an effect that may protect against neuroexcitotoxicity.",
      "citation": {
        "type": "PubMed",
        "reference": "27607061",
        "name": "Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology",
        "title": "Tau Tubulin Kinase TTBK2 Sensitivity of Glutamate Receptor GluK2.",
        "volume": "39",
        "pages": "1444-52",
        "date": "2016-01-01",
        "first": "Nieding K",
        "last": "Strutz-Seebohm N",
        "authors": [
          "Lang F",
          "Matschke V",
          "Meuth SG",
          "Nieding K",
          "Seebohm G",
          "Strutz-Seebohm N"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 669,
      "target": 180,
      "key": "32d243df192470940572a11d3bcc6fa1e9276e5b62e26695a007f52fba81f9592408a7457d9d04d8899c986a08bfc797a60f0a89bc54130b900e34431d3df4b4"
    },
    {
      "line": 1707,
      "relation": "positiveCorrelation",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 180,
      "target": 486,
      "key": "987b537addfd44057188b05bd7faffc8c2e2d6983bfaccad961b32767f514413b64a9790f436d449b31bbe7e7f59cfcefe11513b1930f47e1fe3d43d239d65a6"
    },
    {
      "line": 1713,
      "relation": "isA",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          }
        }
      },
      "source": 180,
      "target": 112,
      "key": "73319448b7eca84e996228381066ba9a3fd4211a14f7ce2bed14e67714837eb2dc0aa325e7f24f3c0379561822ac619bc3a9a61b1303d1bde255bd6456a0887b"
    },
    {
      "line": 1456,
      "relation": "negativeCorrelation",
      "evidence": "These findings indicate that TTBK2 with EB1/3 phosphorylates KIF2A and antagonizes KIF2A-induced depolymerization at MT plus ends for cell migration.",
      "citation": {
        "type": "PubMed",
        "reference": "26323690",
        "name": "The Journal of cell biology",
        "title": "TTBK2 with EB1/3 regulates microtubule dynamics in migrating cells through KIF2A phosphorylation.",
        "volume": "210",
        "pages": "737-51",
        "date": "2015-08-31",
        "first": "Watanabe T",
        "last": "Kaibuchi K",
        "authors": [
          "Arimura N",
          "Hoshino M",
          "Ishidate F",
          "Kaibuchi K",
          "Kakeno M",
          "Matsui T",
          "Matsuzawa K",
          "Nishioka T",
          "Shirahige A",
          "Sugiyama I",
          "Taya S",
          "Watanabe T"
        ]
      },
      "source": 466,
      "target": 185,
      "key": "0271716c9f0a7346cfbb9f898dfa4bad4cd0b7bed948f17b3019e5b940e5e6b4cdfa6d367eca3ca5fdd9351eecc13b34c802d71d235e49ec5ab62e791fa2c417"
    },
    {
      "relation": "hasVariant",
      "source": 465,
      "target": 466,
      "key": "4e254f00a27f2b52e94ea43147cee0aa9c973be47afb2b08c5fe6cec97b61300a53aed8406829f6f312781eca54254d3aef99530abeff77ab0b17d8252e3bcd6"
    },
    {
      "line": 1456,
      "relation": "negativeCorrelation",
      "evidence": "These findings indicate that TTBK2 with EB1/3 phosphorylates KIF2A and antagonizes KIF2A-induced depolymerization at MT plus ends for cell migration.",
      "citation": {
        "type": "PubMed",
        "reference": "26323690",
        "name": "The Journal of cell biology",
        "title": "TTBK2 with EB1/3 regulates microtubule dynamics in migrating cells through KIF2A phosphorylation.",
        "volume": "210",
        "pages": "737-51",
        "date": "2015-08-31",
        "first": "Watanabe T",
        "last": "Kaibuchi K",
        "authors": [
          "Arimura N",
          "Hoshino M",
          "Ishidate F",
          "Kaibuchi K",
          "Kakeno M",
          "Matsui T",
          "Matsuzawa K",
          "Nishioka T",
          "Shirahige A",
          "Sugiyama I",
          "Taya S",
          "Watanabe T"
        ]
      },
      "source": 185,
      "target": 466,
      "key": "0399421c46e0710ea0bac85558177c9bcfda7861a7559897cb5cb7ae0325176829bcc2b9b11167c9d57c909c911f29cf5e7cba7fd0cb8a14d89d4cf371589534"
    },
    {
      "line": 1467,
      "relation": "positiveCorrelation",
      "evidence": "Upregulation of SLC5A1 Na-copled Glucose transport",
      "citation": {
        "type": "PubMed",
        "reference": "26323690",
        "name": "The Journal of cell biology",
        "title": "TTBK2 with EB1/3 regulates microtubule dynamics in migrating cells through KIF2A phosphorylation.",
        "volume": "210",
        "pages": "737-51",
        "date": "2015-08-31",
        "first": "Watanabe T",
        "last": "Kaibuchi K",
        "authors": [
          "Arimura N",
          "Hoshino M",
          "Ishidate F",
          "Kaibuchi K",
          "Kakeno M",
          "Matsui T",
          "Matsuzawa K",
          "Nishioka T",
          "Shirahige A",
          "Sugiyama I",
          "Taya S",
          "Watanabe T"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 680,
      "target": 183,
      "key": "173f42c66fad578de5c8120eb7af86caee4cb4daff4f856eaef5c3126b8c6f9a174f5864574cefe6fe3989f34dae36f949a1f62cee0d92d2e4b673c3cc190d43"
    },
    {
      "line": 1467,
      "relation": "positiveCorrelation",
      "evidence": "Upregulation of SLC5A1 Na-copled Glucose transport",
      "citation": {
        "type": "PubMed",
        "reference": "26323690",
        "name": "The Journal of cell biology",
        "title": "TTBK2 with EB1/3 regulates microtubule dynamics in migrating cells through KIF2A phosphorylation.",
        "volume": "210",
        "pages": "737-51",
        "date": "2015-08-31",
        "first": "Watanabe T",
        "last": "Kaibuchi K",
        "authors": [
          "Arimura N",
          "Hoshino M",
          "Ishidate F",
          "Kaibuchi K",
          "Kakeno M",
          "Matsui T",
          "Matsuzawa K",
          "Nishioka T",
          "Shirahige A",
          "Sugiyama I",
          "Taya S",
          "Watanabe T"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 183,
      "target": 680,
      "key": "fe0f5f2d8b9317f2bea9c8ea2f04d02998acc76ccaabc59df7d38b2dcfebb038e475857ab9961f871ee9c22400bdef3a5ca411c52615902f023e2d8caba2373e"
    },
    {
      "line": 1475,
      "relation": "association",
      "evidence": "TTBK2 bound EB1 and Cep164 through its SxIP motifs and a proline-rich motif, respectively. Using TTBK2 variants that contained mutations in the SxIP or proline-rich motifs, we obtained evidence that Cep164, but not EB1, is essential for centriolar localization of TTBK2. Therefore, Cep164 binding is essential for the function of TTBK2 in promoting CP110 removal and ciliogenesis. We also provide evidence that TTBK2 has the potential to effectively phosphorylate Cep164 and Cep97 and inhibits the interaction between Cep164 and its binding partner Dishevelled-3 (an important regulator of ciliogenesis) in a kinase activity-dependent manner.",
      "citation": {
        "type": "PubMed",
        "reference": "26323690",
        "name": "The Journal of cell biology",
        "title": "TTBK2 with EB1/3 regulates microtubule dynamics in migrating cells through KIF2A phosphorylation.",
        "volume": "210",
        "pages": "737-51",
        "date": "2015-08-31",
        "first": "Watanabe T",
        "last": "Kaibuchi K",
        "authors": [
          "Arimura N",
          "Hoshino M",
          "Ishidate F",
          "Kaibuchi K",
          "Kakeno M",
          "Matsui T",
          "Matsuzawa K",
          "Nishioka T",
          "Shirahige A",
          "Sugiyama I",
          "Taya S",
          "Watanabe T"
        ]
      },
      "source": 403,
      "target": 735,
      "key": "e0ff89fda42deab590d9d458bcc0b5a575d623f755c2f34c65fb36a6589039236773d8a41f89f33e06e1d1bfc1c059a5286907683aa3873bc759241092ec556a"
    },
    {
      "line": 1477,
      "relation": "positiveCorrelation",
      "evidence": "TTBK2 bound EB1 and Cep164 through its SxIP motifs and a proline-rich motif, respectively. Using TTBK2 variants that contained mutations in the SxIP or proline-rich motifs, we obtained evidence that Cep164, but not EB1, is essential for centriolar localization of TTBK2. Therefore, Cep164 binding is essential for the function of TTBK2 in promoting CP110 removal and ciliogenesis. We also provide evidence that TTBK2 has the potential to effectively phosphorylate Cep164 and Cep97 and inhibits the interaction between Cep164 and its binding partner Dishevelled-3 (an important regulator of ciliogenesis) in a kinase activity-dependent manner.",
      "citation": {
        "type": "PubMed",
        "reference": "26323690",
        "name": "The Journal of cell biology",
        "title": "TTBK2 with EB1/3 regulates microtubule dynamics in migrating cells through KIF2A phosphorylation.",
        "volume": "210",
        "pages": "737-51",
        "date": "2015-08-31",
        "first": "Watanabe T",
        "last": "Kaibuchi K",
        "authors": [
          "Arimura N",
          "Hoshino M",
          "Ishidate F",
          "Kaibuchi K",
          "Kakeno M",
          "Matsui T",
          "Matsuzawa K",
          "Nishioka T",
          "Shirahige A",
          "Sugiyama I",
          "Taya S",
          "Watanabe T"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 403,
      "target": 735,
      "key": "c6d5efba3f9a54fd9cd98ed337ec1ecef3e2f62c9ce09ff154d6f0f15dd654ec49b8bc9d648d4d529d70b54446e4bc703669d00cd413acd26f615c28538b6ff2"
    },
    {
      "relation": "hasVariant",
      "source": 403,
      "target": 404,
      "key": "9ee58530ce7f997229e7b56c814aa443dde6b01e1ac3656b72eb132db2747f4d878142788ffc717bdc0736f48d2aaa8b4349f983a1387fb77d221cfddc6ddfdf"
    },
    {
      "line": 1482,
      "relation": "partOf",
      "evidence": "TTBK2 bound EB1 and Cep164 through its SxIP motifs and a proline-rich motif, respectively. Using TTBK2 variants that contained mutations in the SxIP or proline-rich motifs, we obtained evidence that Cep164, but not EB1, is essential for centriolar localization of TTBK2. Therefore, Cep164 binding is essential for the function of TTBK2 in promoting CP110 removal and ciliogenesis. We also provide evidence that TTBK2 has the potential to effectively phosphorylate Cep164 and Cep97 and inhibits the interaction between Cep164 and its binding partner Dishevelled-3 (an important regulator of ciliogenesis) in a kinase activity-dependent manner.",
      "citation": {
        "type": "PubMed",
        "reference": "26323690",
        "name": "The Journal of cell biology",
        "title": "TTBK2 with EB1/3 regulates microtubule dynamics in migrating cells through KIF2A phosphorylation.",
        "volume": "210",
        "pages": "737-51",
        "date": "2015-08-31",
        "first": "Watanabe T",
        "last": "Kaibuchi K",
        "authors": [
          "Arimura N",
          "Hoshino M",
          "Ishidate F",
          "Kaibuchi K",
          "Kakeno M",
          "Matsui T",
          "Matsuzawa K",
          "Nishioka T",
          "Shirahige A",
          "Sugiyama I",
          "Taya S",
          "Watanabe T"
        ]
      },
      "source": 403,
      "target": 234,
      "key": "0421f339e2fd767f5d397d34c7de3a01e91e5aa747718fd726906221e76273a7e6a1c75e7971b806427d83c0c54e5a99353cf9f4877beb3e2c76d6436c234ec0"
    },
    {
      "line": 1476,
      "relation": "association",
      "evidence": "TTBK2 bound EB1 and Cep164 through its SxIP motifs and a proline-rich motif, respectively. Using TTBK2 variants that contained mutations in the SxIP or proline-rich motifs, we obtained evidence that Cep164, but not EB1, is essential for centriolar localization of TTBK2. Therefore, Cep164 binding is essential for the function of TTBK2 in promoting CP110 removal and ciliogenesis. We also provide evidence that TTBK2 has the potential to effectively phosphorylate Cep164 and Cep97 and inhibits the interaction between Cep164 and its binding partner Dishevelled-3 (an important regulator of ciliogenesis) in a kinase activity-dependent manner.",
      "citation": {
        "type": "PubMed",
        "reference": "26323690",
        "name": "The Journal of cell biology",
        "title": "TTBK2 with EB1/3 regulates microtubule dynamics in migrating cells through KIF2A phosphorylation.",
        "volume": "210",
        "pages": "737-51",
        "date": "2015-08-31",
        "first": "Watanabe T",
        "last": "Kaibuchi K",
        "authors": [
          "Arimura N",
          "Hoshino M",
          "Ishidate F",
          "Kaibuchi K",
          "Kakeno M",
          "Matsui T",
          "Matsuzawa K",
          "Nishioka T",
          "Shirahige A",
          "Sugiyama I",
          "Taya S",
          "Watanabe T"
        ]
      },
      "source": 485,
      "target": 735,
      "key": "0c35805c7c69f910f972492f524287f6c070ecd29a2500de2bf852f638c6439f553dd2c41b5606939e2862a5741157790aead97d961fd7b101dcd0536c9616e6"
    },
    {
      "line": 1481,
      "relation": "negativeCorrelation",
      "evidence": "TTBK2 bound EB1 and Cep164 through its SxIP motifs and a proline-rich motif, respectively. Using TTBK2 variants that contained mutations in the SxIP or proline-rich motifs, we obtained evidence that Cep164, but not EB1, is essential for centriolar localization of TTBK2. Therefore, Cep164 binding is essential for the function of TTBK2 in promoting CP110 removal and ciliogenesis. We also provide evidence that TTBK2 has the potential to effectively phosphorylate Cep164 and Cep97 and inhibits the interaction between Cep164 and its binding partner Dishevelled-3 (an important regulator of ciliogenesis) in a kinase activity-dependent manner.",
      "citation": {
        "type": "PubMed",
        "reference": "26323690",
        "name": "The Journal of cell biology",
        "title": "TTBK2 with EB1/3 regulates microtubule dynamics in migrating cells through KIF2A phosphorylation.",
        "volume": "210",
        "pages": "737-51",
        "date": "2015-08-31",
        "first": "Watanabe T",
        "last": "Kaibuchi K",
        "authors": [
          "Arimura N",
          "Hoshino M",
          "Ishidate F",
          "Kaibuchi K",
          "Kakeno M",
          "Matsui T",
          "Matsuzawa K",
          "Nishioka T",
          "Shirahige A",
          "Sugiyama I",
          "Taya S",
          "Watanabe T"
        ]
      },
      "source": 404,
      "target": 234,
      "key": "15b764a277527bee36e86badf5a6e7801284cd74a10045bb71e5f4fdbf648cef392b83d986ed0dfd92fe14214185a2b37465b5bb65105c384c28af4481db2e42"
    },
    {
      "relation": "hasVariant",
      "source": 405,
      "target": 406,
      "key": "a1160558d8058946bc26fd36d87c8525aec374f469b26296df12ec50e7e4e8d0c69a89ee464b1b65c7282d165be7f200875de851ed19c2625deda76134944e88"
    },
    {
      "relation": "hasComponent",
      "source": 234,
      "target": 403,
      "key": "11f3ace3cd0d8f522e0d4c3d9510898b9c3b56a776373d64b4c5bdb27772060d1ea19273f9188e7670bbef0a69cc46c5a8233d399cdd76a07291f3a5b8006e65"
    },
    {
      "relation": "hasComponent",
      "source": 234,
      "target": 442,
      "key": "b5532e67b471c967a65852a979dfa380c99249a4d5114e490418f0242ffa4e175f08fd402e33985b9287d08240d6ad0063bdfe4de2ad8c1cd186437f030ab65c"
    },
    {
      "line": 1481,
      "relation": "negativeCorrelation",
      "evidence": "TTBK2 bound EB1 and Cep164 through its SxIP motifs and a proline-rich motif, respectively. Using TTBK2 variants that contained mutations in the SxIP or proline-rich motifs, we obtained evidence that Cep164, but not EB1, is essential for centriolar localization of TTBK2. Therefore, Cep164 binding is essential for the function of TTBK2 in promoting CP110 removal and ciliogenesis. We also provide evidence that TTBK2 has the potential to effectively phosphorylate Cep164 and Cep97 and inhibits the interaction between Cep164 and its binding partner Dishevelled-3 (an important regulator of ciliogenesis) in a kinase activity-dependent manner.",
      "citation": {
        "type": "PubMed",
        "reference": "26323690",
        "name": "The Journal of cell biology",
        "title": "TTBK2 with EB1/3 regulates microtubule dynamics in migrating cells through KIF2A phosphorylation.",
        "volume": "210",
        "pages": "737-51",
        "date": "2015-08-31",
        "first": "Watanabe T",
        "last": "Kaibuchi K",
        "authors": [
          "Arimura N",
          "Hoshino M",
          "Ishidate F",
          "Kaibuchi K",
          "Kakeno M",
          "Matsui T",
          "Matsuzawa K",
          "Nishioka T",
          "Shirahige A",
          "Sugiyama I",
          "Taya S",
          "Watanabe T"
        ]
      },
      "source": 234,
      "target": 404,
      "key": "5d4dfb4279d8d02c95d28029e7a630ab48efe8303d7528f29019445b7b4f8d551386629a31413e8be6a5bfddd1d0ee9458fe507ed93495bc6cee2f6a5562525e"
    },
    {
      "line": 1483,
      "relation": "partOf",
      "evidence": "TTBK2 bound EB1 and Cep164 through its SxIP motifs and a proline-rich motif, respectively. Using TTBK2 variants that contained mutations in the SxIP or proline-rich motifs, we obtained evidence that Cep164, but not EB1, is essential for centriolar localization of TTBK2. Therefore, Cep164 binding is essential for the function of TTBK2 in promoting CP110 removal and ciliogenesis. We also provide evidence that TTBK2 has the potential to effectively phosphorylate Cep164 and Cep97 and inhibits the interaction between Cep164 and its binding partner Dishevelled-3 (an important regulator of ciliogenesis) in a kinase activity-dependent manner.",
      "citation": {
        "type": "PubMed",
        "reference": "26323690",
        "name": "The Journal of cell biology",
        "title": "TTBK2 with EB1/3 regulates microtubule dynamics in migrating cells through KIF2A phosphorylation.",
        "volume": "210",
        "pages": "737-51",
        "date": "2015-08-31",
        "first": "Watanabe T",
        "last": "Kaibuchi K",
        "authors": [
          "Arimura N",
          "Hoshino M",
          "Ishidate F",
          "Kaibuchi K",
          "Kakeno M",
          "Matsui T",
          "Matsuzawa K",
          "Nishioka T",
          "Shirahige A",
          "Sugiyama I",
          "Taya S",
          "Watanabe T"
        ]
      },
      "source": 442,
      "target": 234,
      "key": "6c888ac9dd6b091be977c97f0eb2eb79905024f615a13fde1ca3b947e70db920d2951b9775b2df805d102c99329a79f1590bf5fc6e56e7763361259ee283b8c4"
    },
    {
      "line": 1491,
      "relation": "negativeCorrelation",
      "evidence": "Overexpression of TTBK1 was sufficient in inducing spatial learning impairment in mice, which is associated with enhanced Cdk5 activity and reduction in cell surface level of NR2B. Over-expressionof TTBK1 transgene in JNPL3 mice resulted in accumulation of pre-tangle forms of tau. Inaddition, TTBK1 expression plays a unique role in accelerating motor neuron degeneration and neuroinflammation in JNPL3mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24808823",
        "name": "Frontiers in molecular neuroscience",
        "title": "Tau-tubulin kinase.",
        "volume": "7",
        "pages": "33",
        "date": "2014-01-01",
        "first": "Ikezu S",
        "last": "Ikezu T",
        "authors": [
          "Ikezu S",
          "Ikezu T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 853,
      "target": 197,
      "key": "cc20f62fa1a5b2f9343c6dce1dcbca1c90383be8ef0bcdc5fc192b716736284444f1e463bb01ce4560005b280a4725aca2663cad878ffc412ab14420c8313fd1"
    },
    {
      "line": 1494,
      "relation": "increases",
      "evidence": "Overexpression of TTBK1 was sufficient in inducing spatial learning impairment in mice, which is associated with enhanced Cdk5 activity and reduction in cell surface level of NR2B. Over-expressionof TTBK1 transgene in JNPL3 mice resulted in accumulation of pre-tangle forms of tau. Inaddition, TTBK1 expression plays a unique role in accelerating motor neuron degeneration and neuroinflammation in JNPL3mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24808823",
        "name": "Frontiers in molecular neuroscience",
        "title": "Tau-tubulin kinase.",
        "volume": "7",
        "pages": "33",
        "date": "2014-01-01",
        "first": "Ikezu S",
        "last": "Ikezu T",
        "authors": [
          "Ikezu S",
          "Ikezu T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 853,
      "target": 158,
      "key": "ee5bb54683988a2054bc78223655181aed34cb957d01988e07e1666c53b1477141715afac8152f0b5cba51e8a6ebd8a9c7e49a631e84f85c06259bb03f5e195d"
    },
    {
      "line": 1495,
      "relation": "increases",
      "evidence": "Overexpression of TTBK1 was sufficient in inducing spatial learning impairment in mice, which is associated with enhanced Cdk5 activity and reduction in cell surface level of NR2B. Over-expressionof TTBK1 transgene in JNPL3 mice resulted in accumulation of pre-tangle forms of tau. Inaddition, TTBK1 expression plays a unique role in accelerating motor neuron degeneration and neuroinflammation in JNPL3mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24808823",
        "name": "Frontiers in molecular neuroscience",
        "title": "Tau-tubulin kinase.",
        "volume": "7",
        "pages": "33",
        "date": "2014-01-01",
        "first": "Ikezu S",
        "last": "Ikezu T",
        "authors": [
          "Ikezu S",
          "Ikezu T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 853,
      "target": 190,
      "key": "20ad93ce7aba3b902322ed7b3765b5573104e16b2ef2556fe0c53cf6fe62547151e68e96a2e14efd2c4b11b7a722cfa47ac9628c94911279dcffef8e18f566a5"
    },
    {
      "line": 1491,
      "relation": "negativeCorrelation",
      "evidence": "Overexpression of TTBK1 was sufficient in inducing spatial learning impairment in mice, which is associated with enhanced Cdk5 activity and reduction in cell surface level of NR2B. Over-expressionof TTBK1 transgene in JNPL3 mice resulted in accumulation of pre-tangle forms of tau. Inaddition, TTBK1 expression plays a unique role in accelerating motor neuron degeneration and neuroinflammation in JNPL3mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24808823",
        "name": "Frontiers in molecular neuroscience",
        "title": "Tau-tubulin kinase.",
        "volume": "7",
        "pages": "33",
        "date": "2014-01-01",
        "first": "Ikezu S",
        "last": "Ikezu T",
        "authors": [
          "Ikezu S",
          "Ikezu T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 197,
      "target": 853,
      "key": "098619576e0bfe9a7f391b6f211dd1fc8d17fd016edf014b0e4f3e0c9d0d11ca4691897429c2e3f3da01071fabebba3509a2fe369fac24a27572a99e466cc868"
    },
    {
      "line": 1492,
      "relation": "negativeCorrelation",
      "evidence": "Overexpression of TTBK1 was sufficient in inducing spatial learning impairment in mice, which is associated with enhanced Cdk5 activity and reduction in cell surface level of NR2B. Over-expressionof TTBK1 transgene in JNPL3 mice resulted in accumulation of pre-tangle forms of tau. Inaddition, TTBK1 expression plays a unique role in accelerating motor neuron degeneration and neuroinflammation in JNPL3mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24808823",
        "name": "Frontiers in molecular neuroscience",
        "title": "Tau-tubulin kinase.",
        "volume": "7",
        "pages": "33",
        "date": "2014-01-01",
        "first": "Ikezu S",
        "last": "Ikezu T",
        "authors": [
          "Ikezu S",
          "Ikezu T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 197,
      "target": 777,
      "key": "03c41ced1e0ce7633023d43523c266d4da2cb672776c18b22d27ec17f0f5aeb1fc551eb54f05308643c484ad50bc16e3a4a7171c16ac265e6b5ca6c5fe61ea72"
    },
    {
      "line": 1493,
      "relation": "positiveCorrelation",
      "evidence": "Overexpression of TTBK1 was sufficient in inducing spatial learning impairment in mice, which is associated with enhanced Cdk5 activity and reduction in cell surface level of NR2B. Over-expressionof TTBK1 transgene in JNPL3 mice resulted in accumulation of pre-tangle forms of tau. Inaddition, TTBK1 expression plays a unique role in accelerating motor neuron degeneration and neuroinflammation in JNPL3mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24808823",
        "name": "Frontiers in molecular neuroscience",
        "title": "Tau-tubulin kinase.",
        "volume": "7",
        "pages": "33",
        "date": "2014-01-01",
        "first": "Ikezu S",
        "last": "Ikezu T",
        "authors": [
          "Ikezu S",
          "Ikezu T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "bel",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "bel",
            "name": "cell surface"
          }
        }
      },
      "source": 197,
      "target": 792,
      "key": "c2817188ba7c3d00d783ceb160aa577ff07ed52d5153cbaef1244c9bf106e2c9547d481de865f5e2d133a3e8ba320948c635e3126f03f40dfdce5bf68dec55d9"
    },
    {
      "line": 2806,
      "relation": "negativeCorrelation",
      "evidence": "Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor known to increase the level of many antioxidants, including glutathione-S transferase (GST), and is negatively regulated by the activity of GSK-3β. Our results indicated the increased nuclear localization of Nrf2 and level of GST, suggesting the increased activity of the transcription factor as a result of GSK-3β suppression, consistent with the decreased oxidative stress observed. Consistent with the improved learning and memory, and consistent with GSK-3b being a tau kinase, we observed decreased tau phosphorylation in brain of GAO-treated SAMP8 mice compared to that of RAO-treated SAMP8 mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24355211",
        "name": "Free radical biology &amp; medicine",
        "title": "Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease.",
        "volume": "67",
        "pages": "387-95",
        "date": "2014-02-01",
        "first": "Farr SA",
        "last": "Butterfield DA",
        "authors": [
          "Butterfield DA",
          "Farr SA",
          "Kumar V",
          "Morley JE",
          "Murphy MP",
          "Niehoff ML",
          "Platt TL",
          "Ripley JL",
          "Sultana R",
          "Zhang Z"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "SAMP8 mice": true
        }
      },
      "source": 197,
      "target": 456,
      "key": "40447a57dc94bfc1010697d473dba471640c1856a8d0e3d79ae89daa4d46b0bc97fe98c7495d54ea8b0c9593b28079ad1a5f86141ae29b88e3d4725f61102021"
    },
    {
      "line": 3341,
      "relation": "positiveCorrelation",
      "evidence": "SIRT1 activation or elevation ameliorates pathology and neurodegeneration in AD (Qin et al., 2006; Kim et al., 2007). Loss of SIRT1 induces impairment of learning and memory (Gao et al., 2010; Michán et al., 2010).",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "source": 197,
      "target": 677,
      "key": "dee9503bb8aedbe15a474df3ff4a15284272636cb5e8968b80c392d19004df806b502492923443e8ffc579ff59a2bd0686defbc73867990877b1c7db42e88b78"
    },
    {
      "line": 3649,
      "relation": "negativeCorrelation",
      "evidence": "In 25-month-old mice, the number of errors and the latency in the learning phase negatively correlated with the Sumo3 level in the dorsal hippocampus.",
      "citation": {
        "type": "PubMed",
        "reference": "21843595",
        "name": "Neuroscience letters",
        "title": "Profiles of SUMO and ubiquitin conjugation in an Alzheimer's disease model.",
        "volume": "502",
        "pages": "201-8",
        "date": "2011-09-20",
        "first": "McMillan LE",
        "last": "Cimarosti H",
        "authors": [
          "Brown JT",
          "Cimarosti H",
          "Henley JM",
          "McMillan LE"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 197,
      "target": 850,
      "key": "72a864015ad0ea452a13d8661e9a8fa6491a73dc3683401adce194584713ee39fe811037cc851461639eae6ce6e1d47f5c14ccca5f70e83106973fe6a7fc1dba"
    },
    {
      "line": 1493,
      "relation": "positiveCorrelation",
      "evidence": "Overexpression of TTBK1 was sufficient in inducing spatial learning impairment in mice, which is associated with enhanced Cdk5 activity and reduction in cell surface level of NR2B. Over-expressionof TTBK1 transgene in JNPL3 mice resulted in accumulation of pre-tangle forms of tau. Inaddition, TTBK1 expression plays a unique role in accelerating motor neuron degeneration and neuroinflammation in JNPL3mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24808823",
        "name": "Frontiers in molecular neuroscience",
        "title": "Tau-tubulin kinase.",
        "volume": "7",
        "pages": "33",
        "date": "2014-01-01",
        "first": "Ikezu S",
        "last": "Ikezu T",
        "authors": [
          "Ikezu S",
          "Ikezu T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "bel",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "bel",
            "name": "cell surface"
          }
        }
      },
      "source": 792,
      "target": 197,
      "key": "f8236f81a5cc592e12d814504cb6615ffd4b242027e30ed5f821a439d47c735aacc97f5dfc50881ed224e7f82615819429f7c66c8af51717859815a4305062f1"
    },
    {
      "relation": "hasVariant",
      "source": 792,
      "target": 793,
      "key": "b3aad8f02efcc0089d1421dc76cfaae838a1a5be176a90116dc497ef5fe21e97ac0be3f152e97960724432de288615917f9b623daed698560fb45b80d5fbcf7e"
    },
    {
      "line": 1502,
      "relation": "increases",
      "evidence": "All five SAP kinases generated the AT270 epitope, indicative of phosphorylation of T181 in tau.",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Enzyme_Acitvity": {
          "1 U/ml": true
        }
      },
      "source": 481,
      "target": 577,
      "key": "e9158e7abaf9c0159cfd335fc9ce2fee4bcab6d68823013d972494b978402bba28e1d5d8d2dd067e768fff3a62bfbbc7e28cbe05ace9f7e83cada5f4694f463e"
    },
    {
      "line": 1503,
      "relation": "increases",
      "evidence": "All five SAP kinases generated the AT270 epitope, indicative of phosphorylation of T181 in tau.",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Enzyme_Acitvity": {
          "1 U/ml": true
        }
      },
      "source": 478,
      "target": 577,
      "key": "08f31f7460094a3224bada0a1f09b9324a581dbd72b80bbcedbd5390e4979dc57b7154cf30b765e3bb59331030e09b125a1d3d433dbef84c54533f4a92720bad"
    },
    {
      "line": 1527,
      "relation": "increases",
      "evidence": "Finally, phosphorylation of S422 in tau, as recognisedby antibody AP422, was generated most e¤ciently by SAPK3/p38gamma, SAPK4/p38delta and SAPK2b/p38beta",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Enzyme_Acitvity": {
          "1 U/ml": true
        }
      },
      "source": 478,
      "target": 569,
      "key": "0987d2dc91067267dd89ef62cdbafe88fe459fade6848cfe413d642fcbb53b31bd00c67faed44c68cd43ec816bc8080697d782c9d7c38f13c21d7495acd02034"
    },
    {
      "line": 1504,
      "relation": "increases",
      "evidence": "All five SAP kinases generated the AT270 epitope, indicative of phosphorylation of T181 in tau.",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Enzyme_Acitvity": {
          "1 U/ml": true
        }
      },
      "source": 479,
      "target": 577,
      "key": "6b4cc366d38a989515631339fc7c3ca84cf63651a05dd6e1f27899c9f946a2355dff3eeff995e087aa4417b1d2303910a828d6b0070bbf96bc3c31c660c03930"
    },
    {
      "line": 1512,
      "relation": "increases",
      "evidence": "For AT8, which recognises phosphorylated S202 and T205 in tau, SAPK3/p38gamma gave the strongest labelling",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Enzyme_Acitvity": {
          "1 U/ml": true
        }
      },
      "source": 479,
      "target": 579,
      "key": "9131e45be113d63b85fc7292dbd98e39b3d8079971ff61b03ff89b32868fa35dfcbb90a5f0f3f7144752abdc8136b0f9f48efabd7ae3ea5a31fab434f5cd5f36"
    },
    {
      "line": 1513,
      "relation": "increases",
      "evidence": "For AT8, which recognises phosphorylated S202 and T205 in tau, SAPK3/p38gamma gave the strongest labelling",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Enzyme_Acitvity": {
          "1 U/ml": true
        }
      },
      "source": 479,
      "target": 544,
      "key": "3166caa25bdfc6fbd3a3453eaae3f4fab7978ed12208b3328be49a6051e255358bdba4d3cd9a3dcca30ca41b821a4b4cadc1d1edeeb4957c000dfc9d2653ce96"
    },
    {
      "line": 1516,
      "relation": "increases",
      "evidence": "The AD2 epitope, which corresponds to phosphorylated S396 and S404 in tau, was generated most effectively by SAPK3/p38gamma and SAPK4/p38delta",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Enzyme_Acitvity": {
          "1 U/ml": true
        }
      },
      "source": 479,
      "target": 584,
      "key": "cb95886d29a20b1ff589748f23c04bbf5fe807b7223b91a99317f8da715fa6cd8f1019afc6b37e3044fa7d27432bd280cb84adc9da7b23d7576acc32897d5627"
    },
    {
      "line": 1517,
      "relation": "increases",
      "evidence": "The AD2 epitope, which corresponds to phosphorylated S396 and S404 in tau, was generated most effectively by SAPK3/p38gamma and SAPK4/p38delta",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Enzyme_Acitvity": {
          "1 U/ml": true
        }
      },
      "source": 479,
      "target": 565,
      "key": "554c9658ce2cb3793af052048e055d18354638b26119d399672d897e8224059bbf3b0391ec674d676aa2b407091c39e58db567dff353169c41e3efd5b44fb488"
    },
    {
      "line": 1525,
      "relation": "increases",
      "evidence": "Finally, phosphorylation of S422 in tau, as recognisedby antibody AP422, was generated most e¤ciently by SAPK3/p38gamma, SAPK4/p38delta and SAPK2b/p38beta",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Enzyme_Acitvity": {
          "1 U/ml": true
        }
      },
      "source": 479,
      "target": 569,
      "key": "9c2220eeb260a65c7e9cb6cbc10da895ff3aff40ad395c63c8cec65cca29577efa8d81376f255818715f07e1b161a498f8e1efc936175de41ae4ad23def6da5d"
    },
    {
      "line": 1505,
      "relation": "increases",
      "evidence": "All five SAP kinases generated the AT270 epitope, indicative of phosphorylation of T181 in tau.",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Enzyme_Acitvity": {
          "1 U/ml": true
        }
      },
      "source": 480,
      "target": 577,
      "key": "a73ee3186ddd23e0225f55a237bf9e6f1a397f866c4d75984bd691355d71a3b44e0a0906bfadd3ecdb93a3f9688171210cd133dcdbfed0144724a4681cd6f44f"
    },
    {
      "line": 1518,
      "relation": "increases",
      "evidence": "The AD2 epitope, which corresponds to phosphorylated S396 and S404 in tau, was generated most effectively by SAPK3/p38gamma and SAPK4/p38delta",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Enzyme_Acitvity": {
          "1 U/ml": true
        }
      },
      "source": 480,
      "target": 584,
      "key": "9b5d4d89e1e8f08c5e3bf88a63fe3cf26c729afd5ea776c646a15377ce422874a0ff1c0c2fb1ffc7af2ce830fdfa979b9a16ba4560beea3984e167f341a9e69d"
    },
    {
      "line": 1519,
      "relation": "increases",
      "evidence": "The AD2 epitope, which corresponds to phosphorylated S396 and S404 in tau, was generated most effectively by SAPK3/p38gamma and SAPK4/p38delta",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Enzyme_Acitvity": {
          "1 U/ml": true
        }
      },
      "source": 480,
      "target": 565,
      "key": "ac8a1e6395b425d5fa24fb60066bea0b783e046cc6301b870ae598d11cc07bac118da045d947ef033cfd3da8033c2f4431fbfb88d846b24b86eddba1659e8011"
    },
    {
      "line": 1526,
      "relation": "increases",
      "evidence": "Finally, phosphorylation of S422 in tau, as recognisedby antibody AP422, was generated most e¤ciently by SAPK3/p38gamma, SAPK4/p38delta and SAPK2b/p38beta",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Enzyme_Acitvity": {
          "1 U/ml": true
        }
      },
      "source": 480,
      "target": 569,
      "key": "10370b563c0f86a01f9263da7d0b836dd373fc755fed7bd923a37a88bf5ad5132929ab5dedef47f74aee2d34ab3b595c0194c7fcc0abe4c05c39a1eb418ccac0"
    },
    {
      "line": 1521,
      "relation": "partOf",
      "evidence": "The AD2 epitope, which corresponds to phosphorylated S396 and S404 in tau, was generated most effectively by SAPK3/p38gamma and SAPK4/p38delta",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Enzyme_Acitvity": {
          "1 U/ml": true
        }
      },
      "source": 584,
      "target": 332,
      "key": "96674bbcca4194854ba431a1c45c14a904ce7acc134cebd2d0ce73075c13a812a6f4676ff2bd78dd7d4db3857935f1b2fe51d9a0d03b92329f551cce745b815b"
    },
    {
      "line": 1541,
      "relation": "increases",
      "evidence": "When combined with ERK2 catalyzed phosphorylation, the turn-like disrupting G207V mutation in TauF8 hence leads to fast aggregation that already occurs during the phosphorylation reaction.",
      "citation": {
        "type": "PubMed",
        "reference": "28784767",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Identification of the Tau phosphorylation pattern that drives its aggregation.",
        "volume": "114",
        "pages": "9080-9085",
        "date": "2017-08-22",
        "first": "Despres C",
        "last": "Smet-Nocca C",
        "authors": [
          "Baulieu EE",
          "Byrne C",
          "Cantrelle FX",
          "Chambraud B",
          "Despres C",
          "Huvent I",
          "Jacquot Y",
          "Landrieu I",
          "Lippens G",
          "Qi H",
          "Smet-Nocca C"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "NMR Spectroscopy": true,
          "Thioflavin T Assay": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 477,
      "target": 544,
      "key": "fdb700850b99f2eca859e532b98019d3c5a9e9c91471c77facc5c205bda85e182154ed4ed8ce6e64b8cf67633489b2c1064f48a8bdf5d2ac5813297e1e3cdd5c"
    },
    {
      "line": 1542,
      "relation": "increases",
      "evidence": "When combined with ERK2 catalyzed phosphorylation, the turn-like disrupting G207V mutation in TauF8 hence leads to fast aggregation that already occurs during the phosphorylation reaction.",
      "citation": {
        "type": "PubMed",
        "reference": "28784767",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Identification of the Tau phosphorylation pattern that drives its aggregation.",
        "volume": "114",
        "pages": "9080-9085",
        "date": "2017-08-22",
        "first": "Despres C",
        "last": "Smet-Nocca C",
        "authors": [
          "Baulieu EE",
          "Byrne C",
          "Cantrelle FX",
          "Chambraud B",
          "Despres C",
          "Huvent I",
          "Jacquot Y",
          "Landrieu I",
          "Lippens G",
          "Qi H",
          "Smet-Nocca C"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "NMR Spectroscopy": true,
          "Thioflavin T Assay": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 477,
      "target": 579,
      "key": "3416d6868046f661b2d2434dc727cd801dc8172498170f7d6cd4443f1355bd5cffb015ba9efbe7a0b60e7112454c45bc95245c211c83697cbf595b4ecaff71e3"
    },
    {
      "line": 3914,
      "relation": "negativeCorrelation",
      "evidence": "Since Erk1/2 activity has been shown to induce cdk5 (Harada et al, 2001), miR-125b-induced Erk1/2 activation through DUSP6 downregulation might ultimately stimulate aberrant cdk5/p35 activation and, consequently, enhance pathological tau phosphorylation at multiple sites",
      "citation": {
        "type": "PubMed",
        "reference": "25001178",
        "name": "The EMBO journal",
        "title": "MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease.",
        "volume": "33",
        "pages": "1667-80",
        "date": "2014-08-01",
        "first": "Banzhaf-Strathmann J",
        "last": "Edbauer D",
        "authors": [
          "Arzberger T",
          "Banzhaf-Strathmann J",
          "Benito E",
          "Edbauer D",
          "Fischer A",
          "Kretzschmar H",
          "May S",
          "Tahirovic S"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 477,
      "target": 441,
      "key": "a20d2e9d3da27b4fc450e68ab6fe48acbaeae3bde0f7a9e0477072db3540cb33beb054473e293f4dc894b003552f74c43d757bcf81dd6830e2bafc1c58903eb9"
    },
    {
      "line": 3915,
      "relation": "positiveCorrelation",
      "evidence": "Since Erk1/2 activity has been shown to induce cdk5 (Harada et al, 2001), miR-125b-induced Erk1/2 activation through DUSP6 downregulation might ultimately stimulate aberrant cdk5/p35 activation and, consequently, enhance pathological tau phosphorylation at multiple sites",
      "citation": {
        "type": "PubMed",
        "reference": "25001178",
        "name": "The EMBO journal",
        "title": "MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease.",
        "volume": "33",
        "pages": "1667-80",
        "date": "2014-08-01",
        "first": "Banzhaf-Strathmann J",
        "last": "Edbauer D",
        "authors": [
          "Arzberger T",
          "Banzhaf-Strathmann J",
          "Benito E",
          "Edbauer D",
          "Fischer A",
          "Kretzschmar H",
          "May S",
          "Tahirovic S"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 477,
      "target": 400,
      "key": "0e7fa65b9a36ee27c9abad2ba2f0e571a5840257da083f1d5675a87ade7c2a7f23538842ca1635d5edc30b4b8c422576088c099259189533202c57dde94082ac"
    },
    {
      "line": 1545,
      "relation": "increases",
      "evidence": "When combined with ERK2 catalyzed phosphorylation, the turn-like disrupting G207V mutation in TauF8 hence leads to fast aggregation that already occurs during the phosphorylation reaction.",
      "citation": {
        "type": "PubMed",
        "reference": "28784767",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Identification of the Tau phosphorylation pattern that drives its aggregation.",
        "volume": "114",
        "pages": "9080-9085",
        "date": "2017-08-22",
        "first": "Despres C",
        "last": "Smet-Nocca C",
        "authors": [
          "Baulieu EE",
          "Byrne C",
          "Cantrelle FX",
          "Chambraud B",
          "Despres C",
          "Huvent I",
          "Jacquot Y",
          "Landrieu I",
          "Lippens G",
          "Qi H",
          "Smet-Nocca C"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "NMR Spectroscopy": true,
          "Thioflavin T Assay": true
        }
      },
      "source": 631,
      "target": 201,
      "key": "904cfa730c90888cb34c04ecc96f1ab86e3539cb180af59b129c06f8a8b070f17065e960e1caedf13a52f573731e436d369e230a12e917eb24b3a9cd2abeed6d"
    },
    {
      "line": 1546,
      "relation": "increases",
      "evidence": "When combined with ERK2 catalyzed phosphorylation, the turn-like disrupting G207V mutation in TauF8 hence leads to fast aggregation that already occurs during the phosphorylation reaction.",
      "citation": {
        "type": "PubMed",
        "reference": "28784767",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Identification of the Tau phosphorylation pattern that drives its aggregation.",
        "volume": "114",
        "pages": "9080-9085",
        "date": "2017-08-22",
        "first": "Despres C",
        "last": "Smet-Nocca C",
        "authors": [
          "Baulieu EE",
          "Byrne C",
          "Cantrelle FX",
          "Chambraud B",
          "Despres C",
          "Huvent I",
          "Jacquot Y",
          "Landrieu I",
          "Lippens G",
          "Qi H",
          "Smet-Nocca C"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "NMR Spectroscopy": true,
          "Thioflavin T Assay": true
        }
      },
      "source": 545,
      "target": 111,
      "key": "3efef572861f74499b497cfb8bb8ba1197da6ab71479762185fcbde51699b20cd7dfd0285b64757c7247081690768bca1c8e073cbe7c563a0844977c11a63078"
    },
    {
      "line": 1552,
      "relation": "decreases",
      "evidence": "Our finding that the resulting Tau species with phosphorylation at Ser202/Th205, but with a disrupted turn-like structure, forms abundant fibers detectable by thioflavin fluorescence or electron microscopy (Figs. 2 and 4) suggests the initial turn-like structure induced by the phosphorylation of only Ser202 and Thr205 is protective against aggregation.",
      "citation": {
        "type": "PubMed",
        "reference": "28784767",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Identification of the Tau phosphorylation pattern that drives its aggregation.",
        "volume": "114",
        "pages": "9080-9085",
        "date": "2017-08-22",
        "first": "Despres C",
        "last": "Smet-Nocca C",
        "authors": [
          "Baulieu EE",
          "Byrne C",
          "Cantrelle FX",
          "Chambraud B",
          "Despres C",
          "Huvent I",
          "Jacquot Y",
          "Landrieu I",
          "Lippens G",
          "Qi H",
          "Smet-Nocca C"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "NMR Spectroscopy": true,
          "Thioflavin T Assay": true
        }
      },
      "source": 111,
      "target": 201,
      "key": "2e52494230ef2c7330c0ea28bd61af7e21e6b20a962f2f271f22f935f24661e9efaa770159bed5df5c8d0afc75ca2cb581ad6c2fd6fa489772c66190c3b27a56"
    },
    {
      "line": 1563,
      "relation": "decreases",
      "evidence": "Indeed, Tau phosphorylation at the three positions, Ser202/Thr205/Ser208, while not at Ser262, is sufficient to induce aggregation without the addition of any exogenous aggregation inducer.",
      "citation": {
        "type": "PubMed",
        "reference": "28784767",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Identification of the Tau phosphorylation pattern that drives its aggregation.",
        "volume": "114",
        "pages": "9080-9085",
        "date": "2017-08-22",
        "first": "Despres C",
        "last": "Smet-Nocca C",
        "authors": [
          "Baulieu EE",
          "Byrne C",
          "Cantrelle FX",
          "Chambraud B",
          "Despres C",
          "Huvent I",
          "Jacquot Y",
          "Landrieu I",
          "Lippens G",
          "Qi H",
          "Smet-Nocca C"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "NMR Spectroscopy": true,
          "Thioflavin T Assay": true
        }
      },
      "source": 111,
      "target": 201,
      "key": "efad21c7ca7061855440287b4a65d4e9f5cf22445ce77f1acf3471a2958ed5e4d287e2f84d0bc5378e91a0672d6566aeabc0073ca640f3145467db88fff80f0a"
    },
    {
      "line": 1547,
      "relation": "decreases",
      "evidence": "When combined with ERK2 catalyzed phosphorylation, the turn-like disrupting G207V mutation in TauF8 hence leads to fast aggregation that already occurs during the phosphorylation reaction.",
      "citation": {
        "type": "PubMed",
        "reference": "28784767",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Identification of the Tau phosphorylation pattern that drives its aggregation.",
        "volume": "114",
        "pages": "9080-9085",
        "date": "2017-08-22",
        "first": "Despres C",
        "last": "Smet-Nocca C",
        "authors": [
          "Baulieu EE",
          "Byrne C",
          "Cantrelle FX",
          "Chambraud B",
          "Despres C",
          "Huvent I",
          "Jacquot Y",
          "Landrieu I",
          "Lippens G",
          "Qi H",
          "Smet-Nocca C"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "NMR Spectroscopy": true,
          "Thioflavin T Assay": true
        }
      },
      "source": 609,
      "target": 111,
      "key": "43f49dd906a13d66889569627e9866604eafa1a245698ba3fa8a205471327422d0440633cc504d3968f159f053440c2eb40bd521da54069fdcdaf6a384a27bda"
    },
    {
      "line": 1560,
      "relation": "equivalentTo",
      "evidence": "Indeed, Tau phosphorylation at the three positions, Ser202/Thr205/Ser208, while not at Ser262, is sufficient to induce aggregation without the addition of any exogenous aggregation inducer.",
      "citation": {
        "type": "PubMed",
        "reference": "28784767",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Identification of the Tau phosphorylation pattern that drives its aggregation.",
        "volume": "114",
        "pages": "9080-9085",
        "date": "2017-08-22",
        "first": "Despres C",
        "last": "Smet-Nocca C",
        "authors": [
          "Baulieu EE",
          "Byrne C",
          "Cantrelle FX",
          "Chambraud B",
          "Despres C",
          "Huvent I",
          "Jacquot Y",
          "Landrieu I",
          "Lippens G",
          "Qi H",
          "Smet-Nocca C"
        ]
      },
      "annotations": {
        "Method": {
          "Electron Microscopy, Transmission": true,
          "NMR Spectroscopy": true,
          "Thioflavin T Assay": true
        }
      },
      "source": 546,
      "target": 336,
      "key": "0aca94050bc354228ff2fab06728b2b74aa181c9b23f32e792da595fc726f11186a359d5ed6c692d097c6b7f1062d580761b0fdea8e31467453dc82bbc74587e"
    },
    {
      "line": 1572,
      "relation": "partOf",
      "evidence": "Using the same tau-1 monoclonal antibody and electron microscopy with colloidal gold-labeled secondary antibodies, tau was also found in very low amounts in astrocytes [16] and oligodendrocytes [17], and this was confirmed by tau mRNA expression analysis in the mouse brain [18].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 942,
      "target": 77,
      "key": "3ac68aeb13a26afa2d50705ffd476678f15a925a4873c1cf02e2fb93c4acb1736f175a4f490dc01693bdcb360d981ac797ad1ca5436123f4ff9144ed30eaedfb"
    },
    {
      "line": 1573,
      "relation": "partOf",
      "evidence": "Using the same tau-1 monoclonal antibody and electron microscopy with colloidal gold-labeled secondary antibodies, tau was also found in very low amounts in astrocytes [16] and oligodendrocytes [17], and this was confirmed by tau mRNA expression analysis in the mouse brain [18].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 942,
      "target": 78,
      "key": "d3c5ff36cc0ebe28357606e9e92086703988b30bcb25f664577ba515e8a5986a47c1a7232bd2f58020904e4356636460286895392a9a1ae08e5a37f7ef460875"
    },
    {
      "line": 1579,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 589,
      "target": 908,
      "key": "fc1e16d3e43c097079610881ff36a7d5c83ef0e92d8140430f84dba31e58bff7cc9e72340c87dde38539b88c385c4b567b22dc4d939e0cbb5ee31839942fd3a7"
    },
    {
      "line": 2208,
      "relation": "positiveCorrelation",
      "evidence": "We found an increase in Syk activation in DNs surrounding Aβ deposits as well as in neurons displaying an accumulation of phosphorylated Tau at Y18 and elevated levels of MC1 pathogenic tau conformers in AD brain sections whereas only weak immunoreactivity for pSyk was observed in brain sections from a non-demented control",
      "citation": {
        "type": "PubMed",
        "reference": "28877763",
        "name": "Acta neuropathologica communications",
        "title": "Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.",
        "volume": "5",
        "pages": "69",
        "date": "2017-09-06",
        "first": "Schweig JE",
        "last": "Paris D",
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Mouzon B",
          "Mullan M",
          "Paris D",
          "Schweig JE",
          "Yao H"
        ]
      },
      "source": 589,
      "target": 706,
      "key": "0a876ed8bbd11ff76e5f9977d9e6979f66af5e5bd9d7b0402f685b2136fd3d907cf7b322d667ac454eaf6346a248d7c01cd4e4ceed473fc7eff4d370648b4a7e"
    },
    {
      "line": 1580,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 572,
      "target": 908,
      "key": "e8fb2e852d01edea8f6964696cc3ef47fb4eae7338eaefbe25f0ea14335085b3d596b4aef89578f7eda895a35d8b78cf42d413142854e3e0baa9923c8912fa36"
    },
    {
      "line": 1581,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 587,
      "target": 908,
      "key": "e0ddd3dc7ad26d80f50c57a146496ec96ea7275550900e90301cd17b7e880e44eef88c8da39c478955f9307dbfd86eae242e2b69e9eecdf40e2d29825cfdd3ec"
    },
    {
      "line": 1582,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 588,
      "target": 908,
      "key": "cfcba9f7d43462ce9ac835d6febbb5ab118100512283f634279129329f3f7a67d42e5c32b7477ce8f98c3e1a3bece0dddfa7c5b6ae091fa4d390c9661891e9d3"
    },
    {
      "line": 1583,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 539,
      "target": 908,
      "key": "c67fb751dedba8ab132cb9971667154d3355e5289d6dcd136ab559b6fc0634c9d11a6df44c7a84830e87b3449ce74497a57d7dd61c8c51dff410e39181c4c6fe"
    },
    {
      "line": 1584,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 573,
      "target": 908,
      "key": "18e9f750e95fb6f123839c0871d7d3f2ec11db2d9dfc7b11c4b918fb306137c9fd31745f52b415beb24dd5a8d5b3edbdf25421c0f7d084d0222c8c6448480f2f"
    },
    {
      "line": 1585,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 574,
      "target": 908,
      "key": "6f85e96a3bd2bfc3384794b2d1f2cfc330170f9095cc27ae9ec8f92b97f81729e24cca80a24421f3ca8e6dc4bb17c4ee7b954eed019142fe9257361455b7ae9a"
    },
    {
      "line": 1586,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 576,
      "target": 908,
      "key": "5ac79358f2bb6e39592168f92a34b50c278378f23c96266407576e9effb11ac67835ba906271d917fca87796ecc8ce1e4c6062111fbae98de035fbc5b62d9657"
    },
    {
      "line": 1587,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 578,
      "target": 908,
      "key": "e4bb6c8bb7a182595a6fab4442b0baa42ec3a1d892690f0722a9505ded1355bee46c08da3f6d191255f2e91649b716e7e93cebcc1ee68b46baeecbdcf2d8c59b"
    },
    {
      "line": 1588,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 540,
      "target": 908,
      "key": "458cf9a627e62157c7acdc48912a40540f97478da48f85b05c57bfe89466fac75049fb979445d7368dc4769b57ec8882426115c8d2c21920b2a105cf8e5adfe5"
    },
    {
      "line": 1589,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 541,
      "target": 908,
      "key": "983026ec0ad5223593e5a8ee6fcbabefbdb46806b0113340993492464738b09a172237280c0209598920faac92ed06d053000b5122f025e0c35a368e8e6692d6"
    },
    {
      "line": 1590,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 590,
      "target": 908,
      "key": "4cf017f9f7181d44b7eb217ad0fa36d664d0bb190a4587fbaffc1cf4ff2a3eff4a327e06ef6a6d49ea9854dcadf639312197d7a36f8f39084bceb9e316043b46"
    },
    {
      "line": 1594,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 553,
      "target": 908,
      "key": "e518fe4a49e3f8a640e001e4c60b7cc424187d760a7b5ddd53b02ba66f6c4a24e3bb0e9f1d6bded91ee4ddf2724b097a7e2a576976458c0b2b1f7f9b9a170adf"
    },
    {
      "line": 1595,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 554,
      "target": 908,
      "key": "ac27090db1aba6a0df5f1d53b9b908f0c0ebf8c55f836e8f028ecde0c067983606c73b7580a5e00f76e425838549cd0b3c767da12456868967f6fec6f4be0166"
    },
    {
      "line": 1596,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 555,
      "target": 908,
      "key": "0744df10a89f1e831d7dcfdb78eaa3ee6ce838843931cc065165f6cddbe024b9675ea71b96c80c9690f8dbf5934cbd48c80d25ddcb958e941bb7dec22a8750cd"
    },
    {
      "line": 1597,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 557,
      "target": 908,
      "key": "ffe94231170c9b77a28a345bfd697ccfc9abae84fca5b58938962a3eac8ceda5d09e78be0fc3549ff544f34e28cd9489a8f9117e01e3fc90cfcf0ff9deecbbd5"
    },
    {
      "line": 1768,
      "relation": "positiveCorrelation",
      "evidence": "Immunohistochemical analyses using isoform-selective antibodies demonstrated that MARK4 in a phosphorylated form colocalizes with p-tau Ser262 in granulovacuolar degeneration bodies (GVDs) that progressively accumulate in AD.",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 557,
      "target": 636,
      "key": "c34daad4093e6e66ef19712d94ef6d5240099dd2c0c169aa711cf5d1a81aaa26aec3c08980640a1c5a08ed8d6da1b51592216f4e25699f553c9e07adbe86b4a0"
    },
    {
      "line": 1770,
      "relation": "positiveCorrelation",
      "evidence": "Immunohistochemical analyses using isoform-selective antibodies demonstrated that MARK4 in a phosphorylated form colocalizes with p-tau Ser262 in granulovacuolar degeneration bodies (GVDs) that progressively accumulate in AD.",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 557,
      "target": 129,
      "key": "ef38de7e10ad61eba5656004f1391a605282c706a69b88ccfe32913ab72a731ec37da92a2c6475c32b459531b6bdb23deeb34e1510b68eee689b673f862d8a02"
    },
    {
      "line": 1775,
      "relation": "partOf",
      "evidence": "It has been reported that serine 262 in tau, which is specifically phosphorylated by MARK, is in a hyperphosphorylated form in the neurofibrillary deposits found in Alzheimer’s disease brains (15).",
      "citation": {
        "type": "PubMed",
        "reference": "22692785",
        "name": "International journal of molecular medicine",
        "title": "Reduction of protein kinase MARK4 in the brains of experimental scrapie rodents and human prion disease correlates with deposits of PrP(Sc).",
        "volume": "30",
        "pages": "569-78",
        "date": "2012-09-01",
        "first": "Gong HS",
        "last": "Dong XP",
        "authors": [
          "Chen C",
          "Dong XP",
          "Gong HS",
          "Guo Y",
          "Liu Y",
          "Shi Q",
          "Tian C",
          "Wang SB",
          "Xie WL",
          "Xu Y",
          "Zhang BY",
          "Zhang J"
        ]
      },
      "source": 557,
      "target": 81,
      "key": "08ae7cf48353f898f06142001e91c8eb894e782b518304a1fd767f2e29b91893fd2e4017756f7e7a6e14584a54029ca79f1e8d8ad1daa60ec55c2b2dfaa6d165"
    },
    {
      "line": 1800,
      "relation": "positiveCorrelation",
      "evidence": "We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "annotations": {
        "Tau_Motif": {
          "KXGS": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 557,
      "target": 759,
      "key": "3fe9b4921687fef769242ce91f79ce2c79dff377c1dfdaf8df93feb1f34dc1c1f97a8920a2afbb4b2b362942a201a6aa8e21874a445e4bf4d2511a6aaf52220a"
    },
    {
      "line": 1802,
      "relation": "partOf",
      "evidence": "We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "annotations": {
        "Tau_Motif": {
          "KXGS": true
        }
      },
      "source": 557,
      "target": 113,
      "key": "172b4f80ff8146fa156aa5a3e69b7e359ef69e53ec0fff8b577703b5a2192d6348c455b2f4a0cddc1c02f61a2b78dd7d3e1dda566b456d2749458536363c66d9"
    },
    {
      "line": 2000,
      "relation": "negativeCorrelation",
      "evidence": "These data suggest that tau hyperphosphorylation at Thr231, Ser262, and Ser396 by DAPK1 renders the cells more resistant to the kinase-induced apoptotic cell death, providing new insights into the tau-involved apoptotic abortion in the course of chronic neurodegeneration.",
      "citation": {
        "type": "PubMed",
        "reference": "23948915",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Phosphorylation of tau by death-associated protein kinase 1 antagonizes the kinase-induced cell apoptosis.",
        "volume": "37",
        "pages": "795-808",
        "date": "2013-01-01",
        "first": "Duan DX",
        "last": "Liu GP",
        "authors": [
          "Chai GS",
          "Chen NN",
          "Cheng XS",
          "Duan DX",
          "Hu Y",
          "Liu GP",
          "Luo Y",
          "Ni ZF",
          "Wang JZ"
        ]
      },
      "source": 557,
      "target": 174,
      "key": "cb354457e55dae9d9ae05b935efd51696e6bc1192f69c9a4f3d89241413827ec4a9f77e736292ffebdd8806440ce79883155cd1bd67f169c8c8ac4dd89fdb1c2"
    },
    {
      "line": 2333,
      "relation": "negativeCorrelation",
      "evidence": "Endogenous miR-195 was knocked down using over-expression of its antisense molecule (pre-AMO-miR-195) via a lentivirus (lenti-pre-AMO-miR-195); this knockdown increased the tau phosphorylation at Ser202/Thr205, Ser262, Thr231, Ser422, and the Cdk5/p25 activation, but over-expression of miR-195 using lenti-pre-miR-195 decreased the tau phosphorylation and Cdk5/p25 activation.",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 557,
      "target": 264,
      "key": "8dc295ba2cbee47919f40cbc242a1aa8fb019653f38e59fcc6964a45d2f69d01d82108f4ad0f77ad2afeb3f8b3d5b616b84ba024403a4a6776ad1288c8c93857"
    },
    {
      "line": 2508,
      "relation": "positiveCorrelation",
      "evidence": "Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Research_Model": {
          "rTg4510 mice": true
        }
      },
      "source": 557,
      "target": 513,
      "key": "e2e3c918cf9306ca3c8291bc0ca33a4e77b6d87a3fdd302fe4affe56ccf2d55d25eb98e0c32774b2ee7483594eeb0784d0a4e9dfe9a1ae6afd6749d1099deded"
    },
    {
      "line": 2759,
      "relation": "positiveCorrelation",
      "evidence": "Using transgenic Drosophila expressing human tau, we found that RNAi-mediated knockdown of milton or Miro, an adaptor protein essential for axonal transport of mitochondria, enhanced human tau-induced neurodegeneration. Tau phosphorylation at an AD-related site Ser262 increased with knockdown of milton or Miro; and partitioning defective-1 (PAR-1), the Drosophila homolog of mammalian microtubule affinity-regulating kinase, mediated this increase of tau phosphorylation. Tau phosphorylation at Ser262 has been reported to promote tau detachment from microtubules, and we found that the levels of microtubule-unbound free tau increased by milton knockdown. Blocking tau phosphorylation at Ser262 site by PAR-1 knockdown or by mutating the Ser262 site to unphosphorylatable alanine suppressed the enhancement of tau-induced neurodegeneration caused by milton knockdown. Furthermore, knockdown of milton or Miro increased the levels of active PAR-1.",
      "citation": {
        "type": "PubMed",
        "reference": "22952452",
        "name": "PLoS genetics",
        "title": "Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1.",
        "volume": "8",
        "pages": "e1002918",
        "date": "2012-01-01",
        "first": "Iijima-Ando K",
        "last": "Iijima KM",
        "authors": [
          "Iijima KM",
          "Iijima-Ando K",
          "Lu B",
          "Maruko-Otake A",
          "Ohtake Y",
          "Sekiya M",
          "Suzuki E"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "source": 557,
      "target": 143,
      "key": "f4b88f465c6a572761ce36c72df5739ccaf9880fe71cf66239d7c2d9ca6d1633080d2ec9f794144439765ece33a7b4dbf563b1a65c72b3d0300531e0254d107e"
    },
    {
      "line": 1598,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 558,
      "target": 908,
      "key": "5ba262ecd81609b34de528d8ff5ab8c503e0598ec5893384bcf94eeefe82a93fc77c11ebc1ffa1c49b6399417b2b849866f0dfa6f1b16661f697181b465ff1d3"
    },
    {
      "line": 1599,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 563,
      "target": 908,
      "key": "e36b4fa72d09609ecaff933f5a3dae911fec47fe95c23b19f850b94886c8741f96fce7ff6d71008101b298e45557b10a3c3e0f73ac4dfc85dee54868f63398b0"
    },
    {
      "line": 1801,
      "relation": "positiveCorrelation",
      "evidence": "We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "annotations": {
        "Tau_Motif": {
          "KXGS": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 563,
      "target": 759,
      "key": "13d8c8174c6b7d2b0ac645866ce644d327470232d7dce67043a648ed1da85162e498f9f42f21cb97920a1efa9e685c359cae53992a9b9de71d0e3002aad13f69"
    },
    {
      "line": 1803,
      "relation": "partOf",
      "evidence": "We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "annotations": {
        "Tau_Motif": {
          "KXGS": true
        }
      },
      "source": 563,
      "target": 113,
      "key": "02db8be044b823652c2745808d0fd1d1e1a6fdd3bdf6908ffd1fda88e3ddad0b00b96a5f6bca434dfc6379f47d39405d0354e1419ee3594d8dd8770a033d52fc"
    },
    {
      "line": 2509,
      "relation": "positiveCorrelation",
      "evidence": "Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Research_Model": {
          "rTg4510 mice": true
        }
      },
      "source": 563,
      "target": 513,
      "key": "8704fdf47e89d1ed04e144341ed955b80affd57d5cf583ed51fe4fe92bb5fb896a93d8e9fe8377963971650a86fb221e97a049a3098989246ca4ffe04d3aa9b1"
    },
    {
      "line": 1600,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 592,
      "target": 908,
      "key": "b0e2748ab9d57bc250d5d7062271916cb710fe577bc441ddbd74a67c5ecb48aad9b9d58b7c567afcd84e7e3fe88322f6b3d625722093b9bde5e64369a509c537"
    },
    {
      "line": 1601,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 585,
      "target": 908,
      "key": "8e5d9d7f608e8219797f3dcb9d7fdf05be13fea764c7d3ce7ce6c7104fdb520ac44baf2a3cc12d02f843842b86889fc41def0c88610ac5b8402756b1263dd681"
    },
    {
      "line": 1602,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 566,
      "target": 908,
      "key": "5bf9e384246c7807dd4f3726275e8982a9c0e7746422a05acb95103b3cc1c3bdf8bab185f3eff1564a8aea177058c2568a24a893e98a94ebcdadb27b7cedab4f"
    },
    {
      "line": 1603,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 571,
      "target": 908,
      "key": "65c403254636d27e19e7cfdf92aeee359414183d42c81b26bd316086a207881f4f420457769fd5875f2419bc208b3a5f3ecedad7daf033b77cc0b5d22a55fcbd"
    },
    {
      "line": 1604,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 586,
      "target": 908,
      "key": "8e74d4e43b7ea16f1e5b8a9fad175ec232634bfb7fae33678bc9a153b9f1b77066106e3ea3c4abc5d9a2673a2d7ffdbfb89cd203cdc4adc65d443128eec0836c"
    },
    {
      "line": 1605,
      "relation": "positiveCorrelation",
      "evidence": "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies. Red color denotes amino acids phosphorylation in AD brain.",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 570,
      "target": 908,
      "key": "3771e9a88a0c0980d7101675294841949b34b5b09cb1ec4456cb35bbf9addc81faeb7b5f37865d56d1edab7c0bf0fa6d300a614ed6d26a26c382171384ec3d97"
    },
    {
      "line": 1612,
      "relation": "association",
      "evidence": "Apart from binding to MT, the repeat domains of tau also bind to tubulin deacetylase, histone deacetylase 6 (HDAC6) [68] and apolipoprotein E (apoE) more with the ",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 459,
      "target": 130,
      "key": "f11a0481e4ec8f741d58329b357b25fb928012c4fe0787a174b4fa364b62616461b5c47cd2b25bf866277e077c167f4f81392344fb68c1209877a25b341e4ac0"
    },
    {
      "line": 2661,
      "relation": "positiveCorrelation",
      "evidence": "We demonstrate that elevated HDAC6 activity increases phosphorylation of tau at the 12E8 epitope (pS262/356), a phospho-epitope present within the KXGS motifs of tau’s microtubule-binding domain. The phosphorylation of KXGS motifs within tau by the kinase Par-1/MARK2 is required for tau proteotoxicity in Drosophila [29], observed at very early stages of NFT formation in AD brain [30], and appears to prime tau for subsequent phosphorylation events",
      "citation": {
        "type": "PubMed",
        "reference": "25031639",
        "name": "Alzheimer's research &amp; therapy",
        "title": "Acetylation: a new key to unlock tau's role in neurodegeneration.",
        "volume": "6",
        "pages": "29",
        "date": "2014-01-01",
        "first": "Cook C",
        "last": "Petrucelli L",
        "authors": [
          "Carlomagno Y",
          "Cook C",
          "Petrucelli L",
          "Stankowski JN",
          "Stetler C"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 459,
      "target": 113,
      "key": "18955013986eef5cf59be4f2f98d9dd7055bd2ff17754adde1cd89efa57f82984e6fe0a4a5b48670d444addabe0057607ad5d1805728bd2a46919fddbd03a7db"
    },
    {
      "line": 2979,
      "relation": "negativeCorrelation",
      "evidence": "In the present study, we tested the potential of two selective HDAC6 inhibitors, tubastatin A and ACY-1215, to rescue cognitive deficits in a mouse model of AD. We found that both tubastatin A and ACY-1215 alleviated behavioral deficits, altered amyloid-β (Aβ) load, and reduced tau hyperphosphorylation in AD mice without obvious adverse effects. Our data suggested that tubastatin A and ACY-1215 not only promoted tubulin acetylation, but also reduced production and facilitated autophagic clearance of Aβ and hyperphosphorylated tau.",
      "citation": {
        "type": "PubMed",
        "reference": "24844691",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice.",
        "volume": "41",
        "pages": "1193-205",
        "date": "2014-01-01",
        "first": "Zhang L",
        "last": "Qin C",
        "authors": [
          "Huang L",
          "Liu C",
          "Qin C",
          "Sheng SL",
          "Sui XL",
          "Tao JJ",
          "Wu J",
          "Xu YF",
          "Yao ZG",
          "Zhang L",
          "Zhu H"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 459,
      "target": 303,
      "key": "56f3b1e0243f645081512257956e402d192a0b0df71b7715ba33a561b0ed44d71cb8662aa8d502f5a5fc2f2c55ad8afc00b5b062b65e5cd090d3d0326111c2cb"
    },
    {
      "line": 3011,
      "relation": "negativeCorrelation",
      "evidence": "The N-terminus of β-catenin has phosphorylation, ubiquitination, and acetylation sites that regulate its stability and signaling. In the absence of a Wnt signal, Ser33, Ser37, and Thr41 are constitutively phosphorylated by glycogen synthase kinase 3β (GSK3β). β-Catenin phosphorylated at these sites is recognized by β-transducin repeat-containing protein (βTrCP), which results in ubiquitination and degradation by the ubiquitin-proteasome pathway. The N-terminal regulatory domain of β-catenin also includes Ser45, a phosphorylation site for Casein Kinase 1α (CK1α) and Lys49, which is acetylated by the acetyltransferase p300/CBP-associated factor (PCAF). The relevance of Lys49 acetylation and Ser45 phosphorylation to the function of β-catenin is an active area of investigation. We find that HDAC6 inhibitors increase Lys49 acetylation and Ser45 phosphorylation but do not affect Ser33, Ser37, and Thr41 phosphorylation. Lys49 acetylation results in decreased ubiquitination of β-catenin in the presence of proteasome inhibition. While increased Lys49 acetylation does not affect total levels of β-catenin, it results in increased membrane localization of β-catenin.",
      "citation": {
        "type": "PubMed",
        "reference": "25546293",
        "name": "ACS chemical biology",
        "title": "HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of β-catenin in human iPSC-derived neuronal cells.",
        "volume": "10",
        "pages": "883-90",
        "date": "2015-03-20",
        "first": "Iaconelli J",
        "last": "Karmacharya R",
        "authors": [
          "Berkovitch SS",
          "Chattopadhyay S",
          "Haggarty SJ",
          "Huang JH",
          "Iaconelli J",
          "Karmacharya R",
          "Mazitschek R",
          "Schreiber SL"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 459,
      "target": 421,
      "key": "03bb5100a720538a02b8a8b874324295c880090b3b79e7a4b1d9fed1b4ffbc16b0f386849e93871c9d5801dbc0b62b94303de8fbf6a57e15918c531f374b5db7"
    },
    {
      "line": 3261,
      "relation": "negativeCorrelation",
      "evidence": "Overexpressed tau was hyperphosphorylated and resulted in decreased MT density and greater fragmentation. Using genetic screen, a histone deacetylase 6 (HDAC6) null mutation rescued tau-induced MT defects in both muscles and neurons. Genetic and pharmacological inhibition of the tubulin-specific deacetylase activity of HDAC6 indicates that the rescue effect may be mediated by increased MT acetylation.",
      "citation": {
        "type": "PubMed",
        "reference": "23487739",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila.",
        "volume": "110",
        "pages": "4604-9",
        "date": "2013-03-19",
        "first": "Xiong Y",
        "last": "Zhang YQ",
        "authors": [
          "Jin S",
          "Wu J",
          "Xiong Y",
          "Xu Z",
          "Zhang YQ",
          "Zhao K"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 459,
      "target": 87,
      "key": "8ee1fd16d66f7544fd77683bd55dfb68e35035a8365e5bc4b10c05080c540d0f9b7a2be29e18cee92882f8489e63694526ba0baeec1c64672480a1c6735d175c"
    },
    {
      "line": 3262,
      "relation": "decreases",
      "evidence": "Overexpressed tau was hyperphosphorylated and resulted in decreased MT density and greater fragmentation. Using genetic screen, a histone deacetylase 6 (HDAC6) null mutation rescued tau-induced MT defects in both muscles and neurons. Genetic and pharmacological inhibition of the tubulin-specific deacetylase activity of HDAC6 indicates that the rescue effect may be mediated by increased MT acetylation.",
      "citation": {
        "type": "PubMed",
        "reference": "23487739",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila.",
        "volume": "110",
        "pages": "4604-9",
        "date": "2013-03-19",
        "first": "Xiong Y",
        "last": "Zhang YQ",
        "authors": [
          "Jin S",
          "Wu J",
          "Xiong Y",
          "Xu Z",
          "Zhang YQ",
          "Zhao K"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 459,
      "target": 768,
      "key": "f48583a07613cc60a15105ac2ad12a07da64d6050dd11e3a049bb4228085c02949693c8611bf77b57ed9a04a1e20f75d48d65f4a821adb23c164a78469b71321"
    },
    {
      "line": 3365,
      "relation": "positiveCorrelation",
      "evidence": "HDAC6 inhibition leads to a significant reduction in tau levels as detected by the human tau-specific antibody E1 (Fig. 6 (a and c) and supplemental Fig. S6). We also observed a striking decrease in phosphorylation at Ser-324, which was statistically significant even when normalizing to E1 to control for the reduction in tau levels (Fig. 6 (a and b) and supplemental Fig. S6).",
      "citation": {
        "type": "PubMed",
        "reference": "28760828",
        "name": "The Journal of biological chemistry",
        "title": "An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.",
        "volume": "292",
        "pages": "15277-15286",
        "date": "2017-09-15",
        "first": "Carlomagno Y",
        "last": "Cook C",
        "authors": [
          "Carlomagno Y",
          "Castanedes-Casey M",
          "Chung DC",
          "Cook C",
          "DeTure M",
          "Dickson DW",
          "Dunmore J",
          "Madden BJ",
          "Petrucelli L",
          "Tong J",
          "Yue M"
        ]
      },
      "source": 459,
      "target": 486,
      "key": "a125d6df6bfe80e66d1ed9e3ccd39432953ea1f9f43a60c1f692afbe2dd716b2f88a5d0592513f3c3264d8623740c12dabffbe52e59f4de631061f47e2d68e23"
    },
    {
      "line": 3366,
      "relation": "positiveCorrelation",
      "evidence": "HDAC6 inhibition leads to a significant reduction in tau levels as detected by the human tau-specific antibody E1 (Fig. 6 (a and c) and supplemental Fig. S6). We also observed a striking decrease in phosphorylation at Ser-324, which was statistically significant even when normalizing to E1 to control for the reduction in tau levels (Fig. 6 (a and b) and supplemental Fig. S6).",
      "citation": {
        "type": "PubMed",
        "reference": "28760828",
        "name": "The Journal of biological chemistry",
        "title": "An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.",
        "volume": "292",
        "pages": "15277-15286",
        "date": "2017-09-15",
        "first": "Carlomagno Y",
        "last": "Cook C",
        "authors": [
          "Carlomagno Y",
          "Castanedes-Casey M",
          "Chung DC",
          "Cook C",
          "DeTure M",
          "Dickson DW",
          "Dunmore J",
          "Madden BJ",
          "Petrucelli L",
          "Tong J",
          "Yue M"
        ]
      },
      "source": 459,
      "target": 561,
      "key": "629987366b04c82a2159841db71a4539954fa36208e90aae8843b13ee3068a302dcc6b4632367f20939448e2658b4db983b970dcbec7f074fa888fb171a08e17"
    },
    {
      "line": 3392,
      "relation": "positiveCorrelation",
      "evidence": "This study aimed to investigate the protective effects and mechanism of the novel HDAC6 inhibitor, MPT0G211, using an AD model. Our results indicated that MPT0G211 significantly reduced tau phosphorylation and aggregation, the processes highly correlated with the formation of NFTs. This HDAC6 inhibitory activity resulted in an increase in acetylated Hsp90, which decreased Hsp90 and HDAC6 binding, causing ubiquitination of phosphorylated tau proteins. In addition, a significant increase of phospho-glycogen synthase kinase-3β (phospho-GSK3β) on Ser9 (the inactive form) through Akt phosphorylation was associated with the inhibition of phospho-tau Ser396 in response to MPT0G211 treatment.",
      "citation": {
        "type": "PubMed",
        "reference": "29844403",
        "name": "Cell death &amp; disease",
        "title": "The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.",
        "volume": "9",
        "pages": "655",
        "date": "2018-05-29",
        "first": "Fan SJ",
        "last": "Yang CR",
        "authors": [
          "Fan SJ",
          "Huang FI",
          "Liou JP",
          "Yang CR"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true,
          "SH-SY5Y": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 459,
      "target": 758,
      "key": "bcdf8edfc7d3fbec5ab8f31f7e06ed890ed2115cf1884ca57b50e66efd26f12e5af4d1bbfe6072bced8531bce2dd967f48bb3d207931aa334477e2a6e3da18ee"
    },
    {
      "line": 1613,
      "relation": "association",
      "evidence": "Apart from binding to MT, the repeat domains of tau also bind to tubulin deacetylase, histone deacetylase 6 (HDAC6) [68] and apolipoprotein E (apoE) more with the ",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 308,
      "target": 362,
      "key": "80b2847b1d38fbe739bb686ec9f0a8c73e85c57fd522ad03c8e489a155f975a1e402d94df0a5b875b7f61190fa7c4d54dbfbca2d04e4e1c117e9ddf7bd77b9ac"
    },
    {
      "line": 1622,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 134,
      "target": 467,
      "key": "4c13a0bd3869116278142d0715e54d3536fa16009c56402806c35ee886f2ba0eddbae8d5c34e77b8c526e9cc96154dd49514f95214695ed28f6b96701bf5fcc8"
    },
    {
      "line": 1623,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 134,
      "target": 448,
      "key": "3ca60cd2271d1f423a6425ebfcfb51133a794cace0bf2b04713cae4fa5f61f3b26bee04de5d55d88c7bd629856e20a37f70212cafb06f58acaab2d033e875370"
    },
    {
      "line": 1624,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 134,
      "target": 688,
      "key": "5f3f4ac99a3d0623d9930779ae36480bf6ba264214ce6008f8a9dc9d470036e82b591afa4c5e313b089b6c4f2c8fa97c1ae48116b5329aa98260266032a4c7bd"
    },
    {
      "line": 1625,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 134,
      "target": 452,
      "key": "b412a090412fcccdcd108e680468750097145f377e5c0273859da5de185a3a5681e5a289068d7fb09f8032214db6d7dfd6440e07c871d72902bf8926e1b5fe8e"
    },
    {
      "line": 1626,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 134,
      "target": 300,
      "key": "d8c9eb37f5471ba1711c1a2449de9784dbeb1c0f43bfd09dde2925bbdf626b49728978164c1b1f1aadde8a00020bae85e7b73e92a330c723d06c4b4801a2e85f"
    },
    {
      "line": 1627,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 134,
      "target": 66,
      "key": "b9ab4e41387e40199872d6764c9954e0767959d645b83cddba806af894bd0619f8bb2f37d22f1ca5580e1d6095dff2860699a3542b113dbcaf4d82cbb6ae6d1f"
    },
    {
      "line": 1628,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 134,
      "target": 28,
      "key": "cbaa2b20471378d160dd12107119ca59daaa46118ef03922e8ca794c250e7004eb15208c72826bd2e69b0c9559bc270509c54b2831647cce9c626acc23be7c81"
    },
    {
      "line": 1629,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 134,
      "target": 647,
      "key": "e07429103a51b6597b2850d46be8019827c9c7936ede8b958f497fa03d20dd8b47e025764fe4281ad60b899abaf64ff99f023c09fdc33356785818144d115d1d"
    },
    {
      "line": 1631,
      "relation": "partOf",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 134,
      "target": 486,
      "key": "9fcb971dc5e42eed1610a34e8ec8f6a82afc96bea98705b4a7010e13f59bc7961e1c782d8206e77db084263c79e80ab00330c06bed6f38e2f1b80ef35f983783"
    },
    {
      "line": 1635,
      "relation": "association",
      "evidence": "In synapses, the projection domain of tau interacts with protein kinase Fyn (plays an important role during myelination [75]), postsynaptic density protein 95 (PSD-95) [76], and N-methyl-D-aspartate receptors (NMDAR).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 134,
      "target": 450,
      "key": "fc455ab13ecd177ce68f0a566af4c2c2d59dd88aaeef1e8716e1380981383a38ec309b80cf3a2049df81532f0aebee853f86bf4b7649a7791129c70f1fe85303"
    },
    {
      "line": 1636,
      "relation": "association",
      "evidence": "In synapses, the projection domain of tau interacts with protein kinase Fyn (plays an important role during myelination [75]), postsynaptic density protein 95 (PSD-95) [76], and N-methyl-D-aspartate receptors (NMDAR).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 134,
      "target": 438,
      "key": "a785b5e7d80dc67d9aee128b3a2276d79b56e9a1199013483a6f3dd138dfbb7441b5a80102fc29e232f7d5e93cd7137514b34ce3f97aacf72630a671c50f8294"
    },
    {
      "line": 1637,
      "relation": "association",
      "evidence": "In synapses, the projection domain of tau interacts with protein kinase Fyn (plays an important role during myelination [75]), postsynaptic density protein 95 (PSD-95) [76], and N-methyl-D-aspartate receptors (NMDAR).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 134,
      "target": 769,
      "key": "b4e4c65d0fdff3f6b8fd962e53de05e22d49b134e7b42d7cc9dd150193269f50493c588f536d4f02cc457cc037deffe7a29641ba124db1bf41c67711ad57aa7a"
    },
    {
      "line": 1622,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 467,
      "target": 134,
      "key": "540201637442973ecf4f6100b038d659f91ccac9dafd93ab54a4bbb12b6a1242893eba44e081954fc22616a69ac0d0e302e037944164ebe7d7aece3e840ff4d0"
    },
    {
      "line": 1623,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 448,
      "target": 134,
      "key": "9bba87b8832ac1bb62d195b7dfb8d8f18e30e3ecbc7e3cd154cdd242805987f7013536110888cc992c3897d50c4794feecd7811828943a36024caa614457d3c5"
    },
    {
      "line": 1624,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 688,
      "target": 134,
      "key": "b3f5c4ba498a3f9dd6c546ccdc7b4074a5f7b2844b686703bc3b4a975fa2d3d9fcf5d1a73a9c68aba5a9e7b8baa6c22a790ec787352c98abd723a956e536d3bc"
    },
    {
      "line": 1625,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 452,
      "target": 134,
      "key": "0f9c00d35acaee49ab5204c75a29a65199ce807c01ed5e9a0806ee6370371c852ff5a436900fb8a98e89578b41dd105eda762dc829426fca94285a3e0f7124ad"
    },
    {
      "line": 1626,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 300,
      "target": 134,
      "key": "4d94e0aaee4257ad13373ed57a9b8ccc30eabc547af8f887dbfa0e2d0e1e5337f8539b294228c5bfed491c60cf5faabfbee5a8dbfb22de032d14892d773ed294"
    },
    {
      "line": 1627,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 66,
      "target": 134,
      "key": "6863687999172b7570d5b9775a16a36d45b765014116aa54862a516232789f08a3efd90fa47d0b95254a60ba54724cb155f0e41f60886013ee4377ed47ba55d7"
    },
    {
      "line": 1628,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 28,
      "target": 134,
      "key": "455a9dd30f84f0702a62bd2721d581bbd4eb90a9966e9db20b72b1c5939dfab66b1b8c540fd68de774bbc820f9b77e8dfbce4ddeb311efc54436ee125e6a1b82"
    },
    {
      "line": 1629,
      "relation": "association",
      "evidence": "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases), growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1, and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 647,
      "target": 134,
      "key": "6a4e0518e8cd0a5154b71041f2de81c33f6e381ec6078a2af08c230e6d57c7c0b1c9ef03be99f695ff7242ca3a93e49c527b19e88d1594cc9d77e6f6569fccfd"
    },
    {
      "line": 1930,
      "relation": "decreases",
      "evidence": "In contrast, Pin1/PINN-1 (a DAPK interaction-partner and a peptidyl-prolyl isomerase involved in chronic neurodegenerative conditions) suppresses neurodegeneration in our excitotoxicity model.",
      "citation": {
        "type": "PubMed",
        "reference": "25899010",
        "name": "BMC neuroscience",
        "title": "Death Associated Protein Kinase (DAPK) -mediated neurodegenerative mechanisms in nematode excitotoxicity.",
        "volume": "16",
        "pages": "25",
        "date": "2015-04-23",
        "first": "Del Rosario JS",
        "last": "Mano I",
        "authors": [
          "Ahmed T",
          "Amjad U",
          "An J",
          "Asemota D",
          "Del Rosario JS",
          "Feldmann KG",
          "Ko B",
          "Mahmud T",
          "Mano I",
          "Mei S",
          "Salama M"
        ]
      },
      "annotations": {
        "Species": {
          "6239": true
        }
      },
      "source": 647,
      "target": 139,
      "key": "471c89c8bdb4bed02d6a558c7f6000addacd1a1fdffec2ec636e415db1c69a41a7bdec431982db2276bdf0d29681c0b9c43fac61161687a375987ad798a50168"
    },
    {
      "line": 1932,
      "relation": "negativeCorrelation",
      "evidence": "In contrast, Pin1/PINN-1 (a DAPK interaction-partner and a peptidyl-prolyl isomerase involved in chronic neurodegenerative conditions) suppresses neurodegeneration in our excitotoxicity model.",
      "citation": {
        "type": "PubMed",
        "reference": "25899010",
        "name": "BMC neuroscience",
        "title": "Death Associated Protein Kinase (DAPK) -mediated neurodegenerative mechanisms in nematode excitotoxicity.",
        "volume": "16",
        "pages": "25",
        "date": "2015-04-23",
        "first": "Del Rosario JS",
        "last": "Mano I",
        "authors": [
          "Ahmed T",
          "Amjad U",
          "An J",
          "Asemota D",
          "Del Rosario JS",
          "Feldmann KG",
          "Ko B",
          "Mahmud T",
          "Mano I",
          "Mei S",
          "Salama M"
        ]
      },
      "annotations": {
        "Species": {
          "6239": true
        }
      },
      "source": 647,
      "target": 431,
      "key": "fa9fec6e5889ee39d1179fe24a5a71f7ca319ac85f6163664aafc9dcb310a3311d8173f0f71fa952f6fc9dd4178c957b641974314ec9ff7006eccae24de6d969"
    },
    {
      "relation": "hasVariant",
      "source": 647,
      "target": 651,
      "key": "840fccb76ef921f083cdcc06fcf6fc1d06a04d8dc3834f3b48a3d58655b15febb203cfe16142c15f3eb2927e9b3c4ad639fba19319615dff4e49a3b43d8c2ce6"
    },
    {
      "line": 3939,
      "relation": "increases",
      "evidence": "The high degree of colocalization between pSmad2/3 and ubiquitin (Figure 7) provides additional evidence for a forced degradation of Smad2 via the proteasome pathway in AD which is controlled through binding of Pin1",
      "citation": {
        "type": "PubMed",
        "reference": "24964035",
        "name": "Neuropathology and applied neurobiology",
        "title": "Pin1 promotes degradation of Smad proteins and their interaction with phosphorylated tau in Alzheimer's disease.",
        "volume": "40",
        "pages": "815-32",
        "date": "2014-12-01",
        "first": "Ueberham U",
        "last": "Arendt T",
        "authors": [
          "Arendt T",
          "Brückner MK",
          "Gruschka H",
          "Hilbrich I",
          "Holzer M",
          "Rohn S",
          "Ueberham E",
          "Ueberham U",
          "Wodischeck S"
        ]
      },
      "object": {
        "modifier": "Degradation"
      },
      "source": 647,
      "target": 682,
      "key": "19d257f17659efa30a5a2331b1b224e6c68f8f4c1c68d305138c690a0cc51dd22341cea004627d924c8a67c695ed9933f3fdff1096210fe3735f0b1dc1a1454d"
    },
    {
      "line": 3943,
      "relation": "increases",
      "evidence": "The results demonstrate a direct interaction of Smad2 with phospho-tau (Figure 8B) which is clearly enhanced in the presence of Pin1. ",
      "citation": {
        "type": "PubMed",
        "reference": "24964035",
        "name": "Neuropathology and applied neurobiology",
        "title": "Pin1 promotes degradation of Smad proteins and their interaction with phosphorylated tau in Alzheimer's disease.",
        "volume": "40",
        "pages": "815-32",
        "date": "2014-12-01",
        "first": "Ueberham U",
        "last": "Arendt T",
        "authors": [
          "Arendt T",
          "Brückner MK",
          "Gruschka H",
          "Hilbrich I",
          "Holzer M",
          "Rohn S",
          "Ueberham E",
          "Ueberham U",
          "Wodischeck S"
        ]
      },
      "source": 647,
      "target": 240,
      "key": "6d067807f6d5ebec93a7caff21308aa12559976a699223dde9f447b2803f50669f587272ff4af2e6a6f421b0f0ec95f8d1dd3c5c8a4a2d3e77ca4c90a6474427"
    },
    {
      "line": 3954,
      "relation": "decreases",
      "evidence": "Pin1 accelerates cis to trans conversion to prevent accumulation of pathogenic cis p-tau conformation in AD, providing the first structural evidence for how Pin1 protects against AD.",
      "citation": {
        "type": "PubMed",
        "reference": "23157676",
        "name": "Current molecular medicine",
        "title": "Distinct functions of cis and trans phosphorylated tau in Alzheimer's disease and their therapeutic implications.",
        "volume": "13",
        "pages": "1098-109",
        "date": "2013-08-01",
        "first": "Nakamura K",
        "last": "Lu KP",
        "authors": [
          "Lu KP",
          "Nakamura K",
          "Zhou XZ"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 647,
      "target": 357,
      "key": "02ec62ea995e99309a63de25dbd84ce12b73ab8ec157415859ae3048298d1413a5b5e7ba5353728299c138ca0e8ca7945e6552c348dfb7195c793c543dd9c056"
    },
    {
      "line": 3967,
      "relation": "association",
      "evidence": "We find that phosphorylated (p-) SER235-PRO, but not pTHR231-PRO, is exclusively catalyzed by full-length Pin1 and isolated PPIase domain.",
      "citation": {
        "type": "PubMed",
        "reference": "26996941",
        "name": "Journal of molecular biology",
        "title": "Molecular Mechanism of Pin1-Tau Recognition and Catalysis.",
        "volume": "428",
        "pages": "1760-75",
        "date": "2016-05-08",
        "first": "Eichner T",
        "last": "Kern D",
        "authors": [
          "Buosi V",
          "Eichner T",
          "Kern D",
          "Kutter S",
          "Labeikovsky W"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 647,
      "target": 552,
      "key": "8e42b7ac3588cfeb5c65aa536f8dfdd0e92c80166eca698066035b25f0c5022c0181f61199c5e53f2a9b2c38a32fb28306664a3e08ad341e7eee337a1d585e7a"
    },
    {
      "relation": "hasVariant",
      "source": 647,
      "target": 649,
      "key": "fc00102ad47a3fb50536c9958ec8e6c41bb0ae16f45f7b2dea47c537bc439f6cededf7848e2439766f6814ba91053f5ecdc6a89db7dd593710301b3f871ba2f9"
    },
    {
      "relation": "hasVariant",
      "source": 647,
      "target": 650,
      "key": "32ed8fc4f4da85213d0d6312f95d2763ca4460b73d9e35f586c8ee5a6a96c8168fe915bf6f1085d96628ba5f6cad8aa7bf669fe6caff2ed1e27828132800d63c"
    },
    {
      "relation": "hasVariant",
      "source": 647,
      "target": 648,
      "key": "cf8f90f4281b61f0b127c4b98d3cb90d2840f6ca01007400d5e33eb39d19ad3b81df404bf9953f3c05c7d87ec7879f8eb98e8821922448d28ff05abafebcbf63"
    },
    {
      "line": 3995,
      "relation": "directlyDecreases",
      "evidence": "Pin1 binds to phosphorylated Thr231 of tau and facilitates the dephosphorylation of phosphoThr231 through isomerization (Galas et al., 2006; Hamdane et al., 2006; Lu et al., 1999a). Phosphorylation at Thr231 on tau is associated with the early events of tau aggregation and NFT (Augustinack et al., 2002). Pin1 binds and isomerizes the proline imidic peptide bond following the phosphothreonine 231",
      "citation": {
        "type": "PubMed",
        "reference": "22926167",
        "name": "Neurobiology of aging",
        "title": "Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker.",
        "volume": "34",
        "pages": "757-69",
        "date": "2013-03-01",
        "first": "Ando K",
        "last": "Buée L",
        "authors": [
          "Ando K",
          "Blum D",
          "Bretteville A",
          "Buée L",
          "Bégard S",
          "Bélarbi K",
          "Caillet-Boudin ML",
          "Demey-Thomas E",
          "Dourlen P",
          "Drobecq H",
          "Eddarkaoui S",
          "Galas MC",
          "Ghestem A",
          "Hamdane M",
          "Landrieu I",
          "Lippens G",
          "Maurage CA",
          "Melnyk P",
          "Sambo AV",
          "Sergeant N",
          "Smet C",
          "Verdier Y",
          "Vingtdeux V",
          "Vinh J"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 647,
      "target": 583,
      "key": "a989a4d3e3e442ead366d998eec2cdaac43b0a8be4178578eea415f489b72007c3afcf902bcb1ff2ba6f68c9a691da3b81543ba9233c8239226a8a5cb0f62623"
    },
    {
      "line": 4008,
      "relation": "positiveCorrelation",
      "evidence": "Pin1 is indicated to facilitate Tau dephosphorylation via PP2A by binding to the phospho-Thr-231-Pro or phospho-Thr-212-Pro site",
      "citation": {
        "type": "PubMed",
        "reference": "19401603",
        "name": "The Journal of biological chemistry",
        "title": "Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau.",
        "volume": "284",
        "pages": "16840-7",
        "date": "2009-06-19",
        "first": "Yotsumoto K",
        "last": "Hisanaga S",
        "authors": [
          "Asada A",
          "Hasegawa M",
          "Hisanaga S",
          "Ishiguro K",
          "Kimura T",
          "Oikawa T",
          "Saito T",
          "Uchida C",
          "Uchida T",
          "Yotsumoto K"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 647,
      "target": 657,
      "key": "5c031af0365e1eebe59684e747f5d0e17a8b49303c009c3abfd2e2b5a3bab50f56a7eecdee9a5c837a35213d97d8e0794adadb1128b61c1dce938ccbb7faf2f5"
    },
    {
      "line": 4011,
      "relation": "directlyDecreases",
      "evidence": "Pin1 is indicated to facilitate Tau dephosphorylation via PP2A by binding to the phospho-Thr-231-Pro or phospho-Thr-212-Pro site",
      "citation": {
        "type": "PubMed",
        "reference": "19401603",
        "name": "The Journal of biological chemistry",
        "title": "Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau.",
        "volume": "284",
        "pages": "16840-7",
        "date": "2009-06-19",
        "first": "Yotsumoto K",
        "last": "Hisanaga S",
        "authors": [
          "Asada A",
          "Hasegawa M",
          "Hisanaga S",
          "Ishiguro K",
          "Kimura T",
          "Oikawa T",
          "Saito T",
          "Uchida C",
          "Uchida T",
          "Yotsumoto K"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 647,
      "target": 580,
      "key": "7eb58488904cc93690145388b630a9eb6a31e9ef0917bcadd42c1fdda2496f99765784acd4bc21900aad1f44930a32e62310f0d0f55310b155f532628a1ac3e6"
    },
    {
      "line": 1635,
      "relation": "association",
      "evidence": "In synapses, the projection domain of tau interacts with protein kinase Fyn (plays an important role during myelination [75]), postsynaptic density protein 95 (PSD-95) [76], and N-methyl-D-aspartate receptors (NMDAR).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 450,
      "target": 134,
      "key": "ee215c2c21761087f570d6fc223b3b6d28f92fc63dd5ea2cbae39096dc8951fe9dac82168ee38ff2411e6fe5d0a9e66f29285ae998d9fadf71e16d33edcc430b"
    },
    {
      "line": 1636,
      "relation": "association",
      "evidence": "In synapses, the projection domain of tau interacts with protein kinase Fyn (plays an important role during myelination [75]), postsynaptic density protein 95 (PSD-95) [76], and N-methyl-D-aspartate receptors (NMDAR).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 438,
      "target": 134,
      "key": "88752bbb9ec5ab6916e6596b5efdf006bf1931ed43b9ab14a5199a8f63da037d3c23308d99a3d2ae9b2961878b95a8a18ad0fed3f1182dfedda6ec7976996c32"
    },
    {
      "line": 1637,
      "relation": "association",
      "evidence": "In synapses, the projection domain of tau interacts with protein kinase Fyn (plays an important role during myelination [75]), postsynaptic density protein 95 (PSD-95) [76], and N-methyl-D-aspartate receptors (NMDAR).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 769,
      "target": 134,
      "key": "e9b5810275b1a6871ef4ce3d664d0ca0bcd4afd3cf4426317b81f8ba8b154b675e648a013919f7911a357d1d2a0726571f836102a61d357169f7bbcf1fc5ee86"
    },
    {
      "line": 1645,
      "relation": "negativeCorrelation",
      "evidence": "An additional “knot” of tau being entangled in epigenetic landscape of neurodegeneration comes from the finding that by acting as a HDAC6 inhibitor, tau is being indirectly involved in both (dys)regulation of transcriptional activity and impairment of autophagic clearance by the ubiquitin proteasome system [81,82].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 213,
      "target": 486,
      "key": "80ee8d5b2c402decd6a32839ceb7c454a8c53450e10238a56d355cc53ffbbf89203b922716b564e487a13c5803f27746b7cf53ab2f283204be3e544400c70161"
    },
    {
      "line": 3429,
      "relation": "negativeCorrelation",
      "evidence": "It has been reported that the proteasomal machinery is modified by O-GlcNAcylation [53,126] and that after modification by OGT, the proteasome is inhibited [53]. Intriguingly, it has been proposed that a genetic impairment in the OGA gene results in proteasomal dysfunction through a lack of hydrolysis of the inhibitory O-GlcNAc residues of the 19S regulatory cap. Indeed, the OGA gene is located in the 10q locus [127,128], a chromosomal region frequently mutated in AD. The impairment of OGA in AD and the subsequent static OGlcNAcylation of the proteasome may explain why the latter fails to degrade neuronal aggregates. In addition, it has been reported that OGlcNAcylation reduces the sensitivity of intracellular proteins to proteasomal degradation by directly modifying them [43,129,130]. The two phenomena could thus act synergistically: a protein could escape degradation by means of its own O-GlcNAcylation and by the inhibitory effect of glycosylation on the proteasome, leading to a considerable decrease in the turnover of proteins that in turn may aggregate and cause neuronal death.",
      "citation": {
        "type": "PubMed",
        "reference": "19732809",
        "name": "Biochimica et biophysica acta",
        "title": "Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease.",
        "volume": "1800",
        "pages": "67-79",
        "date": "2010-02-01",
        "first": "Lefebvre T",
        "last": "Michalski JC",
        "authors": [
          "Dehennaut V",
          "Drougat L",
          "Guinez C",
          "Lefebvre T",
          "Michalski JC",
          "Mir AM",
          "Mortuaire M",
          "Olivier S",
          "Vercoutter-Edouart AS"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 213,
      "target": 107,
      "key": "5f86cb63298b66887af1cf93bfa3afeed0c2fd42022c2e5648471a7006dee01dabfc92eac763c1453320009f6ab0d8bdf43a931af12853bdaa0cc1200688366c"
    },
    {
      "line": 3430,
      "relation": "positiveCorrelation",
      "evidence": "It has been reported that the proteasomal machinery is modified by O-GlcNAcylation [53,126] and that after modification by OGT, the proteasome is inhibited [53]. Intriguingly, it has been proposed that a genetic impairment in the OGA gene results in proteasomal dysfunction through a lack of hydrolysis of the inhibitory O-GlcNAc residues of the 19S regulatory cap. Indeed, the OGA gene is located in the 10q locus [127,128], a chromosomal region frequently mutated in AD. The impairment of OGA in AD and the subsequent static OGlcNAcylation of the proteasome may explain why the latter fails to degrade neuronal aggregates. In addition, it has been reported that OGlcNAcylation reduces the sensitivity of intracellular proteins to proteasomal degradation by directly modifying them [43,129,130]. The two phenomena could thus act synergistically: a protein could escape degradation by means of its own O-GlcNAcylation and by the inhibitory effect of glycosylation on the proteasome, leading to a considerable decrease in the turnover of proteins that in turn may aggregate and cause neuronal death.",
      "citation": {
        "type": "PubMed",
        "reference": "19732809",
        "name": "Biochimica et biophysica acta",
        "title": "Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease.",
        "volume": "1800",
        "pages": "67-79",
        "date": "2010-02-01",
        "first": "Lefebvre T",
        "last": "Michalski JC",
        "authors": [
          "Dehennaut V",
          "Drougat L",
          "Guinez C",
          "Lefebvre T",
          "Michalski JC",
          "Mir AM",
          "Mortuaire M",
          "Olivier S",
          "Vercoutter-Edouart AS"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 213,
      "target": 259,
      "key": "8fadff3c5127a5604249bb80079fa43496916889f2823c1e2015bae67f8fecf8d5e7722a5b695e427cc8518eab017941917f9e16fd04ae7b40ade94a743accf4"
    },
    {
      "line": 3448,
      "relation": "decreases",
      "evidence": "We identified three specific RNA aptamers of USP14 (USP14-1, USP14-2, and USP14-3) that inhibited its deubiquitinating activity. The nucleotide sequences of these non-cytotoxic USP14 aptamers contained conserved GGAGG motifs, with G-rich regions upstream, and similar secondary structures. They efficiently elevated proteasomal activity, as determined by the increased degradation of small fluorogenic peptide substrates and physiological polyubiquitinated Sic1 proteins. Additionally, proteasomal degradation of tau proteins was facilitated in the presence of the UPS14 aptamers in vitro.",
      "citation": {
        "type": "PubMed",
        "reference": "26041011",
        "name": "Scientific reports",
        "title": "Facilitated Tau Degradation by USP14 Aptamers via Enhanced Proteasome Activity.",
        "volume": "5",
        "pages": "10757",
        "date": "2015-06-04",
        "first": "Lee JH",
        "last": "Lee MJ",
        "authors": [
          "Choi WH",
          "Hong C",
          "Jiang Y",
          "Kim DE",
          "Lee JH",
          "Lee MJ",
          "Shin SK"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 213,
      "target": 112,
      "key": "cb32036a0d844ef68fce6f92b2530de89ec6533a79c87ce006baecea32c84ad03cd451f8d3102219cf8a700d0b871b87eaa13327595d43a34fcb019f406f867e"
    },
    {
      "line": 3505,
      "relation": "positiveCorrelation",
      "evidence": "PKA stimulation attenuated proteasome dysfunction, probably through proteasome subunit phosphorylation resulting in lower levels of aggregated tau and improvements in cognitive performance.",
      "citation": {
        "type": "PubMed",
        "reference": "26692334",
        "name": "Nature medicine",
        "title": "Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.",
        "volume": "22",
        "pages": "46-53",
        "date": "2016-01-01",
        "first": "Myeku N",
        "last": "Duff KE",
        "authors": [
          "Clelland CL",
          "Duff KE",
          "Emrani S",
          "Goldberg AL",
          "Kukushkin NV",
          "Myeku N",
          "Yu WH"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 213,
      "target": 299,
      "key": "6f0f40ff690700023e75f6525db773af4b6265f179c4fc9c05e5645354e526082467c75d0a52f0db61b3e24ae0ff79bdb5aa20240dd983d123635ae59d3f98ac"
    },
    {
      "line": 1654,
      "relation": "positiveCorrelation",
      "evidence": "On the other side, sarkosyl extracts from the filaments of PSP [129], corticobasal degeneration (CBD; [130]), argyrophilic grain disease (AgD; [131]), and some cases of FTDP-17, contain tau protein that separates as doublets of 64 and 69 kDa and are predominantly composed of tau isoforms with 4R (class II tauopathies), whereas sarkosyl extracts from filaments of Pick’s disease are characterized by the presence of pathological tau doublets of 60 and 64 kDa and contain mainly 3R tau isoforms (class III tauopathy).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 307,
      "target": 905,
      "key": "b71c0720905eda8b25052257ffd64d019771fe4bb1bcdeb2fbb624d9651891825fed2bf124bc29cfa1416a65b33ecf82d70a09eb9c18c7a337bf3a9e8cfc5e9a"
    },
    {
      "line": 1655,
      "relation": "positiveCorrelation",
      "evidence": "On the other side, sarkosyl extracts from the filaments of PSP [129], corticobasal degeneration (CBD; [130]), argyrophilic grain disease (AgD; [131]), and some cases of FTDP-17, contain tau protein that separates as doublets of 64 and 69 kDa and are predominantly composed of tau isoforms with 4R (class II tauopathies), whereas sarkosyl extracts from filaments of Pick’s disease are characterized by the presence of pathological tau doublets of 60 and 64 kDa and contain mainly 3R tau isoforms (class III tauopathy).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 307,
      "target": 904,
      "key": "e623e63650876aeb23e76396d6996ba58af4598bf9598018b5369fdbef1128ed0376fc9cae8bfe4c578937a2ed93266e1d58b075d77243c2bfb3f18c8d144ed3"
    },
    {
      "line": 1656,
      "relation": "positiveCorrelation",
      "evidence": "On the other side, sarkosyl extracts from the filaments of PSP [129], corticobasal degeneration (CBD; [130]), argyrophilic grain disease (AgD; [131]), and some cases of FTDP-17, contain tau protein that separates as doublets of 64 and 69 kDa and are predominantly composed of tau isoforms with 4R (class II tauopathies), whereas sarkosyl extracts from filaments of Pick’s disease are characterized by the presence of pathological tau doublets of 60 and 64 kDa and contain mainly 3R tau isoforms (class III tauopathy).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 307,
      "target": 918,
      "key": "6611cee75753a33ffec1254daf1ea160fbdb0ff205ca0087e266056dcb7ebbc565193e441cf417e7e80928113390dae554da03c94b9686fc0d5593fb6f5c528c"
    },
    {
      "line": 2132,
      "relation": "negativeCorrelation",
      "evidence": "Inhibition of Dyrk1A enhanced tau exon 10 inclusion, leading to an increase in 4R-tau/3R-tau ratio in differentiated-human neuronal progenitors and in the neonatal rat brains. Accompanied with overexpression of Dyrk1A, 3R-tau was increased and 4R-tau was decreased in the neonatal brains of Ts65Dn mice, a model of Down syndrome.",
      "citation": {
        "type": "PubMed",
        "reference": "28775333",
        "name": "Scientific reports",
        "title": "Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D.",
        "volume": "7",
        "pages": "7240",
        "date": "2017-08-03",
        "first": "Wang P",
        "last": "Sun X",
        "authors": [
          "Chen L",
          "Sun X",
          "Wang L",
          "Wang P"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 307,
      "target": 786,
      "key": "858672cc175a08fd3dae07449686a61d2189fec2404bde2439d30d91754276d36933cd75318dd9337e7572db68d5c6b93bf05411312c49b1d22032712e056aff"
    },
    {
      "line": 3282,
      "relation": "partOf",
      "evidence": "Thus, K280 acetylation is a feature found in a variety of human 4R or 3R/4R tauopathies including AD, but not 3R-tauopathies such as PiD.",
      "citation": {
        "type": "PubMed",
        "reference": "21427723",
        "name": "Nature communications",
        "title": "The acetylation of tau inhibits its function and promotes pathological tau aggregation.",
        "volume": "2",
        "pages": "252",
        "date": "2011-01-01",
        "first": "Cohen TJ",
        "last": "Lee VM",
        "authors": [
          "Cohen TJ",
          "Guo JL",
          "Hurtado DE",
          "Kwong LK",
          "Lee VM",
          "Mills IP",
          "Trojanowski JQ"
        ]
      },
      "source": 307,
      "target": 903,
      "key": "2309d9e318c7ad0c4164704f17299593f4b84ec78e82ae6d3858f06cad8ca1405e05e266f7739e5bb5343b0e8980a95bc05275ef3ff9d559a902abf701b7e751"
    },
    {
      "line": 3546,
      "relation": "positiveCorrelation",
      "evidence": "Aggregation-induced increases in PAD exposure and oligomerization are common features among all tau isoforms. The extent of PAD exposure and oligomerization was larger for tau aggregates composed of 4-repeat isoforms compared with those made of 3-repeat isoforms.",
      "citation": {
        "type": "PubMed",
        "reference": "27574109",
        "name": "Neurobiology of aging",
        "title": "Analysis of isoform-specific tau aggregates suggests a common toxic mechanism involving similar pathological conformations and axonal transport inhibition.",
        "volume": "47",
        "pages": "113-126",
        "date": "2016-11-01",
        "first": "Cox K",
        "last": "Kanaan NM",
        "authors": [
          "Abdelmesih B",
          "Brady ST",
          "Combs B",
          "Cox K",
          "Kanaan NM",
          "Morfini G"
        ]
      },
      "source": 307,
      "target": 359,
      "key": "7cda66570dc2f9304e6859716c3b999988d651e0dedbbd9ac4ddb9a92f1e4ed70b223556640a86878418bf2aa5ba1d7d05ada2efd1b77e64393bb8ee98144771"
    },
    {
      "line": 1655,
      "relation": "positiveCorrelation",
      "evidence": "On the other side, sarkosyl extracts from the filaments of PSP [129], corticobasal degeneration (CBD; [130]), argyrophilic grain disease (AgD; [131]), and some cases of FTDP-17, contain tau protein that separates as doublets of 64 and 69 kDa and are predominantly composed of tau isoforms with 4R (class II tauopathies), whereas sarkosyl extracts from filaments of Pick’s disease are characterized by the presence of pathological tau doublets of 60 and 64 kDa and contain mainly 3R tau isoforms (class III tauopathy).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 904,
      "target": 307,
      "key": "66c14057aa5e0d373c90fbe15f9d4d05ab873b9ea1a574507a7c6ead9ebaf9126b5290b7ea7eaa7e8cba86823bcccf3d533f1d0b52cf01b54e048e9198a75db0"
    },
    {
      "line": 1658,
      "relation": "positiveCorrelation",
      "evidence": "On the other side, sarkosyl extracts from the filaments of PSP [129], corticobasal degeneration (CBD; [130]), argyrophilic grain disease (AgD; [131]), and some cases of FTDP-17, contain tau protein that separates as doublets of 64 and 69 kDa and are predominantly composed of tau isoforms with 4R (class II tauopathies), whereas sarkosyl extracts from filaments of Pick’s disease are characterized by the presence of pathological tau doublets of 60 and 64 kDa and contain mainly 3R tau isoforms (class III tauopathy).",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 914,
      "target": 306,
      "key": "401007aa644d5c7e9de8f9d45b5476ef911daaf5b852637d8499a4c9c4e4e4c5f9704470b450736c6729a813f033f825de4c4d17605ad199b331e0395e6ba166"
    },
    {
      "line": 1675,
      "relation": "positiveCorrelation",
      "evidence": "A PSEN1 mutation causes a Pick’s disease phenotype including FTD tau pathology without deposition of Abeta [145]; some MAPT single nucleotide polymorphisms have also been linked to sporadic Parkinson’s disease (PD, [146]);",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 914,
      "target": 664,
      "key": "2151a6707705dd92c3998a05e41e4168906c28038b68faf115488574844eebd05469f7549a6a651f140f3f7c066d8e3803a3f780b762b7c57574f8136a7ad49c"
    },
    {
      "line": 1665,
      "relation": "positiveCorrelation",
      "evidence": "Poorkaj et al. reported two exonic mutations (P301L and V337M) in two families with FTDP-17 [139], while Hutton et al. reported six different mutations in 10 families: three of these mutations (G272V, P301L and R406W) were missense mutations in exons, while the other three were in the 5' splice site of exon 10 [140].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 913,
      "target": 625,
      "key": "8ef3a3419c27dc9a539ed42fb37d87c0928ff620241cf69c40857b3d0206a9a8569c9400f938a16c369b23afff2d7545c4f22177d22ad9424b425e706d0098b8"
    },
    {
      "line": 1666,
      "relation": "positiveCorrelation",
      "evidence": "Poorkaj et al. reported two exonic mutations (P301L and V337M) in two families with FTDP-17 [139], while Hutton et al. reported six different mutations in 10 families: three of these mutations (G272V, P301L and R406W) were missense mutations in exons, while the other three were in the 5' splice site of exon 10 [140].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 913,
      "target": 630,
      "key": "b1431a68c26a9ccc8c701a33e5a893950dfb882a9116d92c5a1be9c6bc32d9911e0b60e4f69f2d826beb87e997fb6baa1288105402a1270b9d523d611d4fb559"
    },
    {
      "line": 1667,
      "relation": "positiveCorrelation",
      "evidence": "Poorkaj et al. reported two exonic mutations (P301L and V337M) in two families with FTDP-17 [139], while Hutton et al. reported six different mutations in 10 families: three of these mutations (G272V, P301L and R406W) were missense mutations in exons, while the other three were in the 5' splice site of exon 10 [140].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 913,
      "target": 611,
      "key": "65c2c45102e6454b57878352ed079a9a29ed542c4e7bee1e7b2e6a8d10564d3d5626e46d840dc82102c3775b13acdf2ce8c7427186d0daccd0a535f33c7dbc1f"
    },
    {
      "line": 1668,
      "relation": "positiveCorrelation",
      "evidence": "Poorkaj et al. reported two exonic mutations (P301L and V337M) in two families with FTDP-17 [139], while Hutton et al. reported six different mutations in 10 families: three of these mutations (G272V, P301L and R406W) were missense mutations in exons, while the other three were in the 5' splice site of exon 10 [140].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 913,
      "target": 600,
      "key": "c9224d0b462b91607ad4874c05ea7ededf22bd7692a72c9b6e473fba44def6bf20a959e972c04afd8db5b6388402a1bc425e58140938966632cda289b46d1b32"
    },
    {
      "line": 1674,
      "relation": "positiveCorrelation",
      "evidence": "A PSEN1 mutation causes a Pick’s disease phenotype including FTD tau pathology without deposition of Abeta [145]; some MAPT single nucleotide polymorphisms have also been linked to sporadic Parkinson’s disease (PD, [146]);",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 913,
      "target": 664,
      "key": "bf8db243fdb090bff7d3ad6c548cb6cb4ed4906ba35b0d377b0314e8d41b9bb8eea871b782cc2d6feb265132c535a1ec0f5bbab5c7446f648cab31b4f0a84a11"
    },
    {
      "line": 1666,
      "relation": "positiveCorrelation",
      "evidence": "Poorkaj et al. reported two exonic mutations (P301L and V337M) in two families with FTDP-17 [139], while Hutton et al. reported six different mutations in 10 families: three of these mutations (G272V, P301L and R406W) were missense mutations in exons, while the other three were in the 5' splice site of exon 10 [140].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 630,
      "target": 913,
      "key": "015327f4a9872cbef0e971fbac53fea1ec6b04003d6ee4266a8170c3e9ad1d1c77973bbb6ded7049c34b955998de5c1d4f4363affac69f27e4e7c9b5d8b0513f"
    },
    {
      "line": 1667,
      "relation": "positiveCorrelation",
      "evidence": "Poorkaj et al. reported two exonic mutations (P301L and V337M) in two families with FTDP-17 [139], while Hutton et al. reported six different mutations in 10 families: three of these mutations (G272V, P301L and R406W) were missense mutations in exons, while the other three were in the 5' splice site of exon 10 [140].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 611,
      "target": 913,
      "key": "95fa29ea9dfe4bbfa2d424096e9186648c2d1573c273f24414fc453aa727d521eddda8d604a9e2a9467ba44f5b64e7642951311ca1f1be12ad0fe898777ba73d"
    },
    {
      "line": 1668,
      "relation": "positiveCorrelation",
      "evidence": "Poorkaj et al. reported two exonic mutations (P301L and V337M) in two families with FTDP-17 [139], while Hutton et al. reported six different mutations in 10 families: three of these mutations (G272V, P301L and R406W) were missense mutations in exons, while the other three were in the 5' splice site of exon 10 [140].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 600,
      "target": 913,
      "key": "295b9b810c85154939421a9cd4d6544c9e42864917caf428805626d38fc9cb3f7e8558b67774774808217652a66ac17d22ec7d7ba5f0cef1d3a83193071d758b"
    },
    {
      "line": 1674,
      "relation": "positiveCorrelation",
      "evidence": "A PSEN1 mutation causes a Pick’s disease phenotype including FTD tau pathology without deposition of Abeta [145]; some MAPT single nucleotide polymorphisms have also been linked to sporadic Parkinson’s disease (PD, [146]);",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 664,
      "target": 913,
      "key": "d412bebd2d3636dbc7953bd6b1ba45b48699d15bd4dbcbd1ee0500e8ea450c2fc9cff3f5e440c146a19dccc5792baa73cdb68abb870a47f6bc4b0b7062e654f6"
    },
    {
      "line": 1675,
      "relation": "positiveCorrelation",
      "evidence": "A PSEN1 mutation causes a Pick’s disease phenotype including FTD tau pathology without deposition of Abeta [145]; some MAPT single nucleotide polymorphisms have also been linked to sporadic Parkinson’s disease (PD, [146]);",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 664,
      "target": 914,
      "key": "9c4d387a8e4805fdc03c571a1210c7e02bc61ea369cadc988bcc316203b6ad9331c6062c986736303bdd7aafbef2cc84e7eed0176e2da30e3630d5af6265d353"
    },
    {
      "line": 1676,
      "relation": "causesNoChange",
      "evidence": "A PSEN1 mutation causes a Pick’s disease phenotype including FTD tau pathology without deposition of Abeta [145]; some MAPT single nucleotide polymorphisms have also been linked to sporadic Parkinson’s disease (PD, [146]);",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 664,
      "target": 11,
      "key": "d5f4321191be9857ea84dd3ad827d1e57b9de2c2f62c939f139eed9443cfecbf5e7bef940ef5107e432b6be48469b5c3442845091c0535f16f718d93f17751a9"
    },
    {
      "relation": "hasVariant",
      "source": 663,
      "target": 664,
      "key": "bac52af0d0adc7830aca23c4cc56ac599002e35db60c9a57dea1d3577f276c6ac7b3076dad0813a4928ae1bbe5cbc1d0d10439f18b9f09285e6540dd3d850672"
    },
    {
      "line": 1678,
      "relation": "association",
      "evidence": "A PSEN1 mutation causes a Pick’s disease phenotype including FTD tau pathology without deposition of Abeta [145]; some MAPT single nucleotide polymorphisms have also been linked to sporadic Parkinson’s disease (PD, [146]);",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 250,
      "target": 915,
      "key": "ed69e3d6615a2da201debc3ad91c03831bb90cd626da972958a6aaca0db3949a747627d911f84d02cd80dbed7f28a3a7f17ea58fbe3c8cc8a1be7f9e0f173e73"
    },
    {
      "line": 1678,
      "relation": "association",
      "evidence": "A PSEN1 mutation causes a Pick’s disease phenotype including FTD tau pathology without deposition of Abeta [145]; some MAPT single nucleotide polymorphisms have also been linked to sporadic Parkinson’s disease (PD, [146]);",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 915,
      "target": 250,
      "key": "d9f51278435ca136d35d80bc4ad32b362487b816357d16444f6a4c301fb2e6cdaf2214555465b243e8faffab20ce93a5db33ce7c610a3a4c868aa163322f6bc1"
    },
    {
      "line": 1679,
      "relation": "association",
      "evidence": "A PSEN1 mutation causes a Pick’s disease phenotype including FTD tau pathology without deposition of Abeta [145]; some MAPT single nucleotide polymorphisms have also been linked to sporadic Parkinson’s disease (PD, [146]);",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 915,
      "target": 249,
      "key": "fcb0823c86eb1bb6c81ee77233fe93527e7313338b84fa3feb8dbc51d3b35844251e1953d7c0eb6285b46e42ae386f94b4ceac6bc189ab118f56c04720a7dd2c"
    },
    {
      "line": 2593,
      "relation": "positiveCorrelation",
      "evidence": "Using mass spectrometry, we identified multiple sites on recombinant tau that are phosphorylated by LRRK2 in vitro, including pT149 and pT153, which are phospho-epitopes that to date have been largely unexplored. Importantly, we demonstrate that expression of transgenic LRRK2 in a mouse model of tauopathy increased the aggregation of insoluble tau and its phosphorylation at T149, T153, T205, and S199/S202/T205 epitopes.",
      "citation": {
        "type": "PubMed",
        "reference": "24113872",
        "name": "Acta neuropathologica",
        "title": "LRRK2 phosphorylates novel tau epitopes and promotes tauopathy.",
        "volume": "126",
        "pages": "809-27",
        "date": "2013-12-01",
        "first": "Bailey RM",
        "last": "Lewis J",
        "authors": [
          "Bailey RM",
          "Covy JP",
          "Dickson DW",
          "Farrer MJ",
          "Giasson BI",
          "Knight J",
          "Lewis J",
          "Melrose HL",
          "Miles S",
          "Rousseau L",
          "Watkinson R"
        ]
      },
      "source": 915,
      "target": 469,
      "key": "a7e36eeeda1d4850a1c037aeeef0c7afc0a9193cccf2c7489a5e8cb8f3927cf34dbd62ae11b19d69646f6293da0acb43ccd689fd3c665bff2f9255e4d2bd545a"
    },
    {
      "line": 1679,
      "relation": "association",
      "evidence": "A PSEN1 mutation causes a Pick’s disease phenotype including FTD tau pathology without deposition of Abeta [145]; some MAPT single nucleotide polymorphisms have also been linked to sporadic Parkinson’s disease (PD, [146]);",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 249,
      "target": 915,
      "key": "368420dda3d044d037b5efd993914081522ea68a7c23afc9c939137d0bb3cabf31f9011d2e173a1c8df3a1521ef8a6762c96a470071f00f0661805b31838b797"
    },
    {
      "line": 1685,
      "relation": "association",
      "evidence": "The tau fragment first isolated from the PHF core is approximately 100 amino acids in length. Its N-terminus was defined by sequence analysis [30,56], and its C-terminus was defined by epitope mapping of MN423. Immunoreactivity was shown to depend on a specific C-terminal trunctation at Glu391 [33,150].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 358,
      "target": 608,
      "key": "8992f67b82af658ff56922b34f6a7ed811e39f9d4d8dc0ab1b50dc40167f0410a9f1e4e5d1637f9c4a842f97219c0d7f353e98b5e242c6c2ce5be277e748917d"
    },
    {
      "line": 1686,
      "relation": "partOf",
      "evidence": "The tau fragment first isolated from the PHF core is approximately 100 amino acids in length. Its N-terminus was defined by sequence analysis [30,56], and its C-terminus was defined by epitope mapping of MN423. Immunoreactivity was shown to depend on a specific C-terminal trunctation at Glu391 [33,150].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 358,
      "target": 81,
      "key": "78a1c02d3631575bc99d2a4127ce52a73cc81cb2dc3276b96dda2d31683b48dfb70ae64affa49f17523f5afab8e41c9a94005fd3acb1c33ca296eab0fe7e99a2"
    },
    {
      "line": 1691,
      "relation": "negativeCorrelation",
      "evidence": "In a prospective study three different synaptic protein (synaptophysin, SNAP-25 and syntaxin) were found to be progressively decreased in neocortex at Braak stages III-VI [158], NFT-bearing neurons demonstrating, for example, a 35%–57% reduction in synaptophysin mRNA in AD brain [159].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "Braak_Stage": {
          "Stage III": true,
          "Stage VI": true
        }
      },
      "source": 935,
      "target": 81,
      "key": "9935918cf1fd993ef09a1110daa665c8ea8348a3d91118e73c54d26081a25d76090d697456845f349cfcef2a395eaedbc331c91b02eef030a43dde19d8c0ad95"
    },
    {
      "line": 1692,
      "relation": "negativeCorrelation",
      "evidence": "In a prospective study three different synaptic protein (synaptophysin, SNAP-25 and syntaxin) were found to be progressively decreased in neocortex at Braak stages III-VI [158], NFT-bearing neurons demonstrating, for example, a 35%–57% reduction in synaptophysin mRNA in AD brain [159].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "Braak_Stage": {
          "Stage III": true,
          "Stage VI": true
        }
      },
      "source": 684,
      "target": 81,
      "key": "9a570e0fab93d148f476645f7908fa8122d95fdd69298545fcfea2a2e471cd455dee9d32839c5ec00875ba3b16cb2f94666f769b77b776168c7f4ccfba9aba81"
    },
    {
      "relation": "hasVariant",
      "source": 684,
      "target": 685,
      "key": "7b3fe8af7ee0e3176ce8fde18fd6d6d6506d1cdb383d1fe815c0ea9d76bee55489e5bda57de6c8d9b70a1bff314c9ed52b18b1aea1cb503779c00c7bb1b753b4"
    },
    {
      "line": 1693,
      "relation": "negativeCorrelation",
      "evidence": "In a prospective study three different synaptic protein (synaptophysin, SNAP-25 and syntaxin) were found to be progressively decreased in neocortex at Braak stages III-VI [158], NFT-bearing neurons demonstrating, for example, a 35%–57% reduction in synaptophysin mRNA in AD brain [159].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "annotations": {
        "Braak_Stage": {
          "Stage III": true,
          "Stage VI": true
        }
      },
      "source": 762,
      "target": 81,
      "key": "91079534f4579921a046271493d7037213e800ae111544c7f2c8194e991913bac2bdd19b6bd9855c12ef444d6e976fc53a42440afd35c3bbfb8bdb2f8dff5631"
    },
    {
      "relation": "hasComponent",
      "source": 221,
      "target": 54,
      "key": "3bf31bc9d56fa49ae100ac6176a8b3d8ff7cf3a93d204a336c8f69f9ac4e03500e3c32b74164ece368c9e9270c17f0dc327313cd5680686e326b508dd789723e"
    },
    {
      "relation": "hasComponent",
      "source": 221,
      "target": 325,
      "key": "158011fc2cfdf300f52510b6c098ec0b69a9b49afd8eb147092d7c23ef2865716ab866b89a201281946c94c838511a8ad6fff5232a06e7d6299f82d751f41bb8"
    },
    {
      "line": 1710,
      "relation": "positiveCorrelation",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 221,
      "target": 199,
      "key": "3587754b45964bf42ba328703ac468e1aecd325d77f8dbdf768375a4e20f1aa9a2804416e5be65f4516142e82f1a2aa2597f4c9ffada9b2091692c7971f51c4b"
    },
    {
      "line": 1709,
      "relation": "partOf",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 54,
      "target": 221,
      "key": "8429d1a7d2c824afae5b257d581baa64db8fc8f5cd572dfdb332b2749d43de45fdf26489d5fff8f1a84de95e4808f28b26ba0249ca4897d4265e54606620b86f"
    },
    {
      "line": 3559,
      "relation": "increases",
      "evidence": "Tau contains cysteine residues in the microtubule binding region following alternative splicing of exon 10, and formation of intermolecular cysteine disulfide bonds accelerates tau aggregation. 8-Nitro-cGMP (novel second messenger of NO) exposure induced S-guanylation of tau both in vitro and in tau-overexpressed HEK293T cells. S-guanylated tau inhibited heparin-induced tau aggregation (thioflavin T). S-guanylated tau could not form tau granules and fibrils (AFM) inhibited at the step of tau oligomer formation. In P301L tau-expressing Neuro2A cells, 8-nitro-cGMP reduced the amount of sarcosyl-insoluble tau. NO-linked chemical modification on cysteine residues of tau could block tau aggregation",
      "citation": {
        "type": "PubMed",
        "reference": "27601475",
        "name": "The Journal of biological chemistry",
        "title": "Modification of Tau by 8-Nitroguanosine 3',5'-Cyclic Monophosphate (8-Nitro-cGMP): EFFECTS OF NITRIC OXIDE-LINKED CHEMICAL MODIFICATION ON TAU AGGREGATION.",
        "volume": "291",
        "pages": "22714-22720",
        "date": "2016-10-21",
        "first": "Yoshitake J",
        "last": "Takashima A",
        "authors": [
          "Akaike T",
          "Ida T",
          "Matsushita K",
          "Soeda Y",
          "Sumioka A",
          "Takashima A",
          "Yoshikawa M",
          "Yoshitake J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true,
          "HEK293T": true
        }
      },
      "source": 54,
      "target": 325,
      "key": "e5972648ba046a66d06a01b1c4d7bf530cb66452b1d1e3e5222d60fc55d0f39896c2f81434cb12b9ae5d70007ba6f68ed037a0bd751d56f7f906d765176b605e"
    },
    {
      "line": 1710,
      "relation": "positiveCorrelation",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 199,
      "target": 221,
      "key": "f2c2e9e9b90ee1316a76a065ed4ed5b20e12fa12ab213fc7e7a3e63534e4c6b6d2e2ee6876d85f6d6fe0f25cc4b6450cc4cb8423a089970df73690eb2bb06193"
    },
    {
      "line": 1712,
      "relation": "isA",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          }
        }
      },
      "source": 199,
      "target": 112,
      "key": "24bd1bf43abb1a8d103b387db43c591b4aaeaa59812d0f5e21d4d8db74a206b1e88b6a18994c0e31a91e97da284994a1367bcaa92033d42e24311d23a40f7d27"
    },
    {
      "line": 1714,
      "relation": "isA",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          }
        }
      },
      "source": 177,
      "target": 112,
      "key": "1b04ea43e2eb034e8f58e3ca1431df9aede87f400a0a67c69d6306558c4049479228227bce7d849708a166274a4b4f1530dc9641d4036544ea565fd8b745e1db"
    },
    {
      "line": 1715,
      "relation": "increases",
      "evidence": "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]). In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170]. As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD. Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appea rs that microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Neurons"
          }
        }
      },
      "source": 79,
      "target": 112,
      "key": "45ae793fa48745830fa19f7df50420848aab589c46e0b045e98b66252f5c8153bfc416b811f1e87c1b4bb7a3e0bbdde80346eb8621f503c8a29a5cf64147765c"
    },
    {
      "line": 1719,
      "relation": "decreases",
      "evidence": "Green coffee, a non-toxic small molecule, found to be an inhibitor of protein phosphatase 2A methylesterase, was shown to improve cognitive and motor performance in mouse models with tau pathology",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 35,
      "target": 271,
      "key": "a25c373f74c0a912f7bc26154b193105e97dd3967e3173993758ad5b95e118629e890928432374c115319055e324360db6017348f5e13e15d032b2b6f897019e"
    },
    {
      "line": 1720,
      "relation": "positiveCorrelation",
      "evidence": "Green coffee, a non-toxic small molecule, found to be an inhibitor of protein phosphatase 2A methylesterase, was shown to improve cognitive and motor performance in mouse models with tau pathology",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 35,
      "target": 215,
      "key": "12dcc795accfae2b842c39ea8e73df9b0844bf86c263c063978db67736812bdf3789bde055d3fa0e6b79d02c169ebdcf98db2629a29b7bd1e9c817708b42e4eb"
    },
    {
      "line": 3925,
      "relation": "decreases",
      "evidence": "Western blot analyses showed a decrease of methyl-PP2A and an increase of demethyl-PP2A with a concomitant reduction in the methyl/demethyl PP2A ratio in both PSP (74%) and AD (76%) brains, associated with an LCMT-1 decrease and a demethylating enzyme increase, protein phosphatase methylesterase (PME-1), in both diseases.",
      "citation": {
        "type": "PubMed",
        "reference": "29281045",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.",
        "volume": "77",
        "pages": "139-148",
        "date": "2018-02-01",
        "first": "Park HJ",
        "last": "Mouradian MM",
        "authors": [
          "Adler CH",
          "Beach TG",
          "Braithwaite SP",
          "Lee KW",
          "Mouradian MM",
          "Oh S",
          "Park HJ",
          "Stock JB",
          "Voronkov M",
          "Yan R",
          "Zhang J"
        ]
      },
      "annotations": {
        "Method": {
          "Western Blot": true
        }
      },
      "source": 271,
      "target": 659,
      "key": "805efa1add60c1245336640eb2af1feb09aad720cc0fef84d4bddef488f58dfe7a382eea32f0a5d3e9f2b264ee3de1631d59961dcbe6cd74c83839d987cb9b9d"
    },
    {
      "line": 1720,
      "relation": "positiveCorrelation",
      "evidence": "Green coffee, a non-toxic small molecule, found to be an inhibitor of protein phosphatase 2A methylesterase, was shown to improve cognitive and motor performance in mouse models with tau pathology",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 215,
      "target": 35,
      "key": "125d155de6156a4f71794e70a488a03bba0933595baa0fb8c114d14c1776b4b7c8212ad107e73347c4850d6d3f531efceb6e982a4a52be0eb02cafbe8335eac2"
    },
    {
      "line": 1725,
      "relation": "increases",
      "evidence": "A quite different strategy is to target tau clearance—e.g., by rapamycin that induces macroautophagy [175], inhibitors of Hsp90 chaperone protein that binds to misfolded proteins or by immunotherapeutic approaches [176].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 73,
      "target": 198,
      "key": "4312191070867dd437cbf42be447e46b196aa8dcf40ac8a38e896624af4c2695a208411468e68f21bc3421d21635ea506e9c67b6397fb268773e16935aa0210f"
    },
    {
      "line": 1726,
      "relation": "decreases",
      "evidence": "A quite different strategy is to target tau clearance—e.g., by rapamycin that induces macroautophagy [175], inhibitors of Hsp90 chaperone protein that binds to misfolded proteins or by immunotherapeutic approaches [176].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 198,
      "target": 486,
      "key": "ecf1ba2592d2d3f91f5d039786bc86cb5a471a80034b8d2269323b1217e44dc7edd5ee826c2772a2a227a6f47776d4a124030cacbfdd3e06801004a0723863dc"
    },
    {
      "line": 1727,
      "relation": "decreases",
      "evidence": "A quite different strategy is to target tau clearance—e.g., by rapamycin that induces macroautophagy [175], inhibitors of Hsp90 chaperone protein that binds to misfolded proteins or by immunotherapeutic approaches [176].",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 327,
      "target": 569,
      "key": "05e15921a83678f7cb401857c8c9a3a636012d1b6bd730461197d46cf4a397ab101829aeac70adee18966686b298653b047f6c6504ca9cd9217ba49e3624a4c8"
    },
    {
      "line": 1732,
      "relation": "decreases",
      "evidence": "MB is a phenothiazine that crosses the blood brain barrier and acts as a redox cycler. Moreover, besides its beneficial properties as being able to improve energy metabolism and to act as an antioxidant, it is also able to reduce tau protein aggregation",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 24,
      "target": 325,
      "key": "e59734f640d875806be3668a0ef970c793b509421bb79a10e28bfeb9a41734159df45cff6d330cd40eddaa9e38b64d2c93c877ae8a1c30479081ba5fe66aae4c"
    },
    {
      "line": 1733,
      "relation": "decreases",
      "evidence": "MB is a phenothiazine that crosses the blood brain barrier and acts as a redox cycler. Moreover, besides its beneficial properties as being able to improve energy metabolism and to act as an antioxidant, it is also able to reduce tau protein aggregation",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 24,
      "target": 396,
      "key": "cb1106737af558a125ff854ebd50d99cffd1c9db65e8af2a58a020fe9a32328b0a632fb655706efc3a4d9e199b3733552fdc54ebf62bdd043c3a875f359cd51d"
    },
    {
      "line": 1734,
      "relation": "decreases",
      "evidence": "MB is a phenothiazine that crosses the blood brain barrier and acts as a redox cycler. Moreover, besides its beneficial properties as being able to improve energy metabolism and to act as an antioxidant, it is also able to reduce tau protein aggregation",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 24,
      "target": 397,
      "key": "c7cb295d3d788d4c588ddabaa5d5448ca51140adde35814e3bbd89d0d81e9e731905ee128632f4266ac6d892861591aa7480e66c0c6c91a290657791ffde492d"
    },
    {
      "line": 1861,
      "relation": "decreases",
      "evidence": "In 293T culture, MB decreased MARK4-mediated Tau phosphorylation in a dose dependent manner. MB down-regulates MARK4 protein level through ubiquitin-proteasome pathway and inhibition of MARK4 kinase activity in vitro.",
      "citation": {
        "type": "PubMed",
        "reference": "23666762",
        "name": "Neuromolecular medicine",
        "title": "Role of individual MARK isoforms in phosphorylation of tau at Ser²⁶² in Alzheimer's disease.",
        "volume": "15",
        "pages": "458-69",
        "date": "2013-09-01",
        "first": "Gu GJ",
        "last": "Kamali-Moghaddam M",
        "authors": [
          "Blokzijl A",
          "Classon C",
          "Gu GJ",
          "Kamali-Moghaddam M",
          "Landegren U",
          "Lund H",
          "Sunnemark D",
          "Wu D",
          "von Euler G"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293T": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 24,
      "target": 635,
      "key": "f0843c8653c2872755862df4efd2b78ee96b04c7f9dbc0d7218d590833e5eaead0240b49becc2778928e924d9bd9f591eed7a9a455912a3812ab77b55fec44ff"
    },
    {
      "line": 1862,
      "relation": "increases",
      "evidence": "In 293T culture, MB decreased MARK4-mediated Tau phosphorylation in a dose dependent manner. MB down-regulates MARK4 protein level through ubiquitin-proteasome pathway and inhibition of MARK4 kinase activity in vitro.",
      "citation": {
        "type": "PubMed",
        "reference": "23666762",
        "name": "Neuromolecular medicine",
        "title": "Role of individual MARK isoforms in phosphorylation of tau at Ser²⁶² in Alzheimer's disease.",
        "volume": "15",
        "pages": "458-69",
        "date": "2013-09-01",
        "first": "Gu GJ",
        "last": "Kamali-Moghaddam M",
        "authors": [
          "Blokzijl A",
          "Classon C",
          "Gu GJ",
          "Kamali-Moghaddam M",
          "Landegren U",
          "Lund H",
          "Sunnemark D",
          "Wu D",
          "von Euler G"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293T": true
        }
      },
      "object": {
        "modifier": "Degradation"
      },
      "source": 24,
      "target": 635,
      "key": "77e2c828834be3dc206293f00d481027fde62ee22d5b706ba871152a06a0c1693d810d36115ea98e4196f2d57477df21c00100bebbc2e280bc846ad096c87ca6"
    },
    {
      "line": 3146,
      "relation": "decreases",
      "evidence": "Thus, K → Q substitutions within the critical PHF6* motif, in the apparent absence of other tau PTMs, appears sufficient to accelerate tau aggregation in vitro.",
      "citation": {
        "type": "PubMed",
        "reference": "28287136",
        "name": "Scientific reports",
        "title": "A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy.",
        "volume": "7",
        "pages": "44102",
        "date": "2017-03-13",
        "first": "Trzeciakiewicz H",
        "last": "Cohen TJ",
        "authors": [
          "Cohen TJ",
          "Madden V",
          "Tripathy A",
          "Trzeciakiewicz H",
          "Tseng JH",
          "Wander CM",
          "Yuan CX"
        ]
      },
      "source": 24,
      "target": 490,
      "key": "3cb320490b43c578d6434007272863c3d172915e7b12b60dfd2ff4c73b6144cc8f42d776610ed588f11ddef83d38542ab12c077253674c3a45aa049ab0b239ad"
    },
    {
      "line": 1921,
      "relation": "association",
      "evidence": "Overexpression of wild-type UNC5C causes low-grade death, intensified by an AD-linked mutation T835M inhibited by a AD-linked survival factor, calmodulin-like skin protein (CLSP), and a natural ligand of UNC5C, netrin1. T835M-UNC5C-induced neuronal cell death is mediated by an intracellular death-signaling cascade, consisting of DAPK1/protein kinase D/apoptosis signal-regulating kinase 1 (ASK1)/JNK/NADPH oxidase/caspases, which merges at ASK1 with a death-signaling cascade, mediated by amyloid ß precursor protein (APP).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 397,
      "target": 291,
      "key": "5bb434ebd5b9afd03defa820e978aaef8ca30273915d873ecf201baa17853f49eb5c7c44ccd9e759008c73212025a919b344ba2a862c0777c98e4324af39708e"
    },
    {
      "line": 1922,
      "relation": "association",
      "evidence": "Overexpression of wild-type UNC5C causes low-grade death, intensified by an AD-linked mutation T835M inhibited by a AD-linked survival factor, calmodulin-like skin protein (CLSP), and a natural ligand of UNC5C, netrin1. T835M-UNC5C-induced neuronal cell death is mediated by an intracellular death-signaling cascade, consisting of DAPK1/protein kinase D/apoptosis signal-regulating kinase 1 (ASK1)/JNK/NADPH oxidase/caspases, which merges at ASK1 with a death-signaling cascade, mediated by amyloid ß precursor protein (APP).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 397,
      "target": 473,
      "key": "b19d80bc4677d2036995fb89048af5ce6c4937d620541e7d1e125ddc53177e7edf3fbf200f13bbee1d5fe272db33f4bad6dc159315c20751571437d1bc540fa7"
    },
    {
      "line": 1923,
      "relation": "increases",
      "evidence": "Overexpression of wild-type UNC5C causes low-grade death, intensified by an AD-linked mutation T835M inhibited by a AD-linked survival factor, calmodulin-like skin protein (CLSP), and a natural ligand of UNC5C, netrin1. T835M-UNC5C-induced neuronal cell death is mediated by an intracellular death-signaling cascade, consisting of DAPK1/protein kinase D/apoptosis signal-regulating kinase 1 (ASK1)/JNK/NADPH oxidase/caspases, which merges at ASK1 with a death-signaling cascade, mediated by amyloid ß precursor protein (APP).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "source": 397,
      "target": 189,
      "key": "e613976915c04582ef1e0e99e767e10f7eb5a756f24b4d6541a924421e28a0407f81e858b4c539bfa530a42f0ea7f3772f40aaa26e790aa94cdd02788d4062b2"
    },
    {
      "line": 1738,
      "relation": "positiveCorrelation",
      "evidence": "Recently, it has been proposed that tau protein acetylation may be responsible for tau aggregation in AD. Grinberg and collaborators detected tau acetylation at Lys274 in all tauopathies (both primary and secondary), except in AgD",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 497,
      "target": 325,
      "key": "88acffc56c792aaaa763b4815b7c1f0764eb3a8806e80cb17568902ad0fab9ac79f161c4f4737760c64a1291e44b53a1a413dd5a5eda002ab6b8370a6b4f38aa"
    },
    {
      "line": 3173,
      "relation": "decreases",
      "evidence": "Here we report abnormal acetylation of K274 and K281 on tau, identified in AD brains, promotes memory loss and disrupts synaptic plasticity by reducing postsynaptic KIdney/BRAin (KIBRA) protein, a memory-associated protein.Transgenic mice expressing human tau with lysine-to-glutamine mutations to mimic K274 and K281 acetylation (tauKQ) exhibit AD-related memory deficits and impaired hippocampal long-term potentiation (LTP). TauKQ reduces synaptic KIBRA levels and disrupts activity-induced postsynaptic actin remodeling and AMPA receptor insertion. The LTP deficit was rescued by promoting actin polymerization or by KIBRA expression. In AD patients with dementia, we found enhanced tau acetylation is linked to loss of KIBRA.",
      "citation": {
        "type": "PubMed",
        "reference": "27041503",
        "name": "Neuron",
        "title": "Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss.",
        "volume": "90",
        "pages": "245-60",
        "date": "2016-04-20",
        "first": "Tracy TE",
        "last": "Gan L",
        "authors": [
          "Cong X",
          "Ellerby LM",
          "Gan L",
          "Huganir RL",
          "Le D",
          "Li Y",
          "Lo I",
          "Min SW",
          "Minami SS",
          "Ponnusamy R",
          "Schilling B",
          "Sohn PD",
          "Tracy TE",
          "Wang C",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 497,
      "target": 752,
      "key": "42730380f09c90c46dc990a50236daf7a9dc46bbffa7b431c4b85f3455a6778713bed406ac998e9791ee508dd169330f6689f76a0990904f65d05ac135b41171"
    },
    {
      "line": 3175,
      "relation": "decreases",
      "evidence": "Here we report abnormal acetylation of K274 and K281 on tau, identified in AD brains, promotes memory loss and disrupts synaptic plasticity by reducing postsynaptic KIdney/BRAin (KIBRA) protein, a memory-associated protein.Transgenic mice expressing human tau with lysine-to-glutamine mutations to mimic K274 and K281 acetylation (tauKQ) exhibit AD-related memory deficits and impaired hippocampal long-term potentiation (LTP). TauKQ reduces synaptic KIBRA levels and disrupts activity-induced postsynaptic actin remodeling and AMPA receptor insertion. The LTP deficit was rescued by promoting actin polymerization or by KIBRA expression. In AD patients with dementia, we found enhanced tau acetylation is linked to loss of KIBRA.",
      "citation": {
        "type": "PubMed",
        "reference": "27041503",
        "name": "Neuron",
        "title": "Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss.",
        "volume": "90",
        "pages": "245-60",
        "date": "2016-04-20",
        "first": "Tracy TE",
        "last": "Gan L",
        "authors": [
          "Cong X",
          "Ellerby LM",
          "Gan L",
          "Huganir RL",
          "Le D",
          "Li Y",
          "Lo I",
          "Min SW",
          "Minami SS",
          "Ponnusamy R",
          "Schilling B",
          "Sohn PD",
          "Tracy TE",
          "Wang C",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 497,
      "target": 171,
      "key": "6782ed703270b5e321c277b5b8298a0c5d2ab8a76cf9fd69cc6fde54d038781de5325f432ad670b8335f9ff612ebd237acd7430404eaac1ee0c2d4092ba74791"
    },
    {
      "line": 1742,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 69,
      "target": 325,
      "key": "8eba196d2862222f9f3fefc4ee286b89cf06e9e65760228e0cde2a5c0df85ab509acf6ae32075b8d0d332d87c54daefff2c18d3e349c31347a5da0281fd14e5d"
    },
    {
      "line": 1743,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 160,
      "target": 325,
      "key": "f6d0e654486dac8b80a5df5df21d0c98f773ab4b561c30b92f048d8c6b855e38028a485b6568c930c2f237b0b199be7ee23c9597330dc2b0d90159a36f5df43d"
    },
    {
      "line": 1744,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 157,
      "target": 325,
      "key": "eac5fafd11d15ee91275b849d5b653c93c28606435085e498501a0b6cc9411ba7925cb2e48783cbdc5f6ccf05e218788c7ed212eff585d1eee3a00d6576caf7a"
    },
    {
      "line": 1745,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 161,
      "target": 325,
      "key": "2c13499388c2105b40f6e09e04047c0fc54ba0e7b99343138681b5a7f1c36dd261052d2319e955920eb64eb3fd805d0d55fd90ded3446598e751bc447f7dc2b8"
    },
    {
      "line": 1747,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 75,
      "target": 325,
      "key": "4fb0e9d949c0eda66d7acb5367a5c0525f2f5aea5724d6b7ec33b37c9e9663e4311f3fcb4318df89eb3b1f809d30faf57722dfbe0353fa5a199c7d1a9198f3e7"
    },
    {
      "line": 1748,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 159,
      "target": 325,
      "key": "c648c5e92bc8e11576e71c63a33c7104f8d81b6700cdddbe9aa1790cdbe39f16e6525e0cec76ad2df7971801a08f1d42867c7dc811a8cef4f5e308461cdde938"
    },
    {
      "line": 1749,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 58,
      "target": 325,
      "key": "9cdf4a190a082aaef14190a4bbb26717a76cccf4bbf0c057069cc41a3d7b256c67224840b40b8016d91887af2458e4892f490a9ac606ed6a817a50ee4b20117b"
    },
    {
      "line": 1750,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 37,
      "target": 325,
      "key": "54fa723daac53bcdf9c856f5ad4943806282560dad81b24140ff6a8b84ca2a9d3c2b32e9eacb09e0e6963744d4b0717c09129e9f7115f1e39160513bc9696ce6"
    },
    {
      "line": 1751,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 57,
      "target": 325,
      "key": "39779b7df7b2f518fd863b8c40517627498e11625657196766b8290c08fa65003c9b249befc345816ac4eaf5c009d8a480796673692072ec27b147c14a251503"
    },
    {
      "line": 1752,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 151,
      "target": 325,
      "key": "588661b3010bdfdd2f0129780d57ee7af1c7f3a42be954a64bc1811d2487b5451edbbea19b07e367628cffd9665bf953f830ad3203dd3f78072575c8768e1070"
    },
    {
      "line": 1754,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 62,
      "target": 325,
      "key": "92cb1311d3aa2ee7265b0646b010fa637415ccd57af360f465833783165f05f70f2a1b7bf0034914c96dda0227462f10cf5078c072ca412086b17b1e0a2d44b4"
    },
    {
      "line": 1756,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 49,
      "target": 325,
      "key": "502aabf691a0cddcba5990db36c097fc0c41b16b5bfb9781ffee384f159394654c5820f4a3ea4f412fbd5ca33315cafb06a0b741661c590f0d360a45066ec1ab"
    },
    {
      "line": 1757,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 46,
      "target": 325,
      "key": "9539f4de2f25cad96204445f3001ea67fc9d912dd4a8f8e8e726ad7fdab7baadb282b6aeb012731fcb6cebf158854b515dfc551bf6f7b631a0a4e76f37eaeef7"
    },
    {
      "line": 1758,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 48,
      "target": 325,
      "key": "cafe6957593c74852126108eef81a739b7780e2919475fa7e37a0db07f91c4374886f7756c6d267e75b52e6ae249d7e62e8d5221d8817e9b6f33d9aba30a05ac"
    },
    {
      "line": 1759,
      "relation": "decreases",
      "evidence": "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines and benzothiazoles, and polyphenols and anthraquinones",
      "citation": {
        "type": "PubMed",
        "reference": "26751493",
        "name": "Biomolecules",
        "title": "Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.",
        "volume": "6",
        "pages": "6",
        "date": "2016-01-06",
        "first": "Šimić G",
        "last": "Hof PR",
        "authors": [
          "Babić Leko M",
          "Bažadona D",
          "Buée L",
          "Delalle I",
          "Di Giovanni G",
          "Harrington C",
          "Hof PR",
          "Jovanov-Milošević N",
          "Wischik C",
          "Wray S",
          "de Silva R",
          "Šimić G"
        ]
      },
      "source": 67,
      "target": 325,
      "key": "c3a86422c33d7fdae2d208ddfe7e3b08b7c94e9134a82d9f638a01ed28a77c9ad1be48e7f53bf29013bf7e9c85055dd7d79b607fd321503d99ec1b0e6be0df27"
    },
    {
      "line": 1768,
      "relation": "positiveCorrelation",
      "evidence": "Immunohistochemical analyses using isoform-selective antibodies demonstrated that MARK4 in a phosphorylated form colocalizes with p-tau Ser262 in granulovacuolar degeneration bodies (GVDs) that progressively accumulate in AD.",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 636,
      "target": 557,
      "key": "114b585a4f63a28d5cf2150812f3202577e9d5b2cae695c61c1aa0ba43ee724ba3cc30df6e049edd4ddc10454e9ef0f36c6d559400ee5bbfa895a5669f7daa00"
    },
    {
      "line": 1769,
      "relation": "positiveCorrelation",
      "evidence": "Immunohistochemical analyses using isoform-selective antibodies demonstrated that MARK4 in a phosphorylated form colocalizes with p-tau Ser262 in granulovacuolar degeneration bodies (GVDs) that progressively accumulate in AD.",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 636,
      "target": 129,
      "key": "3b3c7289b1566f54c61fe5ae65242178bcc8a97a0f162b7ea3a9b4cb5005bed77930842a83cc378c98cd944309d79befb8567ec27ab34bdfa33c47a560582459"
    },
    {
      "relation": "hasVariant",
      "source": 635,
      "target": 636,
      "key": "37fab3237e6e9107ea5539f832ab6e9c0122b1ea5e0dde91be1bb9f0f95d77945b291ed842d29b1a961c9b547874a5448dfdec6696f69b0825f0aa7da1c0743b"
    },
    {
      "line": 1780,
      "relation": "negativeCorrelation",
      "evidence": "MARK4 was extremely decreased in the brain regions with a mass of PrPSc in a G114V gCJD patient, but was clearly observable in the regions with a minimum amount of PrPSc or without detectable PrPSc in a D178N FFI patient.",
      "citation": {
        "type": "PubMed",
        "reference": "22692785",
        "name": "International journal of molecular medicine",
        "title": "Reduction of protein kinase MARK4 in the brains of experimental scrapie rodents and human prion disease correlates with deposits of PrP(Sc).",
        "volume": "30",
        "pages": "569-78",
        "date": "2012-09-01",
        "first": "Gong HS",
        "last": "Dong XP",
        "authors": [
          "Chen C",
          "Dong XP",
          "Gong HS",
          "Guo Y",
          "Liu Y",
          "Shi Q",
          "Tian C",
          "Wang SB",
          "Xie WL",
          "Xu Y",
          "Zhang BY",
          "Zhang J"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Creutzfeldt-Jakob Syndrome": true,
          "Insomnia, Fatal Familial": true
        }
      },
      "source": 635,
      "target": 366,
      "key": "219305de5a03e7a2dfbd73f8dcfe1018347cc187879600d6f7b198dfdbdf51e16d7498e7e788ac4a08d6e9a73755e516e07176cd708172d240de7a417b454709"
    },
    {
      "line": 1854,
      "relation": "positiveCorrelation",
      "evidence": "In cells, a CagA peptide inhibited tau phosphorylation at Ser²6² mediated by MARK4 but not other MARK isoforms. A strong and significant elevation of MARK4 expression and MARK4-tau interactions in AD brains correlated with the Braak stages of the disease.",
      "citation": {
        "type": "PubMed",
        "reference": "23666762",
        "name": "Neuromolecular medicine",
        "title": "Role of individual MARK isoforms in phosphorylation of tau at Ser²⁶² in Alzheimer's disease.",
        "volume": "15",
        "pages": "458-69",
        "date": "2013-09-01",
        "first": "Gu GJ",
        "last": "Kamali-Moghaddam M",
        "authors": [
          "Blokzijl A",
          "Classon C",
          "Gu GJ",
          "Kamali-Moghaddam M",
          "Landegren U",
          "Lund H",
          "Sunnemark D",
          "Wu D",
          "von Euler G"
        ]
      },
      "source": 635,
      "target": 908,
      "key": "1ed243f0b1350afb8e17dd73d4b50f49a4b28ae97516b2fcb66e65270b9d9b4e41a4129b0828873feddf84558c864c0551456a09c663bb76ce7acc061d88cb84"
    },
    {
      "line": 2682,
      "relation": "increases",
      "evidence": "Overexpression of MARK4 led to tau hyperphosphorylation, reduced expression of synaptic markers, and loss of dendritic spines and synapses, phenotypes also observed after Aβ treatment. Importantly, expression of a non-phosphorylatable form of tau with the PAR-1/MARK site mutated blocked the synaptic toxicity induced by MARK4 overexpression or Aβ treatment. To probe the involvement of endogenous MARK kinases in mediating the synaptic toxicity of Aβ, we employed a peptide inhibitor capable of effectively and specifically inhibiting the activities of all PAR-1/MARK family members. This inhibitor abrogated the toxic effects of Aβ oligomers on dendritic spines and synapses as assayed at the morphological and electrophysiological levels.",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 635,
      "target": 113,
      "key": "fcc896c58ce6e8855b2af7d98d793a85125d3e5da76cf6ca8ba136cf5bda312352ddee52af3d7324e1a75a4e0e0248aeacd2fda79729733665c903dcbc86cc2c"
    },
    {
      "line": 2683,
      "relation": "negativeCorrelation",
      "evidence": "Overexpression of MARK4 led to tau hyperphosphorylation, reduced expression of synaptic markers, and loss of dendritic spines and synapses, phenotypes also observed after Aβ treatment. Importantly, expression of a non-phosphorylatable form of tau with the PAR-1/MARK site mutated blocked the synaptic toxicity induced by MARK4 overexpression or Aβ treatment. To probe the involvement of endogenous MARK kinases in mediating the synaptic toxicity of Aβ, we employed a peptide inhibitor capable of effectively and specifically inhibiting the activities of all PAR-1/MARK family members. This inhibitor abrogated the toxic effects of Aβ oligomers on dendritic spines and synapses as assayed at the morphological and electrophysiological levels.",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 635,
      "target": 863,
      "key": "a1cc8074041c7b85208716aa4b1348d97f5f63ed63997701cedc76136e70bce3f3bd2d73093e55b05f59fde2896f95a9693af067c60e29a9ed61fa5dddc1e34a"
    },
    {
      "line": 2684,
      "relation": "negativeCorrelation",
      "evidence": "Overexpression of MARK4 led to tau hyperphosphorylation, reduced expression of synaptic markers, and loss of dendritic spines and synapses, phenotypes also observed after Aβ treatment. Importantly, expression of a non-phosphorylatable form of tau with the PAR-1/MARK site mutated blocked the synaptic toxicity induced by MARK4 overexpression or Aβ treatment. To probe the involvement of endogenous MARK kinases in mediating the synaptic toxicity of Aβ, we employed a peptide inhibitor capable of effectively and specifically inhibiting the activities of all PAR-1/MARK family members. This inhibitor abrogated the toxic effects of Aβ oligomers on dendritic spines and synapses as assayed at the morphological and electrophysiological levels.",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 635,
      "target": 865,
      "key": "3f784e60a177974f1542210281bbe9084d75ad5a12852cdb07c74edf0d864df28dfd2aee215cee71069d359b553f9385f3b2ac730cf3cb8a1d06d4c210d2a142"
    },
    {
      "line": 2685,
      "relation": "negativeCorrelation",
      "evidence": "Overexpression of MARK4 led to tau hyperphosphorylation, reduced expression of synaptic markers, and loss of dendritic spines and synapses, phenotypes also observed after Aβ treatment. Importantly, expression of a non-phosphorylatable form of tau with the PAR-1/MARK site mutated blocked the synaptic toxicity induced by MARK4 overexpression or Aβ treatment. To probe the involvement of endogenous MARK kinases in mediating the synaptic toxicity of Aβ, we employed a peptide inhibitor capable of effectively and specifically inhibiting the activities of all PAR-1/MARK family members. This inhibitor abrogated the toxic effects of Aβ oligomers on dendritic spines and synapses as assayed at the morphological and electrophysiological levels.",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 635,
      "target": 80,
      "key": "0b7ec8592bcd62e4466012f27232478917e3071306ac748cf38b59b4c8fe57169b231df31777f192c0a813e387205c9cde749a0b40af8ebbb501e5abcf2ee3f1"
    },
    {
      "line": 2686,
      "relation": "negativeCorrelation",
      "evidence": "Overexpression of MARK4 led to tau hyperphosphorylation, reduced expression of synaptic markers, and loss of dendritic spines and synapses, phenotypes also observed after Aβ treatment. Importantly, expression of a non-phosphorylatable form of tau with the PAR-1/MARK site mutated blocked the synaptic toxicity induced by MARK4 overexpression or Aβ treatment. To probe the involvement of endogenous MARK kinases in mediating the synaptic toxicity of Aβ, we employed a peptide inhibitor capable of effectively and specifically inhibiting the activities of all PAR-1/MARK family members. This inhibitor abrogated the toxic effects of Aβ oligomers on dendritic spines and synapses as assayed at the morphological and electrophysiological levels.",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 635,
      "target": 89,
      "key": "d518dc9840a2f8e3ad8c1f85e10244c2c2b4cf72983908b9bd693855298ace2c1385f08b8853bf73cd6dd8b3ea3df015139c9a5f2249f98c984a7487fd4f4417"
    },
    {
      "line": 1769,
      "relation": "positiveCorrelation",
      "evidence": "Immunohistochemical analyses using isoform-selective antibodies demonstrated that MARK4 in a phosphorylated form colocalizes with p-tau Ser262 in granulovacuolar degeneration bodies (GVDs) that progressively accumulate in AD.",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 129,
      "target": 636,
      "key": "ec2a5f90c9e53f347cafcaef8bdc7d80fa12ddda144608f04ad92d53588f71c181e6cd0552dec33deb5afcbbbb687b5d29f7e6f41865e285a515f8584e9d98d2"
    },
    {
      "line": 1770,
      "relation": "positiveCorrelation",
      "evidence": "Immunohistochemical analyses using isoform-selective antibodies demonstrated that MARK4 in a phosphorylated form colocalizes with p-tau Ser262 in granulovacuolar degeneration bodies (GVDs) that progressively accumulate in AD.",
      "citation": {
        "type": "PubMed",
        "reference": "11943212",
        "name": "FEBS letters",
        "title": "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.",
        "volume": "515",
        "pages": "151-4",
        "date": "2002-03-27",
        "first": "Buée-Scherrer V",
        "last": "Goedert M",
        "authors": [
          "Buée-Scherrer V",
          "Goedert M"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 129,
      "target": 557,
      "key": "1c1051cd20b8f06cb6ebcf903717d83b3497a5642ec63ae83d6911c0623da4e7e55f2cbd3bf5b7b805bb4c953bfe47a340e552f048808308eb713674b6ec6f56"
    },
    {
      "line": 1780,
      "relation": "negativeCorrelation",
      "evidence": "MARK4 was extremely decreased in the brain regions with a mass of PrPSc in a G114V gCJD patient, but was clearly observable in the regions with a minimum amount of PrPSc or without detectable PrPSc in a D178N FFI patient.",
      "citation": {
        "type": "PubMed",
        "reference": "22692785",
        "name": "International journal of molecular medicine",
        "title": "Reduction of protein kinase MARK4 in the brains of experimental scrapie rodents and human prion disease correlates with deposits of PrP(Sc).",
        "volume": "30",
        "pages": "569-78",
        "date": "2012-09-01",
        "first": "Gong HS",
        "last": "Dong XP",
        "authors": [
          "Chen C",
          "Dong XP",
          "Gong HS",
          "Guo Y",
          "Liu Y",
          "Shi Q",
          "Tian C",
          "Wang SB",
          "Xie WL",
          "Xu Y",
          "Zhang BY",
          "Zhang J"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Creutzfeldt-Jakob Syndrome": true,
          "Insomnia, Fatal Familial": true
        }
      },
      "source": 366,
      "target": 635,
      "key": "c75da77d46137b6fe8f550a58aefc96864b4e64524ab5887472a152c03060794f92ec045959f3ed9c494c4891147bc40dbc0fc66d79a49552312dd1c22331e9b"
    },
    {
      "line": 1785,
      "relation": "decreases",
      "evidence": "These finding highlight that treatment of PrP106-126 in cultured cells does not alter the level of total tau, but induces a reduction of p-tau262.",
      "citation": {
        "type": "PubMed",
        "reference": "22692785",
        "name": "International journal of molecular medicine",
        "title": "Reduction of protein kinase MARK4 in the brains of experimental scrapie rodents and human prion disease correlates with deposits of PrP(Sc).",
        "volume": "30",
        "pages": "569-78",
        "date": "2012-09-01",
        "first": "Gong HS",
        "last": "Dong XP",
        "authors": [
          "Chen C",
          "Dong XP",
          "Gong HS",
          "Guo Y",
          "Liu Y",
          "Shi Q",
          "Tian C",
          "Wang SB",
          "Xie WL",
          "Xu Y",
          "Zhang BY",
          "Zhang J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "PC12": true,
          "SK-N-SH": true
        }
      },
      "source": 324,
      "target": 557,
      "key": "4b144f62dc76bf95dca7b02b506102e09089f299ec0a7c61665b7baf056eef6acfce1c67a217c4fe27d12d817ee43a0b5f22a049d6520125cceb3c0765e0b062"
    },
    {
      "line": 1793,
      "relation": "positiveCorrelation",
      "evidence": "To probe the involvement of endogenous MARK kinases in mediating the synaptic toxicity of Aβ, we employed a peptide inhibitor capable of effectively and specifically inhibiting the activities of all PAR-1/MARK family members. This inhibitor abrogated the toxic effects of Aβ oligomers on dendritic spines and synapses as assayed at the morphological and electrophysiological levels.",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 759,
      "target": 124,
      "key": "27b20fa981b689ed8bd1bf40e6d6afbe1268e23eac1a4b1bf538d45ce3c80f62f4bfc3e0ad1fc419071f18cc7e4a6b49e263ad7a0de52a493f01e37972d75f19"
    },
    {
      "line": 1800,
      "relation": "positiveCorrelation",
      "evidence": "We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "annotations": {
        "Tau_Motif": {
          "KXGS": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 759,
      "target": 557,
      "key": "7b41398cea9e95773639591461e89c8db361c9263b11a247b6b8c98376db9c2294a71139b4a5825daf4ff5c7fb5c6f2d6271455f44ee836e2e042617a80db34a"
    },
    {
      "line": 1801,
      "relation": "positiveCorrelation",
      "evidence": "We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "annotations": {
        "Tau_Motif": {
          "KXGS": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 759,
      "target": 563,
      "key": "e52e3cb037634fcce5c2b36e330169e28fc5e6175b83133e3b6cf7425cad9e200bb53f66ca48b727888c9743878ef316e9eb694d04572a7493e39cd7c709991d"
    },
    {
      "line": 1793,
      "relation": "positiveCorrelation",
      "evidence": "To probe the involvement of endogenous MARK kinases in mediating the synaptic toxicity of Aβ, we employed a peptide inhibitor capable of effectively and specifically inhibiting the activities of all PAR-1/MARK family members. This inhibitor abrogated the toxic effects of Aβ oligomers on dendritic spines and synapses as assayed at the morphological and electrophysiological levels.",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 124,
      "target": 759,
      "key": "ac92bf18892aeaeb05d93bf6e792a1ec72604819235805440d4e1466b85143accb312da29df8bcfe1d19adb175f0a8cb9a77375a071a9baad3f68383b9924210"
    },
    {
      "line": 1805,
      "relation": "positiveCorrelation",
      "evidence": "We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A). It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "source": 113,
      "target": 117,
      "key": "db7607e8ebac3b5b76c4fa217edc7dde444bd2ccb63766e562bb4d3a71939770a685aa36242d83ff439604c192cd4c65978545e933b5f4a7222891be1a6f0838"
    },
    {
      "line": 2661,
      "relation": "positiveCorrelation",
      "evidence": "We demonstrate that elevated HDAC6 activity increases phosphorylation of tau at the 12E8 epitope (pS262/356), a phospho-epitope present within the KXGS motifs of tau’s microtubule-binding domain. The phosphorylation of KXGS motifs within tau by the kinase Par-1/MARK2 is required for tau proteotoxicity in Drosophila [29], observed at very early stages of NFT formation in AD brain [30], and appears to prime tau for subsequent phosphorylation events",
      "citation": {
        "type": "PubMed",
        "reference": "25031639",
        "name": "Alzheimer's research &amp; therapy",
        "title": "Acetylation: a new key to unlock tau's role in neurodegeneration.",
        "volume": "6",
        "pages": "29",
        "date": "2014-01-01",
        "first": "Cook C",
        "last": "Petrucelli L",
        "authors": [
          "Carlomagno Y",
          "Cook C",
          "Petrucelli L",
          "Stankowski JN",
          "Stetler C"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 113,
      "target": 459,
      "key": "1a40cb3c765bb5f66793b9d159ff0374f2d7901d3316d3f4b67a41cfe2e7c2a0c65a696fa977c93f04480931a02f8b623ae4031091d9fc3c0299d61a5f329652"
    },
    {
      "line": 2662,
      "relation": "partOf",
      "evidence": "We demonstrate that elevated HDAC6 activity increases phosphorylation of tau at the 12E8 epitope (pS262/356), a phospho-epitope present within the KXGS motifs of tau’s microtubule-binding domain. The phosphorylation of KXGS motifs within tau by the kinase Par-1/MARK2 is required for tau proteotoxicity in Drosophila [29], observed at very early stages of NFT formation in AD brain [30], and appears to prime tau for subsequent phosphorylation events",
      "citation": {
        "type": "PubMed",
        "reference": "25031639",
        "name": "Alzheimer's research &amp; therapy",
        "title": "Acetylation: a new key to unlock tau's role in neurodegeneration.",
        "volume": "6",
        "pages": "29",
        "date": "2014-01-01",
        "first": "Cook C",
        "last": "Petrucelli L",
        "authors": [
          "Carlomagno Y",
          "Cook C",
          "Petrucelli L",
          "Stankowski JN",
          "Stetler C"
        ]
      },
      "source": 113,
      "target": 318,
      "key": "0dc9076acdd4b82dc7d82c572958889a95b0a457e2a66c14e0bcfbe6f18a1c28eea8792f94311424f51086c7c49dd4988bc63532976ea151eb2b58f3176a2fb6"
    },
    {
      "line": 2670,
      "relation": "negativeCorrelation",
      "evidence": "In particular, previous studies have demonstrated that the tau ubiquitin ligase, CHIP, is unable to bind and ubiquitinate tau species phosphorylated by Par-1/MARK2 on the 12E8 epitope (S262/356) [33], a p-tau species that is also resistant to degradation upon treatment with Hsp90 inhibitors [32,33]. Tau phosphorylated at the PHF1 epitope (S396/404) is still susceptible to degradation following Hsp90 inhibition and actually exhibits an enhanced interaction with Hsp90",
      "citation": {
        "type": "PubMed",
        "reference": "25031639",
        "name": "Alzheimer's research &amp; therapy",
        "title": "Acetylation: a new key to unlock tau's role in neurodegeneration.",
        "volume": "6",
        "pages": "29",
        "date": "2014-01-01",
        "first": "Cook C",
        "last": "Petrucelli L",
        "authors": [
          "Carlomagno Y",
          "Cook C",
          "Petrucelli L",
          "Stankowski JN",
          "Stetler C"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 113,
      "target": 691,
      "key": "578c6bb466675f5a8e64ce3b8055ce5aa78770510cf5e14156cfca232407fc496e6fec7b0cc49a88add7e3ffe28195a7ee4c789bd07fb67b4ba20d011d77ccdd"
    },
    {
      "line": 1814,
      "relation": "positiveCorrelation",
      "evidence": "Human microtubule affinity-regulating kinase 4S (hMARK4S),undetectable in human neural progenitor cells (HNPCs) and NTera2 (NT2) cells, is up-regulated in both cell systems from the very early stages of neuronal differentiation, suggesting euronal commitment is marked by MARK4S up-regulation.",
      "citation": {
        "type": "PubMed",
        "reference": "16973293",
        "name": "Neuroscience",
        "title": "Distinct expression pattern of microtubule-associated protein/microtubule affinity-regulating kinase 4 in differentiated neurons.",
        "volume": "143",
        "pages": "83-94",
        "date": "2006-11-17",
        "first": "Moroni RF",
        "last": "Beghini A",
        "authors": [
          "Beghini A",
          "Colapietro P",
          "De Biasi S",
          "Larizza L",
          "Moroni RF"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HNPC": true,
          "NT2": true
        }
      },
      "source": 321,
      "target": 191,
      "key": "292bc80c6781f8ede1dbdde1cf3aee87d4c34c5d436a935c9cbf7afa167568c59e12a9d48f0fc71a918faf7e1546ac2d0d35a402c2fd09fb2a379e632989e66b"
    },
    {
      "line": 1815,
      "relation": "isA",
      "evidence": "Human microtubule affinity-regulating kinase 4S (hMARK4S),undetectable in human neural progenitor cells (HNPCs) and NTera2 (NT2) cells, is up-regulated in both cell systems from the very early stages of neuronal differentiation, suggesting euronal commitment is marked by MARK4S up-regulation.",
      "citation": {
        "type": "PubMed",
        "reference": "16973293",
        "name": "Neuroscience",
        "title": "Distinct expression pattern of microtubule-associated protein/microtubule affinity-regulating kinase 4 in differentiated neurons.",
        "volume": "143",
        "pages": "83-94",
        "date": "2006-11-17",
        "first": "Moroni RF",
        "last": "Beghini A",
        "authors": [
          "Beghini A",
          "Colapietro P",
          "De Biasi S",
          "Larizza L",
          "Moroni RF"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HNPC": true,
          "NT2": true
        }
      },
      "source": 321,
      "target": 635,
      "key": "5d1d18c7caa5fd5504432fef20e858ffad96055dd8e098bad4dd4f01a9e79e0b9243634a69245a5542b20a56d4cca734984ce1d8c680d7643732451fe3f0cce0"
    },
    {
      "line": 1814,
      "relation": "positiveCorrelation",
      "evidence": "Human microtubule affinity-regulating kinase 4S (hMARK4S),undetectable in human neural progenitor cells (HNPCs) and NTera2 (NT2) cells, is up-regulated in both cell systems from the very early stages of neuronal differentiation, suggesting euronal commitment is marked by MARK4S up-regulation.",
      "citation": {
        "type": "PubMed",
        "reference": "16973293",
        "name": "Neuroscience",
        "title": "Distinct expression pattern of microtubule-associated protein/microtubule affinity-regulating kinase 4 in differentiated neurons.",
        "volume": "143",
        "pages": "83-94",
        "date": "2006-11-17",
        "first": "Moroni RF",
        "last": "Beghini A",
        "authors": [
          "Beghini A",
          "Colapietro P",
          "De Biasi S",
          "Larizza L",
          "Moroni RF"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HNPC": true,
          "NT2": true
        }
      },
      "source": 191,
      "target": 321,
      "key": "85271ba31682d842cf4d5b86eac820361e6d16943b2cb58c35aa1e207cfde1408f7622470ed02af016c5ba1cc9db7076ccf0bb6fe7f0d055a70c118428dee7ec"
    },
    {
      "line": 1827,
      "relation": "increases",
      "evidence": "Only middle-aged Tet-mev-1 mice showed JNK/MARK activation and Ca2+ overload, particularly in astrocytes with decreased hippocampal GFAP and S100ß, but without pathological features such as apoptosis, amyloidosis, and lactic acidosis in neurons and astrocytes. This led to decreasing levels of glial fibrillary acidic protein and S100β in the hippocampal area.",
      "citation": {
        "type": "PubMed",
        "reference": "27623715",
        "name": "Aging cell",
        "title": "Endogenous reactive oxygen species cause astrocyte defects and neuronal dysfunctions in the hippocampus: a new model for aging brain.",
        "volume": "16",
        "pages": "39-51",
        "date": "2017-02-01",
        "first": "Ishii T",
        "last": "Ishii N",
        "authors": [
          "Hartman PS",
          "Ishii N",
          "Ishii T",
          "Kawabe N",
          "Miyazawa M",
          "Nakata M",
          "Onouchi H",
          "Sugita K",
          "Takanashi Y",
          "Yamamoto Y",
          "Yanagihara R",
          "Yasuda K"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Study_Group": {
          "Tet-mev-1 mice": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Cell": {
          "astrocyte": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 205,
      "target": 291,
      "key": "77b76f4ff097c838d8dc2485e479a5565240616e501d42f05232b3154d05dd4cd84529b7f88bc5a9e7e77a228ef93869f183ed11df7f29568a15cbb18af99c06"
    },
    {
      "line": 1828,
      "relation": "increases",
      "evidence": "Only middle-aged Tet-mev-1 mice showed JNK/MARK activation and Ca2+ overload, particularly in astrocytes with decreased hippocampal GFAP and S100ß, but without pathological features such as apoptosis, amyloidosis, and lactic acidosis in neurons and astrocytes. This led to decreasing levels of glial fibrillary acidic protein and S100β in the hippocampal area.",
      "citation": {
        "type": "PubMed",
        "reference": "27623715",
        "name": "Aging cell",
        "title": "Endogenous reactive oxygen species cause astrocyte defects and neuronal dysfunctions in the hippocampus: a new model for aging brain.",
        "volume": "16",
        "pages": "39-51",
        "date": "2017-02-01",
        "first": "Ishii T",
        "last": "Ishii N",
        "authors": [
          "Hartman PS",
          "Ishii N",
          "Ishii T",
          "Kawabe N",
          "Miyazawa M",
          "Nakata M",
          "Onouchi H",
          "Sugita K",
          "Takanashi Y",
          "Yamamoto Y",
          "Yanagihara R",
          "Yasuda K"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Study_Group": {
          "Tet-mev-1 mice": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Cell": {
          "astrocyte": true
        }
      },
      "source": 205,
      "target": 13,
      "key": "2222352e33e9a3ef0c79ca6ab58169563e81a79704fde84e2677cd9af026735623e5c39d3c550cc6047a037a69b984aacc4864611cfa686fa6b5502f05e6be25"
    },
    {
      "line": 1829,
      "relation": "decreases",
      "evidence": "Only middle-aged Tet-mev-1 mice showed JNK/MARK activation and Ca2+ overload, particularly in astrocytes with decreased hippocampal GFAP and S100ß, but without pathological features such as apoptosis, amyloidosis, and lactic acidosis in neurons and astrocytes. This led to decreasing levels of glial fibrillary acidic protein and S100β in the hippocampal area.",
      "citation": {
        "type": "PubMed",
        "reference": "27623715",
        "name": "Aging cell",
        "title": "Endogenous reactive oxygen species cause astrocyte defects and neuronal dysfunctions in the hippocampus: a new model for aging brain.",
        "volume": "16",
        "pages": "39-51",
        "date": "2017-02-01",
        "first": "Ishii T",
        "last": "Ishii N",
        "authors": [
          "Hartman PS",
          "Ishii N",
          "Ishii T",
          "Kawabe N",
          "Miyazawa M",
          "Nakata M",
          "Onouchi H",
          "Sugita K",
          "Takanashi Y",
          "Yamamoto Y",
          "Yanagihara R",
          "Yasuda K"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Study_Group": {
          "Tet-mev-1 mice": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Cell": {
          "astrocyte": true
        }
      },
      "source": 205,
      "target": 673,
      "key": "4b828774f449af2f3addc3265df959850c8f5ecf57f998355521bb4d1c93354a609df7682b71b90792d44acaf021263a45e13b4a23c39f8245524af3d98872e4"
    },
    {
      "line": 1831,
      "relation": "causesNoChange",
      "evidence": "Only middle-aged Tet-mev-1 mice showed JNK/MARK activation and Ca2+ overload, particularly in astrocytes with decreased hippocampal GFAP and S100ß, but without pathological features such as apoptosis, amyloidosis, and lactic acidosis in neurons and astrocytes. This led to decreasing levels of glial fibrillary acidic protein and S100β in the hippocampal area.",
      "citation": {
        "type": "PubMed",
        "reference": "27623715",
        "name": "Aging cell",
        "title": "Endogenous reactive oxygen species cause astrocyte defects and neuronal dysfunctions in the hippocampus: a new model for aging brain.",
        "volume": "16",
        "pages": "39-51",
        "date": "2017-02-01",
        "first": "Ishii T",
        "last": "Ishii N",
        "authors": [
          "Hartman PS",
          "Ishii N",
          "Ishii T",
          "Kawabe N",
          "Miyazawa M",
          "Nakata M",
          "Onouchi H",
          "Sugita K",
          "Takanashi Y",
          "Yamamoto Y",
          "Yanagihara R",
          "Yasuda K"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Study_Group": {
          "Tet-mev-1 mice": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Cell": {
          "astrocyte": true,
          "neuron": true
        }
      },
      "source": 205,
      "target": 174,
      "key": "063095011cb0dc126b2d2b47c6678a9516c7b0a94633afa5a8efa23240ad3fca561209e95f336fd61aa8e78749b41c8a7da52e4fa11b00fdf6ccbe7b9cbfaf7d"
    },
    {
      "line": 1832,
      "relation": "causesNoChange",
      "evidence": "Only middle-aged Tet-mev-1 mice showed JNK/MARK activation and Ca2+ overload, particularly in astrocytes with decreased hippocampal GFAP and S100ß, but without pathological features such as apoptosis, amyloidosis, and lactic acidosis in neurons and astrocytes. This led to decreasing levels of glial fibrillary acidic protein and S100β in the hippocampal area.",
      "citation": {
        "type": "PubMed",
        "reference": "27623715",
        "name": "Aging cell",
        "title": "Endogenous reactive oxygen species cause astrocyte defects and neuronal dysfunctions in the hippocampus: a new model for aging brain.",
        "volume": "16",
        "pages": "39-51",
        "date": "2017-02-01",
        "first": "Ishii T",
        "last": "Ishii N",
        "authors": [
          "Hartman PS",
          "Ishii N",
          "Ishii T",
          "Kawabe N",
          "Miyazawa M",
          "Nakata M",
          "Onouchi H",
          "Sugita K",
          "Takanashi Y",
          "Yamamoto Y",
          "Yanagihara R",
          "Yasuda K"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Study_Group": {
          "Tet-mev-1 mice": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Cell": {
          "astrocyte": true,
          "neuron": true
        }
      },
      "source": 205,
      "target": 907,
      "key": "4baf24f74ccf487db7a3ded6f2ba6e050b5af65a4db7ec56e2c1206a7a37fe6c61eb8d134c6fecbc7b29100d554f92523d184caeeae8a3f97c5d25c4cc54f96f"
    },
    {
      "line": 1833,
      "relation": "causesNoChange",
      "evidence": "Only middle-aged Tet-mev-1 mice showed JNK/MARK activation and Ca2+ overload, particularly in astrocytes with decreased hippocampal GFAP and S100ß, but without pathological features such as apoptosis, amyloidosis, and lactic acidosis in neurons and astrocytes. This led to decreasing levels of glial fibrillary acidic protein and S100β in the hippocampal area.",
      "citation": {
        "type": "PubMed",
        "reference": "27623715",
        "name": "Aging cell",
        "title": "Endogenous reactive oxygen species cause astrocyte defects and neuronal dysfunctions in the hippocampus: a new model for aging brain.",
        "volume": "16",
        "pages": "39-51",
        "date": "2017-02-01",
        "first": "Ishii T",
        "last": "Ishii N",
        "authors": [
          "Hartman PS",
          "Ishii N",
          "Ishii T",
          "Kawabe N",
          "Miyazawa M",
          "Nakata M",
          "Onouchi H",
          "Sugita K",
          "Takanashi Y",
          "Yamamoto Y",
          "Yanagihara R",
          "Yasuda K"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Study_Group": {
          "Tet-mev-1 mice": true
        },
        "Anatomy": {
          "hippocampal formation": true
        },
        "Cell": {
          "astrocyte": true,
          "neuron": true
        }
      },
      "source": 205,
      "target": 172,
      "key": "8e22fc3aa6b56897816a93f78865fef6d5b4493ba166870dfd8ec9c41a80163a2a4497b6d8f71393e178485e3da1ac3dc2a9548836473abed6ca5bebbde6dbe7"
    },
    {
      "line": 2725,
      "relation": "decreases",
      "evidence": "Primary cortical neurons exposed to the mitochondrial toxin NaN3 (0.1-3 mM) were submitted to oxidative stress with H2O2 (30-150 μM), to mimic conditions observed in neurodegenerative disorders. The effects of such treatment on a series of parameters useful in characterizing neuronal damage were investigated: (i) the basal release of glutamate, evaluated as (3)H-d-Aspartate efflux, was sharply, concentration-dependently, increased; (ii) the phosphorylation status of intracellular markers known to be involved in the neurodegenerative processes, in particular in Alzheimer disease: tau and GSK3β were increased, as well as the protein level of β-secretase (BACE1) and p35/25 evaluated by Western blotting, while (iii) the cell metabolic activity, measured with the MTT method, was reduced, in a concentration- and time-dependent manner. The latter effect, as well as tau hyperphosphorylation, was prevented both by a mixture of antioxidant drugs (100 μM ascorbic acid, 10 μM trolox, 100 μM glutathione) and by the anti-Alzheimer drug, memantine, 20 μM.",
      "citation": {
        "type": "PubMed",
        "reference": "23722080",
        "name": "Neurochemistry international",
        "title": "In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease.",
        "volume": "63",
        "pages": "112-20",
        "date": "2013-08-01",
        "first": "Selvatici R",
        "last": "Siniscalchi A",
        "authors": [
          "Marani L",
          "Marino S",
          "Selvatici R",
          "Siniscalchi A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 205,
      "target": 88,
      "key": "8e1a360306277d46ce9f8346b32755e6b1811e47713488d845be3f756507db7fb09417631dd2aba83fd0386ae17c57fd83cad79fff54a2d6023b5a63261ca537"
    },
    {
      "line": 2805,
      "relation": "positiveCorrelation",
      "evidence": "Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor known to increase the level of many antioxidants, including glutathione-S transferase (GST), and is negatively regulated by the activity of GSK-3β. Our results indicated the increased nuclear localization of Nrf2 and level of GST, suggesting the increased activity of the transcription factor as a result of GSK-3β suppression, consistent with the decreased oxidative stress observed. Consistent with the improved learning and memory, and consistent with GSK-3b being a tau kinase, we observed decreased tau phosphorylation in brain of GAO-treated SAMP8 mice compared to that of RAO-treated SAMP8 mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24355211",
        "name": "Free radical biology &amp; medicine",
        "title": "Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease.",
        "volume": "67",
        "pages": "387-95",
        "date": "2014-02-01",
        "first": "Farr SA",
        "last": "Butterfield DA",
        "authors": [
          "Butterfield DA",
          "Farr SA",
          "Kumar V",
          "Morley JE",
          "Murphy MP",
          "Niehoff ML",
          "Platt TL",
          "Ripley JL",
          "Sultana R",
          "Zhang Z"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "SAMP8 mice": true
        }
      },
      "source": 205,
      "target": 456,
      "key": "6c71c8c05edfc5e2868dec5a122d0c28e74a2320b700b2c38259447ca1ddfef8e8eee31d5210e6a353764d5234ff51d1e968d6d48776a1fc1958e00e484336fd"
    },
    {
      "line": 2818,
      "relation": "increases",
      "evidence": ">8 phosphates per tau molecules (vs 2 in adult healthy brain); can also be increased during development, hibernation and temperature, heat and oxydative stress These phosphorylated states are detected by specific antibodies and are targets of proline-directed kinases (SP motifs), non-proline kinases (KXGS motif) Weakens tau-MT interaction especially S261 in R1 and S214 in proline-rich domain",
      "citation": {
        "type": "PubMed",
        "reference": "8226987",
        "name": "The Journal of biological chemistry",
        "title": "Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease.",
        "volume": "268",
        "pages": "24374-84",
        "date": "1993-11-15",
        "first": "Köpke E",
        "last": "Grundke-Iqbal I",
        "authors": [
          "Alonso AC",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Köpke E",
          "Shaikh S",
          "Tung YC"
        ]
      },
      "source": 205,
      "target": 516,
      "key": "167e5b1ebe4541fddf99975ec66854af9e4eaac7e2afe1e7557990b54a031514325e0c2e0a40f647de2986dc83610c060ba847e7a09cf590f18faf1ddf461f76"
    },
    {
      "line": 2935,
      "relation": "increases",
      "evidence": "Though whole tau assembled poorly, constructs containing three internal repeats (corresponding to the fetal tau isoform) formed PHFs reproducibly. This ability depended on intermolecular disulfide bridges formed by the single Cys-322. Blocking the SH group, mutating Cys for Ala, or keeping T in a reducing environment all inhibited assembly. On the other hand, Cys-322 can be oxidized, and this leads to PHF assembly (ref. 11; this report). In vitro this is achieved most easily by using constructs of the 'fetal' isoform of T (htau23) that has only three repeats. Conversely, reducing agents or the second repeat or T can be viewed as 'antidotes' against PHF assembly.The synthetic PHFs bound the dye thioflavin S used in Alzheimer disease diagnostics.",
      "citation": {
        "type": "PubMed",
        "reference": "7667312",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments.",
        "volume": "92",
        "pages": "8463-7",
        "date": "1995-08-29",
        "first": "Schweers O",
        "last": "Mandelkow E",
        "authors": [
          "Biernat J",
          "Mandelkow E",
          "Mandelkow EM",
          "Schweers O"
        ]
      },
      "source": 205,
      "target": 132,
      "key": "0aa12fae18b2be719522350db69aee018742bbaac7d4eb51f6a7d99491687d2b03ccf1435473a00c354d115c333726547e53710fe74066e1f42c896b04d64e72"
    },
    {
      "line": 1848,
      "relation": "increases",
      "evidence": "In parallel, phosphorylation of tau at Ser262 in MARK-transfected cells was investigated using a rabbit antibody recognizing phosphorylated Ser262 of tau (AGG5759) and a mouse anti-tau antibody (SC-21796) (Fig. S1a3). Tau was shown to interact with each of the transfected MARK isoforms (Fig. 1) and to be phosphorylated at Ser262 (Fig. 2). Staurosporine, a non-selective kinase inhibitor, significantly inhibited interactions between tau and each of the four MARK isoforms after treatment with 20 lM staurosporine for 1 h (Fig. 1; p = 0.02 for MARK1–, MARK2– and MARK3–tau interactions and p = 3 9 10-6 for MARK4–tau interaction). Treatment with staurosporine also significantly reduced PLA signals for tau phosphorylation at Ser262 (Fig. 2; p = 0.04 for MARK1- and p = 0.02 for MARK2- and MARK3- and p = 1 9 10-5 for MARK4-mediated tau phosphorylation)",
      "citation": {
        "type": "PubMed",
        "reference": "23666762",
        "name": "Neuromolecular medicine",
        "title": "Role of individual MARK isoforms in phosphorylation of tau at Ser²⁶² in Alzheimer's disease.",
        "volume": "15",
        "pages": "458-69",
        "date": "2013-09-01",
        "first": "Gu GJ",
        "last": "Kamali-Moghaddam M",
        "authors": [
          "Blokzijl A",
          "Classon C",
          "Gu GJ",
          "Kamali-Moghaddam M",
          "Landegren U",
          "Lund H",
          "Sunnemark D",
          "Wu D",
          "von Euler G"
        ]
      },
      "source": 326,
      "target": 557,
      "key": "c40535811c31665b3e7a7bc11a8b309bef44907728065b1e2fe40f51c869e0708498fd6ae543bd7e4b71bab5ea5499862f5c442185069f2a30958f42dd6fa803"
    },
    {
      "line": 1849,
      "relation": "increases",
      "evidence": "In parallel, phosphorylation of tau at Ser262 in MARK-transfected cells was investigated using a rabbit antibody recognizing phosphorylated Ser262 of tau (AGG5759) and a mouse anti-tau antibody (SC-21796) (Fig. S1a3). Tau was shown to interact with each of the transfected MARK isoforms (Fig. 1) and to be phosphorylated at Ser262 (Fig. 2). Staurosporine, a non-selective kinase inhibitor, significantly inhibited interactions between tau and each of the four MARK isoforms after treatment with 20 lM staurosporine for 1 h (Fig. 1; p = 0.02 for MARK1–, MARK2– and MARK3–tau interactions and p = 3 9 10-6 for MARK4–tau interaction). Treatment with staurosporine also significantly reduced PLA signals for tau phosphorylation at Ser262 (Fig. 2; p = 0.04 for MARK1- and p = 0.02 for MARK2- and MARK3- and p = 1 9 10-5 for MARK4-mediated tau phosphorylation)",
      "citation": {
        "type": "PubMed",
        "reference": "23666762",
        "name": "Neuromolecular medicine",
        "title": "Role of individual MARK isoforms in phosphorylation of tau at Ser²⁶² in Alzheimer's disease.",
        "volume": "15",
        "pages": "458-69",
        "date": "2013-09-01",
        "first": "Gu GJ",
        "last": "Kamali-Moghaddam M",
        "authors": [
          "Blokzijl A",
          "Classon C",
          "Gu GJ",
          "Kamali-Moghaddam M",
          "Landegren U",
          "Lund H",
          "Sunnemark D",
          "Wu D",
          "von Euler G"
        ]
      },
      "source": 330,
      "target": 557,
      "key": "13ccfcc8eebc08886a15ddba40086d47fcdc2d464dc62f364eb07bfe1f51272ef1eeb9723b2397a3734b8f6e52b549d2d1c5e8590b50182c13ec340c8c939e75"
    },
    {
      "line": 1853,
      "relation": "decreases",
      "evidence": "In cells, a CagA peptide inhibited tau phosphorylation at Ser²6² mediated by MARK4 but not other MARK isoforms. A strong and significant elevation of MARK4 expression and MARK4-tau interactions in AD brains correlated with the Braak stages of the disease.",
      "citation": {
        "type": "PubMed",
        "reference": "23666762",
        "name": "Neuromolecular medicine",
        "title": "Role of individual MARK isoforms in phosphorylation of tau at Ser²⁶² in Alzheimer's disease.",
        "volume": "15",
        "pages": "458-69",
        "date": "2013-09-01",
        "first": "Gu GJ",
        "last": "Kamali-Moghaddam M",
        "authors": [
          "Blokzijl A",
          "Classon C",
          "Gu GJ",
          "Kamali-Moghaddam M",
          "Landegren U",
          "Lund H",
          "Sunnemark D",
          "Wu D",
          "von Euler G"
        ]
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 314,
      "target": 635,
      "key": "9aabace0c2128368ec3ebc52cfe861c050361b22d223983bad0a4d7c0a4a13aef655eed0ce643dc014bc981e7e95152e9c33bc98fe3d143800db5559cfb55f11"
    },
    {
      "line": 1880,
      "relation": "increases",
      "evidence": "DAPK1, but not its kinase deficient mutant (K42A), significantly increased human Aβ secretion in neuronal cell culture models. Moreover, knockdown of DAPK1 expression or inhibition of DAPK1 catalytic activity significantly decreased Aβ secretion. Furthermore, DAPK1, but not K42A, triggered Thr668 phosphorylation of APP, which may initiate and facilitate amyloidogenic APP processing leading to the generation of Aβ.",
      "citation": {
        "type": "PubMed",
        "reference": "27094130",
        "name": "Human molecular genetics",
        "title": "Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein.",
        "volume": "25",
        "pages": "2498-2513",
        "date": "2016-06-15",
        "first": "Kim BM",
        "last": "Ho Lee T",
        "authors": [
          "Chen CH",
          "Ho Lee T",
          "Kim BM",
          "Suh J",
          "Tanzi RE",
          "You MH"
        ]
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "bel",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "bel",
            "name": "extracellular space"
          }
        }
      },
      "source": 431,
      "target": 376,
      "key": "f9c858485a54b7eadd0af5bb8113f81966548fb96e4ac615a3ac043fc1928dd03fd284ae3d022aeb326a86582b0dda1918016cd29a24baad223e0072602507e9"
    },
    {
      "line": 1881,
      "relation": "positiveCorrelation",
      "evidence": "DAPK1, but not its kinase deficient mutant (K42A), significantly increased human Aβ secretion in neuronal cell culture models. Moreover, knockdown of DAPK1 expression or inhibition of DAPK1 catalytic activity significantly decreased Aβ secretion. Furthermore, DAPK1, but not K42A, triggered Thr668 phosphorylation of APP, which may initiate and facilitate amyloidogenic APP processing leading to the generation of Aβ.",
      "citation": {
        "type": "PubMed",
        "reference": "27094130",
        "name": "Human molecular genetics",
        "title": "Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein.",
        "volume": "25",
        "pages": "2498-2513",
        "date": "2016-06-15",
        "first": "Kim BM",
        "last": "Ho Lee T",
        "authors": [
          "Chen CH",
          "Ho Lee T",
          "Kim BM",
          "Suh J",
          "Tanzi RE",
          "You MH"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "bel",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "bel",
            "name": "extracellular space"
          }
        }
      },
      "source": 431,
      "target": 376,
      "key": "0264da4d2c7f0bac60c09d62930e63172e2ffe54e0a1ca6c619c3f0b56b0842144f39814f8a487f26d50a1eee3ea66b58ee2100a3c7e844f55ce1df3b25d1861"
    },
    {
      "line": 1882,
      "relation": "increases",
      "evidence": "DAPK1, but not its kinase deficient mutant (K42A), significantly increased human Aβ secretion in neuronal cell culture models. Moreover, knockdown of DAPK1 expression or inhibition of DAPK1 catalytic activity significantly decreased Aβ secretion. Furthermore, DAPK1, but not K42A, triggered Thr668 phosphorylation of APP, which may initiate and facilitate amyloidogenic APP processing leading to the generation of Aβ.",
      "citation": {
        "type": "PubMed",
        "reference": "27094130",
        "name": "Human molecular genetics",
        "title": "Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein.",
        "volume": "25",
        "pages": "2498-2513",
        "date": "2016-06-15",
        "first": "Kim BM",
        "last": "Ho Lee T",
        "authors": [
          "Chen CH",
          "Ho Lee T",
          "Kim BM",
          "Suh J",
          "Tanzi RE",
          "You MH"
        ]
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "bel",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "bel",
            "name": "extracellular space"
          }
        }
      },
      "source": 431,
      "target": 375,
      "key": "5b2eaa68ab874cfbaa10b6c31a414f4d792d30239b224002316f891203ecec414ce11ddfadf86987cfc8439160af5773f6a64f0fac0e5a2fa4d1dc9ffcf5c97f"
    },
    {
      "line": 1883,
      "relation": "positiveCorrelation",
      "evidence": "DAPK1, but not its kinase deficient mutant (K42A), significantly increased human Aβ secretion in neuronal cell culture models. Moreover, knockdown of DAPK1 expression or inhibition of DAPK1 catalytic activity significantly decreased Aβ secretion. Furthermore, DAPK1, but not K42A, triggered Thr668 phosphorylation of APP, which may initiate and facilitate amyloidogenic APP processing leading to the generation of Aβ.",
      "citation": {
        "type": "PubMed",
        "reference": "27094130",
        "name": "Human molecular genetics",
        "title": "Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein.",
        "volume": "25",
        "pages": "2498-2513",
        "date": "2016-06-15",
        "first": "Kim BM",
        "last": "Ho Lee T",
        "authors": [
          "Chen CH",
          "Ho Lee T",
          "Kim BM",
          "Suh J",
          "Tanzi RE",
          "You MH"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "bel",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "bel",
            "name": "extracellular space"
          }
        }
      },
      "source": 431,
      "target": 375,
      "key": "3292f5fad6faabeda03a9ad7ef8a88678be322655875f304862d0777cfc5115427cf31f4ca6a57cae7cd41e79c6a2672ddc560f45a28b9fdfd9c42b8952fa4ed"
    },
    {
      "relation": "hasVariant",
      "source": 431,
      "target": 433,
      "key": "bdfc6bfcdfb887f04e033b4469238d3005081ed96ad549369d7b60d70c9bf763256e53d897c2d2de0434442edb35f4687730d0202d9644609f1e2cb85e177f6e"
    },
    {
      "relation": "hasVariant",
      "source": 431,
      "target": 434,
      "key": "652126e66324a7af03124a8556e1dd056efea49e11ec2d0e5bdd57f26f93616c34337ba866b91ef00e5f767ce6c26bfd46356dfe0131115b27c1fa6df5d1cfaa"
    },
    {
      "relation": "hasVariant",
      "source": 431,
      "target": 432,
      "key": "478cec2a1832b584338758d337ef0542d48236f219fded2f7af8cc135d3a88213be84824788f2250c91083c4e2b70b047a659c80774f80034ed9bf844c654158"
    },
    {
      "line": 1896,
      "relation": "increases",
      "evidence": "Furthermore, DAPK1-induced APP phosphorylation was suppressed when DAPK1 ΔDD was introduced (Fig. 4G), indicating that DAPK1 regulates Aβ secretion through APP Thr668 phosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "27094130",
        "name": "Human molecular genetics",
        "title": "Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein.",
        "volume": "25",
        "pages": "2498-2513",
        "date": "2016-06-15",
        "first": "Kim BM",
        "last": "Ho Lee T",
        "authors": [
          "Chen CH",
          "Ho Lee T",
          "Kim BM",
          "Suh J",
          "Tanzi RE",
          "You MH"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 431,
      "target": 378,
      "key": "7dcb8d7c5c7fdbf5b9129e8cf09686ac23074671abf1c1a33cb515f47a8e3ba660ce0b8c3ca71710e158cf207cbd6990372476782483b0a0994df8f64c1432f0"
    },
    {
      "line": 1906,
      "relation": "increases",
      "evidence": "Overexpression of UNC5B induces neuronal death by activating death-associated protein kinase (DAPK1) (19) via protein phosphatase 2A-mediated dephosphorylation of DAPK1 (20).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 431,
      "target": 189,
      "key": "1c6ab028025639bacdc909a14ded10e135ccdfc368da90c7daad5156bb560d7fd73d4fd485a854956c905f366e0e0772d44705dac05fae5f6e0c78266a81b02a"
    },
    {
      "line": 1931,
      "relation": "positiveCorrelation",
      "evidence": "In contrast, Pin1/PINN-1 (a DAPK interaction-partner and a peptidyl-prolyl isomerase involved in chronic neurodegenerative conditions) suppresses neurodegeneration in our excitotoxicity model.",
      "citation": {
        "type": "PubMed",
        "reference": "25899010",
        "name": "BMC neuroscience",
        "title": "Death Associated Protein Kinase (DAPK) -mediated neurodegenerative mechanisms in nematode excitotoxicity.",
        "volume": "16",
        "pages": "25",
        "date": "2015-04-23",
        "first": "Del Rosario JS",
        "last": "Mano I",
        "authors": [
          "Ahmed T",
          "Amjad U",
          "An J",
          "Asemota D",
          "Del Rosario JS",
          "Feldmann KG",
          "Ko B",
          "Mahmud T",
          "Mano I",
          "Mei S",
          "Salama M"
        ]
      },
      "annotations": {
        "Species": {
          "6239": true
        }
      },
      "source": 431,
      "target": 139,
      "key": "c763e76947c585ecc7a4942a5a9cdb21fd15fbdc3d1061b1c81336828d4ed433a35a9a112a269ce90407e6f0951fa62134a6554e3258e59d810a39f8114f62ab"
    },
    {
      "line": 1932,
      "relation": "negativeCorrelation",
      "evidence": "In contrast, Pin1/PINN-1 (a DAPK interaction-partner and a peptidyl-prolyl isomerase involved in chronic neurodegenerative conditions) suppresses neurodegeneration in our excitotoxicity model.",
      "citation": {
        "type": "PubMed",
        "reference": "25899010",
        "name": "BMC neuroscience",
        "title": "Death Associated Protein Kinase (DAPK) -mediated neurodegenerative mechanisms in nematode excitotoxicity.",
        "volume": "16",
        "pages": "25",
        "date": "2015-04-23",
        "first": "Del Rosario JS",
        "last": "Mano I",
        "authors": [
          "Ahmed T",
          "Amjad U",
          "An J",
          "Asemota D",
          "Del Rosario JS",
          "Feldmann KG",
          "Ko B",
          "Mahmud T",
          "Mano I",
          "Mei S",
          "Salama M"
        ]
      },
      "annotations": {
        "Species": {
          "6239": true
        }
      },
      "source": 431,
      "target": 647,
      "key": "7b7baeaaff219b36b37616e7931b49ec324dd607f1857c592e7277e535b570757991a63c83259cc4b02ad7eb37cefc6d87eaba221378e13d49c02a1bdf2a8c78"
    },
    {
      "line": 1944,
      "relation": "negativeCorrelation",
      "evidence": "In this report, we describe a novel mechanism of action determined by the JunD component of AP-1, a factor enhancing cell survival in v-Src-transformed cells. We show that the loss of JunD results in the aberrant activation of a genetic program leading to cell death. This program requires the activation of the tumor suppressor death-associated protein kinase 1 (DAPK1). Since DAPK1 is phosphorylated and inhibited by v-Src, these results highlight the importance of this kinase and the multiple mechanisms controlled by v-Src to antagonize the tumor suppressor function of DAPK1.",
      "citation": {
        "type": "PubMed",
        "reference": "27795443",
        "name": "Journal of virology",
        "title": "JunD/AP-1 Antagonizes the Induction of DAPK1 To Promote the Survival of v-Src-Transformed Cells.",
        "volume": "91",
        "date": "2017-01-01",
        "first": "Maślikowski BM",
        "last": "Bédard PA",
        "authors": [
          "Bédard PA",
          "Fielding B",
          "Maślikowski BM",
          "Wang L",
          "Wu Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "Chicken embryo fibroblasts": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 431,
      "target": 462,
      "key": "f70c1bd536db46a818c0dd39a48d75a7055411987c05973b6c08df601d73761b4207fb43c9079b7f41aa64e0e7cfcac745e61f2c8b599c5da8f6a90c51db2934"
    },
    {
      "line": 1945,
      "relation": "increases",
      "evidence": "In this report, we describe a novel mechanism of action determined by the JunD component of AP-1, a factor enhancing cell survival in v-Src-transformed cells. We show that the loss of JunD results in the aberrant activation of a genetic program leading to cell death. This program requires the activation of the tumor suppressor death-associated protein kinase 1 (DAPK1). Since DAPK1 is phosphorylated and inhibited by v-Src, these results highlight the importance of this kinase and the multiple mechanisms controlled by v-Src to antagonize the tumor suppressor function of DAPK1.",
      "citation": {
        "type": "PubMed",
        "reference": "27795443",
        "name": "Journal of virology",
        "title": "JunD/AP-1 Antagonizes the Induction of DAPK1 To Promote the Survival of v-Src-Transformed Cells.",
        "volume": "91",
        "date": "2017-01-01",
        "first": "Maślikowski BM",
        "last": "Bédard PA",
        "authors": [
          "Bédard PA",
          "Fielding B",
          "Maślikowski BM",
          "Wang L",
          "Wu Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "Chicken embryo fibroblasts": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 431,
      "target": 174,
      "key": "e47d8c35391fe4bd29d1d7c421d94a3bcffd9b6e3d43b4c7b6b846bcccb5cd36161fc13b5244c6d619bfcaa1cd67b96cbc92139ba079d04ec479bc72a5ddce15"
    },
    {
      "line": 1977,
      "relation": "increases",
      "evidence": "We showed previously that DAPK1 phosphorylates Ser71 in the catalytic active site of Pin1, thereby inhibiting its cellular function.",
      "citation": {
        "type": "PubMed",
        "reference": "24853415",
        "name": "Cell death &amp; disease",
        "title": "Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function.",
        "volume": "5",
        "pages": "e1237",
        "date": "2014-05-22",
        "first": "Kim BM",
        "last": "Lee TH",
        "authors": [
          "Chen CH",
          "Hong Y",
          "Kim BM",
          "Kimchi A",
          "Lee S",
          "Lee TH",
          "You MH",
          "Zhou XZ"
        ]
      },
      "source": 431,
      "target": 651,
      "key": "e01e9299fa5fc3b85d2aa2d7b8877f208be3edd9cb96ab7275cf64065559f0e8250d6fb6e3b1a20788667bcb4f6809cfbc64c6c8902fa4a2450bce0b07319185"
    },
    {
      "line": 1984,
      "relation": "increases",
      "evidence": "As shown in Figure 7a, compared with the vector control, DAPK1, but not DAPK1K42A, increased the phosphorylation of exogenous tau protein in HeLa cells, as detected by Thr231-specific (AT180), Ser262-specific, and Ser396-specific (PHF-13) antibodies that recognize specific tau phosphoepitopes and/or abnormal conformations specific to AD NFT.",
      "citation": {
        "type": "PubMed",
        "reference": "24853415",
        "name": "Cell death &amp; disease",
        "title": "Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function.",
        "volume": "5",
        "pages": "e1237",
        "date": "2014-05-22",
        "first": "Kim BM",
        "last": "Lee TH",
        "authors": [
          "Chen CH",
          "Hong Y",
          "Kim BM",
          "Kimchi A",
          "Lee S",
          "Lee TH",
          "You MH",
          "Zhou XZ"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HeLa": true
        }
      },
      "source": 431,
      "target": 557,
      "key": "52f1e0ee2cca86dfdd29de508d322f610009bde9be241fa47b1467e407a73a86a0ed4199c5162af1fa23723b897d767b216238368b8ea2473699ba2b53d38118"
    },
    {
      "line": 1997,
      "relation": "increases",
      "evidence": "These data suggest that tau hyperphosphorylation at Thr231, Ser262, and Ser396 by DAPK1 renders the cells more resistant to the kinase-induced apoptotic cell death, providing new insights into the tau-involved apoptotic abortion in the course of chronic neurodegeneration.",
      "citation": {
        "type": "PubMed",
        "reference": "23948915",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Phosphorylation of tau by death-associated protein kinase 1 antagonizes the kinase-induced cell apoptosis.",
        "volume": "37",
        "pages": "795-808",
        "date": "2013-01-01",
        "first": "Duan DX",
        "last": "Liu GP",
        "authors": [
          "Chai GS",
          "Chen NN",
          "Cheng XS",
          "Duan DX",
          "Hu Y",
          "Liu GP",
          "Luo Y",
          "Ni ZF",
          "Wang JZ"
        ]
      },
      "source": 431,
      "target": 557,
      "key": "181cb7511e74d578fce8c3d9d9c8a8e75342fc1c55c338a960a5d8afa2e0b0c50e976e7f21966fd4773574674dafd564c97331630707ff9e217c68c84661b74b"
    },
    {
      "line": 1985,
      "relation": "increases",
      "evidence": "As shown in Figure 7a, compared with the vector control, DAPK1, but not DAPK1K42A, increased the phosphorylation of exogenous tau protein in HeLa cells, as detected by Thr231-specific (AT180), Ser262-specific, and Ser396-specific (PHF-13) antibodies that recognize specific tau phosphoepitopes and/or abnormal conformations specific to AD NFT.",
      "citation": {
        "type": "PubMed",
        "reference": "24853415",
        "name": "Cell death &amp; disease",
        "title": "Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function.",
        "volume": "5",
        "pages": "e1237",
        "date": "2014-05-22",
        "first": "Kim BM",
        "last": "Lee TH",
        "authors": [
          "Chen CH",
          "Hong Y",
          "Kim BM",
          "Kimchi A",
          "Lee S",
          "Lee TH",
          "You MH",
          "Zhou XZ"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HeLa": true
        }
      },
      "source": 431,
      "target": 564,
      "key": "b778ce5ada409f05c2df5a93b102b2a46a301685e557ffe9cc886ff27191b8bedde8aa683e9374514336441a6d178e6276a36dad7e6b196f35531521f107eb7e"
    },
    {
      "line": 1998,
      "relation": "increases",
      "evidence": "These data suggest that tau hyperphosphorylation at Thr231, Ser262, and Ser396 by DAPK1 renders the cells more resistant to the kinase-induced apoptotic cell death, providing new insights into the tau-involved apoptotic abortion in the course of chronic neurodegeneration.",
      "citation": {
        "type": "PubMed",
        "reference": "23948915",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Phosphorylation of tau by death-associated protein kinase 1 antagonizes the kinase-induced cell apoptosis.",
        "volume": "37",
        "pages": "795-808",
        "date": "2013-01-01",
        "first": "Duan DX",
        "last": "Liu GP",
        "authors": [
          "Chai GS",
          "Chen NN",
          "Cheng XS",
          "Duan DX",
          "Hu Y",
          "Liu GP",
          "Luo Y",
          "Ni ZF",
          "Wang JZ"
        ]
      },
      "source": 431,
      "target": 564,
      "key": "7842925c8ccf8813dc14827dc5289fef01490dc26f46eca00e2b7defcf2081e3214edbb9dadbb0dbfe4be53f8435b91772668f2957b5dabbb35950d99640ca7c"
    },
    {
      "line": 1986,
      "relation": "increases",
      "evidence": "As shown in Figure 7a, compared with the vector control, DAPK1, but not DAPK1K42A, increased the phosphorylation of exogenous tau protein in HeLa cells, as detected by Thr231-specific (AT180), Ser262-specific, and Ser396-specific (PHF-13) antibodies that recognize specific tau phosphoepitopes and/or abnormal conformations specific to AD NFT.",
      "citation": {
        "type": "PubMed",
        "reference": "24853415",
        "name": "Cell death &amp; disease",
        "title": "Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function.",
        "volume": "5",
        "pages": "e1237",
        "date": "2014-05-22",
        "first": "Kim BM",
        "last": "Lee TH",
        "authors": [
          "Chen CH",
          "Hong Y",
          "Kim BM",
          "Kimchi A",
          "Lee S",
          "Lee TH",
          "You MH",
          "Zhou XZ"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HeLa": true
        }
      },
      "source": 431,
      "target": 583,
      "key": "d2af464f204d0506eaaccf27cfefad6f9db6382cc8220a29b3a866b084bdb3083202d5c40517696a669976d01ace7a0c7e0ae26834d3764fe1e1f46d4a6c41a4"
    },
    {
      "line": 1999,
      "relation": "increases",
      "evidence": "These data suggest that tau hyperphosphorylation at Thr231, Ser262, and Ser396 by DAPK1 renders the cells more resistant to the kinase-induced apoptotic cell death, providing new insights into the tau-involved apoptotic abortion in the course of chronic neurodegeneration.",
      "citation": {
        "type": "PubMed",
        "reference": "23948915",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Phosphorylation of tau by death-associated protein kinase 1 antagonizes the kinase-induced cell apoptosis.",
        "volume": "37",
        "pages": "795-808",
        "date": "2013-01-01",
        "first": "Duan DX",
        "last": "Liu GP",
        "authors": [
          "Chai GS",
          "Chen NN",
          "Cheng XS",
          "Duan DX",
          "Hu Y",
          "Liu GP",
          "Luo Y",
          "Ni ZF",
          "Wang JZ"
        ]
      },
      "source": 431,
      "target": 583,
      "key": "2633e76ef10708a61df37511010d9dfb4d7e91d614c07dfda750cc40ce870c51e3c65634cca3bc8e28dc1027bb232b358d784e93349829d03488117ec9b36bb9"
    },
    {
      "line": 1990,
      "relation": "positiveCorrelation",
      "evidence": "DAPK1-mediated increase in tau protein expression and stability were accompanied by increased Pin1 Ser71 phosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24853415",
        "name": "Cell death &amp; disease",
        "title": "Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function.",
        "volume": "5",
        "pages": "e1237",
        "date": "2014-05-22",
        "first": "Kim BM",
        "last": "Lee TH",
        "authors": [
          "Chen CH",
          "Hong Y",
          "Kim BM",
          "Kimchi A",
          "Lee S",
          "Lee TH",
          "You MH",
          "Zhou XZ"
        ]
      },
      "source": 431,
      "target": 486,
      "key": "b695e80d096ad6589f3f572ca8711285b946272fa0be284cda998f93f3eb2dd081065e913645dcd1aea0aa8abad7b9cbb74db77df9c7153bcdde845123a64392"
    },
    {
      "line": 2009,
      "relation": "directlyIncreases",
      "evidence": "Furthermore, silencing of both MARK1 and MARK2 blocked DAPK-induced tau S262 phosphorylation (Figure 3e). More importantly, a decrease of pS262 tau, but not total tau, was observed in brain extracts derived from DAPK−/− mice, compared with that from DAPK+/+ mice (Figure 3f). These results strongly suggest a role of endogenous DAPK in stimulating the activity of endogenous MARK, which in turn phosphorylates tau in neurons.",
      "citation": {
        "type": "PubMed",
        "reference": "21311567",
        "name": "Cell death and differentiation",
        "title": "DAPK activates MARK1/2 to regulate microtubule assembly, neuronal differentiation, and tau toxicity.",
        "volume": "18",
        "pages": "1507-20",
        "date": "2011-09-01",
        "first": "Wu PR",
        "last": "Chen RH",
        "authors": [
          "Chen GC",
          "Chen RH",
          "Chen YH",
          "Chien CT",
          "Chou HJ",
          "Huang YP",
          "Kimchi A",
          "Lin MY",
          "Tsai PI",
          "Wu PR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 431,
      "target": 633,
      "key": "78d66a240f7ce4c7115e13e78b5c4e84f2c02a3670471b11355b954a5d333033ccf7261225a4d1f0ce0a32cc874d0808014582d0e4fbe901b4d561481af1602d"
    },
    {
      "line": 2010,
      "relation": "directlyIncreases",
      "evidence": "Furthermore, silencing of both MARK1 and MARK2 blocked DAPK-induced tau S262 phosphorylation (Figure 3e). More importantly, a decrease of pS262 tau, but not total tau, was observed in brain extracts derived from DAPK−/− mice, compared with that from DAPK+/+ mice (Figure 3f). These results strongly suggest a role of endogenous DAPK in stimulating the activity of endogenous MARK, which in turn phosphorylates tau in neurons.",
      "citation": {
        "type": "PubMed",
        "reference": "21311567",
        "name": "Cell death and differentiation",
        "title": "DAPK activates MARK1/2 to regulate microtubule assembly, neuronal differentiation, and tau toxicity.",
        "volume": "18",
        "pages": "1507-20",
        "date": "2011-09-01",
        "first": "Wu PR",
        "last": "Chen RH",
        "authors": [
          "Chen GC",
          "Chen RH",
          "Chen YH",
          "Chien CT",
          "Chou HJ",
          "Huang YP",
          "Kimchi A",
          "Lin MY",
          "Tsai PI",
          "Wu PR"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 431,
      "target": 634,
      "key": "b7f89cf868f86ab35dc255ed94c99d32cc91b86d96ea858f8f2c7ad5c6a0c0622ae75e8c47430ff63a48035783deefd86e38bb74f7401f02c7c30b217b75fe1b"
    },
    {
      "line": 2016,
      "relation": "decreases",
      "evidence": "Importantly, depletion of MARK1/2 reversed the inhibitory effect of DAPK on MT regrowth (Figure 5c, right panel). These results indicate that the DAPK–MARK signaling axis inhibits MT assembly and stability.",
      "citation": {
        "type": "PubMed",
        "reference": "21311567",
        "name": "Cell death and differentiation",
        "title": "DAPK activates MARK1/2 to regulate microtubule assembly, neuronal differentiation, and tau toxicity.",
        "volume": "18",
        "pages": "1507-20",
        "date": "2011-09-01",
        "first": "Wu PR",
        "last": "Chen RH",
        "authors": [
          "Chen GC",
          "Chen RH",
          "Chen YH",
          "Chien CT",
          "Chou HJ",
          "Huang YP",
          "Kimchi A",
          "Lin MY",
          "Tsai PI",
          "Wu PR"
        ]
      },
      "source": 431,
      "target": 186,
      "key": "4ab2e20baddbf7d5466daa9cdd490a4ab0e6c590b3741afbe7855bf3cd6a9314b344aef619077d5a6a4d986cfdd453dd04319d00be0584ce94d56b46c83c17c8"
    },
    {
      "line": 1883,
      "relation": "positiveCorrelation",
      "evidence": "DAPK1, but not its kinase deficient mutant (K42A), significantly increased human Aβ secretion in neuronal cell culture models. Moreover, knockdown of DAPK1 expression or inhibition of DAPK1 catalytic activity significantly decreased Aβ secretion. Furthermore, DAPK1, but not K42A, triggered Thr668 phosphorylation of APP, which may initiate and facilitate amyloidogenic APP processing leading to the generation of Aβ.",
      "citation": {
        "type": "PubMed",
        "reference": "27094130",
        "name": "Human molecular genetics",
        "title": "Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein.",
        "volume": "25",
        "pages": "2498-2513",
        "date": "2016-06-15",
        "first": "Kim BM",
        "last": "Ho Lee T",
        "authors": [
          "Chen CH",
          "Ho Lee T",
          "Kim BM",
          "Suh J",
          "Tanzi RE",
          "You MH"
        ]
      },
      "subject": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "bel",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "bel",
            "name": "extracellular space"
          }
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 375,
      "target": 431,
      "key": "c892e3017dc308ed525f2f6df7465c9971974a9e7a6f8bd4fd83011ad436ee1435f750c83b4d97ce3210a8776722ed9f0eb9048a2451b42e024e0083a9238374"
    },
    {
      "line": 2879,
      "relation": "biomarkerFor",
      "evidence": "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24401760",
        "name": "Brain : a journal of neurology",
        "title": "Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.",
        "volume": "137",
        "pages": "537-52",
        "date": "2014-02-01",
        "first": "Stygelbout V",
        "last": "Brion JP",
        "authors": [
          "Ando K",
          "Brion JP",
          "D'Amico E",
          "Duyckaerts C",
          "Erneux C",
          "Jia Y",
          "Leroy K",
          "Luo HR",
          "Pouillon V",
          "Schurmans S",
          "Stygelbout V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "5xFAD mice": true
        }
      },
      "source": 375,
      "target": 908,
      "key": "ee5f2b5013a76601a971f41e8f05c361d4c892e9af0c6c6be1041da88dd396df78332149954b133f759612037fb32d8ff0ace43621fc4f2163439c2c024ab310"
    },
    {
      "line": 1887,
      "relation": "association",
      "evidence": "In contrast, the DAPK1 fragments from 1 to 1423, from 637 to 1423 and from 848 to 1423 efficiently bound to APP, suggesting that the death domain (1271–1423, DD) is likely bound to APP (Fig. 4F).",
      "citation": {
        "type": "PubMed",
        "reference": "27094130",
        "name": "Human molecular genetics",
        "title": "Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein.",
        "volume": "25",
        "pages": "2498-2513",
        "date": "2016-06-15",
        "first": "Kim BM",
        "last": "Ho Lee T",
        "authors": [
          "Chen CH",
          "Ho Lee T",
          "Kim BM",
          "Suh J",
          "Tanzi RE",
          "You MH"
        ]
      },
      "source": 433,
      "target": 374,
      "key": "fdf4bae614203af3b6e1edf19dce076bbd43de3326b46958742826463154b537547c818cf64fa730c32bcb0dee128a72f7ecae382021781bb5385f9160445217"
    },
    {
      "line": 1893,
      "relation": "partOf",
      "evidence": "In contrast, the DAPK1 fragments from 1 to 1423, from 637 to 1423 and from 848 to 1423 efficiently bound to APP, suggesting that the death domain (1271–1423, DD) is likely bound to APP (Fig. 4F).",
      "citation": {
        "type": "PubMed",
        "reference": "27094130",
        "name": "Human molecular genetics",
        "title": "Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein.",
        "volume": "25",
        "pages": "2498-2513",
        "date": "2016-06-15",
        "first": "Kim BM",
        "last": "Ho Lee T",
        "authors": [
          "Chen CH",
          "Ho Lee T",
          "Kim BM",
          "Suh J",
          "Tanzi RE",
          "You MH"
        ]
      },
      "source": 433,
      "target": 431,
      "key": "ec22173e04c3df3d7ef68e40fdaaf2808abe4d207eb92390eefeb1c53bcbff4f692f23b957ecd3f2f938ac9ca15b5362ea84beaa8b857ef917139505747fa90a"
    },
    {
      "line": 1888,
      "relation": "association",
      "evidence": "In contrast, the DAPK1 fragments from 1 to 1423, from 637 to 1423 and from 848 to 1423 efficiently bound to APP, suggesting that the death domain (1271–1423, DD) is likely bound to APP (Fig. 4F).",
      "citation": {
        "type": "PubMed",
        "reference": "27094130",
        "name": "Human molecular genetics",
        "title": "Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein.",
        "volume": "25",
        "pages": "2498-2513",
        "date": "2016-06-15",
        "first": "Kim BM",
        "last": "Ho Lee T",
        "authors": [
          "Chen CH",
          "Ho Lee T",
          "Kim BM",
          "Suh J",
          "Tanzi RE",
          "You MH"
        ]
      },
      "source": 434,
      "target": 374,
      "key": "c606dc9e789a635cc499b41e74c800d26c24ebccae0485d659d353c7a9393b52e35d4e838c0c03ee244a394a0d4c09ae8410e1660712381a1d962eb146084f22"
    },
    {
      "line": 1892,
      "relation": "partOf",
      "evidence": "In contrast, the DAPK1 fragments from 1 to 1423, from 637 to 1423 and from 848 to 1423 efficiently bound to APP, suggesting that the death domain (1271–1423, DD) is likely bound to APP (Fig. 4F).",
      "citation": {
        "type": "PubMed",
        "reference": "27094130",
        "name": "Human molecular genetics",
        "title": "Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein.",
        "volume": "25",
        "pages": "2498-2513",
        "date": "2016-06-15",
        "first": "Kim BM",
        "last": "Ho Lee T",
        "authors": [
          "Chen CH",
          "Ho Lee T",
          "Kim BM",
          "Suh J",
          "Tanzi RE",
          "You MH"
        ]
      },
      "source": 434,
      "target": 431,
      "key": "75ce17f4fa1c2fdbf90ecb2fecdf482d96ae6851342fe7f47fe5d857f3c11c25bc34b8faf625eddb844461e64a945bc69fcee60e1c6f1083b2330ff41eaa9829"
    },
    {
      "line": 1889,
      "relation": "association",
      "evidence": "In contrast, the DAPK1 fragments from 1 to 1423, from 637 to 1423 and from 848 to 1423 efficiently bound to APP, suggesting that the death domain (1271–1423, DD) is likely bound to APP (Fig. 4F).",
      "citation": {
        "type": "PubMed",
        "reference": "27094130",
        "name": "Human molecular genetics",
        "title": "Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein.",
        "volume": "25",
        "pages": "2498-2513",
        "date": "2016-06-15",
        "first": "Kim BM",
        "last": "Ho Lee T",
        "authors": [
          "Chen CH",
          "Ho Lee T",
          "Kim BM",
          "Suh J",
          "Tanzi RE",
          "You MH"
        ]
      },
      "source": 432,
      "target": 374,
      "key": "6f75c13bcf243007ff0121e88e883eb2a625f8bc70cd36a32790300aac58283392ed7681bf45982f9612bf875b49c665a09c1e5dcf4ef39e4730f617bb218244"
    },
    {
      "line": 1890,
      "relation": "equivalentTo",
      "evidence": "In contrast, the DAPK1 fragments from 1 to 1423, from 637 to 1423 and from 848 to 1423 efficiently bound to APP, suggesting that the death domain (1271–1423, DD) is likely bound to APP (Fig. 4F).",
      "citation": {
        "type": "PubMed",
        "reference": "27094130",
        "name": "Human molecular genetics",
        "title": "Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein.",
        "volume": "25",
        "pages": "2498-2513",
        "date": "2016-06-15",
        "first": "Kim BM",
        "last": "Ho Lee T",
        "authors": [
          "Chen CH",
          "Ho Lee T",
          "Kim BM",
          "Suh J",
          "Tanzi RE",
          "You MH"
        ]
      },
      "source": 432,
      "target": 756,
      "key": "fc7e666a07feca42f713aa4fadfaee63d60727c2790aa85a54587383ac73211800cb2ffb7053d26f2ca1ee0f8c1331a54ff0c370b468610a17de70afb9536a87"
    },
    {
      "line": 1890,
      "relation": "equivalentTo",
      "evidence": "In contrast, the DAPK1 fragments from 1 to 1423, from 637 to 1423 and from 848 to 1423 efficiently bound to APP, suggesting that the death domain (1271–1423, DD) is likely bound to APP (Fig. 4F).",
      "citation": {
        "type": "PubMed",
        "reference": "27094130",
        "name": "Human molecular genetics",
        "title": "Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein.",
        "volume": "25",
        "pages": "2498-2513",
        "date": "2016-06-15",
        "first": "Kim BM",
        "last": "Ho Lee T",
        "authors": [
          "Chen CH",
          "Ho Lee T",
          "Kim BM",
          "Suh J",
          "Tanzi RE",
          "You MH"
        ]
      },
      "source": 756,
      "target": 432,
      "key": "9b61c59f9bde4161e7b811b3292943ba19177ab2c9c5fd6c973207cb7537aed006e41c85bfc7f6c4b22492602445586c5e9c46b8b6878125892ad2235e337ca7"
    },
    {
      "line": 1891,
      "relation": "partOf",
      "evidence": "In contrast, the DAPK1 fragments from 1 to 1423, from 637 to 1423 and from 848 to 1423 efficiently bound to APP, suggesting that the death domain (1271–1423, DD) is likely bound to APP (Fig. 4F).",
      "citation": {
        "type": "PubMed",
        "reference": "27094130",
        "name": "Human molecular genetics",
        "title": "Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein.",
        "volume": "25",
        "pages": "2498-2513",
        "date": "2016-06-15",
        "first": "Kim BM",
        "last": "Ho Lee T",
        "authors": [
          "Chen CH",
          "Ho Lee T",
          "Kim BM",
          "Suh J",
          "Tanzi RE",
          "You MH"
        ]
      },
      "source": 756,
      "target": 431,
      "key": "91007ad369884ae6a057daa9421580793dbc9fd4ddae43c800b5b99fedac94f143eceb7b1092136a845a37b82f56e0df2812a26ae785c6e7823584a9d9d95860"
    },
    {
      "line": 1897,
      "relation": "regulates",
      "evidence": "Furthermore, DAPK1-induced APP phosphorylation was suppressed when DAPK1 ΔDD was introduced (Fig. 4G), indicating that DAPK1 regulates Aβ secretion through APP Thr668 phosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "27094130",
        "name": "Human molecular genetics",
        "title": "Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein.",
        "volume": "25",
        "pages": "2498-2513",
        "date": "2016-06-15",
        "first": "Kim BM",
        "last": "Ho Lee T",
        "authors": [
          "Chen CH",
          "Ho Lee T",
          "Kim BM",
          "Suh J",
          "Tanzi RE",
          "You MH"
        ]
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "bel",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "bel",
            "name": "extracellular space"
          }
        }
      },
      "source": 378,
      "target": 375,
      "key": "49e44d4b789d2459d172d1eabf74e6558d31faad323bdf0d4df2f39d227bb32f99e9f06df6fd036aa60fcc39a5afb63268c100406d717d182b1dbe8002eccfe9"
    },
    {
      "line": 1898,
      "relation": "regulates",
      "evidence": "Furthermore, DAPK1-induced APP phosphorylation was suppressed when DAPK1 ΔDD was introduced (Fig. 4G), indicating that DAPK1 regulates Aβ secretion through APP Thr668 phosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "27094130",
        "name": "Human molecular genetics",
        "title": "Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein.",
        "volume": "25",
        "pages": "2498-2513",
        "date": "2016-06-15",
        "first": "Kim BM",
        "last": "Ho Lee T",
        "authors": [
          "Chen CH",
          "Ho Lee T",
          "Kim BM",
          "Suh J",
          "Tanzi RE",
          "You MH"
        ]
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "bel",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "bel",
            "name": "extracellular space"
          }
        }
      },
      "source": 378,
      "target": 376,
      "key": "a9015a8b371ab1a62e6a23f7221581be0244567ae84beb9ec06b6d2f91a98d2ff996bcb367861566646ed6037611b0208d69b3f31e1d478a1e9d2ecbf7046c3f"
    },
    {
      "line": 1903,
      "relation": "increases",
      "evidence": "Overexpression of UNC5B induces neuronal death by activating death-associated protein kinase (DAPK1) (19) via protein phosphatase 2A-mediated dephosphorylation of DAPK1 (20).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 740,
      "target": 431,
      "key": "2b957cc743cf6771213e7f1b5537e0e0ce60837e986a3aa2d6a4d2b5a6b3822601cbbd76c1b81c15d4bf8a5eebe7537f62b81252e628d8cd1d2723daba751687"
    },
    {
      "line": 1904,
      "relation": "positiveCorrelation",
      "evidence": "Overexpression of UNC5B induces neuronal death by activating death-associated protein kinase (DAPK1) (19) via protein phosphatase 2A-mediated dephosphorylation of DAPK1 (20).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 740,
      "target": 301,
      "key": "deea2893c030204e44680e55626033b145e828039e30c600917c12db0f8a2646e2f46efedcd127796a0e2d071d0554fdce127667bc80c32d1d463d73aeebe3fa"
    },
    {
      "line": 1913,
      "relation": "positiveCorrelation",
      "evidence": "Overexpression of wild-type UNC5C causes low-grade death, intensified by an AD-linked mutation T835M inhibited by a AD-linked survival factor, calmodulin-like skin protein (CLSP), and a natural ligand of UNC5C, netrin1. T835M-UNC5C-induced neuronal cell death is mediated by an intracellular death-signaling cascade, consisting of DAPK1/protein kinase D/apoptosis signal-regulating kinase 1 (ASK1)/JNK/NADPH oxidase/caspases, which merges at ASK1 with a death-signaling cascade, mediated by amyloid ß precursor protein (APP).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "source": 189,
      "target": 741,
      "key": "e1f42e9cfdc4e335c7f0abc5030a190cd2279d9a002403447f2a7c34a7e2e65fa113d1355c13004d7a3ffc8f56db303cad94e3ddf036da11d2212a82cb29fab3"
    },
    {
      "line": 1913,
      "relation": "positiveCorrelation",
      "evidence": "Overexpression of wild-type UNC5C causes low-grade death, intensified by an AD-linked mutation T835M inhibited by a AD-linked survival factor, calmodulin-like skin protein (CLSP), and a natural ligand of UNC5C, netrin1. T835M-UNC5C-induced neuronal cell death is mediated by an intracellular death-signaling cascade, consisting of DAPK1/protein kinase D/apoptosis signal-regulating kinase 1 (ASK1)/JNK/NADPH oxidase/caspases, which merges at ASK1 with a death-signaling cascade, mediated by amyloid ß precursor protein (APP).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "source": 741,
      "target": 189,
      "key": "21336f3be4803a57bf608cebfd1bbf9f4003531fc92ed310fb627a7ee2dbf8752f7e267e1d03bd34175c4dc49f6814cbe89b6275cffcda8a57bc2f18fc0ebbe1"
    },
    {
      "relation": "hasVariant",
      "source": 741,
      "target": 742,
      "key": "bba4106056001cb99d456fa1358b13ecf7d87bd958aeb3b33af6786861d8856cdfe3832ec5c50378782f351cc2b3de02cf739bf0d5d31819666ce440634da278"
    },
    {
      "line": 1914,
      "relation": "increases",
      "evidence": "Overexpression of wild-type UNC5C causes low-grade death, intensified by an AD-linked mutation T835M inhibited by a AD-linked survival factor, calmodulin-like skin protein (CLSP), and a natural ligand of UNC5C, netrin1. T835M-UNC5C-induced neuronal cell death is mediated by an intracellular death-signaling cascade, consisting of DAPK1/protein kinase D/apoptosis signal-regulating kinase 1 (ASK1)/JNK/NADPH oxidase/caspases, which merges at ASK1 with a death-signaling cascade, mediated by amyloid ß precursor protein (APP).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "source": 742,
      "target": 189,
      "key": "d96a69fef01f4b138c2427791b20cc7c93002220bb10c12a1a5afde0c14d18c06fccefb9272dd6d960f3a4ef25b6058a4cbe18a77e8ab25e925953d47806710a"
    },
    {
      "line": 1917,
      "relation": "positiveCorrelation",
      "evidence": "Overexpression of wild-type UNC5C causes low-grade death, intensified by an AD-linked mutation T835M inhibited by a AD-linked survival factor, calmodulin-like skin protein (CLSP), and a natural ligand of UNC5C, netrin1. T835M-UNC5C-induced neuronal cell death is mediated by an intracellular death-signaling cascade, consisting of DAPK1/protein kinase D/apoptosis signal-regulating kinase 1 (ASK1)/JNK/NADPH oxidase/caspases, which merges at ASK1 with a death-signaling cascade, mediated by amyloid ß precursor protein (APP).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 742,
      "target": 662,
      "key": "279f3216c37511b603866862cc3a4100b6f05d68808e89d756559ea2d81a3cd05be0322da747a4dc7136d2d63995251f3e01523434a7b74c36659c0a5dee34db"
    },
    {
      "line": 1915,
      "relation": "decreases",
      "evidence": "Overexpression of wild-type UNC5C causes low-grade death, intensified by an AD-linked mutation T835M inhibited by a AD-linked survival factor, calmodulin-like skin protein (CLSP), and a natural ligand of UNC5C, netrin1. T835M-UNC5C-induced neuronal cell death is mediated by an intracellular death-signaling cascade, consisting of DAPK1/protein kinase D/apoptosis signal-regulating kinase 1 (ASK1)/JNK/NADPH oxidase/caspases, which merges at ASK1 with a death-signaling cascade, mediated by amyloid ß precursor protein (APP).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "source": 391,
      "target": 742,
      "key": "c1caa167dbb14d4a566528638e9608884ec227fe4a3d2c5e39d7ffb40bad8715efcb29a12b15a366b997f6fff77c0dc6e3b8e4c78de54fdad517a6ed26c92fd1"
    },
    {
      "line": 1916,
      "relation": "decreases",
      "evidence": "Overexpression of wild-type UNC5C causes low-grade death, intensified by an AD-linked mutation T835M inhibited by a AD-linked survival factor, calmodulin-like skin protein (CLSP), and a natural ligand of UNC5C, netrin1. T835M-UNC5C-induced neuronal cell death is mediated by an intracellular death-signaling cascade, consisting of DAPK1/protein kinase D/apoptosis signal-regulating kinase 1 (ASK1)/JNK/NADPH oxidase/caspases, which merges at ASK1 with a death-signaling cascade, mediated by amyloid ß precursor protein (APP).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "source": 645,
      "target": 742,
      "key": "b74052e9b3d67f19d74ad6563ceec76141ea463751f9a3a5baed4d19f818f941067d5c9828181c1a7f5f0516fd0324404963a922243562a2747e3f8e025537ee"
    },
    {
      "line": 1917,
      "relation": "positiveCorrelation",
      "evidence": "Overexpression of wild-type UNC5C causes low-grade death, intensified by an AD-linked mutation T835M inhibited by a AD-linked survival factor, calmodulin-like skin protein (CLSP), and a natural ligand of UNC5C, netrin1. T835M-UNC5C-induced neuronal cell death is mediated by an intracellular death-signaling cascade, consisting of DAPK1/protein kinase D/apoptosis signal-regulating kinase 1 (ASK1)/JNK/NADPH oxidase/caspases, which merges at ASK1 with a death-signaling cascade, mediated by amyloid ß precursor protein (APP).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 662,
      "target": 742,
      "key": "85e9e33db716b7495b2f3f8437405706ad16b2712a38c8d86aa1b2edd1db1a6ac3b136798894a95e576e62df12ee3e33cbc214c68955bef879b1e363f8c3db11"
    },
    {
      "line": 1918,
      "relation": "positiveCorrelation",
      "evidence": "Overexpression of wild-type UNC5C causes low-grade death, intensified by an AD-linked mutation T835M inhibited by a AD-linked survival factor, calmodulin-like skin protein (CLSP), and a natural ligand of UNC5C, netrin1. T835M-UNC5C-induced neuronal cell death is mediated by an intracellular death-signaling cascade, consisting of DAPK1/protein kinase D/apoptosis signal-regulating kinase 1 (ASK1)/JNK/NADPH oxidase/caspases, which merges at ASK1 with a death-signaling cascade, mediated by amyloid ß precursor protein (APP).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 662,
      "target": 473,
      "key": "534f89c17cd887b8c5283ae7042ffa17a7a140086f8d7339a5cb47b48ae8d5c77c6171fb4fc369cbcb7b17c95b02f500dc6f37667b1b57f64677300a92682cb7"
    },
    {
      "line": 1918,
      "relation": "positiveCorrelation",
      "evidence": "Overexpression of wild-type UNC5C causes low-grade death, intensified by an AD-linked mutation T835M inhibited by a AD-linked survival factor, calmodulin-like skin protein (CLSP), and a natural ligand of UNC5C, netrin1. T835M-UNC5C-induced neuronal cell death is mediated by an intracellular death-signaling cascade, consisting of DAPK1/protein kinase D/apoptosis signal-regulating kinase 1 (ASK1)/JNK/NADPH oxidase/caspases, which merges at ASK1 with a death-signaling cascade, mediated by amyloid ß precursor protein (APP).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 473,
      "target": 662,
      "key": "61c7721392005c63f02019429c1d9c22ee4cb855796adf11ef3fc091163c8e2b69a6f45254fdec76cd2978db8ff7be10b4b9f9a06509fb819f15b8ac1f58d918"
    },
    {
      "line": 1919,
      "relation": "increases",
      "evidence": "Overexpression of wild-type UNC5C causes low-grade death, intensified by an AD-linked mutation T835M inhibited by a AD-linked survival factor, calmodulin-like skin protein (CLSP), and a natural ligand of UNC5C, netrin1. T835M-UNC5C-induced neuronal cell death is mediated by an intracellular death-signaling cascade, consisting of DAPK1/protein kinase D/apoptosis signal-regulating kinase 1 (ASK1)/JNK/NADPH oxidase/caspases, which merges at ASK1 with a death-signaling cascade, mediated by amyloid ß precursor protein (APP).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 473,
      "target": 291,
      "key": "97a05042e71bb860dc965165f73a81413cf78db791bc855fa9d9393515397690c2b8f0c7a0e6eae476dc68033c69d2a09cd82018367adfcd656b6088b281bce5"
    },
    {
      "line": 1922,
      "relation": "association",
      "evidence": "Overexpression of wild-type UNC5C causes low-grade death, intensified by an AD-linked mutation T835M inhibited by a AD-linked survival factor, calmodulin-like skin protein (CLSP), and a natural ligand of UNC5C, netrin1. T835M-UNC5C-induced neuronal cell death is mediated by an intracellular death-signaling cascade, consisting of DAPK1/protein kinase D/apoptosis signal-regulating kinase 1 (ASK1)/JNK/NADPH oxidase/caspases, which merges at ASK1 with a death-signaling cascade, mediated by amyloid ß precursor protein (APP).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 473,
      "target": 397,
      "key": "f06f3a338f10191938993565b767adf30bf092a5ceeea02213a2fbf023df2154db7c25f217ae32a8047dacc41abe16993eefb101edb4f741e537d77a9699a6f1"
    },
    {
      "line": 1920,
      "relation": "positiveCorrelation",
      "evidence": "Overexpression of wild-type UNC5C causes low-grade death, intensified by an AD-linked mutation T835M inhibited by a AD-linked survival factor, calmodulin-like skin protein (CLSP), and a natural ligand of UNC5C, netrin1. T835M-UNC5C-induced neuronal cell death is mediated by an intracellular death-signaling cascade, consisting of DAPK1/protein kinase D/apoptosis signal-regulating kinase 1 (ASK1)/JNK/NADPH oxidase/caspases, which merges at ASK1 with a death-signaling cascade, mediated by amyloid ß precursor protein (APP).",
      "citation": {
        "type": "PubMed",
        "reference": "27068745",
        "name": "The Journal of biological chemistry",
        "title": "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.",
        "volume": "291",
        "pages": "12282-93",
        "date": "2016-06-03",
        "first": "Hashimoto Y",
        "last": "Matsuoka M",
        "authors": [
          "Hashimoto Y",
          "Kusakari S",
          "Matsuoka M",
          "Nawa M",
          "Toyama Y"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 266,
      "target": 291,
      "key": "3e20f1ae31ba650bd35568f152a89b6c350bcd74a7fd73544022debbbe222f1f4de682e38a10a1e1552b16fb131a65cca5578286c0547f7c78d0c7e339c557ad"
    },
    {
      "line": 1931,
      "relation": "positiveCorrelation",
      "evidence": "In contrast, Pin1/PINN-1 (a DAPK interaction-partner and a peptidyl-prolyl isomerase involved in chronic neurodegenerative conditions) suppresses neurodegeneration in our excitotoxicity model.",
      "citation": {
        "type": "PubMed",
        "reference": "25899010",
        "name": "BMC neuroscience",
        "title": "Death Associated Protein Kinase (DAPK) -mediated neurodegenerative mechanisms in nematode excitotoxicity.",
        "volume": "16",
        "pages": "25",
        "date": "2015-04-23",
        "first": "Del Rosario JS",
        "last": "Mano I",
        "authors": [
          "Ahmed T",
          "Amjad U",
          "An J",
          "Asemota D",
          "Del Rosario JS",
          "Feldmann KG",
          "Ko B",
          "Mahmud T",
          "Mano I",
          "Mei S",
          "Salama M"
        ]
      },
      "annotations": {
        "Species": {
          "6239": true
        }
      },
      "source": 139,
      "target": 431,
      "key": "eedff21bf97609d9fe06d0a27936fa156a1eba09a8933d978d9377d2f0878b84cac43bf0077c5c8cf326484dd2bffa443fe073f8678b555ac6d75bfb05bbfd6a"
    },
    {
      "line": 1943,
      "relation": "decreases",
      "evidence": "In this report, we describe a novel mechanism of action determined by the JunD component of AP-1, a factor enhancing cell survival in v-Src-transformed cells. We show that the loss of JunD results in the aberrant activation of a genetic program leading to cell death. This program requires the activation of the tumor suppressor death-associated protein kinase 1 (DAPK1). Since DAPK1 is phosphorylated and inhibited by v-Src, these results highlight the importance of this kinase and the multiple mechanisms controlled by v-Src to antagonize the tumor suppressor function of DAPK1.",
      "citation": {
        "type": "PubMed",
        "reference": "27795443",
        "name": "Journal of virology",
        "title": "JunD/AP-1 Antagonizes the Induction of DAPK1 To Promote the Survival of v-Src-Transformed Cells.",
        "volume": "91",
        "date": "2017-01-01",
        "first": "Maślikowski BM",
        "last": "Bédard PA",
        "authors": [
          "Bédard PA",
          "Fielding B",
          "Maślikowski BM",
          "Wang L",
          "Wu Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "Chicken embryo fibroblasts": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 462,
      "target": 174,
      "key": "b6aba616059c7d2368a5adf476b6e266344afaad720c28f036b53051680dcb6f8692234b4680a453845ac3ef3f820bcfd629f17bf0e2896f7fb03e94d0273f2e"
    },
    {
      "line": 1944,
      "relation": "negativeCorrelation",
      "evidence": "In this report, we describe a novel mechanism of action determined by the JunD component of AP-1, a factor enhancing cell survival in v-Src-transformed cells. We show that the loss of JunD results in the aberrant activation of a genetic program leading to cell death. This program requires the activation of the tumor suppressor death-associated protein kinase 1 (DAPK1). Since DAPK1 is phosphorylated and inhibited by v-Src, these results highlight the importance of this kinase and the multiple mechanisms controlled by v-Src to antagonize the tumor suppressor function of DAPK1.",
      "citation": {
        "type": "PubMed",
        "reference": "27795443",
        "name": "Journal of virology",
        "title": "JunD/AP-1 Antagonizes the Induction of DAPK1 To Promote the Survival of v-Src-Transformed Cells.",
        "volume": "91",
        "date": "2017-01-01",
        "first": "Maślikowski BM",
        "last": "Bédard PA",
        "authors": [
          "Bédard PA",
          "Fielding B",
          "Maślikowski BM",
          "Wang L",
          "Wu Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "Chicken embryo fibroblasts": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 462,
      "target": 431,
      "key": "054fa9b20557c6905a534e6beb5f8fba54497a554486aab141b57ae70d15549547499adc4b231bd3f2741586f4a7383a76de5b5d0cee9ddb409e846c3db9b66f"
    },
    {
      "line": 1953,
      "relation": "partOf",
      "evidence": "Unexpectedly, impairment of the basic loop interaction site completely abolishes calcium/calmodulin binding and DAPK2 activity is reduced to a residual level, indicative of coupled binding to the two sites.",
      "citation": {
        "type": "PubMed",
        "reference": "27133022",
        "name": "Structure (London, England : 1993)",
        "title": "Death-Associated Protein Kinase Activity Is Regulated by Coupled Calcium/Calmodulin Binding to Two Distinct Sites.",
        "volume": "24",
        "pages": "851-61",
        "date": "2016-06-07",
        "first": "Simon B",
        "last": "Wilmanns M",
        "authors": [
          "Hart DJ",
          "Hoffmann JE",
          "Huart AS",
          "Komadina D",
          "Kursula P",
          "McCarthy AA",
          "Mertens HD",
          "Schultz C",
          "Simon B",
          "Svergun DI",
          "Temmerman K",
          "Vahokoski J",
          "Wilmanns M",
          "Yumerefendi H"
        ]
      },
      "source": 315,
      "target": 435,
      "key": "8f3729b1a5d6b03004538e9c27ac00fbfce40a420643b8ad2ac3c890bce4c8c40e3ce9810cac68ab064024a090e91228801493780b3cf6b54d080671f89ed37a"
    },
    {
      "line": 1954,
      "relation": "positiveCorrelation",
      "evidence": "Unexpectedly, impairment of the basic loop interaction site completely abolishes calcium/calmodulin binding and DAPK2 activity is reduced to a residual level, indicative of coupled binding to the two sites.",
      "citation": {
        "type": "PubMed",
        "reference": "27133022",
        "name": "Structure (London, England : 1993)",
        "title": "Death-Associated Protein Kinase Activity Is Regulated by Coupled Calcium/Calmodulin Binding to Two Distinct Sites.",
        "volume": "24",
        "pages": "851-61",
        "date": "2016-06-07",
        "first": "Simon B",
        "last": "Wilmanns M",
        "authors": [
          "Hart DJ",
          "Hoffmann JE",
          "Huart AS",
          "Komadina D",
          "Kursula P",
          "McCarthy AA",
          "Mertens HD",
          "Schultz C",
          "Simon B",
          "Svergun DI",
          "Temmerman K",
          "Vahokoski J",
          "Wilmanns M",
          "Yumerefendi H"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 315,
      "target": 435,
      "key": "15505c6591c482ab65427f7616cd18d21ab474ad6b548e12662904c307adc1faa3819c53d87160ac73dfad31efdaf00772910aa2a8dbbdc72d92bcb5c72d75e2"
    },
    {
      "line": 1955,
      "relation": "positiveCorrelation",
      "evidence": "Unexpectedly, impairment of the basic loop interaction site completely abolishes calcium/calmodulin binding and DAPK2 activity is reduced to a residual level, indicative of coupled binding to the two sites.",
      "citation": {
        "type": "PubMed",
        "reference": "27133022",
        "name": "Structure (London, England : 1993)",
        "title": "Death-Associated Protein Kinase Activity Is Regulated by Coupled Calcium/Calmodulin Binding to Two Distinct Sites.",
        "volume": "24",
        "pages": "851-61",
        "date": "2016-06-07",
        "first": "Simon B",
        "last": "Wilmanns M",
        "authors": [
          "Hart DJ",
          "Hoffmann JE",
          "Huart AS",
          "Komadina D",
          "Kursula P",
          "McCarthy AA",
          "Mertens HD",
          "Schultz C",
          "Simon B",
          "Svergun DI",
          "Temmerman K",
          "Vahokoski J",
          "Wilmanns M",
          "Yumerefendi H"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 315,
      "target": 282,
      "key": "6757bab53d5f838f43e835e1d4f10d2b68462b6681cd71d78f209196db208f94df6b2e88b66c33e5aa85da450f510d8c00962b9e32620bef81cf5073688acd8e"
    },
    {
      "line": 1954,
      "relation": "positiveCorrelation",
      "evidence": "Unexpectedly, impairment of the basic loop interaction site completely abolishes calcium/calmodulin binding and DAPK2 activity is reduced to a residual level, indicative of coupled binding to the two sites.",
      "citation": {
        "type": "PubMed",
        "reference": "27133022",
        "name": "Structure (London, England : 1993)",
        "title": "Death-Associated Protein Kinase Activity Is Regulated by Coupled Calcium/Calmodulin Binding to Two Distinct Sites.",
        "volume": "24",
        "pages": "851-61",
        "date": "2016-06-07",
        "first": "Simon B",
        "last": "Wilmanns M",
        "authors": [
          "Hart DJ",
          "Hoffmann JE",
          "Huart AS",
          "Komadina D",
          "Kursula P",
          "McCarthy AA",
          "Mertens HD",
          "Schultz C",
          "Simon B",
          "Svergun DI",
          "Temmerman K",
          "Vahokoski J",
          "Wilmanns M",
          "Yumerefendi H"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 435,
      "target": 315,
      "key": "8c9e95b3eb09c053bef809e83b06068daf1d778db1f4650deb97412dbf33228a33596960ae06c32a94ccf0fae29e5e1f00f895f8eb8c0a80c49da9cbca2f05d8"
    },
    {
      "line": 1955,
      "relation": "positiveCorrelation",
      "evidence": "Unexpectedly, impairment of the basic loop interaction site completely abolishes calcium/calmodulin binding and DAPK2 activity is reduced to a residual level, indicative of coupled binding to the two sites.",
      "citation": {
        "type": "PubMed",
        "reference": "27133022",
        "name": "Structure (London, England : 1993)",
        "title": "Death-Associated Protein Kinase Activity Is Regulated by Coupled Calcium/Calmodulin Binding to Two Distinct Sites.",
        "volume": "24",
        "pages": "851-61",
        "date": "2016-06-07",
        "first": "Simon B",
        "last": "Wilmanns M",
        "authors": [
          "Hart DJ",
          "Hoffmann JE",
          "Huart AS",
          "Komadina D",
          "Kursula P",
          "McCarthy AA",
          "Mertens HD",
          "Schultz C",
          "Simon B",
          "Svergun DI",
          "Temmerman K",
          "Vahokoski J",
          "Wilmanns M",
          "Yumerefendi H"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 282,
      "target": 315,
      "key": "4a79e88fc3cd0f80d86c737c09885d14eeb8ffd13a5cdc0de9c3269af201d4f5a536749ba1c38d301e957bca79370fc61025c35a2623a9e84691f81b1fbd1474"
    },
    {
      "line": 1956,
      "relation": "increases",
      "evidence": "Unexpectedly, impairment of the basic loop interaction site completely abolishes calcium/calmodulin binding and DAPK2 activity is reduced to a residual level, indicative of coupled binding to the two sites.",
      "citation": {
        "type": "PubMed",
        "reference": "27133022",
        "name": "Structure (London, England : 1993)",
        "title": "Death-Associated Protein Kinase Activity Is Regulated by Coupled Calcium/Calmodulin Binding to Two Distinct Sites.",
        "volume": "24",
        "pages": "851-61",
        "date": "2016-06-07",
        "first": "Simon B",
        "last": "Wilmanns M",
        "authors": [
          "Hart DJ",
          "Hoffmann JE",
          "Huart AS",
          "Komadina D",
          "Kursula P",
          "McCarthy AA",
          "Mertens HD",
          "Schultz C",
          "Simon B",
          "Svergun DI",
          "Temmerman K",
          "Vahokoski J",
          "Wilmanns M",
          "Yumerefendi H"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 282,
      "target": 435,
      "key": "9ed014bcca7d11c678411a267cea388d1545c396a5e591fdfa54f8c5420eade87ed3d3110678a3bc29f2f3b0521a6a80e5b78263692962fc6fb67a837e7bd519"
    },
    {
      "line": 1963,
      "relation": "association",
      "evidence": "Direct interaction of DAPK1 with Tau causes spine loss and subsequently neuronal death. DAPK1 phosphorylates Tau protein at Ser262 (pS(262)) in cortical neurons of stroke mice.",
      "citation": {
        "type": "PubMed",
        "reference": "25995053",
        "name": "Cerebral cortex (New York, N.Y. : 1991)",
        "title": "A Novel Mechanism of Spine Damages in Stroke via DAPK1 and Tau.",
        "volume": "25",
        "pages": "4559-71",
        "date": "2015-11-01",
        "first": "Pei L",
        "last": "Lu Y",
        "authors": [
          "Bi L",
          "Guo Y",
          "Jin H",
          "Li H",
          "Lu Y",
          "Pang P",
          "Pei L",
          "Shang Y",
          "Shu S",
          "Tian Q",
          "Tian T",
          "Wang S",
          "Wei N",
          "Wu J",
          "Xu M",
          "Yan H",
          "Yang X",
          "Yao C",
          "Zhu LQ"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Stroke": true
        }
      },
      "source": 781,
      "target": 803,
      "key": "f52128c69f33f9e37a515611fe7d53b607267fa8784781028012d373e47784cf20938f675beb62f5e791a3916ce688b831f8d70ba2bf456e8c2e41dbcf46e429"
    },
    {
      "line": 1964,
      "relation": "directlyIncreases",
      "evidence": "Direct interaction of DAPK1 with Tau causes spine loss and subsequently neuronal death. DAPK1 phosphorylates Tau protein at Ser262 (pS(262)) in cortical neurons of stroke mice.",
      "citation": {
        "type": "PubMed",
        "reference": "25995053",
        "name": "Cerebral cortex (New York, N.Y. : 1991)",
        "title": "A Novel Mechanism of Spine Damages in Stroke via DAPK1 and Tau.",
        "volume": "25",
        "pages": "4559-71",
        "date": "2015-11-01",
        "first": "Pei L",
        "last": "Lu Y",
        "authors": [
          "Bi L",
          "Guo Y",
          "Jin H",
          "Li H",
          "Lu Y",
          "Pang P",
          "Pei L",
          "Shang Y",
          "Shu S",
          "Tian Q",
          "Tian T",
          "Wang S",
          "Wei N",
          "Wu J",
          "Xu M",
          "Yan H",
          "Yang X",
          "Yao C",
          "Zhu LQ"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Stroke": true
        }
      },
      "source": 781,
      "target": 241,
      "key": "5899f0852bcd97451dd802242c29a9d43f418a777645cebed1bce56ccc81d9472ea3b12b4c7814bb699537ec7a6a636d827ea8258699155e4e68b29f13c4930e"
    },
    {
      "line": 1968,
      "relation": "increases",
      "evidence": "Direct interaction of DAPK1 with Tau causes spine loss and subsequently neuronal death. DAPK1 phosphorylates Tau protein at Ser262 (pS(262)) in cortical neurons of stroke mice.",
      "citation": {
        "type": "PubMed",
        "reference": "25995053",
        "name": "Cerebral cortex (New York, N.Y. : 1991)",
        "title": "A Novel Mechanism of Spine Damages in Stroke via DAPK1 and Tau.",
        "volume": "25",
        "pages": "4559-71",
        "date": "2015-11-01",
        "first": "Pei L",
        "last": "Lu Y",
        "authors": [
          "Bi L",
          "Guo Y",
          "Jin H",
          "Li H",
          "Lu Y",
          "Pang P",
          "Pei L",
          "Shang Y",
          "Shu S",
          "Tian Q",
          "Tian T",
          "Wang S",
          "Wei N",
          "Wu J",
          "Xu M",
          "Yan H",
          "Yang X",
          "Yao C",
          "Zhu LQ"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Stroke": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 781,
      "target": 821,
      "key": "9cc16f7417a992aedd56f652edd4b5dcc84a85e2377eba315ce3151a5b66ed15fc7bdb3e9bcd2f3ce225189349a94bcce0147800d4b0e17dec7aab8c09530318"
    },
    {
      "relation": "hasComponent",
      "source": 241,
      "target": 781,
      "key": "a576cce2d35448bdc7c63ea77a28c67484177faf16b91dce95105154816b8668d66de4c290645d0961743ad2369b130bee411350e0a51463a989a38a78804943"
    },
    {
      "relation": "hasComponent",
      "source": 241,
      "target": 803,
      "key": "be439661722d27ce6ad19157e1f898f2ae7388027827adc89cd765efe5a55b6627cda41a8d13abb4efb7c2ff3f0dd6f18180a8786b48c6b64d013916f4ace108"
    },
    {
      "line": 1966,
      "relation": "increases",
      "evidence": "Direct interaction of DAPK1 with Tau causes spine loss and subsequently neuronal death. DAPK1 phosphorylates Tau protein at Ser262 (pS(262)) in cortical neurons of stroke mice.",
      "citation": {
        "type": "PubMed",
        "reference": "25995053",
        "name": "Cerebral cortex (New York, N.Y. : 1991)",
        "title": "A Novel Mechanism of Spine Damages in Stroke via DAPK1 and Tau.",
        "volume": "25",
        "pages": "4559-71",
        "date": "2015-11-01",
        "first": "Pei L",
        "last": "Lu Y",
        "authors": [
          "Bi L",
          "Guo Y",
          "Jin H",
          "Li H",
          "Lu Y",
          "Pang P",
          "Pei L",
          "Shang Y",
          "Shu S",
          "Tian Q",
          "Tian T",
          "Wang S",
          "Wei N",
          "Wu J",
          "Xu M",
          "Yan H",
          "Yang X",
          "Yao C",
          "Zhu LQ"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Stroke": true
        }
      },
      "source": 241,
      "target": 189,
      "key": "e2aec72795989d821634527fd60f4f5b97324243d122d53b4d839c1b22586d0584ad43b1aba0ffc2e7155f0682f323f3502dd44fa0e4d9debaaf2641903b11f4"
    },
    {
      "line": 1969,
      "relation": "decreases",
      "evidence": "Direct interaction of DAPK1 with Tau causes spine loss and subsequently neuronal death. DAPK1 phosphorylates Tau protein at Ser262 (pS(262)) in cortical neurons of stroke mice.",
      "citation": {
        "type": "PubMed",
        "reference": "25995053",
        "name": "Cerebral cortex (New York, N.Y. : 1991)",
        "title": "A Novel Mechanism of Spine Damages in Stroke via DAPK1 and Tau.",
        "volume": "25",
        "pages": "4559-71",
        "date": "2015-11-01",
        "first": "Pei L",
        "last": "Lu Y",
        "authors": [
          "Bi L",
          "Guo Y",
          "Jin H",
          "Li H",
          "Lu Y",
          "Pang P",
          "Pei L",
          "Shang Y",
          "Shu S",
          "Tian Q",
          "Tian T",
          "Wang S",
          "Wei N",
          "Wu J",
          "Xu M",
          "Yan H",
          "Yang X",
          "Yao C",
          "Zhu LQ"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Stroke": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 821,
      "target": 80,
      "key": "8109b942868f7386246b7b3653516d1ca352ac3f893f7d0f015c361d8de77b2047a1338a95d5407885917a5a3e9663c96180b07c506bda0ff8e4e8a173974b2e"
    },
    {
      "line": 2426,
      "relation": "positiveCorrelation",
      "evidence": "CRF-OE mice had significantly elevated tau-P compared to wild type (WT) mice at the AT8 (S202/T204), PHF-1 (S396/404), S262, and S422 sites. Treating CRF-OE mice with R121919 blocked phosphorylation at the AT8 (S202/T204) and PHF-1 (S396/404) sites, but not at the S262 and S422 sites and reduced phosphorylation of c-Jun N Terminal Kinase (JNK).",
      "citation": {
        "type": "PubMed",
        "reference": "25125464",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.",
        "volume": "43",
        "pages": "967-76",
        "date": "2015-01-01",
        "first": "Campbell SN",
        "last": "Rissman RA",
        "authors": [
          "Campbell SN",
          "Masliah E",
          "Monte L",
          "Rice KC",
          "Rissman RA",
          "Roe AD",
          "Taché Y",
          "Zhang C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 821,
      "target": 779,
      "key": "15537e321a3f08f3c3ffdc3cf5e767b81392a37d0d8fa502c57ac563f3ea1cf2b8b8bb23015608eef56530954cfb47835cef307ee59602016beec7f2a11b7688"
    },
    {
      "line": 1978,
      "relation": "decreases",
      "evidence": "We showed previously that DAPK1 phosphorylates Ser71 in the catalytic active site of Pin1, thereby inhibiting its cellular function.",
      "citation": {
        "type": "PubMed",
        "reference": "24853415",
        "name": "Cell death &amp; disease",
        "title": "Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function.",
        "volume": "5",
        "pages": "e1237",
        "date": "2014-05-22",
        "first": "Kim BM",
        "last": "Lee TH",
        "authors": [
          "Chen CH",
          "Hong Y",
          "Kim BM",
          "Kimchi A",
          "Lee S",
          "Lee TH",
          "You MH",
          "Zhou XZ"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 651,
      "target": 647,
      "key": "ec67f37a9bafed2162dc8e28d901349683f1b781d7d67cd43abb9661a000a0aabf54021307156667d92523b982ebbab19eccf2e6e21e1c8a6fde32136e960375"
    },
    {
      "line": 1991,
      "relation": "positiveCorrelation",
      "evidence": "DAPK1-mediated increase in tau protein expression and stability were accompanied by increased Pin1 Ser71 phosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24853415",
        "name": "Cell death &amp; disease",
        "title": "Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function.",
        "volume": "5",
        "pages": "e1237",
        "date": "2014-05-22",
        "first": "Kim BM",
        "last": "Lee TH",
        "authors": [
          "Chen CH",
          "Hong Y",
          "Kim BM",
          "Kimchi A",
          "Lee S",
          "Lee TH",
          "You MH",
          "Zhou XZ"
        ]
      },
      "source": 651,
      "target": 486,
      "key": "21477d7b60a570ac7948162ad9dac01ade601c7a6b5985582e37248b56cd49762eb817721a0c6d5d28b074a03a69acc84185b007820fb9bade18d3539f644795"
    },
    {
      "line": 3987,
      "relation": "negativeCorrelation",
      "evidence": "Because Pin1 has at least 4 major isovariants in addition to the native polypeptide, this means that Pin1 has 4 (possibly more) posttranslational modifications including phosphorylation at 3 sites (Ser16 and Ser65/Ser71), N-acetylation (amino-terminus and Lys46) and oxidation (Met130 and 146). In all experimental conditions, including tau-overexpressing cells, tau transgenic mice and AD brains, global levels of Pin1 posttranslational modifications were decreased compared with control conditions.",
      "citation": {
        "type": "PubMed",
        "reference": "22926167",
        "name": "Neurobiology of aging",
        "title": "Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker.",
        "volume": "34",
        "pages": "757-69",
        "date": "2013-03-01",
        "first": "Ando K",
        "last": "Buée L",
        "authors": [
          "Ando K",
          "Blum D",
          "Bretteville A",
          "Buée L",
          "Bégard S",
          "Bélarbi K",
          "Caillet-Boudin ML",
          "Demey-Thomas E",
          "Dourlen P",
          "Drobecq H",
          "Eddarkaoui S",
          "Galas MC",
          "Ghestem A",
          "Hamdane M",
          "Landrieu I",
          "Lippens G",
          "Maurage CA",
          "Melnyk P",
          "Sambo AV",
          "Sergeant N",
          "Smet C",
          "Verdier Y",
          "Vingtdeux V",
          "Vinh J"
        ]
      },
      "source": 651,
      "target": 486,
      "key": "7bfb7b435f007840c10563cbc4846b815cd6e82b346ce9fdc3bf084627be3bc7ed60a801df34ff1448c5c8adfd0d46bd48a14b5d00150c192f56d04683d315ad"
    },
    {
      "line": 2012,
      "relation": "increases",
      "evidence": "Furthermore, silencing of both MARK1 and MARK2 blocked DAPK-induced tau S262 phosphorylation (Figure 3e). More importantly, a decrease of pS262 tau, but not total tau, was observed in brain extracts derived from DAPK−/− mice, compared with that from DAPK+/+ mice (Figure 3f). These results strongly suggest a role of endogenous DAPK in stimulating the activity of endogenous MARK, which in turn phosphorylates tau in neurons.",
      "citation": {
        "type": "PubMed",
        "reference": "21311567",
        "name": "Cell death and differentiation",
        "title": "DAPK activates MARK1/2 to regulate microtubule assembly, neuronal differentiation, and tau toxicity.",
        "volume": "18",
        "pages": "1507-20",
        "date": "2011-09-01",
        "first": "Wu PR",
        "last": "Chen RH",
        "authors": [
          "Chen GC",
          "Chen RH",
          "Chen YH",
          "Chien CT",
          "Chou HJ",
          "Huang YP",
          "Kimchi A",
          "Lin MY",
          "Tsai PI",
          "Wu PR"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 633,
      "target": 557,
      "key": "bca6870a443c4b7fd69b0cbd5375b3ade8a4070bd4d1416ae3c7e0e7e0acde289be710aa0b57a7d1323f32e9975afeda909499ad64c321dbef88d067acbee084"
    },
    {
      "line": 2758,
      "relation": "directlyIncreases",
      "evidence": "Using transgenic Drosophila expressing human tau, we found that RNAi-mediated knockdown of milton or Miro, an adaptor protein essential for axonal transport of mitochondria, enhanced human tau-induced neurodegeneration. Tau phosphorylation at an AD-related site Ser262 increased with knockdown of milton or Miro; and partitioning defective-1 (PAR-1), the Drosophila homolog of mammalian microtubule affinity-regulating kinase, mediated this increase of tau phosphorylation. Tau phosphorylation at Ser262 has been reported to promote tau detachment from microtubules, and we found that the levels of microtubule-unbound free tau increased by milton knockdown. Blocking tau phosphorylation at Ser262 site by PAR-1 knockdown or by mutating the Ser262 site to unphosphorylatable alanine suppressed the enhancement of tau-induced neurodegeneration caused by milton knockdown. Furthermore, knockdown of milton or Miro increased the levels of active PAR-1.",
      "citation": {
        "type": "PubMed",
        "reference": "22952452",
        "name": "PLoS genetics",
        "title": "Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1.",
        "volume": "8",
        "pages": "e1002918",
        "date": "2012-01-01",
        "first": "Iijima-Ando K",
        "last": "Iijima KM",
        "authors": [
          "Iijima KM",
          "Iijima-Ando K",
          "Lu B",
          "Maruko-Otake A",
          "Ohtake Y",
          "Sekiya M",
          "Suzuki E"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 633,
      "target": 557,
      "key": "7ba6187e9cb4ec6be9a5863473ba90c3360d2dcbced4af3352667e5722bf7a4cf9d1f722dcde0ac88cd0de544e4745db5910e03b4d0c478311908f1ba1db6b3a"
    },
    {
      "line": 2018,
      "relation": "decreases",
      "evidence": "Importantly, depletion of MARK1/2 reversed the inhibitory effect of DAPK on MT regrowth (Figure 5c, right panel). These results indicate that the DAPK–MARK signaling axis inhibits MT assembly and stability.",
      "citation": {
        "type": "PubMed",
        "reference": "21311567",
        "name": "Cell death and differentiation",
        "title": "DAPK activates MARK1/2 to regulate microtubule assembly, neuronal differentiation, and tau toxicity.",
        "volume": "18",
        "pages": "1507-20",
        "date": "2011-09-01",
        "first": "Wu PR",
        "last": "Chen RH",
        "authors": [
          "Chen GC",
          "Chen RH",
          "Chen YH",
          "Chien CT",
          "Chou HJ",
          "Huang YP",
          "Kimchi A",
          "Lin MY",
          "Tsai PI",
          "Wu PR"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 633,
      "target": 186,
      "key": "d1e2224e2a099777f5a3260e39473e73df04f9ae1b9dbaa758c274a285610023f2e9c016c53c0b69d55243a4017093464ccde3e38d1f7fb9ad671a78cc031d1a"
    },
    {
      "line": 2760,
      "relation": "negativeCorrelation",
      "evidence": "Using transgenic Drosophila expressing human tau, we found that RNAi-mediated knockdown of milton or Miro, an adaptor protein essential for axonal transport of mitochondria, enhanced human tau-induced neurodegeneration. Tau phosphorylation at an AD-related site Ser262 increased with knockdown of milton or Miro; and partitioning defective-1 (PAR-1), the Drosophila homolog of mammalian microtubule affinity-regulating kinase, mediated this increase of tau phosphorylation. Tau phosphorylation at Ser262 has been reported to promote tau detachment from microtubules, and we found that the levels of microtubule-unbound free tau increased by milton knockdown. Blocking tau phosphorylation at Ser262 site by PAR-1 knockdown or by mutating the Ser262 site to unphosphorylatable alanine suppressed the enhancement of tau-induced neurodegeneration caused by milton knockdown. Furthermore, knockdown of milton or Miro increased the levels of active PAR-1.",
      "citation": {
        "type": "PubMed",
        "reference": "22952452",
        "name": "PLoS genetics",
        "title": "Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1.",
        "volume": "8",
        "pages": "e1002918",
        "date": "2012-01-01",
        "first": "Iijima-Ando K",
        "last": "Iijima KM",
        "authors": [
          "Iijima KM",
          "Iijima-Ando K",
          "Lu B",
          "Maruko-Otake A",
          "Ohtake Y",
          "Sekiya M",
          "Suzuki E"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "source": 633,
      "target": 733,
      "key": "8a5980f3ac156366dbb46dfb1608309e2def4edf21795c5ec82ab449876b9dce3878c39283a04d64cd51e01cc89d254d8b0471cd786107b3cd5212d2d507ac76"
    },
    {
      "line": 2761,
      "relation": "negativeCorrelation",
      "evidence": "Using transgenic Drosophila expressing human tau, we found that RNAi-mediated knockdown of milton or Miro, an adaptor protein essential for axonal transport of mitochondria, enhanced human tau-induced neurodegeneration. Tau phosphorylation at an AD-related site Ser262 increased with knockdown of milton or Miro; and partitioning defective-1 (PAR-1), the Drosophila homolog of mammalian microtubule affinity-regulating kinase, mediated this increase of tau phosphorylation. Tau phosphorylation at Ser262 has been reported to promote tau detachment from microtubules, and we found that the levels of microtubule-unbound free tau increased by milton knockdown. Blocking tau phosphorylation at Ser262 site by PAR-1 knockdown or by mutating the Ser262 site to unphosphorylatable alanine suppressed the enhancement of tau-induced neurodegeneration caused by milton knockdown. Furthermore, knockdown of milton or Miro increased the levels of active PAR-1.",
      "citation": {
        "type": "PubMed",
        "reference": "22952452",
        "name": "PLoS genetics",
        "title": "Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1.",
        "volume": "8",
        "pages": "e1002918",
        "date": "2012-01-01",
        "first": "Iijima-Ando K",
        "last": "Iijima KM",
        "authors": [
          "Iijima KM",
          "Iijima-Ando K",
          "Lu B",
          "Maruko-Otake A",
          "Ohtake Y",
          "Sekiya M",
          "Suzuki E"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "source": 633,
      "target": 672,
      "key": "1b1ba3edc5e5cdd7b37f90686daa64b777298319f437e71888adc8f1d9b96e8bb8ead497cb2c99caa8a47425724b58e5371203d4c261ea73fa5b7334f767d3b1"
    },
    {
      "line": 2011,
      "relation": "increases",
      "evidence": "Furthermore, silencing of both MARK1 and MARK2 blocked DAPK-induced tau S262 phosphorylation (Figure 3e). More importantly, a decrease of pS262 tau, but not total tau, was observed in brain extracts derived from DAPK−/− mice, compared with that from DAPK+/+ mice (Figure 3f). These results strongly suggest a role of endogenous DAPK in stimulating the activity of endogenous MARK, which in turn phosphorylates tau in neurons.",
      "citation": {
        "type": "PubMed",
        "reference": "21311567",
        "name": "Cell death and differentiation",
        "title": "DAPK activates MARK1/2 to regulate microtubule assembly, neuronal differentiation, and tau toxicity.",
        "volume": "18",
        "pages": "1507-20",
        "date": "2011-09-01",
        "first": "Wu PR",
        "last": "Chen RH",
        "authors": [
          "Chen GC",
          "Chen RH",
          "Chen YH",
          "Chien CT",
          "Chou HJ",
          "Huang YP",
          "Kimchi A",
          "Lin MY",
          "Tsai PI",
          "Wu PR"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 634,
      "target": 557,
      "key": "a254e1bd51ba7e87c7692a935fe73aa24ca5f2fdc4dabcf8853adb62435ac11dcde48d6c35ef71df3353f9a1170f87d1893c72a84ecfa78907c5739fd35176a8"
    },
    {
      "line": 2643,
      "relation": "directlyIncreases",
      "evidence": "While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were ∼45−58% phosphorylated (Table 1). Using wild-type MARK2cat at 25 °C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.",
      "citation": {
        "type": "PubMed",
        "reference": "24251416",
        "name": "Biochemistry",
        "title": "Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.",
        "volume": "52",
        "pages": "9068-79",
        "date": "2013-12-17",
        "first": "Schwalbe M",
        "last": "Zweckstetter M",
        "authors": [
          "Bibow S",
          "Biernat J",
          "Blackledge M",
          "Jensen MR",
          "Kadavath H",
          "Mandelkow E",
          "Ozenne V",
          "Schwalbe M",
          "Zweckstetter M"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 634,
      "target": 557,
      "key": "469028357db820a1612d3ad7d3a522a0c6fa7f952dc2353d78c13e68fd5025ceeb3406cd6a43a5d75ea154845f358851b3294877061f18a5f7a5850cf7a51c5c"
    },
    {
      "line": 2775,
      "relation": "directlyIncreases",
      "evidence": "Several kinases such as microtubule-affinity regulating kinase (MARK), protein kinase A, calcium calmodulin kinase II, and checkpoint kinase 2 are known to phosphorylate tau on Ser(262) in vitro. In this study, we took advantage of the in situ proximity ligation assay to investigate the role of MARK2, one of the four MARK isoforms, in AD. We demonstrate that MARK2 interacts with tau and phosphorylates tau at Ser(262) in stably transfected NIH/3T3 cells expressing human recombinant tau. Staurosporine, a protein kinase inhibitor, significantly reduced the interaction between MARK2 and tau, and also phosphorylation of tau at Ser(262).",
      "citation": {
        "type": "PubMed",
        "reference": "23001711",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Elevated MARK2-dependent phosphorylation of Tau in Alzheimer's disease.",
        "volume": "33",
        "pages": "699-713",
        "date": "2013-01-01",
        "first": "Gu GJ",
        "last": "Kamali-Moghaddam M",
        "authors": [
          "Agerman K",
          "Eckersley S",
          "Gu GJ",
          "Kamali-Moghaddam M",
          "Kvist AJ",
          "Landegren U",
          "Lund H",
          "Milner R",
          "Nilsson LN",
          "Sunnemark D",
          "Wu D"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "NIH/3T3": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 634,
      "target": 557,
      "key": "d08804d93f72158abf47d778e49e122ea2233dfbaec9696de12c13549b3067887cc860739a29d368a767a2b078f4508f00d413b389487d305a02d0b42e0f77ca"
    },
    {
      "line": 2017,
      "relation": "decreases",
      "evidence": "Importantly, depletion of MARK1/2 reversed the inhibitory effect of DAPK on MT regrowth (Figure 5c, right panel). These results indicate that the DAPK–MARK signaling axis inhibits MT assembly and stability.",
      "citation": {
        "type": "PubMed",
        "reference": "21311567",
        "name": "Cell death and differentiation",
        "title": "DAPK activates MARK1/2 to regulate microtubule assembly, neuronal differentiation, and tau toxicity.",
        "volume": "18",
        "pages": "1507-20",
        "date": "2011-09-01",
        "first": "Wu PR",
        "last": "Chen RH",
        "authors": [
          "Chen GC",
          "Chen RH",
          "Chen YH",
          "Chien CT",
          "Chou HJ",
          "Huang YP",
          "Kimchi A",
          "Lin MY",
          "Tsai PI",
          "Wu PR"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 634,
      "target": 186,
      "key": "2c7d91091bdbc72b8b1fb999037d76c6db07100070b602d7f1c861338a19112c83a00be9392eba911fc02365bf386b65bcb2ff42be4b849ae2374e1b66b07dc3"
    },
    {
      "line": 2644,
      "relation": "directlyIncreases",
      "evidence": "While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were ∼45−58% phosphorylated (Table 1). Using wild-type MARK2cat at 25 °C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.",
      "citation": {
        "type": "PubMed",
        "reference": "24251416",
        "name": "Biochemistry",
        "title": "Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.",
        "volume": "52",
        "pages": "9068-79",
        "date": "2013-12-17",
        "first": "Schwalbe M",
        "last": "Zweckstetter M",
        "authors": [
          "Bibow S",
          "Biernat J",
          "Blackledge M",
          "Jensen MR",
          "Kadavath H",
          "Mandelkow E",
          "Ozenne V",
          "Schwalbe M",
          "Zweckstetter M"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 634,
      "target": 561,
      "key": "959e3f3379bf4f7a4bfddbbede623489e84925651a5c56137030932c755d115b8d14b6d3d8c1dc39d6919cd5f7bdb024927e15b6e076c71dc5f7aa6060eceea1"
    },
    {
      "line": 2645,
      "relation": "directlyIncreases",
      "evidence": "While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were ∼45−58% phosphorylated (Table 1). Using wild-type MARK2cat at 25 °C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.",
      "citation": {
        "type": "PubMed",
        "reference": "24251416",
        "name": "Biochemistry",
        "title": "Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.",
        "volume": "52",
        "pages": "9068-79",
        "date": "2013-12-17",
        "first": "Schwalbe M",
        "last": "Zweckstetter M",
        "authors": [
          "Bibow S",
          "Biernat J",
          "Blackledge M",
          "Jensen MR",
          "Kadavath H",
          "Mandelkow E",
          "Ozenne V",
          "Schwalbe M",
          "Zweckstetter M"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 634,
      "target": 563,
      "key": "717715808a9a2abeae10cb041263b5fd0f66219a4a9cfe12756c624362133abce5be2d0611aba6af2f79063e847ce93e24e24929adc00b5a36ffeea05dc647f3"
    },
    {
      "line": 2646,
      "relation": "directlyIncreases",
      "evidence": "While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were ∼45−58% phosphorylated (Table 1). Using wild-type MARK2cat at 25 °C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.",
      "citation": {
        "type": "PubMed",
        "reference": "24251416",
        "name": "Biochemistry",
        "title": "Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.",
        "volume": "52",
        "pages": "9068-79",
        "date": "2013-12-17",
        "first": "Schwalbe M",
        "last": "Zweckstetter M",
        "authors": [
          "Bibow S",
          "Biernat J",
          "Blackledge M",
          "Jensen MR",
          "Kadavath H",
          "Mandelkow E",
          "Ozenne V",
          "Schwalbe M",
          "Zweckstetter M"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 634,
      "target": 559,
      "key": "2534d690bce73f21e487135b3c9c208a0b816cfc4626af8a82afeb582d74dc6139c93a01fa0d043fc68bc2c6af2d066505153ffe73063752c7a8cd6362eedbe4"
    },
    {
      "line": 2648,
      "relation": "directlyIncreases",
      "evidence": "While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were ∼45−58% phosphorylated (Table 1). Using wild-type MARK2cat at 25 °C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.",
      "citation": {
        "type": "PubMed",
        "reference": "24251416",
        "name": "Biochemistry",
        "title": "Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.",
        "volume": "52",
        "pages": "9068-79",
        "date": "2013-12-17",
        "first": "Schwalbe M",
        "last": "Zweckstetter M",
        "authors": [
          "Bibow S",
          "Biernat J",
          "Blackledge M",
          "Jensen MR",
          "Kadavath H",
          "Mandelkow E",
          "Ozenne V",
          "Schwalbe M",
          "Zweckstetter M"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 634,
      "target": 560,
      "key": "afbc0cd779781b3e970d4f1d2c9a6e4b7f7275c56b6592a8171ca641b311f82c729cf6c1fd4cac2d2b6a1233fc560b8a33b2e0def7be8474f67c1e66623b0d8c"
    },
    {
      "line": 2650,
      "relation": "directlyIncreases",
      "evidence": "While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were ∼45−58% phosphorylated (Table 1). Using wild-type MARK2cat at 25 °C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.",
      "citation": {
        "type": "PubMed",
        "reference": "24251416",
        "name": "Biochemistry",
        "title": "Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.",
        "volume": "52",
        "pages": "9068-79",
        "date": "2013-12-17",
        "first": "Schwalbe M",
        "last": "Zweckstetter M",
        "authors": [
          "Bibow S",
          "Biernat J",
          "Blackledge M",
          "Jensen MR",
          "Kadavath H",
          "Mandelkow E",
          "Ozenne V",
          "Schwalbe M",
          "Zweckstetter M"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 634,
      "target": 562,
      "key": "49ae11c4a271fff31a75f67c1bd30cf7857f13ada2e5cb2b18fedbf1419cc942a783ac44f25ecfd99b0edbcfa0f82c4aa6630ba100684164b61e51c0f8d8cead"
    },
    {
      "line": 2652,
      "relation": "directlyIncreases",
      "evidence": "While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were ∼45−58% phosphorylated (Table 1). Using wild-type MARK2cat at 25 °C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.",
      "citation": {
        "type": "PubMed",
        "reference": "24251416",
        "name": "Biochemistry",
        "title": "Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.",
        "volume": "52",
        "pages": "9068-79",
        "date": "2013-12-17",
        "first": "Schwalbe M",
        "last": "Zweckstetter M",
        "authors": [
          "Bibow S",
          "Biernat J",
          "Blackledge M",
          "Jensen MR",
          "Kadavath H",
          "Mandelkow E",
          "Ozenne V",
          "Schwalbe M",
          "Zweckstetter M"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 634,
      "target": 567,
      "key": "16644673d63fc779f15ffa63830ffd1393b9755989ffe9f13991dc88c4d560c45b7a061b26a6d195ad551d31c7ab46365c30a20dde538006f59cdfd7471f6649"
    },
    {
      "line": 2653,
      "relation": "directlyIncreases",
      "evidence": "While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were ∼45−58% phosphorylated (Table 1). Using wild-type MARK2cat at 25 °C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.",
      "citation": {
        "type": "PubMed",
        "reference": "24251416",
        "name": "Biochemistry",
        "title": "Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.",
        "volume": "52",
        "pages": "9068-79",
        "date": "2013-12-17",
        "first": "Schwalbe M",
        "last": "Zweckstetter M",
        "authors": [
          "Bibow S",
          "Biernat J",
          "Blackledge M",
          "Jensen MR",
          "Kadavath H",
          "Mandelkow E",
          "Ozenne V",
          "Schwalbe M",
          "Zweckstetter M"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 634,
      "target": 568,
      "key": "4fff548b198ec5f7524dc87112abf42629822e5f0cbcb5e48f31b5b75aeba3bbf16d27e0189ec78927db1083787fc5c397438beb2021f655c240f242abdc1f3e"
    },
    {
      "line": 2669,
      "relation": "increases",
      "evidence": "In particular, previous studies have demonstrated that the tau ubiquitin ligase, CHIP, is unable to bind and ubiquitinate tau species phosphorylated by Par-1/MARK2 on the 12E8 epitope (S262/356) [33], a p-tau species that is also resistant to degradation upon treatment with Hsp90 inhibitors [32,33]. Tau phosphorylated at the PHF1 epitope (S396/404) is still susceptible to degradation following Hsp90 inhibition and actually exhibits an enhanced interaction with Hsp90",
      "citation": {
        "type": "PubMed",
        "reference": "25031639",
        "name": "Alzheimer's research &amp; therapy",
        "title": "Acetylation: a new key to unlock tau's role in neurodegeneration.",
        "volume": "6",
        "pages": "29",
        "date": "2014-01-01",
        "first": "Cook C",
        "last": "Petrucelli L",
        "authors": [
          "Carlomagno Y",
          "Cook C",
          "Petrucelli L",
          "Stankowski JN",
          "Stetler C"
        ]
      },
      "source": 634,
      "target": 113,
      "key": "b5c02248f46ffaba4c0d455cecbaf70d6757823afba300171646aa5f752c70d5b7d0e9e5ec85e23511f8916add6ea6b54f66e2b9a55b2e84f92fbf310807b0cc"
    },
    {
      "line": 2025,
      "relation": "association",
      "evidence": "Moreover, we found that Hap1 bound Dcaf7 competitively in cytoplasm with dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), a protein implicated in Down syndrome (DS). Depleting Hap1 promoted the DYRK1A-Dcaf7 interaction and increased the DYRK1A protein level.",
      "citation": {
        "type": "PubMed",
        "reference": "28137862",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "DYRK1A regulates Hap1-Dcaf7/WDR68 binding with implication for delayed growth in Down syndrome.",
        "volume": "114",
        "pages": "E1224-E1233",
        "date": "2017-02-14",
        "first": "Xiang J",
        "last": "Li XJ",
        "authors": [
          "Gaertig MA",
          "Li S",
          "Li XJ",
          "Reeves RH",
          "Xiang J",
          "Xin N",
          "Yang S"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 782,
      "target": 786,
      "key": "f8cc98fedcb9ce2e496a686b9d849e3f629707361afd51681fb335c2d1a003fd072be018fd18a4fee891f1180d5276cf66a0c22ed209f24eca5e3edcd6b9e0c0"
    },
    {
      "line": 2026,
      "relation": "partOf",
      "evidence": "Moreover, we found that Hap1 bound Dcaf7 competitively in cytoplasm with dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), a protein implicated in Down syndrome (DS). Depleting Hap1 promoted the DYRK1A-Dcaf7 interaction and increased the DYRK1A protein level.",
      "citation": {
        "type": "PubMed",
        "reference": "28137862",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "DYRK1A regulates Hap1-Dcaf7/WDR68 binding with implication for delayed growth in Down syndrome.",
        "volume": "114",
        "pages": "E1224-E1233",
        "date": "2017-02-14",
        "first": "Xiang J",
        "last": "Li XJ",
        "authors": [
          "Gaertig MA",
          "Li S",
          "Li XJ",
          "Reeves RH",
          "Xiang J",
          "Xin N",
          "Yang S"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 782,
      "target": 242,
      "key": "93880533782eba966be6c69148df98d2e3272feed7391223eaa35a9b022c8a59e301e65785cc4d745f34155ab1ffb3fb64c1bdb1de86c0a87257b4e97ac7a07b"
    },
    {
      "line": 2028,
      "relation": "association",
      "evidence": "Moreover, we found that Hap1 bound Dcaf7 competitively in cytoplasm with dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), a protein implicated in Down syndrome (DS). Depleting Hap1 promoted the DYRK1A-Dcaf7 interaction and increased the DYRK1A protein level.",
      "citation": {
        "type": "PubMed",
        "reference": "28137862",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "DYRK1A regulates Hap1-Dcaf7/WDR68 binding with implication for delayed growth in Down syndrome.",
        "volume": "114",
        "pages": "E1224-E1233",
        "date": "2017-02-14",
        "first": "Xiang J",
        "last": "Li XJ",
        "authors": [
          "Gaertig MA",
          "Li S",
          "Li XJ",
          "Reeves RH",
          "Xiang J",
          "Xin N",
          "Yang S"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 782,
      "target": 797,
      "key": "99b85219261407e1bb3951e98728e4194c2cef1f7d49512f9feb9c5a6ac02992a4b2b6a7fe826f078514cf1c6d22e0f0c7ce97fdc83488b75e9f80ba390e6353"
    },
    {
      "line": 2025,
      "relation": "association",
      "evidence": "Moreover, we found that Hap1 bound Dcaf7 competitively in cytoplasm with dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), a protein implicated in Down syndrome (DS). Depleting Hap1 promoted the DYRK1A-Dcaf7 interaction and increased the DYRK1A protein level.",
      "citation": {
        "type": "PubMed",
        "reference": "28137862",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "DYRK1A regulates Hap1-Dcaf7/WDR68 binding with implication for delayed growth in Down syndrome.",
        "volume": "114",
        "pages": "E1224-E1233",
        "date": "2017-02-14",
        "first": "Xiang J",
        "last": "Li XJ",
        "authors": [
          "Gaertig MA",
          "Li S",
          "Li XJ",
          "Reeves RH",
          "Xiang J",
          "Xin N",
          "Yang S"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 786,
      "target": 782,
      "key": "892b91794c54fc2985271bb5b3c63840e714b9b9a5faa18f9c683aee610ea111a98ef44159f3f74b70e6e5f9045183340ab46334097af6e62a87803d7fbe4d17"
    },
    {
      "line": 2027,
      "relation": "partOf",
      "evidence": "Moreover, we found that Hap1 bound Dcaf7 competitively in cytoplasm with dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), a protein implicated in Down syndrome (DS). Depleting Hap1 promoted the DYRK1A-Dcaf7 interaction and increased the DYRK1A protein level.",
      "citation": {
        "type": "PubMed",
        "reference": "28137862",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "DYRK1A regulates Hap1-Dcaf7/WDR68 binding with implication for delayed growth in Down syndrome.",
        "volume": "114",
        "pages": "E1224-E1233",
        "date": "2017-02-14",
        "first": "Xiang J",
        "last": "Li XJ",
        "authors": [
          "Gaertig MA",
          "Li S",
          "Li XJ",
          "Reeves RH",
          "Xiang J",
          "Xin N",
          "Yang S"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 786,
      "target": 242,
      "key": "bd05f2c610c55738a1097c7b32e272941ce1875a77d533d3010b1c1aa86c5ce909b395f1a85e983370b9cbcfa85b648633106aa2a54a97689d8ec3b256078e0c"
    },
    {
      "line": 2029,
      "relation": "negativeCorrelation",
      "evidence": "Moreover, we found that Hap1 bound Dcaf7 competitively in cytoplasm with dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), a protein implicated in Down syndrome (DS). Depleting Hap1 promoted the DYRK1A-Dcaf7 interaction and increased the DYRK1A protein level.",
      "citation": {
        "type": "PubMed",
        "reference": "28137862",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "DYRK1A regulates Hap1-Dcaf7/WDR68 binding with implication for delayed growth in Down syndrome.",
        "volume": "114",
        "pages": "E1224-E1233",
        "date": "2017-02-14",
        "first": "Xiang J",
        "last": "Li XJ",
        "authors": [
          "Gaertig MA",
          "Li S",
          "Li XJ",
          "Reeves RH",
          "Xiang J",
          "Xin N",
          "Yang S"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 786,
      "target": 797,
      "key": "4a3994b01eb55d8b7bec93b357f52e614ba3fee60863483215d30940f74b981a722370a5b9b8d46925ac7ef7fb50def99a1e91f171412a6e9916d2d3c5f76b12"
    },
    {
      "line": 2040,
      "relation": "positiveCorrelation",
      "evidence": "The normalization of the Dyrk1A gene dosage did not rescue the reduced cerebellar volume but increased the size of the granular and molecular layers, the densities of granular and Purkinje cells, and dendritic arborization.",
      "citation": {
        "type": "PubMed",
        "reference": "29221819",
        "name": "Neurobiology of disease",
        "title": "Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.",
        "volume": "110",
        "pages": "206-217",
        "date": "2018-02-01",
        "first": "García-Cerro S",
        "last": "Martínez-Cué C",
        "authors": [
          "Berciano MT",
          "García-Cerro S",
          "Lafarga M",
          "Lantigua S",
          "Martínez-Cué C",
          "Padro D",
          "Ramos-Cabrer P",
          "Rueda N",
          "Vidal V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 786,
      "target": 128,
      "key": "3914c42e89c87ccfd956904ee2443b7e36e256202f08ba53b22fb5e3fa6bafc3085eb50b7d37506ab55071e107ea6411868a282d513b542cacfa089909f32050"
    },
    {
      "line": 2041,
      "relation": "positiveCorrelation",
      "evidence": "The normalization of the Dyrk1A gene dosage did not rescue the reduced cerebellar volume but increased the size of the granular and molecular layers, the densities of granular and Purkinje cells, and dendritic arborization.",
      "citation": {
        "type": "PubMed",
        "reference": "29221819",
        "name": "Neurobiology of disease",
        "title": "Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.",
        "volume": "110",
        "pages": "206-217",
        "date": "2018-02-01",
        "first": "García-Cerro S",
        "last": "Martínez-Cué C",
        "authors": [
          "Berciano MT",
          "García-Cerro S",
          "Lafarga M",
          "Lantigua S",
          "Martínez-Cué C",
          "Padro D",
          "Ramos-Cabrer P",
          "Rueda N",
          "Vidal V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 786,
      "target": 131,
      "key": "f1a8ea2f47934e723f1c3e2c34036e0502e534ec2da57442c4a408091318d0f3863be989b182dc7a8f44cfbe6a6bd11765772c023e9b7207729edec43a64f9eb"
    },
    {
      "line": 2042,
      "relation": "positiveCorrelation",
      "evidence": "The normalization of the Dyrk1A gene dosage did not rescue the reduced cerebellar volume but increased the size of the granular and molecular layers, the densities of granular and Purkinje cells, and dendritic arborization.",
      "citation": {
        "type": "PubMed",
        "reference": "29221819",
        "name": "Neurobiology of disease",
        "title": "Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.",
        "volume": "110",
        "pages": "206-217",
        "date": "2018-02-01",
        "first": "García-Cerro S",
        "last": "Martínez-Cué C",
        "authors": [
          "Berciano MT",
          "García-Cerro S",
          "Lafarga M",
          "Lantigua S",
          "Martínez-Cué C",
          "Padro D",
          "Ramos-Cabrer P",
          "Rueda N",
          "Vidal V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 786,
      "target": 109,
      "key": "a842efd270c6a4b23618329936b2cc3c2f9c5c8a2d386b1f258a1c1f7943b0845d7067ffb305ff0b3ec428862bd9a43101e07a263f2cbe4212f762ff4a44c953"
    },
    {
      "line": 2043,
      "relation": "positiveCorrelation",
      "evidence": "The normalization of the Dyrk1A gene dosage did not rescue the reduced cerebellar volume but increased the size of the granular and molecular layers, the densities of granular and Purkinje cells, and dendritic arborization.",
      "citation": {
        "type": "PubMed",
        "reference": "29221819",
        "name": "Neurobiology of disease",
        "title": "Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.",
        "volume": "110",
        "pages": "206-217",
        "date": "2018-02-01",
        "first": "García-Cerro S",
        "last": "Martínez-Cué C",
        "authors": [
          "Berciano MT",
          "García-Cerro S",
          "Lafarga M",
          "Lantigua S",
          "Martínez-Cué C",
          "Padro D",
          "Ramos-Cabrer P",
          "Rueda N",
          "Vidal V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 786,
      "target": 181,
      "key": "a829c9b0f677035de97b8450cbf4e406e3ddc7d2bb4152832f16ec61b0fa192260b005d8962a792700f0e4e1e9af4af86d62e5c5ea1ea398c205be2267af20c4"
    },
    {
      "line": 2049,
      "relation": "positiveCorrelation",
      "evidence": "Normalizing the gene dosage of Dyrk1A in the TS mouse rescued the density of senescent cells in the cingulate cortex, hippocampus and septum, prevented cholinergic neuron degeneration, and reduced App expression in the hippocampus, Aß load in the cortex and hippocampus, the expression of phosphorylated tau at the Ser202 residue in the hippocampus and cerebellum and the levels of total tau in the cortex, hippocampus and cerebellum.",
      "citation": {
        "type": "PubMed",
        "reference": "29221819",
        "name": "Neurobiology of disease",
        "title": "Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.",
        "volume": "110",
        "pages": "206-217",
        "date": "2018-02-01",
        "first": "García-Cerro S",
        "last": "Martínez-Cué C",
        "authors": [
          "Berciano MT",
          "García-Cerro S",
          "Lafarga M",
          "Lantigua S",
          "Martínez-Cué C",
          "Padro D",
          "Ramos-Cabrer P",
          "Rueda N",
          "Vidal V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        },
        "Anatomy": {
          "hippocampal formation": true,
          "septum": true,
          "cingulate cortex": true
        }
      },
      "source": 786,
      "target": 179,
      "key": "cee5b8e9bb0cfe544e25fccf1ac6753afed3a4d23cb091f8d85d3bd53565f4d2814d774ef1d0e22cd87f6f2bf2c7f21c25cd36f5b08746097350c0915ef1973f"
    },
    {
      "line": 2050,
      "relation": "positiveCorrelation",
      "evidence": "Normalizing the gene dosage of Dyrk1A in the TS mouse rescued the density of senescent cells in the cingulate cortex, hippocampus and septum, prevented cholinergic neuron degeneration, and reduced App expression in the hippocampus, Aß load in the cortex and hippocampus, the expression of phosphorylated tau at the Ser202 residue in the hippocampus and cerebellum and the levels of total tau in the cortex, hippocampus and cerebellum.",
      "citation": {
        "type": "PubMed",
        "reference": "29221819",
        "name": "Neurobiology of disease",
        "title": "Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.",
        "volume": "110",
        "pages": "206-217",
        "date": "2018-02-01",
        "first": "García-Cerro S",
        "last": "Martínez-Cué C",
        "authors": [
          "Berciano MT",
          "García-Cerro S",
          "Lafarga M",
          "Lantigua S",
          "Martínez-Cué C",
          "Padro D",
          "Ramos-Cabrer P",
          "Rueda N",
          "Vidal V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        },
        "Anatomy": {
          "hippocampal formation": true,
          "septum": true,
          "cingulate cortex": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 786,
      "target": 125,
      "key": "2a36fc80fb3b8b87b2e5a2ae1ff6b4fec88286fab3ee3b132e033ee7eb19d03c4b92db093c1fd42a92c94635fe779d9914a27da993ccacef240d996209d0f42f"
    },
    {
      "line": 2053,
      "relation": "negativeCorrelation",
      "evidence": "Normalizing the gene dosage of Dyrk1A in the TS mouse rescued the density of senescent cells in the cingulate cortex, hippocampus and septum, prevented cholinergic neuron degeneration, and reduced App expression in the hippocampus, Aß load in the cortex and hippocampus, the expression of phosphorylated tau at the Ser202 residue in the hippocampus and cerebellum and the levels of total tau in the cortex, hippocampus and cerebellum.",
      "citation": {
        "type": "PubMed",
        "reference": "29221819",
        "name": "Neurobiology of disease",
        "title": "Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.",
        "volume": "110",
        "pages": "206-217",
        "date": "2018-02-01",
        "first": "García-Cerro S",
        "last": "Martínez-Cué C",
        "authors": [
          "Berciano MT",
          "García-Cerro S",
          "Lafarga M",
          "Lantigua S",
          "Martínez-Cué C",
          "Padro D",
          "Ramos-Cabrer P",
          "Rueda N",
          "Vidal V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 786,
      "target": 770,
      "key": "427ed8b81b9f5bf281dd64303b347581b058cde9f679113c91a90322a9dcd28da20d44eb1c63805c13595b572c5f199890d69d5870a047fe40aa1360a800c09e"
    },
    {
      "line": 2056,
      "relation": "negativeCorrelation",
      "evidence": "Normalizing the gene dosage of Dyrk1A in the TS mouse rescued the density of senescent cells in the cingulate cortex, hippocampus and septum, prevented cholinergic neuron degeneration, and reduced App expression in the hippocampus, Aß load in the cortex and hippocampus, the expression of phosphorylated tau at the Ser202 residue in the hippocampus and cerebellum and the levels of total tau in the cortex, hippocampus and cerebellum.",
      "citation": {
        "type": "PubMed",
        "reference": "29221819",
        "name": "Neurobiology of disease",
        "title": "Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.",
        "volume": "110",
        "pages": "206-217",
        "date": "2018-02-01",
        "first": "García-Cerro S",
        "last": "Martínez-Cué C",
        "authors": [
          "Berciano MT",
          "García-Cerro S",
          "Lafarga M",
          "Lantigua S",
          "Martínez-Cué C",
          "Padro D",
          "Ramos-Cabrer P",
          "Rueda N",
          "Vidal V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        },
        "Anatomy": {
          "hippocampal formation": true,
          "cerebral cortex": true
        }
      },
      "source": 786,
      "target": 11,
      "key": "9c12616a6f15d46b7d57f72d8222d37a8ef87da85abea3d7e8f1d39f0f6fa32ac692a3822dc9d51e89fea826e02a024fbc49b8410a13edb5ef1904a270d01454"
    },
    {
      "line": 2059,
      "relation": "negativeCorrelation",
      "evidence": "Normalizing the gene dosage of Dyrk1A in the TS mouse rescued the density of senescent cells in the cingulate cortex, hippocampus and septum, prevented cholinergic neuron degeneration, and reduced App expression in the hippocampus, Aß load in the cortex and hippocampus, the expression of phosphorylated tau at the Ser202 residue in the hippocampus and cerebellum and the levels of total tau in the cortex, hippocampus and cerebellum.",
      "citation": {
        "type": "PubMed",
        "reference": "29221819",
        "name": "Neurobiology of disease",
        "title": "Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.",
        "volume": "110",
        "pages": "206-217",
        "date": "2018-02-01",
        "first": "García-Cerro S",
        "last": "Martínez-Cué C",
        "authors": [
          "Berciano MT",
          "García-Cerro S",
          "Lafarga M",
          "Lantigua S",
          "Martínez-Cué C",
          "Padro D",
          "Ramos-Cabrer P",
          "Rueda N",
          "Vidal V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        },
        "Anatomy": {
          "cerebellum": true,
          "hippocampal formation": true
        }
      },
      "source": 786,
      "target": 816,
      "key": "9eedf6664951afc931ee9dfee51d42d2dcc1565f2f11cfa9b271485d3cb3d9f7b957bc24240b0d5411edbf3b85513abb4a43a0901552f3bbf2b8f861924a85ce"
    },
    {
      "line": 2062,
      "relation": "negativeCorrelation",
      "evidence": "Normalizing the gene dosage of Dyrk1A in the TS mouse rescued the density of senescent cells in the cingulate cortex, hippocampus and septum, prevented cholinergic neuron degeneration, and reduced App expression in the hippocampus, Aß load in the cortex and hippocampus, the expression of phosphorylated tau at the Ser202 residue in the hippocampus and cerebellum and the levels of total tau in the cortex, hippocampus and cerebellum.",
      "citation": {
        "type": "PubMed",
        "reference": "29221819",
        "name": "Neurobiology of disease",
        "title": "Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.",
        "volume": "110",
        "pages": "206-217",
        "date": "2018-02-01",
        "first": "García-Cerro S",
        "last": "Martínez-Cué C",
        "authors": [
          "Berciano MT",
          "García-Cerro S",
          "Lafarga M",
          "Lantigua S",
          "Martínez-Cué C",
          "Padro D",
          "Ramos-Cabrer P",
          "Rueda N",
          "Vidal V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        },
        "Anatomy": {
          "cerebellum": true,
          "hippocampal formation": true,
          "cerebral cortex": true
        }
      },
      "source": 786,
      "target": 803,
      "key": "d5bbf5edc4112f272903538c0629c2a8b2912ba3926cf084656e6034a75b4b6892083c7f4088fc5adc53102fff78f7df0de3f46e93c3ddbf0a439632b2b18866"
    },
    {
      "line": 2094,
      "relation": "decreases",
      "evidence": "DYRK1A overexpression induced dramatic deficits in the serotonin contents of the four brain areas tested and major deficits in dopamine and adrenaline contents especially in the hypothalamus.",
      "citation": {
        "type": "PubMed",
        "reference": "28540658",
        "name": "Molecular neurobiology",
        "title": "Overexpression of the DYRK1A Gene (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A) Induces Alterations of the Serotoninergic and Dopaminergic Processing in Murine Brain Tissues.",
        "volume": "55",
        "pages": "3822-3831",
        "date": "2018-05-01",
        "first": "London J",
        "last": "Janel N",
        "authors": [
          "Assayag E",
          "Bui LC",
          "Dairou J",
          "Daubigney F",
          "Delabar JM",
          "Janel N",
          "London J",
          "Luquet S",
          "Magnan C",
          "Medjaoui H",
          "Rouch C",
          "Souchet B"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "dorsal plus ventral thalamus": true,
          "hypothalamus": true,
          "hippocampal formation": true,
          "striatum": true
        }
      },
      "source": 786,
      "target": 72,
      "key": "b3e7e4484dffdff880f0d22bd526acdd5a435cda12e50e9cb411feb3696668ee92fa3f60f804c3fc8bef7c0b1c0d99df0b42e7a41f2156b8f3c3ae694e391750"
    },
    {
      "line": 2097,
      "relation": "decreases",
      "evidence": "DYRK1A overexpression induced dramatic deficits in the serotonin contents of the four brain areas tested and major deficits in dopamine and adrenaline contents especially in the hypothalamus.",
      "citation": {
        "type": "PubMed",
        "reference": "28540658",
        "name": "Molecular neurobiology",
        "title": "Overexpression of the DYRK1A Gene (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A) Induces Alterations of the Serotoninergic and Dopaminergic Processing in Murine Brain Tissues.",
        "volume": "55",
        "pages": "3822-3831",
        "date": "2018-05-01",
        "first": "London J",
        "last": "Janel N",
        "authors": [
          "Assayag E",
          "Bui LC",
          "Dairou J",
          "Daubigney F",
          "Delabar JM",
          "Janel N",
          "London J",
          "Luquet S",
          "Magnan C",
          "Medjaoui H",
          "Rouch C",
          "Souchet B"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hypothalamus": true
        }
      },
      "source": 786,
      "target": 47,
      "key": "8e4fa6a1f5928c8fb85519ce28958239d0a711c9ea601131b1b2c564979ff4d6ae261f80a34b2b659a53f9fc9f244720d36c873270d436bef8f2ac06a9203fc1"
    },
    {
      "line": 2098,
      "relation": "decreases",
      "evidence": "DYRK1A overexpression induced dramatic deficits in the serotonin contents of the four brain areas tested and major deficits in dopamine and adrenaline contents especially in the hypothalamus.",
      "citation": {
        "type": "PubMed",
        "reference": "28540658",
        "name": "Molecular neurobiology",
        "title": "Overexpression of the DYRK1A Gene (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A) Induces Alterations of the Serotoninergic and Dopaminergic Processing in Murine Brain Tissues.",
        "volume": "55",
        "pages": "3822-3831",
        "date": "2018-05-01",
        "first": "London J",
        "last": "Janel N",
        "authors": [
          "Assayag E",
          "Bui LC",
          "Dairou J",
          "Daubigney F",
          "Delabar JM",
          "Janel N",
          "London J",
          "Luquet S",
          "Magnan C",
          "Medjaoui H",
          "Rouch C",
          "Souchet B"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hypothalamus": true
        }
      },
      "source": 786,
      "target": 42,
      "key": "6fcdd60f2ff4da99a96b839e9a58c1aac269b5fe28eaac812649b09fb404146e43d8875b35306bec463f21b43547cf2a7a2c5d51683ecad690697c0bfdd82af2"
    },
    {
      "line": 2131,
      "relation": "positiveCorrelation",
      "evidence": "Inhibition of Dyrk1A enhanced tau exon 10 inclusion, leading to an increase in 4R-tau/3R-tau ratio in differentiated-human neuronal progenitors and in the neonatal rat brains. Accompanied with overexpression of Dyrk1A, 3R-tau was increased and 4R-tau was decreased in the neonatal brains of Ts65Dn mice, a model of Down syndrome.",
      "citation": {
        "type": "PubMed",
        "reference": "28775333",
        "name": "Scientific reports",
        "title": "Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D.",
        "volume": "7",
        "pages": "7240",
        "date": "2017-08-03",
        "first": "Wang P",
        "last": "Sun X",
        "authors": [
          "Chen L",
          "Sun X",
          "Wang L",
          "Wang P"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 786,
      "target": 306,
      "key": "70a6fff1b37515fd08ca1976614f8eae70ae55bda562c64b951e9128b73c0561b0af625a329689917c0c3c4479c23636b87bc158beab1c15d6d3b56d40b30d65"
    },
    {
      "line": 2132,
      "relation": "negativeCorrelation",
      "evidence": "Inhibition of Dyrk1A enhanced tau exon 10 inclusion, leading to an increase in 4R-tau/3R-tau ratio in differentiated-human neuronal progenitors and in the neonatal rat brains. Accompanied with overexpression of Dyrk1A, 3R-tau was increased and 4R-tau was decreased in the neonatal brains of Ts65Dn mice, a model of Down syndrome.",
      "citation": {
        "type": "PubMed",
        "reference": "28775333",
        "name": "Scientific reports",
        "title": "Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D.",
        "volume": "7",
        "pages": "7240",
        "date": "2017-08-03",
        "first": "Wang P",
        "last": "Sun X",
        "authors": [
          "Chen L",
          "Sun X",
          "Wang L",
          "Wang P"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 786,
      "target": 307,
      "key": "8dc752f319b2c4314d3008d831c1ee7792c37089177622537388a2f44d67e0f4ca729fd4e7c81dc3a784bc1d44730763e329bb8edf8d3f5cbafb60fe596eb400"
    },
    {
      "line": 2140,
      "relation": "positiveCorrelation",
      "evidence": "Treatment with Dyrk1A inhibitor, green tea flavonol epigallocatechin-gallate (EGCG), from gestation to adulthood suppressed 3R-tau expression and rescued anxiety and memory deficits in Ts65Dn mouse brains.",
      "citation": {
        "type": "PubMed",
        "reference": "28775333",
        "name": "Scientific reports",
        "title": "Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D.",
        "volume": "7",
        "pages": "7240",
        "date": "2017-08-03",
        "first": "Wang P",
        "last": "Sun X",
        "authors": [
          "Chen L",
          "Sun X",
          "Wang L",
          "Wang P"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 786,
      "target": 919,
      "key": "a3de8bb4703315e780c0572fc516897d5f3952a75e3a1d99f31325ebf901f4a738500ded9c2c581b423a1c247990fb668d161025f7abb07e520e25dcd55eca96"
    },
    {
      "line": 2141,
      "relation": "negativeCorrelation",
      "evidence": "Treatment with Dyrk1A inhibitor, green tea flavonol epigallocatechin-gallate (EGCG), from gestation to adulthood suppressed 3R-tau expression and rescued anxiety and memory deficits in Ts65Dn mouse brains.",
      "citation": {
        "type": "PubMed",
        "reference": "28775333",
        "name": "Scientific reports",
        "title": "Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D.",
        "volume": "7",
        "pages": "7240",
        "date": "2017-08-03",
        "first": "Wang P",
        "last": "Sun X",
        "authors": [
          "Chen L",
          "Sun X",
          "Wang L",
          "Wang P"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 786,
      "target": 200,
      "key": "dd63d83b25e5ea6ea70c3fe38baec4924de295bf10512af22d7f699a3609307bf59af14efe970ded3526d51c34b21c7944d38f6de3f3348568140e6866d4135b"
    },
    {
      "relation": "hasComponent",
      "source": 242,
      "target": 782,
      "key": "9741f7e626b5a37db5b21c458c6fadbdb9373bd729f43176447893cf3ad99fd0fee5b2c8992e268040a50330f06c072d5f0ad69cb6839bfee2ea88c44500e600"
    },
    {
      "relation": "hasComponent",
      "source": 242,
      "target": 786,
      "key": "8442e52d3ddb11cd4f00d4b4a2b45ca9d391d0deab6a54c5951cd617bf03fdf5772cebec9d93f50ca6830039521ae68dacbfe6b7513053f21cd33f72875da508"
    },
    {
      "line": 2030,
      "relation": "negativeCorrelation",
      "evidence": "Moreover, we found that Hap1 bound Dcaf7 competitively in cytoplasm with dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), a protein implicated in Down syndrome (DS). Depleting Hap1 promoted the DYRK1A-Dcaf7 interaction and increased the DYRK1A protein level.",
      "citation": {
        "type": "PubMed",
        "reference": "28137862",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "DYRK1A regulates Hap1-Dcaf7/WDR68 binding with implication for delayed growth in Down syndrome.",
        "volume": "114",
        "pages": "E1224-E1233",
        "date": "2017-02-14",
        "first": "Xiang J",
        "last": "Li XJ",
        "authors": [
          "Gaertig MA",
          "Li S",
          "Li XJ",
          "Reeves RH",
          "Xiang J",
          "Xin N",
          "Yang S"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 242,
      "target": 797,
      "key": "4c8df606d482cc437cde002014e35a91aaf090ec50f61e6017b6bdbb4c4a26da1f0723a490f73adb1e57ba1bda23e3304284d2f08571d4fed48c73b53e7e8924"
    },
    {
      "line": 2028,
      "relation": "association",
      "evidence": "Moreover, we found that Hap1 bound Dcaf7 competitively in cytoplasm with dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), a protein implicated in Down syndrome (DS). Depleting Hap1 promoted the DYRK1A-Dcaf7 interaction and increased the DYRK1A protein level.",
      "citation": {
        "type": "PubMed",
        "reference": "28137862",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "DYRK1A regulates Hap1-Dcaf7/WDR68 binding with implication for delayed growth in Down syndrome.",
        "volume": "114",
        "pages": "E1224-E1233",
        "date": "2017-02-14",
        "first": "Xiang J",
        "last": "Li XJ",
        "authors": [
          "Gaertig MA",
          "Li S",
          "Li XJ",
          "Reeves RH",
          "Xiang J",
          "Xin N",
          "Yang S"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 797,
      "target": 782,
      "key": "815621a1ea2d9ed8282379d58d92749f41340383dd1da9bef75583adb84ab7d95edcf80d43a1cb313a6d950be6c7ad80aa90ca98de9dbf4ecba91299ffca16df"
    },
    {
      "line": 2029,
      "relation": "negativeCorrelation",
      "evidence": "Moreover, we found that Hap1 bound Dcaf7 competitively in cytoplasm with dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), a protein implicated in Down syndrome (DS). Depleting Hap1 promoted the DYRK1A-Dcaf7 interaction and increased the DYRK1A protein level.",
      "citation": {
        "type": "PubMed",
        "reference": "28137862",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "DYRK1A regulates Hap1-Dcaf7/WDR68 binding with implication for delayed growth in Down syndrome.",
        "volume": "114",
        "pages": "E1224-E1233",
        "date": "2017-02-14",
        "first": "Xiang J",
        "last": "Li XJ",
        "authors": [
          "Gaertig MA",
          "Li S",
          "Li XJ",
          "Reeves RH",
          "Xiang J",
          "Xin N",
          "Yang S"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 797,
      "target": 786,
      "key": "4e3df1c3bd7c00b38ba11945a42625833a69fbd4ee407cfa2bfd56139b3bbf3d634ed3a3a8a6b8c60bced7edc6a6542fc2ed7d66b5997dffc15a97cb13d4785a"
    },
    {
      "line": 2030,
      "relation": "negativeCorrelation",
      "evidence": "Moreover, we found that Hap1 bound Dcaf7 competitively in cytoplasm with dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), a protein implicated in Down syndrome (DS). Depleting Hap1 promoted the DYRK1A-Dcaf7 interaction and increased the DYRK1A protein level.",
      "citation": {
        "type": "PubMed",
        "reference": "28137862",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "DYRK1A regulates Hap1-Dcaf7/WDR68 binding with implication for delayed growth in Down syndrome.",
        "volume": "114",
        "pages": "E1224-E1233",
        "date": "2017-02-14",
        "first": "Xiang J",
        "last": "Li XJ",
        "authors": [
          "Gaertig MA",
          "Li S",
          "Li XJ",
          "Reeves RH",
          "Xiang J",
          "Xin N",
          "Yang S"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 797,
      "target": 242,
      "key": "3105e2aff819e460040407b7fa470d8490aa19940b53c98e536666d943635d8d1ede042da30c8c73cb192852b9218ffd9c235a4b38aa8cdd1b7583a7ed1d2cf0"
    },
    {
      "line": 2040,
      "relation": "positiveCorrelation",
      "evidence": "The normalization of the Dyrk1A gene dosage did not rescue the reduced cerebellar volume but increased the size of the granular and molecular layers, the densities of granular and Purkinje cells, and dendritic arborization.",
      "citation": {
        "type": "PubMed",
        "reference": "29221819",
        "name": "Neurobiology of disease",
        "title": "Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.",
        "volume": "110",
        "pages": "206-217",
        "date": "2018-02-01",
        "first": "García-Cerro S",
        "last": "Martínez-Cué C",
        "authors": [
          "Berciano MT",
          "García-Cerro S",
          "Lafarga M",
          "Lantigua S",
          "Martínez-Cué C",
          "Padro D",
          "Ramos-Cabrer P",
          "Rueda N",
          "Vidal V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 128,
      "target": 786,
      "key": "263981772f65947c09fcbb0d3f1e6bf28d679a29b7c33331bd3c12d406b59279be6e92e1a397cb2d54eeeb1e5ecfa5187f9e8659c9600de3d6899b04257bdfc4"
    },
    {
      "line": 2041,
      "relation": "positiveCorrelation",
      "evidence": "The normalization of the Dyrk1A gene dosage did not rescue the reduced cerebellar volume but increased the size of the granular and molecular layers, the densities of granular and Purkinje cells, and dendritic arborization.",
      "citation": {
        "type": "PubMed",
        "reference": "29221819",
        "name": "Neurobiology of disease",
        "title": "Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.",
        "volume": "110",
        "pages": "206-217",
        "date": "2018-02-01",
        "first": "García-Cerro S",
        "last": "Martínez-Cué C",
        "authors": [
          "Berciano MT",
          "García-Cerro S",
          "Lafarga M",
          "Lantigua S",
          "Martínez-Cué C",
          "Padro D",
          "Ramos-Cabrer P",
          "Rueda N",
          "Vidal V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 131,
      "target": 786,
      "key": "5b1b956bdc61564761fea79b6a980bc9d8f207f736feddaabbd2efe43214e6455ffa932f954215f5e38f039b63ae93eb2c7bd41d0d2e4a0c3382f640e70f8322"
    },
    {
      "line": 2042,
      "relation": "positiveCorrelation",
      "evidence": "The normalization of the Dyrk1A gene dosage did not rescue the reduced cerebellar volume but increased the size of the granular and molecular layers, the densities of granular and Purkinje cells, and dendritic arborization.",
      "citation": {
        "type": "PubMed",
        "reference": "29221819",
        "name": "Neurobiology of disease",
        "title": "Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.",
        "volume": "110",
        "pages": "206-217",
        "date": "2018-02-01",
        "first": "García-Cerro S",
        "last": "Martínez-Cué C",
        "authors": [
          "Berciano MT",
          "García-Cerro S",
          "Lafarga M",
          "Lantigua S",
          "Martínez-Cué C",
          "Padro D",
          "Ramos-Cabrer P",
          "Rueda N",
          "Vidal V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 109,
      "target": 786,
      "key": "60a6c8cf1e5c948ea4174b082e711fc9e2c4ebc765d71838609781ffd5f7f139024f82154f4fd9cea00f2f5895ed82d8123a2309061afb1b8a3232d5fb64969c"
    },
    {
      "line": 2043,
      "relation": "positiveCorrelation",
      "evidence": "The normalization of the Dyrk1A gene dosage did not rescue the reduced cerebellar volume but increased the size of the granular and molecular layers, the densities of granular and Purkinje cells, and dendritic arborization.",
      "citation": {
        "type": "PubMed",
        "reference": "29221819",
        "name": "Neurobiology of disease",
        "title": "Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.",
        "volume": "110",
        "pages": "206-217",
        "date": "2018-02-01",
        "first": "García-Cerro S",
        "last": "Martínez-Cué C",
        "authors": [
          "Berciano MT",
          "García-Cerro S",
          "Lafarga M",
          "Lantigua S",
          "Martínez-Cué C",
          "Padro D",
          "Ramos-Cabrer P",
          "Rueda N",
          "Vidal V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 181,
      "target": 786,
      "key": "b7f7c8c313eef6ded5398d76ca0839ae59a1961625254f52eacb649c6702bceba65f73d1bba3c9a568290ba535a5b7672bc0f99120fbccb1442fb7b2fe5b1713"
    },
    {
      "line": 2049,
      "relation": "positiveCorrelation",
      "evidence": "Normalizing the gene dosage of Dyrk1A in the TS mouse rescued the density of senescent cells in the cingulate cortex, hippocampus and septum, prevented cholinergic neuron degeneration, and reduced App expression in the hippocampus, Aß load in the cortex and hippocampus, the expression of phosphorylated tau at the Ser202 residue in the hippocampus and cerebellum and the levels of total tau in the cortex, hippocampus and cerebellum.",
      "citation": {
        "type": "PubMed",
        "reference": "29221819",
        "name": "Neurobiology of disease",
        "title": "Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.",
        "volume": "110",
        "pages": "206-217",
        "date": "2018-02-01",
        "first": "García-Cerro S",
        "last": "Martínez-Cué C",
        "authors": [
          "Berciano MT",
          "García-Cerro S",
          "Lafarga M",
          "Lantigua S",
          "Martínez-Cué C",
          "Padro D",
          "Ramos-Cabrer P",
          "Rueda N",
          "Vidal V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        },
        "Anatomy": {
          "hippocampal formation": true,
          "septum": true,
          "cingulate cortex": true
        }
      },
      "source": 179,
      "target": 786,
      "key": "6d588a0ed5f1a4ce4d930dbe6ba6bf9d16d52c4619bb59e44a1cbca9fcc6770ebbf596d480fb66d137be25efda87912970cfca8d1559f52aebe2e662b154edee"
    },
    {
      "line": 2050,
      "relation": "positiveCorrelation",
      "evidence": "Normalizing the gene dosage of Dyrk1A in the TS mouse rescued the density of senescent cells in the cingulate cortex, hippocampus and septum, prevented cholinergic neuron degeneration, and reduced App expression in the hippocampus, Aß load in the cortex and hippocampus, the expression of phosphorylated tau at the Ser202 residue in the hippocampus and cerebellum and the levels of total tau in the cortex, hippocampus and cerebellum.",
      "citation": {
        "type": "PubMed",
        "reference": "29221819",
        "name": "Neurobiology of disease",
        "title": "Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.",
        "volume": "110",
        "pages": "206-217",
        "date": "2018-02-01",
        "first": "García-Cerro S",
        "last": "Martínez-Cué C",
        "authors": [
          "Berciano MT",
          "García-Cerro S",
          "Lafarga M",
          "Lantigua S",
          "Martínez-Cué C",
          "Padro D",
          "Ramos-Cabrer P",
          "Rueda N",
          "Vidal V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        },
        "Anatomy": {
          "hippocampal formation": true,
          "septum": true,
          "cingulate cortex": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 125,
      "target": 786,
      "key": "97426f9f06aa5e82cc49e37fb7a30d1de49748627912be1568250526879efa14198b40877e01b840f169c653d23570a152c87e8be9ae5cc9bb25866f725adf3e"
    },
    {
      "line": 2053,
      "relation": "negativeCorrelation",
      "evidence": "Normalizing the gene dosage of Dyrk1A in the TS mouse rescued the density of senescent cells in the cingulate cortex, hippocampus and septum, prevented cholinergic neuron degeneration, and reduced App expression in the hippocampus, Aß load in the cortex and hippocampus, the expression of phosphorylated tau at the Ser202 residue in the hippocampus and cerebellum and the levels of total tau in the cortex, hippocampus and cerebellum.",
      "citation": {
        "type": "PubMed",
        "reference": "29221819",
        "name": "Neurobiology of disease",
        "title": "Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.",
        "volume": "110",
        "pages": "206-217",
        "date": "2018-02-01",
        "first": "García-Cerro S",
        "last": "Martínez-Cué C",
        "authors": [
          "Berciano MT",
          "García-Cerro S",
          "Lafarga M",
          "Lantigua S",
          "Martínez-Cué C",
          "Padro D",
          "Ramos-Cabrer P",
          "Rueda N",
          "Vidal V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 770,
      "target": 786,
      "key": "c60eb28d1b53357952004f89f2987bb24428a29b726f108bb9cd78c9f28c4237201383cf71aa8b47f15cfbeb8bceb434c7872b08d9c6248fab48b552ed326af9"
    },
    {
      "line": 2075,
      "relation": "decreases",
      "evidence": "ID-8 indeed showed selectivity against the CMGC kinase family, with DYRK1B, GSK3B and DYRK1A being the top three kinase targets. Although a biotinylated derivative of ID-8 bound DYRK2 and DYRK4 in affinity chromatography pull down assays (Hasegawa et al., 2012), ID-8 itself showed little activity against these kinases, or against DYRK3. Next we determined IC50 values for a subset of these kinase targets, using the same 33P incorporation assay (Table 1).",
      "citation": {
        "type": "PubMed",
        "reference": "28884684",
        "name": "eLife",
        "title": "Inhibition of DYRK1A disrupts neural lineage specificationin human pluripotent stem cells.",
        "volume": "6",
        "date": "2017-09-08",
        "first": "Bellmaine SF",
        "last": "Pera M",
        "authors": [
          "Bellmaine SF",
          "Cuddy CE",
          "Elefanty AG",
          "Manallack DT",
          "Ovchinnikov DA",
          "Pera M",
          "Stanley EG",
          "Williams SJ",
          "Wolvetang EJ"
        ]
      },
      "annotations": {
        "IC50": {
          "54 nM": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 103,
      "target": 444,
      "key": "98eeed9dafcdb0e2624f026b4a659af88231d06b6cdadc4f4f2c5d2afa0bfa89165f89a85c1fde1e7899973178a8ecb7881ca0de3a2e3854f9a7e6552b3ad988"
    },
    {
      "line": 2078,
      "relation": "decreases",
      "evidence": "ID-8 indeed showed selectivity against the CMGC kinase family, with DYRK1B, GSK3B and DYRK1A being the top three kinase targets. Although a biotinylated derivative of ID-8 bound DYRK2 and DYRK4 in affinity chromatography pull down assays (Hasegawa et al., 2012), ID-8 itself showed little activity against these kinases, or against DYRK3. Next we determined IC50 values for a subset of these kinase targets, using the same 33P incorporation assay (Table 1).",
      "citation": {
        "type": "PubMed",
        "reference": "28884684",
        "name": "eLife",
        "title": "Inhibition of DYRK1A disrupts neural lineage specificationin human pluripotent stem cells.",
        "volume": "6",
        "date": "2017-09-08",
        "first": "Bellmaine SF",
        "last": "Pera M",
        "authors": [
          "Bellmaine SF",
          "Cuddy CE",
          "Elefanty AG",
          "Manallack DT",
          "Ovchinnikov DA",
          "Pera M",
          "Stanley EG",
          "Williams SJ",
          "Wolvetang EJ"
        ]
      },
      "annotations": {
        "IC50": {
          "450 nM": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 103,
      "target": 456,
      "key": "b0be23a9cf2f51ef8d5f1f378c5e1127e63d9a8d96ecefc71bf98c3b92d4ca1bdea3afab9792e08990e724a7f887e6be30500ca164505f66e0aceb2f31ad83f7"
    },
    {
      "line": 2081,
      "relation": "decreases",
      "evidence": "ID-8 indeed showed selectivity against the CMGC kinase family, with DYRK1B, GSK3B and DYRK1A being the top three kinase targets. Although a biotinylated derivative of ID-8 bound DYRK2 and DYRK4 in affinity chromatography pull down assays (Hasegawa et al., 2012), ID-8 itself showed little activity against these kinases, or against DYRK3. Next we determined IC50 values for a subset of these kinase targets, using the same 33P incorporation assay (Table 1).",
      "citation": {
        "type": "PubMed",
        "reference": "28884684",
        "name": "eLife",
        "title": "Inhibition of DYRK1A disrupts neural lineage specificationin human pluripotent stem cells.",
        "volume": "6",
        "date": "2017-09-08",
        "first": "Bellmaine SF",
        "last": "Pera M",
        "authors": [
          "Bellmaine SF",
          "Cuddy CE",
          "Elefanty AG",
          "Manallack DT",
          "Ovchinnikov DA",
          "Pera M",
          "Stanley EG",
          "Williams SJ",
          "Wolvetang EJ"
        ]
      },
      "annotations": {
        "IC50": {
          "78 nM": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 103,
      "target": 443,
      "key": "d803e67c9517e7afe6bf09a76a37c942f262d4dec7c1d85b383fd4dfae9615fbd17d86a9758b5b2038e4e2966783257649651da3e8e24a9fd86383d03bee8fd5"
    },
    {
      "line": 2086,
      "relation": "decreases",
      "evidence": "Here we present evidence that the indole compound ID-8 and a series of related molecules act to inhibit the neural specification of hESC through inhibition of DYRK1A.",
      "citation": {
        "type": "PubMed",
        "reference": "28884684",
        "name": "eLife",
        "title": "Inhibition of DYRK1A disrupts neural lineage specificationin human pluripotent stem cells.",
        "volume": "6",
        "date": "2017-09-08",
        "first": "Bellmaine SF",
        "last": "Pera M",
        "authors": [
          "Bellmaine SF",
          "Cuddy CE",
          "Elefanty AG",
          "Manallack DT",
          "Ovchinnikov DA",
          "Pera M",
          "Stanley EG",
          "Williams SJ",
          "Wolvetang EJ"
        ]
      },
      "source": 103,
      "target": 192,
      "key": "260f1ffe2d2a8a99f0718482412cd16657ce4b3883adb2f3efcf895df099a5c841b7982a4a68f175e77ac5737cd51b1a8e8a9674502d593928099278962beb8b"
    },
    {
      "line": 2085,
      "relation": "positiveCorrelation",
      "evidence": "Here we present evidence that the indole compound ID-8 and a series of related molecules act to inhibit the neural specification of hESC through inhibition of DYRK1A.",
      "citation": {
        "type": "PubMed",
        "reference": "28884684",
        "name": "eLife",
        "title": "Inhibition of DYRK1A disrupts neural lineage specificationin human pluripotent stem cells.",
        "volume": "6",
        "date": "2017-09-08",
        "first": "Bellmaine SF",
        "last": "Pera M",
        "authors": [
          "Bellmaine SF",
          "Cuddy CE",
          "Elefanty AG",
          "Manallack DT",
          "Ovchinnikov DA",
          "Pera M",
          "Stanley EG",
          "Williams SJ",
          "Wolvetang EJ"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 443,
      "target": 192,
      "key": "037f5171caf2c517d0f9c84fcdb3d0197fff03ee8d7f178a49395c0b8b83381705ae1976159cd7f3574be9a3694ece404536b9f0e8399b568cc0b549f68fe20a"
    },
    {
      "line": 2108,
      "relation": "negativeCorrelation",
      "evidence": "Neprilysin, a major Aß-degrading enzyme, was downregulated in DS patient-derived fibroblasts. Treatment with harmine, a DYRK1A inhibitor and gene knockdown of DYRK1A, upregulated neprilysin in fibroblasts.",
      "citation": {
        "type": "PubMed",
        "reference": "28250274",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.",
        "volume": "40",
        "pages": "327-333",
        "date": "2017-01-01",
        "first": "Kawakubo T",
        "last": "Asai M",
        "authors": [
          "Asai M",
          "Iwata N",
          "Kawakubo T",
          "Mori R",
          "Shirotani K"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Down Syndrome": true
        },
        "Cell_Line": {
          "Human fibroblasts": true
        }
      },
      "source": 443,
      "target": 640,
      "key": "fb6858cbeab8f2e8519af972819e38a8cbc3ab523e8706355432f51a101ddc56a01a601494c122affcb45161ef0ed56efa303d97c24cdc28de9376e3f88413c9"
    },
    {
      "line": 2150,
      "relation": "biomarkerFor",
      "evidence": "Receiver-operating characteristic curves and logistic regression analyses showed that combined assessment of DYRK1A, BDNF and homocysteine has a sensitivity of 0.952, a specificity of 0.889 and an accuracy of 0.933 in testing for AD. The blood levels of these markers provide a diagnosis assessment profile. Combined assessment of these three markers outperforms most of the previous markers and could become a useful substitute to the current panel of AD biomarkers.",
      "citation": {
        "type": "PubMed",
        "reference": "28632203",
        "name": "Translational psychiatry",
        "title": "Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer's disease.",
        "volume": "7",
        "pages": "e1154",
        "date": "2017-06-20",
        "first": "Janel N",
        "last": "Delabar JM",
        "authors": [
          "Alexopoulos P",
          "Arbones M",
          "Badel A",
          "Camproux AC",
          "Delabar JM",
          "Dubois B",
          "Feraudet-Tarisse C",
          "Janel N",
          "Lagarde J",
          "Lamari F",
          "Lamourette P",
          "Paul JL",
          "Potier MC",
          "Sarazin M",
          "Simon S"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Anatomy": {
          "blood plasma": true
        }
      },
      "source": 443,
      "target": 908,
      "key": "856398b5f0e92f2a7fb86514e651cb29005639bfa31e7eb4f38187220c8bc50fcac4ad7b84050d0a88432b5e17425f4f2ca9a7afd3cecd7465cfaf2fcda0bb5c"
    },
    {
      "line": 2161,
      "relation": "regulates",
      "evidence": "We conclude that the Dyrk1a dosage is critical for proper neurite and axonal outgrowth and that the two nonsense mutations, R205X and E239X, are loss-of-function mutants.",
      "citation": {
        "type": "PubMed",
        "reference": "28167836",
        "name": "Molecular psychiatry",
        "title": "Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development.",
        "volume": "23",
        "pages": "747-758",
        "date": "2018-03-01",
        "first": "Dang T",
        "last": "Wu BL",
        "authors": [
          "An Y",
          "Cheng C",
          "Dang T",
          "Duan WY",
          "Qiu ZL",
          "Tong DL",
          "Wu BB",
          "Wu BL",
          "Wu M",
          "Wu W",
          "Ye K",
          "Yu B",
          "Zhang WX",
          "Zhang YF"
        ]
      },
      "annotations": {
        "HBP_Disease": {
          "Autism Spectrum Disorder (ASD)": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 443,
      "target": 142,
      "key": "1abc9a535584dfee88755f21f3976ac5977f12c0c295421784f17f48c98cceed7517246eee59258649576a2e92d657ec542aed7bb8eac04da042061ab7417e48"
    },
    {
      "line": 2162,
      "relation": "regulates",
      "evidence": "We conclude that the Dyrk1a dosage is critical for proper neurite and axonal outgrowth and that the two nonsense mutations, R205X and E239X, are loss-of-function mutants.",
      "citation": {
        "type": "PubMed",
        "reference": "28167836",
        "name": "Molecular psychiatry",
        "title": "Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development.",
        "volume": "23",
        "pages": "747-758",
        "date": "2018-03-01",
        "first": "Dang T",
        "last": "Wu BL",
        "authors": [
          "An Y",
          "Cheng C",
          "Dang T",
          "Duan WY",
          "Qiu ZL",
          "Tong DL",
          "Wu BB",
          "Wu BL",
          "Wu M",
          "Wu W",
          "Ye K",
          "Yu B",
          "Zhang WX",
          "Zhang YF"
        ]
      },
      "annotations": {
        "HBP_Disease": {
          "Autism Spectrum Disorder (ASD)": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 443,
      "target": 85,
      "key": "829f14cb88a8329886c9cce2ce5b8b5f9d644dfc61383051b00c811b60aa45c89a72e731563ee8ff0c691598337b7dcede70b7b95c331d87c5431e038dd16b64"
    },
    {
      "line": 2085,
      "relation": "positiveCorrelation",
      "evidence": "Here we present evidence that the indole compound ID-8 and a series of related molecules act to inhibit the neural specification of hESC through inhibition of DYRK1A.",
      "citation": {
        "type": "PubMed",
        "reference": "28884684",
        "name": "eLife",
        "title": "Inhibition of DYRK1A disrupts neural lineage specificationin human pluripotent stem cells.",
        "volume": "6",
        "date": "2017-09-08",
        "first": "Bellmaine SF",
        "last": "Pera M",
        "authors": [
          "Bellmaine SF",
          "Cuddy CE",
          "Elefanty AG",
          "Manallack DT",
          "Ovchinnikov DA",
          "Pera M",
          "Stanley EG",
          "Williams SJ",
          "Wolvetang EJ"
        ]
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 192,
      "target": 443,
      "key": "6c3643a9618dfc67966f32ce214c923c43ad997c045e30013d174f72abdf47f69f8be4ad847c7432f8e7e6e45833faed4374090b67d53169462c1411444bac09"
    },
    {
      "line": 2107,
      "relation": "decreases",
      "evidence": "Neprilysin, a major Aß-degrading enzyme, was downregulated in DS patient-derived fibroblasts. Treatment with harmine, a DYRK1A inhibitor and gene knockdown of DYRK1A, upregulated neprilysin in fibroblasts.",
      "citation": {
        "type": "PubMed",
        "reference": "28250274",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.",
        "volume": "40",
        "pages": "327-333",
        "date": "2017-01-01",
        "first": "Kawakubo T",
        "last": "Asai M",
        "authors": [
          "Asai M",
          "Iwata N",
          "Kawakubo T",
          "Mori R",
          "Shirotani K"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Down Syndrome": true
        },
        "Cell_Line": {
          "Human fibroblasts": true
        }
      },
      "source": 53,
      "target": 443,
      "key": "fb7a928abb75122d3b220c7859970d9b78d7494aabf1f8b92124bb5df7337f33648fcf4b81e54b61732b63b026ab88cae08857dd7ab1052d68c591d39193e9e4"
    },
    {
      "line": 2109,
      "relation": "increases",
      "evidence": "Neprilysin, a major Aß-degrading enzyme, was downregulated in DS patient-derived fibroblasts. Treatment with harmine, a DYRK1A inhibitor and gene knockdown of DYRK1A, upregulated neprilysin in fibroblasts.",
      "citation": {
        "type": "PubMed",
        "reference": "28250274",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.",
        "volume": "40",
        "pages": "327-333",
        "date": "2017-01-01",
        "first": "Kawakubo T",
        "last": "Asai M",
        "authors": [
          "Asai M",
          "Iwata N",
          "Kawakubo T",
          "Mori R",
          "Shirotani K"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Down Syndrome": true
        },
        "Cell_Line": {
          "Human fibroblasts": true
        }
      },
      "source": 53,
      "target": 640,
      "key": "75f2b19762a9b473a3627b994af1e7def929294b68ff316aa6b9d186ac532ebb2ed28e3c99220dc4204be0cc6e37faac5e7608c1b55032dd937ab5742352a700"
    },
    {
      "line": 2176,
      "relation": "increases",
      "evidence": "DNA binding and stabilising",
      "citation": {
        "type": "PubMed",
        "reference": "29077046",
        "name": "Molecules (Basel, Switzerland)",
        "title": "Binding of Harmine Derivatives to DNA: A Spectroscopic Investigation.",
        "volume": "22",
        "date": "2017-10-27",
        "first": "Pagano B",
        "last": "Giancola C",
        "authors": [
          "Caterino M",
          "Filosa R",
          "Giancola C",
          "Pagano B"
        ]
      },
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "source": 53,
      "target": 220,
      "key": "3a2f7bcee614b39cf5993b82f346e0cb4f0dcb85c7ba1409fe9b8c38b2ddcede2dbbb55df295df7052ff12a91b102e94f1589dbfea8f021ddf30de8dd1a09567"
    },
    {
      "line": 2108,
      "relation": "negativeCorrelation",
      "evidence": "Neprilysin, a major Aß-degrading enzyme, was downregulated in DS patient-derived fibroblasts. Treatment with harmine, a DYRK1A inhibitor and gene knockdown of DYRK1A, upregulated neprilysin in fibroblasts.",
      "citation": {
        "type": "PubMed",
        "reference": "28250274",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.",
        "volume": "40",
        "pages": "327-333",
        "date": "2017-01-01",
        "first": "Kawakubo T",
        "last": "Asai M",
        "authors": [
          "Asai M",
          "Iwata N",
          "Kawakubo T",
          "Mori R",
          "Shirotani K"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Down Syndrome": true
        },
        "Cell_Line": {
          "Human fibroblasts": true
        }
      },
      "source": 640,
      "target": 443,
      "key": "6d420114ea6f566d587cc2fe6854094647dbd90560d55245e9849c2557558eea9d4e51e4aa03fe1a454c7dc5fe5ba3524a1962c4bbefa83e708cdb43f1e799d5"
    },
    {
      "line": 2110,
      "relation": "increases",
      "evidence": "Neprilysin, a major Aß-degrading enzyme, was downregulated in DS patient-derived fibroblasts. Treatment with harmine, a DYRK1A inhibitor and gene knockdown of DYRK1A, upregulated neprilysin in fibroblasts.",
      "citation": {
        "type": "PubMed",
        "reference": "28250274",
        "name": "Biological &amp; pharmaceutical bulletin",
        "title": "Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.",
        "volume": "40",
        "pages": "327-333",
        "date": "2017-01-01",
        "first": "Kawakubo T",
        "last": "Asai M",
        "authors": [
          "Asai M",
          "Iwata N",
          "Kawakubo T",
          "Mori R",
          "Shirotani K"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Down Syndrome": true
        },
        "Cell_Line": {
          "Human fibroblasts": true
        }
      },
      "object": {
        "modifier": "Degradation"
      },
      "source": 640,
      "target": 11,
      "key": "c21d318b782598c6d1ce7970ffd0ce424fb1c3f090c94ea4e6f048520d8471b95707a25ea5f04d61d2556a54f5f5c7de39a8b1a3d93dd157ef53cc6261172e00"
    },
    {
      "line": 2120,
      "relation": "increases",
      "evidence": "Here we demonstrated that MEF2D could upregulate DYRK1A gene expression through specific activation of DYRK1A isoform 5 gene transcription. The coordinated expression of DYRK1A and MEF2D in mouse brain development indicated a possibility of the cross-interaction of these two genes during neurodevelopment. The DYRK1A kinase activity was also affected by MEF2D's transcriptional regulation of DYRK1A.",
      "citation": {
        "type": "PubMed",
        "reference": "28775333",
        "name": "Scientific reports",
        "title": "Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D.",
        "volume": "7",
        "pages": "7240",
        "date": "2017-08-03",
        "first": "Wang P",
        "last": "Sun X",
        "authors": [
          "Chen L",
          "Sun X",
          "Wang L",
          "Wang P"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 837,
      "target": 940,
      "key": "3b9215d40c3c581cd918c613638576284a495da7bed19882f51fc4947b6517575bdd9d344faf145f200e72b243fc9729ec990e9698b3f1ae6ec80b267f9a8ee2"
    },
    {
      "line": 2121,
      "relation": "increases",
      "evidence": "Here we demonstrated that MEF2D could upregulate DYRK1A gene expression through specific activation of DYRK1A isoform 5 gene transcription. The coordinated expression of DYRK1A and MEF2D in mouse brain development indicated a possibility of the cross-interaction of these two genes during neurodevelopment. The DYRK1A kinase activity was also affected by MEF2D's transcriptional regulation of DYRK1A.",
      "citation": {
        "type": "PubMed",
        "reference": "28775333",
        "name": "Scientific reports",
        "title": "Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D.",
        "volume": "7",
        "pages": "7240",
        "date": "2017-08-03",
        "first": "Wang P",
        "last": "Sun X",
        "authors": [
          "Chen L",
          "Sun X",
          "Wang L",
          "Wang P"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 837,
      "target": 786,
      "key": "13971c04bffd01d4c332e6abe61e04a16ab525905d592648f6348746c9b654a36883e6907a308a6ea2ff4a5005b9625b37a9a8e1151d752d2184a7222473c6d6"
    },
    {
      "line": 2136,
      "relation": "decreases",
      "evidence": "Treatment with Dyrk1A inhibitor, green tea flavonol epigallocatechin-gallate (EGCG), from gestation to adulthood suppressed 3R-tau expression and rescued anxiety and memory deficits in Ts65Dn mouse brains.",
      "citation": {
        "type": "PubMed",
        "reference": "28775333",
        "name": "Scientific reports",
        "title": "Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D.",
        "volume": "7",
        "pages": "7240",
        "date": "2017-08-03",
        "first": "Wang P",
        "last": "Sun X",
        "authors": [
          "Chen L",
          "Sun X",
          "Wang L",
          "Wang P"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 2,
      "target": 786,
      "key": "8b443b7e746fe4301e159caeb655e1924baa21afd47074df8480b79e9217281edb46dfc4a08c991790489b3be7102baeb9cf6fb433cdef0d3b07fa48bd917796"
    },
    {
      "line": 2137,
      "relation": "negativeCorrelation",
      "evidence": "Treatment with Dyrk1A inhibitor, green tea flavonol epigallocatechin-gallate (EGCG), from gestation to adulthood suppressed 3R-tau expression and rescued anxiety and memory deficits in Ts65Dn mouse brains.",
      "citation": {
        "type": "PubMed",
        "reference": "28775333",
        "name": "Scientific reports",
        "title": "Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D.",
        "volume": "7",
        "pages": "7240",
        "date": "2017-08-03",
        "first": "Wang P",
        "last": "Sun X",
        "authors": [
          "Chen L",
          "Sun X",
          "Wang L",
          "Wang P"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 2,
      "target": 306,
      "key": "a4a1f4198e6f7613e86780356a4b1433499362e3d74eef7e71651572676cdc75e8435094d7d0d37d14eae982b7670e52c72b8ab419fbd580dd07068dc9fa49cf"
    },
    {
      "line": 2138,
      "relation": "decreases",
      "evidence": "Treatment with Dyrk1A inhibitor, green tea flavonol epigallocatechin-gallate (EGCG), from gestation to adulthood suppressed 3R-tau expression and rescued anxiety and memory deficits in Ts65Dn mouse brains.",
      "citation": {
        "type": "PubMed",
        "reference": "28775333",
        "name": "Scientific reports",
        "title": "Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D.",
        "volume": "7",
        "pages": "7240",
        "date": "2017-08-03",
        "first": "Wang P",
        "last": "Sun X",
        "authors": [
          "Chen L",
          "Sun X",
          "Wang L",
          "Wang P"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 2,
      "target": 919,
      "key": "67101e8ff519d17aacf4f78314e3a56172c506b043f0a727ae029ca609bc5c81d5e7ee5f272396e480596d3d175f3493af9e44676e3b742e5d1dc783ea8e75ad"
    },
    {
      "line": 2139,
      "relation": "positiveCorrelation",
      "evidence": "Treatment with Dyrk1A inhibitor, green tea flavonol epigallocatechin-gallate (EGCG), from gestation to adulthood suppressed 3R-tau expression and rescued anxiety and memory deficits in Ts65Dn mouse brains.",
      "citation": {
        "type": "PubMed",
        "reference": "28775333",
        "name": "Scientific reports",
        "title": "Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D.",
        "volume": "7",
        "pages": "7240",
        "date": "2017-08-03",
        "first": "Wang P",
        "last": "Sun X",
        "authors": [
          "Chen L",
          "Sun X",
          "Wang L",
          "Wang P"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 2,
      "target": 200,
      "key": "7a05b280c6fcae5247d2beef23e1e6516b7f5386e782296ad3ca9d7821eb3b48f19c07c62351211fdaa0a67a6746d4229c96e8873790c8ce2ef818ca48a31f8b"
    },
    {
      "line": 2140,
      "relation": "positiveCorrelation",
      "evidence": "Treatment with Dyrk1A inhibitor, green tea flavonol epigallocatechin-gallate (EGCG), from gestation to adulthood suppressed 3R-tau expression and rescued anxiety and memory deficits in Ts65Dn mouse brains.",
      "citation": {
        "type": "PubMed",
        "reference": "28775333",
        "name": "Scientific reports",
        "title": "Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D.",
        "volume": "7",
        "pages": "7240",
        "date": "2017-08-03",
        "first": "Wang P",
        "last": "Sun X",
        "authors": [
          "Chen L",
          "Sun X",
          "Wang L",
          "Wang P"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 919,
      "target": 786,
      "key": "d1609a8e8011877b822bf334e17e4e5a3560fa27e2f3c20621af1a1e2d19dff203a9ecb9cb09ccad5b0b36b5f3c19ad6eaaff9fac02159d0437873efa7d345c4"
    },
    {
      "line": 2139,
      "relation": "positiveCorrelation",
      "evidence": "Treatment with Dyrk1A inhibitor, green tea flavonol epigallocatechin-gallate (EGCG), from gestation to adulthood suppressed 3R-tau expression and rescued anxiety and memory deficits in Ts65Dn mouse brains.",
      "citation": {
        "type": "PubMed",
        "reference": "28775333",
        "name": "Scientific reports",
        "title": "Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D.",
        "volume": "7",
        "pages": "7240",
        "date": "2017-08-03",
        "first": "Wang P",
        "last": "Sun X",
        "authors": [
          "Chen L",
          "Sun X",
          "Wang L",
          "Wang P"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 200,
      "target": 2,
      "key": "a614d9b5e7ef2986842cca916cc2c1b4bd1a0e37c1d2185b3f5784d727db8780787e583f4fd266d554df580bd8ca1cfca39d687a64bad6cb3b820ba1827ebcf7"
    },
    {
      "line": 2141,
      "relation": "negativeCorrelation",
      "evidence": "Treatment with Dyrk1A inhibitor, green tea flavonol epigallocatechin-gallate (EGCG), from gestation to adulthood suppressed 3R-tau expression and rescued anxiety and memory deficits in Ts65Dn mouse brains.",
      "citation": {
        "type": "PubMed",
        "reference": "28775333",
        "name": "Scientific reports",
        "title": "Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D.",
        "volume": "7",
        "pages": "7240",
        "date": "2017-08-03",
        "first": "Wang P",
        "last": "Sun X",
        "authors": [
          "Chen L",
          "Sun X",
          "Wang L",
          "Wang P"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "Ts65Dn mice": true
        },
        "MeSHDisease": {
          "Down Syndrome": true,
          "Alzheimer Disease": true
        }
      },
      "source": 200,
      "target": 786,
      "key": "2f96df75ed8e759ae855af864af6beab653290c365d29e32e5e24c20b94ed8573fd8fbfcd11137cf3e65f3dc9fa34a41e81f0bad8bdb61ebd6ed5c9465269e7d"
    },
    {
      "line": 2807,
      "relation": "negativeCorrelation",
      "evidence": "Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor known to increase the level of many antioxidants, including glutathione-S transferase (GST), and is negatively regulated by the activity of GSK-3β. Our results indicated the increased nuclear localization of Nrf2 and level of GST, suggesting the increased activity of the transcription factor as a result of GSK-3β suppression, consistent with the decreased oxidative stress observed. Consistent with the improved learning and memory, and consistent with GSK-3b being a tau kinase, we observed decreased tau phosphorylation in brain of GAO-treated SAMP8 mice compared to that of RAO-treated SAMP8 mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24355211",
        "name": "Free radical biology &amp; medicine",
        "title": "Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease.",
        "volume": "67",
        "pages": "387-95",
        "date": "2014-02-01",
        "first": "Farr SA",
        "last": "Butterfield DA",
        "authors": [
          "Butterfield DA",
          "Farr SA",
          "Kumar V",
          "Morley JE",
          "Murphy MP",
          "Niehoff ML",
          "Platt TL",
          "Ripley JL",
          "Sultana R",
          "Zhang Z"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "SAMP8 mice": true
        }
      },
      "source": 200,
      "target": 456,
      "key": "72c0c94e075aab79cf1b160cc3f45928e6e2faa35934af5a27cb90254aef64859e77eb9397a5f44f5146988ef6c50462475ad5e0b7904034ade200196a81777e"
    },
    {
      "line": 3179,
      "relation": "positiveCorrelation",
      "evidence": "Here we report abnormal acetylation of K274 and K281 on tau, identified in AD brains, promotes memory loss and disrupts synaptic plasticity by reducing postsynaptic KIdney/BRAin (KIBRA) protein, a memory-associated protein.Transgenic mice expressing human tau with lysine-to-glutamine mutations to mimic K274 and K281 acetylation (tauKQ) exhibit AD-related memory deficits and impaired hippocampal long-term potentiation (LTP). TauKQ reduces synaptic KIBRA levels and disrupts activity-induced postsynaptic actin remodeling and AMPA receptor insertion. The LTP deficit was rescued by promoting actin polymerization or by KIBRA expression. In AD patients with dementia, we found enhanced tau acetylation is linked to loss of KIBRA.",
      "citation": {
        "type": "PubMed",
        "reference": "27041503",
        "name": "Neuron",
        "title": "Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss.",
        "volume": "90",
        "pages": "245-60",
        "date": "2016-04-20",
        "first": "Tracy TE",
        "last": "Gan L",
        "authors": [
          "Cong X",
          "Ellerby LM",
          "Gan L",
          "Huganir RL",
          "Le D",
          "Li Y",
          "Lo I",
          "Min SW",
          "Minami SS",
          "Ponnusamy R",
          "Schilling B",
          "Sohn PD",
          "Tracy TE",
          "Wang C",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 200,
      "target": 204,
      "key": "fd4dbc842dd89629f261d4cc80d56069305e4775079bb60d380d2d604d65aa97dc131d25ddfe5974e20216a7eb9dff56902b49990da758e05da60a68d047d427"
    },
    {
      "line": 3342,
      "relation": "positiveCorrelation",
      "evidence": "SIRT1 activation or elevation ameliorates pathology and neurodegeneration in AD (Qin et al., 2006; Kim et al., 2007). Loss of SIRT1 induces impairment of learning and memory (Gao et al., 2010; Michán et al., 2010).",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "source": 200,
      "target": 677,
      "key": "b46f91afb3d30bd84f1e9b0f925ae9f345b6fd0abb515bead9dac9284adc2bfd5c5ccd0b4b82168d58745e94bc40ebf30f174f182aca08224f9712183fcec961"
    },
    {
      "line": 3383,
      "relation": "association",
      "evidence": "RGFP966, a selective HDAC3 inhibitor, has been shown to affect sensory cortical plasticity and memory formation (Bieszczad et al., 2015).",
      "citation": {
        "type": "PubMed",
        "reference": "28771976",
        "name": "Aging cell",
        "title": "HDAC3 negatively regulates spatial memory in a mouse model of Alzheimer's disease.",
        "volume": "16",
        "pages": "1073-1082",
        "date": "2017-10-01",
        "first": "Zhu X",
        "last": "Xu Y",
        "authors": [
          "Jin J",
          "Liu Y",
          "Wang S",
          "Xu Y",
          "Ye X",
          "Yu L",
          "Zhu X"
        ]
      },
      "source": 200,
      "target": 144,
      "key": "a465c44f1f694ba1e89740e57cd2fa7ea5329ee2b7d288c63ad299b1e9bbd5c55a13facca0d7e9fee91bc3e0341c64a85667463c81ebe42f0927d0e61c59fb37"
    },
    {
      "line": 3650,
      "relation": "negativeCorrelation",
      "evidence": "In 25-month-old mice, the number of errors and the latency in the learning phase negatively correlated with the Sumo3 level in the dorsal hippocampus.",
      "citation": {
        "type": "PubMed",
        "reference": "21843595",
        "name": "Neuroscience letters",
        "title": "Profiles of SUMO and ubiquitin conjugation in an Alzheimer's disease model.",
        "volume": "502",
        "pages": "201-8",
        "date": "2011-09-20",
        "first": "McMillan LE",
        "last": "Cimarosti H",
        "authors": [
          "Brown JT",
          "Cimarosti H",
          "Henley JM",
          "McMillan LE"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 200,
      "target": 850,
      "key": "64a59aaf859ea7076abd9ba0a98bbbfc133ba63d7e4e9e133bad2ac48197ed868f50efe3b57c857f7e373c74d37a6b9c55fc2f43ba9442da14da6e4f3e302b0e"
    },
    {
      "line": 2151,
      "relation": "biomarkerFor",
      "evidence": "Receiver-operating characteristic curves and logistic regression analyses showed that combined assessment of DYRK1A, BDNF and homocysteine has a sensitivity of 0.952, a specificity of 0.889 and an accuracy of 0.933 in testing for AD. The blood levels of these markers provide a diagnosis assessment profile. Combined assessment of these three markers outperforms most of the previous markers and could become a useful substitute to the current panel of AD biomarkers.",
      "citation": {
        "type": "PubMed",
        "reference": "28632203",
        "name": "Translational psychiatry",
        "title": "Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer's disease.",
        "volume": "7",
        "pages": "e1154",
        "date": "2017-06-20",
        "first": "Janel N",
        "last": "Delabar JM",
        "authors": [
          "Alexopoulos P",
          "Arbones M",
          "Badel A",
          "Camproux AC",
          "Delabar JM",
          "Dubois B",
          "Feraudet-Tarisse C",
          "Janel N",
          "Lagarde J",
          "Lamari F",
          "Lamourette P",
          "Paul JL",
          "Potier MC",
          "Sarazin M",
          "Simon S"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Anatomy": {
          "blood plasma": true
        }
      },
      "source": 389,
      "target": 908,
      "key": "94dae42339d214aff3ed2b564262282b9c4fcd87ce54c04b9e8d48f9ea9e74c0fe94ef16086bff72f6bd03e71c5863fc6e761c8a912c0f76bda8021618006b10"
    },
    {
      "relation": "hasComponent",
      "source": 246,
      "target": 55,
      "key": "eb96ef95f5b36b61cf4146267113d7ab8d2ad9775bde9dba68decc99c108bab55916c2ae457b32df12f9a978f311e5e06d705376ba799c600337e0f75fd830d7"
    },
    {
      "relation": "hasComponent",
      "source": 246,
      "target": 389,
      "key": "89d1073f2dba12a16f9a16032133486f1bf8ef91b2b12764d02fed1b45422fa3b80e56110bc345d8f96032dae4e4b37eeda8677bfc00a0bd8af9ea4f0f0fd188"
    },
    {
      "relation": "hasComponent",
      "source": 246,
      "target": 443,
      "key": "0ee11ad89a0ed538e54cfe2b93db45fa7df94faab1ef89eda0ddca39dad7a37926dbef2e521e4c65ebc8646540ae72834779eec7c36fa0247b9f0d60f84f425f"
    },
    {
      "line": 2153,
      "relation": "biomarkerFor",
      "evidence": "Receiver-operating characteristic curves and logistic regression analyses showed that combined assessment of DYRK1A, BDNF and homocysteine has a sensitivity of 0.952, a specificity of 0.889 and an accuracy of 0.933 in testing for AD. The blood levels of these markers provide a diagnosis assessment profile. Combined assessment of these three markers outperforms most of the previous markers and could become a useful substitute to the current panel of AD biomarkers.",
      "citation": {
        "type": "PubMed",
        "reference": "28632203",
        "name": "Translational psychiatry",
        "title": "Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer's disease.",
        "volume": "7",
        "pages": "e1154",
        "date": "2017-06-20",
        "first": "Janel N",
        "last": "Delabar JM",
        "authors": [
          "Alexopoulos P",
          "Arbones M",
          "Badel A",
          "Camproux AC",
          "Delabar JM",
          "Dubois B",
          "Feraudet-Tarisse C",
          "Janel N",
          "Lagarde J",
          "Lamari F",
          "Lamourette P",
          "Paul JL",
          "Potier MC",
          "Sarazin M",
          "Simon S"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Anatomy": {
          "blood plasma": true
        }
      },
      "source": 246,
      "target": 908,
      "key": "6cf991a3a8d0dabee26d47ebc8b3c36c5399b5f4510248fa99df67bcf29da28f71ccd0d82c5551f7f0eca7561a029e203b341f2e3fbdd105d21d7edc7ad60172"
    },
    {
      "line": 2164,
      "relation": "decreases",
      "evidence": "We conclude that the Dyrk1a dosage is critical for proper neurite and axonal outgrowth and that the two nonsense mutations, R205X and E239X, are loss-of-function mutants.",
      "citation": {
        "type": "PubMed",
        "reference": "28167836",
        "name": "Molecular psychiatry",
        "title": "Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development.",
        "volume": "23",
        "pages": "747-758",
        "date": "2018-03-01",
        "first": "Dang T",
        "last": "Wu BL",
        "authors": [
          "An Y",
          "Cheng C",
          "Dang T",
          "Duan WY",
          "Qiu ZL",
          "Tong DL",
          "Wu BB",
          "Wu BL",
          "Wu M",
          "Wu W",
          "Ye K",
          "Yu B",
          "Zhang WX",
          "Zhang YF"
        ]
      },
      "annotations": {
        "HBP_Disease": {
          "Autism Spectrum Disorder (ASD)": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 322,
      "target": 443,
      "key": "bbba13ff6e8a1acca55dd657f24f6682c9dd2fbbc366999879c3791c56c91c987c4f1d26d3253cb35715fd4dfea83b5c712265a027ed43089b402d90f0f6f69a"
    },
    {
      "line": 2167,
      "relation": "positiveCorrelation",
      "evidence": "We conclude that the Dyrk1a dosage is critical for proper neurite and axonal outgrowth and that the two nonsense mutations, R205X and E239X, are loss-of-function mutants.",
      "citation": {
        "type": "PubMed",
        "reference": "28167836",
        "name": "Molecular psychiatry",
        "title": "Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development.",
        "volume": "23",
        "pages": "747-758",
        "date": "2018-03-01",
        "first": "Dang T",
        "last": "Wu BL",
        "authors": [
          "An Y",
          "Cheng C",
          "Dang T",
          "Duan WY",
          "Qiu ZL",
          "Tong DL",
          "Wu BB",
          "Wu BL",
          "Wu M",
          "Wu W",
          "Ye K",
          "Yu B",
          "Zhang WX",
          "Zhang YF"
        ]
      },
      "annotations": {
        "HBP_Disease": {
          "Autism Spectrum Disorder (ASD)": true
        }
      },
      "source": 322,
      "target": 909,
      "key": "be5679ca98bbda2de4211c0b054bbc81a99c8d3942362934eca464821b74392c938d788d61dbdf2e98096dea297a85ba8081e49cf94ddc958c848494f56f7ef5"
    },
    {
      "line": 2165,
      "relation": "decreases",
      "evidence": "We conclude that the Dyrk1a dosage is critical for proper neurite and axonal outgrowth and that the two nonsense mutations, R205X and E239X, are loss-of-function mutants.",
      "citation": {
        "type": "PubMed",
        "reference": "28167836",
        "name": "Molecular psychiatry",
        "title": "Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development.",
        "volume": "23",
        "pages": "747-758",
        "date": "2018-03-01",
        "first": "Dang T",
        "last": "Wu BL",
        "authors": [
          "An Y",
          "Cheng C",
          "Dang T",
          "Duan WY",
          "Qiu ZL",
          "Tong DL",
          "Wu BB",
          "Wu BL",
          "Wu M",
          "Wu W",
          "Ye K",
          "Yu B",
          "Zhang WX",
          "Zhang YF"
        ]
      },
      "annotations": {
        "HBP_Disease": {
          "Autism Spectrum Disorder (ASD)": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 323,
      "target": 443,
      "key": "83232055f0cbb2b63746c9dcf3608fb0481e077414b856ffedd75a9ac8db4728472b0f19cc4f8b392b5ef7d201d919611a0abe8319df9ec4cc14f531f165d980"
    },
    {
      "line": 2168,
      "relation": "positiveCorrelation",
      "evidence": "We conclude that the Dyrk1a dosage is critical for proper neurite and axonal outgrowth and that the two nonsense mutations, R205X and E239X, are loss-of-function mutants.",
      "citation": {
        "type": "PubMed",
        "reference": "28167836",
        "name": "Molecular psychiatry",
        "title": "Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development.",
        "volume": "23",
        "pages": "747-758",
        "date": "2018-03-01",
        "first": "Dang T",
        "last": "Wu BL",
        "authors": [
          "An Y",
          "Cheng C",
          "Dang T",
          "Duan WY",
          "Qiu ZL",
          "Tong DL",
          "Wu BB",
          "Wu BL",
          "Wu M",
          "Wu W",
          "Ye K",
          "Yu B",
          "Zhang WX",
          "Zhang YF"
        ]
      },
      "annotations": {
        "HBP_Disease": {
          "Autism Spectrum Disorder (ASD)": true
        }
      },
      "source": 323,
      "target": 909,
      "key": "9c94c6bdef0e95969b9c06e4c1f801c4aceff0ee183b84c7743817d51ee12a9ff566d9d6d66bfc497977ccb395b4c11d1b0b5431dbc515e917d11d9f99b43304"
    },
    {
      "line": 2167,
      "relation": "positiveCorrelation",
      "evidence": "We conclude that the Dyrk1a dosage is critical for proper neurite and axonal outgrowth and that the two nonsense mutations, R205X and E239X, are loss-of-function mutants.",
      "citation": {
        "type": "PubMed",
        "reference": "28167836",
        "name": "Molecular psychiatry",
        "title": "Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development.",
        "volume": "23",
        "pages": "747-758",
        "date": "2018-03-01",
        "first": "Dang T",
        "last": "Wu BL",
        "authors": [
          "An Y",
          "Cheng C",
          "Dang T",
          "Duan WY",
          "Qiu ZL",
          "Tong DL",
          "Wu BB",
          "Wu BL",
          "Wu M",
          "Wu W",
          "Ye K",
          "Yu B",
          "Zhang WX",
          "Zhang YF"
        ]
      },
      "annotations": {
        "HBP_Disease": {
          "Autism Spectrum Disorder (ASD)": true
        }
      },
      "source": 909,
      "target": 322,
      "key": "53c62efa75d8d60a175b95595c427c723c7a70158d77d79ec5a950b8b5d08f733afbaf3c102ae64ac74b32a1d07bbdc0ca2b7a89bd5bafe4efb7ab4e00050c86"
    },
    {
      "line": 2168,
      "relation": "positiveCorrelation",
      "evidence": "We conclude that the Dyrk1a dosage is critical for proper neurite and axonal outgrowth and that the two nonsense mutations, R205X and E239X, are loss-of-function mutants.",
      "citation": {
        "type": "PubMed",
        "reference": "28167836",
        "name": "Molecular psychiatry",
        "title": "Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development.",
        "volume": "23",
        "pages": "747-758",
        "date": "2018-03-01",
        "first": "Dang T",
        "last": "Wu BL",
        "authors": [
          "An Y",
          "Cheng C",
          "Dang T",
          "Duan WY",
          "Qiu ZL",
          "Tong DL",
          "Wu BB",
          "Wu BL",
          "Wu M",
          "Wu W",
          "Ye K",
          "Yu B",
          "Zhang WX",
          "Zhang YF"
        ]
      },
      "annotations": {
        "HBP_Disease": {
          "Autism Spectrum Disorder (ASD)": true
        }
      },
      "source": 909,
      "target": 323,
      "key": "07041c9f4353655b9c8207779428058c87c53df28e8d9c7dee71bb7a1523f5c821352b15f11310e3b1b735715319b3125eb18955b1b02213e9ad3dad09d7c809"
    },
    {
      "relation": "hasComponent",
      "source": 220,
      "target": 53,
      "key": "060a4066ab11a37ffe508781b149de176c70659190802c1922a811483ca4d76c1c314b93752fb810c508d3aa62908774e66d00faa5bd578006dc2bacc76b5125"
    },
    {
      "relation": "hasComponent",
      "source": 220,
      "target": 258,
      "key": "15e6d4eae50f35df9ddad6ba052156a086c8d69a453d4cb374df9a1ef2f2ed05ac1f92b8971446f615690f85decf04fd5640f7f5e1f28c5037758cc6aca79525"
    },
    {
      "line": 2186,
      "relation": "positiveCorrelation",
      "evidence": "Additionally, we show that Syk overexpression leads to increased tau accumulation and promotes tau hyperphosphorylation at multiple epitopes in human neuron-like SH-SY5Y cells, further supporting a role of Syk in the formation of tau pathogenic species. Collectively, our data show that Syk activation occurs following Aβ deposition and the formation of tau pathological species.",
      "citation": {
        "type": "PubMed",
        "reference": "28877763",
        "name": "Acta neuropathologica communications",
        "title": "Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.",
        "volume": "5",
        "pages": "69",
        "date": "2017-09-06",
        "first": "Schweig JE",
        "last": "Paris D",
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Mouzon B",
          "Mullan M",
          "Paris D",
          "Schweig JE",
          "Yao H"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "APPPS1 mice": true
        },
        "Anatomy": {
          "hippocampal formation": true,
          "cerebral cortex": true
        }
      },
      "source": 851,
      "target": 822,
      "key": "e0e6b143f4b6d853d6f525e8fc4771b4aabac3cbe56fa92e4a524c2d52c3de85fae32dfd15f246289d3a5fbc3d286c95440ddf4b2a7629b19c52c22e8c2aa302"
    },
    {
      "relation": "hasVariant",
      "source": 851,
      "target": 852,
      "key": "25787833614cfbe41dd75099b08d1d53a8a0e2ec882887079d382b1a44a52f19d8dc05268929232a3f110cf384aa18b1a6375c366950bb8cd48400cbb8bb71bc"
    },
    {
      "line": 2197,
      "relation": "positiveCorrelation",
      "evidence": "Interestingly, Syk upregulation in SH-SY5Y cells leads to a significant increase (1.7-fold) in phosphorylated tau at Y18 (Fig. 14c, p < 0.01) and at S396/404 (Fig. 14d, 3-fold, p < 0.0001) compared to control cells. Total tau levels are also significantly increased following Syk overexpression (Fig. 14e, 4.2-fold, p < 0.0001).",
      "citation": {
        "type": "PubMed",
        "reference": "28877763",
        "name": "Acta neuropathologica communications",
        "title": "Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.",
        "volume": "5",
        "pages": "69",
        "date": "2017-09-06",
        "first": "Schweig JE",
        "last": "Paris D",
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Mouzon B",
          "Mullan M",
          "Paris D",
          "Schweig JE",
          "Yao H"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "APPPS1 mice": true
        },
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 851,
      "target": 836,
      "key": "b900b2d49e3472cc5da8e38d3b53a8db809fd56e753df030e9eae70f987a505ec6d0e39647ed83a2e83ab39afe96c941cc20af55e9ade948d363acf7172b5f47"
    },
    {
      "line": 2259,
      "relation": "positiveCorrelation",
      "evidence": "We further validated Syk as a target-regulating Aβ by showing that pharmacological inhibition of Syk or down-regulation of Syk expression reduces Aβ production and increases the clearance of Aβ across the BBB mimicking (-)-nilvadipine effects. Moreover, treatment of transgenic mice overexpressing Aβ and transgenic Tau P301S mice with a selective Syk inhibitor respectively decreased brain Aβ accumulation and Tau hyperphosphorylation at multiple AD relevant epitopes.",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 851,
      "target": 836,
      "key": "251cc78fd03306bdee022d098586359374cb517b32860d708263df60d1d7ca394f9185099fdd460b1bcf546703a0d605151f59a4c9eb6476f9122f13095f492a"
    },
    {
      "line": 2198,
      "relation": "positiveCorrelation",
      "evidence": "Interestingly, Syk upregulation in SH-SY5Y cells leads to a significant increase (1.7-fold) in phosphorylated tau at Y18 (Fig. 14c, p < 0.01) and at S396/404 (Fig. 14d, 3-fold, p < 0.0001) compared to control cells. Total tau levels are also significantly increased following Syk overexpression (Fig. 14e, 4.2-fold, p < 0.0001).",
      "citation": {
        "type": "PubMed",
        "reference": "28877763",
        "name": "Acta neuropathologica communications",
        "title": "Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.",
        "volume": "5",
        "pages": "69",
        "date": "2017-09-06",
        "first": "Schweig JE",
        "last": "Paris D",
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Mouzon B",
          "Mullan M",
          "Paris D",
          "Schweig JE",
          "Yao H"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "APPPS1 mice": true
        },
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 851,
      "target": 823,
      "key": "e8876c270aa9cb15cd6e26a8c8ea7c5a0e89792328d08814669444fcd6f446711a511df3c62d98183a67d9d5afaaed0c5935f562da000fd94976f8fac9ba9199"
    },
    {
      "line": 2260,
      "relation": "positiveCorrelation",
      "evidence": "We further validated Syk as a target-regulating Aβ by showing that pharmacological inhibition of Syk or down-regulation of Syk expression reduces Aβ production and increases the clearance of Aβ across the BBB mimicking (-)-nilvadipine effects. Moreover, treatment of transgenic mice overexpressing Aβ and transgenic Tau P301S mice with a selective Syk inhibitor respectively decreased brain Aβ accumulation and Tau hyperphosphorylation at multiple AD relevant epitopes.",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 851,
      "target": 823,
      "key": "79b20bb88ec682c0d7ed63f2472c019d48a7ddec8ced605edcb14d99e668bf8b16f4681cc3dd8723d29749e184653643e831d978b58eba38a21bfee846daa4e9"
    },
    {
      "line": 2199,
      "relation": "positiveCorrelation",
      "evidence": "Interestingly, Syk upregulation in SH-SY5Y cells leads to a significant increase (1.7-fold) in phosphorylated tau at Y18 (Fig. 14c, p < 0.01) and at S396/404 (Fig. 14d, 3-fold, p < 0.0001) compared to control cells. Total tau levels are also significantly increased following Syk overexpression (Fig. 14e, 4.2-fold, p < 0.0001).",
      "citation": {
        "type": "PubMed",
        "reference": "28877763",
        "name": "Acta neuropathologica communications",
        "title": "Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.",
        "volume": "5",
        "pages": "69",
        "date": "2017-09-06",
        "first": "Schweig JE",
        "last": "Paris D",
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Mouzon B",
          "Mullan M",
          "Paris D",
          "Schweig JE",
          "Yao H"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "APPPS1 mice": true
        },
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 851,
      "target": 825,
      "key": "93a71c1eaca98446f5d77958ef4ee661f0eb438370ff2fa4e180202e1c80dd369f89cfb111ba71502aa12b835e8e7571ebdb84eff736788580e27ae942510b03"
    },
    {
      "line": 2261,
      "relation": "positiveCorrelation",
      "evidence": "We further validated Syk as a target-regulating Aβ by showing that pharmacological inhibition of Syk or down-regulation of Syk expression reduces Aβ production and increases the clearance of Aβ across the BBB mimicking (-)-nilvadipine effects. Moreover, treatment of transgenic mice overexpressing Aβ and transgenic Tau P301S mice with a selective Syk inhibitor respectively decreased brain Aβ accumulation and Tau hyperphosphorylation at multiple AD relevant epitopes.",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 851,
      "target": 825,
      "key": "5e537db3927ccb16e3f120228912ea00e52de18beae1e11ebaac5ed317536e112da1b5bde20837e6627bfe0c524f939676161b023423586d71311ea06d3e0aea"
    },
    {
      "line": 2200,
      "relation": "positiveCorrelation",
      "evidence": "Interestingly, Syk upregulation in SH-SY5Y cells leads to a significant increase (1.7-fold) in phosphorylated tau at Y18 (Fig. 14c, p < 0.01) and at S396/404 (Fig. 14d, 3-fold, p < 0.0001) compared to control cells. Total tau levels are also significantly increased following Syk overexpression (Fig. 14e, 4.2-fold, p < 0.0001).",
      "citation": {
        "type": "PubMed",
        "reference": "28877763",
        "name": "Acta neuropathologica communications",
        "title": "Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.",
        "volume": "5",
        "pages": "69",
        "date": "2017-09-06",
        "first": "Schweig JE",
        "last": "Paris D",
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Mouzon B",
          "Mullan M",
          "Paris D",
          "Schweig JE",
          "Yao H"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "APPPS1 mice": true
        },
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 851,
      "target": 803,
      "key": "8cf54de42afa3032bc22bcdcdb66eb693eeb5d49e0141bd61e499b04cceb577f0ef1610b2da56cd8adf9c3fefec0fc1177d3bf290f4f5b33cae902dba9cfc4dc"
    },
    {
      "line": 2258,
      "relation": "positiveCorrelation",
      "evidence": "We further validated Syk as a target-regulating Aβ by showing that pharmacological inhibition of Syk or down-regulation of Syk expression reduces Aβ production and increases the clearance of Aβ across the BBB mimicking (-)-nilvadipine effects. Moreover, treatment of transgenic mice overexpressing Aβ and transgenic Tau P301S mice with a selective Syk inhibitor respectively decreased brain Aβ accumulation and Tau hyperphosphorylation at multiple AD relevant epitopes.",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 851,
      "target": 11,
      "key": "0fadb63a33d1867752b24c36d488691f1295cc96b634716c9367fc9f58109298fc7594b09fd5db257723e9dd29799bef23563faa9e61ec814c3c2b5e2c191a33"
    },
    {
      "line": 2263,
      "relation": "positiveCorrelation",
      "evidence": "We further validated Syk as a target-regulating Aβ by showing that pharmacological inhibition of Syk or down-regulation of Syk expression reduces Aβ production and increases the clearance of Aβ across the BBB mimicking (-)-nilvadipine effects. Moreover, treatment of transgenic mice overexpressing Aβ and transgenic Tau P301S mice with a selective Syk inhibitor respectively decreased brain Aβ accumulation and Tau hyperphosphorylation at multiple AD relevant epitopes.",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 851,
      "target": 816,
      "key": "4d8e72dae6a1b46a95b41ff164e54366894862fa76df6826d7db26093014f1f634babea71891be393a22b3ad3acc2450e4b2b72a7cdabef7593d974f91dfdd68"
    },
    {
      "line": 2186,
      "relation": "positiveCorrelation",
      "evidence": "Additionally, we show that Syk overexpression leads to increased tau accumulation and promotes tau hyperphosphorylation at multiple epitopes in human neuron-like SH-SY5Y cells, further supporting a role of Syk in the formation of tau pathogenic species. Collectively, our data show that Syk activation occurs following Aβ deposition and the formation of tau pathological species.",
      "citation": {
        "type": "PubMed",
        "reference": "28877763",
        "name": "Acta neuropathologica communications",
        "title": "Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.",
        "volume": "5",
        "pages": "69",
        "date": "2017-09-06",
        "first": "Schweig JE",
        "last": "Paris D",
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Mouzon B",
          "Mullan M",
          "Paris D",
          "Schweig JE",
          "Yao H"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "APPPS1 mice": true
        },
        "Anatomy": {
          "hippocampal formation": true,
          "cerebral cortex": true
        }
      },
      "source": 822,
      "target": 851,
      "key": "a15e71e1af28d97a1efee0b76f2f488a8d07336bdddc04776810508e2bc5b4ad367cb55c3cb9604c57d22ba0182c3ae8dc0bd73a77d53f23fcd40feb6a846a7a"
    },
    {
      "line": 2191,
      "relation": "positiveCorrelation",
      "evidence": "The upregulation of Syk activation observed in the brains of Tg APPsw and Tg PS1/APPsw is mainly attributable to pSyk accumulations in dystrophic neurites that are associated with Aβ plaques and increase with age and Aβ burden.",
      "citation": {
        "type": "PubMed",
        "reference": "28877763",
        "name": "Acta neuropathologica communications",
        "title": "Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.",
        "volume": "5",
        "pages": "69",
        "date": "2017-09-06",
        "first": "Schweig JE",
        "last": "Paris D",
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Mouzon B",
          "Mullan M",
          "Paris D",
          "Schweig JE",
          "Yao H"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "APPPS1 mice": true
        }
      },
      "source": 852,
      "target": 917,
      "key": "d0a686be52cbc7dc38f5d413a80173c75b49d3106ea314307f8e71e9013edcef2a1ccd84e31257b60ef53e0c643984e0763a1ec6febbb629cb7f02d94731814a"
    },
    {
      "line": 2192,
      "relation": "partOf",
      "evidence": "The upregulation of Syk activation observed in the brains of Tg APPsw and Tg PS1/APPsw is mainly attributable to pSyk accumulations in dystrophic neurites that are associated with Aβ plaques and increase with age and Aβ burden.",
      "citation": {
        "type": "PubMed",
        "reference": "28877763",
        "name": "Acta neuropathologica communications",
        "title": "Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.",
        "volume": "5",
        "pages": "69",
        "date": "2017-09-06",
        "first": "Schweig JE",
        "last": "Paris D",
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Mouzon B",
          "Mullan M",
          "Paris D",
          "Schweig JE",
          "Yao H"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "APPPS1 mice": true
        }
      },
      "source": 852,
      "target": 127,
      "key": "df3c6bf3ad12006603f3e108f2f94434273a5ff38886a16ae3e842eea5b4471ec457eac984fac8474d0eacccf1f4cb0d34143074b0335cbc7691cb5299bb5230"
    },
    {
      "line": 2197,
      "relation": "positiveCorrelation",
      "evidence": "Interestingly, Syk upregulation in SH-SY5Y cells leads to a significant increase (1.7-fold) in phosphorylated tau at Y18 (Fig. 14c, p < 0.01) and at S396/404 (Fig. 14d, 3-fold, p < 0.0001) compared to control cells. Total tau levels are also significantly increased following Syk overexpression (Fig. 14e, 4.2-fold, p < 0.0001).",
      "citation": {
        "type": "PubMed",
        "reference": "28877763",
        "name": "Acta neuropathologica communications",
        "title": "Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.",
        "volume": "5",
        "pages": "69",
        "date": "2017-09-06",
        "first": "Schweig JE",
        "last": "Paris D",
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Mouzon B",
          "Mullan M",
          "Paris D",
          "Schweig JE",
          "Yao H"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "APPPS1 mice": true
        },
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "source": 836,
      "target": 851,
      "key": "edf1583d2366d3931e7e31e746134e3b33841577ab6832b16ad6c1c8d1adfd14bb42ee290e3596b7e6b8a4e87e4551c2a849fa62ca0c5f5850ec273cb5f59f19"
    },
    {
      "line": 2259,
      "relation": "positiveCorrelation",
      "evidence": "We further validated Syk as a target-regulating Aβ by showing that pharmacological inhibition of Syk or down-regulation of Syk expression reduces Aβ production and increases the clearance of Aβ across the BBB mimicking (-)-nilvadipine effects. Moreover, treatment of transgenic mice overexpressing Aβ and transgenic Tau P301S mice with a selective Syk inhibitor respectively decreased brain Aβ accumulation and Tau hyperphosphorylation at multiple AD relevant epitopes.",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 836,
      "target": 851,
      "key": "120439853bfd1424628585cd1def523aea1f3b0253a532797af1162f358c44e06940214589f390f1cab1a67ca07234d7fc15b4dfb3764340e1630138515bbe2a"
    },
    {
      "line": 2207,
      "relation": "positiveCorrelation",
      "evidence": "We found an increase in Syk activation in DNs surrounding Aβ deposits as well as in neurons displaying an accumulation of phosphorylated Tau at Y18 and elevated levels of MC1 pathogenic tau conformers in AD brain sections whereas only weak immunoreactivity for pSyk was observed in brain sections from a non-demented control",
      "citation": {
        "type": "PubMed",
        "reference": "28877763",
        "name": "Acta neuropathologica communications",
        "title": "Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.",
        "volume": "5",
        "pages": "69",
        "date": "2017-09-06",
        "first": "Schweig JE",
        "last": "Paris D",
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Mouzon B",
          "Mullan M",
          "Paris D",
          "Schweig JE",
          "Yao H"
        ]
      },
      "source": 706,
      "target": 917,
      "key": "2be9bee2aee441a5bf0aaca18af9a6d312fd4be373bc40280c3f498c54232fc02793fb697f5be3335e3e1e0b629c4d779f5a9d38485cf7ab67b2ce20acab1aec"
    },
    {
      "line": 2208,
      "relation": "positiveCorrelation",
      "evidence": "We found an increase in Syk activation in DNs surrounding Aβ deposits as well as in neurons displaying an accumulation of phosphorylated Tau at Y18 and elevated levels of MC1 pathogenic tau conformers in AD brain sections whereas only weak immunoreactivity for pSyk was observed in brain sections from a non-demented control",
      "citation": {
        "type": "PubMed",
        "reference": "28877763",
        "name": "Acta neuropathologica communications",
        "title": "Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.",
        "volume": "5",
        "pages": "69",
        "date": "2017-09-06",
        "first": "Schweig JE",
        "last": "Paris D",
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Mouzon B",
          "Mullan M",
          "Paris D",
          "Schweig JE",
          "Yao H"
        ]
      },
      "source": 706,
      "target": 589,
      "key": "13028f270de3cf808cc1b5bf07c2de00ab2cd5342da04564474be0578b37b96b313d30731f74f143c211940ffbe0ec9e7a5e121bee0e921c2f67312f6bbc97cd"
    },
    {
      "relation": "hasVariant",
      "source": 705,
      "target": 706,
      "key": "0e7b434f72b721fce057e792c53e5c7688b5c3562da70f57b6d2c61f5979ac36a5d0186410bb0ddeba84b4a2bac946684c8f2cedac625558debb3688b7b2dcf1"
    },
    {
      "line": 2228,
      "relation": "partOf",
      "evidence": "Pretangles contained either paired helical filaments (PHFs) or PtdIns(4,5)P2-immunopositive small vesicles (approximately 1 µm in diameter) with nearly identical topology to granulovacuolar degeneration (GVD) bodies. Various combinations of these vesicles and GVD bodies, the latter of which are pathological hallmarks observed within the neurons of AD patients, were found concurrently in neurons.These vesicles and GVD bodies were both immunopositive not only for PtdIns(4,5)P2, but also for several tau kinases such as glycogen synthase kinase-3ß and spleen tyrosine kinase.",
      "citation": {
        "type": "PubMed",
        "reference": "26501932",
        "name": "Neuropathology and applied neurobiology",
        "title": "The identification of raft-derived tau-associated vesicles that are incorporated into immature tangles and paired helical filaments.",
        "volume": "42",
        "pages": "639-653",
        "date": "2016-12-01",
        "first": "Nishikawa T",
        "last": "Matsumoto M",
        "authors": [
          "Hosomi N",
          "Izumi Y",
          "Maruyama H",
          "Matsumoto M",
          "Miyazaki Y",
          "Nakamori M",
          "Nishikawa T",
          "Takahashi T"
        ]
      },
      "source": 705,
      "target": 158,
      "key": "3c8095fc2f712473c690a867f52e304596a849bd6a6fc16cff260f8a00224f15751d9608ee7893a8c07eede57faa4e4d501d87f1261a74b18ca592d1eda4567e"
    },
    {
      "line": 2231,
      "relation": "partOf",
      "evidence": "Pretangles contained either paired helical filaments (PHFs) or PtdIns(4,5)P2-immunopositive small vesicles (approximately 1 µm in diameter) with nearly identical topology to granulovacuolar degeneration (GVD) bodies. Various combinations of these vesicles and GVD bodies, the latter of which are pathological hallmarks observed within the neurons of AD patients, were found concurrently in neurons.These vesicles and GVD bodies were both immunopositive not only for PtdIns(4,5)P2, but also for several tau kinases such as glycogen synthase kinase-3ß and spleen tyrosine kinase.",
      "citation": {
        "type": "PubMed",
        "reference": "26501932",
        "name": "Neuropathology and applied neurobiology",
        "title": "The identification of raft-derived tau-associated vesicles that are incorporated into immature tangles and paired helical filaments.",
        "volume": "42",
        "pages": "639-653",
        "date": "2016-12-01",
        "first": "Nishikawa T",
        "last": "Matsumoto M",
        "authors": [
          "Hosomi N",
          "Izumi Y",
          "Maruyama H",
          "Matsumoto M",
          "Miyazaki Y",
          "Nakamori M",
          "Nishikawa T",
          "Takahashi T"
        ]
      },
      "source": 705,
      "target": 102,
      "key": "56e729dfc50735e975ebd97fb90bea60565984c9089a03e53dbe3e54df007857f9b9db9e3bfe7b943d4b747c442b2cf278c627999121617611b565e00e38ae78"
    },
    {
      "line": 2271,
      "relation": "negativeCorrelation",
      "evidence": "We observed that pharmacological inhibition of Syk with BAY61-3606 stimulates Ser-9 phosphorylation of GSK3β in SH-SY5Y cells (Fig. 9, A and B) suggesting that blocking Syk activity results in GSK3β inhibition.",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 705,
      "target": 457,
      "key": "46c3da0a93e8af3ac33263a22d88f373efab1ad4471e27029f2c655e2c728408d84a3408785a50aa2af9b6d3debf5ea2890b5491cb1f1f82dd320bf84d7c3076"
    },
    {
      "line": 2272,
      "relation": "positiveCorrelation",
      "evidence": "We observed that pharmacological inhibition of Syk with BAY61-3606 stimulates Ser-9 phosphorylation of GSK3β in SH-SY5Y cells (Fig. 9, A and B) suggesting that blocking Syk activity results in GSK3β inhibition.",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 705,
      "target": 456,
      "key": "0433462b04b934ad78b75c4ff5257d46ae962ade8f94d5cbf4e3bbc0f1e2e405261b0feb740b7dc63ce9a99fb8a6210e38e24f5eeced78c1367bb3b8dbb03e63"
    },
    {
      "line": 2217,
      "relation": "increases",
      "evidence": "We report herein that Syk is also a tau kinase, phosphorylating tau in vitro and in CHO cells when both proteins are expressed exogenously. In CHO cells, we have also demonstrated by co-immunoprecipitation that Syk binds to tau. Finally, by site-directed mutagenesis substituting the tyrosine residues of tau with phenylalanine, we established that tyrosine 18 was the primary residue in tau phosphorylated by Syk.",
      "citation": {
        "type": "PubMed",
        "reference": "18070606",
        "name": "Biochimica et biophysica acta",
        "title": "The microtubule-associated protein tau is phosphorylated by Syk.",
        "volume": "1783",
        "pages": "188-92",
        "date": "2008-02-01",
        "first": "Lebouvier T",
        "last": "Derkinderen P",
        "authors": [
          "Anderton BH",
          "Derkinderen P",
          "Geahlen RL",
          "Hanger DP",
          "Lardeux B",
          "Lebouvier T",
          "Reynolds CH",
          "Scales TM"
        ]
      },
      "annotations": {
        "Species": {
          "10029": true
        },
        "Cell_Line": {
          "CHO": true
        }
      },
      "source": 901,
      "target": 885,
      "key": "de9b159b9aee97d7795ab46c62bb32c63174447116f066635f4a4c9e71b3ed14461e384d506b8d34810fb4541ba84232ee23b3a9a7c17a28d135f91e0d0a0f2f"
    },
    {
      "line": 2227,
      "relation": "partOf",
      "evidence": "Pretangles contained either paired helical filaments (PHFs) or PtdIns(4,5)P2-immunopositive small vesicles (approximately 1 µm in diameter) with nearly identical topology to granulovacuolar degeneration (GVD) bodies. Various combinations of these vesicles and GVD bodies, the latter of which are pathological hallmarks observed within the neurons of AD patients, were found concurrently in neurons.These vesicles and GVD bodies were both immunopositive not only for PtdIns(4,5)P2, but also for several tau kinases such as glycogen synthase kinase-3ß and spleen tyrosine kinase.",
      "citation": {
        "type": "PubMed",
        "reference": "26501932",
        "name": "Neuropathology and applied neurobiology",
        "title": "The identification of raft-derived tau-associated vesicles that are incorporated into immature tangles and paired helical filaments.",
        "volume": "42",
        "pages": "639-653",
        "date": "2016-12-01",
        "first": "Nishikawa T",
        "last": "Matsumoto M",
        "authors": [
          "Hosomi N",
          "Izumi Y",
          "Maruyama H",
          "Matsumoto M",
          "Miyazaki Y",
          "Nakamori M",
          "Nishikawa T",
          "Takahashi T"
        ]
      },
      "source": 3,
      "target": 84,
      "key": "7ef8bbd09276a84549483f3b66405056f0cd234e027dea039cf9bae051c70157ead0007fd0c04b834f182e96c35c7859f9de2442b92d0145368d91bd500de035"
    },
    {
      "line": 2229,
      "relation": "association",
      "evidence": "Pretangles contained either paired helical filaments (PHFs) or PtdIns(4,5)P2-immunopositive small vesicles (approximately 1 µm in diameter) with nearly identical topology to granulovacuolar degeneration (GVD) bodies. Various combinations of these vesicles and GVD bodies, the latter of which are pathological hallmarks observed within the neurons of AD patients, were found concurrently in neurons.These vesicles and GVD bodies were both immunopositive not only for PtdIns(4,5)P2, but also for several tau kinases such as glycogen synthase kinase-3ß and spleen tyrosine kinase.",
      "citation": {
        "type": "PubMed",
        "reference": "26501932",
        "name": "Neuropathology and applied neurobiology",
        "title": "The identification of raft-derived tau-associated vesicles that are incorporated into immature tangles and paired helical filaments.",
        "volume": "42",
        "pages": "639-653",
        "date": "2016-12-01",
        "first": "Nishikawa T",
        "last": "Matsumoto M",
        "authors": [
          "Hosomi N",
          "Izumi Y",
          "Maruyama H",
          "Matsumoto M",
          "Miyazaki Y",
          "Nakamori M",
          "Nishikawa T",
          "Takahashi T"
        ]
      },
      "source": 3,
      "target": 102,
      "key": "79fd3d9c17dce5572f079953a2e096d6df6fbd787a62f84260885c972eacefe8295f1d54e1bb462533102f48a2669572ce44b2eb5af6fc429f47bea236dc5936"
    },
    {
      "line": 2230,
      "relation": "partOf",
      "evidence": "Pretangles contained either paired helical filaments (PHFs) or PtdIns(4,5)P2-immunopositive small vesicles (approximately 1 µm in diameter) with nearly identical topology to granulovacuolar degeneration (GVD) bodies. Various combinations of these vesicles and GVD bodies, the latter of which are pathological hallmarks observed within the neurons of AD patients, were found concurrently in neurons.These vesicles and GVD bodies were both immunopositive not only for PtdIns(4,5)P2, but also for several tau kinases such as glycogen synthase kinase-3ß and spleen tyrosine kinase.",
      "citation": {
        "type": "PubMed",
        "reference": "26501932",
        "name": "Neuropathology and applied neurobiology",
        "title": "The identification of raft-derived tau-associated vesicles that are incorporated into immature tangles and paired helical filaments.",
        "volume": "42",
        "pages": "639-653",
        "date": "2016-12-01",
        "first": "Nishikawa T",
        "last": "Matsumoto M",
        "authors": [
          "Hosomi N",
          "Izumi Y",
          "Maruyama H",
          "Matsumoto M",
          "Miyazaki Y",
          "Nakamori M",
          "Nishikawa T",
          "Takahashi T"
        ]
      },
      "source": 3,
      "target": 158,
      "key": "83e5b213cfee36ea7de1595bb107ca3608377be264265ae12ac4a22d7f9596818d2b13f876bf8cca46f914ed841e3e01df596371cdae1ad4ac1645e05e2ed4dc"
    },
    {
      "line": 2229,
      "relation": "association",
      "evidence": "Pretangles contained either paired helical filaments (PHFs) or PtdIns(4,5)P2-immunopositive small vesicles (approximately 1 µm in diameter) with nearly identical topology to granulovacuolar degeneration (GVD) bodies. Various combinations of these vesicles and GVD bodies, the latter of which are pathological hallmarks observed within the neurons of AD patients, were found concurrently in neurons.These vesicles and GVD bodies were both immunopositive not only for PtdIns(4,5)P2, but also for several tau kinases such as glycogen synthase kinase-3ß and spleen tyrosine kinase.",
      "citation": {
        "type": "PubMed",
        "reference": "26501932",
        "name": "Neuropathology and applied neurobiology",
        "title": "The identification of raft-derived tau-associated vesicles that are incorporated into immature tangles and paired helical filaments.",
        "volume": "42",
        "pages": "639-653",
        "date": "2016-12-01",
        "first": "Nishikawa T",
        "last": "Matsumoto M",
        "authors": [
          "Hosomi N",
          "Izumi Y",
          "Maruyama H",
          "Matsumoto M",
          "Miyazaki Y",
          "Nakamori M",
          "Nishikawa T",
          "Takahashi T"
        ]
      },
      "source": 102,
      "target": 3,
      "key": "ac95398feefb1eb87f6857867122698879bb5e2c9504c468134f6dd9fa190a5025b0e9b4eb6986f48e1e114aa3cf4ef2862981ce4263f477b04768dee7d56480"
    },
    {
      "line": 2238,
      "relation": "decreases",
      "evidence": "We have previously shown that the L-type calcium channel (LCC) antagonist nilvadipine reduces brain amyloid-β (Aβ) accumulation by affecting both Aβ production and Aβ clearance across the blood-brain barrier (BBB).",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "source": 38,
      "target": 11,
      "key": "59acd59a10f862103590600cdcbfe2b09ebd6b4ecd0170e456f7a955fc6a197578932f4677537de6c32cc22fa876073b2f06b08163b3fc924bbbdccee501062c"
    },
    {
      "line": 2239,
      "relation": "directlyDecreases",
      "evidence": "We have previously shown that the L-type calcium channel (LCC) antagonist nilvadipine reduces brain amyloid-β (Aβ) accumulation by affecting both Aβ production and Aβ clearance across the blood-brain barrier (BBB).",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "source": 38,
      "target": 208,
      "key": "a1e278188dbc9a5ab07e1b95298886be844ab398b46b34a3ebaba0e7dbbbf8849727d90e4ad86b41714136c07e3292edd8a3605428de77dfdf048415fddd43e0"
    },
    {
      "line": 2246,
      "relation": "decreases",
      "evidence": "Western blot analyses of brain homogenates show that (−)-nilvadipine significantly reduces Tau phosphorylation in AT8 (phosphorylated Ser-199/Ser-202/Thr-205) and PHF-1 (phosphorylated Ser-396/Ser-404) epitopes",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "source": 38,
      "target": 543,
      "key": "c5dee2ad31d4f4cd82ed1196f12e67a7b289e27590db58c3cede82fbcd9fa1125bfe54807c8a5758c6047fd5d8dcf9979a1a80da008fc88eec6b278e6e35080e"
    },
    {
      "line": 2247,
      "relation": "decreases",
      "evidence": "Western blot analyses of brain homogenates show that (−)-nilvadipine significantly reduces Tau phosphorylation in AT8 (phosphorylated Ser-199/Ser-202/Thr-205) and PHF-1 (phosphorylated Ser-396/Ser-404) epitopes",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "source": 38,
      "target": 544,
      "key": "5a4bf22b6aa1a194f5388bb32649c26ea379d53815aeeb2bb5b9b9ae566b28aaf7d59090626fb774f81e66862af02c7122fde642d7103fd68db4cdd5649ab167"
    },
    {
      "line": 2248,
      "relation": "decreases",
      "evidence": "Western blot analyses of brain homogenates show that (−)-nilvadipine significantly reduces Tau phosphorylation in AT8 (phosphorylated Ser-199/Ser-202/Thr-205) and PHF-1 (phosphorylated Ser-396/Ser-404) epitopes",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "source": 38,
      "target": 579,
      "key": "75d1fbcd1b2bc39de1cb1d3307a162149df49ea784a52b3dc31379c002a7c54c1d837fb965d5a67824502d5c8cea51dbfa980e4bb3f24bd5c01ca77e5314fc1d"
    },
    {
      "line": 2250,
      "relation": "decreases",
      "evidence": "Western blot analyses of brain homogenates show that (−)-nilvadipine significantly reduces Tau phosphorylation in AT8 (phosphorylated Ser-199/Ser-202/Thr-205) and PHF-1 (phosphorylated Ser-396/Ser-404) epitopes",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "source": 38,
      "target": 564,
      "key": "bd76cbea1355fecd15a81a8dfc16f75b73c2c9cbffc502e4fe436e7589f1922e3e55fa34c5c2572e792d2b7d7a7a6456a221e39988a2f17eee555d609654ac9e"
    },
    {
      "line": 2251,
      "relation": "decreases",
      "evidence": "Western blot analyses of brain homogenates show that (−)-nilvadipine significantly reduces Tau phosphorylation in AT8 (phosphorylated Ser-199/Ser-202/Thr-205) and PHF-1 (phosphorylated Ser-396/Ser-404) epitopes",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "source": 38,
      "target": 565,
      "key": "18fb5f26f63cdad1c351be093b3760bcf5fc8121cc49c82ddf742a788b6ee68a61fe517a40ed9d3cd5f31e8356579da64a60dbaf20fe1b363065978e3a2d4dc2"
    },
    {
      "line": 2264,
      "relation": "equivalentTo",
      "evidence": "We further validated Syk as a target-regulating Aβ by showing that pharmacological inhibition of Syk or down-regulation of Syk expression reduces Aβ production and increases the clearance of Aβ across the BBB mimicking (-)-nilvadipine effects. Moreover, treatment of transgenic mice overexpressing Aβ and transgenic Tau P301S mice with a selective Syk inhibitor respectively decreased brain Aβ accumulation and Tau hyperphosphorylation at multiple AD relevant epitopes.",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 116,
      "target": 544,
      "key": "da85c8849c7539aa5ca766f90dfcb313266ef0f5be9c26a05ac7c45b729dd3cd597b50b3217b4228fa78178043f3a9eb4c2d4fee5fe67146148f38519e818a14"
    },
    {
      "line": 2270,
      "relation": "directlyDecreases",
      "evidence": "We observed that pharmacological inhibition of Syk with BAY61-3606 stimulates Ser-9 phosphorylation of GSK3β in SH-SY5Y cells (Fig. 9, A and B) suggesting that blocking Syk activity results in GSK3β inhibition.",
      "citation": {
        "type": "PubMed",
        "reference": "25331948",
        "name": "The Journal of biological chemistry",
        "title": "The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.",
        "volume": "289",
        "pages": "33927-44",
        "date": "2014-12-05",
        "first": "Paris D",
        "last": "Mullan M",
        "authors": [
          "Ait-Ghezala G",
          "Bachmeier C",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Jin C",
          "Laco G",
          "Lin Y",
          "Mullan M",
          "Paris D"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "SH-SY5Y": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 93,
      "target": 705,
      "key": "ea82c391daa508baaf0a3e9553ccb8c8e905e3c839751a1f8516cd6b26184b9a295e76fbee013aa007dd5329572857df24836d5d63a65a2a28843743c11f726d"
    },
    {
      "line": 2279,
      "relation": "positiveCorrelation",
      "evidence": "We found that GSK3β mRNA was overexpressed only in patients with initial AD, with no effect on the levels of the protein. On the other hand, we unexpectedly observed the decrease of the inactive GSK3β in cortex from AD patients at Braak stages I-II, whereas considerable increase was observed in AD patients at stages V-VI compared to the control subjects.",
      "citation": {
        "type": "PubMed",
        "reference": "28176663",
        "name": "Current Alzheimer research",
        "title": "GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.",
        "volume": "14",
        "pages": "753-759",
        "date": "2017-01-01",
        "first": "Nicolia V",
        "last": "Fuso A",
        "authors": [
          "Cavallaro RA",
          "Ciraci V",
          "Ferrer I",
          "Fuso A",
          "Nicolia V",
          "Scarpa S"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 95,
      "target": 456,
      "key": "5dceb84ffbc3cc92eae1b73c0e03469fb2b427b9eeb5bb60a05ef3705696a572eda044c2df7f305a2cab30458705cc03c4e7f805cc870a209058dfcb61bcce38"
    },
    {
      "line": 2280,
      "relation": "positiveCorrelation",
      "evidence": "We found that GSK3β mRNA was overexpressed only in patients with initial AD, with no effect on the levels of the protein. On the other hand, we unexpectedly observed the decrease of the inactive GSK3β in cortex from AD patients at Braak stages I-II, whereas considerable increase was observed in AD patients at stages V-VI compared to the control subjects.",
      "citation": {
        "type": "PubMed",
        "reference": "28176663",
        "name": "Current Alzheimer research",
        "title": "GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.",
        "volume": "14",
        "pages": "753-759",
        "date": "2017-01-01",
        "first": "Nicolia V",
        "last": "Fuso A",
        "authors": [
          "Cavallaro RA",
          "Ciraci V",
          "Ferrer I",
          "Fuso A",
          "Nicolia V",
          "Scarpa S"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 96,
      "target": 456,
      "key": "e34a2c6d42b6d5def67edb121c904f7ae7e90906de2007b1dee4bf1e96092928bd490c196f49f34032f0857593d6e19c83da6a65d306522d9bd573ba8dddf385"
    },
    {
      "line": 2282,
      "relation": "negativeCorrelation",
      "evidence": "We found that GSK3β mRNA was overexpressed only in patients with initial AD, with no effect on the levels of the protein. On the other hand, we unexpectedly observed the decrease of the inactive GSK3β in cortex from AD patients at Braak stages I-II, whereas considerable increase was observed in AD patients at stages V-VI compared to the control subjects.",
      "citation": {
        "type": "PubMed",
        "reference": "28176663",
        "name": "Current Alzheimer research",
        "title": "GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.",
        "volume": "14",
        "pages": "753-759",
        "date": "2017-01-01",
        "first": "Nicolia V",
        "last": "Fuso A",
        "authors": [
          "Cavallaro RA",
          "Ciraci V",
          "Ferrer I",
          "Fuso A",
          "Nicolia V",
          "Scarpa S"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 97,
      "target": 456,
      "key": "e52b8fae37e58d9d9300ef6b4f639a93d83374a2865025c3e7d6a227f7ff81e6b6cb7445d875b805c4740b278436ed52a8537690b17698f46bd2f1b6876d6826"
    },
    {
      "line": 2296,
      "relation": "increases",
      "evidence": "Thus, our results suggest that Tau hyperphosphorylation was a result of ribosylated AGEs, rather than due to a direct reaction involving D-ribose.",
      "citation": {
        "type": "PubMed",
        "reference": "28176663",
        "name": "Current Alzheimer research",
        "title": "GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.",
        "volume": "14",
        "pages": "753-759",
        "date": "2017-01-01",
        "first": "Nicolia V",
        "last": "Fuso A",
        "authors": [
          "Cavallaro RA",
          "Ciraci V",
          "Ferrer I",
          "Fuso A",
          "Nicolia V",
          "Scarpa S"
        ]
      },
      "source": 123,
      "target": 577,
      "key": "3cf9e1cfa40aef49ebff307384da129720dd07dd331a41a063a01590355cc6b86382fc96519bc07b4443b3c7e6b5acf75967c50fca6a9c515b6e1b73a44228c8"
    },
    {
      "line": 2297,
      "relation": "increases",
      "evidence": "Thus, our results suggest that Tau hyperphosphorylation was a result of ribosylated AGEs, rather than due to a direct reaction involving D-ribose.",
      "citation": {
        "type": "PubMed",
        "reference": "28176663",
        "name": "Current Alzheimer research",
        "title": "GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.",
        "volume": "14",
        "pages": "753-759",
        "date": "2017-01-01",
        "first": "Nicolia V",
        "last": "Fuso A",
        "authors": [
          "Cavallaro RA",
          "Ciraci V",
          "Ferrer I",
          "Fuso A",
          "Nicolia V",
          "Scarpa S"
        ]
      },
      "source": 123,
      "target": 551,
      "key": "4411d43441a3fab51b7ccc1c35f49dbe0fcbd15240c22004a529f1916db23701e8ea9f6120ac23ca6352fcb78ba0272ad22b1b0d2b5cfee7a9ce81eb5af6141e"
    },
    {
      "line": 2298,
      "relation": "increases",
      "evidence": "Thus, our results suggest that Tau hyperphosphorylation was a result of ribosylated AGEs, rather than due to a direct reaction involving D-ribose.",
      "citation": {
        "type": "PubMed",
        "reference": "28176663",
        "name": "Current Alzheimer research",
        "title": "GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.",
        "volume": "14",
        "pages": "753-759",
        "date": "2017-01-01",
        "first": "Nicolia V",
        "last": "Fuso A",
        "authors": [
          "Cavallaro RA",
          "Ciraci V",
          "Ferrer I",
          "Fuso A",
          "Nicolia V",
          "Scarpa S"
        ]
      },
      "source": 123,
      "target": 564,
      "key": "cb2064b6b75b53bacbb6f398471440ea56d20cec38e378984ac2a821a4cf1501d61df4da3c90fc8e5f287cfbd50ca2753d003bc1a8d2fe28350a862680ffcc4f"
    },
    {
      "line": 2407,
      "relation": "increases",
      "evidence": "In this study, we demonstrated that GLP-1RA could inhibit oxidative stress and repair mitochondrial damage in addition to decreasing tau hyperphosphorylation in PC12 cells treated with AGEs. Importantly, we first observed AGEs in the circulatory system could induce tau hyperphosphorylation after we injected AGEs (1μg/kg bodyweight) into the mice tail vein. We found GLP-1RA could promote mitochondrial biogenesis and antioxidant system via regulating peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) signaling pathway in vivo besides down-regulating the activity of glycogen synthase kinase 3β (GSK-3β) to reverse tau hyperphosphorylation directly.",
      "citation": {
        "type": "PubMed",
        "reference": "25987199",
        "name": "Neuroscience",
        "title": "Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: Studies in vivo and in vitro.",
        "volume": "300",
        "pages": "75-84",
        "date": "2015-08-06",
        "first": "An FM",
        "last": "Gao XD",
        "authors": [
          "An FM",
          "Chen S",
          "Gao XD",
          "Liu AR",
          "Wang Y",
          "Xu Z",
          "Yao WB",
          "Yin L"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 123,
      "target": 516,
      "key": "dea066975aa36b693cfcc5efb88a3efb3c1399b1bec3a5f1116fd1f277c3ae39b490457193be9efb8fbc69e9c15e0247076688f60ef5c720af3070699f45963d"
    },
    {
      "line": 2412,
      "relation": "negativeCorrelation",
      "evidence": "In this study, we demonstrated that GLP-1RA could inhibit oxidative stress and repair mitochondrial damage in addition to decreasing tau hyperphosphorylation in PC12 cells treated with AGEs. Importantly, we first observed AGEs in the circulatory system could induce tau hyperphosphorylation after we injected AGEs (1μg/kg bodyweight) into the mice tail vein. We found GLP-1RA could promote mitochondrial biogenesis and antioxidant system via regulating peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) signaling pathway in vivo besides down-regulating the activity of glycogen synthase kinase 3β (GSK-3β) to reverse tau hyperphosphorylation directly.",
      "citation": {
        "type": "PubMed",
        "reference": "25987199",
        "name": "Neuroscience",
        "title": "Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: Studies in vivo and in vitro.",
        "volume": "300",
        "pages": "75-84",
        "date": "2015-08-06",
        "first": "An FM",
        "last": "Gao XD",
        "authors": [
          "An FM",
          "Chen S",
          "Gao XD",
          "Liu AR",
          "Wang Y",
          "Xu Z",
          "Yao WB",
          "Yin L"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 123,
      "target": 791,
      "key": "fcf2518e37b1822454361d82c012a26167cdcf37362c12aeab1740779a2c05d49b09d406e78fb00a9f2663ff447eaec51f21d1cd9cf84cd1ce0ffd73d2d12687"
    },
    {
      "relation": "hasComponent",
      "source": 228,
      "target": 400,
      "key": "4c4c39116aaf8ac11caf4eeb26011cb924f6fa76fb7d847258f34c0a57d51a23f397e26c71558ae563c900397794f066ecbe6d6279a4d8b93d38958f91acb9ec"
    },
    {
      "line": 2308,
      "relation": "increases",
      "evidence": "To perform its function, Cdk5 must bind to the neuron-specific regulatory subunit protein p35, which is beneficial for neuronal development (Tsai et al. 1994; Chae et al. 1997). However, truncation of p35 and conversion to p25 (Patrick et al. 1999) is found in the forebrain of rats after focal cerebral ischemia and in AD patients, and these alterations are deleterious to the brain",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 228,
      "target": 400,
      "key": "54183d88248fe4ac721f3605430c942325973e43aa952c38f3a4140c669de2dbb528ed703baa80457773eecba922b261403b53b0aee459c30dbad31b73b40f8a"
    },
    {
      "relation": "hasComponent",
      "source": 228,
      "target": 401,
      "key": "63a1ef8227b8e54efb120f2eea96d69ce9f3cf995e0e2a9f02c85b6a11d15ec36443f14f2017c8fed0bd59e6c976a7656aee06d08da576cf0f2680d6af81ec53"
    },
    {
      "line": 2309,
      "relation": "negativeCorrelation",
      "evidence": "To perform its function, Cdk5 must bind to the neuron-specific regulatory subunit protein p35, which is beneficial for neuronal development (Tsai et al. 1994; Chae et al. 1997). However, truncation of p35 and conversion to p25 (Patrick et al. 1999) is found in the forebrain of rats after focal cerebral ischemia and in AD patients, and these alterations are deleterious to the brain",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "source": 311,
      "target": 401,
      "key": "2a07b88ec8b9dcba3ce021c6483c47282ad27aa33023ee9bde8a7984cd904fda28893fef07218c8b0c81717ffdcf919f7d30552b1ac617f002ffa64ce18bf82c"
    },
    {
      "line": 2310,
      "relation": "equivalentTo",
      "evidence": "To perform its function, Cdk5 must bind to the neuron-specific regulatory subunit protein p35, which is beneficial for neuronal development (Tsai et al. 1994; Chae et al. 1997). However, truncation of p35 and conversion to p25 (Patrick et al. 1999) is found in the forebrain of rats after focal cerebral ischemia and in AD patients, and these alterations are deleterious to the brain",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "source": 311,
      "target": 402,
      "key": "a39b89392fdcb43e9f022096da9fc2322a3c6f5a7b0c9fe5003026c1596902d4a8b9c15406ebaafb5ab92e1c7cbf828fb0c4ec7b71703ad4abe7b9af782ec39e"
    },
    {
      "line": 2311,
      "relation": "positiveCorrelation",
      "evidence": "To perform its function, Cdk5 must bind to the neuron-specific regulatory subunit protein p35, which is beneficial for neuronal development (Tsai et al. 1994; Chae et al. 1997). However, truncation of p35 and conversion to p25 (Patrick et al. 1999) is found in the forebrain of rats after focal cerebral ischemia and in AD patients, and these alterations are deleterious to the brain",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "source": 311,
      "target": 908,
      "key": "4b1af413adbbb91f9df89079943591a9a745d3840914f49d63f03279325521b9cda5438b1b0adb953f0d911bce8a05253297eeee60e88003da06c1ebd5c5516e"
    },
    {
      "line": 2314,
      "relation": "positiveCorrelation",
      "evidence": "The accumulation of p25 involves neurofibrillary tangle (NFT) formation via regulation of tau phosphorylation (Wen et al. 2007; Su and Tsai 2011)",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "source": 311,
      "target": 81,
      "key": "784ad5e3bed219ef46148f19550bf4443cfa486f4c5b9d93d11404b5a5f325ef9464a390ef80a32d700386b91dd06d8540bfb4d5793c7f7746b5caee7b769276"
    },
    {
      "line": 2389,
      "relation": "positiveCorrelation",
      "evidence": "We demonstrated that the treatment of cultured hippocampal neurons with 125 µM glutamate for 20 min induced the cleavage of p35 to produce the p25 fragment 6 h after glutamate treatment, and the maximal levels of p25 were detected at 12 h (Fig. 1A), which is consistent with a peak in tau hyperphosphorylation (AT8).",
      "citation": {
        "type": "PubMed",
        "reference": "27087442",
        "name": "Current Alzheimer research",
        "title": "APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.",
        "volume": "13",
        "pages": "1048-55",
        "date": "2016-01-01",
        "first": "Zhou M",
        "last": "Chen X",
        "authors": [
          "Chen X",
          "Collins N",
          "Dai X",
          "Huang T",
          "LaDu MJ",
          "Lin L",
          "Shen H",
          "Wei Z",
          "Wu X",
          "Xiao N",
          "York J",
          "Zhang J",
          "Zhou M",
          "Zhu Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 311,
      "target": 336,
      "key": "369bc6f65d07549a0474f340d075bc5e593c2a6d4080f295dc41f792aa83d5524dfd95bac447a201876a7bc525d5149674cff50019a32fb0c4e4beb6a59bd0aa"
    },
    {
      "line": 2554,
      "relation": "directlyIncreases",
      "evidence": "Tau peptides containing phosphorylated S202, T205, and T396 were found only in Tg mice, supporting our results using AT8 and PHF1 antibodies",
      "citation": {
        "type": "PubMed",
        "reference": "14642273",
        "name": "Neuron",
        "title": "Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.",
        "volume": "40",
        "pages": "471-83",
        "date": "2003-10-30",
        "first": "Cruz JC",
        "last": "Tsai LH",
        "authors": [
          "Cruz JC",
          "Goldman JA",
          "Shih H",
          "Tsai LH",
          "Tseng HC"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "p25 transgenic mice": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 311,
      "target": 777,
      "key": "90b2ae46f3a8b4d4637fe5c9db5255ca207890e7e44136daf7535a89a1dd924653dd70690a81d92db266b4739048b2b451333dec5fb8af876144c9fae32851a8"
    },
    {
      "line": 2568,
      "relation": "increases",
      "evidence": "Tau peptides containing phosphorylated S202, T205, and T396 were found only in Tg mice, supporting our results using AT8 and PHF1 antibodies",
      "citation": {
        "type": "PubMed",
        "reference": "14642273",
        "name": "Neuron",
        "title": "Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.",
        "volume": "40",
        "pages": "471-83",
        "date": "2003-10-30",
        "first": "Cruz JC",
        "last": "Tsai LH",
        "authors": [
          "Cruz JC",
          "Goldman JA",
          "Shih H",
          "Tsai LH",
          "Tseng HC"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "p25 transgenic mice": true
        }
      },
      "source": 311,
      "target": 325,
      "key": "28dba1e1baaa55294e5c9205126f27bf064dd7962cae8bf21c1d963d8d307198f429f422f33e54bcc87e710336c18fc6f34fd5409aacb100f2754a2255f26606"
    },
    {
      "line": 2310,
      "relation": "equivalentTo",
      "evidence": "To perform its function, Cdk5 must bind to the neuron-specific regulatory subunit protein p35, which is beneficial for neuronal development (Tsai et al. 1994; Chae et al. 1997). However, truncation of p35 and conversion to p25 (Patrick et al. 1999) is found in the forebrain of rats after focal cerebral ischemia and in AD patients, and these alterations are deleterious to the brain",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "source": 402,
      "target": 311,
      "key": "0022eb873fe4da2ced5445d3be0eb3898fdccd933ad9d1f95556a94ee344dc5c2238ec76782d1767f13c2634a984e8a294c7b3933b5968ba5606f347eb7864a7"
    },
    {
      "line": 2320,
      "relation": "increases",
      "evidence": "We observed that 2VO leads to tau hyperphosphorylation at Ser202/Thr205, Ser262, Thr231, and Ser422 and to the conversion from cyclin-dependent kinase 5 (Cdk5)/p35 to Cdk5/p25 in rat hippocampi. ",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 100,
      "target": 878,
      "key": "336203a0717a14d2912fedbe232dda5f062b8a3c63174394e467b0e00c52ea37c94dec55343b6cdf79a1a2e0fe294e2c54cce7dbb0e147da2cb16817cfb0f8d6"
    },
    {
      "line": 2321,
      "relation": "increases",
      "evidence": "We observed that 2VO leads to tau hyperphosphorylation at Ser202/Thr205, Ser262, Thr231, and Ser422 and to the conversion from cyclin-dependent kinase 5 (Cdk5)/p35 to Cdk5/p25 in rat hippocampi. ",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 100,
      "target": 883,
      "key": "d1711ae68ba30840e5ebcba7eab2cccd6ea87e2051f13608cf6ec4000c2b3446d2077e8c720f435863fda7b19117e8b8b2598386c624f653de2773a80e876e06"
    },
    {
      "line": 2322,
      "relation": "increases",
      "evidence": "We observed that 2VO leads to tau hyperphosphorylation at Ser202/Thr205, Ser262, Thr231, and Ser422 and to the conversion from cyclin-dependent kinase 5 (Cdk5)/p35 to Cdk5/p25 in rat hippocampi. ",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 100,
      "target": 879,
      "key": "9d5d2cda47a447d738d50ab8f824ef877a33b6368836d9b770e60649022846849724f628fc5942efbce1ecd608aeeae4e02c06b63ba84438f74976c9ddc6d5f1"
    },
    {
      "line": 2323,
      "relation": "increases",
      "evidence": "We observed that 2VO leads to tau hyperphosphorylation at Ser202/Thr205, Ser262, Thr231, and Ser422 and to the conversion from cyclin-dependent kinase 5 (Cdk5)/p35 to Cdk5/p25 in rat hippocampi. ",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 100,
      "target": 884,
      "key": "63a83bc06c308d4c34c6e9249045a09fe85954fe8e7c990ee1e796837330a131d4752d4f256ea292dc5b9cfed8340f7af423cec4349829c56139b51b57b5b2ee"
    },
    {
      "line": 2324,
      "relation": "increases",
      "evidence": "We observed that 2VO leads to tau hyperphosphorylation at Ser202/Thr205, Ser262, Thr231, and Ser422 and to the conversion from cyclin-dependent kinase 5 (Cdk5)/p35 to Cdk5/p25 in rat hippocampi. ",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 100,
      "target": 882,
      "key": "5fafb62841aa9f380f95990cfa377ee394dfc4cf4d6a9f115985cf5c3c270554b4bb51da37288eb8d3fdaec16014ee07fd5df79e988d5a69bf964d7712d10a2d"
    },
    {
      "line": 2325,
      "relation": "increases",
      "evidence": "We observed that 2VO leads to tau hyperphosphorylation at Ser202/Thr205, Ser262, Thr231, and Ser422 and to the conversion from cyclin-dependent kinase 5 (Cdk5)/p35 to Cdk5/p25 in rat hippocampi. ",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 100,
      "target": 311,
      "key": "6f651a06fdef1af85e35ea58f27a3d293e7d71d581205ae7fa6db2bbf3c3dd9fc59681a71fe22319d00cc42cfc24b8ad5736bda23ee7473e71b14d20968eef95"
    },
    {
      "line": 2344,
      "relation": "increases",
      "evidence": "Chronic Brain hypoperfusion (CBH) elevates nuclear factor-kB (NF-kB), which binds with the promoter sequences of miR-195 and negatively regulates its expression. Down-regulated miR-195 up-regulates APP and BACE1 and increases Aß levels. Some Aß then enter the intracellular space and activate calpain, promoting the conversion of Cdk5/p35 to Cdk5/p25 and catalyzes the degradation of IkB (inhibitor of NF-?B)and directly phosphorylates Tau. Down-regulated miR-195 up-regulates p35, which provides the active substrates of p25",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 100,
      "target": 294,
      "key": "74ec80f1f2b3e79d5a7d12c64304f16679a6dbdd05bcf6f3ac742188a346e3c02f893025f9064d573b52b0869e1f8337fc61b75271a0dae292201a376c74df12"
    },
    {
      "line": 2331,
      "relation": "negativeCorrelation",
      "evidence": "Endogenous miR-195 was knocked down using over-expression of its antisense molecule (pre-AMO-miR-195) via a lentivirus (lenti-pre-AMO-miR-195); this knockdown increased the tau phosphorylation at Ser202/Thr205, Ser262, Thr231, Ser422, and the Cdk5/p25 activation, but over-expression of miR-195 using lenti-pre-miR-195 decreased the tau phosphorylation and Cdk5/p25 activation.",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 264,
      "target": 544,
      "key": "b91650ea7e1a167a0bc0db540dfac489a546d7dc6c7a8b46af41baaab11844e2b658ec8b751883f4a1044cf81df89aba5f836f26db7e614dd60e8e7d5c63865b"
    },
    {
      "line": 2332,
      "relation": "negativeCorrelation",
      "evidence": "Endogenous miR-195 was knocked down using over-expression of its antisense molecule (pre-AMO-miR-195) via a lentivirus (lenti-pre-AMO-miR-195); this knockdown increased the tau phosphorylation at Ser202/Thr205, Ser262, Thr231, Ser422, and the Cdk5/p25 activation, but over-expression of miR-195 using lenti-pre-miR-195 decreased the tau phosphorylation and Cdk5/p25 activation.",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 264,
      "target": 579,
      "key": "5becf7fd9cac5ea97cd9009be8b958157e89e4779b317a6774de8c471521b346eb6111643c3dac5b0893e5bdf25dacdf5d95edf526119eb165d85256ef52439f"
    },
    {
      "line": 2333,
      "relation": "negativeCorrelation",
      "evidence": "Endogenous miR-195 was knocked down using over-expression of its antisense molecule (pre-AMO-miR-195) via a lentivirus (lenti-pre-AMO-miR-195); this knockdown increased the tau phosphorylation at Ser202/Thr205, Ser262, Thr231, Ser422, and the Cdk5/p25 activation, but over-expression of miR-195 using lenti-pre-miR-195 decreased the tau phosphorylation and Cdk5/p25 activation.",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 264,
      "target": 557,
      "key": "081ad2edd10c2f6f09483e3921dc15b9777f94cad03326346b6d84a10e30d1e296fba07be50fd5b544e86c88639135a00d06c004978fb712daef6b081528c2ce"
    },
    {
      "line": 2334,
      "relation": "negativeCorrelation",
      "evidence": "Endogenous miR-195 was knocked down using over-expression of its antisense molecule (pre-AMO-miR-195) via a lentivirus (lenti-pre-AMO-miR-195); this knockdown increased the tau phosphorylation at Ser202/Thr205, Ser262, Thr231, Ser422, and the Cdk5/p25 activation, but over-expression of miR-195 using lenti-pre-miR-195 decreased the tau phosphorylation and Cdk5/p25 activation.",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 264,
      "target": 583,
      "key": "a8012c8ab22fd90e123abfbe69843e6aa3d5afd3f59064110437f6f613a18429ff1393146f528dfa692e44c01e7eefb0efd6b1f213d61f3888ab07d8e92dd49e"
    },
    {
      "line": 2335,
      "relation": "negativeCorrelation",
      "evidence": "Endogenous miR-195 was knocked down using over-expression of its antisense molecule (pre-AMO-miR-195) via a lentivirus (lenti-pre-AMO-miR-195); this knockdown increased the tau phosphorylation at Ser202/Thr205, Ser262, Thr231, Ser422, and the Cdk5/p25 activation, but over-expression of miR-195 using lenti-pre-miR-195 decreased the tau phosphorylation and Cdk5/p25 activation.",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 264,
      "target": 569,
      "key": "14c01558cbfe80920b50df2a0caaa88ab37a84d848a901987bf1042596e2fff982e2cc6aeca13e23a6c3c44972cb387ba7a35d3984618dd0ad884d777c02d055"
    },
    {
      "line": 2338,
      "relation": "increases",
      "evidence": "A dual luciferase reporter assay showed that miR-195 bound to the Cdk5r1 gene, which encodes p35 protein, in the 3'UTR and inhibited p35 expression.",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 264,
      "target": 223,
      "key": "b7aa9f5f09cda5fd04e08db50b7c5bc21941ca6a1cf1a7a2865dfbf7c198f22167fa095dfade9447f7ea20141a2b49a460b3cb98bb00cab167a750367909b7b6"
    },
    {
      "line": 2347,
      "relation": "negativeCorrelation",
      "evidence": "Chronic Brain hypoperfusion (CBH) elevates nuclear factor-kB (NF-kB), which binds with the promoter sequences of miR-195 and negatively regulates its expression. Down-regulated miR-195 up-regulates APP and BACE1 and increases Aß levels. Some Aß then enter the intracellular space and activate calpain, promoting the conversion of Cdk5/p35 to Cdk5/p25 and catalyzes the degradation of IkB (inhibitor of NF-?B)and directly phosphorylates Tau. Down-regulated miR-195 up-regulates p35, which provides the active substrates of p25",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 264,
      "target": 858,
      "key": "9ac8e56dface5553412f8c6d4cd0901ec1c00923183750784c724f03732cd1210d93efdde7c505845de81b3e344c50403d7a9d9fd30caa156671ca2e3e4637cc"
    },
    {
      "line": 2348,
      "relation": "negativeCorrelation",
      "evidence": "Chronic Brain hypoperfusion (CBH) elevates nuclear factor-kB (NF-kB), which binds with the promoter sequences of miR-195 and negatively regulates its expression. Down-regulated miR-195 up-regulates APP and BACE1 and increases Aß levels. Some Aß then enter the intracellular space and activate calpain, promoting the conversion of Cdk5/p35 to Cdk5/p25 and catalyzes the degradation of IkB (inhibitor of NF-?B)and directly phosphorylates Tau. Down-regulated miR-195 up-regulates p35, which provides the active substrates of p25",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 264,
      "target": 859,
      "key": "38a33b258fd5b183aabdf2a4e173d5a70c2ba82a48df2063642422e37b0e9fd0a01d6960c10091ad72fa0a500a8978539787bd9737a8b481b3406cdf399661ce"
    },
    {
      "line": 2349,
      "relation": "negativeCorrelation",
      "evidence": "Chronic Brain hypoperfusion (CBH) elevates nuclear factor-kB (NF-kB), which binds with the promoter sequences of miR-195 and negatively regulates its expression. Down-regulated miR-195 up-regulates APP and BACE1 and increases Aß levels. Some Aß then enter the intracellular space and activate calpain, promoting the conversion of Cdk5/p35 to Cdk5/p25 and catalyzes the degradation of IkB (inhibitor of NF-?B)and directly phosphorylates Tau. Down-regulated miR-195 up-regulates p35, which provides the active substrates of p25",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 264,
      "target": 11,
      "key": "62b4f79e19e676ab201d1d8adfceba1ae0c21354a2a1dca50cb12ca8a523bb621ef1e48bb0a2e4291c6c668d08e0b662eb8a4d984d218f75e36c26ed0d67ecea"
    },
    {
      "line": 2352,
      "relation": "negativeCorrelation",
      "evidence": "Chronic Brain hypoperfusion (CBH) elevates nuclear factor-kB (NF-kB), which binds with the promoter sequences of miR-195 and negatively regulates its expression. Down-regulated miR-195 up-regulates APP and BACE1 and increases Aß levels. Some Aß then enter the intracellular space and activate calpain, promoting the conversion of Cdk5/p35 to Cdk5/p25 and catalyzes the degradation of IkB (inhibitor of NF-?B)and directly phosphorylates Tau. Down-regulated miR-195 up-regulates p35, which provides the active substrates of p25",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 264,
      "target": 861,
      "key": "fdc64a1cfdbb7981cebb69b35062c2cb4375c0822476a6d1f21aa3eba9cb68fc3fb4d8869862ce11de1234b68f74eb64c9cf176b31c6f706a83c515a79211c36"
    },
    {
      "relation": "hasComponent",
      "source": 223,
      "target": 262,
      "key": "5248e63b10acf99c130ee9ec1492549b8dc5755832712f9e803e1fa4cbc419431489909d474e127ba9c97fa0d2f6715c64a230eeb1d2cf4dbd710a9cae498918"
    },
    {
      "relation": "hasComponent",
      "source": 223,
      "target": 264,
      "key": "0ba7307716f24f9d4b0d2303195b7db0f5a711a58a117ef4a8c1cec3371a3a5cb4a047de8ba0e1e5557a2ff49857935c57ac372df631b0b80d7c55d734c02da3"
    },
    {
      "line": 2339,
      "relation": "decreases",
      "evidence": "A dual luciferase reporter assay showed that miR-195 bound to the Cdk5r1 gene, which encodes p35 protein, in the 3'UTR and inhibited p35 expression.",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 223,
      "target": 944,
      "key": "cf52b6e1af2bae044a02500b9ffe1fd7918baace155d96c4362c5c4cfeb813cc2957b23c00b5e417ceab7a02360bfad19388934ac2d58e071238782e76c922c1"
    },
    {
      "line": 2345,
      "relation": "increases",
      "evidence": "Chronic Brain hypoperfusion (CBH) elevates nuclear factor-kB (NF-kB), which binds with the promoter sequences of miR-195 and negatively regulates its expression. Down-regulated miR-195 up-regulates APP and BACE1 and increases Aß levels. Some Aß then enter the intracellular space and activate calpain, promoting the conversion of Cdk5/p35 to Cdk5/p25 and catalyzes the degradation of IkB (inhibitor of NF-?B)and directly phosphorylates Tau. Down-regulated miR-195 up-regulates p35, which provides the active substrates of p25",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 294,
      "target": 222,
      "key": "62b9224024d413875625c549fd14701ff17c7363edcc8d29ed6c1125dde06b34ab79a3f28a323c22b787f35bf70858c7dee4ea15cb3f621295ea0a929cf40e91"
    },
    {
      "relation": "hasVariant",
      "source": 294,
      "target": 295,
      "key": "dde7e7b70a46fefc7e34ffc41841b5edb014955108367d93856e684762eeead97df21903bd5022e21d771f6c396029892b5d6419381bb5956297adf7cc180d1a"
    },
    {
      "relation": "hasComponent",
      "source": 222,
      "target": 261,
      "key": "9d6289422370ec3a776037730c646e9db3070673bb6634a1c0567ea77aa48fb0ab72d87922c08af01c9d0d62637eb97a934783093aeb4ff0c4439576fbcb2eeb"
    },
    {
      "relation": "hasComponent",
      "source": 222,
      "target": 294,
      "key": "e2d12bdd235bad06fc4c218dabef08e4ba2c91239fe3b46f665c6797a3ab7a877047db2914e9a259b03c2a236cfa4fade198c68eeaa9c088d5bcd0f3ddab8064"
    },
    {
      "line": 2346,
      "relation": "decreases",
      "evidence": "Chronic Brain hypoperfusion (CBH) elevates nuclear factor-kB (NF-kB), which binds with the promoter sequences of miR-195 and negatively regulates its expression. Down-regulated miR-195 up-regulates APP and BACE1 and increases Aß levels. Some Aß then enter the intracellular space and activate calpain, promoting the conversion of Cdk5/p35 to Cdk5/p25 and catalyzes the degradation of IkB (inhibitor of NF-?B)and directly phosphorylates Tau. Down-regulated miR-195 up-regulates p35, which provides the active substrates of p25",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 222,
      "target": 264,
      "key": "0b610e7cb9c9e9e142917066d0985e0a364ca799022a12355b0534101983a9d590e53bfda9014747dc04012f17925968a24048c11f0ca123f697715c594cb85f"
    },
    {
      "line": 2347,
      "relation": "negativeCorrelation",
      "evidence": "Chronic Brain hypoperfusion (CBH) elevates nuclear factor-kB (NF-kB), which binds with the promoter sequences of miR-195 and negatively regulates its expression. Down-regulated miR-195 up-regulates APP and BACE1 and increases Aß levels. Some Aß then enter the intracellular space and activate calpain, promoting the conversion of Cdk5/p35 to Cdk5/p25 and catalyzes the degradation of IkB (inhibitor of NF-?B)and directly phosphorylates Tau. Down-regulated miR-195 up-regulates p35, which provides the active substrates of p25",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 858,
      "target": 264,
      "key": "82e42b1b32b3b4c33cb695b6ad0318faabc8dcd3420d6b1da30bf7346b8c0cc3e96f83f209289a1fa880a76c05ea0dd21419445e37cf05abb6c066cbd9df1999"
    },
    {
      "line": 2348,
      "relation": "negativeCorrelation",
      "evidence": "Chronic Brain hypoperfusion (CBH) elevates nuclear factor-kB (NF-kB), which binds with the promoter sequences of miR-195 and negatively regulates its expression. Down-regulated miR-195 up-regulates APP and BACE1 and increases Aß levels. Some Aß then enter the intracellular space and activate calpain, promoting the conversion of Cdk5/p35 to Cdk5/p25 and catalyzes the degradation of IkB (inhibitor of NF-?B)and directly phosphorylates Tau. Down-regulated miR-195 up-regulates p35, which provides the active substrates of p25",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 859,
      "target": 264,
      "key": "f79cab73cb09c43d09ee259924d1a21bd65518c2df308005c7864d7d01dea47cbdf257dd7d326d95fa696a0fe9ead1f0b8e953f2bdbaa9cb303d6de09c5a52c9"
    },
    {
      "line": 2351,
      "relation": "positiveCorrelation",
      "evidence": "Chronic Brain hypoperfusion (CBH) elevates nuclear factor-kB (NF-kB), which binds with the promoter sequences of miR-195 and negatively regulates its expression. Down-regulated miR-195 up-regulates APP and BACE1 and increases Aß levels. Some Aß then enter the intracellular space and activate calpain, promoting the conversion of Cdk5/p35 to Cdk5/p25 and catalyzes the degradation of IkB (inhibitor of NF-?B)and directly phosphorylates Tau. Down-regulated miR-195 up-regulates p35, which provides the active substrates of p25",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 760,
      "target": 861,
      "key": "fea7c94ee24aa7c17c98741daafceae1a79d742ed6336e7157352c9e0ce9e55dcd5779a79aeec6bf94bb26106296c1a9b474b5acd511182d4e81e018010de1b2"
    },
    {
      "line": 2351,
      "relation": "positiveCorrelation",
      "evidence": "Chronic Brain hypoperfusion (CBH) elevates nuclear factor-kB (NF-kB), which binds with the promoter sequences of miR-195 and negatively regulates its expression. Down-regulated miR-195 up-regulates APP and BACE1 and increases Aß levels. Some Aß then enter the intracellular space and activate calpain, promoting the conversion of Cdk5/p35 to Cdk5/p25 and catalyzes the degradation of IkB (inhibitor of NF-?B)and directly phosphorylates Tau. Down-regulated miR-195 up-regulates p35, which provides the active substrates of p25",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 861,
      "target": 760,
      "key": "96519d7663237170367ab564af60e7b3d38558ab14c83edbd545c5c599e9e6d849d85d3233881055a3e8b1e057f3b0dd7ba74699706b6b81405225be76cf97d0"
    },
    {
      "line": 2352,
      "relation": "negativeCorrelation",
      "evidence": "Chronic Brain hypoperfusion (CBH) elevates nuclear factor-kB (NF-kB), which binds with the promoter sequences of miR-195 and negatively regulates its expression. Down-regulated miR-195 up-regulates APP and BACE1 and increases Aß levels. Some Aß then enter the intracellular space and activate calpain, promoting the conversion of Cdk5/p35 to Cdk5/p25 and catalyzes the degradation of IkB (inhibitor of NF-?B)and directly phosphorylates Tau. Down-regulated miR-195 up-regulates p35, which provides the active substrates of p25",
      "citation": {
        "type": "PubMed",
        "reference": "26118667",
        "name": "Journal of neurochemistry",
        "title": "Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.",
        "volume": "134",
        "pages": "1139-51",
        "date": "2015-09-01",
        "first": "Sun LH",
        "last": "Ai J",
        "authors": [
          "Ai J",
          "Ban T",
          "Bao YN",
          "Chen QX",
          "Hu XL",
          "Jiang XM",
          "Liu CD",
          "Pei SC",
          "Su XL",
          "Sun LH",
          "Sun LL",
          "Wang X",
          "Yan ML",
          "Zhao LJ",
          "Zong DK"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 861,
      "target": 264,
      "key": "04df1f15dcaa537466e8774ebaff9a781c2d07742780a7492aca93a586842cb384a86c3247d529e74d860a85c1f88df100b5acc5b6fca6e07f3dbf4392dd3e96"
    },
    {
      "line": 2361,
      "relation": "increases",
      "evidence": "The levels of CDK5, its regulatory subunits (p35 and p25) and calpain (including calpain1 and calpain2), but not GSK3ß, were significantly increased in E4FAD mice compared to E3FAD mice.",
      "citation": {
        "type": "PubMed",
        "reference": "27087442",
        "name": "Current Alzheimer research",
        "title": "APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.",
        "volume": "13",
        "pages": "1048-55",
        "date": "2016-01-01",
        "first": "Zhou M",
        "last": "Chen X",
        "authors": [
          "Chen X",
          "Collins N",
          "Dai X",
          "Huang T",
          "LaDu MJ",
          "Lin L",
          "Shen H",
          "Wei Z",
          "Wu X",
          "Xiao N",
          "York J",
          "Zhang J",
          "Zhou M",
          "Zhu Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "E4FAD mice": true
        }
      },
      "source": 309,
      "target": 777,
      "key": "7ac2c219db1b8e35007b32ddcd9ed34bb4030f2b898272681a2ca9410237dd29303a73dde5f14b8157dbecd183c9d53f42738522329bad283dbf418a8e22e4e4"
    },
    {
      "line": 2362,
      "relation": "increases",
      "evidence": "The levels of CDK5, its regulatory subunits (p35 and p25) and calpain (including calpain1 and calpain2), but not GSK3ß, were significantly increased in E4FAD mice compared to E3FAD mice.",
      "citation": {
        "type": "PubMed",
        "reference": "27087442",
        "name": "Current Alzheimer research",
        "title": "APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.",
        "volume": "13",
        "pages": "1048-55",
        "date": "2016-01-01",
        "first": "Zhou M",
        "last": "Chen X",
        "authors": [
          "Chen X",
          "Collins N",
          "Dai X",
          "Huang T",
          "LaDu MJ",
          "Lin L",
          "Shen H",
          "Wei Z",
          "Wu X",
          "Xiao N",
          "York J",
          "Zhang J",
          "Zhou M",
          "Zhu Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "E4FAD mice": true
        }
      },
      "source": 309,
      "target": 311,
      "key": "90b8ad7ed4d029604836e28aaac92e1140b285767f648b3768d18d46efa0f32fd12fc6b5f578703d529042e24cacd0b9e0f02581d80cdcca7c885b88e627eb31"
    },
    {
      "line": 2363,
      "relation": "increases",
      "evidence": "The levels of CDK5, its regulatory subunits (p35 and p25) and calpain (including calpain1 and calpain2), but not GSK3ß, were significantly increased in E4FAD mice compared to E3FAD mice.",
      "citation": {
        "type": "PubMed",
        "reference": "27087442",
        "name": "Current Alzheimer research",
        "title": "APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.",
        "volume": "13",
        "pages": "1048-55",
        "date": "2016-01-01",
        "first": "Zhou M",
        "last": "Chen X",
        "authors": [
          "Chen X",
          "Collins N",
          "Dai X",
          "Huang T",
          "LaDu MJ",
          "Lin L",
          "Shen H",
          "Wei Z",
          "Wu X",
          "Xiao N",
          "York J",
          "Zhang J",
          "Zhou M",
          "Zhu Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "E4FAD mice": true
        }
      },
      "source": 309,
      "target": 778,
      "key": "0c13fbc06fbcee0f9b38bd06cf8e654dc809cbd31fb530762f70527364b30ebd927e42b656111c79f86cc2f7e39c9f8a0974d1a6b566fd906e5cde5e03868d5f"
    },
    {
      "line": 2364,
      "relation": "increases",
      "evidence": "The levels of CDK5, its regulatory subunits (p35 and p25) and calpain (including calpain1 and calpain2), but not GSK3ß, were significantly increased in E4FAD mice compared to E3FAD mice.",
      "citation": {
        "type": "PubMed",
        "reference": "27087442",
        "name": "Current Alzheimer research",
        "title": "APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.",
        "volume": "13",
        "pages": "1048-55",
        "date": "2016-01-01",
        "first": "Zhou M",
        "last": "Chen X",
        "authors": [
          "Chen X",
          "Collins N",
          "Dai X",
          "Huang T",
          "LaDu MJ",
          "Lin L",
          "Shen H",
          "Wei Z",
          "Wu X",
          "Xiao N",
          "York J",
          "Zhang J",
          "Zhou M",
          "Zhu Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "E4FAD mice": true
        }
      },
      "source": 309,
      "target": 775,
      "key": "084f10f7bd5866636f7eaf0cff9eb56045d07eb5df8834972943ffab50b5db243e63e068a90cffca32013baa26d7dff1bd44d8236db5e72ff570761d9262f2ee"
    },
    {
      "line": 2365,
      "relation": "increases",
      "evidence": "The levels of CDK5, its regulatory subunits (p35 and p25) and calpain (including calpain1 and calpain2), but not GSK3ß, were significantly increased in E4FAD mice compared to E3FAD mice.",
      "citation": {
        "type": "PubMed",
        "reference": "27087442",
        "name": "Current Alzheimer research",
        "title": "APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.",
        "volume": "13",
        "pages": "1048-55",
        "date": "2016-01-01",
        "first": "Zhou M",
        "last": "Chen X",
        "authors": [
          "Chen X",
          "Collins N",
          "Dai X",
          "Huang T",
          "LaDu MJ",
          "Lin L",
          "Shen H",
          "Wei Z",
          "Wu X",
          "Xiao N",
          "York J",
          "Zhang J",
          "Zhou M",
          "Zhu Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "E4FAD mice": true
        }
      },
      "source": 309,
      "target": 776,
      "key": "d2955377e72bb60bb79a225450facb4ebab0b4e0a2276e92fc92924cf395f27a6d7362200f65c0509350f55cf404f9232d26c5b7d0181d1828244137e063d062"
    },
    {
      "line": 2366,
      "relation": "causesNoChange",
      "evidence": "The levels of CDK5, its regulatory subunits (p35 and p25) and calpain (including calpain1 and calpain2), but not GSK3ß, were significantly increased in E4FAD mice compared to E3FAD mice.",
      "citation": {
        "type": "PubMed",
        "reference": "27087442",
        "name": "Current Alzheimer research",
        "title": "APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.",
        "volume": "13",
        "pages": "1048-55",
        "date": "2016-01-01",
        "first": "Zhou M",
        "last": "Chen X",
        "authors": [
          "Chen X",
          "Collins N",
          "Dai X",
          "Huang T",
          "LaDu MJ",
          "Lin L",
          "Shen H",
          "Wei Z",
          "Wu X",
          "Xiao N",
          "York J",
          "Zhang J",
          "Zhou M",
          "Zhu Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "E4FAD mice": true
        }
      },
      "source": 309,
      "target": 794,
      "key": "9a3a346df95ba7fd86fbddb9e3e453730723f10d7aaf7947d5e591746ca6a0c7bc074957783c30ac8eb9804a58bc7efd74eb023fcbf45277562b2807edee613e"
    },
    {
      "line": 3798,
      "relation": "directlyDecreases",
      "evidence": "Our results indicated a significant down-regulation of PPP2R5E gene expression and reduction in PP2A activity by ApoE4 compared with ApoE3. This may also explain an elevated Tau phosphorylation in AD human brains that featured at least one ApoE4 allele.",
      "citation": {
        "type": "PubMed",
        "reference": "28720530",
        "name": "Molecular and cellular neurosciences",
        "title": "Downregulation of protein phosphatase 2A by apolipoprotein E: Implications for Alzheimer's disease.",
        "volume": "83",
        "pages": "83-91",
        "date": "2017-09-01",
        "first": "Theendakara V",
        "last": "Rao RV",
        "authors": [
          "Bredesen DE",
          "Rao RV",
          "Theendakara V"
        ]
      },
      "source": 309,
      "target": 660,
      "key": "cdd1df48338c6c109e9215d2d734deb6efac0fc195d65205fad427f020e2b4dbd6af72a557e5d946a1d77cf512ac816ff5da28657eb41bd9ef7098854d82a0f8"
    },
    {
      "line": 3800,
      "relation": "negativeCorrelation",
      "evidence": "Our results indicated a significant down-regulation of PPP2R5E gene expression and reduction in PP2A activity by ApoE4 compared with ApoE3. This may also explain an elevated Tau phosphorylation in AD human brains that featured at least one ApoE4 allele.",
      "citation": {
        "type": "PubMed",
        "reference": "28720530",
        "name": "Molecular and cellular neurosciences",
        "title": "Downregulation of protein phosphatase 2A by apolipoprotein E: Implications for Alzheimer's disease.",
        "volume": "83",
        "pages": "83-91",
        "date": "2017-09-01",
        "first": "Theendakara V",
        "last": "Rao RV",
        "authors": [
          "Bredesen DE",
          "Rao RV",
          "Theendakara V"
        ]
      },
      "source": 309,
      "target": 214,
      "key": "75c6312482a331c1c2b295809c79c67d63e2f54fa38cbcac116e3bf428e02d83d664d9101b7f7cefda606f7ab7fea3844927f77746ff0db22775bfa818a53021"
    },
    {
      "line": 2377,
      "relation": "negativeCorrelation",
      "evidence": "Our data showed that CDK5 knock down induced an increase in p35 protein levels and Rac activity in triple transgenic Alzheimer's mice, which correlated with the recovery of cognitive function; these findings confirm that increased p35 and active Rac are involved in neuroprotection. In summary, our data suggest that p35 acts as a mediator of Rho GTPase activity and contributes to the neuroprotection induced by CDK5 RNAi.",
      "citation": {
        "type": "PubMed",
        "reference": "27087442",
        "name": "Current Alzheimer research",
        "title": "APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.",
        "volume": "13",
        "pages": "1048-55",
        "date": "2016-01-01",
        "first": "Zhou M",
        "last": "Chen X",
        "authors": [
          "Chen X",
          "Collins N",
          "Dai X",
          "Huang T",
          "LaDu MJ",
          "Lin L",
          "Shen H",
          "Wei Z",
          "Wu X",
          "Xiao N",
          "York J",
          "Zhang J",
          "Zhou M",
          "Zhu Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 778,
      "target": 777,
      "key": "5648c3443f64f26539424531a8bdb598634f550b6af998c8980d087adb9bcad354593a595878ed83e365a2e9cb0dcc898df08530517aaab13cbc1a6c2951dfec"
    },
    {
      "line": 2380,
      "relation": "positiveCorrelation",
      "evidence": "Our data showed that CDK5 knock down induced an increase in p35 protein levels and Rac activity in triple transgenic Alzheimer's mice, which correlated with the recovery of cognitive function; these findings confirm that increased p35 and active Rac are involved in neuroprotection. In summary, our data suggest that p35 acts as a mediator of Rho GTPase activity and contributes to the neuroprotection induced by CDK5 RNAi.",
      "citation": {
        "type": "PubMed",
        "reference": "27087442",
        "name": "Current Alzheimer research",
        "title": "APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.",
        "volume": "13",
        "pages": "1048-55",
        "date": "2016-01-01",
        "first": "Zhou M",
        "last": "Chen X",
        "authors": [
          "Chen X",
          "Collins N",
          "Dai X",
          "Huang T",
          "LaDu MJ",
          "Lin L",
          "Shen H",
          "Wei Z",
          "Wu X",
          "Xiao N",
          "York J",
          "Zhang J",
          "Zhou M",
          "Zhu Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 778,
      "target": 168,
      "key": "00871e9ae46305494dc662d030ecea16d3c25de463bf2dfcae17ab4773314234c0ae8bac0e8f8b592952afb06005631dc263a5e0377163adae085738fd19d24a"
    },
    {
      "line": 2378,
      "relation": "negativeCorrelation",
      "evidence": "Our data showed that CDK5 knock down induced an increase in p35 protein levels and Rac activity in triple transgenic Alzheimer's mice, which correlated with the recovery of cognitive function; these findings confirm that increased p35 and active Rac are involved in neuroprotection. In summary, our data suggest that p35 acts as a mediator of Rho GTPase activity and contributes to the neuroprotection induced by CDK5 RNAi.",
      "citation": {
        "type": "PubMed",
        "reference": "27087442",
        "name": "Current Alzheimer research",
        "title": "APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.",
        "volume": "13",
        "pages": "1048-55",
        "date": "2016-01-01",
        "first": "Zhou M",
        "last": "Chen X",
        "authors": [
          "Chen X",
          "Collins N",
          "Dai X",
          "Huang T",
          "LaDu MJ",
          "Lin L",
          "Shen H",
          "Wei Z",
          "Wu X",
          "Xiao N",
          "York J",
          "Zhang J",
          "Zhou M",
          "Zhu Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 367,
      "target": 777,
      "key": "3787f3228141a84b83d1942eb9e58b1b1511b3d33ec9e0e6adb171eb2a6ac1d51eaa5945bbd8ee66e9921b77baad9aad662104e3fde4a1e601b5e8a504c2bac5"
    },
    {
      "line": 2381,
      "relation": "positiveCorrelation",
      "evidence": "Our data showed that CDK5 knock down induced an increase in p35 protein levels and Rac activity in triple transgenic Alzheimer's mice, which correlated with the recovery of cognitive function; these findings confirm that increased p35 and active Rac are involved in neuroprotection. In summary, our data suggest that p35 acts as a mediator of Rho GTPase activity and contributes to the neuroprotection induced by CDK5 RNAi.",
      "citation": {
        "type": "PubMed",
        "reference": "27087442",
        "name": "Current Alzheimer research",
        "title": "APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.",
        "volume": "13",
        "pages": "1048-55",
        "date": "2016-01-01",
        "first": "Zhou M",
        "last": "Chen X",
        "authors": [
          "Chen X",
          "Collins N",
          "Dai X",
          "Huang T",
          "LaDu MJ",
          "Lin L",
          "Shen H",
          "Wei Z",
          "Wu X",
          "Xiao N",
          "York J",
          "Zhang J",
          "Zhou M",
          "Zhu Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 367,
      "target": 168,
      "key": "b231ba2c663c5279d72a5304f0a6f0da2e54ee2209d41213eef803b93dbb05e16f48cfca850cbbd9b58c70bc24942459ef18a9a8845977c32623b1677e6cab08"
    },
    {
      "line": 2379,
      "relation": "negativeCorrelation",
      "evidence": "Our data showed that CDK5 knock down induced an increase in p35 protein levels and Rac activity in triple transgenic Alzheimer's mice, which correlated with the recovery of cognitive function; these findings confirm that increased p35 and active Rac are involved in neuroprotection. In summary, our data suggest that p35 acts as a mediator of Rho GTPase activity and contributes to the neuroprotection induced by CDK5 RNAi.",
      "citation": {
        "type": "PubMed",
        "reference": "27087442",
        "name": "Current Alzheimer research",
        "title": "APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.",
        "volume": "13",
        "pages": "1048-55",
        "date": "2016-01-01",
        "first": "Zhou M",
        "last": "Chen X",
        "authors": [
          "Chen X",
          "Collins N",
          "Dai X",
          "Huang T",
          "LaDu MJ",
          "Lin L",
          "Shen H",
          "Wei Z",
          "Wu X",
          "Xiao N",
          "York J",
          "Zhang J",
          "Zhou M",
          "Zhu Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 920,
      "target": 777,
      "key": "540847a1d12247992285855f462bd76541e0e13875563226fdcbfe8c0480213eee33c6d84737f659979b7a90614c14fcec9d74fbc0527a3acf125d75a7a546c2"
    },
    {
      "line": 2388,
      "relation": "increases",
      "evidence": "We demonstrated that the treatment of cultured hippocampal neurons with 125 µM glutamate for 20 min induced the cleavage of p35 to produce the p25 fragment 6 h after glutamate treatment, and the maximal levels of p25 were detected at 12 h (Fig. 1A), which is consistent with a peak in tau hyperphosphorylation (AT8).",
      "citation": {
        "type": "PubMed",
        "reference": "27087442",
        "name": "Current Alzheimer research",
        "title": "APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.",
        "volume": "13",
        "pages": "1048-55",
        "date": "2016-01-01",
        "first": "Zhou M",
        "last": "Chen X",
        "authors": [
          "Chen X",
          "Collins N",
          "Dai X",
          "Huang T",
          "LaDu MJ",
          "Lin L",
          "Shen H",
          "Wei Z",
          "Wu X",
          "Xiao N",
          "York J",
          "Zhang J",
          "Zhou M",
          "Zhu Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 19,
      "target": 311,
      "key": "5c7055574c74ab44cbfd9794b1ec941929fdfd8ab621405fc00baff7c6dc01659d0a89262a0afe34e59aea09d985b4b805fc12228048b0fd16fac223cbf8a41f"
    },
    {
      "line": 2409,
      "relation": "positiveCorrelation",
      "evidence": "In this study, we demonstrated that GLP-1RA could inhibit oxidative stress and repair mitochondrial damage in addition to decreasing tau hyperphosphorylation in PC12 cells treated with AGEs. Importantly, we first observed AGEs in the circulatory system could induce tau hyperphosphorylation after we injected AGEs (1μg/kg bodyweight) into the mice tail vein. We found GLP-1RA could promote mitochondrial biogenesis and antioxidant system via regulating peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) signaling pathway in vivo besides down-regulating the activity of glycogen synthase kinase 3β (GSK-3β) to reverse tau hyperphosphorylation directly.",
      "citation": {
        "type": "PubMed",
        "reference": "25987199",
        "name": "Neuroscience",
        "title": "Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: Studies in vivo and in vitro.",
        "volume": "300",
        "pages": "75-84",
        "date": "2015-08-06",
        "first": "An FM",
        "last": "Gao XD",
        "authors": [
          "An FM",
          "Chen S",
          "Gao XD",
          "Liu AR",
          "Wang Y",
          "Xu Z",
          "Yao WB",
          "Yin L"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 88,
      "target": 839,
      "key": "ce36cf4686cf3907f32c5255131512c35349001fdf168205373c2f64875c8f21c1a79bed4be3f5b7dd7cea3fa0a7f713098d5a2d5ce2d322bfb878ce0567a894"
    },
    {
      "line": 2754,
      "relation": "positiveCorrelation",
      "evidence": "Using transgenic Drosophila expressing human tau, we found that RNAi-mediated knockdown of milton or Miro, an adaptor protein essential for axonal transport of mitochondria, enhanced human tau-induced neurodegeneration. Tau phosphorylation at an AD-related site Ser262 increased with knockdown of milton or Miro; and partitioning defective-1 (PAR-1), the Drosophila homolog of mammalian microtubule affinity-regulating kinase, mediated this increase of tau phosphorylation. Tau phosphorylation at Ser262 has been reported to promote tau detachment from microtubules, and we found that the levels of microtubule-unbound free tau increased by milton knockdown. Blocking tau phosphorylation at Ser262 site by PAR-1 knockdown or by mutating the Ser262 site to unphosphorylatable alanine suppressed the enhancement of tau-induced neurodegeneration caused by milton knockdown. Furthermore, knockdown of milton or Miro increased the levels of active PAR-1.",
      "citation": {
        "type": "PubMed",
        "reference": "22952452",
        "name": "PLoS genetics",
        "title": "Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1.",
        "volume": "8",
        "pages": "e1002918",
        "date": "2012-01-01",
        "first": "Iijima-Ando K",
        "last": "Iijima KM",
        "authors": [
          "Iijima KM",
          "Iijima-Ando K",
          "Lu B",
          "Maruko-Otake A",
          "Ohtake Y",
          "Sekiya M",
          "Suzuki E"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 88,
      "target": 733,
      "key": "01d1bbcead75d2bcf0679d7684d5ada65cfef20e6c4a9991710a5cda42a7119f0f9d2f5f8b3bdc0272d83df63b04bb2af1e6954a69c243a7212b849749907a55"
    },
    {
      "line": 2755,
      "relation": "positiveCorrelation",
      "evidence": "Using transgenic Drosophila expressing human tau, we found that RNAi-mediated knockdown of milton or Miro, an adaptor protein essential for axonal transport of mitochondria, enhanced human tau-induced neurodegeneration. Tau phosphorylation at an AD-related site Ser262 increased with knockdown of milton or Miro; and partitioning defective-1 (PAR-1), the Drosophila homolog of mammalian microtubule affinity-regulating kinase, mediated this increase of tau phosphorylation. Tau phosphorylation at Ser262 has been reported to promote tau detachment from microtubules, and we found that the levels of microtubule-unbound free tau increased by milton knockdown. Blocking tau phosphorylation at Ser262 site by PAR-1 knockdown or by mutating the Ser262 site to unphosphorylatable alanine suppressed the enhancement of tau-induced neurodegeneration caused by milton knockdown. Furthermore, knockdown of milton or Miro increased the levels of active PAR-1.",
      "citation": {
        "type": "PubMed",
        "reference": "22952452",
        "name": "PLoS genetics",
        "title": "Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1.",
        "volume": "8",
        "pages": "e1002918",
        "date": "2012-01-01",
        "first": "Iijima-Ando K",
        "last": "Iijima KM",
        "authors": [
          "Iijima KM",
          "Iijima-Ando K",
          "Lu B",
          "Maruko-Otake A",
          "Ohtake Y",
          "Sekiya M",
          "Suzuki E"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 88,
      "target": 672,
      "key": "15db3467aa27be082c9600495857269d5df26ab7e866f64594acef551e39b6858e073709ad48523427026caa9cfc674fd92a1ee43ff036b468152e687bd1f99f"
    },
    {
      "line": 2880,
      "relation": "biomarkerFor",
      "evidence": "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24401760",
        "name": "Brain : a journal of neurology",
        "title": "Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.",
        "volume": "137",
        "pages": "537-52",
        "date": "2014-02-01",
        "first": "Stygelbout V",
        "last": "Brion JP",
        "authors": [
          "Ando K",
          "Brion JP",
          "D'Amico E",
          "Duyckaerts C",
          "Erneux C",
          "Jia Y",
          "Leroy K",
          "Luo HR",
          "Pouillon V",
          "Schurmans S",
          "Stygelbout V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "5xFAD mice": true
        }
      },
      "source": 516,
      "target": 908,
      "key": "940b0e05b160558b09d1d4c2441acbcdb476ce4b859b15981a68bf6f02d6d82ce28a4f7c69fb29ba75776faff9dc30ff47ba96a7d6d968f65f9cf05aa1e814a7"
    },
    {
      "line": 3260,
      "relation": "decreases",
      "evidence": "Overexpressed tau was hyperphosphorylated and resulted in decreased MT density and greater fragmentation. Using genetic screen, a histone deacetylase 6 (HDAC6) null mutation rescued tau-induced MT defects in both muscles and neurons. Genetic and pharmacological inhibition of the tubulin-specific deacetylase activity of HDAC6 indicates that the rescue effect may be mediated by increased MT acetylation.",
      "citation": {
        "type": "PubMed",
        "reference": "23487739",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila.",
        "volume": "110",
        "pages": "4604-9",
        "date": "2013-03-19",
        "first": "Xiong Y",
        "last": "Zhang YQ",
        "authors": [
          "Jin S",
          "Wu J",
          "Xiong Y",
          "Xu Z",
          "Zhang YQ",
          "Zhao K"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "source": 516,
      "target": 87,
      "key": "d27b6e592bf75a98eb0e8116483015e0f7f4569fe17d9af643c3a756b839f8479cb9c645dc06547f7baf69b5bd7435db3eae55ed833c216c6f410c7d59b62206"
    },
    {
      "line": 3436,
      "relation": "negativeCorrelation",
      "evidence": "These results are in accord with our previous study showing that Tau hyperphosphorylation is associated with a decrease in its O-GlcNAcylation level. A recent observation argues for the hypothesis that O-GlcNAcylation occurs first and that its modification reflects on the phosphorylation status.",
      "citation": {
        "type": "PubMed",
        "reference": "19732809",
        "name": "Biochimica et biophysica acta",
        "title": "Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease.",
        "volume": "1800",
        "pages": "67-79",
        "date": "2010-02-01",
        "first": "Lefebvre T",
        "last": "Michalski JC",
        "authors": [
          "Dehennaut V",
          "Drougat L",
          "Guinez C",
          "Lefebvre T",
          "Michalski JC",
          "Mir AM",
          "Mortuaire M",
          "Olivier S",
          "Vercoutter-Edouart AS"
        ]
      },
      "source": 516,
      "target": 513,
      "key": "e303bbb04098d1508e438882f77dfc61258cce8089a807f96f994401c57bff614648acbe06cb66102efacbce1eeba075922f7524dc37eb61b069e6d4b90f911b"
    },
    {
      "line": 2408,
      "relation": "increases",
      "evidence": "In this study, we demonstrated that GLP-1RA could inhibit oxidative stress and repair mitochondrial damage in addition to decreasing tau hyperphosphorylation in PC12 cells treated with AGEs. Importantly, we first observed AGEs in the circulatory system could induce tau hyperphosphorylation after we injected AGEs (1μg/kg bodyweight) into the mice tail vein. We found GLP-1RA could promote mitochondrial biogenesis and antioxidant system via regulating peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) signaling pathway in vivo besides down-regulating the activity of glycogen synthase kinase 3β (GSK-3β) to reverse tau hyperphosphorylation directly.",
      "citation": {
        "type": "PubMed",
        "reference": "25987199",
        "name": "Neuroscience",
        "title": "Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: Studies in vivo and in vitro.",
        "volume": "300",
        "pages": "75-84",
        "date": "2015-08-06",
        "first": "An FM",
        "last": "Gao XD",
        "authors": [
          "An FM",
          "Chen S",
          "Gao XD",
          "Liu AR",
          "Wang Y",
          "Xu Z",
          "Yao WB",
          "Yin L"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 791,
      "target": 839,
      "key": "c5cf9221c9aed3edc47d5364d9d1650db693f008a99751e2a972238605ce8d3f06d32c9e74ea855a982e5339981c36f47d44b730e91ef4e76df65b027d8b71b3"
    },
    {
      "line": 2410,
      "relation": "decreases",
      "evidence": "In this study, we demonstrated that GLP-1RA could inhibit oxidative stress and repair mitochondrial damage in addition to decreasing tau hyperphosphorylation in PC12 cells treated with AGEs. Importantly, we first observed AGEs in the circulatory system could induce tau hyperphosphorylation after we injected AGEs (1μg/kg bodyweight) into the mice tail vein. We found GLP-1RA could promote mitochondrial biogenesis and antioxidant system via regulating peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) signaling pathway in vivo besides down-regulating the activity of glycogen synthase kinase 3β (GSK-3β) to reverse tau hyperphosphorylation directly.",
      "citation": {
        "type": "PubMed",
        "reference": "25987199",
        "name": "Neuroscience",
        "title": "Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: Studies in vivo and in vitro.",
        "volume": "300",
        "pages": "75-84",
        "date": "2015-08-06",
        "first": "An FM",
        "last": "Gao XD",
        "authors": [
          "An FM",
          "Chen S",
          "Gao XD",
          "Liu AR",
          "Wang Y",
          "Xu Z",
          "Yao WB",
          "Yin L"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 791,
      "target": 794,
      "key": "e1b86628bf85db426425724d29c15482cf40e21a90b1f5283a14ef317f9abd448bb720c4835ffce1d0ed8446e6fd4a12d51a63c29d396181184a2e0c294d737a"
    },
    {
      "line": 2411,
      "relation": "decreases",
      "evidence": "In this study, we demonstrated that GLP-1RA could inhibit oxidative stress and repair mitochondrial damage in addition to decreasing tau hyperphosphorylation in PC12 cells treated with AGEs. Importantly, we first observed AGEs in the circulatory system could induce tau hyperphosphorylation after we injected AGEs (1μg/kg bodyweight) into the mice tail vein. We found GLP-1RA could promote mitochondrial biogenesis and antioxidant system via regulating peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) signaling pathway in vivo besides down-regulating the activity of glycogen synthase kinase 3β (GSK-3β) to reverse tau hyperphosphorylation directly.",
      "citation": {
        "type": "PubMed",
        "reference": "25987199",
        "name": "Neuroscience",
        "title": "Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: Studies in vivo and in vitro.",
        "volume": "300",
        "pages": "75-84",
        "date": "2015-08-06",
        "first": "An FM",
        "last": "Gao XD",
        "authors": [
          "An FM",
          "Chen S",
          "Gao XD",
          "Liu AR",
          "Wang Y",
          "Xu Z",
          "Yao WB",
          "Yin L"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 791,
      "target": 808,
      "key": "c93380eead8e680adcfb833814e89d275c1808ae253349d04553674d45c1b312d0ee72bae96ae4cef99711e6c32dfd1783b5b50116192db2381ee127b7ea00ea"
    },
    {
      "line": 2412,
      "relation": "negativeCorrelation",
      "evidence": "In this study, we demonstrated that GLP-1RA could inhibit oxidative stress and repair mitochondrial damage in addition to decreasing tau hyperphosphorylation in PC12 cells treated with AGEs. Importantly, we first observed AGEs in the circulatory system could induce tau hyperphosphorylation after we injected AGEs (1μg/kg bodyweight) into the mice tail vein. We found GLP-1RA could promote mitochondrial biogenesis and antioxidant system via regulating peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) signaling pathway in vivo besides down-regulating the activity of glycogen synthase kinase 3β (GSK-3β) to reverse tau hyperphosphorylation directly.",
      "citation": {
        "type": "PubMed",
        "reference": "25987199",
        "name": "Neuroscience",
        "title": "Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: Studies in vivo and in vitro.",
        "volume": "300",
        "pages": "75-84",
        "date": "2015-08-06",
        "first": "An FM",
        "last": "Gao XD",
        "authors": [
          "An FM",
          "Chen S",
          "Gao XD",
          "Liu AR",
          "Wang Y",
          "Xu Z",
          "Yao WB",
          "Yin L"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 791,
      "target": 123,
      "key": "c206f74b7751398dcdecebbafe2e0bdd03b2a51c712ef36362b1b610c2a352dabec2351ab65a856cdf35d048515d5320ba74d0c522dca2cfcac0443e0a3ac8bd"
    },
    {
      "line": 2409,
      "relation": "positiveCorrelation",
      "evidence": "In this study, we demonstrated that GLP-1RA could inhibit oxidative stress and repair mitochondrial damage in addition to decreasing tau hyperphosphorylation in PC12 cells treated with AGEs. Importantly, we first observed AGEs in the circulatory system could induce tau hyperphosphorylation after we injected AGEs (1μg/kg bodyweight) into the mice tail vein. We found GLP-1RA could promote mitochondrial biogenesis and antioxidant system via regulating peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) signaling pathway in vivo besides down-regulating the activity of glycogen synthase kinase 3β (GSK-3β) to reverse tau hyperphosphorylation directly.",
      "citation": {
        "type": "PubMed",
        "reference": "25987199",
        "name": "Neuroscience",
        "title": "Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: Studies in vivo and in vitro.",
        "volume": "300",
        "pages": "75-84",
        "date": "2015-08-06",
        "first": "An FM",
        "last": "Gao XD",
        "authors": [
          "An FM",
          "Chen S",
          "Gao XD",
          "Liu AR",
          "Wang Y",
          "Xu Z",
          "Yao WB",
          "Yin L"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 839,
      "target": 88,
      "key": "b4b653ef178c9975a6417ef83337c887c09623eca0860c2ec1d66ad39c374532f99b83879328760764dd0e35b02ce88262246dcce591f461a84c7ed41b4db1ac"
    },
    {
      "line": 3821,
      "relation": "negativeCorrelation",
      "evidence": "We found strong Tau hyperphosphorylation in brain samples from R6/2 and 140CAG Tg knock-in, associated with a significant reduction in the levels of Tau phosphatases (PP1, PP2A and PP2B), with no apparent involvement of major Tau kinases.",
      "citation": {
        "type": "PubMed",
        "reference": "25143394",
        "name": "Human molecular genetics",
        "title": "Mutant huntingtin alters Tau phosphorylation and subcellular distribution.",
        "volume": "24",
        "pages": "76-85",
        "date": "2015-01-01",
        "first": "Blum D",
        "last": "Outeiro TF",
        "authors": [
          "Basquin M",
          "Blum D",
          "Brouillet E",
          "Buée L",
          "Demeyer D",
          "Francelle L",
          "Gerhardt E",
          "Herrera F",
          "Mendes T",
          "Obriot H",
          "Outeiro TF",
          "Sergeant N"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "HD murine model": true
        }
      },
      "source": 808,
      "target": 840,
      "key": "d642884f70f3b339937463ed33e8efde0d71a0633807d99cb908e9474e497802e4aa69fd7f89514228de7ef28283dee1f74a9524a89109f72c944ba3ca1e2649"
    },
    {
      "line": 3822,
      "relation": "negativeCorrelation",
      "evidence": "We found strong Tau hyperphosphorylation in brain samples from R6/2 and 140CAG Tg knock-in, associated with a significant reduction in the levels of Tau phosphatases (PP1, PP2A and PP2B), with no apparent involvement of major Tau kinases.",
      "citation": {
        "type": "PubMed",
        "reference": "25143394",
        "name": "Human molecular genetics",
        "title": "Mutant huntingtin alters Tau phosphorylation and subcellular distribution.",
        "volume": "24",
        "pages": "76-85",
        "date": "2015-01-01",
        "first": "Blum D",
        "last": "Outeiro TF",
        "authors": [
          "Basquin M",
          "Blum D",
          "Brouillet E",
          "Buée L",
          "Demeyer D",
          "Francelle L",
          "Gerhardt E",
          "Herrera F",
          "Mendes T",
          "Obriot H",
          "Outeiro TF",
          "Sergeant N"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "HD murine model": true
        }
      },
      "source": 808,
      "target": 844,
      "key": "e0ff763c6689463397e100ffe7a11a2eb8437005ffecd1759c74c6fb7258acf6c1f4c27013168a53c893219772973826bd5ad3b2934c2771f23096a65e369286"
    },
    {
      "line": 3823,
      "relation": "negativeCorrelation",
      "evidence": "We found strong Tau hyperphosphorylation in brain samples from R6/2 and 140CAG Tg knock-in, associated with a significant reduction in the levels of Tau phosphatases (PP1, PP2A and PP2B), with no apparent involvement of major Tau kinases.",
      "citation": {
        "type": "PubMed",
        "reference": "25143394",
        "name": "Human molecular genetics",
        "title": "Mutant huntingtin alters Tau phosphorylation and subcellular distribution.",
        "volume": "24",
        "pages": "76-85",
        "date": "2015-01-01",
        "first": "Blum D",
        "last": "Outeiro TF",
        "authors": [
          "Basquin M",
          "Blum D",
          "Brouillet E",
          "Buée L",
          "Demeyer D",
          "Francelle L",
          "Gerhardt E",
          "Herrera F",
          "Mendes T",
          "Obriot H",
          "Outeiro TF",
          "Sergeant N"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "HD murine model": true
        }
      },
      "source": 808,
      "target": 841,
      "key": "517b4ddc1d0b542945b2a142942614b6cd8259a25286824d6ef5bb1e25b116e46bfe3ccd41dc450b541e43dd41b0dda0e6734ffb2749c1bdbd092c26eefb39c9"
    },
    {
      "line": 3835,
      "relation": "negativeCorrelation",
      "evidence": "PP2A expression decreased, whereas, PP1 and PP5 expression increased in lead-exposed rats. These results demonstrate that early postnatal exposure to lead decrease PP2A expression and induce tau hyperphosphorylation at several serine and threonine residues.",
      "citation": {
        "type": "PubMed",
        "reference": "23134599",
        "name": "Acta biologica Hungarica",
        "title": "Early postnatal lead exposure induces tau phosphorylation in the brain of young rats.",
        "volume": "63",
        "pages": "411-25",
        "date": "2012-12-01",
        "first": "Rahman A",
        "last": "Attur S",
        "authors": [
          "Al-Khaledi G",
          "Attur S",
          "Khan I",
          "Khan KM",
          "Rahman A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 808,
      "target": 897,
      "key": "a348f3302c4bbd7002fb4743e2ad8d9fafa3236bb0af2c74e26880be78c4bbdfb1a6ec6309759737953e87b2a1b86e05d66815bdb080eb763916fbc5ce18088f"
    },
    {
      "line": 2422,
      "relation": "increases",
      "evidence": "CRF-OE mice had significantly elevated tau-P compared to wild type (WT) mice at the AT8 (S202/T204), PHF-1 (S396/404), S262, and S422 sites. Treating CRF-OE mice with R121919 blocked phosphorylation at the AT8 (S202/T204) and PHF-1 (S396/404) sites, but not at the S262 and S422 sites and reduced phosphorylation of c-Jun N Terminal Kinase (JNK).",
      "citation": {
        "type": "PubMed",
        "reference": "25125464",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.",
        "volume": "43",
        "pages": "967-76",
        "date": "2015-01-01",
        "first": "Campbell SN",
        "last": "Rissman RA",
        "authors": [
          "Campbell SN",
          "Masliah E",
          "Monte L",
          "Rice KC",
          "Rissman RA",
          "Roe AD",
          "Taché Y",
          "Zhang C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 779,
      "target": 336,
      "key": "b46d5584eb2a0335d67c08be19ac54a3a74b53b68a1c102791a8c395b17f5480d189f18dd716891424e94b3f592695a6221477e45a1b8fe7cd05a4de7860931b"
    },
    {
      "line": 2423,
      "relation": "increases",
      "evidence": "CRF-OE mice had significantly elevated tau-P compared to wild type (WT) mice at the AT8 (S202/T204), PHF-1 (S396/404), S262, and S422 sites. Treating CRF-OE mice with R121919 blocked phosphorylation at the AT8 (S202/T204) and PHF-1 (S396/404) sites, but not at the S262 and S422 sites and reduced phosphorylation of c-Jun N Terminal Kinase (JNK).",
      "citation": {
        "type": "PubMed",
        "reference": "25125464",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.",
        "volume": "43",
        "pages": "967-76",
        "date": "2015-01-01",
        "first": "Campbell SN",
        "last": "Rissman RA",
        "authors": [
          "Campbell SN",
          "Masliah E",
          "Monte L",
          "Rice KC",
          "Rissman RA",
          "Roe AD",
          "Taché Y",
          "Zhang C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 779,
      "target": 117,
      "key": "39225281c6a36b71c1cb09fddb7daccdea0031451a5a0be5d51640028757d000f56d65b7812e4acbfef67ac4ae2dcd35a6a9995fdf2c812fdc014ef10a78f30d"
    },
    {
      "line": 2426,
      "relation": "positiveCorrelation",
      "evidence": "CRF-OE mice had significantly elevated tau-P compared to wild type (WT) mice at the AT8 (S202/T204), PHF-1 (S396/404), S262, and S422 sites. Treating CRF-OE mice with R121919 blocked phosphorylation at the AT8 (S202/T204) and PHF-1 (S396/404) sites, but not at the S262 and S422 sites and reduced phosphorylation of c-Jun N Terminal Kinase (JNK).",
      "citation": {
        "type": "PubMed",
        "reference": "25125464",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.",
        "volume": "43",
        "pages": "967-76",
        "date": "2015-01-01",
        "first": "Campbell SN",
        "last": "Rissman RA",
        "authors": [
          "Campbell SN",
          "Masliah E",
          "Monte L",
          "Rice KC",
          "Rissman RA",
          "Roe AD",
          "Taché Y",
          "Zhang C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 779,
      "target": 821,
      "key": "6386deb57b4239a01e49c3fc11d83b7eaec6912940ac896ef70d66e1e5d9cf61b141076fa35570ce0a4d19fe7ae9709d8ddf473994b53a82f993160576a843b6"
    },
    {
      "line": 2427,
      "relation": "positiveCorrelation",
      "evidence": "CRF-OE mice had significantly elevated tau-P compared to wild type (WT) mice at the AT8 (S202/T204), PHF-1 (S396/404), S262, and S422 sites. Treating CRF-OE mice with R121919 blocked phosphorylation at the AT8 (S202/T204) and PHF-1 (S396/404) sites, but not at the S262 and S422 sites and reduced phosphorylation of c-Jun N Terminal Kinase (JNK).",
      "citation": {
        "type": "PubMed",
        "reference": "25125464",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.",
        "volume": "43",
        "pages": "967-76",
        "date": "2015-01-01",
        "first": "Campbell SN",
        "last": "Rissman RA",
        "authors": [
          "Campbell SN",
          "Masliah E",
          "Monte L",
          "Rice KC",
          "Rissman RA",
          "Roe AD",
          "Taché Y",
          "Zhang C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 779,
      "target": 826,
      "key": "818d1e1081e903dbb5afc24ec230af50e443969bde920f8c3f7976b44d9157211de6dbec8510dcbba4875d41f9de35f16ed7e2bec1db6399b86139755e750fb7"
    },
    {
      "line": 2424,
      "relation": "positiveCorrelation",
      "evidence": "CRF-OE mice had significantly elevated tau-P compared to wild type (WT) mice at the AT8 (S202/T204), PHF-1 (S396/404), S262, and S422 sites. Treating CRF-OE mice with R121919 blocked phosphorylation at the AT8 (S202/T204) and PHF-1 (S396/404) sites, but not at the S262 and S422 sites and reduced phosphorylation of c-Jun N Terminal Kinase (JNK).",
      "citation": {
        "type": "PubMed",
        "reference": "25125464",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.",
        "volume": "43",
        "pages": "967-76",
        "date": "2015-01-01",
        "first": "Campbell SN",
        "last": "Rissman RA",
        "authors": [
          "Campbell SN",
          "Masliah E",
          "Monte L",
          "Rice KC",
          "Rissman RA",
          "Roe AD",
          "Taché Y",
          "Zhang C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 780,
      "target": 336,
      "key": "e3056ef7e5683858555f4690cb3dabcdb3f8eeda91cb973ed53063bd99d21b897fcbe139ff2d03adbb221c2f7c8b20ad81d1b37e07e9a83d3493b5685e7ae75f"
    },
    {
      "line": 2425,
      "relation": "positiveCorrelation",
      "evidence": "CRF-OE mice had significantly elevated tau-P compared to wild type (WT) mice at the AT8 (S202/T204), PHF-1 (S396/404), S262, and S422 sites. Treating CRF-OE mice with R121919 blocked phosphorylation at the AT8 (S202/T204) and PHF-1 (S396/404) sites, but not at the S262 and S422 sites and reduced phosphorylation of c-Jun N Terminal Kinase (JNK).",
      "citation": {
        "type": "PubMed",
        "reference": "25125464",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.",
        "volume": "43",
        "pages": "967-76",
        "date": "2015-01-01",
        "first": "Campbell SN",
        "last": "Rissman RA",
        "authors": [
          "Campbell SN",
          "Masliah E",
          "Monte L",
          "Rice KC",
          "Rissman RA",
          "Roe AD",
          "Taché Y",
          "Zhang C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 780,
      "target": 117,
      "key": "47f31773d705fcf38a6c272f6e13f5aef771a27076c4ff8cb1cca64e544fe7af2047c8fa0dfc2467246ac84bf3031f09d24021f8895251fe09ce56e61e62ab13"
    },
    {
      "line": 2428,
      "relation": "positiveCorrelation",
      "evidence": "CRF-OE mice had significantly elevated tau-P compared to wild type (WT) mice at the AT8 (S202/T204), PHF-1 (S396/404), S262, and S422 sites. Treating CRF-OE mice with R121919 blocked phosphorylation at the AT8 (S202/T204) and PHF-1 (S396/404) sites, but not at the S262 and S422 sites and reduced phosphorylation of c-Jun N Terminal Kinase (JNK).",
      "citation": {
        "type": "PubMed",
        "reference": "25125464",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.",
        "volume": "43",
        "pages": "967-76",
        "date": "2015-01-01",
        "first": "Campbell SN",
        "last": "Rissman RA",
        "authors": [
          "Campbell SN",
          "Masliah E",
          "Monte L",
          "Rice KC",
          "Rissman RA",
          "Roe AD",
          "Taché Y",
          "Zhang C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 780,
      "target": 802,
      "key": "470a3fc4f25c16745aacf19b6407fa828065c990f4273985b2ff5a678bf387088cb62850835294336a5c85789beeb4c1a51ddc3a528f5dc5d98a92d1f122c8be"
    },
    {
      "line": 2429,
      "relation": "positiveCorrelation",
      "evidence": "CRF-OE mice had significantly elevated tau-P compared to wild type (WT) mice at the AT8 (S202/T204), PHF-1 (S396/404), S262, and S422 sites. Treating CRF-OE mice with R121919 blocked phosphorylation at the AT8 (S202/T204) and PHF-1 (S396/404) sites, but not at the S262 and S422 sites and reduced phosphorylation of c-Jun N Terminal Kinase (JNK).",
      "citation": {
        "type": "PubMed",
        "reference": "25125464",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.",
        "volume": "43",
        "pages": "967-76",
        "date": "2015-01-01",
        "first": "Campbell SN",
        "last": "Rissman RA",
        "authors": [
          "Campbell SN",
          "Masliah E",
          "Monte L",
          "Rice KC",
          "Rissman RA",
          "Roe AD",
          "Taché Y",
          "Zhang C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 780,
      "target": 112,
      "key": "3a165aebae398c3c633866f90b91ae2e4f71f08452643f0a70949473011786243787d48564f758d1d31f65f61d424fa06df084b9766a71cdf423fd2cae806541"
    },
    {
      "line": 2427,
      "relation": "positiveCorrelation",
      "evidence": "CRF-OE mice had significantly elevated tau-P compared to wild type (WT) mice at the AT8 (S202/T204), PHF-1 (S396/404), S262, and S422 sites. Treating CRF-OE mice with R121919 blocked phosphorylation at the AT8 (S202/T204) and PHF-1 (S396/404) sites, but not at the S262 and S422 sites and reduced phosphorylation of c-Jun N Terminal Kinase (JNK).",
      "citation": {
        "type": "PubMed",
        "reference": "25125464",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.",
        "volume": "43",
        "pages": "967-76",
        "date": "2015-01-01",
        "first": "Campbell SN",
        "last": "Rissman RA",
        "authors": [
          "Campbell SN",
          "Masliah E",
          "Monte L",
          "Rice KC",
          "Rissman RA",
          "Roe AD",
          "Taché Y",
          "Zhang C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 826,
      "target": 779,
      "key": "2b4b52d4c60bc016e6c988490b29af9aac76377b8e547f19f341d1f7eca7f977b2772d9d7888a1db6c41a11fe744574a9eb7a33cccd4727c82bb13f074e64939"
    },
    {
      "line": 2428,
      "relation": "positiveCorrelation",
      "evidence": "CRF-OE mice had significantly elevated tau-P compared to wild type (WT) mice at the AT8 (S202/T204), PHF-1 (S396/404), S262, and S422 sites. Treating CRF-OE mice with R121919 blocked phosphorylation at the AT8 (S202/T204) and PHF-1 (S396/404) sites, but not at the S262 and S422 sites and reduced phosphorylation of c-Jun N Terminal Kinase (JNK).",
      "citation": {
        "type": "PubMed",
        "reference": "25125464",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.",
        "volume": "43",
        "pages": "967-76",
        "date": "2015-01-01",
        "first": "Campbell SN",
        "last": "Rissman RA",
        "authors": [
          "Campbell SN",
          "Masliah E",
          "Monte L",
          "Rice KC",
          "Rissman RA",
          "Roe AD",
          "Taché Y",
          "Zhang C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 802,
      "target": 780,
      "key": "294d0ca7829f7a3dfad96b196c7ada262b0b2981fb5c969850da386f9f03d7923a9681ab09cb05b4789d9c60e744159a82d25ed4f349a4d6b6b26d12fa06840e"
    },
    {
      "line": 2440,
      "relation": "positiveCorrelation",
      "evidence": "Analysis of synaptosomes revealed that FynCA accumulated at high levels in the spine, resulting in increased levels of the NMDA receptor subunit NR2b phosphorylated at residue Y1472. Tau was strongly phosphorylated at the AT8 epitope S202/T205 as shown by Western blot and immunohistochemistry indicating that an increased tyrosine kinase activity of Fyn has down-stream consequences for serine/threonine-directed phosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "25125464",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.",
        "volume": "43",
        "pages": "967-76",
        "date": "2015-01-01",
        "first": "Campbell SN",
        "last": "Rissman RA",
        "authors": [
          "Campbell SN",
          "Masliah E",
          "Monte L",
          "Rice KC",
          "Rissman RA",
          "Roe AD",
          "Taché Y",
          "Zhang C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 788,
      "target": 82,
      "key": "72c218f464c3b452c6363ccd2d99e0ba60de7bee11c4572c26b3e724beaa7b7cec0618f8e4cdf9f18a72cd0901438622128557663e76ba10d1d024d4dd291a8a"
    },
    {
      "line": 2441,
      "relation": "increases",
      "evidence": "Analysis of synaptosomes revealed that FynCA accumulated at high levels in the spine, resulting in increased levels of the NMDA receptor subunit NR2b phosphorylated at residue Y1472. Tau was strongly phosphorylated at the AT8 epitope S202/T205 as shown by Western blot and immunohistochemistry indicating that an increased tyrosine kinase activity of Fyn has down-stream consequences for serine/threonine-directed phosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "25125464",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.",
        "volume": "43",
        "pages": "967-76",
        "date": "2015-01-01",
        "first": "Campbell SN",
        "last": "Rissman RA",
        "authors": [
          "Campbell SN",
          "Masliah E",
          "Monte L",
          "Rice KC",
          "Rissman RA",
          "Roe AD",
          "Taché Y",
          "Zhang C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 788,
      "target": 793,
      "key": "6b41a58672a260ddbc9e40bb4da48bec4be672b5c7e660f950721dc13c4747224edc94f1e82236b7d97b4f0e6f47c2ee1cc4368e1e40f2d3cf57dfed32fde5e0"
    },
    {
      "line": 2442,
      "relation": "increases",
      "evidence": "Analysis of synaptosomes revealed that FynCA accumulated at high levels in the spine, resulting in increased levels of the NMDA receptor subunit NR2b phosphorylated at residue Y1472. Tau was strongly phosphorylated at the AT8 epitope S202/T205 as shown by Western blot and immunohistochemistry indicating that an increased tyrosine kinase activity of Fyn has down-stream consequences for serine/threonine-directed phosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "25125464",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.",
        "volume": "43",
        "pages": "967-76",
        "date": "2015-01-01",
        "first": "Campbell SN",
        "last": "Rissman RA",
        "authors": [
          "Campbell SN",
          "Masliah E",
          "Monte L",
          "Rice KC",
          "Rissman RA",
          "Roe AD",
          "Taché Y",
          "Zhang C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 788,
      "target": 336,
      "key": "e7154d4ea25094592b28ea672f480a4ab29b58c897a99d07e2ef9d02e77db1a29f94f6261e95b094300364200580c71827072d717967b9113601fd813a30b641"
    },
    {
      "line": 2440,
      "relation": "positiveCorrelation",
      "evidence": "Analysis of synaptosomes revealed that FynCA accumulated at high levels in the spine, resulting in increased levels of the NMDA receptor subunit NR2b phosphorylated at residue Y1472. Tau was strongly phosphorylated at the AT8 epitope S202/T205 as shown by Western blot and immunohistochemistry indicating that an increased tyrosine kinase activity of Fyn has down-stream consequences for serine/threonine-directed phosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "25125464",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.",
        "volume": "43",
        "pages": "967-76",
        "date": "2015-01-01",
        "first": "Campbell SN",
        "last": "Rissman RA",
        "authors": [
          "Campbell SN",
          "Masliah E",
          "Monte L",
          "Rice KC",
          "Rissman RA",
          "Roe AD",
          "Taché Y",
          "Zhang C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 82,
      "target": 788,
      "key": "76d2d2e3c5d815c3b9beb3c50ca33cd53824d114177e2f131864e0da2f20cb1617fc8b7f2512ff250815f1f2950fca9182f70d9d02c3eee917aa2120fc854361"
    },
    {
      "line": 2452,
      "relation": "directlyIncreases",
      "evidence": "The single kinase and sequential kinase-catalyzed Fc-phosphorylations points to dramatic changes around the Fc group in the Fc-phosphorylated tau films. Additional surface characterization of the Fc-tau films by time-of-flight secondary ion-mass spectrometry and X-ray photoelectron spectroscopy revealed that Fc-phosphorylations influence the tau orientation and conformation on surfaces.",
      "citation": {
        "type": "PubMed",
        "reference": "23687953",
        "name": "ACS chemical neuroscience",
        "title": "Electrochemical investigations into kinase-catalyzed transformations of tau protein.",
        "volume": "4",
        "pages": "1194-203",
        "date": "2013-08-21",
        "first": "Rains MK",
        "last": "Kraatz HB",
        "authors": [
          "Freeman D",
          "Kraatz HB",
          "Martić S",
          "Rains MK"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 370,
      "target": 591,
      "key": "c4d6fc3fede337b336413eb4dbdbfec018f29d22edbe3ead5c9e64bae57e66bb78658d441c5b6383e26ca915f40120d650bedd33f18e72d6f675cc59c0250bc9"
    },
    {
      "line": 2468,
      "relation": "equivalentTo",
      "evidence": "Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift in mobility as a result of phosphorylation-like changes, we conclude that they have the characteristics of hyperphosphorylated tau. These mutants will therefore be referred to as pseudo-hyperphosphorylated tau throughout the manuscript. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.",
      "citation": {
        "type": "PubMed",
        "reference": "19459590",
        "name": "Biochemistry",
        "title": "Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.",
        "volume": "48",
        "pages": "6002-11",
        "date": "2009-06-30",
        "first": "Sun Q",
        "last": "Gamblin TC",
        "authors": [
          "Gamblin TC",
          "Sun Q"
        ]
      },
      "source": 337,
      "target": 544,
      "key": "03309c5ce3bbfb4809fc4c888c2a1c33f32708df1ca79e6def9f8240919e159ee9bbbbc33253b01804696aa7632ac86ffac166538e618c58ab5e76bfa4c58db2"
    },
    {
      "line": 2471,
      "relation": "decreases",
      "evidence": "Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift in mobility as a result of phosphorylation-like changes, we conclude that they have the characteristics of hyperphosphorylated tau. These mutants will therefore be referred to as pseudo-hyperphosphorylated tau throughout the manuscript. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.",
      "citation": {
        "type": "PubMed",
        "reference": "19459590",
        "name": "Biochemistry",
        "title": "Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.",
        "volume": "48",
        "pages": "6002-11",
        "date": "2009-06-30",
        "first": "Sun Q",
        "last": "Gamblin TC",
        "authors": [
          "Gamblin TC",
          "Sun Q"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 337,
      "target": 486,
      "key": "2b51dcc7a2fe841218d980d2ce76c773058a9e693a7a3b4e429e35acea4574ad1d883e1d747f7fb70a55868f1ef3b6d0f500b25b4dae4d59dbb994ef970280e7"
    },
    {
      "line": 2482,
      "relation": "equivalentTo",
      "evidence": "Hence, LTD-inducing NMDA receptor activation leads to an increase in tau phosphorylation at sites PHF-1, AT180, as well as AT8 and to a reduction at AT100.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 115,
      "target": 583,
      "key": "a769955d9abae84ee3004af2bfde1c888a32cc62a1228a962e9bbe347525f71623be38329f6d9f9fafa65dbbc5d06ea3ca1266ba6a27b5ac89e7cdb380e6cf9c"
    },
    {
      "line": 2544,
      "relation": "positiveCorrelation",
      "evidence": "We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia. In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes. Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3α/β at tyrosine 279/216 also showed an intense rather than moderate AT8 (phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with fibrillar tau pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "23294633",
        "name": "Neurobiology of aging",
        "title": "Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.",
        "volume": "34",
        "pages": "1369-79",
        "date": "2013-05-01",
        "first": "Köhler C",
        "last": "Götz J",
        "authors": [
          "Dinekov M",
          "Götz J",
          "Köhler C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "pR5 mice": true
        }
      },
      "source": 114,
      "target": 625,
      "key": "172cc608dfed0fbced30a2fb487b53d61ce25ec950ea476e75da65cdba7e23c39c32af09ae73a89453568cf7c8a91efe8da7aeb5b0bcb0234667e2e3bc6a8efc"
    },
    {
      "line": 2484,
      "relation": "partOf",
      "evidence": "Hence, LTD-inducing NMDA receptor activation leads to an increase in tau phosphorylation at sites PHF-1, AT180, as well as AT8 and to a reduction at AT100.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 581,
      "target": 114,
      "key": "bed900c7540ee5476309fda9aa94a94dd16c69de3b7057a3208632a34bd708dc7b8e9094f27531e9aba51288f65f21f8a81d9a8e228ea5fbc963de8a1364290d"
    },
    {
      "line": 2485,
      "relation": "partOf",
      "evidence": "Hence, LTD-inducing NMDA receptor activation leads to an increase in tau phosphorylation at sites PHF-1, AT180, as well as AT8 and to a reduction at AT100.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 550,
      "target": 114,
      "key": "1d27ba55ee8f409e9a098e7c3187719e52463a8aab63be4766f7ac9e4c226a12e3934bc262dcdc6333cc023b8f4d57540077dc3d63264cbe097eddec94fb48bc"
    },
    {
      "relation": "hasComponent",
      "source": 237,
      "target": 450,
      "key": "9791fed951cdcad3becdcad58f443f6ee8253bb367584217e822f216db7c3e24d1bf61e776d43bc57648385805cf1cc066f1226160bfdd1bc9838789f3747265"
    },
    {
      "relation": "hasComponent",
      "source": 237,
      "target": 803,
      "key": "a777bd3ec1c7016891c29f9a683896cd747a1636c56bd9f2ff0f2b1375aad79dfae2431666fb9d56332f2994c90498ef609853d3862ea6ce1aae828011d1bc61"
    },
    {
      "line": 2504,
      "relation": "directlyDecreases",
      "evidence": "Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Research_Model": {
          "rTg4510 mice": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 119,
      "target": 272,
      "key": "5516efee9ae6370a04a7788b86195f405a5b5063270c67e3f47481cbc586d35f52c11fe5b5d870e19290e59c5f692a2a37b826f74e0cad18c8444d8a1992d999"
    },
    {
      "line": 2505,
      "relation": "increases",
      "evidence": "Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological tau species without altering the phosphorylation of non-pathological tau.",
      "citation": {
        "type": "PubMed",
        "reference": "22833681",
        "name": "The Journal of biological chemistry",
        "title": "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.",
        "volume": "287",
        "pages": "32040-53",
        "date": "2012-09-14",
        "first": "Mondragón-Rodríguez S",
        "last": "Boehm J",
        "authors": [
          "Boehm J",
          "Bourgeois C",
          "Dudilot A",
          "Lauzon M",
          "Leclerc N",
          "Mondragón-Rodríguez S",
          "Trillaud-Doppia E"
        ]
      },
      "annotations": {
        "Research_Model": {
          "rTg4510 mice": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 272,
      "target": 807,
      "key": "00c8fe96e6c3b874a424b0942fc995ff89d5911ac13c759b3f0ac6dde7dcd793f869f16aa807a6126159ccafdf2c08cb8d73a050ff7b27bbf6bc9970ca716ffd"
    },
    {
      "line": 2523,
      "relation": "positiveCorrelation",
      "evidence": "We developed a transgenic mouse, named TPR50, harboring human P301S tau. Tau phosphorylation in the hippocampus of TPR50 mice increased with age, particularly at S202/T205. Therefore, cognitive dysfunction in TPR50 mice may result from early MT dysfunction and impaired axonal transport rather than accumulation of insoluble tau and neurodegeneration.",
      "citation": {
        "type": "PubMed",
        "reference": "24406748",
        "name": "Neuroscience research",
        "title": "Early-onset cognitive deficits and axonal transport dysfunction in P301S mutant tau transgenic mice.",
        "volume": "80",
        "pages": "76-85",
        "date": "2014-03-01",
        "first": "Onishi T",
        "last": "Iwashita H",
        "authors": [
          "Hattori M",
          "Horiguchi T",
          "Iwashita H",
          "Matsumoto Y",
          "Nakamura K",
          "Obayashi Y",
          "Onishi T",
          "Yano T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "TPR50 mice": true
        }
      },
      "source": 626,
      "target": 544,
      "key": "3405409837116ad0d681170e553167780a4ed440da741cdfbc630ac8992ce5fbca633b55d0a82dd3b3eb57f7f43f69e616f8e6bce29f087e5f62b2092bcc1c44"
    },
    {
      "line": 2524,
      "relation": "positiveCorrelation",
      "evidence": "We developed a transgenic mouse, named TPR50, harboring human P301S tau. Tau phosphorylation in the hippocampus of TPR50 mice increased with age, particularly at S202/T205. Therefore, cognitive dysfunction in TPR50 mice may result from early MT dysfunction and impaired axonal transport rather than accumulation of insoluble tau and neurodegeneration.",
      "citation": {
        "type": "PubMed",
        "reference": "24406748",
        "name": "Neuroscience research",
        "title": "Early-onset cognitive deficits and axonal transport dysfunction in P301S mutant tau transgenic mice.",
        "volume": "80",
        "pages": "76-85",
        "date": "2014-03-01",
        "first": "Onishi T",
        "last": "Iwashita H",
        "authors": [
          "Hattori M",
          "Horiguchi T",
          "Iwashita H",
          "Matsumoto Y",
          "Nakamura K",
          "Obayashi Y",
          "Onishi T",
          "Yano T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "TPR50 mice": true
        }
      },
      "source": 626,
      "target": 579,
      "key": "bab1557e73185d3c0d333839df20cb3c445937c3682e17ca683120bf15848689473c130b154892f125c6f7372837b40b2ea617721cac7190741a2f1be9946e3f"
    },
    {
      "line": 2525,
      "relation": "increases",
      "evidence": "We developed a transgenic mouse, named TPR50, harboring human P301S tau. Tau phosphorylation in the hippocampus of TPR50 mice increased with age, particularly at S202/T205. Therefore, cognitive dysfunction in TPR50 mice may result from early MT dysfunction and impaired axonal transport rather than accumulation of insoluble tau and neurodegeneration.",
      "citation": {
        "type": "PubMed",
        "reference": "24406748",
        "name": "Neuroscience research",
        "title": "Early-onset cognitive deficits and axonal transport dysfunction in P301S mutant tau transgenic mice.",
        "volume": "80",
        "pages": "76-85",
        "date": "2014-03-01",
        "first": "Onishi T",
        "last": "Iwashita H",
        "authors": [
          "Hattori M",
          "Horiguchi T",
          "Iwashita H",
          "Matsumoto Y",
          "Nakamura K",
          "Obayashi Y",
          "Onishi T",
          "Yano T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "TPR50 mice": true
        }
      },
      "source": 626,
      "target": 913,
      "key": "512ff60b1fbe02eb03e59feee88ea0a868520634a95b1308c6a70105aeb13d5e1afed4adbc7e975795c2d2e61edfc65611aba565e427cf7640633e1fc8eb3e22"
    },
    {
      "line": 2526,
      "relation": "decreases",
      "evidence": "We developed a transgenic mouse, named TPR50, harboring human P301S tau. Tau phosphorylation in the hippocampus of TPR50 mice increased with age, particularly at S202/T205. Therefore, cognitive dysfunction in TPR50 mice may result from early MT dysfunction and impaired axonal transport rather than accumulation of insoluble tau and neurodegeneration.",
      "citation": {
        "type": "PubMed",
        "reference": "24406748",
        "name": "Neuroscience research",
        "title": "Early-onset cognitive deficits and axonal transport dysfunction in P301S mutant tau transgenic mice.",
        "volume": "80",
        "pages": "76-85",
        "date": "2014-03-01",
        "first": "Onishi T",
        "last": "Iwashita H",
        "authors": [
          "Hattori M",
          "Horiguchi T",
          "Iwashita H",
          "Matsumoto Y",
          "Nakamura K",
          "Obayashi Y",
          "Onishi T",
          "Yano T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "TPR50 mice": true
        }
      },
      "source": 626,
      "target": 175,
      "key": "d293517f2c9aa2e2a470dbc56b0eb07c361186f1bda71d894b7da8e70bce240983633f1da5f900a61963f5e2a3b92528eca331f8fb9c1a66283a218f4548f5f0"
    },
    {
      "line": 2527,
      "relation": "decreases",
      "evidence": "We developed a transgenic mouse, named TPR50, harboring human P301S tau. Tau phosphorylation in the hippocampus of TPR50 mice increased with age, particularly at S202/T205. Therefore, cognitive dysfunction in TPR50 mice may result from early MT dysfunction and impaired axonal transport rather than accumulation of insoluble tau and neurodegeneration.",
      "citation": {
        "type": "PubMed",
        "reference": "24406748",
        "name": "Neuroscience research",
        "title": "Early-onset cognitive deficits and axonal transport dysfunction in P301S mutant tau transgenic mice.",
        "volume": "80",
        "pages": "76-85",
        "date": "2014-03-01",
        "first": "Onishi T",
        "last": "Iwashita H",
        "authors": [
          "Hattori M",
          "Horiguchi T",
          "Iwashita H",
          "Matsumoto Y",
          "Nakamura K",
          "Obayashi Y",
          "Onishi T",
          "Yano T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "TPR50 mice": true
        }
      },
      "source": 626,
      "target": 920,
      "key": "54a61bcdc765775292b04b86e7a711d47e2dc79957ae8f5e75198419a775375b71df32e5e4759a1a8877907487f7f774e73cd6457efed5e0effba15fc2697610"
    },
    {
      "line": 2538,
      "relation": "positiveCorrelation",
      "evidence": "We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia. In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes. Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3α/β at tyrosine 279/216 also showed an intense rather than moderate AT8 (phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with fibrillar tau pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "23294633",
        "name": "Neurobiology of aging",
        "title": "Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.",
        "volume": "34",
        "pages": "1369-79",
        "date": "2013-05-01",
        "first": "Köhler C",
        "last": "Götz J",
        "authors": [
          "Dinekov M",
          "Götz J",
          "Köhler C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "pR5 mice": true
        }
      },
      "source": 796,
      "target": 625,
      "key": "e773e2bef54ea24cfaaacb1b4854a292b8894744659412921f0ed5647755193402704a2f3ec7bf32aeaa19d64f0744a47f7880f88a18740cdd38cb51382cebc2"
    },
    {
      "line": 2540,
      "relation": "increases",
      "evidence": "We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia. In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes. Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3α/β at tyrosine 279/216 also showed an intense rather than moderate AT8 (phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with fibrillar tau pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "23294633",
        "name": "Neurobiology of aging",
        "title": "Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.",
        "volume": "34",
        "pages": "1369-79",
        "date": "2013-05-01",
        "first": "Köhler C",
        "last": "Götz J",
        "authors": [
          "Dinekov M",
          "Götz J",
          "Köhler C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "pR5 mice": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 796,
      "target": 794,
      "key": "dbde04124b844aef02c87cfb99a35aa2bad0ed42a1949aa83fc13a8d6f7f23cd68f321256098c86b0939aa3085571ef51439983b4a7d689099fca4194c69ce0d"
    },
    {
      "line": 2539,
      "relation": "positiveCorrelation",
      "evidence": "We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia. In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes. Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3α/β at tyrosine 279/216 also showed an intense rather than moderate AT8 (phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with fibrillar tau pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "23294633",
        "name": "Neurobiology of aging",
        "title": "Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.",
        "volume": "34",
        "pages": "1369-79",
        "date": "2013-05-01",
        "first": "Köhler C",
        "last": "Götz J",
        "authors": [
          "Dinekov M",
          "Götz J",
          "Köhler C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "pR5 mice": true
        }
      },
      "source": 795,
      "target": 625,
      "key": "8698211579652dba7fbab06ad9279d353681755370eddb0b6fc9b9357e7b161b20a9e0a574a0b04fddecf056ce31cf844b5908ce2971071145dd600e8f02a10c"
    },
    {
      "line": 2541,
      "relation": "increases",
      "evidence": "We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia. In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes. Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3α/β at tyrosine 279/216 also showed an intense rather than moderate AT8 (phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with fibrillar tau pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "23294633",
        "name": "Neurobiology of aging",
        "title": "Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.",
        "volume": "34",
        "pages": "1369-79",
        "date": "2013-05-01",
        "first": "Köhler C",
        "last": "Götz J",
        "authors": [
          "Dinekov M",
          "Götz J",
          "Köhler C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "pR5 mice": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 795,
      "target": 794,
      "key": "a248e496588d060ace5c90b8b093722caf3d933ebcc5dc08b029eb1fe080cb283f0c47dfed7c95c279d46b045814f665719a9dde28950e03d748ad118f63a008"
    },
    {
      "line": 2579,
      "relation": "positiveCorrelation",
      "evidence": "E391-3610 mice (higher expressers) exhibit robust somatodendritic distribution of phospho- Ser 202/Thr 205 tau throughout the cortex, in hippocampal CA3 pyramidal neurons, CA1 apical dendrites and cell bodies and dentate granule cells.",
      "citation": {
        "type": "PubMed",
        "reference": "22002427",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Truncation of tau at E391 promotes early pathologic changes in transgenic mice.",
        "volume": "70",
        "pages": "1006-19",
        "date": "2011-11-01",
        "first": "McMillan PJ",
        "last": "Schellenberg G",
        "authors": [
          "Kraemer BC",
          "Leverenz JB",
          "McMillan PJ",
          "Raskind M",
          "Robinson L",
          "Schellenberg G"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "hTau E391 transgenic mice": true
        },
        "Anatomy": {
          "cerebral cortex": true,
          "CA1 field of hippocampus": true,
          "CA3 field of hippocampus": true,
          "dentate gyrus granule cell layer": true
        }
      },
      "source": 547,
      "target": 608,
      "key": "60e694fb97b9ef54940ec5f863a9a737022369c74b8512870233a56e7dadeef2765405d92138105924f8484aa25558433d15cbe0eb2877a7556e3ba82cea6f1a"
    },
    {
      "line": 2581,
      "relation": "positiveCorrelation",
      "evidence": "E391-3610 mice (higher expressers) exhibit robust somatodendritic distribution of phospho- Ser 202/Thr 205 tau throughout the cortex, in hippocampal CA3 pyramidal neurons, CA1 apical dendrites and cell bodies and dentate granule cells.",
      "citation": {
        "type": "PubMed",
        "reference": "22002427",
        "name": "Journal of neuropathology and experimental neurology",
        "title": "Truncation of tau at E391 promotes early pathologic changes in transgenic mice.",
        "volume": "70",
        "pages": "1006-19",
        "date": "2011-11-01",
        "first": "McMillan PJ",
        "last": "Schellenberg G",
        "authors": [
          "Kraemer BC",
          "Leverenz JB",
          "McMillan PJ",
          "Raskind M",
          "Robinson L",
          "Schellenberg G"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "hTau E391 transgenic mice": true
        },
        "Anatomy": {
          "cerebral cortex": true,
          "CA1 field of hippocampus": true,
          "CA3 field of hippocampus": true,
          "dentate gyrus granule cell layer": true
        }
      },
      "source": 547,
      "target": 81,
      "key": "abb0df23c3ba7293885035725f131a9187b93666167ac9e91dfca5a3809c74215d87c32ba83c918c4b5fae3440570a279a138a311444e1f027037b6995af0b93"
    },
    {
      "line": 2593,
      "relation": "positiveCorrelation",
      "evidence": "Using mass spectrometry, we identified multiple sites on recombinant tau that are phosphorylated by LRRK2 in vitro, including pT149 and pT153, which are phospho-epitopes that to date have been largely unexplored. Importantly, we demonstrate that expression of transgenic LRRK2 in a mouse model of tauopathy increased the aggregation of insoluble tau and its phosphorylation at T149, T153, T205, and S199/S202/T205 epitopes.",
      "citation": {
        "type": "PubMed",
        "reference": "24113872",
        "name": "Acta neuropathologica",
        "title": "LRRK2 phosphorylates novel tau epitopes and promotes tauopathy.",
        "volume": "126",
        "pages": "809-27",
        "date": "2013-12-01",
        "first": "Bailey RM",
        "last": "Lewis J",
        "authors": [
          "Bailey RM",
          "Covy JP",
          "Dickson DW",
          "Farrer MJ",
          "Giasson BI",
          "Knight J",
          "Lewis J",
          "Melrose HL",
          "Miles S",
          "Rousseau L",
          "Watkinson R"
        ]
      },
      "source": 469,
      "target": 915,
      "key": "57271373defec5614e4cb23a56ff652f0e5df6e51617dd0dfd3b44753f746af5eb988c78403fc9f08cbc76cc2e98bc9464d1d39db45a39e8dd59011f6012917c"
    },
    {
      "line": 2596,
      "relation": "directlyIncreases",
      "evidence": "Using mass spectrometry, we identified multiple sites on recombinant tau that are phosphorylated by LRRK2 in vitro, including pT149 and pT153, which are phospho-epitopes that to date have been largely unexplored. Importantly, we demonstrate that expression of transgenic LRRK2 in a mouse model of tauopathy increased the aggregation of insoluble tau and its phosphorylation at T149, T153, T205, and S199/S202/T205 epitopes.",
      "citation": {
        "type": "PubMed",
        "reference": "24113872",
        "name": "Acta neuropathologica",
        "title": "LRRK2 phosphorylates novel tau epitopes and promotes tauopathy.",
        "volume": "126",
        "pages": "809-27",
        "date": "2013-12-01",
        "first": "Bailey RM",
        "last": "Lewis J",
        "authors": [
          "Bailey RM",
          "Covy JP",
          "Dickson DW",
          "Farrer MJ",
          "Giasson BI",
          "Knight J",
          "Lewis J",
          "Melrose HL",
          "Miles S",
          "Rousseau L",
          "Watkinson R"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "LRRK2 transgenic mice": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 469,
      "target": 827,
      "key": "5cba668ab14e2f28b0f459e8d2a8af3986bd55b1c11dc00f706b8203e3df3e379c3daf79036a33836a0a4f546c916bc2d5e0166a83701c94d78072e39052a2b2"
    },
    {
      "line": 2597,
      "relation": "directlyIncreases",
      "evidence": "Using mass spectrometry, we identified multiple sites on recombinant tau that are phosphorylated by LRRK2 in vitro, including pT149 and pT153, which are phospho-epitopes that to date have been largely unexplored. Importantly, we demonstrate that expression of transgenic LRRK2 in a mouse model of tauopathy increased the aggregation of insoluble tau and its phosphorylation at T149, T153, T205, and S199/S202/T205 epitopes.",
      "citation": {
        "type": "PubMed",
        "reference": "24113872",
        "name": "Acta neuropathologica",
        "title": "LRRK2 phosphorylates novel tau epitopes and promotes tauopathy.",
        "volume": "126",
        "pages": "809-27",
        "date": "2013-12-01",
        "first": "Bailey RM",
        "last": "Lewis J",
        "authors": [
          "Bailey RM",
          "Covy JP",
          "Dickson DW",
          "Farrer MJ",
          "Giasson BI",
          "Knight J",
          "Lewis J",
          "Melrose HL",
          "Miles S",
          "Rousseau L",
          "Watkinson R"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "LRRK2 transgenic mice": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 469,
      "target": 828,
      "key": "691f950a6006399cc52ecb545cb810001df5b20e021bba7073e90b5086b2ea022899fa9325f69508836e4ce72420a11a0f647778ad703d76d609179d03cb59dc"
    },
    {
      "line": 2598,
      "relation": "directlyIncreases",
      "evidence": "Using mass spectrometry, we identified multiple sites on recombinant tau that are phosphorylated by LRRK2 in vitro, including pT149 and pT153, which are phospho-epitopes that to date have been largely unexplored. Importantly, we demonstrate that expression of transgenic LRRK2 in a mouse model of tauopathy increased the aggregation of insoluble tau and its phosphorylation at T149, T153, T205, and S199/S202/T205 epitopes.",
      "citation": {
        "type": "PubMed",
        "reference": "24113872",
        "name": "Acta neuropathologica",
        "title": "LRRK2 phosphorylates novel tau epitopes and promotes tauopathy.",
        "volume": "126",
        "pages": "809-27",
        "date": "2013-12-01",
        "first": "Bailey RM",
        "last": "Lewis J",
        "authors": [
          "Bailey RM",
          "Covy JP",
          "Dickson DW",
          "Farrer MJ",
          "Giasson BI",
          "Knight J",
          "Lewis J",
          "Melrose HL",
          "Miles S",
          "Rousseau L",
          "Watkinson R"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "LRRK2 transgenic mice": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 469,
      "target": 831,
      "key": "a74cffe800c55d1ab423659cbb6edf7919ae0c570ee0e09d69d164bbbc9185ec2367785bcf62fe2476aa1ae87cd1d735235648c46fe76babd3485b96a1131f4a"
    },
    {
      "line": 2599,
      "relation": "directlyIncreases",
      "evidence": "Using mass spectrometry, we identified multiple sites on recombinant tau that are phosphorylated by LRRK2 in vitro, including pT149 and pT153, which are phospho-epitopes that to date have been largely unexplored. Importantly, we demonstrate that expression of transgenic LRRK2 in a mouse model of tauopathy increased the aggregation of insoluble tau and its phosphorylation at T149, T153, T205, and S199/S202/T205 epitopes.",
      "citation": {
        "type": "PubMed",
        "reference": "24113872",
        "name": "Acta neuropathologica",
        "title": "LRRK2 phosphorylates novel tau epitopes and promotes tauopathy.",
        "volume": "126",
        "pages": "809-27",
        "date": "2013-12-01",
        "first": "Bailey RM",
        "last": "Lewis J",
        "authors": [
          "Bailey RM",
          "Covy JP",
          "Dickson DW",
          "Farrer MJ",
          "Giasson BI",
          "Knight J",
          "Lewis J",
          "Melrose HL",
          "Miles S",
          "Rousseau L",
          "Watkinson R"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "LRRK2 transgenic mice": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 469,
      "target": 336,
      "key": "a15f1ae22a74756d83dca86c32f903a09d263d8c0828b53ba7e8d610dfeb669d4fbd4afc35cc26cebad91932208d48d0a6daaf77a8bedcff7f371fc4460a7703"
    },
    {
      "line": 2600,
      "relation": "directlyIncreases",
      "evidence": "Using mass spectrometry, we identified multiple sites on recombinant tau that are phosphorylated by LRRK2 in vitro, including pT149 and pT153, which are phospho-epitopes that to date have been largely unexplored. Importantly, we demonstrate that expression of transgenic LRRK2 in a mouse model of tauopathy increased the aggregation of insoluble tau and its phosphorylation at T149, T153, T205, and S199/S202/T205 epitopes.",
      "citation": {
        "type": "PubMed",
        "reference": "24113872",
        "name": "Acta neuropathologica",
        "title": "LRRK2 phosphorylates novel tau epitopes and promotes tauopathy.",
        "volume": "126",
        "pages": "809-27",
        "date": "2013-12-01",
        "first": "Bailey RM",
        "last": "Lewis J",
        "authors": [
          "Bailey RM",
          "Covy JP",
          "Dickson DW",
          "Farrer MJ",
          "Giasson BI",
          "Knight J",
          "Lewis J",
          "Melrose HL",
          "Miles S",
          "Rousseau L",
          "Watkinson R"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "LRRK2 transgenic mice": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 469,
      "target": 325,
      "key": "97aaa2467968625cbb26b3ecead7b466efd3208cae4ad3af278b7288fcc48831742d60ad9aaaf94e5f849a3905da496a7a90a3a6dc771fa8fd16397ff9573381"
    },
    {
      "line": 2607,
      "relation": "biomarkerFor",
      "evidence": "Finally, these data validate PHF-1 as an efficient marker for AD cytopathology following the progression of tau aggregation into NFT.",
      "citation": {
        "type": "PubMed",
        "reference": "24033439",
        "name": "Neuropathology and applied neurobiology",
        "title": "Phosphorylation of tau protein at sites Ser(396-404) is one of the earliest events in Alzheimer's disease and Down syndrome.",
        "volume": "40",
        "pages": "121-35",
        "date": "2014-02-01",
        "first": "Mondragón-Rodríguez S",
        "last": "Williams S",
        "authors": [
          "Acevedo-Aquino MC",
          "Luna-Muñoz J",
          "Mondragón-Rodríguez S",
          "Perry G",
          "Williams S"
        ]
      },
      "source": 338,
      "target": 908,
      "key": "531b9b85d7a59d4d2896fb8570f9b1b630ac8594ad8c07d9f00703ba7b89e2725147bcc7c2734f9c77fc257236997fc3bd4639496f60221a064c62cad18b1568"
    },
    {
      "line": 2608,
      "relation": "increases",
      "evidence": "Finally, these data validate PHF-1 as an efficient marker for AD cytopathology following the progression of tau aggregation into NFT.",
      "citation": {
        "type": "PubMed",
        "reference": "24033439",
        "name": "Neuropathology and applied neurobiology",
        "title": "Phosphorylation of tau protein at sites Ser(396-404) is one of the earliest events in Alzheimer's disease and Down syndrome.",
        "volume": "40",
        "pages": "121-35",
        "date": "2014-02-01",
        "first": "Mondragón-Rodríguez S",
        "last": "Williams S",
        "authors": [
          "Acevedo-Aquino MC",
          "Luna-Muñoz J",
          "Mondragón-Rodríguez S",
          "Perry G",
          "Williams S"
        ]
      },
      "source": 338,
      "target": 81,
      "key": "ccb1a6b3a11c2ade14d67436124b659f7a7575bdd1d6580e8ff965d0ae28f5487013d6a7e2507d1cd902116e2c17a50e3418310346b477a71f69b50935ac327f"
    },
    {
      "line": 2622,
      "relation": "positiveCorrelation",
      "evidence": "Phosphorylation at the epitope Ser202/Thr205 is regarded as a good marker for late-stage NFTs (5, 72). Hyman and colleagues (5) demonstrated that AT8 immunoreactivity is present primarily in eNFTs and in certain cases in iNFTs. These investigators also found that AT8 revealed dense neuropil thread staining.",
      "citation": {
        "type": "PubMed",
        "reference": "22253473",
        "name": "FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "title": "Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.",
        "volume": "26",
        "pages": "1946-59",
        "date": "2012-05-01",
        "first": "Lasagna-Reeves CA",
        "last": "Kayed R",
        "authors": [
          "Castillo-Carranza DL",
          "Jackson GR",
          "Kayed R",
          "Lasagna-Reeves CA",
          "Sarmiento J",
          "Sengupta U",
          "Troncoso J"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Disease_Progression": {
          "Late Stage": true
        }
      },
      "source": 169,
      "target": 336,
      "key": "8420f4659e5e62f6c98dd394657ad3e1c262a61ee6dd553491875f3f23bf858dcb99915567a4430dcf4d01595b8a616a6bc250c63c2125cb9e9f5297554d2d9f"
    },
    {
      "line": 3361,
      "relation": "positiveCorrelation",
      "evidence": "Our findings indicate that several acetylation sites in tau are responsive to HDAC6 and that acetylation on Lys-321 (within a KCGS motif) is both essential for acetylation-mediated inhibition of tau aggregation in vitro and a molecular tactic for preventing phosphorylation on the downstream Ser-324 residue. Tau phosphorylation of Ser-324 (pSer-324) has not previously been evaluated in the context of tauopathy, and here we observed increased deposition of pSer-324-positive tau both in mouse models of tauopathy and in patients with Alzheimer's disease. These findings uncover a novel acetylation-phosphorylation switch at Lys-321/Ser-324 that coordinately regulates tau polymerization and function.",
      "citation": {
        "type": "PubMed",
        "reference": "28760828",
        "name": "The Journal of biological chemistry",
        "title": "An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.",
        "volume": "292",
        "pages": "15277-15286",
        "date": "2017-09-15",
        "first": "Carlomagno Y",
        "last": "Cook C",
        "authors": [
          "Carlomagno Y",
          "Castanedes-Casey M",
          "Chung DC",
          "Cook C",
          "DeTure M",
          "Dickson DW",
          "Dunmore J",
          "Madden BJ",
          "Petrucelli L",
          "Tong J",
          "Yue M"
        ]
      },
      "source": 561,
      "target": 325,
      "key": "9b13786fb0f95e29472fe78b3fdb152663be80279e0e124ce9c6e04a9a8fc0a8fd1cc9a4c08443424d78f11d2f31fe8ee8062310a34104caebc197ad1597f0fb"
    },
    {
      "line": 3366,
      "relation": "positiveCorrelation",
      "evidence": "HDAC6 inhibition leads to a significant reduction in tau levels as detected by the human tau-specific antibody E1 (Fig. 6 (a and c) and supplemental Fig. S6). We also observed a striking decrease in phosphorylation at Ser-324, which was statistically significant even when normalizing to E1 to control for the reduction in tau levels (Fig. 6 (a and b) and supplemental Fig. S6).",
      "citation": {
        "type": "PubMed",
        "reference": "28760828",
        "name": "The Journal of biological chemistry",
        "title": "An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.",
        "volume": "292",
        "pages": "15277-15286",
        "date": "2017-09-15",
        "first": "Carlomagno Y",
        "last": "Cook C",
        "authors": [
          "Carlomagno Y",
          "Castanedes-Casey M",
          "Chung DC",
          "Cook C",
          "DeTure M",
          "Dickson DW",
          "Dunmore J",
          "Madden BJ",
          "Petrucelli L",
          "Tong J",
          "Yue M"
        ]
      },
      "source": 561,
      "target": 459,
      "key": "a6dd483c84969d4fa8fabe79b0bf77f90a1d90330635606d8d07c021ddf743de17d664035ea7914dbe4689155f08629ddc0863c267c2d7f5af9461eca47ec73a"
    },
    {
      "line": 2647,
      "relation": "partOf",
      "evidence": "While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were ∼45−58% phosphorylated (Table 1). Using wild-type MARK2cat at 25 °C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.",
      "citation": {
        "type": "PubMed",
        "reference": "24251416",
        "name": "Biochemistry",
        "title": "Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.",
        "volume": "52",
        "pages": "9068-79",
        "date": "2013-12-17",
        "first": "Schwalbe M",
        "last": "Zweckstetter M",
        "authors": [
          "Bibow S",
          "Biernat J",
          "Blackledge M",
          "Jensen MR",
          "Kadavath H",
          "Mandelkow E",
          "Ozenne V",
          "Schwalbe M",
          "Zweckstetter M"
        ]
      },
      "source": 559,
      "target": 363,
      "key": "4c66fa5f88028e166d91fdfd92e15b37141153d1025b30903d40414f5610afd2502d98417b45bc59b41037b2302f1622683e9457e7578e7e28919c28a639744e"
    },
    {
      "line": 2649,
      "relation": "partOf",
      "evidence": "While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were ∼45−58% phosphorylated (Table 1). Using wild-type MARK2cat at 25 °C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.",
      "citation": {
        "type": "PubMed",
        "reference": "24251416",
        "name": "Biochemistry",
        "title": "Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.",
        "volume": "52",
        "pages": "9068-79",
        "date": "2013-12-17",
        "first": "Schwalbe M",
        "last": "Zweckstetter M",
        "authors": [
          "Bibow S",
          "Biernat J",
          "Blackledge M",
          "Jensen MR",
          "Kadavath H",
          "Mandelkow E",
          "Ozenne V",
          "Schwalbe M",
          "Zweckstetter M"
        ]
      },
      "source": 560,
      "target": 363,
      "key": "080988a692a49149f14e5ee55dfbeec948ee519b46215350ac14683bb8b810bc1d09a0a58388bac22398ac0418faec1219c93f43b68f57b0e67ef30763ed1422"
    },
    {
      "line": 2651,
      "relation": "partOf",
      "evidence": "While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated, Ser-293 in the second repeat was only 84% phosphorylated (Table 1). Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4) and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352, Ser-413, and Ser-416 were ∼45−58% phosphorylated (Table 1). Using wild-type MARK2cat at 25 °C and pH 6.8, the same phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated.",
      "citation": {
        "type": "PubMed",
        "reference": "24251416",
        "name": "Biochemistry",
        "title": "Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.",
        "volume": "52",
        "pages": "9068-79",
        "date": "2013-12-17",
        "first": "Schwalbe M",
        "last": "Zweckstetter M",
        "authors": [
          "Bibow S",
          "Biernat J",
          "Blackledge M",
          "Jensen MR",
          "Kadavath H",
          "Mandelkow E",
          "Ozenne V",
          "Schwalbe M",
          "Zweckstetter M"
        ]
      },
      "source": 562,
      "target": 365,
      "key": "3fd4272075259da867ce23863c15b28f8f7b67334058ba026c73627e6ccdd5fe1b2cb71d1081594edacb205ed07096a7adfb93135fda2805d98da717aa0672ef"
    },
    {
      "line": 2670,
      "relation": "negativeCorrelation",
      "evidence": "In particular, previous studies have demonstrated that the tau ubiquitin ligase, CHIP, is unable to bind and ubiquitinate tau species phosphorylated by Par-1/MARK2 on the 12E8 epitope (S262/356) [33], a p-tau species that is also resistant to degradation upon treatment with Hsp90 inhibitors [32,33]. Tau phosphorylated at the PHF1 epitope (S396/404) is still susceptible to degradation following Hsp90 inhibition and actually exhibits an enhanced interaction with Hsp90",
      "citation": {
        "type": "PubMed",
        "reference": "25031639",
        "name": "Alzheimer's research &amp; therapy",
        "title": "Acetylation: a new key to unlock tau's role in neurodegeneration.",
        "volume": "6",
        "pages": "29",
        "date": "2014-01-01",
        "first": "Cook C",
        "last": "Petrucelli L",
        "authors": [
          "Carlomagno Y",
          "Cook C",
          "Petrucelli L",
          "Stankowski JN",
          "Stetler C"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 691,
      "target": 113,
      "key": "f24bb70f731ff7726aaf50bde2212da54784718bb92aa0b422fa1a8ad549d42f2a7d32ffd2f8a5998bfe1df52257dce71a07b7f4f1a1c0d14a7f99ac277bb3d0"
    },
    {
      "line": 2671,
      "relation": "increases",
      "evidence": "In particular, previous studies have demonstrated that the tau ubiquitin ligase, CHIP, is unable to bind and ubiquitinate tau species phosphorylated by Par-1/MARK2 on the 12E8 epitope (S262/356) [33], a p-tau species that is also resistant to degradation upon treatment with Hsp90 inhibitors [32,33]. Tau phosphorylated at the PHF1 epitope (S396/404) is still susceptible to degradation following Hsp90 inhibition and actually exhibits an enhanced interaction with Hsp90",
      "citation": {
        "type": "PubMed",
        "reference": "25031639",
        "name": "Alzheimer's research &amp; therapy",
        "title": "Acetylation: a new key to unlock tau's role in neurodegeneration.",
        "volume": "6",
        "pages": "29",
        "date": "2014-01-01",
        "first": "Cook C",
        "last": "Petrucelli L",
        "authors": [
          "Carlomagno Y",
          "Cook C",
          "Petrucelli L",
          "Stankowski JN",
          "Stetler C"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Degradation"
      },
      "source": 691,
      "target": 486,
      "key": "287546bb775f0426132519313714cdf1584c4e73b2e21c5584d1a1534dc7e785b0fae8d28bac506864156bf88c6486562a00ff517a3de186a0a117edd1d64a4c"
    },
    {
      "line": 3454,
      "relation": "association",
      "evidence": "the ACR (APP cytosolic region) interacts with the E3 ubiquitin-protein ligases Stub1, which binds the NH2 terminus of the ACR, and CRL4(CRBN), which is formed by Cul4a/b, Ddb1, and Crbn, and interacts with the COOH terminus of the ACR via Crbn.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 691,
      "target": 310,
      "key": "bb5303a65f41da28288152bf47b885d044442d7335eb3558f09664e6ecb86ad064e972e001534eb01909be1b6301ff4c5b8a426df128d1eb00f182c3647e3d95"
    },
    {
      "line": 3455,
      "relation": "isA",
      "evidence": "the ACR (APP cytosolic region) interacts with the E3 ubiquitin-protein ligases Stub1, which binds the NH2 terminus of the ACR, and CRL4(CRBN), which is formed by Cul4a/b, Ddb1, and Crbn, and interacts with the COOH terminus of the ACR via Crbn.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 691,
      "target": 217,
      "key": "6d457a16174461a2dd5537a460d90d63f1dc0aedc1792726f4d29153bd47910216c13565e9947563b45cc48db0cfe1c9e570505339218f7c74ec1b9a06e077e8"
    },
    {
      "line": 2683,
      "relation": "negativeCorrelation",
      "evidence": "Overexpression of MARK4 led to tau hyperphosphorylation, reduced expression of synaptic markers, and loss of dendritic spines and synapses, phenotypes also observed after Aβ treatment. Importantly, expression of a non-phosphorylatable form of tau with the PAR-1/MARK site mutated blocked the synaptic toxicity induced by MARK4 overexpression or Aβ treatment. To probe the involvement of endogenous MARK kinases in mediating the synaptic toxicity of Aβ, we employed a peptide inhibitor capable of effectively and specifically inhibiting the activities of all PAR-1/MARK family members. This inhibitor abrogated the toxic effects of Aβ oligomers on dendritic spines and synapses as assayed at the morphological and electrophysiological levels.",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 863,
      "target": 635,
      "key": "43ab7528b45a9bb23366245bd658f2e1cf15aff944e7d321f3bdea5e27782bc04d5b71cba6913f6a52c1a6bd075c87f1458d4bd833d366972e37c28e4eec93e3"
    },
    {
      "line": 2684,
      "relation": "negativeCorrelation",
      "evidence": "Overexpression of MARK4 led to tau hyperphosphorylation, reduced expression of synaptic markers, and loss of dendritic spines and synapses, phenotypes also observed after Aβ treatment. Importantly, expression of a non-phosphorylatable form of tau with the PAR-1/MARK site mutated blocked the synaptic toxicity induced by MARK4 overexpression or Aβ treatment. To probe the involvement of endogenous MARK kinases in mediating the synaptic toxicity of Aβ, we employed a peptide inhibitor capable of effectively and specifically inhibiting the activities of all PAR-1/MARK family members. This inhibitor abrogated the toxic effects of Aβ oligomers on dendritic spines and synapses as assayed at the morphological and electrophysiological levels.",
      "citation": {
        "type": "PubMed",
        "reference": "22156579",
        "name": "Human molecular genetics",
        "title": "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.",
        "volume": "21",
        "pages": "1384-90",
        "date": "2012-03-15",
        "first": "Yu W",
        "last": "Lu B",
        "authors": [
          "Lu B",
          "Malenka R",
          "Polepalli J",
          "Rajadas J",
          "Wagh D",
          "Yu W"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 865,
      "target": 635,
      "key": "2718c7379b868c9a4baa8526ed6ae45e2696916b6008d911e8bf89beea42ff545894be916fc7d58676be0fd55dabab7d33e42bc6ed0b1aec8e320f94264c8baf"
    },
    {
      "line": 2706,
      "relation": "increases",
      "evidence": "When overexpressed in rat hippocampal primary neurons, 14-3-3z causes an increase in Ser(262) phosphorylation, a decrease in the amount of microtubule-bound tau, a reduction in the amount of polymerized microtubules, as well as microtubule instability. Downregulation of synaptophysin in 14-3-3z overexpressing neurons was mitigated by inhibiting the proteosome, indicating that 14-3-3z promotes proteosomal degradation of synaptophysin. When 14-3-3z overexpressing neurons were treated with the microtubule stabilizing drug taxol, tau Ser(262) phosphorylation decreased and synaptophysin level was restored.",
      "citation": {
        "type": "PubMed",
        "reference": "22941973",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain.",
        "volume": "33",
        "pages": "249-63",
        "date": "2013-01-01",
        "first": "Sahara N",
        "last": "Lewis J",
        "authors": [
          "DeTure M",
          "Dickson DW",
          "Ebrahim AS",
          "Kang D",
          "Knight J",
          "Lewis J",
          "Pedersen JT",
          "Ren Y",
          "Sahara N",
          "Volbracht C",
          "Yen SH"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 753,
      "target": 879,
      "key": "4acdbd9eaadadbfc0b282db11ab729aeea34aa218c370157d39049d81ba192dd9f1df566ba204e853bec8a443cbf6a26c68b5c93f13716b21b3fe045c663d252"
    },
    {
      "line": 2707,
      "relation": "decreases",
      "evidence": "When overexpressed in rat hippocampal primary neurons, 14-3-3z causes an increase in Ser(262) phosphorylation, a decrease in the amount of microtubule-bound tau, a reduction in the amount of polymerized microtubules, as well as microtubule instability. Downregulation of synaptophysin in 14-3-3z overexpressing neurons was mitigated by inhibiting the proteosome, indicating that 14-3-3z promotes proteosomal degradation of synaptophysin. When 14-3-3z overexpressing neurons were treated with the microtubule stabilizing drug taxol, tau Ser(262) phosphorylation decreased and synaptophysin level was restored.",
      "citation": {
        "type": "PubMed",
        "reference": "22941973",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain.",
        "volume": "33",
        "pages": "249-63",
        "date": "2013-01-01",
        "first": "Sahara N",
        "last": "Lewis J",
        "authors": [
          "DeTure M",
          "Dickson DW",
          "Ebrahim AS",
          "Kang D",
          "Knight J",
          "Lewis J",
          "Pedersen JT",
          "Ren Y",
          "Sahara N",
          "Volbracht C",
          "Yen SH"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 753,
      "target": 186,
      "key": "7d9a5bd2d4934005d2194b1fac0dd05b3667597ba80edb92b8fd0340cf5fe952939b9005b1e9e36a6406237aee0c744bf76b8189c58a8ae6a150f46523791d4a"
    },
    {
      "line": 2708,
      "relation": "increases",
      "evidence": "When overexpressed in rat hippocampal primary neurons, 14-3-3z causes an increase in Ser(262) phosphorylation, a decrease in the amount of microtubule-bound tau, a reduction in the amount of polymerized microtubules, as well as microtubule instability. Downregulation of synaptophysin in 14-3-3z overexpressing neurons was mitigated by inhibiting the proteosome, indicating that 14-3-3z promotes proteosomal degradation of synaptophysin. When 14-3-3z overexpressing neurons were treated with the microtubule stabilizing drug taxol, tau Ser(262) phosphorylation decreased and synaptophysin level was restored.",
      "citation": {
        "type": "PubMed",
        "reference": "22941973",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain.",
        "volume": "33",
        "pages": "249-63",
        "date": "2013-01-01",
        "first": "Sahara N",
        "last": "Lewis J",
        "authors": [
          "DeTure M",
          "Dickson DW",
          "Ebrahim AS",
          "Kang D",
          "Knight J",
          "Lewis J",
          "Pedersen JT",
          "Ren Y",
          "Sahara N",
          "Volbracht C",
          "Yen SH"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Degradation"
      },
      "source": 753,
      "target": 902,
      "key": "160c78227e3b05a7431b15d3085e84e476a62834b1a4b91dc7ced6eca5015cddd450200508839e4b1f67725609f77e08659238a552887da4d0466e43c1a88e03"
    },
    {
      "line": 2709,
      "relation": "negativeCorrelation",
      "evidence": "When overexpressed in rat hippocampal primary neurons, 14-3-3z causes an increase in Ser(262) phosphorylation, a decrease in the amount of microtubule-bound tau, a reduction in the amount of polymerized microtubules, as well as microtubule instability. Downregulation of synaptophysin in 14-3-3z overexpressing neurons was mitigated by inhibiting the proteosome, indicating that 14-3-3z promotes proteosomal degradation of synaptophysin. When 14-3-3z overexpressing neurons were treated with the microtubule stabilizing drug taxol, tau Ser(262) phosphorylation decreased and synaptophysin level was restored.",
      "citation": {
        "type": "PubMed",
        "reference": "22941973",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain.",
        "volume": "33",
        "pages": "249-63",
        "date": "2013-01-01",
        "first": "Sahara N",
        "last": "Lewis J",
        "authors": [
          "DeTure M",
          "Dickson DW",
          "Ebrahim AS",
          "Kang D",
          "Knight J",
          "Lewis J",
          "Pedersen JT",
          "Ren Y",
          "Sahara N",
          "Volbracht C",
          "Yen SH"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 753,
      "target": 64,
      "key": "bd57eed34eed2c1108d49d654100463beaa9709d45bb6fbb0aff85a6b82e826b3dbfaf6d390bb1fd6e7b97573c22af43ef330f8b8a8bb37cadf9cdfbc390109d"
    },
    {
      "line": 2709,
      "relation": "negativeCorrelation",
      "evidence": "When overexpressed in rat hippocampal primary neurons, 14-3-3z causes an increase in Ser(262) phosphorylation, a decrease in the amount of microtubule-bound tau, a reduction in the amount of polymerized microtubules, as well as microtubule instability. Downregulation of synaptophysin in 14-3-3z overexpressing neurons was mitigated by inhibiting the proteosome, indicating that 14-3-3z promotes proteosomal degradation of synaptophysin. When 14-3-3z overexpressing neurons were treated with the microtubule stabilizing drug taxol, tau Ser(262) phosphorylation decreased and synaptophysin level was restored.",
      "citation": {
        "type": "PubMed",
        "reference": "22941973",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain.",
        "volume": "33",
        "pages": "249-63",
        "date": "2013-01-01",
        "first": "Sahara N",
        "last": "Lewis J",
        "authors": [
          "DeTure M",
          "Dickson DW",
          "Ebrahim AS",
          "Kang D",
          "Knight J",
          "Lewis J",
          "Pedersen JT",
          "Ren Y",
          "Sahara N",
          "Volbracht C",
          "Yen SH"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 64,
      "target": 753,
      "key": "d1e91c205d4b57e1a6077ba10f14330d82b0b03e05aae0ff82b93593421916c6896f7ccc6c8dc406792f9ccc239210b599399f4dbbe9a5dd15a2f11ed3c3ab6d"
    },
    {
      "line": 2710,
      "relation": "decreases",
      "evidence": "When overexpressed in rat hippocampal primary neurons, 14-3-3z causes an increase in Ser(262) phosphorylation, a decrease in the amount of microtubule-bound tau, a reduction in the amount of polymerized microtubules, as well as microtubule instability. Downregulation of synaptophysin in 14-3-3z overexpressing neurons was mitigated by inhibiting the proteosome, indicating that 14-3-3z promotes proteosomal degradation of synaptophysin. When 14-3-3z overexpressing neurons were treated with the microtubule stabilizing drug taxol, tau Ser(262) phosphorylation decreased and synaptophysin level was restored.",
      "citation": {
        "type": "PubMed",
        "reference": "22941973",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain.",
        "volume": "33",
        "pages": "249-63",
        "date": "2013-01-01",
        "first": "Sahara N",
        "last": "Lewis J",
        "authors": [
          "DeTure M",
          "Dickson DW",
          "Ebrahim AS",
          "Kang D",
          "Knight J",
          "Lewis J",
          "Pedersen JT",
          "Ren Y",
          "Sahara N",
          "Volbracht C",
          "Yen SH"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 64,
      "target": 879,
      "key": "e820fc585f960392d4ad6d7016f2f97dabe16279e08b6a4459e2bd4fd614b106516aef24a53514023d00774687ef7a66f0665fa7f90f9e8ad87fb17c0135972e"
    },
    {
      "line": 2723,
      "relation": "directlyDecreases",
      "evidence": "Primary cortical neurons exposed to the mitochondrial toxin NaN3 (0.1-3 mM) were submitted to oxidative stress with H2O2 (30-150 μM), to mimic conditions observed in neurodegenerative disorders. The effects of such treatment on a series of parameters useful in characterizing neuronal damage were investigated: (i) the basal release of glutamate, evaluated as (3)H-d-Aspartate efflux, was sharply, concentration-dependently, increased; (ii) the phosphorylation status of intracellular markers known to be involved in the neurodegenerative processes, in particular in Alzheimer disease: tau and GSK3β were increased, as well as the protein level of β-secretase (BACE1) and p35/25 evaluated by Western blotting, while (iii) the cell metabolic activity, measured with the MTT method, was reduced, in a concentration- and time-dependent manner. The latter effect, as well as tau hyperphosphorylation, was prevented both by a mixture of antioxidant drugs (100 μM ascorbic acid, 10 μM trolox, 100 μM glutathione) and by the anti-Alzheimer drug, memantine, 20 μM.",
      "citation": {
        "type": "PubMed",
        "reference": "23722080",
        "name": "Neurochemistry international",
        "title": "In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease.",
        "volume": "63",
        "pages": "112-20",
        "date": "2013-08-01",
        "first": "Selvatici R",
        "last": "Siniscalchi A",
        "authors": [
          "Marani L",
          "Marino S",
          "Selvatici R",
          "Siniscalchi A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 32,
      "target": 88,
      "key": "fd7d4f300ab0593d523152033b699b63abb46601d02603181852ac83ad7705bc45bc493f5cdc8e802d188dd197f3af5b257bbf6f6e40871171795b17fcfb4e84"
    },
    {
      "line": 2726,
      "relation": "positiveCorrelation",
      "evidence": "Primary cortical neurons exposed to the mitochondrial toxin NaN3 (0.1-3 mM) were submitted to oxidative stress with H2O2 (30-150 μM), to mimic conditions observed in neurodegenerative disorders. The effects of such treatment on a series of parameters useful in characterizing neuronal damage were investigated: (i) the basal release of glutamate, evaluated as (3)H-d-Aspartate efflux, was sharply, concentration-dependently, increased; (ii) the phosphorylation status of intracellular markers known to be involved in the neurodegenerative processes, in particular in Alzheimer disease: tau and GSK3β were increased, as well as the protein level of β-secretase (BACE1) and p35/25 evaluated by Western blotting, while (iii) the cell metabolic activity, measured with the MTT method, was reduced, in a concentration- and time-dependent manner. The latter effect, as well as tau hyperphosphorylation, was prevented both by a mixture of antioxidant drugs (100 μM ascorbic acid, 10 μM trolox, 100 μM glutathione) and by the anti-Alzheimer drug, memantine, 20 μM.",
      "citation": {
        "type": "PubMed",
        "reference": "23722080",
        "name": "Neurochemistry international",
        "title": "In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease.",
        "volume": "63",
        "pages": "112-20",
        "date": "2013-08-01",
        "first": "Selvatici R",
        "last": "Siniscalchi A",
        "authors": [
          "Marani L",
          "Marino S",
          "Selvatici R",
          "Siniscalchi A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 32,
      "target": 245,
      "key": "213d0ef0c9ef7e458dbbc3f9e6f63215f6f24760efd252f3182e773b936314e50b9ef5568a5c68d27f9fa29c0cc6d483a1f7189ebf2f39f716383f441e6cccfc"
    },
    {
      "relation": "hasComponent",
      "source": 245,
      "target": 21,
      "key": "d45e25b8b76e4a96b6c5c12bd2816477b1669180fa54e48569f86fdf2df0c87223e19247de7ad39ea4a51dda1657adc76a8bec29f10df0518c1bb9551e110b72"
    },
    {
      "line": 2727,
      "relation": "positiveCorrelation",
      "evidence": "Primary cortical neurons exposed to the mitochondrial toxin NaN3 (0.1-3 mM) were submitted to oxidative stress with H2O2 (30-150 μM), to mimic conditions observed in neurodegenerative disorders. The effects of such treatment on a series of parameters useful in characterizing neuronal damage were investigated: (i) the basal release of glutamate, evaluated as (3)H-d-Aspartate efflux, was sharply, concentration-dependently, increased; (ii) the phosphorylation status of intracellular markers known to be involved in the neurodegenerative processes, in particular in Alzheimer disease: tau and GSK3β were increased, as well as the protein level of β-secretase (BACE1) and p35/25 evaluated by Western blotting, while (iii) the cell metabolic activity, measured with the MTT method, was reduced, in a concentration- and time-dependent manner. The latter effect, as well as tau hyperphosphorylation, was prevented both by a mixture of antioxidant drugs (100 μM ascorbic acid, 10 μM trolox, 100 μM glutathione) and by the anti-Alzheimer drug, memantine, 20 μM.",
      "citation": {
        "type": "PubMed",
        "reference": "23722080",
        "name": "Neurochemistry international",
        "title": "In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease.",
        "volume": "63",
        "pages": "112-20",
        "date": "2013-08-01",
        "first": "Selvatici R",
        "last": "Siniscalchi A",
        "authors": [
          "Marani L",
          "Marino S",
          "Selvatici R",
          "Siniscalchi A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 245,
      "target": 21,
      "key": "c9b2a4b883723026ace474db338597912f20fbaf323d37b7323d2fd223268440128b86996655552e66fefa81bf65a79c8b68cedc26bcaff85ce3d09a7c66f41e"
    },
    {
      "relation": "hasComponent",
      "source": 245,
      "target": 32,
      "key": "f55ceb3e14443aa75a272f5be2100adb1dcdf0abc6d7fc875e01440dc9210bad7790fa9f31166862d25e94a05849fb6fabd78dfeb8e8bd0f8f4c9988816c80e9"
    },
    {
      "line": 2726,
      "relation": "positiveCorrelation",
      "evidence": "Primary cortical neurons exposed to the mitochondrial toxin NaN3 (0.1-3 mM) were submitted to oxidative stress with H2O2 (30-150 μM), to mimic conditions observed in neurodegenerative disorders. The effects of such treatment on a series of parameters useful in characterizing neuronal damage were investigated: (i) the basal release of glutamate, evaluated as (3)H-d-Aspartate efflux, was sharply, concentration-dependently, increased; (ii) the phosphorylation status of intracellular markers known to be involved in the neurodegenerative processes, in particular in Alzheimer disease: tau and GSK3β were increased, as well as the protein level of β-secretase (BACE1) and p35/25 evaluated by Western blotting, while (iii) the cell metabolic activity, measured with the MTT method, was reduced, in a concentration- and time-dependent manner. The latter effect, as well as tau hyperphosphorylation, was prevented both by a mixture of antioxidant drugs (100 μM ascorbic acid, 10 μM trolox, 100 μM glutathione) and by the anti-Alzheimer drug, memantine, 20 μM.",
      "citation": {
        "type": "PubMed",
        "reference": "23722080",
        "name": "Neurochemistry international",
        "title": "In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease.",
        "volume": "63",
        "pages": "112-20",
        "date": "2013-08-01",
        "first": "Selvatici R",
        "last": "Siniscalchi A",
        "authors": [
          "Marani L",
          "Marino S",
          "Selvatici R",
          "Siniscalchi A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 245,
      "target": 32,
      "key": "ff41fad2ec9bf74e0db22a42a3736f49d1678e42e7f0cb11f3fb2f33f7abda52bee98555421022ccf5f6f4305761ba6f9bcc4490b6241f872a0f69b918f426d4"
    },
    {
      "line": 2728,
      "relation": "increases",
      "evidence": "Primary cortical neurons exposed to the mitochondrial toxin NaN3 (0.1-3 mM) were submitted to oxidative stress with H2O2 (30-150 μM), to mimic conditions observed in neurodegenerative disorders. The effects of such treatment on a series of parameters useful in characterizing neuronal damage were investigated: (i) the basal release of glutamate, evaluated as (3)H-d-Aspartate efflux, was sharply, concentration-dependently, increased; (ii) the phosphorylation status of intracellular markers known to be involved in the neurodegenerative processes, in particular in Alzheimer disease: tau and GSK3β were increased, as well as the protein level of β-secretase (BACE1) and p35/25 evaluated by Western blotting, while (iii) the cell metabolic activity, measured with the MTT method, was reduced, in a concentration- and time-dependent manner. The latter effect, as well as tau hyperphosphorylation, was prevented both by a mixture of antioxidant drugs (100 μM ascorbic acid, 10 μM trolox, 100 μM glutathione) and by the anti-Alzheimer drug, memantine, 20 μM.",
      "citation": {
        "type": "PubMed",
        "reference": "23722080",
        "name": "Neurochemistry international",
        "title": "In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease.",
        "volume": "63",
        "pages": "112-20",
        "date": "2013-08-01",
        "first": "Selvatici R",
        "last": "Siniscalchi A",
        "authors": [
          "Marani L",
          "Marino S",
          "Selvatici R",
          "Siniscalchi A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 245,
      "target": 19,
      "key": "9a5dfbb9367033ad0066e5906012d153345a6e4fa4b21205686dc2b973e5c8290e657e965124daf089c32d0c59a7f1fb9db99808df90f258b324063e20c9ab59"
    },
    {
      "line": 2729,
      "relation": "increases",
      "evidence": "Primary cortical neurons exposed to the mitochondrial toxin NaN3 (0.1-3 mM) were submitted to oxidative stress with H2O2 (30-150 μM), to mimic conditions observed in neurodegenerative disorders. The effects of such treatment on a series of parameters useful in characterizing neuronal damage were investigated: (i) the basal release of glutamate, evaluated as (3)H-d-Aspartate efflux, was sharply, concentration-dependently, increased; (ii) the phosphorylation status of intracellular markers known to be involved in the neurodegenerative processes, in particular in Alzheimer disease: tau and GSK3β were increased, as well as the protein level of β-secretase (BACE1) and p35/25 evaluated by Western blotting, while (iii) the cell metabolic activity, measured with the MTT method, was reduced, in a concentration- and time-dependent manner. The latter effect, as well as tau hyperphosphorylation, was prevented both by a mixture of antioxidant drugs (100 μM ascorbic acid, 10 μM trolox, 100 μM glutathione) and by the anti-Alzheimer drug, memantine, 20 μM.",
      "citation": {
        "type": "PubMed",
        "reference": "23722080",
        "name": "Neurochemistry international",
        "title": "In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease.",
        "volume": "63",
        "pages": "112-20",
        "date": "2013-08-01",
        "first": "Selvatici R",
        "last": "Siniscalchi A",
        "authors": [
          "Marani L",
          "Marino S",
          "Selvatici R",
          "Siniscalchi A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 245,
      "target": 879,
      "key": "6ce192d6a4bec1441e69e03533f5da65857557f956c3c4c23445230ea0a4575033696bf311e628ec1e03e404d6d8a4b24927eae78f88add42f0f0c2d1fc518fe"
    },
    {
      "line": 2730,
      "relation": "increases",
      "evidence": "Primary cortical neurons exposed to the mitochondrial toxin NaN3 (0.1-3 mM) were submitted to oxidative stress with H2O2 (30-150 μM), to mimic conditions observed in neurodegenerative disorders. The effects of such treatment on a series of parameters useful in characterizing neuronal damage were investigated: (i) the basal release of glutamate, evaluated as (3)H-d-Aspartate efflux, was sharply, concentration-dependently, increased; (ii) the phosphorylation status of intracellular markers known to be involved in the neurodegenerative processes, in particular in Alzheimer disease: tau and GSK3β were increased, as well as the protein level of β-secretase (BACE1) and p35/25 evaluated by Western blotting, while (iii) the cell metabolic activity, measured with the MTT method, was reduced, in a concentration- and time-dependent manner. The latter effect, as well as tau hyperphosphorylation, was prevented both by a mixture of antioxidant drugs (100 μM ascorbic acid, 10 μM trolox, 100 μM glutathione) and by the anti-Alzheimer drug, memantine, 20 μM.",
      "citation": {
        "type": "PubMed",
        "reference": "23722080",
        "name": "Neurochemistry international",
        "title": "In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease.",
        "volume": "63",
        "pages": "112-20",
        "date": "2013-08-01",
        "first": "Selvatici R",
        "last": "Siniscalchi A",
        "authors": [
          "Marani L",
          "Marino S",
          "Selvatici R",
          "Siniscalchi A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 245,
      "target": 881,
      "key": "1b1eae0cec855c3a818e287befdc4aea83198aa3cc277b4603c8edfc0075b9f769952e78d1fa14516dc2a9a3e7ddfa28527c335c6a74c41b8663d78c93ec83bc"
    },
    {
      "line": 2731,
      "relation": "increases",
      "evidence": "Primary cortical neurons exposed to the mitochondrial toxin NaN3 (0.1-3 mM) were submitted to oxidative stress with H2O2 (30-150 μM), to mimic conditions observed in neurodegenerative disorders. The effects of such treatment on a series of parameters useful in characterizing neuronal damage were investigated: (i) the basal release of glutamate, evaluated as (3)H-d-Aspartate efflux, was sharply, concentration-dependently, increased; (ii) the phosphorylation status of intracellular markers known to be involved in the neurodegenerative processes, in particular in Alzheimer disease: tau and GSK3β were increased, as well as the protein level of β-secretase (BACE1) and p35/25 evaluated by Western blotting, while (iii) the cell metabolic activity, measured with the MTT method, was reduced, in a concentration- and time-dependent manner. The latter effect, as well as tau hyperphosphorylation, was prevented both by a mixture of antioxidant drugs (100 μM ascorbic acid, 10 μM trolox, 100 μM glutathione) and by the anti-Alzheimer drug, memantine, 20 μM.",
      "citation": {
        "type": "PubMed",
        "reference": "23722080",
        "name": "Neurochemistry international",
        "title": "In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease.",
        "volume": "63",
        "pages": "112-20",
        "date": "2013-08-01",
        "first": "Selvatici R",
        "last": "Siniscalchi A",
        "authors": [
          "Marani L",
          "Marino S",
          "Selvatici R",
          "Siniscalchi A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 245,
      "target": 859,
      "key": "6316ad513fc05c1aeecc03b9f33b3e03f884ee6eb98c9ae0a90d2a83b4ebcc38111a620b8771cf6c3b71dc9e0a5746e4a12f0f72bff884eb511c5b668c06ceb1"
    },
    {
      "line": 2732,
      "relation": "increases",
      "evidence": "Primary cortical neurons exposed to the mitochondrial toxin NaN3 (0.1-3 mM) were submitted to oxidative stress with H2O2 (30-150 μM), to mimic conditions observed in neurodegenerative disorders. The effects of such treatment on a series of parameters useful in characterizing neuronal damage were investigated: (i) the basal release of glutamate, evaluated as (3)H-d-Aspartate efflux, was sharply, concentration-dependently, increased; (ii) the phosphorylation status of intracellular markers known to be involved in the neurodegenerative processes, in particular in Alzheimer disease: tau and GSK3β were increased, as well as the protein level of β-secretase (BACE1) and p35/25 evaluated by Western blotting, while (iii) the cell metabolic activity, measured with the MTT method, was reduced, in a concentration- and time-dependent manner. The latter effect, as well as tau hyperphosphorylation, was prevented both by a mixture of antioxidant drugs (100 μM ascorbic acid, 10 μM trolox, 100 μM glutathione) and by the anti-Alzheimer drug, memantine, 20 μM.",
      "citation": {
        "type": "PubMed",
        "reference": "23722080",
        "name": "Neurochemistry international",
        "title": "In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease.",
        "volume": "63",
        "pages": "112-20",
        "date": "2013-08-01",
        "first": "Selvatici R",
        "last": "Siniscalchi A",
        "authors": [
          "Marani L",
          "Marino S",
          "Selvatici R",
          "Siniscalchi A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 245,
      "target": 311,
      "key": "062831fe3f27ab0f276904b3b268bfae4201c93c0167753b8a5d28e3bf99877b2622afacceb71466ab94e40fb961d4d7215f3e736ebd3a1457dcdad58d1ca60a"
    },
    {
      "line": 2733,
      "relation": "decreases",
      "evidence": "Primary cortical neurons exposed to the mitochondrial toxin NaN3 (0.1-3 mM) were submitted to oxidative stress with H2O2 (30-150 μM), to mimic conditions observed in neurodegenerative disorders. The effects of such treatment on a series of parameters useful in characterizing neuronal damage were investigated: (i) the basal release of glutamate, evaluated as (3)H-d-Aspartate efflux, was sharply, concentration-dependently, increased; (ii) the phosphorylation status of intracellular markers known to be involved in the neurodegenerative processes, in particular in Alzheimer disease: tau and GSK3β were increased, as well as the protein level of β-secretase (BACE1) and p35/25 evaluated by Western blotting, while (iii) the cell metabolic activity, measured with the MTT method, was reduced, in a concentration- and time-dependent manner. The latter effect, as well as tau hyperphosphorylation, was prevented both by a mixture of antioxidant drugs (100 μM ascorbic acid, 10 μM trolox, 100 μM glutathione) and by the anti-Alzheimer drug, memantine, 20 μM.",
      "citation": {
        "type": "PubMed",
        "reference": "23722080",
        "name": "Neurochemistry international",
        "title": "In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease.",
        "volume": "63",
        "pages": "112-20",
        "date": "2013-08-01",
        "first": "Selvatici R",
        "last": "Siniscalchi A",
        "authors": [
          "Marani L",
          "Marino S",
          "Selvatici R",
          "Siniscalchi A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 245,
      "target": 178,
      "key": "a9e84a07ba3c5ca6bfd79e897ebb6df52aa5e4d342c3617230899577410e3e1ea17ec7f59990d5e451af587f416dc389fac8c6e9c5afb0587e01624826597376"
    },
    {
      "relation": "hasComponent",
      "source": 244,
      "target": 6,
      "key": "0e4ec23e422b416dd1a1ea74bdd339d90324d4e3316116e0bc508a59f49980b83dc1f6844ae53b73f99c624d0be9e358f749b223b360d7a731c7336ebe46bacd"
    },
    {
      "relation": "hasComponent",
      "source": 244,
      "target": 40,
      "key": "0ed6c9527ae74a0fc55fc7ede73c6a0c4347b4bce37badf4793cfe83a5d35e9f33fcd66c7d48da0f275ce5c4b634171cc46fbbc6a2d869bbd853b83836133191"
    },
    {
      "relation": "hasComponent",
      "source": 244,
      "target": 51,
      "key": "63572c704d599622a909e5e10026ade69c3b6dd942273fccb9ed908fffe73701b64529e3718c410372829df9bab26fc31735a45124271cd95448b88262e2006f"
    },
    {
      "line": 2734,
      "relation": "decreases",
      "evidence": "Primary cortical neurons exposed to the mitochondrial toxin NaN3 (0.1-3 mM) were submitted to oxidative stress with H2O2 (30-150 μM), to mimic conditions observed in neurodegenerative disorders. The effects of such treatment on a series of parameters useful in characterizing neuronal damage were investigated: (i) the basal release of glutamate, evaluated as (3)H-d-Aspartate efflux, was sharply, concentration-dependently, increased; (ii) the phosphorylation status of intracellular markers known to be involved in the neurodegenerative processes, in particular in Alzheimer disease: tau and GSK3β were increased, as well as the protein level of β-secretase (BACE1) and p35/25 evaluated by Western blotting, while (iii) the cell metabolic activity, measured with the MTT method, was reduced, in a concentration- and time-dependent manner. The latter effect, as well as tau hyperphosphorylation, was prevented both by a mixture of antioxidant drugs (100 μM ascorbic acid, 10 μM trolox, 100 μM glutathione) and by the anti-Alzheimer drug, memantine, 20 μM.",
      "citation": {
        "type": "PubMed",
        "reference": "23722080",
        "name": "Neurochemistry international",
        "title": "In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease.",
        "volume": "63",
        "pages": "112-20",
        "date": "2013-08-01",
        "first": "Selvatici R",
        "last": "Siniscalchi A",
        "authors": [
          "Marani L",
          "Marino S",
          "Selvatici R",
          "Siniscalchi A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 244,
      "target": 879,
      "key": "09dd590e14ff7bacec1a2a3287253ad17dbe21679d484acb3d106de7836a848df8d8e252e0b6aad0f1a6a2fe62da29c944e16b5c8cb545f1542643968c7adb79"
    },
    {
      "line": 2735,
      "relation": "decreases",
      "evidence": "Primary cortical neurons exposed to the mitochondrial toxin NaN3 (0.1-3 mM) were submitted to oxidative stress with H2O2 (30-150 μM), to mimic conditions observed in neurodegenerative disorders. The effects of such treatment on a series of parameters useful in characterizing neuronal damage were investigated: (i) the basal release of glutamate, evaluated as (3)H-d-Aspartate efflux, was sharply, concentration-dependently, increased; (ii) the phosphorylation status of intracellular markers known to be involved in the neurodegenerative processes, in particular in Alzheimer disease: tau and GSK3β were increased, as well as the protein level of β-secretase (BACE1) and p35/25 evaluated by Western blotting, while (iii) the cell metabolic activity, measured with the MTT method, was reduced, in a concentration- and time-dependent manner. The latter effect, as well as tau hyperphosphorylation, was prevented both by a mixture of antioxidant drugs (100 μM ascorbic acid, 10 μM trolox, 100 μM glutathione) and by the anti-Alzheimer drug, memantine, 20 μM.",
      "citation": {
        "type": "PubMed",
        "reference": "23722080",
        "name": "Neurochemistry international",
        "title": "In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease.",
        "volume": "63",
        "pages": "112-20",
        "date": "2013-08-01",
        "first": "Selvatici R",
        "last": "Siniscalchi A",
        "authors": [
          "Marani L",
          "Marino S",
          "Selvatici R",
          "Siniscalchi A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 244,
      "target": 881,
      "key": "a288fbce71f730b84d2c4d87f265ceca72c13a81b2918a089b55e5a06644fb9311f2e930f881305a1b44f37d4628d6e6d4499b816f78c7670dfce2ff8f07f32b"
    },
    {
      "line": 2736,
      "relation": "increases",
      "evidence": "Primary cortical neurons exposed to the mitochondrial toxin NaN3 (0.1-3 mM) were submitted to oxidative stress with H2O2 (30-150 μM), to mimic conditions observed in neurodegenerative disorders. The effects of such treatment on a series of parameters useful in characterizing neuronal damage were investigated: (i) the basal release of glutamate, evaluated as (3)H-d-Aspartate efflux, was sharply, concentration-dependently, increased; (ii) the phosphorylation status of intracellular markers known to be involved in the neurodegenerative processes, in particular in Alzheimer disease: tau and GSK3β were increased, as well as the protein level of β-secretase (BACE1) and p35/25 evaluated by Western blotting, while (iii) the cell metabolic activity, measured with the MTT method, was reduced, in a concentration- and time-dependent manner. The latter effect, as well as tau hyperphosphorylation, was prevented both by a mixture of antioxidant drugs (100 μM ascorbic acid, 10 μM trolox, 100 μM glutathione) and by the anti-Alzheimer drug, memantine, 20 μM.",
      "citation": {
        "type": "PubMed",
        "reference": "23722080",
        "name": "Neurochemistry international",
        "title": "In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease.",
        "volume": "63",
        "pages": "112-20",
        "date": "2013-08-01",
        "first": "Selvatici R",
        "last": "Siniscalchi A",
        "authors": [
          "Marani L",
          "Marino S",
          "Selvatici R",
          "Siniscalchi A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 244,
      "target": 178,
      "key": "cada9c8365ba24a358801e9ca829bae340b36e46bfd244b8d4df93597cfa4a11f626247111e103863fab43d21e7bd0067bd2b92e93ca2145adcc1a6d583553ef"
    },
    {
      "line": 2737,
      "relation": "decreases",
      "evidence": "Primary cortical neurons exposed to the mitochondrial toxin NaN3 (0.1-3 mM) were submitted to oxidative stress with H2O2 (30-150 μM), to mimic conditions observed in neurodegenerative disorders. The effects of such treatment on a series of parameters useful in characterizing neuronal damage were investigated: (i) the basal release of glutamate, evaluated as (3)H-d-Aspartate efflux, was sharply, concentration-dependently, increased; (ii) the phosphorylation status of intracellular markers known to be involved in the neurodegenerative processes, in particular in Alzheimer disease: tau and GSK3β were increased, as well as the protein level of β-secretase (BACE1) and p35/25 evaluated by Western blotting, while (iii) the cell metabolic activity, measured with the MTT method, was reduced, in a concentration- and time-dependent manner. The latter effect, as well as tau hyperphosphorylation, was prevented both by a mixture of antioxidant drugs (100 μM ascorbic acid, 10 μM trolox, 100 μM glutathione) and by the anti-Alzheimer drug, memantine, 20 μM.",
      "citation": {
        "type": "PubMed",
        "reference": "23722080",
        "name": "Neurochemistry international",
        "title": "In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease.",
        "volume": "63",
        "pages": "112-20",
        "date": "2013-08-01",
        "first": "Selvatici R",
        "last": "Siniscalchi A",
        "authors": [
          "Marani L",
          "Marino S",
          "Selvatici R",
          "Siniscalchi A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 60,
      "target": 879,
      "key": "264c9619b3fdd139848bb9e13c39d304d095c2eb289acbfb8fa1e4661bbd54d99e0f2c040c2b97398845c92f5bc7f74ff5cfc8be98f151db9125840037300bfc"
    },
    {
      "line": 2738,
      "relation": "decreases",
      "evidence": "Primary cortical neurons exposed to the mitochondrial toxin NaN3 (0.1-3 mM) were submitted to oxidative stress with H2O2 (30-150 μM), to mimic conditions observed in neurodegenerative disorders. The effects of such treatment on a series of parameters useful in characterizing neuronal damage were investigated: (i) the basal release of glutamate, evaluated as (3)H-d-Aspartate efflux, was sharply, concentration-dependently, increased; (ii) the phosphorylation status of intracellular markers known to be involved in the neurodegenerative processes, in particular in Alzheimer disease: tau and GSK3β were increased, as well as the protein level of β-secretase (BACE1) and p35/25 evaluated by Western blotting, while (iii) the cell metabolic activity, measured with the MTT method, was reduced, in a concentration- and time-dependent manner. The latter effect, as well as tau hyperphosphorylation, was prevented both by a mixture of antioxidant drugs (100 μM ascorbic acid, 10 μM trolox, 100 μM glutathione) and by the anti-Alzheimer drug, memantine, 20 μM.",
      "citation": {
        "type": "PubMed",
        "reference": "23722080",
        "name": "Neurochemistry international",
        "title": "In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease.",
        "volume": "63",
        "pages": "112-20",
        "date": "2013-08-01",
        "first": "Selvatici R",
        "last": "Siniscalchi A",
        "authors": [
          "Marani L",
          "Marino S",
          "Selvatici R",
          "Siniscalchi A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 60,
      "target": 881,
      "key": "af05bca35f92ba8e6c879f798da68bf5bb8d5f10ac623c70a867cbe6f3737615358aa95a2eed84feee4ca48fc400ad63b427f7498e3af90cb02cef9c7fb48481"
    },
    {
      "line": 2739,
      "relation": "increases",
      "evidence": "Primary cortical neurons exposed to the mitochondrial toxin NaN3 (0.1-3 mM) were submitted to oxidative stress with H2O2 (30-150 μM), to mimic conditions observed in neurodegenerative disorders. The effects of such treatment on a series of parameters useful in characterizing neuronal damage were investigated: (i) the basal release of glutamate, evaluated as (3)H-d-Aspartate efflux, was sharply, concentration-dependently, increased; (ii) the phosphorylation status of intracellular markers known to be involved in the neurodegenerative processes, in particular in Alzheimer disease: tau and GSK3β were increased, as well as the protein level of β-secretase (BACE1) and p35/25 evaluated by Western blotting, while (iii) the cell metabolic activity, measured with the MTT method, was reduced, in a concentration- and time-dependent manner. The latter effect, as well as tau hyperphosphorylation, was prevented both by a mixture of antioxidant drugs (100 μM ascorbic acid, 10 μM trolox, 100 μM glutathione) and by the anti-Alzheimer drug, memantine, 20 μM.",
      "citation": {
        "type": "PubMed",
        "reference": "23722080",
        "name": "Neurochemistry international",
        "title": "In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease.",
        "volume": "63",
        "pages": "112-20",
        "date": "2013-08-01",
        "first": "Selvatici R",
        "last": "Siniscalchi A",
        "authors": [
          "Marani L",
          "Marino S",
          "Selvatici R",
          "Siniscalchi A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 60,
      "target": 178,
      "key": "df3c3189a06ba4f84df4d53f1da369c55bf6302005a7d89de643c12284f29001a076c269989db99f5d4a30ea04581f6184267c39eb3100c5a06abfcaecbd198d"
    },
    {
      "line": 2742,
      "relation": "decreases",
      "evidence": "Primary cortical neurons exposed to the mitochondrial toxin NaN3 (0.1-3 mM) were submitted to oxidative stress with H2O2 (30-150 μM), to mimic conditions observed in neurodegenerative disorders. The effects of such treatment on a series of parameters useful in characterizing neuronal damage were investigated: (i) the basal release of glutamate, evaluated as (3)H-d-Aspartate efflux, was sharply, concentration-dependently, increased; (ii) the phosphorylation status of intracellular markers known to be involved in the neurodegenerative processes, in particular in Alzheimer disease: tau and GSK3β were increased, as well as the protein level of β-secretase (BACE1) and p35/25 evaluated by Western blotting, while (iii) the cell metabolic activity, measured with the MTT method, was reduced, in a concentration- and time-dependent manner. The latter effect, as well as tau hyperphosphorylation, was prevented both by a mixture of antioxidant drugs (100 μM ascorbic acid, 10 μM trolox, 100 μM glutathione) and by the anti-Alzheimer drug, memantine, 20 μM.",
      "citation": {
        "type": "PubMed",
        "reference": "23722080",
        "name": "Neurochemistry international",
        "title": "In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease.",
        "volume": "63",
        "pages": "112-20",
        "date": "2013-08-01",
        "first": "Selvatici R",
        "last": "Siniscalchi A",
        "authors": [
          "Marani L",
          "Marino S",
          "Selvatici R",
          "Siniscalchi A"
        ]
      },
      "source": 60,
      "target": 908,
      "key": "3ffd45793f91fbbdb29cf7ce76e0bed6bcea7c7c289350bfa863abe7d7105c1845a217070d17cf5b758bb928f05ee80bf16ecd887cb01b1245a7b9c94e0e8447"
    },
    {
      "line": 2754,
      "relation": "positiveCorrelation",
      "evidence": "Using transgenic Drosophila expressing human tau, we found that RNAi-mediated knockdown of milton or Miro, an adaptor protein essential for axonal transport of mitochondria, enhanced human tau-induced neurodegeneration. Tau phosphorylation at an AD-related site Ser262 increased with knockdown of milton or Miro; and partitioning defective-1 (PAR-1), the Drosophila homolog of mammalian microtubule affinity-regulating kinase, mediated this increase of tau phosphorylation. Tau phosphorylation at Ser262 has been reported to promote tau detachment from microtubules, and we found that the levels of microtubule-unbound free tau increased by milton knockdown. Blocking tau phosphorylation at Ser262 site by PAR-1 knockdown or by mutating the Ser262 site to unphosphorylatable alanine suppressed the enhancement of tau-induced neurodegeneration caused by milton knockdown. Furthermore, knockdown of milton or Miro increased the levels of active PAR-1.",
      "citation": {
        "type": "PubMed",
        "reference": "22952452",
        "name": "PLoS genetics",
        "title": "Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1.",
        "volume": "8",
        "pages": "e1002918",
        "date": "2012-01-01",
        "first": "Iijima-Ando K",
        "last": "Iijima KM",
        "authors": [
          "Iijima KM",
          "Iijima-Ando K",
          "Lu B",
          "Maruko-Otake A",
          "Ohtake Y",
          "Sekiya M",
          "Suzuki E"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 733,
      "target": 88,
      "key": "7172cbe9121781ac606dd968ffda75428dd316eeb3a198bf95e12b1b66bd141287fd33e8577f239da529817c89572a2f51e74080cf0423c23353874cbe5e1d58"
    },
    {
      "line": 2756,
      "relation": "decreases",
      "evidence": "Using transgenic Drosophila expressing human tau, we found that RNAi-mediated knockdown of milton or Miro, an adaptor protein essential for axonal transport of mitochondria, enhanced human tau-induced neurodegeneration. Tau phosphorylation at an AD-related site Ser262 increased with knockdown of milton or Miro; and partitioning defective-1 (PAR-1), the Drosophila homolog of mammalian microtubule affinity-regulating kinase, mediated this increase of tau phosphorylation. Tau phosphorylation at Ser262 has been reported to promote tau detachment from microtubules, and we found that the levels of microtubule-unbound free tau increased by milton knockdown. Blocking tau phosphorylation at Ser262 site by PAR-1 knockdown or by mutating the Ser262 site to unphosphorylatable alanine suppressed the enhancement of tau-induced neurodegeneration caused by milton knockdown. Furthermore, knockdown of milton or Miro increased the levels of active PAR-1.",
      "citation": {
        "type": "PubMed",
        "reference": "22952452",
        "name": "PLoS genetics",
        "title": "Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1.",
        "volume": "8",
        "pages": "e1002918",
        "date": "2012-01-01",
        "first": "Iijima-Ando K",
        "last": "Iijima KM",
        "authors": [
          "Iijima KM",
          "Iijima-Ando K",
          "Lu B",
          "Maruko-Otake A",
          "Ohtake Y",
          "Sekiya M",
          "Suzuki E"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "source": 733,
      "target": 557,
      "key": "346c9820a596bfdd38caaed70588aecde7d44b8c8e5e12e64ccc0d67bd8bf7c432ca179ff2d6c599f54716e9f9f380cf9b5807d690851dac5039098b2bce5556"
    },
    {
      "line": 2760,
      "relation": "negativeCorrelation",
      "evidence": "Using transgenic Drosophila expressing human tau, we found that RNAi-mediated knockdown of milton or Miro, an adaptor protein essential for axonal transport of mitochondria, enhanced human tau-induced neurodegeneration. Tau phosphorylation at an AD-related site Ser262 increased with knockdown of milton or Miro; and partitioning defective-1 (PAR-1), the Drosophila homolog of mammalian microtubule affinity-regulating kinase, mediated this increase of tau phosphorylation. Tau phosphorylation at Ser262 has been reported to promote tau detachment from microtubules, and we found that the levels of microtubule-unbound free tau increased by milton knockdown. Blocking tau phosphorylation at Ser262 site by PAR-1 knockdown or by mutating the Ser262 site to unphosphorylatable alanine suppressed the enhancement of tau-induced neurodegeneration caused by milton knockdown. Furthermore, knockdown of milton or Miro increased the levels of active PAR-1.",
      "citation": {
        "type": "PubMed",
        "reference": "22952452",
        "name": "PLoS genetics",
        "title": "Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1.",
        "volume": "8",
        "pages": "e1002918",
        "date": "2012-01-01",
        "first": "Iijima-Ando K",
        "last": "Iijima KM",
        "authors": [
          "Iijima KM",
          "Iijima-Ando K",
          "Lu B",
          "Maruko-Otake A",
          "Ohtake Y",
          "Sekiya M",
          "Suzuki E"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "source": 733,
      "target": 633,
      "key": "502acc7d3620a6c76bfd7cf7240fdc380164b2b39eaef909ee2986c04986bf6afe50a9353bf94f05e626589e718fae9f7b7950a2e5849ebb42f9a9b09fe46c8b"
    },
    {
      "line": 2755,
      "relation": "positiveCorrelation",
      "evidence": "Using transgenic Drosophila expressing human tau, we found that RNAi-mediated knockdown of milton or Miro, an adaptor protein essential for axonal transport of mitochondria, enhanced human tau-induced neurodegeneration. Tau phosphorylation at an AD-related site Ser262 increased with knockdown of milton or Miro; and partitioning defective-1 (PAR-1), the Drosophila homolog of mammalian microtubule affinity-regulating kinase, mediated this increase of tau phosphorylation. Tau phosphorylation at Ser262 has been reported to promote tau detachment from microtubules, and we found that the levels of microtubule-unbound free tau increased by milton knockdown. Blocking tau phosphorylation at Ser262 site by PAR-1 knockdown or by mutating the Ser262 site to unphosphorylatable alanine suppressed the enhancement of tau-induced neurodegeneration caused by milton knockdown. Furthermore, knockdown of milton or Miro increased the levels of active PAR-1.",
      "citation": {
        "type": "PubMed",
        "reference": "22952452",
        "name": "PLoS genetics",
        "title": "Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1.",
        "volume": "8",
        "pages": "e1002918",
        "date": "2012-01-01",
        "first": "Iijima-Ando K",
        "last": "Iijima KM",
        "authors": [
          "Iijima KM",
          "Iijima-Ando K",
          "Lu B",
          "Maruko-Otake A",
          "Ohtake Y",
          "Sekiya M",
          "Suzuki E"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 672,
      "target": 88,
      "key": "448a9c844d16be0f2c6f2a23be5cd3345e689b8e47e9a0d19622131204cfbe7f1d646aec6238522a855a1ef36d31e9e36ff3a2a7ab86a79c3dccf04930d5e242"
    },
    {
      "line": 2757,
      "relation": "decreases",
      "evidence": "Using transgenic Drosophila expressing human tau, we found that RNAi-mediated knockdown of milton or Miro, an adaptor protein essential for axonal transport of mitochondria, enhanced human tau-induced neurodegeneration. Tau phosphorylation at an AD-related site Ser262 increased with knockdown of milton or Miro; and partitioning defective-1 (PAR-1), the Drosophila homolog of mammalian microtubule affinity-regulating kinase, mediated this increase of tau phosphorylation. Tau phosphorylation at Ser262 has been reported to promote tau detachment from microtubules, and we found that the levels of microtubule-unbound free tau increased by milton knockdown. Blocking tau phosphorylation at Ser262 site by PAR-1 knockdown or by mutating the Ser262 site to unphosphorylatable alanine suppressed the enhancement of tau-induced neurodegeneration caused by milton knockdown. Furthermore, knockdown of milton or Miro increased the levels of active PAR-1.",
      "citation": {
        "type": "PubMed",
        "reference": "22952452",
        "name": "PLoS genetics",
        "title": "Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1.",
        "volume": "8",
        "pages": "e1002918",
        "date": "2012-01-01",
        "first": "Iijima-Ando K",
        "last": "Iijima KM",
        "authors": [
          "Iijima KM",
          "Iijima-Ando K",
          "Lu B",
          "Maruko-Otake A",
          "Ohtake Y",
          "Sekiya M",
          "Suzuki E"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "source": 672,
      "target": 557,
      "key": "c01091559c7c2ccc6203c605ae3fc7b9a15faf8b363b6b3c77b1d530414ff559556522e39825ec8ae8c2b2063309d83e0f44ab3fccd7f9166df2f93f93e3af85"
    },
    {
      "line": 2761,
      "relation": "negativeCorrelation",
      "evidence": "Using transgenic Drosophila expressing human tau, we found that RNAi-mediated knockdown of milton or Miro, an adaptor protein essential for axonal transport of mitochondria, enhanced human tau-induced neurodegeneration. Tau phosphorylation at an AD-related site Ser262 increased with knockdown of milton or Miro; and partitioning defective-1 (PAR-1), the Drosophila homolog of mammalian microtubule affinity-regulating kinase, mediated this increase of tau phosphorylation. Tau phosphorylation at Ser262 has been reported to promote tau detachment from microtubules, and we found that the levels of microtubule-unbound free tau increased by milton knockdown. Blocking tau phosphorylation at Ser262 site by PAR-1 knockdown or by mutating the Ser262 site to unphosphorylatable alanine suppressed the enhancement of tau-induced neurodegeneration caused by milton knockdown. Furthermore, knockdown of milton or Miro increased the levels of active PAR-1.",
      "citation": {
        "type": "PubMed",
        "reference": "22952452",
        "name": "PLoS genetics",
        "title": "Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1.",
        "volume": "8",
        "pages": "e1002918",
        "date": "2012-01-01",
        "first": "Iijima-Ando K",
        "last": "Iijima KM",
        "authors": [
          "Iijima KM",
          "Iijima-Ando K",
          "Lu B",
          "Maruko-Otake A",
          "Ohtake Y",
          "Sekiya M",
          "Suzuki E"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "source": 672,
      "target": 633,
      "key": "cd9a590b5ec9f9717234f2a37c1fb9c22ee222e0598b1dce17f071242ceaf8c4f90ce713496e00ed07535b8b7f54f62c581b35fac43f0f1908012571eb6d067b"
    },
    {
      "line": 2772,
      "relation": "increases",
      "evidence": "Several kinases such as microtubule-affinity regulating kinase (MARK), protein kinase A, calcium calmodulin kinase II, and checkpoint kinase 2 are known to phosphorylate tau on Ser(262) in vitro. In this study, we took advantage of the in situ proximity ligation assay to investigate the role of MARK2, one of the four MARK isoforms, in AD. We demonstrate that MARK2 interacts with tau and phosphorylates tau at Ser(262) in stably transfected NIH/3T3 cells expressing human recombinant tau. Staurosporine, a protein kinase inhibitor, significantly reduced the interaction between MARK2 and tau, and also phosphorylation of tau at Ser(262).",
      "citation": {
        "type": "PubMed",
        "reference": "23001711",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Elevated MARK2-dependent phosphorylation of Tau in Alzheimer's disease.",
        "volume": "33",
        "pages": "699-713",
        "date": "2013-01-01",
        "first": "Gu GJ",
        "last": "Kamali-Moghaddam M",
        "authors": [
          "Agerman K",
          "Eckersley S",
          "Gu GJ",
          "Kamali-Moghaddam M",
          "Kvist AJ",
          "Landegren U",
          "Lund H",
          "Milner R",
          "Nilsson LN",
          "Sunnemark D",
          "Wu D"
        ]
      },
      "source": 275,
      "target": 557,
      "key": "55b9e8a60b276979107f91aa5271b4b1adc041018340f47d4c3bc4cfae83726f4627f79dbb14e875a4092a3c84f7f1d6d45c577d9bca9cd5ba8e49632a064a70"
    },
    {
      "line": 2773,
      "relation": "increases",
      "evidence": "Several kinases such as microtubule-affinity regulating kinase (MARK), protein kinase A, calcium calmodulin kinase II, and checkpoint kinase 2 are known to phosphorylate tau on Ser(262) in vitro. In this study, we took advantage of the in situ proximity ligation assay to investigate the role of MARK2, one of the four MARK isoforms, in AD. We demonstrate that MARK2 interacts with tau and phosphorylates tau at Ser(262) in stably transfected NIH/3T3 cells expressing human recombinant tau. Staurosporine, a protein kinase inhibitor, significantly reduced the interaction between MARK2 and tau, and also phosphorylation of tau at Ser(262).",
      "citation": {
        "type": "PubMed",
        "reference": "23001711",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Elevated MARK2-dependent phosphorylation of Tau in Alzheimer's disease.",
        "volume": "33",
        "pages": "699-713",
        "date": "2013-01-01",
        "first": "Gu GJ",
        "last": "Kamali-Moghaddam M",
        "authors": [
          "Agerman K",
          "Eckersley S",
          "Gu GJ",
          "Kamali-Moghaddam M",
          "Kvist AJ",
          "Landegren U",
          "Lund H",
          "Milner R",
          "Nilsson LN",
          "Sunnemark D",
          "Wu D"
        ]
      },
      "source": 407,
      "target": 557,
      "key": "508ce9704b93864de6c4bd6bc1c2ab3b78123ac619dacf0fb4f86ba1f1a4491e80a5ed9f4251163fabb1ccc351ea5ac8ef85845634b6c0fbdc4fe811dba28312"
    },
    {
      "line": 2786,
      "relation": "increases",
      "evidence": "In this study, we address the structural impact of phosphorylation of the Tau protein by Nuclear Magnetic Resonance (NMR) spectroscopy on a functional fragment of Tau (Tau[Ser208-Ser324] = TauF4). TauF4 was phosphorylated by the proline-directed CDK2/CycA3 kinase on Thr231 (generating the AT180 epitope), Ser235, and equally on Thr212 and Thr217 in the Proline-rich region (Tau[Ser208-Gln244] or PRR). These modifications strongly decrease the capacity of TauF4 to polymerize tubulin into microtubules. While all the NMR parameters are consistent with a globally disordered Tau protein fragment, local clusters of structuration can be defined. The most salient result of our NMR analysis is that phosphorylation in the PRR stabilizes a short α-helix that runs from pSer235 till the very beginning of the microtubule-binding region (Tau[Thr245-Ser324] or MTBR of TauF4).",
      "citation": {
        "type": "PubMed",
        "reference": "22072628",
        "name": "Proteins",
        "title": "Structural characterization by nuclear magnetic resonance of the impact of phosphorylation in the proline-rich region of the disordered Tau protein.",
        "volume": "80",
        "pages": "454-62",
        "date": "2012-02-01",
        "first": "Sibille N",
        "last": "Landrieu I",
        "authors": [
          "Amniai L",
          "Fauquant C",
          "Huvent I",
          "Landrieu I",
          "Leroy A",
          "Lippens G",
          "Sibille N",
          "Verdegem D",
          "Wieruszeski JM"
        ]
      },
      "source": 399,
      "target": 115,
      "key": "32146104399ef060acf2b3e5af14cd840f8183c8cadf793fd9d59bbe3970c35b2107422cedb95dca17a1f3f757ea9cdf0ac715149104a78ec36b786924dd790c"
    },
    {
      "line": 2787,
      "relation": "directlyIncreases",
      "evidence": "In this study, we address the structural impact of phosphorylation of the Tau protein by Nuclear Magnetic Resonance (NMR) spectroscopy on a functional fragment of Tau (Tau[Ser208-Ser324] = TauF4). TauF4 was phosphorylated by the proline-directed CDK2/CycA3 kinase on Thr231 (generating the AT180 epitope), Ser235, and equally on Thr212 and Thr217 in the Proline-rich region (Tau[Ser208-Gln244] or PRR). These modifications strongly decrease the capacity of TauF4 to polymerize tubulin into microtubules. While all the NMR parameters are consistent with a globally disordered Tau protein fragment, local clusters of structuration can be defined. The most salient result of our NMR analysis is that phosphorylation in the PRR stabilizes a short α-helix that runs from pSer235 till the very beginning of the microtubule-binding region (Tau[Thr245-Ser324] or MTBR of TauF4).",
      "citation": {
        "type": "PubMed",
        "reference": "22072628",
        "name": "Proteins",
        "title": "Structural characterization by nuclear magnetic resonance of the impact of phosphorylation in the proline-rich region of the disordered Tau protein.",
        "volume": "80",
        "pages": "454-62",
        "date": "2012-02-01",
        "first": "Sibille N",
        "last": "Landrieu I",
        "authors": [
          "Amniai L",
          "Fauquant C",
          "Huvent I",
          "Landrieu I",
          "Leroy A",
          "Lippens G",
          "Sibille N",
          "Verdegem D",
          "Wieruszeski JM"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 399,
      "target": 552,
      "key": "d0b1e72524904b6c505c4f9284a5bd3bfc06186bc4f108e81bda4c857a9895f6788247822ad4c282a6ff38b717c4fdc65e456f245ea446f3f07e7f6fe3005a9c"
    },
    {
      "line": 2788,
      "relation": "directlyIncreases",
      "evidence": "In this study, we address the structural impact of phosphorylation of the Tau protein by Nuclear Magnetic Resonance (NMR) spectroscopy on a functional fragment of Tau (Tau[Ser208-Ser324] = TauF4). TauF4 was phosphorylated by the proline-directed CDK2/CycA3 kinase on Thr231 (generating the AT180 epitope), Ser235, and equally on Thr212 and Thr217 in the Proline-rich region (Tau[Ser208-Gln244] or PRR). These modifications strongly decrease the capacity of TauF4 to polymerize tubulin into microtubules. While all the NMR parameters are consistent with a globally disordered Tau protein fragment, local clusters of structuration can be defined. The most salient result of our NMR analysis is that phosphorylation in the PRR stabilizes a short α-helix that runs from pSer235 till the very beginning of the microtubule-binding region (Tau[Thr245-Ser324] or MTBR of TauF4).",
      "citation": {
        "type": "PubMed",
        "reference": "22072628",
        "name": "Proteins",
        "title": "Structural characterization by nuclear magnetic resonance of the impact of phosphorylation in the proline-rich region of the disordered Tau protein.",
        "volume": "80",
        "pages": "454-62",
        "date": "2012-02-01",
        "first": "Sibille N",
        "last": "Landrieu I",
        "authors": [
          "Amniai L",
          "Fauquant C",
          "Huvent I",
          "Landrieu I",
          "Leroy A",
          "Lippens G",
          "Sibille N",
          "Verdegem D",
          "Wieruszeski JM"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 399,
      "target": 580,
      "key": "203c3dc3b8038385f994acaadec1947689e96f42e896b92afa4092906e2ba20126c207821caa371b6b8ade86f6afbccd9ac045d16803bb8613143c8427515f7e"
    },
    {
      "line": 2789,
      "relation": "directlyIncreases",
      "evidence": "In this study, we address the structural impact of phosphorylation of the Tau protein by Nuclear Magnetic Resonance (NMR) spectroscopy on a functional fragment of Tau (Tau[Ser208-Ser324] = TauF4). TauF4 was phosphorylated by the proline-directed CDK2/CycA3 kinase on Thr231 (generating the AT180 epitope), Ser235, and equally on Thr212 and Thr217 in the Proline-rich region (Tau[Ser208-Gln244] or PRR). These modifications strongly decrease the capacity of TauF4 to polymerize tubulin into microtubules. While all the NMR parameters are consistent with a globally disordered Tau protein fragment, local clusters of structuration can be defined. The most salient result of our NMR analysis is that phosphorylation in the PRR stabilizes a short α-helix that runs from pSer235 till the very beginning of the microtubule-binding region (Tau[Thr245-Ser324] or MTBR of TauF4).",
      "citation": {
        "type": "PubMed",
        "reference": "22072628",
        "name": "Proteins",
        "title": "Structural characterization by nuclear magnetic resonance of the impact of phosphorylation in the proline-rich region of the disordered Tau protein.",
        "volume": "80",
        "pages": "454-62",
        "date": "2012-02-01",
        "first": "Sibille N",
        "last": "Landrieu I",
        "authors": [
          "Amniai L",
          "Fauquant C",
          "Huvent I",
          "Landrieu I",
          "Leroy A",
          "Lippens G",
          "Sibille N",
          "Verdegem D",
          "Wieruszeski JM"
        ]
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 399,
      "target": 582,
      "key": "9d2c09e35d38cc5c920182f36133594626635ea094706867d88109175b78cdc1b4aa816596222581ba9d8a635e3f6b3baa208d3229a8d72b121c152e8667fdf6"
    },
    {
      "line": 2790,
      "relation": "partOf",
      "evidence": "In this study, we address the structural impact of phosphorylation of the Tau protein by Nuclear Magnetic Resonance (NMR) spectroscopy on a functional fragment of Tau (Tau[Ser208-Ser324] = TauF4). TauF4 was phosphorylated by the proline-directed CDK2/CycA3 kinase on Thr231 (generating the AT180 epitope), Ser235, and equally on Thr212 and Thr217 in the Proline-rich region (Tau[Ser208-Gln244] or PRR). These modifications strongly decrease the capacity of TauF4 to polymerize tubulin into microtubules. While all the NMR parameters are consistent with a globally disordered Tau protein fragment, local clusters of structuration can be defined. The most salient result of our NMR analysis is that phosphorylation in the PRR stabilizes a short α-helix that runs from pSer235 till the very beginning of the microtubule-binding region (Tau[Thr245-Ser324] or MTBR of TauF4).",
      "citation": {
        "type": "PubMed",
        "reference": "22072628",
        "name": "Proteins",
        "title": "Structural characterization by nuclear magnetic resonance of the impact of phosphorylation in the proline-rich region of the disordered Tau protein.",
        "volume": "80",
        "pages": "454-62",
        "date": "2012-02-01",
        "first": "Sibille N",
        "last": "Landrieu I",
        "authors": [
          "Amniai L",
          "Fauquant C",
          "Huvent I",
          "Landrieu I",
          "Leroy A",
          "Lippens G",
          "Sibille N",
          "Verdegem D",
          "Wieruszeski JM"
        ]
      },
      "source": 552,
      "target": 361,
      "key": "ca4f2427e999a01d69191bc883339913132f5ff64c167a57cce4fbac3172cd1617b91166dd55c5d8542f6da9e3e86229f77f94c39349355fe81392cf5aa5155c"
    },
    {
      "line": 3967,
      "relation": "association",
      "evidence": "We find that phosphorylated (p-) SER235-PRO, but not pTHR231-PRO, is exclusively catalyzed by full-length Pin1 and isolated PPIase domain.",
      "citation": {
        "type": "PubMed",
        "reference": "26996941",
        "name": "Journal of molecular biology",
        "title": "Molecular Mechanism of Pin1-Tau Recognition and Catalysis.",
        "volume": "428",
        "pages": "1760-75",
        "date": "2016-05-08",
        "first": "Eichner T",
        "last": "Kern D",
        "authors": [
          "Buosi V",
          "Eichner T",
          "Kern D",
          "Kutter S",
          "Labeikovsky W"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 552,
      "target": 647,
      "key": "221299fd5560db135d50ab127dcd2835ae9b33a9e6f881a55f14198096be761e9b3b76d523f529fb36f80913db55fa9f12aa6cb5f0d9fb13080664a6eb4b6817"
    },
    {
      "line": 2793,
      "relation": "positiveCorrelation",
      "evidence": "In this study, we address the structural impact of phosphorylation of the Tau protein by Nuclear Magnetic Resonance (NMR) spectroscopy on a functional fragment of Tau (Tau[Ser208-Ser324] = TauF4). TauF4 was phosphorylated by the proline-directed CDK2/CycA3 kinase on Thr231 (generating the AT180 epitope), Ser235, and equally on Thr212 and Thr217 in the Proline-rich region (Tau[Ser208-Gln244] or PRR). These modifications strongly decrease the capacity of TauF4 to polymerize tubulin into microtubules. While all the NMR parameters are consistent with a globally disordered Tau protein fragment, local clusters of structuration can be defined. The most salient result of our NMR analysis is that phosphorylation in the PRR stabilizes a short α-helix that runs from pSer235 till the very beginning of the microtubule-binding region (Tau[Thr245-Ser324] or MTBR of TauF4).",
      "citation": {
        "type": "PubMed",
        "reference": "22072628",
        "name": "Proteins",
        "title": "Structural characterization by nuclear magnetic resonance of the impact of phosphorylation in the proline-rich region of the disordered Tau protein.",
        "volume": "80",
        "pages": "454-62",
        "date": "2012-02-01",
        "first": "Sibille N",
        "last": "Landrieu I",
        "authors": [
          "Amniai L",
          "Fauquant C",
          "Huvent I",
          "Landrieu I",
          "Leroy A",
          "Lippens G",
          "Sibille N",
          "Verdegem D",
          "Wieruszeski JM"
        ]
      },
      "source": 361,
      "target": 206,
      "key": "cf08afffde1122296b585fd11f9eadf95ff721c33eb1191859688e0f3b83325eb2667747ce08ba7ac57de00835509a2896a33d59fbf3c12d7e13c2c1e5b2c9b2"
    },
    {
      "relation": "hasVariant",
      "source": 360,
      "target": 361,
      "key": "ded8037f1237e1346f5c31533b7401e79eb36dc365fbce989e5cf57331b2126fcff676bc548718800a45a3056ea0fbd81b7005bbcc87533e7431d4574d146b0f"
    },
    {
      "line": 2793,
      "relation": "positiveCorrelation",
      "evidence": "In this study, we address the structural impact of phosphorylation of the Tau protein by Nuclear Magnetic Resonance (NMR) spectroscopy on a functional fragment of Tau (Tau[Ser208-Ser324] = TauF4). TauF4 was phosphorylated by the proline-directed CDK2/CycA3 kinase on Thr231 (generating the AT180 epitope), Ser235, and equally on Thr212 and Thr217 in the Proline-rich region (Tau[Ser208-Gln244] or PRR). These modifications strongly decrease the capacity of TauF4 to polymerize tubulin into microtubules. While all the NMR parameters are consistent with a globally disordered Tau protein fragment, local clusters of structuration can be defined. The most salient result of our NMR analysis is that phosphorylation in the PRR stabilizes a short α-helix that runs from pSer235 till the very beginning of the microtubule-binding region (Tau[Thr245-Ser324] or MTBR of TauF4).",
      "citation": {
        "type": "PubMed",
        "reference": "22072628",
        "name": "Proteins",
        "title": "Structural characterization by nuclear magnetic resonance of the impact of phosphorylation in the proline-rich region of the disordered Tau protein.",
        "volume": "80",
        "pages": "454-62",
        "date": "2012-02-01",
        "first": "Sibille N",
        "last": "Landrieu I",
        "authors": [
          "Amniai L",
          "Fauquant C",
          "Huvent I",
          "Landrieu I",
          "Leroy A",
          "Lippens G",
          "Sibille N",
          "Verdegem D",
          "Wieruszeski JM"
        ]
      },
      "source": 206,
      "target": 361,
      "key": "2cf9328a9018650cad55f7817cac4f39d882120a3e522ea961a38238ab30130a72313f5b2acfee3f8717981377132749f6ae6eae386bd3b52887fe5f3e1e4918"
    },
    {
      "line": 2794,
      "relation": "association",
      "evidence": "In this study, we address the structural impact of phosphorylation of the Tau protein by Nuclear Magnetic Resonance (NMR) spectroscopy on a functional fragment of Tau (Tau[Ser208-Ser324] = TauF4). TauF4 was phosphorylated by the proline-directed CDK2/CycA3 kinase on Thr231 (generating the AT180 epitope), Ser235, and equally on Thr212 and Thr217 in the Proline-rich region (Tau[Ser208-Gln244] or PRR). These modifications strongly decrease the capacity of TauF4 to polymerize tubulin into microtubules. While all the NMR parameters are consistent with a globally disordered Tau protein fragment, local clusters of structuration can be defined. The most salient result of our NMR analysis is that phosphorylation in the PRR stabilizes a short α-helix that runs from pSer235 till the very beginning of the microtubule-binding region (Tau[Thr245-Ser324] or MTBR of TauF4).",
      "citation": {
        "type": "PubMed",
        "reference": "22072628",
        "name": "Proteins",
        "title": "Structural characterization by nuclear magnetic resonance of the impact of phosphorylation in the proline-rich region of the disordered Tau protein.",
        "volume": "80",
        "pages": "454-62",
        "date": "2012-02-01",
        "first": "Sibille N",
        "last": "Landrieu I",
        "authors": [
          "Amniai L",
          "Fauquant C",
          "Huvent I",
          "Landrieu I",
          "Leroy A",
          "Lippens G",
          "Sibille N",
          "Verdegem D",
          "Wieruszeski JM"
        ]
      },
      "source": 206,
      "target": 488,
      "key": "c6dc2c5c4609562fd7784aa19b2ed5055dc49f9e535861d462ed1af8442caacfb1cedfb80bdf90d99b703d00f2e29700d1e5c846487ac94183f6b37db9964449"
    },
    {
      "line": 2794,
      "relation": "association",
      "evidence": "In this study, we address the structural impact of phosphorylation of the Tau protein by Nuclear Magnetic Resonance (NMR) spectroscopy on a functional fragment of Tau (Tau[Ser208-Ser324] = TauF4). TauF4 was phosphorylated by the proline-directed CDK2/CycA3 kinase on Thr231 (generating the AT180 epitope), Ser235, and equally on Thr212 and Thr217 in the Proline-rich region (Tau[Ser208-Gln244] or PRR). These modifications strongly decrease the capacity of TauF4 to polymerize tubulin into microtubules. While all the NMR parameters are consistent with a globally disordered Tau protein fragment, local clusters of structuration can be defined. The most salient result of our NMR analysis is that phosphorylation in the PRR stabilizes a short α-helix that runs from pSer235 till the very beginning of the microtubule-binding region (Tau[Thr245-Ser324] or MTBR of TauF4).",
      "citation": {
        "type": "PubMed",
        "reference": "22072628",
        "name": "Proteins",
        "title": "Structural characterization by nuclear magnetic resonance of the impact of phosphorylation in the proline-rich region of the disordered Tau protein.",
        "volume": "80",
        "pages": "454-62",
        "date": "2012-02-01",
        "first": "Sibille N",
        "last": "Landrieu I",
        "authors": [
          "Amniai L",
          "Fauquant C",
          "Huvent I",
          "Landrieu I",
          "Leroy A",
          "Lippens G",
          "Sibille N",
          "Verdegem D",
          "Wieruszeski JM"
        ]
      },
      "source": 488,
      "target": 206,
      "key": "b0a8793a6a774c60562aee12f6c5a6331bc4decbcb0fd3b625cdea642ab9f64073763d5113673be7cb2561b8159370ded05d64c9b267cb453817cac2a0bdf53e"
    },
    {
      "line": 2819,
      "relation": "increases",
      "evidence": ">8 phosphates per tau molecules (vs 2 in adult healthy brain); can also be increased during development, hibernation and temperature, heat and oxydative stress These phosphorylated states are detected by specific antibodies and are targets of proline-directed kinases (SP motifs), non-proline kinases (KXGS motif) Weakens tau-MT interaction especially S261 in R1 and S214 in proline-rich domain",
      "citation": {
        "type": "PubMed",
        "reference": "8226987",
        "name": "The Journal of biological chemistry",
        "title": "Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease.",
        "volume": "268",
        "pages": "24374-84",
        "date": "1993-11-15",
        "first": "Köpke E",
        "last": "Grundke-Iqbal I",
        "authors": [
          "Alonso AC",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Köpke E",
          "Shaikh S",
          "Tung YC"
        ]
      },
      "source": 203,
      "target": 516,
      "key": "52df3267ca2896aad0d1c0acf2d79212cc7aa578e5a184474b735bf5aa9a6dd5939254dd71f8cdf754b2a17715617cede1c643914944a91e126b625ed2360881"
    },
    {
      "line": 3418,
      "relation": "association",
      "evidence": " This post-translational modification is likely an indicator of good health since its intracellular level correlates with the availability of extracellular glucose. From a more practical point of view, it has been shown that O-GlcNAcylation impairments contribute to the etiology of cardiovascular diseases, type-2 diabetes and Alzheimer's disease (AD), three illnesses common in occidental societies.",
      "citation": {
        "type": "PubMed",
        "reference": "19732809",
        "name": "Biochimica et biophysica acta",
        "title": "Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease.",
        "volume": "1800",
        "pages": "67-79",
        "date": "2010-02-01",
        "first": "Lefebvre T",
        "last": "Michalski JC",
        "authors": [
          "Dehennaut V",
          "Drougat L",
          "Guinez C",
          "Lefebvre T",
          "Michalski JC",
          "Mir AM",
          "Mortuaire M",
          "Olivier S",
          "Vercoutter-Edouart AS"
        ]
      },
      "source": 203,
      "target": 107,
      "key": "336faad5dae672b218c400ef5478413f0cfcd7f4ecf3042b1970aa97b34fbe04ba68bc9daea45e8a59054602549628c58ea436a7b24e0cd97c33ca27351883a5"
    },
    {
      "line": 2820,
      "relation": "decreases",
      "evidence": ">8 phosphates per tau molecules (vs 2 in adult healthy brain); can also be increased during development, hibernation and temperature, heat and oxydative stress These phosphorylated states are detected by specific antibodies and are targets of proline-directed kinases (SP motifs), non-proline kinases (KXGS motif) Weakens tau-MT interaction especially S261 in R1 and S214 in proline-rich domain",
      "citation": {
        "type": "PubMed",
        "reference": "8226987",
        "name": "The Journal of biological chemistry",
        "title": "Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease.",
        "volume": "268",
        "pages": "24374-84",
        "date": "1993-11-15",
        "first": "Köpke E",
        "last": "Grundke-Iqbal I",
        "authors": [
          "Alonso AC",
          "Grundke-Iqbal I",
          "Iqbal K",
          "Köpke E",
          "Shaikh S",
          "Tung YC"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 556,
      "target": 486,
      "key": "65a4e817ab34144ee253d210cc309aa51022515f84c012705e23bafa702174255d98d28647effa342cc41354d27c56eb319061a6557618650d7ee1078f941ce1"
    },
    {
      "line": 2857,
      "relation": "positiveCorrelation",
      "evidence": "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24401760",
        "name": "Brain : a journal of neurology",
        "title": "Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.",
        "volume": "137",
        "pages": "537-52",
        "date": "2014-02-01",
        "first": "Stygelbout V",
        "last": "Brion JP",
        "authors": [
          "Ando K",
          "Brion JP",
          "D'Amico E",
          "Duyckaerts C",
          "Erneux C",
          "Jia Y",
          "Leroy K",
          "Luo HR",
          "Pouillon V",
          "Schurmans S",
          "Stygelbout V"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 460,
      "target": 917,
      "key": "7becc303ff895eb004a7cfb935a7468cb872c593ba64aa95e23b10fc84ab23d18a3300f6bcfc85aabbc8ae58a516778ff6bd6d29e729c2b8ab9a3afe166ab143"
    },
    {
      "line": 2859,
      "relation": "partOf",
      "evidence": "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24401760",
        "name": "Brain : a journal of neurology",
        "title": "Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.",
        "volume": "137",
        "pages": "537-52",
        "date": "2014-02-01",
        "first": "Stygelbout V",
        "last": "Brion JP",
        "authors": [
          "Ando K",
          "Brion JP",
          "D'Amico E",
          "Duyckaerts C",
          "Erneux C",
          "Jia Y",
          "Leroy K",
          "Luo HR",
          "Pouillon V",
          "Schurmans S",
          "Stygelbout V"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Anatomy": {
          "cerebral cortex": true
        }
      },
      "source": 460,
      "target": 127,
      "key": "c7ebeb640165909945324f97bd75b59280a9f06cffc6622fb1145a464ab813dfe389ba6bc69590ae7fe760bcbbc0218ad8af490b327e4e4d375d32eb6b1b30ab"
    },
    {
      "line": 2864,
      "relation": "increases",
      "evidence": "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24401760",
        "name": "Brain : a journal of neurology",
        "title": "Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.",
        "volume": "137",
        "pages": "537-52",
        "date": "2014-02-01",
        "first": "Stygelbout V",
        "last": "Brion JP",
        "authors": [
          "Ando K",
          "Brion JP",
          "D'Amico E",
          "Duyckaerts C",
          "Erneux C",
          "Jia Y",
          "Leroy K",
          "Luo HR",
          "Pouillon V",
          "Schurmans S",
          "Stygelbout V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Cell_Line": {
          "N2a": true
        }
      },
      "source": 798,
      "target": 174,
      "key": "eb08b2099eba7233180ea1bed26fd1acfab9077b2f4db741b9dafbb228a82083a9ef33d20b6ce9f39c9394e4d0c909202075000cf4f3671e842d35fdba38de64"
    },
    {
      "line": 2865,
      "relation": "increases",
      "evidence": "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24401760",
        "name": "Brain : a journal of neurology",
        "title": "Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.",
        "volume": "137",
        "pages": "537-52",
        "date": "2014-02-01",
        "first": "Stygelbout V",
        "last": "Brion JP",
        "authors": [
          "Ando K",
          "Brion JP",
          "D'Amico E",
          "Duyckaerts C",
          "Erneux C",
          "Jia Y",
          "Leroy K",
          "Luo HR",
          "Pouillon V",
          "Schurmans S",
          "Stygelbout V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Cell_Line": {
          "N2a": true
        }
      },
      "source": 798,
      "target": 771,
      "key": "06feb3f0744345aca46bea86125cf6465bc36ddf3ec8af3a995c52b13dc73080caf0e19ae230cf0ccfd78d611590f6dcc237c433002f1447f253ed099391363c"
    },
    {
      "line": 2874,
      "relation": "increases",
      "evidence": "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24401760",
        "name": "Brain : a journal of neurology",
        "title": "Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.",
        "volume": "137",
        "pages": "537-52",
        "date": "2014-02-01",
        "first": "Stygelbout V",
        "last": "Brion JP",
        "authors": [
          "Ando K",
          "Brion JP",
          "D'Amico E",
          "Duyckaerts C",
          "Erneux C",
          "Jia Y",
          "Leroy K",
          "Luo HR",
          "Pouillon V",
          "Schurmans S",
          "Stygelbout V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "5xFAD mice": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 798,
      "target": 771,
      "key": "8802f079a73dd0f6949764655e5f98a2e8c2d51df26f6169a8b6dd83e66905b3d2d4b284839bbe69367abbb5c6e4873e1e9ff447ac280560ecffdf98151bd749"
    },
    {
      "line": 2872,
      "relation": "increases",
      "evidence": "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24401760",
        "name": "Brain : a journal of neurology",
        "title": "Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.",
        "volume": "137",
        "pages": "537-52",
        "date": "2014-02-01",
        "first": "Stygelbout V",
        "last": "Brion JP",
        "authors": [
          "Ando K",
          "Brion JP",
          "D'Amico E",
          "Duyckaerts C",
          "Erneux C",
          "Jia Y",
          "Leroy K",
          "Luo HR",
          "Pouillon V",
          "Schurmans S",
          "Stygelbout V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "5xFAD mice": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 798,
      "target": 799,
      "key": "d22c2601f4ad7f20b685fe5ff2982744809b07d58f3362c63dda807edfe601ab8df3e2f6a181912220562fb00452be764dd1127293b1af04a38f7b44c95fda37"
    },
    {
      "line": 2873,
      "relation": "increases",
      "evidence": "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24401760",
        "name": "Brain : a journal of neurology",
        "title": "Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.",
        "volume": "137",
        "pages": "537-52",
        "date": "2014-02-01",
        "first": "Stygelbout V",
        "last": "Brion JP",
        "authors": [
          "Ando K",
          "Brion JP",
          "D'Amico E",
          "Duyckaerts C",
          "Erneux C",
          "Jia Y",
          "Leroy K",
          "Luo HR",
          "Pouillon V",
          "Schurmans S",
          "Stygelbout V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "5xFAD mice": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 798,
      "target": 800,
      "key": "948763dfd772c5b0854954f01fcc6fd8e156dc7a14420a9f531364a93847431573b45e402c17b8820b67d8917026ac187c60bcbef82986a34d6a2fac5bbb86d8"
    },
    {
      "line": 2875,
      "relation": "increases",
      "evidence": "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24401760",
        "name": "Brain : a journal of neurology",
        "title": "Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.",
        "volume": "137",
        "pages": "537-52",
        "date": "2014-02-01",
        "first": "Stygelbout V",
        "last": "Brion JP",
        "authors": [
          "Ando K",
          "Brion JP",
          "D'Amico E",
          "Duyckaerts C",
          "Erneux C",
          "Jia Y",
          "Leroy K",
          "Luo HR",
          "Pouillon V",
          "Schurmans S",
          "Stygelbout V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "5xFAD mice": true
        }
      },
      "source": 798,
      "target": 136,
      "key": "e28976cc6b874ad6f46de876ff2f91f4251574ca6d8da8cf6a584dc8a832c6d30d641cc090495d41267ae0f0ce2ab4bfb9ec5beda3c67f19075239791943c112"
    },
    {
      "line": 2876,
      "relation": "increases",
      "evidence": "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24401760",
        "name": "Brain : a journal of neurology",
        "title": "Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.",
        "volume": "137",
        "pages": "537-52",
        "date": "2014-02-01",
        "first": "Stygelbout V",
        "last": "Brion JP",
        "authors": [
          "Ando K",
          "Brion JP",
          "D'Amico E",
          "Duyckaerts C",
          "Erneux C",
          "Jia Y",
          "Leroy K",
          "Luo HR",
          "Pouillon V",
          "Schurmans S",
          "Stygelbout V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "5xFAD mice": true
        }
      },
      "source": 798,
      "target": 375,
      "key": "5a3020ff8d67621b38eb680ba0c6926be7780faf22048345065dde8e768fd0ad8b4630da0bf6f309586ff39391f3af1949df085729f0bf8cd6e886ca36651bd3"
    },
    {
      "line": 2877,
      "relation": "increases",
      "evidence": "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24401760",
        "name": "Brain : a journal of neurology",
        "title": "Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.",
        "volume": "137",
        "pages": "537-52",
        "date": "2014-02-01",
        "first": "Stygelbout V",
        "last": "Brion JP",
        "authors": [
          "Ando K",
          "Brion JP",
          "D'Amico E",
          "Duyckaerts C",
          "Erneux C",
          "Jia Y",
          "Leroy K",
          "Luo HR",
          "Pouillon V",
          "Schurmans S",
          "Stygelbout V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "5xFAD mice": true
        }
      },
      "source": 798,
      "target": 516,
      "key": "4b3949709f51c63f83b838eba89b8dcc89af67354f864c27759b36fa5516fbd366683551a40680a8015e5f22db91e01c56c71319f892115ec0e50fcd2b24e124"
    },
    {
      "line": 2866,
      "relation": "positiveCorrelation",
      "evidence": "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24401760",
        "name": "Brain : a journal of neurology",
        "title": "Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.",
        "volume": "137",
        "pages": "537-52",
        "date": "2014-02-01",
        "first": "Stygelbout V",
        "last": "Brion JP",
        "authors": [
          "Ando K",
          "Brion JP",
          "D'Amico E",
          "Duyckaerts C",
          "Erneux C",
          "Jia Y",
          "Leroy K",
          "Luo HR",
          "Pouillon V",
          "Schurmans S",
          "Stygelbout V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Cell_Line": {
          "N2a": true
        }
      },
      "source": 771,
      "target": 11,
      "key": "8a1e75ce8d8cecf2869acf71bf90bcc84a4146bfb45f959779aa85aa8aaa8b5b8ca486d8d399fed03648afbc3d73d8dd54def2aae31fd1779d01da4967a52bfa"
    },
    {
      "line": 2867,
      "relation": "directlyDecreases",
      "evidence": "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24401760",
        "name": "Brain : a journal of neurology",
        "title": "Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.",
        "volume": "137",
        "pages": "537-52",
        "date": "2014-02-01",
        "first": "Stygelbout V",
        "last": "Brion JP",
        "authors": [
          "Ando K",
          "Brion JP",
          "D'Amico E",
          "Duyckaerts C",
          "Erneux C",
          "Jia Y",
          "Leroy K",
          "Luo HR",
          "Pouillon V",
          "Schurmans S",
          "Stygelbout V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Cell_Line": {
          "N2a": true
        }
      },
      "source": 110,
      "target": 799,
      "key": "ae4a1bb2aeaa77122b046e125fc4d655883083f098f911f901199517437c1607a522c506560c07fb3173e6fdc6bb587b43aad305953f3066c19fd949520e5785"
    },
    {
      "line": 2868,
      "relation": "directlyDecreases",
      "evidence": "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24401760",
        "name": "Brain : a journal of neurology",
        "title": "Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.",
        "volume": "137",
        "pages": "537-52",
        "date": "2014-02-01",
        "first": "Stygelbout V",
        "last": "Brion JP",
        "authors": [
          "Ando K",
          "Brion JP",
          "D'Amico E",
          "Duyckaerts C",
          "Erneux C",
          "Jia Y",
          "Leroy K",
          "Luo HR",
          "Pouillon V",
          "Schurmans S",
          "Stygelbout V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Cell_Line": {
          "N2a": true
        }
      },
      "source": 110,
      "target": 800,
      "key": "9475d8d42472e8a9435cae05e7774ac319a90bad01fead8aaa479dcda223178a796fd361a8cbb482fca76498ab279b3ecbd04eb14677672422da578e9a652fb9"
    },
    {
      "line": 2869,
      "relation": "decreases",
      "evidence": "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques. In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides. In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides. Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation. However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity, resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "24401760",
        "name": "Brain : a journal of neurology",
        "title": "Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.",
        "volume": "137",
        "pages": "537-52",
        "date": "2014-02-01",
        "first": "Stygelbout V",
        "last": "Brion JP",
        "authors": [
          "Ando K",
          "Brion JP",
          "D'Amico E",
          "Duyckaerts C",
          "Erneux C",
          "Jia Y",
          "Leroy K",
          "Luo HR",
          "Pouillon V",
          "Schurmans S",
          "Stygelbout V"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Cell_Line": {
          "N2a": true
        }
      },
      "source": 110,
      "target": 11,
      "key": "ff02d19b0e491e753fa7b262057eabfc75abdd5ac5ac298a1fe7bbafd84413ed5f2400aff93e076ec71172b020969456b194c137f9843e03741691f1895426fa"
    },
    {
      "line": 2893,
      "relation": "directlyDecreases",
      "evidence": "Small molecules in the diaminothiazole class are potent Tau kinase inhibitors that target CDK5 and GSK3β. Lead compounds from the series have IC50 values toward CDK5/p25 and GSK3β in the low nanomolar range and no observed toxicity in the therapeutic dose range. Neuronal protective effects and decreased PHF-1 immunoreactivity were observed in two animal models, 3×Tg-AD and CK-p25. Treatment nearly eliminated Sarkosyl-insoluble Tau with the most prominent effect on the phosphorylation at Ser-404. Treatment also induced the recovery of memory in a fear conditioning assay.",
      "citation": {
        "type": "PubMed",
        "reference": "23737518",
        "name": "The Journal of biological chemistry",
        "title": "Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models.",
        "volume": "288",
        "pages": "22042-56",
        "date": "2013-07-26",
        "first": "Zhang X",
        "last": "Kosik KS",
        "authors": [
          "Cornwell ME",
          "Cuny GD",
          "Hernandez I",
          "Kosik KS",
          "Laha JK",
          "Mair W",
          "Rei D",
          "Steen JA",
          "Tsai LH",
          "Zhang X"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Half_life": {
          "30 min": true
        },
        "IC50": {
          "30 nM": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 104,
      "target": 860,
      "key": "669c87c244808cc0d28bc886a5ae90a0ba2d2161a9fa06f777cd8ea13e7aac32f2f7a7395c3dfd637da6d04cf1a7ad22e1d15a5ce0c43f9f3afd2102830a519c"
    },
    {
      "line": 2895,
      "relation": "decreases",
      "evidence": "Small molecules in the diaminothiazole class are potent Tau kinase inhibitors that target CDK5 and GSK3β. Lead compounds from the series have IC50 values toward CDK5/p25 and GSK3β in the low nanomolar range and no observed toxicity in the therapeutic dose range. Neuronal protective effects and decreased PHF-1 immunoreactivity were observed in two animal models, 3×Tg-AD and CK-p25. Treatment nearly eliminated Sarkosyl-insoluble Tau with the most prominent effect on the phosphorylation at Ser-404. Treatment also induced the recovery of memory in a fear conditioning assay.",
      "citation": {
        "type": "PubMed",
        "reference": "23737518",
        "name": "The Journal of biological chemistry",
        "title": "Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models.",
        "volume": "288",
        "pages": "22042-56",
        "date": "2013-07-26",
        "first": "Zhang X",
        "last": "Kosik KS",
        "authors": [
          "Cornwell ME",
          "Cuny GD",
          "Hernandez I",
          "Kosik KS",
          "Laha JK",
          "Mair W",
          "Rei D",
          "Steen JA",
          "Tsai LH",
          "Zhang X"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Half_life": {
          "30 min": true
        }
      },
      "source": 104,
      "target": 117,
      "key": "67c3408be9610fd1dd54b7a8a0bb8bf780a86568413682b6f46c5b0105e3ac40b06fb2d05c4a30805f315a3ff25257b5e6fbbe6098044f363b482d031127980e"
    },
    {
      "line": 2896,
      "relation": "decreases",
      "evidence": "Small molecules in the diaminothiazole class are potent Tau kinase inhibitors that target CDK5 and GSK3β. Lead compounds from the series have IC50 values toward CDK5/p25 and GSK3β in the low nanomolar range and no observed toxicity in the therapeutic dose range. Neuronal protective effects and decreased PHF-1 immunoreactivity were observed in two animal models, 3×Tg-AD and CK-p25. Treatment nearly eliminated Sarkosyl-insoluble Tau with the most prominent effect on the phosphorylation at Ser-404. Treatment also induced the recovery of memory in a fear conditioning assay.",
      "citation": {
        "type": "PubMed",
        "reference": "23737518",
        "name": "The Journal of biological chemistry",
        "title": "Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models.",
        "volume": "288",
        "pages": "22042-56",
        "date": "2013-07-26",
        "first": "Zhang X",
        "last": "Kosik KS",
        "authors": [
          "Cornwell ME",
          "Cuny GD",
          "Hernandez I",
          "Kosik KS",
          "Laha JK",
          "Mair W",
          "Rei D",
          "Steen JA",
          "Tsai LH",
          "Zhang X"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Half_life": {
          "30 min": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 104,
      "target": 311,
      "key": "c2b57c4b6d741a4fd647eac252262627ca8cdeaf7da53d87a3a3082e5f72f75b954173282397ec7d378f6a873d5fb2d4b5f096d9d4225e26feaed0ddd98f333e"
    },
    {
      "line": 2898,
      "relation": "directlyDecreases",
      "evidence": "Small molecules in the diaminothiazole class are potent Tau kinase inhibitors that target CDK5 and GSK3β. Lead compounds from the series have IC50 values toward CDK5/p25 and GSK3β in the low nanomolar range and no observed toxicity in the therapeutic dose range. Neuronal protective effects and decreased PHF-1 immunoreactivity were observed in two animal models, 3×Tg-AD and CK-p25. Treatment nearly eliminated Sarkosyl-insoluble Tau with the most prominent effect on the phosphorylation at Ser-404. Treatment also induced the recovery of memory in a fear conditioning assay.",
      "citation": {
        "type": "PubMed",
        "reference": "23737518",
        "name": "The Journal of biological chemistry",
        "title": "Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models.",
        "volume": "288",
        "pages": "22042-56",
        "date": "2013-07-26",
        "first": "Zhang X",
        "last": "Kosik KS",
        "authors": [
          "Cornwell ME",
          "Cuny GD",
          "Hernandez I",
          "Kosik KS",
          "Laha JK",
          "Mair W",
          "Rei D",
          "Steen JA",
          "Tsai LH",
          "Zhang X"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Half_life": {
          "30 min": true
        },
        "IC50": {
          "45 nM": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 104,
      "target": 866,
      "key": "c4a898efaa6f39e5c9759438b4457db01b43836faa8f1739df09a2df1288c3c3e2a9d75b901deffbed3dc827f16a8c9bb2a937b3411961b2624c68eeaf83d6bb"
    },
    {
      "line": 2901,
      "relation": "isA",
      "evidence": "Small molecules in the diaminothiazole class are potent Tau kinase inhibitors that target CDK5 and GSK3β. Lead compounds from the series have IC50 values toward CDK5/p25 and GSK3β in the low nanomolar range and no observed toxicity in the therapeutic dose range. Neuronal protective effects and decreased PHF-1 immunoreactivity were observed in two animal models, 3×Tg-AD and CK-p25. Treatment nearly eliminated Sarkosyl-insoluble Tau with the most prominent effect on the phosphorylation at Ser-404. Treatment also induced the recovery of memory in a fear conditioning assay.",
      "citation": {
        "type": "PubMed",
        "reference": "23737518",
        "name": "The Journal of biological chemistry",
        "title": "Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models.",
        "volume": "288",
        "pages": "22042-56",
        "date": "2013-07-26",
        "first": "Zhang X",
        "last": "Kosik KS",
        "authors": [
          "Cornwell ME",
          "Cuny GD",
          "Hernandez I",
          "Kosik KS",
          "Laha JK",
          "Mair W",
          "Rei D",
          "Steen JA",
          "Tsai LH",
          "Zhang X"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 104,
      "target": 149,
      "key": "de46d5147284351b58a868c4fff9d5af4050943ee25cb1efae84202e94efc64349f97f75f812536b3825b6d18a835f0446f33feb958b9a8daad1da122833d9ab"
    },
    {
      "line": 2902,
      "relation": "isA",
      "evidence": "Small molecules in the diaminothiazole class are potent Tau kinase inhibitors that target CDK5 and GSK3β. Lead compounds from the series have IC50 values toward CDK5/p25 and GSK3β in the low nanomolar range and no observed toxicity in the therapeutic dose range. Neuronal protective effects and decreased PHF-1 immunoreactivity were observed in two animal models, 3×Tg-AD and CK-p25. Treatment nearly eliminated Sarkosyl-insoluble Tau with the most prominent effect on the phosphorylation at Ser-404. Treatment also induced the recovery of memory in a fear conditioning assay.",
      "citation": {
        "type": "PubMed",
        "reference": "23737518",
        "name": "The Journal of biological chemistry",
        "title": "Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models.",
        "volume": "288",
        "pages": "22042-56",
        "date": "2013-07-26",
        "first": "Zhang X",
        "last": "Kosik KS",
        "authors": [
          "Cornwell ME",
          "Cuny GD",
          "Hernandez I",
          "Kosik KS",
          "Laha JK",
          "Mair W",
          "Rei D",
          "Steen JA",
          "Tsai LH",
          "Zhang X"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 105,
      "target": 149,
      "key": "9d0c5139da973f4a516bc54727a941f1f65fc874a6a6f9622734c2f2859246cdd6955c8067cae06aae92f58c857bb73c3addcdb64b2b119d97a771e7be6f8b34"
    },
    {
      "line": 2906,
      "relation": "directlyDecreases",
      "evidence": "Small molecules in the diaminothiazole class are potent Tau kinase inhibitors that target CDK5 and GSK3β. Lead compounds from the series have IC50 values toward CDK5/p25 and GSK3β in the low nanomolar range and no observed toxicity in the therapeutic dose range. Neuronal protective effects and decreased PHF-1 immunoreactivity were observed in two animal models, 3×Tg-AD and CK-p25. Treatment nearly eliminated Sarkosyl-insoluble Tau with the most prominent effect on the phosphorylation at Ser-404. Treatment also induced the recovery of memory in a fear conditioning assay.",
      "citation": {
        "type": "PubMed",
        "reference": "23737518",
        "name": "The Journal of biological chemistry",
        "title": "Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models.",
        "volume": "288",
        "pages": "22042-56",
        "date": "2013-07-26",
        "first": "Zhang X",
        "last": "Kosik KS",
        "authors": [
          "Cornwell ME",
          "Cuny GD",
          "Hernandez I",
          "Kosik KS",
          "Laha JK",
          "Mair W",
          "Rei D",
          "Steen JA",
          "Tsai LH",
          "Zhang X"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Half_life": {
          "29 min": true
        },
        "IC50": {
          "62 nM": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 105,
      "target": 860,
      "key": "c7e0fe12200924e5a5d8d2854f3d3e4fa130427e37e6a43a97a4b00facabc16165c04dedd500ad77728c8da814d200b9c668315bb3d122a04372b8f63c50a6c1"
    },
    {
      "line": 2909,
      "relation": "directlyDecreases",
      "evidence": "Small molecules in the diaminothiazole class are potent Tau kinase inhibitors that target CDK5 and GSK3β. Lead compounds from the series have IC50 values toward CDK5/p25 and GSK3β in the low nanomolar range and no observed toxicity in the therapeutic dose range. Neuronal protective effects and decreased PHF-1 immunoreactivity were observed in two animal models, 3×Tg-AD and CK-p25. Treatment nearly eliminated Sarkosyl-insoluble Tau with the most prominent effect on the phosphorylation at Ser-404. Treatment also induced the recovery of memory in a fear conditioning assay.",
      "citation": {
        "type": "PubMed",
        "reference": "23737518",
        "name": "The Journal of biological chemistry",
        "title": "Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models.",
        "volume": "288",
        "pages": "22042-56",
        "date": "2013-07-26",
        "first": "Zhang X",
        "last": "Kosik KS",
        "authors": [
          "Cornwell ME",
          "Cuny GD",
          "Hernandez I",
          "Kosik KS",
          "Laha JK",
          "Mair W",
          "Rei D",
          "Steen JA",
          "Tsai LH",
          "Zhang X"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Half_life": {
          "29 min": true
        },
        "IC50": {
          "19 nM": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 105,
      "target": 866,
      "key": "d1d5d501cdc0316b9755173360f7ad615d0c52fdd46eccc484a04c20a6a8b0bd5520130ecf77c01e05176de506fc07d21118718f5518ebbdd034f2b8bbb95e09"
    },
    {
      "line": 2903,
      "relation": "isA",
      "evidence": "Small molecules in the diaminothiazole class are potent Tau kinase inhibitors that target CDK5 and GSK3β. Lead compounds from the series have IC50 values toward CDK5/p25 and GSK3β in the low nanomolar range and no observed toxicity in the therapeutic dose range. Neuronal protective effects and decreased PHF-1 immunoreactivity were observed in two animal models, 3×Tg-AD and CK-p25. Treatment nearly eliminated Sarkosyl-insoluble Tau with the most prominent effect on the phosphorylation at Ser-404. Treatment also induced the recovery of memory in a fear conditioning assay.",
      "citation": {
        "type": "PubMed",
        "reference": "23737518",
        "name": "The Journal of biological chemistry",
        "title": "Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models.",
        "volume": "288",
        "pages": "22042-56",
        "date": "2013-07-26",
        "first": "Zhang X",
        "last": "Kosik KS",
        "authors": [
          "Cornwell ME",
          "Cuny GD",
          "Hernandez I",
          "Kosik KS",
          "Laha JK",
          "Mair W",
          "Rei D",
          "Steen JA",
          "Tsai LH",
          "Zhang X"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 106,
      "target": 149,
      "key": "f274218b2ce6edfd4d311d641249e4d0c0a768a3318a1ce5e2c42898eb1b33943a9b99ae344a277c8af408b1a17f5cb84fdba833f60e2a0a6a2d99d15ca93f04"
    },
    {
      "line": 2914,
      "relation": "directlyDecreases",
      "evidence": "Small molecules in the diaminothiazole class are potent Tau kinase inhibitors that target CDK5 and GSK3β. Lead compounds from the series have IC50 values toward CDK5/p25 and GSK3β in the low nanomolar range and no observed toxicity in the therapeutic dose range. Neuronal protective effects and decreased PHF-1 immunoreactivity were observed in two animal models, 3×Tg-AD and CK-p25. Treatment nearly eliminated Sarkosyl-insoluble Tau with the most prominent effect on the phosphorylation at Ser-404. Treatment also induced the recovery of memory in a fear conditioning assay.",
      "citation": {
        "type": "PubMed",
        "reference": "23737518",
        "name": "The Journal of biological chemistry",
        "title": "Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models.",
        "volume": "288",
        "pages": "22042-56",
        "date": "2013-07-26",
        "first": "Zhang X",
        "last": "Kosik KS",
        "authors": [
          "Cornwell ME",
          "Cuny GD",
          "Hernandez I",
          "Kosik KS",
          "Laha JK",
          "Mair W",
          "Rei D",
          "Steen JA",
          "Tsai LH",
          "Zhang X"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Half_life": {
          "70 min": true
        },
        "IC50": {
          "90 nM": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 106,
      "target": 860,
      "key": "ee3b03212ce8119f60f54c3c8e12e3ad0d12ab77bedea4db8b115b65bc8c8275892e6d5388340f12202661b0ff0f28618f4c901099d3f5452cbf7538e584b7be"
    },
    {
      "line": 2917,
      "relation": "directlyDecreases",
      "evidence": "Small molecules in the diaminothiazole class are potent Tau kinase inhibitors that target CDK5 and GSK3β. Lead compounds from the series have IC50 values toward CDK5/p25 and GSK3β in the low nanomolar range and no observed toxicity in the therapeutic dose range. Neuronal protective effects and decreased PHF-1 immunoreactivity were observed in two animal models, 3×Tg-AD and CK-p25. Treatment nearly eliminated Sarkosyl-insoluble Tau with the most prominent effect on the phosphorylation at Ser-404. Treatment also induced the recovery of memory in a fear conditioning assay.",
      "citation": {
        "type": "PubMed",
        "reference": "23737518",
        "name": "The Journal of biological chemistry",
        "title": "Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models.",
        "volume": "288",
        "pages": "22042-56",
        "date": "2013-07-26",
        "first": "Zhang X",
        "last": "Kosik KS",
        "authors": [
          "Cornwell ME",
          "Cuny GD",
          "Hernandez I",
          "Kosik KS",
          "Laha JK",
          "Mair W",
          "Rei D",
          "Steen JA",
          "Tsai LH",
          "Zhang X"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Half_life": {
          "70 min": true
        },
        "IC50": {
          "38 nM": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 106,
      "target": 866,
      "key": "7ed9e642c17cf2908c19845e840a5700d47c80d7a8ede37bc6489d51659862be2d23cb7982a0260b240d0bf40b28826e3c3cc29f20440f1d62f0fb8a9fcdf99b"
    },
    {
      "line": 2934,
      "relation": "decreases",
      "evidence": "Though whole tau assembled poorly, constructs containing three internal repeats (corresponding to the fetal tau isoform) formed PHFs reproducibly. This ability depended on intermolecular disulfide bridges formed by the single Cys-322. Blocking the SH group, mutating Cys for Ala, or keeping T in a reducing environment all inhibited assembly. On the other hand, Cys-322 can be oxidized, and this leads to PHF assembly (ref. 11; this report). In vitro this is achieved most easily by using constructs of the 'fetal' isoform of T (htau23) that has only three repeats. Conversely, reducing agents or the second repeat or T can be viewed as 'antidotes' against PHF assembly.The synthetic PHFs bound the dye thioflavin S used in Alzheimer disease diagnostics.",
      "citation": {
        "type": "PubMed",
        "reference": "7667312",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments.",
        "volume": "92",
        "pages": "8463-7",
        "date": "1995-08-29",
        "first": "Schweers O",
        "last": "Mandelkow E",
        "authors": [
          "Biernat J",
          "Mandelkow E",
          "Mandelkow EM",
          "Schweers O"
        ]
      },
      "source": 605,
      "target": 132,
      "key": "f9c4da0b98c496ffb8589dcd2be4afee88cc1b679527c90bbaf819aca5c69a8a1ec68515ca6c56348a0ca005cd420d545c54705a70c085c1cb42bbc25f672f02"
    },
    {
      "line": 2936,
      "relation": "positiveCorrelation",
      "evidence": "Though whole tau assembled poorly, constructs containing three internal repeats (corresponding to the fetal tau isoform) formed PHFs reproducibly. This ability depended on intermolecular disulfide bridges formed by the single Cys-322. Blocking the SH group, mutating Cys for Ala, or keeping T in a reducing environment all inhibited assembly. On the other hand, Cys-322 can be oxidized, and this leads to PHF assembly (ref. 11; this report). In vitro this is achieved most easily by using constructs of the 'fetal' isoform of T (htau23) that has only three repeats. Conversely, reducing agents or the second repeat or T can be viewed as 'antidotes' against PHF assembly.The synthetic PHFs bound the dye thioflavin S used in Alzheimer disease diagnostics.",
      "citation": {
        "type": "PubMed",
        "reference": "7667312",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments.",
        "volume": "92",
        "pages": "8463-7",
        "date": "1995-08-29",
        "first": "Schweers O",
        "last": "Mandelkow E",
        "authors": [
          "Biernat J",
          "Mandelkow E",
          "Mandelkow EM",
          "Schweers O"
        ]
      },
      "source": 120,
      "target": 132,
      "key": "093a0f805bd4e845977f0d4fda71c9ab0496d7cffe19b2b9958023584c80200443f3aa2bae4259e32741cc7d79866803509a69d3d5b1ef22e9344cc4bf8c9c82"
    },
    {
      "line": 2952,
      "relation": "directlyDecreases",
      "evidence": "In this study, we modified the PCAF inhibitor by chemical derivatization and selected compound C-30-27 as the most potent PCAF inhibitor. We demonstrated that C-30-27 selectively inhibited acetylation-dependent nuclear factor-κB (NF-κB) at Lys-122 and suppressed the NF-κB-mediated inflammatory response induced by lipopolysaccharide (LPS) or Aβ in both BV2 and Neuro-2A (N2A) cells. Finally, we demonstrated that C-30-27 improved cognitive deficits, as well as the capacity for locomotion and the damaged cholinergic system in the Aβ-treated rats.",
      "citation": {
        "type": "PubMed",
        "reference": "25672970",
        "name": "International journal of molecular medicine",
        "title": "Selective PCAF inhibitor ameliorates cognitive and behavioral deficits by suppressing NF-κB-mediated neuroinflammation induced by Aβ in a model of Alzheimer's disease.",
        "volume": "35",
        "pages": "1109-18",
        "date": "2015-04-01",
        "first": "Park SY",
        "last": "Yoon HG",
        "authors": [
          "Bae D",
          "Kim MJ",
          "Kim S",
          "Kim YJ",
          "Lee YH",
          "Na Y",
          "Park SY",
          "Yoon HG"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true,
          "BV2": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 98,
      "target": 463,
      "key": "01de1626ac869682797d7f7fd153b3481cf5afb9192aa25510fe4d7a96d801acdd7891da6a648e2f4cc2ace6156647a160ee48cb6d1e7bd123d3e3c30b0a8720"
    },
    {
      "line": 2959,
      "relation": "increases",
      "evidence": "In this study, we modified the PCAF inhibitor by chemical derivatization and selected compound C-30-27 as the most potent PCAF inhibitor. We demonstrated that C-30-27 selectively inhibited acetylation-dependent nuclear factor-κB (NF-κB) at Lys-122 and suppressed the NF-κB-mediated inflammatory response induced by lipopolysaccharide (LPS) or Aβ in both BV2 and Neuro-2A (N2A) cells. Finally, we demonstrated that C-30-27 improved cognitive deficits, as well as the capacity for locomotion and the damaged cholinergic system in the Aβ-treated rats.",
      "citation": {
        "type": "PubMed",
        "reference": "25672970",
        "name": "International journal of molecular medicine",
        "title": "Selective PCAF inhibitor ameliorates cognitive and behavioral deficits by suppressing NF-κB-mediated neuroinflammation induced by Aβ in a model of Alzheimer's disease.",
        "volume": "35",
        "pages": "1109-18",
        "date": "2015-04-01",
        "first": "Park SY",
        "last": "Yoon HG",
        "authors": [
          "Bae D",
          "Kim MJ",
          "Kim S",
          "Kim YJ",
          "Lee YH",
          "Na Y",
          "Park SY",
          "Yoon HG"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 98,
      "target": 920,
      "key": "4d5fa87ea1979557b85894d356cb226a064a2c19b0c2fd0290eeb4530f51b6ee6f646ec607d0cb61abf273ec59caa448041722be4334b80a11c0c75de3e8a3d8"
    },
    {
      "line": 2953,
      "relation": "positiveCorrelation",
      "evidence": "In this study, we modified the PCAF inhibitor by chemical derivatization and selected compound C-30-27 as the most potent PCAF inhibitor. We demonstrated that C-30-27 selectively inhibited acetylation-dependent nuclear factor-κB (NF-κB) at Lys-122 and suppressed the NF-κB-mediated inflammatory response induced by lipopolysaccharide (LPS) or Aβ in both BV2 and Neuro-2A (N2A) cells. Finally, we demonstrated that C-30-27 improved cognitive deficits, as well as the capacity for locomotion and the damaged cholinergic system in the Aβ-treated rats.",
      "citation": {
        "type": "PubMed",
        "reference": "25672970",
        "name": "International journal of molecular medicine",
        "title": "Selective PCAF inhibitor ameliorates cognitive and behavioral deficits by suppressing NF-κB-mediated neuroinflammation induced by Aβ in a model of Alzheimer's disease.",
        "volume": "35",
        "pages": "1109-18",
        "date": "2015-04-01",
        "first": "Park SY",
        "last": "Yoon HG",
        "authors": [
          "Bae D",
          "Kim MJ",
          "Kim S",
          "Kim YJ",
          "Lee YH",
          "Na Y",
          "Park SY",
          "Yoon HG"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true,
          "BV2": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 463,
      "target": 295,
      "key": "c7fb1076d13a0c0c656b84285aee63f48e5105e1859bcc6d2d918863f302252d638e6b0a03620824c81dae96364cc40525ed35666476f6d8fa0af4db4108dd01"
    },
    {
      "line": 3004,
      "relation": "increases",
      "evidence": "The N-terminus of β-catenin has phosphorylation, ubiquitination, and acetylation sites that regulate its stability and signaling. In the absence of a Wnt signal, Ser33, Ser37, and Thr41 are constitutively phosphorylated by glycogen synthase kinase 3β (GSK3β). β-Catenin phosphorylated at these sites is recognized by β-transducin repeat-containing protein (βTrCP), which results in ubiquitination and degradation by the ubiquitin-proteasome pathway. The N-terminal regulatory domain of β-catenin also includes Ser45, a phosphorylation site for Casein Kinase 1α (CK1α) and Lys49, which is acetylated by the acetyltransferase p300/CBP-associated factor (PCAF). The relevance of Lys49 acetylation and Ser45 phosphorylation to the function of β-catenin is an active area of investigation. We find that HDAC6 inhibitors increase Lys49 acetylation and Ser45 phosphorylation but do not affect Ser33, Ser37, and Thr41 phosphorylation. Lys49 acetylation results in decreased ubiquitination of β-catenin in the presence of proteasome inhibition. While increased Lys49 acetylation does not affect total levels of β-catenin, it results in increased membrane localization of β-catenin.",
      "citation": {
        "type": "PubMed",
        "reference": "25546293",
        "name": "ACS chemical biology",
        "title": "HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of β-catenin in human iPSC-derived neuronal cells.",
        "volume": "10",
        "pages": "883-90",
        "date": "2015-03-20",
        "first": "Iaconelli J",
        "last": "Karmacharya R",
        "authors": [
          "Berkovitch SS",
          "Chattopadhyay S",
          "Haggarty SJ",
          "Huang JH",
          "Iaconelli J",
          "Karmacharya R",
          "Mazitschek R",
          "Schreiber SL"
        ]
      },
      "source": 463,
      "target": 421,
      "key": "4466d6dec66fb37c0d253def25694f48c380312337b1f81df49a97a86b5dd32b1e77eca6cad71ab1b3f3c26f1a19eeb3a7b4825b4fcae86eac36f04cca2907cf"
    },
    {
      "line": 3246,
      "relation": "positiveCorrelation",
      "evidence": "Here we show through systematic epigenetic studies that the histone acetyltransferase p300/CBP-associated factor (PCAF) promotes acetylation of histone 3 Lys 9 at the promoters of established key regeneration-associated genes following a peripheral but not a central axonal injury. Furthermore, we find that extracellular signal-regulated kinase (ERK)-mediated retrograde signalling is required for PCAF-dependent regenerative gene reprogramming. Finally, PCAF is necessary for conditioning-dependent axonal regeneration and also singularly promotes regeneration after spinal cord injury. ",
      "citation": {
        "type": "PubMed",
        "reference": "24686445",
        "name": "Nature communications",
        "title": "PCAF-dependent epigenetic changes promote axonal regeneration in the central nervous system.",
        "volume": "5",
        "pages": "3527",
        "date": "2014-04-01",
        "first": "Puttagunta R",
        "last": "Di Giovanni S",
        "authors": [
          "Boutillier AL",
          "Bradke F",
          "Di Giovanni S",
          "Gaub P",
          "Hervera A",
          "Joshi Y",
          "Laskowski CJ",
          "Lindner R",
          "Nguyen T",
          "Puttagunta R",
          "Rathore KI",
          "Schmandke A",
          "Sória MG",
          "Tedeschi A"
        ]
      },
      "annotations": {
        "Anatomy": {
          "dorsal root ganglion": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 463,
      "target": 288,
      "key": "d2796847660ae3128ba4e89135761a5d05483abf5c90ba7ff4e95f69b13c28d0008c75eba1e02b18b1389b831858d5eb86b901b57ae21e89d54f473841a50d23"
    },
    {
      "line": 3248,
      "relation": "increases",
      "evidence": "Here we show through systematic epigenetic studies that the histone acetyltransferase p300/CBP-associated factor (PCAF) promotes acetylation of histone 3 Lys 9 at the promoters of established key regeneration-associated genes following a peripheral but not a central axonal injury. Furthermore, we find that extracellular signal-regulated kinase (ERK)-mediated retrograde signalling is required for PCAF-dependent regenerative gene reprogramming. Finally, PCAF is necessary for conditioning-dependent axonal regeneration and also singularly promotes regeneration after spinal cord injury. ",
      "citation": {
        "type": "PubMed",
        "reference": "24686445",
        "name": "Nature communications",
        "title": "PCAF-dependent epigenetic changes promote axonal regeneration in the central nervous system.",
        "volume": "5",
        "pages": "3527",
        "date": "2014-04-01",
        "first": "Puttagunta R",
        "last": "Di Giovanni S",
        "authors": [
          "Boutillier AL",
          "Bradke F",
          "Di Giovanni S",
          "Gaub P",
          "Hervera A",
          "Joshi Y",
          "Laskowski CJ",
          "Lindner R",
          "Nguyen T",
          "Puttagunta R",
          "Rathore KI",
          "Schmandke A",
          "Sória MG",
          "Tedeschi A"
        ]
      },
      "annotations": {
        "Anatomy": {
          "dorsal root ganglion": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 463,
      "target": 317,
      "key": "1b9754e604c66fd2082582797d6a3af6b476cf321a614f342c421e5f1ab3746711b9d3242dc17686da983591597cd2b6d0d35070408a3711081149545636ec6f"
    },
    {
      "line": 2953,
      "relation": "positiveCorrelation",
      "evidence": "In this study, we modified the PCAF inhibitor by chemical derivatization and selected compound C-30-27 as the most potent PCAF inhibitor. We demonstrated that C-30-27 selectively inhibited acetylation-dependent nuclear factor-κB (NF-κB) at Lys-122 and suppressed the NF-κB-mediated inflammatory response induced by lipopolysaccharide (LPS) or Aβ in both BV2 and Neuro-2A (N2A) cells. Finally, we demonstrated that C-30-27 improved cognitive deficits, as well as the capacity for locomotion and the damaged cholinergic system in the Aβ-treated rats.",
      "citation": {
        "type": "PubMed",
        "reference": "25672970",
        "name": "International journal of molecular medicine",
        "title": "Selective PCAF inhibitor ameliorates cognitive and behavioral deficits by suppressing NF-κB-mediated neuroinflammation induced by Aβ in a model of Alzheimer's disease.",
        "volume": "35",
        "pages": "1109-18",
        "date": "2015-04-01",
        "first": "Park SY",
        "last": "Yoon HG",
        "authors": [
          "Bae D",
          "Kim MJ",
          "Kim S",
          "Kim YJ",
          "Lee YH",
          "Na Y",
          "Park SY",
          "Yoon HG"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true,
          "BV2": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 295,
      "target": 463,
      "key": "5eb07779320cef09d405fc56e05fb4831b42dafff77e0064bd91e39c57f3015de43f6941456509b6211ad2f3d9c959ca21922a603535c9bacaaf34d1f0b47987"
    },
    {
      "line": 2966,
      "relation": "increases",
      "evidence": "Taking data from three independent experiments, the apparent Km of the p300 AT domain for histone H4 was determined to be 2.7 µM.",
      "citation": {
        "type": "PubMed",
        "reference": "11691934",
        "name": "Nucleic acids research",
        "title": "Functional analysis of the p300 acetyltransferase domain: the PHD finger of p300 but not of CBP is dispensable for enzymatic activity.",
        "volume": "29",
        "pages": "4462-71",
        "date": "2001-11-01",
        "first": "Bordoli L",
        "last": "Eckner R",
        "authors": [
          "Bordoli L",
          "Eckner R",
          "Hüsser S",
          "Lüthi U",
          "Netsch M",
          "Osmani H"
        ]
      },
      "annotations": {
        "Km": {
          "2.7 µM": true
        }
      },
      "source": 447,
      "target": 277,
      "key": "2caba5468ed7c7ecaa753b9ad16efb5c704436e8bfe8a262b1e6d487d0d6c639d84fe8ef00fb5ebb1b9259e0db74705d826c3afe62fe8222cfa201623de48bf0"
    },
    {
      "line": 3291,
      "relation": "increases",
      "evidence": "Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293T": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 447,
      "target": 491,
      "key": "603b0cfc225e3b54758b1e73e4a0479bd1584b86b77ff6e80b9eb934c89be0982c42bd80fbe090cbf41979f71058ab8595fefb25191a8c1e2d9bb9450fd04f35"
    },
    {
      "line": 3292,
      "relation": "increases",
      "evidence": "Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293T": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 447,
      "target": 492,
      "key": "eb9c88d1b95a8e06cf711e81b01468dfe9e35cd5b104817eac5c191083a6c6ba161c460e0f8490214a339ace59b2ce01dd28e4dae8733bf57c1356301385a0b8"
    },
    {
      "line": 3293,
      "relation": "increases",
      "evidence": "Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293T": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 447,
      "target": 493,
      "key": "46d6f59ae7a5af54ddc317511c6ddf7f4afb800aecbc0daab18d13dd3de8bf0c9be02b0bda26c63ad8a2c6d00906e458322ff9bc68fd8a6ea66d1b517c4c052c"
    },
    {
      "line": 3294,
      "relation": "increases",
      "evidence": "Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293T": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 447,
      "target": 495,
      "key": "66a1ec04b82f828b4985e036fa95e0317978b5790e33f1e288e0d200993f24dc83e776ca40e4c6170918a6bbf2d3256de286aed7e9bf708006e63e1c710e494a"
    },
    {
      "line": 3295,
      "relation": "increases",
      "evidence": "Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293T": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 447,
      "target": 497,
      "key": "f85ae5c97a2e6ac6751c3ccdf85c7115c4975c0d9312de8569dcd3dfc06adaf2c35fa37a702d736335a540837cc9c0e3c569e97006f7d05ce139e4b30e9292a2"
    },
    {
      "line": 3296,
      "relation": "increases",
      "evidence": "Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293T": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 447,
      "target": 498,
      "key": "4df1fa3853cf97d97a957faf49078a0dd17bcc86b0f49a9df1aed533cb7ad73f1bebd01755bed2b940726e9e9eeeaf24c9d09a89ae1eced3ed3f72e00bd0760a"
    },
    {
      "line": 3297,
      "relation": "increases",
      "evidence": "Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293T": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 447,
      "target": 499,
      "key": "e9ae26bcf0ee9c02328007fc616b3bcbfc7ae5d9c75166f44dff875c13bc2c57d6c845128b15ff90b64c98ce9c011dd0e26208277161fd0b24979aba73d8adbc"
    },
    {
      "line": 3298,
      "relation": "increases",
      "evidence": "Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293T": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 447,
      "target": 500,
      "key": "c83c9e114c3c3437a5070000eed9f6ee3760777b59247b363205acbc1045ce55c54242bebca03c7a4bf689579f3f5be4d4f1b3dfc328e503d3ed4cee6bad28a4"
    },
    {
      "line": 3299,
      "relation": "increases",
      "evidence": "Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293T": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 447,
      "target": 501,
      "key": "6a7c3b78ed6df47c8db54df8421be7071dd372e7f07e53c85206986ed7417979e64a434ce7184450d848cf1e264d519d82d232df6fc5eaf3774be1353a438eb3"
    },
    {
      "line": 3300,
      "relation": "increases",
      "evidence": "Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293T": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 447,
      "target": 502,
      "key": "f62780514d7da8609e4b3a5c9ba1a6920938a7c3913185f25916bc30c001f22a78de324b9947592b0bc9b1f8ac50f3af325681187b546ade99c56e43144df49e"
    },
    {
      "line": 3301,
      "relation": "increases",
      "evidence": "Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293T": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 447,
      "target": 503,
      "key": "b2ce82c03b4b94276bab63f6669e1df98e9a89627f684d93143cda4d4c8864ca879bbe4103374cf9f7eda8c61f7c2407ad3e7551f30a16a799686608c9c1e84d"
    },
    {
      "line": 3302,
      "relation": "increases",
      "evidence": "Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293T": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 447,
      "target": 504,
      "key": "7379af73190ec7731796c7dcf86ecaa848577c04256be5bf1c66822cd256cc369da8b4d0b427f66893ae20f8773ca229bdafcb93a307b195553f9e3826ceba18"
    },
    {
      "line": 3303,
      "relation": "increases",
      "evidence": "Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293T": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 447,
      "target": 507,
      "key": "c98145cdd2513a793a8d149c4a72d8bb623d4b1465f770a001f51b10e7422fa35a3ce7526c27c1d1b8000ab8566705f91d89535455e07726858ccc78a378f3f4"
    },
    {
      "line": 3304,
      "relation": "increases",
      "evidence": "Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293T": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 447,
      "target": 508,
      "key": "00c422d823026805af769935d041e4239a9d72ae4d30175bf423c0d1cbff3697e86340873eba017b4460a3a3afc1f2672b25b0015f15fafdeff68ec3b4dbb326"
    },
    {
      "line": 3305,
      "relation": "increases",
      "evidence": "Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293T": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 447,
      "target": 509,
      "key": "3b35863f4f51ae2e7e05ec50c41d928cf4d3c64ba041781a3836bd139a86a755d05d5a9eb5f06d7ddcfb09b4921df212ecce70f54bf12f52d3241fe882ea0f1a"
    },
    {
      "line": 3306,
      "relation": "increases",
      "evidence": "Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293T": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 447,
      "target": 510,
      "key": "93acbe1ff2baaa4dccb747c7724fd86a32df3ec0ec749dddb57558ad2830b8fc61ac87347a8cf0848b607c91fdf7421a99b2d69d5b7e3c066600cdf7815d797d"
    },
    {
      "line": 3307,
      "relation": "increases",
      "evidence": "Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293T": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 447,
      "target": 511,
      "key": "9b568dc2e67c71e799de6a12e50608e9ac935b1be4610cbd73272304c4f4eb0b1d01679b6ebdf4b88b2dff7b305947a59ef5109ddbd8ddfc2fe9326e6dfdd055"
    },
    {
      "line": 3308,
      "relation": "increases",
      "evidence": "Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A). A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1). Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses, suggesting variable acetylation at these sites in vitro. ",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293T": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 447,
      "target": 512,
      "key": "8d96bac0ce03f250aa93ee71459dd5c5f11d3133e32e85b3f0d0394020e11940c310436010be2f00fc7aa1e03190896b25914df6e53b4afe10820fc1e15687ae"
    },
    {
      "relation": "hasVariant",
      "source": 276,
      "target": 277,
      "key": "8f89bae0c3580323b25f2662b94bf2744da41a67415ff9abc15a17b220cd0a87f99c3af3ddb73e5c0c28110fe3dd4a5242ccd5ec5ea08f8c1f766abedfeb2d2f"
    },
    {
      "line": 2977,
      "relation": "directlyDecreases",
      "evidence": "In the present study, we tested the potential of two selective HDAC6 inhibitors, tubastatin A and ACY-1215, to rescue cognitive deficits in a mouse model of AD. We found that both tubastatin A and ACY-1215 alleviated behavioral deficits, altered amyloid-β (Aβ) load, and reduced tau hyperphosphorylation in AD mice without obvious adverse effects. Our data suggested that tubastatin A and ACY-1215 not only promoted tubulin acetylation, but also reduced production and facilitated autophagic clearance of Aβ and hyperphosphorylated tau.",
      "citation": {
        "type": "PubMed",
        "reference": "24844691",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice.",
        "volume": "41",
        "pages": "1193-205",
        "date": "2014-01-01",
        "first": "Zhang L",
        "last": "Qin C",
        "authors": [
          "Huang L",
          "Liu C",
          "Qin C",
          "Sheng SL",
          "Sui XL",
          "Tao JJ",
          "Wu J",
          "Xu YF",
          "Yao ZG",
          "Zhang L",
          "Zhu H"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 121,
      "target": 459,
      "key": "f75233887c1c82bb8c5bc4eae5c49260df690d74e97ab01c68e81265e8ec3c51196ec63e4286876fac04958aecaad79ceca52532e8cf15fbc4c6a43f13bc8e5a"
    },
    {
      "line": 2980,
      "relation": "decreases",
      "evidence": "In the present study, we tested the potential of two selective HDAC6 inhibitors, tubastatin A and ACY-1215, to rescue cognitive deficits in a mouse model of AD. We found that both tubastatin A and ACY-1215 alleviated behavioral deficits, altered amyloid-β (Aβ) load, and reduced tau hyperphosphorylation in AD mice without obvious adverse effects. Our data suggested that tubastatin A and ACY-1215 not only promoted tubulin acetylation, but also reduced production and facilitated autophagic clearance of Aβ and hyperphosphorylated tau.",
      "citation": {
        "type": "PubMed",
        "reference": "24844691",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice.",
        "volume": "41",
        "pages": "1193-205",
        "date": "2014-01-01",
        "first": "Zhang L",
        "last": "Qin C",
        "authors": [
          "Huang L",
          "Liu C",
          "Qin C",
          "Sheng SL",
          "Sui XL",
          "Tao JJ",
          "Wu J",
          "Xu YF",
          "Yao ZG",
          "Zhang L",
          "Zhu H"
        ]
      },
      "source": 121,
      "target": 11,
      "key": "f1154ad5b8d01ec945fbc64fbfb6882a09835e045f11e20c18f9eb949e6030d7f475879bc25ade48b5a2776841ef3a2727e05aaeb65fd5e0b7b327ef79146699"
    },
    {
      "line": 2982,
      "relation": "decreases",
      "evidence": "In the present study, we tested the potential of two selective HDAC6 inhibitors, tubastatin A and ACY-1215, to rescue cognitive deficits in a mouse model of AD. We found that both tubastatin A and ACY-1215 alleviated behavioral deficits, altered amyloid-β (Aβ) load, and reduced tau hyperphosphorylation in AD mice without obvious adverse effects. Our data suggested that tubastatin A and ACY-1215 not only promoted tubulin acetylation, but also reduced production and facilitated autophagic clearance of Aβ and hyperphosphorylated tau.",
      "citation": {
        "type": "PubMed",
        "reference": "24844691",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice.",
        "volume": "41",
        "pages": "1193-205",
        "date": "2014-01-01",
        "first": "Zhang L",
        "last": "Qin C",
        "authors": [
          "Huang L",
          "Liu C",
          "Qin C",
          "Sheng SL",
          "Sui XL",
          "Tao JJ",
          "Wu J",
          "Xu YF",
          "Yao ZG",
          "Zhang L",
          "Zhu H"
        ]
      },
      "source": 121,
      "target": 516,
      "key": "fae7643244e42a7c1cde446a8de15610d60872a46b1394ed211368f9485701ec4ffa9e5d1c664a10218a084fbc8c8fc9ca0440f6c06c5aba78b4ee1e483ca236"
    },
    {
      "line": 2978,
      "relation": "directlyDecreases",
      "evidence": "In the present study, we tested the potential of two selective HDAC6 inhibitors, tubastatin A and ACY-1215, to rescue cognitive deficits in a mouse model of AD. We found that both tubastatin A and ACY-1215 alleviated behavioral deficits, altered amyloid-β (Aβ) load, and reduced tau hyperphosphorylation in AD mice without obvious adverse effects. Our data suggested that tubastatin A and ACY-1215 not only promoted tubulin acetylation, but also reduced production and facilitated autophagic clearance of Aβ and hyperphosphorylated tau.",
      "citation": {
        "type": "PubMed",
        "reference": "24844691",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice.",
        "volume": "41",
        "pages": "1193-205",
        "date": "2014-01-01",
        "first": "Zhang L",
        "last": "Qin C",
        "authors": [
          "Huang L",
          "Liu C",
          "Qin C",
          "Sheng SL",
          "Sui XL",
          "Tao JJ",
          "Wu J",
          "Xu YF",
          "Yao ZG",
          "Zhang L",
          "Zhu H"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 91,
      "target": 459,
      "key": "f8be3e237fbdbe7404217fc5903900432cafa345b0256306765b1e8cad5ad4548f690cb2ffbf158fcff8084796f2a4f9061ab177cd9f987a66e75304a5fa0340"
    },
    {
      "line": 2981,
      "relation": "decreases",
      "evidence": "In the present study, we tested the potential of two selective HDAC6 inhibitors, tubastatin A and ACY-1215, to rescue cognitive deficits in a mouse model of AD. We found that both tubastatin A and ACY-1215 alleviated behavioral deficits, altered amyloid-β (Aβ) load, and reduced tau hyperphosphorylation in AD mice without obvious adverse effects. Our data suggested that tubastatin A and ACY-1215 not only promoted tubulin acetylation, but also reduced production and facilitated autophagic clearance of Aβ and hyperphosphorylated tau.",
      "citation": {
        "type": "PubMed",
        "reference": "24844691",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice.",
        "volume": "41",
        "pages": "1193-205",
        "date": "2014-01-01",
        "first": "Zhang L",
        "last": "Qin C",
        "authors": [
          "Huang L",
          "Liu C",
          "Qin C",
          "Sheng SL",
          "Sui XL",
          "Tao JJ",
          "Wu J",
          "Xu YF",
          "Yao ZG",
          "Zhang L",
          "Zhu H"
        ]
      },
      "source": 91,
      "target": 11,
      "key": "136579f8ad6094d5b16aa00ae3548e695f0bacbda3d8b60d5587b6a9ef8727685b7345fe87faa7dc7960392a2b5386e4b8a3eed4f25f074819228bf4b0f02621"
    },
    {
      "line": 3000,
      "relation": "increases",
      "evidence": "The N-terminus of β-catenin has phosphorylation, ubiquitination, and acetylation sites that regulate its stability and signaling. In the absence of a Wnt signal, Ser33, Ser37, and Thr41 are constitutively phosphorylated by glycogen synthase kinase 3β (GSK3β). β-Catenin phosphorylated at these sites is recognized by β-transducin repeat-containing protein (βTrCP), which results in ubiquitination and degradation by the ubiquitin-proteasome pathway. The N-terminal regulatory domain of β-catenin also includes Ser45, a phosphorylation site for Casein Kinase 1α (CK1α) and Lys49, which is acetylated by the acetyltransferase p300/CBP-associated factor (PCAF). The relevance of Lys49 acetylation and Ser45 phosphorylation to the function of β-catenin is an active area of investigation. We find that HDAC6 inhibitors increase Lys49 acetylation and Ser45 phosphorylation but do not affect Ser33, Ser37, and Thr41 phosphorylation. Lys49 acetylation results in decreased ubiquitination of β-catenin in the presence of proteasome inhibition. While increased Lys49 acetylation does not affect total levels of β-catenin, it results in increased membrane localization of β-catenin.",
      "citation": {
        "type": "PubMed",
        "reference": "25546293",
        "name": "ACS chemical biology",
        "title": "HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of β-catenin in human iPSC-derived neuronal cells.",
        "volume": "10",
        "pages": "883-90",
        "date": "2015-03-20",
        "first": "Iaconelli J",
        "last": "Karmacharya R",
        "authors": [
          "Berkovitch SS",
          "Chattopadhyay S",
          "Haggarty SJ",
          "Huang JH",
          "Iaconelli J",
          "Karmacharya R",
          "Mazitschek R",
          "Schreiber SL"
        ]
      },
      "object": {
        "modifier": "Degradation"
      },
      "source": 422,
      "target": 420,
      "key": "9606df0ad78c2783ca6db72ce4d4cceb86f7a109c2b49a89b32d111fd6328d59b5c950d6e72cae39a0c26074be6087ebf3fff9fde080aa792599fb89b3c3d37f"
    },
    {
      "line": 3001,
      "relation": "increases",
      "evidence": "The N-terminus of β-catenin has phosphorylation, ubiquitination, and acetylation sites that regulate its stability and signaling. In the absence of a Wnt signal, Ser33, Ser37, and Thr41 are constitutively phosphorylated by glycogen synthase kinase 3β (GSK3β). β-Catenin phosphorylated at these sites is recognized by β-transducin repeat-containing protein (βTrCP), which results in ubiquitination and degradation by the ubiquitin-proteasome pathway. The N-terminal regulatory domain of β-catenin also includes Ser45, a phosphorylation site for Casein Kinase 1α (CK1α) and Lys49, which is acetylated by the acetyltransferase p300/CBP-associated factor (PCAF). The relevance of Lys49 acetylation and Ser45 phosphorylation to the function of β-catenin is an active area of investigation. We find that HDAC6 inhibitors increase Lys49 acetylation and Ser45 phosphorylation but do not affect Ser33, Ser37, and Thr41 phosphorylation. Lys49 acetylation results in decreased ubiquitination of β-catenin in the presence of proteasome inhibition. While increased Lys49 acetylation does not affect total levels of β-catenin, it results in increased membrane localization of β-catenin.",
      "citation": {
        "type": "PubMed",
        "reference": "25546293",
        "name": "ACS chemical biology",
        "title": "HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of β-catenin in human iPSC-derived neuronal cells.",
        "volume": "10",
        "pages": "883-90",
        "date": "2015-03-20",
        "first": "Iaconelli J",
        "last": "Karmacharya R",
        "authors": [
          "Berkovitch SS",
          "Chattopadhyay S",
          "Haggarty SJ",
          "Huang JH",
          "Iaconelli J",
          "Karmacharya R",
          "Mazitschek R",
          "Schreiber SL"
        ]
      },
      "object": {
        "modifier": "Degradation"
      },
      "source": 424,
      "target": 420,
      "key": "d204641bfae4aa4266a6d0176970fb59a930c2d668daa9d7ddf4c3c3428d808f1d30ab1a8e5a9e72fee268a0beb09c174aede675e510380efcf67d9c891b9873"
    },
    {
      "line": 3002,
      "relation": "increases",
      "evidence": "The N-terminus of β-catenin has phosphorylation, ubiquitination, and acetylation sites that regulate its stability and signaling. In the absence of a Wnt signal, Ser33, Ser37, and Thr41 are constitutively phosphorylated by glycogen synthase kinase 3β (GSK3β). β-Catenin phosphorylated at these sites is recognized by β-transducin repeat-containing protein (βTrCP), which results in ubiquitination and degradation by the ubiquitin-proteasome pathway. The N-terminal regulatory domain of β-catenin also includes Ser45, a phosphorylation site for Casein Kinase 1α (CK1α) and Lys49, which is acetylated by the acetyltransferase p300/CBP-associated factor (PCAF). The relevance of Lys49 acetylation and Ser45 phosphorylation to the function of β-catenin is an active area of investigation. We find that HDAC6 inhibitors increase Lys49 acetylation and Ser45 phosphorylation but do not affect Ser33, Ser37, and Thr41 phosphorylation. Lys49 acetylation results in decreased ubiquitination of β-catenin in the presence of proteasome inhibition. While increased Lys49 acetylation does not affect total levels of β-catenin, it results in increased membrane localization of β-catenin.",
      "citation": {
        "type": "PubMed",
        "reference": "25546293",
        "name": "ACS chemical biology",
        "title": "HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of β-catenin in human iPSC-derived neuronal cells.",
        "volume": "10",
        "pages": "883-90",
        "date": "2015-03-20",
        "first": "Iaconelli J",
        "last": "Karmacharya R",
        "authors": [
          "Berkovitch SS",
          "Chattopadhyay S",
          "Haggarty SJ",
          "Huang JH",
          "Iaconelli J",
          "Karmacharya R",
          "Mazitschek R",
          "Schreiber SL"
        ]
      },
      "object": {
        "modifier": "Degradation"
      },
      "source": 425,
      "target": 420,
      "key": "076f7f892be321fca4f5510eb7e9796bacd44326c0fb75319510a963e5566a0b09091a64a22797b0f296bf9e0db1788332f4ee2eb6d0a6865d98ab31e0bd73f4"
    },
    {
      "line": 3005,
      "relation": "decreases",
      "evidence": "The N-terminus of β-catenin has phosphorylation, ubiquitination, and acetylation sites that regulate its stability and signaling. In the absence of a Wnt signal, Ser33, Ser37, and Thr41 are constitutively phosphorylated by glycogen synthase kinase 3β (GSK3β). β-Catenin phosphorylated at these sites is recognized by β-transducin repeat-containing protein (βTrCP), which results in ubiquitination and degradation by the ubiquitin-proteasome pathway. The N-terminal regulatory domain of β-catenin also includes Ser45, a phosphorylation site for Casein Kinase 1α (CK1α) and Lys49, which is acetylated by the acetyltransferase p300/CBP-associated factor (PCAF). The relevance of Lys49 acetylation and Ser45 phosphorylation to the function of β-catenin is an active area of investigation. We find that HDAC6 inhibitors increase Lys49 acetylation and Ser45 phosphorylation but do not affect Ser33, Ser37, and Thr41 phosphorylation. Lys49 acetylation results in decreased ubiquitination of β-catenin in the presence of proteasome inhibition. While increased Lys49 acetylation does not affect total levels of β-catenin, it results in increased membrane localization of β-catenin.",
      "citation": {
        "type": "PubMed",
        "reference": "25546293",
        "name": "ACS chemical biology",
        "title": "HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of β-catenin in human iPSC-derived neuronal cells.",
        "volume": "10",
        "pages": "883-90",
        "date": "2015-03-20",
        "first": "Iaconelli J",
        "last": "Karmacharya R",
        "authors": [
          "Berkovitch SS",
          "Chattopadhyay S",
          "Haggarty SJ",
          "Huang JH",
          "Iaconelli J",
          "Karmacharya R",
          "Mazitschek R",
          "Schreiber SL"
        ]
      },
      "source": 421,
      "target": 426,
      "key": "739a0309876d5a779b1c71612b1068604feb62e7be4c58fa8b82b272a55f84be8be7824b9bebe7a75a01a13875280cbb70b1eb95391601174f9bda98f786e58f"
    },
    {
      "line": 3006,
      "relation": "increases",
      "evidence": "The N-terminus of β-catenin has phosphorylation, ubiquitination, and acetylation sites that regulate its stability and signaling. In the absence of a Wnt signal, Ser33, Ser37, and Thr41 are constitutively phosphorylated by glycogen synthase kinase 3β (GSK3β). β-Catenin phosphorylated at these sites is recognized by β-transducin repeat-containing protein (βTrCP), which results in ubiquitination and degradation by the ubiquitin-proteasome pathway. The N-terminal regulatory domain of β-catenin also includes Ser45, a phosphorylation site for Casein Kinase 1α (CK1α) and Lys49, which is acetylated by the acetyltransferase p300/CBP-associated factor (PCAF). The relevance of Lys49 acetylation and Ser45 phosphorylation to the function of β-catenin is an active area of investigation. We find that HDAC6 inhibitors increase Lys49 acetylation and Ser45 phosphorylation but do not affect Ser33, Ser37, and Thr41 phosphorylation. Lys49 acetylation results in decreased ubiquitination of β-catenin in the presence of proteasome inhibition. While increased Lys49 acetylation does not affect total levels of β-catenin, it results in increased membrane localization of β-catenin.",
      "citation": {
        "type": "PubMed",
        "reference": "25546293",
        "name": "ACS chemical biology",
        "title": "HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of β-catenin in human iPSC-derived neuronal cells.",
        "volume": "10",
        "pages": "883-90",
        "date": "2015-03-20",
        "first": "Iaconelli J",
        "last": "Karmacharya R",
        "authors": [
          "Berkovitch SS",
          "Chattopadhyay S",
          "Haggarty SJ",
          "Huang JH",
          "Iaconelli J",
          "Karmacharya R",
          "Mazitschek R",
          "Schreiber SL"
        ]
      },
      "object": {
        "location": {
          "namespace": "GO",
          "name": "membrane"
        }
      },
      "source": 421,
      "target": 420,
      "key": "012eeeca201b8743494005f8e679260cef7a541d8fa5a9068be57e44c1696a4e6faff03b506bd10c02132e56f9ae8d42a67702483f8fb36e34e1186c2f1b4a51"
    },
    {
      "line": 3011,
      "relation": "negativeCorrelation",
      "evidence": "The N-terminus of β-catenin has phosphorylation, ubiquitination, and acetylation sites that regulate its stability and signaling. In the absence of a Wnt signal, Ser33, Ser37, and Thr41 are constitutively phosphorylated by glycogen synthase kinase 3β (GSK3β). β-Catenin phosphorylated at these sites is recognized by β-transducin repeat-containing protein (βTrCP), which results in ubiquitination and degradation by the ubiquitin-proteasome pathway. The N-terminal regulatory domain of β-catenin also includes Ser45, a phosphorylation site for Casein Kinase 1α (CK1α) and Lys49, which is acetylated by the acetyltransferase p300/CBP-associated factor (PCAF). The relevance of Lys49 acetylation and Ser45 phosphorylation to the function of β-catenin is an active area of investigation. We find that HDAC6 inhibitors increase Lys49 acetylation and Ser45 phosphorylation but do not affect Ser33, Ser37, and Thr41 phosphorylation. Lys49 acetylation results in decreased ubiquitination of β-catenin in the presence of proteasome inhibition. While increased Lys49 acetylation does not affect total levels of β-catenin, it results in increased membrane localization of β-catenin.",
      "citation": {
        "type": "PubMed",
        "reference": "25546293",
        "name": "ACS chemical biology",
        "title": "HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of β-catenin in human iPSC-derived neuronal cells.",
        "volume": "10",
        "pages": "883-90",
        "date": "2015-03-20",
        "first": "Iaconelli J",
        "last": "Karmacharya R",
        "authors": [
          "Berkovitch SS",
          "Chattopadhyay S",
          "Haggarty SJ",
          "Huang JH",
          "Iaconelli J",
          "Karmacharya R",
          "Mazitschek R",
          "Schreiber SL"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 421,
      "target": 459,
      "key": "0a112e18908fc74ccb75ea59b5e728a7359ccdd83bf558a71dddd8c981834e1bce6619044411ce46456f172a690e52fe61e0bba066b0b0654c2eddb4660ea730"
    },
    {
      "line": 3007,
      "relation": "directlyDecreases",
      "evidence": "The N-terminus of β-catenin has phosphorylation, ubiquitination, and acetylation sites that regulate its stability and signaling. In the absence of a Wnt signal, Ser33, Ser37, and Thr41 are constitutively phosphorylated by glycogen synthase kinase 3β (GSK3β). β-Catenin phosphorylated at these sites is recognized by β-transducin repeat-containing protein (βTrCP), which results in ubiquitination and degradation by the ubiquitin-proteasome pathway. The N-terminal regulatory domain of β-catenin also includes Ser45, a phosphorylation site for Casein Kinase 1α (CK1α) and Lys49, which is acetylated by the acetyltransferase p300/CBP-associated factor (PCAF). The relevance of Lys49 acetylation and Ser45 phosphorylation to the function of β-catenin is an active area of investigation. We find that HDAC6 inhibitors increase Lys49 acetylation and Ser45 phosphorylation but do not affect Ser33, Ser37, and Thr41 phosphorylation. Lys49 acetylation results in decreased ubiquitination of β-catenin in the presence of proteasome inhibition. While increased Lys49 acetylation does not affect total levels of β-catenin, it results in increased membrane localization of β-catenin.",
      "citation": {
        "type": "PubMed",
        "reference": "25546293",
        "name": "ACS chemical biology",
        "title": "HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of β-catenin in human iPSC-derived neuronal cells.",
        "volume": "10",
        "pages": "883-90",
        "date": "2015-03-20",
        "first": "Iaconelli J",
        "last": "Karmacharya R",
        "authors": [
          "Berkovitch SS",
          "Chattopadhyay S",
          "Haggarty SJ",
          "Huang JH",
          "Iaconelli J",
          "Karmacharya R",
          "Mazitschek R",
          "Schreiber SL"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 76,
      "target": 459,
      "key": "c94fc06403749b9304ff2a3c68c3a15fa803c14be598fbdc641a4295f4c2f55f0a29b9dc5af749cca37785cd81fdf53710d23a1f7170fe75cda3fd2274fe026a"
    },
    {
      "line": 3008,
      "relation": "increases",
      "evidence": "The N-terminus of β-catenin has phosphorylation, ubiquitination, and acetylation sites that regulate its stability and signaling. In the absence of a Wnt signal, Ser33, Ser37, and Thr41 are constitutively phosphorylated by glycogen synthase kinase 3β (GSK3β). β-Catenin phosphorylated at these sites is recognized by β-transducin repeat-containing protein (βTrCP), which results in ubiquitination and degradation by the ubiquitin-proteasome pathway. The N-terminal regulatory domain of β-catenin also includes Ser45, a phosphorylation site for Casein Kinase 1α (CK1α) and Lys49, which is acetylated by the acetyltransferase p300/CBP-associated factor (PCAF). The relevance of Lys49 acetylation and Ser45 phosphorylation to the function of β-catenin is an active area of investigation. We find that HDAC6 inhibitors increase Lys49 acetylation and Ser45 phosphorylation but do not affect Ser33, Ser37, and Thr41 phosphorylation. Lys49 acetylation results in decreased ubiquitination of β-catenin in the presence of proteasome inhibition. While increased Lys49 acetylation does not affect total levels of β-catenin, it results in increased membrane localization of β-catenin.",
      "citation": {
        "type": "PubMed",
        "reference": "25546293",
        "name": "ACS chemical biology",
        "title": "HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of β-catenin in human iPSC-derived neuronal cells.",
        "volume": "10",
        "pages": "883-90",
        "date": "2015-03-20",
        "first": "Iaconelli J",
        "last": "Karmacharya R",
        "authors": [
          "Berkovitch SS",
          "Chattopadhyay S",
          "Haggarty SJ",
          "Huang JH",
          "Iaconelli J",
          "Karmacharya R",
          "Mazitschek R",
          "Schreiber SL"
        ]
      },
      "source": 76,
      "target": 421,
      "key": "19f3435478e7eff5a75800677011c1c188ec07d00f6d7db9c5cfffd6d4a97f691ed2488c5398c5aa5b6cd1e385ca339edb56edb482ca8ce48107a844e801b5ee"
    },
    {
      "line": 3009,
      "relation": "directlyDecreases",
      "evidence": "The N-terminus of β-catenin has phosphorylation, ubiquitination, and acetylation sites that regulate its stability and signaling. In the absence of a Wnt signal, Ser33, Ser37, and Thr41 are constitutively phosphorylated by glycogen synthase kinase 3β (GSK3β). β-Catenin phosphorylated at these sites is recognized by β-transducin repeat-containing protein (βTrCP), which results in ubiquitination and degradation by the ubiquitin-proteasome pathway. The N-terminal regulatory domain of β-catenin also includes Ser45, a phosphorylation site for Casein Kinase 1α (CK1α) and Lys49, which is acetylated by the acetyltransferase p300/CBP-associated factor (PCAF). The relevance of Lys49 acetylation and Ser45 phosphorylation to the function of β-catenin is an active area of investigation. We find that HDAC6 inhibitors increase Lys49 acetylation and Ser45 phosphorylation but do not affect Ser33, Ser37, and Thr41 phosphorylation. Lys49 acetylation results in decreased ubiquitination of β-catenin in the presence of proteasome inhibition. While increased Lys49 acetylation does not affect total levels of β-catenin, it results in increased membrane localization of β-catenin.",
      "citation": {
        "type": "PubMed",
        "reference": "25546293",
        "name": "ACS chemical biology",
        "title": "HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of β-catenin in human iPSC-derived neuronal cells.",
        "volume": "10",
        "pages": "883-90",
        "date": "2015-03-20",
        "first": "Iaconelli J",
        "last": "Karmacharya R",
        "authors": [
          "Berkovitch SS",
          "Chattopadhyay S",
          "Haggarty SJ",
          "Huang JH",
          "Iaconelli J",
          "Karmacharya R",
          "Mazitschek R",
          "Schreiber SL"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 148,
      "target": 459,
      "key": "921c16ad8f88faed551202b7563fc2af35cc78f1175b1d73660d547a05a1a6577daf07b9b909fc461bf0d7f845ea8885ba01e78aa463f5cc04da33d54af43b90"
    },
    {
      "line": 3010,
      "relation": "increases",
      "evidence": "The N-terminus of β-catenin has phosphorylation, ubiquitination, and acetylation sites that regulate its stability and signaling. In the absence of a Wnt signal, Ser33, Ser37, and Thr41 are constitutively phosphorylated by glycogen synthase kinase 3β (GSK3β). β-Catenin phosphorylated at these sites is recognized by β-transducin repeat-containing protein (βTrCP), which results in ubiquitination and degradation by the ubiquitin-proteasome pathway. The N-terminal regulatory domain of β-catenin also includes Ser45, a phosphorylation site for Casein Kinase 1α (CK1α) and Lys49, which is acetylated by the acetyltransferase p300/CBP-associated factor (PCAF). The relevance of Lys49 acetylation and Ser45 phosphorylation to the function of β-catenin is an active area of investigation. We find that HDAC6 inhibitors increase Lys49 acetylation and Ser45 phosphorylation but do not affect Ser33, Ser37, and Thr41 phosphorylation. Lys49 acetylation results in decreased ubiquitination of β-catenin in the presence of proteasome inhibition. While increased Lys49 acetylation does not affect total levels of β-catenin, it results in increased membrane localization of β-catenin.",
      "citation": {
        "type": "PubMed",
        "reference": "25546293",
        "name": "ACS chemical biology",
        "title": "HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of β-catenin in human iPSC-derived neuronal cells.",
        "volume": "10",
        "pages": "883-90",
        "date": "2015-03-20",
        "first": "Iaconelli J",
        "last": "Karmacharya R",
        "authors": [
          "Berkovitch SS",
          "Chattopadhyay S",
          "Haggarty SJ",
          "Huang JH",
          "Iaconelli J",
          "Karmacharya R",
          "Mazitschek R",
          "Schreiber SL"
        ]
      },
      "source": 148,
      "target": 421,
      "key": "0d4825f268bd1d25ee4ef8744c61adba6005279f4177949155b7766f224108f4c469e821c236f848f8f50ce5c7b03bef0cb7fb29db287f3cee9c2bbfe0c974e5"
    },
    {
      "line": 3017,
      "relation": "directlyDecreases",
      "evidence": "In conclusion, ST7612AA1, prodrug of ST7464AA1, is the first of a new generation of HDAC inhibitors, very potent, orally administered, and well tolerated. It is a thiol derivative, pan-histone deacetylase inhibitor, active against a broad panel of cancer cell lines and in vivo tumor models.",
      "citation": {
        "type": "PubMed",
        "reference": "27917100",
        "name": "Current bioactive compounds",
        "title": "Synthesis of ST7612AA1, a Novel Oral HDAC Inhibitor, via Radical  Thioacetic Acid Addition.",
        "volume": "12",
        "pages": "282-288",
        "date": "2016-12-01",
        "first": "Battistuzzi G",
        "last": "Giannini G",
        "authors": [
          "Battistuzzi G",
          "Giannini G"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 145,
      "target": 290,
      "key": "dbebd975e23a5a93eba7d95798cf1477a2ba4c6fd73dfe644fc8812140615c8bfa6d57b30bf8b7f3ef90c5ec3224317c0fc6a6090592739b81b1c312ab7a6f2a"
    },
    {
      "line": 3273,
      "relation": "decreases",
      "evidence": "Although low-level tau acetylation was observed in untreated HEK-T40 cells, treatment with the pan histone deacetylase (HDAC) inhibitor trichostatin A (TSA), but not the Sir2 class inhibitor nicotinamide, resulted in a dramatic increase in acetylated tau levels.",
      "citation": {
        "type": "PubMed",
        "reference": "21427723",
        "name": "Nature communications",
        "title": "The acetylation of tau inhibits its function and promotes pathological tau aggregation.",
        "volume": "2",
        "pages": "252",
        "date": "2011-01-01",
        "first": "Cohen TJ",
        "last": "Lee VM",
        "authors": [
          "Cohen TJ",
          "Guo JL",
          "Hurtado DE",
          "Kwong LK",
          "Lee VM",
          "Mills IP",
          "Trojanowski JQ"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 290,
      "target": 490,
      "key": "20d6b50679c62c007a2df5d9bbaa46c4e614371758f18784fdf4d1d1518a970877ca911b1d3acb6984e5827438fa0234c9775c6fd9265ee132450d84dfbedb07"
    },
    {
      "line": 3023,
      "relation": "directlyDecreases",
      "evidence": "Modification of the cap group of biphenylacrylohydroxamic acid-based HDAC inhibitors led to the identification of a new derivative (3) characterized by an indolyl-substituted 4-phenylcinnamic skeleton.",
      "citation": {
        "type": "PubMed",
        "reference": "26890116",
        "name": "European journal of medicinal chemistry",
        "title": "Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.",
        "volume": "112",
        "pages": "99-105",
        "date": "2016-04-13",
        "first": "Cincinelli R",
        "last": "Dallavalle S",
        "authors": [
          "Cincinelli R",
          "Cuendet M",
          "Dallavalle S",
          "De Cesare M",
          "Giannini G",
          "Musso L",
          "Nurisso A",
          "Simoes-Pires C",
          "Zuco V",
          "Zunino F",
          "Zwick V"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 94,
      "target": 290,
      "key": "b0f39cc5f1708dc391c04837153527cc29879a0e04bea21a182ad85f3440c3bf211612aeeb0bd88d0d2dc31f5170f69b311064ffd5ad539903a1f6d30eff240b"
    },
    {
      "line": 3031,
      "relation": "directlyDecreases",
      "evidence": "Highly potent, substrate competitive HDAC6 selective inhibitors were identified (12ac:IC 50 = 65 nM and K i = 110 nM). Trithiocarbonate analogues with an aminoquinoline-substituted pyridinyl-thienoacetyl cap demonstrate a cytotoxicity profile and potency comparable to that of suberoylanilide hydroxamic acid (SAHA) as an approved cancer drug.",
      "citation": {
        "type": "PubMed",
        "reference": "18558669",
        "name": "Journal of medicinal chemistry",
        "title": "Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles.",
        "volume": "51",
        "pages": "3985-4001",
        "date": "2008-07-10",
        "first": "Dehmel F",
        "last": "Beckers T",
        "authors": [
          "Beckers T",
          "Burkhardt C",
          "Ciossek T",
          "Dehmel F",
          "Fettis K",
          "Julius H",
          "Maier T",
          "Stengel T",
          "Weinbrenner S",
          "Wieland H"
        ]
      },
      "annotations": {
        "Ki": {
          "110 nM": true
        },
        "IC50": {
          "65 nM": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 146,
      "target": 459,
      "key": "382c980f11cd72afbfa20087b26b8b0238fa8eb4c6797925b162e8e1a5be04b1e1cc4c4121b063e3e74920fc1f13726c8ec15e84ad13ec3599f521473dfc46e9"
    },
    {
      "line": 3042,
      "relation": "decreases",
      "evidence": "Here we show that the protein deacetylase SIRT1 reduces tau acetylation in a mouse model of neurodegeneration. SIRT1 deficiency in the brain aggravates synapse loss and behavioral disinhibition, and SIRT1 overexpression ameliorates propagation of tau pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "P301S mice": true
        }
      },
      "source": 847,
      "target": 805,
      "key": "945d0a37092b7fd094d9c8c2c84137abf59d12d29e6491b3ea9e08f1bf414fc5134f833d61c4b59f9ca295a53eb4cd018d21f940c2ba24af1f53bd78c2415c3b"
    },
    {
      "line": 3043,
      "relation": "positiveCorrelation",
      "evidence": "Here we show that the protein deacetylase SIRT1 reduces tau acetylation in a mouse model of neurodegeneration. SIRT1 deficiency in the brain aggravates synapse loss and behavioral disinhibition, and SIRT1 overexpression ameliorates propagation of tau pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "P301S mice": true
        }
      },
      "source": 847,
      "target": 83,
      "key": "1fcc279939308a92ced3040fd4162f6bc608a63844068d0be9b0563737fd806a3ed4203204e586146646fdcfa6da0e599c55d86bad5d5078cbdc53a109fe0dbb"
    },
    {
      "line": 3044,
      "relation": "negativeCorrelation",
      "evidence": "Here we show that the protein deacetylase SIRT1 reduces tau acetylation in a mouse model of neurodegeneration. SIRT1 deficiency in the brain aggravates synapse loss and behavioral disinhibition, and SIRT1 overexpression ameliorates propagation of tau pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "P301S mice": true
        }
      },
      "source": 847,
      "target": 908,
      "key": "4c0ccca890400a132280903c19ea46d551483eadfa029644cf089582052a5d6b504987a01e1c4127cd206561993416e3dd622dadf1c0959b3f12404053c03a08"
    },
    {
      "relation": "hasVariant",
      "source": 847,
      "target": 848,
      "key": "01d794cf8e2231e8c363716bf385cfd744968ca6550e812c275c9a46794dc3de5ef811a6d87a5a8964565528a154d04939067df610aab0499f825b02c1c5ddd1"
    },
    {
      "line": 3043,
      "relation": "positiveCorrelation",
      "evidence": "Here we show that the protein deacetylase SIRT1 reduces tau acetylation in a mouse model of neurodegeneration. SIRT1 deficiency in the brain aggravates synapse loss and behavioral disinhibition, and SIRT1 overexpression ameliorates propagation of tau pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "P301S mice": true
        }
      },
      "source": 83,
      "target": 847,
      "key": "eab3b34cc2799932ee4f975ecbf26b8117bc14e2ceaeb8d36bf959ee8dd6494923c7c4f76d9a2cd668747bcdebb9d7076746313a82e7397b9ea35872ac2da29c"
    },
    {
      "line": 3053,
      "relation": "negativeCorrelation",
      "evidence": "After pretreating hTau neurons with oligo Aβ-42 (1000 ng/ml), Sirt3 levels were reduced (Fig. 6b and e). This reduction in Sirt3 was translated into an increase in total tau and Ac-tau.",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 849,
      "target": 376,
      "key": "2394dfb486ef60ebf8a45110adcaf2dd75d22fd20d63d62a2a5bed471f82905501fbf6bba13d44686830c108bf87b2859aa07ea8578ab676e72198f8fd6bc2df"
    },
    {
      "line": 3054,
      "relation": "negativeCorrelation",
      "evidence": "After pretreating hTau neurons with oligo Aβ-42 (1000 ng/ml), Sirt3 levels were reduced (Fig. 6b and e). This reduction in Sirt3 was translated into an increase in total tau and Ac-tau.",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 849,
      "target": 486,
      "key": "ec72f5b3aecabaad9db527b95931e2d51ad7b3846a62c7fa72208152d3eb90ee9a774e064bef2fb8b53ccfba9900663de6b38dd152130981d2d2a5f8f3f1e311"
    },
    {
      "line": 3055,
      "relation": "negativeCorrelation",
      "evidence": "After pretreating hTau neurons with oligo Aβ-42 (1000 ng/ml), Sirt3 levels were reduced (Fig. 6b and e). This reduction in Sirt3 was translated into an increase in total tau and Ac-tau.",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 849,
      "target": 490,
      "key": "f1b839bf5b99a8b03209fbf7903a14aaff879d339b6e4f1ba7c7ef1d2d02ba8646c0cc9c7fda0815c91da7430ce677dcb799e76c97234758435321f1480ff46b"
    },
    {
      "line": 3061,
      "relation": "negativeCorrelation",
      "evidence": "Sirt3 levels were reduced in the entorhinal cortex, the middle temporal gyrus, and the superior frontal gyrus of AD subjects compared to those of CN and was associated with poorer test scores of neuropsychological evaluation and the severity of tau pathology.",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "annotations": {
        "Anatomy": {
          "entorhinal cortex": true,
          "middle temporal gyrus": true,
          "superior frontal gyrus": true
        }
      },
      "source": 849,
      "target": 908,
      "key": "84c3d059bcec4aa2d3601426811fdb70aa1f9a6e55ec7d958aa82b9465f72b5254d48d44401718ba537b50c239b9c82dff171e3395ee96a954e024f4083701f1"
    },
    {
      "line": 3055,
      "relation": "negativeCorrelation",
      "evidence": "After pretreating hTau neurons with oligo Aβ-42 (1000 ng/ml), Sirt3 levels were reduced (Fig. 6b and e). This reduction in Sirt3 was translated into an increase in total tau and Ac-tau.",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 490,
      "target": 849,
      "key": "8c15bf198407ba1ea2a05e55bb5a32610c9a163452572edbf6725ebc1308e3a8ae235f11fb0cddfe1e2d96655e0be12ed3de0b7749c8f328366e9db2d8aee265"
    },
    {
      "line": 3181,
      "relation": "decreases",
      "evidence": "Here we report abnormal acetylation of K274 and K281 on tau, identified in AD brains, promotes memory loss and disrupts synaptic plasticity by reducing postsynaptic KIdney/BRAin (KIBRA) protein, a memory-associated protein.Transgenic mice expressing human tau with lysine-to-glutamine mutations to mimic K274 and K281 acetylation (tauKQ) exhibit AD-related memory deficits and impaired hippocampal long-term potentiation (LTP). TauKQ reduces synaptic KIBRA levels and disrupts activity-induced postsynaptic actin remodeling and AMPA receptor insertion. The LTP deficit was rescued by promoting actin polymerization or by KIBRA expression. In AD patients with dementia, we found enhanced tau acetylation is linked to loss of KIBRA.",
      "citation": {
        "type": "PubMed",
        "reference": "27041503",
        "name": "Neuron",
        "title": "Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss.",
        "volume": "90",
        "pages": "245-60",
        "date": "2016-04-20",
        "first": "Tracy TE",
        "last": "Gan L",
        "authors": [
          "Cong X",
          "Ellerby LM",
          "Gan L",
          "Huganir RL",
          "Le D",
          "Li Y",
          "Lo I",
          "Min SW",
          "Minami SS",
          "Ponnusamy R",
          "Schilling B",
          "Sohn PD",
          "Tracy TE",
          "Wang C",
          "Zhou Y"
        ]
      },
      "source": 490,
      "target": 752,
      "key": "f823aba01a9e1af71d666199c21671ebed8dfcb8c1c5e79f8c0387e2070b0852c836ac36f5cdbb42a87945a623b905c259cb661bdcad4acc9b481705d5bc2b49"
    },
    {
      "line": 3319,
      "relation": "negativeCorrelation",
      "evidence": "Thus, the increase in ac-tau induced by SIRT1 deficiency is accompanied by accumulation of pathogenic p-tau in primary neurons. In mouse brains, deleting SIRT1, which elevated ac-tau, also increased AT8-positive p-tau.",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 490,
      "target": 677,
      "key": "8a57ca510d6d965a54c74426e2496322c6028b9241b15359061bee2f6e0f0a25696d2f554a573207825543ebd0789be443f307631ff32aef18144174b987ce91"
    },
    {
      "line": 3321,
      "relation": "positiveCorrelation",
      "evidence": "Thus, the increase in ac-tau induced by SIRT1 deficiency is accompanied by accumulation of pathogenic p-tau in primary neurons. In mouse brains, deleting SIRT1, which elevated ac-tau, also increased AT8-positive p-tau.",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 490,
      "target": 336,
      "key": "4fa19688170652ec68b9185b03e0aecc0dea2908a539904fd46f1b488e5c8ee9b6c722fe16347b4f3cd81291d44a109370551bd2394fea30a099c223412e7fbc"
    },
    {
      "line": 3072,
      "relation": "positiveCorrelation",
      "evidence": "We also tested for ac-tau 280 in early stage Alzheimer's disease (Braak stage 1). Histopathological examination using the ac tau 280 antibody was performed in three Alzheimer's cases and three CTE patients. Presence of ac-tau 280 was confirmed in all cases at early sites of disease manifestation. These findings suggest that tau acetylation may precede tau phosphorylation and could be the first ",
      "citation": {
        "type": "PubMed",
        "reference": "29276758",
        "name": "Journal of neurology and neurosurgery",
        "title": "Role of Tau Acetylation in Alzheimer's Disease and Chronic Traumatic Encephalopathy: The Way Forward for Successful Treatment.",
        "volume": "4",
        "date": "2017-01-01",
        "first": "Lucke-Wold B",
        "last": "Ross J",
        "authors": [
          "Lucke-Wold B",
          "Nolan R",
          "Omalu B",
          "Ornstein M",
          "Rosen C",
          "Ross J",
          "Seidel K",
          "Udo R"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Braak_Stage": {
          "Stage I": true
        }
      },
      "source": 498,
      "target": 908,
      "key": "bc9de9728e03321d9ffa44a9200eaae02af383f5dfd678c7c7c8f6dcf812f0945485d81b0d1bfbdc451edb72c726e57d96fd5269f46992eec0f0ca90fc255ccd"
    },
    {
      "line": 3278,
      "relation": "positiveCorrelation",
      "evidence": "Thus, K280 acetylation is a feature found in a variety of human 4R or 3R/4R tauopathies including AD, but not 3R-tauopathies such as PiD.",
      "citation": {
        "type": "PubMed",
        "reference": "21427723",
        "name": "Nature communications",
        "title": "The acetylation of tau inhibits its function and promotes pathological tau aggregation.",
        "volume": "2",
        "pages": "252",
        "date": "2011-01-01",
        "first": "Cohen TJ",
        "last": "Lee VM",
        "authors": [
          "Cohen TJ",
          "Guo JL",
          "Hurtado DE",
          "Kwong LK",
          "Lee VM",
          "Mills IP",
          "Trojanowski JQ"
        ]
      },
      "source": 498,
      "target": 908,
      "key": "3ff0fe4b54b45e77d32737d08b31c17bbcf78d7d59fb03c20d68d6764bca561be2a17bf82d1a8461fcaacc522fdcdd89e3dc68ab77f750e5169158e36d99d327"
    },
    {
      "line": 3073,
      "relation": "decreases",
      "evidence": "We also tested for ac-tau 280 in early stage Alzheimer's disease (Braak stage 1). Histopathological examination using the ac tau 280 antibody was performed in three Alzheimer's cases and three CTE patients. Presence of ac-tau 280 was confirmed in all cases at early sites of disease manifestation. These findings suggest that tau acetylation may precede tau phosphorylation and could be the first ",
      "citation": {
        "type": "PubMed",
        "reference": "29276758",
        "name": "Journal of neurology and neurosurgery",
        "title": "Role of Tau Acetylation in Alzheimer's Disease and Chronic Traumatic Encephalopathy: The Way Forward for Successful Treatment.",
        "volume": "4",
        "date": "2017-01-01",
        "first": "Lucke-Wold B",
        "last": "Ross J",
        "authors": [
          "Lucke-Wold B",
          "Nolan R",
          "Omalu B",
          "Ornstein M",
          "Rosen C",
          "Ross J",
          "Seidel K",
          "Udo R"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Braak_Stage": {
          "Stage I": true
        }
      },
      "source": 498,
      "target": 168,
      "key": "40530defa28d13bb1b7923fec6c09ea16513a1301044fac43f511b84c517daf05b1c4a5cd927bb946c648e0647962612d41ea71b3aff409d9986301f6c373d4b"
    },
    {
      "line": 3077,
      "relation": "positiveCorrelation",
      "evidence": "We also tested for ac-tau 280 in early stage Alzheimer's disease (Braak stage 1). Histopathological examination using the ac tau 280 antibody was performed in three Alzheimer's cases and three CTE patients. Presence of ac-tau 280 was confirmed in all cases at early sites of disease manifestation. These findings suggest that tau acetylation may precede tau phosphorylation and could be the first ",
      "citation": {
        "type": "PubMed",
        "reference": "29276758",
        "name": "Journal of neurology and neurosurgery",
        "title": "Role of Tau Acetylation in Alzheimer's Disease and Chronic Traumatic Encephalopathy: The Way Forward for Successful Treatment.",
        "volume": "4",
        "date": "2017-01-01",
        "first": "Lucke-Wold B",
        "last": "Ross J",
        "authors": [
          "Lucke-Wold B",
          "Nolan R",
          "Omalu B",
          "Ornstein M",
          "Rosen C",
          "Ross J",
          "Seidel K",
          "Udo R"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Chronic Traumatic Encephalopathy": true
        }
      },
      "source": 498,
      "target": 910,
      "key": "1cf110b309c476e1d8959f7ac7b4c4e48869efd15da41c979699dda9e9ec7ebb0014cb0488baf73ca9f2e429510cd541638626ea4a0f8245f9b8ce4f264d84c0"
    },
    {
      "line": 3123,
      "relation": "association",
      "evidence": "We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter, thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties. We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo. These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo.",
      "citation": {
        "type": "PubMed",
        "reference": "28855586",
        "name": "Scientific reports",
        "title": "Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity.",
        "volume": "7",
        "pages": "9984",
        "date": "2017-08-30",
        "first": "Gorsky MK",
        "last": "Partridge L",
        "authors": [
          "Augustin H",
          "Burnouf S",
          "Dols J",
          "Gorsky MK",
          "Grönke S",
          "Partridge L",
          "Sofola-Adesakin O",
          "Weigelt CM"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "source": 498,
      "target": 247,
      "key": "7884ce5b5efde416b89ab5d1dcca059f9cafa981b00c94fa8b91f5a42ca168f3147285193c8f79d6ac486ea74493b9002e55e7fd62a931a36ca9acf0f3a5b3c6"
    },
    {
      "line": 3136,
      "relation": "decreases",
      "evidence": "Surprisingly, we show that tau acetylation alters phosphorylation at residues S202/T205 (comprising the AT8 epitope), indicating acetylation-dephosphorylation cross-talk. Using a series of biochemical approaches, we found that K280/K281 acetylation impaired tau-mediated MT assembly function and also significantly enhanced tau aggregation. We also demonstrate that methylene blue, a reported tau aggregation inhibitor, modulates tau acetylation, a novel mechanism of action for this class of compounds",
      "citation": {
        "type": "PubMed",
        "reference": "28287136",
        "name": "Scientific reports",
        "title": "A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy.",
        "volume": "7",
        "pages": "44102",
        "date": "2017-03-13",
        "first": "Trzeciakiewicz H",
        "last": "Cohen TJ",
        "authors": [
          "Cohen TJ",
          "Madden V",
          "Tripathy A",
          "Trzeciakiewicz H",
          "Tseng JH",
          "Wander CM",
          "Yuan CX"
        ]
      },
      "source": 498,
      "target": 544,
      "key": "25dae601a845d61800e78d7396f77167ef49cdee627242aa9a4464f1f9e9adebb8385bf07f74386dfbc2e2c8a7e24b645da7ca81e735d765987afb38de639a33"
    },
    {
      "line": 3138,
      "relation": "increases",
      "evidence": "Surprisingly, we show that tau acetylation alters phosphorylation at residues S202/T205 (comprising the AT8 epitope), indicating acetylation-dephosphorylation cross-talk. Using a series of biochemical approaches, we found that K280/K281 acetylation impaired tau-mediated MT assembly function and also significantly enhanced tau aggregation. We also demonstrate that methylene blue, a reported tau aggregation inhibitor, modulates tau acetylation, a novel mechanism of action for this class of compounds",
      "citation": {
        "type": "PubMed",
        "reference": "28287136",
        "name": "Scientific reports",
        "title": "A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy.",
        "volume": "7",
        "pages": "44102",
        "date": "2017-03-13",
        "first": "Trzeciakiewicz H",
        "last": "Cohen TJ",
        "authors": [
          "Cohen TJ",
          "Madden V",
          "Tripathy A",
          "Trzeciakiewicz H",
          "Tseng JH",
          "Wander CM",
          "Yuan CX"
        ]
      },
      "source": 498,
      "target": 112,
      "key": "5108ef103f969f531136c9c1afb4dc219dc1755fc3a0b423948a7c538912d4e95239f2ef564639f2d82f730b9273b2fdd19312d4c929b8ca3cb3206cb986fd2d"
    },
    {
      "line": 3141,
      "relation": "partOf",
      "evidence": "Surprisingly, we show that tau acetylation alters phosphorylation at residues S202/T205 (comprising the AT8 epitope), indicating acetylation-dephosphorylation cross-talk. Using a series of biochemical approaches, we found that K280/K281 acetylation impaired tau-mediated MT assembly function and also significantly enhanced tau aggregation. We also demonstrate that methylene blue, a reported tau aggregation inhibitor, modulates tau acetylation, a novel mechanism of action for this class of compounds",
      "citation": {
        "type": "PubMed",
        "reference": "28287136",
        "name": "Scientific reports",
        "title": "A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy.",
        "volume": "7",
        "pages": "44102",
        "date": "2017-03-13",
        "first": "Trzeciakiewicz H",
        "last": "Cohen TJ",
        "authors": [
          "Cohen TJ",
          "Madden V",
          "Tripathy A",
          "Trzeciakiewicz H",
          "Tseng JH",
          "Wander CM",
          "Yuan CX"
        ]
      },
      "source": 498,
      "target": 355,
      "key": "d6734aa0dff91715586ab3649af2076abf03ace8480a38d40d714801852c25039d5df7e27be8f33e57f5bfd291497ca3b5ace0ac5180ed4304a0cc2f280623ea"
    },
    {
      "line": 3189,
      "relation": "increases",
      "evidence": "hTau-K280Q mutants showed significantly increased phosphorylation on S262 as compared to both hTau-wt and hTau-K280R flies, when normalised to total hTau (K9JA) levels (**p < 0.01, one-way ANOVA, Fig. 4b,c). Mis-expression of pseudo-acetylated K280Q-hTau in the adult fly nervous system potently exacerbated fly locomotion defects and photoreceptor neurodegeneration.",
      "citation": {
        "type": "PubMed",
        "reference": "26940749",
        "name": "Scientific reports",
        "title": "Acetylation mimic of lysine 280 exacerbates human Tau neurotoxicity in vivo.",
        "volume": "6",
        "pages": "22685",
        "date": "2016-03-04",
        "first": "Gorsky MK",
        "last": "Partridge L",
        "authors": [
          "Burnouf S",
          "Dols J",
          "Gorsky MK",
          "Mandelkow E",
          "Partridge L"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "source": 498,
      "target": 557,
      "key": "d2cb24163a5d213c8f01aa70207270f04a0a3b8e3596f4a1398aca6b401ef465e0a3a6815078389b35e3b50970ffd29c1fab1771b6681cb881004cdb9a9b1426"
    },
    {
      "line": 3190,
      "relation": "increases",
      "evidence": "hTau-K280Q mutants showed significantly increased phosphorylation on S262 as compared to both hTau-wt and hTau-K280R flies, when normalised to total hTau (K9JA) levels (**p < 0.01, one-way ANOVA, Fig. 4b,c). Mis-expression of pseudo-acetylated K280Q-hTau in the adult fly nervous system potently exacerbated fly locomotion defects and photoreceptor neurodegeneration.",
      "citation": {
        "type": "PubMed",
        "reference": "26940749",
        "name": "Scientific reports",
        "title": "Acetylation mimic of lysine 280 exacerbates human Tau neurotoxicity in vivo.",
        "volume": "6",
        "pages": "22685",
        "date": "2016-03-04",
        "first": "Gorsky MK",
        "last": "Partridge L",
        "authors": [
          "Burnouf S",
          "Dols J",
          "Gorsky MK",
          "Mandelkow E",
          "Partridge L"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "source": 498,
      "target": 143,
      "key": "245b9b5d92129f174d8d3961f05b2217331007bb958964daa5e4ca80daf18939912205600759d42d7387b7564654b23adadbb7898e816f75d0644ea03e1a445e"
    },
    {
      "line": 3219,
      "relation": "isA",
      "evidence": "Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.",
      "citation": {
        "type": "PubMed",
        "reference": "26192747",
        "name": "Nature neuroscience",
        "title": "Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.",
        "volume": "18",
        "pages": "1183-9",
        "date": "2015-08-01",
        "first": "Morris M",
        "last": "Mucke L",
        "authors": [
          "Burlingame AL",
          "Ioanoviciu A",
          "Knudsen GM",
          "Maeda S",
          "Morris M",
          "Mucke L",
          "Trinidad JC"
        ]
      },
      "source": 498,
      "target": 490,
      "key": "07cf63a9c481a8f597999b52eee7f93779ef73b99916e6798faecf91b759cd267d72f3efdd017b1943e5ab302483183fa215408c3ca821d49ba23c8c70b74b23"
    },
    {
      "line": 3229,
      "relation": "partOf",
      "evidence": "Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.",
      "citation": {
        "type": "PubMed",
        "reference": "26192747",
        "name": "Nature neuroscience",
        "title": "Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.",
        "volume": "18",
        "pages": "1183-9",
        "date": "2015-08-01",
        "first": "Morris M",
        "last": "Mucke L",
        "authors": [
          "Burlingame AL",
          "Ioanoviciu A",
          "Knudsen GM",
          "Maeda S",
          "Morris M",
          "Mucke L",
          "Trinidad JC"
        ]
      },
      "source": 498,
      "target": 130,
      "key": "3ebe3353da84002c3af1f0a675cb56b1b3a1a175e381ba8611f953d2f883860a01aa5e22f22eecf6a84cd05cd6a19b75ad3103c90bf195824328399b01d6b9fd"
    },
    {
      "line": 3279,
      "relation": "positiveCorrelation",
      "evidence": "Thus, K280 acetylation is a feature found in a variety of human 4R or 3R/4R tauopathies including AD, but not 3R-tauopathies such as PiD.",
      "citation": {
        "type": "PubMed",
        "reference": "21427723",
        "name": "Nature communications",
        "title": "The acetylation of tau inhibits its function and promotes pathological tau aggregation.",
        "volume": "2",
        "pages": "252",
        "date": "2011-01-01",
        "first": "Cohen TJ",
        "last": "Lee VM",
        "authors": [
          "Cohen TJ",
          "Guo JL",
          "Hurtado DE",
          "Kwong LK",
          "Lee VM",
          "Mills IP",
          "Trojanowski JQ"
        ]
      },
      "source": 498,
      "target": 905,
      "key": "0daf844a4cf6d719973b59c73b17b0370404ad476e77b3d9e3f1274e9859ecb66ec6515a54fe657ffbd99901a363801ffa63aa6a13b2ccd5abc8a85f9638ec6e"
    },
    {
      "line": 3089,
      "relation": "directlyDecreases",
      "evidence": "Here we report the discovery of a new first-in-class small-molecule (CM-414) that acts as a dual inhibitor of PDE5 and HDACs. We have used this compound as a chemical probe to validate this systems therapeutics strategy, where an increase in the activation of cAMP/cGMP-responsive element-binding protein (CREB) induced by PDE5 inhibition, combined with moderate HDAC class I inhibition, leads to efficient histone acetylation. This molecule rescued the impaired long-term potentiation evident in hippocampal slices from APP/PS1 mice. Chronic treatment of Tg2576 mice with CM-414 diminished brain Aβ and tau phosphorylation (pTau) levels, increased the inactive form of GSK3β, reverted the decrease in dendritic spine density on hippocampal neurons, and reversed their cognitive deficits, at least in part by inducing the expression of genes related to synaptic transmission.",
      "citation": {
        "type": "PubMed",
        "reference": "27550730",
        "name": "Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology",
        "title": "A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice.",
        "volume": "42",
        "pages": "524-539",
        "date": "2017-01-01",
        "first": "Cuadrado-Tejedor M",
        "last": "Garcia-Osta A",
        "authors": [
          "Cuadrado-Tejedor M",
          "Franco R",
          "Garcia-Barroso C",
          "Garcia-Osta A",
          "Mederos S",
          "Oyarzabal J",
          "Perea G",
          "Pérez-González M",
          "Rabal O",
          "Segura V",
          "Sánchez-Arias JA",
          "Ugarte A"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 99,
      "target": 838,
      "key": "6c988b48d4527c62cb69b1eeadffc30ace76249fa2dae95e8223f72399fb6d18f6c57943009bc77e1938426d9e0bcefaff2c1ef1dafe8068136e172823c0fa47"
    },
    {
      "line": 3090,
      "relation": "directlyDecreases",
      "evidence": "Here we report the discovery of a new first-in-class small-molecule (CM-414) that acts as a dual inhibitor of PDE5 and HDACs. We have used this compound as a chemical probe to validate this systems therapeutics strategy, where an increase in the activation of cAMP/cGMP-responsive element-binding protein (CREB) induced by PDE5 inhibition, combined with moderate HDAC class I inhibition, leads to efficient histone acetylation. This molecule rescued the impaired long-term potentiation evident in hippocampal slices from APP/PS1 mice. Chronic treatment of Tg2576 mice with CM-414 diminished brain Aβ and tau phosphorylation (pTau) levels, increased the inactive form of GSK3β, reverted the decrease in dendritic spine density on hippocampal neurons, and reversed their cognitive deficits, at least in part by inducing the expression of genes related to synaptic transmission.",
      "citation": {
        "type": "PubMed",
        "reference": "27550730",
        "name": "Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology",
        "title": "A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice.",
        "volume": "42",
        "pages": "524-539",
        "date": "2017-01-01",
        "first": "Cuadrado-Tejedor M",
        "last": "Garcia-Osta A",
        "authors": [
          "Cuadrado-Tejedor M",
          "Franco R",
          "Garcia-Barroso C",
          "Garcia-Osta A",
          "Mederos S",
          "Oyarzabal J",
          "Perea G",
          "Pérez-González M",
          "Rabal O",
          "Segura V",
          "Sánchez-Arias JA",
          "Ugarte A"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 99,
      "target": 274,
      "key": "d796b54aad4c8eaaa47625549c24fb4f1bce9c74d161b45b2b239c1ec12991e98dbd916ed86a3fa0ac49dd62befb7c2319cd024dff704307c95375a0be22daf5"
    },
    {
      "line": 3092,
      "relation": "decreases",
      "evidence": "Here we report the discovery of a new first-in-class small-molecule (CM-414) that acts as a dual inhibitor of PDE5 and HDACs. We have used this compound as a chemical probe to validate this systems therapeutics strategy, where an increase in the activation of cAMP/cGMP-responsive element-binding protein (CREB) induced by PDE5 inhibition, combined with moderate HDAC class I inhibition, leads to efficient histone acetylation. This molecule rescued the impaired long-term potentiation evident in hippocampal slices from APP/PS1 mice. Chronic treatment of Tg2576 mice with CM-414 diminished brain Aβ and tau phosphorylation (pTau) levels, increased the inactive form of GSK3β, reverted the decrease in dendritic spine density on hippocampal neurons, and reversed their cognitive deficits, at least in part by inducing the expression of genes related to synaptic transmission.",
      "citation": {
        "type": "PubMed",
        "reference": "27550730",
        "name": "Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology",
        "title": "A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice.",
        "volume": "42",
        "pages": "524-539",
        "date": "2017-01-01",
        "first": "Cuadrado-Tejedor M",
        "last": "Garcia-Osta A",
        "authors": [
          "Cuadrado-Tejedor M",
          "Franco R",
          "Garcia-Barroso C",
          "Garcia-Osta A",
          "Mederos S",
          "Oyarzabal J",
          "Perea G",
          "Pérez-González M",
          "Rabal O",
          "Segura V",
          "Sánchez-Arias JA",
          "Ugarte A"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 99,
      "target": 11,
      "key": "e21c90a75a74b0fcc716528deda4205f00e951dbd0a484e1f78140b0f6f94ad732d4f9aa6bbb567c40a333ac59baead88e5a9af95684fbc1a1d182d156679af5"
    },
    {
      "line": 3093,
      "relation": "decreases",
      "evidence": "Here we report the discovery of a new first-in-class small-molecule (CM-414) that acts as a dual inhibitor of PDE5 and HDACs. We have used this compound as a chemical probe to validate this systems therapeutics strategy, where an increase in the activation of cAMP/cGMP-responsive element-binding protein (CREB) induced by PDE5 inhibition, combined with moderate HDAC class I inhibition, leads to efficient histone acetylation. This molecule rescued the impaired long-term potentiation evident in hippocampal slices from APP/PS1 mice. Chronic treatment of Tg2576 mice with CM-414 diminished brain Aβ and tau phosphorylation (pTau) levels, increased the inactive form of GSK3β, reverted the decrease in dendritic spine density on hippocampal neurons, and reversed their cognitive deficits, at least in part by inducing the expression of genes related to synaptic transmission.",
      "citation": {
        "type": "PubMed",
        "reference": "27550730",
        "name": "Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology",
        "title": "A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice.",
        "volume": "42",
        "pages": "524-539",
        "date": "2017-01-01",
        "first": "Cuadrado-Tejedor M",
        "last": "Garcia-Osta A",
        "authors": [
          "Cuadrado-Tejedor M",
          "Franco R",
          "Garcia-Barroso C",
          "Garcia-Osta A",
          "Mederos S",
          "Oyarzabal J",
          "Perea G",
          "Pérez-González M",
          "Rabal O",
          "Segura V",
          "Sánchez-Arias JA",
          "Ugarte A"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 99,
      "target": 811,
      "key": "c5fd772e6d0ed027ccbf85b0e91b986d4c206193720873be82d9a42d538ff51dc6c352dc3e39391ae4ca1fba6c15ddf9d1e4b98b34ce472bed647824c04d9273"
    },
    {
      "line": 3094,
      "relation": "decreases",
      "evidence": "Here we report the discovery of a new first-in-class small-molecule (CM-414) that acts as a dual inhibitor of PDE5 and HDACs. We have used this compound as a chemical probe to validate this systems therapeutics strategy, where an increase in the activation of cAMP/cGMP-responsive element-binding protein (CREB) induced by PDE5 inhibition, combined with moderate HDAC class I inhibition, leads to efficient histone acetylation. This molecule rescued the impaired long-term potentiation evident in hippocampal slices from APP/PS1 mice. Chronic treatment of Tg2576 mice with CM-414 diminished brain Aβ and tau phosphorylation (pTau) levels, increased the inactive form of GSK3β, reverted the decrease in dendritic spine density on hippocampal neurons, and reversed their cognitive deficits, at least in part by inducing the expression of genes related to synaptic transmission.",
      "citation": {
        "type": "PubMed",
        "reference": "27550730",
        "name": "Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology",
        "title": "A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice.",
        "volume": "42",
        "pages": "524-539",
        "date": "2017-01-01",
        "first": "Cuadrado-Tejedor M",
        "last": "Garcia-Osta A",
        "authors": [
          "Cuadrado-Tejedor M",
          "Franco R",
          "Garcia-Barroso C",
          "Garcia-Osta A",
          "Mederos S",
          "Oyarzabal J",
          "Perea G",
          "Pérez-González M",
          "Rabal O",
          "Segura V",
          "Sánchez-Arias JA",
          "Ugarte A"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 99,
      "target": 794,
      "key": "ec06687a4e27c58f780dec972aa025a91ca1aa940427b500020e3f9a115c6cb9b22fd98b875d5bce18bdd92d24570cd2e742c5dfba04139680bbbe8d8e1a0dae"
    },
    {
      "line": 3091,
      "relation": "negativeCorrelation",
      "evidence": "Here we report the discovery of a new first-in-class small-molecule (CM-414) that acts as a dual inhibitor of PDE5 and HDACs. We have used this compound as a chemical probe to validate this systems therapeutics strategy, where an increase in the activation of cAMP/cGMP-responsive element-binding protein (CREB) induced by PDE5 inhibition, combined with moderate HDAC class I inhibition, leads to efficient histone acetylation. This molecule rescued the impaired long-term potentiation evident in hippocampal slices from APP/PS1 mice. Chronic treatment of Tg2576 mice with CM-414 diminished brain Aβ and tau phosphorylation (pTau) levels, increased the inactive form of GSK3β, reverted the decrease in dendritic spine density on hippocampal neurons, and reversed their cognitive deficits, at least in part by inducing the expression of genes related to synaptic transmission.",
      "citation": {
        "type": "PubMed",
        "reference": "27550730",
        "name": "Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology",
        "title": "A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice.",
        "volume": "42",
        "pages": "524-539",
        "date": "2017-01-01",
        "first": "Cuadrado-Tejedor M",
        "last": "Garcia-Osta A",
        "authors": [
          "Cuadrado-Tejedor M",
          "Franco R",
          "Garcia-Barroso C",
          "Garcia-Osta A",
          "Mederos S",
          "Oyarzabal J",
          "Perea G",
          "Pérez-González M",
          "Rabal O",
          "Segura V",
          "Sánchez-Arias JA",
          "Ugarte A"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 646,
      "target": 284,
      "key": "358488a86a344833a4810e6fdeaf4f2a253baf53bbcfe51fbdf093619d9f08a53dc3377dcd94c20efc416ceccf9216beb7618aea3574b7188edcdbfd1829dbdf"
    },
    {
      "line": 3107,
      "relation": "increases",
      "evidence": "We found that NO production and tau acetylation at Lys280 occurred in the brain tissue in mice and in cultured mouse cortical neurons in response to exposure to amyloid-β1-42 (Aβ1-42), a peptide that is also implicated in AD. An increased abundance of NO facilitated the S-nitrosylation (SNO) of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). S-nitrosylated GAPDH (GAPDH-SNO) promoted the acetylation and activation of the acetyltransferase p300 and facilitated the nitrosylation and inactivation of the deacetylase sirtuin 1 (SIRT1). The abundance of GAPDH-SNO was increased in postmortem brain samples from AD patients. Preventing the increase in GAPDH-SNO abundance in both cultured neurons and mice, either by overexpression of the nitrosylation mutant of GAPDH (GAPDH C150S) or by treatment with the GAPDH nitrosylation inhibitor CGP3466B (also known as omigapil), abrogated Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice, suggesting that this drug might be repurposed to treat patients with AD.",
      "citation": {
        "type": "PubMed",
        "reference": "29559585",
        "name": "Science signaling",
        "title": "Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-β.",
        "volume": "11",
        "date": "2018-03-20",
        "first": "Sen T",
        "last": "Sen N",
        "authors": [
          "Saha P",
          "Sen N",
          "Sen T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 26,
      "target": 790,
      "key": "9b8ec78043872048688f6c24f68395dbc32572468c524a76c93fefb21a8eb1c177e33e2257f70f48ddf81935059d1a41b33826b3e505df30e51b5a0641c4e4cb"
    },
    {
      "line": 3557,
      "relation": "positiveCorrelation",
      "evidence": "Tau contains cysteine residues in the microtubule binding region following alternative splicing of exon 10, and formation of intermolecular cysteine disulfide bonds accelerates tau aggregation. 8-Nitro-cGMP (novel second messenger of NO) exposure induced S-guanylation of tau both in vitro and in tau-overexpressed HEK293T cells. S-guanylated tau inhibited heparin-induced tau aggregation (thioflavin T). S-guanylated tau could not form tau granules and fibrils (AFM) inhibited at the step of tau oligomer formation. In P301L tau-expressing Neuro2A cells, 8-nitro-cGMP reduced the amount of sarcosyl-insoluble tau. NO-linked chemical modification on cysteine residues of tau could block tau aggregation",
      "citation": {
        "type": "PubMed",
        "reference": "27601475",
        "name": "The Journal of biological chemistry",
        "title": "Modification of Tau by 8-Nitroguanosine 3',5'-Cyclic Monophosphate (8-Nitro-cGMP): EFFECTS OF NITRIC OXIDE-LINKED CHEMICAL MODIFICATION ON TAU AGGREGATION.",
        "volume": "291",
        "pages": "22714-22720",
        "date": "2016-10-21",
        "first": "Yoshitake J",
        "last": "Takashima A",
        "authors": [
          "Akaike T",
          "Ida T",
          "Matsushita K",
          "Soeda Y",
          "Sumioka A",
          "Takashima A",
          "Yoshikawa M",
          "Yoshitake J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true,
          "HEK293T": true
        }
      },
      "source": 26,
      "target": 90,
      "key": "0963f06a0490001b9065767deec5ea8b9d580c208b3003601988a705e06872b6a741554b7d4bcd7d487c921ea03f8720037a13fd0e6bae08b8e704dbec1dc7c1"
    },
    {
      "line": 3108,
      "relation": "increases",
      "evidence": "We found that NO production and tau acetylation at Lys280 occurred in the brain tissue in mice and in cultured mouse cortical neurons in response to exposure to amyloid-β1-42 (Aβ1-42), a peptide that is also implicated in AD. An increased abundance of NO facilitated the S-nitrosylation (SNO) of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). S-nitrosylated GAPDH (GAPDH-SNO) promoted the acetylation and activation of the acetyltransferase p300 and facilitated the nitrosylation and inactivation of the deacetylase sirtuin 1 (SIRT1). The abundance of GAPDH-SNO was increased in postmortem brain samples from AD patients. Preventing the increase in GAPDH-SNO abundance in both cultured neurons and mice, either by overexpression of the nitrosylation mutant of GAPDH (GAPDH C150S) or by treatment with the GAPDH nitrosylation inhibitor CGP3466B (also known as omigapil), abrogated Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice, suggesting that this drug might be repurposed to treat patients with AD.",
      "citation": {
        "type": "PubMed",
        "reference": "29559585",
        "name": "Science signaling",
        "title": "Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-β.",
        "volume": "11",
        "date": "2018-03-20",
        "first": "Sen T",
        "last": "Sen N",
        "authors": [
          "Saha P",
          "Sen N",
          "Sen T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 790,
      "target": 787,
      "key": "d637461c9038bbc84e04eb272c05181d71a9ae62a7d22fb6e9e0aa68cfacbd9c81609d66398dfde476eb5783572165732f1f0a67c00f7fee1b87786a9b3213ce"
    },
    {
      "line": 3111,
      "relation": "positiveCorrelation",
      "evidence": "We found that NO production and tau acetylation at Lys280 occurred in the brain tissue in mice and in cultured mouse cortical neurons in response to exposure to amyloid-β1-42 (Aβ1-42), a peptide that is also implicated in AD. An increased abundance of NO facilitated the S-nitrosylation (SNO) of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). S-nitrosylated GAPDH (GAPDH-SNO) promoted the acetylation and activation of the acetyltransferase p300 and facilitated the nitrosylation and inactivation of the deacetylase sirtuin 1 (SIRT1). The abundance of GAPDH-SNO was increased in postmortem brain samples from AD patients. Preventing the increase in GAPDH-SNO abundance in both cultured neurons and mice, either by overexpression of the nitrosylation mutant of GAPDH (GAPDH C150S) or by treatment with the GAPDH nitrosylation inhibitor CGP3466B (also known as omigapil), abrogated Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice, suggesting that this drug might be repurposed to treat patients with AD.",
      "citation": {
        "type": "PubMed",
        "reference": "29559585",
        "name": "Science signaling",
        "title": "Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-β.",
        "volume": "11",
        "date": "2018-03-20",
        "first": "Sen T",
        "last": "Sen N",
        "authors": [
          "Saha P",
          "Sen N",
          "Sen T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 790,
      "target": 806,
      "key": "2b32dc586d73fbf8fe5c52768e542e8249cf11966502bd22128c677bdce9552b41c59f83859437c2a9442b2efea1ac6fb168b29065761ae63574d7735f12c614"
    },
    {
      "relation": "hasVariant",
      "source": 789,
      "target": 790,
      "key": "f654f957c8b371fa6042291c82a57d6dad153c8256d5f7153218b442dbc8707a9c5ce68dd37e49ac92c9ea508cbaa2874daf8e74e2fe3a552fbdd1838139644a"
    },
    {
      "line": 3109,
      "relation": "positiveCorrelation",
      "evidence": "We found that NO production and tau acetylation at Lys280 occurred in the brain tissue in mice and in cultured mouse cortical neurons in response to exposure to amyloid-β1-42 (Aβ1-42), a peptide that is also implicated in AD. An increased abundance of NO facilitated the S-nitrosylation (SNO) of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). S-nitrosylated GAPDH (GAPDH-SNO) promoted the acetylation and activation of the acetyltransferase p300 and facilitated the nitrosylation and inactivation of the deacetylase sirtuin 1 (SIRT1). The abundance of GAPDH-SNO was increased in postmortem brain samples from AD patients. Preventing the increase in GAPDH-SNO abundance in both cultured neurons and mice, either by overexpression of the nitrosylation mutant of GAPDH (GAPDH C150S) or by treatment with the GAPDH nitrosylation inhibitor CGP3466B (also known as omigapil), abrogated Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice, suggesting that this drug might be repurposed to treat patients with AD.",
      "citation": {
        "type": "PubMed",
        "reference": "29559585",
        "name": "Science signaling",
        "title": "Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-β.",
        "volume": "11",
        "date": "2018-03-20",
        "first": "Sen T",
        "last": "Sen N",
        "authors": [
          "Saha P",
          "Sen N",
          "Sen T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 787,
      "target": 848,
      "key": "d5d9cacad645129f230c343a90af22ffb95722a09ed436ad8f11e8b0b5b1a4b71fd3f5ccc20b3c60bc5118f24ff2ce1daf6b655512f05e375a23eee8ffe89000"
    },
    {
      "line": 3109,
      "relation": "positiveCorrelation",
      "evidence": "We found that NO production and tau acetylation at Lys280 occurred in the brain tissue in mice and in cultured mouse cortical neurons in response to exposure to amyloid-β1-42 (Aβ1-42), a peptide that is also implicated in AD. An increased abundance of NO facilitated the S-nitrosylation (SNO) of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). S-nitrosylated GAPDH (GAPDH-SNO) promoted the acetylation and activation of the acetyltransferase p300 and facilitated the nitrosylation and inactivation of the deacetylase sirtuin 1 (SIRT1). The abundance of GAPDH-SNO was increased in postmortem brain samples from AD patients. Preventing the increase in GAPDH-SNO abundance in both cultured neurons and mice, either by overexpression of the nitrosylation mutant of GAPDH (GAPDH C150S) or by treatment with the GAPDH nitrosylation inhibitor CGP3466B (also known as omigapil), abrogated Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice, suggesting that this drug might be repurposed to treat patients with AD.",
      "citation": {
        "type": "PubMed",
        "reference": "29559585",
        "name": "Science signaling",
        "title": "Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-β.",
        "volume": "11",
        "date": "2018-03-20",
        "first": "Sen T",
        "last": "Sen N",
        "authors": [
          "Saha P",
          "Sen N",
          "Sen T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 848,
      "target": 787,
      "key": "2e4d62d0c7eefb8222de486a637ddc4cd56b4938b0e8e77bf5fb10dd4ff982d799e78f7dfb6d7da86545f34752711b0ee287a5e6a0e1a7083e38f21ebb524115"
    },
    {
      "line": 3110,
      "relation": "increases",
      "evidence": "We found that NO production and tau acetylation at Lys280 occurred in the brain tissue in mice and in cultured mouse cortical neurons in response to exposure to amyloid-β1-42 (Aβ1-42), a peptide that is also implicated in AD. An increased abundance of NO facilitated the S-nitrosylation (SNO) of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). S-nitrosylated GAPDH (GAPDH-SNO) promoted the acetylation and activation of the acetyltransferase p300 and facilitated the nitrosylation and inactivation of the deacetylase sirtuin 1 (SIRT1). The abundance of GAPDH-SNO was increased in postmortem brain samples from AD patients. Preventing the increase in GAPDH-SNO abundance in both cultured neurons and mice, either by overexpression of the nitrosylation mutant of GAPDH (GAPDH C150S) or by treatment with the GAPDH nitrosylation inhibitor CGP3466B (also known as omigapil), abrogated Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice, suggesting that this drug might be repurposed to treat patients with AD.",
      "citation": {
        "type": "PubMed",
        "reference": "29559585",
        "name": "Science signaling",
        "title": "Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-β.",
        "volume": "11",
        "date": "2018-03-20",
        "first": "Sen T",
        "last": "Sen N",
        "authors": [
          "Saha P",
          "Sen N",
          "Sen T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 848,
      "target": 847,
      "key": "233192db970cb809ce25922a612b4bbafb6cfbf365063fff7290aed2b905ae4d10b10fb27b33e4ae7193dbb6980346a13b3391580f0f8ea21216a6024d188d26"
    },
    {
      "line": 3111,
      "relation": "positiveCorrelation",
      "evidence": "We found that NO production and tau acetylation at Lys280 occurred in the brain tissue in mice and in cultured mouse cortical neurons in response to exposure to amyloid-β1-42 (Aβ1-42), a peptide that is also implicated in AD. An increased abundance of NO facilitated the S-nitrosylation (SNO) of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). S-nitrosylated GAPDH (GAPDH-SNO) promoted the acetylation and activation of the acetyltransferase p300 and facilitated the nitrosylation and inactivation of the deacetylase sirtuin 1 (SIRT1). The abundance of GAPDH-SNO was increased in postmortem brain samples from AD patients. Preventing the increase in GAPDH-SNO abundance in both cultured neurons and mice, either by overexpression of the nitrosylation mutant of GAPDH (GAPDH C150S) or by treatment with the GAPDH nitrosylation inhibitor CGP3466B (also known as omigapil), abrogated Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice, suggesting that this drug might be repurposed to treat patients with AD.",
      "citation": {
        "type": "PubMed",
        "reference": "29559585",
        "name": "Science signaling",
        "title": "Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-β.",
        "volume": "11",
        "date": "2018-03-20",
        "first": "Sen T",
        "last": "Sen N",
        "authors": [
          "Saha P",
          "Sen N",
          "Sen T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 806,
      "target": 790,
      "key": "0c16b7a4b7c28371acc3a937392ae504bad7d33ac90d3bde41875e54716576ea5bfa7ed18b3043eac396b6498aaee403e8a44a084ff719d2d27c6fc14427ef14"
    },
    {
      "line": 3112,
      "relation": "decreases",
      "evidence": "We found that NO production and tau acetylation at Lys280 occurred in the brain tissue in mice and in cultured mouse cortical neurons in response to exposure to amyloid-β1-42 (Aβ1-42), a peptide that is also implicated in AD. An increased abundance of NO facilitated the S-nitrosylation (SNO) of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). S-nitrosylated GAPDH (GAPDH-SNO) promoted the acetylation and activation of the acetyltransferase p300 and facilitated the nitrosylation and inactivation of the deacetylase sirtuin 1 (SIRT1). The abundance of GAPDH-SNO was increased in postmortem brain samples from AD patients. Preventing the increase in GAPDH-SNO abundance in both cultured neurons and mice, either by overexpression of the nitrosylation mutant of GAPDH (GAPDH C150S) or by treatment with the GAPDH nitrosylation inhibitor CGP3466B (also known as omigapil), abrogated Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice, suggesting that this drug might be repurposed to treat patients with AD.",
      "citation": {
        "type": "PubMed",
        "reference": "29559585",
        "name": "Science signaling",
        "title": "Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-β.",
        "volume": "11",
        "date": "2018-03-20",
        "first": "Sen T",
        "last": "Sen N",
        "authors": [
          "Saha P",
          "Sen N",
          "Sen T"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 138,
      "target": 790,
      "key": "e0ea34f96cc873bb444edf4a657d028d05c945cd7bb891a106048e6e08a1d19348d26a109e7cd345e1a35bd23d26af14e703f28c1ab3817189b65a178c481e8d"
    },
    {
      "line": 3122,
      "relation": "association",
      "evidence": "We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter, thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties. We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo. These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo.",
      "citation": {
        "type": "PubMed",
        "reference": "28855586",
        "name": "Scientific reports",
        "title": "Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity.",
        "volume": "7",
        "pages": "9984",
        "date": "2017-08-30",
        "first": "Gorsky MK",
        "last": "Partridge L",
        "authors": [
          "Augustin H",
          "Burnouf S",
          "Dols J",
          "Gorsky MK",
          "Grönke S",
          "Partridge L",
          "Sofola-Adesakin O",
          "Weigelt CM"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "source": 491,
      "target": 247,
      "key": "7c0d0fa2858b48079bb554bafb146e500706881321a87ad57e91e859cbb87705e1981fd9bbdc4cd3ad3c542cbf2a916c761a9e6a39df1dff8d1a574d42492e85"
    },
    {
      "line": 3216,
      "relation": "isA",
      "evidence": "Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.",
      "citation": {
        "type": "PubMed",
        "reference": "26192747",
        "name": "Nature neuroscience",
        "title": "Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.",
        "volume": "18",
        "pages": "1183-9",
        "date": "2015-08-01",
        "first": "Morris M",
        "last": "Mucke L",
        "authors": [
          "Burlingame AL",
          "Ioanoviciu A",
          "Knudsen GM",
          "Maeda S",
          "Morris M",
          "Mucke L",
          "Trinidad JC"
        ]
      },
      "source": 491,
      "target": 490,
      "key": "9a06bdadbf9dcb0a6d999a44e08eb8e3e5b71bce1ae7f7002adb10b85ef216538b141600c40bc07014663129ddd1875ff6814df2528acb8445bec4cc0fad556c"
    },
    {
      "relation": "hasComponent",
      "source": 247,
      "target": 491,
      "key": "972d0c8a05927bf97b0a5eb2c011126a25145c1f4db0a2c52d7b464b9b00276d13aed48579d91b3842c590413d0c97d1603d58a39dc42937305b94e0f456e680"
    },
    {
      "line": 3122,
      "relation": "association",
      "evidence": "We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter, thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties. We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo. These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo.",
      "citation": {
        "type": "PubMed",
        "reference": "28855586",
        "name": "Scientific reports",
        "title": "Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity.",
        "volume": "7",
        "pages": "9984",
        "date": "2017-08-30",
        "first": "Gorsky MK",
        "last": "Partridge L",
        "authors": [
          "Augustin H",
          "Burnouf S",
          "Dols J",
          "Gorsky MK",
          "Grönke S",
          "Partridge L",
          "Sofola-Adesakin O",
          "Weigelt CM"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "source": 247,
      "target": 491,
      "key": "6b03f4ae0ebed5bb8c2f7c5d67e7a8505bce61393f825525b59efe37f8b1957dc27ffdab4b99d344239c2be87eb84fa16897a3954c289ebd0b82b7a2d44f3b0f"
    },
    {
      "relation": "hasComponent",
      "source": 247,
      "target": 498,
      "key": "94c8b4e238fabee7ab89369035c4e095e7beebac6a99996d92c8f4e995023950ce07b50697b8262b2c10d49ae0d2f8b3dbcd4b2acaa79e959809d03cedfec1a4"
    },
    {
      "line": 3123,
      "relation": "association",
      "evidence": "We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter, thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties. We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo. These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo.",
      "citation": {
        "type": "PubMed",
        "reference": "28855586",
        "name": "Scientific reports",
        "title": "Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity.",
        "volume": "7",
        "pages": "9984",
        "date": "2017-08-30",
        "first": "Gorsky MK",
        "last": "Partridge L",
        "authors": [
          "Augustin H",
          "Burnouf S",
          "Dols J",
          "Gorsky MK",
          "Grönke S",
          "Partridge L",
          "Sofola-Adesakin O",
          "Weigelt CM"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "source": 247,
      "target": 498,
      "key": "c51573f93e899a994987860fe42d68671622e940a68919c1cde72503e41bfbd7c612d0117a923960aeb396411dea906c64931e983f2e73b860337899d88eaf7d"
    },
    {
      "relation": "hasComponent",
      "source": 247,
      "target": 499,
      "key": "7714a6a3ce31d8b3df2a54fb3e821a3f1b8c61b547d8a2e53ffc2d5aae7a535487f95b5298996f69471e90e01328d6e4e03377ad695a80349580c470f5acba91"
    },
    {
      "line": 3124,
      "relation": "association",
      "evidence": "We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter, thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties. We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo. These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo.",
      "citation": {
        "type": "PubMed",
        "reference": "28855586",
        "name": "Scientific reports",
        "title": "Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity.",
        "volume": "7",
        "pages": "9984",
        "date": "2017-08-30",
        "first": "Gorsky MK",
        "last": "Partridge L",
        "authors": [
          "Augustin H",
          "Burnouf S",
          "Dols J",
          "Gorsky MK",
          "Grönke S",
          "Partridge L",
          "Sofola-Adesakin O",
          "Weigelt CM"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "source": 247,
      "target": 499,
      "key": "7fea6503700b9f900854104dcab68139d85231dcd00c6dd02605ab9105f4a7105e77429ff0616e8d47d971aba9b686c267d5a69c2d5633a8ef15e08f7118b629"
    },
    {
      "relation": "hasComponent",
      "source": 247,
      "target": 508,
      "key": "d0fb3105e939189ddaa93591906857820e832e46f0281feb34f0f53f328bb65aaea7f5c2e3215c649ebfb57f0072c48723782359527cc4e77f5e64dfab754057"
    },
    {
      "line": 3125,
      "relation": "association",
      "evidence": "We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter, thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties. We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo. These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo.",
      "citation": {
        "type": "PubMed",
        "reference": "28855586",
        "name": "Scientific reports",
        "title": "Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity.",
        "volume": "7",
        "pages": "9984",
        "date": "2017-08-30",
        "first": "Gorsky MK",
        "last": "Partridge L",
        "authors": [
          "Augustin H",
          "Burnouf S",
          "Dols J",
          "Gorsky MK",
          "Grönke S",
          "Partridge L",
          "Sofola-Adesakin O",
          "Weigelt CM"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "source": 247,
      "target": 508,
      "key": "52959ea83a45f2f3413867050450cad9264613716399cf5c38f84269c107ac025b47e713a914538e2d55a91fd914294512f4091ebced75b93c5b4097918d192b"
    },
    {
      "line": 3126,
      "relation": "decreases",
      "evidence": "We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter, thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties. We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo. These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo.",
      "citation": {
        "type": "PubMed",
        "reference": "28855586",
        "name": "Scientific reports",
        "title": "Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity.",
        "volume": "7",
        "pages": "9984",
        "date": "2017-08-30",
        "first": "Gorsky MK",
        "last": "Partridge L",
        "authors": [
          "Augustin H",
          "Burnouf S",
          "Dols J",
          "Gorsky MK",
          "Grönke S",
          "Partridge L",
          "Sofola-Adesakin O",
          "Weigelt CM"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "source": 247,
      "target": 538,
      "key": "eff4f6c14ac63a085ef6f7672cc22995fe32bb4a093427a76a769f3c5d77a268e43241635572800584ff60153061a6ed4abcc97ff8c5cd8b617720d97b8ff568"
    },
    {
      "line": 3127,
      "relation": "decreases",
      "evidence": "We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter, thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties. We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo. These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo.",
      "citation": {
        "type": "PubMed",
        "reference": "28855586",
        "name": "Scientific reports",
        "title": "Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity.",
        "volume": "7",
        "pages": "9984",
        "date": "2017-08-30",
        "first": "Gorsky MK",
        "last": "Partridge L",
        "authors": [
          "Augustin H",
          "Burnouf S",
          "Dols J",
          "Gorsky MK",
          "Grönke S",
          "Partridge L",
          "Sofola-Adesakin O",
          "Weigelt CM"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 247,
      "target": 486,
      "key": "cf11e3ce68d23b882d2a6c2d9a057d02e2b9da67724d05a49da93514bdb8d1d7c3c455c4d0dc0a5b30d777c3b1d90f5f36420dfc6f622c9449749e35396ff59d"
    },
    {
      "line": 3128,
      "relation": "negativeCorrelation",
      "evidence": "We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter, thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties. We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo. These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo.",
      "citation": {
        "type": "PubMed",
        "reference": "28855586",
        "name": "Scientific reports",
        "title": "Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity.",
        "volume": "7",
        "pages": "9984",
        "date": "2017-08-30",
        "first": "Gorsky MK",
        "last": "Partridge L",
        "authors": [
          "Augustin H",
          "Burnouf S",
          "Dols J",
          "Gorsky MK",
          "Grönke S",
          "Partridge L",
          "Sofola-Adesakin O",
          "Weigelt CM"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 247,
      "target": 11,
      "key": "d2fb0d21f66ff2bffa68356f211c65dd9c13b052e6fae57e8b508d6babca1aa83e53664c2c4dce96e48a26b730508b5bac2d9244f44cf344154fe63ec91ff5bd"
    },
    {
      "line": 3124,
      "relation": "association",
      "evidence": "We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter, thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties. We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo. These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo.",
      "citation": {
        "type": "PubMed",
        "reference": "28855586",
        "name": "Scientific reports",
        "title": "Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity.",
        "volume": "7",
        "pages": "9984",
        "date": "2017-08-30",
        "first": "Gorsky MK",
        "last": "Partridge L",
        "authors": [
          "Augustin H",
          "Burnouf S",
          "Dols J",
          "Gorsky MK",
          "Grönke S",
          "Partridge L",
          "Sofola-Adesakin O",
          "Weigelt CM"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "source": 499,
      "target": 247,
      "key": "64a90cd1fd344e72379564cdde6a6196f88b149dceb8c7c64cfced50945cd353b5b2e685a9b7df87a3f2e0d99682c12248f0c6acacbdc1c5207de702c593cdac"
    },
    {
      "line": 3137,
      "relation": "decreases",
      "evidence": "Surprisingly, we show that tau acetylation alters phosphorylation at residues S202/T205 (comprising the AT8 epitope), indicating acetylation-dephosphorylation cross-talk. Using a series of biochemical approaches, we found that K280/K281 acetylation impaired tau-mediated MT assembly function and also significantly enhanced tau aggregation. We also demonstrate that methylene blue, a reported tau aggregation inhibitor, modulates tau acetylation, a novel mechanism of action for this class of compounds",
      "citation": {
        "type": "PubMed",
        "reference": "28287136",
        "name": "Scientific reports",
        "title": "A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy.",
        "volume": "7",
        "pages": "44102",
        "date": "2017-03-13",
        "first": "Trzeciakiewicz H",
        "last": "Cohen TJ",
        "authors": [
          "Cohen TJ",
          "Madden V",
          "Tripathy A",
          "Trzeciakiewicz H",
          "Tseng JH",
          "Wander CM",
          "Yuan CX"
        ]
      },
      "source": 499,
      "target": 579,
      "key": "1597cb3fb12e88db6b38a86eeac26394a26cd5cb3f564ea3c9c7194fdcb973ed716141de3595d3535cac75e9c1c36d63c590362a55761643d0b0726d2ac5aed8"
    },
    {
      "line": 3139,
      "relation": "increases",
      "evidence": "Surprisingly, we show that tau acetylation alters phosphorylation at residues S202/T205 (comprising the AT8 epitope), indicating acetylation-dephosphorylation cross-talk. Using a series of biochemical approaches, we found that K280/K281 acetylation impaired tau-mediated MT assembly function and also significantly enhanced tau aggregation. We also demonstrate that methylene blue, a reported tau aggregation inhibitor, modulates tau acetylation, a novel mechanism of action for this class of compounds",
      "citation": {
        "type": "PubMed",
        "reference": "28287136",
        "name": "Scientific reports",
        "title": "A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy.",
        "volume": "7",
        "pages": "44102",
        "date": "2017-03-13",
        "first": "Trzeciakiewicz H",
        "last": "Cohen TJ",
        "authors": [
          "Cohen TJ",
          "Madden V",
          "Tripathy A",
          "Trzeciakiewicz H",
          "Tseng JH",
          "Wander CM",
          "Yuan CX"
        ]
      },
      "source": 499,
      "target": 112,
      "key": "2313ae45db20d4da05662228cadea95838f4e6921caab6738a4c6c0c7433a7d25b2e847b302e08331c002d07f284c298ca230d3522d6efc2580ffdb14611c4f8"
    },
    {
      "line": 3140,
      "relation": "partOf",
      "evidence": "Surprisingly, we show that tau acetylation alters phosphorylation at residues S202/T205 (comprising the AT8 epitope), indicating acetylation-dephosphorylation cross-talk. Using a series of biochemical approaches, we found that K280/K281 acetylation impaired tau-mediated MT assembly function and also significantly enhanced tau aggregation. We also demonstrate that methylene blue, a reported tau aggregation inhibitor, modulates tau acetylation, a novel mechanism of action for this class of compounds",
      "citation": {
        "type": "PubMed",
        "reference": "28287136",
        "name": "Scientific reports",
        "title": "A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy.",
        "volume": "7",
        "pages": "44102",
        "date": "2017-03-13",
        "first": "Trzeciakiewicz H",
        "last": "Cohen TJ",
        "authors": [
          "Cohen TJ",
          "Madden V",
          "Tripathy A",
          "Trzeciakiewicz H",
          "Tseng JH",
          "Wander CM",
          "Yuan CX"
        ]
      },
      "source": 499,
      "target": 355,
      "key": "36c49e45e7f2ff4dbc89480bb14c901d618c467fd6a577a0a0f3463b2fad35ecf64274a2b1f6e8108f47f1e95b5158a3da4c9f71f0397b86c473f9db0d03e9e5"
    },
    {
      "line": 3174,
      "relation": "decreases",
      "evidence": "Here we report abnormal acetylation of K274 and K281 on tau, identified in AD brains, promotes memory loss and disrupts synaptic plasticity by reducing postsynaptic KIdney/BRAin (KIBRA) protein, a memory-associated protein.Transgenic mice expressing human tau with lysine-to-glutamine mutations to mimic K274 and K281 acetylation (tauKQ) exhibit AD-related memory deficits and impaired hippocampal long-term potentiation (LTP). TauKQ reduces synaptic KIBRA levels and disrupts activity-induced postsynaptic actin remodeling and AMPA receptor insertion. The LTP deficit was rescued by promoting actin polymerization or by KIBRA expression. In AD patients with dementia, we found enhanced tau acetylation is linked to loss of KIBRA.",
      "citation": {
        "type": "PubMed",
        "reference": "27041503",
        "name": "Neuron",
        "title": "Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss.",
        "volume": "90",
        "pages": "245-60",
        "date": "2016-04-20",
        "first": "Tracy TE",
        "last": "Gan L",
        "authors": [
          "Cong X",
          "Ellerby LM",
          "Gan L",
          "Huganir RL",
          "Le D",
          "Li Y",
          "Lo I",
          "Min SW",
          "Minami SS",
          "Ponnusamy R",
          "Schilling B",
          "Sohn PD",
          "Tracy TE",
          "Wang C",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 499,
      "target": 752,
      "key": "d4c2bf0f5fd6403266c0955d0b76ed9c684e1fdc7fc622998f4a2f13bbda323fe75d6e1e0d4b31a040375056de8f47088e7726886459094a3d3813f9ec5ec346"
    },
    {
      "line": 3176,
      "relation": "decreases",
      "evidence": "Here we report abnormal acetylation of K274 and K281 on tau, identified in AD brains, promotes memory loss and disrupts synaptic plasticity by reducing postsynaptic KIdney/BRAin (KIBRA) protein, a memory-associated protein.Transgenic mice expressing human tau with lysine-to-glutamine mutations to mimic K274 and K281 acetylation (tauKQ) exhibit AD-related memory deficits and impaired hippocampal long-term potentiation (LTP). TauKQ reduces synaptic KIBRA levels and disrupts activity-induced postsynaptic actin remodeling and AMPA receptor insertion. The LTP deficit was rescued by promoting actin polymerization or by KIBRA expression. In AD patients with dementia, we found enhanced tau acetylation is linked to loss of KIBRA.",
      "citation": {
        "type": "PubMed",
        "reference": "27041503",
        "name": "Neuron",
        "title": "Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss.",
        "volume": "90",
        "pages": "245-60",
        "date": "2016-04-20",
        "first": "Tracy TE",
        "last": "Gan L",
        "authors": [
          "Cong X",
          "Ellerby LM",
          "Gan L",
          "Huganir RL",
          "Le D",
          "Li Y",
          "Lo I",
          "Min SW",
          "Minami SS",
          "Ponnusamy R",
          "Schilling B",
          "Sohn PD",
          "Tracy TE",
          "Wang C",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 499,
      "target": 171,
      "key": "00b8762bee3364b5c965b20a61f450c828f9bd5384ed69d106daa5f63421b85c1fcefb504aa289095d4db120ecd5e1a90d0f9d7759ca2741604a2d37bd64422a"
    },
    {
      "line": 3125,
      "relation": "association",
      "evidence": "We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter, thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties. We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo. These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo.",
      "citation": {
        "type": "PubMed",
        "reference": "28855586",
        "name": "Scientific reports",
        "title": "Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity.",
        "volume": "7",
        "pages": "9984",
        "date": "2017-08-30",
        "first": "Gorsky MK",
        "last": "Partridge L",
        "authors": [
          "Augustin H",
          "Burnouf S",
          "Dols J",
          "Gorsky MK",
          "Grönke S",
          "Partridge L",
          "Sofola-Adesakin O",
          "Weigelt CM"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "source": 508,
      "target": 247,
      "key": "c827935fa0a49ae5325be8be029ad2e8ee1980c50c0013cd7219816ca5fbaa77488af1c0de3a5cf95cdcc872d5fd430c4c78f91e2d6f15ce89f8fed6f88da10c"
    },
    {
      "line": 3225,
      "relation": "isA",
      "evidence": "Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.",
      "citation": {
        "type": "PubMed",
        "reference": "26192747",
        "name": "Nature neuroscience",
        "title": "Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.",
        "volume": "18",
        "pages": "1183-9",
        "date": "2015-08-01",
        "first": "Morris M",
        "last": "Mucke L",
        "authors": [
          "Burlingame AL",
          "Ioanoviciu A",
          "Knudsen GM",
          "Maeda S",
          "Morris M",
          "Mucke L",
          "Trinidad JC"
        ]
      },
      "source": 508,
      "target": 490,
      "key": "f2f25f25a2b51ff8189775dbf1c8f599338d9ffcb4d6e5beb2df0c27717ae5428e16df29ac84b200b2e069bb1479b92da75c0065682a1a16045fae5c79e0875f"
    },
    {
      "line": 3235,
      "relation": "partOf",
      "evidence": "Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.",
      "citation": {
        "type": "PubMed",
        "reference": "26192747",
        "name": "Nature neuroscience",
        "title": "Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.",
        "volume": "18",
        "pages": "1183-9",
        "date": "2015-08-01",
        "first": "Morris M",
        "last": "Mucke L",
        "authors": [
          "Burlingame AL",
          "Ioanoviciu A",
          "Knudsen GM",
          "Maeda S",
          "Morris M",
          "Mucke L",
          "Trinidad JC"
        ]
      },
      "source": 508,
      "target": 130,
      "key": "81f73f71932dd80d0160f666aaa8b295087eca4b45605f2e0fcf2339c9e1f18b69a1d5f0faf70726036e2a6a6be7f3799f1ccf19e0e12a0c4a40097cb62a7370"
    },
    {
      "line": 3152,
      "relation": "equivalentTo",
      "evidence": "All three MAPs possess highly lysine-rich MTBRs that mediate MAP-MT electrostatic interactions, indicating the potential for conserved acetylation within their repeats. Notably, tau/MAP4 alignments showed conservation of critical tau residues K280/K281 within the 2nd repeat motif 275VQIINK/K281, and the combined tau/MAP2c/MAP4 alignment showed conservation of the 3rd repeat motif harboring tau lysine K311, 306VQIVYK311",
      "citation": {
        "type": "PubMed",
        "reference": "28002468",
        "name": "PloS one",
        "title": "Conserved Lysine Acetylation within the Microtubule-Binding Domain Regulates MAP2/Tau Family Members.",
        "volume": "11",
        "pages": "e0168913",
        "date": "2016-01-01",
        "first": "Hwang AW",
        "last": "Cohen TJ",
        "authors": [
          "Cohen TJ",
          "Friedmann D",
          "Hwang AW",
          "Lee VM",
          "Marmorstein R",
          "Trzeciakiewicz H",
          "Yuan CX"
        ]
      },
      "source": 355,
      "target": 476,
      "key": "82d7f26e3dae0fa06c4da28661d887d1bc799ce838a6926521186d70dd61bd64ea6787734f40cd3ae6024563a6626180df212b91bfbd0a728503ac4fda452ce7"
    },
    {
      "line": 3153,
      "relation": "equivalentTo",
      "evidence": "All three MAPs possess highly lysine-rich MTBRs that mediate MAP-MT electrostatic interactions, indicating the potential for conserved acetylation within their repeats. Notably, tau/MAP4 alignments showed conservation of critical tau residues K280/K281 within the 2nd repeat motif 275VQIINK/K281, and the combined tau/MAP2c/MAP4 alignment showed conservation of the 3rd repeat motif harboring tau lysine K311, 306VQIVYK311",
      "citation": {
        "type": "PubMed",
        "reference": "28002468",
        "name": "PloS one",
        "title": "Conserved Lysine Acetylation within the Microtubule-Binding Domain Regulates MAP2/Tau Family Members.",
        "volume": "11",
        "pages": "e0168913",
        "date": "2016-01-01",
        "first": "Hwang AW",
        "last": "Cohen TJ",
        "authors": [
          "Cohen TJ",
          "Friedmann D",
          "Hwang AW",
          "Lee VM",
          "Marmorstein R",
          "Trzeciakiewicz H",
          "Yuan CX"
        ]
      },
      "source": 355,
      "target": 475,
      "key": "fdfc7a6a9ec0ac9789add0f86140827b1244b9173c22c6f2361982fca9f13f3d0d617c7697fce33c93bfd7ba15329173ed631270a5e8edf4073556acb21b4262"
    },
    {
      "line": 3577,
      "relation": "positiveCorrelation",
      "evidence": "We also show that two of the tau mutations found in hereditary frontotemporal dementias, DeltaK280 and P301L, have a much stronger tendency for PHF aggregation which correlates with their high propensity for beta-structure around the hexapeptide motifs.",
      "citation": {
        "type": "PubMed",
        "reference": "11606569",
        "name": "The Journal of biological chemistry",
        "title": "Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure.",
        "volume": "276",
        "pages": "48165-74",
        "date": "2001-12-21",
        "first": "von Bergen M",
        "last": "Mandelkow E",
        "authors": [
          "Barghorn S",
          "Biernat J",
          "Li L",
          "Mandelkow E",
          "Mandelkow EM",
          "Marx A",
          "von Bergen M"
        ]
      },
      "source": 355,
      "target": 618,
      "key": "25f16c404214bc7bb7cc8d1f9a3191ca9e98e9737e3ed0e037d61307d6fb11eddac6b932516c5fc18f9d46f4b55dfee402ff821a43bab3049183f0964fa520dd"
    },
    {
      "line": 3579,
      "relation": "positiveCorrelation",
      "evidence": "We also show that two of the tau mutations found in hereditary frontotemporal dementias, DeltaK280 and P301L, have a much stronger tendency for PHF aggregation which correlates with their high propensity for beta-structure around the hexapeptide motifs.",
      "citation": {
        "type": "PubMed",
        "reference": "11606569",
        "name": "The Journal of biological chemistry",
        "title": "Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure.",
        "volume": "276",
        "pages": "48165-74",
        "date": "2001-12-21",
        "first": "von Bergen M",
        "last": "Mandelkow E",
        "authors": [
          "Barghorn S",
          "Biernat J",
          "Li L",
          "Mandelkow E",
          "Mandelkow EM",
          "Marx A",
          "von Bergen M"
        ]
      },
      "source": 355,
      "target": 625,
      "key": "4906ee97bd52b29cb155257e0f2793400dd073df6e128d795665d70ca0afe92424f2f1fdd7e974744f271f005cc4303bf4799dfae91f83114a7ab6357655bb14"
    },
    {
      "line": 3582,
      "relation": "increases",
      "evidence": "We also show that two of the tau mutations found in hereditary frontotemporal dementias, DeltaK280 and P301L, have a much stronger tendency for PHF aggregation which correlates with their high propensity for beta-structure around the hexapeptide motifs.",
      "citation": {
        "type": "PubMed",
        "reference": "11606569",
        "name": "The Journal of biological chemistry",
        "title": "Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure.",
        "volume": "276",
        "pages": "48165-74",
        "date": "2001-12-21",
        "first": "von Bergen M",
        "last": "Mandelkow E",
        "authors": [
          "Barghorn S",
          "Biernat J",
          "Li L",
          "Mandelkow E",
          "Mandelkow EM",
          "Marx A",
          "von Bergen M"
        ]
      },
      "source": 355,
      "target": 325,
      "key": "6bfd17689a4ec453447856421a791f6491207f9c0ad67fbc67e4d3941d5c7d719da79f531259952068f4de26a1756d0a263ff909178dd1679fd6d77065537baf"
    },
    {
      "line": 3145,
      "relation": "increases",
      "evidence": "Thus, K → Q substitutions within the critical PHF6* motif, in the apparent absence of other tau PTMs, appears sufficient to accelerate tau aggregation in vitro.",
      "citation": {
        "type": "PubMed",
        "reference": "28287136",
        "name": "Scientific reports",
        "title": "A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy.",
        "volume": "7",
        "pages": "44102",
        "date": "2017-03-13",
        "first": "Trzeciakiewicz H",
        "last": "Cohen TJ",
        "authors": [
          "Cohen TJ",
          "Madden V",
          "Tripathy A",
          "Trzeciakiewicz H",
          "Tseng JH",
          "Wander CM",
          "Yuan CX"
        ]
      },
      "source": 617,
      "target": 112,
      "key": "add4a64f47fb252e30a21055c3f9b7ac7e32da6dbce143a1edf9c12380992c6c2750c892053809860785dba0abbabe26d5775d819f18c3a4740fc9c449179ef3"
    },
    {
      "line": 3152,
      "relation": "equivalentTo",
      "evidence": "All three MAPs possess highly lysine-rich MTBRs that mediate MAP-MT electrostatic interactions, indicating the potential for conserved acetylation within their repeats. Notably, tau/MAP4 alignments showed conservation of critical tau residues K280/K281 within the 2nd repeat motif 275VQIINK/K281, and the combined tau/MAP2c/MAP4 alignment showed conservation of the 3rd repeat motif harboring tau lysine K311, 306VQIVYK311",
      "citation": {
        "type": "PubMed",
        "reference": "28002468",
        "name": "PloS one",
        "title": "Conserved Lysine Acetylation within the Microtubule-Binding Domain Regulates MAP2/Tau Family Members.",
        "volume": "11",
        "pages": "e0168913",
        "date": "2016-01-01",
        "first": "Hwang AW",
        "last": "Cohen TJ",
        "authors": [
          "Cohen TJ",
          "Friedmann D",
          "Hwang AW",
          "Lee VM",
          "Marmorstein R",
          "Trzeciakiewicz H",
          "Yuan CX"
        ]
      },
      "source": 476,
      "target": 355,
      "key": "024c45b9ff1c8feb20fb5d393db225602131ba3dfbfbf89bf433d38e5f0581e3937c11ac5d4918d2d8f785c9dff6698ef9b3b2d6cc0f20f0d8af3686697f42dd"
    },
    {
      "relation": "hasVariant",
      "source": 474,
      "target": 476,
      "key": "1f84354b8d196adbd72c917eca3f40c4096852cab5c80f2d0919cd9500228bce1829d4a7bbbba91ac574280244146779593f6c26b69ba4a55eb1efe262322858"
    },
    {
      "relation": "hasVariant",
      "source": 474,
      "target": 475,
      "key": "821cc64aa813e371d5ef0b3b089a0e395d891de1f6562de68199974d6b31084cc4de62e8df2690a0821bda4d1c0c9e516667edaf91736b1f2e6d997f6aed7ab8"
    },
    {
      "line": 3153,
      "relation": "equivalentTo",
      "evidence": "All three MAPs possess highly lysine-rich MTBRs that mediate MAP-MT electrostatic interactions, indicating the potential for conserved acetylation within their repeats. Notably, tau/MAP4 alignments showed conservation of critical tau residues K280/K281 within the 2nd repeat motif 275VQIINK/K281, and the combined tau/MAP2c/MAP4 alignment showed conservation of the 3rd repeat motif harboring tau lysine K311, 306VQIVYK311",
      "citation": {
        "type": "PubMed",
        "reference": "28002468",
        "name": "PloS one",
        "title": "Conserved Lysine Acetylation within the Microtubule-Binding Domain Regulates MAP2/Tau Family Members.",
        "volume": "11",
        "pages": "e0168913",
        "date": "2016-01-01",
        "first": "Hwang AW",
        "last": "Cohen TJ",
        "authors": [
          "Cohen TJ",
          "Friedmann D",
          "Hwang AW",
          "Lee VM",
          "Marmorstein R",
          "Trzeciakiewicz H",
          "Yuan CX"
        ]
      },
      "source": 475,
      "target": 355,
      "key": "9cb1c57afed553222d2855b1075e209a46bf08341f3125ce4c025d3ea629b0790e91d008f6c7cc32e04d9c17515c00c7e7a4ad02d7fa74e98ee34bc31803e92f"
    },
    {
      "line": 3154,
      "relation": "equivalentTo",
      "evidence": "All three MAPs possess highly lysine-rich MTBRs that mediate MAP-MT electrostatic interactions, indicating the potential for conserved acetylation within their repeats. Notably, tau/MAP4 alignments showed conservation of critical tau residues K280/K281 within the 2nd repeat motif 275VQIINK/K281, and the combined tau/MAP2c/MAP4 alignment showed conservation of the 3rd repeat motif harboring tau lysine K311, 306VQIVYK311",
      "citation": {
        "type": "PubMed",
        "reference": "28002468",
        "name": "PloS one",
        "title": "Conserved Lysine Acetylation within the Microtubule-Binding Domain Regulates MAP2/Tau Family Members.",
        "volume": "11",
        "pages": "e0168913",
        "date": "2016-01-01",
        "first": "Hwang AW",
        "last": "Cohen TJ",
        "authors": [
          "Cohen TJ",
          "Friedmann D",
          "Hwang AW",
          "Lee VM",
          "Marmorstein R",
          "Trzeciakiewicz H",
          "Yuan CX"
        ]
      },
      "source": 471,
      "target": 356,
      "key": "fccc8ccdcdfba56ccbecb07a9208d22c2810f46044776a57b57b962a55deda53de3b575e9affdff8aeeb7467e3b74334b472fc4535641f4bb97c013132409847"
    },
    {
      "relation": "hasVariant",
      "source": 470,
      "target": 471,
      "key": "3b121ef353b306a558455526fcf00737a6aaaf8bae43ecfa85c986d2d020b44ae4a6e3226a29e3c3792dead02af05c1b042ac02495b013d8120b1d965774cc5d"
    },
    {
      "relation": "hasVariant",
      "source": 470,
      "target": 472,
      "key": "1f1ac9d603718cc77bea1d1c0e2be07fc0cba67da3f91300ff7c27d26958c3753351dd66de22fa82a28fa411025f8321a7be71c59dad70f0505495523ab439ff"
    },
    {
      "line": 3159,
      "relation": "increases",
      "evidence": "Similar to tau, MAP2 acetylation can occur in a cysteine-dependent auto-regulatory manner in the presence of acetyl-CoA. Tubulin reduced MAP2 acetylation, suggesting tubulin binding dictates MAP acetylation status.",
      "citation": {
        "type": "PubMed",
        "reference": "28002468",
        "name": "PloS one",
        "title": "Conserved Lysine Acetylation within the Microtubule-Binding Domain Regulates MAP2/Tau Family Members.",
        "volume": "11",
        "pages": "e0168913",
        "date": "2016-01-01",
        "first": "Hwang AW",
        "last": "Cohen TJ",
        "authors": [
          "Cohen TJ",
          "Friedmann D",
          "Hwang AW",
          "Lee VM",
          "Marmorstein R",
          "Trzeciakiewicz H",
          "Yuan CX"
        ]
      },
      "source": 8,
      "target": 126,
      "key": "6c77f449ba48eb868b80af9d90ca638d4fd270444a0e8e950361aa4aa25fb5fee8aa1b941fb017bd8ab7161ae14f93a06291491ba0da7b6413a7f51f42177c8c"
    },
    {
      "line": 3160,
      "relation": "increases",
      "evidence": "Similar to tau, MAP2 acetylation can occur in a cysteine-dependent auto-regulatory manner in the presence of acetyl-CoA. Tubulin reduced MAP2 acetylation, suggesting tubulin binding dictates MAP acetylation status.",
      "citation": {
        "type": "PubMed",
        "reference": "28002468",
        "name": "PloS one",
        "title": "Conserved Lysine Acetylation within the Microtubule-Binding Domain Regulates MAP2/Tau Family Members.",
        "volume": "11",
        "pages": "e0168913",
        "date": "2016-01-01",
        "first": "Hwang AW",
        "last": "Cohen TJ",
        "authors": [
          "Cohen TJ",
          "Friedmann D",
          "Hwang AW",
          "Lee VM",
          "Marmorstein R",
          "Trzeciakiewicz H",
          "Yuan CX"
        ]
      },
      "source": 126,
      "target": 490,
      "key": "489df1729c7a206303eb6069a51e3d0679976e801a374d678efd589abf7bd81afa0f47f81abdf60de3b5e249ed16c4af974260b84c25e98a910c4cf0bdcbba9f"
    },
    {
      "line": 3161,
      "relation": "increases",
      "evidence": "Similar to tau, MAP2 acetylation can occur in a cysteine-dependent auto-regulatory manner in the presence of acetyl-CoA. Tubulin reduced MAP2 acetylation, suggesting tubulin binding dictates MAP acetylation status.",
      "citation": {
        "type": "PubMed",
        "reference": "28002468",
        "name": "PloS one",
        "title": "Conserved Lysine Acetylation within the Microtubule-Binding Domain Regulates MAP2/Tau Family Members.",
        "volume": "11",
        "pages": "e0168913",
        "date": "2016-01-01",
        "first": "Hwang AW",
        "last": "Cohen TJ",
        "authors": [
          "Cohen TJ",
          "Friedmann D",
          "Hwang AW",
          "Lee VM",
          "Marmorstein R",
          "Trzeciakiewicz H",
          "Yuan CX"
        ]
      },
      "source": 126,
      "target": 472,
      "key": "9c4095267ef62d56c1c3fd34fc0b145f3c0521bcc4fd03caacac847e9612ad89da4652f8991291fb8a78ce7558ede51e7e0be8cb257b77c01604b9f843db5e1f"
    },
    {
      "line": 3178,
      "relation": "negativeCorrelation",
      "evidence": "Here we report abnormal acetylation of K274 and K281 on tau, identified in AD brains, promotes memory loss and disrupts synaptic plasticity by reducing postsynaptic KIdney/BRAin (KIBRA) protein, a memory-associated protein.Transgenic mice expressing human tau with lysine-to-glutamine mutations to mimic K274 and K281 acetylation (tauKQ) exhibit AD-related memory deficits and impaired hippocampal long-term potentiation (LTP). TauKQ reduces synaptic KIBRA levels and disrupts activity-induced postsynaptic actin remodeling and AMPA receptor insertion. The LTP deficit was rescued by promoting actin polymerization or by KIBRA expression. In AD patients with dementia, we found enhanced tau acetylation is linked to loss of KIBRA.",
      "citation": {
        "type": "PubMed",
        "reference": "27041503",
        "name": "Neuron",
        "title": "Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss.",
        "volume": "90",
        "pages": "245-60",
        "date": "2016-04-20",
        "first": "Tracy TE",
        "last": "Gan L",
        "authors": [
          "Cong X",
          "Ellerby LM",
          "Gan L",
          "Huganir RL",
          "Le D",
          "Li Y",
          "Lo I",
          "Min SW",
          "Minami SS",
          "Ponnusamy R",
          "Schilling B",
          "Sohn PD",
          "Tracy TE",
          "Wang C",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 752,
      "target": 204,
      "key": "783bca80779a40488e4141905a764ce98d566ffdcc64bd04f8c00549b71423dcb398c02e84e6a91eeefc8722171c4d3a0f36a542d92186d5e52209906d40dc66"
    },
    {
      "line": 3177,
      "relation": "negativeCorrelation",
      "evidence": "Here we report abnormal acetylation of K274 and K281 on tau, identified in AD brains, promotes memory loss and disrupts synaptic plasticity by reducing postsynaptic KIdney/BRAin (KIBRA) protein, a memory-associated protein.Transgenic mice expressing human tau with lysine-to-glutamine mutations to mimic K274 and K281 acetylation (tauKQ) exhibit AD-related memory deficits and impaired hippocampal long-term potentiation (LTP). TauKQ reduces synaptic KIBRA levels and disrupts activity-induced postsynaptic actin remodeling and AMPA receptor insertion. The LTP deficit was rescued by promoting actin polymerization or by KIBRA expression. In AD patients with dementia, we found enhanced tau acetylation is linked to loss of KIBRA.",
      "citation": {
        "type": "PubMed",
        "reference": "27041503",
        "name": "Neuron",
        "title": "Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss.",
        "volume": "90",
        "pages": "245-60",
        "date": "2016-04-20",
        "first": "Tracy TE",
        "last": "Gan L",
        "authors": [
          "Cong X",
          "Ellerby LM",
          "Gan L",
          "Huganir RL",
          "Le D",
          "Li Y",
          "Lo I",
          "Min SW",
          "Minami SS",
          "Ponnusamy R",
          "Schilling B",
          "Sohn PD",
          "Tracy TE",
          "Wang C",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 171,
      "target": 204,
      "key": "116ce28b074c88afa8bc9c268cd3d4deb3492792abf367e24f84f4a6c48ef889142a6515543387d9ae6c6b8a07dc8f6cbd77ea0ee31627816d85d4e988c08441"
    },
    {
      "line": 3199,
      "relation": "decreases",
      "evidence": "The acetyl-mimicking mutant K174Q slows tau turnover and induces cognitive deficits in vivo. Acetyltransferase p300-induced tau acetylation is inhibited by salsalate and salicylate, which enhance tau turnover and reduce tau levels. In the PS19 transgenic mouse model of FTD, administration of salsalate after disease onset inhibited p300 activity, lowered levels of total tau and tau acetylated at K174, rescued tau-induced memory deficits and prevented hippocampal atrophy.",
      "citation": {
        "type": "PubMed",
        "reference": "26390242",
        "name": "Nature medicine",
        "title": "Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits.",
        "volume": "21",
        "pages": "1154-62",
        "date": "2015-10-01",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Chen X",
          "Cong X",
          "Defensor E",
          "Ellerby L",
          "Gan L",
          "Gestwicki J",
          "Gibson BW",
          "Johnson J",
          "Krogan N",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Minami SS",
          "Mok SA",
          "Schilling B",
          "Shamloo M",
          "Shirakawa K",
          "Sohn PD",
          "Tracy TE",
          "Verdin E",
          "Wang C",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Degradation"
      },
      "source": 492,
      "target": 486,
      "key": "4cb39a5da24649d2aadcc901128d28aa79b7c3f04bd47f5db2e29ca0cdafa381a0edf631ef2f269fa41c97316dcab06216dd2cdd1902f194e9da6106b3357446"
    },
    {
      "line": 3200,
      "relation": "increases",
      "evidence": "The acetyl-mimicking mutant K174Q slows tau turnover and induces cognitive deficits in vivo. Acetyltransferase p300-induced tau acetylation is inhibited by salsalate and salicylate, which enhance tau turnover and reduce tau levels. In the PS19 transgenic mouse model of FTD, administration of salsalate after disease onset inhibited p300 activity, lowered levels of total tau and tau acetylated at K174, rescued tau-induced memory deficits and prevented hippocampal atrophy.",
      "citation": {
        "type": "PubMed",
        "reference": "26390242",
        "name": "Nature medicine",
        "title": "Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits.",
        "volume": "21",
        "pages": "1154-62",
        "date": "2015-10-01",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Chen X",
          "Cong X",
          "Defensor E",
          "Ellerby L",
          "Gan L",
          "Gestwicki J",
          "Gibson BW",
          "Johnson J",
          "Krogan N",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Minami SS",
          "Mok SA",
          "Schilling B",
          "Shamloo M",
          "Shirakawa K",
          "Sohn PD",
          "Tracy TE",
          "Verdin E",
          "Wang C",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 492,
      "target": 544,
      "key": "f6cf7049af1ced4dc4ffc96ac48006d7a63f113a25659d13ea7846631515a82785534df0b04aba6f002fd5c84f7fdb577f02ac797748193ce447003c86a78826"
    },
    {
      "line": 3201,
      "relation": "increases",
      "evidence": "The acetyl-mimicking mutant K174Q slows tau turnover and induces cognitive deficits in vivo. Acetyltransferase p300-induced tau acetylation is inhibited by salsalate and salicylate, which enhance tau turnover and reduce tau levels. In the PS19 transgenic mouse model of FTD, administration of salsalate after disease onset inhibited p300 activity, lowered levels of total tau and tau acetylated at K174, rescued tau-induced memory deficits and prevented hippocampal atrophy.",
      "citation": {
        "type": "PubMed",
        "reference": "26390242",
        "name": "Nature medicine",
        "title": "Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits.",
        "volume": "21",
        "pages": "1154-62",
        "date": "2015-10-01",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Chen X",
          "Cong X",
          "Defensor E",
          "Ellerby L",
          "Gan L",
          "Gestwicki J",
          "Gibson BW",
          "Johnson J",
          "Krogan N",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Minami SS",
          "Mok SA",
          "Schilling B",
          "Shamloo M",
          "Shirakawa K",
          "Sohn PD",
          "Tracy TE",
          "Verdin E",
          "Wang C",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 492,
      "target": 579,
      "key": "9fab3599e18f4733772f14f8a0772e78d65261b6e75898946892894314a5e8e6c1d64fe3500980758c18f791446f75e77acf94a721eb0e1ae4af7e04bc2d4b57"
    },
    {
      "line": 3203,
      "relation": "increases",
      "evidence": "The acetyl-mimicking mutant K174Q slows tau turnover and induces cognitive deficits in vivo. Acetyltransferase p300-induced tau acetylation is inhibited by salsalate and salicylate, which enhance tau turnover and reduce tau levels. In the PS19 transgenic mouse model of FTD, administration of salsalate after disease onset inhibited p300 activity, lowered levels of total tau and tau acetylated at K174, rescued tau-induced memory deficits and prevented hippocampal atrophy.",
      "citation": {
        "type": "PubMed",
        "reference": "26390242",
        "name": "Nature medicine",
        "title": "Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits.",
        "volume": "21",
        "pages": "1154-62",
        "date": "2015-10-01",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Chen X",
          "Cong X",
          "Defensor E",
          "Ellerby L",
          "Gan L",
          "Gestwicki J",
          "Gibson BW",
          "Johnson J",
          "Krogan N",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Minami SS",
          "Mok SA",
          "Schilling B",
          "Shamloo M",
          "Shirakawa K",
          "Sohn PD",
          "Tracy TE",
          "Verdin E",
          "Wang C",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 492,
      "target": 143,
      "key": "88284293f31c0416df1ba45713f0d71bb4b04fd6f664c3ce8c422034d34a98f04f90c9ffdf84cc2e5b004dd45aba40c05ebb1adc4eb057dc8f803156b298d933"
    },
    {
      "line": 3332,
      "relation": "negativeCorrelation",
      "evidence": "SIRT1 deficiency exacerbates premature mortality, synapse loss, and behavioral disinhibition in tauP301S TG mice of both sexes. SIRT1 overexpression into the hippocampus reduces acetylated K174 tau and significantly attenuates the spread of tau pathology into anatomically connected brain regions of tauP301S transgenic mice of both sexes.",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "P301S mice": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 492,
      "target": 677,
      "key": "2c2b7e2ef3aa8ebbd39affffb227a679903704f4e012a2d740b713aee948f5f2dad3faf8c592295a2f246354da68b45ef91f167789681a42c2c51d2e4d414b50"
    },
    {
      "line": 3207,
      "relation": "directlyDecreases",
      "evidence": "The acetyl-mimicking mutant K174Q slows tau turnover and induces cognitive deficits in vivo. Acetyltransferase p300-induced tau acetylation is inhibited by salsalate and salicylate, which enhance tau turnover and reduce tau levels. In the PS19 transgenic mouse model of FTD, administration of salsalate after disease onset inhibited p300 activity, lowered levels of total tau and tau acetylated at K174, rescued tau-induced memory deficits and prevented hippocampal atrophy.",
      "citation": {
        "type": "PubMed",
        "reference": "26390242",
        "name": "Nature medicine",
        "title": "Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits.",
        "volume": "21",
        "pages": "1154-62",
        "date": "2015-10-01",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Chen X",
          "Cong X",
          "Defensor E",
          "Ellerby L",
          "Gan L",
          "Gestwicki J",
          "Gibson BW",
          "Johnson J",
          "Krogan N",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Minami SS",
          "Mok SA",
          "Schilling B",
          "Shamloo M",
          "Shirakawa K",
          "Sohn PD",
          "Tracy TE",
          "Verdin E",
          "Wang C",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "PS19 mice": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 71,
      "target": 447,
      "key": "97cd52a652b51303d6bddd2469b1a6c5575af19b3acd8790c8ba5121d737c1d1cbfe7e799bbdc042c560a5aa95bbb72ec8770f3663fe2209a92f9f8e50a38f26"
    },
    {
      "line": 3208,
      "relation": "decreases",
      "evidence": "The acetyl-mimicking mutant K174Q slows tau turnover and induces cognitive deficits in vivo. Acetyltransferase p300-induced tau acetylation is inhibited by salsalate and salicylate, which enhance tau turnover and reduce tau levels. In the PS19 transgenic mouse model of FTD, administration of salsalate after disease onset inhibited p300 activity, lowered levels of total tau and tau acetylated at K174, rescued tau-induced memory deficits and prevented hippocampal atrophy.",
      "citation": {
        "type": "PubMed",
        "reference": "26390242",
        "name": "Nature medicine",
        "title": "Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits.",
        "volume": "21",
        "pages": "1154-62",
        "date": "2015-10-01",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Chen X",
          "Cong X",
          "Defensor E",
          "Ellerby L",
          "Gan L",
          "Gestwicki J",
          "Gibson BW",
          "Johnson J",
          "Krogan N",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Minami SS",
          "Mok SA",
          "Schilling B",
          "Shamloo M",
          "Shirakawa K",
          "Sohn PD",
          "Tracy TE",
          "Verdin E",
          "Wang C",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "PS19 mice": true
        }
      },
      "source": 71,
      "target": 492,
      "key": "b3dd4c2537cadb38dc37922f9b8ea6efe8db09e0df1bb03c943a6177fc16254a9b338db225c67c9f8b39c0f2d69c19c640439d8cb221f4e7c4f0564e22cc8349"
    },
    {
      "line": 3209,
      "relation": "decreases",
      "evidence": "The acetyl-mimicking mutant K174Q slows tau turnover and induces cognitive deficits in vivo. Acetyltransferase p300-induced tau acetylation is inhibited by salsalate and salicylate, which enhance tau turnover and reduce tau levels. In the PS19 transgenic mouse model of FTD, administration of salsalate after disease onset inhibited p300 activity, lowered levels of total tau and tau acetylated at K174, rescued tau-induced memory deficits and prevented hippocampal atrophy.",
      "citation": {
        "type": "PubMed",
        "reference": "26390242",
        "name": "Nature medicine",
        "title": "Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits.",
        "volume": "21",
        "pages": "1154-62",
        "date": "2015-10-01",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Chen X",
          "Cong X",
          "Defensor E",
          "Ellerby L",
          "Gan L",
          "Gestwicki J",
          "Gibson BW",
          "Johnson J",
          "Krogan N",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Minami SS",
          "Mok SA",
          "Schilling B",
          "Shamloo M",
          "Shirakawa K",
          "Sohn PD",
          "Tracy TE",
          "Verdin E",
          "Wang C",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "PS19 mice": true
        }
      },
      "source": 71,
      "target": 486,
      "key": "008119f9ca0fc15405b50b0b19fd0e72e7ef741cf25709585354ca9dbc101210f2e4eae60c50aff3523fb080a9ad967e001a2bc33a436233f01a460eb7d97725"
    },
    {
      "line": 3210,
      "relation": "positiveCorrelation",
      "evidence": "The acetyl-mimicking mutant K174Q slows tau turnover and induces cognitive deficits in vivo. Acetyltransferase p300-induced tau acetylation is inhibited by salsalate and salicylate, which enhance tau turnover and reduce tau levels. In the PS19 transgenic mouse model of FTD, administration of salsalate after disease onset inhibited p300 activity, lowered levels of total tau and tau acetylated at K174, rescued tau-induced memory deficits and prevented hippocampal atrophy.",
      "citation": {
        "type": "PubMed",
        "reference": "26390242",
        "name": "Nature medicine",
        "title": "Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits.",
        "volume": "21",
        "pages": "1154-62",
        "date": "2015-10-01",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Chen X",
          "Cong X",
          "Defensor E",
          "Ellerby L",
          "Gan L",
          "Gestwicki J",
          "Gibson BW",
          "Johnson J",
          "Krogan N",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Minami SS",
          "Mok SA",
          "Schilling B",
          "Shamloo M",
          "Shirakawa K",
          "Sohn PD",
          "Tracy TE",
          "Verdin E",
          "Wang C",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "PS19 mice": true
        }
      },
      "source": 71,
      "target": 167,
      "key": "2f8903a54dc9157b3c525f92dc9feeac22c6ca6d63d9fec9a7e8b18ab42a09ad6580e178f51b93a302d6f6ed20e5f23bfc8a069e33279b27d546b6cb6d312521"
    },
    {
      "line": 3210,
      "relation": "positiveCorrelation",
      "evidence": "The acetyl-mimicking mutant K174Q slows tau turnover and induces cognitive deficits in vivo. Acetyltransferase p300-induced tau acetylation is inhibited by salsalate and salicylate, which enhance tau turnover and reduce tau levels. In the PS19 transgenic mouse model of FTD, administration of salsalate after disease onset inhibited p300 activity, lowered levels of total tau and tau acetylated at K174, rescued tau-induced memory deficits and prevented hippocampal atrophy.",
      "citation": {
        "type": "PubMed",
        "reference": "26390242",
        "name": "Nature medicine",
        "title": "Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits.",
        "volume": "21",
        "pages": "1154-62",
        "date": "2015-10-01",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Chen X",
          "Cong X",
          "Defensor E",
          "Ellerby L",
          "Gan L",
          "Gestwicki J",
          "Gibson BW",
          "Johnson J",
          "Krogan N",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Minami SS",
          "Mok SA",
          "Schilling B",
          "Shamloo M",
          "Shirakawa K",
          "Sohn PD",
          "Tracy TE",
          "Verdin E",
          "Wang C",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "PS19 mice": true
        }
      },
      "source": 167,
      "target": 71,
      "key": "1b167641da18b99c03a47f18be65b1227a69d712336f5df9b77def2c2dbdb1e2ef7cd9a3de53e2b4832f4869b5186f1e5b107ca7f74a3d284de1acaa2e51eaf2"
    },
    {
      "line": 3217,
      "relation": "isA",
      "evidence": "Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.",
      "citation": {
        "type": "PubMed",
        "reference": "26192747",
        "name": "Nature neuroscience",
        "title": "Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.",
        "volume": "18",
        "pages": "1183-9",
        "date": "2015-08-01",
        "first": "Morris M",
        "last": "Mucke L",
        "authors": [
          "Burlingame AL",
          "Ioanoviciu A",
          "Knudsen GM",
          "Maeda S",
          "Morris M",
          "Mucke L",
          "Trinidad JC"
        ]
      },
      "source": 494,
      "target": 490,
      "key": "33f9591b6b633190ec6a0314042aa555d9b71a254cc97a58c0a8e371aea31da045198cbcd0e4d9ec1fc84da0623a3c11c57f0a0e8d895e1fb5aaed2edda7c926"
    },
    {
      "line": 3218,
      "relation": "isA",
      "evidence": "Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.",
      "citation": {
        "type": "PubMed",
        "reference": "26192747",
        "name": "Nature neuroscience",
        "title": "Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.",
        "volume": "18",
        "pages": "1183-9",
        "date": "2015-08-01",
        "first": "Morris M",
        "last": "Mucke L",
        "authors": [
          "Burlingame AL",
          "Ioanoviciu A",
          "Knudsen GM",
          "Maeda S",
          "Morris M",
          "Mucke L",
          "Trinidad JC"
        ]
      },
      "source": 496,
      "target": 490,
      "key": "59d0784f8142565faa298d7de2dc0d57230c92dc421f6d4325f11b50242edaad4929031a8457c8e2d3a93a969bc50293d499f2bdbe8b332093e49b37a934e5ab"
    },
    {
      "line": 3228,
      "relation": "partOf",
      "evidence": "Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.",
      "citation": {
        "type": "PubMed",
        "reference": "26192747",
        "name": "Nature neuroscience",
        "title": "Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.",
        "volume": "18",
        "pages": "1183-9",
        "date": "2015-08-01",
        "first": "Morris M",
        "last": "Mucke L",
        "authors": [
          "Burlingame AL",
          "Ioanoviciu A",
          "Knudsen GM",
          "Maeda S",
          "Morris M",
          "Mucke L",
          "Trinidad JC"
        ]
      },
      "source": 496,
      "target": 130,
      "key": "a2092d54a943cca87881e69e9bc5b111f1c9f887ec5feaba0e89226c2c9f443af9c314704c67c4d9d234dda723a8da70f5dabbb468ef43ac2c349329100e5010"
    },
    {
      "line": 3220,
      "relation": "isA",
      "evidence": "Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.",
      "citation": {
        "type": "PubMed",
        "reference": "26192747",
        "name": "Nature neuroscience",
        "title": "Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.",
        "volume": "18",
        "pages": "1183-9",
        "date": "2015-08-01",
        "first": "Morris M",
        "last": "Mucke L",
        "authors": [
          "Burlingame AL",
          "Ioanoviciu A",
          "Knudsen GM",
          "Maeda S",
          "Morris M",
          "Mucke L",
          "Trinidad JC"
        ]
      },
      "source": 502,
      "target": 490,
      "key": "a20a0c625f7d70ea4eb1d534ee6bd5a9df9808da97bf7a9da3209c9fdb1b0cc6e1f932b3a617734a06eb4d6d6e528db38bd189472cef3fc0aef88fb8f1b0837f"
    },
    {
      "line": 3230,
      "relation": "partOf",
      "evidence": "Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.",
      "citation": {
        "type": "PubMed",
        "reference": "26192747",
        "name": "Nature neuroscience",
        "title": "Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.",
        "volume": "18",
        "pages": "1183-9",
        "date": "2015-08-01",
        "first": "Morris M",
        "last": "Mucke L",
        "authors": [
          "Burlingame AL",
          "Ioanoviciu A",
          "Knudsen GM",
          "Maeda S",
          "Morris M",
          "Mucke L",
          "Trinidad JC"
        ]
      },
      "source": 502,
      "target": 130,
      "key": "f96c9a05d686a75c8a1d91b16db59bec170ea47ebc4d7f8a33dc9325f58696a7ee6fe99a0466cdfc89ffdc842a6fce37b576c3396b3911b747371c5a2dc4fccd"
    },
    {
      "line": 3221,
      "relation": "isA",
      "evidence": "Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.",
      "citation": {
        "type": "PubMed",
        "reference": "26192747",
        "name": "Nature neuroscience",
        "title": "Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.",
        "volume": "18",
        "pages": "1183-9",
        "date": "2015-08-01",
        "first": "Morris M",
        "last": "Mucke L",
        "authors": [
          "Burlingame AL",
          "Ioanoviciu A",
          "Knudsen GM",
          "Maeda S",
          "Morris M",
          "Mucke L",
          "Trinidad JC"
        ]
      },
      "source": 503,
      "target": 490,
      "key": "381c002c75e9d9ae207dce399d9361a8114d24570d0b9bfdd66d623a0947e3c8bbbebbab47efddf6e166869d836d4701724096a28f717c1d8dbd287a9577b546"
    },
    {
      "line": 3231,
      "relation": "partOf",
      "evidence": "Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.",
      "citation": {
        "type": "PubMed",
        "reference": "26192747",
        "name": "Nature neuroscience",
        "title": "Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.",
        "volume": "18",
        "pages": "1183-9",
        "date": "2015-08-01",
        "first": "Morris M",
        "last": "Mucke L",
        "authors": [
          "Burlingame AL",
          "Ioanoviciu A",
          "Knudsen GM",
          "Maeda S",
          "Morris M",
          "Mucke L",
          "Trinidad JC"
        ]
      },
      "source": 503,
      "target": 130,
      "key": "e9b298b9ae8c06a77c7dd5dccf2f703c200d1e03160c8778e08aa5a9cb4f69561637f05e06d3d53d11a193f1bc9c8e327ba6ea4c17f699874ff8fe67b8e87773"
    },
    {
      "line": 3359,
      "relation": "decreases",
      "evidence": "Our findings indicate that several acetylation sites in tau are responsive to HDAC6 and that acetylation on Lys-321 (within a KCGS motif) is both essential for acetylation-mediated inhibition of tau aggregation in vitro and a molecular tactic for preventing phosphorylation on the downstream Ser-324 residue. Tau phosphorylation of Ser-324 (pSer-324) has not previously been evaluated in the context of tauopathy, and here we observed increased deposition of pSer-324-positive tau both in mouse models of tauopathy and in patients with Alzheimer's disease. These findings uncover a novel acetylation-phosphorylation switch at Lys-321/Ser-324 that coordinately regulates tau polymerization and function.",
      "citation": {
        "type": "PubMed",
        "reference": "28760828",
        "name": "The Journal of biological chemistry",
        "title": "An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.",
        "volume": "292",
        "pages": "15277-15286",
        "date": "2017-09-15",
        "first": "Carlomagno Y",
        "last": "Cook C",
        "authors": [
          "Carlomagno Y",
          "Castanedes-Casey M",
          "Chung DC",
          "Cook C",
          "DeTure M",
          "Dickson DW",
          "Dunmore J",
          "Madden BJ",
          "Petrucelli L",
          "Tong J",
          "Yue M"
        ]
      },
      "source": 503,
      "target": 325,
      "key": "1f66ba0856ff2b67409694253748e21463024514533ef274773c23bdffd5c99648b06246391b6f541f2be84a213433e5bec7987d5f76048e895c47eb8d4be138"
    },
    {
      "line": 3360,
      "relation": "decreases",
      "evidence": "Our findings indicate that several acetylation sites in tau are responsive to HDAC6 and that acetylation on Lys-321 (within a KCGS motif) is both essential for acetylation-mediated inhibition of tau aggregation in vitro and a molecular tactic for preventing phosphorylation on the downstream Ser-324 residue. Tau phosphorylation of Ser-324 (pSer-324) has not previously been evaluated in the context of tauopathy, and here we observed increased deposition of pSer-324-positive tau both in mouse models of tauopathy and in patients with Alzheimer's disease. These findings uncover a novel acetylation-phosphorylation switch at Lys-321/Ser-324 that coordinately regulates tau polymerization and function.",
      "citation": {
        "type": "PubMed",
        "reference": "28760828",
        "name": "The Journal of biological chemistry",
        "title": "An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.",
        "volume": "292",
        "pages": "15277-15286",
        "date": "2017-09-15",
        "first": "Carlomagno Y",
        "last": "Cook C",
        "authors": [
          "Carlomagno Y",
          "Castanedes-Casey M",
          "Chung DC",
          "Cook C",
          "DeTure M",
          "Dickson DW",
          "Dunmore J",
          "Madden BJ",
          "Petrucelli L",
          "Tong J",
          "Yue M"
        ]
      },
      "source": 503,
      "target": 561,
      "key": "440886efff5af6d594c58aa886fd00cd4da3d8703cad377e5099b233e62e9e84206892d13641010b4108e8dc0a079c730ceb2fb664dfa948f19b84fc14d24fb1"
    },
    {
      "line": 3222,
      "relation": "isA",
      "evidence": "Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.",
      "citation": {
        "type": "PubMed",
        "reference": "26192747",
        "name": "Nature neuroscience",
        "title": "Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.",
        "volume": "18",
        "pages": "1183-9",
        "date": "2015-08-01",
        "first": "Morris M",
        "last": "Mucke L",
        "authors": [
          "Burlingame AL",
          "Ioanoviciu A",
          "Knudsen GM",
          "Maeda S",
          "Morris M",
          "Mucke L",
          "Trinidad JC"
        ]
      },
      "source": 504,
      "target": 490,
      "key": "4294cd0db49ba6c2868a1ef656567e5b514cc1524a6d45f235ba0e9f040bcd46d4d372e36a83b010209b6dea6a9422614bf3032edc7a3d55a7f7dcc5f39c8ba9"
    },
    {
      "line": 3232,
      "relation": "partOf",
      "evidence": "Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.",
      "citation": {
        "type": "PubMed",
        "reference": "26192747",
        "name": "Nature neuroscience",
        "title": "Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.",
        "volume": "18",
        "pages": "1183-9",
        "date": "2015-08-01",
        "first": "Morris M",
        "last": "Mucke L",
        "authors": [
          "Burlingame AL",
          "Ioanoviciu A",
          "Knudsen GM",
          "Maeda S",
          "Morris M",
          "Mucke L",
          "Trinidad JC"
        ]
      },
      "source": 504,
      "target": 130,
      "key": "dddc0a8a363251590567113c472aec4373946a2d45263eb8a7dd06403f5b30d1be7b4d510d5af8fdc17cf8497dbe98e5cde6ff9c4ccb35126f565f681d9dfb52"
    },
    {
      "line": 3223,
      "relation": "isA",
      "evidence": "Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.",
      "citation": {
        "type": "PubMed",
        "reference": "26192747",
        "name": "Nature neuroscience",
        "title": "Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.",
        "volume": "18",
        "pages": "1183-9",
        "date": "2015-08-01",
        "first": "Morris M",
        "last": "Mucke L",
        "authors": [
          "Burlingame AL",
          "Ioanoviciu A",
          "Knudsen GM",
          "Maeda S",
          "Morris M",
          "Mucke L",
          "Trinidad JC"
        ]
      },
      "source": 505,
      "target": 490,
      "key": "0a50bdae79563995b6cf623c784e67430af79e42510e8ad7a526264024496e2d9fe3f9172204f11ad3f2882c68ffc416a10f4f861f98a65dd5c1d4748bc908d2"
    },
    {
      "line": 3233,
      "relation": "partOf",
      "evidence": "Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.",
      "citation": {
        "type": "PubMed",
        "reference": "26192747",
        "name": "Nature neuroscience",
        "title": "Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.",
        "volume": "18",
        "pages": "1183-9",
        "date": "2015-08-01",
        "first": "Morris M",
        "last": "Mucke L",
        "authors": [
          "Burlingame AL",
          "Ioanoviciu A",
          "Knudsen GM",
          "Maeda S",
          "Morris M",
          "Mucke L",
          "Trinidad JC"
        ]
      },
      "source": 505,
      "target": 130,
      "key": "149843f5735c94c713d0198df3060680d61b52b3f1cff19f64e378fbc99e5cdce14d63b8afde2212e0208487a4d3e6019f36d008ff0de5838814efdc84b50624"
    },
    {
      "line": 3224,
      "relation": "isA",
      "evidence": "Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.",
      "citation": {
        "type": "PubMed",
        "reference": "26192747",
        "name": "Nature neuroscience",
        "title": "Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.",
        "volume": "18",
        "pages": "1183-9",
        "date": "2015-08-01",
        "first": "Morris M",
        "last": "Mucke L",
        "authors": [
          "Burlingame AL",
          "Ioanoviciu A",
          "Knudsen GM",
          "Maeda S",
          "Morris M",
          "Mucke L",
          "Trinidad JC"
        ]
      },
      "source": 506,
      "target": 490,
      "key": "aae1cf51469216a6deb56d3a373c087565bd66e3bc01298fbab06f0cd194206d1d70b98ad88d3496933ff26ead7cff811d8d41ad8df411b400687a30aaba826e"
    },
    {
      "line": 3234,
      "relation": "partOf",
      "evidence": "Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.",
      "citation": {
        "type": "PubMed",
        "reference": "26192747",
        "name": "Nature neuroscience",
        "title": "Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.",
        "volume": "18",
        "pages": "1183-9",
        "date": "2015-08-01",
        "first": "Morris M",
        "last": "Mucke L",
        "authors": [
          "Burlingame AL",
          "Ioanoviciu A",
          "Knudsen GM",
          "Maeda S",
          "Morris M",
          "Mucke L",
          "Trinidad JC"
        ]
      },
      "source": 506,
      "target": 130,
      "key": "4ed08b21ba3620742a43979add3d38d21cf8af42697b9137d20dc9adf66f193edeece33d646a6226dae2c5e11f73ce27ba9bc01ac050a9d4ac6c0334a482ce47"
    },
    {
      "line": 3226,
      "relation": "isA",
      "evidence": "Clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau.",
      "citation": {
        "type": "PubMed",
        "reference": "26192747",
        "name": "Nature neuroscience",
        "title": "Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.",
        "volume": "18",
        "pages": "1183-9",
        "date": "2015-08-01",
        "first": "Morris M",
        "last": "Mucke L",
        "authors": [
          "Burlingame AL",
          "Ioanoviciu A",
          "Knudsen GM",
          "Maeda S",
          "Morris M",
          "Mucke L",
          "Trinidad JC"
        ]
      },
      "source": 511,
      "target": 490,
      "key": "7688085b61602419f0d96caac5ec2a3706a813d8dc05dfab1e34e92241cf3103003298079b03e7bb365d4b8d231f56beb03ba73d2e89bffc75cdd76a7eba9e98"
    },
    {
      "line": 3243,
      "relation": "increases",
      "evidence": "Here we show through systematic epigenetic studies that the histone acetyltransferase p300/CBP-associated factor (PCAF) promotes acetylation of histone 3 Lys 9 at the promoters of established key regeneration-associated genes following a peripheral but not a central axonal injury. Furthermore, we find that extracellular signal-regulated kinase (ERK)-mediated retrograde signalling is required for PCAF-dependent regenerative gene reprogramming. Finally, PCAF is necessary for conditioning-dependent axonal regeneration and also singularly promotes regeneration after spinal cord injury. ",
      "citation": {
        "type": "PubMed",
        "reference": "24686445",
        "name": "Nature communications",
        "title": "PCAF-dependent epigenetic changes promote axonal regeneration in the central nervous system.",
        "volume": "5",
        "pages": "3527",
        "date": "2014-04-01",
        "first": "Puttagunta R",
        "last": "Di Giovanni S",
        "authors": [
          "Boutillier AL",
          "Bradke F",
          "Di Giovanni S",
          "Gaub P",
          "Hervera A",
          "Joshi Y",
          "Laskowski CJ",
          "Lindner R",
          "Nguyen T",
          "Puttagunta R",
          "Rathore KI",
          "Schmandke A",
          "Sória MG",
          "Tedeschi A"
        ]
      },
      "annotations": {
        "Anatomy": {
          "dorsal root ganglion": true
        }
      },
      "source": 133,
      "target": 644,
      "key": "8f2a778c7d3e7dec9ad8686d0d18270e608a9f68e40b2e8a1be75af5ffa31800b17fc84a7d6c5f5ca4b2e09b4ac75a0d2f61f11d2a7c029b59f272349d779252"
    },
    {
      "line": 3244,
      "relation": "increases",
      "evidence": "Here we show through systematic epigenetic studies that the histone acetyltransferase p300/CBP-associated factor (PCAF) promotes acetylation of histone 3 Lys 9 at the promoters of established key regeneration-associated genes following a peripheral but not a central axonal injury. Furthermore, we find that extracellular signal-regulated kinase (ERK)-mediated retrograde signalling is required for PCAF-dependent regenerative gene reprogramming. Finally, PCAF is necessary for conditioning-dependent axonal regeneration and also singularly promotes regeneration after spinal cord injury. ",
      "citation": {
        "type": "PubMed",
        "reference": "24686445",
        "name": "Nature communications",
        "title": "PCAF-dependent epigenetic changes promote axonal regeneration in the central nervous system.",
        "volume": "5",
        "pages": "3527",
        "date": "2014-04-01",
        "first": "Puttagunta R",
        "last": "Di Giovanni S",
        "authors": [
          "Boutillier AL",
          "Bradke F",
          "Di Giovanni S",
          "Gaub P",
          "Hervera A",
          "Joshi Y",
          "Laskowski CJ",
          "Lindner R",
          "Nguyen T",
          "Puttagunta R",
          "Rathore KI",
          "Schmandke A",
          "Sória MG",
          "Tedeschi A"
        ]
      },
      "annotations": {
        "Anatomy": {
          "dorsal root ganglion": true
        }
      },
      "source": 644,
      "target": 289,
      "key": "01c4a4b39420732372ab8770eba040d58428e0ced0807d9e1ca9adf93ff650580d03722e8559c30943fb1cfbdc6a0799e22b20d026eb4a69ad9a83cd51a04f40"
    },
    {
      "line": 3247,
      "relation": "increases",
      "evidence": "Here we show through systematic epigenetic studies that the histone acetyltransferase p300/CBP-associated factor (PCAF) promotes acetylation of histone 3 Lys 9 at the promoters of established key regeneration-associated genes following a peripheral but not a central axonal injury. Furthermore, we find that extracellular signal-regulated kinase (ERK)-mediated retrograde signalling is required for PCAF-dependent regenerative gene reprogramming. Finally, PCAF is necessary for conditioning-dependent axonal regeneration and also singularly promotes regeneration after spinal cord injury. ",
      "citation": {
        "type": "PubMed",
        "reference": "24686445",
        "name": "Nature communications",
        "title": "PCAF-dependent epigenetic changes promote axonal regeneration in the central nervous system.",
        "volume": "5",
        "pages": "3527",
        "date": "2014-04-01",
        "first": "Puttagunta R",
        "last": "Di Giovanni S",
        "authors": [
          "Boutillier AL",
          "Bradke F",
          "Di Giovanni S",
          "Gaub P",
          "Hervera A",
          "Joshi Y",
          "Laskowski CJ",
          "Lindner R",
          "Nguyen T",
          "Puttagunta R",
          "Rathore KI",
          "Schmandke A",
          "Sória MG",
          "Tedeschi A"
        ]
      },
      "annotations": {
        "Anatomy": {
          "dorsal root ganglion": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 644,
      "target": 463,
      "key": "373f5cfc76c67a8ef46384a8aa7b700ba21028bcbd61a48bfb37d593f1645ce1c755bee1bb25cc42c6c79704d68eb777ef4a7edebb209ff9ab17a1a8afd154e2"
    },
    {
      "line": 3245,
      "relation": "increases",
      "evidence": "Here we show through systematic epigenetic studies that the histone acetyltransferase p300/CBP-associated factor (PCAF) promotes acetylation of histone 3 Lys 9 at the promoters of established key regeneration-associated genes following a peripheral but not a central axonal injury. Furthermore, we find that extracellular signal-regulated kinase (ERK)-mediated retrograde signalling is required for PCAF-dependent regenerative gene reprogramming. Finally, PCAF is necessary for conditioning-dependent axonal regeneration and also singularly promotes regeneration after spinal cord injury. ",
      "citation": {
        "type": "PubMed",
        "reference": "24686445",
        "name": "Nature communications",
        "title": "PCAF-dependent epigenetic changes promote axonal regeneration in the central nervous system.",
        "volume": "5",
        "pages": "3527",
        "date": "2014-04-01",
        "first": "Puttagunta R",
        "last": "Di Giovanni S",
        "authors": [
          "Boutillier AL",
          "Bradke F",
          "Di Giovanni S",
          "Gaub P",
          "Hervera A",
          "Joshi Y",
          "Laskowski CJ",
          "Lindner R",
          "Nguyen T",
          "Puttagunta R",
          "Rathore KI",
          "Schmandke A",
          "Sória MG",
          "Tedeschi A"
        ]
      },
      "annotations": {
        "Anatomy": {
          "dorsal root ganglion": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 289,
      "target": 288,
      "key": "241d34e2d7d5594551c02d0e3d7dda6fbe7f6e629094a842b3d06f1c8a06101f3b302567ca9a3a97ce5b9ba9809c8219a956ffb9a1a8bfbe3b81f72f83e69104"
    },
    {
      "line": 3249,
      "relation": "increases",
      "evidence": "Here we show through systematic epigenetic studies that the histone acetyltransferase p300/CBP-associated factor (PCAF) promotes acetylation of histone 3 Lys 9 at the promoters of established key regeneration-associated genes following a peripheral but not a central axonal injury. Furthermore, we find that extracellular signal-regulated kinase (ERK)-mediated retrograde signalling is required for PCAF-dependent regenerative gene reprogramming. Finally, PCAF is necessary for conditioning-dependent axonal regeneration and also singularly promotes regeneration after spinal cord injury. ",
      "citation": {
        "type": "PubMed",
        "reference": "24686445",
        "name": "Nature communications",
        "title": "PCAF-dependent epigenetic changes promote axonal regeneration in the central nervous system.",
        "volume": "5",
        "pages": "3527",
        "date": "2014-04-01",
        "first": "Puttagunta R",
        "last": "Di Giovanni S",
        "authors": [
          "Boutillier AL",
          "Bradke F",
          "Di Giovanni S",
          "Gaub P",
          "Hervera A",
          "Joshi Y",
          "Laskowski CJ",
          "Lindner R",
          "Nguyen T",
          "Puttagunta R",
          "Rathore KI",
          "Schmandke A",
          "Sória MG",
          "Tedeschi A"
        ]
      },
      "annotations": {
        "Anatomy": {
          "dorsal root ganglion": true
        }
      },
      "source": 317,
      "target": 929,
      "key": "5ad3699939c5aa8ee1b9c50941c1801ec1a4520936030c94b3bb9a211610bdd49b0c093230cabb792ad881bef18cb6ded46563e9cb9d628e09abb088ea22854f"
    },
    {
      "line": 3250,
      "relation": "increases",
      "evidence": "Here we show through systematic epigenetic studies that the histone acetyltransferase p300/CBP-associated factor (PCAF) promotes acetylation of histone 3 Lys 9 at the promoters of established key regeneration-associated genes following a peripheral but not a central axonal injury. Furthermore, we find that extracellular signal-regulated kinase (ERK)-mediated retrograde signalling is required for PCAF-dependent regenerative gene reprogramming. Finally, PCAF is necessary for conditioning-dependent axonal regeneration and also singularly promotes regeneration after spinal cord injury. ",
      "citation": {
        "type": "PubMed",
        "reference": "24686445",
        "name": "Nature communications",
        "title": "PCAF-dependent epigenetic changes promote axonal regeneration in the central nervous system.",
        "volume": "5",
        "pages": "3527",
        "date": "2014-04-01",
        "first": "Puttagunta R",
        "last": "Di Giovanni S",
        "authors": [
          "Boutillier AL",
          "Bradke F",
          "Di Giovanni S",
          "Gaub P",
          "Hervera A",
          "Joshi Y",
          "Laskowski CJ",
          "Lindner R",
          "Nguyen T",
          "Puttagunta R",
          "Rathore KI",
          "Schmandke A",
          "Sória MG",
          "Tedeschi A"
        ]
      },
      "annotations": {
        "Anatomy": {
          "dorsal root ganglion": true
        }
      },
      "source": 317,
      "target": 928,
      "key": "eddf9ac68439d6a8a708aaf7e16faec5b4f5d993169bc8b6fdd0b31f812a3bbde60cb73a1571e95f20c005764690ba113ae9381d81a8afdc844ae81a51d7bcb6"
    },
    {
      "line": 3251,
      "relation": "increases",
      "evidence": "Here we show through systematic epigenetic studies that the histone acetyltransferase p300/CBP-associated factor (PCAF) promotes acetylation of histone 3 Lys 9 at the promoters of established key regeneration-associated genes following a peripheral but not a central axonal injury. Furthermore, we find that extracellular signal-regulated kinase (ERK)-mediated retrograde signalling is required for PCAF-dependent regenerative gene reprogramming. Finally, PCAF is necessary for conditioning-dependent axonal regeneration and also singularly promotes regeneration after spinal cord injury. ",
      "citation": {
        "type": "PubMed",
        "reference": "24686445",
        "name": "Nature communications",
        "title": "PCAF-dependent epigenetic changes promote axonal regeneration in the central nervous system.",
        "volume": "5",
        "pages": "3527",
        "date": "2014-04-01",
        "first": "Puttagunta R",
        "last": "Di Giovanni S",
        "authors": [
          "Boutillier AL",
          "Bradke F",
          "Di Giovanni S",
          "Gaub P",
          "Hervera A",
          "Joshi Y",
          "Laskowski CJ",
          "Lindner R",
          "Nguyen T",
          "Puttagunta R",
          "Rathore KI",
          "Schmandke A",
          "Sória MG",
          "Tedeschi A"
        ]
      },
      "annotations": {
        "Anatomy": {
          "dorsal root ganglion": true
        }
      },
      "source": 317,
      "target": 923,
      "key": "0948fb16565099d32b32311993917c53c3db5ab1c5d4e30bbfb8c040007b3c0056e00b9138125fdd0f307ac6da2e90bdcffa117f439c66d7d804e66c1ed9aa3f"
    },
    {
      "relation": "hasVariant",
      "source": 316,
      "target": 317,
      "key": "da8ab6ab3b8c043f7ebb41a29b8fd2c1c855ed3dbbbd3eb475227944e5ffd4847abe535f3917efffc539fb3b8e3973d98d3b33048070a76a63048674899b6824"
    },
    {
      "line": 3261,
      "relation": "negativeCorrelation",
      "evidence": "Overexpressed tau was hyperphosphorylated and resulted in decreased MT density and greater fragmentation. Using genetic screen, a histone deacetylase 6 (HDAC6) null mutation rescued tau-induced MT defects in both muscles and neurons. Genetic and pharmacological inhibition of the tubulin-specific deacetylase activity of HDAC6 indicates that the rescue effect may be mediated by increased MT acetylation.",
      "citation": {
        "type": "PubMed",
        "reference": "23487739",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila.",
        "volume": "110",
        "pages": "4604-9",
        "date": "2013-03-19",
        "first": "Xiong Y",
        "last": "Zhang YQ",
        "authors": [
          "Jin S",
          "Wu J",
          "Xiong Y",
          "Xu Z",
          "Zhang YQ",
          "Zhao K"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 87,
      "target": 459,
      "key": "e94b3642592784115f417452401a7bf4d44ff280c279e702d979d3d64d036b2e4ba0863392e7351cff386c119f8b608ac2300ee11777d4182b4fe95c6b29629f"
    },
    {
      "relation": "hasVariant",
      "source": 767,
      "target": 768,
      "key": "c21b021037064e0a33012491cc256ebe8bb3f8682a4f48acb73a63e94d16d513b897b18c3f8eddb438990d2d936d71837bcf053b649aebb7da156af6d3e037ee"
    },
    {
      "line": 3263,
      "relation": "directlyDecreases",
      "evidence": "Overexpressed tau was hyperphosphorylated and resulted in decreased MT density and greater fragmentation. Using genetic screen, a histone deacetylase 6 (HDAC6) null mutation rescued tau-induced MT defects in both muscles and neurons. Genetic and pharmacological inhibition of the tubulin-specific deacetylase activity of HDAC6 indicates that the rescue effect may be mediated by increased MT acetylation.",
      "citation": {
        "type": "PubMed",
        "reference": "23487739",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila.",
        "volume": "110",
        "pages": "4604-9",
        "date": "2013-03-19",
        "first": "Xiong Y",
        "last": "Zhang YQ",
        "authors": [
          "Jin S",
          "Wu J",
          "Xiong Y",
          "Xu Z",
          "Zhang YQ",
          "Zhao K"
        ]
      },
      "annotations": {
        "Species": {
          "7227": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 147,
      "target": 459,
      "key": "1edaa59e616891b6cf446aae35144fc8257f9daa26d493776ebf38ca3e32397c1d9ece7b5635ff8eb9ac58ef9fdacba32aa5f6b78d28ba28d2c85f752537d608"
    },
    {
      "line": 3272,
      "relation": "directlyDecreases",
      "evidence": "Although low-level tau acetylation was observed in untreated HEK-T40 cells, treatment with the pan histone deacetylase (HDAC) inhibitor trichostatin A (TSA), but not the Sir2 class inhibitor nicotinamide, resulted in a dramatic increase in acetylated tau levels.",
      "citation": {
        "type": "PubMed",
        "reference": "21427723",
        "name": "Nature communications",
        "title": "The acetylation of tau inhibits its function and promotes pathological tau aggregation.",
        "volume": "2",
        "pages": "252",
        "date": "2011-01-01",
        "first": "Cohen TJ",
        "last": "Lee VM",
        "authors": [
          "Cohen TJ",
          "Guo JL",
          "Hurtado DE",
          "Kwong LK",
          "Lee VM",
          "Mills IP",
          "Trojanowski JQ"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 36,
      "target": 290,
      "key": "e559b7c158d048233551b42fe9668c018e0ad27a1dd2be8c49cd5405034a1f94f430aa814d6eec68c8c80df74843bfc96ed06b6470b3711ce84a9ad954eb8a29"
    },
    {
      "line": 3274,
      "relation": "increases",
      "evidence": "Although low-level tau acetylation was observed in untreated HEK-T40 cells, treatment with the pan histone deacetylase (HDAC) inhibitor trichostatin A (TSA), but not the Sir2 class inhibitor nicotinamide, resulted in a dramatic increase in acetylated tau levels.",
      "citation": {
        "type": "PubMed",
        "reference": "21427723",
        "name": "Nature communications",
        "title": "The acetylation of tau inhibits its function and promotes pathological tau aggregation.",
        "volume": "2",
        "pages": "252",
        "date": "2011-01-01",
        "first": "Cohen TJ",
        "last": "Lee VM",
        "authors": [
          "Cohen TJ",
          "Guo JL",
          "Hurtado DE",
          "Kwong LK",
          "Lee VM",
          "Mills IP",
          "Trojanowski JQ"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "HEK293": true
        }
      },
      "source": 36,
      "target": 490,
      "key": "07736ffd713dc5329c8a66d309c2e386c7497004ca3a85b7747742768ee54e54fe6b4037011248b18f4f10db0d34d4abe52f7b84d0495b45482fbf1b1cfee4f5"
    },
    {
      "line": 3314,
      "relation": "directlyDecreases",
      "evidence": "Next, we treated primary neurons with C646, a pyrazolone-containing small-molecule inhibitor of p300 with a Ki of 400 nM (Bowers et al., 2010). Under cell-free conditions, C646 at 10 μM inhibits p300 in a highly selective manner (86% inhibition vs. <10% for the six other acetyltransferases) (Bowers et al., 2010). Inhibition of p300 with C646 (20 μM) drastically reduced levels of ac-tau in primary neurons within 8 h.",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 137,
      "target": 447,
      "key": "97c9da3104ce2be4d087c40e7e7f5051b914673eb70ad62df170af696d71f81b53259f45cbc9313ea7c4ec54c7301f0e0116fa4af893266ef3ac31f2578fb628"
    },
    {
      "line": 3315,
      "relation": "decreases",
      "evidence": "Next, we treated primary neurons with C646, a pyrazolone-containing small-molecule inhibitor of p300 with a Ki of 400 nM (Bowers et al., 2010). Under cell-free conditions, C646 at 10 μM inhibits p300 in a highly selective manner (86% inhibition vs. <10% for the six other acetyltransferases) (Bowers et al., 2010). Inhibition of p300 with C646 (20 μM) drastically reduced levels of ac-tau in primary neurons within 8 h.",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "source": 137,
      "target": 490,
      "key": "02ae66197019bdf2ba5ce500410ad2249e57435e20ca09f6ab6f12c3cc286f15db5a10117fe65622364dc431373bd7e7b0c12eff3e9cdad405ed59612687a9d4"
    },
    {
      "line": 3319,
      "relation": "negativeCorrelation",
      "evidence": "Thus, the increase in ac-tau induced by SIRT1 deficiency is accompanied by accumulation of pathogenic p-tau in primary neurons. In mouse brains, deleting SIRT1, which elevated ac-tau, also increased AT8-positive p-tau.",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 677,
      "target": 490,
      "key": "544c071ddf1852f5300bd1e8b980d2ccf40dc350be3b9defd649e6e45ff5437ba6c13067c88085009b08acb9c12ea2ac4aa24d60a0bf044623a2bfdf8804b957"
    },
    {
      "line": 3322,
      "relation": "negativeCorrelation",
      "evidence": "Thus, the increase in ac-tau induced by SIRT1 deficiency is accompanied by accumulation of pathogenic p-tau in primary neurons. In mouse brains, deleting SIRT1, which elevated ac-tau, also increased AT8-positive p-tau.",
      "citation": {
        "type": "PubMed",
        "reference": "20869593",
        "name": "Neuron",
        "title": "Acetylation of tau inhibits its degradation and contributes to tauopathy.",
        "volume": "67",
        "pages": "953-66",
        "date": "2010-09-23",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Cho SH",
          "Cole PA",
          "Gan L",
          "Haroutunian V",
          "Huang EJ",
          "Masliah E",
          "Meyers D",
          "Min SW",
          "Mukherjee C",
          "Ott M",
          "Schroeder S",
          "Seeley WW",
          "Shen Y",
          "Zhou Y"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 677,
      "target": 336,
      "key": "f8dcb37a63b124bdc33a5390a075e44b1e101f5978d5dbff06e583c986dc273b3fd0e23f50f3ba1d56006d2e3ef85195159748ebcc7f47ce036f461875f35417"
    },
    {
      "line": 3332,
      "relation": "negativeCorrelation",
      "evidence": "SIRT1 deficiency exacerbates premature mortality, synapse loss, and behavioral disinhibition in tauP301S TG mice of both sexes. SIRT1 overexpression into the hippocampus reduces acetylated K174 tau and significantly attenuates the spread of tau pathology into anatomically connected brain regions of tauP301S transgenic mice of both sexes.",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "P301S mice": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 677,
      "target": 492,
      "key": "f23835a2d600115d98a7002aa20bf2f172f2472e63297b338c02657d7d9b44d5a73b1bc2cd0877f06437f943898d963def8c74b610fdbd0c0540913adc3d5f44"
    },
    {
      "line": 3333,
      "relation": "negativeCorrelation",
      "evidence": "SIRT1 deficiency exacerbates premature mortality, synapse loss, and behavioral disinhibition in tauP301S TG mice of both sexes. SIRT1 overexpression into the hippocampus reduces acetylated K174 tau and significantly attenuates the spread of tau pathology into anatomically connected brain regions of tauP301S transgenic mice of both sexes.",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "P301S mice": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 677,
      "target": 108,
      "key": "7de7b5f8d5fae4b4da279e6f96ccda9c5b927e889fbac61437a9b65591bf5300064df9e4c87a7a622718a20d0117262865c0a2314b8c403e3d06b53cd83b9803"
    },
    {
      "line": 3340,
      "relation": "negativeCorrelation",
      "evidence": "SIRT1 activation or elevation ameliorates pathology and neurodegeneration in AD (Qin et al., 2006; Kim et al., 2007). Loss of SIRT1 induces impairment of learning and memory (Gao et al., 2010; Michán et al., 2010).",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 677,
      "target": 908,
      "key": "b369c7b8f8a114cc8150b628cb0345f167a5d0ca70b4d295a080ede5accd502d07a18d4fb1075d8ce09054d6032e8d859b52f15c8f29a4c3611963fee02a6f69"
    },
    {
      "line": 3341,
      "relation": "positiveCorrelation",
      "evidence": "SIRT1 activation or elevation ameliorates pathology and neurodegeneration in AD (Qin et al., 2006; Kim et al., 2007). Loss of SIRT1 induces impairment of learning and memory (Gao et al., 2010; Michán et al., 2010).",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "source": 677,
      "target": 197,
      "key": "6ef3d635f76b53251ef721ba1104be43e74f596b08de288580aa55ad129b081334200b0a46dd65e7923d4a8c283a2ed01753f9d0341cbb016d96aa122702a062"
    },
    {
      "line": 3342,
      "relation": "positiveCorrelation",
      "evidence": "SIRT1 activation or elevation ameliorates pathology and neurodegeneration in AD (Qin et al., 2006; Kim et al., 2007). Loss of SIRT1 induces impairment of learning and memory (Gao et al., 2010; Michán et al., 2010).",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "source": 677,
      "target": 200,
      "key": "8124340daf1e58ff76d242d8fd7bb29d27d5a75245aaffa13abf848c2b7b0eec2cac3f0361eddcaf1005859111f2d22368a27522aa6e0e74d6389776666a2c07"
    },
    {
      "line": 3349,
      "relation": "directlyDecreases",
      "evidence": "We found that SIRT1 interacts with and deacetylates SC35, and inhibits SC35-promoted tau exon 10 inclusion. Substituting K52 residue of SC35 by arginine impairs the role of SC35 in tau exon 10 inclusion. These results suggest that SIRT1 may serve as a therapeutic target for tauopathy by regulating SC35-mediated tau exon 10 splicing.",
      "citation": {
        "type": "PubMed",
        "reference": "29226865",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "SIRT1 Deacetylates SC35 and Suppresses Its Function in Tau Exon 10 Inclusion.",
        "volume": "61",
        "pages": "561-570",
        "date": "2018-01-01",
        "first": "Yin X",
        "last": "Qian W",
        "authors": [
          "Jiang X",
          "Liu F",
          "Qian S",
          "Qian W",
          "Wang J",
          "Yin X"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 677,
      "target": 690,
      "key": "7123707f434d2c1e5d077679bf8fde911fe3c094c3c736cca9d2fc1bf82de5f23490945a603df37fe2c40c813ee72c90754c31e1915a71db96a6a6cf506e65e2"
    },
    {
      "line": 3333,
      "relation": "negativeCorrelation",
      "evidence": "SIRT1 deficiency exacerbates premature mortality, synapse loss, and behavioral disinhibition in tauP301S TG mice of both sexes. SIRT1 overexpression into the hippocampus reduces acetylated K174 tau and significantly attenuates the spread of tau pathology into anatomically connected brain regions of tauP301S transgenic mice of both sexes.",
      "citation": {
        "type": "PubMed",
        "reference": "29540553",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.",
        "volume": "38",
        "pages": "3680-3688",
        "date": "2018-04-11",
        "first": "Min SW",
        "last": "Gan L",
        "authors": [
          "Devidze N",
          "Gan L",
          "Gestwicki JE",
          "Johnson JR",
          "Krogan NJ",
          "Li Y",
          "Masliah E",
          "Min SW",
          "Mok SA",
          "Sohn PD"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "P301S mice": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 108,
      "target": 677,
      "key": "aa04b2894a15beff2581758270b77dcfe40764079577bdea6a2c6efaa08c5c14899460705e14ac21937e428fd8ad13b733cd0fd85fbdcfefd80f0fa5626d462e"
    },
    {
      "line": 3350,
      "relation": "positiveCorrelation",
      "evidence": "We found that SIRT1 interacts with and deacetylates SC35, and inhibits SC35-promoted tau exon 10 inclusion. Substituting K52 residue of SC35 by arginine impairs the role of SC35 in tau exon 10 inclusion. These results suggest that SIRT1 may serve as a therapeutic target for tauopathy by regulating SC35-mediated tau exon 10 splicing.",
      "citation": {
        "type": "PubMed",
        "reference": "29226865",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "SIRT1 Deacetylates SC35 and Suppresses Its Function in Tau Exon 10 Inclusion.",
        "volume": "61",
        "pages": "561-570",
        "date": "2018-01-01",
        "first": "Yin X",
        "last": "Qian W",
        "authors": [
          "Jiang X",
          "Liu F",
          "Qian S",
          "Qian W",
          "Wang J",
          "Yin X"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 690,
      "target": 689,
      "key": "92aafdf13cb7d554001d60263afa30bfba1aec5586385db5e59717d2435a6f19385ab5bbc8b111b339ace9b60383c8524fa828b5927516e16dc4bb07945c9a32"
    },
    {
      "relation": "hasVariant",
      "source": 689,
      "target": 690,
      "key": "09ebc84bd09a7e7f9dc3c2cecbff657f52577bb5bc53f88f74612534446e2021ae7a6dc14a7cb6ead700db74843264f394042ded13d96d56ccad665e16a86c58"
    },
    {
      "line": 3350,
      "relation": "positiveCorrelation",
      "evidence": "We found that SIRT1 interacts with and deacetylates SC35, and inhibits SC35-promoted tau exon 10 inclusion. Substituting K52 residue of SC35 by arginine impairs the role of SC35 in tau exon 10 inclusion. These results suggest that SIRT1 may serve as a therapeutic target for tauopathy by regulating SC35-mediated tau exon 10 splicing.",
      "citation": {
        "type": "PubMed",
        "reference": "29226865",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "SIRT1 Deacetylates SC35 and Suppresses Its Function in Tau Exon 10 Inclusion.",
        "volume": "61",
        "pages": "561-570",
        "date": "2018-01-01",
        "first": "Yin X",
        "last": "Qian W",
        "authors": [
          "Jiang X",
          "Liu F",
          "Qian S",
          "Qian W",
          "Wang J",
          "Yin X"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 689,
      "target": 690,
      "key": "248768fa5035300f479b9f3a15026e784e8ad7538f179d828cbae97663df72dcc13252a0e8744be191504c37bb60223c1a75002acb74ade45466ac3737209b76"
    },
    {
      "line": 3351,
      "relation": "increases",
      "evidence": "We found that SIRT1 interacts with and deacetylates SC35, and inhibits SC35-promoted tau exon 10 inclusion. Substituting K52 residue of SC35 by arginine impairs the role of SC35 in tau exon 10 inclusion. These results suggest that SIRT1 may serve as a therapeutic target for tauopathy by regulating SC35-mediated tau exon 10 splicing.",
      "citation": {
        "type": "PubMed",
        "reference": "29226865",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "SIRT1 Deacetylates SC35 and Suppresses Its Function in Tau Exon 10 Inclusion.",
        "volume": "61",
        "pages": "561-570",
        "date": "2018-01-01",
        "first": "Yin X",
        "last": "Qian W",
        "authors": [
          "Jiang X",
          "Liu F",
          "Qian S",
          "Qian W",
          "Wang J",
          "Yin X"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 689,
      "target": 307,
      "key": "4066831ebc849c7766ca12081df06f0de176b5f62c59fc4b044424efac3226afe7a2fcf87d525c0adbe5b2b895ec2bd5ea139dc073323c96f7c6aca1989cd3ae"
    },
    {
      "line": 3374,
      "relation": "increases",
      "evidence": "HDAC3 overexpression in the hippocampus increases Aß levels, activates microglia, and decreases dendritic spine density in 6-month-old APP/PS1 mice.",
      "citation": {
        "type": "PubMed",
        "reference": "28771976",
        "name": "Aging cell",
        "title": "HDAC3 negatively regulates spatial memory in a mouse model of Alzheimer's disease.",
        "volume": "16",
        "pages": "1073-1082",
        "date": "2017-10-01",
        "first": "Zhu X",
        "last": "Xu Y",
        "authors": [
          "Jin J",
          "Liu Y",
          "Wang S",
          "Xu Y",
          "Ye X",
          "Yu L",
          "Zhu X"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "APPPS1 mice": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 458,
      "target": 79,
      "key": "11b444e5ba672b9759d1106c82b2e9311b79f321cf6858b77d96db1d6961ea3eea3f881ac1e9becd2a6dbce5d92c4e2017b79fd2d678904be15be2c30a5548a3"
    },
    {
      "line": 3375,
      "relation": "increases",
      "evidence": "HDAC3 overexpression in the hippocampus increases Aß levels, activates microglia, and decreases dendritic spine density in 6-month-old APP/PS1 mice.",
      "citation": {
        "type": "PubMed",
        "reference": "28771976",
        "name": "Aging cell",
        "title": "HDAC3 negatively regulates spatial memory in a mouse model of Alzheimer's disease.",
        "volume": "16",
        "pages": "1073-1082",
        "date": "2017-10-01",
        "first": "Zhu X",
        "last": "Xu Y",
        "authors": [
          "Jin J",
          "Liu Y",
          "Wang S",
          "Xu Y",
          "Ye X",
          "Yu L",
          "Zhu X"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "APPPS1 mice": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 458,
      "target": 11,
      "key": "dc668c5ba18ef2a7e16b2f1369f885e2b012f1710ca9b361ec5763dc5342b56429d1f4653e9c748938c21f7fc58119050d1a7cf4dda8d568ecc20c182f393120"
    },
    {
      "line": 3376,
      "relation": "decreases",
      "evidence": "HDAC3 overexpression in the hippocampus increases Aß levels, activates microglia, and decreases dendritic spine density in 6-month-old APP/PS1 mice.",
      "citation": {
        "type": "PubMed",
        "reference": "28771976",
        "name": "Aging cell",
        "title": "HDAC3 negatively regulates spatial memory in a mouse model of Alzheimer's disease.",
        "volume": "16",
        "pages": "1073-1082",
        "date": "2017-10-01",
        "first": "Zhu X",
        "last": "Xu Y",
        "authors": [
          "Jin J",
          "Liu Y",
          "Wang S",
          "Xu Y",
          "Ye X",
          "Yu L",
          "Zhu X"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "APPPS1 mice": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 458,
      "target": 80,
      "key": "6e61648fe7185469dd667699523a5fc4042bbacafc08f52eb4ed11dbb86c00e145fa73b13729097ee6782d97edae869ab0687ed7a335cc642a200b901a56b55a"
    },
    {
      "line": 3382,
      "relation": "directlyDecreases",
      "evidence": "RGFP966, a selective HDAC3 inhibitor, has been shown to affect sensory cortical plasticity and memory formation (Bieszczad et al., 2015).",
      "citation": {
        "type": "PubMed",
        "reference": "28771976",
        "name": "Aging cell",
        "title": "HDAC3 negatively regulates spatial memory in a mouse model of Alzheimer's disease.",
        "volume": "16",
        "pages": "1073-1082",
        "date": "2017-10-01",
        "first": "Zhu X",
        "last": "Xu Y",
        "authors": [
          "Jin J",
          "Liu Y",
          "Wang S",
          "Xu Y",
          "Ye X",
          "Yu L",
          "Zhu X"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 144,
      "target": 458,
      "key": "a5069dedcff350c787e92fb8734cc6389859ca572506185a89c72ace2e3a76fb1f1eecc3d6049357575af55500f6ed36961aa0f772cc5354bdee7dd02ab5678b"
    },
    {
      "line": 3383,
      "relation": "association",
      "evidence": "RGFP966, a selective HDAC3 inhibitor, has been shown to affect sensory cortical plasticity and memory formation (Bieszczad et al., 2015).",
      "citation": {
        "type": "PubMed",
        "reference": "28771976",
        "name": "Aging cell",
        "title": "HDAC3 negatively regulates spatial memory in a mouse model of Alzheimer's disease.",
        "volume": "16",
        "pages": "1073-1082",
        "date": "2017-10-01",
        "first": "Zhu X",
        "last": "Xu Y",
        "authors": [
          "Jin J",
          "Liu Y",
          "Wang S",
          "Xu Y",
          "Ye X",
          "Yu L",
          "Zhu X"
        ]
      },
      "source": 144,
      "target": 200,
      "key": "30750bd47677a947a9406ae432681e3d50912a80d69e68ed44786588b293d78a7f9cef4b7e34272e3b8b8288ceeefa1b1a2e46c96ecd6397c5c070fff10bcdc5"
    },
    {
      "line": 3391,
      "relation": "directlyDecreases",
      "evidence": "This study aimed to investigate the protective effects and mechanism of the novel HDAC6 inhibitor, MPT0G211, using an AD model. Our results indicated that MPT0G211 significantly reduced tau phosphorylation and aggregation, the processes highly correlated with the formation of NFTs. This HDAC6 inhibitory activity resulted in an increase in acetylated Hsp90, which decreased Hsp90 and HDAC6 binding, causing ubiquitination of phosphorylated tau proteins. In addition, a significant increase of phospho-glycogen synthase kinase-3β (phospho-GSK3β) on Ser9 (the inactive form) through Akt phosphorylation was associated with the inhibition of phospho-tau Ser396 in response to MPT0G211 treatment.",
      "citation": {
        "type": "PubMed",
        "reference": "29844403",
        "name": "Cell death &amp; disease",
        "title": "The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.",
        "volume": "9",
        "pages": "655",
        "date": "2018-05-29",
        "first": "Fan SJ",
        "last": "Yang CR",
        "authors": [
          "Fan SJ",
          "Huang FI",
          "Liou JP",
          "Yang CR"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true,
          "SH-SY5Y": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 140,
      "target": 459,
      "key": "b065e1d1bda5b6ac39142ca9fd228295d430bc2f0a25d98f33389999ab413662f2bd12d45610f2d6ec3dc0d0f071c2af40877e834846f20ceb7e60711e181fe6"
    },
    {
      "line": 3393,
      "relation": "increases",
      "evidence": "This study aimed to investigate the protective effects and mechanism of the novel HDAC6 inhibitor, MPT0G211, using an AD model. Our results indicated that MPT0G211 significantly reduced tau phosphorylation and aggregation, the processes highly correlated with the formation of NFTs. This HDAC6 inhibitory activity resulted in an increase in acetylated Hsp90, which decreased Hsp90 and HDAC6 binding, causing ubiquitination of phosphorylated tau proteins. In addition, a significant increase of phospho-glycogen synthase kinase-3β (phospho-GSK3β) on Ser9 (the inactive form) through Akt phosphorylation was associated with the inhibition of phospho-tau Ser396 in response to MPT0G211 treatment.",
      "citation": {
        "type": "PubMed",
        "reference": "29844403",
        "name": "Cell death &amp; disease",
        "title": "The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.",
        "volume": "9",
        "pages": "655",
        "date": "2018-05-29",
        "first": "Fan SJ",
        "last": "Yang CR",
        "authors": [
          "Fan SJ",
          "Huang FI",
          "Liou JP",
          "Yang CR"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true,
          "SH-SY5Y": true
        }
      },
      "source": 140,
      "target": 457,
      "key": "439c1d23fd900731e8901c4de1bb80754dd2e222df380d4f6e4d52deec77d25d314f9c1e4bc4e72fd01b364b2eb755af2adf19b53b70cbd9d5bc139e8d285ff7"
    },
    {
      "line": 3396,
      "relation": "decreases",
      "evidence": "This study aimed to investigate the protective effects and mechanism of the novel HDAC6 inhibitor, MPT0G211, using an AD model. Our results indicated that MPT0G211 significantly reduced tau phosphorylation and aggregation, the processes highly correlated with the formation of NFTs. This HDAC6 inhibitory activity resulted in an increase in acetylated Hsp90, which decreased Hsp90 and HDAC6 binding, causing ubiquitination of phosphorylated tau proteins. In addition, a significant increase of phospho-glycogen synthase kinase-3β (phospho-GSK3β) on Ser9 (the inactive form) through Akt phosphorylation was associated with the inhibition of phospho-tau Ser396 in response to MPT0G211 treatment.",
      "citation": {
        "type": "PubMed",
        "reference": "29844403",
        "name": "Cell death &amp; disease",
        "title": "The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.",
        "volume": "9",
        "pages": "655",
        "date": "2018-05-29",
        "first": "Fan SJ",
        "last": "Yang CR",
        "authors": [
          "Fan SJ",
          "Huang FI",
          "Liou JP",
          "Yang CR"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true,
          "SH-SY5Y": true
        }
      },
      "source": 140,
      "target": 564,
      "key": "5665f3aff6c5198c9ae5fc920d6e025667631bbf7e651f46f41acab3a8c540dd82167d52b9bbecbc58908c7f72e8114cb87394ddee36eb61dd2dd6fedbfb705a"
    },
    {
      "line": 3401,
      "relation": "decreases",
      "evidence": "This study aimed to investigate the protective effects and mechanism of the novel HDAC6 inhibitor, MPT0G211, using an AD model. Our results indicated that MPT0G211 significantly reduced tau phosphorylation and aggregation, the processes highly correlated with the formation of NFTs. This HDAC6 inhibitory activity resulted in an increase in acetylated Hsp90, which decreased Hsp90 and HDAC6 binding, causing ubiquitination of phosphorylated tau proteins. In addition, a significant increase of phospho-glycogen synthase kinase-3β (phospho-GSK3β) on Ser9 (the inactive form) through Akt phosphorylation was associated with the inhibition of phospho-tau Ser396 in response to MPT0G211 treatment.",
      "citation": {
        "type": "PubMed",
        "reference": "29844403",
        "name": "Cell death &amp; disease",
        "title": "The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.",
        "volume": "9",
        "pages": "655",
        "date": "2018-05-29",
        "first": "Fan SJ",
        "last": "Yang CR",
        "authors": [
          "Fan SJ",
          "Huang FI",
          "Liou JP",
          "Yang CR"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "APPswe x P301L transgenic mice": true
        }
      },
      "source": 140,
      "target": 565,
      "key": "7778c99d4e5472cc76aade98173127244a1d8d7fa524b8e36a6b6bb2b70aaef3e5ba419752c226765eb64bf69ad4fa09a43a73fe01d8982910d9d9083c752f31"
    },
    {
      "line": 3405,
      "relation": "increases",
      "evidence": "These results clearly indicated that MPT0G211 can penetrate the BBB, where it potentially ameliorates learning and memory deficits.",
      "citation": {
        "type": "PubMed",
        "reference": "29844403",
        "name": "Cell death &amp; disease",
        "title": "The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.",
        "volume": "9",
        "pages": "655",
        "date": "2018-05-29",
        "first": "Fan SJ",
        "last": "Yang CR",
        "authors": [
          "Fan SJ",
          "Huang FI",
          "Liou JP",
          "Yang CR"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "APPswe x P301L transgenic mice": true
        }
      },
      "source": 140,
      "target": 197,
      "key": "6e6f1cbc8cd8e89b5a46233f1d75154710cbcec644363543721f98d5be0214fdb91b383616791c9afba954473fbf12d547438377fbc77dbcb6e2684536b80cdc"
    },
    {
      "line": 3406,
      "relation": "increases",
      "evidence": "These results clearly indicated that MPT0G211 can penetrate the BBB, where it potentially ameliorates learning and memory deficits.",
      "citation": {
        "type": "PubMed",
        "reference": "29844403",
        "name": "Cell death &amp; disease",
        "title": "The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.",
        "volume": "9",
        "pages": "655",
        "date": "2018-05-29",
        "first": "Fan SJ",
        "last": "Yang CR",
        "authors": [
          "Fan SJ",
          "Huang FI",
          "Liou JP",
          "Yang CR"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "APPswe x P301L transgenic mice": true
        }
      },
      "source": 140,
      "target": 200,
      "key": "b92dddccfcff1528c4cb64d547d1129c4565e4e2bba7a14edea015e37318f5e19c3d515fddb4f65969ab296c98daba01b26c2404bebcda09d7a92ed475546653"
    },
    {
      "line": 3392,
      "relation": "positiveCorrelation",
      "evidence": "This study aimed to investigate the protective effects and mechanism of the novel HDAC6 inhibitor, MPT0G211, using an AD model. Our results indicated that MPT0G211 significantly reduced tau phosphorylation and aggregation, the processes highly correlated with the formation of NFTs. This HDAC6 inhibitory activity resulted in an increase in acetylated Hsp90, which decreased Hsp90 and HDAC6 binding, causing ubiquitination of phosphorylated tau proteins. In addition, a significant increase of phospho-glycogen synthase kinase-3β (phospho-GSK3β) on Ser9 (the inactive form) through Akt phosphorylation was associated with the inhibition of phospho-tau Ser396 in response to MPT0G211 treatment.",
      "citation": {
        "type": "PubMed",
        "reference": "29844403",
        "name": "Cell death &amp; disease",
        "title": "The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.",
        "volume": "9",
        "pages": "655",
        "date": "2018-05-29",
        "first": "Fan SJ",
        "last": "Yang CR",
        "authors": [
          "Fan SJ",
          "Huang FI",
          "Liou JP",
          "Yang CR"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true,
          "SH-SY5Y": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 758,
      "target": 459,
      "key": "799be1d52b974b02d7335aa57ec0f821f231d910067d79311f935a91f72bda87989f34f98b59373fa44cfa085983deb41b53336475b790805b267415d2ed06cd"
    },
    {
      "line": 3416,
      "relation": "negativeCorrelation",
      "evidence": " This post-translational modification is likely an indicator of good health since its intracellular level correlates with the availability of extracellular glucose. From a more practical point of view, it has been shown that O-GlcNAcylation impairments contribute to the etiology of cardiovascular diseases, type-2 diabetes and Alzheimer's disease (AD), three illnesses common in occidental societies.",
      "citation": {
        "type": "PubMed",
        "reference": "19732809",
        "name": "Biochimica et biophysica acta",
        "title": "Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease.",
        "volume": "1800",
        "pages": "67-79",
        "date": "2010-02-01",
        "first": "Lefebvre T",
        "last": "Michalski JC",
        "authors": [
          "Dehennaut V",
          "Drougat L",
          "Guinez C",
          "Lefebvre T",
          "Michalski JC",
          "Mir AM",
          "Mortuaire M",
          "Olivier S",
          "Vercoutter-Edouart AS"
        ]
      },
      "source": 107,
      "target": 908,
      "key": "8bc93de642aae7d6d70914d3f33bbdd337fa38b5c84d400b1a8ffc5e4e3cad2cef0e7c89f479ea827a1faa6824c09e7cb034f2bf038d4fbdd9be9a4c675e50cd"
    },
    {
      "line": 3417,
      "relation": "negativeCorrelation",
      "evidence": " This post-translational modification is likely an indicator of good health since its intracellular level correlates with the availability of extracellular glucose. From a more practical point of view, it has been shown that O-GlcNAcylation impairments contribute to the etiology of cardiovascular diseases, type-2 diabetes and Alzheimer's disease (AD), three illnesses common in occidental societies.",
      "citation": {
        "type": "PubMed",
        "reference": "19732809",
        "name": "Biochimica et biophysica acta",
        "title": "Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease.",
        "volume": "1800",
        "pages": "67-79",
        "date": "2010-02-01",
        "first": "Lefebvre T",
        "last": "Michalski JC",
        "authors": [
          "Dehennaut V",
          "Drougat L",
          "Guinez C",
          "Lefebvre T",
          "Michalski JC",
          "Mir AM",
          "Mortuaire M",
          "Olivier S",
          "Vercoutter-Edouart AS"
        ]
      },
      "source": 107,
      "target": 912,
      "key": "449fa5626abedd54eefcf1d655802aabccb5ee84a8c60ec69a6d32eff9610d3efecfa09634f72ca16b67cfb6e48228926b126744e2bdbc1dce58b4bc3aad08a0"
    },
    {
      "line": 3418,
      "relation": "association",
      "evidence": " This post-translational modification is likely an indicator of good health since its intracellular level correlates with the availability of extracellular glucose. From a more practical point of view, it has been shown that O-GlcNAcylation impairments contribute to the etiology of cardiovascular diseases, type-2 diabetes and Alzheimer's disease (AD), three illnesses common in occidental societies.",
      "citation": {
        "type": "PubMed",
        "reference": "19732809",
        "name": "Biochimica et biophysica acta",
        "title": "Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease.",
        "volume": "1800",
        "pages": "67-79",
        "date": "2010-02-01",
        "first": "Lefebvre T",
        "last": "Michalski JC",
        "authors": [
          "Dehennaut V",
          "Drougat L",
          "Guinez C",
          "Lefebvre T",
          "Michalski JC",
          "Mir AM",
          "Mortuaire M",
          "Olivier S",
          "Vercoutter-Edouart AS"
        ]
      },
      "source": 107,
      "target": 203,
      "key": "b4a615eff4bcfb1c49d598f0e298db42d3b07f0bfc1de4bb4394c0a7b6f4b0f139be2686b0488d34056c785fffafbf72918339cb4e1c7b52b9b8693dd6323df7"
    },
    {
      "line": 3429,
      "relation": "negativeCorrelation",
      "evidence": "It has been reported that the proteasomal machinery is modified by O-GlcNAcylation [53,126] and that after modification by OGT, the proteasome is inhibited [53]. Intriguingly, it has been proposed that a genetic impairment in the OGA gene results in proteasomal dysfunction through a lack of hydrolysis of the inhibitory O-GlcNAc residues of the 19S regulatory cap. Indeed, the OGA gene is located in the 10q locus [127,128], a chromosomal region frequently mutated in AD. The impairment of OGA in AD and the subsequent static OGlcNAcylation of the proteasome may explain why the latter fails to degrade neuronal aggregates. In addition, it has been reported that OGlcNAcylation reduces the sensitivity of intracellular proteins to proteasomal degradation by directly modifying them [43,129,130]. The two phenomena could thus act synergistically: a protein could escape degradation by means of its own O-GlcNAcylation and by the inhibitory effect of glycosylation on the proteasome, leading to a considerable decrease in the turnover of proteins that in turn may aggregate and cause neuronal death.",
      "citation": {
        "type": "PubMed",
        "reference": "19732809",
        "name": "Biochimica et biophysica acta",
        "title": "Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease.",
        "volume": "1800",
        "pages": "67-79",
        "date": "2010-02-01",
        "first": "Lefebvre T",
        "last": "Michalski JC",
        "authors": [
          "Dehennaut V",
          "Drougat L",
          "Guinez C",
          "Lefebvre T",
          "Michalski JC",
          "Mir AM",
          "Mortuaire M",
          "Olivier S",
          "Vercoutter-Edouart AS"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 107,
      "target": 213,
      "key": "22d48ef49eb36603f3702c18670cf918ce5baf5d687da488ef90502eb1e6b09086e436bcfc85009e0ad9f84521ef707dacb912e9833789b89eb60939bb03beda"
    },
    {
      "line": 3417,
      "relation": "negativeCorrelation",
      "evidence": " This post-translational modification is likely an indicator of good health since its intracellular level correlates with the availability of extracellular glucose. From a more practical point of view, it has been shown that O-GlcNAcylation impairments contribute to the etiology of cardiovascular diseases, type-2 diabetes and Alzheimer's disease (AD), three illnesses common in occidental societies.",
      "citation": {
        "type": "PubMed",
        "reference": "19732809",
        "name": "Biochimica et biophysica acta",
        "title": "Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease.",
        "volume": "1800",
        "pages": "67-79",
        "date": "2010-02-01",
        "first": "Lefebvre T",
        "last": "Michalski JC",
        "authors": [
          "Dehennaut V",
          "Drougat L",
          "Guinez C",
          "Lefebvre T",
          "Michalski JC",
          "Mir AM",
          "Mortuaire M",
          "Olivier S",
          "Vercoutter-Edouart AS"
        ]
      },
      "source": 912,
      "target": 107,
      "key": "4ceaf038777929c24b9ceca6a236d742b44f83dae20c1fca2baa84a832778060f63a1b4874aac57d4b4c7d103200b8340ccc2106d03ac20be777f4802d6ebe95"
    },
    {
      "line": 3430,
      "relation": "positiveCorrelation",
      "evidence": "It has been reported that the proteasomal machinery is modified by O-GlcNAcylation [53,126] and that after modification by OGT, the proteasome is inhibited [53]. Intriguingly, it has been proposed that a genetic impairment in the OGA gene results in proteasomal dysfunction through a lack of hydrolysis of the inhibitory O-GlcNAc residues of the 19S regulatory cap. Indeed, the OGA gene is located in the 10q locus [127,128], a chromosomal region frequently mutated in AD. The impairment of OGA in AD and the subsequent static OGlcNAcylation of the proteasome may explain why the latter fails to degrade neuronal aggregates. In addition, it has been reported that OGlcNAcylation reduces the sensitivity of intracellular proteins to proteasomal degradation by directly modifying them [43,129,130]. The two phenomena could thus act synergistically: a protein could escape degradation by means of its own O-GlcNAcylation and by the inhibitory effect of glycosylation on the proteasome, leading to a considerable decrease in the turnover of proteins that in turn may aggregate and cause neuronal death.",
      "citation": {
        "type": "PubMed",
        "reference": "19732809",
        "name": "Biochimica et biophysica acta",
        "title": "Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease.",
        "volume": "1800",
        "pages": "67-79",
        "date": "2010-02-01",
        "first": "Lefebvre T",
        "last": "Michalski JC",
        "authors": [
          "Dehennaut V",
          "Drougat L",
          "Guinez C",
          "Lefebvre T",
          "Michalski JC",
          "Mir AM",
          "Mortuaire M",
          "Olivier S",
          "Vercoutter-Edouart AS"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 259,
      "target": 213,
      "key": "4f3819cad19cfea49ce57b071c579e251b1ecb38e9f9f7eadf42b1c210a2b0d2b8ad2486154e6615f6825a4667d55f894518bdc4e2448c3d2b15b1eef0c6ed6f"
    },
    {
      "line": 3447,
      "relation": "decreases",
      "evidence": "We identified three specific RNA aptamers of USP14 (USP14-1, USP14-2, and USP14-3) that inhibited its deubiquitinating activity. The nucleotide sequences of these non-cytotoxic USP14 aptamers contained conserved GGAGG motifs, with G-rich regions upstream, and similar secondary structures. They efficiently elevated proteasomal activity, as determined by the increased degradation of small fluorogenic peptide substrates and physiological polyubiquitinated Sic1 proteins. Additionally, proteasomal degradation of tau proteins was facilitated in the presence of the UPS14 aptamers in vitro.",
      "citation": {
        "type": "PubMed",
        "reference": "26041011",
        "name": "Scientific reports",
        "title": "Facilitated Tau Degradation by USP14 Aptamers via Enhanced Proteasome Activity.",
        "volume": "5",
        "pages": "10757",
        "date": "2015-06-04",
        "first": "Lee JH",
        "last": "Lee MJ",
        "authors": [
          "Choi WH",
          "Hong C",
          "Jiang Y",
          "Kim DE",
          "Lee JH",
          "Lee MJ",
          "Shin SK"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 743,
      "target": 213,
      "key": "d0a336e1e6e87067f0ee6fca1fd775dd76a771572c0566e6f55d243fca33c60789b1fbf7c851ace1fa6854d827171c1edc29b486f605f18ac725e09eef3cbbbd"
    },
    {
      "line": 3449,
      "relation": "decreases",
      "evidence": "We identified three specific RNA aptamers of USP14 (USP14-1, USP14-2, and USP14-3) that inhibited its deubiquitinating activity. The nucleotide sequences of these non-cytotoxic USP14 aptamers contained conserved GGAGG motifs, with G-rich regions upstream, and similar secondary structures. They efficiently elevated proteasomal activity, as determined by the increased degradation of small fluorogenic peptide substrates and physiological polyubiquitinated Sic1 proteins. Additionally, proteasomal degradation of tau proteins was facilitated in the presence of the UPS14 aptamers in vitro.",
      "citation": {
        "type": "PubMed",
        "reference": "26041011",
        "name": "Scientific reports",
        "title": "Facilitated Tau Degradation by USP14 Aptamers via Enhanced Proteasome Activity.",
        "volume": "5",
        "pages": "10757",
        "date": "2015-06-04",
        "first": "Lee JH",
        "last": "Lee MJ",
        "authors": [
          "Choi WH",
          "Hong C",
          "Jiang Y",
          "Kim DE",
          "Lee JH",
          "Lee MJ",
          "Shin SK"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 122,
      "target": 743,
      "key": "a36aac5ee3accc9d4c6124af54c5f12baaa28714273e543aa951323339bcea7c363843f424346e743ad3c691665e09bbfa4ff3a414d0a3a20b1f34804bd87ebd"
    },
    {
      "line": 3454,
      "relation": "association",
      "evidence": "the ACR (APP cytosolic region) interacts with the E3 ubiquitin-protein ligases Stub1, which binds the NH2 terminus of the ACR, and CRL4(CRBN), which is formed by Cul4a/b, Ddb1, and Crbn, and interacts with the COOH terminus of the ACR via Crbn.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 310,
      "target": 691,
      "key": "3e13a91fc0d63bb3cc3e42ceca66848f108b586b2aac2218fe90e40a8951f4de11189e709d8f05bf622df676f296c9fb1cfedf1b504d6b5a93e775f6dfcf1696"
    },
    {
      "line": 3456,
      "relation": "association",
      "evidence": "the ACR (APP cytosolic region) interacts with the E3 ubiquitin-protein ligases Stub1, which binds the NH2 terminus of the ACR, and CRL4(CRBN), which is formed by Cul4a/b, Ddb1, and Crbn, and interacts with the COOH terminus of the ACR via Crbn.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 310,
      "target": 313,
      "key": "98cc745a7c0cca8ff043b0abc3316cc78d0baf7e5a0de8417231bd342968c8f1d00020ec25e4225ab404a2a71c1118c5706b36d2809e1588b64cc18fe85cf101"
    },
    {
      "line": 3462,
      "relation": "increases",
      "evidence": "As reported in Table 6, several brain-derived proteins associated with the ACR bait were ubiquitinated. These proteins can be separated into four groups as follows: (a) group 1, proteins of the ubiquitin-conjugating system; (b) group 2, presynaptic proteins; (c) group 3, other proteins implicated in AD; and (d) group 4, phosphorylation-dependent ACR interactors.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 310,
      "target": 675,
      "key": "af26fbcba6e062ecd8fe6ecb066cb41189d3c43a6931358e6cd6397c9843f20ac105b047e6d115a5a94ac8f0c0d6260770e0936d5ac3a800bcc21fcf192d4b33"
    },
    {
      "line": 3463,
      "relation": "increases",
      "evidence": "As reported in Table 6, several brain-derived proteins associated with the ACR bait were ubiquitinated. These proteins can be separated into four groups as follows: (a) group 1, proteins of the ubiquitin-conjugating system; (b) group 2, presynaptic proteins; (c) group 3, other proteins implicated in AD; and (d) group 4, phosphorylation-dependent ACR interactors.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 310,
      "target": 702,
      "key": "d43078a39756a201560dbb0c10c3f18b5326c6d1e1b7e4555d66871b7d85be7e6fca90319121741a2fb25c24faf19883168b7e5e1ad37f4871cb1967588085e4"
    },
    {
      "line": 3464,
      "relation": "increases",
      "evidence": "As reported in Table 6, several brain-derived proteins associated with the ACR bait were ubiquitinated. These proteins can be separated into four groups as follows: (a) group 1, proteins of the ubiquitin-conjugating system; (b) group 2, presynaptic proteins; (c) group 3, other proteins implicated in AD; and (d) group 4, phosphorylation-dependent ACR interactors.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 310,
      "target": 704,
      "key": "e34f3e4f04a1c346d5f049b2798fb0ee785f4e584c2800dfb570f2f23656c39771c8d8b5cce653bd3a328717a86d78d241aea2dd16876de64961e351ddf870e6"
    },
    {
      "line": 3465,
      "relation": "increases",
      "evidence": "As reported in Table 6, several brain-derived proteins associated with the ACR bait were ubiquitinated. These proteins can be separated into four groups as follows: (a) group 1, proteins of the ubiquitin-conjugating system; (b) group 2, presynaptic proteins; (c) group 3, other proteins implicated in AD; and (d) group 4, phosphorylation-dependent ACR interactors.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 310,
      "target": 745,
      "key": "89f2a2fd9a7242aebeed93b355371f7bc51e25ad5f259858e45c82b32c5d4b1a83c57aec9a6e44658abfb22c6a26e64b497d048682b6376e5cf8a23a866859cb"
    },
    {
      "line": 3466,
      "relation": "increases",
      "evidence": "As reported in Table 6, several brain-derived proteins associated with the ACR bait were ubiquitinated. These proteins can be separated into four groups as follows: (a) group 1, proteins of the ubiquitin-conjugating system; (b) group 2, presynaptic proteins; (c) group 3, other proteins implicated in AD; and (d) group 4, phosphorylation-dependent ACR interactors.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 310,
      "target": 386,
      "key": "5ea632dda68479e4041f73b95028547f8cebbc281f86f2b7e9d1d273bdbb17499519210e1a20ef67491bbc1239bd52523b66f8101ea30f9d83bf5dfd23c2222c"
    },
    {
      "line": 3467,
      "relation": "increases",
      "evidence": "As reported in Table 6, several brain-derived proteins associated with the ACR bait were ubiquitinated. These proteins can be separated into four groups as follows: (a) group 1, proteins of the ubiquitin-conjugating system; (b) group 2, presynaptic proteins; (c) group 3, other proteins implicated in AD; and (d) group 4, phosphorylation-dependent ACR interactors.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 310,
      "target": 679,
      "key": "a716cd068976f0d981a16057ac2a352a319cac05ae9e2c9ee78c4e8805b4a6aa06cbeb04a22c59d6ec33e0981856785ca9795a797f802cbae223feb5a2d4f240"
    },
    {
      "line": 3468,
      "relation": "increases",
      "evidence": "As reported in Table 6, several brain-derived proteins associated with the ACR bait were ubiquitinated. These proteins can be separated into four groups as follows: (a) group 1, proteins of the ubiquitin-conjugating system; (b) group 2, presynaptic proteins; (c) group 3, other proteins implicated in AD; and (d) group 4, phosphorylation-dependent ACR interactors.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 310,
      "target": 716,
      "key": "1b95f0964134233a966f0c30e02c0ba6a4aba5a48b82091409132113e9cadba79f108be260c8a09df292e584dd524c92f7b42a552169de99c58a2b5e37c798d0"
    },
    {
      "line": 3469,
      "relation": "increases",
      "evidence": "As reported in Table 6, several brain-derived proteins associated with the ACR bait were ubiquitinated. These proteins can be separated into four groups as follows: (a) group 1, proteins of the ubiquitin-conjugating system; (b) group 2, presynaptic proteins; (c) group 3, other proteins implicated in AD; and (d) group 4, phosphorylation-dependent ACR interactors.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 310,
      "target": 718,
      "key": "2ced4b6b5881b923214ff72c294de5195b141c7c12b61bc21df1904db54cb8397ab5c2a8d682ee28975ae014ee3744ae7e099f9833dad838f8b2f260c4a78da9"
    },
    {
      "line": 3470,
      "relation": "increases",
      "evidence": "As reported in Table 6, several brain-derived proteins associated with the ACR bait were ubiquitinated. These proteins can be separated into four groups as follows: (a) group 1, proteins of the ubiquitin-conjugating system; (b) group 2, presynaptic proteins; (c) group 3, other proteins implicated in AD; and (d) group 4, phosphorylation-dependent ACR interactors.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 310,
      "target": 666,
      "key": "1ce9f7122e254b249a60b4ec3bc42ceb11a9e1921518a3bb05a7a4f9093f096f4e1d1927b9901aee5f8e10b3c81935dce6adadbc191aede72fcfb443f651dab8"
    },
    {
      "line": 3471,
      "relation": "increases",
      "evidence": "As reported in Table 6, several brain-derived proteins associated with the ACR bait were ubiquitinated. These proteins can be separated into four groups as follows: (a) group 1, proteins of the ubiquitin-conjugating system; (b) group 2, presynaptic proteins; (c) group 3, other proteins implicated in AD; and (d) group 4, phosphorylation-dependent ACR interactors.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 310,
      "target": 685,
      "key": "ffa90d38edc4d407cc67d3b6fb5fe475631fa0f0376aea429369aeed39f2e68c7690c2286f025d5498b7a6ec52da2f0a73686557470df6e9f13965e7e92a7cd8"
    },
    {
      "line": 3472,
      "relation": "increases",
      "evidence": "As reported in Table 6, several brain-derived proteins associated with the ACR bait were ubiquitinated. These proteins can be separated into four groups as follows: (a) group 1, proteins of the ubiquitin-conjugating system; (b) group 2, presynaptic proteins; (c) group 3, other proteins implicated in AD; and (d) group 4, phosphorylation-dependent ACR interactors.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 310,
      "target": 714,
      "key": "b49fb2663e1540086ed4f0310c5e6f625dde2fff916ecdc8aa57ed8caaa42ef8efe7d677114d00adfcc8ae0d63dfde1bcf3a56638765f6f02e8db52e68da3ec6"
    },
    {
      "line": 3473,
      "relation": "increases",
      "evidence": "As reported in Table 6, several brain-derived proteins associated with the ACR bait were ubiquitinated. These proteins can be separated into four groups as follows: (a) group 1, proteins of the ubiquitin-conjugating system; (b) group 2, presynaptic proteins; (c) group 3, other proteins implicated in AD; and (d) group 4, phosphorylation-dependent ACR interactors.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 310,
      "target": 712,
      "key": "fc4a9c16740a5da5032b0525f42071f915b58d500ace1cb1a1a38c62f4bcbd6b7e18e0de26f8a7292d134824ed4cfe9ede77f56511a3ac0f0ce1c974c0473122"
    },
    {
      "line": 3474,
      "relation": "increases",
      "evidence": "As reported in Table 6, several brain-derived proteins associated with the ACR bait were ubiquitinated. These proteins can be separated into four groups as follows: (a) group 1, proteins of the ubiquitin-conjugating system; (b) group 2, presynaptic proteins; (c) group 3, other proteins implicated in AD; and (d) group 4, phosphorylation-dependent ACR interactors.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 310,
      "target": 668,
      "key": "3e2557e9d2e83711cf8f57ac2ed0d08d844a1023429c0a0b0e65c8d7bc05c03bdce536ad388bc64844951c8d24550e5e313f6d7b4ba59fb4beb268584803ff9b"
    },
    {
      "line": 3475,
      "relation": "increases",
      "evidence": "As reported in Table 6, several brain-derived proteins associated with the ACR bait were ubiquitinated. These proteins can be separated into four groups as follows: (a) group 1, proteins of the ubiquitin-conjugating system; (b) group 2, presynaptic proteins; (c) group 3, other proteins implicated in AD; and (d) group 4, phosphorylation-dependent ACR interactors.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 310,
      "target": 373,
      "key": "a33f8a2f619f8ba7b6e0c143f2c3304ee065cc67b4a9d08bef3ab52c64475724d45d2f06dfec8bec1bbbbfcee47aa1642b609fefd475acd8c8cb46922b0e74a0"
    },
    {
      "line": 3476,
      "relation": "increases",
      "evidence": "As reported in Table 6, several brain-derived proteins associated with the ACR bait were ubiquitinated. These proteins can be separated into four groups as follows: (a) group 1, proteins of the ubiquitin-conjugating system; (b) group 2, presynaptic proteins; (c) group 3, other proteins implicated in AD; and (d) group 4, phosphorylation-dependent ACR interactors.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 310,
      "target": 594,
      "key": "749ef901396fb5a387086ee3e4b5fef20816430e64472cc9512f9786c959c6070063b266a6ceaedac6be76e60af342b15e23c4da2eb310980b01635439d8c7ed"
    },
    {
      "line": 3479,
      "relation": "regulates",
      "evidence": "Together with the evidence that CRBN and CUL4B are linked to intellectual disability suggests a pathogenic mechanism, in which APP acts as a modulator of E3 ubiquitin-protein ligase(s).",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 310,
      "target": 217,
      "key": "dbb09359e0e5bef4d2a8faf40dcc254f229877b027bb22e8837b8ccba4a4584f43b3d1d2579acaf43a361df76f371508dd093ff7645a8a0b475162ec83b2bf84"
    },
    {
      "line": 3456,
      "relation": "association",
      "evidence": "the ACR (APP cytosolic region) interacts with the E3 ubiquitin-protein ligases Stub1, which binds the NH2 terminus of the ACR, and CRL4(CRBN), which is formed by Cul4a/b, Ddb1, and Crbn, and interacts with the COOH terminus of the ACR via Crbn.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 313,
      "target": 310,
      "key": "d6ceee36e455965c8611b4760b46189d868d834d20e9a23adf29966f491c5beef6ac315471f637087db3925feb142729838971d38a8c9a72bfd59930657369c5"
    },
    {
      "line": 3457,
      "relation": "equivalentTo",
      "evidence": "the ACR (APP cytosolic region) interacts with the E3 ubiquitin-protein ligases Stub1, which binds the NH2 terminus of the ACR, and CRL4(CRBN), which is formed by Cul4a/b, Ddb1, and Crbn, and interacts with the COOH terminus of the ACR via Crbn.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 313,
      "target": 235,
      "key": "b3edda750f034bfd3ab34100cd20995bc46c18fbe209896c3928b52bece9b3435d5b8cae6bed3d7454220ef5932bf4c4bbc83ba31c71733a0312a16b5c60f901"
    },
    {
      "line": 3458,
      "relation": "isA",
      "evidence": "the ACR (APP cytosolic region) interacts with the E3 ubiquitin-protein ligases Stub1, which binds the NH2 terminus of the ACR, and CRL4(CRBN), which is formed by Cul4a/b, Ddb1, and Crbn, and interacts with the COOH terminus of the ACR via Crbn.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 313,
      "target": 217,
      "key": "3fac81f24e3be6272861820b19796c667df1c8bcc7b7e600b32e2a8e6843e6405aff71091835e1b4d5e0e1396941af373c3629e7adcab9a492ae559540986d20"
    },
    {
      "relation": "hasComponent",
      "source": 235,
      "target": 408,
      "key": "277cceb648050a5af4f0cc9bc72f14d11154deb453bf954a3e0f4ca1e19e3c3cc9fe478697404c1070f1c521d9f6572884228587b639d95a69678188dbdd9edd"
    },
    {
      "relation": "hasComponent",
      "source": 235,
      "target": 429,
      "key": "80a3570e302c0641b5cbc8f4babc8d21b85254fe81bf63d86512ceaaee7b4fa3fe4f0067e60c531706e20012df0b61b7262f0a3a48f313bc1f8625d502dc79a5"
    },
    {
      "relation": "hasComponent",
      "source": 235,
      "target": 430,
      "key": "4af0f3576c8b461218318a17f702e52df950ba735f0551613dfbfbabd954bb8347cd29760becc6105d2af390b153715c9b23cee3daf318429f73a391d17cf43a"
    },
    {
      "relation": "hasComponent",
      "source": 235,
      "target": 436,
      "key": "13382f89b7bd110285e1dc697c6b0dc4b57d67d1fd82f46aaabc29d4960dea97bc2e2cb17d0e67c7497c591891c89685e333a567763466f967470a35fd838067"
    },
    {
      "line": 3457,
      "relation": "equivalentTo",
      "evidence": "the ACR (APP cytosolic region) interacts with the E3 ubiquitin-protein ligases Stub1, which binds the NH2 terminus of the ACR, and CRL4(CRBN), which is formed by Cul4a/b, Ddb1, and Crbn, and interacts with the COOH terminus of the ACR via Crbn.",
      "citation": {
        "type": "PubMed",
        "reference": "27325702",
        "name": "The Journal of biological chemistry",
        "title": "Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.",
        "volume": "291",
        "pages": "17209-27",
        "date": "2016-08-12",
        "first": "Del Prete D",
        "last": "D'Adamio L",
        "authors": [
          "D'Adamio L",
          "Del Prete D",
          "Rajadhyaksha AM",
          "Rice RC"
        ]
      },
      "source": 235,
      "target": 313,
      "key": "b439d835c9182d50d6029e54092ac93dd8e318010f07814da8a336da2d4f173fdb6a280cf8490ce2a0ae9330fb16945958e016be154bac7360cf10dc265d8ef8"
    },
    {
      "relation": "hasVariant",
      "source": 674,
      "target": 675,
      "key": "75e011feaf5e931bf427d97582bc211d2ff1ea608f2028fa61ac752b51635bb806640803954c19b34b90da7748cd979f23ed4fa0e8cbf797e7dbd74f8b212ee0"
    },
    {
      "relation": "hasVariant",
      "source": 703,
      "target": 704,
      "key": "f550c4c4f9f6442cba795f39702bcccbc11867b6575f92c79cfcfc33478b22c9b2d168b3760d2a0145989765dd58be2d39e8cbb118ae29c0e154fa0ce7da5678"
    },
    {
      "relation": "hasVariant",
      "source": 744,
      "target": 745,
      "key": "0e17ad5d901ba6b1bafeed1030031732b1bc964fdae57e44c127c0762d88a52cfe40b83d5f8cb791bb36c85e7a6a5d86be389fcd5d6a1c339b4b21775fc5593a"
    },
    {
      "relation": "hasVariant",
      "source": 385,
      "target": 386,
      "key": "b3604e8ed68d64eba6766e715c543a83107b147eab4cf4dfed18f6c9c273d7e37ab0b4c8c43e99666b3fd9153b566500f89076badbf3a7107a2d52d1d3c7057c"
    },
    {
      "relation": "hasVariant",
      "source": 678,
      "target": 679,
      "key": "b44f45d837a686af82f7a3ee061469eb373d3d034e3f709d79e6b10107ba3b00ba81b61be9250dd8475b7af071da856f4915e6046fdd24564c28d4ef791a1ac4"
    },
    {
      "relation": "hasVariant",
      "source": 717,
      "target": 718,
      "key": "d4bf1a4ba427d10ca565fdc0185dfef95e8309900d5367a9d604857d8a1931d8a9e68ae9ed4e31f01eea94e695380f35ab6344eaacb6f50887a55d849dc2ea72"
    },
    {
      "relation": "hasVariant",
      "source": 665,
      "target": 666,
      "key": "06f53ae8ad16b46a7e03b0486895318a93e63d055fbd7bc463c18626df397763b5420ac0370b0495de6199d39c00a89432b5878933d882d3bc0abb5c151587c4"
    },
    {
      "relation": "hasVariant",
      "source": 713,
      "target": 714,
      "key": "dece9d0b39b60c369f1ea114bf44ad7b2c7b137ad9be676721c6bc9ced22416742e6d1a94e09b573a76e93578deb2422df8a1d1de1af0337cf4b994d2a43c6d0"
    },
    {
      "relation": "hasVariant",
      "source": 667,
      "target": 668,
      "key": "cac99505bad20a8e8936844cd3297f4b1e43fdf4e27f12891fe1d4eb525838e38ad4e7d06e8a885ec6efdf80dd91aca181075ce87786f3d90438a7b24a7ee473"
    },
    {
      "relation": "hasVariant",
      "source": 372,
      "target": 373,
      "key": "d1a86dba13219083e7ece22653a919dc38d25b67bf43698f29268565dcdf7b375120de5484992f4403962c682b73971c695cf83c1d4d702b203e188d98ec1ae1"
    },
    {
      "line": 3487,
      "relation": "positiveCorrelation",
      "evidence": "Furthermore, the enhanced SUMO-immunoreactivity, costained with the hyperphosphorylated tau, is detected in cerebral cortex of the AD brains, and β-amyloid exposure of rat primary hippocampal neurons induces a dose-dependent SUMOylation of the hyperphosphorylated tau. Our findings suggest that tau SUMOylation reciprocally stimulates its phosphorylation and inhibits the ubiquitination-mediated tau degradation, which provides a new insight into the AD-like tau accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "25378699",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination.",
        "volume": "111",
        "pages": "16586-91",
        "date": "2014-11-18",
        "first": "Luo HB",
        "last": "Wang JZ",
        "authors": [
          "Feng Y",
          "Jiang J",
          "Liu XH",
          "Liu ZC",
          "Luo HB",
          "Shu XJ",
          "Wang JZ",
          "Wang XC",
          "Xia YY",
          "Xiong YS",
          "Ye K",
          "Yin G",
          "Yu G",
          "Zeng K"
        ]
      },
      "object": {
        "modifier": "Degradation"
      },
      "source": 594,
      "target": 486,
      "key": "9e4d3c4bcd315653c697776c6f6eeab5de5da3d40f6297ed7de3ad458ed7b65e583f50f28f668aca75d005304ffa6de9f8dad48bddb315c935ed32f1cf27f4f9"
    },
    {
      "line": 3513,
      "relation": "negativeCorrelation",
      "evidence": "We show that axotrophin/MARCH7, a RING-variant domain containing protein with similarity to E3 ubiquitin ligases interacts with tau. We find here that tau becomes mono-ubiquitinated by recombinant tau-interacting RING-variant domain, which diminishes its microtubule-binding. Tau becomes mono-ubiquitinated by recombinant tau-interacting RING-variant domain reducing microtubule-binding.",
      "citation": {
        "type": "PubMed",
        "reference": "24905733",
        "name": "Biochimica et biophysica acta",
        "title": "Axotrophin/MARCH7 acts as an E3 ubiquitin ligase and ubiquitinates tau protein in vitro impairing microtubule binding.",
        "volume": "1842",
        "pages": "1527-38",
        "date": "2014-09-01",
        "first": "Flach K",
        "last": "Holzer M",
        "authors": [
          "Albrecht F",
          "Arendt T",
          "Arsalan-Werner A",
          "Flach K",
          "Goedert M",
          "Herrmann L",
          "Hilbrich I",
          "Holzer M",
          "Ramminger E"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 594,
      "target": 486,
      "key": "e856eff13673c13b561a538ba6599f372fc27b64faac2957fd2e55761679d129a87502b4099bc308ee5f269a33d9a80984624881d2a08a480bc4d1c848d39fa9"
    },
    {
      "line": 3485,
      "relation": "positiveCorrelation",
      "evidence": "Furthermore, the enhanced SUMO-immunoreactivity, costained with the hyperphosphorylated tau, is detected in cerebral cortex of the AD brains, and β-amyloid exposure of rat primary hippocampal neurons induces a dose-dependent SUMOylation of the hyperphosphorylated tau. Our findings suggest that tau SUMOylation reciprocally stimulates its phosphorylation and inhibits the ubiquitination-mediated tau degradation, which provides a new insight into the AD-like tau accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "25378699",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination.",
        "volume": "111",
        "pages": "16586-91",
        "date": "2014-11-18",
        "first": "Luo HB",
        "last": "Wang JZ",
        "authors": [
          "Feng Y",
          "Jiang J",
          "Liu XH",
          "Liu ZC",
          "Luo HB",
          "Shu XJ",
          "Wang JZ",
          "Wang XC",
          "Xia YY",
          "Xiong YS",
          "Ye K",
          "Yin G",
          "Yu G",
          "Zeng K"
        ]
      },
      "source": 593,
      "target": 538,
      "key": "29d94a87b4add5e994406f9967fdf1e605847ad45998f23505400315335f6c00c91c2f5b2894973ec25a71944e5b3b99b6d64c2985b6b5a75bc2a52ddf47b042"
    },
    {
      "line": 3486,
      "relation": "decreases",
      "evidence": "Furthermore, the enhanced SUMO-immunoreactivity, costained with the hyperphosphorylated tau, is detected in cerebral cortex of the AD brains, and β-amyloid exposure of rat primary hippocampal neurons induces a dose-dependent SUMOylation of the hyperphosphorylated tau. Our findings suggest that tau SUMOylation reciprocally stimulates its phosphorylation and inhibits the ubiquitination-mediated tau degradation, which provides a new insight into the AD-like tau accumulation.",
      "citation": {
        "type": "PubMed",
        "reference": "25378699",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination.",
        "volume": "111",
        "pages": "16586-91",
        "date": "2014-11-18",
        "first": "Luo HB",
        "last": "Wang JZ",
        "authors": [
          "Feng Y",
          "Jiang J",
          "Liu XH",
          "Liu ZC",
          "Luo HB",
          "Shu XJ",
          "Wang JZ",
          "Wang XC",
          "Xia YY",
          "Xiong YS",
          "Ye K",
          "Yin G",
          "Yu G",
          "Zeng K"
        ]
      },
      "source": 593,
      "target": 594,
      "key": "353f6339606ec8f998c04350b264c18175356f2025d7c39fa88df12b2fe45215b88172286617849babda6b67afa773c4df3088afdade5ef8066c897a38c191fb"
    },
    {
      "line": 3718,
      "relation": "positiveCorrelation",
      "evidence": "Both brain proteins were preferentially modified by SUMO1, as compared with SUMO2 or SUMO3. Tau contains two SUMO consensus sequences with Lys(340) as the major sumoylation site. Although both tau and alpha-synuclein are targets for proteasomal degradation, only tau sumoylation was affected by inhibitors of the proteasome pathway. Treatment with the phosphatase inhibitor, okadaic acid, or the microtubule depolymerizing drug, colchicine, up-regulated tau sumoylation.",
      "citation": {
        "type": "PubMed",
        "reference": "16464864",
        "name": "The Journal of biological chemistry",
        "title": "Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein.",
        "volume": "281",
        "pages": "9919-24",
        "date": "2006-04-14",
        "first": "Dorval V",
        "last": "Fraser PE",
        "authors": [
          "Dorval V",
          "Fraser PE"
        ]
      },
      "source": 593,
      "target": 544,
      "key": "4d352ba5efc18c1eb450a2b6ef80da33dd5705ef9f3ab56c7186cfa4f81fab3c0b14d64c24609d6b4127156a4f7a7d051e8c98c43b107364f4ab2f433f23ead8"
    },
    {
      "line": 3499,
      "relation": "directlyDecreases",
      "evidence": "Rolipram is a specific phosphodiesterase type 4 (PDE4) inhibitor that increases cAMP levels in multiple tissues in vivo. The chymotrypsin-like activity of the 26S proteasomes in crude extracts was elevated after administration of db-cAMP or rolipram but was blocked by epoxomicin",
      "citation": {
        "type": "PubMed",
        "reference": "26692334",
        "name": "Nature medicine",
        "title": "Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.",
        "volume": "22",
        "pages": "46-53",
        "date": "2016-01-01",
        "first": "Myeku N",
        "last": "Duff KE",
        "authors": [
          "Clelland CL",
          "Duff KE",
          "Emrani S",
          "Goldberg AL",
          "Kukushkin NV",
          "Myeku N",
          "Yu WH"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 70,
      "target": 296,
      "key": "392e73cac034c9893c5c256264ffe7db24743e9fba2d3b5b15fc08c317ab86bd0575f24f2c2125bfc18c470184264e6d346990324fca20974de913dc9ba91774"
    },
    {
      "line": 3500,
      "relation": "positiveCorrelation",
      "evidence": "Rolipram is a specific phosphodiesterase type 4 (PDE4) inhibitor that increases cAMP levels in multiple tissues in vivo. The chymotrypsin-like activity of the 26S proteasomes in crude extracts was elevated after administration of db-cAMP or rolipram but was blocked by epoxomicin",
      "citation": {
        "type": "PubMed",
        "reference": "26692334",
        "name": "Nature medicine",
        "title": "Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.",
        "volume": "22",
        "pages": "46-53",
        "date": "2016-01-01",
        "first": "Myeku N",
        "last": "Duff KE",
        "authors": [
          "Clelland CL",
          "Duff KE",
          "Emrani S",
          "Goldberg AL",
          "Kukushkin NV",
          "Myeku N",
          "Yu WH"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 70,
      "target": 299,
      "key": "235c8cedbb1eaf8b6bea31cbf73ff342f33c265f07615a887dc30dd802c1b2803ca909ee758141a1ec75d096f21a6cf9fcbbf48d8d088984cb1f9a624d3489c9"
    },
    {
      "line": 3501,
      "relation": "increases",
      "evidence": "Rolipram is a specific phosphodiesterase type 4 (PDE4) inhibitor that increases cAMP levels in multiple tissues in vivo. The chymotrypsin-like activity of the 26S proteasomes in crude extracts was elevated after administration of db-cAMP or rolipram but was blocked by epoxomicin",
      "citation": {
        "type": "PubMed",
        "reference": "26692334",
        "name": "Nature medicine",
        "title": "Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.",
        "volume": "22",
        "pages": "46-53",
        "date": "2016-01-01",
        "first": "Myeku N",
        "last": "Duff KE",
        "authors": [
          "Clelland CL",
          "Duff KE",
          "Emrani S",
          "Goldberg AL",
          "Kukushkin NV",
          "Myeku N",
          "Yu WH"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 70,
      "target": 213,
      "key": "0bbed4c6b46aee6bdd2be1653d48eebaabecc7f8536f12ff8543ae46ead3a13f9775d193f5c7b1e8d2c15edccb8de299615b270058fa2e4dcbe0e4e466ee0aef"
    },
    {
      "line": 3502,
      "relation": "decreases",
      "evidence": "Rolipram is a specific phosphodiesterase type 4 (PDE4) inhibitor that increases cAMP levels in multiple tissues in vivo. The chymotrypsin-like activity of the 26S proteasomes in crude extracts was elevated after administration of db-cAMP or rolipram but was blocked by epoxomicin",
      "citation": {
        "type": "PubMed",
        "reference": "26692334",
        "name": "Nature medicine",
        "title": "Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.",
        "volume": "22",
        "pages": "46-53",
        "date": "2016-01-01",
        "first": "Myeku N",
        "last": "Duff KE",
        "authors": [
          "Clelland CL",
          "Duff KE",
          "Emrani S",
          "Goldberg AL",
          "Kukushkin NV",
          "Myeku N",
          "Yu WH"
        ]
      },
      "source": 70,
      "target": 112,
      "key": "875043a63d3d09515c15027cd675d0cf0affbb22dc42311b9c97a5949e05a1d782695197b52b38b8578d0fd932b4b93f78422fd0545b6ff43e956920f1848bc5"
    },
    {
      "line": 3512,
      "relation": "increases",
      "evidence": "We show that axotrophin/MARCH7, a RING-variant domain containing protein with similarity to E3 ubiquitin ligases interacts with tau. We find here that tau becomes mono-ubiquitinated by recombinant tau-interacting RING-variant domain, which diminishes its microtubule-binding. Tau becomes mono-ubiquitinated by recombinant tau-interacting RING-variant domain reducing microtubule-binding.",
      "citation": {
        "type": "PubMed",
        "reference": "24905733",
        "name": "Biochimica et biophysica acta",
        "title": "Axotrophin/MARCH7 acts as an E3 ubiquitin ligase and ubiquitinates tau protein in vitro impairing microtubule binding.",
        "volume": "1842",
        "pages": "1527-38",
        "date": "2014-09-01",
        "first": "Flach K",
        "last": "Holzer M",
        "authors": [
          "Albrecht F",
          "Arendt T",
          "Arsalan-Werner A",
          "Flach K",
          "Goedert M",
          "Herrmann L",
          "Hilbrich I",
          "Holzer M",
          "Ramminger E"
        ]
      },
      "source": 632,
      "target": 594,
      "key": "a2f18073d1f52db51b4e28b2a3188ef221b32fc5abb5890a9a07e0f311cae6cd7400a2e370f7be9ffcee719542f2bc69a6b71a061e6aeb04f98e5a9bcf674fbc"
    },
    {
      "line": 3519,
      "relation": "positiveCorrelation",
      "evidence": "Ubiquitination occurs at lysines (K254, K257 K311) in repeat domain; participates in triage process",
      "citation": {
        "type": "PubMed",
        "reference": "8391280",
        "name": "Neuron",
        "title": "Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments.",
        "volume": "10",
        "pages": "1151-60",
        "date": "1993-06-01",
        "first": "Morishima-Kawashima M",
        "last": "Ihara Y",
        "authors": [
          "Hasegawa M",
          "Ihara Y",
          "Morishima-Kawashima M",
          "Suzuki M",
          "Takio K",
          "Titani K"
        ]
      },
      "source": 596,
      "target": 132,
      "key": "48a9644bfc39a55052abeaad289b7c5bd7c35cf7d4068ecc1accf43f90ded7a7a40046aa37f8068474bd9d6ebcd1841be78d156ccd0729a9a8db538f39f5d853"
    },
    {
      "line": 3520,
      "relation": "positiveCorrelation",
      "evidence": "Ubiquitination occurs at lysines (K254, K257 K311) in repeat domain; participates in triage process",
      "citation": {
        "type": "PubMed",
        "reference": "8391280",
        "name": "Neuron",
        "title": "Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments.",
        "volume": "10",
        "pages": "1151-60",
        "date": "1993-06-01",
        "first": "Morishima-Kawashima M",
        "last": "Ihara Y",
        "authors": [
          "Hasegawa M",
          "Ihara Y",
          "Morishima-Kawashima M",
          "Suzuki M",
          "Takio K",
          "Titani K"
        ]
      },
      "source": 597,
      "target": 132,
      "key": "6cad424ffecc5cb17fdb170aba4deff7785e96d138fea01abec5e848305697544284a1889539849737584ab951d83c8e7fff6eb5b6a5acf215a75ea54bb08a33"
    },
    {
      "line": 3534,
      "relation": "association",
      "evidence": "Previously, we have shown that TNT1 is a marker of PAD exposure and that this event occurs early in the progression of Alzheimer’s disease. Establishing whether this was true for all N-terminal antibodies was important for understanding more about PAD exposure in Alzheimer’s disease. We significantly extend these findings with TNT1 and show that TNT2 behaves similarly as a marker of PAD exposure. In contrast, other N-terminal antibodies, with slightly different epitopes, do not function as pathological, PAD exposure-specific markers and recognize all forms of tau similarly. Here, we found that TNT1 and TNT2 appear in Braak I–II stages and do not colocalize with ThR in the diffuse, granular pre-tangle pathology conclusively demonstrating that PAD exposure is an early event.",
      "citation": {
        "type": "PubMed",
        "reference": "27260838",
        "name": "Neurobiology of disease",
        "title": "Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodies.",
        "volume": "94",
        "pages": "18-31",
        "date": "2016-10-01",
        "first": "Combs B",
        "last": "Kanaan NM",
        "authors": [
          "Combs B",
          "Hamel C",
          "Kanaan NM"
        ]
      },
      "annotations": {
        "Braak_Stage": {
          "Stage I": true,
          "Stage II": true
        }
      },
      "source": 328,
      "target": 359,
      "key": "7df4203b715793960b6906f9b11c496f2ad30b0d92fc12d0046bd5e83e9dc10af76e613e7220171302cc2060d3e23e51cab637f86a722cdc8b66a07a8a928f69"
    },
    {
      "line": 3535,
      "relation": "association",
      "evidence": "Previously, we have shown that TNT1 is a marker of PAD exposure and that this event occurs early in the progression of Alzheimer’s disease. Establishing whether this was true for all N-terminal antibodies was important for understanding more about PAD exposure in Alzheimer’s disease. We significantly extend these findings with TNT1 and show that TNT2 behaves similarly as a marker of PAD exposure. In contrast, other N-terminal antibodies, with slightly different epitopes, do not function as pathological, PAD exposure-specific markers and recognize all forms of tau similarly. Here, we found that TNT1 and TNT2 appear in Braak I–II stages and do not colocalize with ThR in the diffuse, granular pre-tangle pathology conclusively demonstrating that PAD exposure is an early event.",
      "citation": {
        "type": "PubMed",
        "reference": "27260838",
        "name": "Neurobiology of disease",
        "title": "Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodies.",
        "volume": "94",
        "pages": "18-31",
        "date": "2016-10-01",
        "first": "Combs B",
        "last": "Kanaan NM",
        "authors": [
          "Combs B",
          "Hamel C",
          "Kanaan NM"
        ]
      },
      "annotations": {
        "Braak_Stage": {
          "Stage I": true,
          "Stage II": true
        }
      },
      "source": 329,
      "target": 359,
      "key": "cd9ae95b1bd9efb2fbc0e8a01b06fda298abce74cb0d1a2f5c985083ad92dd3d842a7a62f76a500739944ffcba892d1706ec1c5fbb80629094de53c4d11ade05"
    },
    {
      "line": 3539,
      "relation": "positiveCorrelation",
      "evidence": "Apparent ThR-positive ghost tangles (i.e., without nuclei (Braak et al., 1994)) are no longer labeled by TNT1 or TNT2, which confirms that PAD exposure is lost in the latest stages of NFT evolution.",
      "citation": {
        "type": "PubMed",
        "reference": "27260838",
        "name": "Neurobiology of disease",
        "title": "Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodies.",
        "volume": "94",
        "pages": "18-31",
        "date": "2016-10-01",
        "first": "Combs B",
        "last": "Kanaan NM",
        "authors": [
          "Combs B",
          "Hamel C",
          "Kanaan NM"
        ]
      },
      "source": 369,
      "target": 359,
      "key": "9f5ddccef81837ec6f7a03d459e37baf3dde50b2d98455d056ed66c570f9f207d4c39edd35635217ba5f01a65326e5db45da6c307048b3fb922cef83068ed28d"
    },
    {
      "line": 3556,
      "relation": "decreases",
      "evidence": "Tau contains cysteine residues in the microtubule binding region following alternative splicing of exon 10, and formation of intermolecular cysteine disulfide bonds accelerates tau aggregation. 8-Nitro-cGMP (novel second messenger of NO) exposure induced S-guanylation of tau both in vitro and in tau-overexpressed HEK293T cells. S-guanylated tau inhibited heparin-induced tau aggregation (thioflavin T). S-guanylated tau could not form tau granules and fibrils (AFM) inhibited at the step of tau oligomer formation. In P301L tau-expressing Neuro2A cells, 8-nitro-cGMP reduced the amount of sarcosyl-insoluble tau. NO-linked chemical modification on cysteine residues of tau could block tau aggregation",
      "citation": {
        "type": "PubMed",
        "reference": "27601475",
        "name": "The Journal of biological chemistry",
        "title": "Modification of Tau by 8-Nitroguanosine 3',5'-Cyclic Monophosphate (8-Nitro-cGMP): EFFECTS OF NITRIC OXIDE-LINKED CHEMICAL MODIFICATION ON TAU AGGREGATION.",
        "volume": "291",
        "pages": "22714-22720",
        "date": "2016-10-21",
        "first": "Yoshitake J",
        "last": "Takashima A",
        "authors": [
          "Akaike T",
          "Ida T",
          "Matsushita K",
          "Soeda Y",
          "Sumioka A",
          "Takashima A",
          "Yoshikawa M",
          "Yoshitake J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true,
          "HEK293T": true
        }
      },
      "source": 90,
      "target": 118,
      "key": "2d0ea4fb9cc8bbf461458872af0fd6c9b68c4ee37dcd14e256eac6d499013830e158c4ee1955e68e09c2c3057ccd2e2e42a093bd2bb9a4d790a8a120ef97ff19"
    },
    {
      "line": 3557,
      "relation": "positiveCorrelation",
      "evidence": "Tau contains cysteine residues in the microtubule binding region following alternative splicing of exon 10, and formation of intermolecular cysteine disulfide bonds accelerates tau aggregation. 8-Nitro-cGMP (novel second messenger of NO) exposure induced S-guanylation of tau both in vitro and in tau-overexpressed HEK293T cells. S-guanylated tau inhibited heparin-induced tau aggregation (thioflavin T). S-guanylated tau could not form tau granules and fibrils (AFM) inhibited at the step of tau oligomer formation. In P301L tau-expressing Neuro2A cells, 8-nitro-cGMP reduced the amount of sarcosyl-insoluble tau. NO-linked chemical modification on cysteine residues of tau could block tau aggregation",
      "citation": {
        "type": "PubMed",
        "reference": "27601475",
        "name": "The Journal of biological chemistry",
        "title": "Modification of Tau by 8-Nitroguanosine 3',5'-Cyclic Monophosphate (8-Nitro-cGMP): EFFECTS OF NITRIC OXIDE-LINKED CHEMICAL MODIFICATION ON TAU AGGREGATION.",
        "volume": "291",
        "pages": "22714-22720",
        "date": "2016-10-21",
        "first": "Yoshitake J",
        "last": "Takashima A",
        "authors": [
          "Akaike T",
          "Ida T",
          "Matsushita K",
          "Soeda Y",
          "Sumioka A",
          "Takashima A",
          "Yoshikawa M",
          "Yoshitake J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true,
          "HEK293T": true
        }
      },
      "source": 90,
      "target": 26,
      "key": "2bee6094cf3d318a9881d6bf20609842df478053b20d077458f8b9b4bdc7ea8c4364b6893d93ff8ccb6a2b88a905833c6ae42bc762d48a67b2a81afac29232c2"
    },
    {
      "line": 3558,
      "relation": "directlyIncreases",
      "evidence": "Tau contains cysteine residues in the microtubule binding region following alternative splicing of exon 10, and formation of intermolecular cysteine disulfide bonds accelerates tau aggregation. 8-Nitro-cGMP (novel second messenger of NO) exposure induced S-guanylation of tau both in vitro and in tau-overexpressed HEK293T cells. S-guanylated tau inhibited heparin-induced tau aggregation (thioflavin T). S-guanylated tau could not form tau granules and fibrils (AFM) inhibited at the step of tau oligomer formation. In P301L tau-expressing Neuro2A cells, 8-nitro-cGMP reduced the amount of sarcosyl-insoluble tau. NO-linked chemical modification on cysteine residues of tau could block tau aggregation",
      "citation": {
        "type": "PubMed",
        "reference": "27601475",
        "name": "The Journal of biological chemistry",
        "title": "Modification of Tau by 8-Nitroguanosine 3',5'-Cyclic Monophosphate (8-Nitro-cGMP): EFFECTS OF NITRIC OXIDE-LINKED CHEMICAL MODIFICATION ON TAU AGGREGATION.",
        "volume": "291",
        "pages": "22714-22720",
        "date": "2016-10-21",
        "first": "Yoshitake J",
        "last": "Takashima A",
        "authors": [
          "Akaike T",
          "Ida T",
          "Matsushita K",
          "Soeda Y",
          "Sumioka A",
          "Takashima A",
          "Yoshikawa M",
          "Yoshitake J"
        ]
      },
      "annotations": {
        "Cell_Line": {
          "N2a": true,
          "HEK293T": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 265,
      "target": 26,
      "key": "59d31f890ead606fdeaa6e3393b2daa268cc46d7ee4d1a5a0464cca870b93fee809a0f0fc44c7bf5852f99287b006d934f463494df5a659e8948beb9d491f9e6"
    },
    {
      "line": 3568,
      "relation": "positiveCorrelation",
      "evidence": "Highlighting the relevance of these findings to human disease, pS422 tau was found to colocalize with tau oligomers and with a fraction of tau showing increased PAD exposure in the human AD brain. This study identifies novel effects of pS422 on tau biochemical properties, including prolonged nucleation and enhanced dimer formation, which correlate with a distinct inhibitory effect on FAT.",
      "citation": {
        "type": "PubMed",
        "reference": "27373205",
        "name": "Experimental neurology",
        "title": "Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport.",
        "volume": "283",
        "pages": "318-29",
        "date": "2016-09-01",
        "first": "Tiernan CT",
        "last": "Kanaan NM",
        "authors": [
          "Brady ST",
          "Combs B",
          "Counts SE",
          "Cox K",
          "Kanaan NM",
          "Morfini G",
          "Tiernan CT"
        ]
      },
      "source": 331,
      "target": 569,
      "key": "6eea12dea54e5271d8900b88e645db9aa4afde646001c69aac9a46138abb4ffa5efc78a6b604ae3edb81e357b808de5c39910a62cfa12150cf542346751250d8"
    },
    {
      "line": 3576,
      "relation": "equivalentTo",
      "evidence": "We also show that two of the tau mutations found in hereditary frontotemporal dementias, DeltaK280 and P301L, have a much stronger tendency for PHF aggregation which correlates with their high propensity for beta-structure around the hexapeptide motifs.",
      "citation": {
        "type": "PubMed",
        "reference": "11606569",
        "name": "The Journal of biological chemistry",
        "title": "Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure.",
        "volume": "276",
        "pages": "48165-74",
        "date": "2001-12-21",
        "first": "von Bergen M",
        "last": "Mandelkow E",
        "authors": [
          "Barghorn S",
          "Biernat J",
          "Li L",
          "Mandelkow E",
          "Mandelkow EM",
          "Marx A",
          "von Bergen M"
        ]
      },
      "source": 618,
      "target": 252,
      "key": "2a2f09f28edd4eb18a6441989250b774ba23719ead446c1fdcba0d8148730ee02e12d253397e814e21cd4d4de584e9ab6245162f6789c8302d4efc52374b3eaa"
    },
    {
      "line": 3577,
      "relation": "positiveCorrelation",
      "evidence": "We also show that two of the tau mutations found in hereditary frontotemporal dementias, DeltaK280 and P301L, have a much stronger tendency for PHF aggregation which correlates with their high propensity for beta-structure around the hexapeptide motifs.",
      "citation": {
        "type": "PubMed",
        "reference": "11606569",
        "name": "The Journal of biological chemistry",
        "title": "Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure.",
        "volume": "276",
        "pages": "48165-74",
        "date": "2001-12-21",
        "first": "von Bergen M",
        "last": "Mandelkow E",
        "authors": [
          "Barghorn S",
          "Biernat J",
          "Li L",
          "Mandelkow E",
          "Mandelkow EM",
          "Marx A",
          "von Bergen M"
        ]
      },
      "source": 618,
      "target": 355,
      "key": "ae7185ea61e142fadd4ff30aef6636e9fe6142bd999c0a41009a7c4ba0f73e319182b5b8eb24094c8597ff996ab426e67336bfb97eecada67d5ab632b24a09f1"
    },
    {
      "line": 3578,
      "relation": "positiveCorrelation",
      "evidence": "We also show that two of the tau mutations found in hereditary frontotemporal dementias, DeltaK280 and P301L, have a much stronger tendency for PHF aggregation which correlates with their high propensity for beta-structure around the hexapeptide motifs.",
      "citation": {
        "type": "PubMed",
        "reference": "11606569",
        "name": "The Journal of biological chemistry",
        "title": "Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure.",
        "volume": "276",
        "pages": "48165-74",
        "date": "2001-12-21",
        "first": "von Bergen M",
        "last": "Mandelkow E",
        "authors": [
          "Barghorn S",
          "Biernat J",
          "Li L",
          "Mandelkow E",
          "Mandelkow EM",
          "Marx A",
          "von Bergen M"
        ]
      },
      "source": 618,
      "target": 356,
      "key": "1f1bba478f370bdec7bba5d8010771fe2f5a8814f6693706c43b2dfd6fb27cf78d6e0a2e8dee315d07add31ce1d3009ed8cfef91db9be75bfb0d5f434675f167"
    },
    {
      "line": 3576,
      "relation": "equivalentTo",
      "evidence": "We also show that two of the tau mutations found in hereditary frontotemporal dementias, DeltaK280 and P301L, have a much stronger tendency for PHF aggregation which correlates with their high propensity for beta-structure around the hexapeptide motifs.",
      "citation": {
        "type": "PubMed",
        "reference": "11606569",
        "name": "The Journal of biological chemistry",
        "title": "Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure.",
        "volume": "276",
        "pages": "48165-74",
        "date": "2001-12-21",
        "first": "von Bergen M",
        "last": "Mandelkow E",
        "authors": [
          "Barghorn S",
          "Biernat J",
          "Li L",
          "Mandelkow E",
          "Mandelkow EM",
          "Marx A",
          "von Bergen M"
        ]
      },
      "source": 252,
      "target": 618,
      "key": "c00a75a34cd809b6f5e9954636118244e4f9d87e419fe9e8aa5297a848c5caac11b904570ea455b56ae47d782e09121c275c9d54f3822c5a6daabcf243a96610"
    },
    {
      "line": 3600,
      "relation": "positiveCorrelation",
      "evidence": "The tauopathy mice that we used contained the P301L mutation, which is implicated in some genetic tauopathies. In addition, this mutation, along with the related P301S mutation, has been associated with increased inflammation in the brain as well as retinal deficits",
      "citation": {
        "type": "PubMed",
        "reference": "27716675",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases.",
        "volume": "55",
        "pages": "1083-1099",
        "date": "2017-01-01",
        "first": "Nilson AN",
        "last": "Kayed R",
        "authors": [
          "Barton Whittle T",
          "Castillo-Carranza DL",
          "English KC",
          "Gerson JE",
          "Gupta P",
          "Kayed R",
          "Nicolas Crain C",
          "Nilson AN",
          "Sengupta U",
          "Xue J",
          "Zhang W"
        ]
      },
      "source": 154,
      "target": 625,
      "key": "a2eb9f8b1391c958c383165dfb119abc58adc467854f657c37aa23c0551666054c81caf4feb305bfabf6c37b9bda0f3fdc1956c7f2a9ba2fa432a5e3f3632af0"
    },
    {
      "line": 3601,
      "relation": "positiveCorrelation",
      "evidence": "The tauopathy mice that we used contained the P301L mutation, which is implicated in some genetic tauopathies. In addition, this mutation, along with the related P301S mutation, has been associated with increased inflammation in the brain as well as retinal deficits",
      "citation": {
        "type": "PubMed",
        "reference": "27716675",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases.",
        "volume": "55",
        "pages": "1083-1099",
        "date": "2017-01-01",
        "first": "Nilson AN",
        "last": "Kayed R",
        "authors": [
          "Barton Whittle T",
          "Castillo-Carranza DL",
          "English KC",
          "Gerson JE",
          "Gupta P",
          "Kayed R",
          "Nicolas Crain C",
          "Nilson AN",
          "Sengupta U",
          "Xue J",
          "Zhang W"
        ]
      },
      "source": 154,
      "target": 253,
      "key": "fa09230583074ce3d96b3fe747ab7c6154ab008cd1ea8f9285b850c3e29a141186ed78c7dc6d1f8dc20f8ae9fa17842c83152951e2e585e7492d1370683b6d10"
    },
    {
      "line": 3604,
      "relation": "positiveCorrelation",
      "evidence": "Tau Oligomers co-localize with astrocytes, microglia, and HMGB1, a pro-inflammatory cytokine, are present in the retina and are associated with inflammatory cells.",
      "citation": {
        "type": "PubMed",
        "reference": "27716675",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases.",
        "volume": "55",
        "pages": "1083-1099",
        "date": "2017-01-01",
        "first": "Nilson AN",
        "last": "Kayed R",
        "authors": [
          "Barton Whittle T",
          "Castillo-Carranza DL",
          "English KC",
          "Gerson JE",
          "Gupta P",
          "Kayed R",
          "Nicolas Crain C",
          "Nilson AN",
          "Sengupta U",
          "Xue J",
          "Zhang W"
        ]
      },
      "source": 154,
      "target": 118,
      "key": "884b15dfa2303b3420727eb2e942cbf89b0dd08a73083996afd38b9bb9f7d69b359ab9c0f990217684bbb7b8be826eb7356edbaaf331b404a3c37b0b88729549"
    },
    {
      "line": 3601,
      "relation": "positiveCorrelation",
      "evidence": "The tauopathy mice that we used contained the P301L mutation, which is implicated in some genetic tauopathies. In addition, this mutation, along with the related P301S mutation, has been associated with increased inflammation in the brain as well as retinal deficits",
      "citation": {
        "type": "PubMed",
        "reference": "27716675",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases.",
        "volume": "55",
        "pages": "1083-1099",
        "date": "2017-01-01",
        "first": "Nilson AN",
        "last": "Kayed R",
        "authors": [
          "Barton Whittle T",
          "Castillo-Carranza DL",
          "English KC",
          "Gerson JE",
          "Gupta P",
          "Kayed R",
          "Nicolas Crain C",
          "Nilson AN",
          "Sengupta U",
          "Xue J",
          "Zhang W"
        ]
      },
      "source": 253,
      "target": 154,
      "key": "aafe05464ac9593c18f247ec534427a76129f62c3e91045053504a45d02e18f9f8f63eb24b6ba7035ea007f72979a232d528c3f951b5f2f38d7df9b9ed631ffe"
    },
    {
      "line": 3621,
      "relation": "positiveCorrelation",
      "evidence": "The plasma level of SUMO1 was significantly increased in dementia patients, as compared to control groups. The levels of SUMO1 correlated to decreased Mini-Mental State Examination (r =-0.123, p = 0.029). These results suggest that elevated plasma SUMO1 levels may be associated with AD.",
      "citation": {
        "type": "PubMed",
        "reference": "27716675",
        "name": "Journal of Alzheimer's disease : JAD",
        "title": "Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases.",
        "volume": "55",
        "pages": "1083-1099",
        "date": "2017-01-01",
        "first": "Nilson AN",
        "last": "Kayed R",
        "authors": [
          "Barton Whittle T",
          "Castillo-Carranza DL",
          "English KC",
          "Gerson JE",
          "Gupta P",
          "Kayed R",
          "Nicolas Crain C",
          "Nilson AN",
          "Sengupta U",
          "Xue J",
          "Zhang W"
        ]
      },
      "source": 692,
      "target": 908,
      "key": "2856847600ec976b52a75f80552c089978c72534cb4ff509f9c64a3b5482096d908c5faf19a5c7c5835509bcc4df1ff8d31304a7ce051a2f5eb3606f2c344d99"
    },
    {
      "line": 3641,
      "relation": "partOf",
      "evidence": "That SUMO-1 co-localizes with a subset of lysosomes in neurodegenerative diseases with glial protein aggregates and in glial cell culture models of protein aggregation suggests a role for SUMO-1 in lysosome function.",
      "citation": {
        "type": "PubMed",
        "reference": "23229893",
        "name": "Neurotoxicity research",
        "title": "SUMO-1 is associated with a subset of lysosomes in glial protein aggregate diseases.",
        "volume": "23",
        "pages": "1-21",
        "date": "2013-01-01",
        "first": "Wong MB",
        "last": "Pountney DL",
        "authors": [
          "Gai WP",
          "Goodwin J",
          "Meedeniya AC",
          "Norazit A",
          "Pountney DL",
          "Richter-Landsberg C",
          "Wong MB"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Supranuclear Palsy, Progressive": true,
          "Multiple System Atrophy": true
        }
      },
      "source": 692,
      "target": 86,
      "key": "aa1d113fb2d8b1729605c14dbf4f2bbd8bc86351926b9266bbe7ce8669c357acf5dfc20f41709d75a5f24551d38ff068fc5171a34d85ae64c30bc8186d2555be"
    },
    {
      "line": 3678,
      "relation": "partOf",
      "evidence": "Noradrenaline (NA) attenuated the LPS-induced reductions and increased SUMO-1 above basal levels. Over-expression of SUMO-1, Ubc9, or SENP1 reduced the activation of a NOS2 promoter, whereas activation of a 4 x NFkappaB binding-element reporter was only reduced by SUMO-1. ChIP studies revealed interactions of SUMO-1 and C/EBPbeta with C/EBP binding sites on the NOS2 promoter that were modulated by LPS and NA. SUMO-1 co-precipitated with C/EBPbeta confirmed by FRET analysis",
      "citation": {
        "type": "PubMed",
        "reference": "19323834",
        "name": "Journal of neuroinflammation",
        "title": "Modulation of inducible nitric oxide synthase expression by sumoylation.",
        "volume": "6",
        "pages": "12",
        "date": "2009-03-26",
        "first": "Akar CA",
        "last": "Feinstein DL",
        "authors": [
          "Akar CA",
          "Feinstein DL"
        ]
      },
      "annotations": {
        "Method": {
          "Fluorescence Resonance Energy Transfer": true,
          "Chromatin Immunoprecipitation": true
        }
      },
      "source": 692,
      "target": 224,
      "key": "f270a92b60a674a2f7895d31d480a3992aaf2eb09440e8a8647ef1c9b562e092ddc51f6ea5ddefe95460e890a3dc5d1b21e774ccb2a044abedfdb777892f49de"
    },
    {
      "line": 3690,
      "relation": "increases",
      "evidence": "Lysines 587 and 595 of APP, immediately adjacent to the site of beta-secretase cleavage, are covalently modified by SUMO proteins in vivo. Sumoylation of these lysine residues is associated with decreased levels of Abeta aggregates. The results demonstrate that the SUMO E2 enzyme (ubc9) is present within the endoplasmic reticulum, indicating how APP, and perhaps other proteins that enter this compartment, can be sumoylated.",
      "citation": {
        "type": "PubMed",
        "reference": "18675254",
        "name": "Biochemical and biophysical research communications",
        "title": "Sumoylation of amyloid precursor protein negatively regulates Abeta aggregate levels.",
        "volume": "374",
        "pages": "673-8",
        "date": "2008-10-03",
        "first": "Zhang YQ",
        "last": "Sarge KD",
        "authors": [
          "Sarge KD",
          "Zhang YQ"
        ]
      },
      "source": 692,
      "target": 380,
      "key": "6e7d1a7a4f0581027b313b48f5668a30273d1409354abcea96ed8083654c381608bde540b0dea0f6cfac8fbcb53cd7ae14acb89d031796b0aed9af3f040b87ad"
    },
    {
      "line": 3691,
      "relation": "increases",
      "evidence": "Lysines 587 and 595 of APP, immediately adjacent to the site of beta-secretase cleavage, are covalently modified by SUMO proteins in vivo. Sumoylation of these lysine residues is associated with decreased levels of Abeta aggregates. The results demonstrate that the SUMO E2 enzyme (ubc9) is present within the endoplasmic reticulum, indicating how APP, and perhaps other proteins that enter this compartment, can be sumoylated.",
      "citation": {
        "type": "PubMed",
        "reference": "18675254",
        "name": "Biochemical and biophysical research communications",
        "title": "Sumoylation of amyloid precursor protein negatively regulates Abeta aggregate levels.",
        "volume": "374",
        "pages": "673-8",
        "date": "2008-10-03",
        "first": "Zhang YQ",
        "last": "Sarge KD",
        "authors": [
          "Sarge KD",
          "Zhang YQ"
        ]
      },
      "source": 692,
      "target": 381,
      "key": "52c4b62d0824c41bba9b9725f39c128f7d32c2b6a60e67cc10ddc3395f9bee7af13769c0b7fae8756ba3c10dcdde456d4a5d92c3f777628cf6c6761a46118f09"
    },
    {
      "line": 3713,
      "relation": "increases",
      "evidence": "Both brain proteins were preferentially modified by SUMO1, as compared with SUMO2 or SUMO3. Tau contains two SUMO consensus sequences with Lys(340) as the major sumoylation site. Although both tau and alpha-synuclein are targets for proteasomal degradation, only tau sumoylation was affected by inhibitors of the proteasome pathway. Treatment with the phosphatase inhibitor, okadaic acid, or the microtubule depolymerizing drug, colchicine, up-regulated tau sumoylation.",
      "citation": {
        "type": "PubMed",
        "reference": "16464864",
        "name": "The Journal of biological chemistry",
        "title": "Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein.",
        "volume": "281",
        "pages": "9919-24",
        "date": "2006-04-14",
        "first": "Dorval V",
        "last": "Fraser PE",
        "authors": [
          "Dorval V",
          "Fraser PE"
        ]
      },
      "source": 692,
      "target": 593,
      "key": "9c9b2e1c2885110f43fad8aea98d3e0df99c3fd43683ff4c12a41e54fbefd6b24ddc59d153f4160d70c0960acea8dff71bc4fbbe44908b0044059aced0626559"
    },
    {
      "line": 3714,
      "relation": "increases",
      "evidence": "Both brain proteins were preferentially modified by SUMO1, as compared with SUMO2 or SUMO3. Tau contains two SUMO consensus sequences with Lys(340) as the major sumoylation site. Although both tau and alpha-synuclein are targets for proteasomal degradation, only tau sumoylation was affected by inhibitors of the proteasome pathway. Treatment with the phosphatase inhibitor, okadaic acid, or the microtubule depolymerizing drug, colchicine, up-regulated tau sumoylation.",
      "citation": {
        "type": "PubMed",
        "reference": "16464864",
        "name": "The Journal of biological chemistry",
        "title": "Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein.",
        "volume": "281",
        "pages": "9919-24",
        "date": "2006-04-14",
        "first": "Dorval V",
        "last": "Fraser PE",
        "authors": [
          "Dorval V",
          "Fraser PE"
        ]
      },
      "source": 692,
      "target": 687,
      "key": "78e63e927b2b1144ce0d53dab8e013e078bbb3cdfc16ff80a5a649ec1fcf6970833ae29b37746d749f751dbe2fd97e7cc80698ab4d13b6ca8c6e3eccf99c5f79"
    },
    {
      "line": 3630,
      "relation": "positiveCorrelation",
      "evidence": "The genotype distribution of a polymorphism in intron 7 (rs761059) differed between AD cases and controls, with an adjusted odds ratio (OR) of 1.45 (p=0.046, 95% CI: 1.01-2.08). One haplotype (ht2 CAGAG) was found in 14.0% of the AD patients and in 11.1% of the controls (p=0.04, OR=1.43. 95% CI; 1.01-2.01). Stratification by the ApoE gave no significant difference between the groups but when stratified by gender, two SNPs (rs8052688, rs8063) were significantly associated with the risk of MCI among women.",
      "citation": {
        "type": "PubMed",
        "reference": "19765634",
        "name": "Neuroscience letters",
        "title": "Ubc9 gene polymorphisms and late-onset Alzheimer's disease in the Korean population: a genetic association study.",
        "volume": "465",
        "pages": "272-5",
        "date": "2009-11-20",
        "first": "Ahn K",
        "last": "Koh YH",
        "authors": [
          "Ahn K",
          "Jo SA",
          "Kim DK",
          "Koh YH",
          "Park MH",
          "Song JH"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Korean population": true
        }
      },
      "source": 254,
      "target": 908,
      "key": "3bc07e2afe1e34445272c42dc3dc3274af508ddedcc271d276f6a3b42de97a2a8df387e7345fe2cad94215a3888c195d4c778c90ca62c0603809fa5887ad23a4"
    },
    {
      "line": 3632,
      "relation": "positiveCorrelation",
      "evidence": "The genotype distribution of a polymorphism in intron 7 (rs761059) differed between AD cases and controls, with an adjusted odds ratio (OR) of 1.45 (p=0.046, 95% CI: 1.01-2.08). One haplotype (ht2 CAGAG) was found in 14.0% of the AD patients and in 11.1% of the controls (p=0.04, OR=1.43. 95% CI; 1.01-2.01). Stratification by the ApoE gave no significant difference between the groups but when stratified by gender, two SNPs (rs8052688, rs8063) were significantly associated with the risk of MCI among women.",
      "citation": {
        "type": "PubMed",
        "reference": "19765634",
        "name": "Neuroscience letters",
        "title": "Ubc9 gene polymorphisms and late-onset Alzheimer's disease in the Korean population: a genetic association study.",
        "volume": "465",
        "pages": "272-5",
        "date": "2009-11-20",
        "first": "Ahn K",
        "last": "Koh YH",
        "authors": [
          "Ahn K",
          "Jo SA",
          "Kim DK",
          "Koh YH",
          "Park MH",
          "Song JH"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Korean population": true
        },
        "Gender": {
          "Female": true
        }
      },
      "source": 256,
      "target": 911,
      "key": "80a380f1edc24f5dc8e5788a4f58428d1ccddec001a54f560c5606a03f5a90f32ad3c79091cb4208e4512031f3dc171da6e74fd041575377008e69263e84155d"
    },
    {
      "line": 3633,
      "relation": "positiveCorrelation",
      "evidence": "The genotype distribution of a polymorphism in intron 7 (rs761059) differed between AD cases and controls, with an adjusted odds ratio (OR) of 1.45 (p=0.046, 95% CI: 1.01-2.08). One haplotype (ht2 CAGAG) was found in 14.0% of the AD patients and in 11.1% of the controls (p=0.04, OR=1.43. 95% CI; 1.01-2.01). Stratification by the ApoE gave no significant difference between the groups but when stratified by gender, two SNPs (rs8052688, rs8063) were significantly associated with the risk of MCI among women.",
      "citation": {
        "type": "PubMed",
        "reference": "19765634",
        "name": "Neuroscience letters",
        "title": "Ubc9 gene polymorphisms and late-onset Alzheimer's disease in the Korean population: a genetic association study.",
        "volume": "465",
        "pages": "272-5",
        "date": "2009-11-20",
        "first": "Ahn K",
        "last": "Koh YH",
        "authors": [
          "Ahn K",
          "Jo SA",
          "Kim DK",
          "Koh YH",
          "Park MH",
          "Song JH"
        ]
      },
      "annotations": {
        "Study_Group": {
          "Korean population": true
        },
        "Gender": {
          "Female": true
        }
      },
      "source": 257,
      "target": 911,
      "key": "5a5fc46b5594377c3e93f1988ac7920996e2bcd5db8ab459d9842e0f7a5cb6b2609dabceae47a5a7162b7d3e817e560c7a23a22694647dcdb22107fd4763ad18"
    },
    {
      "line": 3649,
      "relation": "negativeCorrelation",
      "evidence": "In 25-month-old mice, the number of errors and the latency in the learning phase negatively correlated with the Sumo3 level in the dorsal hippocampus.",
      "citation": {
        "type": "PubMed",
        "reference": "21843595",
        "name": "Neuroscience letters",
        "title": "Profiles of SUMO and ubiquitin conjugation in an Alzheimer's disease model.",
        "volume": "502",
        "pages": "201-8",
        "date": "2011-09-20",
        "first": "McMillan LE",
        "last": "Cimarosti H",
        "authors": [
          "Brown JT",
          "Cimarosti H",
          "Henley JM",
          "McMillan LE"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 850,
      "target": 197,
      "key": "0a81e41e6c66ab9316c8986c68c0ca5424fddc2af5afef7a8a5f43ec6514c122c074c45e7ebbab075a4e2b9bf45b1845b151fd66b5a9f9753dc33cdf79ef2c4d"
    },
    {
      "line": 3650,
      "relation": "negativeCorrelation",
      "evidence": "In 25-month-old mice, the number of errors and the latency in the learning phase negatively correlated with the Sumo3 level in the dorsal hippocampus.",
      "citation": {
        "type": "PubMed",
        "reference": "21843595",
        "name": "Neuroscience letters",
        "title": "Profiles of SUMO and ubiquitin conjugation in an Alzheimer's disease model.",
        "volume": "502",
        "pages": "201-8",
        "date": "2011-09-20",
        "first": "McMillan LE",
        "last": "Cimarosti H",
        "authors": [
          "Brown JT",
          "Cimarosti H",
          "Henley JM",
          "McMillan LE"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Anatomy": {
          "hippocampal formation": true
        }
      },
      "source": 850,
      "target": 200,
      "key": "9a7ed6909d12911f8b47785bd649f6f9985ef8ac45e19f26ff10cc73c26e93f5a277f5d73695850b2c71a33e6caccdab3d022c4490eb9a5323672ddb60935142"
    },
    {
      "line": 3660,
      "relation": "increases",
      "evidence": "LXR ligands inhibit neither STAT1 phosphorylation nor STAT1 translocation to the nucleus but, rather, inhibit STAT1 binding to promoters and the expression of IRF1, TNFalpha, and IL-6, downstream effectors of STAT1 action. LXRbeta forms a trimer with PIAS1-pSTAT1, whereas LXRalpha formed a trimer with HDAC4-pSTAT1, mediated by direct ligand binding to the LXR proteins. Both PIAS1 and HDAC4 belong to the SUMO E3 ligase family and LXRbeta and LXRalpha were SUMO-conjugated by PIAS1 or HDAC4, respectively, and SUMOylation was blocked by transient transfection of appropriate individual siRNAs, reversing LXR-induced suppression of IRF1 and TNFalpha expression.",
      "citation": {
        "type": "PubMed",
        "reference": "19782030",
        "name": "Molecular cell",
        "title": "Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes.",
        "volume": "35",
        "pages": "806-17",
        "date": "2009-09-24",
        "first": "Lee JH",
        "last": "Jou I",
        "authors": [
          "Joe EH",
          "Jou I",
          "Kim OS",
          "Lee CS",
          "Lee JH",
          "Park SJ",
          "Park SM",
          "Woo JH"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Cell": {
          "astrocyte": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 900,
      "target": 946,
      "key": "29df4a46f46a024544032af6d488db2367a5329aadbb7ef7f48564d26dca4cbe78f2c90094e956bf36d910cd676fafdd7e0c5e5efb4f5cfb5f6a2d717e7665c0"
    },
    {
      "line": 3661,
      "relation": "increases",
      "evidence": "LXR ligands inhibit neither STAT1 phosphorylation nor STAT1 translocation to the nucleus but, rather, inhibit STAT1 binding to promoters and the expression of IRF1, TNFalpha, and IL-6, downstream effectors of STAT1 action. LXRbeta forms a trimer with PIAS1-pSTAT1, whereas LXRalpha formed a trimer with HDAC4-pSTAT1, mediated by direct ligand binding to the LXR proteins. Both PIAS1 and HDAC4 belong to the SUMO E3 ligase family and LXRbeta and LXRalpha were SUMO-conjugated by PIAS1 or HDAC4, respectively, and SUMOylation was blocked by transient transfection of appropriate individual siRNAs, reversing LXR-induced suppression of IRF1 and TNFalpha expression.",
      "citation": {
        "type": "PubMed",
        "reference": "19782030",
        "name": "Molecular cell",
        "title": "Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes.",
        "volume": "35",
        "pages": "806-17",
        "date": "2009-09-24",
        "first": "Lee JH",
        "last": "Jou I",
        "authors": [
          "Joe EH",
          "Jou I",
          "Kim OS",
          "Lee CS",
          "Lee JH",
          "Park SJ",
          "Park SM",
          "Woo JH"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Cell": {
          "astrocyte": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 900,
      "target": 947,
      "key": "45febf73f46516378615f3ba567038ca8c19e221eb7fa8a686f49143db26ce502aa40e6d92765b33aa76c0b6d58504e29080153ead60b107f72f26a11a5389fb"
    },
    {
      "line": 3662,
      "relation": "increases",
      "evidence": "LXR ligands inhibit neither STAT1 phosphorylation nor STAT1 translocation to the nucleus but, rather, inhibit STAT1 binding to promoters and the expression of IRF1, TNFalpha, and IL-6, downstream effectors of STAT1 action. LXRbeta forms a trimer with PIAS1-pSTAT1, whereas LXRalpha formed a trimer with HDAC4-pSTAT1, mediated by direct ligand binding to the LXR proteins. Both PIAS1 and HDAC4 belong to the SUMO E3 ligase family and LXRbeta and LXRalpha were SUMO-conjugated by PIAS1 or HDAC4, respectively, and SUMOylation was blocked by transient transfection of appropriate individual siRNAs, reversing LXR-induced suppression of IRF1 and TNFalpha expression.",
      "citation": {
        "type": "PubMed",
        "reference": "19782030",
        "name": "Molecular cell",
        "title": "Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes.",
        "volume": "35",
        "pages": "806-17",
        "date": "2009-09-24",
        "first": "Lee JH",
        "last": "Jou I",
        "authors": [
          "Joe EH",
          "Jou I",
          "Kim OS",
          "Lee CS",
          "Lee JH",
          "Park SJ",
          "Park SM",
          "Woo JH"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Cell": {
          "astrocyte": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 900,
      "target": 945,
      "key": "515e5eaed6a3568b75e9c02fe89ef582a26b7383a6c5c8403e073eb82a7ae06bc8ed564a7711b07fadabbea2ae08ce4647ed522c5fdcfeeb000c1fd40f763348"
    },
    {
      "line": 3663,
      "relation": "increases",
      "evidence": "LXR ligands inhibit neither STAT1 phosphorylation nor STAT1 translocation to the nucleus but, rather, inhibit STAT1 binding to promoters and the expression of IRF1, TNFalpha, and IL-6, downstream effectors of STAT1 action. LXRbeta forms a trimer with PIAS1-pSTAT1, whereas LXRalpha formed a trimer with HDAC4-pSTAT1, mediated by direct ligand binding to the LXR proteins. Both PIAS1 and HDAC4 belong to the SUMO E3 ligase family and LXRbeta and LXRalpha were SUMO-conjugated by PIAS1 or HDAC4, respectively, and SUMOylation was blocked by transient transfection of appropriate individual siRNAs, reversing LXR-induced suppression of IRF1 and TNFalpha expression.",
      "citation": {
        "type": "PubMed",
        "reference": "19782030",
        "name": "Molecular cell",
        "title": "Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes.",
        "volume": "35",
        "pages": "806-17",
        "date": "2009-09-24",
        "first": "Lee JH",
        "last": "Jou I",
        "authors": [
          "Joe EH",
          "Jou I",
          "Kim OS",
          "Lee CS",
          "Lee JH",
          "Park SJ",
          "Park SM",
          "Woo JH"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Cell": {
          "astrocyte": true
        }
      },
      "source": 895,
      "target": 890,
      "key": "5392320182594f1116604160668613c521cd78940ce8affead45a95ebbe7bec27e211d00b1eff76ad6c4b0006c758f27a05c9a2443978c5105ce194efdb1b18f"
    },
    {
      "line": 3665,
      "relation": "increases",
      "evidence": "LXR ligands inhibit neither STAT1 phosphorylation nor STAT1 translocation to the nucleus but, rather, inhibit STAT1 binding to promoters and the expression of IRF1, TNFalpha, and IL-6, downstream effectors of STAT1 action. LXRbeta forms a trimer with PIAS1-pSTAT1, whereas LXRalpha formed a trimer with HDAC4-pSTAT1, mediated by direct ligand binding to the LXR proteins. Both PIAS1 and HDAC4 belong to the SUMO E3 ligase family and LXRbeta and LXRalpha were SUMO-conjugated by PIAS1 or HDAC4, respectively, and SUMOylation was blocked by transient transfection of appropriate individual siRNAs, reversing LXR-induced suppression of IRF1 and TNFalpha expression.",
      "citation": {
        "type": "PubMed",
        "reference": "19782030",
        "name": "Molecular cell",
        "title": "Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes.",
        "volume": "35",
        "pages": "806-17",
        "date": "2009-09-24",
        "first": "Lee JH",
        "last": "Jou I",
        "authors": [
          "Joe EH",
          "Jou I",
          "Kim OS",
          "Lee CS",
          "Lee JH",
          "Park SJ",
          "Park SM",
          "Woo JH"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Cell": {
          "astrocyte": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 890,
      "target": 900,
      "key": "e4f09af4d9e8c86cd9c211feaeeb14547a3ae292cd1a273a777d623d69a9fd716986f1dcde0d17741fdcdf775a1127577c8c764eb7ab313ff27b7bdcf54e2f22"
    },
    {
      "relation": "hasVariant",
      "source": 889,
      "target": 890,
      "key": "e00decaeaaa5730a62b4d67d0e0ce8c343d273ae4e3b0dd47a7706712d274c69c3d91396e9e9083a8adc0391409b3145e8dbfaf3ab13f84100b08b1785e0e97c"
    },
    {
      "line": 3664,
      "relation": "increases",
      "evidence": "LXR ligands inhibit neither STAT1 phosphorylation nor STAT1 translocation to the nucleus but, rather, inhibit STAT1 binding to promoters and the expression of IRF1, TNFalpha, and IL-6, downstream effectors of STAT1 action. LXRbeta forms a trimer with PIAS1-pSTAT1, whereas LXRalpha formed a trimer with HDAC4-pSTAT1, mediated by direct ligand binding to the LXR proteins. Both PIAS1 and HDAC4 belong to the SUMO E3 ligase family and LXRbeta and LXRalpha were SUMO-conjugated by PIAS1 or HDAC4, respectively, and SUMOylation was blocked by transient transfection of appropriate individual siRNAs, reversing LXR-induced suppression of IRF1 and TNFalpha expression.",
      "citation": {
        "type": "PubMed",
        "reference": "19782030",
        "name": "Molecular cell",
        "title": "Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes.",
        "volume": "35",
        "pages": "806-17",
        "date": "2009-09-24",
        "first": "Lee JH",
        "last": "Jou I",
        "authors": [
          "Joe EH",
          "Jou I",
          "Kim OS",
          "Lee CS",
          "Lee JH",
          "Park SJ",
          "Park SM",
          "Woo JH"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Cell": {
          "astrocyte": true
        }
      },
      "source": 868,
      "target": 892,
      "key": "8da743a16ae18434419c073654a9bf56e44693a93ec245c3f92d24ed520be9a9b7913b135ecbc4ea1671e8cdd534edc6b7216e0e86579d2a7bf2a7133ea2c6ce"
    },
    {
      "line": 3666,
      "relation": "increases",
      "evidence": "LXR ligands inhibit neither STAT1 phosphorylation nor STAT1 translocation to the nucleus but, rather, inhibit STAT1 binding to promoters and the expression of IRF1, TNFalpha, and IL-6, downstream effectors of STAT1 action. LXRbeta forms a trimer with PIAS1-pSTAT1, whereas LXRalpha formed a trimer with HDAC4-pSTAT1, mediated by direct ligand binding to the LXR proteins. Both PIAS1 and HDAC4 belong to the SUMO E3 ligase family and LXRbeta and LXRalpha were SUMO-conjugated by PIAS1 or HDAC4, respectively, and SUMOylation was blocked by transient transfection of appropriate individual siRNAs, reversing LXR-induced suppression of IRF1 and TNFalpha expression.",
      "citation": {
        "type": "PubMed",
        "reference": "19782030",
        "name": "Molecular cell",
        "title": "Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes.",
        "volume": "35",
        "pages": "806-17",
        "date": "2009-09-24",
        "first": "Lee JH",
        "last": "Jou I",
        "authors": [
          "Joe EH",
          "Jou I",
          "Kim OS",
          "Lee CS",
          "Lee JH",
          "Park SJ",
          "Park SM",
          "Woo JH"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "Cell": {
          "astrocyte": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 892,
      "target": 900,
      "key": "fb59f70d5f49fe78f1e51cc3c9952ae3cac3fe0cf2e1d4db04ecc92e0247828857a69c571cda2ce6a5a8ce769f18ff6ed81cc82dc52a30371828aa11a405db63"
    },
    {
      "relation": "hasVariant",
      "source": 891,
      "target": 892,
      "key": "d952d2751c543321345510c386fdbb40b2166a0ab1c4ac22f18070268d8c89fce887ec952a6a04c7926496f96749e9d4e7c68554b6c55a2dedd0b4f179833602"
    },
    {
      "line": 3677,
      "relation": "increases",
      "evidence": "Noradrenaline (NA) attenuated the LPS-induced reductions and increased SUMO-1 above basal levels. Over-expression of SUMO-1, Ubc9, or SENP1 reduced the activation of a NOS2 promoter, whereas activation of a 4 x NFkappaB binding-element reporter was only reduced by SUMO-1. ChIP studies revealed interactions of SUMO-1 and C/EBPbeta with C/EBP binding sites on the NOS2 promoter that were modulated by LPS and NA. SUMO-1 co-precipitated with C/EBPbeta confirmed by FRET analysis",
      "citation": {
        "type": "PubMed",
        "reference": "19323834",
        "name": "Journal of neuroinflammation",
        "title": "Modulation of inducible nitric oxide synthase expression by sumoylation.",
        "volume": "6",
        "pages": "12",
        "date": "2009-03-26",
        "first": "Akar CA",
        "last": "Feinstein DL",
        "authors": [
          "Akar CA",
          "Feinstein DL"
        ]
      },
      "annotations": {
        "Method": {
          "Fluorescence Resonance Energy Transfer": true,
          "Chromatin Immunoprecipitation": true
        }
      },
      "source": 63,
      "target": 692,
      "key": "bc38ed7eb37f3a62c77f27dcb533afc9baa56408657eb123e80288861211f063c1a51545e681e411884b75e4a6ad008f7e3f9bf04243a647ed34af350da16d44"
    },
    {
      "relation": "hasComponent",
      "source": 224,
      "target": 283,
      "key": "3b363022b0846637810c59c207bf8e484ae14bcb314fd6d682bd292dcb53971244f79e669ecd1851f804fd91506c160a779bfaf7c38d9db10833f8c83a3bd5d3"
    },
    {
      "relation": "hasComponent",
      "source": 224,
      "target": 692,
      "key": "d7898e7b9c01e87b7ded843629034ea323017efafea8ffcc66e6a1d514ee167b0865c7d19e164aad8fd45ac5273035d8a54be6475cd262c8e53e552bd309cf0a"
    },
    {
      "line": 3680,
      "relation": "directlyDecreases",
      "evidence": "Noradrenaline (NA) attenuated the LPS-induced reductions and increased SUMO-1 above basal levels. Over-expression of SUMO-1, Ubc9, or SENP1 reduced the activation of a NOS2 promoter, whereas activation of a 4 x NFkappaB binding-element reporter was only reduced by SUMO-1. ChIP studies revealed interactions of SUMO-1 and C/EBPbeta with C/EBP binding sites on the NOS2 promoter that were modulated by LPS and NA. SUMO-1 co-precipitated with C/EBPbeta confirmed by FRET analysis",
      "citation": {
        "type": "PubMed",
        "reference": "19323834",
        "name": "Journal of neuroinflammation",
        "title": "Modulation of inducible nitric oxide synthase expression by sumoylation.",
        "volume": "6",
        "pages": "12",
        "date": "2009-03-26",
        "first": "Akar CA",
        "last": "Feinstein DL",
        "authors": [
          "Akar CA",
          "Feinstein DL"
        ]
      },
      "annotations": {
        "Method": {
          "Fluorescence Resonance Energy Transfer": true,
          "Chromatin Immunoprecipitation": true
        }
      },
      "source": 224,
      "target": 934,
      "key": "fd1ba8c9ae6873eba20fd3612c0b3ac5521c211ea81dad4166b789f8ee01a3928582bd42ba44094a6205975ce4d94619c54856418d51ec084a60e1e33c4c58da"
    },
    {
      "line": 3679,
      "relation": "partOf",
      "evidence": "Noradrenaline (NA) attenuated the LPS-induced reductions and increased SUMO-1 above basal levels. Over-expression of SUMO-1, Ubc9, or SENP1 reduced the activation of a NOS2 promoter, whereas activation of a 4 x NFkappaB binding-element reporter was only reduced by SUMO-1. ChIP studies revealed interactions of SUMO-1 and C/EBPbeta with C/EBP binding sites on the NOS2 promoter that were modulated by LPS and NA. SUMO-1 co-precipitated with C/EBPbeta confirmed by FRET analysis",
      "citation": {
        "type": "PubMed",
        "reference": "19323834",
        "name": "Journal of neuroinflammation",
        "title": "Modulation of inducible nitric oxide synthase expression by sumoylation.",
        "volume": "6",
        "pages": "12",
        "date": "2009-03-26",
        "first": "Akar CA",
        "last": "Feinstein DL",
        "authors": [
          "Akar CA",
          "Feinstein DL"
        ]
      },
      "annotations": {
        "Method": {
          "Fluorescence Resonance Energy Transfer": true,
          "Chromatin Immunoprecipitation": true
        }
      },
      "source": 283,
      "target": 224,
      "key": "05562e19d0e8f6c08d136114595dcb8826090cf4c2533236aee64e949561469b1a4510fbb3f218869fe6630808e65af4c3332f34d09f979bb33befa30444dbae"
    },
    {
      "line": 3681,
      "relation": "directlyDecreases",
      "evidence": "Noradrenaline (NA) attenuated the LPS-induced reductions and increased SUMO-1 above basal levels. Over-expression of SUMO-1, Ubc9, or SENP1 reduced the activation of a NOS2 promoter, whereas activation of a 4 x NFkappaB binding-element reporter was only reduced by SUMO-1. ChIP studies revealed interactions of SUMO-1 and C/EBPbeta with C/EBP binding sites on the NOS2 promoter that were modulated by LPS and NA. SUMO-1 co-precipitated with C/EBPbeta confirmed by FRET analysis",
      "citation": {
        "type": "PubMed",
        "reference": "19323834",
        "name": "Journal of neuroinflammation",
        "title": "Modulation of inducible nitric oxide synthase expression by sumoylation.",
        "volume": "6",
        "pages": "12",
        "date": "2009-03-26",
        "first": "Akar CA",
        "last": "Feinstein DL",
        "authors": [
          "Akar CA",
          "Feinstein DL"
        ]
      },
      "annotations": {
        "Method": {
          "Fluorescence Resonance Energy Transfer": true,
          "Chromatin Immunoprecipitation": true
        }
      },
      "source": 739,
      "target": 934,
      "key": "baec2ece6af8c04c97f5c416628df5c7e98f372b5ee99ea28544ad80949f37dfbe08bef0fb32ee2236e3298e6667c8baf6c176a29ce66bd587b86e376cfc7fa9"
    },
    {
      "line": 3696,
      "relation": "partOf",
      "evidence": "Lysines 587 and 595 of APP, immediately adjacent to the site of beta-secretase cleavage, are covalently modified by SUMO proteins in vivo. Sumoylation of these lysine residues is associated with decreased levels of Abeta aggregates. The results demonstrate that the SUMO E2 enzyme (ubc9) is present within the endoplasmic reticulum, indicating how APP, and perhaps other proteins that enter this compartment, can be sumoylated.",
      "citation": {
        "type": "PubMed",
        "reference": "18675254",
        "name": "Biochemical and biophysical research communications",
        "title": "Sumoylation of amyloid precursor protein negatively regulates Abeta aggregate levels.",
        "volume": "374",
        "pages": "673-8",
        "date": "2008-10-03",
        "first": "Zhang YQ",
        "last": "Sarge KD",
        "authors": [
          "Sarge KD",
          "Zhang YQ"
        ]
      },
      "source": 739,
      "target": 211,
      "key": "87f966b3c903c9b12dfbc5713694d42addeea5408f1d4dcad7dcf697fbb4d502b38ed778ab22d3a1211b9d7405d761bbae3f5c524a168add82eed2654872ac5c"
    },
    {
      "line": 3682,
      "relation": "directlyDecreases",
      "evidence": "Noradrenaline (NA) attenuated the LPS-induced reductions and increased SUMO-1 above basal levels. Over-expression of SUMO-1, Ubc9, or SENP1 reduced the activation of a NOS2 promoter, whereas activation of a 4 x NFkappaB binding-element reporter was only reduced by SUMO-1. ChIP studies revealed interactions of SUMO-1 and C/EBPbeta with C/EBP binding sites on the NOS2 promoter that were modulated by LPS and NA. SUMO-1 co-precipitated with C/EBPbeta confirmed by FRET analysis",
      "citation": {
        "type": "PubMed",
        "reference": "19323834",
        "name": "Journal of neuroinflammation",
        "title": "Modulation of inducible nitric oxide synthase expression by sumoylation.",
        "volume": "6",
        "pages": "12",
        "date": "2009-03-26",
        "first": "Akar CA",
        "last": "Feinstein DL",
        "authors": [
          "Akar CA",
          "Feinstein DL"
        ]
      },
      "annotations": {
        "Method": {
          "Fluorescence Resonance Energy Transfer": true,
          "Chromatin Immunoprecipitation": true
        }
      },
      "source": 676,
      "target": 934,
      "key": "a1d09b1283fcd0cb8c172d507fcd7c06fcf6713b28d8b3b85192b54f77e4805eb9cf86c5d5dae86564521c92e086b7ffbd1066647ae5c973615d63e6e0f2ee22"
    },
    {
      "line": 3694,
      "relation": "decreases",
      "evidence": "Lysines 587 and 595 of APP, immediately adjacent to the site of beta-secretase cleavage, are covalently modified by SUMO proteins in vivo. Sumoylation of these lysine residues is associated with decreased levels of Abeta aggregates. The results demonstrate that the SUMO E2 enzyme (ubc9) is present within the endoplasmic reticulum, indicating how APP, and perhaps other proteins that enter this compartment, can be sumoylated.",
      "citation": {
        "type": "PubMed",
        "reference": "18675254",
        "name": "Biochemical and biophysical research communications",
        "title": "Sumoylation of amyloid precursor protein negatively regulates Abeta aggregate levels.",
        "volume": "374",
        "pages": "673-8",
        "date": "2008-10-03",
        "first": "Zhang YQ",
        "last": "Sarge KD",
        "authors": [
          "Sarge KD",
          "Zhang YQ"
        ]
      },
      "source": 380,
      "target": 11,
      "key": "3d6c575d5e8d97e16082b15c00d13e7ef8f2265a954fe7fcec4f267f77be5e0b8e3e39b214344b2ee34f261d763026c2d30f0cfaddc3776727c82f3858ae8204"
    },
    {
      "line": 3695,
      "relation": "decreases",
      "evidence": "Lysines 587 and 595 of APP, immediately adjacent to the site of beta-secretase cleavage, are covalently modified by SUMO proteins in vivo. Sumoylation of these lysine residues is associated with decreased levels of Abeta aggregates. The results demonstrate that the SUMO E2 enzyme (ubc9) is present within the endoplasmic reticulum, indicating how APP, and perhaps other proteins that enter this compartment, can be sumoylated.",
      "citation": {
        "type": "PubMed",
        "reference": "18675254",
        "name": "Biochemical and biophysical research communications",
        "title": "Sumoylation of amyloid precursor protein negatively regulates Abeta aggregate levels.",
        "volume": "374",
        "pages": "673-8",
        "date": "2008-10-03",
        "first": "Zhang YQ",
        "last": "Sarge KD",
        "authors": [
          "Sarge KD",
          "Zhang YQ"
        ]
      },
      "source": 381,
      "target": 11,
      "key": "c9242ebf7d948cdb894c2b1680bbed3e5d53bc3f0fc14c199286221f874ca0651301c9a293bc41a291187d57c55573ef71c50841abdf8e80bc0d1541974de15e"
    },
    {
      "line": 3692,
      "relation": "increases",
      "evidence": "Lysines 587 and 595 of APP, immediately adjacent to the site of beta-secretase cleavage, are covalently modified by SUMO proteins in vivo. Sumoylation of these lysine residues is associated with decreased levels of Abeta aggregates. The results demonstrate that the SUMO E2 enzyme (ubc9) is present within the endoplasmic reticulum, indicating how APP, and perhaps other proteins that enter this compartment, can be sumoylated.",
      "citation": {
        "type": "PubMed",
        "reference": "18675254",
        "name": "Biochemical and biophysical research communications",
        "title": "Sumoylation of amyloid precursor protein negatively regulates Abeta aggregate levels.",
        "volume": "374",
        "pages": "673-8",
        "date": "2008-10-03",
        "first": "Zhang YQ",
        "last": "Sarge KD",
        "authors": [
          "Sarge KD",
          "Zhang YQ"
        ]
      },
      "source": 693,
      "target": 380,
      "key": "b3a3755571d9c27189afce8dd6ba018a52bb7bcb3f908db9ef2121064acf5b7fca2a2b6c5286fcff5d8cd3da402834c5a0bc7e070bcdd28690463d28f976680c"
    },
    {
      "line": 3693,
      "relation": "increases",
      "evidence": "Lysines 587 and 595 of APP, immediately adjacent to the site of beta-secretase cleavage, are covalently modified by SUMO proteins in vivo. Sumoylation of these lysine residues is associated with decreased levels of Abeta aggregates. The results demonstrate that the SUMO E2 enzyme (ubc9) is present within the endoplasmic reticulum, indicating how APP, and perhaps other proteins that enter this compartment, can be sumoylated.",
      "citation": {
        "type": "PubMed",
        "reference": "18675254",
        "name": "Biochemical and biophysical research communications",
        "title": "Sumoylation of amyloid precursor protein negatively regulates Abeta aggregate levels.",
        "volume": "374",
        "pages": "673-8",
        "date": "2008-10-03",
        "first": "Zhang YQ",
        "last": "Sarge KD",
        "authors": [
          "Sarge KD",
          "Zhang YQ"
        ]
      },
      "source": 693,
      "target": 381,
      "key": "4c29b7cd1ceec34c8a8c001bef7248fc62af9764d37aea5f950e206924ad728e54601daba9148e492e8c908126744b64858919f403779e78a777c8cf6c9ae4b0"
    },
    {
      "line": 3703,
      "relation": "increases",
      "evidence": "SUMO3 overexpression significantly increased Abeta40 and Abeta42 secretion, which was accompanied by an increase in full-length APP and its C-terminal fragments. These effects of SUMO3 were independent of its covalent attachment or chain formation, as mutants lacking the motifs responsible for SUMO chain formation or SUMO conjugation led to similar changes in Abeta. SUMO3 overexpression also up-regulated the expression of the transmembrane protease BACE (beta-amyloid-cleaving enzyme), but failed to affect levels of several other unrelated proteins.",
      "citation": {
        "type": "PubMed",
        "reference": "17346237",
        "name": "The Biochemical journal",
        "title": "Modulation of Abeta generation by small ubiquitin-like modifiers does not require conjugation to target proteins.",
        "volume": "404",
        "pages": "309-16",
        "date": "2007-06-01",
        "first": "Dorval V",
        "last": "Fraser PE",
        "authors": [
          "Dorval V",
          "Fraser PE",
          "Hay RT",
          "Mathews PM",
          "Mazzella MJ"
        ]
      },
      "source": 694,
      "target": 387,
      "key": "6042789227feda6fac9d45bdc52476bb1cb592388b5a07882c4bfa7c0f42d5b4343c545848493e774e7963ae6e16660d40152bfafccd3cc1b513d049f51cfe13"
    },
    {
      "line": 3704,
      "relation": "increases",
      "evidence": "SUMO3 overexpression significantly increased Abeta40 and Abeta42 secretion, which was accompanied by an increase in full-length APP and its C-terminal fragments. These effects of SUMO3 were independent of its covalent attachment or chain formation, as mutants lacking the motifs responsible for SUMO chain formation or SUMO conjugation led to similar changes in Abeta. SUMO3 overexpression also up-regulated the expression of the transmembrane protease BACE (beta-amyloid-cleaving enzyme), but failed to affect levels of several other unrelated proteins.",
      "citation": {
        "type": "PubMed",
        "reference": "17346237",
        "name": "The Biochemical journal",
        "title": "Modulation of Abeta generation by small ubiquitin-like modifiers does not require conjugation to target proteins.",
        "volume": "404",
        "pages": "309-16",
        "date": "2007-06-01",
        "first": "Dorval V",
        "last": "Fraser PE",
        "authors": [
          "Dorval V",
          "Fraser PE",
          "Hay RT",
          "Mathews PM",
          "Mazzella MJ"
        ]
      },
      "source": 694,
      "target": 375,
      "key": "a1128ad581a5482ab13049cd4b0add27c325ee4db6af94cd84afa63e2afdfadb1fb915c5d2487f11b806b1a0a0556337feb5011462bb1e455bfa7595e8d00994"
    },
    {
      "line": 3705,
      "relation": "increases",
      "evidence": "SUMO3 overexpression significantly increased Abeta40 and Abeta42 secretion, which was accompanied by an increase in full-length APP and its C-terminal fragments. These effects of SUMO3 were independent of its covalent attachment or chain formation, as mutants lacking the motifs responsible for SUMO chain formation or SUMO conjugation led to similar changes in Abeta. SUMO3 overexpression also up-regulated the expression of the transmembrane protease BACE (beta-amyloid-cleaving enzyme), but failed to affect levels of several other unrelated proteins.",
      "citation": {
        "type": "PubMed",
        "reference": "17346237",
        "name": "The Biochemical journal",
        "title": "Modulation of Abeta generation by small ubiquitin-like modifiers does not require conjugation to target proteins.",
        "volume": "404",
        "pages": "309-16",
        "date": "2007-06-01",
        "first": "Dorval V",
        "last": "Fraser PE",
        "authors": [
          "Dorval V",
          "Fraser PE",
          "Hay RT",
          "Mathews PM",
          "Mazzella MJ"
        ]
      },
      "source": 694,
      "target": 376,
      "key": "4d106b08c24013a629c294aa8377cb35064aac499db0df756c0695947627d55efaf48870dd752fa3fcaf3fde7a875283fbe3c9a58cab76a0be7fe6c4cea14a04"
    },
    {
      "relation": "hasVariant",
      "source": 686,
      "target": 687,
      "key": "4f0fb5e017b69cffeda36cfe0ecbbc2dece40ca290712b7cb3ad2ea5da48ad94460f62d746a7551c47d65494d8b07deeb73cc1bb3d29d816488790ddc013c8c6"
    },
    {
      "line": 3715,
      "relation": "increases",
      "evidence": "Both brain proteins were preferentially modified by SUMO1, as compared with SUMO2 or SUMO3. Tau contains two SUMO consensus sequences with Lys(340) as the major sumoylation site. Although both tau and alpha-synuclein are targets for proteasomal degradation, only tau sumoylation was affected by inhibitors of the proteasome pathway. Treatment with the phosphatase inhibitor, okadaic acid, or the microtubule depolymerizing drug, colchicine, up-regulated tau sumoylation.",
      "citation": {
        "type": "PubMed",
        "reference": "16464864",
        "name": "The Journal of biological chemistry",
        "title": "Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein.",
        "volume": "281",
        "pages": "9919-24",
        "date": "2006-04-14",
        "first": "Dorval V",
        "last": "Fraser PE",
        "authors": [
          "Dorval V",
          "Fraser PE"
        ]
      },
      "source": 27,
      "target": 593,
      "key": "4db286ec2b38de59f8c78d546fe1a29947d6c8220788c23ed9bfd8fdb0291c29b7689e88ad86721bb00079731c74cc1ef6aa5409900bd7b883ba337004b4b1e2"
    },
    {
      "line": 3717,
      "relation": "positiveCorrelation",
      "evidence": "Both brain proteins were preferentially modified by SUMO1, as compared with SUMO2 or SUMO3. Tau contains two SUMO consensus sequences with Lys(340) as the major sumoylation site. Although both tau and alpha-synuclein are targets for proteasomal degradation, only tau sumoylation was affected by inhibitors of the proteasome pathway. Treatment with the phosphatase inhibitor, okadaic acid, or the microtubule depolymerizing drug, colchicine, up-regulated tau sumoylation.",
      "citation": {
        "type": "PubMed",
        "reference": "16464864",
        "name": "The Journal of biological chemistry",
        "title": "Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein.",
        "volume": "281",
        "pages": "9919-24",
        "date": "2006-04-14",
        "first": "Dorval V",
        "last": "Fraser PE",
        "authors": [
          "Dorval V",
          "Fraser PE"
        ]
      },
      "source": 27,
      "target": 544,
      "key": "aad8d238b449862955d7910a810c21f26865cbdafe8d5be67c1b7348e6df742760ee9d5ca6f0b6179bc893607f55179ed8d9db347a2c072099ec834d70064c1f"
    },
    {
      "line": 3716,
      "relation": "increases",
      "evidence": "Both brain proteins were preferentially modified by SUMO1, as compared with SUMO2 or SUMO3. Tau contains two SUMO consensus sequences with Lys(340) as the major sumoylation site. Although both tau and alpha-synuclein are targets for proteasomal degradation, only tau sumoylation was affected by inhibitors of the proteasome pathway. Treatment with the phosphatase inhibitor, okadaic acid, or the microtubule depolymerizing drug, colchicine, up-regulated tau sumoylation.",
      "citation": {
        "type": "PubMed",
        "reference": "16464864",
        "name": "The Journal of biological chemistry",
        "title": "Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein.",
        "volume": "281",
        "pages": "9919-24",
        "date": "2006-04-14",
        "first": "Dorval V",
        "last": "Fraser PE",
        "authors": [
          "Dorval V",
          "Fraser PE"
        ]
      },
      "source": 45,
      "target": 593,
      "key": "494845cb74a7c93eb8172030ca31e54520cff10c07e0a2f51d6dd20d03c9803aa7172e258cef94c7fcb23f1ad458588fa2985c49b2ff6bba780473eb9e29b38f"
    },
    {
      "line": 3725,
      "relation": "increases",
      "evidence": "Increased protein sumoylation resulting from overexpression of SUMO-3 reduces Abeta production and reducing endogenous protein sumoylation with dominant-negative SUMO-3 mutants increases Abeta production. Mutant SUMO-3, K11R, which can only be monomerically conjugated to target proteins, has an opposite effect on Abeta generation to that by SUMO-3, which can form polymeric chains on target proteins. Polysumoylation reduces whereas monosumoylation or undersumoylation enhances Abeta generation.",
      "citation": {
        "type": "PubMed",
        "reference": "12506199",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Positive and negative regulation of APP amyloidogenesis by sumoylation.",
        "volume": "100",
        "pages": "259-64",
        "date": "2003-01-07",
        "first": "Li Y",
        "last": "Cordell B",
        "authors": [
          "Cordell B",
          "Li Y",
          "Liu YW",
          "Quon D",
          "Wang H",
          "Wang S"
        ]
      },
      "source": 379,
      "target": 11,
      "key": "8152460ccb76f3a4965a04d0c29844ce784aec0363c4df7ee5570d20bb81714960837976cb74ab1de95d8ef2953078cfc15df130c6b8b9cab59a82f84cf1633e"
    },
    {
      "line": 3726,
      "relation": "decreases",
      "evidence": "Increased protein sumoylation resulting from overexpression of SUMO-3 reduces Abeta production and reducing endogenous protein sumoylation with dominant-negative SUMO-3 mutants increases Abeta production. Mutant SUMO-3, K11R, which can only be monomerically conjugated to target proteins, has an opposite effect on Abeta generation to that by SUMO-3, which can form polymeric chains on target proteins. Polysumoylation reduces whereas monosumoylation or undersumoylation enhances Abeta generation.",
      "citation": {
        "type": "PubMed",
        "reference": "12506199",
        "name": "Proceedings of the National Academy of Sciences of the United States of America",
        "title": "Positive and negative regulation of APP amyloidogenesis by sumoylation.",
        "volume": "100",
        "pages": "259-64",
        "date": "2003-01-07",
        "first": "Li Y",
        "last": "Cordell B",
        "authors": [
          "Cordell B",
          "Li Y",
          "Liu YW",
          "Quon D",
          "Wang H",
          "Wang S"
        ]
      },
      "source": 377,
      "target": 11,
      "key": "504786b8e0f9946eb7083f3a16d2c352e7b098987d17d34658bc0110717aecd5b6d80d1d0fd2e7d6352b80e8d030a595f280a84494b67976c48fc6ba0546d8b0"
    },
    {
      "line": 3741,
      "relation": "directlyDecreases",
      "evidence": "We recently found that overexpression of TDP-43 enhances tau exon 10 inclusion and tau mRNA instability. Overexpression of PP1α and PP1γ, but not PP1β, suppressed TDP-43 phosphorylation at Ser403/404 and Ser409/410 and TDP-43-induced tau exon 10 inclusion.",
      "citation": {
        "type": "PubMed",
        "reference": "29334120",
        "name": "FEBS letters",
        "title": "Protein Phosphatase 1 dephosphorylates TDP-43 and suppresses its function in tau exon 10 inclusion.",
        "volume": "592",
        "pages": "402-410",
        "date": "2018-02-01",
        "first": "Gu J",
        "last": "Liu F",
        "authors": [
          "Chen F",
          "Gong CX",
          "Gu J",
          "Hu W",
          "Iqbal K",
          "Liu F",
          "Miao S",
          "Wang W",
          "Wu F"
        ]
      },
      "source": 653,
      "target": 724,
      "key": "d0ec18a368f48eae1e7a11986655abd884ae3b68a2f474148a855d3fa44582ce7456bf4da8791594908bd92190e7e7204e6b5f984d9e85602056b31fb21af846"
    },
    {
      "line": 3742,
      "relation": "directlyDecreases",
      "evidence": "We recently found that overexpression of TDP-43 enhances tau exon 10 inclusion and tau mRNA instability. Overexpression of PP1α and PP1γ, but not PP1β, suppressed TDP-43 phosphorylation at Ser403/404 and Ser409/410 and TDP-43-induced tau exon 10 inclusion.",
      "citation": {
        "type": "PubMed",
        "reference": "29334120",
        "name": "FEBS letters",
        "title": "Protein Phosphatase 1 dephosphorylates TDP-43 and suppresses its function in tau exon 10 inclusion.",
        "volume": "592",
        "pages": "402-410",
        "date": "2018-02-01",
        "first": "Gu J",
        "last": "Liu F",
        "authors": [
          "Chen F",
          "Gong CX",
          "Gu J",
          "Hu W",
          "Iqbal K",
          "Liu F",
          "Miao S",
          "Wang W",
          "Wu F"
        ]
      },
      "source": 653,
      "target": 725,
      "key": "197d0643d3e5c4944cfa2089590e506cdcf9799ba3eebe1874af3e801a54bc93b9ee4d4afc6bd96342302b646a42f1d78679b6fba8a95b6a751e0136dcf19fed"
    },
    {
      "line": 3743,
      "relation": "directlyDecreases",
      "evidence": "We recently found that overexpression of TDP-43 enhances tau exon 10 inclusion and tau mRNA instability. Overexpression of PP1α and PP1γ, but not PP1β, suppressed TDP-43 phosphorylation at Ser403/404 and Ser409/410 and TDP-43-induced tau exon 10 inclusion.",
      "citation": {
        "type": "PubMed",
        "reference": "29334120",
        "name": "FEBS letters",
        "title": "Protein Phosphatase 1 dephosphorylates TDP-43 and suppresses its function in tau exon 10 inclusion.",
        "volume": "592",
        "pages": "402-410",
        "date": "2018-02-01",
        "first": "Gu J",
        "last": "Liu F",
        "authors": [
          "Chen F",
          "Gong CX",
          "Gu J",
          "Hu W",
          "Iqbal K",
          "Liu F",
          "Miao S",
          "Wang W",
          "Wu F"
        ]
      },
      "source": 653,
      "target": 726,
      "key": "39112887f9a486824bfd444d21da5ffac8a1a9113a73b2a7c71169354c2a05fdeea57c8e9b610ad1e1325febe6025f8bd4a55c06fb0c30306329b88ea0bb3aad"
    },
    {
      "line": 3744,
      "relation": "directlyDecreases",
      "evidence": "We recently found that overexpression of TDP-43 enhances tau exon 10 inclusion and tau mRNA instability. Overexpression of PP1α and PP1γ, but not PP1β, suppressed TDP-43 phosphorylation at Ser403/404 and Ser409/410 and TDP-43-induced tau exon 10 inclusion.",
      "citation": {
        "type": "PubMed",
        "reference": "29334120",
        "name": "FEBS letters",
        "title": "Protein Phosphatase 1 dephosphorylates TDP-43 and suppresses its function in tau exon 10 inclusion.",
        "volume": "592",
        "pages": "402-410",
        "date": "2018-02-01",
        "first": "Gu J",
        "last": "Liu F",
        "authors": [
          "Chen F",
          "Gong CX",
          "Gu J",
          "Hu W",
          "Iqbal K",
          "Liu F",
          "Miao S",
          "Wang W",
          "Wu F"
        ]
      },
      "source": 653,
      "target": 727,
      "key": "2f2eb5defd7e49a3a2c6bbeca2fa4a233f20865bd603c426cd65d3d824a864e66c8306b8d9eda6c5076c71bde48b05a99e7746358e5e9c5c2ac84ca4c96c9033"
    },
    {
      "line": 3750,
      "relation": "increases",
      "evidence": "We recently found that overexpression of TDP-43 enhances tau exon 10 inclusion and tau mRNA instability. Overexpression of PP1α and PP1γ, but not PP1β, suppressed TDP-43 phosphorylation at Ser403/404 and Ser409/410 and TDP-43-induced tau exon 10 inclusion.",
      "citation": {
        "type": "PubMed",
        "reference": "29334120",
        "name": "FEBS letters",
        "title": "Protein Phosphatase 1 dephosphorylates TDP-43 and suppresses its function in tau exon 10 inclusion.",
        "volume": "592",
        "pages": "402-410",
        "date": "2018-02-01",
        "first": "Gu J",
        "last": "Liu F",
        "authors": [
          "Chen F",
          "Gong CX",
          "Gu J",
          "Hu W",
          "Iqbal K",
          "Liu F",
          "Miao S",
          "Wang W",
          "Wu F"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 726,
      "target": 721,
      "key": "11dab0f3e543b62c7922aa1f4389a1ffef4fa24b50c4d54d6f784ff46376e2c02a5ad1bb614d7cbb471d805e38e75863c5f8fd3e8cc4dd730e24b72f4460f505"
    },
    {
      "line": 3751,
      "relation": "increases",
      "evidence": "We recently found that overexpression of TDP-43 enhances tau exon 10 inclusion and tau mRNA instability. Overexpression of PP1α and PP1γ, but not PP1β, suppressed TDP-43 phosphorylation at Ser403/404 and Ser409/410 and TDP-43-induced tau exon 10 inclusion.",
      "citation": {
        "type": "PubMed",
        "reference": "29334120",
        "name": "FEBS letters",
        "title": "Protein Phosphatase 1 dephosphorylates TDP-43 and suppresses its function in tau exon 10 inclusion.",
        "volume": "592",
        "pages": "402-410",
        "date": "2018-02-01",
        "first": "Gu J",
        "last": "Liu F",
        "authors": [
          "Chen F",
          "Gong CX",
          "Gu J",
          "Hu W",
          "Iqbal K",
          "Liu F",
          "Miao S",
          "Wang W",
          "Wu F"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 727,
      "target": 721,
      "key": "1ddf19cb865c112624f73e5c84a6003d2361ded4f712ebfd3c5e570ebac6614cadd03dcbbab89d6ebfab910c24c6d4afcee0b43f78ccf30e8b67ecd473bdd8c4"
    },
    {
      "line": 3745,
      "relation": "directlyDecreases",
      "evidence": "We recently found that overexpression of TDP-43 enhances tau exon 10 inclusion and tau mRNA instability. Overexpression of PP1α and PP1γ, but not PP1β, suppressed TDP-43 phosphorylation at Ser403/404 and Ser409/410 and TDP-43-induced tau exon 10 inclusion.",
      "citation": {
        "type": "PubMed",
        "reference": "29334120",
        "name": "FEBS letters",
        "title": "Protein Phosphatase 1 dephosphorylates TDP-43 and suppresses its function in tau exon 10 inclusion.",
        "volume": "592",
        "pages": "402-410",
        "date": "2018-02-01",
        "first": "Gu J",
        "last": "Liu F",
        "authors": [
          "Chen F",
          "Gong CX",
          "Gu J",
          "Hu W",
          "Iqbal K",
          "Liu F",
          "Miao S",
          "Wang W",
          "Wu F"
        ]
      },
      "source": 652,
      "target": 723,
      "key": "90a2eeee9e8b8acf28e465e36e4e81dd5d60a9d0203284d3ddad658459eee65c844a5de900e686522cd6841fd4ad68ca54f1af45df242fec1d6ecf49759e41b8"
    },
    {
      "line": 3746,
      "relation": "directlyDecreases",
      "evidence": "We recently found that overexpression of TDP-43 enhances tau exon 10 inclusion and tau mRNA instability. Overexpression of PP1α and PP1γ, but not PP1β, suppressed TDP-43 phosphorylation at Ser403/404 and Ser409/410 and TDP-43-induced tau exon 10 inclusion.",
      "citation": {
        "type": "PubMed",
        "reference": "29334120",
        "name": "FEBS letters",
        "title": "Protein Phosphatase 1 dephosphorylates TDP-43 and suppresses its function in tau exon 10 inclusion.",
        "volume": "592",
        "pages": "402-410",
        "date": "2018-02-01",
        "first": "Gu J",
        "last": "Liu F",
        "authors": [
          "Chen F",
          "Gong CX",
          "Gu J",
          "Hu W",
          "Iqbal K",
          "Liu F",
          "Miao S",
          "Wang W",
          "Wu F"
        ]
      },
      "source": 652,
      "target": 724,
      "key": "42a5b2aaa5da211678b72efef9f2a73ba5614b374c495f61a48f274b05bbf5be036050ea5b4349bada670b68656cbf4fea1727dcf0224add0da6f75f3f42682e"
    },
    {
      "line": 3747,
      "relation": "directlyDecreases",
      "evidence": "We recently found that overexpression of TDP-43 enhances tau exon 10 inclusion and tau mRNA instability. Overexpression of PP1α and PP1γ, but not PP1β, suppressed TDP-43 phosphorylation at Ser403/404 and Ser409/410 and TDP-43-induced tau exon 10 inclusion.",
      "citation": {
        "type": "PubMed",
        "reference": "29334120",
        "name": "FEBS letters",
        "title": "Protein Phosphatase 1 dephosphorylates TDP-43 and suppresses its function in tau exon 10 inclusion.",
        "volume": "592",
        "pages": "402-410",
        "date": "2018-02-01",
        "first": "Gu J",
        "last": "Liu F",
        "authors": [
          "Chen F",
          "Gong CX",
          "Gu J",
          "Hu W",
          "Iqbal K",
          "Liu F",
          "Miao S",
          "Wang W",
          "Wu F"
        ]
      },
      "source": 652,
      "target": 725,
      "key": "45985528c5dfe6b574f5cc7f8eda994953c6721093c65fcd11265e6d59c07906c6a042e3c8c93249950dfdc68468a773b0c939fbc630f61781fe9d270e953233"
    },
    {
      "line": 3748,
      "relation": "directlyDecreases",
      "evidence": "We recently found that overexpression of TDP-43 enhances tau exon 10 inclusion and tau mRNA instability. Overexpression of PP1α and PP1γ, but not PP1β, suppressed TDP-43 phosphorylation at Ser403/404 and Ser409/410 and TDP-43-induced tau exon 10 inclusion.",
      "citation": {
        "type": "PubMed",
        "reference": "29334120",
        "name": "FEBS letters",
        "title": "Protein Phosphatase 1 dephosphorylates TDP-43 and suppresses its function in tau exon 10 inclusion.",
        "volume": "592",
        "pages": "402-410",
        "date": "2018-02-01",
        "first": "Gu J",
        "last": "Liu F",
        "authors": [
          "Chen F",
          "Gong CX",
          "Gu J",
          "Hu W",
          "Iqbal K",
          "Liu F",
          "Miao S",
          "Wang W",
          "Wu F"
        ]
      },
      "source": 652,
      "target": 726,
      "key": "81bdd9342192cc75544abc3d9888e26e18e65533932f7817fde7198ed6b931d1192783fd30aff2af110d967c676805e512e14ef224d11a3b7caf913f284478bf"
    },
    {
      "line": 3749,
      "relation": "directlyDecreases",
      "evidence": "We recently found that overexpression of TDP-43 enhances tau exon 10 inclusion and tau mRNA instability. Overexpression of PP1α and PP1γ, but not PP1β, suppressed TDP-43 phosphorylation at Ser403/404 and Ser409/410 and TDP-43-induced tau exon 10 inclusion.",
      "citation": {
        "type": "PubMed",
        "reference": "29334120",
        "name": "FEBS letters",
        "title": "Protein Phosphatase 1 dephosphorylates TDP-43 and suppresses its function in tau exon 10 inclusion.",
        "volume": "592",
        "pages": "402-410",
        "date": "2018-02-01",
        "first": "Gu J",
        "last": "Liu F",
        "authors": [
          "Chen F",
          "Gong CX",
          "Gu J",
          "Hu W",
          "Iqbal K",
          "Liu F",
          "Miao S",
          "Wang W",
          "Wu F"
        ]
      },
      "source": 652,
      "target": 727,
      "key": "90a95d6f825c8976e4dfc6e230d939f8497eb9ae5ea0e6dad368b63df71bbb584fe86466b5ca808250bf70dbd5f0de9f4afc9fc4f7de7c46a9e0ae525ff9f884"
    },
    {
      "line": 3757,
      "relation": "directlyDecreases",
      "evidence": "The growth arrest and DNA damage protein (GADD) 34 is up-regulated in response to ER stress and regulates subunit of protein phosphatase 1 (PP1) complex that dephosphorylates eukaryotic translation initiator factor 2α (elF2α).",
      "citation": {
        "type": "PubMed",
        "reference": "26142647",
        "name": "Neuroscience letters",
        "title": "Increased GADD34 in oligodendrocytes in Alzheimer's disease.",
        "volume": "602",
        "pages": "50-5",
        "date": "2015-08-18",
        "first": "Honjo Y",
        "last": "Kawakami K",
        "authors": [
          "Ayaki T",
          "Honjo Y",
          "Horibe T",
          "Ito H",
          "Kawakami K",
          "Mori H",
          "Takahashi R",
          "Tomiyama T"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 652,
      "target": 446,
      "key": "ca3b682575184a933b04f55c98d034123c6b7d3ae6af6dca299c7ac2cf0905105b354782c4c4f11df06e9270d1acd62273f3d1fbf059418d42ed3e43809a18cc"
    },
    {
      "line": 3846,
      "relation": "directlyDecreases",
      "evidence": "Filamentous, but not soluble, forms of wild-type tau inhibit anterograde, kinesin-based fast axonal transport (FAT) by activating axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK3), independent of microtubule binding. Amino acids 2-18 of tau, comprising a phosphatase-activating domain (PAD), are necessary and sufficient for activation of this pathway. Various pathogenic forms of tau displaying increased exposure of PAD inhibited anterograde FAT in squid axoplasm. Immunohistochemical studies using a novel PAD-specific monoclonal antibody in human postmortem tissue indicated that increased PAD exposure represents an early pathogenic event in AD that closely associates in time with AT8 immunoreactivity. We propose a model of pathogenesis in which disease-associated changes in tau conformation lead to increased exposure of PAD, activation of PP1-GSK3, and inhibition of FAT",
      "citation": {
        "type": "PubMed",
        "reference": "21734277",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "volume": "31",
        "pages": "9858-68",
        "date": "2011-07-06",
        "first": "Kanaan NM",
        "last": "Binder LI",
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 652,
      "target": 457,
      "key": "cc13dc07a9a2a7c32c59fb375772dc9ba5e64539b4fd6303a9bf7c3d6e481eaea1e67e910bd01762e2e348dcd014fa8f52c13f1166dccc60590b1d2bc4db9752"
    },
    {
      "line": 3848,
      "relation": "increases",
      "evidence": "Filamentous, but not soluble, forms of wild-type tau inhibit anterograde, kinesin-based fast axonal transport (FAT) by activating axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK3), independent of microtubule binding. Amino acids 2-18 of tau, comprising a phosphatase-activating domain (PAD), are necessary and sufficient for activation of this pathway. Various pathogenic forms of tau displaying increased exposure of PAD inhibited anterograde FAT in squid axoplasm. Immunohistochemical studies using a novel PAD-specific monoclonal antibody in human postmortem tissue indicated that increased PAD exposure represents an early pathogenic event in AD that closely associates in time with AT8 immunoreactivity. We propose a model of pathogenesis in which disease-associated changes in tau conformation lead to increased exposure of PAD, activation of PP1-GSK3, and inhibition of FAT",
      "citation": {
        "type": "PubMed",
        "reference": "21734277",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "volume": "31",
        "pages": "9858-68",
        "date": "2011-07-06",
        "first": "Kanaan NM",
        "last": "Binder LI",
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 652,
      "target": 456,
      "key": "1000c490ab1ad69ce437d46852a01e75e56fc3162aebf9a0fe13c47a73278f51d43ba9b148ebc52e40dea518eb8936f64ef3241e22e30a957bb5ffcb48115863"
    },
    {
      "line": 3852,
      "relation": "negativeCorrelation",
      "evidence": "Filamentous, but not soluble, forms of wild-type tau inhibit anterograde, kinesin-based fast axonal transport (FAT) by activating axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK3), independent of microtubule binding. Amino acids 2-18 of tau, comprising a phosphatase-activating domain (PAD), are necessary and sufficient for activation of this pathway. Various pathogenic forms of tau displaying increased exposure of PAD inhibited anterograde FAT in squid axoplasm. Immunohistochemical studies using a novel PAD-specific monoclonal antibody in human postmortem tissue indicated that increased PAD exposure represents an early pathogenic event in AD that closely associates in time with AT8 immunoreactivity. We propose a model of pathogenesis in which disease-associated changes in tau conformation lead to increased exposure of PAD, activation of PP1-GSK3, and inhibition of FAT",
      "citation": {
        "type": "PubMed",
        "reference": "21734277",
        "name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "title": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "volume": "31",
        "pages": "9858-68",
        "date": "2011-07-06",
        "first": "Kanaan NM",
        "last": "Binder LI",
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 652,
      "target": 175,
      "key": "3cd61332314806bda7bebe85ed38314edf653e560da1adf8aa9261e5bd917d0f0884fcf6e396bcb89cf7077c2c0aec380bb2f67bd40e64965b8e5acb3b9a8bc0"
    },
    {
      "line": 3910,
      "relation": "directlyDecreases",
      "evidence": "In primary neurons, overexpression of miR-125b causes tau hyperphosphorylation and an upregulation of p35, cdk5, and p44/42-MAPK signaling. In parallel, the phosphatases DUSP6 and PPP1CA and the anti-apoptotic factor Bcl-W are downregulated as direct targets of miR-125b. Knockdown of these phosphatases induces tau hyperphosphorylation, and overexpression of PPP1CA and Bcl-W prevents miR-125b-induced tau phosphorylation, suggesting that they mediate the effects of miR-125b on tau. Conversely, suppression of miR-125b in neurons by tough decoys reduces tau phosphorylation and kinase expression/activity. Injecting miR-125b into the hippocampus of mice impairs associative learning and is accompanied by downregulation of Bcl-W, DUSP6, and PPP1CA, resulting in increased tau phosphorylation in vivo. Importantly, DUSP6 and PPP1CA are also reduced in AD brains.",
      "citation": {
        "type": "PubMed",
        "reference": "25001178",
        "name": "The EMBO journal",
        "title": "MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease.",
        "volume": "33",
        "pages": "1667-80",
        "date": "2014-08-01",
        "first": "Banzhaf-Strathmann J",
        "last": "Edbauer D",
        "authors": [
          "Arzberger T",
          "Banzhaf-Strathmann J",
          "Benito E",
          "Edbauer D",
          "Fischer A",
          "Kretzschmar H",
          "May S",
          "Tahirovic S"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 652,
      "target": 516,
      "key": "35d341a2d86baf18fb93a28bc91a8b728a9580cbf508b56cc4bf99445b21d958e5e05bf1e0351c3a62642d4bea7a9e52d9d776ff7516bc06e1d847e348323a21"
    },
    {
      "line": 3756,
      "relation": "regulates",
      "evidence": "The growth arrest and DNA damage protein (GADD) 34 is up-regulated in response to ER stress and regulates subunit of protein phosphatase 1 (PP1) complex that dephosphorylates eukaryotic translation initiator factor 2α (elF2α).",
      "citation": {
        "type": "PubMed",
        "reference": "26142647",
        "name": "Neuroscience letters",
        "title": "Increased GADD34 in oligodendrocytes in Alzheimer's disease.",
        "volume": "602",
        "pages": "50-5",
        "date": "2015-08-18",
        "first": "Honjo Y",
        "last": "Kawakami K",
        "authors": [
          "Ayaki T",
          "Honjo Y",
          "Horibe T",
          "Ito H",
          "Kawakami K",
          "Mori H",
          "Takahashi R",
          "Tomiyama T"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 654,
      "target": 652,
      "key": "08c2b9459346858395a0c6d795980ba9f870a49a83b5b536557a24a5e554aa42bd1772a2bf3e06aee2d5df42acff600a040877c4f0f0cfb777b77554bc8e34bd"
    },
    {
      "relation": "hasVariant",
      "source": 445,
      "target": 446,
      "key": "e16ce97626ff0848c0e3a6a250b01d22525b3eb8963e68259e8930ae75d8bfbbc3de54568705254d0b61a215a6932ec17ada476ca7355f25b10639066d7c9cb0"
    },
    {
      "line": 3764,
      "relation": "decreases",
      "evidence": "These findings suggest a scenario in which MC-LR-mediated demethylation of PP2Ac is associated with GSK-3β phosphorylation at Ser9 and contributes to dissociation of Bα from PP2Ac, which would result in Bα degradation and disruption of PP2A/Bα-tau interactions, thus promoting tau hyperphosphorylation and paired helical filaments-tau accumulation and, consequently, axonal degeneration and cell death.",
      "citation": {
        "type": "PubMed",
        "reference": "29228318",
        "name": "Toxicological sciences : an official journal of the Society of Toxicology",
        "title": "Microcystin-Leucine-Arginine Induces Tau Pathology Through Bα Degradation via Protein Phosphatase 2A Demethylation and Associated Glycogen Synthase Kinase-3β Phosphorylation.",
        "volume": "162",
        "pages": "475-487",
        "date": "2018-04-01",
        "first": "Zhang Y",
        "last": "Yuan T",
        "authors": [
          "Fan Y",
          "Feng Y",
          "Li Y",
          "Qian W",
          "Wang E",
          "Wang Y",
          "Yin H",
          "Yuan T",
          "Zhang J",
          "Zhang Y"
        ]
      },
      "source": 25,
      "target": 658,
      "key": "1b6b4bb35850ea5486f928f6f2baaeda70e6c110bc5b34af9d837460bbde93c5413f91457976b3958377d4ea1330be6220b7d7d6bfcdd718a0262d0a2b477978"
    },
    {
      "line": 3777,
      "relation": "negativeCorrelation",
      "evidence": "Interestingly, the middle-aged rats have higher levels of PTP-1B, lower phosphorylation of IRS-1, Akt, GSK3β, mTOR, and TrkB. Also, the aging process increased Tau phosphorylation and β-amyloid content in the hippocampus region. In summary, this study provides new evidence that aging-related PTP1B increasing, contributing to insulin resistance and the onset of the AD.",
      "citation": {
        "type": "PubMed",
        "reference": "29421605",
        "name": "Experimental gerontology",
        "title": "Impaired insulin signaling and spatial learning in middle-aged rats: The role of PTP1B.",
        "volume": "104",
        "pages": "66-71",
        "date": "2018-04-01",
        "first": "Kuga GK",
        "last": "Pauli JR",
        "authors": [
          "Botezelli JD",
          "Cintra DE",
          "Gaspar RC",
          "Gomes RJ",
          "Kuga GK",
          "Leme JACA",
          "Muñoz VR",
          "Nakandakari SCBR",
          "Pauli JR",
          "Ropelle ER",
          "da Silva ASR",
          "de Moura LP"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 899,
      "target": 870,
      "key": "cfcbad0187e77cecdfe84b50fe128600513235319ec1871ed5cbc5c915401087abc40ed44154f1fb48f12c06042626b831f88156129a93b0b27620cc64bec03e"
    },
    {
      "line": 3778,
      "relation": "negativeCorrelation",
      "evidence": "Interestingly, the middle-aged rats have higher levels of PTP-1B, lower phosphorylation of IRS-1, Akt, GSK3β, mTOR, and TrkB. Also, the aging process increased Tau phosphorylation and β-amyloid content in the hippocampus region. In summary, this study provides new evidence that aging-related PTP1B increasing, contributing to insulin resistance and the onset of the AD.",
      "citation": {
        "type": "PubMed",
        "reference": "29421605",
        "name": "Experimental gerontology",
        "title": "Impaired insulin signaling and spatial learning in middle-aged rats: The role of PTP1B.",
        "volume": "104",
        "pages": "66-71",
        "date": "2018-04-01",
        "first": "Kuga GK",
        "last": "Pauli JR",
        "authors": [
          "Botezelli JD",
          "Cintra DE",
          "Gaspar RC",
          "Gomes RJ",
          "Kuga GK",
          "Leme JACA",
          "Muñoz VR",
          "Nakandakari SCBR",
          "Pauli JR",
          "Ropelle ER",
          "da Silva ASR",
          "de Moura LP"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 899,
      "target": 857,
      "key": "a6fbf16168be0c80090963d85ac2095b531cfd3c24e700797dbc56eaa16072f1d5996bb9fea2139a0b400460f1865133c9174e4fe8c6d311a4385b3e67b38994"
    },
    {
      "line": 3779,
      "relation": "negativeCorrelation",
      "evidence": "Interestingly, the middle-aged rats have higher levels of PTP-1B, lower phosphorylation of IRS-1, Akt, GSK3β, mTOR, and TrkB. Also, the aging process increased Tau phosphorylation and β-amyloid content in the hippocampus region. In summary, this study provides new evidence that aging-related PTP1B increasing, contributing to insulin resistance and the onset of the AD.",
      "citation": {
        "type": "PubMed",
        "reference": "29421605",
        "name": "Experimental gerontology",
        "title": "Impaired insulin signaling and spatial learning in middle-aged rats: The role of PTP1B.",
        "volume": "104",
        "pages": "66-71",
        "date": "2018-04-01",
        "first": "Kuga GK",
        "last": "Pauli JR",
        "authors": [
          "Botezelli JD",
          "Cintra DE",
          "Gaspar RC",
          "Gomes RJ",
          "Kuga GK",
          "Leme JACA",
          "Muñoz VR",
          "Nakandakari SCBR",
          "Pauli JR",
          "Ropelle ER",
          "da Silva ASR",
          "de Moura LP"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 899,
      "target": 867,
      "key": "da4bdd74e6ff9f1231d890e32efc77df3b73194e68ca884bd93decf2a5e265f80bd24bd6869689908f19edbf155ccd4483c2ace21d5ef5c8cb84b31f4f7af49e"
    },
    {
      "line": 3780,
      "relation": "negativeCorrelation",
      "evidence": "Interestingly, the middle-aged rats have higher levels of PTP-1B, lower phosphorylation of IRS-1, Akt, GSK3β, mTOR, and TrkB. Also, the aging process increased Tau phosphorylation and β-amyloid content in the hippocampus region. In summary, this study provides new evidence that aging-related PTP1B increasing, contributing to insulin resistance and the onset of the AD.",
      "citation": {
        "type": "PubMed",
        "reference": "29421605",
        "name": "Experimental gerontology",
        "title": "Impaired insulin signaling and spatial learning in middle-aged rats: The role of PTP1B.",
        "volume": "104",
        "pages": "66-71",
        "date": "2018-04-01",
        "first": "Kuga GK",
        "last": "Pauli JR",
        "authors": [
          "Botezelli JD",
          "Cintra DE",
          "Gaspar RC",
          "Gomes RJ",
          "Kuga GK",
          "Leme JACA",
          "Muñoz VR",
          "Nakandakari SCBR",
          "Pauli JR",
          "Ropelle ER",
          "da Silva ASR",
          "de Moura LP"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 899,
      "target": 888,
      "key": "f3f9bdc14856c6548fb59bf276cd1c426ca1141bab8a8e1113ed5f5a03941ccb6850cecef253c507d6e291f3bed63e06d2ab1e61063f45ce3df3b1e6fbcbd7f1"
    },
    {
      "line": 3781,
      "relation": "negativeCorrelation",
      "evidence": "Interestingly, the middle-aged rats have higher levels of PTP-1B, lower phosphorylation of IRS-1, Akt, GSK3β, mTOR, and TrkB. Also, the aging process increased Tau phosphorylation and β-amyloid content in the hippocampus region. In summary, this study provides new evidence that aging-related PTP1B increasing, contributing to insulin resistance and the onset of the AD.",
      "citation": {
        "type": "PubMed",
        "reference": "29421605",
        "name": "Experimental gerontology",
        "title": "Impaired insulin signaling and spatial learning in middle-aged rats: The role of PTP1B.",
        "volume": "104",
        "pages": "66-71",
        "date": "2018-04-01",
        "first": "Kuga GK",
        "last": "Pauli JR",
        "authors": [
          "Botezelli JD",
          "Cintra DE",
          "Gaspar RC",
          "Gomes RJ",
          "Kuga GK",
          "Leme JACA",
          "Muñoz VR",
          "Nakandakari SCBR",
          "Pauli JR",
          "Ropelle ER",
          "da Silva ASR",
          "de Moura LP"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 899,
      "target": 894,
      "key": "5cc40e1eb7e3311f3b015d3b0a600a65c27f1aac2d0b7db882349706246ed1061106c85a546105b53d86c6f84b7b87856c1c2510816185f6a7d65092ec958f29"
    },
    {
      "line": 3777,
      "relation": "negativeCorrelation",
      "evidence": "Interestingly, the middle-aged rats have higher levels of PTP-1B, lower phosphorylation of IRS-1, Akt, GSK3β, mTOR, and TrkB. Also, the aging process increased Tau phosphorylation and β-amyloid content in the hippocampus region. In summary, this study provides new evidence that aging-related PTP1B increasing, contributing to insulin resistance and the onset of the AD.",
      "citation": {
        "type": "PubMed",
        "reference": "29421605",
        "name": "Experimental gerontology",
        "title": "Impaired insulin signaling and spatial learning in middle-aged rats: The role of PTP1B.",
        "volume": "104",
        "pages": "66-71",
        "date": "2018-04-01",
        "first": "Kuga GK",
        "last": "Pauli JR",
        "authors": [
          "Botezelli JD",
          "Cintra DE",
          "Gaspar RC",
          "Gomes RJ",
          "Kuga GK",
          "Leme JACA",
          "Muñoz VR",
          "Nakandakari SCBR",
          "Pauli JR",
          "Ropelle ER",
          "da Silva ASR",
          "de Moura LP"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 870,
      "target": 899,
      "key": "b432674584db1c041fba1ba6bc0e615931c9371f799707a630070849c34db98414d7d8ae32837b03b2b890c2c6bf41cfa4351b7c5c8dc65bb6c59273f4479e8e"
    },
    {
      "relation": "hasVariant",
      "source": 869,
      "target": 870,
      "key": "b79606a96c98d2a4d6b15154347c9c226c7937506a996c2d38269fd539313bdac2dc419e722522596972e71fef38c7fcb0bff9bc47b9414d8d2c76f02497031f"
    },
    {
      "line": 3778,
      "relation": "negativeCorrelation",
      "evidence": "Interestingly, the middle-aged rats have higher levels of PTP-1B, lower phosphorylation of IRS-1, Akt, GSK3β, mTOR, and TrkB. Also, the aging process increased Tau phosphorylation and β-amyloid content in the hippocampus region. In summary, this study provides new evidence that aging-related PTP1B increasing, contributing to insulin resistance and the onset of the AD.",
      "citation": {
        "type": "PubMed",
        "reference": "29421605",
        "name": "Experimental gerontology",
        "title": "Impaired insulin signaling and spatial learning in middle-aged rats: The role of PTP1B.",
        "volume": "104",
        "pages": "66-71",
        "date": "2018-04-01",
        "first": "Kuga GK",
        "last": "Pauli JR",
        "authors": [
          "Botezelli JD",
          "Cintra DE",
          "Gaspar RC",
          "Gomes RJ",
          "Kuga GK",
          "Leme JACA",
          "Muñoz VR",
          "Nakandakari SCBR",
          "Pauli JR",
          "Ropelle ER",
          "da Silva ASR",
          "de Moura LP"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 857,
      "target": 899,
      "key": "ee6e27f00efd071cd74f457dfffab7ec459a328a6f3b9c5adc1d5f1e9d5393dd1d4049fae40b3837db455d291cd8495b2a2a70a522be5dbd4efa38f1f87454ae"
    },
    {
      "relation": "hasVariant",
      "source": 856,
      "target": 857,
      "key": "5aabefef64b861b3347d30cf92339457662d6e5841b0538b7cd77df5e92e30e62761115c7d5ad684a8f9b6c15f7065870e63ae71f51ce2d75a25f17f43e4a438"
    },
    {
      "line": 3779,
      "relation": "negativeCorrelation",
      "evidence": "Interestingly, the middle-aged rats have higher levels of PTP-1B, lower phosphorylation of IRS-1, Akt, GSK3β, mTOR, and TrkB. Also, the aging process increased Tau phosphorylation and β-amyloid content in the hippocampus region. In summary, this study provides new evidence that aging-related PTP1B increasing, contributing to insulin resistance and the onset of the AD.",
      "citation": {
        "type": "PubMed",
        "reference": "29421605",
        "name": "Experimental gerontology",
        "title": "Impaired insulin signaling and spatial learning in middle-aged rats: The role of PTP1B.",
        "volume": "104",
        "pages": "66-71",
        "date": "2018-04-01",
        "first": "Kuga GK",
        "last": "Pauli JR",
        "authors": [
          "Botezelli JD",
          "Cintra DE",
          "Gaspar RC",
          "Gomes RJ",
          "Kuga GK",
          "Leme JACA",
          "Muñoz VR",
          "Nakandakari SCBR",
          "Pauli JR",
          "Ropelle ER",
          "da Silva ASR",
          "de Moura LP"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 867,
      "target": 899,
      "key": "d84820ac28b7bbe416c0e9a267bd9a14e1667cfecbed1b7675f6e5acad08412cd6b45621e30807c231efc40cf39d4d3a3177c21d8d74b8c153e114a5774594eb"
    },
    {
      "line": 3780,
      "relation": "negativeCorrelation",
      "evidence": "Interestingly, the middle-aged rats have higher levels of PTP-1B, lower phosphorylation of IRS-1, Akt, GSK3β, mTOR, and TrkB. Also, the aging process increased Tau phosphorylation and β-amyloid content in the hippocampus region. In summary, this study provides new evidence that aging-related PTP1B increasing, contributing to insulin resistance and the onset of the AD.",
      "citation": {
        "type": "PubMed",
        "reference": "29421605",
        "name": "Experimental gerontology",
        "title": "Impaired insulin signaling and spatial learning in middle-aged rats: The role of PTP1B.",
        "volume": "104",
        "pages": "66-71",
        "date": "2018-04-01",
        "first": "Kuga GK",
        "last": "Pauli JR",
        "authors": [
          "Botezelli JD",
          "Cintra DE",
          "Gaspar RC",
          "Gomes RJ",
          "Kuga GK",
          "Leme JACA",
          "Muñoz VR",
          "Nakandakari SCBR",
          "Pauli JR",
          "Ropelle ER",
          "da Silva ASR",
          "de Moura LP"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 888,
      "target": 899,
      "key": "edbcc7553e12f015c2a29c6a52490f1834ff3817c10d668383acb691aa2e283b761d53aff512380d912b673b848d8adc171f37288fc1af68ccdd7ccbdcff5bb2"
    },
    {
      "relation": "hasVariant",
      "source": 887,
      "target": 888,
      "key": "253b95659825a676af8c96543c2096cdf1fff2be0efd78de516bfb251506c1a53df2ae83531144c9218c303103fe7cbe24d6ce45897bfe4bda5a20ff70c37649"
    },
    {
      "line": 3781,
      "relation": "negativeCorrelation",
      "evidence": "Interestingly, the middle-aged rats have higher levels of PTP-1B, lower phosphorylation of IRS-1, Akt, GSK3β, mTOR, and TrkB. Also, the aging process increased Tau phosphorylation and β-amyloid content in the hippocampus region. In summary, this study provides new evidence that aging-related PTP1B increasing, contributing to insulin resistance and the onset of the AD.",
      "citation": {
        "type": "PubMed",
        "reference": "29421605",
        "name": "Experimental gerontology",
        "title": "Impaired insulin signaling and spatial learning in middle-aged rats: The role of PTP1B.",
        "volume": "104",
        "pages": "66-71",
        "date": "2018-04-01",
        "first": "Kuga GK",
        "last": "Pauli JR",
        "authors": [
          "Botezelli JD",
          "Cintra DE",
          "Gaspar RC",
          "Gomes RJ",
          "Kuga GK",
          "Leme JACA",
          "Muñoz VR",
          "Nakandakari SCBR",
          "Pauli JR",
          "Ropelle ER",
          "da Silva ASR",
          "de Moura LP"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 894,
      "target": 899,
      "key": "78a598238193a2492bc6b9a88d55f9f3f9a51201cc4944d01de632482b13b23df98655e2cfc4cd3b09a9dee676f6a724ce092ea91ec6a1a47d7dc6a4002d0d2e"
    },
    {
      "relation": "hasVariant",
      "source": 893,
      "target": 894,
      "key": "cff444757509dee21edf2e19bffa2d522348d411658d5d3e490eeb1913f445c73ffdccbf6dd68dc1a6df25e5471ebc09529978e27bd37affb3a267d651dd7717"
    },
    {
      "line": 3789,
      "relation": "directlyIncreases",
      "evidence": "Here we show that resveratrol treatment directly interferes with the MID1-α4-PP2A degradation complex by reducing MID1 protein expression in vitro and in vivo. This leads to an increase of microtubule-associated PP2A activity and a time- and dose-dependent dephosphorylation of Tau. Interestingly, we further show that MID1 expression is elevated in AD tissue.",
      "citation": {
        "type": "PubMed",
        "reference": "29062069",
        "name": "Scientific reports",
        "title": "Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex.",
        "volume": "7",
        "pages": "13753",
        "date": "2017-10-23",
        "first": "Schweiger S",
        "last": "Krauß S",
        "authors": [
          "Ehninger D",
          "Hettich MM",
          "Kickstein E",
          "Krauß S",
          "Matthes F",
          "Pfurtscheller S",
          "Posey K",
          "Schneider R",
          "Schweiger S",
          "Weber S"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 68,
      "target": 657,
      "key": "9a8d0bf5a7bc193b068018252bc5b1d0c1a14b07213987ab5b73da1e2c232fa26f1f1d3ce2ef0e0118923ca5aaa7e1b302ba1f766eeeb84434adcdc67a8a50a4"
    },
    {
      "line": 3791,
      "relation": "directlyDecreases",
      "evidence": "Here we show that resveratrol treatment directly interferes with the MID1-α4-PP2A degradation complex by reducing MID1 protein expression in vitro and in vivo. This leads to an increase of microtubule-associated PP2A activity and a time- and dose-dependent dephosphorylation of Tau. Interestingly, we further show that MID1 expression is elevated in AD tissue.",
      "citation": {
        "type": "PubMed",
        "reference": "29062069",
        "name": "Scientific reports",
        "title": "Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex.",
        "volume": "7",
        "pages": "13753",
        "date": "2017-10-23",
        "first": "Schweiger S",
        "last": "Krauß S",
        "authors": [
          "Ehninger D",
          "Hettich MM",
          "Kickstein E",
          "Krauß S",
          "Matthes F",
          "Pfurtscheller S",
          "Posey K",
          "Schneider R",
          "Schweiger S",
          "Weber S"
        ]
      },
      "source": 68,
      "target": 639,
      "key": "0b5edf1912c1a9649a8059351714c6aa486acb7432ca7a1e3f024d3edebd68248e5aa64d17854d6562fb24aa963748a5d0266f869dbbd8867f2c1a07577848a5"
    },
    {
      "line": 3790,
      "relation": "decreases",
      "evidence": "Here we show that resveratrol treatment directly interferes with the MID1-α4-PP2A degradation complex by reducing MID1 protein expression in vitro and in vivo. This leads to an increase of microtubule-associated PP2A activity and a time- and dose-dependent dephosphorylation of Tau. Interestingly, we further show that MID1 expression is elevated in AD tissue.",
      "citation": {
        "type": "PubMed",
        "reference": "29062069",
        "name": "Scientific reports",
        "title": "Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex.",
        "volume": "7",
        "pages": "13753",
        "date": "2017-10-23",
        "first": "Schweiger S",
        "last": "Krauß S",
        "authors": [
          "Ehninger D",
          "Hettich MM",
          "Kickstein E",
          "Krauß S",
          "Matthes F",
          "Pfurtscheller S",
          "Posey K",
          "Schneider R",
          "Schweiger S",
          "Weber S"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 639,
      "target": 657,
      "key": "616551ff91eaeee3e3a0cf2f70d289c0c093ca6756828601f2ddcb37cbbc280974a8ab723bc1d49b6bb369b708ddc70819fee628e345e24ee0ff663da59244ed"
    },
    {
      "line": 3799,
      "relation": "partOf",
      "evidence": "Our results indicated a significant down-regulation of PPP2R5E gene expression and reduction in PP2A activity by ApoE4 compared with ApoE3. This may also explain an elevated Tau phosphorylation in AD human brains that featured at least one ApoE4 allele.",
      "citation": {
        "type": "PubMed",
        "reference": "28720530",
        "name": "Molecular and cellular neurosciences",
        "title": "Downregulation of protein phosphatase 2A by apolipoprotein E: Implications for Alzheimer's disease.",
        "volume": "83",
        "pages": "83-91",
        "date": "2017-09-01",
        "first": "Theendakara V",
        "last": "Rao RV",
        "authors": [
          "Bredesen DE",
          "Rao RV",
          "Theendakara V"
        ]
      },
      "source": 660,
      "target": 214,
      "key": "e5a8201ea95aad199680a56a0dae095bb836f08f795f1bed533e593ec3312159e2d4016d86c09776d17f1d949c495000db8c8ae96a1b2d153d6abd00aab6f9dc"
    },
    {
      "line": 3800,
      "relation": "negativeCorrelation",
      "evidence": "Our results indicated a significant down-regulation of PPP2R5E gene expression and reduction in PP2A activity by ApoE4 compared with ApoE3. This may also explain an elevated Tau phosphorylation in AD human brains that featured at least one ApoE4 allele.",
      "citation": {
        "type": "PubMed",
        "reference": "28720530",
        "name": "Molecular and cellular neurosciences",
        "title": "Downregulation of protein phosphatase 2A by apolipoprotein E: Implications for Alzheimer's disease.",
        "volume": "83",
        "pages": "83-91",
        "date": "2017-09-01",
        "first": "Theendakara V",
        "last": "Rao RV",
        "authors": [
          "Bredesen DE",
          "Rao RV",
          "Theendakara V"
        ]
      },
      "source": 214,
      "target": 309,
      "key": "74a14b5703dd0b7889127ea6ae938beb17b36e77d20aba9f345f122dea1fc8c5c70402e199de7c5b64bf78156dca82b1176f8c3b13934a165366423c54807dfa"
    },
    {
      "line": 3809,
      "relation": "decreases",
      "evidence": "Folic acid reduced tau hyperphosphorylation at Ser396 in the brain of diabetes mellitus (DM) mice. In addition, PP2A methylation and DNMT1 mRNA expression were significantly increased in DM mice post folic acid treatment. GSK-3β phosphorylation was not regulated by folic acid administration. Folic acid can reduce tau phosphorylation by regulating PP2A methylation in diabetic mice.",
      "citation": {
        "type": "PubMed",
        "reference": "28422052",
        "name": "International journal of molecular sciences",
        "title": "Folic Acid Reduces Tau Phosphorylation by Regulating PP2A Methylation in Streptozotocin-Induced Diabetic Mice.",
        "volume": "18",
        "date": "2017-04-19",
        "first": "Zheng M",
        "last": "Liu H",
        "authors": [
          "Gao Y",
          "Huang G",
          "Li M",
          "Liu H",
          "Zheng M",
          "Zou C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "streptozotocin (STZ)-induced DB murine model": true
        }
      },
      "source": 18,
      "target": 823,
      "key": "c09662cf1302b069aa76329654bce8fc48857aa5b833618942fae34edfbf06108596db0e470196d582392491464a4767f76130f631196db39fd67f5547250061"
    },
    {
      "line": 3810,
      "relation": "increases",
      "evidence": "Folic acid reduced tau hyperphosphorylation at Ser396 in the brain of diabetes mellitus (DM) mice. In addition, PP2A methylation and DNMT1 mRNA expression were significantly increased in DM mice post folic acid treatment. GSK-3β phosphorylation was not regulated by folic acid administration. Folic acid can reduce tau phosphorylation by regulating PP2A methylation in diabetic mice.",
      "citation": {
        "type": "PubMed",
        "reference": "28422052",
        "name": "International journal of molecular sciences",
        "title": "Folic Acid Reduces Tau Phosphorylation by Regulating PP2A Methylation in Streptozotocin-Induced Diabetic Mice.",
        "volume": "18",
        "date": "2017-04-19",
        "first": "Zheng M",
        "last": "Liu H",
        "authors": [
          "Gao Y",
          "Huang G",
          "Li M",
          "Liu H",
          "Zheng M",
          "Zou C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "streptozotocin (STZ)-induced DB murine model": true
        }
      },
      "source": 18,
      "target": 783,
      "key": "966dda5a8dfc5aeddf98ad17ca3a73d1922b344198fea6b859c29b2b392e3d472fd769d61f42e508dc151743fbb5030b491e1e282f48a8222db454863b3508a1"
    },
    {
      "line": 3811,
      "relation": "increases",
      "evidence": "Folic acid reduced tau hyperphosphorylation at Ser396 in the brain of diabetes mellitus (DM) mice. In addition, PP2A methylation and DNMT1 mRNA expression were significantly increased in DM mice post folic acid treatment. GSK-3β phosphorylation was not regulated by folic acid administration. Folic acid can reduce tau phosphorylation by regulating PP2A methylation in diabetic mice.",
      "citation": {
        "type": "PubMed",
        "reference": "28422052",
        "name": "International journal of molecular sciences",
        "title": "Folic Acid Reduces Tau Phosphorylation by Regulating PP2A Methylation in Streptozotocin-Induced Diabetic Mice.",
        "volume": "18",
        "date": "2017-04-19",
        "first": "Zheng M",
        "last": "Liu H",
        "authors": [
          "Gao Y",
          "Huang G",
          "Li M",
          "Liu H",
          "Zheng M",
          "Zou C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "streptozotocin (STZ)-induced DB murine model": true
        }
      },
      "source": 783,
      "target": 846,
      "key": "f52d7555dbc5eb550d3ed8e554397b4006375b83c2645261eaea0446725c4c792d74514a4a8294a4ae258b6401a8d79c8412b0f0ecb796096dc9c40fd5936901"
    },
    {
      "line": 3812,
      "relation": "decreases",
      "evidence": "Folic acid reduced tau hyperphosphorylation at Ser396 in the brain of diabetes mellitus (DM) mice. In addition, PP2A methylation and DNMT1 mRNA expression were significantly increased in DM mice post folic acid treatment. GSK-3β phosphorylation was not regulated by folic acid administration. Folic acid can reduce tau phosphorylation by regulating PP2A methylation in diabetic mice.",
      "citation": {
        "type": "PubMed",
        "reference": "28422052",
        "name": "International journal of molecular sciences",
        "title": "Folic Acid Reduces Tau Phosphorylation by Regulating PP2A Methylation in Streptozotocin-Induced Diabetic Mice.",
        "volume": "18",
        "date": "2017-04-19",
        "first": "Zheng M",
        "last": "Liu H",
        "authors": [
          "Gao Y",
          "Huang G",
          "Li M",
          "Liu H",
          "Zheng M",
          "Zou C"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "streptozotocin (STZ)-induced DB murine model": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 846,
      "target": 844,
      "key": "b4d8cff10af0e07647dc7009d8ed1f3f971830accff5bee24a08c06d31eb8153b7a3d4df1c27ead126bcdf12c9a1a9adc500b448b6a949d735cb4ea7cd49ea9b"
    },
    {
      "line": 3821,
      "relation": "negativeCorrelation",
      "evidence": "We found strong Tau hyperphosphorylation in brain samples from R6/2 and 140CAG Tg knock-in, associated with a significant reduction in the levels of Tau phosphatases (PP1, PP2A and PP2B), with no apparent involvement of major Tau kinases.",
      "citation": {
        "type": "PubMed",
        "reference": "25143394",
        "name": "Human molecular genetics",
        "title": "Mutant huntingtin alters Tau phosphorylation and subcellular distribution.",
        "volume": "24",
        "pages": "76-85",
        "date": "2015-01-01",
        "first": "Blum D",
        "last": "Outeiro TF",
        "authors": [
          "Basquin M",
          "Blum D",
          "Brouillet E",
          "Buée L",
          "Demeyer D",
          "Francelle L",
          "Gerhardt E",
          "Herrera F",
          "Mendes T",
          "Obriot H",
          "Outeiro TF",
          "Sergeant N"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "HD murine model": true
        }
      },
      "source": 840,
      "target": 808,
      "key": "a403339512dd3e695dc8ad9f8789e5a0e8875e0124b6a1ed33d445abee3f6d0ba347cc6308f1e1906bc20cefe0648aa9394d797f96576d77ad51bec402f27eed"
    },
    {
      "line": 3823,
      "relation": "negativeCorrelation",
      "evidence": "We found strong Tau hyperphosphorylation in brain samples from R6/2 and 140CAG Tg knock-in, associated with a significant reduction in the levels of Tau phosphatases (PP1, PP2A and PP2B), with no apparent involvement of major Tau kinases.",
      "citation": {
        "type": "PubMed",
        "reference": "25143394",
        "name": "Human molecular genetics",
        "title": "Mutant huntingtin alters Tau phosphorylation and subcellular distribution.",
        "volume": "24",
        "pages": "76-85",
        "date": "2015-01-01",
        "first": "Blum D",
        "last": "Outeiro TF",
        "authors": [
          "Basquin M",
          "Blum D",
          "Brouillet E",
          "Buée L",
          "Demeyer D",
          "Francelle L",
          "Gerhardt E",
          "Herrera F",
          "Mendes T",
          "Obriot H",
          "Outeiro TF",
          "Sergeant N"
        ]
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "Research_Model": {
          "HD murine model": true
        }
      },
      "source": 841,
      "target": 808,
      "key": "26d2ce11d552f44db8623f9629c9197139d8b5f2656896ff9199cf4a6aba9ccd71bfc7d9a186d348dc6d7abf7c630c585c0b53e3011442af14f354b1c511620c"
    },
    {
      "line": 3832,
      "relation": "decreases",
      "evidence": "PP2A expression decreased, whereas, PP1 and PP5 expression increased in lead-exposed rats. These results demonstrate that early postnatal exposure to lead decrease PP2A expression and induce tau hyperphosphorylation at several serine and threonine residues.",
      "citation": {
        "type": "PubMed",
        "reference": "23134599",
        "name": "Acta biologica Hungarica",
        "title": "Early postnatal lead exposure induces tau phosphorylation in the brain of young rats.",
        "volume": "63",
        "pages": "411-25",
        "date": "2012-12-01",
        "first": "Rahman A",
        "last": "Attur S",
        "authors": [
          "Al-Khaledi G",
          "Attur S",
          "Khan I",
          "Khan KM",
          "Rahman A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 22,
      "target": 897,
      "key": "2a2c8864cf146c8dfbb13c10ce5b16403dde98fb199d9a3bc0dabf58309b6ecd99fb05c487ca7ab70d014668addb16942c768557b6d7c8d512c498f026fcd27c"
    },
    {
      "line": 3833,
      "relation": "increases",
      "evidence": "PP2A expression decreased, whereas, PP1 and PP5 expression increased in lead-exposed rats. These results demonstrate that early postnatal exposure to lead decrease PP2A expression and induce tau hyperphosphorylation at several serine and threonine residues.",
      "citation": {
        "type": "PubMed",
        "reference": "23134599",
        "name": "Acta biologica Hungarica",
        "title": "Early postnatal lead exposure induces tau phosphorylation in the brain of young rats.",
        "volume": "63",
        "pages": "411-25",
        "date": "2012-12-01",
        "first": "Rahman A",
        "last": "Attur S",
        "authors": [
          "Al-Khaledi G",
          "Attur S",
          "Khan I",
          "Khan KM",
          "Rahman A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 22,
      "target": 896,
      "key": "6250535682ef2f911fdde8d2fd37e5ce57fcf9d27903762649dd8064886b9eb2a2050b2f7534e0017f002de1a1ee077528d7c95e158e7cfb900963d2a7eafeca"
    },
    {
      "line": 3834,
      "relation": "increases",
      "evidence": "PP2A expression decreased, whereas, PP1 and PP5 expression increased in lead-exposed rats. These results demonstrate that early postnatal exposure to lead decrease PP2A expression and induce tau hyperphosphorylation at several serine and threonine residues.",
      "citation": {
        "type": "PubMed",
        "reference": "23134599",
        "name": "Acta biologica Hungarica",
        "title": "Early postnatal lead exposure induces tau phosphorylation in the brain of young rats.",
        "volume": "63",
        "pages": "411-25",
        "date": "2012-12-01",
        "first": "Rahman A",
        "last": "Attur S",
        "authors": [
          "Al-Khaledi G",
          "Attur S",
          "Khan I",
          "Khan KM",
          "Rahman A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 22,
      "target": 898,
      "key": "994d2082c202ec5a136c8957a4f67ff9556553d1c00f450b708e9a029e29cd2bf119120d971b4b591fd651a075c629ae07b91b08628cbd85ee1b426b5cce89ef"
    },
    {
      "line": 3835,
      "relation": "negativeCorrelation",
      "evidence": "PP2A expression decreased, whereas, PP1 and PP5 expression increased in lead-exposed rats. These results demonstrate that early postnatal exposure to lead decrease PP2A expression and induce tau hyperphosphorylation at several serine and threonine residues.",
      "citation": {
        "type": "PubMed",
        "reference": "23134599",
        "name": "Acta biologica Hungarica",
        "title": "Early postnatal lead exposure induces tau phosphorylation in the brain of young rats.",
        "volume": "63",
        "pages": "411-25",
        "date": "2012-12-01",
        "first": "Rahman A",
        "last": "Attur S",
        "authors": [
          "Al-Khaledi G",
          "Attur S",
          "Khan I",
          "Khan KM",
          "Rahman A"
        ]
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 897,
      "target": 808,
      "key": "aba5ca82f9e28ceb77aef3533ec107a1ba673737c40a1d9c500f82673af2b84de00d353388f9adcad3ab94386a9b6b687ba557c5d3fb4ceb9c9fb7b0b3b899a7"
    },
    {
      "line": 3864,
      "relation": "directlyIncreases",
      "evidence": "In NGF-exposed PC12 cells, Egr-1 activates Cdk5 to promote phosphorylation of tau and inactivates PP1 via phosphorylation. Cdk5 phosphorylates Ser(396/404) directly. By phosphorylating and inactivating PP1, Cdk5 promotes tau phosphorylation at Ser(262) indirectly.",
      "citation": {
        "type": "PubMed",
        "reference": "21489990",
        "name": "The Journal of biological chemistry",
        "title": "Early growth response 1 (Egr-1) regulates phosphorylation of microtubule-associated protein tau in mammalian brain.",
        "volume": "286",
        "pages": "20569-81",
        "date": "2011-06-10",
        "first": "Lu Y",
        "last": "Paudel HK",
        "authors": [
          "Han D",
          "Li T",
          "Lu Y",
          "Paudel HK",
          "Qureshi HY"
        ]
      },
      "annotations": {
        "CellLine": {
          "PC12": true
        },
        "Species": {
          "10116": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 896,
      "target": 879,
      "key": "c3e46e1f6b0fabdba6a7b3c25910dd34ff432e984e66a79da6f047ceb52c801faaf698052bca67f99f891e93114b9ab818bf09afb376659fadc0b526e25aa54d"
    },
    {
      "line": 3860,
      "relation": "directlyIncreases",
      "evidence": "In NGF-exposed PC12 cells, Egr-1 activates Cdk5 to promote phosphorylation of tau and inactivates PP1 via phosphorylation. Cdk5 phosphorylates Ser(396/404) directly. By phosphorylating and inactivating PP1, Cdk5 promotes tau phosphorylation at Ser(262) indirectly.",
      "citation": {
        "type": "PubMed",
        "reference": "21489990",
        "name": "The Journal of biological chemistry",
        "title": "Early growth response 1 (Egr-1) regulates phosphorylation of microtubule-associated protein tau in mammalian brain.",
        "volume": "286",
        "pages": "20569-81",
        "date": "2011-06-10",
        "first": "Lu Y",
        "last": "Paudel HK",
        "authors": [
          "Han D",
          "Li T",
          "Lu Y",
          "Paudel HK",
          "Qureshi HY"
        ]
      },
      "annotations": {
        "CellLine": {
          "PC12": true
        },
        "Species": {
          "10116": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 864,
      "target": 860,
      "key": "877dffba3cfa357f7af2bd627c25ef63ee3f496adda16545b7ccbb041524f42fa5090681bde8006f90258476529c2e4ba496b78e32a4e0ba02697aa0b303388e"
    },
    {
      "line": 3873,
      "relation": "decreases",
      "evidence": "Kynurenic pathway is overactive in AD. QA is co-localized with hyperphosphorylated tau within cortical neurons in AD brain. In primary cultures of human neurons, QA treatment increased tau phosphorylation at serine 199/202, threonine 231 and serine 396/404 in a dose dependent manner. This increase in tau phosphorylation was paralleled by a substantial decrease in the total protein phosphatase activity, mostly in PP2A expression and modest in PP1.",
      "citation": {
        "type": "PubMed",
        "reference": "19623258",
        "name": "PloS one",
        "title": "The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.",
        "volume": "4",
        "pages": "e6344",
        "date": "2009-07-22",
        "first": "Rahman A",
        "last": "Guillemin GJ",
        "authors": [
          "Braidy N",
          "Brew BJ",
          "Cullen KM",
          "Guillemin GJ",
          "Rahman A",
          "Ting K"
        ]
      },
      "source": 31,
      "target": 657,
      "key": "e95ee0fd7b068007e8197f6c8a764968b955669c537c47dbf2376e2765115772d90b766e5a63b47fbe4b1e4944cbfc3f7ce97310458e93d679e4a1d4bb3412a1"
    },
    {
      "line": 3874,
      "relation": "decreases",
      "evidence": "Kynurenic pathway is overactive in AD. QA is co-localized with hyperphosphorylated tau within cortical neurons in AD brain. In primary cultures of human neurons, QA treatment increased tau phosphorylation at serine 199/202, threonine 231 and serine 396/404 in a dose dependent manner. This increase in tau phosphorylation was paralleled by a substantial decrease in the total protein phosphatase activity, mostly in PP2A expression and modest in PP1.",
      "citation": {
        "type": "PubMed",
        "reference": "19623258",
        "name": "PloS one",
        "title": "The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.",
        "volume": "4",
        "pages": "e6344",
        "date": "2009-07-22",
        "first": "Rahman A",
        "last": "Guillemin GJ",
        "authors": [
          "Braidy N",
          "Brew BJ",
          "Cullen KM",
          "Guillemin GJ",
          "Rahman A",
          "Ting K"
        ]
      },
      "source": 31,
      "target": 652,
      "key": "85f2f9c1fc972c4b57e83c3f97ac2a3073b1726dbc8f74fec928e60c301d3b779e920082dbee450aecb1e069c53f86d94aa43e333a7b1ba2b1dc79fca941f36d"
    },
    {
      "line": 3875,
      "relation": "directlyIncreases",
      "evidence": "Kynurenic pathway is overactive in AD. QA is co-localized with hyperphosphorylated tau within cortical neurons in AD brain. In primary cultures of human neurons, QA treatment increased tau phosphorylation at serine 199/202, threonine 231 and serine 396/404 in a dose dependent manner. This increase in tau phosphorylation was paralleled by a substantial decrease in the total protein phosphatase activity, mostly in PP2A expression and modest in PP1.",
      "citation": {
        "type": "PubMed",
        "reference": "19623258",
        "name": "PloS one",
        "title": "The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.",
        "volume": "4",
        "pages": "e6344",
        "date": "2009-07-22",
        "first": "Rahman A",
        "last": "Guillemin GJ",
        "authors": [
          "Braidy N",
          "Brew BJ",
          "Cullen KM",
          "Guillemin GJ",
          "Rahman A",
          "Ting K"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 31,
      "target": 209,
      "key": "fc4bdc7cc060502abc8ab9afff5f027dd1b7ca3304593ec9d80d2250cf51b71da3e668e05ebfb692fea1e7354c7ec5e4b8f8d3d4971e5b4aa27ecec7617cc86a"
    },
    {
      "line": 3884,
      "relation": "increases",
      "evidence": "Using PCR arrays, QA significantly induces 10 genes in human neurons known to be associated with AD pathology with 6 belonging to pathways involved in tau phosphorylation and 4 of them in neuroprotection.",
      "citation": {
        "type": "PubMed",
        "reference": "19623258",
        "name": "PloS one",
        "title": "The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.",
        "volume": "4",
        "pages": "e6344",
        "date": "2009-07-22",
        "first": "Rahman A",
        "last": "Guillemin GJ",
        "authors": [
          "Braidy N",
          "Brew BJ",
          "Cullen KM",
          "Guillemin GJ",
          "Rahman A",
          "Ting K"
        ]
      },
      "source": 31,
      "target": 924,
      "key": "4c9dcfa6571d6f983212426afbda54ae027821f5c5ead8dade8339f0b77b3208833697cfe540e65586f5c8ea8e697eb1f340c543a4fe05770391b81abc55f53e"
    },
    {
      "line": 3885,
      "relation": "increases",
      "evidence": "Using PCR arrays, QA significantly induces 10 genes in human neurons known to be associated with AD pathology with 6 belonging to pathways involved in tau phosphorylation and 4 of them in neuroprotection.",
      "citation": {
        "type": "PubMed",
        "reference": "19623258",
        "name": "PloS one",
        "title": "The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.",
        "volume": "4",
        "pages": "e6344",
        "date": "2009-07-22",
        "first": "Rahman A",
        "last": "Guillemin GJ",
        "authors": [
          "Braidy N",
          "Brew BJ",
          "Cullen KM",
          "Guillemin GJ",
          "Rahman A",
          "Ting K"
        ]
      },
      "source": 31,
      "target": 933,
      "key": "1ac8892d4de9b99dc10b6dc25552b9bc3c05397ed8f4f196c17f1261e1178be58aa1e898ab8171c5e0cfc505a0e4624988922eb1952744e71f570f95f7f9f1a2"
    },
    {
      "line": 3886,
      "relation": "increases",
      "evidence": "Using PCR arrays, QA significantly induces 10 genes in human neurons known to be associated with AD pathology with 6 belonging to pathways involved in tau phosphorylation and 4 of them in neuroprotection.",
      "citation": {
        "type": "PubMed",
        "reference": "19623258",
        "name": "PloS one",
        "title": "The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.",
        "volume": "4",
        "pages": "e6344",
        "date": "2009-07-22",
        "first": "Rahman A",
        "last": "Guillemin GJ",
        "authors": [
          "Braidy N",
          "Brew BJ",
          "Cullen KM",
          "Guillemin GJ",
          "Rahman A",
          "Ting K"
        ]
      },
      "source": 31,
      "target": 939,
      "key": "52527bf70337749e4e98d0f222a9dcb156e2f183296bc5e594e4d8eb4ceda22c459c90af1ea25644a9fb269ed8c87d277fddd52af28be82eed53cbe51ef365a1"
    },
    {
      "line": 3887,
      "relation": "increases",
      "evidence": "Using PCR arrays, QA significantly induces 10 genes in human neurons known to be associated with AD pathology with 6 belonging to pathways involved in tau phosphorylation and 4 of them in neuroprotection.",
      "citation": {
        "type": "PubMed",
        "reference": "19623258",
        "name": "PloS one",
        "title": "The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.",
        "volume": "4",
        "pages": "e6344",
        "date": "2009-07-22",
        "first": "Rahman A",
        "last": "Guillemin GJ",
        "authors": [
          "Braidy N",
          "Brew BJ",
          "Cullen KM",
          "Guillemin GJ",
          "Rahman A",
          "Ting K"
        ]
      },
      "source": 31,
      "target": 938,
      "key": "3170d05f92a779247486da24be5dbd352c51db152271e3bf12729f86e8ef95e899e161ca28ab224164c95be68af33bdc6e2199dbd8889d82ad4291a14539d7f0"
    },
    {
      "line": 3888,
      "relation": "increases",
      "evidence": "Using PCR arrays, QA significantly induces 10 genes in human neurons known to be associated with AD pathology with 6 belonging to pathways involved in tau phosphorylation and 4 of them in neuroprotection.",
      "citation": {
        "type": "PubMed",
        "reference": "19623258",
        "name": "PloS one",
        "title": "The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.",
        "volume": "4",
        "pages": "e6344",
        "date": "2009-07-22",
        "first": "Rahman A",
        "last": "Guillemin GJ",
        "authors": [
          "Braidy N",
          "Brew BJ",
          "Cullen KM",
          "Guillemin GJ",
          "Rahman A",
          "Ting K"
        ]
      },
      "source": 31,
      "target": 925,
      "key": "63ce8ba388ed20ba73daf126228be4e98c78f683f91882318dbc024d3af01a94efb6bc8b8c65de51cb7f339ac4b881fc8060741a880bee2abf01e2603bfccd43"
    },
    {
      "line": 3889,
      "relation": "increases",
      "evidence": "Using PCR arrays, QA significantly induces 10 genes in human neurons known to be associated with AD pathology with 6 belonging to pathways involved in tau phosphorylation and 4 of them in neuroprotection.",
      "citation": {
        "type": "PubMed",
        "reference": "19623258",
        "name": "PloS one",
        "title": "The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.",
        "volume": "4",
        "pages": "e6344",
        "date": "2009-07-22",
        "first": "Rahman A",
        "last": "Guillemin GJ",
        "authors": [
          "Braidy N",
          "Brew BJ",
          "Cullen KM",
          "Guillemin GJ",
          "Rahman A",
          "Ting K"
        ]
      },
      "source": 31,
      "target": 931,
      "key": "b3bc8b2a1c1340439bba4fea0b70941f4b6904410501533aab59e0a548c076821eb6fa1fc8b9b02beba694dde54dd6917ec3d2a2762ed86c7ee892eb3d5b92be"
    },
    {
      "line": 3890,
      "relation": "increases",
      "evidence": "Using PCR arrays, QA significantly induces 10 genes in human neurons known to be associated with AD pathology with 6 belonging to pathways involved in tau phosphorylation and 4 of them in neuroprotection.",
      "citation": {
        "type": "PubMed",
        "reference": "19623258",
        "name": "PloS one",
        "title": "The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.",
        "volume": "4",
        "pages": "e6344",
        "date": "2009-07-22",
        "first": "Rahman A",
        "last": "Guillemin GJ",
        "authors": [
          "Braidy N",
          "Brew BJ",
          "Cullen KM",
          "Guillemin GJ",
          "Rahman A",
          "Ting K"
        ]
      },
      "source": 31,
      "target": 934,
      "key": "2dfad8c24c81e4e67d9c6d05c95f0d230220f1af924c2afcfcd640b46a7407a45f47ef8279e42b3bc317cf13b1acbdf641b35d09938aef4f7a1f199e93df519b"
    },
    {
      "line": 3891,
      "relation": "increases",
      "evidence": "Using PCR arrays, QA significantly induces 10 genes in human neurons known to be associated with AD pathology with 6 belonging to pathways involved in tau phosphorylation and 4 of them in neuroprotection.",
      "citation": {
        "type": "PubMed",
        "reference": "19623258",
        "name": "PloS one",
        "title": "The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.",
        "volume": "4",
        "pages": "e6344",
        "date": "2009-07-22",
        "first": "Rahman A",
        "last": "Guillemin GJ",
        "authors": [
          "Braidy N",
          "Brew BJ",
          "Cullen KM",
          "Guillemin GJ",
          "Rahman A",
          "Ting K"
        ]
      },
      "source": 31,
      "target": 926,
      "key": "f565e5c228ba5b22f8150bf663d0fb7d8af1655172a549179faa5dc35605bccfb234fb58f875f3719bc445795dc45bf68af00e40238d3c5d58d294b9ce36d733"
    },
    {
      "line": 3892,
      "relation": "increases",
      "evidence": "Using PCR arrays, QA significantly induces 10 genes in human neurons known to be associated with AD pathology with 6 belonging to pathways involved in tau phosphorylation and 4 of them in neuroprotection.",
      "citation": {
        "type": "PubMed",
        "reference": "19623258",
        "name": "PloS one",
        "title": "The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.",
        "volume": "4",
        "pages": "e6344",
        "date": "2009-07-22",
        "first": "Rahman A",
        "last": "Guillemin GJ",
        "authors": [
          "Braidy N",
          "Brew BJ",
          "Cullen KM",
          "Guillemin GJ",
          "Rahman A",
          "Ting K"
        ]
      },
      "source": 31,
      "target": 927,
      "key": "545a16f88fefef7568b7f32acb31b26ee04d87d26fddc51f3a0a023a98eca55c8fa55cfc0b78b92ffc94e37324cc5affb1a162268e95146c04ff251b648eb8a4"
    },
    {
      "line": 3893,
      "relation": "increases",
      "evidence": "Using PCR arrays, QA significantly induces 10 genes in human neurons known to be associated with AD pathology with 6 belonging to pathways involved in tau phosphorylation and 4 of them in neuroprotection.",
      "citation": {
        "type": "PubMed",
        "reference": "19623258",
        "name": "PloS one",
        "title": "The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.",
        "volume": "4",
        "pages": "e6344",
        "date": "2009-07-22",
        "first": "Rahman A",
        "last": "Guillemin GJ",
        "authors": [
          "Braidy N",
          "Brew BJ",
          "Cullen KM",
          "Guillemin GJ",
          "Rahman A",
          "Ting K"
        ]
      },
      "source": 31,
      "target": 932,
      "key": "5a52fc12d3a799327d62fae0ddec9b62e0916d37a6f6b2ec1a3ca6b94e5adf7a23b5231929be3cf12c9acb123f0c4678d290efeb25cfb90d5a967a332aff9f0e"
    },
    {
      "line": 3879,
      "relation": "positiveCorrelation",
      "evidence": "QA appears to act through NMDA receptor activation similar to other agonists, glutamate and NMDA and was abrogated by the NMDAR antagonist memantine. NMDA receptor agonists, glutamate and NMDA at equimolar concentrations (500 nM) increased tau phosphorylation at serine 199/202 (AT8) and threonine 231 (AT-180), similar to QA.",
      "citation": {
        "type": "PubMed",
        "reference": "19623258",
        "name": "PloS one",
        "title": "The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.",
        "volume": "4",
        "pages": "e6344",
        "date": "2009-07-22",
        "first": "Rahman A",
        "last": "Guillemin GJ",
        "authors": [
          "Braidy N",
          "Brew BJ",
          "Cullen KM",
          "Guillemin GJ",
          "Rahman A",
          "Ting K"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 209,
      "target": 336,
      "key": "db110a52a3d0811ef584a2647db8c16101c91a219d86af823e22d55aa2bc89efcc02aa7da09251f85db704f47c11b3dd9aa993f21905925fb241f80dfb45998b"
    },
    {
      "line": 3880,
      "relation": "positiveCorrelation",
      "evidence": "QA appears to act through NMDA receptor activation similar to other agonists, glutamate and NMDA and was abrogated by the NMDAR antagonist memantine. NMDA receptor agonists, glutamate and NMDA at equimolar concentrations (500 nM) increased tau phosphorylation at serine 199/202 (AT8) and threonine 231 (AT-180), similar to QA.",
      "citation": {
        "type": "PubMed",
        "reference": "19623258",
        "name": "PloS one",
        "title": "The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.",
        "volume": "4",
        "pages": "e6344",
        "date": "2009-07-22",
        "first": "Rahman A",
        "last": "Guillemin GJ",
        "authors": [
          "Braidy N",
          "Brew BJ",
          "Cullen KM",
          "Guillemin GJ",
          "Rahman A",
          "Ting K"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 209,
      "target": 334,
      "key": "2a5c577fb36a455a8f5c5bb71cc991f4ba997d1b1676f84175e4dcf24964caa10705c64ded968849af63db67ba6fafb5884f04cd559dd317b34765f42e9246fa"
    },
    {
      "line": 3880,
      "relation": "positiveCorrelation",
      "evidence": "QA appears to act through NMDA receptor activation similar to other agonists, glutamate and NMDA and was abrogated by the NMDAR antagonist memantine. NMDA receptor agonists, glutamate and NMDA at equimolar concentrations (500 nM) increased tau phosphorylation at serine 199/202 (AT8) and threonine 231 (AT-180), similar to QA.",
      "citation": {
        "type": "PubMed",
        "reference": "19623258",
        "name": "PloS one",
        "title": "The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.",
        "volume": "4",
        "pages": "e6344",
        "date": "2009-07-22",
        "first": "Rahman A",
        "last": "Guillemin GJ",
        "authors": [
          "Braidy N",
          "Brew BJ",
          "Cullen KM",
          "Guillemin GJ",
          "Rahman A",
          "Ting K"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 334,
      "target": 209,
      "key": "1e4d6d5dd02bb72c959bd0bf53a36c20a102c397ce57577c9a6ce5010f6d42e45dfa34af8ad2911e548118289775465074c9fded55c77dbbc5a9d04895700c09"
    },
    {
      "line": 3881,
      "relation": "equivalentTo",
      "evidence": "QA appears to act through NMDA receptor activation similar to other agonists, glutamate and NMDA and was abrogated by the NMDAR antagonist memantine. NMDA receptor agonists, glutamate and NMDA at equimolar concentrations (500 nM) increased tau phosphorylation at serine 199/202 (AT8) and threonine 231 (AT-180), similar to QA.",
      "citation": {
        "type": "PubMed",
        "reference": "19623258",
        "name": "PloS one",
        "title": "The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.",
        "volume": "4",
        "pages": "e6344",
        "date": "2009-07-22",
        "first": "Rahman A",
        "last": "Guillemin GJ",
        "authors": [
          "Braidy N",
          "Brew BJ",
          "Cullen KM",
          "Guillemin GJ",
          "Rahman A",
          "Ting K"
        ]
      },
      "source": 334,
      "target": 583,
      "key": "ebdb6623b7dacad975429a499b738e83d1895202850c4d5fddd51553002f8e47bc162c1a2be58378e01a0d40b4186532d7de8621ce77a091b0b42f527a1cdb97"
    },
    {
      "line": 3903,
      "relation": "increases",
      "evidence": "In primary neurons, overexpression of miR-125b causes tau hyperphosphorylation and an upregulation of p35, cdk5, and p44/42-MAPK signaling. In parallel, the phosphatases DUSP6 and PPP1CA and the anti-apoptotic factor Bcl-W are downregulated as direct targets of miR-125b. Knockdown of these phosphatases induces tau hyperphosphorylation, and overexpression of PPP1CA and Bcl-W prevents miR-125b-induced tau phosphorylation, suggesting that they mediate the effects of miR-125b on tau. Conversely, suppression of miR-125b in neurons by tough decoys reduces tau phosphorylation and kinase expression/activity. Injecting miR-125b into the hippocampus of mice impairs associative learning and is accompanied by downregulation of Bcl-W, DUSP6, and PPP1CA, resulting in increased tau phosphorylation in vivo. Importantly, DUSP6 and PPP1CA are also reduced in AD brains.",
      "citation": {
        "type": "PubMed",
        "reference": "25001178",
        "name": "The EMBO journal",
        "title": "MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease.",
        "volume": "33",
        "pages": "1667-80",
        "date": "2014-08-01",
        "first": "Banzhaf-Strathmann J",
        "last": "Edbauer D",
        "authors": [
          "Arzberger T",
          "Banzhaf-Strathmann J",
          "Benito E",
          "Edbauer D",
          "Fischer A",
          "Kretzschmar H",
          "May S",
          "Tahirovic S"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 263,
      "target": 401,
      "key": "c7441dea8cce869bf5ec6044b651b4cf86fb14e754029c5357b74f8d913f17ef79ed486adf0e6993574b10f1e8e12ae16979baf2979c8e5b8480edaac180a085"
    },
    {
      "line": 3904,
      "relation": "increases",
      "evidence": "In primary neurons, overexpression of miR-125b causes tau hyperphosphorylation and an upregulation of p35, cdk5, and p44/42-MAPK signaling. In parallel, the phosphatases DUSP6 and PPP1CA and the anti-apoptotic factor Bcl-W are downregulated as direct targets of miR-125b. Knockdown of these phosphatases induces tau hyperphosphorylation, and overexpression of PPP1CA and Bcl-W prevents miR-125b-induced tau phosphorylation, suggesting that they mediate the effects of miR-125b on tau. Conversely, suppression of miR-125b in neurons by tough decoys reduces tau phosphorylation and kinase expression/activity. Injecting miR-125b into the hippocampus of mice impairs associative learning and is accompanied by downregulation of Bcl-W, DUSP6, and PPP1CA, resulting in increased tau phosphorylation in vivo. Importantly, DUSP6 and PPP1CA are also reduced in AD brains.",
      "citation": {
        "type": "PubMed",
        "reference": "25001178",
        "name": "The EMBO journal",
        "title": "MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease.",
        "volume": "33",
        "pages": "1667-80",
        "date": "2014-08-01",
        "first": "Banzhaf-Strathmann J",
        "last": "Edbauer D",
        "authors": [
          "Arzberger T",
          "Banzhaf-Strathmann J",
          "Benito E",
          "Edbauer D",
          "Fischer A",
          "Kretzschmar H",
          "May S",
          "Tahirovic S"
        ]
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 263,
      "target": 400,
      "key": "3614312bece661ea77e498591137a80b8179b4a1feb21214fc06cbb10aab0935d6d4d5d982c78f6dd80abb5389125fcf0f1316e356fe269898f99df42ad38769"
    },
    {
      "line": 3905,
      "relation": "increases",
      "evidence": "In primary neurons, overexpression of miR-125b causes tau hyperphosphorylation and an upregulation of p35, cdk5, and p44/42-MAPK signaling. In parallel, the phosphatases DUSP6 and PPP1CA and the anti-apoptotic factor Bcl-W are downregulated as direct targets of miR-125b. Knockdown of these phosphatases induces tau hyperphosphorylation, and overexpression of PPP1CA and Bcl-W prevents miR-125b-induced tau phosphorylation, suggesting that they mediate the effects of miR-125b on tau. Conversely, suppression of miR-125b in neurons by tough decoys reduces tau phosphorylation and kinase expression/activity. Injecting miR-125b into the hippocampus of mice impairs associative learning and is accompanied by downregulation of Bcl-W, DUSP6, and PPP1CA, resulting in increased tau phosphorylation in vivo. Importantly, DUSP6 and PPP1CA are also reduced in AD brains.",
      "citation": {
        "type": "PubMed",
        "reference": "25001178",
        "name": "The EMBO journal",
        "title": "MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease.",
        "volume": "33",
        "pages": "1667-80",
        "date": "2014-08-01",
        "first": "Banzhaf-Strathmann J",
        "last": "Edbauer D",
        "authors": [
          "Arzberger T",
          "Banzhaf-Strathmann J",
          "Benito E",
          "Edbauer D",
          "Fischer A",
          "Kretzschmar H",
          "May S",
          "Tahirovic S"
        ]
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 263,
      "target": 482,
      "key": "61a04038d45dd06057b69ea6dbfd392f2589148125a148ccb65132dc965d392c1643e80044ae2fe8109afa92c5adc8241ed1fe7357eda3c88cd3f117d0e22b3c"
    },
    {
      "line": 3906,
      "relation": "increases",
      "evidence": "In primary neurons, overexpression of miR-125b causes tau hyperphosphorylation and an upregulation of p35, cdk5, and p44/42-MAPK signaling. In parallel, the phosphatases DUSP6 and PPP1CA and the anti-apoptotic factor Bcl-W are downregulated as direct targets of miR-125b. Knockdown of these phosphatases induces tau hyperphosphorylation, and overexpression of PPP1CA and Bcl-W prevents miR-125b-induced tau phosphorylation, suggesting that they mediate the effects of miR-125b on tau. Conversely, suppression of miR-125b in neurons by tough decoys reduces tau phosphorylation and kinase expression/activity. Injecting miR-125b into the hippocampus of mice impairs associative learning and is accompanied by downregulation of Bcl-W, DUSP6, and PPP1CA, resulting in increased tau phosphorylation in vivo. Importantly, DUSP6 and PPP1CA are also reduced in AD brains.",
      "citation": {
        "type": "PubMed",
        "reference": "25001178",
        "name": "The EMBO journal",
        "title": "MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease.",
        "volume": "33",
        "pages": "1667-80",
        "date": "2014-08-01",
        "first": "Banzhaf-Strathmann J",
        "last": "Edbauer D",
        "authors": [
          "Arzberger T",
          "Banzhaf-Strathmann J",
          "Benito E",
          "Edbauer D",
          "Fischer A",
          "Kretzschmar H",
          "May S",
          "Tahirovic S"
        ]
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 263,
      "target": 477,
      "key": "031aa64064de789ca7694ce8ac4358938d21c803d82324642332948e17a7dd14f637cd9aacbb08e8cd2f02f31ef24ece1438fb6cf802a9205b39c3e0c49541b1"
    },
    {
      "line": 3907,
      "relation": "directlyDecreases",
      "evidence": "In primary neurons, overexpression of miR-125b causes tau hyperphosphorylation and an upregulation of p35, cdk5, and p44/42-MAPK signaling. In parallel, the phosphatases DUSP6 and PPP1CA and the anti-apoptotic factor Bcl-W are downregulated as direct targets of miR-125b. Knockdown of these phosphatases induces tau hyperphosphorylation, and overexpression of PPP1CA and Bcl-W prevents miR-125b-induced tau phosphorylation, suggesting that they mediate the effects of miR-125b on tau. Conversely, suppression of miR-125b in neurons by tough decoys reduces tau phosphorylation and kinase expression/activity. Injecting miR-125b into the hippocampus of mice impairs associative learning and is accompanied by downregulation of Bcl-W, DUSP6, and PPP1CA, resulting in increased tau phosphorylation in vivo. Importantly, DUSP6 and PPP1CA are also reduced in AD brains.",
      "citation": {
        "type": "PubMed",
        "reference": "25001178",
        "name": "The EMBO journal",
        "title": "MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease.",
        "volume": "33",
        "pages": "1667-80",
        "date": "2014-08-01",
        "first": "Banzhaf-Strathmann J",
        "last": "Edbauer D",
        "authors": [
          "Arzberger T",
          "Banzhaf-Strathmann J",
          "Benito E",
          "Edbauer D",
          "Fischer A",
          "Kretzschmar H",
          "May S",
          "Tahirovic S"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 263,
      "target": 652,
      "key": "74f444e257aca04a5a244c26c5b7c7707c5171fe6b422d10a2b20296fb49ef410738c5f6997751eb8dc74c797d63ada79fc13efdea765eac328a37c06489145f"
    },
    {
      "line": 3908,
      "relation": "directlyDecreases",
      "evidence": "In primary neurons, overexpression of miR-125b causes tau hyperphosphorylation and an upregulation of p35, cdk5, and p44/42-MAPK signaling. In parallel, the phosphatases DUSP6 and PPP1CA and the anti-apoptotic factor Bcl-W are downregulated as direct targets of miR-125b. Knockdown of these phosphatases induces tau hyperphosphorylation, and overexpression of PPP1CA and Bcl-W prevents miR-125b-induced tau phosphorylation, suggesting that they mediate the effects of miR-125b on tau. Conversely, suppression of miR-125b in neurons by tough decoys reduces tau phosphorylation and kinase expression/activity. Injecting miR-125b into the hippocampus of mice impairs associative learning and is accompanied by downregulation of Bcl-W, DUSP6, and PPP1CA, resulting in increased tau phosphorylation in vivo. Importantly, DUSP6 and PPP1CA are also reduced in AD brains.",
      "citation": {
        "type": "PubMed",
        "reference": "25001178",
        "name": "The EMBO journal",
        "title": "MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease.",
        "volume": "33",
        "pages": "1667-80",
        "date": "2014-08-01",
        "first": "Banzhaf-Strathmann J",
        "last": "Edbauer D",
        "authors": [
          "Arzberger T",
          "Banzhaf-Strathmann J",
          "Benito E",
          "Edbauer D",
          "Fischer A",
          "Kretzschmar H",
          "May S",
          "Tahirovic S"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 263,
      "target": 441,
      "key": "7f32b4c3a840c63265a7c4b8654831073ff485cbad0b26f291d866c3c537133329f304efbdb78401db3671bb96bd964c38480b4c445669945292250124023553"
    },
    {
      "line": 3909,
      "relation": "directlyDecreases",
      "evidence": "In primary neurons, overexpression of miR-125b causes tau hyperphosphorylation and an upregulation of p35, cdk5, and p44/42-MAPK signaling. In parallel, the phosphatases DUSP6 and PPP1CA and the anti-apoptotic factor Bcl-W are downregulated as direct targets of miR-125b. Knockdown of these phosphatases induces tau hyperphosphorylation, and overexpression of PPP1CA and Bcl-W prevents miR-125b-induced tau phosphorylation, suggesting that they mediate the effects of miR-125b on tau. Conversely, suppression of miR-125b in neurons by tough decoys reduces tau phosphorylation and kinase expression/activity. Injecting miR-125b into the hippocampus of mice impairs associative learning and is accompanied by downregulation of Bcl-W, DUSP6, and PPP1CA, resulting in increased tau phosphorylation in vivo. Importantly, DUSP6 and PPP1CA are also reduced in AD brains.",
      "citation": {
        "type": "PubMed",
        "reference": "25001178",
        "name": "The EMBO journal",
        "title": "MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease.",
        "volume": "33",
        "pages": "1667-80",
        "date": "2014-08-01",
        "first": "Banzhaf-Strathmann J",
        "last": "Edbauer D",
        "authors": [
          "Arzberger T",
          "Banzhaf-Strathmann J",
          "Benito E",
          "Edbauer D",
          "Fischer A",
          "Kretzschmar H",
          "May S",
          "Tahirovic S"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 263,
      "target": 388,
      "key": "5c618e6cb7fbf89e9342b3f40f80f904d21efe7f57ad88eb5fced0121469e45f42792ca5e8687daea3ef77e4aab9499b8d6f1b19b174df7b8bc6ce6367a5fb91"
    },
    {
      "line": 3914,
      "relation": "negativeCorrelation",
      "evidence": "Since Erk1/2 activity has been shown to induce cdk5 (Harada et al, 2001), miR-125b-induced Erk1/2 activation through DUSP6 downregulation might ultimately stimulate aberrant cdk5/p35 activation and, consequently, enhance pathological tau phosphorylation at multiple sites",
      "citation": {
        "type": "PubMed",
        "reference": "25001178",
        "name": "The EMBO journal",
        "title": "MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease.",
        "volume": "33",
        "pages": "1667-80",
        "date": "2014-08-01",
        "first": "Banzhaf-Strathmann J",
        "last": "Edbauer D",
        "authors": [
          "Arzberger T",
          "Banzhaf-Strathmann J",
          "Benito E",
          "Edbauer D",
          "Fischer A",
          "Kretzschmar H",
          "May S",
          "Tahirovic S"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 441,
      "target": 477,
      "key": "9a0df02e36b9c96e8c6abdf8365ab83f5b47dd0d1308e76e02f3cde7ee83bce24a3a01c2b2d03f69037f4ebf56f3923817836dcedf70353af99c1c3c43075e09"
    },
    {
      "line": 3948,
      "relation": "decreases",
      "evidence": "Alltogether, this provides evidence for a negative feed-back regulation of Pin1 by Smad. A similar mechanism might be instrumental in AD, where nuclear Smad concentrations are significantly reduced , which potentially contributes to increased levels of Pin1 [16]",
      "citation": {
        "type": "PubMed",
        "reference": "24964035",
        "name": "Neuropathology and applied neurobiology",
        "title": "Pin1 promotes degradation of Smad proteins and their interaction with phosphorylated tau in Alzheimer's disease.",
        "volume": "40",
        "pages": "815-32",
        "date": "2014-12-01",
        "first": "Ueberham U",
        "last": "Arendt T",
        "authors": [
          "Arendt T",
          "Brückner MK",
          "Gruschka H",
          "Hilbrich I",
          "Holzer M",
          "Rohn S",
          "Ueberham E",
          "Ueberham U",
          "Wodischeck S"
        ]
      },
      "source": 682,
      "target": 647,
      "key": "539519ca41ac6c08d92560e85a98765cbdc34dcea585341521cd6ff1ce7fc8dd5eaedcc0dd85d9b3f5e148299a34defe39eebc0d440ffaf7be2176dae273cfef"
    },
    {
      "relation": "hasComponent",
      "source": 240,
      "target": 538,
      "key": "8c352ac59f8310c47a039a7f3cb3203666a2b4760147e838866d86e47de620bba194bcca4a994ef618e1ab9d11c2444d9250eaf2d567b4f92dbb985a02672bf1"
    },
    {
      "relation": "hasComponent",
      "source": 240,
      "target": 682,
      "key": "30f8e219821df81585f08ab99e1bd71d2b530a3678a7a97646ae91fea62e8fc516c9e2a415fcec727a54980c267a6e9dda87b8e3dcc72cd3f8bd2283cf2ed9a9"
    },
    {
      "line": 3949,
      "relation": "decreases",
      "evidence": "Alltogether, this provides evidence for a negative feed-back regulation of Pin1 by Smad. A similar mechanism might be instrumental in AD, where nuclear Smad concentrations are significantly reduced , which potentially contributes to increased levels of Pin1 [16]",
      "citation": {
        "type": "PubMed",
        "reference": "24964035",
        "name": "Neuropathology and applied neurobiology",
        "title": "Pin1 promotes degradation of Smad proteins and their interaction with phosphorylated tau in Alzheimer's disease.",
        "volume": "40",
        "pages": "815-32",
        "date": "2014-12-01",
        "first": "Ueberham U",
        "last": "Arendt T",
        "authors": [
          "Arendt T",
          "Brückner MK",
          "Gruschka H",
          "Hilbrich I",
          "Holzer M",
          "Rohn S",
          "Ueberham E",
          "Ueberham U",
          "Wodischeck S"
        ]
      },
      "source": 683,
      "target": 647,
      "key": "a3ff8722bd37ec14cf6fac65478573c4d081570c938cb163190b9d618e393ff1ee57c05768b3bea94dae255bdcaa6debb15eac41c307c9bfeca8248f5fd778d8"
    },
    {
      "line": 3955,
      "relation": "negativeCorrelation",
      "evidence": "Pin1 accelerates cis to trans conversion to prevent accumulation of pathogenic cis p-tau conformation in AD, providing the first structural evidence for how Pin1 protects against AD.",
      "citation": {
        "type": "PubMed",
        "reference": "23157676",
        "name": "Current molecular medicine",
        "title": "Distinct functions of cis and trans phosphorylated tau in Alzheimer's disease and their therapeutic implications.",
        "volume": "13",
        "pages": "1098-109",
        "date": "2013-08-01",
        "first": "Nakamura K",
        "last": "Lu KP",
        "authors": [
          "Lu KP",
          "Nakamura K",
          "Zhou XZ"
        ]
      },
      "source": 357,
      "target": 908,
      "key": "772627c3a68bc6812fe344a6c51d47b3a5337df4411ad21754c4d3b5d37460729664581e1db5d1c927defb178b6df3164aeeca6f269d7d91b237b559017f7fa2"
    },
    {
      "line": 3956,
      "relation": "increases",
      "evidence": "Pin1 accelerates cis to trans conversion to prevent accumulation of pathogenic cis p-tau conformation in AD, providing the first structural evidence for how Pin1 protects against AD.",
      "citation": {
        "type": "PubMed",
        "reference": "23157676",
        "name": "Current molecular medicine",
        "title": "Distinct functions of cis and trans phosphorylated tau in Alzheimer's disease and their therapeutic implications.",
        "volume": "13",
        "pages": "1098-109",
        "date": "2013-08-01",
        "first": "Nakamura K",
        "last": "Lu KP",
        "authors": [
          "Lu KP",
          "Nakamura K",
          "Zhou XZ"
        ]
      },
      "source": 357,
      "target": 112,
      "key": "5d5ab191f6fc996aeb7c4487994972945558a2767698f88fcf4ebd82d690adacd1f710778fb673d5311a7a4057514cbb0026a4dfb9f6c3c9cef7a7a2327b183c"
    },
    {
      "line": 3957,
      "relation": "partOf",
      "evidence": "Pin1 accelerates cis to trans conversion to prevent accumulation of pathogenic cis p-tau conformation in AD, providing the first structural evidence for how Pin1 protects against AD.",
      "citation": {
        "type": "PubMed",
        "reference": "23157676",
        "name": "Current molecular medicine",
        "title": "Distinct functions of cis and trans phosphorylated tau in Alzheimer's disease and their therapeutic implications.",
        "volume": "13",
        "pages": "1098-109",
        "date": "2013-08-01",
        "first": "Nakamura K",
        "last": "Lu KP",
        "authors": [
          "Lu KP",
          "Nakamura K",
          "Zhou XZ"
        ]
      },
      "source": 357,
      "target": 127,
      "key": "9b963b517b1cdc34a1f069e7549c0c69a585a59971a2c2301a10435e59230774d3e6e673072da1aceead8755d81fe22df644fcf48eb7e84fadd4b71b06bcc931"
    },
    {
      "line": 3962,
      "relation": "association",
      "evidence": "We identified a novel molecular interaction implying the PHF6 peptide of Tau and the FK1/FK2 domains of FKBP52 independent of FK506 binding; suggesting a non-catalytic molecular interaction that might govern the effect of FKBP52 on Tau.",
      "citation": {
        "type": "PubMed",
        "reference": "26903089",
        "name": "Journal of molecular biology",
        "title": "Isomerization and Oligomerization of Truncated and Mutated Tau Forms by FKBP52 are Independent Processes.",
        "volume": "428",
        "pages": "1080-1090",
        "date": "2016-03-27",
        "first": "Kamah A",
        "last": "Lippens G",
        "authors": [
          "Baulieu EE",
          "Byrne C",
          "Cantrelle FX",
          "Chambraud B",
          "Giustiniani J",
          "Guillemeau K",
          "Huvent I",
          "Jacquot Y",
          "Kamah A",
          "Landrieu I",
          "Lippens G",
          "Smet C"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 449,
      "target": 356,
      "key": "3832bb13b548908661134aa029ff298f4d66bc59756dd660fa0a7dedaec7cf122c7bcc6dc3c9ea02cc3570f8d1dd094483a8c0c6cbe821e056a3e88ddbc9163e"
    },
    {
      "line": 3975,
      "relation": "directlyDecreases",
      "evidence": "We then investigated the function of FK506-binding protein (FKBP) 12, which is known to accumulate in neurofibrillary tangles in vivo, on aggregation of the R3 peptide and found that FKBP12 completely prevented the peptide from aggregating at a concentration ratio of 1 : 4 (peptide:FKBP12). FKBP12 also restored the oligomer of the peptide to its monomeric status. Mutational studies on the catalytic center of FKBP12 indicated that peptidyl-prolyl isomerase activity of FKBP12 was essential for prevention of aggregation. Assuming that the propensity of aggregation of the peptide is different in each cis-/trans-isomer, we propose that the aggregation behavior of the R3 peptide can be theoretically described with a simple kinetic scheme, in which only the cis-isomer can aggregate and FKBP12 catalyzes isomerization of the peptide in both the monomeric and aggregative states.",
      "citation": {
        "type": "PubMed",
        "reference": "23832849",
        "name": "Protein engineering, design &amp; selection : PEDS",
        "title": "Peptidyl-prolyl isomerase activity of FK506 binding protein 12 prevents tau peptide from aggregating.",
        "volume": "26",
        "pages": "539-46",
        "date": "2013-09-01",
        "first": "Ikura T",
        "last": "Ito N",
        "authors": [
          "Ikura T",
          "Ito N"
        ]
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 757,
      "target": 364,
      "key": "bce72c9617b5261ddc766f2507478862ffb2cf0422be6deb30bf5041a4e97753b2ba0d84f19eee406a4831ebd7a31e8c25d7d80c50ecea3da1fdd6ae9030059d"
    },
    {
      "line": 3985,
      "relation": "negativeCorrelation",
      "evidence": "Because Pin1 has at least 4 major isovariants in addition to the native polypeptide, this means that Pin1 has 4 (possibly more) posttranslational modifications including phosphorylation at 3 sites (Ser16 and Ser65/Ser71), N-acetylation (amino-terminus and Lys46) and oxidation (Met130 and 146). In all experimental conditions, including tau-overexpressing cells, tau transgenic mice and AD brains, global levels of Pin1 posttranslational modifications were decreased compared with control conditions.",
      "citation": {
        "type": "PubMed",
        "reference": "22926167",
        "name": "Neurobiology of aging",
        "title": "Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker.",
        "volume": "34",
        "pages": "757-69",
        "date": "2013-03-01",
        "first": "Ando K",
        "last": "Buée L",
        "authors": [
          "Ando K",
          "Blum D",
          "Bretteville A",
          "Buée L",
          "Bégard S",
          "Bélarbi K",
          "Caillet-Boudin ML",
          "Demey-Thomas E",
          "Dourlen P",
          "Drobecq H",
          "Eddarkaoui S",
          "Galas MC",
          "Ghestem A",
          "Hamdane M",
          "Landrieu I",
          "Lippens G",
          "Maurage CA",
          "Melnyk P",
          "Sambo AV",
          "Sergeant N",
          "Smet C",
          "Verdier Y",
          "Vingtdeux V",
          "Vinh J"
        ]
      },
      "source": 649,
      "target": 486,
      "key": "61a203f635e34b96917a3ee4a55c96220772c2d3e0c42130879514fa7f467a2d431fa7bcce9e2bf99a0cb8a09bf1eab6de8f5f20eff1a9eff17aa2cd2ee90722"
    },
    {
      "line": 4002,
      "relation": "decreases",
      "evidence": "In fact, phosphorylation of Pin1 at Ser16 inhibits its nuclear localization possibly through inhibition of Pin1 substrate-binding property (Lu et al., 2002) while phosphorylation at Ser65 does not change activity of localization but stabilizes Pin1 by preventing its ubiquitination",
      "citation": {
        "type": "PubMed",
        "reference": "22926167",
        "name": "Neurobiology of aging",
        "title": "Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker.",
        "volume": "34",
        "pages": "757-69",
        "date": "2013-03-01",
        "first": "Ando K",
        "last": "Buée L",
        "authors": [
          "Ando K",
          "Blum D",
          "Bretteville A",
          "Buée L",
          "Bégard S",
          "Bélarbi K",
          "Caillet-Boudin ML",
          "Demey-Thomas E",
          "Dourlen P",
          "Drobecq H",
          "Eddarkaoui S",
          "Galas MC",
          "Ghestem A",
          "Hamdane M",
          "Landrieu I",
          "Lippens G",
          "Maurage CA",
          "Melnyk P",
          "Sambo AV",
          "Sergeant N",
          "Smet C",
          "Verdier Y",
          "Vingtdeux V",
          "Vinh J"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 649,
      "target": 647,
      "key": "22a2f9364fd97430e60b22ef6cc217e149f077498e9ea66c16e39e5d437850b0f8c61176a71c2dcd9955eee912d5b0dd307a77d1e6c8b068f523901de4751e33"
    },
    {
      "line": 3986,
      "relation": "negativeCorrelation",
      "evidence": "Because Pin1 has at least 4 major isovariants in addition to the native polypeptide, this means that Pin1 has 4 (possibly more) posttranslational modifications including phosphorylation at 3 sites (Ser16 and Ser65/Ser71), N-acetylation (amino-terminus and Lys46) and oxidation (Met130 and 146). In all experimental conditions, including tau-overexpressing cells, tau transgenic mice and AD brains, global levels of Pin1 posttranslational modifications were decreased compared with control conditions.",
      "citation": {
        "type": "PubMed",
        "reference": "22926167",
        "name": "Neurobiology of aging",
        "title": "Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker.",
        "volume": "34",
        "pages": "757-69",
        "date": "2013-03-01",
        "first": "Ando K",
        "last": "Buée L",
        "authors": [
          "Ando K",
          "Blum D",
          "Bretteville A",
          "Buée L",
          "Bégard S",
          "Bélarbi K",
          "Caillet-Boudin ML",
          "Demey-Thomas E",
          "Dourlen P",
          "Drobecq H",
          "Eddarkaoui S",
          "Galas MC",
          "Ghestem A",
          "Hamdane M",
          "Landrieu I",
          "Lippens G",
          "Maurage CA",
          "Melnyk P",
          "Sambo AV",
          "Sergeant N",
          "Smet C",
          "Verdier Y",
          "Vingtdeux V",
          "Vinh J"
        ]
      },
      "source": 650,
      "target": 486,
      "key": "055650f4ce1b1fca22c01fb57cf3a9ec0c76759f911d3a770d6bf60fbd712abc9d148908b4553fb04b511fa339671a56752fbdff68948879b3a41d7feb9e5cf2"
    },
    {
      "line": 4001,
      "relation": "increases",
      "evidence": "In fact, phosphorylation of Pin1 at Ser16 inhibits its nuclear localization possibly through inhibition of Pin1 substrate-binding property (Lu et al., 2002) while phosphorylation at Ser65 does not change activity of localization but stabilizes Pin1 by preventing its ubiquitination",
      "citation": {
        "type": "PubMed",
        "reference": "22926167",
        "name": "Neurobiology of aging",
        "title": "Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker.",
        "volume": "34",
        "pages": "757-69",
        "date": "2013-03-01",
        "first": "Ando K",
        "last": "Buée L",
        "authors": [
          "Ando K",
          "Blum D",
          "Bretteville A",
          "Buée L",
          "Bégard S",
          "Bélarbi K",
          "Caillet-Boudin ML",
          "Demey-Thomas E",
          "Dourlen P",
          "Drobecq H",
          "Eddarkaoui S",
          "Galas MC",
          "Ghestem A",
          "Hamdane M",
          "Landrieu I",
          "Lippens G",
          "Maurage CA",
          "Melnyk P",
          "Sambo AV",
          "Sergeant N",
          "Smet C",
          "Verdier Y",
          "Vingtdeux V",
          "Vinh J"
        ]
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 650,
      "target": 647,
      "key": "bc4f00eff43b9e73410669173d6c9123643978608a7cc4745990cdb9f3ea119ee703662c71b621f9e9ba8c9064e1137e229f588b724178da4b8149362614d310"
    },
    {
      "line": 3988,
      "relation": "negativeCorrelation",
      "evidence": "Because Pin1 has at least 4 major isovariants in addition to the native polypeptide, this means that Pin1 has 4 (possibly more) posttranslational modifications including phosphorylation at 3 sites (Ser16 and Ser65/Ser71), N-acetylation (amino-terminus and Lys46) and oxidation (Met130 and 146). In all experimental conditions, including tau-overexpressing cells, tau transgenic mice and AD brains, global levels of Pin1 posttranslational modifications were decreased compared with control conditions.",
      "citation": {
        "type": "PubMed",
        "reference": "22926167",
        "name": "Neurobiology of aging",
        "title": "Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker.",
        "volume": "34",
        "pages": "757-69",
        "date": "2013-03-01",
        "first": "Ando K",
        "last": "Buée L",
        "authors": [
          "Ando K",
          "Blum D",
          "Bretteville A",
          "Buée L",
          "Bégard S",
          "Bélarbi K",
          "Caillet-Boudin ML",
          "Demey-Thomas E",
          "Dourlen P",
          "Drobecq H",
          "Eddarkaoui S",
          "Galas MC",
          "Ghestem A",
          "Hamdane M",
          "Landrieu I",
          "Lippens G",
          "Maurage CA",
          "Melnyk P",
          "Sambo AV",
          "Sergeant N",
          "Smet C",
          "Verdier Y",
          "Vingtdeux V",
          "Vinh J"
        ]
      },
      "source": 648,
      "target": 486,
      "key": "fd534e1b5bdc11324e272b02b29f8a79ff9029767bf80f1d8dcc182c0fc8d3000b4dae605c7ab9552df17cc5433cd6de7605e3350520c15edcc0b923034a8eec"
    },
    {
      "line": 4015,
      "relation": "positiveCorrelation",
      "evidence": "Taken together, these results indicate that the binding of P-Tau to microtubules suppresses its dephosphorylation.",
      "citation": {
        "type": "PubMed",
        "reference": "19401603",
        "name": "The Journal of biological chemistry",
        "title": "Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau.",
        "volume": "284",
        "pages": "16840-7",
        "date": "2009-06-19",
        "first": "Yotsumoto K",
        "last": "Hisanaga S",
        "authors": [
          "Asada A",
          "Hasegawa M",
          "Hisanaga S",
          "Ishiguro K",
          "Kimura T",
          "Oikawa T",
          "Saito T",
          "Uchida C",
          "Uchida T",
          "Yotsumoto K"
        ]
      },
      "source": 216,
      "target": 538,
      "key": "e5b383b0d0497bb4b5c995c29155c0c78a04d5b650491c20d91ddc34ab0f90e284656e4dddc2149049e54be96a259488102927ba792acca3b07ee2c3bd48766d"
    }
  ]
}